PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Mastrobattista, E; Koning, GA; van Bloois, L; Filipe, ACS; Jiskoot, W; Storm, G				Mastrobattista, E; Koning, GA; van Bloois, L; Filipe, ACS; Jiskoot, W; Storm, G			Functional characterization of an endosome-disruptive peptide and its application in cytosolic delivery of immunoliposome-entrapped proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INFLUENZA-VIRUS HEMAGGLUTININ; MEMBRANE-ACTIVE PEPTIDES; N-TERMINAL PEPTIDES; GENE-TRANSFER; SYNTHETIC PEPTIDE; SPECTRAL BEHAVIOR; FUSION PEPTIDE; DESTABILIZATION; LIPOSOMES; OLIGONUCLEOTIDES	Antibody-directed liposomes (immunoliposomes) are frequently used for targeted drug delivery. However, delivery of large biotherapeutic molecules (i.e. peptides, proteins, or nucleic acids) with immunoliposomes is often hampered by an inefficient cytosolic release of entrapped macromolecules after target cell binding and subsequent endocytosis of immunoliposomes. To enhance cytosolic drug delivery from immunoliposomes present inside endosomes, a pH-dependent fusogenic peptide (diINF-7) resembling the NH2-terminal domain of influenza virus hemagglutinin HA-2 subunit was used. Functional characterization of this dimeric peptide showed its ability to induce fusion between liposome membranes and leakage of liposome-entrapped compounds when exposed to low pH. In a second series of experiments, diINF-7 peptides were encapsulated in immunoliposomes to enhance the endosomal escape of diphtheria toxin A chain (DTA), which inhibits protein synthesis when delivered into the cytosol of target cells. Immunoliposomes targeted to the internalizing epidermal growth factor receptor on the surface of ovarian carcinoma cells (OVCAR-3) and containing encapsulated DTA did not show any cytotoxicity toward OVCAR-3 cells. Cytotoxicity was only observed when diINF-7 peptides and DTA were co-encapsulated in the immunoliposomes. Thus, diINF-7 peptides entrapped inside liposomes can greatly enhance cytosolic delivery of liposomal macromolecules by pH-dependent destabilization of endosomal membranes after cellular uptake of liposomes.	Univ Utrecht, Dept Pharmaceut, NL-3508 TB Utrecht, Netherlands	Utrecht University	Storm, G (corresponding author), Univ Utrecht, Dept Pharmaceut, POB 80082, NL-3508 TB Utrecht, Netherlands.	g.storm@pharm.uu.nl	Koning, Gerben A/K-2326-2012; Storm, Gerrit/O-8696-2016; Jiskoot, Wim/A-6877-2016; Mastrobattista, Enrico/O-6670-2016	Koning, Gerben A/0000-0003-3090-2403; Jiskoot, Wim/0000-0002-1012-3456; Mastrobattista, Enrico/0000-0002-6745-2015; da Silva Filipe, Ana Cristina/0000-0002-9442-2903				Arigita C, 1999, PHARMACEUT RES, V16, P1534, DOI 10.1023/A:1015096302720; Bailey AL, 1997, BBA-BIOMEMBRANES, V1324, P232, DOI 10.1016/S0005-2736(96)00228-3; Baru M, 1998, J DRUG TARGET, V6, P191, DOI 10.3109/10611869808997893; Bohm G., 1997, CDNN CD SPECTRA DECO; Brasseur R, 2000, MOL MEMBR BIOL, V17, P31, DOI 10.1080/096876800294461; CARROLL SF, 1988, METHOD ENZYMOL, V165, P218; CARROLL SF, 1988, METHOD ENZYMOL, V165, P68; DUZGUNES N, 1992, J MEMBRANE BIOL, V128, P71, DOI 10.1007/BF00231872; DUZGUNES N, 1988, FEBS LETT, V227, P110, DOI 10.1016/0014-5793(88)80879-2; Fiske CH, 1925, J BIOL CHEM, V66, P375; Freulon I, 2001, BIOCHEM J, V354, P671, DOI 10.1042/0264-6021:3540671; Fujii G, 1999, ADV DRUG DELIVER REV, V38, P257, DOI 10.1016/S0169-409X(99)00032-0; GALLA HJ, 1980, CHEM PHYS LIPIDS, V27, P199, DOI 10.1016/0009-3084(80)90036-5; HAMILTON TC, 1983, CANCER RES, V43, P5379; Han X, 2001, NAT STRUCT BIOL, V8, P715, DOI 10.1038/90434; HENNESSEY JP, 1981, BIOCHEMISTRY-US, V20, P1085, DOI 10.1021/bi00508a007; Ishida T, 1999, FEBS LETT, V460, P129, DOI 10.1016/S0014-5793(99)01320-4; Kaneda Y, 2000, ADV DRUG DELIVER REV, V43, P197, DOI 10.1016/S0169-409X(00)00069-7; KENDALL DA, 1982, J BIOL CHEM, V257, P3892; Kickler A, 1997, BIOCONJUGATE CHEM, V8, P213, DOI 10.1021/bc970009z; Laczko I, 1998, BIOCHEM BIOPH RES CO, V249, P213, DOI 10.1006/bbrc.1998.9109; Matsumoto T, 1999, BIOPHYS CHEM, V79, P153, DOI 10.1016/S0301-4622(99)00051-4; Mechtler K, 1997, NEW J CHEM, V21, P105; MEMOLI A, 1994, J PHARMACEUT BIOMED, V12, P307, DOI 10.1016/0731-7085(94)90004-3; Memoli A, 1999, J PHARMACEUT BIOMED, V19, P627, DOI 10.1016/S0731-7085(98)00229-5; NICHOLS JW, 1980, P NATL ACAD SCI-BIOL, V77, P2038, DOI 10.1073/pnas.77.4.2038; OBERHAUSER B, 1995, DELIVERY STRATEGIES; OELTMANN TN, 1988, METHOD ENZYMOL, V165, P204; OLSON F, 1979, BIOCHIM BIOPHYS ACTA, V557, P9, DOI 10.1016/0005-2736(79)90085-3; Pecheur EI, 1997, BIOCHEMISTRY-US, V36, P3773, DOI 10.1021/bi9622128; Pecheur EI, 1999, J MEMBRANE BIOL, V167, P1, DOI 10.1007/s002329900466; Pichon C, 1997, ANTISENSE NUCLEIC A, V7, P335, DOI 10.1089/oli.1.1997.7.335; Plank C, 1998, ADV DRUG DELIVER REV, V34, P21, DOI 10.1016/S0169-409X(98)00005-2; PLANK C, 1994, J BIOL CHEM, V269, P12918; PUYAL C, 1994, BBA-BIOMEMBRANES, V1195, P259, DOI 10.1016/0005-2736(94)90265-8; ROSSIGNOL M, 1982, BIOCHIM BIOPHYS ACTA, V684, P195, DOI 10.1016/0005-2736(82)90005-0; SCHEULE RK, 1986, BIOCHEMISTRY-US, V25, P4223, DOI 10.1021/bi00363a009; Schoen P, 1999, GENE THER, V6, P823, DOI 10.1038/sj.gt.3300919; STEGMANN T, 1987, EMBO J, V6, P2651, DOI 10.1002/j.1460-2075.1987.tb02556.x; STEINHAUER DA, 1995, J VIROL, V69, P6643, DOI 10.1128/JVI.69.11.6643-6651.1995; SUBBARAO NK, 1987, BIOCHEMISTRY-US, V26, P2964, DOI 10.1021/bi00385a002; Tong SG, 1996, BIOCHEMISTRY-US, V35, P4956, DOI 10.1021/bi9526903; Wagner E, 1999, ADV DRUG DELIVER REV, V38, P279, DOI 10.1016/S0169-409X(99)00033-2; WAGNER E, 1992, P NATL ACAD SCI USA, V89, P7934, DOI 10.1073/pnas.89.17.7934; WHARTON SA, 1988, J GEN VIROL, V69, P1847, DOI 10.1099/0022-1317-69-8-1847	45	149	167	1	34	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 26	2002	277	30					27135	27143		10.1074/jbc.M200429200	http://dx.doi.org/10.1074/jbc.M200429200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	577HR	12021269	hybrid			2023-01-03	WOS:000177055900057
J	Albers, L; Williams, D				Albers, L; Williams, D			Lessons for US postpartum care	LANCET			English	Editorial Material									Univ New Mexico, Hlth Sci Ctr, Albuquerque, NM 87131 USA; Amer Coll Nurse Midwives, Washington, DC USA	University of New Mexico; University of New Mexico's Health Sciences Center	Albers, L (corresponding author), Univ New Mexico, Hlth Sci Ctr, Albuquerque, NM 87131 USA.							Albers LL, 2000, J MIDWIFERY WOM HEAL, V45, P55, DOI 10.1016/S1526-9523(99)00003-3; *AM AC PED AM COLL, 1997, GUID PER CAR, P176; HODNETT ED, 2001, COCHRANE DATABASE SY, V3; PAGE LA, 2000, NEW MIDWIFERY SCI SE, P185; ROOKS JP, 1997, MIDWIFERY CHILDBIRTH, P338; WOLMAN WL, 1993, AM J OBSTET GYNECOL, V168, P1388, DOI 10.1016/S0002-9378(11)90770-4; YARDLEY J, 2001, NY TIMES        0623	7	3	3	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	FEB 2	2002	359	9304					370	371		10.1016/S0140-6736(02)07587-6	http://dx.doi.org/10.1016/S0140-6736(02)07587-6			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	518UP	11844503				2023-01-03	WOS:000173686500003
J	Krogstad, U; Hofoss, D; Hjortdahl, P				Krogstad, U; Hofoss, D; Hjortdahl, P			Continuity of hospital care: beyond the question of personal contact	BRITISH MEDICAL JOURNAL			English	Article							GENERAL-PRACTICE; ORGANIZATION; OUTCOMES; TEAMWORK; ISSUES		Cent Hosp Akershus, HELTEF Fdn Hlth Serv Res, N-1474 Nordbyhagen, Norway; Univ Oslo, Dept Gen Practice & Community Med, N-0316 Oslo, Norway	University of Oslo; University of Oslo	Krogstad, U (corresponding author), Cent Hosp Akershus, HELTEF Fdn Hlth Serv Res, N-1474 Nordbyhagen, Norway.							AIKEN LH, 1994, MED CARE, V32, P771, DOI 10.1097/00005650-199408000-00002; Aiken LH, 1999, MED CARE, V37, P760, DOI 10.1097/00005650-199908000-00006; Aiken LH, 1998, QUAL HEALTH CARE, V7, P222, DOI 10.1136/qshc.7.4.222; [Anonymous], 1949, AM J SOCIOL; BRENNER P, 1984, NOVICE EXPERT EXCELL; Cook RI, 2000, BRIT MED J, V320, P791, DOI 10.1136/bmj.320.7237.791; De Maeseneer J, 2000, BRIT MED J, V320, P1616, DOI 10.1136/bmj.320.7250.1616; Flood A B, 1994, Med Care Rev, V51, P381, DOI 10.1177/107755879405100402; FREEDMAN R, 1987, ALCOHOL, V4, P249, DOI 10.1016/0741-8329(87)90019-X; FREEMAN G, 1985, J ROY COLL GEN PRACT, V35, P423; Freeman G, 1997, BRIT MED J, V314, P1870, DOI 10.1136/bmj.314.7098.1870; Freer SD, 1999, NEW ENGL J MED, V341, P850; Hennen B K, 1975, J Fam Pract, V2, P371; HJORTDAHL P, 1992, BRIT MED J, V304, P1287, DOI 10.1136/bmj.304.6837.1287; Hjortdahl P, 1990, Fam Med, V22, P361; HJORTDAHL P, 1992, FAM PRACT, V9, P3, DOI 10.1093/fampra/9.1.3; Krogstad Unni, 1997, Tidsskrift for den Norske Laegeforening, V117, P4439; Manian FA, 1999, NEW ENGL J MED, V340, P1362, DOI 10.1056/NEJM199904293401712; MINZBERG H, 1971, STRUCTURING ORG; Risser DT, 1999, ANN EMERG MED, V34, P373, DOI 10.1016/S0196-0644(99)70134-4; Schon D. A, 2016, REFLECTIVE PRACTITIO; Sexton JB, 2000, BMJ-BRIT MED J, V320, P745, DOI 10.1136/bmj.320.7237.745; SHERN DL, 1986, COMMUNITY MENT HLT J, V22, P190, DOI 10.1007/BF00756981; Smith L, 2000, J ADV NURS, V31, P812, DOI 10.1046/j.1365-2648.2000.01339.x; Sparbel KJH, 2000, J NURS SCHOLARSHIP, V32, P17, DOI 10.1111/j.1547-5069.2000.00017.x; Sparbel KJH, 2000, J NURS SCHOLARSHIP, V32, P131, DOI 10.1111/j.1547-5069.2000.00131.x; Sturmberg JP, 2000, FAM PRACT, V17, P16, DOI 10.1093/fampra/17.1.16; TRESCH DD, 1985, J AM GERIATR SOC, V33, P819, DOI 10.1111/j.1532-5415.1985.tb05433.x; VEENSTRA M, 2000, PATIENTS EXPERIENCES	29	51	51	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	JAN 5	2002	324	7328					36	38		10.1136/bmj.324.7328.36	http://dx.doi.org/10.1136/bmj.324.7328.36			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	510JV	11777807	Green Published			2023-01-03	WOS:000173205700025
J	Quill, TE; Arnold, RM; Platt, F				Quill, TE; Arnold, RM; Platt, F			"I wish things were different": Expressing wishes in response to loss, futility, and unrealistic hopes	ANNALS OF INTERNAL MEDICINE			English	Editorial Material							EMPATHIC COMMUNICATION; PHYSICIANS; CARE		Univ Rochester, Sch Med & Dent, Rochester, NY 14642 USA; Univ Pittsburgh, Sch Med, Pittsburgh, PA 15213 USA; Univ Colorado, Sch Med, Denver, CO 80205 USA	University of Rochester; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Quill, TE (corresponding author), Univ Rochester, Med Ctr, 601 Elmwood Ave,Box 601, Rochester, NY 14642 USA.							ACKERMAN F, 1991, HASTINGS CENT REP, V21, P27, DOI 10.2307/3562998; BARRETTLENNARD GT, 1993, BRIT J MED PSYCHOL, V66, P3, DOI 10.1111/j.2044-8341.1993.tb01722.x; BRANCH WT, 1993, JAMA-J AM MED ASSOC, V269, P1667, DOI 10.1001/jama.269.13.1667; Byock I, 1997, DYING WELL PROSPECT; Coulehan JL, 2001, ANN INTERN MED, V135, P221, DOI 10.7326/0003-4819-135-3-200108070-00022; FOX RC, 1959, EXPT PERILOUS PHYSIC; GOOD MJD, 1990, CULT MED PSYCHIAT, V14, P59; Kohn L.T., 2000, TO ERR IS HUMAN BUIL; LAZARE A, 1989, OUTPATIENT PSYCHIAT, P157; Levinson W, 2000, JAMA-J AM MED ASSOC, V284, P1021, DOI 10.1001/jama.284.8.1021; Lo B, 1999, ANN INTERN MED, V130, P744, DOI 10.7326/0003-4819-130-9-199905040-00015; MATTHEWS DA, 1993, ANN INTERN MED, V118, P973, DOI 10.7326/0003-4819-118-12-199306150-00010; NIGHTINGALE SD, 1991, J GEN INTERN MED, V6, P420, DOI 10.1007/BF02598163; PLATT FW, 1994, J GEN INTERN MED, V9, P222, DOI 10.1007/BF02600129; Quill T, 1996, MIDWIFE DYING PROCES; QUILL TE, 1995, ANN INTERN MED, V122, P368, DOI 10.7326/0003-4819-122-5-199503010-00008; Quill TE, 2000, JAMA-J AM MED ASSOC, V284, P2502, DOI 10.1001/jama.284.19.2502; RIE MA, 1991, HASTINGS CENT REP, V21, P24, DOI 10.2307/3562997; ROTER DL, 1995, ARCH INTERN MED, V155, P1877, DOI 10.1001/archinte.155.17.1877; Suchman AL, 1997, JAMA-J AM MED ASSOC, V277, P678, DOI 10.1001/jama.277.8.678; [No title captured]; 1993, CONCISE OXFORD ENGLI	22	91	93	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	OCT 2	2001	135	7					551	555		10.7326/0003-4819-135-7-200110020-00022	http://dx.doi.org/10.7326/0003-4819-135-7-200110020-00022			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	477EF	11578166				2023-01-03	WOS:000171269600017
J	Tobin, MJ				Tobin, MJ			Medical progress - Advances in mechanical ventilation	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							RESPIRATORY-DISTRESS SYNDROME; END-EXPIRATORY PRESSURE; ACUTE LUNG INJURY; OBSTRUCTIVE PULMONARY-DISEASE; INTENSIVE-CARE UNIT; TIDAL VOLUME; PERMISSIVE HYPERCAPNIA; PRONE POSITION; ENDOTRACHEAL-TUBE; GAS-EXCHANGE		Edward Hines Jr Vet Affairs Hosp, Div Pulm & Crit Care Med, Hines, IL 60141 USA; Loyola Univ Chicago, Stritch Sch Med, Hines, IL USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); Edward Hines Jr. VA Hospital; Loyola University Chicago	Tobin, MJ (corresponding author), Edward Hines Jr Vet Affairs Hosp, Div Pulm & Crit Care Med, Rte 111N, Hines, IL 60141 USA.							Albert RK, 2000, AM J RESP CRIT CARE, V161, P1660, DOI 10.1164/ajrccm.161.5.9901037; AMATO MBP, 1995, AM J RESP CRIT CARE, V152, P1835, DOI 10.1164/ajrccm.152.6.8520744; Amato MBP, 1998, NEW ENGL J MED, V338, P347, DOI 10.1056/NEJM199802053380602; Anzueto A, 1997, CRIT CARE MED, V25, P1187, DOI 10.1097/00003246-199707000-00021; ARGIRAS EP, 1987, BRIT J ANAESTH, V59, P1278, DOI 10.1093/bja/59.10.1278; BROCHARD L, 1994, AM J RESP CRIT CARE, V150, P896, DOI 10.1164/ajrccm.150.4.7921460; BROCHARD L, 1991, ANESTHESIOLOGY, V75, P739, DOI 10.1097/00000542-199111000-00004; Brochard L, 1998, AM J RESP CRIT CARE, V158, P1831, DOI 10.1164/ajrccm.158.6.9801044; Brochard L, 1994, PRINCIPLES PRACTICE, P239; Brochard L., 1998, PRINCIPLES PRACTICE, P597; Brower RG, 1999, CRIT CARE MED, V27, P1492, DOI 10.1097/00003246-199908000-00015; Brower RG, 2000, NEW ENGL J MED, V342, P1301, DOI 10.1056/nejm200005043421801; Carney DE, 1999, AM J RESP CRIT CARE, V160, P1697, DOI 10.1164/ajrccm.160.5.9812031; Coplin WM, 2000, AM J RESP CRIT CARE, V161, P1530, DOI 10.1164/ajrccm.161.5.9905102; Dambrosio M, 1997, ANESTHESIOLOGY, V87, P495, DOI 10.1097/00000542-199709000-00007; Dreyfuss D, 1998, AM J RESP CRIT CARE, V157, P294, DOI 10.1164/ajrccm.157.1.9604014; Ely EW, 1996, NEW ENGL J MED, V335, P1864, DOI 10.1056/NEJM199612193352502; Epstein SK, 1997, CHEST, V112, P186, DOI 10.1378/chest.112.1.186; EPSTEIN SK, 1995, AM J RESP CRIT CARE, V152, P545, DOI 10.1164/ajrccm.152.2.7633705; Esteban A, 1999, AM J RESP CRIT CARE, V159, P512, DOI 10.1164/ajrccm.159.2.9803106; ESTEBAN A, 1995, NEW ENGL J MED, V332, P345, DOI 10.1056/NEJM199502093320601; Esteban A, 2000, AM J RESP CRIT CARE, V161, P1450, DOI 10.1164/ajrccm.161.5.9902018; Feihl F, 2000, AM J RESP CRIT CARE, V162, P209, DOI 10.1164/ajrccm.162.1.9907119; FEIHL F, 1994, AM J RESP CRIT CARE, V150, P1722, DOI 10.1164/ajrccm.150.6.7952641; GATTINONI L, 1991, ANESTHESIOLOGY, V74, P15, DOI 10.1097/00000542-199101000-00004; GATTINONI L, 1988, ANESTHESIOLOGY, V69, P824, DOI 10.1097/00000542-198812000-00005; Gattinoni L, 1998, AM J RESP CRIT CARE, V158, P3, DOI 10.1164/ajrccm.158.1.9708031; Giannouli E, 1999, AM J RESP CRIT CARE, V159, P1716, DOI 10.1164/ajrccm.159.6.9704025; Harris RS, 2000, AM J RESP CRIT CARE, V161, P432; Hickling KG, 1998, AM J RESP CRIT CARE, V158, P194, DOI 10.1164/ajrccm.158.1.9708049; HICKLING KG, 1990, INTENS CARE MED, V16, P372, DOI 10.1007/BF01735174; Hillberg RE, 1997, NEW ENGL J MED, V337, P1746, DOI 10.1056/NEJM199712113372407; HORTON WG, 1975, ARCH SURG-CHICAGO, V110, P395; Jacob B, 1997, CRIT CARE MED, V25, P253, DOI 10.1097/00003246-199702000-00010; Jaeschke RZ, 1997, CRIT CARE MED, V25, P1514, DOI 10.1097/00003246-199709000-00018; Jubran A, 1997, AM J RESP CRIT CARE, V155, P906, DOI 10.1164/ajrccm.155.3.9117025; Jubran A, 1998, AM J RESP CRIT CARE, V158, P1763, DOI 10.1164/ajrccm.158.6.9804056; JUBRAN A, 1995, AM J RESP CRIT CARE, V152, P129, DOI 10.1164/ajrccm.152.1.7599811; Jubran A, 1997, AM J RESP CRIT CARE, V155, P916, DOI 10.1164/ajrccm.155.3.9117026; KANAREK DJ, 1975, AM REV RESPIR DIS, V112, P457; LAGHI F, 1995, J APPL PHYSIOL, V79, P539, DOI 10.1152/jappl.1995.79.2.539; Laghi F, 1999, AM J RESP CRIT CARE, V160, P1766, DOI 10.1164/ajrccm.160.5.9810086; Leach CL, 1996, NEW ENGL J MED, V335, P761, DOI 10.1056/NEJM199609123351101; LEMAIRE F, 1988, ANESTHESIOLOGY, V69, P171, DOI 10.1097/00000542-198808000-00004; Leung P, 1997, AM J RESP CRIT CARE, V155, P1940, DOI 10.1164/ajrccm.155.6.9196100; Lichtwarck-Aschoff M, 2000, AM J RESP CRIT CARE, V162, P2125, DOI 10.1164/ajrccm.162.6.9910018; Lu Q, 1999, AM J RESP CRIT CARE, V159, P275, DOI 10.1164/ajrccm.159.1.9802082; Maldonado A, 2000, AM J RESP CRIT CARE, V161, P171, DOI 10.1164/ajrccm.161.1.9904080; MARINI JJ, 1985, CHEST, V87, P612, DOI 10.1378/chest.87.5.612; MARINI JJ, 1988, AM REV RESPIR DIS, V138, P1169, DOI 10.1164/ajrccm/138.5.1169; Martynowicz MA, 1999, AM J RESP CRIT CARE, V160, P250, DOI 10.1164/ajrccm.160.1.9808101; MEAD J, 1970, J APPL PHYSIOL, V28, P596, DOI 10.1152/jappl.1970.28.5.596; MEAD J, 1959, J APPL PHYSIOL, V14, P669, DOI 10.1152/jappl.1959.14.5.669; Mure M, 2000, J APPL PHYSIOL, V88, P1076, DOI 10.1152/jappl.2000.88.3.1076; MUTOH T, 1992, AM REV RESPIR DIS, V146, P300, DOI 10.1164/ajrccm/146.2.300; Nava S, 1998, ANN INTERN MED, V128, P721, DOI 10.7326/0003-4819-128-9-199805010-00004; Parthasarathy S, 1999, AM J RESP CRIT CARE, V159, P1023; Parthasarathy S, 2000, AM J RESP CRIT CARE, V162, P546, DOI 10.1164/ajrccm.162.2.9901024; Pelosi P, 1998, AM J RESP CRIT CARE, V157, P387, DOI 10.1164/ajrccm.157.2.97-04023; Pelosi P, 1999, AM J RESP CRIT CARE, V159, P872, DOI 10.1164/ajrccm.159.3.9802090; Pierson DJ, 1994, PRINCIPLES PRACTICE, P813; PUDDY A, 1992, AM REV RESPIR DIS, V146, P787, DOI 10.1164/ajrccm/146.3.787; Puybasset L, 1998, AM J RESP CRIT CARE, V158, P1644, DOI 10.1164/ajrccm.158.5.9802003; REID WD, 1994, J APPL PHYSIOL, V76, P176, DOI 10.1152/jappl.1994.76.1.176; Richecoeur J, 1999, AM J RESP CRIT CARE, V160, P77, DOI 10.1164/ajrccm.160.1.9809006; ROUBY JJ, 1993, INTENS CARE MED, V19, P383, DOI 10.1007/BF01724877; ROUPIE E, 1995, AM J RESP CRIT CARE, V152, P121, DOI 10.1164/ajrccm.152.1.7599810; SASSOON CSH, 1993, AM REV RESPIR DIS, V148, P860, DOI 10.1164/ajrccm/148.4_Pt_1.860; SASSOON CSH, 1995, INTENS CARE MED, V21, P159, DOI 10.1007/BF01726540; SASSOON CSH, 1994, PRINCIPLES PRACTICE, P221; Simon PM, 1999, AM J RESP CRIT CARE, V160, P950, DOI 10.1164/ajrccm.160.3.9712057; Sinderby C, 1999, NAT MED, V5, P1433, DOI 10.1038/71012; Stewart TE, 1998, NEW ENGL J MED, V338, P355, DOI 10.1056/NEJM199802053380603; Straus C, 1998, AM J RESP CRIT CARE, V157, P23, DOI 10.1164/ajrccm.157.1.96-10057; STROETZ RW, 1995, AM J RESP CRIT CARE, V152, P1034, DOI 10.1164/ajrccm.152.3.7663780; Tobin M J, 2000, Respir Care, V45, P417; TOBIN MJ, 1986, AM REV RESPIR DIS, V134, P1111; Tobin MJ, 2000, NEW ENGL J MED, V342, P1360, DOI 10.1056/NEJM200005043421808; TOBIN MJ, 1983, CHEST, V84, P202, DOI 10.1378/chest.84.2.202; TOBIN MJ, 1994, NEW ENGL J MED, V330, P1056, DOI 10.1056/NEJM199404143301507; Tobin MJ, 1994, PRINCIPLES PRACTICE, P1177; Tremblay L, 1997, J CLIN INVEST, V99, P944, DOI 10.1172/JCI119259; Vallverdu I, 1998, AM J RESP CRIT CARE, V158, P1855, DOI 10.1164/ajrccm.158.6.9712135; Vieira SRR, 1998, AM J RESP CRIT CARE, V158, P1571, DOI 10.1164/ajrccm.158.5.9802101; Vieira SRR, 1999, AM J RESP CRIT CARE, V159, P1612, DOI 10.1164/ajrccm.159.5.9805112; WEBB HH, 1974, AM REV RESPIR DIS, V110, P556; YANG KL, 1991, NEW ENGL J MED, V324, P1445, DOI 10.1056/NEJM199105233242101	87	256	283	0	9	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUN 28	2001	344	26					1986	1996		10.1056/NEJM200106283442606	http://dx.doi.org/10.1056/NEJM200106283442606			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	446HQ	11430329				2023-01-03	WOS:000169508200006
J	Georgoulias, V; Papadakis, E; Alexopoulos, A; Tsiafaki, X; Rapti, A; Veslemes, M; Palamidas, P; Vlachonikolis, I				Georgoulias, V; Papadakis, E; Alexopoulos, A; Tsiafaki, X; Rapti, A; Veslemes, M; Palamidas, P; Vlachonikolis, I		Greek Oncology Cooperative Grp Lun	Platinum-based and non-platinum-based chemotherapy in advanced non-small-cell lung cancer: a randomised multicentre trial	LANCET			English	Article							PHASE-II TRIAL; CISPLATIN; DOCETAXEL; GEMCITABINE; ETOPOSIDE; VINDESINE		Univ Gen Hosp Heraklion, Dept Med Oncol, Iraklion 71110, Crete, Greece; Sotiria Gen Hosp, Dept Pulm Dis 1, Athens, Greece; Sotiria Gen Hosp, Dept Pulm Dis 3, Athens, Greece; Agios Savas Canc Hosp, Dept Med Oncol 1, Athens, Greece; Sismanoglion Gen Hosp, Dept Pulm Dis 2, Athens, Greece; Sismanoglion Gen Hosp, Dept Pulm Dis 3, Athens, Greece; Univ Athens, Dept Pulm Dis, Sotiria Gen Hosp, GR-10679 Athens, Greece; Univ Crete, Sch Med, Dept Biostat, Iraklion, Greece	University Hospital of Heraklion; National & Kapodistrian University of Athens; University of Crete	Georgoulias, V (corresponding author), Univ Gen Hosp Heraklion, Dept Med Oncol, POB 1352, Iraklion 71110, Crete, Greece.	georgsec@med.uch.gr						ABBRATT RP, 1994, J CLIN ONCOL, V12, P1821; ALBAIN KS, 1991, J CLIN ONCOL, V9, P1618, DOI 10.1200/JCO.1991.9.9.1618; ALBERTI W, 1995, BRIT MED J, V311, P899; Altman G., 1991, PRACTICAL STAT MED R; Anton A, 1998, LUNG CANCER-J IASLC, V22, P139, DOI 10.1016/S0169-5002(98)00069-5; Armitage P., 1994, STAT METHODS MED RES; Collett D., 1994, MODELLING SURVIVAL D; Cox D.R., 1989, CONCISE ENCY STAT; FEIGAL EG, 1993, SEMIN ONCOL, V20, P185; FOSSELLA FV, 1994, J CLIN ONCOL, V12, P1238, DOI 10.1200/JCO.1994.12.6.1238; Gatzemeier U, 1996, EUR J CANCER, V32A, P243, DOI 10.1016/0959-8049(95)00444-0; GATZEMEIER U, 1991, AM J CLIN ONCOL-CANC, V14, P405, DOI 10.1097/00000421-199110000-00009; Georgoulias V, 1998, ANN ONCOL, V9, P331, DOI 10.1023/A:1008278103446; Georgoulias V, 1999, J CLIN ONCOL, V17, P914, DOI 10.1200/JCO.1999.17.3.914; Gridelli C, 1996, ANN ONCOL, V7, P821; Koo HM, 1999, CANCER RES, V59, P6057; KOSMIDIS PA, 2000, P AN M AM SOC CLIN, V19, P488; Lippe P, 1999, ANN ONCOL, V10, P217, DOI 10.1023/A:1008323604269; LUEDKE DW, 1990, J CLIN ONCOL, V8, P886, DOI 10.1200/JCO.1990.8.5.886; MILLER AB, 1981, CANCER, V47, P207, DOI 10.1002/1097-0142(19810101)47:1<207::AID-CNCR2820470134>3.0.CO;2-6; MILLER VA, 1995, CANCER-AM CANCER SOC, V75, P968, DOI 10.1002/1097-0142(19950215)75:4<968::AID-CNCR2820750411>3.0.CO;2-Y; Rizvi NA, 1999, SEMIN ONCOL, V26, P27; RODENHUIS S, 1988, CANCER RES, V48, P5738; SKLAR MD, 1988, CANCER RES, V48, P793; SOUQUET PJ, 1993, LANCET, V342, P19; Yamamoto N, 2000, ANN ONCOL, V11, P107; Zalcberg J, 1998, J CLIN ONCOL, V16, P1948, DOI 10.1200/JCO.1998.16.5.1948	27	287	295	0	8	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	MAY 12	2001	357	9267					1478	1484		10.1016/S0140-6736(00)04644-4	http://dx.doi.org/10.1016/S0140-6736(00)04644-4			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	431CL	11377599				2023-01-03	WOS:000168614300011
J	Cook, DM				Cook, DM			Shouldn't adults with growth hormone deficiency be offered growth hormone replacement therapy?	ANNALS OF INTERNAL MEDICINE			English	Article							RECOMBINANT HUMAN GH; HYPOPITUITARY ADULTS; SERUM-LIPIDS; CANCER RISK; FACTOR-I; MORTALITY; MEN; LIPOPROTEINS; INCREASES; SEVERITY	Growth hormone as therapy for adults with growth hormone deficiency has not been universally accepted by endocrinologists who treat adult patients. The following are addressed in this commentary: the evidence on safety and efficacy in the literature supporting the idea that growth hormone should be offered as replacement therapy to adults who are growth hormone deficient; common concerns of the average prescribing endocrinologist, including the purported association between insulin-like growth factor-I and malignant neoplasms and quality-of-life issues with long-term therapy; and controversial subjects, such as differences in dosing for adults versus children and diagnostic issues. This analysis should encourage reluctant practitioners to at least consider growth hormone replacement therapy for patients with definite growth hormone deficiency-that is, patients with symptomatic panhypopituitarism.	Oregon Hlth & Sci Univ, Portland, OR 97201 USA	Oregon Health & Science University	Cook, DM (corresponding author), Oregon Hlth & Sci Univ, 3181 SW Sam Jackson Pk Rd,L607, Portland, OR 97201 USA.	cookd@ohsu.edu						Attanasio A, 1998, J CLIN ENDOCR METAB, V83, P379; Bates AS, 1996, J CLIN ENDOCR METAB, V81, P1169, DOI 10.1210/jc.81.3.1169; BATES AS, 1997, J ENDOCRINOL S, V152; BENGTSSON BA, 1993, J CLIN ENDOCR METAB, V76, P309, DOI 10.1210/jc.76.2.309; BENGTSSON BA, 1999, ENDO 1999 C CLIN OR; BESHYAH SA, 1995, J CLIN ENDOCR METAB, V80, P356, DOI 10.1210/jc.80.2.356; Bulow B, 1997, CLIN ENDOCRINOL, V46, P75, DOI 10.1046/j.1365-2265.1997.d01-1749.x; BURMAN P, 1995, J CLIN ENDOCR METAB, V80, P3585, DOI 10.1210/jc.80.12.3585; Capaldo B, 1997, J CLIN ENDOCR METAB, V82, P1378, DOI 10.1210/jc.82.5.1378; Carroll PV, 1998, J CLIN ENDOCR METAB, V83, P382, DOI 10.1210/jc.83.2.382; Chan JM, 1998, SCIENCE, V279, P563, DOI 10.1126/science.279.5350.563; Colao A, 1999, J CLIN ENDOCR METAB, V84, P1919, DOI 10.1210/jc.84.6.1919; Cook DM, 1999, J CLIN ENDOCR METAB, V84, P3956, DOI 10.1210/jc.84.11.3956; CUNEO RC, 1993, METABOLISM, V42, P1519, DOI 10.1016/0026-0495(93)90145-E; Drake WM, 1998, J CLIN ENDOCR METAB, V83, P3913, DOI 10.1210/jc.83.11.3913; EDEN S, 1993, ARTERIOSCLER THROMB, V13, P296, DOI 10.1161/01.ATV.13.2.296; EDWARDS CK, 1991, P NATL ACAD SCI USA, V88, P2274, DOI 10.1073/pnas.88.6.2274; EDWARDS CK, 1988, SCIENCE, V239, P769, DOI 10.1126/science.2829357; Gibney J, 1999, J CLIN ENDOCR METAB, V84, P2596, DOI 10.1210/jc.84.8.2596; Hankinson SE, 1998, LANCET, V351, P1393, DOI 10.1016/S0140-6736(97)10384-1; Hansen TB, 1995, CLIN ENDOCRINOL, V43, P689, DOI 10.1111/j.1365-2265.1995.tb00536.x; Hartman ML, 2002, J CLIN ENDOCR METAB, V87, P477, DOI 10.1210/jc.87.2.477; HOLMES SJ, 1995, CLIN ENDOCRINOL, V43, P151, DOI 10.1111/j.1365-2265.1995.tb01909.x; HOLMES SJ, 1994, J CLIN ENDOCR METAB, V78, P669, DOI 10.1210/jc.78.3.669; Johannsson G, 1996, J CLIN ENDOCR METAB, V81, P2865, DOI 10.1210/jc.81.8.2865; Johannsson G, 1997, J CLIN ENDOCR METAB, V82, P2877, DOI 10.1210/jc.82.9.2877; Johannsson G, 1996, J CLIN ENDOCR METAB, V81, P1575, DOI 10.1210/jc.81.4.1575; Johannsson G, 1999, J CLIN ENDOCR METAB, V84, P4516, DOI 10.1210/jc.84.12.4516; JOHANSSON JO, 1995, NEUROENDOCRINOLOGY, V61, P57, DOI 10.1159/000126813; KIESS W, 1986, NEW ENGL J MED, V314, P321; Ma J, 1999, J NATL CANCER I, V91, P620, DOI 10.1093/jnci/91.7.620; MARKUSSIS V, 1992, LANCET, V340, P1188, DOI 10.1016/0140-6736(92)92892-J; NASS R, 1995, J CLIN ENDOCR METAB, V80, P552, DOI 10.1210/jc.80.2.552; Nishi Y, 1999, J CLIN ENDOCR METAB, V84, P1961, DOI 10.1210/jc.84.6.1961; Orme SM, 1998, J CLIN ENDOCR METAB, V83, P2730, DOI 10.1210/jc.83.8.2730; Pfeifer M, 1999, J CLIN ENDOCR METAB, V84, P453, DOI 10.1210/jc.84.2.453; Rosen T, 1997, EUR J ENDOCRINOL, V137, P240, DOI 10.1530/eje.0.1370240; ROSEN T, 1990, LANCET, V336, P285, DOI 10.1016/0140-6736(90)91812-O; Russell RGG, 1999, BONE, V25, P97, DOI 10.1016/S8756-3282(99)00116-7; RUSSELLJONES DL, 1994, CLIN ENDOCRINOL, V41, P345, DOI 10.1111/j.1365-2265.1994.tb02555.x; Serri O, 1999, J CLIN ENDOCR METAB, V84, P58, DOI 10.1210/jc.84.1.58; Sesmilo G, 2000, ANN INTERN MED, V133, P111, DOI 10.7326/0003-4819-133-2-200007180-00010; Takala J, 1999, NEW ENGL J MED, V341, P785, DOI 10.1056/NEJM199909093411102; Ter Maaten JC, 1999, J CLIN ENDOCR METAB, V84, P2373, DOI 10.1210/jc.84.7.2373; TOMLINSON JW, 2000, BRIT END SOC EUR FED; TOOGOOD AA, 1994, CLIN ENDOCRINOL, V41, P511, DOI 10.1111/j.1365-2265.1994.tb02583.x; Verhelst J, 1997, CLIN ENDOCRINOL, V47, P485, DOI 10.1046/j.1365-2265.1997.3041112.x	47	14	16	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	AUG 6	2002	137	3					197	201		10.7326/0003-4819-137-3-200208060-00012	http://dx.doi.org/10.7326/0003-4819-137-3-200208060-00012			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	580XP	12160368				2023-01-03	WOS:000177262300007
J	Ravdin, P				Ravdin, P			Aromatase inhibitors for the endocrine adjuvant treatment of breast cancer	LANCET			English	Editorial Material							BOWEL-PROJECT P-1; TAMOXIFEN; PREVENTION; THERAPY		Univ Texas, Hlth Sci Ctr, Dept Med Oncol, San Antonio, TX USA	University of Texas System; University of Texas Health San Antonio	Ravdin, P (corresponding author), Univ Texas, Hlth Sci Ctr, Dept Med Oncol, San Antonio, TX USA.							Clarke M, 1998, LANCET, V351, P1451; Day R, 1999, J CLIN ONCOL, V17, P2659, DOI 10.1200/JCO.1999.17.9.2659; DUFFY SR, 2002, P ASCO, V21; Ellis MJ, 2001, J CLIN ONCOL, V19, P3808, DOI 10.1200/JCO.2001.19.18.3808; FALLOWFIELD L, 2002, P AN M AM SOC CLIN, V21, P159; Fisher B, 1998, J NATL CANCER I, V90, P1371, DOI 10.1093/jnci/90.18.1371; Osborne CK, 1998, NEW ENGL J MED, V339, P1609, DOI 10.1056/NEJM199811263392207; RAVDIN PM, 1992, J CLIN ONCOL, V10, P1284, DOI 10.1200/JCO.1992.10.8.1284; WINER E, 2002, AM SOC CLIN ONCOLOGY	9	9	11	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUN 22	2002	359	9324					2126	2127		10.1016/S0140-6736(02)09111-0	http://dx.doi.org/10.1016/S0140-6736(02)09111-0			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	566RJ	12090973				2023-01-03	WOS:000176441800002
J	Lam, M; Oleinick, NL; Nieminen, AL				Lam, M; Oleinick, NL; Nieminen, AL			Photodynamic therapy-induced apoptosis in epidermoid carcinoma cells - Reactive oxygen species and mitochondrial inner membrane permeabilization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOCHROME-C; TRANSITION PORE; CYCLOSPORINE-A; LETHAL INJURY; RELEASE; LOCALIZATION; HEPATOCYTES; DEATH; ACTIVATION; INHIBITION	Photodynamic therapy (PDT), a novel and promising cancer treatment that employs a combination of a photosensitizing chemical and visible light, induces apoptosis in human epidermoid carcinoma A431 cells. However, the precise mechanism of PDT-induced apoptosis is not well characterized. To dissect the pathways of PDT-induced apoptosis, we investigated the involvement of mitochondrial damage by examining a second generation photosensitizer, the silicon phthalocyanine 4 (Pc 4). By using laser-scanning confocal microscopy, we found that Pc 4 localized to cytosolic membranes primarily, but not exclusively, in mitochondria. Formation of mitochondrial reactive oxygen species (ROS) was detected within minutes when cells were exposed to Pc 4 and 670-675 nm light. This was followed by mitochondrial inner membrane permeabilization, depolarization and swelling, cytochrome c release, and apoptotic death. Desferrioxamine prevented mitochondrial ROS production and the events thereafter. Cyclosporin A plus trifluoperazine, blockers of the mitochondrial permeability transition, inhibited mitochondrial inner membrane permeabilization and depolarization without affecting mitochondrial ROS generation. These data indicate that the mitochondrial ROS are critical in initiating mitochondrial inner membrane permeabilization, which leads to mitochondrial swelling, cytochrome c release to the cytosol, and apoptotic death during PDT with Pc 4.	Case Western Reserve Univ, Sch Med, Dept Anat, Cleveland, OH 44106 USA; Case Western Reserve Univ, Sch Med, Dept Radiat Oncol, Cleveland, OH 44106 USA	Case Western Reserve University; Case Western Reserve University	Nieminen, AL (corresponding author), Case Western Reserve Univ, Sch Med, Dept Anat, W520,10900 Euclid Ave, Cleveland, OH 44106 USA.	axn25@po.cwru.edu			NCI NIH HHS [T32 CA 59366] Funding Source: Medline; NATIONAL CANCER INSTITUTE [T32CA059366] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AGARWAL ML, 1993, CANCER RES, V53, P5897; AGARWAL ML, 1991, CANCER RES, V51, P5993; BERG K, 1994, INT J CANCER, V59, P814, DOI 10.1002/ijc.2910590618; BERNARDI P, 1994, J BIOENERG BIOMEMBR, V26, P509, DOI 10.1007/BF00762735; Bernardi P, 1999, EUR J BIOCHEM, V264, P687, DOI 10.1046/j.1432-1327.1999.00725.x; Bradham CA, 1998, MOL CELL BIOL, V18, P6353, DOI 10.1128/MCB.18.11.6353; Broekemeier KM, 1995, BIOCHEMISTRY-US, V34, P16440, DOI 10.1021/bi00050a027; Chen JY, 2000, PHOTOCHEM PHOTOBIOL, V72, P541, DOI 10.1562/0031-8655(2000)072<0541:TBCAIL>2.0.CO;2; Chernyak BV, 1996, EUR J BIOCHEM, V238, P623, DOI 10.1111/j.1432-1033.1996.0623w.x; Chiu SM, 2001, CANCER LETT, V165, P51, DOI 10.1016/S0304-3835(01)00422-0; DAWSON TL, 1993, AM J PHYSIOL, V264, pC961, DOI 10.1152/ajpcell.1993.264.4.C961; DOUGHERTY TJ, 1992, EUR J CANCER, V28A, P1734, DOI 10.1016/0959-8049(92)90080-L; Dougherty TJ, 1998, JNCI-J NATL CANCER I, V90, P889, DOI 10.1093/jnci/90.12.889; EMAUS RK, 1986, BIOCHIM BIOPHYS ACTA, V850, P436, DOI 10.1016/0005-2728(86)90112-X; Goldstein JC, 2000, NAT CELL BIOL, V2, P156, DOI 10.1038/35004029; Hatano E, 2000, J BIOL CHEM, V275, P11814, DOI 10.1074/jbc.275.16.11814; HAWORTH RA, 1979, ARCH BIOCHEM BIOPHYS, V195, P460, DOI 10.1016/0003-9861(79)90372-2; He J, 1997, PHOTOCHEM PHOTOBIOL, V65, P581; HE XY, 1994, PHOTOCHEM PHOTOBIOL, V59, P468, DOI 10.1111/j.1751-1097.1994.tb05066.x; HENDERSON BW, 1992, PHOTOCHEM PHOTOBIOL, V55, P145, DOI 10.1111/j.1751-1097.1992.tb04222.x; HUNTER DR, 1979, ARCH BIOCHEM BIOPHYS, V195, P453, DOI 10.1016/0003-9861(79)90371-0; HUNTER DR, 1979, ARCH BIOCHEM BIOPHYS, V195, P468, DOI 10.1016/0003-9861(79)90373-4; IMBERTI R, 1993, J PHARMACOL EXP THER, V265, P392; JOHNSON LV, 1980, P NATL ACAD SCI-BIOL, V77, P990, DOI 10.1073/pnas.77.2.990; Kessel D, 1999, CELL DEATH DIFFER, V6, P28, DOI 10.1038/sj.cdd.4400446; Kessel D, 1998, J PHOTOCH PHOTOBIO B, V42, P89, DOI 10.1016/S1011-1344(97)00127-9; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; Kowaltowski AJ, 1996, J BIOL CHEM, V271, P2929, DOI 10.1074/jbc.271.6.2929; Kroemer G, 1997, IMMUNOL TODAY, V18, P44, DOI 10.1016/S0167-5699(97)80014-X; Lam M, 1998, J BIOL CHEM, V273, P17307, DOI 10.1074/jbc.273.28.17307; Lemasters JJ, 1999, BIOCHEM SOC SYMP, V66, P205, DOI 10.1042/bss0660205; Lemasters JJ, 1998, BIOFACTORS, V8, P283, DOI 10.1002/biof.5520080316; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; Luo Y, 1996, PHOTOCHEM PHOTOBIOL, V63, P528, DOI 10.1111/j.1751-1097.1996.tb03079.x; MOAN J, 1992, PHOTOCHEM PHOTOBIOL, V55, P931, DOI 10.1111/j.1751-1097.1992.tb08541.x; MOAN J, 1991, PHOTOCHEM PHOTOBIOL, V53, P549, DOI 10.1111/j.1751-1097.1991.tb03669.x; Nieminen AL, 1996, NEUROSCIENCE, V75, P993; NIEMINEN AL, 1995, BIOCHEM J, V307, P99, DOI 10.1042/bj3070099; Nieminen AL, 1997, AM J PHYSIOL-CELL PH, V272, pC1286; Oleinick NL, 1998, RADIAT RES, V150, pS146, DOI 10.2307/3579816; Petit PX, 1998, FEBS LETT, V426, P111, DOI 10.1016/S0014-5793(98)00318-4; Petronilli V, 1999, BIOPHYS J, V76, P725, DOI 10.1016/S0006-3495(99)77239-5; PETRONILLI V, 1994, J BIOL CHEM, V269, P16638; POHFITZPATRICK MB, 1986, PHOTODERMATOLOGY, V3, P148; Reed JC, 1997, CELL, V91, P559, DOI 10.1016/S0092-8674(00)80442-0; RICCHELLI F, 1995, EUR J BIOCHEM, V233, P165, DOI 10.1111/j.1432-1033.1995.165_1.x; Ricchelli F, 1999, BIOCHEMISTRY-US, V38, P9295, DOI 10.1021/bi9900828; Scorrano L, 1999, J BIOL CHEM, V274, P24657, DOI 10.1074/jbc.274.35.24657; Scorrano L, 1999, J BIOL CHEM, V274, P22581, DOI 10.1074/jbc.274.32.22581; Susin SA, 1999, NATURE, V397, P441, DOI 10.1038/17135; Susin SA, 1996, J EXP MED, V184, P1331, DOI 10.1084/jem.184.4.1331; Taguchi H, 1996, INVEST OPHTH VIS SCI, V37, P1444; Trivedi NS, 2000, PHOTOCHEM PHOTOBIOL, V71, P634, DOI 10.1562/0031-8655(2000)071<0634:QAOPLI>2.0.CO;2; Varnes ME, 1999, BIOCHEM BIOPH RES CO, V255, P673, DOI 10.1006/bbrc.1999.0261; Xue LY, 1999, ONCOGENE, V18, P3391, DOI 10.1038/sj.onc.1202687; Xue LY, 2001, ONCOGENE, V20, P3420, DOI 10.1038/sj.onc.1204441; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129; Zou H, 1997, CELL, V90, P405, DOI 10.1016/S0092-8674(00)80501-2	58	258	281	1	48	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 14	2001	276	50					47379	47386		10.1074/jbc.M107678200	http://dx.doi.org/10.1074/jbc.M107678200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	502XR	11579101	hybrid			2023-01-03	WOS:000172768500093
J	Zhen, CL; Sangl, J; Bierman, AS; Miller, MR; Friedman, B; Wickizer, SW; Meyer, GS				Zhen, CL; Sangl, J; Bierman, AS; Miller, MR; Friedman, B; Wickizer, SW; Meyer, GS			Potentially inappropriate medication use in the community-dwelling elderly - Findings from the 1996 Medical Expenditure Panel Survey	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article; Proceedings Paper	Annual Meeting of the Gerontological-Society-of-America	NOV, 2000	WASHINGTON, D.C.	Gerontol Soc Amer			EXPLICIT CRITERIA; NURSING-HOMES; FACILITIES; RESIDENTS	Context Inappropriate medication use is a major patient safety concerr, especially for the elderly population. Using explicit criteria, prior studies have found that 23.5% and 17.5% of the US community-dwelling elderly population used at least 1 of 20 potentially inappropriate medications in 1987 and 1992, respectively. Objectives To determine the prevalence of potentially inappropriate medication use in community-dwelling elderly persons in 1996, to assess trends over 10 years, categorize inappropriate medication use according to explicit criteria, and to examine risk factors for inappropriate medication use. Design, Setting, and Participants Respondents aged 65 years or older (n=2455) to the 1996 Medical Expenditure Panel Survey, a nationally representative survey of the US noninstitutionalized population were included. A 7-member expert panel was convened to categorize inappropriate medications. Main Outcome Measure Prevalence of use of 33 potentially inappropriate medications. Results In 1996, 21.3% (95% confidence interval [CI], 19.5%-23.1%)of community-dwelling elderly patients in the United States received at least 1 of 33 potentially inappropriate medications. Using the expert panel's classifications, about 2.6% of elderly patients (95% Cl, 2.0%-3.2%) used at least 1 of the 11 medications that should always be avoided by elderly patients; 9.1% (95% Cl, 7.9%-10.3%) used at least 1 cf the 8 that would rarely be appropriate; and 13.3% (95% Cl, 11.7%-14.9%) used at least 1 of the 14 medications that have some indications but are often misused. Use of some inappropriate medications declined between 1987 and 1996. Persons with poor health and more prescriptions had a significantly higher risk of inappropriate medication use. Conclusions Overall inappropriate medication use in elderly patients remains a serious problem. Despite challenges in using explicit criteria for assessing inappropriate medications for elderly patients, such criteria can be applied to population-based surveys to identify opportunities to improve quality of care and patient safety. Enhancements of existing data sources to include dosage, duration, and indication may augment national improvement and monitoring efforts.	Agcy Healthcare Res & Qual, Ctr Qual Improvement & Patient Safety, Rockville, MD 20852 USA; Johns Hopkins Univ, Dept Pediat, Baltimore, MD 21218 USA; Univ Rochester, Dept Community & Prevent Med, Rochester, NY USA	Agency for Healthcare Research & Quality; Johns Hopkins University; University of Rochester	Zhen, CL (corresponding author), Agcy Healthcare Res & Qual, Ctr Qual Improvement & Patient Safety, 6011 Execut Blvd,Suite 200, Rockville, MD 20852 USA.							Anderson G M, 1997, J Eval Clin Pract, V3, P283, DOI 10.1046/j.1365-2753.1997.t01-1-00005.x; Aparasu RR, 1997, ANN PHARMACOTHER, V31, P823, DOI 10.1177/106002809703100702; Aparasu RR, 1999, AM J HEALTH-SYST PH, V56, P433, DOI 10.1093/ajhp/56.5.433; BEERS MH, 1991, ARCH INTERN MED, V151, P1825; Beers MH, 1997, ARCH INTERN MED, V157, P1531, DOI 10.1001/archinte.157.14.1531; BEERS MH, 1992, ANN INTERN MED, V117, P684, DOI 10.7326/0003-4819-117-8-684; Blazer D, 2000, J AM GERIATR SOC, V48, P1073, DOI 10.1111/j.1532-5415.2000.tb04782.x; Cantrill JA, 2011, INT J PHARM PRACT, V4, P67, DOI DOI 10.1111/J.2042-7174.1996.TB00844.X; COBBS E, 1999, GERIATRICS REV SYLLA, P120; COHEN SB, 1997, 2 MEPS AG HEALTHC RE; Golden AG, 1999, J AM GERIATR SOC, V47, P948, DOI 10.1111/j.1532-5415.1999.tb01289.x; GOSNEY M, 1984, LANCET, V2, P564; GURWITZ JH, 1994, JAMA-J AM MED ASSOC, V272, P316, DOI 10.1001/jama.272.4.316; Hanlon JT, 2001, J AM GERIATR SOC, V49, P200, DOI 10.1046/j.1532-5415.2001.49042.x; *I MED, 1999, ERR IS HUM BUILD SAF; LEDERLE FA, 1993, ARCH INTERN MED, V153, P705, DOI 10.1001/archinte.153.6.705; LINDLEY CM, 1992, AGE AGEING, V21, P294, DOI 10.1093/ageing/21.4.294; McLeod PJ, 1997, CAN MED ASSOC J, V156, P385; MOELLER JF, 2001, HC010A AG HEALTHC RE; Monane M, 1998, JAMA-J AM MED ASSOC, V280, P1249, DOI 10.1001/jama.280.14.1249; Mort JR, 2000, ARCH INTERN MED, V160, P2825, DOI 10.1001/archinte.160.18.2825; Nash DB., 2000, WHY ELDERLY NEED IND; Newcomer LN, 2000, HEALTH AFFAIR, V19, P59, DOI 10.1377/hlthaff.19.2.59; RAY WA, 1980, AM J PUBLIC HEALTH, V70, P485, DOI 10.2105/AJPH.70.5.485; Rothschild JM, 2000, ARCH INTERN MED, V160, P2717, DOI 10.1001/archinte.160.18.2717; Spore DL, 1997, AM J PUBLIC HEALTH, V87, P404, DOI 10.2105/AJPH.87.3.404; *US GAO, 1995, PRESCR DRUGS ELD MAN; WILLCOX SM, 1994, JAMA-J AM MED ASSOC, V272, P292, DOI 10.1001/jama.272.4.292; WILLIAMS B, 1995, J AM GERIATR SOC, V43, P513, DOI 10.1111/j.1532-5415.1995.tb06098.x	29	151	156	1	6	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 12	2001	286	22					2823	2829		10.1001/jama.286.22.2823	http://dx.doi.org/10.1001/jama.286.22.2823			7	Medicine, General & Internal	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	500YC	11735757	Bronze			2023-01-03	WOS:000172655400030
J	Richardson, TP; Peters, MC; Ennett, AB; Mooney, DJ				Richardson, TP; Peters, MC; Ennett, AB; Mooney, DJ			Polymeric system for dual growth factor delivery	NATURE BIOTECHNOLOGY			English	Article							ANGIOGENESIS; RELEASE; MECHANISMS; SCAFFOLDS; PROTEINS; ACID)	The development of tissues and organs is typically driven by the action of a number of growth factors. However, efforts to regenerate tissues (e.g., bone, blood vessels) typically rely on the delivery of single factors, and this may partially explain the limited clinical utility of many current approaches. One constraint on delivering appropriate combinations of factors is a lack of delivery vehicles that allow for a localized and controlled delivery of more than a single factor. We report a new polymeric system that allows for the tissue-specific delivery of two or more growth factors, with controlled dose and rate of delivery. The utility of this system was investigated in the context of therapeutic angiogenesis. We now demonstrate that dual delivery of vascular endothelial growth factor (VEGF)-165 and platelet-derived growth factor (PDGF)-BB, each with distinct kinetics, from a single, structural polymer scaffold results in the rapid formation of a mature vascular network. This is the first report of a vehicle capable of delivery of multiple angiogenic factors with distinct kinetics, and these results clearly indicate the importance of multiple growth factor action in tissue regeneration and engineering.	Univ Michigan, Dept Biomed Engn, Ann Arbor, MI 48109 USA; Univ Michigan, Dept Biol & Mat Sci, Ann Arbor, MI 48109 USA; Univ Michigan, Dept Chem Engn, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	Mooney, DJ (corresponding author), Univ Michigan, Dept Biomed Engn, Ann Arbor, MI 48109 USA.	mooneyd@umich.edu		Mooney, David/0000-0001-6299-1194	NIDCR NIH HHS [R01 DE 13033, T32 DE 07057] Funding Source: Medline; NIGMS NIH HHS [T32 GM08353] Funding Source: Medline; NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [R01DE013033, T32DE007057] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008353] Funding Source: NIH RePORTER	NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Baumgartner I, 1998, CIRCULATION, V97, P1114, DOI 10.1161/01.CIR.97.12.1114; Benjamin LE, 1999, J CLIN INVEST, V103, P159, DOI 10.1172/JCI5028; Benjamin LE, 1998, DEVELOPMENT, V125, P1591; Carmeliet P, 2000, NAT MED, V6, P389, DOI 10.1038/74651; COHEN S, 1991, PHARMACEUT RES, V8, P713, DOI 10.1023/A:1015841715384; Darland DC, 1999, J CLIN INVEST, V103, P157, DOI 10.1172/JCI6127; EDELMAN ER, 1991, BIOMATERIALS, V12, P619, DOI 10.1016/0142-9612(91)90107-L; Folkman J, 1996, CELL, V87, P1153, DOI 10.1016/S0092-8674(00)81810-3; GOMBOTZ WR, 1995, BIOCONJUGATE CHEM, V6, P332, DOI 10.1021/bc00034a002; Hendel RC, 2000, CIRCULATION, V101, P118, DOI 10.1161/01.CIR.101.2.118; Kuo PYP, 1996, CRIT REV EUKAR GENE, V6, P59, DOI 10.1615/CritRevEukarGeneExpr.v6.i1.40; Langer R, 1998, NATURE, V392, P5; Lee KY, 2000, NATURE, V408, P998, DOI 10.1038/35050141; Luo D, 2000, NAT BIOTECHNOL, V18, P33, DOI 10.1038/71889; Mahoney MJ, 1999, P NATL ACAD SCI USA, V96, P4536, DOI 10.1073/pnas.96.8.4536; Maisonpierre PC, 1997, SCIENCE, V277, P55, DOI 10.1126/science.277.5322.55; Mooney DJ, 1996, BIOMATERIALS, V17, P1417, DOI 10.1016/0142-9612(96)87284-X; Murphy WL, 2000, BIOMATERIALS, V21, P2521, DOI 10.1016/S0142-9612(00)00120-4; MURRAY J, 1984, CANC DRUG DEL, V1, P119, DOI 10.1089/cdd.1984.1.119; Nor JE, 1999, AM J PATHOL, V154, P375, DOI 10.1016/S0002-9440(10)65284-4; Reddi AH, 1998, NAT BIOTECHNOL, V16, P247, DOI 10.1038/nbt0398-247; RICHARDSON TP, 2001, METHODS TISSUE ENG, P653; Risau W, 1997, NATURE, V386, P671, DOI 10.1038/386671a0; Rivard A, 1999, AM J PATHOL, V154, P355, DOI 10.1016/S0002-9440(10)65282-0; Shea LD, 1999, NAT BIOTECHNOL, V17, P551, DOI 10.1038/9853; Sheridan MH, 2000, J CONTROL RELEASE, V64, P91, DOI 10.1016/S0168-3659(99)00138-8; Simons M, 2000, CIRCULATION, V102, pE73, DOI 10.1161/01.CIR.102.11.e73; TAKESHITA S, 1994, CIRCULATION, V90, P228; TAKESHITA S, 1994, J CLIN INVEST, V93, P662, DOI 10.1172/JCI117018; Thurston G, 2000, NAT MED, V6, P460, DOI 10.1038/74725; Weissman IL, 2000, SCIENCE, V287, P1442, DOI 10.1126/science.287.5457.1442; Yancopoulos GD, 2000, NATURE, V407, P242, DOI 10.1038/35025215; Yancopoulos GD, 1998, CELL, V93, P661, DOI 10.1016/S0092-8674(00)81426-9	33	1408	1531	6	336	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	NOV	2001	19	11					1029	1034		10.1038/nbt1101-1029	http://dx.doi.org/10.1038/nbt1101-1029			6	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	489QH	11689847				2023-01-03	WOS:000172002600017
J	Nelsestuen, GL; Stone, M; Martinez, MB; Harvey, SB; Foster, D; Kisiel, W				Nelsestuen, GL; Stone, M; Martinez, MB; Harvey, SB; Foster, D; Kisiel, W			Elevated function of blood clotting factor VIIa mutants that have enhanced affinity for membranes - Behavior in a diffusion-limited reaction	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI PERIPLASM; K-DEPENDENT PROTEINS; TISSUE FACTOR; FACTOR-X; ALKALINE-PHOSPHATASE; ACTIVATION; BINDING; ENZYME; PROTHROMBIN; SITE	Blood clotting factor VIIa is involved in the first step of the blood coagulation cascade, as a membrane-associated enzyme in complex with tissue factor (TF). Factor VIIa is also an important therapeutic agent for hemophilia where its function may include TF-independent as well as TF-dependent mechanisms. This study compared the activity of wild type factor VIIa (WT-VIIa) with that of a mutant with elevated affinity for membrane (P10Q/Q32E, QE-VIIa). Phospholipid and cell-based assays showed the mutant to have up to 40-fold higher function than WT-VIIa in both TF-dependent and TF-independent reactions. Tissue factor-dependent reactions displayed the maximum enhancement when binding had reached equilibrium in competition with another TF-binding protein. In liposome-based assays, the association rate of WT-VIIa with TF occurred at a physical maximum and could not be improved by site-directed mutagenesis. A practical consequence was identical function of WT-VIIa and QE-VIIa in assays that depended entirely on assembly kinetics. Thus, factor VIIa mutants provided unique reagents for probing the mechanism of factor VIIa action. They may also offer superior agents for therapy.	Univ Minnesota, Dept Biochem Mol Biol & Biophys, St Paul, MN 55108 USA; Zymogenet Inc, Seattle, WA 98102 USA; Univ New Mexico, Dept Pathol, Albuquerque, NM 87131 USA	University of Minnesota System; University of Minnesota Twin Cities; Zymogenet Inc.; University of New Mexico	Nelsestuen, GL (corresponding author), Univ Minnesota, Dept Biochem Mol Biol & Biophys, 1479 Gortner Ave, St Paul, MN 55108 USA.	nelsc002@tc.umn.edu			NHLBI NIH HHS [HL 60859] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL060859] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ABBOTT AJ, 1988, FASEB J, V2, P2858, DOI 10.1096/fasebj.2.13.2844615; ANDREE HAM, 1994, BIOCHEMISTRY-US, V33, P4368, DOI 10.1021/bi00180a034; Bach RR, 1997, BLOOD, V89, P3270, DOI 10.1182/blood.V89.9.3270; BILLY D, 1995, J BIOL CHEM, V270, P1029, DOI 10.1074/jbc.270.3.1029; DELISI C, 1981, P NATL ACAD SCI-BIOL, V78, P5569, DOI 10.1073/pnas.78.9.5569; Dickinson CD, 1997, J BIOL CHEM, V272, P19875, DOI 10.1074/jbc.272.32.19875; Dickinson CD, 1996, P NATL ACAD SCI USA, V93, P14379, DOI 10.1073/pnas.93.25.14379; Hedner U, 1996, HAEMOSTASIS, V26, P102; Hedner Ulla, 1993, Transfusion Medicine Reviews, V7, P78, DOI 10.1016/S0887-7963(93)70126-1; Kelly CR, 1997, J BIOL CHEM, V272, P17467, DOI 10.1074/jbc.272.28.17467; LE DT, 1992, J BIOL CHEM, V267, P15447; Lu YF, 1996, BIOCHEMISTRY-US, V35, P8201, DOI 10.1021/bi960281g; Lu YF, 1996, BIOCHEMISTRY-US, V35, P8193, DOI 10.1021/bi960280o; MARTINEZ MB, 1992, BIOCHEMISTRY-US, V31, P11500, DOI 10.1021/bi00161a031; Martinez MB, 1996, BIOCHEMISTRY-US, V35, P1179, DOI 10.1021/bi951955a; MCGEE MP, 1992, J BIOL CHEM, V267, P24333; Monroe DM, 1997, BRIT J HAEMATOL, V99, P542, DOI 10.1046/j.1365-2141.1997.4463256.x; MORRISSEY JH, 1993, BLOOD, V81, P734; NELSESTUEN GL, 1977, BIOCHEMISTRY-US, V16, P4172, DOI 10.1021/bi00638a006; Nelsestuen GL, 1997, BIOCHEMISTRY-US, V36, P9081, DOI 10.1021/bi970720r; Nelsestuen GL, 1999, CHEM PHYS LIPIDS, V101, P37, DOI 10.1016/S0009-3084(99)00053-5; Nelsestuen GL, 2000, VITAM HORM, V58, P355, DOI 10.1016/S0083-6729(00)58031-5; NEUENSCHWANDER PF, 1995, BIOCHEMISTRY-US, V34, P13988, DOI 10.1021/bi00043a004; QUICK AJ, 1959, HEMORRHAGIC DISEASES, P376; RAO LVM, 1990, BLOOD, V75, P1069; Shah AM, 1998, P NATL ACAD SCI USA, V95, P4229, DOI 10.1073/pnas.95.8.4229; Smirnov MD, 1999, BIOCHEMISTRY-US, V38, P3591, DOI 10.1021/bi982538b; Sorensen BB, 1997, J BIOL CHEM, V272, P11863, DOI 10.1074/jbc.272.18.11863; TIMMONS S, 1989, METHOD ENZYMOL, V169, P11; Vergne I, 1999, EUR J BIOCHEM, V264, P369, DOI 10.1046/j.1432-1327.1999.00651.x; WAXMAN E, 1992, BIOCHEMISTRY-US, V31, P3998, DOI 10.1021/bi00131a015	32	20	40	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 26	2001	276	43					39825	39831		10.1074/jbc.M104896200	http://dx.doi.org/10.1074/jbc.M104896200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	485XR	11517221	hybrid			2023-01-03	WOS:000171789200043
J	Kaptchuk, TJ; Eisenberg, DM				Kaptchuk, TJ; Eisenberg, DM			Varieties of healing. 2: A taxonomy of unconventional healing practices	ANNALS OF INTERNAL MEDICINE			English	Review							FOLK MEDICINE; ALTERNATIVE MEDICINE; HEALTH; RELIGION; CARE; TRANSFUSION; BELIEFS; THERAPY; CULTURE; FAITH	The first of two essays in this issue demonstrated that the United States has had a rich history of medical pluralism. This essay seeks to present an overview of contemporary unconventional medical practices in the United States. No clear definition of "alternative medicine" is offered because it is a residual category composed of heterogeneous healing methods. A descriptive taxonomy of contemporary unconventional healing could be more helpful. Two broad categories of unconventional medicine are described here: a more prominent, "mainstream" complementary and alternative medicine (CAM) and a more culture-bound, "parochial" unconventional medicine. The CAM component can be divided into professional groups, layperson-initiated popular health reform movements, New Age healing, alternative psychological therapies, and non-normative scientific enterprises. The parochial category can be divided into ethno-medicine, religious healing, and folk medicine. A topologic examination of U.S. health care can provide an important conceptual framework through which health care providers can understand the current situation in U.S. medical pluralism.	Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School	Kaptchuk, TJ (corresponding author), Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, 330 Brookline Ave,W-K-400, Boston, MA 02215 USA.				NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [U24AR043441] Funding Source: NIH RePORTER; NIAMS NIH HHS [U24 AR43441] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Albanese Catherine L., 1990, NATURE RELIG AM ALGO; ALBRECHT GL, 1982, RES SOCIOLOGY HLTH C, V2; AMUNDSEN DW, 1982, B HIST MED, V56, P326; ANDERSON J, 1997, NEWSDAY         1105, pB10; [Anonymous], 2000, LANCET, V356, P2023; [Anonymous], 1982, CRUSADERS FITNESS HI; Baer H A, 1992, Med Anthropol, V13, P369; Barnes LL, 1998, CULT MED PSYCHIAT, V22, P413, DOI 10.1023/A:1005403825213; BARRETT S, 1985, JAMA-J AM MED ASSOC, V254, P1041, DOI 10.1001/jama.254.8.1041; Braden C.S., 1963, SPIRITS REBELLION RI; Brown Karen McCarthy, 2001, M LOLA VODOU PRIESTE; BURROUGHS H, 1993, ALTERNATIVE HEALING; Cassileth BR, 1996, CANCER INVEST, V14, P396, DOI 10.3109/07357909609012168; CAVENDER AP, 1992, SOUTH MED J, V85, P170, DOI 10.1097/00007611-199202000-00012; Chopra Deepak, 1989, QUANTUM HEALING EXPL; COHEN C, 1992, PRIMARY CARE, V19, P87; COOK C, 1986, SOUTH MED J, V79, P1098, DOI 10.1097/00007611-198609000-00014; COOTER R, 1987, MED FRINGE MED ORTHO; COULEHAN JL, 1985, SOC SCI MED, V21, P383, DOI 10.1016/0277-9536(85)90218-7; Csordas T., 1994, SACRED SELF CULTURAL; Cumberland W.H., 1986, CARING CURING HLTH M; CURRY P, 1987, ASTROLOGY SCI SOC HI; Deutsch RM, 1977, NEW NUTS BERRIES; DICK HG, 1946, J HIST MED, V13, P300; Dossey L., 1991, MEANING MED; DOWLING SJ, 1984, J ROY SOC MED, V77, P634, DOI 10.1177/014107688407700803; Easthope G, 1986, HEALERS ALTERNATIVE; EISENBERG DM, 1993, ANN INTERN MED, V118, P964, DOI 10.7326/0003-4819-118-12-199306150-00009; Eisenberg DM, 1997, ANN INTERN MED, V127, P61, DOI 10.7326/0003-4819-127-1-199707010-00010; Eisenberg DM, 2000, JAMA-J AM MED ASSOC, V283, P885; Eisenberg DM, 1998, JAMA-J AM MED ASSOC, V280, P1569, DOI 10.1001/jama.280.18.1569; Ellwood Robert S, 1979, ALTERNATIVE ALTARS U; English-Lueck J., 1990, HLTH NEW AGE STUDY C; Ernst E, 1996, ARCH INTERN MED, V156, P2162, DOI 10.1001/archinte.156.19.2162; Ernst E, 1997, CIRCULATION, V96, P1031; Ernst E, 1999, FORSCH KOMPLEMENTMED, V6, P7, DOI 10.1159/000021201; Fadiman A., 1997, SPIRIT CATCHES YOU Y; FERNGREN GB, 1992, B HIST MED, V66, P1; FISCH S, 1968, MILBANK FUND Q, V46, P377, DOI 10.2307/3349335; Fox M, 1984, Med Anthropol, V8, P292; FUCHS M, 1975, MED CARE, V13, P915, DOI 10.1097/00005650-197511000-00004; Fuller R.C., 1982, MESMERISM AM CURE SO; Furnham A, 2000, COMPLEMENT THER MED, V8, P82, DOI 10.1054/ctim.2000.0355; FYE WB, 1986, CIRCULATION, V73, P21, DOI 10.1161/01.CIR.73.1.21; GEBHARD B, 1976, AM FOLK MED; GEVITZ N, 1995, MT SINAI J MED, V62, P127; Gevitz N., 1988, OTHER HEALERS UNORTH, P124; Gevitz N., 1982, DOS OSTEOPATHIC MED; GLIK DC, 1988, SOC SCI MED, V27, P1197, DOI 10.1016/0277-9536(88)90349-8; GOLDMAN B, 1991, CAN MED ASSOC J, V144, P218; GOLDSTEIN MS, 1987, J HEALTH SOC BEHAV, V28, P103, DOI 10.2307/2137125; GOOD BJ, 1981, 8 PUBL REG HLTH CAR; Gordon JS., 1996, MANIFESTO NEW MED; GORT EH, 1988, SOC SCI MED, V26, P1061, DOI 10.1016/0277-9536(88)90224-9; HAFNER AW, 1993, READERS GUIDE ALTERN; HAFNER AW, 1992, GUIDE AM MED ASS HIS; HAND W D, 1971, Journal of the History of Medicine and Allied Sciences, V26, P263; Harrell David E., 1978, ALL THINGS ARE POSSI; Harwood A, 1977, Cult Med Psychiatry, V1, P69; Harwood A, 1981, ETHNICITY MED CARE; HELMAN C G, 1978, Culture Medicine and Psychiatry, V2, P107, DOI 10.1007/BF00054580; HERINK R, 1980, PSYCHOTHERAPY HDB; HEXHAM I, 1992, PERSPECTIVES NEW AGE; Hufford DJ, 1997, PRIMARY CARE, V24, P723, DOI 10.1016/S0095-4543(05)70307-9; Jacobs C F, 1990, Med Anthropol, V12, P349; JOHNSON DM, 1986, SOCIOL ANAL, V47, P66, DOI 10.2307/3711279; JOHNSON KP, 1998, E CAYCE CONTEXT; Johnson Shirley M., 1997, Journal of the American Osteopathic Association, V97, P80; JONES RK, 1970, SOCIOLOGY, V4, P181, DOI 10.1177/003803857000400203; Judah J.S, 1967, HIST PHILOS METAPHYS; KANDEL RF, 1976, THESIS STATE U NEW Y; Kaptchuk TJ, 1998, ANN INTERN MED, V129, P1061, DOI 10.7326/0003-4819-129-12-199812150-00011; Kaptchuk TJ, 1998, ARCH INTERN MED, V158, P2215, DOI 10.1001/archinte.158.20.2215; Kaptchuk TJ, 1998, NUTRITION, V14, P471; KAPTCHUK TJ, 2001, FUNDAMENTALS COMPLEM; KAPTCHUK TJ, 2000, WEB THAT HAS NO WEAV; KAPTCHUK TJ, 1986, HEALING ARTS JOURNEY; KARASU TB, 1986, AM J PSYCHIAT, V143, P687; Kaufman M., 1971, HOMEOPATHY AM RISE F; Kelsey Morton T., 1973, HEALING CHRISTIANITY; Kemper K J, 1996, Pediatr Rev, V17, P279, DOI 10.1542/pir.17-8-279; Kerr H., 1983, OCCULT AM NEW HIST P; KING DE, 1988, J FAM PRACTICE, V27, P505; Kirmayer L. J, 1988, BIOMEDICINE EXAMINED; KIRSCHNER HE, 1991, LIVE FOOD JUICES; KLEINMAN AM, 1973, INQUIRY, V16, P206, DOI 10.1080/00201747308601685; KNAPP JE, 1990, NATL STUDY PROFESSIO; Ko CY, 1997, ARCH SURG-CHICAGO, V132, P829; KOENIG HG, 1988, J AM GERIATR SOC, V36, P362, DOI 10.1111/j.1532-5415.1988.tb02365.x; Kohl L, 1989, TAOIST MEDITATION LO; KRIEGER D, 1979, AM J NURS, V79, P660, DOI 10.2307/3462338; LAETZ T, 1991, JAMA-J AM MED ASSOC, V266, P2996, DOI 10.1001/jama.266.21.2996; LEIBOWITZ J, 1990, ALEXANDER TECHNIQUE; LERNER M, 1994, CHOICES HEALING INTE; LEVIN JS, 1986, SOC SCI MED, V23, P889, DOI 10.1016/0277-9536(86)90217-0; Levine HD, 1941, NEW ENGL J MED, V224, P487, DOI 10.1056/NEJM194103202241201; Linden Wolfgang, 1994, Annals of Behavioral Medicine, V16, P35; MANN MC, 1992, ANN INTERN MED, V117, P1042, DOI 10.7326/0003-4819-117-12-1042; MARTINEZ C, 1966, J AMER MED ASSOC, V196, P161, DOI 10.1001/jama.196.2.161; MATHEWS HF, 1987, SOUTHERN MED J, V80, P885, DOI 10.1097/00007611-198707000-00019; MCGUIRE MB, 1983, CULT MED PSYCHIAT, V7, P221, DOI 10.1007/BF00049311; McGuire Meredith, 1988, RITUAL HEALING SUBUR; Melton J.G., 1990, NEW AGE ENCY; MITCHELL BB, 1997, ACUPUNCTURE ORIENTAL; *NAT CTR HLTH STAT, 1975, OFF VIS OST PHYS JAN; National Institutes of Health, 1994, ALT MED EXP MED HOR; OConnor Bonnie Blair, 1995, HEALING TRADITIONS A; OPENHEIM J, 1988, OTHER WORLD SPIRITUA; OSHERSON S, 1981, SOCIAL CONTEXTS HLTH; PACHTER LM, 1994, JAMA-J AM MED ASSOC, V271, P690, DOI 10.1001/jama.271.9.690; *PAN DEF DESCR, 1997, ALTERN THER HEALTH M, V3, P49; Parker G.T., 1973, MIND CURE NEW ENGLAN; PIETRONI PC, 1992, BRIT MED J, V305, P564, DOI 10.1136/bmj.305.6853.564; RINZLER CA, 1991, FEED COLD STARVE FEV; ROTHSTEIN W, 1972, AM PHYSICIANS 19 CEN; RYWERANT Y, 1983, FELDENKRAIS METHOD; SAKETKHOO K, 1978, CHEST, V74, P408, DOI 10.1378/chest.74.4.408; SAKS M, 1992, ALTERNATIVE MED BRIT; Schoepflin R., 1988, OTHER HEALERS UNORTH; SCOTT CS, 1974, PUBLIC HEALTH REP, V89, P524; Segen J. C., 1998, DICT ALTERNATIVE MED; SINGELENBERG R, 1990, SOC SCI MED, V31, P515, DOI 10.1016/0277-9536(90)90048-W; Snow L F, 1978, Cult Med Psychiatry, V2, P69, DOI 10.1007/BF00052450; TAPPEN FM, 1988, HEALING MASSAGE TECH; TROTTER R, 1981, CURANDERISMO MEXICAN; TURNER R, 1998, COMPLEMENTARY THERAP, V6, P141; *US C OFF TECHN AS, 1990, UNC CANC TREATM; Uva J L, 1991, JAMA, V266, P3065; VANPRAAG J, 1997, TALKING HEAVEN MEDIU; WARDWELL W, 1992, CHIROPRACTIC HIST EV; WARDWELL WI, 1994, PERSPECT BIOL MED, V37, P595; Weil A., 1995, SPONTANEOUS HEALING; YAHN G, 1979, JAMA-J AM MED ASSOC, V242, P2202, DOI 10.1001/jama.242.20.2202; YATES JW, 1981, MED PEDIATR ONCOL, V9, P121, DOI 10.1002/mpo.2950090204; Yuasa Yasuo., 1993, BODY SELF CULTIVATIO; Zefron L J, 1975, Nurs Forum, V14, P350, DOI 10.1111/j.1744-6198.1975.tb00596.x; [No title captured]	137	100	100	0	13	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	AUG 7	2001	135	3					196	204		10.7326/0003-4819-135-3-200108070-00012	http://dx.doi.org/10.7326/0003-4819-135-3-200108070-00012			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	460FX	11487487				2023-01-03	WOS:000170298500006
J	Wilkes, MM; Navickis, RJ				Wilkes, MM; Navickis, RJ			Patient survival after human albumin administration - A meta-analysis of randomized, controlled trials	ANNALS OF INTERNAL MEDICINE			English	Review							COLLOID OSMOTIC-PRESSURE; SEVERE OVARIAN HYPERSTIMULATION; VITRO FERTILIZATION PATIENTS; INTRAVENOUS ALBUMIN; SERUM-ALBUMIN; CARDIOPULMONARY BYPASS; PARENTERAL-NUTRITION; EXCHANGE-TRANSFUSION; MAJOR SURGERY; THERAPEUTIC PARACENTESIS	Purpose: To test the hypothesis that albumin administration is not associated with excess mortality. Data Sources: Computer searches of the MEDLINE and EMBASE databases, the Cochrane Library, and Internet documents; hand searching of medical journals; inquiries to investigators and medical directors; and review of reference lists. Study Selection: Randomized, controlled trials comparing albumin therapy with crystalloid therapy, no albumin, or lower doses of albumin. Data Extraction: Two investigators independently extracted data. The primary end point was relative risk for death. Criteria used to assess methodologic quality were blinding, method of allocation concealment, presence of mortality as a study end point, and crossover. Small-trial bias was also investigated. Data Synthesis: Fifty-five trials involving surgery or trauma, burns, hypoalbuminemia, high-risk neonates, ascites, and other indications were included. Albumin administration did not significantly affect mortality in any category of indications. For all trials, the relative risk for death was 1.11 (95% Cl, 0.95 to 1.28). Relative risk was lower among trials with blinding (0.73 [Cl, 0.48 to 1.12]; n = 7), mortality as an end point (1.00 [Cl, 0.84 to 1.18]; n = 17), no crossover (1.04 [Cl, 0.89 to 1.22]; n = 35), and 100 or more patients (0.94 [Cl, 0.77 to 1.14]; n = 10). In trials with two or more such attributes, relative risk was further reduced. Conclusions: overall, no effect of albumin on mortality was detected; any such effect may therefore be small. This finding supports the safety of albumin. The influence of methodologic quality on relative risk for death suggests the need for further well-designed clinical trials.	Hygeia Associates, Grass Valley, CA 95949 USA		Wilkes, MM (corresponding author), Hygeia Associates, 17988 Brewer Rd, Grass Valley, CA 95949 USA.	mwilkes@hygeiaassociates.com						ADAM R, 1991, TRANSPLANT P, V23, P2374; ALDERSON P, 2000, HUMAN ALBUMIN SOLUTI, P2; *ALPH THER CORP, 2000, PRESCR INF ALB HUM U; *BAYER CORP, 1998, PRESCR INF ALB HUM 5; Bell Ewan, 1999, Adverse Drug Reactions and Toxicological Reviews, V18, P149; Berlin JA, 1997, LANCET, V350, P185, DOI 10.1016/S0140-6736(05)62352-5; BLAND RD, 1976, AM J OBSTET GYNECOL, V124, P263, DOI 10.1016/0002-9378(76)90154-X; BLAND RD, 1973, ARCH DIS CHILD, V48, P800, DOI 10.1136/adc.48.10.800; BODENHAMER RM, 1985, ANN THORAC SURG, V40, P374, DOI 10.1016/S0003-4975(10)60072-0; BOLDT J, 1993, ANESTH ANALG, V76, P1185, DOI 10.1213/00000539-199376060-00002; BOLDT J, 1986, INFUS KLIN ERN, V13, P145; BOLDT J, 1992, ANESTH ANALG, V74, P219, DOI 10.1213/00000539-199202000-00008; BOUTROS AR, 1979, CRIT CARE MED, V7, P9, DOI 10.1097/00003246-197901000-00003; BRADBURN MJ, 1998, STATA TECH B, P86; BROWN RO, 1988, CRIT CARE MED, V16, P1177, DOI 10.1097/00003246-198812000-00002; Buhre W, 1997, BRIT J ANAESTH, V79, P311, DOI 10.1093/bja/79.3.311; CARLON GC, 1979, ANESTH ANALG, V58, P13; CHAN G, 1976, J PEDIATR-US, V88, P609, DOI 10.1016/S0022-3476(76)80020-0; Cole RP, 1999, BURNS, V25, P565; COMLEY A, 1968, ARCH DIS CHILD, V43, P151, DOI 10.1136/adc.43.228.151; COOK D, 1999, EVIDENCE BASED MED, V1, P19; DAWIDSON I, 1982, CRIT CARE MED, V10, P597, DOI 10.1097/00003246-198209000-00008; DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2; EBBESEN F, 1981, ACTA PAEDIATR SCAND, V70, P649, DOI 10.1111/j.1651-2227.1981.tb05762.x; Egger M, 1998, BMJ-BRIT MED J, V316, P61, DOI 10.1136/bmj.316.7124.61; Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629; EMERSON TE, 1989, CRIT CARE MED, V17, P690, DOI 10.1097/00003246-198907000-00020; EMERY EF, 1992, ARCH DIS CHILD-FETAL, V67, P1185, DOI 10.1136/adc.67.10_Spec_No.1185; Engelman DT, 1999, J THORAC CARDIOV SUR, V118, P866, DOI 10.1016/S0022-5223(99)70056-5; Ernest D, 1999, CRIT CARE MED, V27, P46, DOI 10.1097/00003246-199901000-00025; Erstad BL, 1996, PHARMACOTHERAPY, V16, P996; Erstad BL, 1999, AM J HEALTH-SYST PH, V56, P1451, DOI 10.1093/ajhp/56.14.1451; Ferguson ND, 1999, INTENS CARE MED, V25, P323, DOI 10.1007/s001340050844; FINLAYSON JS, 1980, SEMIN THROMB HEMOST, V6, P85, DOI 10.1055/s-2007-1005097; FOLEY EF, 1990, ARCH SURG-CHICAGO, V125, P739; GALLAGHER JD, 1985, ANESTH ANALG, V64, P753; GARCIACOMPEAN D, 1993, LIVER, V13, P233; Gentilini P, 1999, J HEPATOL, V30, P639, DOI 10.1016/S0168-8278(99)80194-9; Gibbs J, 1999, ARCH SURG-CHICAGO, V134, P36, DOI 10.1001/archsurg.134.1.36; GINES P, 1988, GASTROENTEROLOGY, V94, P1493, DOI 10.1016/0016-5085(88)90691-9; Goldwasser P, 1997, J CLIN EPIDEMIOL, V50, P693, DOI 10.1016/S0895-4356(97)00015-2; GOLUB R, 1994, CRIT CARE MED, V22, P613, DOI 10.1097/00003246-199404000-00017; GOODWIN CW, 1983, ANN SURG, V197, P520, DOI 10.1097/00000658-198305000-00004; GOSLINGA H, 1992, STROKE, V23, P181, DOI 10.1161/01.STR.23.2.181; Gotzsche PC, 2000, BRIT MED J, V321, P585, DOI 10.1136/bmj.321.7261.585; GREENHALGH DG, 1995, J TRAUMA, V39, P67, DOI 10.1097/00005373-199507000-00009; GREENOUGH A, 1993, EUR J PEDIATR, V152, P157, DOI 10.1007/BF02072495; GRUNDMANN R, 1985, ARCH SURG-CHICAGO, V120, P911; GRUNDMANN R, 1982, INTENS CARE MED, V8, P179, DOI 10.1007/BF01725735; GRUNDMANN R, 1986, LANGENBECK ARCH CHIR, V367, P235, DOI 10.1007/BF01263404; HALLOWELL P, 1978, ANN THORAC SURG, V25, P22, DOI 10.1016/S0003-4975(10)63481-9; HOEFT A, 1991, BRIT J ANAESTH, V66, P73, DOI 10.1093/bja/66.1.73; HONDEBRINK Y, 1997, INTENS CARE MED, V23, pS138; *IMM US INC, 1998, PRESCR INF ALB HUM 5; Isik AZ, 1996, EUR J OBSTET GYN R B, V70, P179, DOI 10.1016/S0301-2115(95)02603-7; JELENKO C, 1979, CRIT CARE MED, V7, P157, DOI 10.1097/00003246-197904000-00003; JONES MM, 1986, OBSTET GYNECOL, V68, P659; KANAREK KS, 1992, JPEN-PARENTER ENTER, V16, P49, DOI 10.1177/014860719201600149; KITCHEN WH, 1960, J PEDIATR-US, V57, P876, DOI 10.1016/S0022-3476(60)80137-0; Lennihan L, 2000, STROKE, V31, P383, DOI 10.1161/01.STR.31.2.383; LONDON MJ, 1992, J THORAC CARDIOV SUR, V104, P284; LOWE RJ, 1977, SURGERY, V81, P676; LUCA A, 1995, HEPATOLOGY, V22, P753, DOI 10.1016/0270-9139(95)90293-7; LUCAS CE, 1978, J TRAUMA, V18, P564, DOI 10.1097/00005373-197808000-00002; Magder S, 1999, J CRIT CARE, V14, P164, DOI 10.1016/S0883-9441(99)90030-8; MANTEL N, 1959, J NATL CANCER I, V22, P719; MARELLI D, 1989, J THORAC CARDIOV SUR, V98, P751; Margarson MP, 1998, ANAESTHESIA, V53, P789, DOI 10.1046/j.1365-2044.1998.00438.x; MATHRU M, 1980, ANESTH ANALG, V59, P655; McClelland DBL, 1998, TRANSFUSION, V38, P690, DOI 10.1046/j.1537-2995.1998.38798346639.x; MCNULTY SE, 1993, ANESTH ANALG, V76, P830; METILDI LA, 1984, SURG GYNECOL OBSTET, V158, P207; NIELSEN OM, 1989, DAN MED BULL, V36, P496; NIELSEN OM, 1985, ACTA CHIR SCAND, V151, P221; NILSSON E, 1980, ACTA CHIR SCAND, V146, P619; Oca MJ, 1999, PEDIAT RES, V45, P1265; OHQVIST G, 1981, SCAND J THORAC CARD, V15, P251, DOI 10.3109/14017438109100582; OHQVIST G, 1981, SCAND J THORAC CARD, V15, P257, DOI 10.3109/14017438109100583; POCKAJ BA, 1994, J IMMUNOTHER, V15, P22, DOI 10.1097/00002371-199401000-00003; Prien T, 1990, J Clin Anesth, V2, P317; RACKOW EC, 1983, CRIT CARE MED, V11, P839, DOI 10.1097/00003246-198311000-00001; Recinos P R, 1975, J Iowa Med Soc, V65, P426; REID DJ, 1988, CLIN PHARMACY, V7, P894; RENNIE M, 1998, BR J INTENS CARE, V8, P185; RING J, 1977, LANCET, V1, P466; Roberts I, 1998, BMJ-BRIT MED J, V317, P235; Rubin H, 1997, CRIT CARE MED, V25, P249, DOI 10.1097/00003246-199702000-00009; SADE RM, 1985, J THORAC CARDIOV SUR, V89, P713; Schmid CH, 1998, STAT MED, V17, P1923, DOI 10.1002/(SICI)1097-0258(19980915)17:17<1923::AID-SIM874>3.0.CO;2-6; SCHULZ KF, 1995, JAMA-J AM MED ASSOC, V273, P408, DOI 10.1001/jama.273.5.408; SHAH DM, 1977, ARCH SURG-CHICAGO, V112, P1161; SHALEV E, 1995, HUM REPROD, V10, P1373, DOI 10.1093/HUMREP/10.6.1373; SHOHAM Z, 1994, FERTIL STERIL, V62, P137; SKILLMAN JJ, 1975, SURGERY, V78, P291; So KW, 1997, ARCH DIS CHILD-FETAL, V76, pF43, DOI 10.1136/fn.76.1.F43; Sort P, 1999, NEW ENGL J MED, V341, P403, DOI 10.1056/NEJM199908053410603; STEICHEN TJ, 1998, STATA TECH B, P84; TOLLOFSRUD S, 1995, ACTA ANAESTH SCAND, V39, P671, DOI 10.1111/j.1399-6576.1995.tb04146.x; TULLIS JL, 1977, JAMA-J AM MED ASSOC, V237, P355; Videm Vibeke, 1993, Perfusion, V8, P409, DOI 10.1177/026765919300800508; VIRGILIO RW, 1979, SURGERY, V85, P129; VIRGILIO RW, 1979, SURG FORUM, V30, P166; von Hoegen I, 2001, CRIT CARE MED, V29, P994, DOI 10.1097/00003246-200105000-00021; Webb AR, 2000, CRIT CARE, V4, pS26, DOI 10.1186/cc967; WILKINSON P, 1962, LANCET, V2, P1125; Woittiez A J, 1998, Ned Tijdschr Geneeskd, V142, P2161; WOJTYSIAK SL, 1992, CRIT CARE MED, V20, P164, DOI 10.1097/00003246-199202000-00005; WONG YK, 1972, ARCH DIS CHILD, V47, P241, DOI 10.1136/adc.47.252.241; WOOD B, 1970, ARCH DIS CHILD, V45, P59, DOI 10.1136/adc.45.239.59; WOODS MS, 1993, AM SURGEON, V59, P758; ZETTERSTROM H, 1981, ACTA ANAESTH SCAND, V25, P125, DOI 10.1111/j.1399-6576.1981.tb01622.x; ZETTERSTROM H, 1981, ACTA ANAESTH SCAND, V25, P133, DOI 10.1111/j.1399-6576.1981.tb01623.x; [No title captured]	113	289	331	0	11	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	AUG 7	2001	135	3					149	164		10.7326/0003-4819-135-3-200108070-00007	http://dx.doi.org/10.7326/0003-4819-135-3-200108070-00007			16	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	460FX	11487482				2023-01-03	WOS:000170298500001
J	Kane, B				Kane, B			Medical marijuana: The continuing story	ANNALS OF INTERNAL MEDICINE			English	Article																			0	6	6	0	3	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUN 19	2001	134	12					1159	1162		10.7326/0003-4819-134-12-200106190-00035	http://dx.doi.org/10.7326/0003-4819-134-12-200106190-00035			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	442YU	11412075				2023-01-03	WOS:000169313200025
J	Calfee, JE				Calfee, JE			Pharmaceutical price controls and patient welfare	ANNALS OF INTERNAL MEDICINE			English	Article							INHALED INSULIN; SEVERE SEPSIS; DEPRESSION; REALITY	Price controls could have a substantial negative effect on pharmaceutical research and development. Extensive research is required before the development costs of a new drug or its benefits are known; most new drug development projects fail, sometimes after substantial financial and time costs. These conditions pose intractable practical problems for the operation of price controls, which cannot rest on objective, predictable standards such as the benefits or costs of individual drugs. In the absence of objective standards, pressure from health care providers and others would create powerful incentives for price regulators to decrease drug prices toward marginal costs of production and distribution, well below levels sufficient to reward innovative research. This downwardly biased price-setting mechanism would apply with particular force to the few successful projects that yield innovative drugs, whose prices would not be set by regulatory authorities until after research expenditures have been incurred and the new drugs are ready to enter the market. Manufacturers will expect price controls to reduce the potential payoffs from breakthrough drugs. This expectation would substantially reduce the incentives to pursue innovative research, as is evident in advanced economies in which price controls are now in force. Once established, price controls for pharmaceuticals, like those for medical services in the Medicare system, would also tend toward complexity and entrenchment of vested interests and could easily become permanent regardless of the harm they cause to patients.	Amer Enterprise Inst Publ Policy Res, Washington, DC 20036 USA	American Enterprise Institute for Public Policy Research	Calfee, JE (corresponding author), Amer Enterprise Inst Publ Policy Res, 1150 17th St NW, Washington, DC 20036 USA.	calfeej@aei.org						Andress G, 2001, BRIT MED J, V322, P419, DOI 10.1136/bmj.322.7283.419; [Anonymous], 1997, PHARM PRICE REGULATI; Ball BG, 2000, JAMA-J AM MED ASSOC, V284, P2788, DOI 10.1001/jama.284.21.2788; Bernard GR, 2001, NEW ENGL J MED, V344, P699, DOI 10.1056/NEJM200103083441001; BERNDT ER, 2000, US DEP HLTH HUM SERV; BOOTH B, 1999, AM MED NEWS     1227; BURTON TM, 2000, WALL STREET J   0630; BUTLER L, 1999, AM MED NEWS     1227; Calfee JE, 2000, PHARMACOECONOMICS, V18, P47, DOI 10.2165/00019053-200018001-00007; CALFEE JE, 2000, PRICES MARKETS PHARM; CALFEE JE, 1997, FEAR PERSUASION NEEW; CALFEE JE, 2001, FRASER FORUM     FEB, P4; CLARKSON KW, 1996, COMPETITIVE STRATEGI, P238; DANZON PM, 1999, REV US CROSS NATL ST; DIMASI JA, 2001, US DEP HLTH HUM SERV; Dubois RW, 2000, HEALTH AFFAIR, V19, P231, DOI 10.1377/hlthaff.19.2.231; *FOOD DRUG ADM, 1999, FED REGISTER, V64, P43197; Gale EAM, 2001, LANCET, V357, P324, DOI 10.1016/S0140-6736(00)03631-X; GLENNERSTER R, 2000, WORLD BANK VACCINE C; Glick ID, 2001, ANN INTERN MED, V134, P47, DOI 10.7326/0003-4819-134-1-200101020-00013; GRABOWSKI HG, 1994, J HEALTH ECON, V13, P383, DOI 10.1016/0167-6296(94)90010-8; Grabowski HG, 2000, PHARMACOECONOMICS, V18, P21, DOI 10.2165/00019053-200018001-00005; GRABOWSKI HG, 1994, HLTH REFORM PHARM IN; GROOPMAN J, 2000, WALL STREE J    0502; *IMS HLTH, 2000, DRUG MON; Kettler H. E., 1998, COMPETITION INNOVATI; KING RT, 1999, WALL STREE J    0219; LANGRETH R, 2001, FORBES MAGAZINE 0222; LANGRETH R, 1999, WALL STREEJ J   0813; LEWERS DT, 2001, AM MED NEWS     0305; Matthay MA, 2001, NEW ENGL J MED, V344, P759, DOI 10.1056/NEJM200103083441009; Mintz M, 2001, WASHINGTON POST 1102, pB1; Monkman D, 2000, BMJ-BRIT MED J, V321, P1299, DOI 10.1136/bmj.321.7272.1299; MOORE SD, 1998, WALL STREET J   1207; Nathan DM, 2001, ANN INTERN MED, V134, P242, DOI 10.7326/0003-4819-134-3-200102060-00016; OLSON E, 1999, NY TIMES        1118; *PAT MED PRIC REV, 2000, ANN REP YEAR END DEC; Pickering TG, 2001, ANN INTERN MED, V134, P72, DOI 10.7326/0003-4819-134-1-200101020-00016; SAGER A, 1999, AFFORDABLE MED AM PR; SEIDEN C, 2001, POTENTIAL BLOCKBUSTE; Spilker B., 1994, MULTINATIONAL PHARM, V2nd; Thomas L. G., 1994, IND CORP CHANGE, V3, P451; Triplett JE, 1999, MEASURING PRICES MED; *US FOOD DRUG ADM, 2001, TEST TUB PAT NEW DRU, P67; WINSLOW R, 2000, WALL STREET J   1214; WINSLOW R, 2000, WALL STREET J   0420, P20; 1999, ECONOMIST       0814; 2000, WORLDS TOP 50 BEST S	48	11	11	0	7	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUN 5	2001	134	11					1060	1064		10.7326/0003-4819-134-11-200106050-00012	http://dx.doi.org/10.7326/0003-4819-134-11-200106050-00012			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	436YL	11388819				2023-01-03	WOS:000168963400006
J	Martinez, E; Mocroft, A; Garcia-Viejo, MA; Perez-Cuevas, JB; Blanco, JL; Mallolas, J; Bianchi, L; Conget, I; Blanch, J; Phillips, A; Gatell, JM				Martinez, E; Mocroft, A; Garcia-Viejo, MA; Perez-Cuevas, JB; Blanco, JL; Mallolas, J; Bianchi, L; Conget, I; Blanch, J; Phillips, A; Gatell, JM			Risk of lipodystrophy in HIV-1-infected patients treated with protease inhibitors: a prospective cohort study	LANCET			English	Article							REVERSE-TRANSCRIPTASE INHIBITORS; NUCLEOSIDE ANALOG THERAPY; ANTIRETROVIRAL-THERAPY; BODY-COMPOSITION; METABOLIC ABNORMALITIES; FAT DISTRIBUTION; HIV-INFECTION; PERIPHERAL LIPODYSTROPHY; INSULIN-RESISTANCE; HYPERLIPIDEMIA	Background Risk factors for lipodystrophy in patients infected with HIV-1 treated with highly active antiretroviral therapy (HAART) containing HIV-1 protease inhibitors are poorly understood. We aimed to identify the risk factors for lipodystrophy in antiretroviral-naive HIV-1-infected adults on HAART. Methods Moderate or severe body-fat changes were clinically assessed and categorised as subcutaneous lipoatrophy, central obesity, or both, in all consecutive antiretroviral-naive HIV-1-infected adults who began HAART with two nucleoside reverse transcriptase inhibitors plus at least one protease inhibitor from October, 1996, to September, 1999. A person-years analysis was used to calculate the incidence of types of lipodystrophy, and Cox proportional hazards models were used to describe the univariate and multivariate factors associated with progression to any lipodystrophy. Findings After a median follow-up of 18 months, 85 (17%) of the 494 patients developed some type of lipodystrophy. The incidences of any lipodystrophy, lipodystrophy with subcutaneous lipoatrophy, and lipodystrophy with central obesity were 11.7 (95% CI 9.2-14.2), 9.2 (7.0-11.4), and 7.7 (5.7-9.7) per 100 patient-years. An increased risk for any lipodystrophy was found among women as compared with men (relative hazard 1.87 [1.07-3.28]), heterosexuals (2.86 [1.50-5.48]), and homosexuals (2.17 [1.07-4.42]) as compared with intravenous drug users, with increasing age (1.33 per 10 years older [1.08-1.62]), and with the duration of exposure to antiretroviral therapy (1.57 per 6 months extra [1.30-1.88]) but not with any individual antiretroviral agent. The factors associated with an increased risk for lipodystrophy with subcutaneous lipoatrophy or lipodystrophy with central obesity were very similar to those associated with any lipodystrophy. The duration of indinavir use may represent an additional contribution for the development of lipodystrophy with central obesity (1.26 per 6 months extra [0.99-1.60]); p=0.064). Interpretation Risk factors associated with development of any lipodystrophy, lipodystrophy with subcutaneous lipoatrophy, and tipodystrophy with central obesity in patients infected with HIV-1 who were receiving HAART containing protease inhibitors are multifactorial and overlapping, and cannot be exclusively ascribed to the duration of exposure to an particular antiretroviral agent.	August Pl I Sunyer Hosp Clin Barcelona, Inst Invest Biomed, Dept Infect Dis, Barcelona 08036, Spain; August Pl I Sunyer Hosp Clin Barcelona, Inst Invest Biomed, Dept Radiol, Barcelona 08036, Spain; August Pl I Sunyer Hosp Clin Barcelona, Inst Invest Biomed, Dept Endocrinol, Barcelona 08036, Spain; UCL, Royal Free & Univ Coll Med Sch, Dept Primary Care & Populat Sci, London NW3 2PF, England; UCL, Royal Free & Univ Coll Med Sch, Royal Free Ctr HIV Med, London NW3 2PF, England	University of Barcelona; Hospital Clinic de Barcelona; IDIBAPS; University of Barcelona; Hospital Clinic de Barcelona; IDIBAPS; University of Barcelona; Hospital Clinic de Barcelona; IDIBAPS; University of London; University College London; University of London; University College London	Martinez, E (corresponding author), Hosp Clin Barcelona, Infect Dis Unit, C Villarroel 170, E-08036 Barcelona, Spain.	esteban@intercom.es	Blanch, Jordi/I-9022-2012; Phillips, Andrew N/B-4427-2008; Mocroft, Amanda/G-8748-2011; Mocroft, Amanda/C-1527-2008; Gatell, Jose M/ABC-3607-2020	Blanch, Jordi/0000-0003-2597-8454; Phillips, Andrew N/0000-0003-2384-4807; Mocroft, Amanda/0000-0001-8316-1122; Mallolas Masferrer, Josep/0000-0002-8365-141X				Brinkman K, 1999, LANCET, V354, P1112, DOI 10.1016/S0140-6736(99)06102-4; Carbonnel F, 1998, AIDS, V12, P1777, DOI 10.1097/00002030-199814000-00009; Carpenter CCJ, 1997, JAMA-J AM MED ASSOC, V277, P1962, DOI 10.1001/jama.277.24.1962; Carr A, 1999, LANCET, V353, P2093, DOI 10.1016/S0140-6736(98)08468-2; Carr A, 1998, AIDS, V12, pF51, DOI 10.1097/00002030-199807000-00003; Carr A, 2000, AIDS, V14, pF25, DOI 10.1097/00002030-200002180-00001; Carr A, 1998, LANCET, V351, P1881, DOI 10.1016/S0140-6736(98)03391-1; CARR A, 1997, 9 ANN C AUSTR SOC HI; DAUCOURT V, 1999, 1 INT WORKSH ADV DRU; Dong KL, 1999, J ACQ IMMUN DEF SYND, V21, P107; FALUTZ J, 1999, 1 INT WORKSH ADV DRU; FLYNN MA, 1989, AM J CLIN NUTR, V50, P713, DOI 10.1093/ajcn/50.4.713; GALLI M, 1990, 1 INT WORKSH ADV DRU; Gervasoni C, 1999, AIDS, V13, P465, DOI 10.1097/00002030-199903110-00004; Hadigan C, 1999, J CLIN ENDOCR METAB, V84, P1932, DOI 10.1210/jc.84.6.1932; Kirk O, 1998, AIDS, V12, P2031, DOI 10.1097/00002030-199815000-00015; Kotler DP, 1999, J ACQ IMMUN DEF SYND, V20, P228, DOI 10.1097/00042560-199903010-00003; Mallal SA, 2000, AIDS, V14, P1309, DOI 10.1097/00002030-200007070-00002; Martinez E, 2000, CLIN INFECT DIS, V31, P1266, DOI 10.1086/317426; Martinez E, 2000, LANCET, V356, P1412, DOI 10.1016/S0140-6736(00)02850-6; Martinez E, 1999, AIDS, V13, P805, DOI 10.1097/00002030-199905070-00009; Martinez E, 1999, CURR OPIN INFECT DIS, V12, P13, DOI 10.1097/00001432-199902000-00003; Miller KD, 1998, LANCET, V351, P871, DOI 10.1016/S0140-6736(97)11518-5; MUURAHAINEN N, 1999, 1 INT WORKSH ADV DRU; Pernerstorfer-Schoen H, 1999, AIDS, V13, P2389, DOI 10.1097/00002030-199912030-00010; Safrin S, 1999, AIDS, V13, P2493, DOI 10.1097/00002030-199912240-00002; Saint-Marc T, 1999, AIDS, V13, P1659, DOI 10.1097/00002030-199909100-00009; Saint-Marc T, 2000, AIDS, V14, P37, DOI 10.1097/00002030-200001070-00005; SCHWARTZ RS, 1990, J GERONTOL, V45, P181; SHIMOKATA H, 1989, J GERONTOL, V44, P66; Silva M, 1998, AIDS, V12, P1645, DOI 10.1097/00002030-199813000-00012; VIARD JP, 1999, 1 INT WORKSH ADV DRU; WARD DJ, 1999, 1 INT WORKSH ADV DRU	33	329	337	0	8	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	FEB 24	2001	357	9256					592	598		10.1016/S0140-6736(00)04056-3	http://dx.doi.org/10.1016/S0140-6736(00)04056-3			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	404UB	11558485				2023-01-03	WOS:000167119100011
J	RAMSAY, JHR				RAMSAY, JHR			A KING, A DOCTOR, AND A CONVENIENT DEATH	BRITISH MEDICAL JOURNAL			English	Editorial Material																			0	8	8	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 28	1994	308	6941					1445	1445		10.1136/bmj.308.6941.1445	http://dx.doi.org/10.1136/bmj.308.6941.1445			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NP420	11644545	Green Published			2023-01-03	WOS:A1994NP42000073
J	Handschin, C; Podvinec, M; Amherd, R; Looser, R; Ourlin, JC; Meyer, UA				Handschin, C; Podvinec, M; Amherd, R; Looser, R; Ourlin, JC; Meyer, UA			Cholesterol and bile acids regulate xenosensor signaling in drug-mediated induction of cytochromes P450	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ORPHAN NUCLEAR RECEPTOR; PREGNANE-X RECEPTOR; CONSTITUTIVE ANDROSTANE RECEPTOR; CHICKEN XENOBIOTIC RECEPTOR; HUMAN LIVER-MICROSOMES; RAT HEPATOCYTES; TRANSCRIPTIONAL ACTIVATION; ANTIEPILEPTIC DRUGS; HORMONE RECEPTORS; LITHOCHOLIC ACID	Cytochromes P450 (CYP) constitute the major enzymatic system for metabolism of xenobiotics. Here we demonstrate that transcriptional activation of CYPs by the drug-sensing nuclear receptors pregnane X receptor, constitutive androstane receptor, and the chicken xenobiotic receptor (CXR) can be modulated by endogenous cholesterol and bile acids. Bile acids induce the chicken drug-activated CYP2H1 via CXR, whereas the hydroxylated metabolites of bile acids and oxysterols inhibit drug induction. The cholesterol-sensing liver X receptor competes with CXR, pregnane X receptor, or constitutive androstane receptor for regulation of drug-responsive enhancers from chicken CYP2H1, human CYP3A4, or human CYP2B6, respectively. Thus, not only cholesterol 7alpha-hydroxylase (CYP7A1), but also drug-inducible CYPs, are diametrically affected by these receptors. Our findings reveal new insights into the increasingly complex network of nuclear receptors regulating lipid homeostasis and drug metabolism.	Univ Basel, Biozentrum, Div Pharmacol Neurobiol, CH-4056 Basel, Switzerland	University of Basel	Meyer, UA (corresponding author), Univ Basel, Biozentrum, Div Pharmacol Neurobiol, Klingelbergstr 50-70, CH-4056 Basel, Switzerland.		Handschin, Christoph/E-6886-2015	Handschin, Christoph/0000-0003-0603-1097; Podvinec, Michael/0000-0002-3267-2173				ANDERSSON M, 1994, BBA-LIPID LIPID MET, V1214, P79, DOI 10.1016/0005-2760(94)90012-4; Araya Z, 1999, BBA-MOL CELL BIOL L, V1438, P47, DOI 10.1016/S1388-1981(99)00031-1; Aynaci FM, 2001, J CHILD NEUROL, V16, P367; BACK P, 1987, PHARMACOL THERAPEUT, V33, P153, DOI 10.1016/0163-7258(87)90044-1; BLOUIN RA, 1993, ARCH BIOCHEM BIOPHYS, V303, P313, DOI 10.1006/abbi.1993.1289; Blumberg B, 1998, GENE DEV, V12, P3149, DOI 10.1101/gad.12.20.3149; Cancado ELR, 1998, AM J GASTROENTEROL, V93, P1510, DOI 10.1111/j.1572-0241.1998.00472.x; Chawla A, 2000, CELL, V103, P1, DOI 10.1016/S0092-8674(00)00097-0; Chawla A, 2001, SCIENCE, V294, P1866, DOI 10.1126/science.294.5548.1866; Chiang JYL, 2001, GENE, V262, P257, DOI 10.1016/S0378-1119(00)00518-7; Dussault I, 2001, J BIOL CHEM, V276, P33309, DOI 10.1074/jbc.C100375200; EIRIS JM, 1995, NEUROLOGY, V45, P1155, DOI 10.1212/WNL.45.6.1155; Fischer S, 1996, CLIN CHIM ACTA, V251, P173, DOI 10.1016/0009-8981(96)06305-X; Forman BM, 1997, P NATL ACAD SCI USA, V94, P10588, DOI 10.1073/pnas.94.20.10588; Furster C, 1999, BBA-MOL CELL BIOL L, V1437, P46, DOI 10.1016/S0005-2760(98)00175-1; Gan XD, 2001, J BIOL CHEM, V276, P48702, DOI 10.1074/jbc.M109402200; Goodwin B, 1999, MOL PHARMACOL, V56, P1329, DOI 10.1124/mol.56.6.1329; Goodwin B, 2000, MOL CELL, V6, P517, DOI 10.1016/S1097-2765(00)00051-4; Handschin C, 2000, J BIOL CHEM, V275, P13362, DOI 10.1074/jbc.275.18.13362; Handschin C, 2001, MOL PHARMACOL, V60, P681; Handschin C, 2001, MOL ENDOCRINOL, V15, P1571, DOI 10.1210/me.15.9.1571; Handschin C, 2000, P NATL ACAD SCI USA, V97, P10769, DOI 10.1073/pnas.97.20.10769; Honkakoski P, 2000, BIOCHEM J, V347, P321, DOI 10.1042/0264-6021:3470321; Jones SA, 2000, MOL ENDOCRINOL, V14, P27, DOI 10.1210/me.14.1.27; Kocarek TA, 1998, MOL PHARMACOL, V54, P474, DOI 10.1124/mol.54.3.474; KOCAREK TA, 1993, TOXICOL APPL PHARM, V120, P298, DOI 10.1006/taap.1993.1115; Kocarek TA, 1998, BIOCHEM PHARMACOL, V55, P1435, DOI 10.1016/S0006-2952(97)00658-8; Lu TT, 2000, MOL CELL, V6, P507, DOI 10.1016/S1097-2765(00)00050-2; MANGELSDORF DJ, 1995, CELL, V83, P841, DOI 10.1016/0092-8674(95)90200-7; Nelson DR, 1999, ARCH BIOCHEM BIOPHYS, V369, P1, DOI 10.1006/abbi.1999.1352; Ourlin JC, 2002, BIOCHEM BIOPH RES CO, V291, P378, DOI 10.1006/bbrc.2002.6464; Penzak SR, 2000, SCAND J INFECT DIS, V32, P111; Plewka A, 1996, EXP TOXICOL PATHOL, V48, P249, DOI 10.1016/S0940-2993(96)80009-1; Repa JJ, 2000, ANNU REV CELL DEV BI, V16, P459, DOI 10.1146/annurev.cellbio.16.1.459; Repa JJ, 2000, SCIENCE, V289, P1524, DOI 10.1126/science.289.5484.1524; Savas U, 1999, MOL PHARMACOL, V56, P851, DOI 10.1124/mol.56.5.851; Schuetz EG, 2001, J BIOL CHEM, V276, P39411, DOI 10.1074/jbc.M106340200; Schwaninger M, 2000, J NEUROL, V247, P687, DOI 10.1007/s004150070111; Sehayek E, 2001, J LIPID RES, V42, P1250; Setchell KDR, 1997, GASTROENTEROLOGY, V112, P226, DOI 10.1016/S0016-5085(97)70239-7; Song C, 2000, STEROIDS, V65, P423, DOI 10.1016/S0039-128X(00)00127-6; Staudinger JL, 2001, P NATL ACAD SCI USA, V98, P3369, DOI 10.1073/pnas.051551698; SUDJANASUGIAMAN E, 1994, J LIPID RES, V35, P319; Sueyoshi T, 1999, J BIOL CHEM, V274, P6043, DOI 10.1074/jbc.274.10.6043; Sugatani J, 2001, HEPATOLOGY, V33, P1232, DOI 10.1053/jhep.2001.24172; SUMMERFIELD JA, 1976, BIOCHEM J, V154, P507, DOI 10.1042/bj1540507; Synold TW, 2001, NAT MED, V7, P584, DOI 10.1038/87912; THOMAS KD, 1984, ISRAEL J MED SCI, V20, P240; Venkateswaran A, 2000, J BIOL CHEM, V275, P14700, DOI 10.1074/jbc.275.19.14700; Verrotti A, 1997, J PAEDIATR CHILD H, V33, P242, DOI 10.1111/j.1440-1754.1997.tb01588.x; Watanabe M, 1996, MED SCI RES, V24, P257; WAXMAN DJ, 1992, BIOCHEM J, V281, P577, DOI 10.1042/bj2810577; Waxman DJ, 1999, ARCH BIOCHEM BIOPHYS, V369, P11, DOI 10.1006/abbi.1999.1351; Wei P, 2000, NATURE, V407, P920, DOI 10.1038/35038112; Wietholtz H, 1996, J HEPATOL, V24, P713, DOI 10.1016/S0168-8278(96)80268-6; Xie W, 2000, NATURE, V406, P435, DOI 10.1038/35019116; Xie W, 2000, GENE DEV, V14, P3014, DOI 10.1101/gad.846800; Xie W, 2001, P NATL ACAD SCI USA, V98, P3375, DOI 10.1073/pnas.051014398; Yilmaz E, 2001, ACTA NEUROL BELG, V101, P217	59	54	55	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 16	2002	277	33					29561	29567		10.1074/jbc.M202739200	http://dx.doi.org/10.1074/jbc.M202739200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	585DW	12045201	Green Accepted, hybrid			2023-01-03	WOS:000177509300029
J	Levy, JA				Levy, JA			HIV-1: hitching a ride on erythrocytes	LANCET			English	Editorial Material							HUMAN-IMMUNODEFICIENCY-VIRUS; FOLLICULAR DENDRITIC CELLS; T-CELLS; IMMUNE-COMPLEXES; TYPE-1; INFECTION; TRANSMIT; BIND; PLASMA		Univ Calif San Francisco, Div Hematol Oncol, San Francisco, CA 94143 USA	University of California System; University of California San Francisco	Levy, JA (corresponding author), Univ Calif San Francisco, Div Hematol Oncol, San Francisco, CA 94143 USA.							BREWER AW, 1992, VET PATHOL, V29, P356, DOI 10.1177/030098589202900412; CAMERON PU, 1992, SCIENCE, V257, P383, DOI 10.1126/science.1352913; HEATH SL, 1995, NATURE, V377, P740, DOI 10.1038/377740a0; Jakubik JJ, 2000, J VIROL, V74, P552, DOI 10.1128/JVI.74.1.552-555.2000; Kacani L, 1998, J VIROL, V72, P6671, DOI 10.1128/JVI.72.8.6671-6677.1998; Levy JA, 1998, LANCET, V352, P982, DOI 10.1016/S0140-6736(98)05391-4; Levy JA, 1998, HIV PATHOGENESIS AID; Liao ZH, 2000, AIDS RES HUM RETROV, V16, P355, DOI 10.1089/088922200309232; Moir S, 2000, J EXP MED, V192, P637, DOI 10.1084/jem.192.5.637; MORROW WJW, 1986, CLIN IMMUNOL IMMUNOP, V40, P515, DOI 10.1016/0090-1229(86)90196-0; Olinger GG, 2000, J VIROL, V74, P8550, DOI 10.1128/JVI.74.18.8550-8557.2000; PAN LZ, 1993, J CLIN MICROBIOL, V31, P283, DOI 10.1128/JCM.31.2.283-288.1993; Pohlmann S, 2001, J VIROL, V75, P10523, DOI 10.1128/JVI.75.21.10523-10526.2001; SPEAR GT, 1991, IMMUNOLOGY, V73, P377; SPEAR GT, 1993, AIDS, V7, P1149, DOI 10.1097/00002030-199309000-00001; SPIEGEL H, 1992, AM J PATHOL, V140, P15; TATENO M, 1989, P NATL ACAD SCI USA, V86, P4287, DOI 10.1073/pnas.86.11.4287; Tsunetsugu-Yokota Y, 1997, VIROLOGY, V239, P259, DOI 10.1006/viro.1997.8895	18	8	8	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUN 29	2002	359	9325					2212	2213		10.1016/S0140-6736(02)09314-5	http://dx.doi.org/10.1016/S0140-6736(02)09314-5			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	567YJ	12103280				2023-01-03	WOS:000176514500002
J	Ernst, E				Ernst, E			The risk-benefit profile of commonly used herbal therapies: Ginkgo, St. John's wort, ginseng, echinacea, saw palmetto, and kava	ANNALS OF INTERNAL MEDICINE			English	Article							BENIGN PROSTATIC HYPERPLASIA; RANDOMIZED CLINICAL-TRIALS; INTERMITTENT CLAUDICATION; CEREBRAL INSUFFICIENCY; COMPLEMENTARY MEDICINE; BILOBA EXTRACT; UNITED-STATES; DEPRESSION; METAANALYSIS; EFFICACY	Because use of herbal remedies is increasing, a risk-benefit profile of commonly used herbs is needed. This article provides a clinically oriented overview of the efficacy and safety of ginkgo, St. John's wort, ginseng, echinacea, saw palmetto, and kava. Wherever possible, assessments are based on systematic reviews of randomized clinical trials. Encouraging data support the efficacy of some of these popular herbal medicinal products, and the potential for doing good seems greater than that for doing harm. The published evidence suggests that ginkgo is of questionable use for memory loss and tinnitus but has some effect on dementia and intermittent claudication. St. John's wort is efficacious for mild to moderate depression, but serious concerns exist about its interactions with several conventional drugs. Well-conducted clinical trials do not support the efficacy of ginseng to treat any condition. Echinacea may be helpful in the treatment or prevention of upper respiratory tract infections, but trial data are not fully convincing. Saw palmetto has been shown in short-term trials to be efficacious in reducing the symptoms of benign prostatic hyperplasia. Kava is an efficacious short-term treatment for anxiety. None of these herbal medicines is free of adverse effects. Because the evidence is incomplete, risk-benefit assessments are not completely reliable, and much knowledge is still lacking.	Univ Exeter, Sch Sport & Hlth Sci, Dept Complementary Med, Exeter EX2 4NT, Devon, England	University of Exeter	Ernst, E (corresponding author), Univ Exeter, Sch Sport & Hlth Sci, Dept Complementary Med, 25 Victoria Pk Rd, Exeter EX2 4NT, Devon, England.	E.Ernst@exeter.ac.uk						Ackermann RT, 2001, ARCH INTERN MED, V161, P813, DOI 10.1001/archinte.161.6.813; Almeida JC, 1996, ANN INTERN MED, V125, P940, DOI 10.7326/0003-4819-125-11-199612010-00023; BAHRKE MS, 1994, SPORTS MED, V18, P229, DOI 10.2165/00007256-199418040-00003; Bauer R., 1991, EC MED PLANT RES, V5, P253; Blumenthal M, 1999, HERBALGRAM, V47, P64; BOHMER D, 1988, HERZ KREISLAUF, V20, P5; BOON H, 1999, BOT PHARM PHARM 47 C; Cupp MJ., 2000, TOXICOLOGY CLIN PHAR; DEFEUDIS FV, 1991, GINKGO BILOBA; DISILVERIO F, 1992, EUR UROL, V21, P309; DREWE J, 2000, PHYTOPHARMAKA 6 FORS; Eisenberg DM, 1997, ANN INTERN MED, V127, P61, DOI 10.7326/0003-4819-127-1-199707010-00010; Eisenberg DM, 1998, JAMA-J AM MED ASSOC, V280, P1569, DOI 10.1001/jama.280.18.1569; Ernst E, 2000, PERFUSION-GERMANY, V13, P60; Ernst E, 2000, PERFUSION, V13, P4; Ernst E, 2000, COMPLEMENT THER MED, V8, P32, DOI 10.1016/S0965-2299(00)90833-1; Ernst E, 1998, AM J MED, V104, P170, DOI 10.1016/S0002-9343(97)00397-5; Ernst E, 2000, BRIT MED J, V321, P707; Ernst E, 1998, EUR J CLIN PHARMACOL, V54, P99, DOI 10.1007/s002280050428; Ernst E, 1999, LANCET, V354, P2014, DOI 10.1016/S0140-6736(99)00418-3; ERNST E, 1994, BRIT MED J, V308, P1640, DOI 10.1136/bmj.308.6944.1640; Ernst E, 1999, CLIN DRUG INVEST, V17, P301, DOI 10.2165/00044011-199917040-00006; Ernst E, 1999, CLIN OTOLARYNGOL, V24, P164, DOI 10.1046/j.1365-2273.1999.00243.x; Ernst E, 1998, PERFUSION, V11, P209; ERNST E, 2000, MEYLERS SIDE EFFECTS, P1649; FETROW CW, 1999, PROFESSIONALS HDB CO; Gallo M, 2000, ARCH INTERN MED, V160, P3141, DOI 10.1001/archinte.160.20.3141; Gaster B, 2000, ARCH INTERN MED, V160, P152, DOI 10.1001/archinte.160.2.152; HOBBS C, 1994, HERBALGRAM S, V30, P1; HOFMANN R, 1996, PSYCHO S, V22, P51; HOPFENMULLER W, 1994, ARZNEIMITTEL-FORSCH, V44-2, P1005; Janetzky K, 1997, AM J HEALTH-SYST PH, V54, P692, DOI 10.1093/ajhp/54.6.692; Jappe U, 1998, J AM ACAD DERMATOL, V38, P104, DOI 10.1016/S0190-9622(98)70547-X; JUSSOFIE A, 1994, PSYCHOPHARMACOLOGY, V116, P469, DOI 10.1007/BF02247480; Kim HL, 1999, J NERV MENT DIS, V187, P532, DOI 10.1097/00005053-199909000-00002; KLEIJNEN J, 1992, BRIT J CLIN PHARMACO, V34, P352, DOI 10.1111/j.1365-2125.1992.tb05642.x; KOLTRINGER P, 1989, PERFUSION, V1, P28; Leng GC, 2000, COCHRANE DATABASE SY; LETZEL H, 1992, VASA-J VASCULAR DIS, V21, P403; LINDE K, 2000, COCHRANE DATABASE SY; Lindenberg D, 1990, Fortschr Med, V108, P49; Lowe FC, 1999, UROLOGY, V53, P671, DOI 10.1016/S0090-4295(98)00664-5; LUETTIG B, 1989, J NATL CANCER I, V81, P669, DOI 10.1093/jnci/81.9.669; Marks LS, 2000, J UROLOGY, V163, P1451, DOI 10.1016/S0022-5347(05)67641-0; Matthews HB, 1999, ENVIRON HEALTH PERSP, V107, P773, DOI 10.2307/3454572; MELCHART D, 2000, COCHRANE DATABASE SY; Moher D, 1999, LANCET, V354, P1896, DOI 10.1016/S0140-6736(99)04149-5; Mullins RJ, 1998, MED J AUSTRALIA, V168, P170, DOI 10.5694/j.1326-5377.1998.tb126773.x; NORTON SA, 1994, J AM ACAD DERMATOL, V31, P89, DOI 10.1016/S0190-9622(94)70142-3; Oken BS, 1998, ARCH NEUROL-CHICAGO, V55, P1409, DOI 10.1001/archneur.55.11.1409; Philipp M, 1999, BRIT MED J, V319, P1534, DOI 10.1136/bmj.319.7224.1534; Piscitelli SC, 2000, LANCET, V355, P547, DOI 10.1016/S0140-6736(99)05712-8; Pittler MH, 2000, AM J MED, V108, P276, DOI 10.1016/S0002-9343(99)00454-4; Pittler MH, 2000, J CLIN PSYCHOPHARM, V20, P84, DOI 10.1097/00004714-200002000-00014; Relman AS, 1999, ARCH INTERN MED, V159, P2122; Ruschitzka F, 2000, LANCET, V355, P548, DOI 10.1016/S0140-6736(99)05467-7; Schulz V, 2000, PERFUSION-GERMANY, V13, P486; SCHULZ V, 1999, RATIONALE PHYTOTHERA; Siegers C.P., 1992, ARZNEIMITTEL-FORSCH, V39, P7; Stevinson C, 1999, CNS DRUGS, V11, P125, DOI 10.2165/00023210-199911020-00004; Stevinson C, 1999, EUR NEUROPSYCHOPHARM, V9, P501, DOI 10.1016/S0924-977X(99)00032-2; Stevinson C, 2000, ANN INTERN MED, V133, P420, DOI 10.7326/0003-4819-133-6-200009190-00009; STOLLER A, 2000, SCHWEIZERISCHE ARZTE, V133, P5; TYLER VE, 2000, HNR, V7, P279; Vogler BK, 1999, EUR J CLIN PHARMACOL, V55, P567, DOI 10.1007/s002280050674; Vuksan V, 2000, ARCH INTERN MED, V160, P1009, DOI 10.1001/archinte.160.7.1009; Wagner PJ, 1999, J FAM PRACTICE, V48, P615; White A., 2001, DESKTOP GUIDE COMPLE; WILKS J, 1999, INT J ALTERNATIV SEP, P1; Williams JW, 2000, ANN INTERN MED, V132, P743, DOI 10.7326/0003-4819-132-9-200005020-00011; WILT T, 2000, COCHRANE DATABASE SY; YOKOZAWA T, 1975, CHEM PHARM BULL, V23, P3095; Yue QY, 2000, LANCET, V355, P576, DOI 10.1016/S0140-6736(05)73227-X; Yun TK, 1998, INT J EPIDEMIOL, V27, P359, DOI 10.1093/ije/27.3.359	74	333	366	0	93	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JAN 1	2002	136	1					42	53		10.7326/0003-4819-136-1-200201010-00010	http://dx.doi.org/10.7326/0003-4819-136-1-200201010-00010			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	510BF	11777363				2023-01-03	WOS:000173188300005
J	Suri, R; Metcalfe, C; Lees, B; Grieve, R; Flather, M; Normand, C; Thompson, S; Bush, A; Wallis, C				Suri, R; Metcalfe, C; Lees, B; Grieve, R; Flather, M; Normand, C; Thompson, S; Bush, A; Wallis, C			Comparison of hypertonic saline and alternate-day or daily recombinant human deoxyribonuclease in children with cystic fibrosis: a randomised trial	LANCET			English	Article							HUMAN DNASE-I; MUCOCILIARY CLEARANCE; PULMONARY-FUNCTION; EFFICACY; SAFETY	Background Daily recombinant human deoxyribonuclease (rhDNase) is an established but expensive treatment in cystic fibrosis. Alternate-day treatment, if equally effective, would reduce the drug cost. Hypertonic saline improved lung function to the same degree as rhDNase in short-term studies. We compared the effectiveness of daily rhDNase, hypertonic saline, and alternate-day rhDNase in children with cystic fibrosis. Methods In an open cross-over trial, 48 children were allocated in random order to 12 weeks of once-daily rhDNase (2.5 mg), alternate-day rhDNase (2.5 mg), and twice-daily 5 mL 7% hypertonic saline. The primary outcome was forced expiratory volume in 1 s (FEV1). Secondary outcomes were forced vital capacity, number of pulmonary exacerbations, weight gain, quality of life, exercise tolerance, and the total costs of hospital and community care. Findings Mean FEV1 increased by 16% (SD 25%), 14% (22%), and 3% (21%) with daily rhDNase, alternate-day rhDNase, and hypertonic saline, respectively. There was no difference between daily and alternate-day rhDNase (2% [95% Cl -4 to 9], p=0.55). However, daily rhDNase showed a significantly greater increase in FEV, than hypertonic saline (8% [2 to 14], p=0.01). The average difference in 12-week cost between daily and alternate-day rhDNase was pound 513 (95% Cl -546 to 1510) and that between daily rhDNase and hypertonic saline was pound 1409 (440 to 2318). None of the secondary clinical outcomes showed significant differences between treatments. Interpretation Hypertonic saline, delivered by jet nebuliser, is not as effective as daily rhDNase, although there is variation in individual response. There is no evidence of a difference between daily and alternate-day rhDNase.	Great Ormond St Hosp Sick Children, Resp Unit, London WC1N 3JH, England; Royal Brompton & Harefield NHS Trust, Dept Resp Paediat, London, England; Royal Brompton & Harefield NHS Trust, Clin Trials & Evaluat Unit, London, England; Univ Bristol, Dept Social Med, Bristol, Avon, England; London Sch Hyg & Trop Med, London WC1, England; MRC, Biostat Unit, Inst Publ Hlth, Cambridge CB2 2BW, England	University of London; University College London; Great Ormond Street Hospital for Children NHS Foundation Trust; Royal Brompton & Harefield NHS Foundation Trust; Royal Brompton Hospital; Royal Brompton & Harefield NHS Foundation Trust; Royal Brompton Hospital; University of Bristol; University of London; London School of Hygiene & Tropical Medicine; MRC Biostatistics Unit; University of Cambridge	Suri, R (corresponding author), Great Ormond St Hosp Sick Children, Resp Unit, 6th Floor,Cardiac Wing, London WC1N 3JH, England.	suriranjan@hotmail.com		Grieve, Richard/0000-0001-8899-1301; Metcalfe, Chris/0000-0001-8318-8907; Normand, Charles/0000-0002-0885-5754				ADAMS L, 1985, CLIN SCI, V69, P7, DOI 10.1042/cs0690007; [Anonymous], 1995, AM J RESP CRIT CARE, V152, P1107, DOI 10.1164/ajrccm.152.3.7663792; Balfour-Lynn IM, 1998, PEDIATR PULM, V25, P278, DOI 10.1002/(SICI)1099-0496(199804)25:4<278::AID-PPUL8>3.0.CO;2-G; BALLMANN M, 1998, PEDIAT PULMONOL S17, V26, P343; *BRIT MED ASS ROY, 1999, BRIT NAT FORM, V38; CHERNICK WS, 1959, PEDIATRICS, V24, P739; COOPER PJ, 1990, PEDIATR PULM, V8, P16, DOI 10.1002/ppul.1950080107; Davies J, 1997, PEDIATR PULM, V23, P243, DOI 10.1002/(SICI)1099-0496(199704)23:4<243::AID-PPUL1>3.0.CO;2-N; Diggle PJ, 1994, ANAL LONGITUDINAL DA, V1st; Drummond M.F., 2015, METHODS EC EVALUATIO, V4; Eng PA, 1996, PEDIATR PULM, V21, P77, DOI 10.1002/(SICI)1099-0496(199602)21:2<77::AID-PPUL3>3.0.CO;2-M; FITZSIMMONS SC, 1993, J PEDIATR-US, V122, P1, DOI 10.1016/S0022-3476(05)83478-X; FUCHS HJ, 1994, NEW ENGL J MED, V331, P637, DOI 10.1056/NEJM199409083311003; Geddes DM, 1999, LANCET, V353, P1727, DOI 10.1016/S0140-6736(98)00411-5; Gift A G, 1989, Rehabil Nurs, V14, P323; Netten A, 1999, UNIT COSTS HLTH SOCI; ORENSTEIN DM, 1989, CHEST, V95, P344, DOI 10.1378/chest.95.2.344; Polgar G, 1971, PULMONARY FUNCTION T; RAMSEY BW, 1994, PEDIATR PULM, V17, P404, DOI 10.1002/ppul.1950170613; RAMSEY BW, 1993, AM REV RESPIR DIS, V148, P145, DOI 10.1164/ajrccm/148.1.145; RANASINHA C, 1993, LANCET, V342, P199, DOI 10.1016/0140-6736(93)92297-7; Riedler J, 1996, J PAEDIATR CHILD H, V32, P48, DOI 10.1111/j.1440-1754.1996.tb01541.x; Robinson M, 1996, AM J RESP CRIT CARE, V153, P1503, DOI 10.1164/ajrccm.153.5.8630593; Robinson M, 1997, THORAX, V52, P900, DOI 10.1136/thx.52.10.900; SHAK S, 1990, P NATL ACAD SCI USA, V87, P9188, DOI 10.1073/pnas.87.23.9188; SMITH G, 1986, J ADOLESCENT HEALTH, V7, P134, DOI 10.1016/S0197-0070(86)80009-2; Smith JJ, 1996, CELL, V85, P229, DOI 10.1016/S0092-8674(00)81099-5; Thompson SG, 2000, BRIT MED J, V320, P1197, DOI 10.1136/bmj.320.7243.1197; Weinstein MC., 1996, COST EFFECTIVENESS H	29	116	120	0	2	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	OCT 20	2001	358	9290					1316	1321		10.1016/S0140-6736(01)06412-1	http://dx.doi.org/10.1016/S0140-6736(01)06412-1			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	484RC	11684212				2023-01-03	WOS:000171702500011
J	Woloshin, S; Schwartz, LM; Tremmel, J; Welch, HG				Woloshin, S; Schwartz, LM; Tremmel, J; Welch, HG			Direct-to-consumer advertisements for prescription drugs: what are Americans being sold?	LANCET			English	Article							JOURNALS; BENEFITS	Background Pharmaceutical companies spent US$1.8 billion on direct-to-consumer advertisements for prescription drugs in 1999. Our aim was to establish what messages are being communicated to the public by these advertisements. Methods We investigated the content of advertisements, which appeared in ten magazines in the USA. We examined seven issues of each of these published between July, 1998, and July, 1999. Findings 67 advertisements appeared a total of 211 times during our study. Of these, 133 (63%) were for drugs to ameliorate symptoms, 54 (26%) to treat disease, and 23 (11%) to prevent illness. In the 67 unique advertisements, promotional techniques used included emotional appeals (45, 67%) and encouragement of consumers to consider medical causes for their experiences (26, 39%). More advertisements described the benefit of medication with vague, qualitative terms (58, 87%), than with data (9, 13%). However, half the advertisements used data to describe side-effects, typically with lists of side-effects that generally occurred infrequently. None mentioned cost. Interpretation Provision of complete information about the benefit of prescription drugs in advertisements would serve the interests of physicians and the public.	Dept Vet Affairs Med Ctr, VA Outcomes Grp, White River Jct, VT 05009 USA; Dartmouth Coll Sch Med, Ctr Evaluat Clin Sci, Hanover, NH USA; Norris Cotton Canc Ctr, Lebanon, NH USA; Dartmouth Hitchcock Med Ctr, Dept Med, Lebanon, NH 03766 USA	VA Outcomes Group; Dartmouth College; Norris Cotton Cancer Center; Dartmouth College	Schwartz, LM (corresponding author), Dept Vet Affairs Med Ctr, VA Outcomes Grp, White River Jct, VT 05009 USA.				NATIONAL CANCER INSTITUTE [R18CA091052] Funding Source: NIH RePORTER; NCI NIH HHS [CA9 1052-01] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		*AM PHARM ASS, 1997, AM PHARM ASS PREV MA; Bell RA, 1999, J GEN INTERN MED, V14, P651, DOI 10.1046/j.1525-1497.1999.01049.x; Bell RA, 1999, J FAM PRACTICE, V48, P446; Bell RA, 2000, J FAM PRACTICE, V49, P1092; Charatan F, 2000, BRIT MED J, V321, P783, DOI 10.1136/bmj.321.7264.783; COHEN EP, 1988, NEW ENGL J MED, V318, P373, DOI 10.1056/NEJM198802113180608; Ferriman, 1999, BMJ, V319, P1208; *FOOD DRUGS ADM, 1985, FED REGISTER, V50, P36677; HAYNES RB, 1978, NEW ENGL J MED, V299, P741, DOI 10.1056/NEJM197810052991403; HERXHEIMER A, 1993, INT J HEALTH SERV, V23, P161, DOI 10.2190/1AK2-X8CX-QQ9E-F6ED; Hoffman JR, 1999, BRIT MED J, V318, P1301, DOI 10.1136/bmj.318.7194.1301; Hollon MF, 1999, JAMA-J AM MED ASSOC, V281, P382, DOI 10.1001/jama.281.4.382; HOMER A, 1999, JAMA-J AM MED ASSOC, V281, P380; Hueston WJ, 1997, ACAD MED, V72, P804, DOI 10.1097/00001888-199709000-00018; HUX JE, 1995, MED DECIS MAKING, V15, P152, DOI 10.1177/0272989X9501500208; Jones M, 1999, J CLIN PHARM THER, V24, P451, DOI 10.1046/j.1365-2710.1999.00255.x; LANDIS JR, 1977, BIOMETRICS, V33, P159, DOI 10.2307/2529310; LEXCHIN J, 1994, CAN MED ASSOC J, V151, P47; Lipsky MS, 1997, J FAM PRACTICE, V45, P495; Moynihan R, 2000, NEW ENGL J MED, V342, P1645, DOI 10.1056/NEJM200006013422206; *OFF MED POL, 2000, ATT BEH ASS DIR CONS; Pines WL, 1999, FOOD DRUG LAW J, V54, P489; Stryer D, 1996, J GEN INTERN MED, V11, P575, DOI 10.1007/BF02599024; TIMMINS N, FINANCIAL TIMES 0720, P200; *US C, 1984, STAFF REP PRESCR DRU; Wilkes MS, 2000, HEALTH AFFAIR, V19, P110, DOI 10.1377/hlthaff.19.2.110; 1998, LANCET, V351, P921; 2001, NUTR FACTS BOX; 2001, DIRECT CONSUMER ADVE; 1998, MEDIAMARK RES MAGAZI; 1996, CONSUMER REPORTS, V61, P62	31	131	132	1	10	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	OCT 6	2001	358	9288					1141	1146		10.1016/S0140-6736(01)06254-7	http://dx.doi.org/10.1016/S0140-6736(01)06254-7			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	479HM	11597668				2023-01-03	WOS:000171399000011
J	Boulay, F; Berthier, F; Schoukroun, G; Raybaut, C; Gendreike, Y; Blaive, B				Boulay, F; Berthier, F; Schoukroun, G; Raybaut, C; Gendreike, Y; Blaive, B			Seasonal variations in hospital admission for deep vein thrombosis and pulmonary embolism: analysis of discharge data	BRITISH MEDICAL JOURNAL			English	Article									Nice Teaching Hosp, Dept Resp Med, F-06003 Nice 1, France; Nice Teaching Hosp, Dept Publ Hlth & Med Informat, F-06003 Nice, France	CHU Nice; CHU Nice	Boulay, F (corresponding author), Nice Teaching Hosp, Dept Publ Hlth & Med Informat, BP 1179, F-06003 Nice 1, France.							Allan TM, 1996, BRIT MED J, V312, P1227; Bounameaux H, 1996, BMJ-BRIT MED J, V312, P284; Oger E, 2000, THROMB HAEMOSTASIS, V83, P657; ROGER JH, 1977, BIOMETRIKA, V64, P152, DOI 10.2307/2335789; WOODHOUSE PR, 1994, LANCET, V343, P435, DOI 10.1016/S0140-6736(94)92689-1	5	77	79	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	SEP 15	2001	323	7313					601	602		10.1136/bmj.323.7313.601	http://dx.doi.org/10.1136/bmj.323.7313.601			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	474CT	11557707	Bronze, Green Published			2023-01-03	WOS:000171087300018
J	Zelphati, O; Wang, Y; Kitada, S; Reed, JC; Felgner, PL; Corbeil, J				Zelphati, O; Wang, Y; Kitada, S; Reed, JC; Felgner, PL; Corbeil, J			Intracellular delivery of proteins with a new lipid-mediated delivery system	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IN-VIVO; CATIONIC LIPOSOMES; CELL-DEATH; MAMMALIAN-CELLS; GENE-TRANSFER; TRANSDUCTION; MECHANISM; EFFICIENT; LYMPHOCYTE; PEPTIDE	There are many very effective methods to introduce transcriptionally active DNA into viable cells but approaches to deliver functional proteins are limited. We have developed a lipid-mediated delivery system that can deliver functional proteins or other bioactive molecules into living cells. This delivery system is composed of a new trifluoroacetylated lipopolyamine (TFA-DODAPL) and dioleoyl phosphatidylethanolamine (DOPE). This cationic formulation successfully delivered antibodies, dextran sulfates, phycobiliproteins, albumin, and enzymes (beta -galactosidase and proteases) into the cytoplasm of numerous adherent and suspension cells. Two systems were used to demonstrate that the proteins were delivered in a functionally active form. First, intracellular beta -galactosidase activity was clearly demonstrated within X-gal-stained cells after TFA-DODAPL:DOPE-mediated delivery of the enzyme. Second, the delivery system mediated delivery of several caspases (caspase 3, caspase 8, and granzyme B) into cultured cell lines and primary cells triggering apoptosis. Mechanistic studies showed that up to 100% of the protein mixed with the lipid formulation was captured into a lipid-protein complex, and up to 50% of the input protein associated with cells. This lipid-mediated transport system makes protein delivery into cultured cells as convenient, effective, and reliable as DNA transfection.	Gene Therapy Syst Inc, San Diego, CA 92121 USA; Burnham Inst, La Jolla, CA 92037 USA; Univ Calif San Diego, Dept Med, La Jolla, CA 92093 USA; San Diego Vet Adm Healthcare Syst, La Jolla, CA 92093 USA	Sanford Burnham Prebys Medical Discovery Institute; University of California System; University of California San Diego	Zelphati, O (corresponding author), Gene Therapy Syst Inc, 10190 Telesis Court, San Diego, CA 92121 USA.		Corbeil, Jacques/AAW-9739-2020	Corbeil, Jacques/0000-0002-9973-2740	NCI NIH HHS [CA55164] Funding Source: Medline; NIAID NIH HHS [AI47703, AI46237, AI36214] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA055164] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P30AI036214, R21AI047703, R01AI046237] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ABARZUA P, 1995, CANCER RES, V55, P3490; Arrigo AP, 1998, BIOL CHEM, V379, P19; BOUSSIF O, 1995, P NATL ACAD SCI USA, V92, P7297, DOI 10.1073/pnas.92.16.7297; DEBS RJ, 1990, J BIOL CHEM, V265, P10189; DEROSSI D, 1994, J BIOL CHEM, V269, P10444; Elliott G, 1997, CELL, V88, P223, DOI 10.1016/S0092-8674(00)81843-7; FARHOOD H, 1995, ANAL BIOCHEM, V225, P89, DOI 10.1006/abio.1995.1112; FAWELL S, 1994, P NATL ACAD SCI USA, V91, P664, DOI 10.1073/pnas.91.2.664; FELGNER JH, 1994, J BIOL CHEM, V269, P2550; FELGNER PL, 1987, P NATL ACAD SCI USA, V84, P7413, DOI 10.1073/pnas.84.21.7413; Fenton M, 1998, J IMMUNOL METHODS, V212, P41, DOI 10.1016/S0022-1759(97)00208-1; Gao X, 1995, GENE THER, V2, P710; Guillaume C, 2000, J PHARM SCI, V89, P639, DOI 10.1002/(SICI)1520-6017(200005)89:5<639::AID-JPS9>3.0.CO;2-L; Hengartner MO, 2000, NATURE, V407, P770, DOI 10.1038/35037710; Huang L, 1995, BIOCHEM BIOPH RES CO, V217, P761, DOI 10.1006/bbrc.1995.2838; Kroemer G, 2000, NAT MED, V6, P513, DOI 10.1038/74994; MARRERO MB, 1995, J BIOL CHEM, V270, P15734, DOI 10.1074/jbc.270.26.15734; Mi ZB, 2000, MOL THER, V2, P339, DOI 10.1006/mthe.2000.0137; Nigg EA, 1997, NATURE, V386, P779, DOI 10.1038/386779a0; PEREZ F, 1992, J CELL SCI, V102, P717; Reed JC, 2000, CURR OPIN BIOTECH, V11, P586, DOI 10.1016/S0958-1669(00)00148-8; Rojas M, 1998, NAT BIOTECHNOL, V16, P370, DOI 10.1038/nbt0498-370; Savill J, 2000, NATURE, V407, P784, DOI 10.1038/35037722; Schwarze SR, 2000, TRENDS CELL BIOL, V10, P290, DOI 10.1016/S0962-8924(00)01771-2; Schwarze SR, 1999, SCIENCE, V285, P1569, DOI 10.1126/science.285.5433.1569; SELLS MA, 1995, BIOTECHNIQUES, V19, P72; Trapani JA, 2000, CURR OPIN IMMUNOL, V12, P323, DOI 10.1016/S0952-7915(00)00094-7; Vocero-Akbani AM, 1999, NAT MED, V5, P29, DOI 10.1038/4710; WALKER C, 1992, P NATL ACAD SCI USA, V89, P7915, DOI 10.1073/pnas.89.17.7915; Xu YH, 1996, BIOCHEMISTRY-US, V35, P5616, DOI 10.1021/bi9602019; ZABNER J, 1995, J BIOL CHEM, V270, P18997, DOI 10.1074/jbc.270.32.18997; Zelphati O, 1996, PHARMACEUT RES, V13, P1367, DOI 10.1023/A:1016026101195; Zelphati O, 1996, P NATL ACAD SCI USA, V93, P11493, DOI 10.1073/pnas.93.21.11493	33	184	218	1	32	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 14	2001	276	37					35103	35110		10.1074/jbc.M104920200	http://dx.doi.org/10.1074/jbc.M104920200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	473DK	11447231	hybrid			2023-01-03	WOS:000171024600100
J	Hu, JD; Ma, XR; Lindner, DJ; Karra, S; Hofmann, ER; Reddy, SPM; Kalvakolanu, DV				Hu, JD; Ma, XR; Lindner, DJ; Karra, S; Hofmann, ER; Reddy, SPM; Kalvakolanu, DV			Modulation of p53 dependent gene expression and cell death through thioredoxin-thioredoxin reductase by the interferon-retinoid combination	ONCOGENE			English	Article						cytokines; vitamin; growth suppression; apoptosis; redox state	HUMAN TUMOR-CELLS; REDOX REGULATION; DNA-BINDING; MOLECULAR-CLONING; SUPPRESSES GROWTH; INDUCED APOPTOSIS; VITAMIN-A; CANCER; RECEPTOR; PROTEIN	We have shown earlier that the IFN-P and all-trans retinoic acid (RA) combination, but not the single agents, induces death in several tumor cell lines. Employing a genetic technique we have identified several Genes associated with Retinoid-IFN induced Mortality (GRIM), One of the GRIMs was human thioredoxin reductase (TR), a redox enzyme. Since the overexpressed TR augments IFN/RA stimulated cell death, we explored the mechanisms of TR-mediated death, Here we show that TR augments cell death by upregulating the transcriptional activity of p53 tumor suppressor. This process does not involve a physical increase in levels of p53, Using redox inactive mutants of TR and its substrate, thioredoxin (Trx), we demonstrate that IFN/ RA-induced regulation of p53 dependent gene expression requires TR and Trx, In contrast-over-expression of wildtype TR or Trx augment the p53 dependent gene expression in response to IFN/RA treatment. Consistent with these results an increased DNA binding activity of p53 was noted in the presence of TR, These studies identify a novel mechanism of p53 mediated cell death regulation involving redox enzymes.	Univ Maryland, Sch Med, Dept Microbiol & Immunol, Greenebaum Canc Ctr,Mol & Cellular Biol Program, Baltimore, MD 21201 USA; Johns Hopkins Univ, Sch Publ Hlth, Dept Environm Sci, Baltimore, MD USA	University System of Maryland; University of Maryland Baltimore; Johns Hopkins University	Kalvakolanu, DV (corresponding author), Univ Maryland, Sch Med, Dept Microbiol & Immunol, Greenebaum Canc Ctr,Mol & Cellular Biol Program, Baltimore, MD 21201 USA.	dkalvako@umaryland.edu	Lindner, Daniel/ABB-5440-2020		NCI NIH HHS [CA 71401, CA 78282] Funding Source: Medline; NHLBI NIH HHS [HL-58122] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA078282, R01CA071401] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL058122, R29HL058122] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Akamatsu Y, 1997, J BIOL CHEM, V272, P14497, DOI 10.1074/jbc.272.23.14497; Arner ESJ, 2000, EUR J BIOCHEM, V267, P6102, DOI 10.1046/j.1432-1327.2000.01701.x; Ausubel F.M., 1994, SHORT PROTOCOLS MOL; BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BALCERKUBICZEK EK, 1995, RADIAT RES, V142, P256, DOI 10.2307/3579133; BISCHOFF JR, 1992, MOL CELL BIOL, V12, P1405, DOI 10.1128/MCB.12.4.1405; Casso D, 1996, MOL GEN GENET, V252, P518, DOI 10.1007/BF02172398; CHO YJ, 1994, SCIENCE, V265, P346, DOI 10.1126/science.8023157; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; DEISS LP, 1991, SCIENCE, V252, P117, DOI 10.1126/science.1901424; DELPHIN C, 1994, EUR J BIOCHEM, V223, P683, DOI 10.1111/j.1432-1033.1994.tb19041.x; Di Leonardo A, 1997, CANCER RES, V57, P1013; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Ema M, 1999, EMBO J, V18, P1905, DOI 10.1093/emboj/18.7.1905; Epstein CB, 1998, ONCOGENE, V16, P2115, DOI 10.1038/sj.onc.1201734; FAN SJ, 1995, CANCER RES, V55, P1649; Gaiddon C, 1999, EMBO J, V18, P5609, DOI 10.1093/emboj/18.20.5609; Glass CK, 1997, CURR OPIN CELL BIOL, V9, P222, DOI 10.1016/S0955-0674(97)80066-X; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Gross A, 1998, EMBO J, V17, P3878, DOI 10.1093/emboj/17.14.3878; GUTTERMAN JU, 1994, P NATL ACAD SCI USA, V91, P1198, DOI 10.1073/pnas.91.4.1198; HAINAUT P, 1993, CANCER RES, V53, P4469; HARTMAN H, 1993, P NATL ACAD SCI USA, V90, P2271, DOI 10.1073/pnas.90.6.2271; HAYASHI T, 1993, J BIOL CHEM, V268, P11380; Hirota K, 1997, P NATL ACAD SCI USA, V94, P3633, DOI 10.1073/pnas.94.8.3633; Hofman ER, 1998, MOL CELL BIOL, V18, P6493, DOI 10.1128/MCB.18.11.6493; Holtschke T, 1996, CELL, V87, P307, DOI 10.1016/S0092-8674(00)81348-3; Jayaraman L, 1999, CELL MOL LIFE SCI, V55, P76, DOI 10.1007/s000180050271; Kaplan DH, 1998, P NATL ACAD SCI USA, V95, P7556, DOI 10.1073/pnas.95.13.7556; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; KESSIS TD, 1993, P NATL ACAD SCI USA, V90, P3988, DOI 10.1073/pnas.90.9.3988; Kurooka H, 1997, GENOMICS, V39, P331, DOI 10.1006/geno.1996.4493; Kuwata T, 2000, BLOOD, V95, P3349, DOI 10.1182/blood.V95.11.3349; Lee KK, 1998, J BIOL CHEM, V273, P19160, DOI 10.1074/jbc.273.30.19160; Lee SR, 1999, J BIOL CHEM, V274, P4722, DOI 10.1074/jbc.274.8.4722; Li H, 2000, SCIENCE, V289, P1159, DOI 10.1126/science.289.5482.1159; Lindner DJ, 1997, CLIN CANCER RES, V3, P931; Liu R, 1998, J BIOL CHEM, V273, P16985, DOI 10.1074/jbc.273.27.16985; Lotan R, 1996, FASEB J, V10, P1031, DOI 10.1096/fasebj.10.9.8801164; LOVE JM, 1994, CURR OPIN CELL BIOL, V6, P825, DOI 10.1016/0955-0674(94)90051-5; MA X, 2001, IN PRESS J BIOL CHEM; MANGELSDORF DJ, 1995, CELL, V83, P841, DOI 10.1016/0092-8674(95)90200-7; Matsui M, 1996, DEV BIOL, V178, P179, DOI 10.1006/dbio.1996.0208; MIYASHITA T, 1995, CELL, V80, P293; MOORE DM, 1994, SEMIN HEMATOL, V31, P31; Nagy L, 1998, CELL DEATH DIFFER, V5, P11, DOI 10.1038/sj.cdd.4400337; Nechushtan A, 1999, EMBO J, V18, P2330, DOI 10.1093/emboj/18.9.2330; Pearson GD, 1998, J BIOL CHEM, V273, P5431, DOI 10.1074/jbc.273.10.5431; Polyak K, 1997, NATURE, V389, P300, DOI 10.1038/38525; Potapova O, 2000, MOL CELL BIOL, V20, P1713, DOI 10.1128/MCB.20.5.1713-1722.2000; Raveh T, 1996, J BIOL CHEM, V271, P25479, DOI 10.1074/jbc.271.41.25479; RESNITZKY D, 1992, P NATL ACAD SCI USA, V89, P402, DOI 10.1073/pnas.89.1.402; RUBARTELLI A, 1995, CANCER RES, V55, P675; SALZ HK, 1994, GENETICS, V136, P1075; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; Somasundaram K, 1997, NATURE, V389, P187, DOI 10.1038/38291; Spyrou G, 1997, J BIOL CHEM, V272, P2936, DOI 10.1074/jbc.272.5.2936; Sun QA, 1999, J BIOL CHEM, V274, P24522, DOI 10.1074/jbc.274.35.24522; Sun SY, 1999, ONCOGENE, V18, P2357, DOI 10.1038/sj.onc.1202543; Sun SY, 2000, CLIN CANCER RES, V6, P1563; Tanioka A, 1997, COLLOID SURFACE B, V9, P17, DOI 10.1016/S0927-7765(97)00006-4; Tiefenbrun N, 1996, MOL CELL BIOL, V16, P3934; TSUKADA T, 1993, ONCOGENE, V8, P3313; Ueno M, 1999, J BIOL CHEM, V274, P35809, DOI 10.1074/jbc.274.50.35809; VanderHeiden MG, 1997, CELL, V91, P627, DOI 10.1016/S0092-8674(00)80450-X; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; WAGNER P, 1993, EUR J BIOCHEM, V217, P731, DOI 10.1111/j.1432-1033.1993.tb18299.x; Xiao WH, 1997, P NATL ACAD SCI USA, V94, P103, DOI 10.1073/pnas.94.1.103	69	27	28	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 12	2001	20	31					4235	4248		10.1038/sj.onc.1204585	http://dx.doi.org/10.1038/sj.onc.1204585			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	452KQ	11464290				2023-01-03	WOS:000169857200014
J	Chadwick, D				Chadwick, D			Vagal-nerve stimulation for epilepsy	LANCET			English	Editorial Material							VAGUS NERVE; SEIZURES; CHILDREN; TRIAL		Univ Liverpool, Walton Ctr Neurol & Neurosurg, Dept Neurol Sci, Liverpool L9 7IJ, Merseyside, England	University of Liverpool; Walton Centre	Chadwick, D (corresponding author), Univ Liverpool, Walton Ctr Neurol & Neurosurg, Dept Neurol Sci, Liverpool L9 7IJ, Merseyside, England.							Annegers JF, 2000, EPILEPSIA, V41, P549, DOI 10.1111/j.1528-1157.2000.tb00208.x; DeGiorgio CM, 2000, EPILEPSIA, V41, P1195, DOI 10.1111/j.1528-1157.2000.tb00325.x; GEORGE R, 1995, NEUROLOGY, V45, P224, DOI 10.1212/wnl.45.2.224; Handforth A, 1998, NEUROLOGY, V51, P48, DOI 10.1212/WNL.51.1.48; Labar D, 2000, DEV MED CHILD NEUROL, V42, P496, DOI 10.1017/S001216220000092X; Marson AG, 2001, J NEUROL NEUROSUR PS, V70, P143, DOI 10.1136/jnnp.70.2.143; MCLACHLAN RS, 1993, EPILEPSIA, V34, P918, DOI 10.1111/j.1528-1157.1993.tb02112.x; Patwardhan RV, 2000, NEUROSURGERY, V47, P1353, DOI 10.1097/00006123-200012000-00016; Salinsky MC, 1996, ARCH NEUROL-CHICAGO, V53, P1176, DOI 10.1001/archneur.1996.00550110128021; Tatum WO, 1999, NEUROLOGY, V52, P1267, DOI 10.1212/WNL.52.6.1267; WOODBURY DM, 1990, EPILEPSIA, V31, pS7, DOI 10.1111/j.1528-1157.1990.tb05852.x; ZABARA J, 1992, EPILEPSIA, V33, P1005, DOI 10.1111/j.1528-1157.1992.tb01751.x	12	20	20	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUN 2	2001	357	9270					1726	1727		10.1016/S0140-6736(00)04933-3	http://dx.doi.org/10.1016/S0140-6736(00)04933-3			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	440BN	11403805				2023-01-03	WOS:000169156200006
J	Moher, M; Yudkin, P; Wright, L; Turner, R; Fuller, A; Schofield, T; Mant, D				Moher, M; Yudkin, P; Wright, L; Turner, R; Fuller, A; Schofield, T; Mant, D		Assessment Implementation Strategi	Cluster randomised controlled trial to compare three methods of promoting secondary prevention of coronary heart disease in primary care	BMJ-BRITISH MEDICAL JOURNAL			English	Article							GENERAL-PRACTITIONERS; INTERVENTION	Objective To assess the effectiveness of three different methods of promoting secondary prevention of coronary heart disease in primary care. Design Pragmatic, unblinded, duster randomised controlled trial. Setting Warwickshire. Subjects 21 general practices received intervention; outcome measured in 1906 patients aged 55-75 years with established coronary heart disease. Interventions Audit of notes with summary feedback to primary health care team (audit group); assistance with setting up a disease register and systematic recall of patients to general practitioner (GP recall group); assistance with setting up a disease register and systematic recall of patients to a nurse led clinic (nurse recall group). Main outcome measures At 18 months' follow up: adequate assessment (defined) of 3 risk factors (blood pressure, cholesterol, and smoking status); prescribing of hypotensive agents, lipid lowering drugs, and antiplatelet drugs; blood pressure, serum cholesterol level, and plasma cotinine levels. Results Adequate assessment of all 3 risk factors was much more common in the nurse and GP recall groups (85%,76%) than the audit group (52%). The advantage in the nurse recall compared with the audit group was 33% (95% confidence interval 19% to 46%); in the GP recall group compared with the audit group 23% (10% to 36%), and in the nurse recall group compared with the GP recall group 9% (-3% to 22%). However, these differences in assessment were not reflected in clinical outcomes. Mean blood pressure (148/80, 147/81, 148/81 mm Hp), total cholesterol (5.4, 5.5, 5.5 mmol/l), and cotinine levels (% probable smokers 17%, 16%, 19%) varied little between the nurse recall, GP recall, and audit groups respectively, as did prescribing of hypotensive and lipid lowering agents. Prescribing of antiplatelet drugs was higher in the nurse recall group (85%) than the GP recall or audit groups (80%, 74%). After adjustment for baseline levels, the advantage in the nurse recall group compared with the audit group was 10% (3% to 17%), in the nurse recall group compared with the GP recall group 8% (1% to 15%) and in the GP recall group compared with the audit group 2'% (- 6% to 10%). Conclusions Setting up a register and recall system improved patient assessment at 18 months' follow up but was not consistently better than audit alone in improving treatment or risk factor levels. Understanding the reasons for this is the key next step in improving the quality of care of patients with coronary heart disease.	Univ Oxford, Inst Hlth Sci, Dept Primary Hlth Care, Oxford OX3 7LF, England; MRC, Clin Trials Unit, London NW1 2AD, England	University of Oxford; Medical Research Council Clinical Trials Unit	Moher, M (corresponding author), Univ Oxford, Inst Hlth Sci, Dept Primary Hlth Care, Oxford OX3 7LF, England.	michael.moher@dphpc.ox.ac.uk	Mant, David CA/C-7763-2009					[Anonymous], 1999, EFFECTIVE HLTH CARE, V5; Bowker TJ, 1996, HEART, V75, P334, DOI 10.1136/hrt.75.4.334; Campbell M, 2000, J Health Serv Res Policy, V5, P12; Campbell NC, 1998, BMJ-BRIT MED J, V316, P1430, DOI 10.1136/bmj.316.7142.1430; Campbell NC, 1998, BMJ-BRIT MED J, V316, P1434, DOI 10.1136/bmj.316.7142.1434; CUPPLES ME, 1994, BRIT MED J, V309, P993, DOI 10.1136/bmj.309.6960.993; *DEP HLTH, 2000, NAT SERV FRAM COR HE; DONNER A, 1994, AM J EPIDEMIOL, V140, P279, DOI 10.1093/oxfordjournals.aje.a117247; Donner A, 1996, J CLIN EPIDEMIOL, V49, P435, DOI 10.1016/0895-4356(95)00511-0; DONNER A, 1981, AM J EPIDEMIOL, V114, P906, DOI 10.1093/oxfordjournals.aje.a113261; Feder G, 1999, BRIT MED J, V318, P1522, DOI 10.1136/bmj.318.7197.1522; FEDER G, 1995, BRIT MED J, V311, P1473, DOI 10.1136/bmj.311.7018.1473; JARVIS MJ, 1987, AM J PUBLIC HEALTH, V77, P1435, DOI 10.2105/AJPH.77.11.1435; Jolly K, 1999, BMJ-BRIT MED J, V318, P706; McCartney P, 1997, BRIT MED J, V315, P35, DOI 10.1136/bmj.315.7099.35; Moher M, 2000, BRIT J GEN PRACT, V50, P706; Moher M., 1995, EVIDENCE EFFECTIVENE; NELSON E, 1987, J CHRON DIS, V40, pS55, DOI 10.1016/S0021-9681(87)80033-4; Omar RZ, 2000, STAT MED, V19, P2675, DOI 10.1002/1097-0258(20001015)19:19<2675::AID-SIM556>3.3.CO;2-1; PIERCE M, 1989, BMJ-BRIT MED J, V299, P160, DOI 10.1136/bmj.299.6692.160; Rogers S, 2000, BRIT MED J, V320, P1580, DOI 10.1136/bmj.320.7249.1580; SHAPER AG, 1985, J EPIDEMIOL COMMUN H, V39, P197, DOI 10.1136/jech.39.3.197; SOUMERAI SB, 1990, JAMA-J AM MED ASSOC, V263, P549, DOI 10.1001/jama.263.4.549; WILLIAMS A, 1990, HEALTH POLICY, V16, P199; Wilson S, 2000, BMJ-BRIT MED J, V321, P24, DOI 10.1136/bmj.321.7252.24	25	101	103	0	3	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUN 2	2001	322	7298					1338	1342A		10.1136/bmj.322.7298.1338	http://dx.doi.org/10.1136/bmj.322.7298.1338			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	440GQ	11387182	Bronze, Green Published, Green Submitted			2023-01-03	WOS:000169167900020
J	Yu, CL; Chen, Y; Cline, GW; Zhang, DY; Zong, HH; Wang, YL; Bergeron, R; Kim, JK; Cushman, SW; Cooney, GJ; Atcheson, B; White, MF; Kraegen, EW; Shulman, GI				Yu, CL; Chen, Y; Cline, GW; Zhang, DY; Zong, HH; Wang, YL; Bergeron, R; Kim, JK; Cushman, SW; Cooney, GJ; Atcheson, B; White, MF; Kraegen, EW; Shulman, GI			Mechanism by which fatty acids inhibit insulin activation of insulin receptor substrate-1 (IRS-1)-associated phosphatidylinositol 3-kinase activity in muscle	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SOLID-PHASE EXTRACTION; SKELETAL-MUSCLE; RESISTANCE; HUMANS; TRIGLYCERIDE; TISSUE; SPECTROSCOPY; ASSOCIATION; THETA; RAT	Recent studies have demonstrated that fatty acids induce insulin resistance in skeletal muscle by blocking insulin activation of insulin receptor substrate-1 (IRS-1)-associated phosphatidylinositol 3-kinase (PI3-kinase). To examine the mechanism by which fatty acids mediate this effect, rats were infused with either a lipid emulsion (consisting mostly of 18:2 fatty acids) or glycerol. Intracellular C18:2 CoA increased in a time-dependent fashion, reaching an similar to6-fold elevation by 5 h, whereas there was no change in the concentration of any other fatty acyl-CoAs. Diacylglycerol (DAG) also increased transiently after 3-4 h of lipid infusion. In contrast there was no increase in intracellular ceramide or triglyceride concentrations during the lipid infusion. Increases in intracellular C18:2 CoA and DAG concentration were associated with protein kinase C (PKC)-theta activation and a reduction in both insulin-stimulated IRS-1 tyrosine phosphorylation and IRS-1 associated PI3-kinase activity, which were associated with an increase in IRS-1 Ser(307) phosphorylation. These data support the hypothesis that an increase in plasma fatty acid concentration results in an increase in intracellular fatty acyl-CoA and DAG concentrations, which results in activation of PKC-theta leading to increased IRS-1 Ser(307) phosphorylation. This in turn leads to decreased IRS-1 tyrosine phosphorylation and decreased activation of IRS-1-associated PI3-kinase activity resulting in decreased insulin-stimulated glucose transport activity.	Yale Univ, Sch Med, Dept Internal Med, New Haven, CT 06510 USA; Yale Univ, Sch Med, Dept Cellular & Mol Physiol, New Haven, CT 06510 USA; Yale Univ, Sch Med, Howard Hughes Med Inst, New Haven, CT 06510 USA; NIDDK, NIH, Bethesda, MD 20814 USA; Harvard Univ, Sch Med, Joslin Diabet Ctr, Howard Hughes Med Inst, Boston, MA 02215 USA; Garvan Inst Med Res, Sydney, NSW, Australia	Yale University; Yale University; Howard Hughes Medical Institute; Yale University; National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); Harvard University; Harvard Medical School; Joslin Diabetes Center, Inc.; Howard Hughes Medical Institute; Garvan Institute of Medical Research	Shulman, GI (corresponding author), Yale Univ, Sch Med, Boyer Ctr Mol Med, Howard Hughes Med Inst, 295 Congress Ave,BCMM 254,Box 9812, New Haven, CT 06536 USA.	gerald.shulman@yale.edu	Shulman, Gerald I./P-7176-2019	Shulman, Gerald I./0000-0003-1529-5668; Kim, Jason/0000-0002-7185-042X	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK040936, P30DK045735] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01 DK-40936, P30 DK-45735, R01 DK040936] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Aguirre V, 2000, J BIOL CHEM, V275, P9047, DOI 10.1074/jbc.275.12.9047; BODEN G, 1995, J CLIN INVEST, V96, P1261, DOI 10.1172/JCI118160; DEUTSCH J, 1994, ANAL BIOCHEM, V220, P321, DOI 10.1006/abio.1994.1344; Dresner A, 1999, J CLIN INVEST, V103, P253, DOI 10.1172/JCI5001; Griffin ME, 1999, DIABETES, V48, P1270, DOI 10.2337/diabetes.48.6.1270; Hotamisligil GS, 1996, SCIENCE, V271, P665, DOI 10.1126/science.271.5249.665; Jacob S, 1999, DIABETES, V48, P1113, DOI 10.2337/diabetes.48.5.1113; Kim JK, 2000, J BIOL CHEM, V275, P8456, DOI 10.1074/jbc.275.12.8456; Kim JK, 2001, P NATL ACAD SCI USA, V98, P7522, DOI 10.1073/pnas.121164498; Kraegen EW, 2001, EXP CLIN ENDOCR DIAB, V109, pS189, DOI 10.1055/s-2001-18581; Krssak M, 1999, DIABETOLOGIA, V42, P113, DOI 10.1007/s001250051123; Laybutt DR, 1999, AM J PHYSIOL-ENDOC M, V277, pE1070, DOI 10.1152/ajpendo.1999.277.6.E1070; Pacheco YM, 1998, J CHROMATOGR B, V714, P127, DOI 10.1016/S0378-4347(98)00231-X; Pan DA, 1997, DIABETES, V46, P983, DOI 10.2337/diabetes.46.6.983; Perseghin G, 1999, DIABETES, V48, P1600, DOI 10.2337/diabetes.48.8.1600; RANDLE PJ, 1963, LANCET, V1, P785; RANDLE PJ, 1964, BIOCHEM J, V93, P652, DOI 10.1042/bj0930652; Roden M, 1996, J CLIN INVEST, V97, P2859, DOI 10.1172/JCI118742; Roden M, 1999, DIABETES, V48, P358, DOI 10.2337/diabetes.48.2.358; SchmitzPeiffer C, 1997, DIABETES, V46, P169, DOI 10.2337/diabetes.46.2.169; STORLIEN LH, 1991, DIABETES, V40, P280, DOI 10.2337/diabetes.40.2.280	21	1120	1158	2	83	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 27	2002	277	52					50230	50236		10.1074/jbc.M200958200	http://dx.doi.org/10.1074/jbc.M200958200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	631QD	12006582	hybrid			2023-01-03	WOS:000180177700005
J	Lai-Kee-Him, J; Chanzy, H; Muller, M; Putaux, JL; Imai, T; Bulone, V				Lai-Kee-Him, J; Chanzy, H; Muller, M; Putaux, JL; Imai, T; Bulone, V			In vitro versus in vivo cellulose microfibrils from plant primary wall synthases: Structural differences	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-GLUCAN SYNTHESIS; COTTON FIBER; X-RAY; MOLECULAR DIRECTIONALITY; ELECTRON-DIFFRACTION; MAGNETIC-RESONANCE; BIOSYNTHESIS; CHITIN; ELONGATION; EXTRACTS	Detergent extracts of microsomal fractions from suspension cultured cells of Rubus fruticosus (blackberry) were tested for their ability to synthesize in vitro sizable quantities of cellulose from UDP-glucose. Both Brij 58 and taurocholate were effective and yielded a substantial percentage of cellulose microfibrils together with (1-->3)-beta-D-glucan (callose). The taurocholate extracts, which did not require the addition of Mg2+, were the most efficient, yielding roughly 20% of cellulose. This cellulose was characterized after callose removal by methylation analysis, electron microscopy, and electron and x-ray synchrotron diffractions; its resistance toward the acid Updegraff reagent was also evaluated. The cellulose microfibrils synthesized in vitro had the same diameter as the endogenous microfibrils isolated from primary cell walls. Both polymers diffracted as cellulose IVI, a disorganized form of cellulose I. Besides these similarities, the in vitro microfibrils had a higher perfection and crystallinity as well as a better resistance toward the Updegraff reagent. These differences can be attributed to the mode of synthesis of the in vitro microfibrils that are able to grow independently in a neighbor-free environment, as opposed to the cellulose in the parent cell walls where new microfibrils have to interweave with the already laid polymers, with the result of a number of structural defects.	Univ Grenoble 1, Ctr Rech Macromol Vegetales, CERMAV, UPR 5301,CNRS, F-38041 Grenoble 9, France; European Synchrotron Radiat Facil, F-38043 Grenoble, France	Centre National de la Recherche Scientifique (CNRS); CNRS - Institute of Chemistry (INC); UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); European Synchrotron Radiation Facility (ESRF)	Bulone, V (corresponding author), Univ Lyon 1, Lab Physicochim Biol, UMR 5013, CNRS, Batiment Chevreul 4 Eme Etage,43 Blvd 11 Novembr, F-69622 Villeurbanne, France.	Vincent.Bulone@univ-lyon1.fr	Müller, Martin/I-9328-2017; Bulone, Vincent/D-7469-2013; Chanzy, Henri D/A-3526-2012; Bulone, Vincent/C-8492-2019; 今井, 友也/M-1834-2019; Putaux, Jean-Luc/A-3488-2012; PUTAUX, Jean-Luc/ABC-5309-2020	Bulone, Vincent/0000-0003-2809-4160; 今井, 友也/0000-0001-7026-0287; Putaux, Jean-Luc/0000-0002-9760-5369; PUTAUX, Jean-Luc/0000-0002-9760-5369; LAI KEE HIM, Josephine/0000-0001-6303-1224				AMOR Y, 1991, PLANT CELL, V3, P989, DOI 10.1105/tpc.3.9.989; AMOR Y, 1995, P NATL ACAD SCI USA, V92, P9353, DOI 10.1073/pnas.92.20.9353; Arioli T, 1998, SCIENCE, V279, P717, DOI 10.1126/science.279.5351.717; ATALLA R, 1999, COMPREHENSIVE NATURA, P573; BLASCHEK W, 1983, Z PFLANZENPHYSIOL, V111, P357, DOI 10.1016/S0044-328X(83)80097-X; Brown RM, 1996, J MACROMOL SCI PURE, VA33, P1345, DOI 10.1080/10601329608014912; BULONE V, 1992, EXP MYCOL, V16, P8, DOI 10.1016/0147-5975(92)90037-R; BULONE V, 1995, PLANT J, V8, P213, DOI 10.1046/j.1365-313X.1995.08020213.x; CHANZY H, 1979, PROTOPLASMA, V100, P303, DOI 10.1007/BF01279318; CHANZY H, 1978, PROTOPLASMA, V94, P299, DOI 10.1007/BF01276778; Delmer DP, 1999, ANNU REV PLANT PHYS, V50, P245, DOI 10.1146/annurev.arplant.50.1.245; DELMER DP, 1995, PLANT CELL, V7, P987, DOI 10.1105/tpc.7.7.987; Dinand E., 1999, US Patent, Patent No. 5964983; EMONS AMC, 1991, BIOSYNTHESIS BIODEGR, P71; Fagard M, 2000, PLANT CELL, V12, P2409, DOI 10.1105/tpc.12.12.2409; FAVIER V, 1995, MACROMOLECULES, V28, P6365, DOI 10.1021/ma00122a053; FEINGOLD DS, 1958, J BIOL CHEM, V233, P783; Franz G, 1990, METHODS PLANT BIOCH, V2, P291; Gautheret R.J., 1959, CULTURE TISSUS VEGET; HAASE J, 1974, COLLOID POLYM SCI, V252, P712, DOI 10.1007/BF01554496; HAMMERSLEY AP, 1994, NUCL INSTRUM METH A, V346, P312, DOI 10.1016/0168-9002(94)90720-X; Han NS, 1998, CARBOHYD RES, V313, P125, DOI 10.1016/S0008-6215(98)00253-5; HARRIS PJ, 1984, CARBOHYD RES, V127, P59, DOI 10.1016/0008-6215(84)85106-X; HAYASHI T, 1987, PLANT PHYSIOL, V83, P1054, DOI 10.1104/pp.83.4.1054; HELLER RENE, 1953, ANN SCI NAT BOT 11E SER, V14, P1; HERTH W, 1984, NATURWISSENSCHAFTEN, V71, P216, DOI 10.1007/BF00490440; Hestrin S., 1963, METHODS CARBOHYDRATE, V3, P4; Him JLK, 2001, EUR J BIOCHEM, V268, P4628, DOI 10.1046/j.1432-1327.2001.02382.x; HRMOVA M, 1993, BIOCHEM J, V289, P453, DOI 10.1042/bj2890453; Imai T, 2002, FEBS LETT, V510, P201, DOI 10.1016/S0014-5793(01)03249-5; Kimura S, 1999, PLANT CELL, V11, P2075, DOI 10.1105/tpc.11.11.2075; Kobayashi S, 2000, BIOMACROMOLECULES, V1, P168, DOI 10.1021/bm990010w; KOBAYASHI S, 1994, MACROMOL CHEM PHYSIC, V195, P1319, DOI 10.1002/macp.1994.021950416; KOGAN G, 1988, BIOPOLYMERS, V27, P1055, DOI 10.1002/bip.360270702; Koyama M, 1997, P NATL ACAD SCI USA, V94, P9091, DOI 10.1073/pnas.94.17.9091; KUBO T, 1940, J SOC CHEM IND JAPAN, V43, pB341; KUDLICKA K, 1995, PLANT PHYSIOL, V107, P111, DOI 10.1104/pp.107.1.111; Kudlicka K, 1997, PLANT PHYSIOL, V115, P643, DOI 10.1104/pp.115.2.643; Kudlicka K, 1996, AM J BOT, V83, P274, DOI 10.2307/2446162; KULSHRESHTHA AK, 1973, J POLYM SCI POL PHYS, V11, P487, DOI 10.1002/pol.1973.180110307; KULSHRESHTHA AK, 1979, J TEXT I, V70, P13, DOI 10.1080/00405007908631510; LI LK, 1993, PLANT PHYSIOL, V101, P1143, DOI 10.1104/pp.101.4.1143; MUELLER SC, 1980, J CELL BIOL, V84, P315, DOI 10.1083/jcb.84.2.315; MUELLER SC, 1976, SCIENCE, V194, P949, DOI 10.1126/science.194.4268.949; NIKAIDO H, 1971, ADV CARBOHYD CHEM BI, V26, P386; NORTHCOTE DH, 1991, BIOSYNTHESIS BIODEGR, P165; OKUDA K, 1993, PLANT PHYSIOL, V101, P1131, DOI 10.1104/pp.101.4.1131; Peng LC, 2002, SCIENCE, V295, P147, DOI 10.1126/science.1064281; PRESTON RD, 1962, POLYMER, V3, P511, DOI 10.1016/0032-3861(62)90099-X; READ SM, 1991, BIOSYNTHESIS BIODEGR, P177; Riekel C, 2000, REP PROG PHYS, V63, P233, DOI 10.1088/0034-4885/63/3/201; Roelofsen PA, 1959, PLANT CELL WALL, P126; RUIZHERRERA J, 1975, P NATL ACAD SCI USA, V72, P2706, DOI 10.1073/pnas.72.7.2706; RUIZHERRERA J, 1974, SCIENCE, V186, P357, DOI 10.1126/science.186.4161.357; SAITO H, 1977, BIOCHEMISTRY-US, V16, P908, DOI 10.1021/bi00624a015; SAITO H, 1979, CARBOHYD RES, V74, P227, DOI 10.1016/S0008-6215(00)84779-5; SAMAIN E, 1995, CARBOHYD RES, V271, P217, DOI 10.1016/0008-6215(95)00022-L; Schulein M, 1997, J BIOTECHNOL, V57, P71, DOI 10.1016/S0168-1656(97)00090-4; SEGAL L, 1971, DECRYSTALLIZED COTTO, P23; Snyder F.W., 1983, J APPL POLYM SCI, V37, P815; SUGIYAMA J, 1991, MACROMOLECULES, V24, P4168, DOI 10.1021/ma00014a033; Sugiyama J, 1999, J MOL BIOL, V286, P247, DOI 10.1006/jmbi.1998.2458; SUGIYAMA J, 1989, CELLULOSE STRUCTURAL, P75; Taylor NG, 1999, PLANT CELL, V11, P769, DOI 10.1105/tpc.11.5.769; Taylor NG, 2000, PLANT CELL, V12, P2529, DOI 10.1105/tpc.12.12.2529; Turner SR, 1997, PLANT CELL, V9, P689, DOI 10.1105/tpc.9.5.689; UPDEGRAFF DM, 1969, ANAL BIOCHEM, V32, P420, DOI 10.1016/S0003-2697(69)80009-6; Wada M, 1997, CELLULOSE, V4, P221, DOI 10.1023/A:1018435806488; WANG MC, 1976, ARCH BIOCHEM BIOPHYS, V175, P351, DOI 10.1016/0003-9861(76)90517-8; WARDROP AB, 1949, NATURE, V164, P366, DOI 10.1038/164366a0; Warren BE, 1990, XRAY DIFFRACTION, P251; WILLISON JHM, 1985, BOTANICAL MICROSCOPY, P181	72	116	126	7	44	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 4	2002	277	40					36931	36939		10.1074/jbc.M203530200	http://dx.doi.org/10.1074/jbc.M203530200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	601LH	12145282	hybrid			2023-01-03	WOS:000178447100005
J	Lacey, JV; Mink, PJ; Lubin, JH; Sherman, ME; Troisi, R; Hartge, P; Schatzkin, A; Schairer, C				Lacey, JV; Mink, PJ; Lubin, JH; Sherman, ME; Troisi, R; Hartge, P; Schatzkin, A; Schairer, C			Menopausal hormone replacement therapy and risk of ovarian cancer	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							NONCONTRACEPTIVE ESTROGEN USE; STATES CASE-CONTROL; BREAST-CANCER; UNITED-STATES; COLLABORATIVE ANALYSIS; EPITHELIAL-CELLS; RECEPTOR-ALPHA; MESSENGER-RNA; FOLLOW-UP; WOMEN	Context The association between menopausal hormone replacement therapy and ovarian cancer is unclear. Objective To determine whether hormone replacement therapy using estrogen only, estrogen-progestin only, or both estrogen only and estrogen-progestin increases ovarian cancer risk. Design A 1979-1998 cohort study of former participants in the Breast Cancer Detection Demonstration Project, a nationwide breast cancer screening program. Setting Twenty-nine US clinical centers. Participants A total of 44241 postmenopausal women (mean age at start of follow-up, 56.6 years). Main Outcome Measure Incident ovarian cancer. Results We identified 329 women who developed ovarian cancer during follow-up. In time-dependent analyses adjusted for age, menopause type, and oral contraceptive use, ever use of estrogen only was significantly associated with ovarian cancer (rate ratio [RR], 1.6; 95% confidence interval [CI], 1.2-2.0). Increasing duration of estrogen-only use was significantly associated with ovarian cancer: RRS for 10 to 19 years and 20 or more years were 1.8 (95% Cl, 1.1-3.0) and 3.2 (95% Cl, 1.7-5.7), respectively (P value for trend <.001), and we observed a 7% (95% Cl, 2%-13%) increase in RR per year of use. We observed significantly elevated RRs with increasing duration of estrogen-only use across all strata of other ovarian cancer risk factors, including women with hysterectomy. The RR for estrogen-progestin use after prior estrogen-only use was 1.5 (95% Cl, 0.91-2.4), but the RR for estrogen-progestin-only use was 1.1 (95% Cl, 0.64-1.7). The RRs for less than 2 years and 2 or more years of estrogen-progestin-only use were 1.6 (95% Cl, 0.78-3.3) and 0.80 (95% Cl, 0.35-1.8), respectively, and there was no evidence of a duration response (P value for trend =30). Conclusion Women who used estrogen-only replacement therapy, particularly for 10 or more years, were at significantly increased risk of ovarian cancer in this study. Women who used short-term estrogen-progestin-only replacement therapy were not at increased risk, but risk associated with short-term and longer-term estrogen-progestin replacement therapy warrants further investigation.	NCI, Div Canc Epidemiol & Genet, Rockville, MD 20852 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Lacey, JV (corresponding author), NCI, Div Canc Epidemiol & Genet, 6120 Execut Blvd,MSC 7234, Rockville, MD 20852 USA.							ADAMI HO, 1989, INT J CANCER, V44, P833, DOI 10.1002/ijc.2910440515; ANNEGERS JF, 1979, CANCER, V43, P723, DOI 10.1002/1097-0142(197902)43:2<723::AID-CNCR2820430248>3.0.CO;2-1; Auersperg N, 1998, SEMIN ONCOL, V25, P281; Bai WL, 2000, IN VITRO CELL DEV-AN, V36, P657; Baldwin WS, 1998, IN VITRO CELL DEV-AN, V34, P649; Beral V, 1999, J Epidemiol Biostat, V4, P191; BOOTH M, 1989, BRIT J CANCER, V60, P592, DOI 10.1038/bjc.1989.320; Brandenberger AW, 1998, J CLIN ENDOCR METAB, V83, P1025, DOI 10.1210/jc.83.3.1025; Breslow NE., 1987, STAT METHODS CANC RE, P81; Brett KM, 1997, AM J EPIDEMIOL, V145, P536; BRINTON LA, 1981, CANCER-AM CANCER SOC, V47, P2517, DOI 10.1002/1097-0142(19810515)47:10<2517::AID-CNCR2820471035>3.0.CO;2-L; Coughlin SS, 2000, J CLIN EPIDEMIOL, V53, P367, DOI 10.1016/S0895-4356(99)00179-1; CRAMER DW, 1983, JNCI-J NATL CANCER I, V71, P711; Garg PP, 1998, OBSTET GYNECOL, V92, P472, DOI 10.1016/S0029-7844(98)00139-2; HARTGE P, 1988, AM J EPIDEMIOL, V127, P990, DOI 10.1093/oxfordjournals.aje.a114902; Hempling RE, 1997, OBSTET GYNECOL, V89, P1012, DOI 10.1016/S0029-7844(97)00118-X; HILDRETH NG, 1981, AM J EPIDEMIOL, V114, P398, DOI 10.1093/oxfordjournals.aje.a113207; HOOVER R, 1977, LANCET, V2, P533; JOHN EM, 1993, JNCI-J NATL CANCER I, V85, P142, DOI 10.1093/jnci/85.2.142; KAUFMAN DW, 1989, AM J EPIDEMIOL, V130, P1142, DOI 10.1093/oxfordjournals.aje.a115441; Lau KM, 1999, P NATL ACAD SCI USA, V96, P5722, DOI 10.1073/pnas.96.10.5722; LAVECCHIA C, 1982, J NATL CANCER I, V69, P1207; LEE NC, 1986, AGING REPROD CLIMACT, P287; McKinney KA, 1998, DRUGS, V56, P49, DOI 10.2165/00003495-199856010-00005; Mink PJ, 1996, EPIDEMIOLOGY, V7, P38, DOI 10.1097/00001648-199601000-00008; Negri E, 1999, INT J CANCER, V80, P848; PARAZZINI F, 1994, INT J CANCER, V57, P135, DOI 10.1002/ijc.2910570124; Persson I, 1996, INT J CANCER, V67, P327, DOI 10.1002/(SICI)1097-0215(19960729)67:3<327::AID-IJC4>3.3.CO;2-J; Pike MC, 1998, AM J EPIDEMIOL, V147, P718; Pike MC, 2000, STEROIDS, V65, P659, DOI 10.1016/S0039-128X(00)00122-7; POLYCHRONOPOULOU A, 1993, INT J CANCER, V55, P402, DOI 10.1002/ijc.2910550312; PRESTON DL, 1996, EPICURE SOFTWARE REL; PURDIE D, 1995, INT J CANCER, V62, P678, DOI 10.1002/ijc.2910620606; Purdie DM, 1999, BRIT J CANCER, V81, P559, DOI 10.1038/sj.bjc.6690731; Riman T, 2002, JNCI-J NATL CANCER I, V94, P497, DOI 10.1093/jnci/94.7.497; Risch HA, 1996, GYNECOL ONCOL, V63, P254, DOI 10.1006/gyno.1996.0315; Risch HA, 1998, JNCI-J NATL CANCER I, V90, P1774, DOI 10.1093/jnci/90.23.1774; Risch HA, 1996, AM J EPIDEMIOL, V144, P363, DOI 10.1093/oxfordjournals.aje.a008937; Rockhill B, 2000, AM J EPIDEMIOL, V151, P404; RODRIGUEZ C, 1995, AM J EPIDEMIOL, V141, P828, DOI 10.1093/oxfordjournals.aje.a117518; Rodriguez C, 2001, JAMA-J AM MED ASSOC, V285, P1460, DOI 10.1001/jama.285.11.1460; SCHAIRER C, 1994, CANCER CAUSE CONTROL, V5, P491, DOI 10.1007/BF01831376; Schairer C, 2000, JAMA-J AM MED ASSOC, V283, P485, DOI 10.1001/jama.283.4.485; Syed V, 2001, CANCER RES, V61, P6768; TZONOU A, 1984, EUR J CANCER CLIN ON, V20, P1045, DOI 10.1016/0277-5379(84)90107-X; WEISS NS, 1982, J NATL CANCER I, V68, P95; Weiss NS, 2001, LANCET, V358, P438, DOI 10.1016/S0140-6736(01)05669-0; WHITTEMORE AS, 1992, AM J EPIDEMIOL, V136, P1184, DOI 10.1093/oxfordjournals.aje.a116427	48	412	446	0	16	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 17	2002	288	3					334	341		10.1001/jama.288.3.334	http://dx.doi.org/10.1001/jama.288.3.334			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	573AK	12117398	Bronze			2023-01-03	WOS:000176807000025
J	Kaptchuk, TJ				Kaptchuk, TJ			The placebo effect in alternative medicine: Can the performance of a healing ritual have clinical significance?	ANNALS OF INTERNAL MEDICINE			English	Review							RANDOMIZED CONTROLLED-TRIALS; BLOOD-PRESSURE RESPONSE; DOUBLE-BLIND; PATIENT COMMUNICATION; TREATMENT ADHERENCE; HEALTH OUTCOMES; UNITED-STATES; HAY-FEVER; PAIN; PHYSICIANS	In alternative medicine, the main question regarding placebo has been whether a given therapy has more than a placebo effect. Just as mainstream medicine ignores the clinical significance of its own placebo effect, the placebo effect of unconventional medicine is disregarded except for polemics. This essay looks at the placebo effect of alternative medicine as a distinct entity. This is done by reviewing current knowledge about the placebo effect and how it may pertain to alternative medicine. The term placebo effect is taken to mean not only the narrow effect of a dummy intervention but also the broad array of nonspecific effects in the patient-physician relationship, including attention; compassionate care; and the modulation of expectations, anxiety, and self-awareness. Five components of the placebo effect-patient, practitioner, patient-practitioner interaction, nature of the illness, and treatment and setting-are examined. Therapeutic patterns that heighten placebo effects are especially prominent in unconventional healing, and it seems possible that the unique drama of this realm may have "enhanced" placebo effects in particular conditions. Ultimately, only prospective trials directly comparing the placebo effects of unconventional and mainstream medicine can provide reliable evidence to support such claims. Nonetheless, the possibility of enhanced placebo effects raises complex conundrums. Can an alternative ritual with only nonspecific psychosocial effects have more positive health outcomes than a proven, specific conventional treatment? What makes therapy legitimate, positive clinical outcomes or culturally acceptable methods of attainment? Who decides?	Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, OMD, Boston, MA 02215 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School	Kaptchuk, TJ (corresponding author), Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, OMD, 330 Brookline Ave, Boston, MA 02215 USA.				NCCIH NIH HHS [1R01AT00402-01, 1R21AT00553] Funding Source: Medline; NIAMS NIH HHS [U24 AR43441] Funding Source: Medline; NATIONAL CENTER FOR COMPLEMENTARY &ALTERNATIVE MEDICINE [R21AT000553, R01AT000402] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [U24AR043441] Funding Source: NIH RePORTER	NCCIH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Complementary & Alternative Medicine); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL CENTER FOR COMPLEMENTARY &ALTERNATIVE MEDICINE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Complementary & Alternative Medicine); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Adler H M, 1997, J Am Board Fam Pract, V10, P28; ADLER HM, 1973, ANN INTERN MED, V78, P595, DOI 10.7326/0003-4819-78-4-595; Affleck D C, 1966, Nebr State Med J, V51, P331; AGRAS WS, 1982, PSYCHOSOM MED, V44, P389; AMIGO I, 1993, J HYPERTENS, V11, P293, DOI 10.1097/00004872-199303000-00010; BASS MJ, 1986, J FAM PRACTICE, V23, P43; BERGMANN JF, 1994, CLIN TRIAL META-ANAL, V29, P41; BOOTZIN RR, 1976, J PERS SOC PSYCHOL, V34, P673; BRANTHWAITE A, 1981, BRIT MED J, V282, P1576, DOI 10.1136/bmj.282.6276.1576; BREWIN CR, 1989, BRIT MED J, V299, P313, DOI 10.1136/bmj.299.6694.313; BRODEUR DW, 1965, PSYCHOPHARMACOLOGIA, V7, P444, DOI 10.1007/BF00402366; BRODY H, 1980, J FAM PRACTICE, V10, P445; BROWN WA, 1992, PSYCHIAT RES, V41, P203, DOI 10.1016/0165-1781(92)90002-K; BUTLER C, 1986, BRIT J CLIN PSYCHOL, V25, P173, DOI 10.1111/j.2044-8260.1986.tb00693.x; CANNER PL, 1980, NEW ENGL J MED, V303, P1038; COOPER WD, 1983, BRIT J CLIN PRACT, V37, P99; COUCH JR, 1987, NEUROEPIDEMIOLOGY, V6, P178, DOI 10.1159/000110117; Crow R., 1999, HEALTH TECHNOL ASSES, V3, P1, DOI [DOI 10.3310/HTA3030, DOI 10.3310/hta3030]; CSORDAS T J, 1988, Medical Anthropology Quarterly, V2, P121, DOI 10.1525/maq.1988.2.2.02a00030; CSORDAS TJ, 1983, CULT MED PSYCHIAT, V7, P333, DOI 10.1007/BF00052238; CZAJKOWSKI SM, 1990, HDB HLTH BEHAV CHANG; De Craen A.J.M., 1998, PLACEBOS PLACEBO EFF; de Craen AJM, 2000, J NEUROL, V247, P183, DOI 10.1007/s004150050560; de Craen AJM, 1999, BRIT J CLIN PHARMACO, V48, P853, DOI 10.1046/j.1365-2125.1999.00094.x; de la Fuente-Fernandez R, 2001, SCIENCE, V293, P1164, DOI 10.1126/science.1060937; Di Blasi Z, 2001, LANCET, V357, P757, DOI 10.1016/S0140-6736(00)04169-6; Diener HC, 1999, CEPHALALGIA, V19, P699, DOI 10.1046/j.1468-2982.1999.019008699.x; DSOUZA MF, 1983, CLIN ALLERGY, V13, P329, DOI 10.1111/j.1365-2222.1983.tb02608.x; DWORKIN SF, 1984, PAIN, V19, P339, DOI 10.1016/0304-3959(84)90080-0; Eisenberg DM, 1998, JAMA-J AM MED ASSOC, V280, P1569, DOI 10.1001/jama.280.18.1569; ERNST E, 1995, BMJ-BRIT MED J, V311, P551, DOI 10.1136/bmj.311.7004.551; Feinstein A.R., 1985, CLIN EPIDEMIOLOGY; Finkler K, 1996, SOC SCI MED, V42, P199, DOI 10.1016/0277-9536(95)00086-0; FISHER S, 1993, J NERV MENT DIS, V181, P345, DOI 10.1097/00005053-199306000-00002; Fisher S, 1964, NEUROPSYCHOPHARMACOL, V3, P149; Flaten MA, 1999, PSYCHOSOM MED, V61, P250, DOI 10.1097/00006842-199903000-00018; Freed CR, 2001, NEW ENGL J MED, V344, P710, DOI 10.1056/NEJM200103083441002; FREUND J, 1972, CLIN PHARMACOL THER, V13, P172; GALLAGHER EJ, 1993, JAMA-J AM MED ASSOC, V270, P742, DOI 10.1001/jama.270.6.742; GODFREY S, 1973, J PSYCHOSOM RES, V17, P293, DOI 10.1016/0022-3999(73)90106-2; Goetz CG, 2000, NEUROLOGY, V54, P710, DOI 10.1212/WNL.54.3.710; GRACELY RH, 1985, LANCET, V1, P43; GRYLL SL, 1978, PSYCHOPHARMACOLOGY, V57, P253, DOI 10.1007/BF00426747; HAHN RA, 1982, CULT MED PSYCHIAT, V6, P219, DOI 10.1007/BF00114192; HASHISH I, 1988, PAIN, V33, P303, DOI 10.1016/0304-3959(88)90289-8; HO KH, 1988, J PSYCHOSOM RES, V32, P197, DOI 10.1016/0022-3999(88)90055-4; HORWITZ RI, 1990, LANCET, V336, P542, DOI 10.1016/0140-6736(90)92095-Y; HORWITZ RI, 1993, ARCH INTERN MED, V153, P1863, DOI 10.1001/archinte.153.16.1863; Hrobjartsson A, 2001, NEW ENGL J MED, V345, P1278; Hrobjartsson A, 2001, NEW ENGL J MED, V344, P1594, DOI 10.1056/NEJM200105243442106; HROBJARTSSON A, 2001, ADV MIND BODY MED, V17, P312; Husten L, 1999, LANCET, V353, P1501, DOI 10.1016/S0140-6736(99)00077-X; Ilnyckyj A, 1997, GASTROENTEROLOGY, V112, P1854, DOI 10.1053/gast.1997.v112.pm9178676; JOHANNES L, 1998, WALL STREET J   1211, pA8; Johannes Laura, 1998, Wall St J (East Ed), pA1; JOHNSON AG, 1994, LANCET, V344, P1140, DOI 10.1016/S0140-6736(94)90637-8; KAGAN G, 1980, J INT MED RES, V8, P404, DOI 10.1177/030006058000800607; KAPLAN SH, 1989, MED CARE, V27, pS110, DOI 10.1097/00005650-198903001-00010; Kaptchuk TJ, 2000, J CLIN EPIDEMIOL, V53, P786, DOI 10.1016/S0895-4356(00)00206-7; Kaptchuk TJ, 1998, LANCET, V351, P1722, DOI 10.1016/S0140-6736(97)10111-8; Kaptchuk TJ, 1998, ANN INTERN MED, V129, P1061, DOI 10.7326/0003-4819-129-12-199812150-00011; Kaptchuk TJ, 2001, J CLIN EPIDEMIOL, V54, P541, DOI 10.1016/S0895-4356(00)00347-4; Kaptchuk TJ, 1998, ARCH INTERN MED, V158, P2215, DOI 10.1001/archinte.158.20.2215; KAPTCHUK TJ, 2001, FUNDAMENTALS COMPLEM; KAPTCHUK TJ, 2000, WEB THAT HAS NO WEAV; KAPTCHUK TJ, 1996, COMPLEMENTARY MED OB; Kincheloe J E, 1991, Quintessence Int, V22, P311; KIRMAYER LJ, 1993, CULT MED PSYCHIAT, V17, P161, DOI 10.1007/BF01379325; KIRMAYER LJ, 1994, CULT MED PSYCHIAT, V18, P183, DOI 10.1007/BF01379449; Kirsch I., 1999, EXPECTANCIES SHAPE E; KOES BW, 1992, SPINE, V17, P28, DOI 10.1097/00007632-199201000-00005; LASAGNA L, 1958, J CLIN INVEST, V37, P533, DOI 10.1172/JCI103635; LIBERMAN RP, 1967, NEUROPSYCHOPHARMACOL, V5, P557; LUPARELLO TJ, 1970, PSYCHOSOM MED, V32, P509, DOI 10.1097/00006842-197009000-00009; LYNOE N, 1993, SOC SCI MED, V36, P767, DOI 10.1016/0277-9536(93)90037-5; Macklin R, 1999, NEW ENGL J MED, V341, P992, DOI 10.1056/NEJM199909233411312; MARCHAND S, 1993, PAIN, V54, P99, DOI 10.1016/0304-3959(93)90104-W; Mattocks KM, 2000, BIOL PSYCHIAT, V47, P693, DOI 10.1016/S0006-3223(00)00839-8; McGuire Meredith, 1988, RITUAL HEALING SUBUR; McPherson K, 1997, J ROY SOC MED, V90, P652, DOI 10.1177/014107689709001205; McQuay H, 1996, PAIN, V64, P331, DOI 10.1016/0304-3959(95)00116-6; Mitchell SH, 1996, PSYCHOPHARMACOLOGY, V125, P371, DOI 10.1007/BF02246020; Moerman DE, 2000, MED ANTHROPOL Q, V14, P51, DOI 10.1525/maq.2000.14.1.51; Moncrieff J, 1998, BRIT J PSYCHIAT, V172, P227, DOI 10.1192/bjp.172.3.227; MORISON RA, 1961, ANN RHEUM DIS, V20, P179, DOI 10.1136/ard.20.2.179; NOVACK DH, 1987, J GEN INTERN MED, V2, P346, DOI 10.1007/BF02596174; OLSSON B, 1989, FAM PRACT, V6, P188, DOI 10.1093/fampra/6.3.188; ONG LML, 1995, SOC SCI MED, V40, P903, DOI 10.1016/0277-9536(94)00155-M; OTHS K, 1994, CULT MED PSYCHIAT, V18, P83, DOI 10.1007/BF01384878; Pillemer SR, 1997, ARTHRITIS RHEUM, V40, P419, DOI 10.1002/art.1780400305; Preston RA, 2000, ARCH INTERN MED, V160, P1449, DOI 10.1001/archinte.160.10.1449; RABKIN JG, 1990, AM J PSYCHIAT, V147, P1622; RILEY JN, 1977, SOC SCI MED, V11, P549, DOI 10.1016/0037-7856(77)90173-1; ROSENBERG NK, 1991, ACTA PSYCHIAT SCAND, V83, P33, DOI 10.1111/j.1600-0447.1991.tb03099.x; SCHWITZG.RK, 1968, BEHAV SCI, V13, P267, DOI 10.1002/bs.3830130402; SHAPIRO AK, 1969, INT PHARMACOPSYCHIAT, V2, P215, DOI 10.1159/000468855; SHAPIRO AP, 1954, PSYCHOSOM MED, V16, P478, DOI 10.1097/00006842-195411000-00002; Shapiro Elaine, 1997, POWERFUL PLACEBO ANC; Shetty N, 1999, CLIN NEUROPHARMACOL, V22, P207; SODERGREN SC, 1999, EXPECTANCIES SHAPE E; SOX HC, 1981, ANN INTERN MED, V95, P680, DOI 10.7326/0003-4819-95-6-680; STERNBACH RA, 1964, PSYCHOPHYSIOLOGY, V1, P67; STEWART MA, 1995, CAN MED ASSOC J, V152, P1423; STORMS MD, 1970, J PERS SOC PSYCHOL, V16, P319, DOI 10.1037/h0029835; SUCHMAN AL, 1992, CLIN PHARMACOL THER, V52, P372, DOI 10.1038/clpt.1992.157; SULLIVAN MD, 1993, J MED PHILOS, V18, P213, DOI 10.1093/jmp/18.2.213; Tambiah S.J., 1990, MAGIC SCI RELIG SCOP; Temple RJ, 1997, CONTROL CLIN TRIALS, V18, P613, DOI 10.1016/S0197-2456(97)00058-5; THOMAS KB, 1987, BRIT MED J, V294, P1200, DOI 10.1136/bmj.294.6581.1200; THOMAS KB, 1994, LANCET, V344, P1066, DOI 10.1016/S0140-6736(94)91716-7; THOMAS M, 1991, AM J CHINESE MED, V19, P95, DOI 10.1142/S0192415X91000156; TURNER JA, 1994, JAMA-J AM MED ASSOC, V271, P1609, DOI 10.1001/jama.271.20.1609; UHLENHUTH EH, 1966, PSYCHOPHARMACOLOGIA, V9, P392, DOI 10.1007/BF00406450; van Weel C, 2001, LANCET, V357, P733, DOI 10.1016/S0140-6736(00)04176-3; Vickers AJ, 2000, J CLIN EPIDEMIOL, V53, P157, DOI 10.1016/S0895-4356(99)00139-0; WALL PD, 1993, CIBA FDN S, V174; Watts RL, 2001, PARKINSONISM RELAT D, V7, pS87; WENNBERG JE, 1990, MODERN METHODS CLIN; WHEATLEY D, 1967, LANCET, V2, P1133; WIED G L, 1953, Arztl Wochensch, V8, P623; WOLF S, 1957, J LAB CLIN MED, V49, P837; Zollman C, 1999, BRIT MED J, V319, P1486, DOI 10.1136/bmj.319.7223.1486	122	366	375	3	60	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUN 4	2002	136	11					817	825		10.7326/0003-4819-136-11-200206040-00011	http://dx.doi.org/10.7326/0003-4819-136-11-200206040-00011			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	558KG	12044130				2023-01-03	WOS:000175964500005
J	Douglass, J; Aroni, R; Goeman, D; Stewart, K; Sawyer, S; Thien, F; Abramson, M				Douglass, J; Aroni, R; Goeman, D; Stewart, K; Sawyer, S; Thien, F; Abramson, M			A qualitative study of action plans for asthma	BRITISH MEDICAL JOURNAL			English	Article							MANAGEMENT PLANS; ADULT ASTHMA; MEDICATIONS	Objectives To investigate the perspectives of patients with asthma on die use of all action plan and the implementation of this plan during an asthma attack that culminated in a visit to an emergency department. Design Qualitative Study. Setting Tertiary teaching hospital, suburban hospital, and rural hospital. Participants 62 patients aged 18 to 69 years who presented to an emergency department with asthma over a two month period. Results 29 participants described having action plans given to them by their doctors. Most patients with action plans reinterpreted their plan from the perspective of their own experiences with asthma. 33 patients did not have an action plan, the most common reason being that they had not been given one by their doctor. Sonic Occupational groups were significantly less likely to have been given an action plan by their doctor than others. Most patients with an action plan found them useful for management of their asthma. Conclusions Action plans were viewed positively by patients. Participants modified their prescribed plan according to their experience of asthma. To facilitate the implementation of a prescribed action plan, doctors laced to acknowledge and include the patient's personal experience of their disease.	Alfred Hosp, Dept Allergy Asthma & Immunol, Prahran, Vic 3181, Australia; Monash Univ, Dept Epidemiol & Prevent Med, Prahran, Vic 3181, Australia; La Trobe Univ, Sch Publ Hlth, Bundoora, Vic 3083, Australia; Cooperat Res Ctr Asthma, Camperdown, NSW 2050, Australia; Monash Univ, Victorian Coll Pharm, Parkville, Vic 3052, Australia; Univ Melbourne, Parkville, Vic 3052, Australia; Royal Childrens Hosp, Ctr Adolescent Hlth, Parkville, Vic 3052, Australia	Florey Institute of Neuroscience & Mental Health; Monash University; La Trobe University; Monash University; University of Melbourne; Royal Children's Hospital Melbourne	Douglass, J (corresponding author), Alfred Hosp, Dept Allergy Asthma & Immunol, Prahran, Vic 3181, Australia.		Abramson, Michael/AAQ-2671-2020	Abramson, Michael/0000-0002-9954-0538; Thien, Francis/0000-0003-0925-6566; Douglass, Jo/0000-0002-1200-8048				Abramson MJ, 2001, AM J RESP CRIT CARE, V163, P12, DOI 10.1164/ajrccm.163.1.9910042; Allen RM, 1998, J ASTHMA, V35, P537, DOI 10.3109/02770909809048956; Australian Bureau of Statistics, 1997, ASCO AUSTR STAND CLA; BEASLEY R, 1989, THORAX, V44, P200, DOI 10.1136/thx.44.3.200; BURNEY PGJ, 1994, EUR RESPIR J, V7, P954, DOI 10.1183/09031936.94.07050954; Clark NM, 2000, BMJ-BRIT MED J, V320, P572, DOI 10.1136/bmj.320.7234.572; DONOVAN JL, 1992, SOC SCI MED, V34, P507, DOI 10.1016/0277-9536(92)90206-6; Fontana A., 1994, HDB QUALITATIVE RES, P361; GIBSON PG, 2000, COCHRANE LIB; GIBSON PG, 2000, CVOCHRANE LIB; GIBSON PG, 1998, COCHRANE LIB; *GLOB IN ASTHM, 2001, ASTHM MAN PREV PRACT; Graham I, 1996, LANCET, V347, P4, DOI 10.1016/S0140-6736(96)91550-0; Jones A, 2000, BMJ-BRIT MED J, V321, P1507, DOI 10.1136/bmj.321.7275.1507; MacDougall C, 1997, QUAL HEALTH RES, V7, P532, DOI 10.1177/104973239700700407; Marks GB, 2000, MED J AUSTRALIA, V173, P407, DOI 10.5694/j.1326-5377.2000.tb139268.x; *NAT ASTHM COUNC A, 2002, ASTHM MAN HDB 2002; Ruffin R, 2001, IMMUNOL CELL BIOL, V79, P191, DOI 10.1046/j.1440-1711.2001.00991.x; Singh AK, 1999, ARCH INTERN MED, V159, P1237, DOI 10.1001/archinte.159.11.1237; [No title captured], DOI DOI 10.1136/THX.52.2008.S1]	20	76	76	0	6	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	APR 27	2002	324	7344					1003	1005		10.1136/bmj.324.7344.1003	http://dx.doi.org/10.1136/bmj.324.7344.1003			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	547UP	11976240	Bronze, Green Published			2023-01-03	WOS:000175350900018
J	Rigg, JRA; Jamrozik, K; Myles, PS; Silbert, BS; Peyton, PJ; Parsons, RW; Collins, KS				Rigg, JRA; Jamrozik, K; Myles, PS; Silbert, BS; Peyton, PJ; Parsons, RW; Collins, KS		MASTER Anaesthesia Trial Study Grp	Epidural anaesthesia and analgesia and outcome of major surgery: a randomised trial	LANCET			English	Article							ABDOMINAL AORTIC-SURGERY; POSTOPERATIVE ANALGESIA; GENERAL-ANESTHESIA; SURGICAL PATIENTS; METAANALYSES; BUPIVACAINE; FENTANYL; AUDIT; NEED	Background Epidural block is widely used to manage major abdominal surgery and postoperative analgesia, but its risks. and benefits are uncertain. We compared adverse outcomes in high-risk patients managed for major surgery with epidural block or alternative analgesic regimens with general anaesthesia in a multicentre randomised trial. Methods 915 patients undergoing major abdominal surgery with one of nine defined comorbid states to identify high-risk status were randomly assigned intraoperative epidural anaesthesia and postoperative epidural analgesia for 72 h with general anaesthesia (site of epidural selected to provide optimum block) or control. The primary endpoint was death at 30 days or major postsurgical morbidity. Analysis by intention to treat involved 447 patients assigned epidural and 441 control. Findings 255 patients (57.1%) in the epidural group and 268 (60.7%) in the control group had at least one morbidity endpoint or died (p=0.29). Mortality at 30 days was low in both groups (epidural 23 [5.1%], control 19 [4.3%], p=0.67). Only one of eight categories of morbid endpoints in individual systems (respiratory failure) occurred less frequently in patients managed with epidural techniques (23% vs 30%, p=0.02). Postoperative epidural analgesia was associated with lower pain scores during the first 3 postoperative days. There were no major adverse consequences of epidural-catheter insertion. Interpretation Most adverse morbid outcomes in high-risk patients undergoing major abdominal surgery are not reduced by use of combined epidural and general anaesthesia and postoperative epidural analgesia. However, the improvement in analgesia, reduction in respiratory failure, and the low risk of serious adverse consequences suggest that many high-risk patients undergoing major intra-abdominal surgery will receive substantial benefit from combined general and epidural anaesthesia intraoperatively with continuing postoperative epidural analgesia.	Univ Western Australia, Dept Publ Hlth, Crawley, WA, Australia; Imperial Coll Fac Med, London, England; Alfred Hosp, Dept Anaesthesia, Melbourne, Vic, Australia; Monash Univ, Melbourne, Vic 3004, Australia; St Vincents Hosp, Melbourne, Vic, Australia; Austin & Repatriat Med Ctr, Melbourne, Vic, Australia	University of Western Australia; Imperial College London; Florey Institute of Neuroscience & Mental Health; Monash University; St Vincent's Hospital Melbourne; Austin Research Institute; Florey Institute of Neuroscience & Mental Health	Rigg, JRA (corresponding author), St John God Hlth Care, Off Safety & Qual, 175 Cambridge St, Subiaco, WA 6008, Australia.	john.rigg@sjog.org.au	Myles, Paul/AAU-9524-2020	Myles, Paul/0000-0002-3324-5456				ABE O, 1992, LANCET, V339, P71; APPLEBY P, 1994, LANCET, V343, P311, DOI 10.1016/S0140-6736(94)91161-4; Ballantyne JC, 1998, ANESTH ANALG, V86, P598, DOI 10.1097/00000539-199803000-00032; BARON JF, 1991, ANESTHESIOLOGY, V75, P611, DOI 10.1097/00000542-199110000-00010; Bode RH, 1996, ANESTHESIOLOGY, V84, P3, DOI 10.1097/00000542-199601000-00002; Broekema AA, 1996, ANESTH ANALG, V82, P754, DOI 10.1097/00000539-199604000-00014; Burstal R, 1998, ANAESTH INTENS CARE, V26, P165, DOI 10.1177/0310057X9802600206; CASASOLA OD, 1994, ANESTHESIOLOGY, V81, P368; CLARKE MJ, 1994, BRIT MED J, V309, P1007, DOI 10.1136/bmj.309.6960.1007; COLLINS R, 1987, STAT MED, V6, P245, DOI 10.1002/sim.4780060308; DAVIES MJ, 1993, ANAESTH INTENS CARE, V21, P790, DOI 10.1177/0310057X9302100607; *EARL BREAST CANC, 1992, LANCET, V339, P1; HJORTSO NC, 1985, ACTA ANAESTH SCAND, V29, P790, DOI 10.1111/j.1399-6576.1985.tb02302.x; LeLorier J, 1997, NEW ENGL J MED, V337, P536, DOI 10.1056/NEJM199708213370806; LIU S, 1995, ANESTHESIOLOGY, V82, P1474, DOI 10.1097/00000542-199506000-00019; Liu SS, 1998, ANESTHESIOLOGY, V88, P688, DOI 10.1097/00000542-199803000-00020; MCPEEK B, 1987, ANESTHESIOLOGY, V66, P723, DOI 10.1097/00000542-198706000-00001; Park WY, 2001, ANN SURG, V234, P560; Pogue J, 1998, LANCET, V351, P47, DOI 10.1016/S0140-6736(97)08461-4; Rigg J R, 1998, Curr Opin Anaesthesiol, V11, P327, DOI 10.1097/00001503-199806000-00016; Rigg JR, 1997, ANAESTH INTENS CARE, V25, P282, DOI 10.1177/0310057X9702500314; RIGG JRA, 1991, ANAESTH INTENS CARE, V19, P404, DOI 10.1177/0310057X9101900318; Rigg JRA, 2000, CONTROL CLIN TRIALS, V21, P244, DOI 10.1016/S0197-2456(00)00045-3; Rigg JRA, 1997, ANESTHESIOLOGY, V86, P1008, DOI 10.1097/00000542-199704000-00037; Rodgers A, 2000, BMJ-BRIT MED J, V321, P1493, DOI 10.1136/bmj.321.7275.1493; SACKETT DL, 1985, CLIN EPIDEMIOLOGY BA, P171; SCOTT DA, 1995, ANESTHESIOLOGY, V83, P727, DOI 10.1097/00000542-199510000-00012; Sniderman AD, 1999, LANCET, V354, P327, DOI 10.1016/S0140-6736(98)11185-6; TUMAN KJ, 1991, ANESTH ANALG, V73, P696; YEAGER MP, 1987, ANESTHESIOLOGY, V66, P729, DOI 10.1097/00000542-198706000-00004; YUSUF S, 1984, STAT MED, V3, P409, DOI 10.1002/sim.4780030421	31	637	667	0	18	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	APR 13	2002	359	9314					1276	1282		10.1016/S0140-6736(02)08266-1	http://dx.doi.org/10.1016/S0140-6736(02)08266-1			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	541NB	11965272				2023-01-03	WOS:000174989700009
J	Lowenstein, E; Wanzer, SH				Lowenstein, E; Wanzer, SH			Sounding board - The US Attorney General's intrusion into medical practice	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Massachusetts Gen Hosp, Boston, MA 02114 USA	Harvard University; Massachusetts General Hospital	Lowenstein, E (corresponding author), Massachusetts Gen Hosp, Boston, MA 02114 USA.							*ACOG, 1999, ACOG PRACT B, V10; *ACOG, 1999, 228 ACOG; ASHCROFT J, 2001, COMMUNICATION   1106; Goldberg AB, 2001, NEW ENGL J MED, V344, P38, DOI 10.1056/NEJM200101043440107; *MED EC, 2002, PHYS DESK REF, P3202; Quill TE, 1997, NEW ENGL J MED, V337, P1768, DOI 10.1056/NEJM199712113372413; Steinbrook R, 2002, NEW ENGL J MED, V346, P460, DOI 10.1056/NEJM200202073460624	7	6	6	0	0	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	FEB 7	2002	346	6					447	448		10.1056/NEJM200202073460613	http://dx.doi.org/10.1056/NEJM200202073460613			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	518UN	11832536				2023-01-03	WOS:000173686400011
J	Bliwise, DL; Kutner, NG; Zhang, R; Parker, KP				Bliwise, DL; Kutner, NG; Zhang, R; Parker, KP			Survival by time of day of hemodialysis in an elderly cohort	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							SLEEP-DEPRIVATION; MORTALITY; NONCOMPLIANCE; CHEMOTHERAPY; DURATION; RAT	Context Patients with end-stage renal disease (ESRD) typically undergo hemodialysis (HD) during the morning or afternoon, with time of treatment generally based on space availability or patient preference. No studies have investigated variation in patient survival as a function of the time of day when they receive dialysis. Objective To investigate the association of elderly patients' HD treatment shift with their continued survival, controlling for well-established HD-related mortality risk factors. Design, Setting, and Participants An 11-year follow-up cohort study conducted among 242 ESRD patients aged 60 years or older who underwent HD at 58 dialysis facilities in Georgia either during a morning shift (n=167) or an afternoon shift (n=75) and who completed baseline (1998) and follow-up (1991) interviews. Main Outcome Measure Mortality from all causes occurring through July 7, 1999, as verified by death-certificate reviews, and compared by morning- vs afternoon-shift HD. Results Morning-shift HD patients survived significantly longer than afternoon-shift patients (median survival, 941 days vs 470 days; P<.001), A Cox proportional hazards model indicated that the morning shift was protective (relative risk, 0.71; 95% confidence interval, 0.53-0.95) independent of age, race, sex, body mass index, functional status, diabetic ESRD, cardiovascular comorbidity, weekly hours of dialysis, and months of dialysis. Conclusions Possible explanations for differential survival in association with morning vs afternoon dialysis include salutary effects of sleep in the morning or less efficient biochemical exchange during afternoon dialysis. Results from this cohort study may warrant prospective observational studies and randomized clinical trials that systematically alter the time of day at which HD is administered.	Emory Univ, Sch Med, Dept Neurol, Atlanta, GA 30322 USA; Emory Univ, Sch Med, Dept Rehabil Med, Atlanta, GA 30322 USA; Emory Univ, Rollins Sch Publ Hlth, Dept Biostat, Atlanta, GA 30322 USA; Emory Univ, Nell Hodgson Woodruff Sch Nursing, Dept Adult & Elder Hlth, Atlanta, GA 30322 USA	Emory University; Emory University; Emory University; Rollins School Public Health; Emory University	Bliwise, DL (corresponding author), Emory Univ, Sch Med, Dept Neurol, WMRB 6000,1639 Pierce Dr, Atlanta, GA 30322 USA.	dbliwis@emory.edu			NIA NIH HHS [AG10643, AG06066, AG05909] Funding Source: Medline; NIDDK NIH HHS [DK42949] Funding Source: Medline; NINDS NIH HHS [NS35343] Funding Source: Medline; NINR NIH HHS [NR04340] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK042949] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NURSING RESEARCH [R01NR004340] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG006066, R01AG010643] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Nursing Research (NINR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF NURSING RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Nursing Research (NINR)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Baines LS, 2000, NEPHRON, V85, P1, DOI 10.1159/000045622; Bliwise D. L, 2000, PRINCIPLES PRACTICE, P26; Bliwise DL, 1999, LUNG BIOL HEALTH DIS, V133, P487; EVERSON CA, 1989, SLEEP, V12, P13, DOI 10.1093/sleep/12.1.13; GARFEIN AJ, 1995, J GERONTOL B-PSYCHOL, V50, pS77, DOI 10.1093/geronb/50B.2.S77; Hanly PJ, 2001, NEW ENGL J MED, V344, P102, DOI 10.1056/NEJM200101113440204; HELD PJ, 1991, JAMA-J AM MED ASSOC, V265, P871, DOI 10.1001/jama.265.7.871; HRUSHESKY WJM, 1988, SEMIN SURG ONCOL, V4, P110; Kimmel PL, 2000, KIDNEY INT, V57, P1141, DOI 10.1046/j.1523-1755.2000.00941.x; KRIPKE DF, 1979, ARCH GEN PSYCHIAT, V36, P103; KUSHIDA CA, 1989, SLEEP, V12, P22, DOI 10.1093/sleep/12.1.22; Kutner N G, 1997, Geriatr Nephrol Urol, V7, P23, DOI 10.1023/A:1008204311582; Kutner Nancy G., 2001, International Urology and Nephrology, V32, P441, DOI 10.1023/A:1017581726362; KUTNER NG, 1991, DIALYSIS TRANSPLANT, V20, P171; KUTNER NG, 1994, AM J KIDNEY DIS, V24, P42, DOI 10.1016/S0272-6386(12)80158-2; KUTNER NG, 1994, RES SOCIOLOGY HLTH C, V11, P127; Kutner NG, 1993, GERIATR NEPHROL UROL, V3, P145; Leggat JE, 1998, AM J KIDNEY DIS, V32, P139, DOI 10.1053/ajkd.1998.v32.pm9669435; Levi F, 1999, J PHARM PHARMACOL, V51, P891, DOI 10.1211/0022357991773302; Levi F, 1999, CANCER-AM CANCER SOC, V85, P2532, DOI 10.1002/(SICI)1097-0142(19990615)85:12<2532::AID-CNCR7>3.0.CO;2-1; MATTANA J, 1995, AM J NEPHROL, V15, P208, DOI 10.1159/000168834; *NIH, 2000, US REN DAT SYST USRD; Parker KP, 2000, SLEEP, V23, P887; SCHAEFER K, 1992, AM J KIDNEY DIS, V19, P460, DOI 10.1016/S0272-6386(12)80955-3; WINGARD DL, 1982, AM J EPIDEMIOL, V116, P765, DOI 10.1093/oxfordjournals.aje.a113466; Wood PA, 1996, CRIT REV EUKAR GENE, V6, P299, DOI 10.1615/CritRevEukarGeneExpr.v6.i4.10	26	35	35	0	4	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 5	2001	286	21					2690	2694		10.1001/jama.286.21.2690	http://dx.doi.org/10.1001/jama.286.21.2690			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	498AU	11730444				2023-01-03	WOS:000172488300028
J	Wu, WC; Rathore, SS; Wang, Y; Radford, MJ; Krumholz, HM				Wu, WC; Rathore, SS; Wang, Y; Radford, MJ; Krumholz, HM			Blood transfusion in elderly patients with acute myocardial infarction.	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CARDIAC COMPENSATION; MEDICARE PATIENTS; OXYGEN DELIVERY; ANEMIA; HEMATOCRIT; MORTALITY; DISEASE; STRATEGIES; TRIAL; RISK	Background: Anemia may have adverse effects in patients with coronary artery disease. However, the benefit of blood transfusion in elderly patients with acute myocardial infarction and various degrees of anemia is uncertain. Methods: We conducted a retrospective study of data on 78,974 Medicare beneficiaries 65 years old or older who were hospitalized with acute myocardial infarction. Patients were categorized according to the hematocrit on admission (5.0 to 24.0 percent, 24.1 to 27.0 percent, 27.1 to 30.0 percent, 30.1 to 33.0 percent, 33.1 to 36.0 percent, 36.1 to 39.0 percent, or 39.1 to 48.0 percent), and data were evaluated to determine whether there was an association between the use of transfusion and 30-day mortality. Results: Patients with lower hematocrit values on admission had higher 30-day mortality rates. Blood transfusion was associated with a reduction in 30-day mortality among patients whose hematocrit on admission fell into the categories ranging from 5.0 to 24.0 percent (adjusted odds ratio, 0.22; 95 percent confidence interval, 0.11 to 0.45) to 30.1 to 33.0 percent (adjusted odds ratio, 0.69; 95 percent confidence interval, 0.53 to 0.89). It was not associated with a reduction in 30-day mortality among those whose hematocrit values fell in the higher ranges. In one of seven subgroup analyses (among patients who survived at least two days), transfusion was not associated with a reduction in mortality for patients with hematocrit values of 30.1 percent or higher. Conclusions: Blood transfusion is associated with a lower short-term mortality rate among elderly patients with acute myocardial infarction if the hematocrit on admission is 30.0 percent or lower and may be effective in patients with a hematocrit as high as 33.0 percent on admission.	Brown Univ, Sch Med, Div Cardiovasc Dis, Providence, RI 02912 USA; Yale Univ, Sch Med, Dept Med, Sect Cardiovasc Med, New Haven, CT 06510 USA; Yale Univ, Sch Med, Dept Epidemiol & Publ Hlth, Sect Hlth Policy & Adm, New Haven, CT 06510 USA; Yale New Haven Med Ctr, Ctr Outcomes Res & Evaluat, New Haven, CT 06504 USA; Qualidigm, Middletown, CT USA	Brown University; Yale University; Yale University; Yale University	Wu, WC (corresponding author), Brown Univ, Sch Med, Div Cardiovasc Dis, Providence, RI 02912 USA.		, Harlan/AAI-2875-2020	Radford, Martha/0000-0001-7503-9557				[Anonymous], 1988, LANCET, V2, P349; [Anonymous], 2005, AM J RESP CRIT CARE, V171, P388, DOI 10.1164/rccm.200405-644ST; BERNSTEIN MJ, 1988, JAMA-J AM MED ASSOC, V260, P2700; Besarab A, 1998, NEW ENGL J MED, V339, P584, DOI 10.1056/NEJM199808273390903; BLAIR SD, 1986, BRIT J SURG, V73, P783, DOI 10.1002/bjs.1800731007; BOTTIGER LE, 1980, ATHEROSCLEROSIS, V36, P389, DOI 10.1016/0021-9150(80)90219-1; BRAZIER J, 1974, SURGERY, V75, P508; Carson JL, 1996, LANCET, V348, P1055, DOI 10.1016/S0140-6736(96)04330-9; CHESEBRO JH, 1987, CIRCULATION, V76, P142, DOI 10.1161/01.CIR.76.1.142; Chiavetta JA, 1996, TRANSFUSION, V36, P699, DOI 10.1046/j.1537-2995.1996.36896374373.x; CZER LSC, 1978, SURG GYNECOL OBSTET, V147, P363; DALEY J, 1988, JAMA-J AM MED ASSOC, V260, P3617, DOI 10.1001/jama.260.24.3617; *DEP HLTH HUM SERV, 1989, DHHS PUBL; Ely EW, 1999, NEW ENGL J MED, V340, P467, DOI 10.1056/NEJM199902113400610; Eschbach J, 1997, AM J KIDNEY DIS, V30, pS192; FAUCI AS, 1998, HARRISONS PRINCIPLES, V1; FLEMING C, 1992, MED CARE, V30, P377, DOI 10.1097/00005650-199205000-00001; Friedman BA, 1982, CLIN LABORATORY ANN, V1, P147; Geha A S, 1978, World J Surg, V2, P645; GRINDON AJ, 1985, JAMA-J AM MED ASSOC, V253, P540, DOI 10.1001/jama.253.4.540; HASLEY PB, 1994, TRANSFUSION, V34, P110, DOI 10.1046/j.1537-2995.1994.34294143936.x; Hebert PC, 1999, NEW ENGL J MED, V340, P409, DOI 10.1056/NEJM199902113400601; Hebert PC, 1997, AM J RESP CRIT CARE, V155, P1618, DOI 10.1164/ajrccm.155.5.9154866; Hebert PC, 1999, NEW ENGL J MED, V340, P1056; HEBERT PC, 1995, JAMA-J AM MED ASSOC, V274, P944; Innes G, 1998, J Emerg Med, V16, P129; JAN KM, 1977, AM J PHYSIOL, V233, pH106, DOI 10.1152/ajpheart.1977.233.1.H106; JOHNSON RG, 1992, J THORAC CARDIOV SUR, V104, P307; JOOSTEN E, 1992, GERONTOLOGY, V38, P111, DOI 10.1159/000213315; KALCHTHALER T, 1980, J AM GERIATR SOC, V28, P108, DOI 10.1111/j.1532-5415.1980.tb00242.x; LEVY PS, 1993, AM J PHYSIOL, V265, pH340, DOI 10.1152/ajpheart.1993.265.1.H340; Marciniak TA, 1998, JAMA-J AM MED ASSOC, V279, P1351, DOI 10.1001/jama.279.17.1351; MOST AS, 1986, CIRCULATION, V74, P1085, DOI 10.1161/01.CIR.74.5.1085; *ROYAL COLL PHYS E, 1994, BRIT J ANAESTH, V73, P857; Silverberg DS, 2000, J AM COLL CARDIOL, V35, P1737, DOI 10.1016/S0735-1097(00)00613-6; Smieja MJ, 1996, CAN MED ASSOC J, V155, P691; SORLIE PD, 1981, AM HEART J, V101, P456, DOI 10.1016/0002-8703(81)90136-8; VAMVAKAS EC, 1994, TRANSFUSION, V34, P464, DOI 10.1046/j.1537-2995.1994.34694295059.x; Weiskopf RB, 1998, JAMA-J AM MED ASSOC, V279, P217, DOI 10.1001/jama.279.3.217; Weiskopf RB, 1998, JAMA-J AM MED ASSOC, V280, P1404; WELCH HG, 1992, ANN INTERN MED, V116, P393, DOI 10.7326/0003-4819-116-5-393; WHO Scientific Group on Nutritional Anaemias & World Health Organization, 1968, NUTR AN REP WHO SCI; WILKERSON DK, 1988, SURGERY, V103, P665; Zimmermann R, 1997, TRANSFUSION, V37, P1075, DOI 10.1046/j.1537-2995.1997.371098016449.x	44	645	675	0	12	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	OCT 25	2001	345	17					1230	1236		10.1056/NEJMoa010615	http://dx.doi.org/10.1056/NEJMoa010615			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	485RU	11680442				2023-01-03	WOS:000171773100002
J	Walter, W; Studitsky, VM				Walter, W; Studitsky, VM			Facilitated transcription through the nucleosome at high ionic strength occurs via a histone octamer transfer mechanism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-POLYMERASE-II; ACTIVE TRANSCRIPTION; CHROMATIN TEMPLATES; SWI/SNF COMPLEX; HEAT-SHOCK; IN-VITRO; ELONGATION; SPT5; DNA; INVITRO	The rate of transcription through the nucleosome, the fine structure of the nucleosomal barrier, and the fate of the nucleosome during transcription at different salt concentrations were analyzed using linear 227-base pair mononucleosomal templates containing a uniquely positioned nucleosome core. At lower ionic strength (30 mm NaCl), the nucleosome constitutes a strong barrier for SP6 RNA polymerase. At higher ionic strength (330 mm NaCl), the rates of transcription on nucleosomal and histone-free DNA templates are very similar. At both higher and lower ionic strengths, the complete histone octamer is transferred over the same distance by fundamentally similar mechanisms. The data indicate that even at the rate of transcription characteristic of histone-free DNA, the transfer intermediates can be formed quite efficiently. This suggests possible mechanisms that could facilitate transcription through the nucleosome at physiological ionic strength.	Wayne State Univ, Sch Med, Dept Biochem & Mol Biol, Detroit, MI 48201 USA; Wayne State Univ, Sch Med, Ctr Mol Med & Genet, Detroit, MI 48201 USA	Wayne State University; Wayne State University	Studitsky, VM (corresponding author), Wayne State Univ, Sch Med, Dept Biochem & Mol Biol, 540 E Canfield Ave,Rm 5123, Detroit, MI 48201 USA.		Studitsky, Vasily/A-9382-2014		NIGMS NIH HHS [GM58650] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM058650] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Andrulis ED, 2000, GENE DEV, V14, P2635, DOI 10.1101/gad.844200; AUSIO J, 1989, J MOL BIOL, V206, P451, DOI 10.1016/0022-2836(89)90493-2; BASHKIN J, 1993, BIOCHEMISTRY-US, V32, P1895, DOI 10.1021/bi00059a002; Bazett-Jones DP, 1999, MOL CELL BIOL, V19, P1470; Bednar J, 1999, MOL CELL, V4, P377, DOI 10.1016/S1097-2765(00)80339-1; Brown SA, 1996, GENE DEV, V10, P1479, DOI 10.1101/gad.10.12.1479; Chang CH, 1997, J BIOL CHEM, V272, P23427, DOI 10.1074/jbc.272.37.23427; Cho H, 1998, MOL CELL BIOL, V18, P5355, DOI 10.1128/MCB.18.9.5355; Conaway JW, 2000, TRENDS BIOCHEM SCI, V25, P375, DOI 10.1016/S0968-0004(00)01615-7; DING HF, 1994, SCIENCE, V265, P796, DOI 10.1126/science.8047885; FOE VE, 1976, CELL, V9, P131, DOI 10.1016/0092-8674(76)90059-3; Hartzog GA, 1998, GENE DEV, V12, P357, DOI 10.1101/gad.12.3.357; IZBAN MG, 1992, J BIOL CHEM, V267, P13647; JORGENSEN ED, 1991, J BIOL CHEM, V266, P645; KAMAKAKA RT, 1990, EMBO J, V9, P3997, DOI 10.1002/j.1460-2075.1990.tb07621.x; Kaplan CD, 2000, GENE DEV, V14, P2623, DOI 10.1101/gad.831900; LeRoy G, 1998, SCIENCE, V282, P1900, DOI 10.1126/science.282.5395.1900; Lorch Y, 1999, CELL, V96, P389, DOI 10.1016/S0092-8674(00)80551-6; Luger K, 1997, NATURE, V389, P251, DOI 10.1038/38444; MATHIS DJ, 1978, NUCLEIC ACIDS RES, V5, P3523, DOI 10.1093/nar/5.10.3523; MCKNIGHT SL, 1979, CELL, V17, P551; MEERSSEMAN G, 1992, EMBO J, V11, P2951, DOI 10.1002/j.1460-2075.1992.tb05365.x; OBRIEN T, 1993, MOL CELL BIOL, V13, P3456, DOI 10.1128/MCB.13.6.3456; Orphanides G, 1998, CELL, V92, P105, DOI 10.1016/S0092-8674(00)80903-4; Orphanides G, 2000, NATURE, V407, P471, DOI 10.1038/35035000; PENNINGS S, 1994, P NATL ACAD SCI USA, V91, P10275, DOI 10.1073/pnas.91.22.10275; POSTNIKOV YV, 1991, NUCLEIC ACIDS RES, V19, P717, DOI 10.1093/nar/19.4.717; Protacio RU, 2000, MOL CELL BIOL, V20, P8866, DOI 10.1128/MCB.20.23.8866-8878.2000; Shilatifard A, 1998, FASEB J, V12, P1437, DOI 10.1096/fasebj.12.14.1437; SIMON RH, 1979, NUCLEIC ACIDS RES, V6, P689, DOI 10.1093/nar/6.2.689; STUDITSKY VM, 1995, CELL, V83, P19, DOI 10.1016/0092-8674(95)90230-9; Studitsky VM, 1997, SCIENCE, V278, P1960, DOI 10.1126/science.278.5345.1960; STUDITSKY VM, 1994, CELL, V76, P371, DOI 10.1016/0092-8674(94)90343-3; UCKER DS, 1984, J BIOL CHEM, V259, P7416; Wada T, 1998, GENE DEV, V12, P343, DOI 10.1101/gad.12.3.343; WASYLYK B, 1979, J MOL BIOL, V128, P411, DOI 10.1016/0022-2836(79)90095-0; WASYLYK B, 1980, EUR J BIOCHEM, V103, P219, DOI 10.1111/j.1432-1033.1980.tb04306.x; WASYLYK B, 1979, EUR J BIOCHEM, V98, P317, DOI 10.1111/j.1432-1033.1979.tb13191.x; Whitehouse I, 1999, NATURE, V400, P784, DOI 10.1038/23506; WILLIAMSON P, 1978, BIOCHEMISTRY-US, V17, P5695, DOI 10.1021/bi00619a015; Wittschieben BO, 1999, MOL CELL, V4, P123, DOI 10.1016/S1097-2765(00)80194-X; Zhou YB, 1998, NATURE, V395, P402, DOI 10.1038/26521	42	13	13	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 3	2001	276	31					29104	29110		10.1074/jbc.M103704200	http://dx.doi.org/10.1074/jbc.M103704200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	461BX	11390400	hybrid			2023-01-03	WOS:000170346000064
J	Rathore, SS; Weinfurt, KP; Gersh, BJ; Oetgen, WJ; Schulman, KA; Solomon, AJ				Rathore, SS; Weinfurt, KP; Gersh, BJ; Oetgen, WJ; Schulman, KA; Solomon, AJ			Treatment of patients with myocardial infarction who present with a paced rhythm	ANNALS OF INTERNAL MEDICINE			English	Article							ELECTROCARDIOGRAPHIC DIAGNOSIS; MEDICARE; OUTCOMES; PACEMAKERS; HOSPITALS; RISK; CARE	Background: A paced rhythm can mask the electrocardiographic features of an acute myocardial infarction, complicating timely recognition and treatment. Objective: To evaluate characteristics, treatment, and outcomes among patients presenting with paced rhythms during myocardial infarction. Design: Retrospective cohort study. Setting: U.S. acute care hospitals. Patients: 102 249 Medicare beneficiaries at least 65 years of age who were treated for acute myocardial infarction between 1994 and 1996. Measurements: Provision of three treatments for acute myocardial infarction (emergent reperfusion, aspirin, and beta -blockers), death at 30 days, and long-term follow-up. Results: 1954 patients (1.9%) presented with paced rhythms during myocardial infarction. These patients were older; were predominantly male; and had higher rates of congestive heart failure, diabetes, and previous infarction. They were significantly less likely to receive emergent reperfusion (relative risk [RR], 0.27 [95% Cl, 0.22 to 0.33]), aspirin (88 at admission, 0.91 [Cl, 0.88 to 0.94]; RR at discharge, 0.87 [Cl, 0.83 to 0.92]), and beta -blockers at admission (RR, 0.89 [Cl, 0.82 to 0.96]). In addition, there was a trend toward decreased use of beta -blockers at discharge (RR, 0.91 [Cl, 0.76 to 1.06]). Crude mortality rates were higher among patients with paced rhythms than among those without at 30 days (25.8% vs. 21.3%; P = 0.001) and at 1 year (47.1% vs. 36.1%; P = 0.001). Among patients with paced rhythms, risk for death at 30 days decreased after adjustment for illness severity and decreased use of therapy (RR, 1.03 [Cl, 0.93 to 1.14]). Patients with paced rhythms remained at additional risk for long-term mortality (hazard ratio, 1.12 [Cl, 1.06 to 1.18]). Conclusions: Patients with paced rhythms were less likely than those without to receive treatment for acute myocardial infarction and had poorer short- and long-term outcomes. However, this mortality risk diminished after adjustment for treatment This suggests that improved recognition and treatment of myocardial infarction may improve outcomes, particularly in the short term.	Georgetown Univ, Med Ctr, Div Cardiol, Washington, DC 20007 USA; Duke Univ, Med Ctr, Duke Clin Res Inst, Durham, NC USA; Mayo Clin & Mayo Fdn, Rochester, MN 55905 USA; Maryland HealthCare Associates, Clinton, MD USA; Delmarva Fdn Med Care, Easton, MD USA	Georgetown University; Duke University; Mayo Clinic	Solomon, AJ (corresponding author), Georgetown Univ, Med Ctr, Div Cardiol, Room M4222,3800 Reservoir Rd NW, Washington, DC 20007 USA.	solomona@gunet.georgetown.edu			PHS HHS [500-96-P623, 500-96-P624] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		ALI M, 1978, ARCH INTERN MED, V138, P1534, DOI 10.1001/archinte.138.10.1534; Barold S S, 1987, Cardiol Clin, V5, P403; BATHEN J, 1973, BRIT HEART J, V35, P1336; Bernstein AD, 1996, AM J CARDIOL, V78, P187, DOI 10.1016/S0002-9149(96)90394-X; *COMM PROF HOSP AC, 1991, INT CLASS DIS 9 REV; CRAGG DR, 1991, ANN INTERN MED, V115, P173, DOI 10.7326/0003-4819-115-3-173; FLEMING C, 1992, MED CARE, V30, P377, DOI 10.1097/00005650-199205000-00001; JENCKS SF, 1992, JAMA-J AM MED ASSOC, V268, P900, DOI 10.1001/jama.268.7.900; Kozlowski FH, 1998, ACAD EMERG MED, V5, P52, DOI 10.1111/j.1553-2712.1998.tb02575.x; Krumholz HM, 1999, CIRCULATION, V99, P2986, DOI 10.1161/01.CIR.99.23.2986; Marciniak TA, 1998, JAMA-J AM MED ASSOC, V279, P1351, DOI 10.1001/jama.279.17.1351; *NAT RES POL CTR L, 1996, GUID OP AOAS DEF RUR; Rathore SS, 2000, J AM COLL CARDIOL, V35, p396A; Rosner MH, 1999, AM J EMERG MED, V17, P182, DOI 10.1016/S0735-6757(99)90058-X; Ryan TJ, 1996, J AM COLL CARDIOL, V28, P1328; Sgarbossa EB, 1996, AM J CARDIOL, V77, P423, DOI 10.1016/S0002-9149(97)89377-0; Shlipak MG, 2000, J AM COLL CARDIOL, V36, P706, DOI 10.1016/S0735-1097(00)00789-0; SMITH EE, 1995, ANN EMERG MED, V25, P274, DOI 10.1016/S0196-0644(95)70342-X; *US CENS BUR, 1992, 1990 CENS POP HOUS; Zhang J, 1998, JAMA-J AM MED ASSOC, V280, P1690, DOI 10.1001/jama.280.19.1690	20	20	20	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	APR 17	2001	134	8					644	651		10.7326/0003-4819-134-8-200104170-00009	http://dx.doi.org/10.7326/0003-4819-134-8-200104170-00009			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	423LJ	11304104				2023-01-03	WOS:000168177500003
J	Halberthal, M; Halperin, ML; Bohn, D				Halberthal, M; Halperin, ML; Bohn, D			Lesson of the week - Acute hyponatraemia in children admitted to hospital: retrospective analysis of factors contributing to its development and resolution	BRITISH MEDICAL JOURNAL			English	Review							PERMANENT BRAIN-DAMAGE; HYPONATREMIA; WOMEN; WATER		Hosp Sick Children, Dept Crit Care Med, Toronto, ON M5G 1X8, Canada; St Michaels Hosp, Div Nephrol, Toronto, ON M5B 1A6, Canada	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University Toronto Affiliates; Saint Michaels Hospital Toronto	Bohn, D (corresponding author), Hosp Sick Children, Dept Crit Care Med, 555 Univ Ave, Toronto, ON M5G 1X8, Canada.							ADELMAN RD, 1996, TXB PEDIAT, P207; ARIEFF AI, 1992, BRIT MED J, V304, P1218, DOI 10.1136/bmj.304.6836.1218; ARIEFF AI, 1986, NEW ENGL J MED, V314, P1529, DOI 10.1056/NEJM198606123142401; AYUS JC, 1992, ANN INTERN MED, V117, P891, DOI 10.7326/0003-4819-117-11-891; Chesney RW, 1998, PEDIATRICS, V102, P399, DOI 10.1542/peds.102.2.399; DARROW DC, 1950, JAMA-J AM MED ASSOC, V143, P365, DOI 10.1001/jama.1950.82910390009011; HALLIDAY M, 1957, PEDIATRICS, V19, P823; HALPERIN ML, 1998, CURRENT THERAPY NEPH, P1; ROSE BD, 1986, AM J MED, V81, P1033, DOI 10.1016/0002-9343(86)90401-8; Soupart A, 1996, CLIN NEPHROL, V46, P149; SPITAL A, 1989, ARCH INTERN MED, V149, P1255, DOI 10.1001/archinte.149.6.1255; Steele A, 1997, ANN INTERN MED, V126, P20, DOI 10.7326/0003-4819-126-1-199701010-00003; Sterns Richard H., 1993, P225; WATTAD A, 1992, CLIN PEDIATR, V31, P153, DOI 10.1177/000992289203100305	14	133	143	0	4	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	MAR 31	2001	322	7289					780	782		10.1136/bmj.322.7289.780	http://dx.doi.org/10.1136/bmj.322.7289.780			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	419HL	11282868	Green Published			2023-01-03	WOS:000167943200031
J	Kenyon, SL; Taylor, DJ; Tarnow-Mordi, W				Kenyon, SL; Taylor, DJ; Tarnow-Mordi, W		ORACLE Collaborative Grp	Broad-spectrum antibiotics for preterm, prelabour rupture of fetal membranes: the ORACLE I randomised trial	LANCET			English	Article							BRONCHOALVEOLAR LAVAGE FLUID; CHRONIC LUNG-DISEASE; CEREBRAL-PALSY; BIRTH-WEIGHT; INFANTS; PREMATURITY; INCREASE; CERVIX; LABOR	Background Preterm, prelabour rupture of the fetal membranes (pPROM) is the commonest antecedent of preterm birth, and can lead to death, neonatal disease, and long-term disability. Previous small trials of antibiotics for pPROM suggested some health benefits for the neonate, but the results were inconclusive. We did a randomised multicentre trial to try to resolve this issue. Methods 4826 women with pPROM were randomly assigned 250 mg erythromycin (n=1197), 325 mg co-amoxiclav (250 mg amoxicillin plus 125 mg clavulanic acid; n=1212), both (n=1192), or placebo (n=1225) four times daily for 10 days or until delivery. The primary outcome measure was a composite of neonatal death, chronic lung disease, or major cerebral abnormality on ultrasonography before discharge from hospital. Analysis was by intention to treat. Findings Two women were lost to follow-up, and there were 15 protocol violations. Among all 2415 infants born to women allocated erythromycin only or placebo, fewer had the primary composite outcome in the erythromycin group (151 of 1190 [12.7%] vs 186 of 1225 [15.2%],p=0.08) than in the placebo group. Among the 2260 singletons in this comparison, significantly fewer had the composite primary outcome in the erythromycin group (125 of 1111[11.2%] vs 166 of 1149 [14.4%], p=0.02). Co-amoxiclav only and coamoxiclav plus erythromycin had no benefit over placebo with regard to this outcome in all infants or in singletons only. Use of erythromycin was also associated with prolongation of pregnancy, reductions in neonatal treatment with surfactant, decreases in oxygen dependence at 28 days of age and older, fewer major cerebral abnormalities on ultrasonography before discharge, and fewer positive blood cultures. Although co-amoxiclav only and co-amoxiclav plus erythromycin were associated with prolongation of pregnancy, they were also associated with a significantly higher rate of neonatal necrotising enterocolitis. Interpretation Erythromycin for women with pPROM is associated with a range of health benefits for the neonate, and thus a probable reduction in childhood disability. However, co-amoxiclav cannot be routinely recommended for pPROM because of its association with neonatal necrotising enterocolitis. A follow-up study of childhood development and disability after pPROM is planned.	Leicester Royal Infirm, Dept Obstet & Gynaecol, Leicester LE2 7LX, Leics, England	University of Leicester	Kenyon, SL (corresponding author), Leicester Royal Infirm, Dept Obstet & Gynaecol, Robert Kilpatrick Bldg,POB 65, Leicester LE2 7LX, Leics, England.			Kenyon, Sara/0000-0002-0756-9617				AbeleHorn M, 1997, INFECTION, V25, P286, DOI 10.1007/BF01720398; [Anonymous], LANCET; BELL SC, 2000, PLACENTA BASIC SCI C, P187; Cox S. M., 1995, American Journal of Obstetrics and Gynecology, V172, P412; EDWARDS AD, 2000, PLACENTA BASIC SCI C, P204; Gomez R, 1997, PRETERM LABOR, P85; Grether JK, 1997, JAMA-J AM MED ASSOC, V278, P207, DOI 10.1001/jama.278.3.207; HEY EN, 1986, BRIT J OBSTET GYNAEC, V93, P1213, DOI 10.1111/j.1471-0528.1986.tb07854.x; KENYON S, 2000, COCHRANE LIB; KOTECHA S, 1995, ARCH DIS CHILD-FETAL, V72, pF90, DOI 10.1136/fn.72.2.F90; Kotecha S, 1996, J PEDIATR-US, V128, P464, DOI 10.1016/S0022-3476(96)70355-4; Kotecha S, 1998, ARCH DIS CHILD-FETAL, V78, pF143, DOI 10.1136/fn.78.2.F143; Kotecha S, 1996, PEDIATR RES, V40, P250, DOI 10.1203/00006450-199608000-00010; KOTECHA S, 1996, EUR J PEDIATR, V155, P514; LAWRENCE G, 1982, LANCET, V1, P137; Maalouf EF, 1999, J PEDIATR-US, V135, P351, DOI 10.1016/S0022-3476(99)70133-2; McGregor JA, 1997, J SOGC, V19, P835; McLaren J, 1999, HUM REPROD, V14, P237, DOI 10.1093/humrep/14.1.237; McLaren J, 1999, HUM REPROD, V14, P2895, DOI 10.1093/humrep/14.11.2895; Medical Research Council (MRC), 1998, MRC CLIN TRIALS SER; MURPHY DJ, 1995, LANCET, V346, P1449, DOI 10.1016/S0140-6736(95)92471-X; NELSON KB, 1985, JAMA-J AM MED ASSOC, V254, P1473, DOI 10.1001/jama.254.11.1473; OGDEN BE, 1984, AM REV RESPIR DIS, V130, P817; RENDLESHORT TJ, 1962, LANCET, V1, P1188; Romero R, 1999, MED FETUS MOTHER, P1581; SPINILLO A, 1995, BRIT J OBSTET GYNAEC, V102, P882, DOI 10.1111/j.1471-0528.1995.tb10875.x; Yoon BH, 2000, AM J OBSTET GYNECOL, V182, P675, DOI 10.1067/mob.2000.104207; Yoon BH, 1996, AM J OBSTET GYNECOL, V174, P1433, DOI 10.1016/S0002-9378(96)70585-9	28	410	434	0	20	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAR 31	2001	357	9261					979	988		10.1016/S0140-6736(00)04233-1	http://dx.doi.org/10.1016/S0140-6736(00)04233-1			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	416QK	11293640				2023-01-03	WOS:000167791500007
J	Rogers, A				Rogers, A			Europe join debate on care for the terminally ill	LANCET			English	News Item																		1999, LANCET, V353, P2220	1	0	0	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUL 3	1999	354	9172					55	55		10.1016/S0140-6736(05)75326-5	http://dx.doi.org/10.1016/S0140-6736(05)75326-5			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	212XP	11657547				2023-01-03	WOS:000081243200035
J	Zinn, C				Zinn, C			Australian doctors renew battle over euthanasia	BRITISH MEDICAL JOURNAL			English	News Item											Zinn, C (corresponding author), GUARDIAN,LONDON,ENGLAND.								0	1	1	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 8	1996	312	7044					1437	1437		10.1136/bmj.312.7044.1437	http://dx.doi.org/10.1136/bmj.312.7044.1437			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UQ296	11644788	Green Published			2023-01-03	WOS:A1996UQ29600007
J	Nelson, HD; Humphrey, LL; Nygren, P; Teutsch, SM; Allan, JD				Nelson, HD; Humphrey, LL; Nygren, P; Teutsch, SM; Allan, JD			Postmenopausal hormone replacement therapy - Scientific review	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Review							CORONARY-HEART-DISEASE; NON-CONTRACEPTIVE ESTROGENS; ACUTE MYOCARDIAL-INFARCTION; WOMEN RECEIVING ESTROGEN; TERM-FOLLOW-UP; BREAST-CANCER; ALZHEIMERS-DISEASE; VENOUS THROMBOEMBOLISM; HIP FRACTURE; RISK-FACTORS	Context Although postmenopausal hormone replacement therapy (HRT) is widely used in the United States, new evidence about its benefits and harms requires reconsideration of its use for the primary prevention of chronic conditions. Objective To assess the benefits and harms of HRT for the primary prevention of cardiovascular disease, thromboembolism, osteoporosis, cancer, dementia, and cholecystitis by reviewing the literature, conducting meta-analyses, and calculating outcome rates. Data Sources All relevant English-language studies were identified in MEDLINE (19662001), HealthSTAR (1975-2001), Cochrane Library databases, and reference lists of key articles. Recent results of the Women's Health Initiative (WHI) and the Heart and Estrogen/progestin Replacement Study (HERS) are included for reported outcomes. Study Selection and Data Extraction We used all published studies of HRT if they contained a comparison group of HRT nonusers and reported data relating to HRT use and clinical outcomes of interest. Studies were excluded if the population was selected according to prior events or presence of conditions associated with higher risks for targeted outcomes. Data Synthesis Meta-analyses of observational studies indicated summary relative risks (RRs) for coronary heart disease (CHD) incidence and mortality that were significantly reduced among current HRT users only, although risk for incidence was not reduced when only studies that controlled for socioeconomic status were included. The WHI reported increased CHD events (hazard ratio [HR], 1.29; 95% confidence interval [CI], 1.02-1.63). Stroke incidence but not mortality was significantly increased among HRT users in the meta-analysis and the WHI. The meta-analysis indicated that risk was significantly elevated for thromboembolic stroke (RR, 1.20; 95% CI, 1.01-1.40) but not subarachnoid or intracerebral stroke. Risk of venous thromboembolism among current HRT users was increased overall (RR, 2.14; 95% CI, 1.64-2.81) and was highest during the first year of use (RR, 3.49; 95% CI, 2.33-5.59) according to a meta-analysis of 12 studies. Protection against osteoporotic fractures is supported by a meta-analysis of 22 estrogen trials, cohort studies, results of the WHI, and trials with bone density outcomes. Current estrogen users have an increased risk of breast cancer that increases with duration of use. Endometrial cancer incidence, but not mortality, is increased with unopposed estrogen use but not with estrogen with progestin. A meta-analysis of 18 observational studies showed a 20% reduction in colon cancer incidence among women who had ever used HRT (RR, 0.80; 95% CI, 0.74-0.86), a finding supported by the WHI. Women symptomatic from menopause had improvement in certain aspects of cognition. Current studies of estrogen and dementia are not definitive. In a cohort study, current HRT users had an age-adjusted RR for cholecystitis of 1.8 (95% CI, 1.6-2.0), increasing to 2.5 (95% CI, 2.0-2.9) after 5 years of use. Conclusions Benefits of HRT include prevention of osteoporotic fractures and colorectal cancer, while prevention of dementia is uncertain. Harms include CHD, stroke, thromboembolic events, breast cancer with 5 or more years of use, and cholecystitis.	Oregon Hlth & Sci Univ, Div Med Informat & Outcomes Res, Portland, OR 97201 USA; Oregon Hlth & Sci Univ, Evidence Based Practice Ctr, Portland, OR 97201 USA; Oregon Hlth & Sci Univ, Dept Med, Portland, OR 97201 USA; Oregon Hlth & Sci Univ, Vet Affairs Med Ctr, Med Serv, Portland, OR 97201 USA; Merck & Co Inc, West Point, PA USA; Univ Texas, Hlth Sci Ctr, Sch Nursing, San Antonio, TX USA	Oregon Health & Science University; Oregon Health & Science University; Oregon Health & Science University; Oregon Health & Science University; US Department of Veterans Affairs; Veterans Health Administration (VHA); Merck & Company; University of Texas System; University of Texas Health San Antonio	Nelson, HD (corresponding author), Oregon Hlth & Sci Univ, Div Med Informat & Outcomes Res, Mail Code BICC 504,3181 SW Sam Jackson Pk Rd, Portland, OR 97201 USA.	nelsonh@ohsu.edu			PHS HHS [290-97-0018] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		AMADUCCI LA, 1986, NEUROLOGY, V36, P922, DOI 10.1212/WNL.36.7.922; ARMSTRONG BK, 1988, MED J AUSTRALIA, V148, P213, DOI 10.5694/j.1326-5377.1988.tb99424.x; Barrett-Connor E, 1998, ANNU REV PUBL HEALTH, V19, P55, DOI 10.1146/annurev.publhealth.19.1.55; BARRETTCONNOR E, 1994, FERTIL STERIL, V62, pS127; BEARD CM, 1989, MAYO CLIN PROC, V64, P1471, DOI 10.1016/S0025-6196(12)65702-4; BRENNER DE, 1994, AM J EPIDEMIOL, V140, P262, DOI 10.1093/oxfordjournals.aje.a117245; BROE GA, 1990, NEUROLOGY, V40, P1698, DOI 10.1212/WNL.40.11.1698; BUSH TL, 1987, CIRCULATION, V75, P1102, DOI 10.1161/01.CIR.75.6.1102; CAULEY JA, 1995, ANN INTERN MED, V122, P9, DOI 10.7326/0003-4819-122-1-199501010-00002; Cauley JA, 2001, AM J MED, V110, P442, DOI 10.1016/S0002-9343(01)00647-7; Cauley JA, 1997, ARCH INTERN MED, V157, P2181, DOI 10.1001/archinte.157.19.2181; COLDITZ GA, 1993, AM J OBSTET GYNECOL, V168, P1473, DOI 10.1016/S0002-9378(11)90784-4; COLDITZ GA, 1995, NEW ENGL J MED, V332, P1589, DOI 10.1056/NEJM199506153322401; *COLL DRUG SURV PR, 1974, NEW ENGL J MED, V290, P15; Coronary Drug Project Research Group, 1977, N Engl J Med, V296, P1185; CRANNEY A, 2000, NAT I HLTH CONS DEV; CRIQUI MH, 1988, AM J EPIDEMIOL, V128, P606, DOI 10.1093/oxfordjournals.aje.a115008; CROFT P, 1989, BRIT MED J, V298, P165, DOI 10.1136/bmj.298.6667.165; Daly E, 1996, LANCET, V348, P1027, DOI 10.1016/S0140-6736(96)24041-3; Daly E, 1996, LANCET, V348, P977, DOI 10.1016/S0140-6736(96)07113-9; DERBY CA, 1995, AM J OBSTET GYNECOL, V173, P544, DOI 10.1016/0002-9378(95)90280-5; DEVOR M, 1992, AM J MED, V92, P275, DOI 10.1016/0002-9343(92)90077-O; DIEHL AK, 1980, SOUTHERN MED J, V73, P438, DOI 10.1097/00007611-198004000-00012; DITKOFF EC, 1991, OBSTET GYNECOL, V78, P991; DUPONT WD, 1991, ARCH INTERN MED, V151, P67, DOI 10.1001/archinte.151.1.67; Duval S, 2000, J AM STAT ASSOC, V95, P89, DOI 10.2307/2669529; Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629; Ettinger B, 1996, OBSTET GYNECOL, V87, P6, DOI 10.1016/0029-7844(95)00358-4; EVERSON RB, 1982, GASTROENTEROLOGY, V82, P4; FARMER ME, 1984, AM J PUBLIC HEALTH, V74, P1374, DOI 10.2105/AJPH.74.12.1374; Fedor-Freybergh P, 1977, Acta Obstet Gynecol Scand Suppl, V64, P1; FINUCANE FF, 1993, ARCH INTERN MED, V153, P73, DOI 10.1001/archinte.153.1.73; FOLSOM AR, 1995, AM J PUBLIC HEALTH, V85, P1128, DOI 10.2105/AJPH.85.8_Pt_1.1128; Fung MM, 1999, J WOMENS HEALTH, V8, P359, DOI 10.1089/jwh.1999.8.359; Grady D, 2002, JAMA-J AM MED ASSOC, V288, P49, DOI 10.1001/jama.288.1.49; GRADY D, 1995, OBSTET GYNECOL, V85, P304, DOI 10.1016/0029-7844(94)00383-O; GRADY D, 1992, ANN INTERN MED, V117, P1016, DOI 10.7326/0003-4819-117-12-1016; GRAVES AB, 1990, ANN NEUROL, V28, P766, DOI 10.1002/ana.410280607; Grodstein F, 1999, EPIDEMIOLOGY, V10, P476, DOI 10.1097/00001648-199909000-00003; Grodstein F, 1999, AM J MED, V106, P574, DOI 10.1016/S0002-9343(99)00063-7; GRODSTEIN F, 1994, OBSTET GYNECOL, V83, P5; Grodstein F, 1996, NEW ENGL J MED, V335, P453, DOI 10.1056/NEJM199608153350701; Grodstein F, 1996, LANCET, V348, P983, DOI 10.1016/S0140-6736(96)07308-4; Grodstein F, 1997, NEW ENGL J MED, V336, P1769, DOI 10.1056/NEJM199706193362501; Grodstein F, 2000, ANN INTERN MED, V133, P933, DOI 10.7326/0003-4819-133-12-200012190-00008; Gutthann SP, 1997, BMJ-BRIT MED J, V314, P796, DOI 10.1136/bmj.314.7083.796; Hackman B W, 1976, Curr Med Res Opin, V4, P303, DOI 10.1185/03007997609109322; Harris RP, 2001, AM J PREV MED, V20, P21, DOI 10.1016/S0749-3797(01)00261-6; Harwood DG, 1999, NEUROLOGY, V52, P551, DOI 10.1212/WNL.52.3.551; Heckbert SR, 1997, ARCH INTERN MED, V157, P1330, DOI 10.1001/archinte.157.12.1330; Hemminki E, 1997, BRIT MED J, V315, P149, DOI 10.1136/bmj.315.7101.149; HENDERSON VW, 1994, ARCH NEUROL-CHICAGO, V51, P896, DOI 10.1001/archneur.1994.00540210068014; HERNANDEZ AM, 1990, EPIDEMIOLOGY, V1, P128; Herrington DM, 2000, NEW ENGL J MED, V343, P522, DOI 10.1056/NEJM200008243430801; HEYMAN A, 1984, ANN NEUROL, V15, P335, DOI 10.1002/ana.410150406; Hoidrup S, 1999, AM J EPIDEMIOL, V149, P993; Holbraaten E, 1999, THROMB HAEMOSTASIS, V82, P1218; HONORE LH, 1980, J REPROD MED, V25, P187; HORWITZ RI, 1990, LANCET, V336, P542, DOI 10.1016/0140-6736(90)92095-Y; Hulley S, 2002, JAMA-J AM MED ASSOC, V288, P58, DOI 10.1001/jama.288.1.58; Hulley S, 1998, JAMA-J AM MED ASSOC, V280, P605, DOI 10.1001/jama.280.7.605; Humphrey LL, 2002, HORMONE REPLACEMENT; HUMPHREY LL, 2002, POSTMENOPAUSAL HORMO; HUMPHREY LL, IN PRESS ANN INTERN; Janowsky JS, 2000, J COGNITIVE NEUROSCI, V12, P407, DOI 10.1162/089892900562228; Jick H, 1996, LANCET, V348, P981, DOI 10.1016/S0140-6736(96)07114-0; JORGENSEN T, 1988, GUT, V29, P433, DOI 10.1136/gut.29.4.433; KAKAR F, 1988, AM J PUBLIC HEALTH, V78, P564, DOI 10.2105/AJPH.78.5.564; Kawas C, 1997, NEUROLOGY, V48, P1517, DOI 10.1212/WNL.48.6.1517; Keating NL, 1999, ANN INTERN MED, V130, P545, DOI 10.7326/0003-4819-130-7-199904060-00002; Keefover RW, 1996, NEUROL CLIN, V14, P337, DOI 10.1016/S0733-8619(05)70260-7; KIEL DP, 1987, NEW ENGL J MED, V317, P1169, DOI 10.1056/NEJM198711053171901; Komulainen MH, 1998, MATURITAS, V31, P45, DOI 10.1016/S0378-5122(98)00085-1; Lacey JV, 2002, JAMA-J AM MED ASSOC, V288, P334, DOI 10.1001/jama.288.3.334; LAVECCHIA C, 1992, J EPIDEMIOL COMMUN H, V46, P234, DOI 10.1136/jech.46.3.234; LeBlanc ES, 2001, JAMA-J AM MED ASSOC, V285, P1489, DOI 10.1001/jama.285.11.1489; LONGSTRETH WT, 1994, ANN INTERN MED, V121, P168, DOI 10.7326/0003-4819-121-3-199408010-00002; Mamdani MM, 2000, CAN MED ASSOC J, V162, P1421; MANN RD, 1994, J CLIN EPIDEMIOL, V47, P307, DOI 10.1016/0895-4356(94)90014-0; Matthews KA, 1996, AM J EPIDEMIOL, V143, P971; MAXIM P, 1995, OSTEOPOROSIS INT, V5, P23, DOI 10.1007/BF01623654; Melton LJ, 1998, OSTEOPOROSIS INT, V8, P341, DOI 10.1007/s001980050073; MELTON LJ, 1989, AM J EPIDEMIOL, V129, P1000, DOI 10.1093/oxfordjournals.aje.a115204; Miller J, 2002, ANN INTERN MED, V136, P680, DOI 10.7326/0003-4819-136-9-200205070-00011; MILLER VT, 1995, JAMA-J AM MED ASSOC, V273, P199, DOI 10.1001/jama.1995.03520270033028; MORTEL KF, 1995, J NEUROPSYCH CLIN N, V7, P334; Mosekilde L, 2000, MATURITAS, V36, P181, DOI 10.1016/S0378-5122(00)00158-4; NACHTIGALL LE, 1979, OBSTET GYNECOL, V54, P74, DOI 10.1097/00006250-197907000-00017; NAESSEN T, 1990, ANN INTERN MED, V113, P95, DOI 10.7326/0003-4819-113-2-95; NELSON HD, 2001, HORMONE REPLACEMENT; PaganiniHill A, 1996, ARCH INTERN MED, V156, P2213, DOI 10.1001/archinte.156.19.2213; Pedersen AT, 1997, LANCET, V350, P1277, DOI 10.1016/S0140-6736(97)06005-4; PEPI Trial, 1995, JAMA-J AM MED ASSOC, V274, P1676; Persson I, 1997, J CLIN EPIDEMIOL, V50, P611, DOI 10.1016/S0895-4356(97)00004-8; Persson I, 1996, INT J CANCER, V67, P327, DOI 10.1002/(SICI)1097-0215(19960729)67:3<327::AID-IJC4>3.3.CO;2-J; PETITTI DB, 1979, JAMA-J AM MED ASSOC, V242, P1150, DOI 10.1001/jama.242.11.1150; Petitti DB, 1998, STROKE, V29, P23, DOI 10.1161/01.STR.29.1.23; PETITTI DB, 1988, GASTROENTEROLOGY, V94, P91, DOI 10.1016/0016-5085(88)90614-2; PETITTI DB, 1987, OBSTET GYNECOL, V70, P289; PFEFFER RI, 1978, AM J EPIDEMIOL, V107, P479, DOI 10.1093/oxfordjournals.aje.a112567; PFEFFER RI, 1978, J CHRON DIS, V31, P389, DOI 10.1016/0021-9681(78)90003-6; PHILLIPS SM, 1992, PSYCHONEUROENDOCRINO, V17, P485, DOI 10.1016/0306-4530(92)90007-T; Polo-Kantola P, 1998, OBSTET GYNECOL, V91, P459, DOI 10.1016/S0029-7844(97)00700-X; Poulter NR, 1997, LANCET, V349, P1202, DOI 10.1016/S0140-6736(97)02358-1; Ries L. A. G., 1999, SEER CANC STAT REV 1; Riman T, 2002, JNCI-J NATL CANCER I, V94, P497, DOI 10.1093/jnci/94.7.497; Rodriguez C, 2001, AM J EPIDEMIOL, V153, P145, DOI 10.1093/aje/153.2.145; ROSENBERG L, 1993, AM J EPIDEMIOL, V137, P54, DOI 10.1093/oxfordjournals.aje.a116602; Rossouw JE, 2002, JAMA-J AM MED ASSOC, V288, P321, DOI 10.1001/jama.288.3.321; Schairer C, 1999, J NATL CANCER I, V91, P264, DOI 10.1093/jnci/91.3.264; SCRAGG RKR, 1984, BRIT MED J, V288, P1795, DOI 10.1136/bmj.288.6433.1795; Sellers TA, 1997, ANN INTERN MED, V127, P973, DOI 10.7326/0003-4819-127-11-199712010-00004; Shaywitz SE, 1999, JAMA-J AM MED ASSOC, V281, P1197, DOI 10.1001/jama.281.13.1197; SHERWIN BB, 1988, PSYCHONEUROENDOCRINO, V13, P345, DOI 10.1016/0306-4530(88)90060-1; Sidney S, 1997, ANN INTERN MED, V127, P501, DOI 10.7326/0003-4819-127-7-199710010-00001; SILLEROARENAS M, 1992, OBSTET GYNECOL, V79, P286; Slavin RE, 1986, EDUC RESEARCHER, V15, P5, DOI DOI 10.3102/0013189X015009005; Sourander L, 1998, LANCET, V352, P1965, DOI 10.1016/S0140-6736(98)05066-1; Spiegelhalter DJ, 1999, WINBUGS VERSION 1 2; STAMPFER MJ, 1991, PREV MED, V20, P47, DOI 10.1016/0091-7435(91)90006-P; STEINBERG KK, 1994, EPIDEMIOLOGY, V5, P415, DOI 10.1097/00001648-199407000-00007; Sutton AJ, 2000, BMJ-BRIT MED J, V320, P1574, DOI 10.1136/bmj.320.7249.1574; Sutton AJAK, 2000, METHODS METAANALYSIS; Tang MX, 1996, LANCET, V348, P429, DOI 10.1016/S0140-6736(96)03356-9; THOMPSON SG, 1989, J EPIDEMIOL COMMUN H, V43, P173, DOI 10.1136/jech.43.2.173; Thrift AG, 1996, STROKE, V27, P2020, DOI 10.1161/01.STR.27.11.2020; Torgerson DJ, 2001, JAMA-J AM MED ASSOC, V285, P2891, DOI 10.1001/jama.285.22.2891; United States Preventive Services Task Force, 1996, GUID CLIN PREV SERV; VANHULLE G, 1976, CONSENSUS MENOPAUSE; Varas-Lorenzo C, 2000, CIRCULATION, V101, P2572, DOI 10.1161/01.CIR.101.22.2572; Varas-Lorenzo C, 1998, AM J EPIDEMIOL, V147, P387; Waring SC, 1999, NEUROLOGY, V52, P965, DOI 10.1212/WNL.52.5.965; Willis DB, 1996, CANCER CAUSE CONTROL, V7, P449, DOI 10.1007/BF00052671; WILSON PWF, 1985, NEW ENGL J MED, V313, P1038, DOI 10.1056/NEJM198510243131702; WOLF PH, 1991, AM J OBSTET GYNECOL, V164, P489, DOI 10.1016/S0002-9378(11)80006-2	135	729	775	0	57	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 21	2002	288	7					872	881		10.1001/jama.288.7.872	http://dx.doi.org/10.1001/jama.288.7.872			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	585FC	12186605	Bronze			2023-01-03	WOS:000177513100030
J	Sutcliffe, AG				Sutcliffe, AG			Death of a child	LANCET			English	Article									Dept Community Child Hlth, London NW3 2PF, England		Sutcliffe, AG (corresponding author), Dept Community Child Hlth, Royal Free Campus, London NW3 2PF, England.			Sutcliffe, Alastair/0000-0001-8542-6155					0	1	1	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUN 15	2002	359	9323					2104	2104		10.1016/S0140-6736(02)08910-9	http://dx.doi.org/10.1016/S0140-6736(02)08910-9			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	562JX	12086779				2023-01-03	WOS:000176194600026
J	Veldink, JH; Wokke, JHJ; van der Wal, G; de Jong, JMBV; van den Berg, LH				Veldink, JH; Wokke, JHJ; van der Wal, G; de Jong, JMBV; van den Berg, LH			Euthanasia and physician-assisted suicide among patients with amyotrophic lateral sclerosis in the netherlands.	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							OF-LIFE DECISIONS; MEDICAL-PRACTICE; END; CARE; ALS; EXPERIENCES; POPULATION; NEUROLOGY; ATTITUDES; OUTCOMES	Background: Amyotrophic lateral sclerosis (ALS) is a disease that causes progressive paralysis leading to respiratory failure. Patients with ALS may consider physician-assisted suicide. However, it is not known how many patients, if given the option, would actually decide to end their lives by physician-assisted suicide or euthanasia nor at what stage of the disease they would choose to do so. Methods: We identified physicians of 279 patients in the Netherlands with a diagnosis of ALS who died between 1994 and 1999. Physicians were asked to fill out a validated questionnaire about the end-of-life decisions that were made. Of 241 eligible physicians, 203 returned the questionnaire (84 percent). Results: Of the 203 patients, 35 (17 percent) chose euthanasia and died that way. An additional six patients (3 percent) died as a result of physician-assisted suicide. Patients to whom religion was important were less likely to have died as a result of euthanasia or physician-assisted suicide. The choice of euthanasia or physician-assisted suicide was not associated with any particular characteristics of the disease or of the patient's care, nor was it associated with income or educational level. Disability before death was significantly more severe in patients who died as a result of euthanasia than among those who died in other ways. Physician-assisted suicide appeared to occur somewhat earlier in the course of the disease than did euthanasia. An additional 48 patients (24 percent) received palliative treatment, which probably shortened their lives. Conclusions: In the Netherlands, we found that one in five patients with ALS died as a result of euthanasia or physician-assisted suicide. (N Engl J Med 2002;346:1638-44.) Copyright (C) 2002 Massachusetts Medical Society.	Univ Med Ctr Utrecht, Dept Neurol, NL-3508 GA Utrecht, Netherlands; Vrije Univ Amsterdam, Med Ctr, Dept Social Med, Amsterdam, Netherlands; Vrije Univ Amsterdam, Med Ctr, Inst Res Extramural Med, Amsterdam, Netherlands; Univ Amsterdam, Acad Med Ctr, Dept Neurol, NL-1105 AZ Amsterdam, Netherlands	Utrecht University; Utrecht University Medical Center; Vrije Universiteit Amsterdam; Vrije Universiteit Amsterdam; University of Amsterdam; Academic Medical Center Amsterdam	van den Berg, LH (corresponding author), Univ Med Ctr Utrecht, Dept Neurol, G-03-228,POB 85500, NL-3508 GA Utrecht, Netherlands.			Veldink, Jan/0000-0001-5572-9657				Albert SM, 1999, J NEUROL SCI, V169, P108, DOI 10.1016/S0022-510X(99)00227-0; Bannink M, 2000, LANCET, V356, P2067, DOI 10.1016/S0140-6736(00)03407-3; Bindels PJE, 1996, LANCET, V347, P499, DOI 10.1016/S0140-6736(96)91138-1; BROOKS BR, 1994, J NEUROL SCI, V124, P96, DOI 10.1016/0022-510X(94)90191-0; Carver AC, 1999, NEUROLOGY, V53, P284, DOI 10.1212/WNL.53.2.284; Deliens L, 2000, LANCET, V356, P1806, DOI 10.1016/S0140-6736(00)03233-5; Ganzini L, 2000, NEW ENGL J MED, V342, P1538; Ganzini L, 2000, NEW ENGL J MED, V342, P557, DOI 10.1056/NEJM200002243420806; Ganzini L, 1998, NEW ENGL J MED, V339, P967, DOI 10.1056/NEJM199810013391406; HAVERKAMP LJ, 1995, BRAIN, V118, P707, DOI 10.1093/brain/118.3.707; Hendin H, 1997, JAMA-J AM MED ASSOC, V277, P1720, DOI 10.1001/jama.277.21.1720; Horikx A, 2000, Ned Tijdschr Geneeskd, V144, P2497; Jochemsen H, 1999, J MED ETHICS, V25, P16, DOI 10.1136/jme.25.1.16; Kuhse H, 1997, MED J AUSTRALIA, V166, P191, DOI 10.5694/j.1326-5377.1997.tb140074.x; Lacomblez L, 1996, NEUROLOGY, V47, pS242, DOI 10.1212/WNL.47.6_Suppl_4.242S; Lavery JV, 2001, LANCET, V358, P362, DOI 10.1016/S0140-6736(01)05555-6; Miller RG, 1999, NEUROLOGY, V52, P1311, DOI 10.1212/WNL.52.7.1311; Murphy PL, 2000, NEUROLOGY, V55, P1581, DOI 10.1212/WNL.55.10.1581; Traynor BJ, 1999, NEUROLOGY, V52, P504, DOI 10.1212/WNL.52.3.504; van der Maas PJ, 1991, LANCET, V338, P669, DOI 10.1016/0140-6736(91)91241-L; van der Maas PJ, 1996, NEW ENGL J MED, V335, P1699, DOI 10.1056/NEJM199611283352227; Voltz R, 1997, J NEUROL, V244, pS2, DOI 10.1007/PL00007721	22	93	93	0	10	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAY 23	2002	346	21					1638	1644		10.1056/NEJMsa012739	http://dx.doi.org/10.1056/NEJMsa012739			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	554GZ	12023997				2023-01-03	WOS:000175728600007
J	Hoving, JL; Koes, BW; de Vet, HCW; van der Windt, DAWM; Assendelft, WJJ; van Mameren, H; Deville, WLJM; Pool, JJM; Scholten, RJPM; Bouter, LM				Hoving, JL; Koes, BW; de Vet, HCW; van der Windt, DAWM; Assendelft, WJJ; van Mameren, H; Deville, WLJM; Pool, JJM; Scholten, RJPM; Bouter, LM			Manual therapy, physical therapy, or continued care by a general practitioner for patients with neck pain - A randomized, controlled trial	ANNALS OF INTERNAL MEDICINE			English	Article							DISABILITY INDEX; CLINICAL-TRIAL; POPULATION; PREVALENCE; COMPLAINTS; HEALTH; BACK; PHYSIOTHERAPY; MANIPULATION; RELIABILITY	Background: Neck pain is a common problem, but the effectiveness of frequently applied conservative therapies has never been directly compared. Objective: To determine the effectiveness of manual therapy, physical therapy, and continued care by a general practitioner. Design: Randomized, controlled trial. Setting: Outpatient care setting in the Netherlands. Patients: 183 patients, 18 to 70 years of age, who had had nonspecific neck pain for at least 2 weeks. Intervention: 6 weeks of manual therapy (specific mobilization techniques) once per week, physical therapy (exercise therapy) twice per week, or continued care by a general practitioner (analgesics, counseling, and education). Measurements: Treatment was considered successful if the patient reported being "completely recovered" or "much improved" on an ordinal six-point scale. Physical dysfunction, pain intensity, and disability were also measured. Results: At 7 weeks, the success rates were 68.3% for manual therapy, 50.8% for physical therapy, and 35.9% for continued care. Statistically significant differences in pain intensity with manual therapy compared with continued care or physical therapy ranged from 0.9 to 1.5 on a scale of 0 to 10. Disability scores also favored manual therapy, but the differences among groups were small. Manual therapy scored consistently better than the other two interventions on most outcome measures. Physical therapy scored better than continued care on some outcome measures, but the differences were not statistically significant. Conclusion: in daily practice, manual therapy is a favorable treatment option for patients with neck pain compared with physical therapy or continued care by a general practitioner.	Cabrini Hosp, Dept Clin Epidemiol, Malvern, Vic 3144, Australia; Monash Univ, Dept Epidemiol & Prevent Med, Cabrini Med Ctr, Malvern, Vic 3144, Australia; Vrije Univ Amsterdam, Med Ctr, Inst Res Extramural Med, Amsterdam, Netherlands; Erasmus Univ, Rotterdam, Netherlands; Univ Maastricht, Maastricht, Netherlands; Dutch Coll Gen Practitioners, Utrecht, Netherlands; Nivel Netherlands Inst Hlth Serv Res, Utrecht, Netherlands	Cabrini Health; Cabrini Health; Monash University; Vrije Universiteit Amsterdam; Erasmus University Rotterdam; Maastricht University; Netherlands Institute for Health Services Research	Hoving, JL (corresponding author), Cabrini Hosp, Dept Clin Epidemiol, Suite 41 183 Wattletree Rd, Malvern, Vic 3144, Australia.	Jan.Hoving@med.monash.edu.au	assendelft, willem/AAW-1854-2021; Deville, Walter/B-5160-2013; Hoving, Jan/C-3744-2017; Hoving, Jan L/O-2235-2013; Assendelft, W.J.J./H-8008-2014; Koes, Bart w/K-4614-2016	assendelft, willem/0000-0002-2966-3778; Hoving, Jan L/0000-0002-0461-4013; Assendelft, W.J.J./0000-0002-2966-3778; Koes, Bart w/0000-0002-0450-9969; de Vet, Henrica/0000-0002-5454-2804; Bouter, Lex/0000-0002-2659-5482				ANDERSSON HI, 1993, CLIN J PAIN, V9, P174, DOI 10.1097/00002508-199309000-00004; Assendelft WJJ, 1996, J FAM PRACTICE, V42, P475; Basmajian JV, 1993, RATIONAL MANUAL THER; BAUMGARTEN K, 1996, FUNCTIEPROFIEL MANUE; Borghouts J, 1999, SCAND J PRIM HEALTH, V17, P215; Borghouts JAJ, 1999, PAIN, V80, P629, DOI 10.1016/S0304-3959(98)00268-1; Borghouts JAJ, 1998, PAIN, V77, P1, DOI 10.1016/S0304-3959(98)00058-X; BOVIM G, 1994, SPINE, V19, P1307, DOI 10.1097/00007632-199406000-00001; BRATTBERG G, 1989, PAIN, V37, P215, DOI 10.1016/0304-3959(89)90133-4; CARLSSON AM, 1983, PAIN, V16, P87, DOI 10.1016/0304-3959(83)90088-X; COOKSON JC, 1979, PHYS THER, V59, P259, DOI 10.1093/ptj/59.3.259; Cote P, 1998, SPINE, V23, P1689, DOI 10.1097/00007632-199808010-00015; Cote P, 2000, SPINE, V25, P1109; Di Fabio RP, 1999, PHYS THER, V79, P50; EssinkBot ML, 1997, MED CARE, V35, P522, DOI 10.1097/00005650-199705000-00008; Faris N, 1996, SOLID STATE TECHNOL, V39, P18; FARRELL JP, 1992, PHYS THER, V72, P843, DOI 10.1093/ptj/72.12.843; FEINSTEIN AR, 1987, CLINIMETRICS, P91; FITZGERALD GK, 1994, PHYS THER, V74, P227, DOI 10.1093/ptj/74.3.227; Gross AR, 1996, RHEUM DIS CLIN N AM, V22, P579, DOI 10.1016/S0889-857X(05)70289-1; GROSS AR, 2000, COCHRANE DB SYST REV, P61; GROSS AR, 1996, ONLINE J CURR CLIN T; Hains F, 1998, J MANIP PHYSIOL THER, V21, P75; Hoving JL, 2001, SPINE, V26, P196, DOI 10.1097/00007632-200101150-00015; JACOBSSON L, 1989, SCAND J RHEUMATOL, V18, P353, DOI 10.3109/03009748909102096; JAESCHKE R, 1990, CONTROL CLIN TRIALS, V11, P43, DOI 10.1016/0197-2456(90)90031-V; Jette AM, 1997, PHYS THER, V77, P145, DOI 10.1093/ptj/77.2.145; Jette DU, 1996, PHYS THER, V76, P930, DOI 10.1093/ptj/76.9.930; Jette DU, 1996, PHYS THER, V76, P945, DOI 10.1093/ptj/76.9.945; KOES BW, 1992, SPINE, V17, P28, DOI 10.1097/00007632-199201000-00005; KOES BW, 1993, J MANIP PHYSIOL THER, V16, P211; KOES BW, 1990, NEDERLANDS TIJDSCHRI, V100, P31; KROESE ME, 1999, INVENTARISATIE BEH 1; LANSER K, 1994, NEKSCHOOL NEKKLACHTE; MAKELA M, 1991, AM J EPIDEMIOL, V134, P1356; NORUSIS MJ, 1999, SPSS 9 0 GUIDE DATA; PICAVET HSJ, 2000, KLACHTEN BEWEGINGSAP; POCOCK SJ, 1989, CLIN TRIALS PRACTICA, P125; Stratford P.W., 1999, PHYSIOTHER CANADA, V51, P107; TAKALA EP, 1994, SCAND J REHABIL MED, V26, P17; van Tulder MW, 2000, NECK BACK PAIN SCI E; VERNON H, 1991, J MANIP PHYSIOL THER, V14, P409; WILLIAMS A, 1990, HEALTH POLICY, V16, P199; 1993, MANUELE THERAPIE WER	44	211	216	0	25	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAY 21	2002	136	10					713	722		10.7326/0003-4819-136-10-200205210-00006	http://dx.doi.org/10.7326/0003-4819-136-10-200205210-00006			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	553FF	12020139	Green Published			2023-01-03	WOS:000175664600001
J	Dey, P; Bundred, N; Gibbs, A; Hopwood, P; Baildam, A; Boggis, C; James, M; Knox, F; Leidecker, V; Woodman, C				Dey, P; Bundred, N; Gibbs, A; Hopwood, P; Baildam, A; Boggis, C; James, M; Knox, F; Leidecker, V; Woodman, C			Costs and benefits of a one stop clinic compared with a dedicated breast clinic: randomised controlled trial	BRITISH MEDICAL JOURNAL			English	Article							DIAGNOSIS; CANCER	Objective To determine the cost to the NHS and the impact on anxiety of a one stop clinic for assessing women with suspected breast cancer. Study design Randomised controlled trial. Participants Women aged 35 or over referred with a breast lump. Study setting Teaching hospital, north west England. Interventions Women were randomly allocated to attend a one stop clinic or a dedicated breast clinic. Outcome measures Reduction in mean anxiety from baseline at 24 hours after the first visit and at 3 weeks and 3 months after diagnosis; mean cost per patient. Results 670 women were randomised. Compared with women who attended the dedicated clinic, patients attending the one stop clinic were less anxious 24 hours after the visit (adjusted mean change in state anxiety - 5.7 (95% confidence interval - 8.4 to - 3.0)) but not at 3 weeks or 3 months after diagnosis. The additional cost to the NI IS of a one stop attendance was 02 per woman; this was largely explained by greater cytopathological and radiological staff costs. Conclusion One stop clinics may not be justified in terms of a reduction in short term anxiety.	Univ Manchester, Ctr Canc Epidemiol, Manchester M20 4QL, Lancs, England; S Manchester Univ Hosp Trust, Withington Hosp, Manchester M20 2LR, Lancs, England; Univ Keele, Ctr Hlth Policy & Planning, Keele ST5 5BG, Staffs, England; Christie Hosp NHS Trust, CRC, Psychol Med Grp, Manchester M20 4BX, Lancs, England	University of Manchester; Keele University; Christie NHS Foundation Trust; Christie Hospital	Dey, P (corresponding author), Univ Manchester, Ctr Canc Epidemiol, Manchester M20 4QL, Lancs, England.							Altman DG, 1995, EUR J CANCER, V31A, P1934, DOI 10.1016/0959-8049(95)00470-X; *CANC GUID SUBGR C, 1996, IMPR OUTC BREAST CAN; Department of Health, 2000, NHS CANC PLAN; Eltahir A, 1999, J ROY COLL SURG EDIN, V44, P226; GUI GPH, 1995, ANN ROY COLL SURG, V77, P24; Harcourt D, 1998, BREAST, V7, P314, DOI 10.1016/S0960-9776(98)90073-X; Hollis S, 1999, BRIT MED J, V319, P670, DOI 10.1136/bmj.319.7211.670; Lowe JB, 1999, CANCER, V85, P1114, DOI 10.1002/(SICI)1097-0142(19990301)85:5<1114::AID-CNCR15>3.0.CO;2-Y; Lucock MP, 1997, BRIT MED J, V315, P572; Mansel R, 1998, EUR J SURG ONCOL, V24, P464, DOI 10.1016/S0748-7983(98)93104-3; McPherson K, 1999, EUR J CANCER, V35, P1598, DOI 10.1016/S0959-8049(99)00196-3; Pocock SJ., 2013, CLIN TRIALS PRACTICA; Poole K, 1997, J ADV NURS, V25, P273, DOI 10.1046/j.1365-2648.1997.1997025273.x; Senn S, 2000, STAT MED, V19, P861, DOI 10.1002/(SICI)1097-0258(20000330)19:6<861::AID-SIM407>3.0.CO;2-F; Speilberger C.D., 1983, STATE TRAIT ANXIETY; Teh W, 1998, EUR J CANCER, V34, P449, DOI 10.1016/S0959-8049(97)10066-1; ZIGMOND AS, 1983, ACTA PSYCHIAT SCAND, V67, P361, DOI 10.1111/j.1600-0447.1983.tb09716.x	17	57	58	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	MAR 2	2002	324	7336					507	+		10.1136/bmj.324.7336.507	http://dx.doi.org/10.1136/bmj.324.7336.507			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	528DT	11872547	Green Published, Bronze			2023-01-03	WOS:000174229700015
J	Coiffier, B; Lepage, E; Briere, J; Herbrecht, R; Tilly, H; Bouabdallah, R; Morel, P; Van den Neste, E; Salles, G; Gaulard, P; Reyes, F; Gisselbrecht, C				Coiffier, B; Lepage, E; Briere, J; Herbrecht, R; Tilly, H; Bouabdallah, R; Morel, P; Van den Neste, E; Salles, G; Gaulard, P; Reyes, F; Gisselbrecht, C			CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma.	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ANTI-CD20 MONOCLONAL-ANTIBODY; NON-HODGKINS-LYMPHOMA; STANDARD REGIMEN CHOP; DETUDE DES LYMPHOMES; PHASE-II; AGGRESSIVE LYMPHOMA; COMBINATION; THERAPY; GRADE; IDEC-C2B8	Background: The standard treatment for patients with diffuse large-B-cell lymphoma is cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP). Rituximab, a chimeric monoclonal antibody against the CD20 B-cell antigen, has therapeutic activity in diffuse large-B-cell lymphoma. We conducted a randomized trial to compare CHOP chemotherapy plus rituximab with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. Methods: Previously untreated patients with diffuse large-B-cell lymphoma, 60 to 80 years old, were randomly assigned to receive either eight cycles of CHOP every three weeks (197 patients) or eight cycles of CHOP plus rituximab given on day 1 of each cycle (202 patients). Results: The rate of complete response was significantly higher in the group that received CHOP plus rituximab than in the group that received CHOP alone (76 percent vs. 63 percent, P=0.005). With a median follow-up of two years, event-free and overall survival times were significantly higher in the CHOP-plus-rituximab group (P<0.001 and P=0.007, respectively). The addition of rituximab to standard CHOP chemotherapy significantly reduced the risk of treatment failure and death (risk ratios, 0.58 [95 percent confidence interval, 0.44 to 0.77] and 0.64 [0.45 to 0.89], respectively). Clinically relevant toxicity was not significantly greater with CHOP plus rituximab. Conclusions: The addition of rituximab to the CHOP regimen increases the complete-response rate and prolongs event-free and overall survival in elderly patients with diffuse large-B-cell lymphoma, without a clinically significant increase in toxicity. (N Engl J Med 2002;346:235-42.) Copyright (C) 2002 Massachusetts Medical Society.	Hospices Civils Lyon, Lyon, France; Univ Lyon 1, F-69365 Lyon, France; Hop Henri Mondor, Paris, France; Hop St Louis, Assistance Publ Hop Paris, Paris, France; Hop Hautepierre, Strasbourg, France; Inst J Paoli I Calmettes, F-13009 Marseille, France; Ctr Henri Becquerel, F-76038 Rouen, France; Ctr Hosp Lens, Lens, France; Catholic Univ Louvain, Brussels, Belgium	CHU Lyon; UDICE-French Research Universities; Universite Claude Bernard Lyon 1; Assistance Publique Hopitaux Paris (APHP); Universite Paris-Est-Creteil-Val-de-Marne (UPEC); Hopital Universitaire Henri-Mondor - APHP; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; UDICE-French Research Universities; Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille; Universite Paris Cite; CHU Strasbourg; UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; UNICANCER; Institut Paoli-Calmette (IPC); UNICANCER; Centre Henri Becquerel; Universite Catholique Louvain	Coiffier, B (corresponding author), Ctr Hosp Lyon Sud, Hematol Serv, F-69495 Pierre Benite, France.	bertrand.coiffier@chu-lyon.fr	Herbrecht, Raoul/D-3471-2013; Herbrecht, Raoul/GVU-1333-2022; Salles, Gilles/Z-2336-2019; Herbrecht, Raoul/AAT-1763-2021	Salles, Gilles/0000-0002-9541-8666; Herbrecht, Raoul/0000-0002-9381-4876				Bastion YB, 1997, J CLIN ONCOL, V15, P2945, DOI 10.1200/JCO.1997.15.8.2945; Chan WC, 1997, BLOOD, V89, P3909; Chan WC, 1997, ANN ONCOL, V8, P973; Cheson, 2000, J CLIN ONCOL, V18, P2351; Cheson BD, 1999, J CLIN ONCOL, V17, P1244, DOI 10.1200/JCO.1999.17.4.1244; COIFFIER B, 1994, ANN ONCOL, V5, P873; Coiffier B, 1998, BLOOD, V92, P1927; Coiffier B, 2000, BLOOD, V96, p223A; COIFFIER B, 1997, TXB MED ONCOLOGY, P265; Czuczman MS, 1999, J CLIN ONCOL, V17, P268, DOI 10.1200/JCO.1999.17.1.268; DIXON DO, 1986, J CLIN ONCOL, V4, P295, DOI 10.1200/JCO.1986.4.3.295; FISHER RI, 1993, NEW ENGL J MED, V328, P1002, DOI 10.1056/NEJM199304083281404; Foran JM, 2000, J CLIN ONCOL, V18, P317, DOI 10.1200/JCO.2000.18.2.317; GORDON LI, 1992, NEW ENGL J MED, V327, P1342, DOI 10.1056/NEJM199211053271903; Haioun C, 2000, J CLIN ONCOL, V18, P3025, DOI 10.1200/JCO.2000.18.16.3025; HARRIS NL, 1994, BLOOD, V84, P1361; Jaffe ES, 2001, WHO CLASSIFICATION T; Jerkeman M, 1999, ANN ONCOL, V10, P1079, DOI 10.1023/A:1008392528248; MALONEY DG, 1994, BLOOD, V84, P2457; Maloney DG, 1997, BLOOD, V90, P2188; McLaughlin P, 1998, J CLIN ONCOL, V16, P2825, DOI 10.1200/JCO.1998.16.8.2825; MEYER RM, 1995, J CLIN ONCOL, V13, P2386, DOI 10.1200/JCO.1995.13.9.2386; *NCI, 1998, CANC THER EV PROGR C; SHIPP MA, 1993, NEW ENGL J MED, V329, P987, DOI 10.1056/nejm199309303291402; SONNEVELD P, 1995, J CLIN ONCOL, V13, P2530, DOI 10.1200/JCO.1995.13.10.2530; Tilly H, 2000, BLOOD, V96, p832A; Tirelli U, 1998, J CLIN ONCOL, V16, P27, DOI 10.1200/JCO.1998.16.1.27; Vose JM, 2001, J CLIN ONCOL, V19, P389, DOI 10.1200/JCO.2001.19.2.389; Zinzani PL, 1999, BLOOD, V94, P33; 1994, GOOD CLIN PRACT J S, V1	30	3952	4152	7	187	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JAN 24	2002	346	4					235	242		10.1056/NEJMoa011795	http://dx.doi.org/10.1056/NEJMoa011795			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	513UR	11807147				2023-01-03	WOS:000173398900003
J	Wald, HL; Aronson, MD				Wald, HL; Aronson, MD			Update in hospital medicine	ANNALS OF INTERNAL MEDICINE			English	Review							RESISTANT ENTEROCOCCUS-FAECIUM; INFECTIONS; HEART; QUINUPRISTIN/DALFOPRISTIN; CATHETERIZATION; THERAPY; LUNG		Univ Penn, Philadelphia, PA 19104 USA; Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA	University of Pennsylvania; Harvard University; Beth Israel Deaconess Medical Center	Wald, HL (corresponding author), Hosp Univ Penn, 3400 Spruce St,3 Silverstein, Philadelphia, PA 19104 USA.	heidi.wald@uphs.upenn.edu						Bernard GR, 2000, JAMA-J AM MED ASSOC, V283, P2568, DOI 10.1001/jama.283.19.2568; BRENNAN TA, 1991, NEW ENGL J MED, V324, P370, DOI 10.1056/NEJM199102073240604; Connors AF, 1996, JAMA-J AM MED ASSOC, V276, P889, DOI 10.1001/jama.276.11.889; Drew RH, 2000, J ANTIMICROB CHEMOTH, V46, P775, DOI 10.1093/jac/46.5.775; Fine MJ, 1997, NEW ENGL J MED, V336, P243, DOI 10.1056/NEJM199701233360402; Fox E, 1999, JAMA-J AM MED ASSOC, V282, P1638, DOI 10.1001/jama.282.17.1638; Jones Ronald N., 1996, American Journal of Medicine, V100, p3S, DOI 10.1016/S0002-9343(96)00102-7; LABERGE JM, 1993, RADIOLOGY, V187, P413, DOI 10.1148/radiology.187.2.8475283; Moellering RC, 1999, J ANTIMICROB CHEMOTH, V44, P251, DOI 10.1093/jac/44.2.251; ROSSLE M, 1994, NEW ENGL J MED, V330, P165, DOI 10.1056/NEJM199401203300303; Winston DJ, 2000, CLIN INFECT DIS, V30, P790, DOI 10.1086/313766	11	0	0	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	DEC 18	2001	135	12					1052	1060		10.7326/0003-4819-135-12-200112180-00009	http://dx.doi.org/10.7326/0003-4819-135-12-200112180-00009			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	502TW	11747384				2023-01-03	WOS:000172759700005
J	Armstrong, AC; Eaton, D; Ewing, JC				Armstrong, AC; Eaton, D; Ewing, JC			Science, medicine, and the future - Cellular immunotherapy for cancer	BMJ-BRITISH MEDICAL JOURNAL			English	Review							ACTIVE-SPECIFIC-IMMUNOTHERAPY; RECOMBINANT INTERLEUKIN-2; LYMPHOCYTES; CARCINOMA; CELLS; VACCINATION; REGRESSION		Christie Hosp NHS Trust, Paterson Inst Canc Res, Dept Med Oncol, Canc Res Campaign, Manchester M20 4BX, Lancs, England	Christie NHS Foundation Trust; Christie Hospital; Paterson Institute for Cancer Research	Armstrong, AC (corresponding author), Christie Hosp NHS Trust, Paterson Inst Canc Res, Dept Med Oncol, Canc Res Campaign, Manchester M20 4BX, Lancs, England.	aarmstrong@picr.man.ac.uk		Armstrong, Anne/0000-0002-0774-7006				AlvarezVallina L, 1996, EUR J IMMUNOL, V26, P2304, DOI 10.1002/eji.1830261006; Bonini C, 1997, SCIENCE, V276, P1719, DOI 10.1126/science.276.5319.1719; Childs R, 2000, NEW ENGL J MED, V343, P750, DOI 10.1056/NEJM200009143431101; Figlin RA, 1999, J CLIN ONCOL, V17, P2521, DOI 10.1200/JCO.1999.17.8.2521; Gao LQ, 2000, BLOOD, V95, P2198, DOI 10.1182/blood.V95.7.2198.007k38_2198_2203; HUANG AYC, 1994, SCIENCE, V264, P961, DOI 10.1126/science.7513904; HWU P, 1995, CANCER RES, V55, P3369; Jeal W, 1997, BIODRUGS, V7, P285, DOI 10.2165/00063030-199707040-00005; Kugler A, 2000, NAT MED, V6, P332, DOI 10.1038/73193; MORTON DL, 1993, ANN NY ACAD SCI, V690, P120; Mutis T, 1999, BLOOD, V93, P2336, DOI 10.1182/blood.V93.7.2336.407k26_2336_2341; Nestle FO, 1998, NAT MED, V4, P328, DOI 10.1038/nm0398-328; Repmann R, 1997, ANTICANCER RES, V17, P2879; Rosenberg SA, 1996, J IMMUNOTHER, V19, P81, DOI 10.1097/00002371-199601000-00009; Simons JW, 1997, CANCER RES, V57, P1537; Vermorken JB, 1999, LANCET, V353, P345, DOI 10.1016/S0140-6736(98)07186-4; 2001, CANCERNET	17	24	26	0	3	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	DEC 1	2001	323	7324					1289	1293		10.1136/bmj.323.7324.1289	http://dx.doi.org/10.1136/bmj.323.7324.1289			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	500YG	11731394	Green Published			2023-01-03	WOS:000172655800020
J	Villareal, DT; Binder, EF; Williams, DB; Schechtman, KB; Yarasheski, KE; Kohrt, WN				Villareal, DT; Binder, EF; Williams, DB; Schechtman, KB; Yarasheski, KE; Kohrt, WN			Bone mineral density response to estrogen replacement in frail elderly women - A randomized controlled trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							POSTMENOPAUSAL OSTEOPOROSIS; VITAMIN-D; THERAPY; CALCIUM; BODY; HIP; AGE; SUPPLEMENTATION; PERFORMANCE; PREVENTION	Context Although hormone replacement therapy (HRT) is an established approach for osteoporosis prevention, little is known about the osteoprotective effects of HRT in frail elderly women. Objective To determine whether HRT increases bone mineral density (BMD) in frail elderly women. Design and Setting Randomized, double-blind, placebo-controlled trial conducted in a US university-based research center from September 1995 to August 2000. Participants Sixty-seven women aged 75 years or older with mild-to-moderate physical frailty. Intervention Participants were randomly assigned to receive conjugated estrogens, 0.625 mg/d, plus trimonthly medroxyprogesterone acetate, 5 mg/d for 13 days (n=45), or matching placebo (n=22), for 9 months. Main Outcome Measures The primary outcome measure was 9-month change in BMD of the lumbar spine and hip, measured by dual-energy x-ray absorptiometry. Secondary outcomes were changes in markers of bone turnover. Results Based on intention-to-treat analyses, HRT resulted in significantly larger increases in BMD of the lumbar spine than placebo (mean change, 4.3% vs 0.4%; between-group difference, 3.9%; 95% confidence interval [CI], 3.5%-4.3%) and total hip (mean change, 1.7% vs -0.1%; between-group difference, 1.8%; 95% Cl, 1.5%-2.1%). Compared with placebo, HRT resulted in significant decreases in serum bone-specific alkaline phosphatase levels (mean change, -24% vs 6%; between-group difference, -30%; 95% Cl, -26% to -33%) and urine N-telopeptide levels (mean change, -48% vs 4%; between-group difference, -52%; 95% CI, -47% to -55%). Conclusions In physically frail elderly women, 9 months of HRT significantly increased BMD compared with placebo in clinically important skeletal regions. Further studies are needed to determine whether these osteogenic effects of HRT in elderly women are associated with a reduction in osteoporotic fractures.	Washington Univ, Sch Med, Div Geriatr & Gerontol,Dept Internal Med, Claude Pepper Older Amer Independence Ctr, St Louis, MO 63108 USA; Washington Univ, Sch Med, Dept Obstet & Gynecol, St Louis, MO 63110 USA; Washington Univ, Sch Med, Div Biostat, St Louis, MO 63110 USA; Univ Colorado, Hlth Sci Ctr, Dept Med, Div Geriatr Med, Denver, CO 80262 USA	Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL); University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Villareal, DT (corresponding author), Washington Univ, Sch Med, Div Geriatr & Gerontol,Dept Internal Med, Claude Pepper Older Amer Independence Ctr, 4488 Forest Pk Blvd, St Louis, MO 63108 USA.	dvillare@im.wustl.edu	Yarasheski, Kevin E/A-3025-2008; Yarasheski, Kevin/AAC-7450-2021	Yarasheski, Kevin/0000-0001-5436-2451	NCRR NIH HHS [K23 RR016191, K23 RR16191-01, RR00036] Funding Source: Medline; NIA NIH HHS [P60 AG013629, AG13629] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [K23RR016191] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [P60AG013629] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Allolio B, 1999, Osteoporos Int, V9 Suppl 2, pS9, DOI 10.1007/PL00004166; ARMAMENTOVILLAREAL R, 1995, J CLIN ENDOCR METAB, V80, P776, DOI 10.1210/jc.80.3.776; Binder EF, 2001, ANN INTERN MED, V134, P754, DOI 10.7326/0003-4819-134-9_Part_1-200105010-00012; Binder EF, 1999, J GERONTOL A-BIOL, V54, pM353, DOI 10.1093/gerona/54.7.M353; Brown M, 2000, J GERONTOL A-BIOL, V55, pM350, DOI 10.1093/gerona/55.6.M350; Bush TL, 1996, JAMA-J AM MED ASSOC, V276, P1389, DOI 10.1001/jama.276.17.1389; CAULEY JA, 1995, ANN INTERN MED, V122, P9, DOI 10.7326/0003-4819-122-1-199501010-00002; CHRISTIANSEN C, 1990, J CLIN ENDOCR METAB, V71, P836, DOI 10.1210/jcem-71-4-836; COSMAN F, 1994, J CLIN ENDOCR METAB, V78, P939, DOI 10.1210/jc.78.4.939; CUMMINGS SR, 1993, LANCET, V341, P72, DOI 10.1016/0140-6736(93)92555-8; DawsonHughes B, 1997, NEW ENGL J MED, V337, P670, DOI 10.1056/NEJM199709043371003; ELDERS PJM, 1988, BONE MINER, V5, P11, DOI 10.1016/0169-6009(88)90003-7; ENSRUD KE, 1995, J BONE MINER RES, V10, P1778; FELSON DT, 1993, NEW ENGL J MED, V329, P1141, DOI 10.1056/NEJM199310143291601; Ferrucci L, 1999, J AM GERIATR SOC, V47, P639, DOI 10.1111/j.1532-5415.1999.tb01583.x; Friedman L.M., 1980, FUNDAMENTALS CLIN TR; Garnero P, 1996, J BONE MINER RES, V11, P1531; GENNARI C, 1990, J CLIN ENDOCR METAB, V71, P1288, DOI 10.1210/jcem-71-5-1288; Handa VL, 1996, J AM GERIATR SOC, V44, P1; Holloszy John O., 1995, P633; HUI SL, 1987, BONE MINER, V2, P141; Kohrt WM, 1998, J APPL PHYSIOL, V84, P1506, DOI 10.1152/jappl.1998.84.5.1506; KOHRT WM, 1995, OSTEOPOROSIS INT, V5, P150, DOI 10.1007/BF02106093; LINDSAY R, 1976, LANCET, V1, P1038; Lindsay R, 1998, ENDOCRIN METAB CLIN, V27, P399, DOI 10.1016/S0889-8529(05)70012-8; LINDSAY R, 1990, OBSTET GYNECOL, V76, P290; LUFKIN EG, 1992, ANN INTERN MED, V117, P1, DOI 10.7326/0003-4819-117-1-1; MARX CW, 1992, J BONE MINER RES, V7, P1275; MCKANE WR, 1995, J CLIN ENDOCR METAB, V80, P3458, DOI 10.1210/jc.80.12.3458; NILAS L, 1988, EUR J CLIN INVEST, V18, P529, DOI 10.1111/j.1365-2362.1988.tb01052.x; QUIGLEY MET, 1987, AM J OBSTET GYNECOL, V156, P1516; Recker RR, 1999, ANN INTERN MED, V130, P897, DOI 10.7326/0003-4819-130-11-199906010-00005; RESNICK NM, 1989, JAMA-J AM MED ASSOC, V261, P1025, DOI 10.1001/jama.261.7.1025; Riggs BL, 1998, J BONE MINER RES, V13, P763, DOI 10.1359/jbmr.1998.13.5.763; Riggs BL, 1998, J BONE MINER RES, V13, P168, DOI 10.1359/jbmr.1998.13.2.168; Rosen CJ, 1997, ENDOCRIN METAB CLIN, V26, P295, DOI 10.1016/S0889-8529(05)70248-6; Schneider DL, 1997, JAMA-J AM MED ASSOC, V277, P543, DOI 10.1001/jama.277.7.543; SEMAN E, 1997, AM J MED, V103, P745; Slemenda Charles, 1997, American Journal of Medicine, V103, p65S, DOI 10.1016/S0002-9343(97)90028-0; Villareal DT, 2000, CLIN ENDOCRINOL, V53, P561, DOI 10.1046/j.1365-2265.2000.01131.x	40	68	69	0	3	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 15	2001	286	7					815	820		10.1001/jama.286.7.815	http://dx.doi.org/10.1001/jama.286.7.815			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	462PU	11497535	Bronze			2023-01-03	WOS:000170429600029
J	Weiss, NS; Rossing, MA				Weiss, NS; Rossing, MA			Oestrogen-replacement therapy and risk of ovarian cancer	LANCET			English	Editorial Material									Univ Washington, Dept Epidemiol, Seattle, WA 98195 USA	University of Washington; University of Washington Seattle	Weiss, NS (corresponding author), Univ Washington, Dept Epidemiol, Seattle, WA 98195 USA.							AEDO AR, 1989, MATURITAS, V11, P147, DOI 10.1016/0378-5122(89)90007-8; Beral V, 1997, LANCET, V350, P1047, DOI 10.1016/S0140-6736(97)08233-0; COOK LS, 2000, WOMEN HLTH; Garg PP, 1998, OBSTET GYNECOL, V92, P472, DOI 10.1016/S0029-7844(98)00139-2; HELZLSOUER KJ, 1995, JAMA-J AM MED ASSOC, V274, P1926, DOI 10.1001/jama.274.24.1926; Rodriguez C, 2001, JAMA-J AM MED ASSOC, V285, P1460, DOI 10.1001/jama.285.11.1460; RODRIGUEZ G, 1999, H HARR OV CANC C STO; Rodriguez GC, 1998, J SOC GYNECOL INVEST, V5, P271, DOI 10.1016/S1071-5576(98)00017-3; WEISS NS, 1996, CANC EPIDEMIOLOGY PR	9	6	6	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	AUG 11	2001	358	9280					438	438		10.1016/S0140-6736(01)05669-0	http://dx.doi.org/10.1016/S0140-6736(01)05669-0			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	463TB	11513905				2023-01-03	WOS:000170492400007
J	Snyder, L; Sulmasy, DP				Snyder, L; Sulmasy, DP		Ethics Human Rights Comm Amer C	Physician-assisted suicide	ANNALS OF INTERNAL MEDICINE			English	Article							PATIENT REQUESTS; EUTHANASIA; OREGON; DEATH; PAIN; LIFE; GUIDELINES; ATTITUDES; MANAGEMENT; END	Medical professional codes have long prohibited physician involvement in assisting a patient's suicide. However, despite ethical and legal prohibitions, calls for the liberalization of this ban have grown in recent years. The medical profession should articulate its views on the arguments for and against changes in public policy and decide whether changes are prudent. In addressing such a contentious issue, physicians, policymakers, and society must fully consider the needs of patients, the vulnerability of particular patient groups, issues of trust and professionalism, and the complexities of end-of-life health care. Physician-assisted suicide is prominent among the issues that define our professional norms and codes of ethics. The American College of Physicians-American Society of Internal Medicine (ACP-ASIM) does not support the legalization of physician-assisted suicide. The routine practice of physician-assisted suicide raises serious ethical and other concerns. Legalization would undermine the patient-physician relationship and the trust necessary to sustain it; after the medical profession's role in society; and endanger the value our society places on life, especially on the lives of disabled, incompetent, and vulnerable individuals. The ACP-ASIM remains thoroughly committed to improving care for patients at the end of life.	Amer Coll Physicians, Amer Soc Internal Med, Philadelphia, PA 19106 USA	American College of Physicians	Snyder, L (corresponding author), Amer Coll Physicians, Amer Soc Internal Med, 190 N Independence Mall W, Philadelphia, PA 19106 USA.							Abrahm JL, 1999, ANN INTERN MED, V131, P37, DOI 10.7326/0003-4819-131-1-199907060-00009; ALPERS A, 1995, JAMA-J AM MED ASSOC, V274, P483, DOI 10.1001/jama.274.6.483; Angell M, 1997, NEW ENGL J MED, V336, P50, DOI 10.1056/NEJM199701023360108; ANNAS GJ, 1994, NEW ENGL J MED, V331, P1240, DOI 10.1056/NEJM199411033311822; Annas GJ, 1996, NEW ENGL J MED, V335, P683, DOI 10.1056/NEJM199608293350924; Bachman JG, 1996, NEW ENGL J MED, V334, P303, DOI 10.1056/NEJM199602013340506; Back AL, 1996, JAMA-J AM MED ASSOC, V275, P919, DOI 10.1001/jama.275.12.919; BAILE WF, 1993, CANCER, V72, P2786, DOI 10.1002/1097-0142(19931101)72:9<2786::AID-CNCR2820720942>3.0.CO;2-2; Baron CH, 1996, HARVARD J LEGIS, V33, P1; BATTIN MP, 1995, ACAD MED, V70, P583; BLENDON RJ, 1992, JAMA-J AM MED ASSOC, V267, P2658, DOI 10.1001/jama.267.19.2658; Block SD, 2000, ANN INTERN MED, V132, P209, DOI 10.7326/0003-4819-132-3-200002010-00007; BOSCHERT S, 1992, INTERNAL MED NE 1201, P3; BOSCHERT S, 1992, INTERNAL MED NE 1201, P20; BROCK DW, 1992, YALE J BIOL MED, V65, P121; BRODY H, 1992, NEW ENGL J MED, V327, P1384, DOI 10.1056/NEJM199211053271912; BUCHAN ML, 1995, J CLIN ETHIC, V6, P53; BYOCK I, 1997, DYING WELL PROSPECT, P245; Byock IR, 1997, MED ETHIC S, P107; CAIN C, 1998, DETROIT NEWS    1104, pA1; Callahan D, 1997, MED ETHIC S, P69; CALLAHAN D, 1992, HASTINGS CENT REP, V22, P52, DOI 10.2307/3562566; Caplan AL, 2000, ANN INTERN MED, V132, P476, DOI 10.7326/0003-4819-132-6-200003210-00009; CAPRON AM, 1992, HASTINGS CENT REP, V22, P30, DOI 10.2307/3562562; CASSEL CK, 1990, NEW ENGL J MED, V323, P750, DOI 10.1056/NEJM199009133231110; Chin AE, 1999, NEW ENGL J MED, V340, P577, DOI 10.1056/NEJM199902183400724; Chochinov HM, 1999, LANCET, V354, P816, DOI 10.1016/S0140-6736(99)80011-7; CHOCHINOV HM, 1995, AM J PSYCHIAT, V152, P1185; Christakis NA, 1996, NEW ENGL J MED, V335, P172, DOI 10.1056/NEJM199607183350306; CLEELAND CS, 1994, NEW ENGL J MED, V330, P592, DOI 10.1056/NEJM199403033300902; Coleman CH, 1996, J LAW MED ETHICS, V24, P217, DOI 10.1111/j.1748-720X.1996.tb01855.x; CONWELL Y, 1991, NEW ENGL J MED, V325, P1100, DOI 10.1056/NEJM199110103251511; COVINSKY KE, 1994, JAMA-J AM MED ASSOC, V272, P1839, DOI 10.1001/jama.272.23.1839; Emanuel EJ, 1996, LANCET, V347, P1805, DOI 10.1016/S0140-6736(96)91621-9; Emanuel Ezekiel, 1997, Atl Mon, V279, P73; Emanuel LL, 1998, JAMA-J AM MED ASSOC, V280, P643, DOI 10.1001/jama.280.7.643; Field MJ, 1997, APPROACHING DEATH IM; Fohr S A, 1998, J Palliat Med, V1, P315, DOI 10.1089/jpm.1998.1.315; Foley K, 1999, HASTINGS CENT REP, V29, P37, DOI 10.2307/3528194; FOLEY KM, 1991, J PAIN SYMPTOM MANAG, V6, P289, DOI 10.1016/0885-3924(91)90052-6; FRIED TR, 1993, ARCH INTERN MED, V153, P722, DOI 10.1001/archinte.153.6.722; GAYLIN W, 1988, JAMA-J AM MED ASSOC, V259, P2139; GERT B, 1994, HASTINGS CENT REP, V24, P13, DOI 10.2307/3562837; GILLESPIE M, 1999, KEVORKIAN FACE MURDE; Glick SM, 1997, AM J MED, V102, P294, DOI 10.1016/S0002-9343(97)00016-8; GOAD M, 2000, PORTLAND PRESS  1108, pA1; GROSS J, 1991, NY TIMES        1107, pB16; Hardwig J, 1997, HASTINGS CENT REP, V27, P34, DOI 10.2307/3527626; Heilig S, 1997, WESTERN J MED, V166, P370; Hendin H, 1999, J CLIN PSYCHIAT, V60, P46; Jochemsen H, 1999, J MED ETHICS, V25, P16, DOI 10.1136/jme.25.1.16; JONES WH, 1923, HIPPOCRATES, V1, P289; Jones WHS, 1923, HIPPOCRATES, P193; KAMISAR Y, 1993, HASTINGS CENT REP, V23, P32, DOI 10.2307/3563366; KAMISAR Y, 1958, MINN LAW REV, V42, P969; KASS LR, 1989, PUBLIC INTEREST, P25; Kissane DW, 1998, LANCET, V352, P1097, DOI 10.1016/S0140-6736(98)05406-3; Kitchens LW, 1998, ANN INTERN MED, V128, P576, DOI 10.7326/0003-4819-128-7-199804010-00012; KNAUS WA, 1995, JAMA-J AM MED ASSOC, V274, P1591, DOI 10.1001/jama.1995.03530200027032; KNAUS WA, 1995, ANN INTERN MED, V122, P191, DOI 10.7326/0003-4819-122-3-199502010-00007; Lee MA, 1996, NEW ENGL J MED, V334, P310, DOI 10.1056/NEJM199602013340507; Lo B, 1999, ANN INTERN MED, V130, P772, DOI 10.7326/0003-4819-130-9-199905040-00018; Lynn J, 1997, J AM GERIATR SOC, V45, P489, DOI 10.1111/j.1532-5415.1997.tb05176.x; MAX MB, 1990, ANN INTERN MED, V113, P885, DOI 10.7326/0003-4819-113-11-885; MILES SH, 1995, HASTINGS CENT REP, V25, P17, DOI 10.2307/3562108; Miller FG, 2000, ANN INTERN MED, V132, P470, DOI 10.7326/0003-4819-132-6-200003210-00008; MILLER FG, 1994, NEW ENGL J MED, V331, P119, DOI 10.1056/NEJM199407143310211; Nuland SB, 2000, NEW ENGL J MED, V342, P583, DOI 10.1056/NEJM200002243420811; *NY STAT TASK FORC, 1994, DEATH IS SOUGHT ASSI; ORENTLICHER D, 1992, JAMA-J AM MED ASSOC, V267, P2229; PELLEGRINO ED, 1993, JAMA-J AM MED ASSOC, V270, P874, DOI 10.1001/jama.270.7.874; PELLEGRINO ED, 1995, ANN INTERN MED, V122, P377, DOI 10.7326/0003-4819-122-5-199503010-00010; Phillips RS, 2000, J AM GERIATR SOC, V48, pS1, DOI 10.1111/j.1532-5415.2000.tb03118.x; PIJNENBORG L, 1993, LANCET, V341, P1196, DOI 10.1016/0140-6736(93)91014-D; PRATT DA, 1999, ALBANY LAW J SCI TEC, V9, P161; Quill TE, 1997, NEW ENGL J MED, V337, P1768, DOI 10.1056/NEJM199712113372413; QUILL TE, 1993, JAMA-J AM MED ASSOC, V270, P870, DOI 10.1001/jama.270.7.870; QUILL TE, 1995, ANN INTERN MED, V122, P368, DOI 10.7326/0003-4819-122-5-199503010-00008; SACHS GA, 1995, J AM GERIATR SOC, V43, P553, DOI 10.1111/j.1532-5415.1995.tb06106.x; SHAPIRO RS, 1994, ARCH INTERN MED, V154, P575, DOI 10.1001/archinte.154.5.575; Simons M, 2000, N Y Times Web, pA3; SIMONS M, 1995, NY TIMES        0909; SINGER PA, 1990, NEW ENGL J MED, V322, P1881, DOI 10.1056/NEJM199006283222610; SNYDER L, 1990, ANN INTERN MED, V112, P802, DOI 10.7326/0003-4819-112-11-802; Sullivan AD, 2000, NEW ENGL J MED, V342, P598, DOI 10.1056/NEJM200002243420822; Sulmasy DP, 1999, ARCH INTERN MED, V159, P545, DOI 10.1001/archinte.159.6.545; Sulmasy DP, 1998, J LAW MED ETHICS, V26, P55, DOI 10.1111/j.1748-720X.1998.tb01906.x; *TASK FORC IMPR CA, 1998, OR DEATH DIGN ACT GU; TOLLE SW, 1996, ETHICAL CHOICES CASE; TROLLOPE A, 1990, FIXED PERIOD NOVEL; van Delden JJM, 1999, J MED ETHICS, V25, P22, DOI 10.1136/jme.25.1.22; VANDELDEN JJM, 1993, HASTINGS CENT REP, V23, P24, DOI 10.2307/3562919; VANDERMAAS PJ, 1992, EUTHANASIA OTHER MED, P43; VONROENN JH, 1993, ANN INTERN MED, V119, P121, DOI 10.7326/0003-4819-119-2-199307150-00005; WANZER SH, 1989, NEW ENGL J MED, V320, P844, DOI 10.1056/NEJM198903303201306; Wolf S M, 1996, Duquesne Law Rev, V35, P455; Young EWD, 1997, WESTERN J MED, V166, P381; [No title captured]	98	37	37	0	12	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	AUG 7	2001	135	3					209	216		10.7326/0003-4819-135-3-200108070-00015	http://dx.doi.org/10.7326/0003-4819-135-3-200108070-00015			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	460FX	11487490				2023-01-03	WOS:000170298500009
J	de Gennes, PG				de Gennes, PG			Ultradivided matter	NATURE			English	Editorial Material									Ecole Super Phys & Chim Ind, F-75231 Paris 05, France	UDICE-French Research Universities; PSL Research University Paris; Ecole Superieure de Physique et de Chimie Industrielles de la Ville de Paris (ESPCI)	de Gennes, PG (corresponding author), Ecole Super Phys & Chim Ind, 10 Rue Vauquelin, F-75231 Paris 05, France.							CABANE B, 2001, COLLECTION ECOLE PHY; ISRAELASHVILI J, 1985, INTERMOLECULAR SURFA; Morawetz H., 1985, POLYM ORIGIN GROWTH; 2001, P 1 LAV SEM COLL EC	4	24	24	0	12	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUL 26	2001	412	6845					385	385		10.1038/35086662	http://dx.doi.org/10.1038/35086662			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	456DQ	11473291				2023-01-03	WOS:000170068200023
J	Rajagopal, MR; Joranson, DE; Gilson, AM				Rajagopal, MR; Joranson, DE; Gilson, AM			Medical use, misuse, and diversion of opioids in India	LANCET			English	Article							TRENDS; CANCER; CARE	In less-developed countries, opioids such as morphine are often not available for pain relief because of excessive regulations imposed to prevent their misuse and diversion. We describe the effect that these draconian measures have had on the availability of drugs for medical use in Kerala, India, and present results of a study, which we did to ascertain whether or not the misuse and diversion of opioids is as prevalent as the government reaction would suggest. We followed 1723 patients in Calicut, India, who were being treated for pain with oral morphine on an -outpatient home-care basis. Over 2 years, we did not identify any instances of misuse or diversion. These results suggest that, in the context of India as a less-developed country, oral morphine can be dispensed safely to patients for use at home. We recommend that palliative care programmes talk to concerned governmental authorities, to make them aware of the medical need for opioids, and communicate with local news media to increase awareness of palliative care and the use of these analgesics. Our project has overcome regulatory barriers that had interrupted availability of morphine and Its use in pain relief in India.	Coll Med, Pain & Palliative Care Clin, Calicut, Kerala, India; Pain & Policy Studies Grp, Madison, WI USA; Univ Wisconsin, Ctr Comprehens Canc, Madison, WI USA	University of Wisconsin System; University of Wisconsin Madison	Rajagopal, MR (corresponding author), Coll Med, Pain & Palliative Care Clin, Calicut, Kerala, India.	pain@vsnl.com						Ajithakumari K, 1997, PALLIATIVE MED, V11, P451, DOI 10.1177/026921639701100604; [Anonymous], 2000, ACH BAL NAT OP CONTR; *I MED, 1997, APPR DEATH IMPR CAR; *INT NARC CONTR BO, 2000, NARC DRUGS EST WORLD; *INT NARC CONTR BO, 1999, NARC DRUGS EST WORLD; *INT NARC CONTR BO, 2000, REP INT NARC CONTR B; *INT NARC CONTR BO, 1989, NARC DRUGS EST WORLD; International Narcotics Control Board, 1996, REP INT NARC CONTR B; International Narcotics Control Board, 1999, REP INT NARC CONTR B; *JAP MIN HLTH WELF, 1999, REP ADM MEAS NARC ST; JORANSON DE, 1993, J PAIN SYMPTOM MANAG, V8, P353, DOI 10.1016/0885-3924(93)90052-W; Joranson DE, 2000, JAMA-J AM MED ASSOC, V283, P1710, DOI 10.1001/jama.283.13.1710; Kumar KS, 2000, PALLIATIVE MED, V14, P183, DOI 10.1191/026921600670697351; SIKORA K, 1998, WHO PROGRAMME CANC C; Sureshkumar K, 1996, PALLIATIVE MED, V10, P293, DOI 10.1177/026921639601000404; TEOH N, 1991, Palliative Medicine, V5, P185, DOI 10.1177/026921639100500302; *WHO, 1990, TECHN REP SER WHO, V804; *WHO, 1998, TECHN REP SER WHO, V882; *WHO COLL CTR POL, 2000, IMPR CANC PAIN REL W; World Health Organization,, 1986, CANC PAIN REL; World Health Organization, 1996, CANC PAIN REL GUID O	21	57	59	0	1	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JUL 14	2001	358	9276					139	143		10.1016/S0140-6736(01)05322-3	http://dx.doi.org/10.1016/S0140-6736(01)05322-3			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	452BR	11463435				2023-01-03	WOS:000169837700033
J	Murphy, EL; Collier, AC; Kalish, LA; Assmann, SF; Para, MF; Flanigan, TP; Kumar, PN; Mintz, L; Wallach, FR; Nemo, GJ				Murphy, EL; Collier, AC; Kalish, LA; Assmann, SF; Para, MF; Flanigan, TP; Kumar, PN; Mintz, L; Wallach, FR; Nemo, GJ		Viral Activation Transfusion Study	Highly active antiretroviral therapy decreases mortality and morbidity in patients with advanced HIV disease	ANNALS OF INTERNAL MEDICINE			English	Article							IMMUNODEFICIENCY-VIRUS-INFECTION; PNEUMOCYSTIS-CARINII-PNEUMONIA; CYTOMEGALOVIRUS RETINITIS; COMBINATION THERAPY; PROTEASE INHIBITORS; INCREASING SURVIVAL; DECLINING MORBIDITY; AIDS PATIENTS; IMPACT; RISK	Background: Mortality and morbidity related to AIDS have decreased among HIV-infected patients taking highly active antiretroviral therapy (HAART), but previous studies may have been confounded by other changes in treatment. Objective: To assess the benefit of HAART in patients with advanced AIDS and anemia. Design: Prospective, multicenter cohort study. Setting: The Viral Activation Transfusion Study (VATS), with enrollment from August 1995 through July 1998 and follow-up through June 1999. Patients: 528 HIV-infected patients with cytomegalovirus (CMV) seropositivity or disease who were receiving a first red blood cell transfusion for anemia. Measurements: In a person-year analysis of follow-up before and after initiation of HAART, Poisson regression was used to calculate crude rate ratios and rate ratios adjusted for CD4 count, HIV RNA level, calendar period, time on study, sex, ethnicity, and injection drug use. Results: At baseline, patients had a median CD4(+) lymphocyte count of 0.015 x 10(9) cell/L, median plasma HIV RNA level of 4.8 log(10) copies/mL, and median hemoglobin concentration of 73 g/L. Use of HAART increased from 1% of active patients in January 1996 to 79% of active patients in January 1999. The crude death rate was 0.24 event/person-year among patients taking HAART and 0.88 event/person-year among those not taking HAART (rate ratio, 0.26; adjusted rate ratio, 0.38; P < 0.001 for both comparisons). Rates of non-CMV disease were 0.15 event/ person-year after HAART and 0.45 event/person-year before HAART (crude rate ratio, 0.34 [P < 0.001]; adjusted rate ratio, 0.66 [P < 0.05]). Rates of CMV disease were 0.10 event/person-year after HAART and 0.25 before HAART (crude rate ratio, 0.42 [P < 0.01]; adjusted rate ratio, 1.01 [P > 0.2]). Results were similar in patients with baseline CD4(+) lymphocyte counts less than 0.010 x 10(9) cells/L. Conclusions: The data support an independent reduction in mortality and opportunistic events attributable to HAART, even in patients with very advanced HIV disease. However, patients with CMV infection or disease may not have a reduction in new CMV events due to HAART.	Univ Calif San Francisco, Dept Lab Med, San Francisco, CA 94143 USA; Univ Washington, Seattle, WA 98104 USA; New England Res Inst, Watertown, MA 02172 USA; Ohio State Univ, Columbus, OH 43210 USA; Brown Univ, Sch Med, Miriam Hosp, Providence, RI 02906 USA; Georgetown Univ, Med Ctr, Washington, DC 20007 USA; Mt Sinai Med Ctr, New York, NY 10029 USA; NHLBI, Bethesda, MD 20892 USA	University of California System; University of California San Francisco; University of Washington; University of Washington Seattle; HealthCore, Inc; University System of Ohio; Ohio State University; Brown University; Lifespan Health Rhode Island; Miriam Hospital; Georgetown University; Icahn School of Medicine at Mount Sinai; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)	Murphy, EL (corresponding author), Univ Calif San Francisco, Dept Lab Med, Box 0884, San Francisco, CA 94143 USA.	murphy@itsa.ucsf.edu			NHLBI NIH HHS [N01-HB-57121] Funding Source: Medline; DIVISION OF BLOOD DISEASES AND RESOURCES [N01HB057121] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); DIVISION OF BLOOD DISEASES AND RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		[Anonymous], 1992, MMWR Recomm Rep, V41, P1; Brodt HR, 1997, AIDS, V11, P1731, DOI 10.1097/00002030-199714000-00010; Busch MP, 1996, TRANSFUSION, V36, P854, DOI 10.1046/j.1537-2995.1996.361097017169.x; BUSCH MP, 1991, TRANSFUSION, V31, P4, DOI 10.1046/j.1537-2995.1991.31191096183.x; Buskin SE, 1999, J ACQ IMMUN DEF SYND, V20, P201, DOI 10.1097/00042560-199902010-00014; Casado JL, 1999, AIDS, V13, P1497, DOI 10.1097/00002030-199908200-00009; Casado JL, 1998, J ACQ IMMUN DEF SYND, V19, P130, DOI 10.1097/00042560-199810010-00005; Clifford DB, 1999, NEUROLOGY, V52, P623, DOI 10.1212/WNL.52.3.623; Colford JM, 1997, AM J EPIDEMIOL, V146, P115, DOI 10.1093/oxfordjournals.aje.a009242; COLLIER AC, IN PRESS JAMA; COMMENGES D, 1993, STAT MED, V12, P1317, DOI 10.1002/sim.4780121404; Correll PK, 1998, MED J AUSTRALIA, V169, P469, DOI 10.5694/j.1326-5377.1998.tb123370.x; Detels R, 1998, JAMA-J AM MED ASSOC, V280, P1497, DOI 10.1001/jama.280.17.1497; Diggle PJ, 1994, ANAL LONGITUDINAL DA, V1st; FAHEY JL, 1990, NEW ENGL J MED, V322, P166, DOI 10.1056/NEJM199001183220305; Gebhardt M, 1998, AIDS, V12, P1195, DOI 10.1097/00002030-199810000-00012; Guest JL, 1999, AM J EPIDEMIOL, V149, pS20; Hogg RS, 1998, JAMA-J AM MED ASSOC, V279, P450, DOI 10.1001/jama.279.6.450; Jacobson MA, 1997, LANCET, V349, P1443, DOI 10.1016/S0140-6736(96)11431-8; Mellors JW, 1996, SCIENCE, V272, P1167, DOI 10.1126/science.272.5265.1167; Michaels SH, 1998, NEW ENGL J MED, V339, P405, DOI 10.1056/NEJM199808063390612; Mocroft A, 1998, LANCET, V352, P1725, DOI 10.1016/S0140-6736(98)03201-2; Mouton Y, 1997, AIDS, V11, pF101, DOI 10.1097/00002030-199712000-00003; Palella FJ, 1998, NEW ENGL J MED, V338, P853, DOI 10.1056/NEJM199803263381301; Pezzotti P, 1999, AIDS, V13, P249, DOI 10.1097/00002030-199902040-00013; *SAN FRANC DEP PUB, 1999, ANN AIDS SURV REP 19; SAS Institute, 1997, SAS STAT SOFTW CHANG; Sendi PP, 1999, AIDS, V13, P1115, DOI 10.1097/00002030-199906180-00016; Sendi PP, 1999, J ACQ IMMUN DEF SYND, V20, P376, DOI 10.1097/00042560-199904010-00008; Spino C, 1997, J ACQ IMMUN DEF SYND, V15, P346, DOI 10.1097/00042560-199708150-00004; Spira R, 1998, J ACQ IMMUN DEF SYND, V18, P358, DOI 10.1097/00042560-199808010-00007; Sullivan PS, 1998, BLOOD, V91, P301, DOI 10.1182/blood.V91.1.301.301_301_308; Torres RA, 1997, NEW ENGL J MED, V336, P1531, DOI 10.1056/NEJM199705223362118; Walsh JC, 1998, AIDS, V12, P613, DOI 10.1097/00002030-199806000-00010; Williams PL, 1999, AIDS, V13, P1035, DOI 10.1097/00002030-199906180-00006	35	438	467	0	15	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUL 3	2001	135	1					17	26		10.7326/0003-4819-135-1-200107030-00005	http://dx.doi.org/10.7326/0003-4819-135-1-200107030-00005			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	449JC	11434728				2023-01-03	WOS:000169680500003
J	Heames, RM; Sado, D; Deakin, CD				Heames, RM; Sado, D; Deakin, CD			Do doctors position defibrillation paddles correctly? Observational study	BRITISH MEDICAL JOURNAL			English	Article									Southampton Gen Hosp NHS Trust, Shackleton Dept Anaesthet, Southampton SO16 6YD, Hants, England		Deakin, CD (corresponding author), Southampton Gen Hosp NHS Trust, Shackleton Dept Anaesthet, Southampton SO16 6YD, Hants, England.							[Anonymous], 2000, RESUSCITATION, V46, P109; [Anonymous], 2000, RESUSCITATION, V46, P73; *EM CARD CAR COMM, 1992, JAMA-J AM MED ASSOC, V268, P2199; LAROSE D, 1993, ANN EMERG MED, V22, P1925, DOI 10.1016/S0196-0644(05)80429-9; Robertson C, 1998, RESUSCITATION, V37, P81, DOI 10.1016/S0300-9572(98)00035-5	5	27	28	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	JUN 9	2001	322	7299					1393	1394		10.1136/bmj.322.7299.1393	http://dx.doi.org/10.1136/bmj.322.7299.1393			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	442KN	11397743	Green Published, Green Submitted, Bronze			2023-01-03	WOS:000169284600016
J	Barbe, F; Mayoralas, LR; Duran, J; Masa, JF; Maimo, A; Montserrat, JM; Monasterio, C; Bosch, M; Ladaria, A; Rubio, M; Rubio, R; Medinas, M; Hernandez, L; Vidal, S; Douglas, NJ; Agusti, AGN				Barbe, F; Mayoralas, LR; Duran, J; Masa, JF; Maimo, A; Montserrat, JM; Monasterio, C; Bosch, M; Ladaria, A; Rubio, M; Rubio, R; Medinas, M; Hernandez, L; Vidal, S; Douglas, NJ; Agusti, AGN			Treatment with continuous positive airway pressure is not effective in patients with sleep apnea but no daytime sleepiness - A randomized, controlled trial	ANNALS OF INTERNAL MEDICINE			English	Article							BLOOD-PRESSURE; CPAP; EFFICACY	Background: The sleep apnea-hypopnea syndrome is defined by a pathologic number of respiratory events during sleep (the apnea-hypopnea index, defined as the number of apnea and hypopnea episodes per hour) and daytime symptoms (mostly, excessive sleepiness). In patients with the sleep apnea syndrome, treatment with continuous positive airway pressure (CPAP) normalizes both the apnea-hypopnea index and diurnal symptoms. However, the effect of CPAP in persons with a pathologic apnea-hypopnea index without daytime sleepiness is unclear. Objective: To investigate the short-term effects of CPAP on quality of life, objective sleepiness, cognitive function, and arterial blood pressure in nonsleepy patients with a pathologic apnea-hypopnea index. Design: Multicenter randomized, placebo-controlled, parallel-group study. Setting: Six teaching hospitals in Spain. Patients: 55 patients with an apnea-hypopnea index of 30 or greater who did not have daytime sleepiness (Epworth Sleepiness Scale score less than or equal to 10). Intervention: Patients were randomly assigned to receive optimal (n = 29) or sham (n = 25) CPAP and were observed for 6 weeks. Measurements: Quality of life, objective sleepiness (Multiple Sleep Latency Test score), cognitive function, and arterial blood pressure. Results: The intervention and control groups were similar in terms of mean (+/- SE) age (54 +/- 2 vs. 52 +/- 2 years), apnea-hypopnea index (54 +/- 3 vs. 57 +/- 4), Epworth Sleepiness Scale score (7.0 +/- 0.4 vs. 7.0 +/- 0.4) and adherence to CPAP treatment (5.0 +/- 0.4 vs. 4.0 +/- 0.5 hours/d). Other variables, such as quality of life, cognitive function, and arterial blood pressure, were also similar in both groups before treatment. After 6 weeks of CPAP or sham CPAP, none of these variables changed significantly. Conclusion: In patients with an apnea-hypopnea index of 30 or greater and no subjective daytime sleepiness, CPAP does not modify quality of life, objective sleepiness, vigilance, attention, memory, information processing, visuomotor coordination, or arterial blood pressure. Treatment with CPAP is therefore not indicated in nonsleepy patients with a pathologic apnea-hypopnea index.	Hosp Univ Son Dureta, Serv Pneumol, Palma de Mallorca 07014, Spain; Hosp San Pedro De Alcantara, Caceres, Spain; Hosp Txagorritxu, Vitoria, Spain; Hosp Joan March, Bunyola, Spain; Hosp Clin Barcelona, Barcelona, Spain; Bellvitge Hosp, Lhospitalet De Llobregat, Spain; Royal Infirm, Edinburgh, Midlothian, Scotland	Hospital Universitari Son Espases; Hospital Universitari Son Dureta; University Hospital of Araba; University of Barcelona; Hospital Clinic de Barcelona; Institut d'Investigacio Biomedica de Bellvitge (IDIBELL); Bellvitge University Hospital; Royal Infirmary of Edinburgh	Agusti, AGN (corresponding author), Hosp Univ Son Dureta, Serv Pneumol, Andrea Doria 55, Palma de Mallorca 07014, Spain.	aagusti@hsd.es	Cantolla, Joaquin Duran/B-6996-2015; Garcia-Navarro, Alvar Agusti/F-4474-2015; Barbé, Ferran/A-5988-2010; Douglas, Neil/B-1491-2013	Garcia-Navarro, Alvar Agusti/0000-0003-3271-3788; Barbé, Ferran/0000-0002-2340-8928; MONTSERRAT, Josep Maria/0000-0003-3098-4605; monasterio ponsa, carmen/0000-0002-6142-0565				Akashiba T, 1999, SLEEP, V22, P849, DOI 10.1093/sleep/22.7.849; ALONSO J, 1995, MED CLIN-BARCELONA, V104, P771; American Sleep Disorders Association. Diagnostic Classification Steering Committee, 1990, INT CLASS SLEEP DIS, pxii, 396; Ballester E, 1999, AM J RESP CRIT CARE, V159, P495, DOI 10.1164/ajrccm.159.2.9804061; Barbe F, 1995, Arch Bronconeumol, V31, P460; Collard P, 1996, AM J RESP CRIT CARE, V154, P454, DOI 10.1164/ajrccm.154.2.8756822; DAVIES RJO, 1994, CLIN SCI, V86, P417, DOI 10.1042/cs0860417; Davies RJO, 2000, AM J RESP CRIT CARE, V161, P1775, DOI 10.1164/ajrccm.161.6.16166a; Engleman HM, 1999, AM J RESP CRIT CARE, V159, P461, DOI 10.1164/ajrccm.159.2.9803121; Engleman HM, 1998, THORAX, V53, P341, DOI 10.1136/thx.53.5.341; Fagard, 1997, Blood Press Monit, V2, P315; Farre R, 1999, LANCET, V353, P1154, DOI 10.1016/S0140-6736(99)01056-9; Flemons WW, 1999, SLEEP, V22, P667, DOI 10.1093/sleep/22.5.667; HEDNER J, 1995, EUR RESPIR J, V8, P222, DOI 10.1183/09031936.95.08020222; Jenkinson C, 1999, LANCET, V353, P2100, DOI 10.1016/S0140-6736(98)10532-9; JOHNS MW, 1991, SLEEP, V14, P540, DOI 10.1093/sleep/14.6.540; Lezack MD, 1995, NEUROPSYCHOLOGICAL A, V3rd; Loube DI, 1999, CHEST, V115, P863, DOI 10.1378/chest.115.3.863; MCHORNEY CA, 1995, QUAL LIFE RES, V4, P293, DOI 10.1007/BF01593882; Munoz A, 2000, EUR RESPIR J, V15, P676, DOI 10.1034/j.1399-3003.2000.15d09.x; Rechtschaffen A., 1968, MANUAL STANDARDIZED; Redline S, 1998, AM J RESP CRIT CARE, V157, P858, DOI 10.1164/ajrccm.157.3.9709042; SMITH PL, 1994, AM J RESP CRIT CARE, V150, P1738; Weaver TE, 1997, SLEEP, V20, P835; Wechsler D., 1981, WECHSLER MEMORY SCAL; WECHSLER D, 1998, WECHSLER ADULTS INTE; Wright J, 1997, BRIT MED J, V314, P851; Wright J, 2000, AM J RESP CRIT CARE, V161, P1776, DOI 10.1164/ajrccm.161.6.16166b; YOUNG T, 1993, NEW ENGL J MED, V328, P1230, DOI 10.1056/NEJM199304293281704	29	403	412	0	13	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUN 5	2001	134	11					1015	1023		10.7326/0003-4819-134-11-200106050-00007	http://dx.doi.org/10.7326/0003-4819-134-11-200106050-00007			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	436YL	11388814				2023-01-03	WOS:000168963400001
J	Larson, EB				Larson, EB			General internal medicine at the crossroads of prosperity and despair: Caring for patients with chronic diseases in an aging society	ANNALS OF INTERNAL MEDICINE			English	Editorial Material							CARE; CONTINUITY; THROMBOSIS; THERAPY; HOME	During the past quarter century, general internal medicine has emerged as a vital discipline. In the realm of patient care, it is the integrating discipline par excellence. Ironically, as general internists face the challenge of integrating advances of dizzying speed and complexity, and as their clinical practice becomes increasingly effective, it has become much more difficult for them to earn a living. General internists find themselves at the crossroads of prosperity and despair. Although general medicine research leads the research agenda in many departments of medicine, it is particularly vulnerable. The necessary multidisciplinary "programmatic" infrastructure is expensive, and results often take many years to obtain, particularly in the study of chronic disease. The educational environment in many institutions is particularly difficult for general medicine, both because the current emphasis on technical skills obscures patients' and learners' real needs and because complex patients on general medicine services are now so ill and their turnover so rapid. General internal medicine and geriatrics are synergistic, especially in today's marketplace. A focus on geriatric medicine could help general medicine continue to flourish. General internists are ideally suited to the integrated care of elderly patients with multiple problems, research opportunities are enormous in the geriatric population, and the teaching of geriatrics requires a high level of generalist skills. Problems that plague current generalist practice have unique significance to older patients. Organizations that represent general internists would do well to join forces with many other advocacy groups, especially those representing the interests of elderly patients and geriatric medicine.	Univ Washington, Med Ctr, Seattle, WA 98195 USA	University of Washington; University of Washington Seattle	Larson, EB (corresponding author), Univ Washington, Med Ctr, Box 356330, Seattle, WA 98195 USA.	ebl@u.washington.edu						Burdi MD, 1999, HEALTH AFFAIR, V18, P134, DOI 10.1377/hlthaff.18.4.134; CAMPION EW, 1984, JAMA-J AM MED ASSOC, V252, P2459; Cunningham PJ, 2000, HEALTH AFFAIR, V19, P158, DOI 10.1377/hlthaff.19.3.158; EICHNA LW, 1980, NEW ENGL J MED, V303, P727, DOI 10.1056/NEJM198009253031304; Every NR, 1996, NEW ENGL J MED, V335, P1253, DOI 10.1056/NEJM199610243351701; FITZGERALD FT, 1990, WESTERN J MED, V152, P377; Grumbach K, 1999, NEW ENGL J MED, V341, P2008, DOI 10.1056/NEJM199912233412611; KASSIRER JP, 1983, NEW ENGL J MED, V309, P921, DOI 10.1056/NEJM198310133091511; KERN DC, 1985, JAMA-J AM MED ASSOC, V254, P70, DOI 10.1001/jama.254.1.70; KOMAROFF AL, 1986, J GEN INTERN MED, V1, P1, DOI 10.1007/BF02596317; Koopman MMW, 1996, NEW ENGL J MED, V334, P682, DOI 10.1056/NEJM199603143341102; LaCombe MA, 1997, ANN INTERN MED, V126, P217, DOI 10.7326/0003-4819-126-3-199702010-00007; Levine M, 1996, NEW ENGL J MED, V334, P677, DOI 10.1056/NEJM199603143341101; LEWIS CE, 1977, NEW ENGL J MED, V297, P423, DOI 10.1056/NEJM197708252970805; LOWRIE EG, 1981, NEW ENGL J MED, V305, P434, DOI 10.1056/NEJM198108203050805; *MA DEP PUBL HLTH, 1975, NEW ENGL J MED, V293, P775; MALMIVAARA A, 1995, NEW ENGL J MED, V332, P351, DOI 10.1056/NEJM199502093320602; Panzer RI, 1991, DIAGNOSTIC STRATEGIE; ROBACK G, 1977, PHYSICIAN DISTRIBUTI; ROBERG N, 1988, JAMA-J AM MED ASSOC, V260, P3645; SACKETT DL, 1987, J GEN INTERN MED, V2, P40, DOI 10.1007/BF02596250; SCHULMAN S, 1995, NEW ENGL J MED, V332, P1661, DOI 10.1056/NEJM199506223322501; WASSON JH, 1984, JAMA-J AM MED ASSOC, V252, P2413	23	31	31	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAY 15	2001	134	10					997	1000		10.7326/0003-4819-134-10-200105150-00013	http://dx.doi.org/10.7326/0003-4819-134-10-200105150-00013			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	432FX	11352700				2023-01-03	WOS:000168682500007
J	Ganzini, L; Nelson, HD; Lee, MA; Kraemer, DF; Schmidt, TA; Delorit, MA				Ganzini, L; Nelson, HD; Lee, MA; Kraemer, DF; Schmidt, TA; Delorit, MA			Oregon physicians' attitudes about and experiences with end-of-life care since passage of the Oregon Death with Dignity Act	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ASSISTED SUICIDE; PATIENT REQUESTS; EUTHANASIA; PAIN; DIE	Context The Oregon Death with Dignity Act, passed by ballot measure in 1994 and enacted in October 1997, legalized physician-assisted suicide for competent, terminally ill Oregonians, but little is known about the effects of the act on clinical practice or physician perspective. Objective To examine Oregon physicians' attitudes toward and practices regarding care of dying patients since the passage of the Death with Dignity Act. Design, Setting, and Participants A self-administered questionnaire was mailed in February 1999 to Oregon physicians eligible to prescribe under the act. Of 3981 eligible physicians, 2641 (66%) returned the questionnaire by August 1999. Main Outcome Measures Physicians' reports of their efforts to improve care for dying patients since 1994, their attitudes, concerns, and sources of information about participating in the Death with Dignity Act, and their conversations with patients regarding assisted suicide. Results A total of 791 respondents (30%) reported that they had increased referrals to hospice. Of the 2094 respondents who cared for terminally ill patients, 76% reported that they made efforts to improve their knowledge of the use of pain medications in the terminally ill. Nine hundred forty-nine responding physicians (36%) had been asked by a patient if they were potentially willing to prescribe a lethal medication, Seven percent of all survey participants reported that 1 or more patients became upset after learning the physician's position on assisted suicide, and 2% reported that 1 or more patients left their care after learning the physician's position on assisted suicide. Of the 73 physicians who were willing to write a lethal prescription and who had received a request from a patient, 20 (27%) were not confident they could determine when a patient had less than 6 months to live. Conclusion Most Oregon physicians who care for terminally ill patients report that since 1994 they have made efforts to improve their ability to care for these patients acid many have had conversations with patients about assisted suicide.	Dept Vet Affairs, Portland, OR USA; Oregon Hlth Sci Univ, Dept Psychiat, Portland, OR 97201 USA; Oregon Hlth Sci Univ, Dept Emergency Med, Portland, OR 97201 USA; Oregon Hlth Sci Univ, Div Med Informat & Outcomes Res, Portland, OR 97201 USA; Oregon Hlth Sci Univ, Ctr Eth & Hlth Care, Portland, OR 97201 USA; Providence Hlth Syst, Portland, OR USA	Oregon Health & Science University; Oregon Health & Science University; Oregon Health & Science University; Oregon Health & Science University	Ganzini, L (corresponding author), Vet Adm Med Ctr, Div Mental Hlth, P31DMH,POB 1034, Portland, OR 97207 USA.							ALPERS A, 1995, JAMA-J AM MED ASSOC, V274, P483, DOI 10.1001/jama.274.6.483; Bernat JL, 1997, SEMIN NEUROL, V17, P271, DOI 10.1055/s-2008-1040939; BLOCK SD, 1995, PSYCHOSOMATICS, V36, P445, DOI 10.1016/S0033-3182(95)71625-5; Caplan A L, 1997, Hosp J, V12, P17; *COMM PHYS ASS DEA, 1996, SUICIDE LIFE-THREAT, V26, P1; Emanuel EJ, 1996, ARCH INTERN MED, V156, P825, DOI 10.1001/archinte.156.8.825; Faber-Langendoen K, 1998, CANCER-AM CANCER SOC, V82, P35, DOI 10.1002/(SICI)1097-0142(19980101)82:1<35::AID-CNCR4>3.3.CO;2-#; FOLEY KM, 1991, J PAIN SYMPTOM MANAG, V6, P289, DOI 10.1016/0885-3924(91)90052-6; Ganzini L, 2000, NEW ENGL J MED, V342, P557, DOI 10.1056/NEJM200002243420806; HALEY K, 1998, OREGON DEATH DIGNITY; Kelly BJ, 1996, AUST NZ J PSYCHIAT, V30, P3, DOI 10.3109/00048679609076068; MILES SH, 1994, JAMA-J AM MED ASSOC, V271, P1786, DOI 10.1001/jama.271.22.1786; Muskin PR, 1998, JAMA-J AM MED ASSOC, V279, P323, DOI 10.1001/jama.279.4.323; Portenoy RK, 1997, PSYCHOSOMATICS, V38, P277, DOI 10.1016/S0033-3182(97)71465-8; Quill TE, 1998, ANN INTERN MED, V128, P552, DOI 10.7326/0003-4819-128-7-199804010-00006; SINGER PA, 1990, NEW ENGL J MED, V322, P1881, DOI 10.1056/NEJM199006283222610; Sullivan AD, 2000, NEW ENGL J MED, V342, P598, DOI 10.1056/NEJM200002243420822; Tolle SW, 2000, WESTERN J MED, V172, P374, DOI 10.1136/ewjm.172.6.374; Tolle SW, 1998, ANN INTERN MED, V128, P567, DOI 10.7326/0003-4819-128-7-199804010-00009; Tolle SW, 1999, ANN INTERN MED, V130, P681, DOI 10.7326/0003-4819-130-8-199904200-00015	20	96	96	0	3	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 9	2001	285	18					2363	2369		10.1001/jama.285.18.2363	http://dx.doi.org/10.1001/jama.285.18.2363			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	427NB	11343484				2023-01-03	WOS:000168411200028
J	Elliott, C				Elliott, C			Philosopher assisted suicide and euthanasia	BRITISH MEDICAL JOURNAL			English	Editorial Material											Elliott, C (corresponding author), MCGILL UNIV,MONTREAL,PQ,CANADA.								0	9	9	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	OCT 26	1996	313	7064					1088	1089						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VP742	11644845				2023-01-03	WOS:A1996VP74200083
J	Curfman, GD				Curfman, GD			Perspective - Hypothermia to protect the brain	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material																			0	35	41	0	1	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	FEB 21	2002	346	8					546	546		10.1056/NEJM200202213460802	http://dx.doi.org/10.1056/NEJM200202213460802			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	522ZK	11856792				2023-01-03	WOS:000173926700001
J	Venema, K; Quintero, FJ; Pardo, JM; Donaire, JP				Venema, K; Quintero, FJ; Pardo, JM; Donaire, JP			The Arabidopsis Na+/H+ exchanger AtNHX1 catalyzes low affinity Na+ and K+ transport in reconstituted liposomes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; TONOPLAST VESICLES; PLASMA-MEMBRANE; ANTIPORT ACTIVITY; ION-TRANSPORT; NACL STRESS; PLANT-CELLS; H+-ATPASE; PROTON; YEAST	In saline environments, plants accumulate Na+ in vacuoles through the activity of tonoplast Na+/H+ antiporters. The first gene for a putative plant vacuolar Na+/H+ antiporter, AtNHX1, was isolated from Arabidopsis and shown to increase plant tolerance to NaCl. However, AtNHX1 mRNA was up-regulated by Na+ or K+ salts in plants and substituted for the homologous protein of yeast to restore tolerance to several toxic cations. To study the ion selectivity of the AtNHX1 protein, we have purified a histidine-tagged version of the protein from yeast microsomes by Ni2+ affinity chromatography, reconstituted the protein into lipid vesicles, and measured cation-dependent H+ exchange with the fluorescent pH indicator pyranine. The protein catalyzed Na+ and K+ transport with similar affinity in the presence of a pH gradient. Li+ and Cs+ ions were also transported with lower affinity. Ion exchange by AtNHX1 was inhibited 70% by the amiloride analog ethylisopropylamiloride. Our data indicate a role for intracellular antiporters in organelle pH control and osmoregulation.	CSIC, Dept Bioquim Biol Celular & Mol Plantas, Estac Expt Zaidin, E-18080 Granada, Spain; CSIC, Inst Recursos Nat & Agrobiol, E-41080 Seville, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Estacion Experimental del Zaidin (EEZ); Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Recursos Naturales y Agrobiologia de Sevilla (IRNAS)	Venema, K (corresponding author), CSIC, Dept Bioquim Biol Celular & Mol Plantas, Estac Expt Zaidin, Apartado 419, E-18080 Granada, Spain.		Venema, Kees/G-9558-2015; Quintero, Francisco J/C-3086-2014; Pardo, Jose M./B-4652-2009; Pardo, Jose M/AAB-5866-2022; Quintero, Francisco J./AAG-2924-2019	Venema, Kees/0000-0001-5177-6464; Quintero, Francisco J/0000-0001-8718-2975; Pardo, Jose M./0000-0003-4510-8624; Pardo, Jose M/0000-0003-4510-8624; Quintero, Francisco J./0000-0001-8718-2975				Apse MP, 1999, SCIENCE, V285, P1256, DOI 10.1126/science.285.5431.1256; Axelsen KB, 1999, BIOCHEMISTRY-US, V38, P7227, DOI 10.1021/bi982482l; Ballesteros E, 1997, PHYSIOL PLANTARUM, V99, P328, DOI 10.1034/j.1399-3054.1997.990217.x; Barkla BJ, 1996, ANNU REV PLANT PHYS, V47, P159, DOI 10.1146/annurev.arplant.47.1.159; BARKLA BJ, 1995, PLANT PHYSIOL, V109, P549, DOI 10.1104/pp.109.2.549; BLAKE MS, 1984, ANAL BIOCHEM, V128, P302; BLUMWALD E, 1987, PHYSIOL PLANTARUM, V69, P731, DOI 10.1111/j.1399-3054.1987.tb01993.x; Blumwald E, 2000, BBA-BIOMEMBRANES, V1465, P140, DOI 10.1016/S0005-2736(00)00135-8; Bowers K, 2000, MOL BIOL CELL, V11, P4277, DOI 10.1091/mbc.11.12.4277; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Buch-Pedersen MJ, 2000, J BIOL CHEM, V275, P39167, DOI 10.1074/jbc.M007537200; BUSH DR, 1993, ANNU REV PLANT PHYS, V44, P513, DOI 10.1146/annurev.pp.44.060193.002501; CID A, 1987, CURR GENET, V12, P105, DOI 10.1007/BF00434664; Counillon L, 2000, J BIOL CHEM, V275, P1, DOI 10.1074/jbc.275.1.1; Darley CP, 2000, BIOCHEM J, V351, P241, DOI 10.1042/0264-6021:3510241; FAFOURNOUX P, 1994, J BIOL CHEM, V269, P2589; Fukada-Tanaka S, 2000, NATURE, V407, P581, DOI 10.1038/35036683; GARBARINO J, 1988, PLANT PHYSIOL, V86, P231, DOI 10.1104/pp.86.1.231; Gaxiola RA, 1999, P NATL ACAD SCI USA, V96, P1480, DOI 10.1073/pnas.96.4.1480; GIBRAT R, 1983, BIOCHIM BIOPHYS ACTA, V736, P196, DOI 10.1016/0005-2736(83)90284-5; GRINSTEIN S, 1989, BIOCHIM BIOPHYS ACTA, V988, P73, DOI 10.1016/0304-4157(89)90004-X; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Montero-Lomeli M, 1999, BIOCHEM CELL BIOL, V77, P25, DOI 10.1139/bcb-77-1-25; NAKAMURA T, 1986, J BIOL CHEM, V261, P678; Nass R, 1999, MICROBIOL-SGM, V145, P3221, DOI 10.1099/00221287-145-11-3221; Nass R, 1997, J BIOL CHEM, V272, P26145, DOI 10.1074/jbc.272.42.26145; Nass R, 1998, J BIOL CHEM, V273, P21054, DOI 10.1074/jbc.273.33.21054; NIU XM, 1995, PLANT PHYSIOL, V109, P735, DOI 10.1104/pp.109.3.735; Numata M, 1998, J BIOL CHEM, V273, P6951, DOI 10.1074/jbc.273.12.6951; Numata M, 2001, J BIOL CHEM, V276, P17387, DOI 10.1074/jbc.M101319200; Orlowski J, 1997, J BIOL CHEM, V272, P22373, DOI 10.1074/jbc.272.36.22373; Pouliquin P, 1999, BIOPHYS J, V76, P360, DOI 10.1016/S0006-3495(99)77203-6; Quintero FJ, 2000, FEBS LETT, V471, P224, DOI 10.1016/S0014-5793(00)01412-5; REA PA, 1992, PLANT PHYSIOL, V100, P723, DOI 10.1104/pp.100.2.723; RENTSCH D, 1995, FEBS LETT, V370, P264, DOI 10.1016/0014-5793(95)00853-2; Ros R, 1998, J BACTERIOL, V180, P3131, DOI 10.1128/JB.180.12.3131-3136.1998; ROSSIGNOL M, 1982, BIOCHIM BIOPHYS ACTA, V684, P195, DOI 10.1016/0005-2736(82)90005-0; Shi HZ, 2000, P NATL ACAD SCI USA, V97, P6896, DOI 10.1073/pnas.120170197; SOHMA Y, 2000, J PHYSL, V527, P16; TSE CM, 1994, CELL PHYSIOL BIOCHEM, V4, P282, DOI 10.1159/000154731; VENEMA K, 1993, BIOCHIM BIOPHYS ACTA, V1146, P87, DOI 10.1016/0005-2736(93)90342-W; Wakabayashi S, 1997, PHYSIOL REV, V77, P51, DOI 10.1152/physrev.1997.77.1.51; Wells KM, 2001, J BIOL CHEM, V276, P3401, DOI 10.1074/jbc.M001688200; YU FH, 1993, J BIOL CHEM, V268, P25536	44	181	202	0	32	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 25	2002	277	4					2413	2418		10.1074/jbc.M105043200	http://dx.doi.org/10.1074/jbc.M105043200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	514CY	11707435	hybrid			2023-01-03	WOS:000173421500008
J	Borghi, L; Schianchi, T; Meschi, T; Guerra, A; Allegri, F; Maggiore, U; Novarini, A				Borghi, L; Schianchi, T; Meschi, T; Guerra, A; Allegri, F; Maggiore, U; Novarini, A			Comparison of two diets for the prevention of recurrent stones in idiopathic hypercalciuria	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							PROTEIN-INDUCED HYPERCALCIURIA; URINARY CALCIUM EXCRETION; KIDNEY-STONES; ANIMAL PROTEIN; NEPHROLITHIASIS; UROLITHIASIS; SODIUM; THIAZIDE; RISK; PROPHYLAXIS	Background A low-calcium diet is recommended to prevent recurrent stones in patients with idiopathic hypercalciuria, yet long-term data on the efficacy of a low-calcium diet are lacking. Recently, the efficacy of a low-calcium diet has been questioned, and greater emphasis has been placed on reducing the intake of animal protein and salt, but again, long-term data are unavailable. Methods We conducted a five-year randomized trial comparing the effect of two diets in 120 men with recurrent calcium oxalate stones and hypercalciuria. Sixty men were assigned to a diet containing a normal amount of calcium (30 mmol per day) but reduced amounts of animal protein (52 g per day) and salt (50 mmol of sodium chloride per day); the other 60 men were assigned to the traditional low-calcium diet, which contained 10 mmol of calcium per day. Results At five years, 12 of the 60 men on the normal-calcium, low-animal-protein, low-salt diet and 23 of the 60 men on the low-calcium diet had had relapses. The unadjusted relative risk of a recurrence for the group on the first diet, as compared with the group on the second diet, was 0.49 (95 percent confidence interval, 0.24 to 0.98; P=0.04). During follow-up, urinary calcium levels dropped significantly in both groups by approximately 170 mg per day (4.2 mmol per day). However, urinary oxalate excretion increased in the men on the low-calcium diet (by an average of 5.4 mg per day [60 mu mol per day]) but decreased in those on the normal-calcium, low-animal-protein, low-salt diet (by an average of 7.2 mg per day [80 mu mol per day]). Conclusions In men with recurrent calcium oxalate stones and hypercalciuria, restricted intake of animal protein and salt, combined with a normal calcium intake, provides greater protection than the traditional low-calcium diet. (N Engl J Med 2002;346:77-84.) Copyright (C) 2002 Massachusetts Medical Society.	Univ Parma, Dept Clin Sci, I-43100 Parma, Italy; Univ Parma, Dept Internal Med & Nephrol, I-43100 Parma, Italy	University of Parma; University of Parma	Borghi, L (corresponding author), Univ Parma, Dept Clin Sci, Via Gramsci 14, I-43100 Parma, Italy.		Meschi, Tiziana/K-5032-2016	Meschi, Tiziana/0000-0002-7538-6863; Maggiore, Umberto/0000-0002-7468-9600				ALLEN LH, 1979, AM J CLIN NUTR, V32, P741, DOI 10.1093/ajcn/32.4.741; BARCELO P, 1993, J UROLOGY, V150, P1761, DOI 10.1016/S0022-5347(17)35888-3; Borghi L, 1996, J UROLOGY, V155, P839, DOI 10.1016/S0022-5347(01)66321-3; BORGHI L, 1990, BRIT J UROL, V65, P231, DOI 10.1111/j.1464-410X.1990.tb14716.x; Borghi L, 1999, KIDNEY INT, V55, P2397, DOI 10.1046/j.1523-1755.1999.00483.x; BRESLAU NA, 1982, J CLIN ENDOCR METAB, V55, P369, DOI 10.1210/jcem-55-2-369; BRESLAU NA, 1988, J CLIN ENDOCR METAB, V66, P140, DOI 10.1210/jcem-66-1-140; BROADUS AE, 1984, NEW ENGL J MED, V311, P73, DOI 10.1056/NEJM198407123110201; BROCKS P, 1981, LANCET, V2, P124, DOI 10.1016/S0140-6736(81)90302-0; COE FL, 1992, NEW ENGL J MED, V327, P1141, DOI 10.1056/NEJM199210153271607; COE FL, 1977, JAMA-J AM MED ASSOC, V238, P1519, DOI 10.1001/jama.238.14.1519; COE FL, 1974, NEW ENGL J MED, V291, P1344; CONYERS RAJ, 1990, CLIN CHEM, V36, P1717; Curhan GC, 1997, ANN INTERN MED, V126, P497, DOI 10.7326/0003-4819-126-7-199704010-00001; CURHAN GC, 1993, NEW ENGL J MED, V328, P833, DOI 10.1056/NEJM199303253281203; EPSTEIN FH, 1968, AM J MED, V45, P700, DOI 10.1016/0002-9343(68)90206-4; ETTINGER B, 1988, J UROLOGY, V139, P679, DOI 10.1016/S0022-5347(17)42599-7; ETTINGER B, 1976, AM J MED, V61, P200, DOI 10.1016/0002-9343(76)90170-4; ETTINGER B, 1986, NEW ENGL J MED, V315, P1386, DOI 10.1056/NEJM198611273152204; Ettinger B, 1997, J UROLOGY, V158, P2069, DOI 10.1016/S0022-5347(01)68155-2; Hiatt RA, 1996, AM J EPIDEMIOL, V144, P25, DOI 10.1093/oxfordjournals.aje.a008851; KLEEMAN CR, 1964, P SOC EXP BIOL MED, V115, P29, DOI 10.3181/00379727-115-28821; LAERUM E, 1984, ACTA MED SCAND, V215, P383; LEMANN J, 1993, NEW ENGL J MED, V328, P880, DOI 10.1056/NEJM199303253281212; Lemann J, 1996, KIDNEY INT, V50, P341; LEMANN J, 1986, KIDNEY INT, V29, P743, DOI 10.1038/ki.1986.60; Lemann JJ, 1989, UROLITHIASIS, P435; LJUNGHALL S, 1984, BRIT J UROL, V56, P122, DOI 10.1111/j.1464-410X.1984.tb05346.x; MARSHALL RW, 1972, CLIN SCI, V43, P91, DOI 10.1042/cs0430091; MCCARRON DA, 1981, AM J NEPHROL, V1, P84, DOI 10.1159/000166496; MCCARRON DA, 1991, CONTRIB NEPHROL, V90, P2; MULDOWNEY FP, 1982, KIDNEY INT, V22, P292, DOI 10.1038/ki.1982.168; NAKADA T, 1988, EUR UROL, V15, P264; OHKAWA M, 1992, BRIT J UROL, V69, P571, DOI 10.1111/j.1464-410X.1992.tb15624.x; PAK CYC, 1980, AM J MED, V69, P19, DOI 10.1016/0002-9343(80)90495-7; PARKS JH, 1994, KIDNEY INT, V45, P1722, DOI 10.1038/ki.1994.224; PHILLIPS MJ, 1967, LANCET, V1, P1354; ROBERTSON WG, 1979, CLIN SCI, V57, P285, DOI 10.1042/cs0570285; SCHOLZ D, 1982, J UROLOGY, V128, P903, DOI 10.1016/S0022-5347(17)53269-3; SILVER J, 1983, LANCET, V2, P484; STRAUSS AL, 1982, AM J MED, V72, P17, DOI 10.1016/0002-9343(82)90566-6; WILLIAMS R E, 1963, Br J Urol, V35, P416, DOI 10.1111/j.1464-410X.1963.tb11762.x; YENDT ER, 1978, KIDNEY INT, V13, P397, DOI 10.1038/ki.1978.58; ZAREMBSK.PM, 1969, CLIN CHIM ACTA, V25, P1, DOI 10.1016/0009-8981(69)90218-6; ZEMEL MB, 1981, J NUTR, V111, P545, DOI 10.1093/jn/111.3.545	45	580	611	0	35	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JAN 10	2002	346	2					77	84		10.1056/NEJMoa010369	http://dx.doi.org/10.1056/NEJMoa010369			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	509EM	11784873				2023-01-03	WOS:000173133400002
J	Knight, EL; Avorn, J				Knight, EL; Avorn, J			Quality indicators for appropriate medication use in vulnerable elders	ANNALS OF INTERNAL MEDICINE			English	Article							CONVERTING ENZYME-INHIBITOR; OVERACTIVE BLADDER; HEART-FAILURE; RISK-FACTORS; HYPOGLYCEMIA; HYPERTENSION; INTERVENTION; OUTPATIENTS; THERAPY; DRUGS		Harvard Univ, Brigham & Womens Hosp, Sch Med, Div Pharmacoepidemiol & Pharmacoecon, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard Medical School	Avorn, J (corresponding author), Harvard Univ, Brigham & Womens Hosp, Sch Med, Div Pharmacoepidemiol & Pharmacoecon, 221 Londwood Ave, Boston, MA 02115 USA.							Abrams P, 1998, BRIT J UROL, V81, P801; *ABT ASS, 1998, EV DRUG US REV DEM P; Appell RA, 1997, UROLOGY, V50, P90, DOI 10.1016/S0090-4295(97)00599-2; ASPLUND K, 1983, DIABETOLOGIA, V24, P412; AVORN J, 2001, GERIATRIC MED; BEERS MH, 1991, ARCH INTERN MED, V151, P1825; BEERS MH, 1992, ANN INTERN MED, V117, P684, DOI 10.7326/0003-4819-117-8-684; Black HR, 1997, ARCH INTERN MED, V157, P2413; Chiquette E, 1998, ARCH INTERN MED, V158, P1641, DOI 10.1001/archinte.158.15.1641; CHRISCHILLES EA, 1992, J GERONTOL, V47, pM137, DOI 10.1093/geronj/47.5.M137; EISENDRATH SJ, 1987, AM J PSYCHIAT, V144, P1062; FERNER RE, 1988, BRIT MED J, V296, P949, DOI 10.1136/bmj.296.6627.949; GOETZ DW, 1989, J ALLERGY CLIN IMMUN, V84, P316, DOI 10.1016/0091-6749(89)90414-4; GONZALEZFERNANDEZ RA, 1990, AM J CARDIOL, V65, P1384, DOI 10.1016/0002-9149(90)91332-Z; GOODYER LI, 1995, BRIT J CLIN PRACT, V49, P173; GRISSO JA, 1991, NEW ENGL J MED, V324, P1326, DOI 10.1056/NEJM199105093241905; Hanlon JT, 1996, AM J MED, V100, P428, DOI 10.1016/S0002-9343(97)89519-8; HIRSH J, 1995, AM J CARDIOL, V75, pB39, DOI 10.1016/0002-9149(95)80009-H; Hirsh J, 1998, CHEST, V114, p445S, DOI 10.1378/chest.114.5_Supplement.445S; HYLEK EM, 1994, ANN INTERN MED, V120, P897, DOI 10.7326/0003-4819-120-11-199406010-00001; Hylek EM, 1996, NEW ENGL J MED, V335, P540, DOI 10.1056/NEJM199608223350802; Kalra PA, 1999, BMJ-BRIT MED J, V318, P234; Knight EL, 1999, AM HEART J, V138, P849, DOI 10.1016/S0002-8703(99)70009-8; Koenig K L, 1994, Acad Emerg Med, V1, P544; LOWE CJ, 1995, BRIT MED J, V310, P1229, DOI 10.1136/bmj.310.6989.1229; MACDONALD JB, 1977, BRIT MED J, V2, P483, DOI 10.1136/bmj.2.6085.483; MacDowall P, 1998, LANCET, V352, P13, DOI 10.1016/S0140-6736(97)11060-1; MARCANTONIO ER, 1994, JAMA-J AM MED ASSOC, V272, P1518, DOI 10.1001/jama.272.19.1518; MONANE M, 1993, ARCH INTERN MED, V153, P633, DOI 10.1001/archinte.153.5.633; Monane M, 1998, JAMA-J AM MED ASSOC, V280, P1249, DOI 10.1001/jama.280.14.1249; PAICE BJ, 1985, ADVERSE DRUG REACT T, V4, P23; POTAMIANOS G, 1982, BRIT J PSYCHIAT, V140, P470, DOI 10.1192/bjp.140.5.470; Psaty BM, 1997, JAMA-J AM MED ASSOC, V277, P739, DOI 10.1001/jama.277.9.739; Reardon LC, 1998, ARCH INTERN MED, V158, P26, DOI 10.1001/archinte.158.1.26; Rich MW, 1996, AM J MED, V101, P270, DOI 10.1016/S0002-9343(96)00172-6; Roter DL, 1998, MED CARE, V36, P1138, DOI 10.1097/00005650-199808000-00004; Sands L, 1997, AM J GERIAT PSYCHIAT, V5, P156; SELTZER HS, 1972, DIABETES, V21, P955, DOI 10.2337/diab.21.9.955; Shekelle PG, 2001, ANN INTERN MED, V135, P647, DOI 10.7326/0003-4819-135-8_Part_2-200110161-00003; SIEGEL D, 1992, JAMA-J AM MED ASSOC, V267, P1083, DOI 10.1001/jama.267.8.1083; SIMONS FER, 1994, NEW ENGL J MED, V330, P1663; SISCOVICK DS, 1994, NEW ENGL J MED, V330, P1852, DOI 10.1056/NEJM199406303302603; Staessen JA, 1997, LANCET, V350, P757, DOI 10.1016/S0140-6736(97)05381-6; WILLCOX SM, 1994, JAMA-J AM MED ASSOC, V272, P292, DOI 10.1001/jama.272.4.292; 1991, JAMA, V165, P3255	45	93	94	0	4	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	OCT 16	2001	135	8	2				703	710		10.7326/0003-4819-135-8_Part_2-200110161-00009	http://dx.doi.org/10.7326/0003-4819-135-8_Part_2-200110161-00009			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	481WA	11601953				2023-01-03	WOS:000171542400009
J	Kessler, RC; Davis, RB; Foster, DF; Van Rompay, MI; Walters, EE; Wilkey, SA; Kaptchuk, TJ; Eisenberg, DM				Kessler, RC; Davis, RB; Foster, DF; Van Rompay, MI; Walters, EE; Wilkey, SA; Kaptchuk, TJ; Eisenberg, DM			Long-term trends in the use of complementary and alternative medical therapies in the United States	ANNALS OF INTERNAL MEDICINE			English	Article							SERVICES; CARE	Background: Although recent research has shown that many people in the United States use complementary and alternative medical (CAM) therapies, little is known about time trends in use. Objective: To present data on time trends in CAM therapy use in the United States over the past half-century. Design: Nationally representative telephone survey of 2055 respondents that obtained information on current use, lifetime use, and age at first use for 20 CAM therapies. Setting: The 48 contiguous U.S. states. Participants: Household residents 18 years of age and older. Measurement: Retrospective self-reports of age at first use for each of 20 CAM therapies. Results: Previously reported analyses of these data showed that more than one third of the U.S. population was currently using CAM therapy in the year of the interview (1997). Subsequent analyses of lifetime use and age at onset showed that 67.6% of respondents had used at least one CAM therapy in their lifetime. Lifetime use steadily increased with age across three age cohorts: Approximately 3 of every 10 respondents in the pre-baby boom cohort, 5 of 10 in the baby boom cohort, and 7 of 10 in the post-baby boom cohort reported using some type of CAM therapy by age 33 years. Of respondents who ever used a CAM therapy, nearly half continued to use many years later. A wide range of individual CAM therapies increased in use over time, and the growth was similar across all major sociodemographic sectors of the study sample. Conclusions: Use of CAM therapies by a large proportion of the study sample is the result of a secular trend that began at least a half century ago. This trend suggests a continuing demand for CAM therapies that will affect health care delivery for the foreseeable future.	Harvard Univ, Sch Med, Dept Hlth Care Policy, Boston, MA 02115 USA; Beth Israel Deaconess Med Ctr, Ctr Alternat Med Res & Educ, Boston, MA 02215 USA	Harvard University; Harvard Medical School; Harvard University; Beth Israel Deaconess Medical Center	Kessler, RC (corresponding author), Harvard Univ, Sch Med, Dept Hlth Care Policy, 180 Longwood Ave, Boston, MA 02115 USA.	kessler@hcp.med.harvard.edu	Van Rompay, Maria/G-9452-2012		NIAMS NIH HHS [U24 AR43441] Funding Source: Medline; NIMH NIH HHS [K05 MH00507] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [U24AR043441] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [K05MH000507] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		Astin JA, 1998, JAMA-J AM MED ASSOC, V279, P1548, DOI 10.1001/jama.279.19.1548; BERLINER HS, 1980, INT J HEALTH SERV, V10, P133, DOI 10.2190/XWR6-5QPX-GEGE-5GWR; CLAYTON D, 1993, STAT MODELS EPIDEMIO, P31; Delbanco T, 1998, JAMA-J AM MED ASSOC, V280, P1560, DOI 10.1001/jama.280.18.1560; Druss BG, 1999, JAMA-J AM MED ASSOC, V282, P651, DOI 10.1001/jama.282.7.651; EISENBERG DM, 1993, NEW ENGL J MED, V328, P246, DOI 10.1056/NEJM199301283280406; Eisenberg DM, 1998, JAMA-J AM MED ASSOC, V280, P1569, DOI 10.1001/jama.280.18.1569; Goldstein M. S., 1992, HLTH MOVEMENT PROMOT; HOLT D, 1979, J ROY STAT SOC A STA, V142, P33, DOI 10.2307/2344652; LEE ES, 1989, ANAL COMPLEXX SURVEY; Paramore LC, 1997, J PAIN SYMPTOM MANAG, V13, P83, DOI 10.1016/S0885-3924(96)00299-0; Pelletier KR, 1997, AM J HEALTH PROMOT, V12, P112, DOI 10.4278/0890-1171-12.2.112; ROTHSTEIN WG, 1985, AM PHYSICIANS 19 CEN; SAS, 1996, SAS US GUID REL 6 12; Shekelle PG, 1996, MED CARE, V34, P863, DOI 10.1097/00005650-199609000-00001; SHYROCK HS, 1971, METHODS MAT DEMOGRAP, V1; *US BUR CENS, 2001, US POP EST AG SEX RA; Wetzel MS, 1998, JAMA-J AM MED ASSOC, V280, P784, DOI 10.1001/jama.280.9.784; Whorton J C, 1986, Pharm Hist, V28, P14; WILLETT JB, 1993, J CONSULT CLIN PSYCH, V61, P952, DOI 10.1037/0022-006X.61.6.952; [No title captured]	21	487	495	0	41	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	AUG 21	2001	135	4					262	268		10.7326/0003-4819-135-4-200108210-00011	http://dx.doi.org/10.7326/0003-4819-135-4-200108210-00011			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	465KE	11511141				2023-01-03	WOS:000170587500005
J	Pantilat, SZ; Markowitz, AJ				Pantilat, SZ; Markowitz, AJ			Initiating end-of-life discussions with seriously ill patients	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article														Markowitz, Amy/0000-0001-9314-2814				Quill TE, 2000, JAMA-J AM MED ASSOC, V284, P2502, DOI 10.1001/jama.284.19.2502	1	3	3	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 13	2001	285	22					2906	2906		10.1001/jama.285.22.2906	http://dx.doi.org/10.1001/jama.285.22.2906			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	440BP	11401613				2023-01-03	WOS:000169156300031
J	Kaushal, R; Bates, DW; Landrigan, C; McKenna, DJ; Clapp, MD; Federico, F; Goldmann, DA				Kaushal, R; Bates, DW; Landrigan, C; McKenna, DJ; Clapp, MD; Federico, F; Goldmann, DA			Medication errors and adverse drug events in pediatric inpatients	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							PHYSICIAN ORDER ENTRY; INTENSIVE-CARE UNIT; OF-MEDICINE REPORT; HOSPITALIZED-PATIENTS; PREVENTION; IMPROVEMENT; PHARMACISTS; MANAGEMENT	Context latrogenic injuries, including medication errors, are an important problem in all hospitalized populations. However, few epidemiological data are available regarding medication errors in the pediatric inpatient setting. Objectives To assess the rates of medication errors, adverse drug events (ADEs), and potential ADEs; to compare pediatric rates with previously reported adult rates; to analyze the major types of errors; and to evaluate the potential impact of prevention strategies. Design, Setting, and Patients Prospective cohort study of 1120 patients admitted to 2 academic institutions during 6 weeks in April and May of 1999. Main Outcome Measures Medication errors, potential ADEs, and ADEs were identified by clinical staff reports and review of medication order sheets, medication administration records, and patient charts. Results We reviewed 10778 medication orders and found 616 medication errors (5.7%), 115 potential ADEs (1.1%), and 26 ADEs (0.24%). Of the 26 ADEs, 5 (19%) were preventable. While the preventable ADE rate was similar to that of a previous adult hospital study, the potential ADE rate was 3 times higher. The rate of potential ADEs was significantly higher in neonates in the neonatal intensive care unit. Most potential ADEs occurred at the stage of drug ordering (79%) and involved incorrect dosing (34%), anti-infective drugs (28%), and intravenous medications (54%), Physician reviewers judged that computerized physician order entry could potentially have prevented 93% and ward-based clinical pharmacists 94% of potential ADEs. Conclusions Medication errors are common in pediatric inpatient settings, and further efforts are needed to reduce them.	Childrens Hosp, Dept Med, Boston, MA 02115 USA; Childrens Hosp, Dept Qual Improvement & Risk Management, Boston, MA 02115 USA; Brigham & Womens Hosp, Div Gen Internal Med, Boston, MA 02115 USA; Massachusetts Gen Hosp, Boston, MA 02114 USA; Risk Management Fdn, Cambridge, MA USA	Harvard University; Boston Children's Hospital; Harvard University; Boston Children's Hospital; Harvard University; Brigham & Women's Hospital; Harvard University; Massachusetts General Hospital	Goldmann, DA (corresponding author), Childrens Hosp, Dept Med, Enders 609,300 Longwood Ave, Boston, MA 02115 USA.	Don.Goldmann@tch.harvard.edu		Landrigan, Christopher/0000-0001-8386-4100	AHRQ HHS [T32 HS00063] Funding Source: Medline; AGENCY FOR HEALTHCARE RESEARCH AND QUALITY [T32HS000063] Funding Source: NIH RePORTER	AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); AGENCY FOR HEALTHCARE RESEARCH AND QUALITY(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)		ALLAN EL, 1990, AM J HOSP PHARM, V47, P555, DOI 10.1093/ajhp/47.3.555; [Anonymous], 1999, ERR IS HUMAN BUILDIN; Ashton CM, 1999, MED CARE, V37, P798, DOI 10.1097/00005650-199908000-00009; BATES DW, 1993, J GEN INTERN MED, V8, P289, DOI 10.1007/BF02600138; Bates DW, 1998, JAMA-J AM MED ASSOC, V280, P1311, DOI 10.1001/jama.280.15.1311; BATES DW, 1995, J GEN INTERN MED, V10, P199, DOI 10.1007/BF02600255; BATES DW, 1995, JAMA-J AM MED ASSOC, V274, P29, DOI 10.1001/jama.274.1.29; Bates DW, 1997, JAMA-J AM MED ASSOC, V277, P307, DOI 10.1001/jama.277.4.307; Bates DW, 1999, J AM MED INFORM ASSN, V6, P313, DOI 10.1136/jamia.1999.00660313; BERWICK DM, 1989, NEW ENGL J MED, V320, P53, DOI 10.1056/NEJM198901053200110; BRENNAN TA, 1991, NEW ENGL J MED, V324, P370, DOI 10.1056/NEJM199102073240604; Brennan TA, 2000, NEW ENGL J MED, V342, P1123, DOI 10.1056/NEJM200004133421510; Classen DC, 1997, JAMA-J AM MED ASSOC, V277, P301, DOI 10.1001/jama.277.4.301; Evans RS, 1998, NEW ENGL J MED, V338, P232, DOI 10.1056/NEJM199801223380406; FOLLI HL, 1987, PEDIATRICS, V79, P718; FORRESTER JW, 1971, TECHNOL REV, V73, P52, DOI 10.1177/003754977101600202; Glauber J, 2000, PEDIATRICS, V105, P1330; *JOINT COMM ACCR H, 1999, COMPR ACCR MAN HOSP; KATONA BG, 1989, AM J HOSP PHARM, V46, P1179, DOI 10.1093/ajhp/46.6.1179; Lazarou J, 1998, JAMA-J AM MED ASSOC, V279, P1200, DOI 10.1001/jama.279.15.1200; Leape L L, 1993, QRB Qual Rev Bull, V19, P144; LEAPE LL, 1994, JAMA-J AM MED ASSOC, V272, P1851, DOI 10.1001/jama.272.23.1851; Leape LL, 2000, JAMA-J AM MED ASSOC, V284, P95, DOI 10.1001/jama.284.1.95; LEAPE LL, 1995, JAMA-J AM MED ASSOC, V274, P35, DOI 10.1001/jama.1995.03530010049034; Leape LL, 1999, JAMA-J AM MED ASSOC, V282, P267, DOI 10.1001/jama.282.3.267; LEAPE LL, 1991, NEW ENGL J MED, V324, P377, DOI 10.1056/NEJM199102073240605; McDonald CJ, 2000, JAMA-J AM MED ASSOC, V284, P93, DOI 10.1001/jama.284.1.93; NARANJO CA, 1981, CLIN PHARMACOL THER, V30, P239, DOI 10.1038/clpt.1981.154; Perrow C, 1984, NORMAL ACCIDENTS; REESON J, 1990, HUMAN ERROR; Thomas EJ, 2000, MED CARE, V38, P261, DOI 10.1097/00005650-200003000-00003	31	1169	1213	1	49	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 25	2001	285	16					2114	2120		10.1001/jama.285.16.2114	http://dx.doi.org/10.1001/jama.285.16.2114			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	422QW	11311101	Bronze			2023-01-03	WOS:000168131600032
J	[Anonymous]				[Anonymous]			Gathering the evidence on medical marijuana	NATURE			English	Editorial Material																		2001, NATURE, V410, P505	1	0	0	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	APR 5	2001	410	6829					613	613						1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	418DJ	11287904				2023-01-03	WOS:000167875400001
J	Lynn, J; Nolan, K; Kabcenell, A; Weissman, D; Milne, C; Berwick, DM				Lynn, J; Nolan, K; Kabcenell, A; Weissman, D; Milne, C; Berwick, DM		End Life Care Consensus Panel	Reforming care for persons near the end of life: The promise of quality improvement	ANNALS OF INTERNAL MEDICINE			English	Article							ADVANCE DIRECTIVES; INSTRUCTIONS; PREFERENCES; MANAGEMENT; SURGERY; TRIAL; DEATH	Most people in developed countries will live with a serious, eventually fatal, chronic condition for months or years before dying; yet, the delivery of health care services has only just recently begun adapting to this reality. Quality improvement methods have been effective in helping clinical services to make substantial changes quickly. Quality improvement requires stating an aim, measuring success, and testing possible improvements. The testing of changes requires a clinical team to Plan, Do, Study, and Act on new insights (the "PDSA cycle"). Repeated PDSA cycles generate deep understanding of complex systems and make sustainable improvements rapidly. This paper discusses a composite case study in a nursing home setting, which builds on experience with multisite collaborative efforts and introduces quality improvement methods in the context of end-of-life care.	Washington Home Ctr Palliat Care Studies, Washington, DC USA; Associates Proc Improvement, Silver Spring, MD USA; Cornell Univ, Ithaca, NY USA; Med Coll Wisconsin, Milwaukee, WI 53226 USA; Inst Healthcare Improvement, Boston, MA USA	Cornell University; Medical College of Wisconsin; Institute for Healthcare Improvement	Lynn, J (corresponding author), Care of Snyder Lois, Amer Soc Internal Med, Ctr Eth & Professionalism, Amer Coll Phys, 190 N Independence Mall W, Philadelphia, PA 19106 USA.							Baer WM, 2000, J AM GERIATR SOC, V48, P879, DOI 10.1111/j.1532-5415.2000.tb06883.x; BAILEY WC, 1990, ARCH INTERN MED, V150, P1664, DOI 10.1001/archinte.150.8.1664; Berwick DM, 1998, ANN INTERN MED, V128, P651, DOI 10.7326/0003-4819-128-8-199804150-00009; *CTR EV CLIN SCI D, 1996, DARTM ATL HLTH CAR; Ditto PH, 2001, ARCH INTERN MED, V161, P421, DOI 10.1001/archinte.161.3.421; EPSTEIN SW, 1979, CAN MED ASSOC J, V120, P813; Hammes BJ, 1998, ARCH INTERN MED, V158, P383, DOI 10.1001/archinte.158.4.383; KNAUS WA, 1995, JAMA-J AM MED ASSOC, V274, P1591, DOI 10.1001/jama.1995.03530200027032; LANGLEY G, 1996, IMPROVEMENT BOOK; LAZOVICH D, 1991, JAMA-J AM MED ASSOC, V266, P3433, DOI 10.1001/jama.266.24.3433; Lynn J, 2000, Jt Comm J Qual Improv, V26, P254; LYNN J, 2000, CTR IMPROVE CARE DYI; OConnor GT, 1996, JAMA-J AM MED ASSOC, V275, P841, DOI 10.1001/jama.275.11.841; Pritchard RS, 1998, J AM GERIATR SOC, V46, P1242, DOI 10.1111/j.1532-5415.1998.tb04540.x; Rich MW, 1999, J CARD FAIL, V5, P64, DOI 10.1016/S1071-9164(99)90026-X; *RW JOHNS FDN, 1998, MON RW JOHNS FDN PUB; SANDMIRE HF, 1994, AM J OBSTET GYNECOL, V170, P1790; SCHNEIDERMAN LJ, 1992, ARCH INTERN MED, V152, P2114, DOI 10.1001/archinte.152.10.2114; Soumeral SB, 1997, JAMA-J AM MED ASSOC, V277, P115, DOI 10.1001/jama.277.2.115; Teno JM, 1997, J AM GERIATR SOC, V45, P508, DOI 10.1111/j.1532-5415.1997.tb05179.x; 2002, PHYSICIAN ORDERS LIF	21	43	43	0	7	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUL 16	2002	137	2					117	122		10.7326/0003-4819-137-2-200207160-00010	http://dx.doi.org/10.7326/0003-4819-137-2-200207160-00010			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	575VN	12118967				2023-01-03	WOS:000176969300006
J	Cox, SR				Cox, SR			Everything	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																			0	1	1	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 12	2002	287	22					2913	2914		10.1001/jama.287.22.2913	http://dx.doi.org/10.1001/jama.287.22.2913			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	561EY	12052101				2023-01-03	WOS:000176128300001
J	Horton, R				Horton, R			Nurse-prescribing in the UK: right but also wrong	LANCET			English	Editorial Material									The Lancet, London NW1 7BY, England		Horton, R (corresponding author), The Lancet, London NW1 7BY, England.							Buchan J, 2002, BMJ-BRIT MED J, V324, P751, DOI 10.1136/bmj.324.7340.751; Dean B, 2002, LANCET, V359, P1373, DOI 10.1016/S0140-6736(02)08350-2; Jones AC, 2002, RHEUMATOLOGY, V41, P14, DOI 10.1093/rheumatology/41.1.14; Leathard HL, 2001, NURS EDUC TODAY, V21, P266, DOI 10.1054/nedt.2001.0553; McCann T V, 2002, J Psychiatr Ment Health Nurs, V9, P175, DOI 10.1046/j.1365-2850.2002.00454.x; Moher M, 2001, BMJ-BRIT MED J, V322, P1338, DOI 10.1136/bmj.322.7298.1338; Nolan P, 2001, J ADV NURS, V36, P527, DOI 10.1046/j.1365-2648.2001.02005.x; Shell R C, 2001, Nurse Pract, V26, P42; 2002, NURSE PRESCRIBING RO; 2002, BMA NEWS        0309, P3	10	27	27	0	1	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JUN 1	2002	359	9321					1875	1876		10.1016/S0140-6736(02)08786-X	http://dx.doi.org/10.1016/S0140-6736(02)08786-X			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	558PL	12057548				2023-01-03	WOS:000175975700005
J	Qasim, A; Malpass, K; O'Gorman, DJ; Heber, ME				Qasim, A; Malpass, K; O'Gorman, DJ; Heber, ME			Quality improvement report - Safety and efficacy of nurse initiated thrombolysis in patients with acute myocardial infarction	BMJ-BRITISH MEDICAL JOURNAL			English	Article							DELAY	Problem Delay in starting thrombolytic treatment in patients arriving at hospital with chest pain who are diagnosed as having acute myocardial infarction. Design Audit of "door to needle times" for patients presenting with chest pain and an electrocardiogram on admission that confirmed acute myocardial infarction. A one year period in each of three phases of development was studied. Background and setting The goal of the national service framework for coronary heart disease is that by April 2002, 75% of eligible patients should receive thrombolysis within 30 minutes of arriving at hospital. A district general hospital introduced a strategy to improve door to needle times. In phase 1 (1989-95), patients with suspected acute myocardial infarction, referred by general practitioners, were assessed in the coronary care unit; all other patients were seen first in the accident and emergency department. In phase 2 (1995-7), all patients with suspected acute myocardial infarction were transferred directly to a fast track area within the coronary care unit, where nurses assess patients and doctors started treatment. Key measures for improvement Median door to needle time in phase 1 of 45 minutes (range 5-300 minutes), with 38% of patients treated within 30 minutes. Median door to needle time in phase 2 of 40 minutes (range 5-180 minutes), with 47% treated within 30 minutes. Strategies for change In phase 3 (1997-2001), all patients with suspected acute myocardial infarction were transferred directly to the fast truck area and assessed by a "coronary care thrombolysis nurse," If electrocardiography confirmed the diagnosis of acute myocardial infarction, the nurse could initiate thrombolytic therapy (subject to guidelines and exclusions determined by the consultant cardiologists). Effects of change Median door to needle time in phase 3 of 15 minutes (range 5-70 minutes), with 80% of patients treated within 30 minutes. Systematic clinical review showed no cases in which a nurse initiated inappropriate thrombolysis. Lessons learnt Thrombolysis started by nurses is safe and effective in patients with acute myocardial infarction. It may provide a way by which tire national service framework's targets for door to needle times can be achieved.	Princess Royal Hosp, Dept Cardiol, Coronary Care Unit, Telford TF6 6TF, Shrops, England		Qasim, A (corresponding author), Princess Royal Hosp, Dept Cardiol, Coronary Care Unit, Apley Castle, Telford TF6 6TF, Shrops, England.	dr@asifqasim.freeserve.co.uk		Qasim, Asif/0000-0003-2394-5819				[Anonymous], 1988, LANCET, V2, P349; [Anonymous], 1986, LANCET, V1, P397; APPLEBY P, 1994, LANCET, V343, P311, DOI 10.1016/S0140-6736(94)91161-4; BIRKHEAD JS, 1992, BMJ-BRIT MED J, V305, P445, DOI 10.1136/bmj.305.6851.445; *DEP HLTH, 2000, NAT SERV FRAM COR HE; FOSTER DB, 1994, AM J EMERG MED, V12, P25, DOI 10.1016/0735-6757(94)90192-9; GATENBY R, 1992, BMJ-BRIT MED J, V305, P548; PELL ACH, 1992, BMJ-BRIT MED J, V304, P83, DOI 10.1136/bmj.304.6819.83; Quinn T, 1998, Intensive Crit Care Nurs, V14, P219, DOI 10.1016/S0964-3397(98)80614-9; Somauroo JD, 1999, J ROY COLL PHYS LOND, V33, P46; WESTON C, 1991, J ROY COLL PHYS LOND, V25, P312; WESTON CFM, 1994, BMJ-BRIT MED J, V308, P767, DOI 10.1136/bmj.308.6931.767	12	22	22	0	3	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUN 1	2002	324	7349					1328	1331		10.1136/bmj.324.7349.1328	http://dx.doi.org/10.1136/bmj.324.7349.1328			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	559TM	12039831	Green Published			2023-01-03	WOS:000176041500024
J	Prough, DS				Prough, DS			Are enough explicit resuscitation directives obtained for critically ill patients?	LANCET			English	Editorial Material							PREFERENCES; PHYSICIANS		Univ Texas, Med Branch, Dept Anesthesiol, Galveston, TX 77555 USA	University of Texas System; University of Texas Medical Branch Galveston	Prough, DS (corresponding author), Univ Texas, Med Branch, Dept Anesthesiol, Galveston, TX 77555 USA.		Prough, Donald S/G-5793-2013	Prough, Donald S/0000-0001-7994-532X				COOK DJ, 1995, JAMA-J AM MED ASSOC, V273, P703, DOI 10.1001/jama.273.9.703; Hakim RB, 1996, ANN INTERN MED, V125, P284, DOI 10.7326/0003-4819-125-4-199608150-00005; Hofmann JC, 1997, ANN INTERN MED, V127, P1, DOI 10.7326/0003-4819-127-1-199707010-00001; Phillips RS, 1996, AM J MED, V100, P128, DOI 10.1016/S0002-9343(97)89450-8	4	1	1	0	2	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	DEC 8	2001	358	9297					1920	1921		10.1016/S0140-6736(01)06972-0	http://dx.doi.org/10.1016/S0140-6736(01)06972-0			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	500HZ	11747909				2023-01-03	WOS:000172622200002
J	Rabow, MW; Markowitz, AJ				Rabow, MW; Markowitz, AJ			Serving patients who may die soon and their families	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article														Markowitz, Amy/0000-0001-9314-2814				Lynn J, 2001, JAMA-J AM MED ASSOC, V285, P925, DOI 10.1001/jama.285.7.925	1	1	2	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 19	2001	286	11					1377	1377		10.1001/jama.286.11.1377	http://dx.doi.org/10.1001/jama.286.11.1377			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	473DJ	11560544				2023-01-03	WOS:000171024500032
J	Lakkaraju, A; Dubinsky, JM; Low, WC; Rahman, YE				Lakkaraju, A; Dubinsky, JM; Low, WC; Rahman, YE			Neurons are protected from excitotoxic death by p53 antisense oligonucleotides delivered in anionic liposomes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; CATIONIC LIPOSOME; GENE-TRANSFER; DNA; PHOSPHOLIPIDS; TRANSFECTION; ACTIVATION; EXPRESSION; APOPTOSIS; MEMBRANES	The potential of anionic liposomes for oligonucleotide delivery was explored because the requirement for a net-positive charge on transfection-competent cationic liposome-DNA complexes is ambiguous. Liposomes composed of phosphatidylglycerol and phosphatidylcholine were monodisperse and encapsulated oligonucleotides with 40-60% efficiency. Ionic strength, bilayer charge density, and oligonucleotide chemistry influenced encapsulation. To demonstrate the biological efficacy of this vector, antisense oligonucleotides to p53 delivered in anionic liposomes were tested in an in vitro model of excitotoxicity. Exposure of hippocampal neurons to glutamate increased p53 protein expression 4-fold and decreased neuronal survival to similar to 35%. Treatment with 1 muM p53 antisense oligonucleotides in anionic liposomes prevented glutamate-induced up-regulation of p53 and increased neuronal survival to similar to 35%. Encapsulated phosphorothioate p53 antisense oligonucleotides were neuroprotective at 5-10-fold lower concentrations than when unencapsulated. Replacing the anionic lipid with phosphatidylserine significantly decreased neuroprotection. p53 antisense oligonucleotides complexed with cationic liposomes were ineffective. Neuroprotection by p53 antisense oligonucleotides in anionic liposomes was comparable with that by glutamate receptor antagonists and a chemical inhibitor of p53. Anionic liposomes were also capable of delivering plasmids and inducing transgene expression in neurons. Anionic liposome-mediated internalization of Cy3-labeled oligonucleotides by neurons and several other cell lines demonstrated the universal applicability of this vector.	Univ Minnesota, Dept Neurosci, Minneapolis, MN 55455 USA; Univ Minnesota, Dept Pharmaceut, Minneapolis, MN 55455 USA; Univ Minnesota, Dept Neurosurg, Minneapolis, MN 55455 USA	University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities	Dubinsky, JM (corresponding author), Univ Minnesota, Dept Neurosci, 6-145 Jackson Hall,321 Church St SE, Minneapolis, MN 55455 USA.	dubin001@tc.umn.edu			NIA NIH HHS [AG10034] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [R01AG010034] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		AKHTAR S, 1991, NUCLEIC ACIDS RES, V19, P5551, DOI 10.1093/nar/19.20.5551; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; AZZAZY HME, 1995, BRAIN RES, V695, P231, DOI 10.1016/0006-8993(95)00710-8; Bally MB, 1999, ADV DRUG DELIVER REV, V38, P291, DOI 10.1016/S0169-409X(99)00034-4; Bandyopadhyay S, 1999, J PHYS CHEM B, V103, P10075, DOI 10.1021/jp9927496; BELL RM, 1991, J BIOL CHEM, V266, P4661; BROSIUS B, 1986, J BIOMOL STRUCT DYN, V4, P271, DOI 10.1080/07391102.1986.10506346; Buchner K, 1999, MOL BRAIN RES, V64, P222, DOI 10.1016/S0169-328X(98)00324-6; Chen RW, 1999, J NEUROSCI, V19, P9654; Chen RW, 1999, J BIOL CHEM, V274, P6039, DOI 10.1074/jbc.274.10.6039; DUBINSKY JM, 1995, J NEUROSCI, V15, P7071; DUBINSKY JM, 1993, J NEUROSCI, V13, P623; Gonzalez-Zulueta M, 1998, J NEUROSCI, V18, P2040; Hartmann G, 1998, J PHARMACOL EXP THER, V285, P920; HUGHES JA, 1994, J PHARM SCI, V83, P597, DOI 10.1002/jps.2600830431; JAASKELAINEN I, 1994, BBA-BIOMEMBRANES, V1195, P115, DOI 10.1016/0005-2736(94)90017-5; Jimenez GS, 1999, ONCOGENE, V18, P7656, DOI 10.1038/sj.onc.1203013; Jordan J, 1997, J NEUROSCI, V17, P1397; Kaech S, 1996, MOL BRAIN RES, V35, P344, DOI 10.1016/0169-328X(95)00238-N; Kodama M, 1996, COLLOID SURFACE A, V109, P283, DOI 10.1016/0927-7757(95)03461-7; Komarov PG, 1999, SCIENCE, V285, P1733, DOI 10.1126/science.285.5434.1733; Lee JM, 1999, NATURE, V399, pA7, DOI 10.1038/399a007; Malghani MS, 1998, J PHYS CHEM B, V102, P8930, DOI 10.1021/jp982413g; Marchenko ND, 2000, J BIOL CHEM, V275, P16202, DOI 10.1074/jbc.275.21.16202; Monnard PA, 1999, LANGMUIR, V15, P7504, DOI 10.1021/la990068w; Morrison RS, 2000, CELL DEATH DIFFER, V7, P868, DOI 10.1038/sj.cdd.4400741; Morrison RS, 1996, J NEUROSCI, V16, P1337; Polyak K, 1997, NATURE, V389, P300, DOI 10.1038/38525; Sattler R, 1999, SCIENCE, V284, P1845, DOI 10.1126/science.284.5421.1845; Schwartz B, 1995, HUM GENE THER, V6, P1515, DOI 10.1089/hum.1995.6.12-1515; SINGER VL, 1995, FASEB J, V9, pA1422; Son KK, 2000, BBA-BIOMEMBRANES, V1466, P11, DOI 10.1016/S0005-2736(00)00176-0; SOUSSI T, 1988, NUCLEIC ACIDS RES, V16, P11384, DOI 10.1093/nar/16.23.11384; Stein CA, 1999, NAT BIOTECHNOL, V17, P209, DOI 10.1038/6909; STEWART JCM, 1980, ANAL BIOCHEM, V104, P10, DOI 10.1016/0003-2697(80)90269-9; TAKENAKA I, 1995, J BIOL CHEM, V270, P5405, DOI 10.1074/jbc.270.10.5405; Wangerek LA, 2001, J GENE MED, V3, P72, DOI 10.1002/1521-2254(200101/02)3:1<72::AID-JGM157>3.0.CO;2-M; WINTERHALTER M, 1993, CHEM PHYS LIPIDS, V64, P35, DOI 10.1016/0009-3084(93)90056-9; Xiang H, 1996, J NEUROSCI, V16, P6753; Xu YH, 1999, BIOPHYS J, V77, P341, DOI 10.1016/S0006-3495(99)76894-3; ZABNER J, 1995, J BIOL CHEM, V270, P18997, DOI 10.1074/jbc.270.32.18997; Zelphati O, 1996, J CONTROL RELEASE, V41, P99, DOI 10.1016/0168-3659(96)01361-2; Zhang YP, 1997, BIOPHYS J, V72, P779, DOI 10.1016/S0006-3495(97)78712-5	43	55	58	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 24	2001	276	34					32000	32007		10.1074/jbc.M100138200	http://dx.doi.org/10.1074/jbc.M100138200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	465WT	11406618	hybrid			2023-01-03	WOS:000170613500073
J	Shapiro, CL; Recht, A				Shapiro, CL; Recht, A			Drug therapy - Side effects of adjuvant treatment of breast cancer	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							BONE-MINERAL DENSITY; QUALITY-OF-LIFE; ESTROGEN REPLACEMENT THERAPY; FIRST-LINE THERAPY; 20-YEAR FOLLOW-UP; RADIATION-THERAPY; POSTMENOPAUSAL WOMEN; CONSERVATIVE SURGERY; CONTRALATERAL BREAST; PREMENOPAUSAL WOMEN		Ohio State Univ, Arthur G James Canc Hosp, Dept Hematol & Oncol, Columbus, OH 43210 USA; Ohio State Univ, Richard J Solove Res Inst, Columbus, OH 43210 USA; Beth Israel Deaconess Med Ctr, Dept Radiat Oncol, Boston, MA 02215 USA; Harvard Univ, Sch Med, Boston, MA USA	James Cancer Hospital & Solove Research Institute; University System of Ohio; Ohio State University; James Cancer Hospital & Solove Research Institute; University System of Ohio; Ohio State University; Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School	Shapiro, CL (corresponding author), Ohio State Univ, Arthur G James Canc Hosp, Dept Hematol & Oncol, 320 W 10th St, Columbus, OH 43210 USA.	shapiro-1@medctr.osu.edu						ABE O, 1995, NEW ENGL J MED, V333, P1444; Abe O, 1998, LANCET, V352, P930; Abe O, 1996, NEW ENGL J MED, V334, P1003; Ahsan H, 1998, ANN INTERN MED, V128, P114, DOI 10.7326/0003-4819-128-2-199801150-00007; ARBUCK SG, 1994, HEMATOL ONCOL CLIN N, V8, P121, DOI 10.1016/S0889-8588(18)30191-6; ARRIAGADA R, 1991, LANCET, V338, P535, DOI 10.1016/0140-6736(91)91100-9; Ashing-Giwa K, 1999, CANCER, V85, P418, DOI 10.1002/(SICI)1097-0142(19990115)85:2<418::AID-CNCR20>3.0.CO;2-9; ASHINGGIWA K, 1999, CANCER, V86, P732; Barton DL, 1998, J CLIN ONCOL, V16, P495, DOI 10.1200/JCO.1998.16.2.495; Berenson J., 2000, Breast Cancer Research and Treatment, V64, P32; Bines J, 1996, J CLIN ONCOL, V14, P1718, DOI 10.1200/JCO.1996.14.5.1718; BLOMQVIST C, 1992, BRIT J CANCER, V66, P1171, DOI 10.1038/bjc.1992.430; BOICE JD, 1992, NEW ENGL J MED, V326, P781, DOI 10.1056/NEJM199203193261201; BONADONNA G, 1995, JAMA-J AM MED ASSOC, V253, P542; Bonneterre J, 2000, J CLIN ONCOL, V18, P3748, DOI 10.1200/JCO.2000.18.22.3748; Bower JE, 2000, J CLIN ONCOL, V18, P743, DOI 10.1200/JCO.2000.18.4.743; Brennan MJ, 1998, CANCER, V83, P2821, DOI 10.1002/(SICI)1097-0142(19981215)83:12B+<2821::AID-CNCR33>3.0.CO;2-G; Broeckel JA, 1998, J CLIN ONCOL, V16, P1689, DOI 10.1200/JCO.1998.16.5.1689; BRYCE CJ, 1998, BREAST CANC RES TREA, V50, P284; BUZDAR AU, 1989, AM J CLIN ONCOL-CANC, V12, P123, DOI 10.1097/00000421-198904000-00007; BUZDAR AU, 1979, JAMA-J AM MED ASSOC, V242, P1509, DOI 10.1001/jama.242.14.1509; CAMORIANO JK, 1990, J CLIN ONCOL, V8, P1327, DOI 10.1200/JCO.1990.8.8.1327; Carlson RW, 1999, ONCOLOGY-NY, V13, P41; Chlebowski RT, 1999, J CLIN ONCOL, V17, P130, DOI 10.1200/JCO.1999.17.1.130; CLARK G, 2000, DIS BREAST, V2, P489; Clarke M, 1998, LANCET, V351, P1451; Cobleigh M, 1995, P AN M AM SOC CLIN, V14, P115; COBLEIGH MA, 1994, JAMA-J AM MED ASSOC, V272, P540, DOI 10.1001/jama.272.7.540; COUZI RJ, 1995, J CLIN ONCOL, V13, P2737, DOI 10.1200/JCO.1995.13.11.2737; Cummings SR, 1999, JAMA-J AM MED ASSOC, V282, P2124; Cummings SR, 1999, JAMA-J AM MED ASSOC, V281, P2189, DOI 10.1001/jama.281.23.2189; CURTIS RE, 1992, NEW ENGL J MED, V326, P1745, DOI 10.1056/NEJM199206253262605; CURTIS RE, 1989, J CLIN ONCOL, V7, P21, DOI 10.1200/JCO.1989.7.1.21; Day R, 1999, J CLIN ONCOL, V17, P2659, DOI 10.1200/JCO.1999.17.9.2659; Delmas PD, 1997, NEW ENGL J MED, V337, P1641, DOI 10.1056/NEJM199712043372301; Delmas PD, 1997, J CLIN ONCOL, V15, P955, DOI 10.1200/JCO.1997.15.3.955; DEMARKWAHNEFRIED W, 1993, J CLIN ONCOL, V11, P1418, DOI 10.1200/JCO.1993.11.7.1418; DemarkWahnefried W, 1997, AM J CLIN NUTR, V65, P1495, DOI 10.1093/ajcn/65.5.1495; Diamandidou E, 1996, J CLIN ONCOL, V14, P2722, DOI 10.1200/JCO.1996.14.10.2722; Dorval M, 1998, J CLIN ONCOL, V16, P487, DOI 10.1200/JCO.1998.16.2.487; Ewer MS, 1999, SEMIN ONCOL, V26, P96; FISHER B, 1985, J CLIN ONCOL, V3, P1640, DOI 10.1200/JCO.1985.3.12.1640; FISHER B, 1990, J CLIN ONCOL, V8, P1483, DOI 10.1200/JCO.1990.8.9.1483; Fisher B, 1999, LANCET, V353, P1993, DOI 10.1016/S0140-6736(99)05036-9; Fisher B, 1998, J NATL CANCER I, V90, P1371, DOI 10.1093/jnci/90.18.1371; FISHER B, 1994, J NATL CANCER I, V86, P527, DOI 10.1093/jnci/86.7.527; FISHER B, 1989, NEW ENGL J MED, V320, P479, DOI 10.1056/NEJM198902233200802; FISHER B, 2000, P AN M AM SOC CLIN, V19, pA72; FRAASS BA, 1985, INT J RADIAT ONCOL, V11, P485, DOI 10.1016/0360-3016(85)90179-8; Ganz PA, 1998, RECENT RESULTS CANC, V152, P396; GELBER RD, 1992, NIH PUBLICATION, P127; GIANNI L, 1995, J CLIN ONCOL, V13, P2688, DOI 10.1200/JCO.1995.13.11.2688; Goldberg, 1996, J CLIN ONCOL, V14, P2411, DOI 10.1200/JCO.1996.14.8.2411; GOLDBERG RM, 1994, J CLIN ONCOL, V12, P155, DOI 10.1200/JCO.1994.12.1.155; Goldhirsch A, 1998, J NATL CANCER I, V90, P1601, DOI 10.1093/jnci/90.21.1601; Goodwin PJ, 1999, J CLIN ONCOL, V17, P120, DOI 10.1200/JCO.1999.17.1.120; Goodwin PJ, 1999, J CLIN ONCOL, V17, P2365, DOI 10.1200/JCO.1999.17.8.2365; Gyenes G, 1998, RADIOTHER ONCOL, V48, P185, DOI 10.1016/S0167-8140(98)00062-0; HANKEY BF, 1983, J NATL CANCER I, V70, P797; HENDERSON IC, 1998, P AN M AM SOC CLIN, V17, pA101; HERRING MK, 1986, AM J CLIN ONCOL-CANC, V9, P269, DOI 10.1097/00000421-198606000-00018; HOJRIS I, 1998, RADIOTHER ONCOL S1, V48, pS120; HOLDENER EE, 1984, RECENT RESULTS CANC, V96, P188; Hortobagyi GN, 1996, NEW ENGL J MED, V335, P1785, DOI 10.1056/NEJM199612123352401; Jonat W., 2000, Breast Cancer Research and Treatment, V64, P29; JONES AL, 1992, BRIT J CANCER, V66, P744, DOI 10.1038/bjc.1992.350; JORDAN VC, 1987, CANCER RES, V47, P4517; KANNEL WB, 1976, ANN INTERN MED, V85, P447, DOI 10.7326/0003-4819-85-4-447; Kristensen B, 1996, BREAST CANCER RES TR, V39, P321, DOI 10.1007/BF01806160; LINGOS TI, 1991, INT J RADIAT ONCOL, V21, P355, DOI 10.1016/0360-3016(91)90782-Y; Loprinzi CL, 1997, J CLIN ONCOL, V15, P969, DOI 10.1200/JCO.1997.15.3.969; LOPRINZI CL, 1994, NEW ENGL J MED, V331, P347, DOI 10.1056/NEJM199408113310602; LOPRINZI CL, 2000, P AN M AM SOC CLIN, V19, pA2; LOVE RR, 1992, NEW ENGL J MED, V326, P852, DOI 10.1056/NEJM199203263261302; LOVE RR, 1991, ANN INTERN MED, V115, P860, DOI 10.7326/0003-4819-115-11-860; Lowenberg B, 1999, NEW ENGL J MED, V341, P1051, DOI 10.1056/NEJM199909303411407; MAMBY CC, 1994, BREAST CANCER RES TR, V30, P311, DOI 10.1007/BF00665973; MCDONALD CC, 1995, BRIT MED J, V311, P977; Miller KD, 1999, CANCER INVEST, V17, P121; Mortimer JE, 1999, J CLIN ONCOL, V17, P1488, DOI 10.1200/JCO.1999.17.5.1488; Nabholtz JM, 2000, J CLIN ONCOL, V18, P3758, DOI 10.1200/JCO.2000.18.22.3758; Natrajan PK, 1999, AM J OBSTET GYNECOL, V181, P288, DOI 10.1016/S0002-9378(99)70550-8; Nayfield SG, 1996, J CLIN ONCOL, V14, P1018, DOI 10.1200/JCO.1996.14.3.1018; NEUGUT AI, 1993, CANCER, V71, P3054, DOI 10.1002/1097-0142(19930515)71:10<3054::AID-CNCR2820711027>3.0.CO;2-N; NIH Consensus statement, 2000, ADJ THER BREAST CANC, V17, P1, DOI [10.1093/jnci/93.13.979, DOI 10.1093/JNCI/93.13.979]; Nixon AJ, 1998, J CLIN ONCOL, V16, P1374, DOI 10.1200/JCO.1998.16.4.1374; Overgaard M, 1997, NEW ENGL J MED, V337, P949, DOI 10.1056/NEJM199710023371401; Ozer H, 2000, J CLIN ONCOL, V18, P3558, DOI 10.1200/JCO.2000.18.20.3558; Pandya KJ, 2000, ANN INTERN MED, V132, P788, DOI 10.7326/0003-4819-132-10-200005160-00004; PASTA LF, 1999, J CLIN ONCOL, V17, P740; Paszat LF, 1998, J CLIN ONCOL, V16, P2625, DOI 10.1200/JCO.1998.16.8.2625; Paszat LF, 1999, INT J RADIAT ONCOL, V43, P755, DOI 10.1016/S0360-3016(98)00412-X; PHILLIPS KA, 1999, PROG P AM SOC CLIN O, V18, pA74; PIERCE SM, 1992, INT J RADIAT ONCOL, V23, P915, DOI 10.1016/0360-3016(92)90895-O; Powles T, 1996, J CLIN ONCOL, V14, P78, DOI 10.1200/JCO.1996.14.1.78; Powles TJ, 1998, J NATL CANCER I, V90, P704, DOI 10.1093/jnci/90.9.704; Pritchard KI, 1996, J CLIN ONCOL, V14, P2731, DOI 10.1200/JCO.1996.14.10.2731; Quella SK, 2000, J CLIN ONCOL, V18, P1068, DOI 10.1200/JCO.2000.18.5.1068; QUIET CA, 1995, J CLIN ONCOL, V13, P1144, DOI 10.1200/JCO.1995.13.5.1144; Ragaz J, 1997, NEW ENGL J MED, V337, P956, DOI 10.1056/NEJM199710023371402; RECHT A, 1995, CANCER, V76, P1491, DOI 10.1002/1097-0142(19951101)76:9<1491::AID-CNCR2820760902>3.0.CO;2-8; Rizk A N, 1999, Drugs R D, V2, P229; ROSEN PP, 1989, J CLIN ONCOL, V7, P355, DOI 10.1200/JCO.1989.7.3.355; ROSEN PP, 1991, J CLIN ONCOL, V9, P1650, DOI 10.1200/JCO.1991.9.9.1650; Rubagotti A, 1996, ANN ONCOL, V7, P239; Rutqvist LE, 1998, INT J RADIAT ONCOL, V40, P359, DOI 10.1016/S0360-3016(97)00765-7; RUTQVIST LE, 1995, J NATL CANCER I, V87, P645, DOI 10.1093/jnci/87.9.645; RUTQVIST LE, 1993, J NATL CANCER I, V85, P1398, DOI 10.1093/jnci/85.17.1398; Saarto T, 1997, J CLIN ONCOL, V15, P1341, DOI 10.1200/JCO.1997.15.4.1341; SAPHNER T, 1991, J CLIN ONCOL, V9, P286, DOI 10.1200/JCO.1991.9.2.286; Schagen SB, 1999, CANCER, V85, P640, DOI 10.1002/(SICI)1097-0142(19990201)85:3<640::AID-CNCR14>3.0.CO;2-G; Shan K, 1996, ANN INTERN MED, V125, P47, DOI 10.7326/0003-4819-125-1-199607010-00008; Shapiro CL, 1998, J CLIN ONCOL, V16, P3493, DOI 10.1200/JCO.1998.16.11.3493; SHAPIRO CL, 1994, NIH PUBLICATION, P101; SLAMON D, 1998, P AN M AM SOC CLIN, V17, pA98; Smart CR, 1997, CA-CANCER J CLIN, V47, P134, DOI 10.3322/canjclin.47.3.134; Smith R., 2000, Breast Cancer Research and Treatment, V64, P27; STORM HH, 1986, BRIT J CANCER, V54, P483, DOI 10.1038/bjc.1986.201; Strobbe LJA, 1998, BREAST CANCER RES TR, V47, P101, DOI 10.1023/A:1005997017102; Suh-Burgmann EJ, 1999, ANN INTERN MED, V131, P127, DOI 10.7326/0003-4819-131-2-199907200-00009; Swain S, 1999, ONCOLOGY-NY, V13, P859; SWAIN S, 1999, ONCOLOGY HUNTINGT, V13, P871; SWAIN S, 1999, ONCOLOGY HUNTINGT, V13, P875; SWAIN S, 1999, ONCOLOGY HUNTINGT, V13, P865; TAGHIAN A, 1991, INT J RADIAT ONCOL, V21, P361, DOI 10.1016/0360-3016(91)90783-Z; TALLMAN MS, 1995, J CLIN ONCOL, V13, P1557, DOI 10.1200/JCO.1995.13.7.1557; TOUBOUL E, 1992, RADIOTHER ONCOL, V25, P167, DOI 10.1016/0167-8140(92)90263-T; VALAGUSSA P, 1994, ANN ONCOL, V5, P209, DOI 10.1093/oxfordjournals.annonc.a058795; VALAGUSSA P, 1994, ANN ONCOL, V5, P803, DOI 10.1093/oxfordjournals.annonc.a059008; van Dam FSAM, 1998, J NATL CANCER I, V90, P210, DOI 10.1093/jnci/90.3.210; Vassilopoulou-Sellin R, 1999, J CLIN ONCOL, V17, P1482, DOI 10.1200/JCO.1999.17.5.1482; Voth EA, 1997, ANN INTERN MED, V126, P791, DOI 10.7326/0003-4819-126-10-199705150-00008; WOOD WC, 1994, NEW ENGL J MED, V331, P139; WOOD WC, 1994, NEW ENGL J MED, V330, P1253, DOI 10.1056/NEJM199405053301801; Zambetti M, 2001, J CLIN ONCOL, V19, P37, DOI 10.1200/JCO.2001.19.1.37; ZAMBETTI M, 1992, NIH PUBLICATION, P77	136	484	512	0	42	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUN 28	2001	344	26					1997	2008		10.1056/NEJM200106283442607	http://dx.doi.org/10.1056/NEJM200106283442607			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	446HQ	11430330				2023-01-03	WOS:000169508200007
J	Hrobjartsson, A; Gotzsche, PC				Hrobjartsson, A; Gotzsche, PC			Is the placebo powerless? An analysis of clinical trials comparing placebo with no treatment.	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							ELECTRICAL NERVE-STIMULATION; RANDOMIZED CONTROLLED TRIAL; COGNITIVE-BEHAVIOR THERAPY; LOW-BACK-PAIN; DOUBLE-BLIND; POSTOPERATIVE PAIN; PARADOXICAL INTENTION; RHEUMATOID-ARTHRITIS; IPRATROPIUM BROMIDE; STRESS MANAGEMENT	Background: Placebo treatments have been reported to help patients with many diseases, but the quality of the evidence supporting this finding has not been rigorously evaluated. Methods: We conducted a systematic review of clinical trials in which patients were randomly assigned to either placebo or no treatment. A placebo could be pharmacologic (e.g., a tablet), physical (e.g., a manipulation), or psychological (e.g., a conversation). Results: We identified 130 trials that met our inclusion criteria. After the exclusion of 16 trials without relevant data on outcomes, there were 32 with binary outcomes (involving 3795 patients, with a median of 51 patients per trial) and 82 with continuous outcomes (involving 4730 patients, with a median of 27 patients per trial). As compared with no treatment, placebo had no significant effect on binary outcomes, regardless of whether these outcomes were subjective or objective. For the trials with continuous outcomes, placebo had a beneficial effect, but the effect decreased with increasing sample size, indicating a possible bias related to the effects of small trials. The pooled standardized mean difference was significant for the trials with subjective outcomes but not for those with objective outcomes. In 27 trials involving the treatment of pain, placebo had a beneficial effect, as indicated by a reduction in the intensity of pain of 6.5 mm on a 100-mm visual-analogue scale. Conclusions: We found little evidence in general that placebos had powerful clinical effects. Although placebos had no significant effects on objective or binary outcomes, they had possible small benefits in studies with continuous subjective outcomes and for the treatment of pain. Outside the setting of clinical trials, there is no justification for the use of placebos. (N Engl J Med 2001;344:1594-602.) Copyright (C) 2001 Massachusetts Medical Society.	Univ Copenhagen, Panum Inst, Dept Med Philosophy & Clin Theory, DK-2200 Copenhagen N, Denmark; Rigshosp, Nord Cochrane Ctr, DK-2100 Copenhagen, Denmark	University of Copenhagen; Rigshospitalet; University of Copenhagen	Hrobjartsson, A (corresponding author), Univ Copenhagen, Panum Inst, Dept Med Philosophy & Clin Theory, Blegdamsvej 3, DK-2200 Copenhagen N, Denmark.							ADRIAANSE AH, 1995, EUR J OBSTET GYN R B, V61, P135, DOI 10.1016/0301-2115(95)02134-S; Altman DG., 1990, PRACTICAL STAT MED R, DOI [10.1201/9780429258589, DOI 10.1201/9780429258589]; Altman DG, 1991, PRACTICAL STAT MED R, P179; Andersen AN, 1990, ACTA OBSTET GYN SCAN, V69, P235, DOI 10.3109/00016349009028686; ANTIVALLE M, 1990, J HUM HYPERTENS, V4, P633; ASCHER LM, 1979, BEHAV RES THER, V17, P408, DOI 10.1016/0005-7967(79)90015-9; Aune Audun, 1998, Tidsskrift for den Norske Laegeforening, V118, P1370; BEECHER HK, 1955, JAMA-J AM MED ASSOC, V159, P1602, DOI 10.1001/jama.1955.02960340022006; Benedetti F, 1997, ANN THORAC SURG, V63, P773, DOI 10.1016/S0003-4975(96)01249-0; BENEDETTI F, 1995, LANCET, V346, P1231, DOI 10.1016/S0140-6736(95)92938-X; BERG I, 1983, J CHILD PSYCHOL PSYC, V24, P543, DOI 10.1111/j.1469-7610.1983.tb00131.x; BLACKMAN S, 1964, AM J PSYCHIAT, V120, P1194, DOI 10.1176/ajp.120.12.1194; BLOCK J, 1980, PSYCHOTHER-THEOR RES, V17, P277, DOI 10.1037/h0085923; BOSLEY F, 1989, J BEHAV MED, V12, P77, DOI 10.1007/BF00844750; BRAMSTON P, 1985, BEHAV RES THER, V23, P239, DOI 10.1016/0005-7967(85)90001-4; Brown WA, 1998, SCI AM, V278, P90, DOI 10.1038/scientificamerican0198-90; Canino Evelyn, 1994, Acta Cientifica Venezolana, V45, P23; Chenard J, 1991, SCI COMPORTEMENT, V21, P225; CLASSEN W, 1983, NEUROPSYCHOBIOLOGY, V10, P44, DOI 10.1159/000117982; *COCHR CONS COMM G, 1999, COCHR LIB; CONN IG, 1986, ANN ROY COLL SURG, V68, P191; Coyne P J, 1995, J Intraven Nurs, V18, P263; CROSBY L, 1994, HEART LUNG, V23, P493; DAVIDSON AM, 1980, BEHAV RES THER, V18, P1, DOI 10.1016/0005-7967(80)90063-7; DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2; DESAINTONGE DMC, 1994, LANCET, V344, P995, DOI 10.1016/S0140-6736(94)91647-0; DIAMOND L, 1995, J ALLERGY CLIN IMMUN, V95, P1139, DOI 10.1016/S0091-6749(95)70219-9; DOUBLE DB, 1993, ACTA PSYCHIAT SCAND, V88, P381, DOI 10.1111/j.1600-0447.1993.tb03477.x; DUNDEE JW, 1986, BRIT MED J, V293, P583, DOI 10.1136/bmj.293.6547.583; Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629; ELLIOTT CH, 1978, J CONSULT CLIN PSYCH, V46, P1330, DOI 10.1037/0022-006X.46.6.1330; ERNST E, 1995, BMJ-BRIT MED J, V311, P551, DOI 10.1136/bmj.311.7004.551; ESPIE CA, 1989, BEHAV RES THER, V27, P79, DOI 10.1016/0005-7967(89)90123-X; FAAS A, 1993, SPINE, V18, P1388; FORSTER EL, 1994, CHEST, V106, P1343, DOI 10.1378/chest.106.5.1343; FRANK E, 1990, ARCH GEN PSYCHIAT, V47, P1093; FRANKEL BL, 1978, PSYCHOSOM MED, V40, P276, DOI 10.1097/00006842-197806000-00002; Frega A., 1994, Clinical and Experimental Obstetrics and Gynecology, V21, P188; FUCHS CZ, 1977, J CONSULT CLIN PSYCH, V45, P206, DOI 10.1037/0022-006X.45.2.206; GODFREY S, 1973, J PSYCHOSOM RES, V17, P293, DOI 10.1016/0022-3999(73)90106-2; Goodenough B, 1997, PAIN, V72, P383, DOI 10.1016/S0304-3959(97)00062-6; GOTZSCHE PC, 1994, LANCET, V344, P925; GOTZSCHE PC, 1991, J CLIN EPIDEMIOL, V44, P613; GOTZSCHE PC, 1990, J CLIN EPIDEMIOL, V43, P1313; GRACELY RH, 1983, NATURE, V306, P264, DOI 10.1038/306264a0; GRECHO (Groupe de Recherches et d'Essais Cliniques en Homeopathie), 1989, PRESSE MED, V18, P59; GUGLIELMI RS, 1982, BIOFEEDBACK SELF-REG, V7, P99; HALL SM, 1974, J CONSULT CLIN PSYCH, V42, P781, DOI 10.1037/h0037575; HANSON RW, 1976, BEHAV THER, V7, P366, DOI 10.1016/S0005-7894(76)80065-2; HARGREAVES A, 1989, NURS RES, V38, P159; HARRISON RF, 1975, LANCET, V1, P605; HASHISH I, 1988, PAIN, V33, P303, DOI 10.1016/0304-3959(88)90289-8; HASHISH I, 1986, BRIT J RHEUMATOL, V25, P77; HAWKINS PJ, 1995, PSYCHO-ONCOLOGY, V4, P101, DOI 10.1002/pon.2960040203; Hayden FG, 1996, ANN INTERN MED, V125, P89, DOI 10.7326/0003-4819-125-2-199607150-00002; Hedges LV., 1985, STAT METHODS META AN, P76, DOI [10.1016/B978-0-08-057065-5.50010-5, DOI 10.1016/B978-0-08-057065-5.50010-5]; HEINZL S, 1981, GYNECOL OBSTET INVES, V12, P29, DOI 10.1159/000299565; HELMS JM, 1987, OBSTET GYNECOL, V69, P51; Hong C.Z., 1993, J MUSCULOSKELET PAIN, V1, P37, DOI [10.1300/J094v01n02_04, DOI 10.1300/J094V01N02_04]; Hrobjartsson A, 1996, EUR J CLIN PHARMACOL, V50, P345, DOI 10.1007/s002280050120; HROBJARTSSON A, 1999, COCHRANE LIB; HUTTON N, 1991, J PEDIATR-US, V118, P125, DOI 10.1016/S0022-3476(05)81865-7; HYMAN GJ, 1986, ADDICT BEHAV, V11, P355, DOI 10.1016/0306-4603(86)90014-6; Irvin JH, 1996, J PSYCHOSOM OBST GYN, V17, P202, DOI 10.3109/01674829609025684; JACOBS MA, 1971, PSYCHOSOM MED, V33, P545, DOI 10.1097/00006842-197111000-00007; JACOBSON NS, 1978, J CONSULT CLIN PSYCH, V46, P442, DOI 10.1037/0022-006X.46.3.442; Karunakaran S, 1997, METABOLISM, V46, P56, DOI 10.1016/S0026-0495(97)90319-X; KENDALL PC, 1979, J CONSULT CLIN PSYCH, V47, P49, DOI 10.1037/0022-006X.47.1.49; Kienle GS, 1997, J CLIN EPIDEMIOL, V50, P1311, DOI 10.1016/S0895-4356(97)00203-5; KILLEN JD, 1990, J CONSULT CLIN PSYCH, V58, P85, DOI 10.1037/0022-006X.58.1.85; KLERMAN GL, 1974, AM J PSYCHIAT, V131, P186, DOI 10.1176/ajp.131.2.186; LANDER J, 1993, PAIN, V52, P209, DOI 10.1016/0304-3959(93)90133-A; LASAGNA L, 1986, J ALLERGY CLIN IMMUN, V78, P161, DOI 10.1016/0091-6749(86)90008-4; LEVINE JD, 1984, NATURE, V312, P755, DOI 10.1038/312755a0; LICK J, 1975, J CONSULT CLIN PSYCH, V43, P557, DOI 10.1037/h0076894; LICK JR, 1977, J CONSULT CLIN PSYCH, V45, P153, DOI 10.1037/0022-006X.45.2.153; Linde K, 1998, LANCET, V351, P220; Linde K, 1997, LANCET, V350, P834, DOI 10.1016/S0140-6736(97)02293-9; Lindholm LH, 1996, J INTERN MED, V240, P13, DOI 10.1046/j.1365-2796.1996.492831000.x; LONGO DJ, 1988, J CONSULT CLIN PSYCH, V56, P61; LORR M, 1961, ARCH GEN PSYCHIAT, V4, P381; Macaluso AD, 1996, ANESTH ANALG, V82, P158, DOI 10.1097/00000539-199601000-00029; MALCOLM RE, 1980, PSYCHOPHARMACOLOGY, V70, P295, DOI 10.1007/BF00427889; MARKLAND D, 1993, BRIT J CLIN PSYCHOL, V32, P493, DOI 10.1111/j.2044-8260.1993.tb01085.x; MAY O, 1988, EUR RESPIR J, V1, P527; MCLACHLAN DRC, 1991, LANCET, V337, P1618; MCLACHLAN DRC, 1991, LANCET, V337, P1304, DOI 10.1016/0140-6736(91)92978-B; MCMILLAN CM, 1994, PHYSIOTHERAPY, V80, P5; Moffett JAK, 1996, PAIN, V67, P121, DOI 10.1016/0304-3959(96)03100-4; MORTON AR, 1993, ANN ALLERGY, V70, P295; MURPHY JK, 1982, BEHAV THER, V13, P681, DOI 10.1016/S0005-7894(82)80024-5; Najnigier B., 1997, ACTA ENDOSCOPICA POL, V7, P125; NANDI DN, 1976, BRIT J PSYCHIAT, V128, P523, DOI 10.1192/bjp.128.6.523; Nawrocki JD, 1997, BRIT J UROL, V79, P389, DOI 10.1046/j.1464-410X.1997.21515.x; NICASSIO P, 1974, J ABNORM PSYCHOL, V83, P253, DOI 10.1037/h0036729; NOCELLA J, 1982, Journal of Pediatric Psychology, V7, P175, DOI 10.1093/jpepsy/7.2.175; OBrien B, 1996, AM J OBSTET GYNECOL, V174, P708, DOI 10.1016/S0002-9378(96)70454-4; OH VMS, 1994, BRIT MED J, V309, P69, DOI 10.1136/bmj.309.6947.69; Parker JC, 1995, ARTHRITIS RHEUM, V38, P1807, DOI 10.1002/art.1780381214; PELHAM WE, 1992, J CONSULT CLIN PSYCH, V60, P282, DOI 10.1037/0022-006X.60.2.282; QUAYHAGEN MP, 1995, NURS RES, V44, P153; RABKIN JG, 1990, AM J PSYCHIAT, V147, P1622; Rawlinson MC, 1985, PLACEBO THEORY RES M, P403; READING AE, 1982, J CLIN PSYCHOL, V38, P504, DOI 10.1002/1097-4679(198207)38:3<504::AID-JCLP2270380307>3.0.CO;2-8; ROSEN GM, 1976, J CONSULT CLIN PSYCH, V44, P208, DOI 10.1037/0022-006X.44.2.208; ROSSI A, 1982, INT J CLIN PHARM TH, V20, P438; ROUGHAN PA, 1981, J SEX MARITAL THER, V7, P223, DOI 10.1080/00926238108405806; Rowbotham MC, 1996, PAIN, V65, P39, DOI 10.1016/0304-3959(95)00146-8; RYBARCZYK BD, 1990, GERONTOLOGIST, V30, P522, DOI 10.1093/geront/30.4.522; SANDERS GE, 1990, J MANIP PHYSIOL THER, V13, P391; SCHULZ KF, 1995, JAMA-J AM MED ASSOC, V273, P408, DOI 10.1001/jama.273.5.408; SEER P, 1980, Journal of Behavioral Medicine, V3, P59, DOI 10.1007/BF00844914; SENEDIAK C, 1985, BEHAV PSYCHOTHER, V13, P265, DOI 10.1017/S0141347300012027; SIPICH JF, 1974, J BEHAV THER EXP PSY, V5, P201, DOI 10.1016/0005-7916(74)90115-3; SPANOS NP, 1995, CONT HYPNOSIS, V12, P12; SPROTT H, 1993, AKTUEL RHEUMATOL, V18, P132, DOI 10.1055/s-2008-1047326; STABHOLZ A, 1991, Clinical Preventive Dentistry, V13, P9; STEWART JE, 1991, J CLIN PERIODONTOL, V18, P219, DOI 10.1111/j.1600-051X.1991.tb00418.x; STRANSKY M, 1989, SOUTHERN MED J, V82, P841, DOI 10.1097/00007611-198907000-00011; TAN SY, 1982, BEHAV RES THER, V20, P535, DOI 10.1016/0005-7967(82)90031-6; TAN SY, 1986, EPILEPSIA, V27, P225, DOI 10.1111/j.1528-1157.1986.tb03533.x; Tarrier N, 1998, BRIT MED J, V317, P303, DOI 10.1136/bmj.317.7154.303; THEROUX MC, 1993, PEDIATRICS, V91, P624; THOMAS KB, 1987, BRIT MED J, V294, P1200, DOI 10.1136/bmj.294.6581.1200; TREMEAU M L, 1992, Journal de Gynecologie Obstetrique et biologie de la Reproduction, V21, P375; TUOMILEHTO J, 1980, ACTA MED SCAND, V208, P45; TURNER RM, 1979, J CONSULT CLIN PSYCH, V47, P500, DOI 10.1037/0022-006X.47.3.500; TYLER DB, 1946, AM J PHYSIOL, V146, P458, DOI 10.1152/ajplegacy.1946.146.3.458; Vlaeyen JWS, 1996, J RHEUMATOL, V23, P1237; WALTON RE, 1993, J ENDODONT, V19, P466, DOI 10.1016/S0099-2399(06)80535-2; WATZL H, 1986, Z KLIN PSYCHOL-FORSC, V15, P333; WEINGAER.AH, 1971, J CONSULT CLIN PSYCH, V36, P422, DOI 10.1037/h0031134; WHITTAKER CB, 1963, BRIT J PSYCHIAT, V109, P422, DOI 10.1192/bjp.109.460.422; WILLIAMS JM, 1988, ADDICT BEHAV, V13, P205, DOI 10.1016/0306-4603(88)90014-7; WILSON A, 1980, J STUD ALCOHOL, V41, P429, DOI 10.15288/jsa.1980.41.429; WOJCIECHOWSKI FL, 1984, GEDRAG GEZOND, V12, P16; YATES RG, 1988, J MANIP PHYSIOL THER, V11, P484	137	1025	1058	0	70	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAY 24	2001	344	21					1594	1602		10.1056/NEJM200105243442106	http://dx.doi.org/10.1056/NEJM200105243442106			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	434RM	11372012	Bronze			2023-01-03	WOS:000168829700006
J	Kelly, C; Newby, DE; Boon, NA; Douglas, NJ				Kelly, C; Newby, DE; Boon, NA; Douglas, NJ			Support ventilation versus conventional oxygen	LANCET			English	Letter							POSITIVE AIRWAY PRESSURE; CARDIOGENIC PULMONARY-EDEMA; FACE MASK		Univ Edinburgh, Royal Infirm, Dept Resp Med, Edinburgh EH3 9YW, Midlothian, Scotland; Univ Edinburgh, Royal Infirm, Dept Cardiol, Edinburgh EH3 9YW, Midlothian, Scotland	Royal Infirmary of Edinburgh; University of Edinburgh; Royal Infirmary of Edinburgh; University of Edinburgh	Kelly, C (corresponding author), Univ Edinburgh, Royal Infirm, Dept Resp Med, Lauriston Pl, Edinburgh EH3 9YW, Midlothian, Scotland.		Newby, David Ernest/AAB-1364-2019; Douglas, Neil/B-1491-2013					BERSTEN AD, 1991, NEW ENGL J MED, V325, P1825, DOI 10.1056/NEJM199112263252601; LIN M, 1995, CHEST, V107, P1379, DOI 10.1378/chest.107.5.1379; Masip J, 2000, LANCET, V356, P2126, DOI 10.1016/S0140-6736(00)03492-9; Mehta S, 1997, CRIT CARE MED, V25, P620, DOI 10.1097/00003246-199704000-00011; RASANEN J, 1985, AM J CARDIOL, V55, P296, DOI 10.1016/0002-9149(85)90364-9	5	8	8	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	APR 7	2001	357	9262					1126	1126		10.1016/S0140-6736(00)04272-0	http://dx.doi.org/10.1016/S0140-6736(00)04272-0			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	420GA	11303601				2023-01-03	WOS:000167996200039
J	Bulford, R				Bulford, R			Personal view - Children have rights too	BRITISH MEDICAL JOURNAL			English	Editorial Material											Bulford, R (corresponding author), ARTICLE 12,8 WAKLEY ST,LONDON EC1V 7QE,ENGLAND.								0	1	1	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 10	1997	314	7091					1421	1422						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WZ169	11644928				2023-01-03	WOS:A1997WZ16900077
J	Zhao, HX; Kinnunen, PKJ				Zhao, HX; Kinnunen, PKJ			Binding of the antimicrobial peptide temporin L to liposomes assessed by Trp fluorescence	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRYPTOPHAN FLUORESCENCE; MODEL MEMBRANES; MAGAININ 2; DEPTH; PROTEIN; PENETRATION; ORIENTATION; ANALOGS; CHARGE; PORES	The structure and membrane topology of the antimicrobial peptide temporin L (FVQWFSKFLGRILNH(2)) were studied using liposomes as model bilayers. Circular dichroic spectra revealed temporin L to adopt an alpha-helical conformation when bound to liposomes. Binding of temporin L to liposomes induced significant blue shifts of the emission spectra of the single Trp residue (Trp(4)) and also changed its quantum yield. The observed changes in the characteristics of the Trp(4) fluorescence are in keeping with the insertion of this residue into the hydrophobic region of the liposomal bilayers. Access of the aqueous quencher acrylamide to Trp(4) decreased in the sequence 1-stearoyl-2-oleoyl-sn-glycero-3-phosphocholine (SOPC)/cholesterol (X-chol = 0.1) > SOPC > SOPC/1-palmitoyl-2-oleoyl-sn-glycero-3-phosphoglycerol (POPG, X-POPG = 0.1) > SOPC/POPG (X-POPG = 0.2) approximate to SOPC/POPG (X-POPG = 0.4), where X represents molar fraction of the indicated lipid. Whereas quenching of Trp(4) by brominated phospholipids was significant in SOPC liposomes, the quenching efficiency was enhanced when the vesicles contained POPG. The depth of insertion of Trp(4) into lipid bilayers was calculated by both the parallax method and distribution analysis and revealed this residue to reside at an average distance of d approximate to 8.0 +/- 0.5 Angstrom from the center of both SOPC and SOPC/POPG bilayers. However, in the presence of cholesterol, d was increased to 9.5 +/- 0.5 Angstrom, thus revealing Trp(4) to become accommodated more superficially in the bilayer. The above data suggest the presence of two populations of temporin L in SOPC- and POPG-containing membranes with parallel and perpendicular orientation with respect to the plane of the membrane surface.	Univ Helsinki, Helsinki Biophys & Biomembrane Grp, Inst Biomed, FIN-00014 Helsinki, Finland	University of Helsinki	Kinnunen, PKJ (corresponding author), Univ Helsinki, Helsinki Biophys & Biomembrane Grp, Inst Biomed, POB 63 Haartmaninkatu 8, FIN-00014 Helsinki, Finland.	Paavo.Kinnunen@Helsinki.fi		Zhao, Hongxia/0000-0002-1606-5621				ARGIOLAS A, 1984, J BIOL CHEM, V259, P106; Bechinger B, 1999, BBA-BIOMEMBRANES, V1462, P157, DOI 10.1016/S0005-2736(99)00205-9; Bernstein LS, 2000, J BIOL CHEM, V275, P18520, DOI 10.1074/jbc.M000618200; BOLEN EJ, 1990, BIOCHEMISTRY-US, V29, P9638, DOI 10.1021/bi00493a019; Breukink E, 1998, BIOCHEMISTRY-US, V37, P8153, DOI 10.1021/bi972797l; CHATTOPADHYAY A, 1987, BIOCHEMISTRY-US, V26, P39, DOI 10.1021/bi00375a006; CULLIS PR, 1978, BIOCHIM BIOPHYS ACTA, V513, P21, DOI 10.1016/0005-2736(78)90108-6; DEKROON AIP, 1990, BIOCHEMISTRY-US, V29, P8229, DOI 10.1021/bi00488a006; Dougherty DA, 1996, SCIENCE, V271, P163, DOI 10.1126/science.271.5246.163; EFTINK MR, 1976, J PHYS CHEM-US, V80, P486, DOI 10.1021/j100546a014; GAZIT E, 1995, BIOCHEMISTRY-US, V34, P11479, DOI 10.1021/bi00036a021; GOMES AV, 1993, BIOCHEMISTRY-US, V32, P5365, DOI 10.1021/bi00071a011; Hong J, 1999, BIOCHEMISTRY-US, V38, P16963, DOI 10.1021/bi991850y; Ladokhin A S, 1993, J Fluoresc, V3, P195, DOI 10.1007/BF00862742; Ladokhin AS, 1999, BIOPHYS J, V76, P946, DOI 10.1016/S0006-3495(99)77258-9; Ladokhin AS, 1997, METHOD ENZYMOL, V278, P462; Langosch D, 1998, PROTEINS, V31, P150, DOI 10.1002/(SICI)1097-0134(19980501)31:2<150::AID-PROT5>3.0.CO;2-Q; Ludtke SJ, 1996, BIOCHEMISTRY-US, V35, P13723, DOI 10.1021/bi9620621; Mangoni ML, 2000, EUR J BIOCHEM, V267, P1447, DOI 10.1046/j.1432-1327.2000.01143.x; Matsuzaki K, 1996, BIOCHEMISTRY-US, V35, P11361, DOI 10.1021/bi960016v; MATSUZAKI K, 1993, BIOCHEMISTRY-US, V32, P11704, DOI 10.1021/bi00094a029; Matsuzaki K, 1997, BBA-BIOMEMBRANES, V1327, P119, DOI 10.1016/S0005-2736(97)00051-5; Matsuzaki K, 1998, BIOCHEMISTRY-US, V37, P11856, DOI 10.1021/bi980539y; MATSUZAKI K, 1991, BIOCHIM BIOPHYS ACTA, V1063, P162, DOI 10.1016/0005-2736(91)90366-G; MATSUZAKI K, 1995, BIOCHEMISTRY-US, V34, P3423, DOI 10.1021/bi00010a034; Matsuzaki K, 1999, BBA-BIOMEMBRANES, V1462, P1, DOI 10.1016/S0005-2736(99)00197-2; MCELHANEY RN, 1999, BIOCHIM BIOPHYS ACTA, V1462, P1; MCINTOSH TJ, 1987, BIOCHEMISTRY-US, V26, P1783, DOI 10.1021/bi00380a042; OPDENKAMP JAF, 1979, ANNU REV BIOCHEM, V48, P47, DOI 10.1146/annurev.bi.48.070179.000403; Oren Z, 1998, BIOPOLYMERS, V47, P451; POUNY Y, 1992, BIOCHEMISTRY-US, V31, P12416, DOI 10.1021/bi00164a017; Shai Y, 1999, BBA-BIOMEMBRANES, V1462, P55, DOI 10.1016/S0005-2736(99)00200-X; Simmaco M, 1996, EUR J BIOCHEM, V242, P788, DOI 10.1111/j.1432-1033.1996.0788r.x; Sitaram N, 1999, BBA-BIOMEMBRANES, V1462, P29, DOI 10.1016/S0005-2736(99)00199-6; VANGINKEL G, 1989, BIOCHIMIE, V71, P23, DOI 10.1016/0300-9084(89)90127-2; WADE D, 1990, P NATL ACAD SCI USA, V87, P4761, DOI 10.1073/pnas.87.12.4761; White SH, 2001, J BIOL CHEM, V276, P32395, DOI 10.1074/jbc.R100008200; White SH, 1998, BBA-REV BIOMEMBRANES, V1376, P339, DOI 10.1016/S0304-4157(98)00021-5; Yau WM, 1998, BIOCHEMISTRY-US, V37, P14713, DOI 10.1021/bi980809c; Zhang LJ, 2000, BIOCHEMISTRY-US, V39, P14504, DOI 10.1021/bi0011173; Zhao HX, 2002, BIOCHEMISTRY-US, V41, P4425, DOI 10.1021/bi011929e; Zhao HX, 2001, BIOPHYS J, V81, P2979, DOI 10.1016/S0006-3495(01)75938-3	42	86	88	1	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 12	2002	277	28					25170	25177		10.1074/jbc.M203186200	http://dx.doi.org/10.1074/jbc.M203186200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	571YP	11991956	hybrid			2023-01-03	WOS:000176747000043
J	Horrobin, DF				Horrobin, DF			Effective clinical innovation: an ethical imperative	LANCET			English	Article									Laxdale, Stirling FK7 9QL, Scotland		Horrobin, DF (corresponding author), Laxdale, Pk House,Laurelhill Business Pk,Polmaise Rd, Stirling FK7 9QL, Scotland.								0	26	26	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAY 25	2002	359	9320					1857	1858		10.1016/S0140-6736(02)08707-X	http://dx.doi.org/10.1016/S0140-6736(02)08707-X			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	555CK	12044395				2023-01-03	WOS:000175775500028
J	Lo, B; Dornbrand, L; Wolf, LE; Groman, M				Lo, B; Dornbrand, L; Wolf, LE; Groman, M			The Wendland case - Withdrawing life support from incompetent patients who are not terminally ill.	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							ADVANCE DIRECTIVES; CARE; PERSPECTIVE; PREFERENCES		Univ Calif San Francisco, San Francisco, CA 94143 USA	University of California System; University of California San Francisco	Lo, B (corresponding author), Univ Calif San Francisco, San Francisco, CA 94143 USA.			Wolf, Leslie/0000-0002-4660-8383	NIMH NIH HHS [MH42459] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTH [P50MH042459] Funding Source: NIH RePORTER	NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		Alpers A, 1999, J LAW MED ETHICS, V27, P74, DOI 10.1111/j.1748-720X.1999.tb01438.x; ANNAS GJ, 1994, NEW ENGL J MED, V330, P1542, DOI 10.1056/NEJM199405263302120; Beauchamp TL, 1994, PRINCIPLES BIOMEDICA, V4th; BLENDON RJ, 1992, JAMA-J AM MED ASSOC, V267, P2658, DOI 10.1001/jama.267.19.2658; Brown JB, 1999, J GEN INTERN MED, V14, P21, DOI 10.1046/j.1525-1497.1999.00276.x; CHIANG H, 2001, SAN FRANCISCO C 0810, pA1; Christakis NA, 2000, BRIT MED J, V320, P469, DOI 10.1136/bmj.320.7233.469; DOLAN M, 2001, LOS ANGELES TIM 0718, pB1; DOLAN M, 2001, LOS ANGELES TIM 0810, pA1; Gordon NP, 1999, ARCH INTERN MED, V159, P701, DOI 10.1001/archinte.159.7.701; Halevy A, 1996, JAMA-J AM MED ASSOC, V276, P571, DOI 10.1001/jama.276.7.571; KNAUS WA, 1995, JAMA-J AM MED ASSOC, V274, P1591, DOI 10.1001/jama.1995.03530200027032; LO B, 2000, RESOLVING ETHICAL DI; Lynn J, 1997, JAMA-J AM MED ASSOC, V277, P1633, DOI 10.1001/jama.277.20.1633; MCKEE M, 2001, AM LAWYER MEDIA 0810, P1; Meier DE, 1996, ARCH INTERN MED, V156, P1227, DOI 10.1001/archinte.156.11.1227; MEISEL A, 1995, RIGHT DIE; MENIKOFF JA, 1992, NEW ENGL J MED, V327, P1165, DOI 10.1056/NEJM199210153271612; *PC STUD ETH PROBL, 1983, DEC FOR LIF SUST TRE; Pellegrino E., 1988, PATIENTS GOOD RESTOR; SEHGAL A, 1992, JAMA-J AM MED ASSOC, V267, P59, DOI 10.1001/jama.267.1.59; Singer PA, 1998, ARCH INTERN MED, V158, P879, DOI 10.1001/archinte.158.8.879; STEINBROOK R, 1990, LOS ANGELES TIM 1227, pA17; Weeks JC, 1998, JAMA-J AM MED ASSOC, V279, P1709, DOI 10.1001/jama.279.21.1709; Weeks JC, 2000, JAMA-J AM MED ASSOC, V283, P203; 1995, JAMA-J AM MED ASSOC, V274, P1591, DOI DOI 10.1001/JAMA.1995.03530200027032	26	22	22	0	4	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAY 9	2002	346	19					1489	1493		10.1056/NEJM200205093461912	http://dx.doi.org/10.1056/NEJM200205093461912			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	549FE	12000822				2023-01-03	WOS:000175433200011
J	Maughan, TS; James, RD; Kerr, DJ; Ledermann, JA; McArdle, C; Seymour, MT; Cohen, D; Hopwood, P; Johnston, C; Stephens, RJ				Maughan, TS; James, RD; Kerr, DJ; Ledermann, JA; McArdle, C; Seymour, MT; Cohen, D; Hopwood, P; Johnston, C; Stephens, RJ		British MRC Colorectal Canc Work	Comparison of survival, palliation, and quality of life with three chemotherapy regimens in metastatic colorectal cancer: a multicentre randomised trial	LANCET			English	Article							HIGH-DOSE LEUCOVORIN; CONTINUOUS-INFUSION; CLINICAL-TRIALS; FLUOROURACIL; BOLUS; ONCOLOGY	Background This randomised trial compared three chemotherapy regimens in the first-line treatment of advanced colorectal cancer, in terms of their effect on overall and progression-free survival; other endpoints included toxicity, symptom palliation, and quality of life. Methods 905 patients were randomly assigned the de Gramont regimen (n=303; folinic acid 200 mg/m(2), fluorouracil bolus 400 mg/m(2), and infusion 600 mg/m(2) on days I and 2, repeated every 14 days), the Lokich regimen (n=301; protracted venous infusion of fluorouracil 300 mg/m(2) daily), or raltitrexed (n=301; 3 mg/m(2) intravenously every 21 days). Analyses were by intention to treat. Findings Median follow-up of survivors was 67 weeks. For the de Gramont, Lokich, and raltitrexed groups, respectively, median survival was 294, 302, and 266 days. The hazard ratios for overall survival were 0.88 (95% Cl 0.70-1.12, p=0.17) for de Gramont versus Lokich, and 0.99 (0.79-1.25, p=0.94) for de Gramont versus raltitrexed. An increase in treatment-related deaths was seen on raltitrexed (de Gramont one, Lolkich two, raltitrexed 18) due to combined gastrointestinal and haematological toxicity. Patients' assessment of quality of life showed that raltitrexed was inferior to the fluorouracil-based regimens, especially in terms of palliation and functioning. Interpretation The deGramont and Lokich regimens were similar in terms of survival, quality of life, and response rates. The Lokich regimen was associated with more central line complications and hand-foot syndrome. Raltitrexed showed similar response rates and overall survival to the de Gramont regimen and was easier to administer, but resulted in greater toxicity and inferior quality of life.	MRC, Clin Trials Unit, Canc Div, London NW1 2DA, England; Velindre Hosp, Dept Oncol, Cardiff, S Glam, Wales; Maidstone Hlth Author, Kent Canc Ctr, Maidstone, Kent, England; Radcliffe Infirm, Dept Clin Pharmacol, Oxford OX2 6HE, England; UCL Hosp, Dept Oncol, London, England; Univ Glasgow, Royal Infirm, Dept Surg, Glasgow G31 2ER, Lanark, Scotland; Cookridge Hosp, Imperial Canc Res Fund, Ctr Clin, Leeds LS16 6QB, W Yorkshire, England; Univ Glamorgan, Sch Business, Pontypridd CF37 1DL, M Glam, Wales; Christie Hosp, Manchester, Lancs, England	Medical Research Council Clinical Trials Unit; Velindre Hospital; Radcliffe Infirmary; University College London Hospitals NHS Foundation Trust; University of London; University College London; Royal Infirmary of Edinburgh; University of Glasgow; Cookridge Hospital; University of South Wales; Christie NHS Foundation Trust; Christie Hospital	Stephens, RJ (corresponding author), MRC, Clin Trials Unit, Canc Div, London NW1 2DA, England.		Maughan, Timothy/D-5032-2011	Seymour, Matthew/0000-0002-2441-9629				AARONSON NK, 1993, J NATL CANCER I, V85, P365, DOI 10.1093/jnci/85.5.365; *CANC RES CAMP, 1993, CANC LARG BOW UK; CLARKE SJ, 1994, ANN ONCOL, V5, P240; Cocconi G, 1998, J CLIN ONCOL, V16, P2943, DOI 10.1200/JCO.1998.16.9.2943; Cunningham D, 1996, ANN ONCOL, V7, P961, DOI 10.1093/oxfordjournals.annonc.a010800; Cunningham D, 1998, LANCET, V352, P1413, DOI 10.1016/S0140-6736(98)02309-5; DEGRAMONT A, 1988, EUR J CANCER CLIN ON, V24, P1499, DOI 10.1016/0277-5379(88)90341-0; deGramont A, 1997, EUR J CANCER, V33, P214, DOI 10.1016/S0959-8049(96)00370-X; deGramont A, 1997, J CLIN ONCOL, V15, P808, DOI 10.1200/JCO.1997.15.2.808; Farrugia DC, 2000, CLIN CANCER RES, V6, P3646; FAYERS P, 1995, EORTCQLQC30 SCORING; FLEMING TR, 1990, J ACQ IMMUN DEF SYND, V3, pS82; HEIDELBERGER C, 1957, NATURE, V179, P663, DOI 10.1038/179663a0; HOPWOOD P, 1994, QUAL LIFE RES, V3, P339, DOI 10.1007/BF00451726; JACKMAN AL, 1991, CANCER RES, V51, P5579; Judson I, 1998, BRIT J CANCER, V78, P1188, DOI 10.1038/bjc.1998.652; KELLER OR, 2001, P AN M AM SOC CLIN, V20, P141; Levy E, 1998, J CLIN ONCOL, V16, P3537, DOI 10.1200/JCO.1998.16.11.3537; LOKICH JJ, 1989, J CLIN ONCOL, V7, P425, DOI 10.1200/JCO.1989.7.4.425; *NHS EX, 1997, IMPR OUTC COL CANC R, P98; Parkin DM, 1999, INT J CANCER, V80, P827, DOI 10.1002/(SICI)1097-0215(19990315)80:6&lt;827::AID-IJC6&gt;3.0.CO;2-P; Pazdur R, 1997, P AN M AM SOC CLIN, V16, P801; PIEDBOIS P, 1992, J CLIN ONCOL, V10, P896; POON MA, 1991, J CLIN ONCOL, V9, P1967, DOI 10.1200/JCO.1991.9.11.1967; Seymour MT, 1998, ANN ONCOL, V9, P47; Seymour MT, 1996, J CLIN ONCOL, V14, P2280, DOI 10.1200/JCO.1996.14.8.2280; Simmonds P C, 2000, BMJ, V321, P531; SOBRERO A, 1999, P AM SOC CLIN ONCOL, V18, P915; SORENSEN JM, 1994, ANN ONCOL, V5, P132; Stephens RJ, 1997, QUAL LIFE RES, V6, P225; Stephens RJ, 1999, BRIT J CANCER, V79, P538, DOI 10.1038/sj.bjc.6690085; THIRION P, 1999, P AM SOC CLIN ONCOL, V18, P912; VINCENT M, 1999, P AM SOC CLIN ONCOL, V18, P930; WHO, 1979, WHO HDB REP RES CANC; Wolmark N, 1998, J CLIN ONCOL, V16, P301; Zalcberg J, 1997, ANTI-CANCER DRUG, V8, pS17, DOI 10.1097/00001813-199708002-00004; ZIGMOND AS, 1983, ACTA PSYCHIAT SCAND, V67, P361, DOI 10.1111/j.1600-0447.1983.tb09716.x	37	122	128	0	5	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAY 4	2002	359	9317					1555	1563		10.1016/S0140-6736(02)08514-8	http://dx.doi.org/10.1016/S0140-6736(02)08514-8			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	549RN	12047964				2023-01-03	WOS:000175460700008
J	Ely, JW; Osheroff, JA; Ebell, MH; Chambliss, ML; Vinson, DC; Stevermer, JJ; Pifer, EA				Ely, JW; Osheroff, JA; Ebell, MH; Chambliss, ML; Vinson, DC; Stevermer, JJ; Pifer, EA			Obstacles to answering doctors' questions about patient care with evidence: qualitative study	BRITISH MEDICAL JOURNAL			English	Article							CLINICAL QUESTIONS; INFORMATION NEEDS; PHYSICIANS; PRACTITIONERS; LANSOPRAZOLE; ESOPHAGITIS; MULTICENTER; OMEPRAZOLE	Objective To describe the obstacles encountered when attempting to answer doctors' questions with evidence. Design Qualitative study. Setting General practices in Iowa. Participants 9 academic generalist doctors, 14 family doctors, and 2 medical librarians. Main outcome measure A taxonomy of obstacles encountered while searching for evidence based answers to doctors' questions. Results 59 obstacles were encountered and organised according to the five steps in asking and answering questions: recognise a gap in knowledge, formulate a question, search for relevant information, formulate an answer, and use the answer to direct patient care. Six obstacles were considered particularly salient by the investigators and practising doctors: the excessive time required to find information; difficulty modifying the original question, which was often vague and open to interpretation; difficulty selecting an optimal strategy to search for information; failure of a seemingly appropriate resource to cover die topic; uncertainty about how to know when all the relevant evidence has been found so that the search can stop; and inadequate synthesis of multiple bits of evidence into a clinically useful statement. Conclusions Many obstacles are encountered when asking and answering questions about how to care for patients. Addressing these obstacles could lead to better patient care by improving clinically oriented information resources.	Univ Iowa, Coll Med, Dept Family Med, Iowa City, IA 52242 USA; Praxis Press, New York, NY 10010 USA; Michigan State Univ, Dept Family Practice, E Lansing, MI 48824 USA; Moses Cone Hosp Family Med Residency, Greensboro, NC 27401 USA; Univ Missouri, Sch Med, Columbia, MO 65212 USA; Univ Penn, Div Gen Internal Med, Philadelphia, PA 19104 USA	University of Iowa; Michigan State University; Moses Cone Memorial Hospital; University of Missouri System; University of Missouri Columbia; University of Pennsylvania	Ely, JW (corresponding author), Univ Iowa, Coll Med, Dept Family Med, Iowa City, IA 52242 USA.		Greiver, Michelle/N-8764-2015	Greiver, Michelle/0000-0001-8957-0285	NLM NIH HHS [R01 LM007179, 1R01LM07179-01] Funding Source: Medline; NATIONAL LIBRARY OF MEDICINE [R01LM007179] Funding Source: NIH RePORTER	NLM NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Library of Medicine (NLM)); NATIONAL LIBRARY OF MEDICINE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Library of Medicine (NLM))		Armstrong E C, 1999, WMJ, V98, P25; Bergus GR, 2000, ARCH FAM MED, V9, P541, DOI 10.1001/archfami.9.6.541; Chambliss ML, 1996, J FAM PRACTICE, V43, P140; COVELL DG, 1985, ANN INTERN MED, V103, P596, DOI 10.7326/0003-4819-103-4-596; Crabtree BF., 1999, DOING QUALITATIVE RE, V2nd ed; Davidoff F, 2000, ANN INTERN MED, V132, P996, DOI 10.7326/0003-4819-132-12-200006200-00012; Davison GC, 1997, J CONSULT CLIN PSYCH, V65, P950, DOI 10.1037/0022-006X.65.6.950; Ebell M, 1999, J Am Board Fam Pract, V12, P225; Ely JW, 2000, BRIT MED J, V321, P429, DOI 10.1136/bmj.321.7258.429; Ely JW, 1999, BRIT MED J, V319, P358, DOI 10.1136/bmj.319.7206.358; Ericsson K.A., 1993, PROTOCOL ANAL VERBAL; Feinstein AR, 1997, AM J MED, V103, P529, DOI 10.1016/S0002-9343(97)00244-1; Fozi K, 2000, Med J Malaysia, V55, P486; Freeman AC, 2001, BRIT MED J, V323, P1100, DOI 10.1136/bmj.323.7321.1100; GORMAN PN, 1995, J AM SOC INFORM SCI, V46, P729, DOI 10.1002/(SICI)1097-4571(199512)46:10<729::AID-ASI3>3.0.CO;2-2; GORMAN PN, 1995, MED DECIS MAKING, V15, P113, DOI 10.1177/0272989X9501500203; Guyatt GH, 2000, BRIT MED J, V320, P954, DOI 10.1136/bmj.320.7240.954; HATLEBAKK JG, 1993, SCAND J GASTROENTERO, V28, P224, DOI 10.3109/00365529309096076; Henderson AR, 1997, EVIDENCE BASED MED P; Hersh WR, 1998, JAMA-J AM MED ASSOC, V280, P1307, DOI 10.1001/jama.280.15.1307; OSHEROFF JA, 1993, B MED LIBR ASSOC, V81, P11; OSHEROFF JA, 1991, ANN INTERN MED, V114, P576, DOI 10.7326/0003-4819-114-7-576; Richter JE, 2000, ARCH INTERN MED, V160, P1803, DOI 10.1001/archinte.160.12.1803; SONTAG SJ, 1992, GASTROENTEROLOGY, V102, P109, DOI 10.1016/0016-5085(92)91790-B; WILLIAMSON JW, 1989, ANN INTERN MED, V110, P151, DOI 10.7326/0003-4819-110-2-151; WILSON SR, 1989, UNPUB USE CRITICAL I	26	236	245	0	13	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	MAR 23	2002	324	7339					710	713		10.1136/bmj.324.7339.710	http://dx.doi.org/10.1136/bmj.324.7339.710			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	535ML	11909789	Green Published, Bronze			2023-01-03	WOS:000174648200020
J	Bernard, SA; Gray, TW; Buist, MD; Jones, BM; Silvester, W; Gutteridge, G; Smith, K				Bernard, SA; Gray, TW; Buist, MD; Jones, BM; Silvester, W; Gutteridge, G; Smith, K			Treatment of comatose survivors of out-of-hospital cardiac arrest with induced hypothermia	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							MILD RESUSCITATIVE HYPOTHERMIA; MODERATE HYPOTHERMIA; BRAIN; ISCHEMIA; TRIAL; DOGS; REPERFUSION; FEASIBILITY; RECOVERY; INJURY	Background: Cardiac arrest outside the hospital is common and has a poor outcome. Studies in laboratory animals suggest that hypothermia induced shortly after the restoration of spontaneous circulation may improve neurologic outcome, but there have been no conclusive studies in humans. In a randomized, controlled trial, we compared the effects of moderate hypothermia and normothermia in patients who remained unconscious after resuscitation from out-of-hospital cardiac arrest. Methods: The study subjects were 77 patients who were randomly assigned to treatment with hypothermia (with the core body temperature reduced to 33degreesC within 2 hours after the return of spontaneous circulation and maintained at that temperature for 12 hours) or normothermia. The primary outcome measure was survival to hospital discharge with sufficiently good neurologic function to be discharged to home or to a rehabilitation facility. Results: The demographic characteristics of the patients were similar in the hypothermia and normothermia groups. Twenty-one of the 43 patients treated with hypothermia (49 percent) survived and had a good outcome -- that is, they were discharged home or to a rehabilitation facility -- as compared with 9 of the 34 treated with normothermia (26 percent, P=0.046). After adjustment for base-line differences in age and time from collapse to the return of spontaneous circulation, the odds ratio for a good outcome with hypothermia as compared with normothermia was 5.25 (95 percent confidence interval, 1.47 to 18.76; P=0.011). Hypothermia was associated with a lower cardiac index, higher systemic vascular resistance, and hyperglycemia. There was no difference in the frequency of adverse events. Conclusions: Our preliminary observations suggest that treatment with moderate hypothermia appears to improve outcomes in patients with coma after resuscitation from out-of-hospital cardiac arrest. Copyright (C) 2002 Massachusetts Medical Society.	Dandenong Hosp, Intens Care Unit, Dandenong, Vic 3175, Australia; Knox Hosp, Intens Care Unit, Melbourne, Vic, Australia; Monash Med Ctr, Dept Emergency Med, Clayton, Vic 3168, Australia; Austin & Repatriat Med Ctr, Dept Intens Care, Heidelberg, Vic, Australia; Monash Univ, Dept Epidemiol & Prevent Med, St Kilda, Australia	Monash University; Austin Research Institute; Florey Institute of Neuroscience & Mental Health; Monash University	Bernard, SA (corresponding author), Dandenong Hosp, Intens Care Unit, David St, Dandenong, Vic 3175, Australia.		Hachimi-Idrissi, Said/I-6422-2018	Hachimi-Idrissi, Said/0000-0002-8455-1410; Smith, Karen/0000-0002-9057-0685; Fischer, Matthias/0000-0003-4728-8497; Kochanek, Patrick/0000-0002-2627-913X				ABRAMSON NS, 1991, NEW ENGL J MED, V324, P1225; ABRAMSON NS, 1986, NEW ENGL J MED, V314, P397; ARCHER FL, 1993, MED J AUSTRALIA, V159, P616; BENSON D W, 1959, Anesth Analg, V38, P423; Bernard S, 1996, ANAESTH INTENS CARE, V24, P382, DOI 10.1177/0310057X9602400315; Bernard S., 1998, EMERG MED AUSTRALAS, V10, P25; Bernard SA, 1997, ANN EMERG MED, V30, P146, DOI 10.1016/S0196-0644(97)70133-1; Bernard SA, 1999, CRIT CARE, V3, P167, DOI 10.1186/cc371; BOHN DJ, 1986, CRIT CARE MED, V14, P529, DOI 10.1097/00003246-198606000-00002; BUSTO R, 1989, STROKE, V20, P904, DOI 10.1161/01.STR.20.7.904; CLEMMER TP, 1992, CRIT CARE MED, V20, P1395, DOI 10.1097/00003246-199210000-00006; Clifton GL, 2001, NEW ENGL J MED, V344, P556, DOI 10.1056/NEJM200102223440803; Colbourne F, 1999, J CEREBR BLOOD F MET, V19, P742, DOI 10.1097/00004647-199907000-00003; CURRY DL, 1970, ENDOCRINOLOGY, V87, P750, DOI 10.1210/endo-87-4-750; EDGREN E, 1994, LANCET, V343, P1055, DOI 10.1016/S0140-6736(94)90179-1; EISENBERG MS, 1990, ANN EMERG MED, V19, P179, DOI 10.1016/S0196-0644(05)81805-0; Gentilello LM, 1997, ANN SURG, V226, P439, DOI 10.1097/00000658-199710000-00005; Hicks SD, 2000, J CEREBR BLOOD F MET, V20, P520, DOI 10.1097/00004647-200003000-00011; Hsu JWY, 1996, ANN EMERG MED, V28, P597, DOI 10.1016/S0196-0644(96)70080-X; ILLIEVICH UM, 1994, ANESTH ANALG, V78, P905; JASTREMSKI M, 1989, JAMA-J AM MED ASSOC, V262, P3427, DOI 10.1001/jama.262.24.3427; Kammersgaard LP, 2000, STROKE, V31, P2251, DOI 10.1161/01.STR.31.9.2251; KUBOYAMA K, 1993, CRIT CARE MED, V21, P1348, DOI 10.1097/00003246-199309000-00019; Marion DW, 1997, NEW ENGL J MED, V336, P540, DOI 10.1056/NEJM199702203360803; MORIMOTO Y, 1993, CRIT CARE MED, V21, P104, DOI 10.1097/00003246-199301000-00020; MYERBURG RJ, 1997, HEART DIS TXB CARDIO, V1, P742; OKU K, 1994, RESUSCITATION, V27, P141, DOI 10.1016/0300-9572(94)90007-8; ROINE RO, 1990, JAMA-J AM MED ASSOC, V264, P3171; Schwab S, 1998, STROKE, V29, P2461, DOI 10.1161/01.STR.29.12.2461; STERZ F, 1991, CRIT CARE MED, V19, P379, DOI 10.1097/00003246-199103000-00017; WEINRAUCH V, 1992, STROKE, V23, P1454, DOI 10.1161/01.STR.23.10.1454; White BC, 1996, ANN EMERG MED, V27, P588, DOI 10.1016/S0196-0644(96)70161-0; WILLIAMS GR, 1958, ANN SURG, V148, P462, DOI 10.1097/00000658-195809000-00014; Yanagawa Y, 1998, RESUSCITATION, V39, P61, DOI 10.1016/S0300-9572(98)00118-X; Zeiner A, 2000, STROKE, V31, P86, DOI 10.1161/01.STR.31.1.86; 1999, STATA STAT SOFTWARE	36	3766	3969	6	143	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	FEB 21	2002	346	8					557	563		10.1056/NEJMoa003289	http://dx.doi.org/10.1056/NEJMoa003289			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	522ZK	11856794				2023-01-03	WOS:000173926700003
J	Carr-Hill, RA; Jamison, JQ; O'Reilly, D; Stevenson, MR; Reid, J; Merriman, B				Carr-Hill, RA; Jamison, JQ; O'Reilly, D; Stevenson, MR; Reid, J; Merriman, B			Risk adjustment for hospital use using social security data: cross sectional small area analysis	BRITISH MEDICAL JOURNAL			English	Article							ALLOCATING RESOURCES; HEALTH AUTHORITIES; INPATIENT SERVICES; CARE; COMPETITION; REFORMS	Objectives To identify demographic and socioeconomic determinants of need for acute hospital treatment at small area level. To establish whether there is a relation between poverty and use of inpatient services. To devise a risk adjustment formula for distributing public funds for hospital services using, as far as possible, variables that can be updated between censuses. Design Cross sectional analysis. Spatial interactive modelling was used to quantify the proximity of the population to health service facilities. Two stage weighted least squares regression was used to model use against supply of hospital and community services and a wide range of potential needs drivers including health, socioeconomic census variables, uptake of income support and family credit, and religious denomination. Setting Northern Ireland. Main outcome measure Intensity of use of inpatient services. Results After endogeneity of supply and use was taken into account, a statistical model was produced that predicted use based on five variables: income support, family credit, elderly people living alone, all ages standardised mortality ratio, and low birth weight. The main effect of the formula produced is to move resources from urban to rural areas. Conclusions This work has produced a population risk adjustment formula for acute hospital treatment in which four of the five variables can be updated annually rather than relying on census derived data. Inclusion of the social security data makes a substantial difference to the model and to the results produced by the formula.	Univ York, Ctr Hlth Econ, York YO10 5DD, N Yorkshire, England; Queens Univ Belfast, Inst Clin Sci, Hlth & Social Care Res Unit, Belfast BT12 6BJ, Antrim, North Ireland; Queens Univ Belfast, No Ireland Canc Registry, Belfast, Antrim, North Ireland	University of York - UK; Queens University Belfast; Queens University Belfast	Jamison, JQ (corresponding author), Queens Univ Belfast, Ctr Social Res, Belfast BT7 1NN, Antrim, North Ireland.							Armitage P., 1971, STAT METHODS MED RES, V1; Batty M., 1976, URBAN MODELLING ALGO; BRENNAN M, 1996, NO NEED WEIGHT COMMU; CARRHILL RA, 1994, BRIT MED J, V309, P1046, DOI 10.1136/bmj.309.6961.1046; Carstairs V, 1995, J EPIDEMIOL COMMUN H, V49, pS3, DOI 10.1136/jech.49.Suppl_2.S3; *DEP HLTH SOC SEC, 1976, SHAR RES HLTH ENG RE; Department of Health and Social Security, 1976, SHAR RES HLTH ENGL R; Elola J, 1996, INT J HEALTH SERV, V26, P239, DOI 10.2190/TC9K-VQBR-NR64-AGVQ; EYLES J, 1991, SOC SCI MED, V33, P489, DOI 10.1016/0277-9536(91)90331-6; GOLDSTEIN H, 1987, MLTILEVEL MODELS ED; JUDGE K, 1994, BRIT MED J, V309, P1031, DOI 10.1136/bmj.309.6961.1031; MADDALA G, 1987, ECONOMETRICS; Marquis MS, 1999, HEALTH AFFAIR, V18, P75, DOI 10.1377/hlthaff.18.6.75; MATSUOKA M, 1990, HEPATOLOGY, V11, P173, DOI 10.1002/hep.1840110204; MAYS N, 1989, COMMUNITY MED, V11, P173; *ORG EC COOP DEV, 1996, HLTH REF WILL CHANG; *ORG EC COOP DEV, 1990, SOC POL STUD, V7; *ORG EC COOP DEV, 1990, SOCIAL POLICY STUDIE, V7; *ORG EC COOP DEV, 1996, HLTH CAR REF WILL CH; Pampalon R, 1996, SOC SCI MED, V42, P909, DOI 10.1016/0277-9536(95)00189-1; Rice N, 1996, J Health Serv Res Policy, V1, P154; SMITH P, 1994, BRIT MED J, V309, P1050, DOI 10.1136/bmj.309.6961.1050; *STAND ADV COMM HU, 1990, REL POL DISCR EQ OPP; Taylor DH, 1998, SOC SCI MED, V47, P713, DOI 10.1016/S0277-9536(98)00109-9; VANDEVEN WPMM, 1994, HEALTH AFFAIR, V13, P120, DOI 10.1377/hlthaff.13.5.120; *WHO, 1996, EUR HLTH REF AN CURR; World Health Organization, 1978, INT CLASS DIS; Wysong JA, 1996, SOZ PRAVENTIV MED, V41, P212, DOI 10.1007/BF01299481	28	12	12	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	FEB 16	2002	324	7334					390	392		10.1136/bmj.324.7334.390	http://dx.doi.org/10.1136/bmj.324.7334.390			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	524HC	11850368	Green Accepted, Bronze, Green Published			2023-01-03	WOS:000174006300015
J	Sanchez, AM; Schreiber, GB; Bethel, J; McCurdy, PR; Glynn, SA; Williams, AE; Gilcher, R				Sanchez, AM; Schreiber, GB; Bethel, J; McCurdy, PR; Glynn, SA; Williams, AE; Gilcher, R		Retrovirus Epidemiology Donor Stud	Prevalence, donation practices, and risk assessment of blood donors with hemochromatosis	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; HEPATITIS-B ANTIGEN; HEREDITARY HEMOCHROMATOSIS; UNITED-STATES; TRANSFUSION; EXCLUSION; ANTIBODY; IMPACT	Context Despite changes in eligibility policies, practical barriers limit blood donations from individuals with hemochromatosis. Increased knowledge of hemochromatosis donor characteristics may help foster further changes that will promote more donations. Objectives To estimate the prevalence of donors diagnosed as having hemochromatosis and to compare rates of unreported deferrable risks for transfusion-transmissible viral infections (TTVIs), positive screening test results for TTVIs, and donation patterns between hemochromatosis patient donors and donors reporting no medical conditions necessitating phlebotomy (non-health-related donors). Design An anonymous mail survey conducted in 1998 as part of the ongoing Retrovirus Epidemiology Donor Study. Setting and Participants Among a stratified probability sample of 92581 blood donors from 8 geographically diverse US blood centers, 52650 (57%) responded. Main Outcome Measures Prevalence of hemochromatosis among blood donors; prevalence of unreported deferrable risks and positive screening test results for TTVIs among hemochromatosis patient donors vs non-health-related donors. Results One hundred ninety-seven respondents (0.4%) identified themselves as hemochromatosis patients and 50079 (95.1%) as non-health-related donors. An estimated 0.8% of all donations were from hemochromatosis patients, 45.8% of whom reported that they had donated blood to treat their illness. The proportion of repeat donors was higher in hemochromatosis patients than in non-health-related donors (83.5% vs 76.5%; P = .03). Among repeat donors, 68.7% of hemochromatosis patients reported donating at least 3 times in the past year compared with 49.1% of non-health-related donors (P<.001). The prevalence of unreported deferrable risks for TTVIs was similar in hemochromatosis patients (2.0%) and non-health-related donors (3.1%) as was the overall prevalence of positive screening test results (1.3% of hemochromatosis patients vs 1.6% of non-health-related donors). Conclusions Although significant numbers of hemochromatosis patients reported donating blood for therapeutic reasons, our findings suggest that this population does not present a greater risk to blood safety than other donors.	WESTAT Corp, Rockville, MD 20850 USA; Amer Red Cross, Jerome H Holland Lab, Rockville, MD USA; NHLBI, Bethesda, MD 20892 USA; Oklahoma Blood Inst, Sylvan N Goldman Ctr, Oklahoma City, OK USA	Westat; American Red Cross; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)	Sanchez, AM (corresponding author), WESTAT Corp, WB 266,1650 Res Blvd, Rockville, MD 20850 USA.				NHLBI NIH HHS [N01-HB-97079, N01-HB-97081, N01-HB-97082, N01-HB-97078, N01-HB-97077, N01-HB-47114, N01-HB-97080] Funding Source: Medline; DIVISION OF BLOOD DISEASES AND RESOURCES [N01HB097078, N01HB097082, N01HB097081, N01HB097080, N01HB097077, N01HB047114, N01HB097079] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); DIVISION OF BLOOD DISEASES AND RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AACH RD, 1980, ANN INTERN MED, V92, P539, DOI 10.7326/0003-4819-92-4-539; ALTER HJ, 1972, ANN INTERN MED, V77, P691, DOI 10.7326/0003-4819-77-5-691; Bartolotta A, 1999, POLYM ENG SCI, V39, P549, DOI 10.1002/pen.11445; Barton JC, 1998, ANN INTERN MED, V129, P932, DOI 10.7326/0003-4819-129-11_Part_2-199812011-00003; Bothwell TH, 1998, SEMIN HEMATOL, V35, P55; CHERUBIN CE, 1971, TRANSFUSION, V11, P25, DOI 10.1111/j.1537-2995.1971.tb04370.x; Conry-Cantilena C, 2000, HEMOCHROMATOSIS: GENETICS, PATHOPHYSIOLOGY, DIAGNOSIS AND TREATMENT, P564; *CTR BIOL EV RES, 2001, GUID IND VAR BLOOD C; CUMMING PD, 1989, NEW ENGL J MED, V321, P941, DOI 10.1056/NEJM198910053211405; *CYT SOFTW CO, 1999, STATXACT 4 SOFTW PRO; DOMEN RE, 1995, TRANSFUS MED REV, V9, P53, DOI 10.1016/S0887-7963(05)80030-6; Eastlund T, 1998, TRANSFUSION, V38, P874, DOI 10.1046/j.1537-2995.1998.38998409009.x; EDWARDS CQ, 1993, NEW ENGL J MED, V328, P1616; EDWARDS CQ, 1988, NEW ENGL J MED, V318, P1355, DOI 10.1056/NEJM198805263182103; Glynn SA, 2000, JAMA-J AM MED ASSOC, V284, P229, DOI 10.1001/jama.284.2.229; GRINDON AJ, 1993, JAMA-J AM MED ASSOC, V270, P880; Jeffrey G, 1999, TRANSFUSION, V39, P549, DOI 10.1046/j.1537-2995.1999.39060549.x; JOHNSON ES, 1994, TRANSFUSION, V34, P769, DOI 10.1046/j.1537-2995.1994.34994378277.x; LEGGETT BA, 1990, BRIT J HAEMATOL, V74, P525, DOI 10.1111/j.1365-2141.1990.tb06345.x; Levstik M, 1998, CAN J GASTROENTEROL, V12, P61, DOI 10.1155/1998/590428; McCullough J, 2000, TRANSFUSION, V40, P143; McDonnell SM, 1999, TRANSFUSION, V39, P651, DOI 10.1046/j.1537-2995.1999.39060651.x; MCLAREN CE, 1995, BLOOD, V86, P2021, DOI 10.1182/blood.V86.5.2021.bloodjournal8652021; Mitka M, 2001, JAMA-J AM MED ASSOC, V285, P1694, DOI 10.1001/jama.285.13.1694; Munsterman KA, 1998, TRANSFUSION, V38, P45, DOI 10.1046/j.1537-2995.1998.38198141497.x; Niederau C, 1996, GASTROENTEROLOGY, V110, P1107, DOI 10.1053/gast.1996.v110.pm8613000; PILIAVIN JA, 1990, TRANSFUSION, V30, P444, DOI 10.1046/j.1537-2995.1990.30590296381.x; Powell LW, 1996, GASTROENTEROLOGY, V110, P1304, DOI 10.1053/gast.1996.v110.agast961304; Sacher RA, 1999, TRANSFUSION, V39, P551, DOI 10.1046/j.1537-2995.1999.39060551.x; Seeff L B, 1988, Transfus Med Rev, V2, P204, DOI 10.1016/S0887-7963(88)70046-2; SZMUNESS W, 1973, J INFECT DIS, V127, P17, DOI 10.1093/infdis/127.1.17; Tan L, 1999, TRANSFUSION, V39, P1018, DOI 10.1046/j.1537-2995.1999.39091018.x; THOMAS DG, 1971, APPLIED STATISTICS, V20, P105, DOI DOI 10.2307/2346643; Walker EM, 1998, ANN CLIN LAB SCI, V28, P300; *WEST INC, 1994, WESVAR SAS PROC; Williams AE, 1997, JAMA-J AM MED ASSOC, V277, P967, DOI 10.1001/jama.277.12.967; Witte DL, 1996, CLIN CHIM ACTA, V245, P139, DOI 10.1016/0009-8981(95)06212-2; Zuck TF, 1995, TRANSFUSION, V35, P944, DOI 10.1046/j.1537-2995.1995.351196110900.x; 1997, P 146 ANN M HOUS DEL	39	22	22	0	4	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 26	2001	286	12					1475	1481		10.1001/jama.286.12.1475	http://dx.doi.org/10.1001/jama.286.12.1475			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	475UX	11572740	Bronze			2023-01-03	WOS:000171188600025
J	Salmeron, S; Liard, R; Elkharrat, D; Muir, JF; Neukirch, F; Ellrodt, A				Salmeron, S; Liard, R; Elkharrat, D; Muir, JF; Neukirch, F; Ellrodt, A		ASUR; SFMU; SPLF	Asthma severity and adequacy of management in accident and emergency departments in France: a prospective study	LANCET			English	Article							ADULT ASTHMA; ROOM VISITS; THERAPY; CARE; CORTICOSTEROIDS; PREVENTION; ALBUTEROL; CHICAGO; COST; SEX	Background Recent guidelines have enabled doctors to establish accident and emergency department management strategies for acute asthma on the basis of severity of exacerbations at presentation. However, there is no available information on acute asthma patients classified according to severity of disease. Our aim was to describe the severity of such exacerbations at presentation, and the adequacy of treatment and management. Methods We did a 12-month multicentre cross-sectional observational cohort study in adult patients with acute asthma who attended one of 37 accident and emergency departments in France. The doctors who examined the patients obtained information using a formatted chart. We classified exacerbations according to severity (life-threatening, severe, or mild to moderate), on the basis of clinical findings and peak expiratory flour value, as defined by currently used guidelines. Findings Of 3772 patients with acute asthma, 975 (26%) had life-threatening attacks, 1834 (49%) had severe exacerbations without life-threatening features, and 963 (26%) had mild to moderate exacerbations. Initial treatment included nebulised beta2 agonists, anticholinergics, and systemic corticosteroids in 3492 (93%), 1841 (49%), and 2252 (60%), respectively. According to severity classification, anticholinergics were used in 494 (51%), 913 (50%), and 434 (45%) of patients in life-threatening, severe, and mild to moderate exacerbations groups, respectively; corticosteroids were given in 666 (68%), 1117 (61%), and 468 (49%), respectively. The overall admission rate was 54.2%, and mean stay was 6.1 (SD 6.0) days. Patients were admitted in 747 (77%), 1018 (55%), and 278 (29%) of cases in life-threatening, severe, and mild to moderate groups, respectively. Three patients died in hospital. Interpretation Acute asthma exacerbations are often life-threatening in patients who attend accident and emergency departments, and management of patients is not ideal, mainly because of underuse of corticosteroids and inappropriate admission rates according to severity.	Hop Univ Bicetre, Serv Med Interne, Unite Pneumol, F-94275 Le Kremlin Bicetre, France; Hop Univ Bicetre, Serv Urgences, F-94275 Le Kremlin Bicetre, France; Assistance Publ Hop Paris, Hop Lariboisiere, Serv Urgences, Paris, France; Hop Bois Guillaume, Serv Pneumol, Rouen, France; INSERM, U408, Unite Epidemiol Malad Resp, Paris, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Bicetre - APHP; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Bicetre - APHP; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Lariboisiere-Fernand-Widal - APHP; UDICE-French Research Universities; Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille; Universite Paris Cite; CHU de Rouen; Institut National de la Sante et de la Recherche Medicale (Inserm)	Salmeron, S (corresponding author), Hop Univ Bicetre, Serv Med Interne, Unite Pneumol, 78 Rue Gen Leclerc, F-94275 Le Kremlin Bicetre, France.	sergio.salmeron@bct.ap-hop-paris.fr						Barr RG, 2000, EUR RESPIR J, V15, P266, DOI 10.1034/j.1399-3003.2000.15b08.x; BARRIOT P, 1987, CHEST, V92, P460, DOI 10.1378/chest.92.3.460; Beasley R, 1998, LANCET, V351, P1225, DOI 10.1016/S0140-6736(97)07302-9; Blais L, 1998, AM J RESP CRIT CARE, V158, P126, DOI 10.1164/ajrccm.158.1.9707107; *BRIT GUID ASTHM M, 1997, THORAX S, V48, pS21; CELLI BR, 1995, AM J RESP CRIT CARE, V152, pS77; EDMOND SD, 1999, ANN EMERG MED, V34, P321; Emerman CL, 1996, CHEST, V109, P708, DOI 10.1378/chest.109.3.708; Hanania NA, 1997, CHEST, V111, P290, DOI 10.1378/chest.111.2.290; Hartert TV, 1996, AM J MED, V100, P386, DOI 10.1016/S0002-9343(97)89513-7; KWONG T, 1989, NZ MED J, V102, P700; Lagerlov P, 2000, EUR RESPIR J, V15, P25, DOI 10.1034/j.1399-3003.2000.15a06.x; Lin RY, 1998, ANN EMERG MED, V31, P208, DOI 10.1016/S0196-0644(98)70308-7; McDermott MF, 1999, CHEST, V116, p167S, DOI 10.1378/chest.116.suppl_2.167S; McDermott MF, 1997, ARCH INTERN MED, V157, P2055, DOI 10.1001/archinte.157.18.2055; MCFADDEN ER, 1995, AM J MED, V99, P651, DOI 10.1016/S0002-9343(99)80253-8; Milks CJ, 1999, ANN ALLERG ASTHMA IM, V83, P208, DOI 10.1016/S1081-1206(10)62641-5; NEWCOMB RW, 1986, J ALLERGY CLIN IMMUN, V77, P309, DOI 10.1016/S0091-6749(86)80109-9; *NIH, 1997, 974051 NIH NAT ASTHM; Partridge MR, 1997, J ACCID EMERG MED, V14, P16; Quadrelli SA, 1998, RESPIRATION, V65, P347, DOI 10.1159/000029294; Rodrigo G, 1999, AM J MED, V107, P363, DOI 10.1016/S0002-9343(99)00243-0; Rodrigo G, 1999, CHEST, V116, P285, DOI 10.1378/chest.116.2.285; Rodrigo G, 1998, CHEST, V114, P1016, DOI 10.1378/chest.114.4.1016; ROSSI OVJ, 1991, RESPIRATION, V58, P21, DOI 10.1159/000195890; Rowe BH, 2000, COCHRANE DATABASE SY; SALMERON S, 1994, AM J RESP CRIT CARE, V149, P1466, DOI 10.1164/ajrccm.149.6.8004299; SALMERON S, 1994, REAN URG, V3, P95; Singh AK, 1999, ARCH INTERN MED, V159, P1237, DOI 10.1001/archinte.159.11.1237; SITBON O, 1993, AM REV RESPIR DIS, V147, pA380; SKOBELOFF EM, 1992, JAMA-J AM MED ASSOC, V268, P3437, DOI 10.1001/jama.268.24.3437; Stanford R, 1999, AM J RESP CRIT CARE, V160, P211, DOI 10.1164/ajrccm.160.1.9811040; Taylor DM, 1999, CHEST, V116, P1638, DOI 10.1378/chest.116.6.1638; Thomas SD, 1999, CHEST, V116, p135S, DOI 10.1378/chest.116.suppl_2.135S; Turner MO, 1998, AM J RESP CRIT CARE, V157, P1804, DOI 10.1164/ajrccm.157.6.9708092	35	99	105	0	4	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	AUG 25	2001	358	9282					629	635		10.1016/S0140-6736(01)05779-8	http://dx.doi.org/10.1016/S0140-6736(01)05779-8			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	465XP	11530150				2023-01-03	WOS:000170615500011
J	Blanck, HM; Khan, LK; Serdula, MK				Blanck, HM; Khan, LK; Serdula, MK			Use of nonprescription weight loss products - Results from a multistate survey	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							DIETARY-SUPPLEMENTS; UNITED-STATES; DOUBLE-BLIND; PHENYLPROPANOLAMINE; PLACEBO; OBESITY	Context Lifestyle changes to lose weight can be difficult; hence, both prescription and nonprescription diet products are appealing. Usage patterns of the nonprescription products phenylpropanolamine (PPA) and ephedra are of particular interest because of recent safety concerns. Objective To estimate the prevalence of overall and specific nonprescription weight loss product use by demographic characteristics, prescription diet pill use, diabetic status, and lifestyle choices. Design and Setting The Behavioral Risk Factor Surveillance System, a random-digit telephone survey conducted in 1998 in 5 states. Florida, Iowa, Michigan, West Virginia, and Wisconsin. Participants Population-based sample of 14679 non institutionalized adults IS years or older. Main Outcome Measures Prevalence of nonprescription weight loss product use in 1996-1998. Results Seven percent reported overall nonprescription weight loss product use, 2% reported PPA use, and 1% reported ephedra product use. Overall use was especially common among young obese women (28.4%). Moreover, 7.9% of normal-weight women reported use. There was no difference in nonprescription weight loss product use by daily consumption of fruits and vegetables; however, more users than nonusers reported being physically active (for those who exercised greater than or equal to 30 minutes 5 times per week, odds ratio, 1.5, 95% confidence interval, 1.2-2.0). Among prescription weight loss product users, 33.8% also took nonprescription product. Conclusions With increasing rates of obesity, nonprescription product use is likely to increase. Clinicians should know about their patients' use of both prescription and nonprescription weight loss products.	Ctr Dis Control & Prevent, Div Nutr & Phys Act, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30341 USA; Ctr Dis Control & Prevent, Epidem Intelligence Serv, Div Appl Publ Hlth Training, Epidemiol Program Off, Atlanta, GA 30341 USA	Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA	Blanck, HM (corresponding author), Ctr Dis Control & Prevent, Div Nutr & Phys Act, Natl Ctr Chron Dis Prevent & Hlth Promot, 4770 Buford Hwy NE,MS K-26, Atlanta, GA 30341 USA.							Allison DB, 2001, CRIT REV FOOD SCI, V41, P1, DOI 10.1080/20014091091661; ASTRUP A, 1991, METABOLISM, V40, P323, DOI 10.1016/0026-0495(91)90117-F; ASTRUP A, 1992, INT J OBESITY, V16, P269; BRADLEY JG, 1991, POSTGRAD MED, V90, P43; Eisenberg DM, 1998, JAMA-J AM MED ASSOC, V280, P1569, DOI 10.1001/jama.280.18.1569; *FDA, 2000, PUBL HLTH ADV SUBJ S; *FDA, 2000, DIET SUPPL CONT SPH; Greenway F, 1999, OBES RES, V7, P370, DOI 10.1002/j.1550-8528.1999.tb00420.x; Gurley BJ, 2000, AM J HEALTH-SYST PH, V57, P963, DOI 10.1093/ajhp/57.10.963; Haller CA, 2000, NEW ENGL J MED, V343, P1833, DOI 10.1056/NEJM200012213432502; Hankin J, 2000, J AM DIET ASSOC, V100, P419, DOI 10.1016/S0002-8223(00)00129-2; INSEL PA, 1991, BETA ADRENERGIC RECE, P295; Kernan WN, 2000, NEW ENGL J MED, V343, P1826, DOI 10.1056/NEJM200012213432501; LAKE CR, 1990, AM J MED, V89, P195, DOI 10.1016/0002-9343(90)90299-S; LEAVY AS, 1993, ANN INTERN MED 2, V119, P661; Lewis CJ, 2001, CRIT REV FOOD SCI, V41, P43, DOI 10.1080/20014091091724; Mokdad AH, 1999, JAMA-J AM MED ASSOC, V282, P1519, DOI 10.1001/jama.282.16.1519; NELSON DE, 1998, P SECT SURV METH AM; PENTEL P, 1984, JAMA-J AM MED ASSOC, V252, P1898, DOI 10.1001/jama.252.14.1898; Radimer KL, 2000, J AM DIET ASSOC, V100, P447, DOI 10.1016/S0002-8223(00)00137-1; Shah BV, 1997, SUDAAN USERS MANUAL; U.S. Department of Health and Human Services, 1996, 76200 US DEP HLTH HU; WILLARD HF, 1990, CHROMOSOMES TODAY, V10, P47; 2000, FED REG, V65, P17477; 1997, FED REG, V62, P30677; [No title captured]	26	97	103	0	10	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 22	2001	286	8					930	935		10.1001/jama.286.8.930	http://dx.doi.org/10.1001/jama.286.8.930			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	465EU	11509057	Bronze			2023-01-03	WOS:000170577300027
J	Hahn, S; Kim, Y; Garner, P				Hahn, S; Kim, Y; Garner, P			Reduced osmolarity oral rehydration solution for treating dehydration due to diarrhoea in children: systematic review	BMJ-BRITISH MEDICAL JOURNAL			English	Article							DOUBLE-BLIND; PERSISTENT DIARRHEA; STANDARD; SODIUM; ABSORPTION; EFFICACY; THERAPY; CHOLERA; INFANTS	Objectives To compare reduced osmolarity oral rehydration solution with standard World Health Organization oral rehydration solution in children with acute diarrhoea, Design Systematic review of randomised controlled trials, Studies 15 randomised controlled trials including 2397 randomised patients. Outcomes The primary outcome was unscheduled intravenous infusion; secondary outcomes were stool output, vomiting, and hyponatraemia. Results In a meta-analysis of nine trials for the primary outcome, reduced osmolarity rehydration solution was associated with fewer unscheduled intravenous infusions compared with standard WHO rehydration solution (odds ratio 0.61, 95% confidence interval 0.47 to 0.81). Three trials reported that no patients required unscheduled intravenous infusion, Trials reporting secondary outcomes suggested that in the reduced osmolarity rehydration solution group, stool output was lower (standardised mean difference in the log scale - 0.214 (95%, confidence interval - 0.305 to - 0.123; 13 trials) and vomiting was less frequent (odds ratio 0.71, 0.55 to 0.92; six trials). Six trials sought presence of hyponatraemia, with events in three studies, but no significant difference between the two arms. Conclusion In children admitted to hospital with dehydration associated with diarrhoea, reduced osmolarity rehydration solution is associated with reduced need for unscheduled intravenous infusions, lower stool volume, and less vomiting compared with standard WHO rehydration solution.	Univ Reading, Med & Pharmaceut Stat Res Unit, Reading RG6 6FN, Berks, England; Seoul Natl Univ, Childrens Hosp, Dept Paediat, Seoul 110774, South Korea; Univ Liverpool, Liverpool Sch Trop Med, Effect Hlth Care Alliance Programme, Int Hlth Div, Liverpool L3 5QA, Merseyside, England	University of Reading; Seoul National University (SNU); Seoul National University Hospital; Liverpool School of Tropical Medicine; University of Liverpool	Hahn, S (corresponding author), Univ York, Dept Hlth Sci & Clin Evaluat, York YO10 5DD, N Yorkshire, England.	s.hahn@rdg.ac.uk	Garner, Paul/Y-8385-2019; Hahn, Seokyung/J-5705-2012; Garner, Paul/HII-5856-2022	Garner, Paul/0000-0002-0607-6941; Hahn, Seokyung/0000-0002-4684-4917				Alam NH, 1999, LANCET, V354, P296, DOI 10.1016/S0140-6736(98)09332-5; Alam NH, 2001, PEDIATRICS, V107, P613, DOI 10.1542/peds.107.4.613; Alam S, 2000, Indian Pediatr, V37, P952; ALMROTH S, 1995, LANCET, V345, P709, DOI 10.1016/S0140-6736(95)90873-0; BERNAL C, 2000, SALUDARTE, V1, P6; BHAN MK, 1995, LANCET, V345, P282, DOI 10.1016/S0140-6736(95)90275-9; BHARGAVA SK, 1984, J PEDIATR GASTR NUTR, V3, P500, DOI 10.1097/00005176-198409000-00004; Dutta P, 2000, ACTA PAEDIATR, V89, P411, DOI 10.1080/080352500750028104; Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629; ElMougi M, 1996, B WORLD HEALTH ORGAN, V74, P471; ELMOUGI M, 1994, J PEDIATR GASTR NUTR, V19, P83, DOI 10.1097/00005176-199407000-00013; FARTHING MJG, 1988, DRUGS, V36, P80, DOI 10.2165/00003495-198800364-00011; Faruque ASG, 1996, ACTA PAEDIATR, V85, P1247, DOI 10.1111/j.1651-2227.1996.tb18240.x; Faruque ASG, 1996, SCAND J INFECT DIS, V28, P87, DOI 10.3109/00365549609027156; FINBERG L, 1973, NEW ENGL J MED, V289, P196, DOI 10.1056/NEJM197307262890407; FONTAINE O, 2000, CD001264 COCHR DAT; FORDTRAN JS, 1968, J CLIN INVEST, V47, P884, DOI 10.1172/JCI105781; GRANT JP, 1983, STATE WORLDS CHILDRE; HUNT JB, 1992, GUT, V33, P479, DOI 10.1136/gut.33.4.479; KIM Y, 2000, COCHRANE LIB; MAHALANABIS D, 1995, ACTA PAEDIATR, V84, P289, DOI 10.1111/j.1651-2227.1995.tb13630.x; MAHALANABIS D, 1973, JOHNS HOPKINS MED J, V132, P197; MARTINEZPANTALE.O, 1998, B MED HOSP INFANT M, V45, P817; Moreno-Sanchez H, 1990, Bol Med Hosp Infant Mex, V47, P630; SANTOSHAM M, 1982, NEW ENGL J MED, V306, P1070, DOI 10.1056/NEJM198205063061802; Santosham M, 1996, J PEDIATR-US, V128, P45, DOI 10.1016/S0022-3476(96)70426-2; SARKER SA, 1995, ACTA PAEDIATR, V84, P775, DOI 10.1111/j.1651-2227.1995.tb13755.x; Sutton AJ, 2000, METHODS METANALYSIS; VELASQUEZJONES L, 1990, CLIN THER, V12, P95	29	73	86	0	6	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUL 14	2001	323	7304					81	85		10.1136/bmj.323.7304.81	http://dx.doi.org/10.1136/bmj.323.7304.81			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	454GD	11451782	Bronze, Green Published			2023-01-03	WOS:000169964100016
J	Bryce, M; Spielman, SR; Greenspan, AM; Kotler, MN				Bryce, M; Spielman, SR; Greenspan, AM; Kotler, MN			Evolving indications for permanent pacemakers	ANNALS OF INTERNAL MEDICINE			English	Review							CONGESTIVE-HEART-FAILURE; HYPERTROPHIC OBSTRUCTIVE CARDIOMYOPATHY; IDIOPATHIC DILATED CARDIOMYOPATHY; RECURRENT ATRIAL-FIBRILLATION; OUTFLOW TRACT OBSTRUCTION; NEURALLY-MEDIATED SYNCOPE; BUNDLE-BRANCH-BLOCK; VASOVAGAL SYNCOPE; DOUBLE-BLIND; HEMODYNAMIC IMPROVEMENT	New indications for permanent cardiac pacing have been developed in recent years, with numerous studies demonstrating improved clinical outcomes in a variety of disorders. Because hypertrophic obstructive cardiomyopathy, dilated cardiomyopathy, heart failure, neurocardiogenic syncope, and atrial fibrillation are common conditions, every clinician should be aware of evolving alternative therapies for them. Observational studies in patients with refractory, symptomatic hypertrophic obstructive cardiomyopathy and significant left ventricular outflow gradient at rest suggest that cardiac pacing may result in symptomatic and hemodynamic improvement. Clinical trials have not shown conclusive evidence regarding the longterm benefit from pacing in these patients, and it is unclear whether pacing will be a preferred treatment option. Preliminary data suggest that pacing is a viable adjunctive therapeutic approach for improving symptoms in patients with dilated cardiomyopathy and heart failure. Mortality benefit has yet to be established, but it is to be hoped that ongoing randomized clinical trials will provide definitive information on that issue. Patients with refractory neurocardiogenic syncope or those who are intolerant of medical treatment may benefit from pacing therapies, especially those that use rate-drop sensor algorithms. Biatrial pacing has emerged as a technique that resynchronizes atrial electrical activity and has been shown to prevent atrial fibrillation. Multisite atrial pacing for the prevention of atrial fibrillation is considered investigational but seems promising. Newer indications for pacing are expected to result in improved clinical outcomes for hypertrophic obstructive cardiomyopathy, dilated cardiomyopathy and heart failure, neurocardiogenic syncope, and the prevention of atrial fibrillation.	Albert Einstein Med Ctr, Div Cardiovasc Dis, Philadelphia, PA 19141 USA	Yeshiva University	Kotler, MN (corresponding author), Albert Einstein Med Ctr, Div Cardiovasc Dis, 5401 Old York Rd,Klein Bldg,Suite 363, Philadelphia, PA 19141 USA.							Aaronson KD, 1997, CIRCULATION, V95, P2660, DOI 10.1161/01.CIR.95.12.2660; ABRAHAM WT, 1999, SAT S AM COLL CARD A; Ammirati F, 1998, PACE, V21, P2178, DOI 10.1111/j.1540-8159.1998.tb01148.x; ANDERSEN HR, 1994, LANCET, V344, P1523, DOI 10.1016/S0140-6736(94)90347-6; Auricchio A, 1999, AM J CARDIOL, V83, p130D; Auricchio A, 1999, CIRCULATION, V99, P2993, DOI 10.1161/01.CIR.99.23.2993; BAKKER P, 1995, PACE, V18, P825; Bakker PF, 1994, PACE, V17, P820; Benditt DG, 1997, PACE, V20, P832, DOI 10.1111/j.1540-8159.1997.tb03916.x; BONOW RO, 1983, AM J CARDIOL, V51, P1386, DOI 10.1016/0002-9149(83)90317-X; CHARDACK WM, 1960, SURGERY, V48, P643; Charles RG, 1997, HEART, V78, P224, DOI 10.1136/hrt.78.3.224; CHIRIFE R, 1994, PACE, V17, P1451, DOI 10.1111/j.1540-8159.1994.tb01508.x; Connolly SJ, 1999, J AM COLL CARDIOL, V33, P16, DOI 10.1016/S0735-1097(98)00549-X; Daubert J. Claude, 1997, P99; Delfaut P, 1998, J AM COLL CARDIOL, V32, P1900, DOI 10.1016/S0735-1097(98)00489-6; Duck H J, 1984, Z Gesamte Inn Med, V39, P437; el-Bedawi K M, 1994, Clin Auton Res, V4, P41; FANANAPAZIR L, 1992, CIRCULATION, V85, P2149, DOI 10.1161/01.CIR.85.6.2149; FANANAPAZIR L, 1994, CIRCULATION, V90, P2731, DOI 10.1161/01.CIR.90.6.2731; FITZPATRICK A, 1991, PACE, V14, P13, DOI 10.1111/j.1540-8159.1991.tb04042.x; FORCINITO M, 1991, J AM COLL CARDIOL, V18, P1, DOI 10.1016/S0735-1097(10)80209-8; Gadler F, 1999, EUR HEART J, V20, P1044, DOI 10.1053/euhj.1998.1331; Gadler F, 1996, J AM COLL CARDIOL, V27, P1219, DOI 10.1016/0735-1097(95)00573-0; Gadler F, 1997, EUR HEART J, V18, P636; GOLD MR, 1995, J AM COLL CARDIOL, V26, P967, DOI 10.1016/0735-1097(95)00292-0; Gras D, 1998, PACE, V21, P2249, DOI 10.1111/j.1540-8159.1998.tb01162.x; Gregoratos G, 1998, CIRCULATION, V97, P1325, DOI 10.1161/01.CIR.97.13.1325; GRINES CL, 1989, CIRCULATION, V79, P845, DOI 10.1161/01.CIR.79.4.845; Hassenstein P, 1967, Verh Dtsch Ges Kreislaufforsch, V33, P242; Hassenstein P, 1975, Thoraxchir Vask Chir, V23, P496; HOCHLEITNER M, 1990, AM J CARDIOL, V66, P198, DOI 10.1016/0002-9149(90)90588-R; HOCHLEITNER M, 1992, AM J CARDIOL, V70, P1320, DOI 10.1016/0002-9149(92)90769-U; JEANRENAUD X, 1992, LANCET, V339, P1318, DOI 10.1016/0140-6736(92)91961-7; Kappenberger L, 1997, EUR HEART J, V18, P1249; KAPPENBERGER L, 1991, ARCH MAL COEUR, V84, P293; Leclercq C., 1998, European Heart Journal, V19, P573; Levy T, 1999, AM J CARDIOL, V84, P426, DOI 10.1016/S0002-9149(99)00327-6; LINDE C, 1995, AM J CARDIOL, V75, P919, DOI 10.1016/S0002-9149(99)80687-0; Maron BJ, 1999, CIRCULATION, V99, P2927, DOI 10.1161/01.CIR.99.22.2927; MENOZZI C, 1993, AM J CARDIOL, V72, P1152, DOI 10.1016/0002-9149(93)90985-L; Misier ARR, 1999, AM J CARDIOL, V83, p237D; Nishimura RA, 1996, J AM COLL CARDIOL, V27, P421, DOI 10.1016/0735-1097(95)00445-9; Nishimura RA, 1997, J AM COLL CARDIOL, V29, P435, DOI 10.1016/S0735-1097(96)00473-1; NISHIMURA RA, 1995, J AM COLL CARDIOL, V25, P281, DOI 10.1016/0735-1097(94)00419-Q; Padeletti L, 1999, J INTERV CARD ELECTR, V3, P35, DOI 10.1023/A:1009867305678; PETERSEN M, 1994, BRIT HEART J, V71, P274; Prakash A., 1997, Journal of the American College of Cardiology, V29, p253A; Prakash A, 1997, PACE, V20, P2434, DOI 10.1111/j.1540-8159.1997.tb06083.x; Raviele A, 1999, CIRCULATION, V99, P1452, DOI 10.1161/01.CIR.99.11.1452; Saksena S, 1996, J AM COLL CARDIOL, V28, P687, DOI 10.1016/0735-1097(96)00232-X; SAMOIL D, 1993, EUR J CARDIAC PACING, V1, P36; Saxon LA, 1999, AM J CARDIOL, V83, p120D; SHAMIM W, 1998, EUR HEART J, V19, P143; Sheldon R, 1999, AM J CARDIOL, V84, p26Q; Sheldon R, 1998, AM J CARDIOL, V81, P158, DOI 10.1016/S0002-9149(97)00891-6; SILVA L, 1989, PACING CLIN ELECTR 2, V12, P1275; SOPHER SM, 1995, CIRCULATION, V92, P2540; SRA JS, 1993, NEW ENGL J MED, V328, P1085, DOI 10.1056/NEJM199304153281504; Sutton R, 1997, PACE, V20, P849, DOI 10.1111/j.1540-8159.1997.tb03920.x; XIAO HB, 1991, BRIT HEART J, V66, P443; XIAO HB, 1992, BRIT HEART J, V68, P403; Yu WC, 1997, CIRCULATION, V96, P2992, DOI 10.1161/01.CIR.96.9.2992; ZOLL PM, 1952, NEW ENGL J MED, V247, P768, DOI 10.1056/NEJM195211132472005	64	5	5	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUN 19	2001	134	12					1130	1141		10.7326/0003-4819-134-12-200106190-00014	http://dx.doi.org/10.7326/0003-4819-134-12-200106190-00014			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	442YU	11412054				2023-01-03	WOS:000169313200007
J	Watanabe, T; Wu, T; Catalano, PJ; Ueki, T; Satriano, R; Benson, AB; Hamilton, SR				Watanabe, T; Wu, T; Catalano, PJ; Ueki, T; Satriano, R; Benson, AB; Hamilton, SR			Molecular predictors of survival after adjuvant chemotherapy for colon cancer.	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							18Q ALLELIC LOSS; MICROSATELLITE INSTABILITY; COLORECTAL-CANCER; MISMATCH REPAIR; CHROMOSOME 18Q; DCC PROTEIN; STAGE-II; FAMILIAL PREDISPOSITION; PROGNOSTIC-SIGNIFICANCE; INTERNATIONAL CRITERIA	Background: Adjuvant chemotherapy improves survival among patients with stage III colon cancer, but no reliable molecular predictors of outcome have been identified. Methods: We evaluated loss of chromosomal material (also called loss of heterozygosity or allelic loss) from chromosomes 18q, 17p, and 8p; cellular levels of p53 and p21(WAF1/CIP1) proteins; and microsatellite instability as molecular markers. We analyzed tumor tissue from 460 patients with stage III and high-risk stage II colon cancer who had been treated with various combinations of adjuvant fluorouracil, leucovorin, and levamisole to determine the ability of these markers to predict survival. Results: Loss of heterozygosity at 18q was present in 155 of 319 cancers (49 percent). High levels of microsatellite instability were found in 62 of 298 tumors (21 percent), and 38 of these 62 tumors (61 percent) had a mutation of the gene for the type II receptor for transforming growth factor beta1 (TGF-beta1). Among patients with microsatellite-stable stage III cancer, five-year overall survival after fluorouracil-based chemotherapy was 74 percent in those whose cancer retained 18q alleles and 50 percent in those with loss of 18q alleles (relative risk of death with loss at 18q, 2.75; 95 percent confidence interval, 1.34 to 5.65; P = 0.006). The five-year survival rate among patients whose cancer had high levels of microsatellite instability was 74 percent in the presence of a mutated gene for the type II receptor for TGF-beta1 and 46 percent if the tumor did not have this mutation (relative risk of death, 2.90; 95 percent confidence interval, 1.14 to 7.35; P = 0.03). Conclusions: Retention of 18q alleles in microsatellite-stable cancers and mutation of the gene for the type II receptor for TGF-beta1 in cancers with high levels of microsatellite instability point to a favorable outcome after adjuvant chemotherapy with fluorouracil-based regimens for stage III colon cancer. (N Engl J Med 2001;344:1196-206.) Copyright (C) 2001 Massachusetts Medical Society.	Univ Texas, MD Anderson Canc Ctr, Div Pathol & Lab Med, Houston, TX 77030 USA; Johns Hopkins Univ, Sch Med, Dept Pathol, Div Gastrointestinal Liver Pathol, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Ctr Oncol, Baltimore, MD 21205 USA; Dana Farber Canc Inst, Dept Biostat Sci, Boston, MA 02115 USA; Univ Penn, Ctr Canc, Dept Hematol Oncol, Philadelphia, PA 19104 USA; Northwestern Univ, Robert H Lurie Comprehens Canc Ctr, Div Hematol Oncol, Chicago, IL 60611 USA; Eastern Cooperat Oncol Grp, Brookline, MA USA	University of Texas System; UTMD Anderson Cancer Center; Johns Hopkins University; Johns Hopkins University; Johns Hopkins Medicine; Harvard University; Dana-Farber Cancer Institute; University of Pennsylvania; Ann & Robert H. Lurie Children's Hospital of Chicago; Northwestern University; Robert H. Lurie Comprehensive Cancer Center	Hamilton, SR (corresponding author), Univ Texas, MD Anderson Canc Ctr, Div Pathol & Lab Med, 1515 Holcombe Blvd,Box 85,G1-3754, Houston, TX 77030 USA.				NATIONAL CANCER INSTITUTE [U10CA023318, U10CA021115, U01CA060100, P50CA062924] Funding Source: NIH RePORTER; NCI NIH HHS [P50 CA062924, CA62924, U10 CA021115, U10 CA023318, CA60100, CA21115] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Agresti A., 1990, CATEGORICAL DATA ANA; Ahnen DJ, 1998, CANCER RES, V58, P1149; Akhurst RJ, 1999, J PATHOL, V187, P82, DOI 10.1002/(SICI)1096-9896(199901)187:1<82::AID-PATH248>3.0.CO;2-8; Arai T, 1998, INT J CANCER, V79, P418, DOI 10.1002/(SICI)1097-0215(19980821)79:4<418::AID-IJC18>3.0.CO;2-0; BAAS IO, 1994, J PATHOL, V172, P5, DOI 10.1002/path.1711720104; Blobe GC, 2000, NEW ENGL J MED, V342, P1350, DOI 10.1056/NEJM200005043421807; Boland CR, 1998, CANCER RES, V58, P5248; Boulaire J, 2000, PATHOL BIOL, V48, P190; Bunz F, 1999, J CLIN INVEST, V104, P263, DOI 10.1172/JCI6863; Carethers JM, 1999, GASTROENTEROLOGY, V117, P123, DOI 10.1016/S0016-5085(99)70558-5; Carethers JM, 1998, GASTROENTEROLOGY, V114, P1188, DOI 10.1016/S0016-5085(98)70424-X; Chan SSY, 1996, CELL, V87, P187, DOI 10.1016/S0092-8674(00)81337-9; Cheng JD, 1999, CLIN CANCER RES, V5, P1057; Chu E, 1999, MOL CELL BIOL, V19, P1582; Chung DC, 1998, GASTROENTEROLOGY, V114, P1330, DOI 10.1016/S0016-5085(98)70441-X; Chung DC, 2000, GASTROENTEROLOGY, V119, P854, DOI 10.1053/gast.2000.16507; Cohn KH, 1997, CANCER, V79, P233; COX DR, 1972, J R STAT SOC B, V34, P187; Cox LS, 1997, J PATHOL, V183, P134, DOI 10.1002/(SICI)1096-9896(199710)183:2<134::AID-PATH960>3.0.CO;2-D; Dietmaier W, 1997, CANCER RES, V57, P4749; Doglioni C, 1996, J PATHOL, V179, P248, DOI 10.1002/(SICI)1096-9896(199607)179:3<248::AID-PATH571>3.0.CO;2-6; El-Deiry WS, 1998, CANCER J - FRANCE, V11, P229; Elsaleh H, 2000, LANCET, V355, P1745, DOI 10.1016/S0140-6736(00)02261-3; Elsaleh H, 2000, ONCOLOGY-BASEL, V58, P52, DOI 10.1159/000012079; FEARON ER, 1996, BIOCHIM BIOPHYS ACTA, V1288, P17; Fujiwara T, 1998, AM J PATHOL, V153, P1063, DOI 10.1016/S0002-9440(10)65651-9; Galanis E, 2000, Surg Oncol Clin N Am, V9, P813; Greenlee RT, 2000, CA-CANCER J CLIN, V50, P7, DOI 10.3322/canjclin.50.1.7; Gryfe R, 2000, NEW ENGL J MED, V342, P69, DOI 10.1056/NEJM200001133420201; Haller DG, 1998, P AN M AM SOC CLIN, V17, p256a; Halling KC, 1999, JNCI-J NATL CANCER I, V91, P1295, DOI 10.1093/jnci/91.15.1295; Herman JG, 1998, P NATL ACAD SCI USA, V95, P6870, DOI 10.1073/pnas.95.12.6870; IINO H, 1994, CANCER, V73, P1324, DOI 10.1002/1097-0142(19940301)73:5<1324::AID-CNCR2820730503>3.0.CO;2-W; IONOV Y, 1993, NATURE, V363, P558, DOI 10.1038/363558a0; ITOH F, 1993, INT J CANCER, V53, P260, DOI 10.1002/ijc.2910530215; JEN J, 1994, NEW ENGL J MED, V331, P213, DOI 10.1056/NEJM199407283310401; Jernvall P, 1999, EUR J CANCER, V35, P197, DOI 10.1016/S0959-8049(98)00306-2; Jernvall P, 1999, BRIT J CANCER, V79, P903, DOI 10.1038/sj.bjc.6690144; Jiricny J, 2000, CURR OPIN GENET DEV, V10, P157, DOI 10.1016/S0959-437X(00)00066-6; Johannsdottir JT, 1999, ANTICANCER RES, V19, P1821; Kane MF, 1997, CANCER RES, V57, P808; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; Kato M, 1996, CANCER, V77, P1729, DOI 10.1002/(SICI)1097-0142(19960415)77:8<1729::AID-CNCR47>3.0.CO;2-Z; KeinoMasu K, 1996, CELL, V87, P175, DOI 10.1016/S0092-8674(00)81336-7; Lanza G, 1998, INT J CANCER, V79, P390, DOI 10.1002/(SICI)1097-0215(19980821)79:4<390::AID-IJC14>3.3.CO;2-M; Laurent-Puig P, 1999, EUR J CANCER PREV, V8, pS39; Lengauer C, 1998, NATURE, V396, P643, DOI 10.1038/25292; LOTHE RA, 1993, CANCER RES, V53, P5849; Lukish JR, 1998, ANN SURG, V227, P51, DOI 10.1097/00000658-199801000-00008; Macdonald JS, 1999, CA-CANCER J CLIN, V49, P202, DOI 10.3322/canjclin.49.4.202; MANTEL NATHAN, 1966, CANCERCHEMOTHERAP REP, V50, P163; Martinez-Lopez E, 1998, GASTROENTEROLOGY, V114, P1180, DOI 10.1016/S0016-5085(98)70423-8; McLeod HL, 1999, BRIT J CANCER, V79, P191, DOI 10.1038/sj.bjc.6690033; Mehlen P, 1998, NATURE, V395, P801, DOI 10.1038/27441; MOERTEL CG, 1995, ANN INTERN MED, V122, P321, DOI 10.7326/0003-4819-122-5-199503010-00001; Moskaluk CA, 1996, HUM PATHOL, V27, P1211, DOI 10.1016/S0046-8177(96)90317-2; Moskaluk CA, 1997, AM J PATHOL, V150, P1547; Nita ME, 1998, BRIT J CANCER, V78, P986, DOI 10.1038/bjc.1998.617; North S, 2000, PATHOL BIOL, V48, P255; OCONNELL MJ, 1992, CANCER-AM CANCER SOC, V70, P1732, DOI 10.1002/1097-0142(19920915)70:4+<1732::AID-CNCR2820701614>3.0.CO;2-#; OConnor PM, 1997, CANCER RES, V57, P4285; Ogunbiyi OA, 1998, J CLIN ONCOL, V16, P427, DOI 10.1200/JCO.1998.16.2.427; OOKAWA K, 1993, INT J CANCER, V53, P382, DOI 10.1002/ijc.2910530307; Perucho M, 1999, CANCER RES, V59, P249; Pirollo KF, 2000, ANTI-CANCER DRUG, V11, P419, DOI 10.1097/00001813-200007000-00002; Prolla TA, 1998, CURR OPIN CELL BIOL, V10, P311, DOI 10.1016/S0955-0674(98)80005-7; Reymond MA, 1998, DIS COLON RECTUM, V41, P755, DOI 10.1007/BF02236264; RIEGERCHRIST KM, 1997, FRONTIERS BIOSCI, V2, P438; Saito M, 1999, ONCOLOGY-BASEL, V56, P134, DOI 10.1159/000011954; Salonga D, 2000, CLIN CANCER RES, V6, P1322; Saltz LB, 2000, NEW ENGL J MED, V343, P905, DOI 10.1056/NEJM200009283431302; Save V, 1998, J PATHOL, V184, P348; Shibata D, 1996, NEW ENGL J MED, V335, P1727, DOI 10.1056/NEJM199612053352303; Smith DM, 2000, INT J MOL MED, V6, P503; Soussi T, 2000, ANN NY ACAD SCI, V910, P121; THIBODEAU SN, 1993, SCIENCE, V260, P816, DOI 10.1126/science.8484122; Valassiadou KE, 1997, ANTICANCER RES, V17, P2571; Wu TT, 1998, AM J PATHOL, V153, P287, DOI 10.1016/S0002-9440(10)65570-8	78	674	702	0	21	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	APR 19	2001	344	16					1196	1206		10.1056/NEJM200104193441603	http://dx.doi.org/10.1056/NEJM200104193441603			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	422PM	11309634	Green Accepted			2023-01-03	WOS:000168127600003
J	Shelton, RC; Keller, MB; Gelenberg, A; Dunner, DL; Hirschfeld, R; Thase, ME; Russell, J; Lydiard, RB; Crits-Cristoph, P; Gallop, R; Todd, L; Hellerstein, D; Goodnick, P; Keitner, G; Stahl, SM; Halbreich, U				Shelton, RC; Keller, MB; Gelenberg, A; Dunner, DL; Hirschfeld, R; Thase, ME; Russell, J; Lydiard, RB; Crits-Cristoph, P; Gallop, R; Todd, L; Hellerstein, D; Goodnick, P; Keitner, G; Stahl, SM; Halbreich, U			Effectiveness of St John's Wort in major depression - A randomized controlled trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							MILD-MODERATE DEPRESSION; ALTERNATIVE MEDICINE; DOUBLE-BLIND; HYPERICUM EXTRACT; CLINICAL-TRIALS; PLACEBO; IMIPRAMINE; LI-160; MULTICENTER; DISORDER	Context Extracts of St John's wort are widely used to treat depression. Although more than 2 dozen clinical trials have been conducted with St John's wort, most have significant flaws in design and do not enable meaningful interpretation. Objective To compare the efficacy and safety of a standardized extract of St John's wort with placebo in outpatients with major depression. Design and Setting Randomized, double-blind, placebo-controlled clinical trial conducted between November 1998 and January 2000 in 11 academic medical centers in the United States. Participants Two hundred adult outpatients (mean age, 42.4 years; 67.0% female; 85.9% white) diagnosed as having major depression and having a baseline Hamilton Rating Scale for Depression (HAM-D) score of at least 20. Intervention Participants completed a 1-week, single-blind run-in of placebo, then were randomly assigned to receive either St John's wort extract (n=98; 900 mg/d for 4 weeks, increased to 1200 mg/d in the absence of an adequate response thereafter) or placebo (n=102) for 8 weeks. Main Outcome Measures The primary outcome measure was rate of change on the HAM-D over the treatment period. Secondary measures included the Beck Depression Inventory (BDI), Hamilton Rating Scale for Anxiety (HAM-A), the Global Assessment of Function (CAF) scale, and the Clinical Global impression-Severity and -Improvement scales (CGI-S and CGI-I). Results The random coefficient analyses for the HAM-D, HAM-A, CGI-S, and CGI-I all showed significant effects for time but not for treatment or time-by-treatment interaction (for HAM-D scores, P<.001, P=.16, and P=.58, respectively). Analysis of covariance showed nonsignificant effects for BDI and GAF scores. The proportion of participants achieving an a priori definition of response did not differ between groups. The number reaching remission of illness was significantly higher with St John's wort than with placebo (P=.02), but the rates were very low in the full intention-to-treat analysis (14/98 [14.3%] vs 5/102 [4.9%], respectively), St John's wort was safe and well tolerated. Headache was the only adverse event that occurred with greater frequency with St John's wort than placebo (39/95 [41%] vs 25/100 [25%], respectively). Conclusion In this study, St John's wort was not effective for treatment of major depression.	Vanderbilt Univ, Dept Psychiat, Nashville, TN USA; Brown Univ, Butler Hosp, Dept Psychiat, Providence, RI 02912 USA; Univ Arizona, Hlth Sci Ctr, Dept Psychiat, Tucson, AZ USA; Univ Washington, Dept Psychiat, Seattle, WA 98195 USA; Univ Texas, Dept Psychiat, Galveston, TX 77555 USA; Univ Pittsburgh, Western Psychiat Inst & Clin, Dept Psychiat, Pittsburgh, PA 15213 USA; Univ S Carolina, Dept Psychiat, Charleston, SC USA; Univ Penn, Dept Psychiat, Philadelphia, PA 19104 USA; Beth Israel Med Ctr, Dept Psychiat, New York, NY 10003 USA; Univ Miami, Sch Med, Dept Psychiat, Miami, FL 33152 USA; Brown Univ, Rhode Isl Hosp, Dept Psychiat, Providence, RI 02903 USA; Univ Calif San Diego, Dept Psychiat, San Diego, CA 92103 USA; SUNY Buffalo, Ctr Clin, Dept Psychiat, Buffalo, NY 14260 USA	Vanderbilt University; Brown University; Butler Hospital Rhode Island; University of Arizona; University of Arizona Health Sciences; University of Washington; University of Washington Seattle; University of Texas System; University of Texas Medical Branch Galveston; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Western Psychiatric Institute & Clinic of UPMC; University of South Carolina; University of Pennsylvania; Harvard University; Beth Israel Deaconess Medical Center; University of Miami; Brown University; Lifespan Health Rhode Island; Rhode Island Hospital; University of California System; University of California San Diego; State University of New York (SUNY) System; State University of New York (SUNY) Buffalo	Shelton, RC (corresponding author), 1500 21st Ave S,Suite 2200, Nashville, TN 37212 USA.		Crits-Christoph, Paul/X-4682-2018	Crits-Christoph, Paul/0000-0001-6858-8451	NATIONAL INSTITUTE OF MENTAL HEALTH [U01MH061590, K24MH001741] Funding Source: NIH RePORTER; NIMH NIH HHS [K24-MH01741, U01 MH061590] Funding Source: Medline	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		American Psychiatric Association, 1994, DIAGN STAT MAN MENT; Angell M, 1998, NEW ENGL J MED, V339, P839, DOI 10.1056/NEJM199809173391210; Astin JA, 1998, JAMA-J AM MED ASSOC, V279, P1548, DOI 10.1001/jama.279.19.1548; BECK AT, 1961, ARCH GEN PSYCHIAT, V4, P561, DOI 10.1001/archpsyc.1961.01710120031004; BERGMANN R, 1993, THERAPIEWOCHE NEUROL, V7, P235; BIALIK RJ, 1995, J PSYCHIATR NEUROSCI, V20, P265; Brenner R, 2000, CLIN THER, V22, P411, DOI 10.1016/S0149-2918(00)89010-4; DITZLER K, 1994, COMPLEMENT THER MED, V2, P5; Ernst E, 1999, LANCET, V354, P2014, DOI 10.1016/S0140-6736(99)00418-3; First M., 1996, CLINICIAN VERSION SC; Fontanarosa PB, 1998, JAMA-J AM MED ASSOC, V280, P1618, DOI 10.1001/jama.280.18.1618; Gaster B, 2000, ARCH INTERN MED, V160, P152, DOI 10.1001/archinte.160.2.152; GUY W, 1967, ECDEU ASSESSMENT MAN, P217; HALAMA P, 1991, NERVENHEILKUNDE, V10, P250; HAMILTON M, 1960, J NEUROL NEUROSUR PS, V23, P56, DOI 10.1136/jnnp.23.1.56; HAMILTON M, 1959, BRIT J MED PSYCHOL, V32, P50, DOI 10.1111/j.2044-8341.1959.tb00467.x; HANSGEN KD, 1994, J GERIATR PSYCHIA S1, V7, P15; HARRER G, 1991, TW NEUROL PSYCHIATR, V5, P710; HARRER G, 1994, J GERIATR PSYCHIA S1, V7, P24; Hoffmann J, 1979, ZFA (Stuttgart), V55, P776; HUBNER WD, 1994, J GERIATR PSYCHIA S1, V7, P12; Jonas WB, 1998, JAMA-J AM MED ASSOC, V280, P1616, DOI 10.1001/jama.280.18.1616; KELLER MB, 1992, ARCH GEN PSYCHIAT, V49, P809; KLERMAN GL, 1992, ARCH GEN PSYCHIAT, V49, P831; KNIEBEL R, 1988, Z ALLG MED, V64, P689; KONIG CD, 1993, THESIS U BASEL BASEL; KUGLER J, 1990, Z ALLG MED, V66, P21; Leber PD, 1998, CONTROL CLIN TRIALS, V19, P178, DOI 10.1016/S0197-2456(97)00118-9; LEHRL S, 1993, NERVENHEILKUNDE, V12, P281; LIEBER P, 1991, PSYCHOPHARMACOL B, V22, P30; Linde K, 1996, BRIT MED J, V313, P253, DOI 10.1136/bmj.313.7052.253; Linde K, 1999, BRIT MED J, V319, P1539; LINDE K, 2000, ST JOHNS WORT DEPRES; Miller CA, 1997, PSYCHOPHARMACOL BULL, V33, P647; OSTERHEIDER M, 1992, FORTSCHR NEUROL PSYC, V60, P210; Pablos-Mendez A, 1998, JAMA-J AM MED ASSOC, V279, P222, DOI 10.1001/jama.279.3.222; Philipp M, 1999, BRIT MED J, V319, P1534, DOI 10.1136/bmj.319.7224.1534; QUANDT J, 1993, ALLGEMEINARZT, V2, P97; Quitkin FM, 1999, AM J PSYCHIAT, V156, P829, DOI 10.1176/ajp.156.6.829; REH C, 1992, THERAPIEWOCHE, V42, P1576; RIIS P, 2000, JAMA-J AM MED ASSOC, V23, P3045; Schlich D, 1987, PSYCHO, V13, P440; Schmidt U, 1993, Fortschr Med, V111, P339; SCHMIDT U, 1989, PSYCHO, V15, P665; Schrader E, 1998, HUM PSYCHOPHARM CLIN, V13, P163, DOI 10.1002/(SICI)1099-1077(199804)13:3<163::AID-HUP5>3.3.CO;2-9; Schrader E, 2000, INT CLIN PSYCHOPHARM, V15, P61, DOI 10.1097/00004850-200015020-00001; SOMMER H, 1994, J GERIATR PSYCHIA S1, V7, P9; STEGER W, 1985, Z ALLG MED, V61, P914; Vastag B, 2000, JAMA-J AM MED ASSOC, V284, P2983, DOI 10.1001/jama.284.23.2983; Vorbach EU, 1997, PHARMACOPSYCHIATRY, V30, P81, DOI 10.1055/s-2007-979524; VORBACH EU, 1994, J GERIATR PSYCHIA S1, V7, P19; WARNECKE G, 1986, Z ALLGEMEINMED, V62, P1111; WERTH W, 1989, KASSENARZT, V15, P64; Wheatley D, 1997, PHARMACOPSYCHIATRY, V30, P77, DOI 10.1055/s-2007-979523; *WHO, 2000, JAMA-J AM MED ASSOC, V284, P3043; WILLIAMS JBW, 1988, ARCH GEN PSYCHIAT, V45, P742; Witte B, 1995, Fortschr Med, V113, P404; Woelk H, 2000, BMJ-BRIT MED J, V321, P536, DOI 10.1136/bmj.321.7260.536	58	251	261	1	27	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 18	2001	285	15					1978	1986		10.1001/jama.285.15.1978	http://dx.doi.org/10.1001/jama.285.15.1978			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	420FY	11308434				2023-01-03	WOS:000167995900026
J	Kinsinger, LS; Harris, R; Woolf, SH; Sox, HC; Lohr, KN				Kinsinger, LS; Harris, R; Woolf, SH; Sox, HC; Lohr, KN			Chemoprevention of breast cancer: A summary of the evidence for the US Preventive Services Task Force	ANNALS OF INTERNAL MEDICINE			English	Article							SURGICAL ADJUVANT BREAST; BOWEL PROJECT P-1; QUALITY-OF-LIFE; POSTMENOPAUSAL WOMEN; RANDOMIZED-TRIAL; TAMOXIFEN THERAPY; HYSTERECTOMIZED WOMEN; CARDIOVASCULAR HEALTH; ESTROGEN-RECEPTORS; SERUM ESTRADIOL	Purpose: Chemoprevention offers promise as a strategy for reducing morbidity and mortality from breast cancer in women. This review examined the evidence for the effectiveness of chemoprevention in women without a history of breast cancer. Data Sources: MEDLINE (1966 to December 2001). Study Selection: English-language, randomized, controlled trials (RCTs) of chemoprevention of breast cancer in women without a previous diagnosis of breast cancer were examined, and 4 relevant trials, 3 involving tamoxifen and 1 involving raloxifene, were selected. Trials that provided data on the harms of tamoxifen or raloxifene, studies of the costs of chemoprevention, and studies of risk assessment were also reviewed. Data Extraction: Four reviewers independently abstracted data on key variables, including study population, sample size, randomization, treatment, and outcomes. Data Synthesis: The largest of the RCTs of tamoxifen reported a 49% reduction in relative risk (0.51 [95% Cl, 0.39 to 0.66]) for invasive cancer among women with an estimated 5-year breast cancer risk of at least 1.66%. The other tamoxifen trials did not observe a statistically significant benefit, but only a few women in each trial took tamoxifen during the entire study period. The raloxifene study of postmenopausal women with osteoporosis found a 76% reduction in relative risk (0.24 [Cl, 0.13 to 0.44]) for invasive breast cancer. Tamoxifen and raloxifene were effective only against estrogen receptor-positive tumors. Both drugs increased risk for venous thromboembolic disease and hot flashes; tamoxifen increased risk for endometrial cancer and stroke. Conclusions: Tamoxifen and raloxifene reduce the incidence of estrogen receptor-positive breast cancer in women. The relative risk reduction seems similar across all breast cancer risk groups. The absolute risk reduction varies by risk factors for breast cancer, however, and must be balanced against the potential harms to judge the appropriateness of treatment for individual women.	Univ N Carolina, Cecil G Sheps Ctr Hlth Serv Res, Chapel Hill, NC 27514 USA; Virginia Commonwealth Univ, Fairfax, VA USA; Amer Coll Physicians, Amer Soc Internal Med, Philadelphia, PA USA; Res Triangle Inst, Res Triangle Pk, NC 27709 USA	University of North Carolina; University of North Carolina Chapel Hill; Virginia Commonwealth University; American College of Physicians; Research Triangle Institute	Kinsinger, LS (corresponding author), Univ N Carolina, Cecil G Sheps Ctr Hlth Serv Res, Chapel Hill, NC 27514 USA.			Lohr, Kathleen/0000-0002-3825-0713	PHS HHS [290-97-0011] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		[Anonymous], 1992, Lancet, V339, P1; [Anonymous], 1998, LANCET, V351, P1451; Armstrong K, 2000, NEW ENGL J MED, V342, P564, DOI 10.1056/NEJM200002243420807; Barrett-Connor E, 2002, JAMA-J AM MED ASSOC, V287, P847, DOI 10.1001/jama.287.7.847; Barrett-Connor E, 1998, MATURITAS, V31, P1; Benichou J, 1996, J CLIN ONCOL, V14, P103, DOI 10.1200/JCO.1996.14.1.103; BONDY ML, 1994, J NATL CANCER I, V86, P620, DOI 10.1093/jnci/86.8.620; BRODERICK JP, 1989, STROKE, V20, P577, DOI 10.1161/01.STR.20.5.577; Bruzzi P, 1998, BRIT MED J, V316, P1181, DOI 10.1136/bmj.316.7139.1181; Cauley JA, 2001, BREAST CANCER RES TR, V65, P125, DOI 10.1023/A:1006478317173; Cauley JA, 1999, ANN INTERN MED, V130, P270, DOI 10.7326/0003-4819-130-4_Part_1-199902160-00004; Chu KC, 1996, JNCI-J NATL CANCER I, V88, P1571, DOI 10.1093/jnci/88.21.1571; Costantino JP, 1999, J NATL CANCER I, V91, P1541, DOI 10.1093/jnci/91.18.1541; Cummings SR, 1999, JAMA-J AM MED ASSOC, V281, P2189, DOI 10.1001/jama.281.23.2189; Cummings SR, 2002, JAMA-J AM MED ASSOC, V287, P216, DOI 10.1001/jama.287.2.216; Cuzick J, 2001, ANN NY ACAD SCI, V949, P123; Daly E, 1996, LANCET, V348, P977, DOI 10.1016/S0140-6736(96)07113-9; Day R, 1999, J CLIN ONCOL, V17, P2659, DOI 10.1200/JCO.1999.17.9.2659; Ettinger B, 1999, JAMA-J AM MED ASSOC, V282, P637, DOI 10.1001/jama.282.7.637; Fisher B, 1992, J Natl Cancer Inst Monogr, P105; Fisher B, 1999, LANCET, V353, P1993, DOI 10.1016/S0140-6736(99)05036-9; Fisher B, 1998, J NATL CANCER I, V90, P1371, DOI 10.1093/jnci/90.18.1371; Fisher B, 1996, JNCI-J NATL CANCER I, V88, P1529, DOI 10.1093/jnci/88.21.1529; Fisher D, 1997, ARACHNE, V4, P78; GAIL MH, 1989, J NATL CANCER I, V81, P1879, DOI 10.1093/jnci/81.24.1879; Gail MH, 1999, J NATL CANCER I, V91, P1829, DOI 10.1093/jnci/91.21.1829; Gail MH, 2001, J NATL CANCER I, V93, P334, DOI 10.1093/jnci/93.5.334; Ganz PA, 2002, JNCI-J NATL CANCER I, V94, P39; Grann VR, 2000, CANCER J, V6, P169; HABEL LA, 1993, EPIDEMIOL REV, V15, P209, DOI 10.1093/oxfordjournals.epirev.a036107; Hankinson SE, 1998, JNCI-J NATL CANCER I, V90, P1292, DOI 10.1093/jnci/90.17.1292; Harris RP, 2001, AM J PREV MED, V20, P21, DOI 10.1016/S0749-3797(01)00261-6; HULKA BS, 1995, LANCET, V346, P883, DOI 10.1016/S0140-6736(95)92713-1; Jemal A, 2002, CA-CANCER J CLIN, V52, P23, DOI 10.3322/canjclin.52.1.23; KELSEY JL, 1993, EPIDEMIOL REV, V15, P36, DOI 10.1093/oxfordjournals.epirev.a036115; Kelsey JL, 1996, ANNU REV PUBL HEALTH, V17, P47, DOI 10.1146/annurev.pu.17.050196.000403; King MC, 2001, JAMA-J AM MED ASSOC, V286, P2251, DOI 10.1001/jama.286.18.2251; KINSINGER L, 2001, IN PRESS CHEMOPROPHY; Kinsinger L S, 2001, Breast Dis, V13, P21; Kuller L, 1998, ARTERIOSCL THROM VAS, V18, P283, DOI 10.1161/01.ATV.18.2.283; LeBlanc ES, 1999, J GEN INTERN MED, V14, P625, DOI 10.1046/j.1525-1497.1999.08108.x; Lippman SM, 1999, JNCI-J NATL CANCER I, V91, P1809, DOI 10.1093/jnci/91.21.1809; LOVE RR, 1990, JNCI-J NATL CANCER I, V82, P1327, DOI 10.1093/jnci/82.16.1327; MacGregor JI, 1998, PHARMACOL REV, V50, P151; Manolio TA, 1996, STROKE, V27, P1479, DOI 10.1161/01.STR.27.9.1479; *NCI NSABP, 2002, PREV STUD TAM RAL ST; *NCI NSABP, 2002, BREAST CANC RISK ASS; Noe LL, 1999, AM J MANAG CARE, V5, pS389; POTTER JD, 1995, CANCER EPIDEM BIOMAR, V4, P319; Powles T, 1998, LANCET, V352, P98; Radmacher MD, 2000, J NATL CANCER I, V92, P48, DOI 10.1093/jnci/92.1.48; Rockhill B, 2001, J NATL CANCER I, V93, P358, DOI 10.1093/jnci/93.5.358; Rockhill B, 2000, J NATL CANCER I, V92, P657, DOI 10.1093/jnci/92.8.657A; Rosamond WD, 1999, STROKE, V30, P736, DOI 10.1161/01.STR.30.4.736; RUTQVIST LE, 1991, J NATL CANCER I, V83, P1299, DOI 10.1093/jnci/83.18.1299; SACCO RL, 1991, STROKE, V22, P1491, DOI 10.1161/01.STR.22.12.1491; Silverstein MD, 1998, ARCH INTERN MED, V158, P585, DOI 10.1001/archinte.158.6.585; SPIEGELMAN D, 1994, J NATL CANCER I, V86, P600, DOI 10.1093/jnci/86.8.600; STANFORD JL, 1986, EPIDEMIOL REV, V8, P42, DOI 10.1093/oxfordjournals.epirev.a036295; Stewart H J, 1992, J Natl Cancer Inst Monogr, P117; Stewart HJ, 2001, JNCI-J NATL CANCER I, V93, P456, DOI 10.1093/jnci/93.6.456; Taylor AL, 1999, J NATL CANCER I, V91, P1792, DOI 10.1093/jnci/91.21.1792; TONIOLO PG, 1995, JNCI-J NATL CANCER I, V87, P190, DOI 10.1093/jnci/87.3.190; Verloop J, 2000, J NATL CANCER I, V92, P128, DOI 10.1093/jnci/92.2.128; Veronesi U, 1998, LANCET, V352, P93; Veronesi U, 2002, LANCET, V359, P1122, DOI 10.1016/S0140-6736(02)08159-X; Veronesi U, 1999, J NATL CANCER I, V91, P1847, DOI 10.1093/jnci/91.21.1847; Walsh BW, 1998, JAMA-J AM MED ASSOC, V279, P1445, DOI 10.1001/jama.279.18.1445; Whisnant JP, 1996, NEUROLOGY, V47, P1420, DOI 10.1212/WNL.47.6.1420; Zhang YQ, 1997, NEW ENGL J MED, V336, P611, DOI 10.1056/NEJM199702273360903; Zmuda JM, 2001, J NATL CANCER I, V93, P930, DOI 10.1093/jnci/93.12.930; 2002, MMWR MORB MORTAL WKL, V51, P49; 1999, J NATL CANC I MONOGR, V25, P1	73	81	84	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUL 2	2002	137	1					59	67		10.7326/0003-4819-137-1-200207020-00017	http://dx.doi.org/10.7326/0003-4819-137-1-200207020-00017			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	569VA	12093250				2023-01-03	WOS:000176622000011
J	Bottomley, A				Bottomley, A			Metastatic colorectal cancer: treatment challenges and quality of life	LANCET			English	Editorial Material							RANDOMIZED CONTROLLED TRIALS; OF-LIFE		European Org Res Treatment Canc, EORTC Data Ctr, Qual Life Unit, B-1200 Brussels, Belgium	European Organisation for Research & Treatment of Cancer	Bottomley, A (corresponding author), European Org Res Treatment Canc, EORTC Data Ctr, Qual Life Unit, B-1200 Brussels, Belgium.	abo@eortc.be						Bottomley A, 2002, LANCET ONCOL, V3, P145, DOI 10.1016/S1470-2045(02)00677-0; Colorectal Canc Collaborative Grp, 2000, BMJ-BRIT MED J, V321, P531; Fayers P., 2013, QUALITY LIFE ASSESSM; FLECHTNER H, 2002, EXPERT REV PHARM OUT, V2, P89; Kong SX, 1997, ANN PHARMACOTHER, V31, P830, DOI 10.1177/106002809703100703; Kramer JA, 2000, EUR J CANCER, V36, P1488, DOI 10.1016/S0959-8049(00)00134-9; Marshall M, 2000, BRIT J PSYCHIAT, V176, P249, DOI 10.1192/bjp.176.3.249; Sanders C, 1998, BRIT MED J, V317, P1191, DOI 10.1136/bmj.317.7167.1191	8	3	4	0	1	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	MAY 4	2002	359	9317					1537	1538		10.1016/S0140-6736(02)08526-4	http://dx.doi.org/10.1016/S0140-6736(02)08526-4			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	549RN	12047959				2023-01-03	WOS:000175460700003
J	Kouroukis, CT; Browman, GP; Esmail, R; Meyer, RM				Kouroukis, CT; Browman, GP; Esmail, R; Meyer, RM			Chemotherapy for older patients with newly diagnosed, advanced-stage, aggressive-histology non-Hodgkin lymphoma: A systematic review	ANNALS OF INTERNAL MEDICINE			English	Review							COLONY-STIMULATING FACTOR; STANDARD REGIMEN CHOP; FACTOR G-CSF; ELDERLY-PATIENTS; RANDOMIZED-TRIAL; INTERMEDIATE-GRADE; MACOP-B; MULTICENTER; MANAGEMENT; PROGNOSIS	Purpose: To conduct a systematic review assessing chemotherapeutic regimens in patients at least 60 years of age with previously untreated, advanced-stage, aggressive-histology non-Hodgkin lymphoma. Data Sources: Computerized databases were searched for reports from 1966 to April 2000. Relevant journals, textbooks, and reference lists of published articles were hand searched. Abstract reports were not considered. Study Selection: Randomized trials comparing different chemotherapy regimens were selected. Two independent assessors, who were blinded to authors, institution, and results of the report, reviewed the retrieved citations. Data Extraction: One author abstracted data on patient characteristics, study quality score, survival, disease response and control, toxicity, and quality of life; pooling was not done because of study heterogeneity. Data Synthesis: 12 randomized trials that compared chemotherapeutic regimens were reviewed. Progression-free and overall survival were improved when anthracycline-containing regimens, such as CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) or CTVP (cyclophosphamide, pirarubicin, vincristine, and prednisone), were compared with other regimens. Conclusions: For treatment of older patients with advanced-stage, aggressive-histology lymphoma who do not have significant comorbid illnesses, an anthracycline-containing regimen, such as CHOP, given in standard doses and schedule, provides for superior outcomes compared with other regimens.	Hamilton Reg Canc Ctr, Hamilton, ON L8V 5C2, Canada; McMaster Univ, Hamilton, ON L8S 4L8, Canada; Hamilton Hlth Sci, Hamilton, ON, Canada	McMaster University; McMaster University; McMaster University	Meyer, RM (corresponding author), Hamilton Reg Canc Ctr, 699 Concess St, Hamilton, ON L8V 5C2, Canada.	ralph.meyer@hrec.on.ca						[Anonymous], 1994, J CLIN ONCOL, V12, P2471; Aoki S, 1998, J EXP CLIN CANC RES, V17, P465; Aviles A, 1997, ANTI-CANCER DRUG, V8, P937, DOI 10.1097/00001813-199711000-00004; Balducci L, 1997, CANCER, V80, P1317, DOI 10.1002/(SICI)1097-0142(19971001)80:7<1317::AID-CNCR18>3.3.CO;2-I; Bastion YB, 1997, J CLIN ONCOL, V15, P2945, DOI 10.1200/JCO.1997.15.8.2945; *BELL HOW INF LEAR, 1997, DIG DISS UMI PROQ; Bjorkholm M, 1999, BLOOD, V94, p599A; Chan WC, 1997, ANN ONCOL, V8, P973; Chen CI, 2000, LEUKEMIA LYMPHOMA, V38, P327, DOI 10.3109/10428190009087023; Coiffier B, 2000, BLOOD, V96, p223A; Cook DJ, 1997, ANN INTERN MED, V126, P376, DOI 10.7326/0003-4819-126-5-199703010-00006; COOPER IA, 1994, J CLIN ONCOL, V12, P769, DOI 10.1200/JCO.1994.12.4.769; DELENA M, 1989, MED ONCOL TUMOR PHAR, V6, P163, DOI 10.1007/BF02985240; Doorduijn JK, 2000, BLOOD, V96, p133A; FISHER RI, 1993, NEW ENGL J MED, V328, P1002, DOI 10.1056/NEJM199304083281404; GORDON LI, 1992, NEW ENGL J MED, V327, P1342, DOI 10.1056/NEJM199211053271903; GREGOIRE G, 1995, J CLIN EPIDEMIOL, V48, P159, DOI 10.1016/0895-4356(94)00098-B; Greil R, 1998, ONCOLOGY-BASEL, V55, P189, DOI 10.1159/000011855; GREINER TC, 1995, CANCER-AM CANCER SOC, V75, P370, DOI 10.1002/1097-0142(19950101)75:1+<370::AID-CNCR2820751319>3.0.CO;2-Q; Haioun C, 1997, J CLIN ONCOL, V15, P1131, DOI 10.1200/JCO.1997.15.3.1131; Jadad AR, 1996, CONTROL CLIN TRIALS, V17, P1, DOI 10.1016/0197-2456(95)00134-4; Jelic S, 1999, NEOPLASMA, V46, P394; LANDIS JR, 1977, BIOMETRICS, V33, P159, DOI 10.2307/2529310; Lichtman SM, 2000, CRIT REV ONCOL HEMAT, V33, P119, DOI 10.1016/S1040-8428(99)00061-X; Martelli M, 1997, DRUGS, V53, P957, DOI 10.2165/00003495-199753060-00005; MCKELVEY EM, 1976, CANCER, V38, P1484, DOI 10.1002/1097-0142(197610)38:4<1484::AID-CNCR2820380407>3.0.CO;2-I; MEYER RM, 1995, J CLIN ONCOL, V13, P2386, DOI 10.1200/JCO.1995.13.9.2386; Moher D, 1996, LANCET, V347, P363, DOI 10.1016/S0140-6736(96)90538-3; Montserrat E, 1996, EUR J HAEMATOL, V57, P377; OReilly SE, 1997, CLIN GERIATR MED, V13, P251; OXMAN AD, 1992, ANN INTERN MED, V116, P78, DOI 10.7326/0003-4819-116-1-78; ROSENBERG SA, 1982, CANCER, V49, P2112; Rusthoven J, 1998, Cancer Prev Control, V2, P179; SHIPP MA, 1993, NEW ENGL J MED, V329, P987, DOI 10.1056/nejm199309303291402; SILINGARDI V, 1995, LEUKEMIA LYMPHOMA, V17, P313, DOI 10.3109/10428199509056837; SONNEVELD P, 1995, J CLIN ONCOL, V13, P2530, DOI 10.1200/JCO.1995.13.10.2530; Sweetenham J W, 1987, Baillieres Clin Haematol, V1, P493, DOI 10.1016/S0950-3536(87)80010-0; Tirelli U, 1998, J CLIN ONCOL, V16, P27, DOI 10.1200/JCO.1998.16.1.27; Tirellki Umberto, 1997, Rays (Rome), V22, P24; *US CENS BUR, 1996, P251130 US CENS BUR; van Spronsen DJ, 1999, ANN HEMATOL, V78, P315, DOI 10.1007/s002770050521; WALTER SD, 1988, PC AGREE VERSION 2 5; Zinzani PL, 1997, BLOOD, V89, P3974	43	34	35	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JAN 15	2002	136	2					144	152		10.7326/0003-4819-136-2-200201150-00012	http://dx.doi.org/10.7326/0003-4819-136-2-200201150-00012			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	512PZ	11790067				2023-01-03	WOS:000173333900007
J	Takata, TS; Page, RL; Joglar, JA				Takata, TS; Page, RL; Joglar, JA			Automated external defibrillators: Technical considerations and clinical promise	ANNALS OF INTERNAL MEDICINE			English	Review							HOSPITAL CARDIAC-ARREST; PUBLIC-ACCESS DEFIBRILLATION; HEART-ASSOCIATION REPORT; MEDICAL-SERVICES SYSTEM; 1ST-RESPONDER DEFIBRILLATION; VENTRICULAR-FIBRILLATION; PEDIATRIC DEFIBRILLATION; RAPID DEFIBRILLATION; COST-EFFECTIVENESS; MONOPHASIC SHOCKS	Early defibrillation is the most important determinant of survival for victims of cardiac arrest due to ventricular fibrillation. The automated external defibrillator (AED) was developed as the result of the American Heart Association's Public Access Defibrillation initiative. The goal of this Initiative Is to place AEDs in strategic locations so that laypersons with minimal training could promptly defibrillate victims of cardiac arrest. Because of changes in design and the use of alternative waveforms for defibrillation, the modem AED is compact and portable, simple to use, and highly efficacious; In addition, it requires little maintenance. Automated external defibrillators have been used successfully by traditional and nontraditional responders as well as laypersons. In special environments, such as casinos and commercial aircraft, AEDs have performed particularly well. State and federal legislation has eased concerns about AED use by extending legal protection to AED users under Good Samaritan laws. Since the experience continues to be positive, AEDs are being used in increasingly diverse community locations, and public awareness is growing. The American Heart Association's initiative is progressing rapidly.	Univ Texas, SW Med Ctr, Dept Internal Med, Div Cardiol, Dallas, TX 75390 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Joglar, JA (corresponding author), Univ Texas, SW Med Ctr, Dept Internal Med, Div Cardiol, Room CS7-102,5323 Harry Hines Blvd, Dallas, TX 75390 USA.	jose.joglar@utsouthwestern.edu	Page, Richard L./L-5501-2014	Page, Richard L./0000-0001-5603-1330				Alexander RE, 1999, J AM DENT ASSOC, V130, P837, DOI 10.14219/jada.archive.1999.0308; American Heart Association, 2020, CIRCULATION, V102, P60, DOI [10.1161/circ.102.suppl_1.I-60, DOI 10.1161/CIRC.102.SUPPL_1.I-60]; American Heart Association, 1997, 1998 HEART STROK STA; [Anonymous], 2000, OFF PRES FED REGIST, V65; Atkins DL, 1998, PEDIATRICS, V101, P393, DOI 10.1542/peds.101.3.393; ATKINS DL, 1994, PEDIATRICS, V94, P90; AUBLE TE, 1995, ANN EMERG MED, V25, P642, DOI 10.1016/S0196-0644(95)70178-8; BABBS CF, 1980, AM HEART J, V99, P734, DOI 10.1016/0002-8703(80)90623-7; BARDY GH, 1995, CIRCULATION, V91, P1768, DOI 10.1161/01.CIR.91.6.1768; Bardy GH, 1996, CIRCULATION, V94, P2507, DOI 10.1161/01.CIR.94.10.2507; BARDY GH, 1994, J CARDIOVASC ELECTR, V5, P725, DOI 10.1111/j.1540-8167.1994.tb01195.x; Becker L, 1998, CIRCULATION, V97, P2106, DOI 10.1161/01.CIR.97.21.2106; Brown J, 2000, JAMA-J AM MED ASSOC, V284, P1438, DOI 10.1001/jama.284.11.1438; Cecchin F, 2000, CIRCULATION, V102, P828; CUMMINS RO, 1984, LANCET, V2, P318; CUMMINS RO, 1990, JAMA-J AM MED ASSOC, V264, P1019, DOI 10.1001/jama.264.8.1019; Eisenberg MS, 2000, JAMA-J AM MED ASSOC, V284, P1435, DOI 10.1001/jama.284.11.1435; FLETCHER GF, 1977, JAMA-J AM MED ASSOC, V238, P2627, DOI 10.1001/jama.238.24.2627; Gliner Bradford E., 1998, Biomedical Instrumentation and Technology, V32, P631; Gundry JW, 1999, CIRCULATION, V100, P1703, DOI 10.1161/01.CIR.100.16.1703; JAGGARAO NSV, 1982, LANCET, V2, P73; KELLERMANN AL, 1993, JAMA-J AM MED ASSOC, V270, P1708, DOI 10.1001/jama.270.14.1708; KELLERMANN AL, 1993, ANN EMERG MED, V22, P1269, DOI 10.1016/S0196-0644(05)80105-2; LARSEN MP, 1993, ANN EMERG MED, V22, P1652, DOI 10.1016/S0196-0644(05)81302-2; Lazar R A, 1997, Bus Health, V15, P55; MARSDEN AK, 1995, BRIT MED J, V311, P49, DOI 10.1136/bmj.311.6996.49; MASON J, 1993, BRIT MED J, V306, P570, DOI 10.1136/bmj.306.6877.570; Mattioni TA, 1999, PACE, V22, P1648, DOI 10.1111/j.1540-8159.1999.tb00385.x; MEAD WF, 1976, CIRCULATION, V53, P187, DOI 10.1161/01.CIR.53.1.187; Mosesso VN, 1998, ANN EMERG MED, V32, P200, DOI 10.1016/S0196-0644(98)70137-4; Newman M, 1995, JEMS, V20, P32; Nichol G, 1998, CIRCULATION, V97, P1309, DOI 10.1161/01.CIR.97.13.1309; Nichol G, 1998, CIRCULATION, V97, P1315, DOI 10.1161/01.CIR.97.13.1315; ORourke MF, 1997, CIRCULATION, V96, P2849, DOI 10.1161/01.CIR.96.9.2849; Page RL, 2000, NEW ENGL J MED, V343, P1210, DOI 10.1056/NEJM200010263431702; Page RL, 2001, NEW ENGL J MED, V344, P773; PEREIRA J, 1999, WALL STREET J   0901, P102; SAMSON RA, 1995, AM J CARDIOL, V75, P544, DOI 10.1016/S0002-9149(99)80606-7; Schneider T, 2000, CIRCULATION, V102, P1780; Smith SC, 1998, CIRCULATION, V97, P1321, DOI 10.1161/01.CIR.97.13.1321; SoRelle R, 1999, CIRCULATION, V99, P2606, DOI 10.1161/01.CIR.99.20.2606; STULTS KR, 1986, CIRCULATION, V73, P701, DOI 10.1161/01.CIR.73.4.701; Valenzuela TD, 2000, NEW ENGL J MED, V343, P1206, DOI 10.1056/NEJM200010263431701; Valenzuela TD, 1997, CIRCULATION, V96, P3308; Waalewijn RA, 1998, RESUSCITATION, V38, P157, DOI 10.1016/S0300-9572(98)00102-6; WEAVER WD, 1988, NEW ENGL J MED, V319, P661, DOI 10.1056/NEJM198809153191101; WEISFELDT ML, 1995, CIRCULATION, V92, P2763, DOI 10.1161/01.CIR.92.9.2763; WEISFELDT ML, 1995, CIRCULATION, V92, P2740, DOI 10.1161/01.CIR.92.9.2740; White R D, 1997, J Interv Card Electrophysiol, V1, P203, DOI 10.1023/A:1009712721915; White RD, 1996, ANN EMERG MED, V28, P480, DOI 10.1016/S0196-0644(96)70109-9; White RD, 1998, RESUSCITATION, V39, P145, DOI 10.1016/S0300-9572(98)00135-X; Willoughby PJ, 2000, CIRCULATION, V102, P828	52	29	30	0	6	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	DEC 4	2001	135	11					990	998		10.7326/0003-4819-135-11-200112040-00011	http://dx.doi.org/10.7326/0003-4819-135-11-200112040-00011			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	498PN	11730400				2023-01-03	WOS:000172520000006
J	Reynolds, EE; Hyman, SE				Reynolds, EE; Hyman, SE			A 28-year-old man addicted to cocaine	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							DRUG-ABUSE; FAMILIAL TRANSMISSION; SUBSTANCE USE; DEPENDENCE; DISORDERS; ALCOHOL; PREVALENCE; DOPAMINE; OUTCOMES; NEURONS		NIMH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Mental Health (NIMH)	Hyman, SE (corresponding author), NIMH, 6001 Execut Blvd,Room 8235,MSC 9669, Bethesda, MD 20892 USA.	shyman@mail.nih.gov						American Psychiatric Association, 1994, DIAGN STAT MAN MENT; Berke JD, 2000, NEURON, V25, P515, DOI 10.1016/S0896-6273(00)81056-9; Berke JD, 1998, J NEUROSCI, V18, P5301, DOI 10.1523/JNEUROSCI.18-14-05301.1998; Biederman J, 1999, PEDIATRICS, V104, part. no., DOI 10.1542/peds.104.2.e20; Bierut LJ, 1998, ARCH GEN PSYCHIAT, V55, P982, DOI 10.1001/archpsyc.55.11.982; Breiter HC, 1997, NEURON, V19, P591, DOI 10.1016/S0896-6273(00)80374-8; Carrera MRA, 2001, P NATL ACAD SCI USA, V98, P1988, DOI 10.1073/pnas.041610998; Chappel JN, 1999, PSYCHIAT CLIN N AM, V22, P425, DOI 10.1016/S0193-953X(05)70085-X; Childress AR, 1999, AM J PSYCHIAT, V156, P11, DOI 10.1176/ajp.156.1.11; DICHIARA G, 1988, P NATL ACAD SCI USA, V85, P5274; FLELLIN DA, 2001, JAMA-J AM MED ASSOC, V286, P1724; Frank DA, 2001, JAMA-J AM MED ASSOC, V285, P1613, DOI 10.1001/jama.285.12.1613; GOODWIN DW, 1973, ARCH GEN PSYCHIAT, V28, P238; HIGGINS ST, 1991, AM J PSYCHIAT, V148, P1218; Hyman SE, 2001, NAT REV NEUROSCI, V2, P695, DOI 10.1038/35094560; HYMAN SE, 2001, SCI AM MED; Kendler KS, 2000, ARCH GEN PSYCHIAT, V57, P261, DOI 10.1001/archpsyc.57.3.261; Kilts CD, 2001, ARCH GEN PSYCHIAT, V58, P334, DOI 10.1001/archpsyc.58.4.334; Koob GF, 1997, SCIENCE, V278, P52, DOI 10.1126/science.278.5335.52; Kosofsky BE, 2001, J COMP NEUROL, V435, P259, DOI 10.1002/cne.1027; Lidow MS, 2001, J COMP NEUROL, V435, P263, DOI 10.1002/cne.1028; McLellan AT, 2000, JAMA-J AM MED ASSOC, V284, P1689, DOI 10.1001/jama.284.13.1689; Merikangas KR, 1998, PSYCHOL MED, V28, P773, DOI 10.1017/S0033291798006941; Merikangas KR, 1998, ARCH GEN PSYCHIAT, V55, P973, DOI 10.1001/archpsyc.55.11.973; Nestler E. J., 2001, MOL NEUROPHARMACOLOG, P355; Nestler EJ, 2001, NAT REV NEUROSCI, V2, P119, DOI 10.1038/35053570; Nestler EJ, 1996, NEURON, V16, P897, DOI 10.1016/S0896-6273(00)80110-5; O'Brien CP, 1998, J PSYCHOPHARMACOL, V12, P15, DOI 10.1177/026988119801200103; O'Leary G, 2000, Curr Psychiatry Rep, V2, P508, DOI 10.1007/s11920-000-0010-x; OBrien CP, 1997, SCIENCE, V278, P66, DOI 10.1126/science.278.5335.66; OBRIEN CP, 1990, ADDICT BEHAV, V15, P355, DOI 10.1016/0306-4603(90)90045-Y; Piazza PV, 1996, ANNU REV PHARMACOL, V36, P359, DOI 10.1146/annurev.pa.36.040196.002043; Robinson TE, 1997, J NEUROSCI, V17, P8491; ROBINSON TE, 1993, BRAIN RES REV, V18, P247, DOI 10.1016/0165-0173(93)90013-P; ROBINSON TE, 1986, BRAIN RES REV, V11, P157, DOI 10.1016/0165-0173(86)90002-0; ROSS HE, 1988, ARCH GEN PSYCHIAT, V45, P1023; ROUNSAVILLE BJ, 1991, ARCH GEN PSYCHIAT, V48, P43; Schultz W, 1997, SCIENCE, V275, P1593, DOI 10.1126/science.275.5306.1593; Sigvardsson S, 1996, ARCH GEN PSYCHIAT, V53, P681; Simpson DD, 1999, ARCH GEN PSYCHIAT, V56, P507, DOI 10.1001/archpsyc.56.6.507; Spanagel R, 1997, TRENDS PHARMACOL SCI, V18, P54, DOI 10.1016/S0165-6147(97)89800-8; *SUBST AB MENT HLT, 1999, SUMM FIND 1998 NAT H, P74; Tsuang MT, 1996, AM J MED GENET, V67, P473, DOI 10.1002/(SICI)1096-8628(19960920)67:5<473::AID-AJMG6>3.3.CO;2-D; *US DHHS CDCP NAT, 2001, FASTATS A Z; Volpicelli JR, 1997, ARCH GEN PSYCHIAT, V54, P737; WARNER LA, 1995, ARCH GEN PSYCHIAT, V52, P219; Weisner C, 2001, JAMA-J AM MED ASSOC, V286, P1715, DOI 10.1001/jama.286.14.1715; White NM, 1996, ADDICTION, V91, P921, DOI 10.1111/j.1360-0443.1996.tb03586.x; WHITE NM, 1989, NEUROSCI BIOBEHAV R, V13, P181, DOI 10.1016/S0149-7634(89)80028-4; *WORK GROUP SUBST, 1995, PRACT GUID TREATM PA	50	11	11	0	4	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 28	2001	286	20					2586	2594		10.1001/jama.286.20.2586	http://dx.doi.org/10.1001/jama.286.20.2586			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	496FH	11722273				2023-01-03	WOS:000172385200033
J	Vandenbroucke, JP; de Craen, AJM				Vandenbroucke, JP; de Craen, AJM			Alternative medicine: A "mirror image" for scientific reasoning in conventional medicine	ANNALS OF INTERNAL MEDICINE			English	Article							CONTROLLED-TRIALS; CLINICAL-TRIALS; VASOVAGAL SYNCOPE; HOMEOPATHY; METAANALYSIS; PACEMAKER; INDUSTRY	A reflection on the scientific behavior of adherents of conventional medicine toward one form of alternative medicine-homeopathy-teaches us that physicians do reject seemingly solid evidence because it is not compatible with theory. Further reflection, however, shows that physicians do the same within conventional medical science: Sometimes they discard a theory because of new facts, but at other times they cling to a theory despite the facts. This essay highlights the seeming contradiction and discusses whether it still permits the building of rational medical science. We propose that rational science Is compatible with physicians' behavior, provided that physicians acknowledge the subjective element in the evaluation of science, as exemplified in the crossword analogy by the philosopher Haack. This type of thinking fits very well with the Bayesian approach to decision making that has been advocated for decades in clinical medicine. It does not lead to complete and uncontrollable subjectivity because discernment between rivaling explanations is still possible through argument and counterargument.	Leiden Univ, Med Ctr, Dept Clin Epidemiol, NL-2300 RC Leiden, Netherlands	Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC	Vandenbroucke, JP (corresponding author), Leiden Univ, Med Ctr, Dept Clin Epidemiol, Bldg 1,POB 9600, NL-2300 RC Leiden, Netherlands.	vdbroucke@mail.medfac.leidenuniv.nl	Vandenbroucke, Jan/AAM-3928-2020	Vandenbroucke, Jan/0000-0001-5668-6716				Benson K, 2000, NEW ENGL J MED, V342, P1878, DOI 10.1056/NEJM200006223422506; Bodenheimer T, 2000, NEW ENGL J MED, V342, P1539, DOI 10.1056/NEJM200005183422024; Boissel JP, 1996, CRITICAL LIT REV EFF; Bone RC, 1996, ANN INTERN MED, V125, P680, DOI 10.7326/0003-4819-125-8-199610150-00009; BROWNER WS, 1987, JAMA-J AM MED ASSOC, V257, P2459, DOI 10.1001/jama.257.18.2459; Concato J, 2000, NEW ENGL J MED, V342, P1887, DOI 10.1056/NEJM200006223422507; Connolly SJ, 1999, J AM COLL CARDIOL, V33, P16, DOI 10.1016/S0735-1097(98)00549-X; CORNFIELD J, 1976, AM J EPIDEMIOL, V104, P408, DOI 10.1093/oxfordjournals.aje.a112313; Djulbegovic B, 2000, LANCET, V356, P635, DOI 10.1016/S0140-6736(00)02605-2; el-Bedawi K M, 1994, Clin Auton Res, V4, P41; Ernst E, 1996, ARCH INTERN MED, V156, P2162, DOI 10.1001/archinte.156.19.2162; Goodman SN, 1999, ANN INTERN MED, V130, P995, DOI 10.7326/0003-4819-130-12-199906150-00008; Gould SJ, 2000, SCIENCE, V287, P253, DOI 10.1126/science.287.5451.253; Haack S., 1998, MANIFESTO PASSIONATE; KLEIJNEN J, 1991, BRIT MED J, V302, P316, DOI 10.1136/bmj.302.6772.316; Langman MJS, 1997, LANCET, V350, P825, DOI 10.1016/S0140-6736(05)62025-9; Linde K, 1997, LANCET, V350, P834, DOI 10.1016/S0140-6736(97)02293-9; OBRIEN E, 1980, LANCET, V2, P1356; Pocock SJ, 2000, NEW ENGL J MED, V342, P1907, DOI 10.1056/NEJM200006223422511; ROCHON PA, 1994, ARCH INTERN MED, V154, P157, DOI 10.1001/archinte.154.2.157; SKRABANEK P, 1986, LANCET, V1, P960; Sterne J, 2001, SYSTEMATIC REV HLTH; Sutton R, 2000, CIRCULATION, V102, P294; Vandenbroucke JP, 1998, LANCET, V352, P2001, DOI 10.1016/S0140-6736(98)10208-8; Vandenbroucke JP, 1997, LANCET, V350, P824, DOI 10.1016/S0140-6736(97)22038-6; Vincent JL, 1998, LANCET, V351, P922; WARREN HS, 1992, NEW ENGL J MED, V326, P1153, DOI 10.1056/NEJM199204233261711; Westendorp RGJ, 1997, LANCET, V349, P170, DOI 10.1016/S0140-6736(96)06413-6; WIERSMA TJ, 1988, KENNIS METHODE, V12, P295; ZIEGLER EJ, 1991, NEW ENGL J MED, V324, P429, DOI 10.1056/NEJM199102143240701	31	57	58	0	6	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	OCT 2	2001	135	7					507	513		10.7326/0003-4819-135-7-200110020-00010	http://dx.doi.org/10.7326/0003-4819-135-7-200110020-00010			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	477EF	11578154				2023-01-03	WOS:000171269600005
J	Langevin, HM; Churchill, DL; Cipolla, MJ				Langevin, HM; Churchill, DL; Cipolla, MJ			Mechanical signaling through connective tissue: a mechanism for the therapeutic effect of acupuncture	FASEB JOURNAL			English	Article						collagen; mechanotransduction; meridian	SMOOTH-MUSCLE-CELLS; EXTRACELLULAR-MATRIX; GENE-EXPRESSION; ENDOTHELIAL-CELLS; SHEAR-STRESS; NITRIC-OXIDE; C-FOS; FIBROBLASTS; FORCES; CYTOSKELETON	The mechanism of action of acupuncture remains largely unknown. The reaction to acupuncture needling known as 'de qi', widely viewed as essential to the therapeutic effect of acupuncture, may be a key to understanding its mechanism of action. De qi includes a characteristic needling sensation, perceived by the patient, and 'needle grasp' perceived by the acupuncturist. During needle grasp, the acupuncturist feels pulling and increased resistance to further movement of the inserted needle. We hypothesize that 1) needle grasp is due to mechanical coupling between the needle and connective tissue with winding of tissue around the needle during needle rotation and 2) needle manipulation transmits a mechanical signal to connective tissue cells via mechanotransduction. Such a mechanism may explain local and remote, as well as long-term effects of acupuncture.	Univ Vermont, Coll Med, Dept Neurol, Burlington, VT 05405 USA	University of Vermont	Langevin, HM (corresponding author), Univ Vermont, Coll Med, Dept Neurol, Given C423, Burlington, VT 05405 USA.	hlangevi@zoo.uvm.edu	Cipolla, Marilyn J./B-7098-2009		NATIONAL CENTER FOR COMPLEMENTARY &ALTERNATIVE MEDICINE [R01AT000133, R21AT000300] Funding Source: NIH RePORTER; NCCIH NIH HHS [R01 AT000133-02, R21 AT00300] Funding Source: Medline	NATIONAL CENTER FOR COMPLEMENTARY &ALTERNATIVE MEDICINE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Complementary & Alternative Medicine); NCCIH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Complementary & Alternative Medicine)		[Anonymous], 1997, NIH CONSENSUS STATEM, V15, P1; APPENZELLER O, 1994, AUTONOMIC NERVOUS SY; Aumailley M, 1998, J MOL MED-JMM, V76, P253, DOI 10.1007/s001090050215; Banes AJ, 1995, BIOCHEM CELL BIOL, V73, P349, DOI 10.1139/o95-043; Bao XP, 2000, AM J PHYSIOL-HEART C, V278, pH1598, DOI 10.1152/ajpheart.2000.278.5.H1598; BESSOU P, 1961, ARCH ITAL BIOL, V99, P293; Brand RA, 1997, ANN MED, V29, P267, DOI 10.3109/07853899708999346; BURRIDGE K, 1988, ANNU REV CELL BIOL, V4, P487, DOI 10.1146/annurev.cellbio.4.1.487; Cassapakis C., 1995, P 3 S SOC AC RES SEP, P1; Cheng X, 1987, CHINESE ACUPUNCTURE; Chicurel ME, 1998, CURR OPIN CELL BIOL, V10, P232, DOI 10.1016/S0955-0674(98)80145-2; Chiquet M, 1999, MATRIX BIOL, V18, P417, DOI 10.1016/S0945-053X(99)00039-6; CHIQUETEHRISMANN R, 1994, J CELL BIOL, V127, P2093, DOI 10.1083/jcb.127.6.2093; CLARK EA, 1995, SCIENCE, V268, P233, DOI 10.1126/science.7716514; DAIFOTIS AG, 1992, J BIOL CHEM, V267, P23455; DARTSCH PC, 1986, EUR J CELL BIOL, V41, P339; DENMEI S, 1990, INTRO MERIDIAN THERA; DESMOULIERE A, 1994, CELL MOTIL CYTOSKEL, V29, P195, DOI 10.1002/cm.970290302; DUBNER R, 1992, TRENDS NEUROSCI, V15, P96, DOI 10.1016/0166-2236(92)90019-5; DUNCAN RL, 1995, CALCIFIED TISSUE INT, V57, P344, DOI 10.1007/BF00302070; Ezzo J, 2000, PAIN, V86, P217, DOI 10.1016/S0304-3959(99)00304-8; Gan LM, 2000, FEBS LETT, V477, P89, DOI 10.1016/S0014-5793(00)01788-9; Giancotti FG, 1999, SCIENCE, V285, P1028, DOI 10.1126/science.285.5430.1028; Glogauer M, 1997, J CELL SCI, V110, P11; GUNN C C, 1976, American Journal of Chinese Medicine, V4, P183, DOI 10.1142/S0192415X76000238; GUNN CC, 1977, AM J ACUPUNCTURE, V5, P115; Gutierrez JA, 1999, AM J PHYSIOL-GASTR L, V277, pG1074, DOI 10.1152/ajpgi.1999.277.5.G1074; HARRIS AK, 1980, SCIENCE, V208, P177, DOI 10.1126/science.6987736; Heidemann SR, 1999, J CELL BIOL, V145, P109, DOI 10.1083/jcb.145.1.109; HELMES JM, 1995, ACUPUNCTURE ENERGETI; Hibbeler R.C., 1995, ENG MECH STATICS DYN; KIMURA M, 1992, AM J CHINESE MED, V20, P25, DOI 10.1142/S0192415X92000047; KOLODNEY MS, 1992, J CELL BIOL, V117, P73, DOI 10.1083/jcb.117.1.73; LANGEVIN HM, 2001, IN PRESS J APPL PHYS; LEVINE JD, 1993, J NEUROSCI, V13, P2273, DOI 10.1523/JNEUROSCI.13-06-02273.1993; Maniotis AJ, 1997, P NATL ACAD SCI USA, V94, P849, DOI 10.1073/pnas.94.3.849; Margolin A, 1998, JAMA-J AM MED ASSOC, V280, P1626, DOI 10.1001/jama.280.18.1626; Muller JM, 1997, CIRC RES, V80, P320, DOI 10.1161/01.RES.80.3.320; O'Callaghan CJ, 2000, HYPERTENSION, V36, P319, DOI 10.1161/01.HYP.36.3.319; Pavalko FM, 1998, AM J PHYSIOL-CELL PH, V275, pC1591; PIROLA CJ, 1994, ENDOCRINOLOGY, V134, P2230, DOI 10.1210/en.134.5.2230; Pohl U, 1996, PFLUG ARCH EUR J PHY, V432, pR107; Rosenfeldt H, 1998, MOL CELL BIOL, V18, P2659, DOI 10.1128/MCB.18.5.2659; RYAN TJ, 1989, J AM ACAD DERMATOL, V21, P115, DOI 10.1016/S0190-9622(89)70156-0; SAPPINO AP, 1990, LAB INVEST, V63, P144; *SHANGH COLL TRAD, 1987, AC COMPR TEXT; Stoltz JF, 2000, BIORHEOLOGY, V37, P3; Stux G, 1995, BASICS ACUPUNCTURE; SUGIMOTO K, 1991, EXP CELL RES, V196, P353, DOI 10.1016/0014-4827(91)90271-U; SUMPIO BE, 1988, J VASC SURG, V7, P130, DOI 10.1067/mva.1988.avs0070130; TILLMAN LJ, 1992, DYNAMICS HUMAN BIOL, P1; Tyagi SC, 1998, J CELL PHYSIOL, V176, P374, DOI 10.1002/(SICI)1097-4652(199808)176:2<374::AID-JCP16>3.0.CO;2-3; Ulett GA, 1998, BIOL PSYCHIAT, V44, P129, DOI 10.1016/S0006-3223(97)00394-6; van Wamel AJ, 2000, ARCH BIOCHEM BIOPHYS, V381, P67, DOI 10.1006/abbi.2000.1947; VINCENT CA, 1986, PAIN, V24, P1, DOI 10.1016/0304-3959(86)90022-9; WANG KM, 1985, SCI SIN B-CHEM B A M, V28, P963; WANG N, 1993, SCIENCE, V260, P1224; White AR, 1998, ALTERN THER HEALTH M, V4, P66; Williams B, 1998, J HYPERTENS, V16, P1921, DOI 10.1097/00004872-199816121-00011; Willis Jr W. D., 1991, SENSORY MECH SPINAL; Wilson E, 1998, HYPERTENSION, V31, P170, DOI 10.1161/01.HYP.31.1.170; WORSLEY JR, 1982, TRADITIONAL CHINESE, V1; YANG J, 1601, GOLDEN NEEDLE OTHER; Ziegler T, 1998, HYPERTENSION, V32, P351, DOI 10.1161/01.HYP.32.2.351; 1994, COMPLETE TRANSLATION	65	268	311	3	60	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	OCT	2001	15	12					2275	2282		10.1096/fj.01-0015hyp	http://dx.doi.org/10.1096/fj.01-0015hyp			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	488DM	11641255				2023-01-03	WOS:000171920400040
J	Korevaar, JC; Jansen, MAM; Dekker, FW; Jager, KJ; Boeschoten, EW; Krediet, RT; Bossuyt, PMM				Korevaar, JC; Jansen, MAM; Dekker, FW; Jager, KJ; Boeschoten, EW; Krediet, RT; Bossuyt, PMM		Netherlands Cooperative Study Adeq	When to initiate dialysis: effect of proposed US guidelines on survival	LANCET			English	Article							RESIDUAL RENAL-FUNCTION; PERITONEAL-DIALYSIS; CONTROLLED TRIALS; DISEASE; STAGE; PROGRESSION; PREDICTORS; PROTEIN; THERAPY	Background Recent guidelines from the US National Kidney Foundation Dialysis Outcomes Quality Initiative recommend an earlier start of dialysis treatment than has been common practice. Their implementation would have a substantial effect on patients' daily lives and would increase costs. The guidelines are largely opinion-based, because evidence is still lacking. Methods As part of a prospective multicentre study in the Netherlands, we included, between January, 1997, and May, 1999, all new patients with end-stage renal disease, for whom data were available on residual renal function 0-4 weeks before the start of dialysis. We recorded date of death or censoring until August, 2000. Findings 94 (37%) of 253 patients started dialysis treatment later than recommended by the US guideline. There was an increased mortality risk for these patients compared with those who started dialysis on time, although it was not significant (adjusted hazard ratio 1.66 [95% Cl 0.95-2-89]). The adjusted difference in estimated survival time after 3 years on dialysis treatment was 2.5 months (1.1-4.0) in favour of timely starters. Conversely, the average delay in dialysis initiation for late starters, the extra time free of dialysis, was at least 4.1 months. Interpretation Although we observed a gain in survival time with a timely start of dialysis, it is probably a reflection of initiating dialysis earlier in the disease. We question the benefit of putting this guideline into daily practice, given the current clinical evidence and the effects it would have on patients and dialysis resources.	Univ Amsterdam, Acad Med Ctr, Dept Clin Epidemiol & Biostat, NL-1100 DD Amsterdam, Netherlands; Univ Amsterdam, Acad Med Ctr, Dianet Dialysis Ctr, NL-1100 DD Amsterdam, Netherlands; Univ Amsterdam, Acad Med Ctr, Dept Nephrol, NL-1100 DD Amsterdam, Netherlands; Leiden Univ, Med Ctr, Dept Clin Epidemiol, Leiden, Netherlands	University of Amsterdam; Academic Medical Center Amsterdam; University of Amsterdam; Academic Medical Center Amsterdam; University of Amsterdam; Academic Medical Center Amsterdam; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC	Korevaar, JC (corresponding author), Univ Amsterdam, Acad Med Ctr, Dept Clin Epidemiol & Biostat, POB 22660, NL-1100 DD Amsterdam, Netherlands.		Bossuyt, Patrick M/AAR-1183-2021; Bossuyt, Patrick M./B-4557-2016; Jager, Kitty J/C-3887-2008; Dekker, Friedo W/B-6452-2011; Krediet, Raymond/GLT-2390-2022; Krediet, Raymond/AAP-3291-2021	Bossuyt, Patrick M/0000-0003-4427-0128; Bossuyt, Patrick M./0000-0003-4427-0128; Dekker, Friedo W/0000-0002-2433-2494; Krediet, Raymond/0000-0002-9851-8507; 				Benson K, 2000, NEW ENGL J MED, V342, P1878, DOI 10.1056/NEJM200006223422506; BERGSTROM J, 1993, KIDNEY INT, V44, P1048, DOI 10.1038/ki.1993.347; Bergstrom J, 1998, PERITON DIALYSIS INT, V18, P467; BONOMINI V, 1985, KIDNEY INT, V28, P57; Concato J, 2000, NEW ENGL J MED, V342, P1887, DOI 10.1056/NEJM200006223422507; Davies SJ, 1998, NEPHROL DIAL TRANSPL, V13, P962, DOI 10.1093/ndt/13.4.962; Fink JC, 1999, AM J KIDNEY DIS, V34, P694, DOI 10.1016/S0272-6386(99)70395-1; Gokal R, 2000, PERITON DIALYSIS INT, V20, P386; HAKIM RM, 1995, J AM SOC NEPHROL, V6, P1319; Hunsicker LG, 1997, KIDNEY INT, V51, P1908, DOI 10.1038/ki.1997.260; Ifudu O, 1998, AM J NEPHROL, V18, P193, DOI 10.1159/000013336; Jacobs C, 2000, NEPHROL DIAL TRANSPL, V15, P305, DOI 10.1093/ndt/15.3.305; KHAN IH, 1993, LANCET, V341, P415, DOI 10.1016/0140-6736(93)93003-J; Moist LM, 2000, J AM SOC NEPHROL, V11, P556, DOI 10.1681/ASN.V113556; *NAT KIDN FDN, 1997, AM J KIDNEY DIS S, V30, pS1; National Kidney Foundation, 1997, AM J KIDNEY DIS, V30, pS67; Obrador GT, 1999, KIDNEY INT, V56, P2227, DOI 10.1046/j.1523-1755.1999.00779.x; Samuelsson O, 1998, J AM SOC NEPHROL, V9, P1482; TATTERSALL J, 1995, AM J NEPHROL, V15, P283, DOI 10.1159/000168850; Tonelli M., 1998, Journal of the American Society of Nephrology, V9, p80A; Van Biesen W, 1999, PERITON DIALYSIS INT, V19, pS273; WATSON PE, 1980, AM J CLIN NUTR, V33, P27, DOI 10.1093/ajcn/33.1.27	22	158	165	0	2	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	SEP 29	2001	358	9287					1046	1050		10.1016/S0140-6736(01)06180-3	http://dx.doi.org/10.1016/S0140-6736(01)06180-3			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	479EY	11589934				2023-01-03	WOS:000171393100009
J	Edlin, BR; Seal, KH; Lorvick, J; Kral, AH; Ciccarone, DH; Moore, LD; Lo, B				Edlin, BR; Seal, KH; Lorvick, J; Kral, AH; Ciccarone, DH; Moore, LD; Lo, B			Is it justifiable to withhold treatment for hepatitis C from illicit-drug users?	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							DIRECTLY OBSERVED THERAPY; INTERFERON-ALPHA; ADHERENCE; TUBERCULOSIS; PROPHYLAXIS; COMBINATION; INFECTION; EQUIPMENT; EXCHANGE; SYRINGE		Univ Calif San Francisco, San Francisco, CA 94143 USA	University of California System; University of California San Francisco	Edlin, BR (corresponding author), Univ Calif San Francisco, Inst Hlth Policy Studies, Urban Hlth Study, 3180 18th St,Suite 302, San Francisco, CA 94110 USA.	bredlin@itsa.ucsf.edu	Edlin, Brian R/F-2966-2018; Ciccarone, Daniel/I-5404-2013	Edlin, Brian R/0000-0001-8172-8797; Lorvick, Jennifer/0000-0002-2836-3028; Kral, Alex/0000-0002-9092-3671; Ciccarone, Daniel/0000-0002-2355-5477	NATIONAL INSTITUTE ON DRUG ABUSE [R01DA013245] Funding Source: NIH RePORTER	NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)		[Anonymous], 1998, MMWR Recomm Rep, V47, P43; [Anonymous], 1998, MMWR Recomm Rep, V47, P1; Bamberger JD, 2000, AM J PUBLIC HEALTH, V90, P699, DOI 10.2105/AJPH.90.5.699; Bangsberg DR, 1999, J GEN INTERN MED, V14, P446, DOI 10.1046/j.1525-1497.1999.05109.x; Beauchamp TL, 1994, PRINCIPLES BIOMEDICA, V4th; Bluthenthal RN, 2000, AIDS, V14, P605, DOI 10.1097/00002030-200003310-00015; BROERS B, 1994, ARCH INTERN MED, V154, P1121, DOI 10.1001/archinte.154.10.1121; Burris S, 2000, ANN INTERN MED, V133, P218, DOI 10.7326/0003-4819-133-3-200008010-00015; Carpenter CCJ, 2000, JAMA-J AM MED ASSOC, V283, P381, DOI 10.1001/jama.283.3.381; Dieperink E, 2000, AM J PSYCHIAT, V157, P867, DOI 10.1176/appi.ajp.157.6.867; *EASL, 1999, J HEPATOL S1, V31, P3; Gerstein D., 1990, TREATING DRUG PROBLE; Gostin Lawrence O., 1999, HLTH HUMAN RIGHTS RE, P54; Gourevitch MN, 1996, J ADDICT DIS, V15, P93, DOI 10.1300/J069v15n01_07; Hagan H, 2001, AM J PUBLIC HEALTH, V91, P42, DOI 10.2105/AJPH.91.1.42; HARRISON K, 1995, J ACQ IMMUN DEF SYND, V10, P386; Haynes R. B., 1979, COMPLIANCE HLTH CARE; JANSSEN HLA, 1994, J HEPATOL, V21, P241, DOI 10.1016/S0168-8278(05)80402-7; King VL, 1999, METHADONE TREATMENT FOR OPIOID DEPENDENCE, P141; Lerner BH, 1998, ANN INTERN MED, V129, P573, DOI 10.7326/0003-4819-129-7-199810010-00012; Liang T. Jake, 2000, Annals of Internal Medicine, V132, P296; Lorvick J, 1999, J URBAN HEALTH, V76, P461, DOI 10.1007/BF02351503; Lorvick J, 2001, AM J PUBLIC HEALTH, V91, P46, DOI 10.2105/AJPH.91.1.46; Maddrey WC, 1999, SEMIN LIVER DIS, V19, P67; Marco A, 1998, EUR RESPIR J, V12, P967, DOI 10.1183/09031936.98.12040967; Marlatt G. A, 2012, HARM REDUCTION PRAGM; McHutchison JG, 1998, NEW ENGL J MED, V339, P1485, DOI 10.1056/NEJM199811193392101; Moatti JP, 2000, AIDS, V14, P151, DOI 10.1097/00002030-200001280-00010; *NIH, 1997, MAN HAP C, V15; *NIH, 1997, INT PREV HIV RISK BE, V15; NORMAND J, 1995, PREVENTING HIV TRANS; OCONNOR PG, 1994, NEW ENGL J MED, V331, P450, DOI 10.1056/NEJM199408183310707; *PAN CLIN PRACT TR, 2001, GUID US ANT AG HIV I; Pariante CM, 1999, LANCET, V354, P131, DOI 10.1016/S0140-6736(98)04793-X; *PUBL HLTH SERV, 1997, HIV PREV B MED ADV P; Quin JW, 1997, AUST NZ J MED, V27, P611, DOI 10.1111/j.1445-5994.1997.tb00985.x; RENAULT PF, 1987, ARCH INTERN MED, V147, P1577, DOI 10.1001/archinte.147.9.1577; ROBERTSON R, 1998, MANAGEMENT DRUG USER; Salomon N, 1997, INT J TUBERC LUNG D, V1, P397; Smirnoff M, 1998, INT J TUBERC LUNG D, V2, P134; Sorensen JL, 1998, AIDS CARE, V10, P297, DOI 10.1080/713612419; SYLVESTRE DL, 2000, ELIMINATING HLTH DIS, P422; THOMAS DL, 1995, MEDICINE, V74, P212, DOI 10.1097/00005792-199507000-00005; *US PREV SERV TASK, 1996, GUID CLIN PREV SERV, P591; Van Thiel DH, 1998, HEPATO-GASTROENTEROL, V45, P328; WARTENBERG AA, 1991, J GEN INTERN MED, V6, pS35, DOI 10.1007/BF02599256; WATTERS JK, 1994, JAMA-J AM MED ASSOC, V271, P115, DOI 10.1001/jama.271.2.115; WILLIAMS I, 1999, AM J MED S, V107, P2, DOI DOI 10.1016/S0002-9343(99)00373-3; Yano M, 1996, HEPATOLOGY, V23, P1334, DOI 10.1002/hep.510230607; Zeuzem S, 2000, NEW ENGL J MED, V343, P1666, DOI 10.1056/NEJM200012073432301	50	172	172	0	3	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUL 19	2001	345	3					211	214		10.1056/NEJM200107193450311	http://dx.doi.org/10.1056/NEJM200107193450311			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	453JM	11463019	Green Accepted			2023-01-03	WOS:000169912800011
J	Bottiger, BW; Bode, C; Kern, S; Gries, A; Gust, R; Glatzer, R; Bauer, H; Motsch, J; Martin, E				Bottiger, BW; Bode, C; Kern, S; Gries, A; Gust, R; Glatzer, R; Bauer, H; Motsch, J; Martin, E			Efficacy and safety of thrombolytic therapy after initially unsuccessful cardiopulmonary resuscitation: a perspective clinical trial	LANCET			English	Article							HOSPITAL CARDIAC-ARREST; MASSIVE PULMONARY-EMBOLISM; ACUTE MYOCARDIAL-INFARCTION; PLASMINOGEN-ACTIVATOR; UTSTEIN STYLE; BOLUS INJECTION; FIBRINOLYSIS; UROKINASE; AGENTS	Background During cardiopulmonary resuscitation (CPR), thrombolysis can help to stabilise patients with pulmonary embolism and myocardial infarction. Moreover, thrombolysis during CPR has beneficial effects on cerebral reperfusion after cardiac arrest. We investigated this new therapeutic approach in patients in whom conventional CPR had been unsuccessful. Methods We assessed, in a prospective study, patients undergoing CPR after out-of-hospital cardiac arrest for cardiological reasons in whom return of spontaneous circulation was not achieved within 15 min. According to the Ustein criteria, our control group consisted of patients who were assessed during 1 year. After this year patients were treated with a bolus of 5000 U of heparin and 50mg, over 2 min, of tissue-type plasminogen activator (rt-PA treated group). This intervention was repeated if return of spontaneous circulation was not achieved within the following 30 min. For controls only CPR was given. Findings Overall, 90 patients were included; heparin and rt-PA were given to 40 patients. There were no bleeding complications related to the CPR procedures. Of the rt-PA group, 68% (27) had return of spontaneous circulation and 58% (23) were admitted to a cardiac intensive care unit, compared with 44% (22; p=0.026) and 30% (15; p=0.009) of the controls, respectively. At 24 h after cardiac arrest a larger proportion of the rt-PA group than of the controls was alive (35% [14] vs 22% [11], p=0.171), and 15% (six) of rt-PA-treated patients and 8% (four) of controls could be discharged from hospital. Interpretation After initially unsuccessful out-of-hospital CPR, thrombolytic therapy combined with heparin is safe and might improve patient outcome. On the basis of our data a randomised controlled trial might be regarded as ethical.	Univ Heidelberg, Dept Anaesthesiol, D-69120 Heidelberg, Germany; Univ Heidelberg, Dept Internal Med, D-69120 Heidelberg, Germany; Univ Freiburg, Dept Internal Med, D-7800 Freiburg, Germany	Ruprecht Karls University Heidelberg; Ruprecht Karls University Heidelberg; University of Freiburg	Bottiger, BW (corresponding author), Univ Heidelberg, Dept Anaesthesiol, D-69120 Heidelberg, Germany.							BODE C, 1994, ANN HEMATOL, V69, pS35, DOI 10.1007/BF02215957; BOTTIGER BW, 1995, CIRCULATION, V92, P2572, DOI 10.1161/01.CIR.92.9.2572; Bottiger BW, 1999, HEART, V82, P674, DOI 10.1136/hrt.82.6.674; BOTTIGER BW, 1994, CHEST, V106, P1281, DOI 10.1378/chest.106.4.1281; BOTTIGER BW, 1994, RESUSCITATION, V28, P45, DOI 10.1016/0300-9572(94)90054-X; BOTTIGER BW, 1997, FIBRINOLYSIS S2, V1, P93; CROWELL JW, 1956, AM J PHYSIOL, V186, P283, DOI 10.1152/ajplegacy.1956.186.2.283; CROWELL JW, 1955, SURGERY, V38, P696; CUMMINS RO, 1991, CIRCULATION, V84, P960, DOI 10.1161/01.CIR.84.2.960; DARIUS H, 1986, J AM COLL CARDIOL, V8, P125, DOI 10.1016/S0735-1097(86)80102-4; *EM CARD CAR COMM, 1992, JAMA-J AM MED ASSOC, V268, P2171; FISCHER FD, 1995, MECH MATER, V21, P1, DOI 10.1016/0167-6636(94)00070-0; Fischer M, 1996, INTENS CARE MED, V22, P1214; Fischer M, 1997, RESUSCITATION, V33, P233, DOI 10.1016/S0300-9572(96)01022-2; Gando S, 1997, THROMB HAEMOSTASIS, V77, P278; Gaszynski W, 1975, Anaesth Resusc Intensive Ther, V3, P125; GOLDHABER SZ, 1992, J AM COLL CARDIOL, V20, P24, DOI 10.1016/0735-1097(92)90132-7; HARTVEIT F, 1970, J PATHOL, V102, P54, DOI 10.1002/path.1711020111; HEKMATPANAH J, 1973, NEUROLOGY, V23, P174, DOI 10.1212/WNL.23.2.174; HOLMBERG S, 1992, RESUSCITATION, V24, P103, DOI 10.1016/0300-9572(92)90015-5; Kim YH, 1999, SCIENCE, V284, P647, DOI 10.1126/science.284.5414.647; Kudenchuk PJ, 1999, NEW ENGL J MED, V341, P871, DOI 10.1056/NEJM199909163411203; LANGDON RW, 1989, ANN EMERG MED, V18, P678, DOI 10.1016/S0196-0644(89)80527-X; LIN SR, 1978, INVEST RADIOL, V13, P490, DOI 10.1097/00004424-197811000-00003; Newman DH, 2000, ANN EMERG MED, V35, P472, DOI 10.1016/S0196-0644(00)70008-4; Safar P, 1996, STROKE, V27, P105, DOI 10.1161/01.STR.27.1.105; Schiele Rudolf, 1996, Journal of the American College of Cardiology, V27, p279A; SCHOLZ KH, 1992, AM J CARDIOL, V69, P724, DOI 10.1016/0002-9149(92)90494-J; SILFVAST T, 1991, J INTERN MED, V229, P331, DOI 10.1111/j.1365-2796.1991.tb00355.x; Spaulding CM, 1997, NEW ENGL J MED, V336, P1629, DOI 10.1056/NEJM199706053362302; Tiffany PA, 1998, ANN EMERG MED, V31, P124, DOI 10.1016/S0196-0644(98)70295-1	31	202	221	0	8	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAY 19	2001	357	9268					1583	1585		10.1016/S0140-6736(00)04726-7	http://dx.doi.org/10.1016/S0140-6736(00)04726-7			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	434RR	11377646				2023-01-03	WOS:000168830100012
J	Tuomilehto, J; Lindstrom, J; Eriksson, JG; Valle, TT; Hamalainen, H; Ilanne-Parikka, P; Keinanen-Kiukaanniemi, S; Laakso, M; Louheranta, A; Rastas, M; Salminen, V; Uusitupa, M; Aunola, S; Cepaitis, Z; Moltchanov, V; Hakumaki, M; Mannelin, M; Martikkala, V; Sundvall, J				Tuomilehto, J; Lindstrom, J; Eriksson, JG; Valle, TT; Hamalainen, H; Ilanne-Parikka, P; Keinanen-Kiukaanniemi, S; Laakso, M; Louheranta, A; Rastas, M; Salminen, V; Uusitupa, M; Aunola, S; Cepaitis, Z; Moltchanov, V; Hakumaki, M; Mannelin, M; Martikkala, V; Sundvall, J		Finnish Diabet Prevention Study Gr	Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance.	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CORONARY-HEART-DISEASE; RISK-FACTORS; EXERCISE; NIDDM; DIET	Background: Type 2 diabetes mellitus is increasingly common, primarily because of increases in the prevalence of a sedentary lifestyle and obesity. Whether type 2 diabetes can be prevented by interventions that affect the lifestyles of subjects at high risk for the disease is not known. Methods: We randomly assigned 522 middle-aged, overweight subjects (172 men and 350 women; mean age, 55 years; mean body-mass index [weight in kilograms divided by the square of the height in meters], 31) with impaired glucose tolerance to either the intervention group or the control group. Each subject in the intervention group received individualized counseling aimed at reducing weight, total intake of fat, and intake of saturated fat and increasing intake of fiber and physical activity. An oral glucose-tolerance test was performed annually; the diagnosis of diabetes was confirmed by a second test. The mean duration of follow-up was 3.2 years. Results: The mean (+/-SD) amount of weight lost between base line and the end of year 1 was 4.2+/-5.1 kg in the intervention group and 0.8+/-3.7 kg in the control group; the net loss by the end of year 2 was 3.5+/-5.5 kg in the intervention group and 0.8+/-4.4 kg in the control group (P<0.001 for both comparisons between the groups). The cumulative incidence of diabetes after four years was 11 percent (95 percent confidence interval, 6 to 15 percent) in the intervention group and 23 percent (95 percent confidence interval, 17 to 29 percent) in the control group. During the trial, the risk of diabetes was reduced by 58 percent (P<0.001) in the intervention group. The reduction in the incidence of diabetes was directly associated with changes in lifestyle. Conclusions: Type 2 diabetes can be prevented by changes in the lifestyles of high-risk subjects. (N Engl J Med 2001;344:1343-50.) Copyright (C) 2001 Massachusetts Medical Society.	Natl Publ Hlth Inst, Dept Epidemiol & Hlth Promot, Diabet & Genet Epidemiol Unit, FIN-00300 Helsinki, Finland; Univ Helsinki, Dept Publ Hlth, FIN-00014 Helsinki, Finland; Social Insurance Inst, Ctr Res & Dev, Turku, Finland; Finnish Diabet Assoc, Dept Internal Med, Tampere, Finland; Tampere Univ Hosp, Tampere, Finland; Univ Oulu, Dept Publ Hlth Sci & Gen Practice, Oulu, Finland; Oulu Univ Hosp, Unit Gen Practice, Oulu, Finland; Univ Kuopio, Dept Clin Nutr, FIN-70211 Kuopio, Finland; Inst Nursing & Hlth Care, Tampere, Finland	Finland National Institute for Health & Welfare; University of Helsinki; Tampere University; Tampere University Hospital; University of Oulu; University of Oulu; University of Eastern Finland	Tuomilehto, J (corresponding author), Natl Publ Hlth Inst, Dept Epidemiol & Hlth Promot, Diabet & Genet Epidemiol Unit, Mannerheimintie 166, FIN-00300 Helsinki, Finland.	jaakko.tuomilehto@ktl.fi	Samaan, M. Constantine/R-1456-2017; Uusitupa, Matti Ilmari Julius/AAX-4929-2020; Cerviño, Alejandro/L-5853-2014	Samaan, M. Constantine/0000-0002-6403-4715; Cerviño, Alejandro/0000-0001-8014-3279; Lindstrom, Jaana/0000-0001-9255-020X				[Anonymous], 1994, World Health Organ Tech Rep Ser, V844, P1; Borch-Johnsen K, 1999, LANCET, V354, P617; Eriksson J, 1999, DIABETOLOGIA, V42, P793, DOI 10.1007/s001250051229; ERIKSSON KF, 1991, DIABETOLOGIA, V34, P891, DOI 10.1007/BF00400196; Haapa E., 1985, ANNOSKUVAKIRJA PICTU; Haffner SM, 2000, CIRCULATION, V101, P975, DOI 10.1161/01.CIR.101.9.975; HAMMAN RF, 1992, DIABETES METAB REV, V8, P287, DOI 10.1002/dmr.5610080402; HARRIS MI, 1989, DIABETES CARE, V12, P464, DOI 10.2337/diacare.12.7.464; HARRIS MI, 1993, DIABETES CARE, V16, P642, DOI 10.2337/diacare.16.4.642; KING H, 1990, DIABETOLOGIA, V33, P3, DOI 10.1007/BF00586454; MANSON JE, 1991, LANCET, V338, P774, DOI 10.1016/0140-6736(91)90664-B; NEEL JV, 1962, AM J HUM GENET, V14, P353; OHLSON LO, 1988, DIABETOLOGIA, V31, P798; Ovaskainen ML, 1996, FOOD CHEM, V57, P133, DOI 10.1016/0308-8146(96)00113-6; Pan XR, 1997, DIABETES CARE, V20, P537, DOI 10.2337/diacare.20.4.537; PARTANEN J, 1995, NEW ENGL J MED, V333, P89, DOI 10.1056/NEJM199507133330203; STERN MP, 1991, DIABETES CARE, V14, P399, DOI 10.2337/diacare.14.5.399; TUOMILEHTO J, 1987, DIABETES CARE, V10, P238, DOI 10.2337/diacare.10.2.238; Tuomilehto J, 1997, INT TXB DIABETES MEL, P1799; UUSITUPA M, 1985, DIABETOLOGIA, V28, P22, DOI 10.1007/BF00276995; World Health Organization, 1985, WHO TECH REP SER, V727, P7; ZIMMET PZ, 1988, DIABETES CARE, V11, P258, DOI 10.2337/diacare.11.3.258	22	5682	5925	18	68	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAY 3	2001	344	18					1343	1350		10.1056/NEJM200105033441801	http://dx.doi.org/10.1056/NEJM200105033441801			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	427NY	11333990				2023-01-03	WOS:000168413500001
J	Varma, C; Camm, AJ				Varma, C; Camm, AJ			Pacing for heart failure	LANCET			English	Review							SHORT ATRIOVENTRICULAR DELAY; DILATED CARDIOMYOPATHY; CHAMBER; PERMANENT; IMPROVEMENTS; ACTIVATION; SITES; BLOCK	Pacing for patients with severe heart failure without bradyarrhythmia has been proposed as an addition to medical therapy over the past decade. Alteration of the normal electrical activation sequence of the heart modifies its mechanical action, especially when ventricular function is poor. Both the site of ventricular-lead placement and timing with the atria have been manipulated in attempts to alleviate the symptoms of heart failure. Most recently, in addition to the conventional two leads used for pacing, a third lead to pace the left ventricle has been advocated in some patients with heart failure. We review the evidence for pacing in heart failure.	Univ London St Georges Hosp, Sch Med, Dept Cardiol Sci, London SW17 0RE, England	St Georges University London	Varma, C (corresponding author), Univ London St Georges Hosp, Sch Med, Dept Cardiol Sci, London SW17 0RE, England.	cvarma@sghms.ac.uk						ALPERT MA, 1986, J AM COLL CARDIOL, V7, P925, DOI 10.1016/S0735-1097(86)80358-8; Auricchio A, 1999, CIRCULATION, V99, P2993, DOI 10.1161/01.CIR.99.23.2993; Auricchio A, 1998, J AM COLL CARDIOL, V31, p31A, DOI 10.1016/S0735-1097(97)83850-8; AURICCHIO A, 1999, AM J CARDIOL, V83, P120; Bakker PF, 1994, PACE, V17, P820; Blanc JJ, 1997, CIRCULATION, V96, P3273; BRECKER SJD, 1992, LANCET, V340, P1308, DOI 10.1016/0140-6736(92)92492-X; Buckingham TA, 1997, PACE, V20, P909, DOI 10.1111/j.1540-8159.1997.tb05493.x; BUTTER C, 2000, PACING CLIN ELECTROP, V23, P589; Cazeau S, 2001, NEW ENGL J MED, V344, P873, DOI 10.1056/NEJM200103223441202; CAZEAU S, 1994, PACE, V17, P1974, DOI 10.1111/j.1540-8159.1994.tb03783.x; Cazeau S, 1996, PACE, V19, P1748, DOI 10.1111/j.1540-8159.1996.tb03218.x; COWELL R, 1994, PACE, V17, P1980, DOI 10.1111/j.1540-8159.1994.tb03784.x; Daubert JC, 1998, PACE, V21, P239, DOI 10.1111/j.1540-8159.1998.tb01096.x; DAUBERT JC, 2000, MUSTIC INVESTIGATORS; DEFAYE P, 1996, EUR J CARDIAC PACING, V6, P198; Deshmukh P, 2000, CIRCULATION, V101, P869, DOI 10.1161/01.CIR.101.8.869; Farwell D, 2000, EUR HEART J, V21, P1246, DOI 10.1053/euhj.1999.1985; GOLD MR, 1995, J AM COLL CARDIOL, V26, P967, DOI 10.1016/0735-1097(95)00292-0; Gold MR, 1997, AM J CARDIOL, V79, P679, DOI 10.1016/S0002-9149(96)00841-7; Gras D, 1998, PACE, V21, P2249, DOI 10.1111/j.1540-8159.1998.tb01162.x; Hamdan MH, 2000, CIRCULATION, V102, P1027, DOI 10.1161/01.CIR.102.9.1027; Higgins SL, 2000, J AM COLL CARDIOL, V36, P824, DOI 10.1016/S0735-1097(00)00795-6; HOCHLEITNER M, 1990, AM J CARDIOL, V66, P198, DOI 10.1016/0002-9149(90)90588-R; Kass DA, 1999, CIRCULATION, V99, P1567, DOI 10.1161/01.CIR.99.12.1567; Kerwin WF, 2000, J AM COLL CARDIOL, V35, P1221, DOI 10.1016/S0735-1097(00)00555-6; LANGENFELD H, 1998, PACING CLIN ELECTROP, V21, P559; Leclercq C, 2000, AM J CARDIOL, V85, P1154, DOI 10.1016/S0002-9149(00)00716-5; Leclercq C, 1998, J AM COLL CARDIOL, V32, P1825, DOI 10.1016/S0735-1097(98)00492-6; LINDE C, 1995, AM J CARDIOL, V75, P919, DOI 10.1016/S0002-9149(99)80687-0; Nelson GS, 2000, CIRCULATION, V102, P3053; Nelson GS, 2000, CIRCULATION, V101, P2703, DOI 10.1161/01.CIR.101.23.2703; NISHIMURA RA, 1995, J AM COLL CARDIOL, V25, P281, DOI 10.1016/0735-1097(94)00419-Q; PAPPONE C, 2000, PACING CLIN ELECTROP, V23, P635; Pitt B, 1999, NEW ENGL J MED, V341, P709, DOI 10.1056/NEJM199909023411001; SAXON L, 1999, AM J CARDIOL, V83, P130; SAXON LA, 2000, PACING CLIN ELECTROP, V22, P830; Varma C, 1999, CIRCULATION, V100, P515; VENKATESHAWAR K, 1999, J AM COLL CARDIOL, V33, pA145; Victor F, 1999, J AM COLL CARDIOL, V33, P311, DOI 10.1016/S0735-1097(98)00589-0; Walker S, 2000, PACE, V23, P985, DOI 10.1111/j.1540-8159.2000.tb00885.x; Wiggers CJ, 1925, AM J PHYSIOL, V73, P346, DOI 10.1152/ajplegacy.1925.73.2.346; WILENSKY RL, 1988, AM J CARDIOL, V62, P276, DOI 10.1016/0002-9149(88)90225-1; XIAO HB, 1993, BRIT HEART J, V69, P166; XIAO HB, 1994, BRIT HEART J, V72, P167; XIAO HB, 1992, BRIT HEART J, V68, P403	46	13	25	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	APR 21	2001	357	9264					1277	1283		10.1016/S0140-6736(00)04409-3	http://dx.doi.org/10.1016/S0140-6736(00)04409-3			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	425YY	11418172				2023-01-03	WOS:000168323300032
J	Winnett, M				Winnett, M			Cries and whiskers	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																			0	1	1	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 21	2002	288	7					806	806		10.1001/jama.288.7.806	http://dx.doi.org/10.1001/jama.288.7.806			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	585FC	12186579				2023-01-03	WOS:000177513100001
J	Egger, M; May, M; Chene, G; Phillips, AN; Ledergerber, B; Dabis, F; Costagliola, D; Monforte, AD; de Wolf, F; Reiss, P; Lundgren, JD; Justice, AC; Staszewski, S; Leport, C; Hogg, RS; Sabin, CA; Gill, MJ; Salzberger, B; Sterne, JAC				Egger, M; May, M; Chene, G; Phillips, AN; Ledergerber, B; Dabis, F; Costagliola, D; Monforte, AD; de Wolf, F; Reiss, P; Lundgren, JD; Justice, AC; Staszewski, S; Leport, C; Hogg, RS; Sabin, CA; Gill, MJ; Salzberger, B; Sterne, JAC		ART Cohort Collaboration	Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies	LANCET			English	Article							CD4 CELL COUNT; IMMUNODEFICIENCY-VIRUS-INFECTION; VIROLOGICAL RESPONSE; VIRAL LOAD; CLINICAL PROGRESSION; CONTROLLED-TRIAL; HIV-1 INFECTION; AIDS; MORTALITY; SURVIVAL	Background Insufficient data are available from single cohort studies to allow estimation of the prognosis of HIV-1 infected, treatment-naive patients who start highly active antiretroviral therapy (HAART). The ART Cohort Collaboration, which includes 13 cohort studies from Europe and North America, was established to fill this knowledge gap. Methods We analysed data on 12 574 adult patients starting HAART with a combination of at least three drugs. Data were analysed by intention-to-continue-treatment, ignoring treatment changes and interruptions. We considered progression to a combined endpoint of a new AIDS-defining disease or death, and to death alone. The prognostic model that generalised best was a Weibull model, stratified by baseline CD4 cell count and transmission group. Findings During 24 310 person-years of follow up, 1094 patients developed AIDS or died and 344 patients died. Baseline CD4 cell count was strongly associated with the probability of progression to AIDS or death: compared with patients starting HAART with less than 50 CD4 cells/muL, adjusted hazard ratios were 0.74 (95% CI 0.62-0.89) for 50-99 cells/muL, 0.52 (0.44-0.63) for 100-199 cells/muL, 0.24 (0.20-0.30) for 200-349 cells/muL, and 0.18 (0.14-0.22) for 350 or more CD4 cells/muL. Baseline HIV-1 viral load was associated with a higher probability of progression only if 100000 copies/mL or above. Other independent predictors of poorer outcome were advanced age, infection through injection-drug use, and a previous diagnosis of AIDS. The probability of progression to AIDS or death at 3 years ranged from 3.4% (2.8-4.1) in patients in the lowest-risk stratum for each prognostic variable, to 50% (43-58) in patients in the highest-risk strata. Interpretation The CD4 cell count at initiation was the dominant prognostic factor in patients starting HAART. Our findings have important implications for clinical management and should be taken into account in future treatment guidelines.	Univ Bern, Dept Social & Prevent Med, CH-3012 Bern, Switzerland; Univ Bristol, Dept Social Med, Bristol, Avon, England; Univ Victor Seglen, INSERM, U330, Bordeaux, France; UCL Royal Free & Univ Coll Med Sch, Dept Primary Care & Populat Sci, London, England; Univ Zurich, Div Infect Dis & Hosp Epidemiol, Zurich, Switzerland; Ctr Hosp Univ Pitie Salpetriere, INSERM, EMI 0214, Paris, France; Univ Milan, Inst Infect & Trop Dis, Milan, Italy; Univ Amsterdam, Acad Med Ctr, HIV Monitoring Fdn, NL-1105 AZ Amsterdam, Netherlands; Univ Amsterdam, Acad Med Ctr, Natl AIDS Therpay Evaluat Ctr, NL-1105 AZ Amsterdam, Netherlands; Univ London Imperial Coll Sci Technol & Med, Sch Med, Dept Infect Dis Epidemiol, London, England; Hvidovre Univ Hosp, Dept Infect Dis, DK-2650 Hvidovre, Denmark; VA Pittsburgh Healthcare Syst, Gen Internal Med Sect, Pittsburgh, PA USA; Goethe Univ Frankfurt, Zentrum Inneren Med, Frankfurt, Germany; Hop Bichat Claude Bernard, Serv Malad Infect & Trop, F-75877 Paris 18, France; BC Ctr Excellence HIV AIDS, Div Epidemiol & Populat Hlth, Vancouver, BC, Canada; Univ Calgary, Div Infect Dis, Calgary, AB, Canada; Klinikum Univ Regensburg, Innere Med Klin 1, Regensburg, Germany	University of Bern; University of Bristol; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite de Bordeaux; University of London; University College London; UCL Medical School; University of Zurich; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; University of Milan; University of Amsterdam; Academic Medical Center Amsterdam; University of Amsterdam; Academic Medical Center Amsterdam; Imperial College London; University of Copenhagen; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Pittsburgh Healthcare System; Goethe University Frankfurt; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Bichat-Claude Bernard - APHP; UDICE-French Research Universities; Universite Paris Cite; B.C. Centre for Excellence in HIV/AIDS; University of Calgary; University of Regensburg	Egger, M (corresponding author), Univ Bern, Dept Social & Prevent Med, CH-3012 Bern, Switzerland.	egger@ispm.unibe.ch	Dodsley, Maria/G-7083-2016; Sterne, Jonathan/Z-3106-2019; Hogg, Robert S/B-2783-2012; chene, genevieve/H-8665-2014; Phillips, Andrew N/B-4427-2008; Costagliola, Dominique/H-5849-2011; Sabin, Caroline/C-2464-2008; Ledergerber, Bruno/B-5656-2009; DABIS, FRANCOIS/S-9298-2019; VALLET, Yannick/F-9979-2011; Lundgren, Jens/AAE-6876-2019; May, Margaret T/E-8099-2013; Gill, Michael John/G-7083-2016	Dodsley, Maria/0000-0001-7587-558X; Sterne, Jonathan/0000-0001-8496-6053; Hogg, Robert S/0000-0003-3463-5488; chene, genevieve/0000-0002-8368-6460; Phillips, Andrew N/0000-0003-2384-4807; Costagliola, Dominique/0000-0003-0765-0869; Sabin, Caroline/0000-0001-5173-2760; Ledergerber, Bruno/0000-0002-6881-4401; DABIS, FRANCOIS/0000-0002-1614-8857; May, Margaret T/0000-0002-9733-1003; Gill, Michael John/0000-0002-8546-8790; Lundgren, Jens/0000-0001-8901-7850; Egger, Matthias/0000-0001-7462-5132	Medical Research Council [G0100221] Funding Source: researchfish; MRC [G0100221] Funding Source: UKRI	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		AKAIKE H, 1974, IEEE T AUTOMAT CONTR, VAC19, P716, DOI 10.1109/TAC.1974.1100705; [Anonymous], 1992, MMWR Recomm Rep, V41, P1; Babiker A, 2000, AIDS RES HUM RETROV, V16, P1123; Becker SL, 2001, J ACQ IMMUN DEF SYND, V26, P72, DOI 10.1097/00126334-200101010-00011; Binquet C, 2001, AM J EPIDEMIOL, V153, P386, DOI 10.1093/aje/153.4.386; Brodt HR, 1997, AIDS, V11, P1731, DOI 10.1097/00002030-199714000-00010; Cameron DW, 1998, LANCET, V351, P543, DOI 10.1016/S0140-6736(97)04161-5; Chaisson RE, 1998, AIDS, V12, P29, DOI 10.1097/00002030-199801000-00004; Egger M, 2001, AIDS, V15, pS193, DOI 10.1097/00002030-200100005-00023; Egger M, 1997, BMJ-BRIT MED J, V315, P1194, DOI 10.1136/bmj.315.7117.1194; ESKILD A, 1993, INT J EPIDEMIOL, V22, P315, DOI 10.1093/ije/22.2.315; Farmer P, 2001, LANCET, V358, P404, DOI 10.1016/S0140-6736(01)05550-7; Fatkenheuer G, 1997, AIDS, V11, pF113, DOI 10.1097/00002030-199714000-00001; Fellay J, 2002, LANCET, V359, P30, DOI 10.1016/S0140-6736(02)07276-8; Frisch M, 2001, JAMA-J AM MED ASSOC, V285, P1736, DOI 10.1001/jama.285.13.1736; Grabar S, 2000, ANN INTERN MED, V133, P401, DOI 10.7326/0003-4819-133-6-200009190-00007; Greub G, 2000, LANCET, V356, P1800, DOI 10.1016/S0140-6736(00)03232-3; Gulick RM, 1997, NEW ENGL J MED, V337, P734, DOI 10.1056/NEJM199709113371102; Hammer SM, 1997, NEW ENGL J MED, V337, P725, DOI 10.1056/NEJM199709113371101; Harrell FE, 1996, STAT MED, V15, P361, DOI 10.1002/(SICI)1097-0258(19960229)15:4<361::AID-SIM168>3.0.CO;2-4; Harrington M, 2000, LANCET, V355, P2147, DOI 10.1016/S0140-6736(00)02388-6; Hogg RS, 1999, CAN MED ASSOC J, V160, P659; Hogg RS, 2001, JAMA-J AM MED ASSOC, V286, P2568, DOI 10.1001/jama.286.20.2568; Hughes MD, 1998, AIDS, V12, P1823, DOI 10.1097/00002030-199814000-00014; Justice AC, 1999, ANN INTERN MED, V130, P515, DOI 10.7326/0003-4819-130-6-199903160-00016; Le Moing V, 2002, J INFECT DIS, V185, P471, DOI 10.1086/338929; Ledergerber B, 1999, LANCET, V353, P863, DOI 10.1016/S0140-6736(99)01122-8; Lederman MM, 2000, JAMA-J AM MED ASSOC, V284, P223, DOI 10.1001/jama.284.2.223; Lundgren JD, 1997, J ACQ IMMUN DEF SYND, V16, P153, DOI 10.1097/00042560-199711010-00003; Lundgren JD, 2002, J INFECT DIS, V185, P178, DOI 10.1086/338267; Mellors JW, 1997, ANN INTERN MED, V126, P946, DOI 10.7326/0003-4819-126-12-199706150-00003; Miettinen O S, 1983, Stat Med, V2, P267, DOI 10.1002/sim.4780020222; Mocroft A, 1999, AIDS, V13, P1255, DOI 10.1097/00002030-199907090-00016; Mocroft A, 1998, LANCET, V352, P1725, DOI 10.1016/S0140-6736(98)03201-2; Mocroft A, 1998, AIDS, V12, P2161, DOI 10.1097/00002030-199816000-00011; Monforte AD, 2000, AIDS, V14, P499, DOI 10.1097/00002030-200003310-00005; Moore AL, 2001, J ACQ IMMUN DEF SYND, V26, P159, DOI 10.1097/00126334-200102010-00008; Nieuwkerk PT, 2001, ARCH INTERN MED, V161, P1962, DOI 10.1001/archinte.161.16.1962; PHILLIPS A N, 1991, Journal of Acquired Immune Deficiency Syndromes, V4, P970; Phillips AN, 2001, JAMA-J AM MED ASSOC, V286, P2560, DOI 10.1001/jama.286.20.2560; Royston P, 2001, STATA J, V1, P1, DOI 10.1177/1536867X0100100101; Saves M, 1999, AIDS, V13, pF115, DOI 10.1097/00002030-199912030-00002; Schuurman R, 1996, J CLIN MICROBIOL, V34, P3016, DOI 10.1128/JCM.34.12.3016-3022.1996; SELWYN PA, 1989, AM J PUBLIC HEALTH, V79, P1358, DOI 10.2105/AJPH.79.10.1358; Spiegelhalter DJ, 2002, J R STAT SOC B, V64, P583, DOI 10.1111/1467-9868.00353; Time from HIV-1 seroconversion to AIDS and death before widespread use of highly-active antiretroviral therapy: A collaborative re-analysis. Collaborative Group on AIDS Incubation and HIV Survival including the CASCADE EU Concerted Action, 2000, RAP ADV ANT THER HIV, V355, P1131; Valdez H, 1999, JAMA-J AM MED ASSOC, V282, P734, DOI 10.1001/jama.282.8.734; Viard JP, 2001, J INFECT DIS, V183, P1290, DOI 10.1086/319678; Yamashita TE, 2001, AIDS, V15, P735, DOI 10.1097/00002030-200104130-00009	49	1187	1234	4	106	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JUL 13	2002	360	9327					119	129		10.1016/S0140-6736(02)09411-4	http://dx.doi.org/10.1016/S0140-6736(02)09411-4			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	573PB	12126821				2023-01-03	WOS:000176839100010
J	Audet, AMJ; Hartman, EE				Audet, AMJ; Hartman, EE			A 40-year-old woman who noticed a medication error, 1 year later	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																		Bates DW, 2001, JAMA-J AM MED ASSOC, V285, P3134, DOI 10.1001/jama.285.24.3134	1	2	2	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 26	2002	287	24					3258	3258		10.1001/jama.287.24.3258	http://dx.doi.org/10.1001/jama.287.24.3258			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	566FF	12076223				2023-01-03	WOS:000176415800031
J	Stapleton, H; Kirkham, M; Thomas, G				Stapleton, H; Kirkham, M; Thomas, G			Qualitative study of evidence based leaflets in maternity care	BMJ-BRITISH MEDICAL JOURNAL			English	Article							SHARED DECISION-MAKING; CHOICE; WOMEN	Objective To examine the use of evidence based leaflets on informed choice in maternity services. Design Non-participant observation of 886 antenatal consultations. 383 in depth interviews with women using maternity services and health professionals providing antenatal care. Setting Women's homes; antenatal and ultrasound clinics in 13 maternity units in Wales. Participants Childbearing women and health professionals who provide antenatal care. Intervention Provision of 10 pairs of Informed Choice leaflets for service users and staff and a training session in their use. Main outcome measures Participants' views and commonly observed responses during consultations and interviews. Results Health professionals were positive about the leaflets and their potential to assist women in making informed choices, but competing demands within the clinical environment undermined their effective use. Time pressures limited discussion, and choice was often not available in practice. A widespread belief that technological intervention would be viewed positively in the event of litigation reinforced notions of "right" and "wrong" choices rather than "informed" choices. Hierarchical power structures resulted in obstetricians defining the norms of clinical practice and hence which choices were possible. Women's trust in health professionals ensured their compliance with professionally defined choices, and only rarely were they observed asking questions or making alternative requests. Midwives rarely discussed the contents of the leaflets or distinguished them from other literature related to pregnancy. The visibility and potential of the leaflets as evidence based decision aids was thus greatly reduced. Conclusions The way in which the leaflets were disseminated affected promotion of informed choice in maternity care. The culture into which the leaflets were introduced supported existing normative patterns of care and this ensured informed compliance rather than informed choice.	Univ Sheffield, Sch Nursing & Midwifery, Womens Informed Childbearing & Hlth Res Grp, Sheffield, S Yorkshire, England; W Wales Gen Hosp, Carmarthenshire NHS Trust, Carmarthen, Dyfed, Wales	University of Sheffield	Stapleton, H (corresponding author), Univ Sheffield, Sch Nursing & Midwifery, Womens Informed Childbearing & Hlth Res Grp, Sheffield, S Yorkshire, England.	h.stapleton@sheffield.ac.uk	Sandall, Jane/D-4146-2009	Sandall, Jane/0000-0003-2000-743X				Barbour R S, 1999, J Health Serv Res Policy, V4, P39; Bekker H., 1999, HEALTH TECHNOL ASSES, V3, P1; Charles C, 1998, SOCIOL HEALTH ILL, V20, P71, DOI 10.1111/1467-9566.00081; Charles C, 1997, SOC SCI MED, V44, P681, DOI 10.1016/S0277-9536(96)00221-3; Davies C., 1995, GENDER PROFESSIONAL; Davies HTO, 2000, QUAL HEALTH CARE, V9, P111, DOI 10.1136/qhc.9.2.111; Department of Health, 1993, CHANGING CHILDBIRTH; DINGWALL R, 1997, CONTEXT METHOD QUALI; Edwards N. P., 2000, MIDWIFE MOTHER RELAT; Elwyn G, 1999, BRIT MED J, V319, P753, DOI 10.1136/bmj.319.7212.753; Entwistle VA, 1998, INT J TECHNOL ASSESS, V14, P212, DOI 10.1017/S0266462300012204; FITZGERALD L, 1999, ORG BEHAV HLTH CARE; GAHAN C, 1999, DOING QUALITATIVE RE; Glaster B. G., 1967, THEORETICAL SENSITIV; Holmes-Rovner Margaret, 2000, Health Expect, V3, P182, DOI 10.1046/j.1369-6513.2000.00093.x; Jones S, 1998, BRIT MED J, V316, P272, DOI 10.1136/bmj.316.7127.272; KIRKHAM M, 2001, INFORMED CHOICE MATE; Levy V, 1999, J ADV NURS, V29, P104, DOI 10.1046/j.1365-2648.1999.00867.x; MACHIN D, 1998, BR J MIDWIFERY, V6, P304; MARTEAU TM, 1989, BRIT J SOC PSYCHOL, V28, P89, DOI 10.1111/j.2044-8309.1989.tb00849.x; McCrea BH, 1998, MIDWIFERY, V14, P174, DOI 10.1016/S0266-6138(98)90032-8; Murphy-Lawless Jo, 1998, READING BIRTH DEATH; O'Cathain A, 2002, BRIT MED J, V324, P643, DOI 10.1136/bmj.324.7338.643; PAIRMAN S, 2000, MIDWIFE MOTHER RELAT; Press N, 1997, SOC SCI MED, V45, P979, DOI 10.1016/S0277-9536(97)00011-7; Proctor S, 1998, BIRTH-ISS PERINAT C, V25, P85, DOI 10.1046/j.1523-536x.1998.00085.x; ROSSER J, 1996, J CLIN EFFECTIVENESS, V1, P143; Roter Debra, 2000, Health Expect, V3, P17, DOI 10.1046/j.1369-6513.2000.00073.x; *ROYAL SOC MED NHS, 1999, EFFECT HLTH CARE B, V5, P1; Strauss A., 1990, BASICS GROUNDED THEO; Wolff N, 2001, J Health Serv Res Policy, V6, P123, DOI 10.1258/1355819011927224	31	109	111	0	6	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	MAR 16	2002	324	7338					639	+		10.1136/bmj.324.7338.639	http://dx.doi.org/10.1136/bmj.324.7338.639			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	532QW	11895821	Bronze, Green Published			2023-01-03	WOS:000174487400021
J	Schiffl, H; Lang, SM; Fischer, R				Schiffl, H; Lang, SM; Fischer, R			Daily hemodialysis and the outcome of acute renal failure	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							DIALYSIS; MORTALITY	Background: Intermittent hemodialysis is widely used as renal-replacement therapy in patients with acute renal failure, but an adequate dose has not been defined. We performed a prospective study to determine the effect of daily intermittent hemodialysis, as compared with conventional (alternate-day) intermittent hemodialysis, on survival among patients with acute renal failure. Methods: A total of 160 patients with acute renal failure were assigned to receive daily or conventional intermittent hemodialysis. Survival was the primary end point of the study. The duration of acute renal failure and the frequency of therapy-related complications were secondary end points. Results: The two study groups were similar with respect to age, sex, cause and severity of acute renal failure, medical or surgical intensive care setting, and the score on the Acute Physiology, Age, and Chronic Health Evaluation. Daily hemodialysis resulted in better control of uremia, fewer hypotensive episodes during hemodialysis, and more rapid resolution of acute renal failure (mean [+/-SD], 9+/-2 vs. 16+/-6 days; P=0.001) than did conventional hemodialysis. The mortality rate, according to the intention-to-treat analysis, was 28 percent for daily dialysis and 46 percent for alternate-day dialysis (P=0.01). In a multiple regression analysis, less frequent hemodialysis (on alternate days, as opposed to daily) was an independent risk factor for death. Conclusions: The high mortality rate among critically ill patients with acute renal failure who require renal-replacement therapy is related to both coexisting conditions and uremic damage to other organ systems. Intensive hemodialysis reduces mortality without increasing hemodynamically induced morbidity. (N Engl J Med 2002;346:305-10.) Copyright (C) 2002 Massachusetts Medical Society.	Univ Munich, Med Klin Innenstadt, Dept Nephrol, D-80336 Munich, Germany; Univ Munich, Med Poliklin Innenstadt, D-80336 Munich, Germany	University of Munich; University of Munich	Schiffl, H (corresponding author), Univ Munich, Med Klin Innenstadt, Dept Nephrol, Ziemssenstr 1, D-80336 Munich, Germany.							Chertow GM, 1998, AM J MED, V104, P343, DOI 10.1016/S0002-9343(98)00058-8; Clark W R, 1997, Adv Ren Replace Ther, V4, P64; DAUGIRDAS JT, 1993, J AM SOC NEPHROL, V4, P1205; DAUGIRDAS JT, 1995, ASAIO, V41, P719; DEPNER TA, 1994, SEMIN DIALYSIS, V7, P315, DOI 10.1111/j.1525-139X.1994.tb00843.x; Evanson JA, 1999, KIDNEY INT, V55, P1501, DOI 10.1046/j.1523-1755.1999.00355.x; Evanson JA, 1998, AM J KIDNEY DIS, V32, P731, DOI 10.1016/S0272-6386(98)70127-1; GILLUM DM, 1986, CLIN NEPHROL, V25, P249; KNAUS WA, 1991, CHEST, V100, P1619, DOI 10.1378/chest.100.6.1619; Levy EM, 1996, JAMA-J AM MED ASSOC, V275, P1489, DOI 10.1001/jama.275.19.1489; McCarthy JT, 1996, MAYO CLIN PROC, V71, P117, DOI 10.4065/71.2.117; Paganini EP, 1996, AM J KIDNEY DIS, V28, pS81, DOI 10.1016/S0272-6386(96)90084-0; Paganini EP, 2001, BLOOD PURIFICAT, V19, P238, DOI 10.1159/000046948; Ronco C, 2000, LANCET, V356, P26, DOI 10.1016/S0140-6736(00)02430-2; WOODROW G, 1992, NEPHROL DIAL TRANSPL, V7, P230, DOI 10.1093/oxfordjournals.ndt.a092111	15	524	572	0	10	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JAN 31	2002	346	5					305	310		10.1056/NEJMoa010877	http://dx.doi.org/10.1056/NEJMoa010877			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	516GJ	11821506				2023-01-03	WOS:000173545300002
J	Griffiths, CEM				Griffiths, CEM			Immunotherapy for psoriasis: from serendipity to selectivity	LANCET			English	Editorial Material							PLAQUE-TYPE PSORIASIS; QUALITY-OF-LIFE; T-CELLS; ANTIBODY		Univ Manchester, Hope Hosp, Sch Med, Dermatol Ctr, Manchester M6 8HD, Lancs, England	University of Manchester	Griffiths, CEM (corresponding author), Univ Manchester, Hope Hosp, Sch Med, Dermatol Ctr, Manchester M6 8HD, Lancs, England.	christopher.griffiths@man.ac.uk	Griffiths, Christopher E.M./P-5448-2014	Griffiths, Christopher E.M./0000-0001-5371-4427				Abrams JR, 2000, J EXP MED, V192, P681, DOI 10.1084/jem.192.5.681; Asadullah K, 1999, ARCH DERMATOL, V135, P187, DOI 10.1001/archderm.135.2.187; Chaudhari U, 2001, LANCET, V357, P1842, DOI 10.1016/S0140-6736(00)04954-0; Ellis CN, 2001, NEW ENGL J MED, V345, P248, DOI 10.1056/NEJM200107263450403; ELLIS CN, 1991, NEW ENGL J MED, V324, P277, DOI 10.1056/NEJM199101313240501; Fortune DG, 1997, BRIT J DERMATOL, V137, P755; Krueger G, 2001, ARCH DERMATOL, V137, P280; Krueger JG, 2000, J AM ACAD DERMATOL, V43, P448, DOI 10.1067/mjd.2000.106515; Mease PJ, 2000, LANCET, V356, P385, DOI 10.1016/S0140-6736(00)02530-7; MUELLER W, 1979, NEW ENGL J MED, V301, P555; Oh CJ, 2000, J AM ACAD DERMATOL, V42, P829, DOI 10.1067/mjd.2000.105948; Papp K, 2001, J AM ACAD DERMATOL, V45, P665, DOI 10.1067/mjd.2001.117850; Richards HL, 1999, J AM ACAD DERMATOL, V41, P581, DOI 10.1016/S0190-9622(99)70301-4; SCHLAAK JF, 1994, J INVEST DERMATOL, V102, P145, DOI 10.1111/1523-1747.ep12371752; VALDIMARSSON H, 1995, IMMUNOL TODAY, V16, P145, DOI 10.1016/0167-5699(95)80132-4; Yawalkar N, 1998, J INVEST DERMATOL, V111, P1053, DOI 10.1046/j.1523-1747.1998.00446.x	16	21	24	0	2	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JAN 26	2002	359	9303					279	280		10.1016/S0140-6736(02)07536-0	http://dx.doi.org/10.1016/S0140-6736(02)07536-0			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	517AC	11830192				2023-01-03	WOS:000173588100006
J	Herbert, RD; Maher, CG; Moseley, AM; Sherrington, C				Herbert, RD; Maher, CG; Moseley, AM; Sherrington, C			Regular review - Effective physiotherapy	BMJ-BRITISH MEDICAL JOURNAL			English	Review							RANDOMIZED CONTROLLED-TRIAL; PULMONARY REHABILITATION; SYSTEMATIC REVIEWS; RISK-FACTORS; EXERCISE; THERAPY; STROKE; INTENSITY; PEOPLE; REDUCE		Univ Sydney, Sch Physiotherapy, Lidcombe, NSW 1825, Australia; Prince Wales Med Res Inst, St Pauls, NSW 2031, Australia; Univ Sydney, Rehabil Studies Unit, Ryde, NSW 1680, Australia	University of Sydney; Prince Wales Medical Research Institute; University of Sydney	Herbert, RD (corresponding author), Univ Sydney, Sch Physiotherapy, POB 170, Lidcombe, NSW 1825, Australia.	R.Herbert@cchs.usyd.edu.au	Sherrington, Catherine/S-9196-2019; Maher, Christopher/AAC-6267-2019	Sherrington, Catherine/0000-0001-8934-4368; Maher, Christopher/0000-0002-1628-7857; Herbert, Rob/0000-0003-4188-9195				ANNANE D, 2001, COCHRANE DATABASE SY; Bo K, 2000, ACTA OBSTET GYN SCAN, V79, P598, DOI 10.1034/j.1600-0412.2000.079007598.x; Cambach W, 1999, ARCH PHYS MED REHAB, V80, P103, DOI 10.1016/S0003-9993(99)90316-7; *CLIN STAND ADV GR, 1994, CLIN STAND ADV GROUP; *CTR EV BAS PHYS, 2001, PEDR PHYS EV DAT; Dromerick AW, 2000, STROKE, V31, P2984, DOI 10.1161/01.STR.31.12.2984; Feine JS, 1997, PAIN, V71, P5, DOI 10.1016/S0304-3959(96)03287-3; FURLAN AD, 2000, COCHRANE DATABASE SY; Gardner MM, 2000, BRIT J SPORT MED, V34, P7, DOI 10.1136/bjsm.34.1.7; Gardner MM, 2001, AGE AGEING, V30, P77, DOI 10.1093/ageing/30.1.77; Gillespie LD, 2001, COCHRANE DATABASE SY; Griffiths TL, 2000, LANCET, V355, P362, DOI 10.1016/S0140-6736(99)07042-7; HAGEN KB, 2001, COCHRANE DATABASE SY; Hannestad YS, 2000, J CLIN EPIDEMIOL, V53, P1150, DOI 10.1016/S0895-4356(00)00232-8; HAYSMITH EJC, 2001, COCHRANE DATABASE SY; HERBISON P, 2001, COCHRANE DATABASE SY; Kwakkel G, 1997, STROKE, V28, P1550, DOI 10.1161/01.STR.28.8.1550; Kwakkel G, 1999, LANCET, V354, P191, DOI 10.1016/S0140-6736(98)09477-X; Moffett JK, 1999, BRIT MED J, V319, P279, DOI 10.1136/bmj.319.7205.279; Murray CJL, 1997, LANCET, V349, P1436, DOI 10.1016/S0140-6736(96)07495-8; NEVITT MC, 1989, JAMA-J AM MED ASSOC, V261, P2663, DOI 10.1001/jama.261.18.2663; Olsen MF, 1997, BRIT J SURG, V84, P1535, DOI 10.1002/bjs.1800841111; Patman S, 2001, AUST J PHYSIOTHER, V47, P7, DOI 10.1016/S0004-9514(14)60294-4; *STROK UN TRIAL CO, 2001, COCHR DAT SYST REV; TINETTI ME, 1994, NEW ENGL J MED, V331, P821, DOI 10.1056/NEJM199409293311301; Van Baar ME, 1999, ARTHRITIS RHEUM-US, V42, P1361, DOI 10.1002/1529-0131(199907)42:7<1361::AID-ANR9>3.0.CO;2-9; VANDENENDE CHM, 2001, COCHRANE DATABASE SY; vanTulder MW, 1997, SPINE, V22, P2128, DOI 10.1097/00007632-199709150-00012; Verhagen AP, 1998, J CLIN EPIDEMIOL, V51, P1235, DOI 10.1016/S0895-4356(98)00131-0; Visintin M, 1998, STROKE, V29, P1122, DOI 10.1161/01.STR.29.6.1122; Waddell G, 1997, BRIT J GEN PRACT, V47, P647	31	16	16	0	8	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	OCT 6	2001	323	7316					788	790		10.1136/bmj.323.7316.788	http://dx.doi.org/10.1136/bmj.323.7316.788			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	481LK	11588084	Green Published			2023-01-03	WOS:000171520600032
J	Stiell, IG; Hebert, PC; Wells, GA; Vandemheen, KL; Tang, ASL; Higginson, LAJ; Dreyer, JF; Clement, C; Battram, E; Watpool, I; Mason, S; Klassen, T; Weitzman, BN				Stiell, IG; Hebert, PC; Wells, GA; Vandemheen, KL; Tang, ASL; Higginson, LAJ; Dreyer, JF; Clement, C; Battram, E; Watpool, I; Mason, S; Klassen, T; Weitzman, BN			Vasopressin versus epinephrine for inhospital cardiac arrest: a randomised controlled trial	LANCET			English	Article							CORONARY PERFUSION-PRESSURE; HIGH-DOSE EPINEPHRINE; ORGAN BLOOD-FLOW; PROLONGED CARDIOPULMONARY-RESUSCITATION; RELEASE; MODEL	Background Survival rates for cardiac arrest patients, both in and out of hospital, are poor. Results of a previous study suggest better outcomes for patients treated with vasopressin than for those given epinephrine, in the out-of-hospital setting. Our aim was to compare the effectiveness and safety of these drugs for the treatment of in-patient cardiac arrest. Methods We did a triple-blind randomised trial in the emergency departments, critical care units, and wards of three Canadian teaching hospitals. We assigned adults who had cardiac arrest and required drug therapy to receive one dose of vasopressin 40 U or epinephrine 1 mg intravenously, as the initial vasopressor. Patients who failed to respond to the study intervention were given epinephrine as a rescue medication. The primary outcomes were survival to hospital discharge, survival to 1 h, and neurological function. Preplanned subgroup assessments included patients with myocardial ischaemia or infarction, initial cardiac rhythm, and age. Findings We assigned 104 patients to vasopressin and 96 to epinephrine. For patients receiving vasopressin or epinephrine survival did not differ for hospital discharge (12 [12%] vs 13 [14%], respectively; p=0.67; 95% CI for absolute increase in survival -11.8% to 7.8%) or for 1 h survival (40 [39%] vs 34 [35%]; p=0.66; -10.9% to 17.0%); survivors had closely similar median mini-mental state examination scores (36 [range 19-38] vs 35 [20-40]; p=0.75) and median cerebral performance category scores (1 vs 1). Interpretation We failed to detect any survival advantage for vasopressin over epjnephrine, We cannot recommend the routine use of vasopressin for inhospital cardiac arrest patients, and disagree with American Heart Association guidelines, which recommend vasopressin as therapy for cardiac arrest.	Univ Ottawa, Div Emergency Med, Ottawa, ON, Canada; Univ Ottawa, Dept Med, Ottawa, ON, Canada; Univ Ottawa, Dept Epidemiol, Ottawa, ON, Canada; Univ Ottawa, Clin Epidemiol Unit, Ottawa, ON, Canada; Univ Ottawa, Inst Heart, Ottawa, ON, Canada; Univ Western Ontario, Div Emergency Med, London, ON, Canada; Univ Alberta, Dept Paediat, Edmonton, AB, Canada	University of Ottawa; University of Ottawa; University of Ottawa; University of Ottawa; University of Ottawa; University of Ottawa Heart Institute; Western University (University of Western Ontario); University of Alberta	Stiell, IG (corresponding author), Ottawa Hlth Res Inst, Clin Epidemiol Unit, Ottawa, ON K1Y 4E9, Canada.	istiell@ohri.ca	Tang, Anthony S/E-6203-2014	Stiell, Ian/0000-0002-2583-6408				Babar SI, 1999, RESUSCITATION, V41, P185, DOI 10.1016/S0300-9572(99)00071-4; BROWN CG, 1992, NEW ENGL J MED, V327, P1051, DOI 10.1056/NEJM199210083271503; CALLAHAM M, 1992, JAMA-J AM MED ASSOC, V268, P2667, DOI 10.1001/jama.268.19.2667; FOX AW, 1988, GEN PHARMACOL, V19, P639, DOI 10.1016/0306-3623(88)90121-8; HAUCK WW, 1986, AM STAT, V40, P318, DOI 10.2307/2684618; ISHIKAWA S, 1984, MINER ELECTROL METAB, V10, P184; KELSEY SF, 1991, CONTROL CLIN TRIALS, V12, P525; Kornberger E, 2000, CRIT CARE MED, V28, P3517, DOI 10.1097/00003246-200010000-00028; LINDNER KH, 1993, ANESTH ANALG, V77, P427; Lindner KH, 1996, HEART, V75, P145, DOI 10.1136/hrt.75.2.145; LINDNER KH, 1992, ANESTHESIOLOGY, V77, P662, DOI 10.1097/00000542-199210000-00008; LINDNER KH, 1995, CIRCULATION, V91, P215, DOI 10.1161/01.CIR.91.1.215; Lindner KH, 1997, LANCET, V349, P535, DOI 10.1016/S0140-6736(97)80087-6; Lindner KH, 1996, ANN INTERN MED, V124, P1061, DOI 10.7326/0003-4819-124-12-199606150-00006; MCALPINE HM, 1988, BRIT HEART J, V60, P117; Morris DC, 1997, ACAD EMERG MED, V4, P878, DOI 10.1111/j.1553-2712.1997.tb03813.x; Mulligan KA, 1997, RESUSCITATION, V35, P265, DOI 10.1016/S0300-9572(97)00060-9; PARADIS NA, 1990, JAMA-J AM MED ASSOC, V263, P1106, DOI 10.1001/jama.263.8.1106; PARADIS NA, 1993, RESUSCITATION, V26, P261, DOI 10.1016/0300-9572(93)90147-I; Prengel AW, 1996, STROKE, V27, P1241, DOI 10.1161/01.STR.27.7.1241; SCHALLER MD, 1987, AM J CARDIOL, V60, P1178, DOI 10.1016/0002-9149(87)90416-4; SHARE L, 1967, ENDOCRINOLOGY, V81, P1140, DOI 10.1210/endo-81-5-1140; SHEN YT, 1991, CIRC RES, V68, P1422, DOI 10.1161/01.RES.68.5.1422; Stiell IG, 1996, JAMA-J AM MED ASSOC, V275, P1417, DOI 10.1001/jama.275.18.1417; STIELL IG, 1992, NEW ENGL J MED, V327, P1045, DOI 10.1056/NEJM199210083271502; TENG EL, 1987, J CLIN PSYCHIAT, V48, P314; Voelckel WG, 2000, CRIT CARE MED, V28, P3777, DOI 10.1097/00003246-200012000-00001; Wenzel V, 2000, J AM COLL CARDIOL, V35, P527, DOI 10.1016/S0735-1097(99)00562-8; Wenzel V, 1999, CRIT CARE MED, V27, P486, DOI 10.1097/00003246-199903000-00022; Wenzel V, 2000, CRIT CARE MED, V28, P1096, DOI 10.1097/00003246-200004000-00031; Wenzel V, 1999, CIRCULATION, V99, P1379, DOI 10.1161/01.CIR.99.10.1379; Wenzel V, 1998, STROKE, V29, P1462, DOI 10.1161/01.STR.29.7.1462; Willerson JT, 2000, CIRCULATION, V102, P1; WILSON MF, 1981, SURG GYNECOL OBSTET, V153, P869; WU WH, 1982, B NEW YORK ACAD MED, V58, P427; 1992, JAMA, V268, P2171	36	213	225	0	10	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JUL 14	2001	358	9276					105	109		10.1016/S0140-6736(01)05328-4	http://dx.doi.org/10.1016/S0140-6736(01)05328-4			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	452BR	11463411				2023-01-03	WOS:000169837700010
J	Nadelman, RB; Nowakowski, J; Fish, D; Falco, RC; Freeman, K; McKenna, D; Welch, P; Marcus, R; Aguero-Rosenfeld, ME; Dennis, DT; Wormser, GP				Nadelman, RB; Nowakowski, J; Fish, D; Falco, RC; Freeman, K; McKenna, D; Welch, P; Marcus, R; Aguero-Rosenfeld, ME; Dennis, DT; Wormser, GP		Tick Bite Study Grp	Prophylaxis with single-dose doxycycline for the prevention of lyme disease after an ixodes scapularis tick bite.	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ENDEMIC AREA; BORRELIA-BURGDORFERI; ERYTHEMA MIGRANS; DURATION; EFFICACY; TRIAL; RISK	Background: It is unclear whether antimicrobial treatment after an Ixodes scapularis tick bite will prevent Lyme disease. Methods: In an area of New York where Lyme disease is hyperendemic, we conducted a randomized, double-blind, placebo-controlled trial of treatment with a single 200-mg dose of doxycycline in 482 subjects who had removed attached I. scapularis ticks from their bodies within the previous 72 hours. At base line, three weeks, and six weeks, subjects were interviewed and examined, and serum antibody tests were performed, along with blood cultures for Borrelia burgdorferi. Results: Erythema migrans developed at the site of the tick bite in a significantly smaller proportion of the subjects in the doxycycline group than of those in the placebo group (1 of 235 subjects [0.4 percent] vs. 8 of 247 subjects [3.2 percent], P<0.04). The efficacy of treatment was 87 percent (95 percent confidence interval, 25 to 98 percent). Objective extracutaneous signs of Lyme disease did not develop in any subject, and there were no asymptomatic seroconversions. Treatment with doxycycline was associated with more frequent adverse effects (in 30.1 percent of subjects, as compared with 11.1 percent of those assigned to placebo; P<0.001), primarily nausea (15.4 percent vs. 2.6 percent) and vomiting (5.8 percent vs. 1.3 percent). Erythema migrans developed more frequently after untreated bites from nymphal ticks than after bites from adult female ticks (8 of 142 bites [5.6 percent] vs. 0 of 97 bites [0 percent], P=0.02). Conclusions: A single 200-mg dose of doxycycline given within 72 hours after an I. scapularis tick bite can prevent the development of Lyme disease. (N Engl J Med 2001;345:79-84.) Copyright (C) 2001 Massachusetts Medical Society.	Westchester Cty Med Ctr, Div Infect Dis, Lyme Dis Diagnost Ctr, Valhalla, NY 10595 USA; New York Med Coll, Dept Med, Div Infect Dis, Valhalla, NY 10595 USA; New York Med Coll, Dept Pathol, Valhalla, NY 10595 USA; Yale Univ, Sch Med, Dept Epidemiol & Publ Hlth, New Haven, CT 06510 USA; Fordham Univ, Louis Calder Ctr, Vector Ecol Lab, Armonk, NY USA; Albert Einstein Coll Med, Dept Epidemiol & Social Med, Bronx, NY 10467 USA; No Westchester Hosp, Mt Kisco, NY USA; Ctr Dis Control & Prevent, Div Vector Borne Infect Dis, Natl Ctr Infect Dis, Ft Collins, CO USA	Westchester Medical Center; New York Medical College; New York Medical College; Yale University; Fordham University; Yeshiva University; Albert Einstein College of Medicine; Centers for Disease Control & Prevention - USA	Nadelman, RB (corresponding author), Westchester Cty Med Ctr, Div Infect Dis, Lyme Dis Diagnost Ctr, Macy Pavil 209 SE, Valhalla, NY 10595 USA.		DeHaas, Keith/I-4957-2017		PHS HHS [U50/CCU 210286, U50/CCU 210280] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		AGRE F, 1993, AM J DIS CHILD, V147, P945, DOI 10.1001/archpedi.1993.02160330035013; [Anonymous], 1999, MED LETT DRUGS THER, V41, P29; Centers for Disease Control and Prevention (CDC), 1995, MMWR Morb Mortal Wkly Rep, V44, P590; COSTELLO CM, 1989, J INFECT DIS, V159, P136, DOI 10.1093/infdis/159.1.136; DEVIGNES F, 2001, J INFECT DIS, V183, P773; Falco RC, 1996, AM J EPIDEMIOL, V143, P187, DOI 10.1093/oxfordjournals.aje.a008728; Falco RC, 1999, AM J EPIDEMIOL, V149, P771, DOI 10.1093/oxfordjournals.aje.a009886; Falco RC, 1998, JAMA-J AM MED ASSOC, V280, P602, DOI 10.1001/jama.280.7.602-a; HENNEKENS CH, 1987, EPIDEMIOLOGY MED, P254; KENYON RH, 1978, J CLIN MICROBIOL, V8, P102; MAGID D, 1992, NEW ENGL J MED, V327, P534, DOI 10.1056/NEJM199208203270806; NADELMAN RB, 1990, AM J MED, V88, P21, DOI 10.1016/0002-9343(90)90122-T; Nadelman RB, 1996, AM J MED, V100, P502, DOI 10.1016/S0002-9343(95)99915-9; OBRIEN PC, 1979, BIOMETRICS, V35, P549, DOI 10.2307/2530245; Orloski K A, 2000, MMWR CDC Surveill Summ, V49, P1; SCHROETER AL, 1971, J AMER MED ASSOC, V218, P711, DOI 10.1001/jama.218.5.711; SHAPIRO ED, 1992, NEW ENGL J MED, V327, P1769, DOI 10.1056/NEJM199212173272501; Sood SK, 1997, J INFECT DIS, V175, P996, DOI 10.1086/514009; Steere AC, 1998, NEW ENGL J MED, V339, P209, DOI 10.1056/NEJM199807233390401; TAKAFUJI ET, 1984, NEW ENGL J MED, V310, P497, DOI 10.1056/NEJM198402233100805; Warshafsky S, 1996, J GEN INTERN MED, V11, P329, DOI 10.1007/BF02600042; Wormser GP, 2000, CLIN INFECT DIS, V31, pS1, DOI 10.1086/314053	22	259	272	0	26	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUL 12	2001	345	2					79	84		10.1056/NEJM200107123450201	http://dx.doi.org/10.1056/NEJM200107123450201			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	451AH	11450675				2023-01-03	WOS:000169776900001
J	Kenyon, SL; Taylor, DJ; Tarnow-Mordi, W				Kenyon, SL; Taylor, DJ; Tarnow-Mordi, W		ORACLE Collaborative Grp	Broad-spectrum antibiotics for spontaneous preterm labour: the ORACLE II randomised trial	LANCET			English	Article							BACTERIAL VAGINOSIS; RABBIT MODEL; METRONIDAZOLE; PREGNANCY; WOMEN; BIRTH	Background Preterm birth after spontaneous preterm labour is associated with death, neonatal disease, and long-term disability. Previous small trials of antibiotics for spontaneous preterm labour have reported inconclusive results. We did a randomised multicentre trial to resolve this issue. Methods 6295 women in spontaneous preterm labour with intact membranes and without evidence of clinical infection were randomly assigned 250 mg erythromycin (n=1611), 325 mg co-amoxiclav (250 mg amoxicillin and 125 mg clavulanic acid; n=1550), both (n=1565), or placebo (n=1569) four times daily for 10 days or until delivery, whichever occurred earlier. The primary outcome measure was a composite of neonatal death, chronic lung disease, or major cerebral abnormality on ultrasonography before discharge from hospital. Analysis was by intention to treat. Findings None of the trial antibiotics was associated with a lower rate of the composite primary outcome than placebo (erythromycin 90 [5.6%], co-amoxiclav 76 [5.0%], both antibiotics 91 [5.9%], vs placebo 78 [5.0%]). However, antibiotic prescription was associated with a lower occurrence of maternal infection. Interpretation This trial provides evidence that antibiotics should not be routinely prescribed for women in spontaneous preterm labour without evidence of clinical infection.	Leicester Royal Infirm, Dept Obstet & Gynaecol, Leicester LE2 7LX, Leics, England	University of Leicester	Kenyon, SL (corresponding author), Leicester Royal Infirm, Dept Obstet & Gynaecol, Robert Kilpatrick Bldg,POB 65, Leicester LE2 7LX, Leics, England.	oracle@le.ac.uk		Kenyon, Sara/0000-0002-0756-9617				BERKOWITZ GS, 1993, EPIDEMIOL REV, V15, P414, DOI 10.1093/oxfordjournals.epirev.a036128; DOMBROSKI RA, 1990, AM J OBSTET GYNECOL, V163, P1938, DOI 10.1016/0002-9378(90)90777-5; FIELD D, 1999, TRENT NEONATAL SURVE; Gomez R, 1997, PRETERM LABOR, P85; GONIK B, 1986, AM J OBSTET GYNECOL, V154, P3, DOI 10.1016/0002-9378(86)90383-2; GUZICK DS, 1985, OBSTET GYNECOL, V65, P11; Hall M. H., 1997, PRETERM LABOR, P1; HALLIDAY HL, 1992, HIGH RISK PREGNANCY, P332; Hauth JC, 1995, NEW ENGL J MED, V333, P1732, DOI 10.1056/NEJM199512283332603; HEDDLESTON L, 1993, AM J OBSTET GYNECOL, V169, P708, DOI 10.1016/0002-9378(93)90647-2; Kenyon SL, 2001, LANCET, V357, P989, DOI 10.1016/S0140-6736(00)04234-3; KING J, 2000, COCHRANE LIB; McDonald HM, 1997, BRIT J OBSTET GYNAEC, V104, P1391, DOI 10.1111/j.1471-0528.1997.tb11009.x; MORALES WJ, 1994, AM J OBSTET GYNECOL, V171, P345, DOI 10.1016/S0002-9378(94)70033-8; NAEYE RL, 1980, LANCET, V1, P192; ROMERO R, 1993, AM J OBSTET GYNECOL, V169, P764, DOI 10.1016/0002-9378(93)90003-2; Romero R, 1997, PRETERM LABOR, P29; Russel P., 1979, AM J DIAG GYN OBSTET, V1, P127; SMAILL F, 2001, COCHRANE LIB	19	261	270	1	7	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	MAR 31	2001	357	9261					989	994		10.1016/S0140-6736(00)04234-3	http://dx.doi.org/10.1016/S0140-6736(00)04234-3			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	416QK	11293641				2023-01-03	WOS:000167791500008
J	Matthews, FE; Dening, T				Matthews, FE; Dening, T		UK Med Res Council Cognitive Funct	Prevalence of dementia in institutional care	LANCET			English	Article								Information about dementia prevalence In residential and nursing care homes helps these institutions to meet residents' needs. We combined residential characteristics ascertained at a screening Interview in 1991-93 with dementia diagnoses from assessment interviews In the UK Medical Research Council Cognitive Function and Ageing Study, a population-based study of 13 004 elderly people. Almost 5% of people aged 65 years or older lived in institution-34% (95% Cl 30-39) of individuals with dementia. Within institutions, dementia prevalence was 62% (52-71), and was slightly higher in women than in men, with no increase by age. That most residents have dementia has Implications for the type of care that institutions provide.	Univ Forvie Site, Inst Publ Hlth, MRC, Biostat Unit, Cambridge CB2 2SR, England; Fulbourne Hosp, Addenbrooks NHS Trust, Cambridge CB1 5EF, England	MRC Biostatistics Unit; University of Cambridge	Matthews, FE (corresponding author), Univ Forvie Site, Inst Publ Hlth, MRC, Biostat Unit, Cambridge CB2 2SR, England.		Matthews, Fiona/O-6932-2015; Dening, Tom/E-1335-2013	Matthews, Fiona/0000-0002-1728-2388; Dening, Tom/0000-0003-3387-4241				Brayne C, 1998, PSYCHOL MED, V28, P319; COPELAND JRM, 1986, PSYCHOL MED, V16, P89, DOI 10.1017/S0033291700057779; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; Macdonald AJD, 2002, AGE AGEING, V31, P58, DOI 10.1093/ageing/31.1.58; *OFF POP CENS SURV, 1994, REV 1991 POP EST SUP	5	126	126	0	7	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUL 20	2002	360	9328					225	226		10.1016/S0140-6736(02)09461-8	http://dx.doi.org/10.1016/S0140-6736(02)09461-8			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	576DX	12133659				2023-01-03	WOS:000176988500014
J	Markowitz, AJ; Rabow, MH				Markowitz, AJ; Rabow, MH			Management of Dyspnea in patients with far-advanced lung disease	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article														Markowitz, Amy/0000-0001-9314-2814				Luce JM, 2001, JAMA-J AM MED ASSOC, V285, P1331, DOI 10.1001/jama.285.10.1331	1	3	3	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 1	2002	287	17					2261	2261		10.1001/jama.287.17.2261	http://dx.doi.org/10.1001/jama.287.17.2261			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	546EZ	11980526				2023-01-03	WOS:000175260600026
J	Renehan, AG; Egger, M; Saunders, MP; O'Dwyer, ST				Renehan, AG; Egger, M; Saunders, MP; O'Dwyer, ST			Impact on survival of intensive follow up after curative resection for colorectal cancer: systematic review and meta-analysis of randomised trials	BMJ-BRITISH MEDICAL JOURNAL			English	Review							RADICAL SURGERY; RECURRENCE; CARCINOMA; PATTERNS; COLON; SURVEILLANCE; MANAGEMENT; QUALITY	Objective To review die evidence from clinical trials of follow up of patients after curative resection for colorectal cancer. Design Systematic review and meta-analysis of randomised controlled trials of intensive compared with control follow up. Main outcome measures All cause mortality at five years (primary outcome). Rates of recurrence of intraluminal, local, and metastatic disease and metachronous (second colorectal primary) cancers (secondary outcomes). Results Five trials, which included 1342 patients, met the inclusion criteria. Intensive follow up was associated with a reduction in all cause mortality (combined risk ratio 0.81, 95% confidence interval 0.70 to 0.94, P=0.007). The effect was most pronounced in the four extramural detection trials that used computed tomography and frequent measurements of serum carcinoembryonic antigen (risk ratio 0.73, 0.60 to 0.89, P=0.002). Intensive follow up was associated with significantly earlier detection of all recurrences (difference in means 8.5 months, 7.6 to 9.4 months, P < 0.001) and an increased detection rate for isolated local recurrences (risk ratio 1.61, 1.12 to 2.32, P=0.011). Conclusions Intensive follow up after curative resection for colorectal cancer improves survival. Large trials are required to identify which components of intensive follow up are most beneficial.	Christie Hosp NHS Trust, Dept Surg, Manchester M20 4BX, Lancs, England; Univ Bristol, Dept Social Med, MRC, Hlth Serv Res Collaborat, Bristol BS8 2PR, Avon, England; Christie Hosp NHS Trust, Dept Clin Oncol, Manchester M20 4BX, Lancs, England	Christie NHS Foundation Trust; Christie Hospital; University of Bristol; Christie NHS Foundation Trust; Christie Hospital	Renehan, AG (corresponding author), Christie Hosp NHS Trust, Dept Surg, Manchester M20 4BX, Lancs, England.	arenehan@picr.man.ac.uk	Renehan, Andrew/K-5992-2015	Renehan, Andrew/0000-0003-4309-4396; Egger, Matthias/0000-0001-7462-5132				ABULAFI AM, 1994, BRIT J SURG, V81, P7, DOI 10.1002/bjs.1800810106; *ASS COL GREAT BRI, 2001, GUID MAN COL CANC; ATKIN WS, 1993, LANCET, V341, P736, DOI 10.1016/0140-6736(93)90499-7; Barillari P, 1996, DIS COLON RECTUM, V39, P388, DOI 10.1007/BF02054052; BRUINVELS DJ, 1994, ANN SURG, V219, P174, DOI 10.1097/00000658-199402000-00009; BRUINVELS DJ, 1995, EUR J SURG, V161, P827; CUNLIFFE WJ, 1984, BRIT J SURG, V71, P941, DOI 10.1002/bjs.1800711210; Deeks JJ, 2001, SYSTEMATIC REV HLTH, P285, DOI DOI 10.1002/9780470693926.CH15; DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2; Dube S, 1997, DIS COLON RECTUM, V40, P35, DOI 10.1007/BF02055679; Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629; GHEZZI P, 1994, JAMA-J AM MED ASSOC, V271, P1587, DOI 10.1001/jama.1994.03510440047031; Juni P, 2001, BMJ-BRIT MED J, V323, P42, DOI 10.1136/bmj.323.7303.42; Kjeldsen BJ, 1997, BRIT J SURG, V84, P666; Kjeldsen BJ, 1997, INT J COLORECTAL DIS, V12, P329, DOI 10.1007/s003840050118; Kjeldsen BJ, 1999, SCAND J GASTROENTERO, V34, P509, DOI 10.1080/003655299750026254; KRONBORG O, 1988, SCAND J GASTROENTERO, V23, P159, DOI 10.3109/00365528809096975; Kuchler T, 1999, HEPATO-GASTROENTEROL, V46, P322; LEFEBVRE A, 2001, SYSTEMATIC REV HLTH, P69; LOCKHARTMUMMERY HE, 1972, DIS COLON RECTUM, V15, P261, DOI 10.1007/BF02589884; LOCKHARTMUMMERY HE, 1972, DIS COLON RECTUM, V15, P61; Makela J, 1992, Surg Oncol, V1, P157, DOI 10.1016/0960-7404(92)90029-K; MAKELA JT, 1995, ARCH SURG-CHICAGO, V130, P1062; MALCOLM AW, 1981, SURG GYNECOL OBSTET, V152, P131; MCCALL JL, 1994, DIS COLON RECTUM, V37, P875, DOI 10.1007/BF02052591; Mella J, 1997, ANN ROY COLL SURG, V79, P206; MELLA J, 1979, ANN R COLL SURG ENGL, V79, P2066; NORTHOVER J, 1994, JAMA-J AM MED ASSOC, V272, P31, DOI 10.1001/jama.1994.03520010041025; OHLSSON B, 1995, DIS COLON RECTUM, V38, P619, DOI 10.1007/BF02054122; PHILLIPS RKS, 1984, BRIT J SURG, V71, P604, DOI 10.1002/bjs.1800710813; Pietra N, 1998, DIS COLON RECTUM, V41, P1127, DOI 10.1007/BF02239434; Pisani P, 1999, INT J CANCER, V83, P18, DOI 10.1002/(SICI)1097-0215(19990924)83:1&lt;18::AID-IJC5&gt;3.0.CO;2-M; Renehan AG, 2000, LANCET, V355, P1095, DOI 10.1016/S0140-6736(05)72214-5; Rosen M, 1998, DIS COLON RECTUM, V41, P1116, DOI 10.1007/BF02239433; Schoemaker D, 1998, GASTROENTEROLOGY, V114, P7, DOI 10.1016/S0016-5085(98)70626-2; *SCOTL INT GUID NE, 2002, CLIN GUID COL CANC 1; VIRGO KS, 1995, ANN SURG ONCOL, V2, P472, DOI 10.1007/BF02307079; WAGHORN A, 1995, BRIT MED J, V311, P1344, DOI 10.1136/bmj.311.7016.1344; WILLETT CG, 1984, ANN SURG, V200, P685, DOI 10.1097/00000658-198412000-00001	40	423	432	0	12	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	APR 6	2002	324	7341					813	816		10.1136/bmj.324.7341.813	http://dx.doi.org/10.1136/bmj.324.7341.813			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	540ZG	11934773	Green Published, Bronze			2023-01-03	WOS:000174960300014
J	Weinberg, PD; Hounshell, J; Sherman, LA; Godwin, J; Ali, S; Tomori, C; Bennett, CL				Weinberg, PD; Hounshell, J; Sherman, LA; Godwin, J; Ali, S; Tomori, C; Bennett, CL			Legal, financial, and public health consequences of HIV contamination of blood and blood products in the 1980s and 1990s	ANNALS OF INTERNAL MEDICINE			English	Article							SAFETY; IMPACT	Ensuring the safety of the blood supply connects politics and science. The business and service sectors share responsibility for the collection and processing of blood donations, and government agencies perform regulatory and surveillance roles. The onset of the AIDS epidemic has challenged the interface among these systems, leading to widespread fears about compromised safety of the blood supply. Because of public concern about blood-supply decisions made in the 1980s, developed countries in the 1990s established reimbursement programs for persons with transfusion-acquired viral infections from blood or blood products, adopted diagnostic tests and procedures that improved the safety of the blood supply, and held criminal judicial investigations of government officials and industry leaders accused of delaying implementation of potential blood-safety measures. In contrast, developing countries continue to struggle with blood-supply safety issues. This paper summarizes the current status of these safety concerns in developed countries, where viral transmission from contaminated blood or blood products is extremely rare, and in developing countries, where up to 10% of HIV infections result from transfusion of blood or blood products.	Vet Affairs Chicago Healthcare Syst, Lakeside Div, Chicago, IL USA; Robert H Lurie Comprehens Canc Ctr, Chicago, IL USA; Northwestern Univ, Chicago, IL 60611 USA; Loyola Univ, Sch Med, Mid W Ctr Hlth Serv & Policy Res, Maywood, IL 60153 USA; Loyola Univ, Sch Med, Cardinal Bernardin Canc Ctr, Maywood, IL 60153 USA	Ann & Robert H. Lurie Children's Hospital of Chicago; Robert H. Lurie Comprehensive Cancer Center; Northwestern University; Loyola University Chicago; Loyola University Chicago	Bennett, CL (corresponding author), Vet Affairs Med Sci Bldg,400 E Ontario St,Suite 2, Chicago, IL 60611 USA.	cbenne@nwu.edu	Tomori, Cecilia/C-5147-2018; Bennett, Charles L/C-2050-2008	Tomori, Cecilia/0000-0003-4235-1821; 				ABBOTT A, 1995, NATURE, V376, P628; ABBOTT A, 1993, NATURE, V366, P98; ABBOTT A, 1993, NATURE, V365, P594, DOI 10.1038/365594b0; ALTER HJ, 1972, ANN INTERN MED, V77, P691, DOI 10.7326/0003-4819-77-5-691; AuBuchon JP, 1997, ANN INTERN MED, V127, P904, DOI 10.7326/0003-4819-127-10-199711150-00009; Barker S, 1996, NATURE, V379, P663, DOI 10.1038/379663a0; Bayer R, 1999, BLOOD FEUDS, P1; BERNTORP E, 1994, THROMB HAEMOSTASIS, V71, P678; BLAKESLEE S, 2000, NY TIMES        0725, P1; BRUNO S, 1998, LANCET, V352, P1916; BUTLER D, 1993, NATURE, V364, P269; BUTLER D, 1995, NATURE, V375, P526, DOI 10.1038/375526a0; BUTLER D, 1994, NATURE, V371, P548; BUTLER D, 1994, NATURE, V370, P404, DOI 10.1038/370404b0; BUTLER D, 1994, NATURE, V370, P319, DOI 10.1038/370319a0; BUTLER D, 1992, NATURE, V359, P764, DOI 10.1038/359764a0; BUTLER D, 1994, NATURE, V367, P304; *CDCP, 1981, MORB MORT WEEKL 0605, P5; *CDCP, 1982, MORB MORT WEEKL 0716; DUNN K, 1993, CAN MED ASSOC J, V148, P609; EFRON S, 2000, LOS ANGELES TIM 0225, pA1; ESMONDE TFG, 1993, LANCET, V341, P205, DOI 10.1016/0140-6736(93)90068-R; HUTCHCRAFT C, 1996, CHICAGO TRIBUNE 0531, P1; JAYARAMAN KS, 1995, NATURE, V376, P285, DOI 10.1038/376285b0; Kapoor D, 2000, Indian J Gastroenterol, V19, P64; KING M, 2000, GAZETTE MONTREA 0312, pA5; Klein MA, 1997, NATURE, V390, P687, DOI 10.1038/37789; Kondro W, 1997, LANCET, V350, P1688, DOI 10.1016/S0140-6736(05)64294-8; Kondro W, 1996, LANCET, V348, P52, DOI 10.1016/S0140-6736(05)64368-1; KREVER H, 1995, COMMISSION INQUIRY B; LACKRITZ EM, 1993, AIDS, V7, P995, DOI 10.1097/00002030-199307000-00014; Leveton Lauren B., 1995, HIV BLOOD SUPPLY ANA, P49; McGregor A, 1998, LANCET, V352, P1916, DOI 10.1016/S0140-6736(05)60413-8; Murray T, 1998, NAT MED, V4, P10, DOI 10.1038/nm0198-010a; *NAT BLOOD DON RES, 1999, REP BLOOD DON TRANSF; Pomfret J., 2001, WASHINGTON POST 0109, pA1; *REUT HLTH INF SER, 1996, HIV AIDS NEWSL  1028; *REUT HLTH INF SER, 1996, HIV AIDS NEWSLI 0924; ROSENDAAL FR, 1991, ANN HEMATOL, V62, P5, DOI 10.1007/BF01714977; Schreiber GB, 1996, NEW ENGL J MED, V334, P1685, DOI 10.1056/NEJM199606273342601; Sherman LA, 2000, TRANSFUSION, V40, P1268, DOI 10.1046/j.1537-2995.2000.40101268.x; Simons M, 1994, NY TIMES, pA1; STARR DP, 1998, EPIC HIST MED COMMER, P304; STARR DP, 1998, EPIC HIST MED COMMER, P303; STARR DP, 1998, BLOOD EPIC HIST MED, P283; STARR DP, 1998, BLOOD EPIC HIST MED, P320; STARR DP, 1998, EPIC HIST MED COMMER, P327; Swinbanks D, 1996, NATURE, V383, P291, DOI 10.1038/383291a0; TASTEMAIN C, 1995, NATURE, V375, P349, DOI 10.1038/375349a0; Tomlinson R, 1997, BRIT MED J, V314, P93; Trebilcock M, 1996, VA LAW REV, V82, P1407, DOI 10.2307/1073680; Warden J, 1998, BRIT MED J, V317, P1548, DOI 10.1136/bmj.317.7172.1548b; WHITNEY CR, 1998, NY TIMES        0718, pA4; WHITNEY CR, 1999, NY TIMES        0611, pA1; *WHO, 2000, SAF BLOOD STARTS ME; *WORLD BANK GROUP, 2001, IND NAT AIDS CONTR P; Zuck TF, 1996, TRANSFUSION, V36, P928, DOI 10.1046/j.1537-2995.1996.361097017181.x; 1997, WASHINGTON TIME 0729, pA12; 2001, SUMMARY RATIONALE DR; 1997, MACLEANS        1020, P110; R RAY HEMOPHILIA REL; 1996, NATURE, V383, P9; 1997, NATURE, V387, P840; 2001, GUILTY VERDIC UPHELD; 1997, IPS WIRE        098; 1997, REUTERS         1017; 1997, UNITED PRESS IN 0730	67	51	56	0	3	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	FEB 19	2002	136	4					312	319		10.7326/0003-4819-136-4-200202190-00011	http://dx.doi.org/10.7326/0003-4819-136-4-200202190-00011			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	523FQ	11848729				2023-01-03	WOS:000173943700008
J	Barsky, AJ; Saintfort, R; Rogers, MP; Borus, JF				Barsky, AJ; Saintfort, R; Rogers, MP; Borus, JF			Nonspecific medication side effects and the nocebo phenomenon	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ADVERSE DRUG-REACTIONS; PLACEBO-RESPONSES; ANTICIPATORY NAUSEA; AIRWAY REACTIVITY; CHEMOTHERAPY; SPECIFICITY; PREVALENCE; SUGGESTION; PENICILLIN; INDUCTION	Patients taking active medications frequently experience adverse, nonspecific side effects that are not a direct result of the specific pharmacological action of the drug. Although this phenomenon is common, distressing, and costly, it is rarely studied and poorly understood. The nocebo phenomenon, in which placebos produce adverse side effects, offers some insight into nonspecific side effect reporting. We performed a focused review of the literature, which identified several factors that appear to be associated with the nocebo phenomenon and/or reporting of nonspecific side effects while taking active medication: the patient's expectations of adverse effects at the outset of treatment; a process of conditioning in which the patient learns from prior experiences to associate medication-taking with somatic symptoms; certain psychological characteristics such as anxiety, depression, and the tendency to somatize; and situational and contextual factors. Physicians and other health care personnel can attempt to ameliorate nonspecific side effects to active medications by identifying in advance those patients most at risk for developing them and by using a collaborative relationship with the patient to explain and help the patient to understand and tolerate these bothersome but nonharmful symptoms.	Brigham & Womens Hosp, Dept Psychiat, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA USA	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School	Barsky, AJ (corresponding author), Brigham & Womens Hosp, Dept Psychiat, 75 Francis St, Boston, MA 02115 USA.							ADER R, 2001, CONDITIONING IMMUNIT; ANDRYKOWSKI MA, 1988, CANCER, V62, P2607, DOI 10.1002/1097-0142(19881215)62:12<2607::AID-CNCR2820621226>3.0.CO;2-S; ANDRYKOWSKI MA, 1987, J CONSULT CLIN PSYCH, V55, P36, DOI 10.1037/0022-006X.55.1.36; [Anonymous], 1991, Arch Intern Med, V151, P1413; BAKER DB, 1988, ARCH ENVIRON HEALTH, V43, P325; Balant LP, 2000, INT J CLIN PHARM TH, V38, P47; Barsky AJ, 1999, ANN INTERN MED, V130, P910, DOI 10.7326/0003-4819-130-11-199906010-00016; BARSKY AJ, 1983, ARCH INTERN MED, V143, P1544, DOI 10.1001/archinte.143.8.1544; Barsky AJ, 1999, PSYCHOSOMATICS, V40, P396, DOI 10.1016/S0033-3182(99)71204-1; Benedetti F, 1997, PAIN, V71, P135, DOI 10.1016/S0304-3959(97)03346-0; Berthelot JM, 2001, JOINT BONE SPINE, V68, P65, DOI 10.1016/S1297-319X(00)00225-6; BLACKWELL B, 1972, LANCET, V1, P1279; BUCKALEW LW, 1982, J CLIN PSYCHOPHARM, V2, P245; Casper RC, 2001, BIOL PSYCHIAT, V49, P158, DOI 10.1016/S0006-3223(00)00966-5; CLARK PI, 1994, ANNU REV PUBL HEALTH, V15, P19; COL N, 1990, ARCH INTERN MED, V150, P841, DOI 10.1001/archinte.150.4.841; CUTLER NR, 1991, DICP ANN PHARMAC, V25, P471, DOI 10.1177/106002809102500506; DAVIS C, 1995, J CLIN PSYCHOPHARM, V15, P347, DOI 10.1097/00004714-199510000-00007; deCraen AJM, 1996, BRIT MED J, V313, P1624, DOI 10.1136/bmj.313.7072.1624; DEKKER E, 1956, J PSYCHOSOM RES, V1, P58, DOI 10.1016/0022-3999(56)90035-6; DHUME VG, 1975, CLINICIAN, V39, P289; Dormann H, 2000, DRUG SAFETY, V22, P161, DOI 10.2165/00002018-200022020-00007; DRICI MD, 1995, BRIT J CLIN PHARMACO, V39, P204, DOI 10.1111/j.1365-2125.1995.tb04434.x; EINARSON TR, 1993, ANN PHARMACOTHER, V27, P282; Eland IA, 1999, BRIT J CLIN PHARMACO, V48, P623; FERGUSON JM, 1993, PSYCHIAT ANN, P20; Flaten MA, 1997, HUM PSYCHOPHARM CLIN, V12, P369, DOI 10.1002/(SICI)1099-1077(199707/08)12:4<369::AID-HUP881>3.3.CO;2-4; Flaten MA, 1999, PSYCHOSOM MED, V61, P250, DOI 10.1097/00006842-199903000-00018; GRAFFLONNEVIG V, 1988, ARCH DIS CHILD, V63, P1342, DOI 10.1136/adc.63.11.1342; Hahn RA, 1997, PREV MED, V26, P607, DOI 10.1006/pmed.1996.0124; Harrington Anne, 1997, PLACEBO EFFECT INTER; HERNANSANZ MD, 1994, ATEN PRIM, V14, P783; Herzhaft G, 1969, Encephale, V58, P486; JEWETT DL, 1990, NEW ENGL J MED, V323, P429, DOI 10.1056/NEJM199008163230701; JOHNSON JA, 1995, ARCH INTERN MED, V155, P1949, DOI 10.1001/archinte.155.18.1949; JOYCE CRB, 1959, BRIT J PHARM CHEMOTH, V14, P512, DOI 10.1111/j.1476-5381.1959.tb00958.x; KAST EC, 1961, ILLINOIS MED J, V119, P390; KATON W, 1992, MED CARE, V30, P67, DOI 10.1097/00005650-199201000-00007; KENNEDY W P, 1961, Med World, V95, P203; Khosla P. P, 1992, Indian Journal of Physiology and Pharmacology, V36, P259; KIRK CR, 1988, BRIT MED J, V296, P1236, DOI 10.1136/bmj.296.6631.1236; KISSEL P, 1974, PLACEBOS EFFECT PLAC; LEESHALEY PR, 1992, PERCEPT MOTOR SKILL, V75, P531, DOI 10.2466/PMS.75.5.531-544; LONG DM, 1989, STEREOT FUNCT NEUROS, V53, P149, DOI 10.1159/000099531; LUPARELLO T, 1968, PSYCHOSOM MED, V30, P819, DOI 10.1097/00006842-196811000-00002; LUPARELLO TJ, 1970, PSYCHOSOM MED, V32, P509, DOI 10.1097/00006842-197009000-00009; MCFADDEN ER, 1969, PSYCHOSOM MED, V31, P134, DOI 10.1097/00006842-196903000-00007; MCNAIR DM, 1970, ARCH GEN PSYCHIAT, V22, P128; Moore N, 1998, BRIT J CLIN PHARMACO, V45, P301, DOI 10.1046/j.1365-2125.1998.00667.x; MORROW GR, 1988, CLIN PSYCHOL REV, V8, P517, DOI 10.1016/0272-7358(88)90077-3; MORSELLI PL, 1970, NATURE, V227, P611, DOI 10.1038/227611a0; MYERS MG, 1987, CLIN PHARMACOL THER, V42, P250, DOI 10.1038/clpt.1987.142; OSWALD NTA, 1983, BRIT MED J, V287, P265, DOI 10.1136/bmj.287.6387.265; PENNEBAKER JW, 1982, PSYCHOL PHYSICAL SYM; POGGE R C, 1963, Med Times, V91, P773; Preston RA, 2000, ARCH INTERN MED, V160, P1449, DOI 10.1001/archinte.160.10.1449; REIDENBERG MM, 1968, NEW ENGL J MED, V279, P678, DOI 10.1056/NEJM196809262791304; ROBERTS AH, 1987, S AFR MED J, V72, P131; ROHT LH, 1985, AM J EPIDEMIOL, V122, P418, DOI 10.1093/oxfordjournals.aje.a114123; ROSENZWEIG P, 1993, CLIN PHARMACOL THER, V54, P578, DOI 10.1038/clpt.1993.190; SCHWEIGER A, 1981, PAVLOVIAN J BIOL SCI, V16, P140; SHEPHERD M, 1993, PSYCHOL MED, V23, P569, DOI 10.1017/S0033291700025356; SIEGEL S, 1976, SCIENCE, V193, P323, DOI 10.1126/science.935870; SIMON GE, 1993, GEN HOSP PSYCHIAT, V15, P399, DOI 10.1016/0163-8343(93)90009-D; Sorensen H T, 1986, Scand J Prim Health Care, V4, P252; SORTLAND O, 1992, ACTA RADIOL, V33, P368; SPRIET A, 1977, EUR J CLIN PHARMACOL, V11, P181, DOI 10.1007/BF00606408; Straus JL, 1996, PSYCHOSOMATICS, V37, P315, DOI 10.1016/S0033-3182(96)71544-X; Strohle A, 2000, J PSYCHIAT RES, V34, P439, DOI 10.1016/S0022-3956(00)00039-X; SURTEES SJ, 1991, BRIT MED J, V302, P1051, DOI 10.1136/bmj.302.6784.1051; Tangrea Joseph A., 1994, Annals of Epidemiology, V4, P327; TURNER JA, 1994, JAMA-J AM MED ASSOC, V271, P1609, DOI 10.1001/jama.271.20.1609; Uhlenhuth EH, 1998, J AFFECT DISORDERS, V47, P183, DOI 10.1016/S0165-0327(97)00125-0; UKENS C, 1999, DRUG TOP, V143, P22; WILSON L, 1994, PAIN, V57, P55, DOI 10.1016/0304-3959(94)90107-4; WOLF S, 1954, JAMA-J AM MED ASSOC, V155, P339, DOI 10.1001/jama.1954.03690220013004	76	525	530	1	64	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 6	2002	287	5					622	627		10.1001/jama.287.5.622	http://dx.doi.org/10.1001/jama.287.5.622			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	518UR	11829702				2023-01-03	WOS:000173686700032
J	Simonsen, L; Morens, DM; Elixhauser, A; Gerber, M; Van Raden, M; Blackwelder, WC				Simonsen, L; Morens, DM; Elixhauser, A; Gerber, M; Van Raden, M; Blackwelder, WC			Effect of rotavirus vaccination programme on trends in admission of infants to hospital for intussusception	LANCET			English	Article							DEVELOPING-COUNTRIES; UNITED-STATES; IMMUNIZATION; INFECTION; CHILDREN; FUTURE	Background Studies have reported a temporal association between a first dose of rotavirus vaccine (Rotashield) and infant intussusception. We investigated the effect of Rotashield vaccination use on intussusception admissions in ten US states. Methods We analysed electronic databases containing 100% hospital discharge records for 1993-99 from ten US states, where an estimated 28% of the birth cohort had received Rotashield (based on manufacturer's net sales data). We examined records of infants admitted to hospital (<365 days old) with any mention of intussusception (international Classification of Diseases, ninth revision. clinical modification code 560.0). Excess admissions for intussusception during the period of Rotashield availability (October 1998 to June 1999) were estimated by direct comparison with the corresponding period of October 1997 to June 1998 (before Rotashield was available) and with adjustment for secular trends during 1993-98 by Poisson regression. Findings Hospital admission for intussusception among infants younger than 365 days of age during the Rotashield period compared with previously was 4% lower (10 cases) by direct comparison and 10% lower (27 cases) by trend comparison, corresponding to a negative population attributable risk. Among infants aged 45-210 days (target age range for a first Rotashield dose), we estimated an increase in intussusception admissions of 1% (one excess admission) by direct comparison and 4% (4.6 excess admissions) by trend comparison, corresponding to a population attributable risk range of one excess admission in 66 000-302 000. Interpretation We found no evidence of increased infant intussusception admissions during the period of Rotashield availability. The total intussusception admission risk attributable to Rotashield was substantially lower than previous estimates based on studies focusing on the immediate postvaccination weeks.	NIAID, NIH, Bethesda, MD 20892 USA; Agcy Healthcare Res & Qual, Rockville, MD USA	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); Agency for Healthcare Research & Quality	Simonsen, L (corresponding author), 6700-B Rockledge Dr,Room 3153, Bethesda, MD 20892 USA.		Simonsen, Lone/K-4531-2014	Simonsen, Lone/0000-0003-1535-8526				*ADV COMM IMM PRAC, 1999, ACIP C ATL OCT 22 19, P1; [Anonymous], M FUT DIR ROT VACC R; Bresee JS, 1999, VACCINE, V17, P2207, DOI 10.1016/S0264-410X(98)00376-4; *CDCP, 1999, MMWR MORB MORTAL WKL, V48; CHANG HGH, IN PRESS PEDIATRICS; DEZOYSA I, 1985, B WORLD HEALTH ORGAN, V63, P569; Ehresman K., 1999, Morbidity and Mortality Weekly Report, V48, P577; Emanuel EJ, 2000, JAMA-J AM MED ASSOC, V283, P2701, DOI 10.1001/jama.283.20.2701; Gay N, 1999, LANCET, V354, P956, DOI 10.1016/S0140-6736(05)75710-X; Glass RI, 1996, J INFECT DIS, V174, pS5, DOI 10.1093/infdis/174.Supplement_1.S5; *I MED, 1986, NEW VACC DEV DIS IMP, V2; Kramarz P, 2001, PEDIATR INFECT DIS J, V20, P410, DOI 10.1097/00006454-200104000-00008; Levin A, 2000, ANN INTERN MED, V133, P661, DOI 10.7326/0003-4819-133-8-200010170-00102; Melton L, 2000, LANCET, V356, P318, DOI 10.1016/S0140-6736(05)73604-7; Murphy TV, 2001, NEW ENGL J MED, V344, P564, DOI 10.1056/NEJM200102223440804; Nakagomi T, 2000, MICROBIOL IMMUNOL, V44, P619, DOI 10.1111/j.1348-0421.2000.tb02542.x; Parashar UD, 2000, PEDIATRICS, V106, P1413, DOI 10.1542/peds.106.6.1413; Rennels MB, 1998, PEDIATR INFECT DIS J, V17, P924, DOI 10.1097/00006454-199810000-00018; Tucker AW, 1998, JAMA-J AM MED ASSOC, V279, P1371, DOI 10.1001/jama.279.17.1371; Weijer C, 2000, BRIT MED J, V321, P525, DOI 10.1136/bmj.321.7260.525	20	92	94	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	OCT 13	2001	358	9289					1224	1229		10.1016/S0140-6736(01)06346-2	http://dx.doi.org/10.1016/S0140-6736(01)06346-2			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	481NX	11675060				2023-01-03	WOS:000171527000012
J	Bodenheimer, TS				Bodenheimer, TS			Affordable prescriptions for the elderly	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							DRUG		Univ Calif San Francisco, Dept Family & Community Med, San Francisco, CA 94143 USA	University of California System; University of California San Francisco	Bodenheimer, TS (corresponding author), Bay W Family Hlth Care, 1580 Valencia St,Suite 201, San Francisco, CA 94110 USA.							Blustein J, 2000, HEALTH AFFAIR, V19, P219, DOI 10.1377/hlthaff.19.2.219; BOWEAN L, 2000, WALL STREET J   0801, pB8; BROOK RH, 1983, NEW ENGL J MED, V309, P1426, DOI 10.1056/NEJM198312083092305; BROOK RH, 1989, JAMA-J AM MED ASSOC, V262, P3027, DOI 10.1001/jama.262.21.3027; BROWN AB, 2001, PATIENT CARE    0330, P22; Davidoff F, 2001, ANN INTERN MED, V134, P1068, DOI 10.7326/0003-4819-134-11-200106050-00014; Federman AD, 2001, JAMA-J AM MED ASSOC, V286, P1732, DOI 10.1001/jama.286.14.1732; HALL S, 2001, NY TIMES MAGAZI 0311, P91; HALL SS, 2001, NY TIMES MAGAZI 0311, P100; HALL SS, 2001, NY TIMES MAGAZI 0311, P40; Hall Stephen, 2001, NY TIMES MAGAZI 0311, P59; Heffler S, 2001, HEALTH AFFAIR, V20, P193, DOI 10.1377/hlthaff.20.2.193; Huang AJ, 2000, JAMA-J AM MED ASSOC, V284, P2240, DOI 10.1001/jama.284.17.2240; Iglehart JK, 2001, NEW ENGL J MED, V344, P1010, DOI 10.1056/NEJM200103293441311; *KAIS FAM FDN, 2001, MED PRESCR DRUGS; KESSLER DA, 1994, NEW ENGL J MED, V331, P1350, DOI 10.1056/NEJM199411173312007; KRELING DH, 2000, PRESCRIPTION DRUG TR; MOON M, 2001, TARGETING MEDICARE D; PAGE L, 2000, AM MED NEWS     0301, P1; Pear R., 2001, NY TIMES B      1025, P1; Phillips DP, 1998, LANCET, V351, P643, DOI 10.1016/S0140-6736(98)24009-8; Rothschild JM, 2000, ARCH INTERN MED, V160, P2717, DOI 10.1001/archinte.160.18.2717; SHULMAN NB, 1986, AM J PUBLIC HEALTH, V76, P1105, DOI 10.2105/AJPH.76.9.1105; Stolberg S G, 2000, N Y Times Web, pA15; Tamblyn R, 2001, JAMA-J AM MED ASSOC, V285, P421, DOI 10.1001/jama.285.4.421; *US ADM AG, 2000, PROF OLD AM; Wazana A, 2000, JAMA-J AM MED ASSOC, V283, P373, DOI 10.1001/jama.283.3.373	27	10	10	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 10	2001	286	14					1762	1763		10.1001/jama.286.14.1762	http://dx.doi.org/10.1001/jama.286.14.1762			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	480NC	11594903				2023-01-03	WOS:000171466800028
J	Groeneveld, PW; Kwong, JL; Liu, YY; Rodriguez, AJ; Jones, MP; Sanders, GD; Garber, AM				Groeneveld, PW; Kwong, JL; Liu, YY; Rodriguez, AJ; Jones, MP; Sanders, GD; Garber, AM			Cost-effectiveness of automated external defibrillators on airlines	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							EMERGENCY MEDICAL-SERVICES; HOSPITAL CARDIAC-ARREST; RAPID DEFIBRILLATION; SURVIVORS; QUALITY; LIFE; ANTIARRHYTHMICS; OUTCOMES; VICTIMS; STATES	Context Installation of automated external defibrillators (AEDs) on passenger aircraft has been shown to improve survival of cardiac arrest in that setting, but the cost-effectiveness of such measures has not been proven. Objective To examine the costs and effectiveness of several different options for AED deployment in the US commercial air transportation system. Design, Setting, and Subjects Decision and cost-effectiveness analysis of a strategy of full deployment on all aircraft as well as several strategies of partial deployment only on larger aircraft, compared with a baseline strategy of no AEDs on aircraft (but training flight attendants in basic life support) for a hypothetical cohort of persons experiencing cardiac arrest aboard US commercial aircraft. Estimates for costs and outcomes were obtained from the medical literature, the Federal Aviation Administration, the Air Transport Association of America, a population-based cohort of Medicare patients, AED manufacturers, and the Bureau of Labor Statistics. Main Outcome Measures Quality-adjusted survival after cardiac arrest; costs of AED deployment on aircraft and of medical care for cardiac arrest survivors. Results Adding AEDs on passenger aircraft with more than 200 passengers would cost $35300 per quality-adjusted life-year (QALY) gained. Additional AEDs on aircraft with capacities between 100 and 200 persons would cost an additional $40800 per added QALY compared with deployment on large-capacity aircraft only, and full deployment on all passenger aircraft would cost an additional $94700 per QALY gained compared with limited deployment on aircraft with capacity greater than 100. Sensitivity analyses indicated that the quality of life, annual mortality rate, and the effectiveness of AEDs in improving survival were the most influential factors in the model. In 85% of Monte Carlo simulations, AED placement on large-capacity aircraft produced cost-effectiveness ratios of less than $50000 per QALY. Conclusion The cost-effectiveness of placing AEDs on commercial aircraft compares favorably with the cost-effectiveness of widely accepted medical interventions and health policy regulations, but is critically dependent on the passenger capacity of the aircraft. Placing AEDs on most US commercial aircraft would meet conventional standards of cost-effectiveness.	Stanford Univ, Ctr Primary Care & Outcomes Res, Stanford, CA 94305 USA; Stanford Univ, Grad Sch Business, Stanford, CA 94305 USA; Stanford Univ, Stanford Biomed Informat, Stanford, CA 94305 USA; Front Line Strateg Management Consulting, Foster City, CA USA; Vet Affairs Palo Alto Hlth Care Syst, Palo Alto, CA USA	Stanford University; Stanford University; Stanford University; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Palo Alto Health Care System	Groeneveld, PW (corresponding author), Stanford Univ, Ctr Primary Care & Outcomes Res, 179 Encina Commons,MC 6019, Stanford, CA 94305 USA.	petegro@healthpolicy.stanford.edu	Garber, Alan M/F-1476-2010	Groeneveld, Peter/0000-0002-7374-4292	AGENCY FOR HEALTHCARE RESEARCH AND QUALITY [F32HS000028, T32HS000028] Funding Source: NIH RePORTER; AHRQ HHS [HS00028-15] Funding Source: Medline	AGENCY FOR HEALTHCARE RESEARCH AND QUALITY(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)		*AIR TRANSP ASS AM, 2000, IND ANN REP 2000; AUBLE TE, 1995, ANN EMERG MED, V25, P642, DOI 10.1016/S0196-0644(95)70178-8; BANTA HD, 1990, JAMA-J AM MED ASSOC, V264, P235, DOI 10.1001/jama.264.2.235; Berek K, 1997, J NEUROL, V244, P556, DOI 10.1007/s004150050143; *BUR LAB STAT, 2000, OCC OUTL HDB; CREWDSON J, 1996, CHICAGO TRIBUNE 0630, P1; de Vos R, 1999, ARCH INTERN MED, V159, P249, DOI 10.1001/archinte.159.3.249; Doubilet P, 1985, Med Decis Making, V5, P157, DOI 10.1177/0272989X8500500205; EISENBERG MS, 1984, JAMA-J AM MED ASSOC, V251, P1723, DOI 10.1001/jama.251.13.1723; EISENBERG MS, 1980, NEW ENGL J MED, V302, P1379, DOI 10.1056/NEJM198006193022502; EISENBERG MS, 1984, AM J EMERG MED, V2, P189, DOI 10.1016/0735-6757(84)90001-9; EVERY N, 1994, DEFIBRILLATION HEART, P182; Ewy GA, 2000, J AM COLL CARDIOL, V35, P830; Federal Aviation Administration, 2001, FED REGISTER, V66, P19028; FLINT P, 1998, INT AIR TRANSP ASS A; Foutz R A, 2000, Prehosp Emerg Care, V4, P314, DOI 10.1080/10903120090941010; FREEMAN KD, 2001, ACAD EMERG MED, V8, P431; Gage BF, 1996, ARCH INTERN MED, V156, P1829, DOI 10.1001/archinte.156.16.1829; GILLUM RF, 1989, CIRCULATION, V79, P756, DOI 10.1161/01.CIR.79.4.756; Graham JD, 1997, JAMA-J AM MED ASSOC, V278, P1418, DOI 10.1001/jama.278.17.1418; Gratton M, 1999, Prehosp Emerg Care, V3, P303, DOI 10.1080/10903129908958958; Graves JR, 1997, RESUSCITATION, V35, P117; HOFER S, 1998, PUBLICATION FEDERAL; *INT AIR TRANSP AS, 2000, CORP AIR TRAV SURV 1; Jermyn B D, 2000, Prehosp Emerg Care, V4, P43, DOI 10.1080/10903120090941632; KELLERMANN AL, 1993, JAMA-J AM MED ASSOC, V270, P1708, DOI 10.1001/jama.270.14.1708; Kim SG, 1997, AM J CARDIOL, V80, P454, DOI 10.1016/S0002-9149(97)00394-9; Marenco JP, 2001, JAMA-J AM MED ASSOC, V285, P1193, DOI 10.1001/jama.285.9.1193; McAnulty J, 1997, NEW ENGL J MED, V337, P1576; *NAT HEART LUNG BL, 2001, STUD LAUNCH TEST PUB; National Center for Health Statistics, 2000, HLTH US 2000; Nichol G, 1999, ANN EMERG MED, V34, P517, DOI 10.1016/S0196-0644(99)80054-7; Nichol G, 1999, ACAD EMERG MED, V6, P95, DOI 10.1111/j.1553-2712.1999.tb01044.x; Nichol G, 1998, CIRCULATION, V97, P1315, DOI 10.1161/01.CIR.97.13.1315; Nichol G, 1996, ANN EMERG MED, V27, P711, DOI 10.1016/S0196-0644(96)70188-9; ORourke MF, 1997, CIRCULATION, V96, P2849, DOI 10.1161/01.CIR.96.9.2849; Owens DK, 1997, ANN INTERN MED, V126, P1, DOI 10.7326/0003-4819-126-1-199701010-00001; Page RL, 1998, CIRCULATION, V97, P1429; Page RL, 2000, NEW ENGL J MED, V343, P1210, DOI 10.1056/NEJM200010263431702; Pasta DJ, 1999, MED DECIS MAKING, V19, P353, DOI 10.1177/0272989X9901900314; Pinski SL, 2000, AM HEART J, V139, P804, DOI 10.1016/S0002-8703(00)90011-5; RAYMAN RB, 1994, JAMA-J AM MED ASSOC, V271, P1657, DOI 10.1001/jama.271.21.1657; Riegel B, 1998, Am J Crit Care, V7, P402; ROINE RO, 1993, JAMA-J AM MED ASSOC, V269, P237, DOI 10.1001/jama.269.2.237; SAPP F, 2001, PUBLICATION FEDERAL; SEDGWICK ML, 1993, RESUSCITATION, V26, P75, DOI 10.1016/0300-9572(93)90166-N; Skogvoll E, 1999, ANN EMERG MED, V33, P409, DOI 10.1016/S0196-0644(99)70305-7; SoRelle R, 1999, CIRCULATION, V99, P2606, DOI 10.1161/01.CIR.99.20.2606; STULTS KR, 1984, NEW ENGL J MED, V310, P219, DOI 10.1056/NEJM198401263100403; Thompson RJ, 1998, AM J CARDIOL, V81, P17, DOI 10.1016/S0002-9149(97)00798-4; TORRANCE GW, 1995, PHARMACOECONOMICS, V7, P503, DOI 10.2165/00019053-199507060-00005; Valenzuela TD, 2000, NEW ENGL J MED, V343, P1206, DOI 10.1056/NEJM200010263431701; Valenzuela TD, 1997, CIRCULATION, V96, P3308; Varon J, 1999, RESUSCITATION, V41, P219, DOI 10.1016/S0300-9572(99)00064-7; VUKOV LF, 1988, ANN EMERG MED, V17, P318, DOI 10.1016/S0196-0644(88)80771-6; WEAVER WD, 1988, NEW ENGL J MED, V319, P661, DOI 10.1056/NEJM198809153191101; Weinstein MC., 1996, COST EFFECTIVENESS H; Weiss JP, 2000, CIRCULATION, V102, P395; Zipes DP, 1998, CIRCULATION, V98, P2334, DOI 10.1161/01.CIR.98.21.2334	59	71	72	0	4	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 26	2001	286	12					1482	1489		10.1001/jama.286.12.1482	http://dx.doi.org/10.1001/jama.286.12.1482			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	475UX	11572741	Bronze			2023-01-03	WOS:000171188600026
J	Krakow, B; Hollifield, M; Johnston, L; Koss, M; Schrader, R; Warner, TD; Tandberg, D; Lauriello, J; McBride, L; Cutchen, L; Cheng, D; Emmons, S; Germain, A; Melendrez, D; Sandoval, D; Prince, H				Krakow, B; Hollifield, M; Johnston, L; Koss, M; Schrader, R; Warner, TD; Tandberg, D; Lauriello, J; McBride, L; Cutchen, L; Cheng, D; Emmons, S; Germain, A; Melendrez, D; Sandoval, D; Prince, H			Imagery rehearsal therapy for chronic nightmares in sexual assault survivors with posttraumatic stress disorder - A randomized controlled trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							SLEEP; DESENSITIZATION; PREVALENCE; INSTRUMENT; INSOMNIA; EFFICACY; SESSION; DREAMS; PTSD	Context Chronic nightmares occur frequently in patients with posttraumatic stress disorder (PTSD) but are not usually a primary target of treatment. Objective To determine if treating chronic nightmares with imagery rehearsal therapy (IRT) reduces the frequency of disturbing dreams, improves sleep quality, and decreases PTSD symptom severity. Design, Setting, and Participants Randomized controlled trial conducted from 1995 to 1999 among 168 women in New Mexico; 95% had moderate-to-severe PTSD, 97% had experienced rape or other sexual assault, 77% reported life-threatening sexual assault, and 58% reported repeated exposure to sexual abuse in childhood or adolescence. Intervention Participants were randomized to receive treatment (n=88) or to the wait-list control group (n=80). The treatment group received IRT in 3 sessions; controls received no additional intervention, but continued any ongoing treatment. Main Outcome Measures cores on the Nightmare Frequency Questionnaire (NFQ), Pittsburgh Sleep Quality Index (PSQI), PTSD Symptom Scale (PSS), and Clinician-Administered PTSD Scale (CAPS) at 3- and 6-month follow-up. Results A total of 114 participants completed follow-up at 3 and/or 6 months. Comparing baseline to follow-up (n=97-114), treatment significantly reduced nights per week with nightmares (Co hen d=1.24; P<.001) and number of nightmares per week (Cohen d=0.85; P<.001) on the NFQ and improved sleep (on the PSQI, Cohen d=0.67; P<.001) and PTSD symptoms (on the PSS, Cohen d=1.00; P<.001 and on the CAPS, Cohen d=1.53; P<.001). Control participants showed small, nonsignificant improvements for the same measures (mean Cohen d=0.21). In a 3-point analysis (n=66-77), improvements occurred in the treatment group at 3-month follow-up (treatment vs control group, Cohen d=1.15 vs 0.07 for nights per week with nightmares; 0.95 vs -0.06 for nightmares per week; 0.77 vs 0.31 on the PSQI, and 1.06 vs 0.31 on the PSS) and were sustained without further intervention or contact between 3 and 6 months. An intent-to-treat analysis (n=168) confirmed significant differences between treatment and control groups for nightmares, sleep, and PTSD (all P<.02) with moderate effect sizes for treatment (mean Cohen d=0.60) and small effect sizes for controls (mean Cohen d=0.14). Posttraumatic stress symptoms decreased by at least 1 level of clinical severity in 65% of the treatment group compared with symptoms worsening or not changing in 69% of controls (chi (2)(1)=12.80; P<.001). Conclusions Imagery rehearsal therapy is a brief, well-tolerated treatment that appears to decrease chronic nightmares, improve sleep quality, and decrease PTSD symptom severity.	Sleep & Human Hlth Inst, Albuquerque, NM 87110 USA; Univ New Mexico, Sch Med, Hlth Sci Ctr, Albuquerque, NM 87131 USA; Univ New Mexico, Sch Med, Dept Emergency Med, Albuquerque, NM 87131 USA; Univ New Mexico, Sch Med, Dept Psychiat, Albuquerque, NM 87131 USA; Univ New Mexico, Sch Med, Dept Family & Community Med, Albuquerque, NM 87131 USA; Univ New Mexico, Dept Math & Stat, Albuquerque, NM 87131 USA; Univ Arizona, Hlth Sci Ctr, Tucson, AZ USA; Univ Montreal, Dept Psychol, Montreal, PQ H3C 3J7, Canada; Hop Sacre Coeur, Lab Reves & Cauchemars, Montreal, PQ H4J 1C5, Canada	University of New Mexico; University of New Mexico's Health Sciences Center; University of New Mexico; University of New Mexico; University of New Mexico; University of New Mexico; University of Arizona; University of Arizona Health Sciences; Universite de Montreal; Universite de Montreal	Krakow, B (corresponding author), Sleep & Human Hlth Inst, 4775 Indian Sch Rd NE,Suite 305, Albuquerque, NM 87110 USA.	bkrakow@salud.unm.edu	WARNER, TEDDY/AAI-6905-2020		NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH053239] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		*AM AC SLEEP MED, 1997, INT CLASS SLEEP DIS, P162; American Psychiatric Association, 2000, DIAGN STAT MAN MENT, V4th; Ballenger JC, 2000, J CLIN PSYCHIAT, V61, P60; Belicki K, 1997, SLEEP RES, V26, P637; BERQUIER A, 1992, J ABNORM PSYCHOL, V101, P246, DOI 10.1037/0021-843X.101.2.246; BISHAY N, 1985, BRIT J PSYCHIAT, V147, P67, DOI 10.1192/bjp.147.1.67; BIXLER EO, 1979, AM J PSYCHIAT, V136, P1257; BLAKE D, 1990, CLIN ADM PTSD SCALE, P1; Bliwise DL, 1996, SLEEP, V19, P462, DOI 10.1093/sleep/19.6.462; Brady K, 2000, JAMA-J AM MED ASSOC, V283, P1837, DOI 10.1001/jama.283.14.1837; Buysse D J, 1989, Psychiatry Res, V28, P193; Cartwright R, 1998, PSYCHIAT RES, V80, P249, DOI 10.1016/S0165-1781(98)00071-7; CELLUCCI AJ, 1978, J BEHAV THER EXP PSY, V9, P109, DOI 10.1016/0005-7916(78)90054-X; Foa EB, 2000, J TRAUMA STRESS, V13, P539, DOI 10.1023/A:1007802031411; FOA EB, 1993, J TRAUMA STRESS, V6, P459, DOI 10.1002/jts.2490060405; FOA EB, 1995, POSTTRAUMATIC STRESS, P46; HALLIDAY G, 1987, CLIN PSYCHOL REV, V7, P501, DOI 10.1016/0272-7358(87)90041-9; Hamilton M., 1967, BRIT J SOC CLIN PSYC, V6, P278, DOI [10.1111/j.2044-8260.1967.tb00530.x, DOI 10.1111/J.2044-8260.1967.TB00530.X]; Hamilton M, 1969, BRIT J PSYCHIAT, V3, P76, DOI DOI 10.1037/T04100-000; HAYNES SN, 1975, PSYCHOL REC, V25, P225, DOI 10.1007/BF03394308; HEDEKER D, 1994, J CONSULT CLIN PSYCH, V62, P757, DOI 10.1037/0022-006X.62.4.757; KALES A, 1980, AM J PSYCHIAT, V137, P1197; KELLNER R, 1992, AM J PSYCHIAT, V149, P659; Kellner R., 1991, ANN CLIN PSYCHIATRY, V3, P67, DOI [10.3109/10401239109147970, DOI 10.3109/10401239109147970]; Kilpatrick D, 1998, DSM 4 SOURCEBOOK, P803; KLINK M, 1987, CHEST, V91, P540, DOI 10.1378/chest.91.4.540; Krakow B, 2000, JAMA-J AM MED ASSOC, V284, P563, DOI 10.1001/jama.284.5.563; Krakow B, 2000, J TRAUMA STRESS, V13, P589, DOI 10.1023/A:1007854015481; KRAKOW B, 1995, BEHAV RES THER, V33, P837, DOI 10.1016/0005-7967(95)00009-M; Krakow B, 2000, Crisis, V21, P163, DOI 10.1027//0227-5910.21.4.163; Krakow B, 2000, J PSYCHOSOM RES, V49, P291, DOI 10.1016/S0022-3999(00)00147-1; Krakow B, 2001, BIOL PSYCHIAT, V49, P948, DOI 10.1016/S0006-3223(00)01087-8; KRAKOW B, 1995, J NERV MENT DIS, V183, P623, DOI 10.1097/00005053-199510000-00002; Krakow B, 2000, COMPR PSYCHIAT, V41, P49, DOI 10.1016/S0010-440X(00)90131-7; KRAKOW B, IN PRESS J TRAUMA ST; KRAKOW B, IN PRESS J ANXIETY D; LANSKY M, 1995, POST TRAUMATIC NIGHT; Levin R, 1998, PSYCHIATRY, V61, P206, DOI 10.1080/00332747.1998.11024832; Mack J.E, 1974, NIGHTMARES HUMAN CON; MARKS I, 1978, BRIT J PSYCHIAT, V133, P461, DOI 10.1192/bjp.133.5.461; MILLER WR, 1983, J CONSULT CLIN PSYCH, V51, P870, DOI 10.1037/0022-006X.51.6.870; MOSCARELLO R, 1991, J AM ACAD PSYCHOAN, V19, P235, DOI 10.1521/jaap.1.1991.19.2.235; NEIDHARDT EJ, 1992, SLEEP, V15, P470; Nielsen T. A., 2000, PRINCIPLES PRACTICE, V3, P753; ROTHBAUM BO, 1992, J TRAUMA STRESS, V5, P455, DOI 10.1002/jts.2490050309; *SAS I INC, 1997, SAS STAT SOFTW CHANG, P571; Sheehan D.V., 1983, ANXIETY DIS; Ware J.E, 1994, PHYS MENTAL HLTH SUM; Wile IS, 1934, AM J ORTHOPSYCHIAT, V4, P449, DOI 10.1111/j.1939-0025.1934.tb06308.x; Youakim JM, 1998, PSYCHOSOMATICS, V39, P168, DOI 10.1016/S0033-3182(98)71365-9; Zadra A, 2000, J ABNORM PSYCHOL, V109, P273, DOI 10.1037/0021-843X.109.2.273	51	334	339	0	54	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 1	2001	286	5					537	545		10.1001/jama.286.5.537	http://dx.doi.org/10.1001/jama.286.5.537			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	458HE	11476655				2023-01-03	WOS:000170188300016
J	Yale, J; Bohnert, HJ				Yale, J; Bohnert, HJ			Transcript expression in Saccharomyces cerevisiae at high salinity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; RESPONSE ELEMENT STRE; OSMOTIC-STRESS; GENE-EXPRESSION; SALT STRESS; PHOSPHATASE CALCINEURIN; SIGNAL-TRANSDUCTION; BUDDING YEAST; 2 ISOENZYMES; HOG PATHWAY	Transcript expression of Saccharomyces cerevisiae at high salinity was determined by microarray analysis of 6144 open reading frames (ORFs). From cells grown in 1 M NaCl for 10, 30, and 90 min, changes in transcript abundance >2-fold were classified, Salinity-induced ORFs increased over time: 107 (10 min), 243 (30 min), and 354 (90 min). Up-regulated, functionally unknown ORFs increased from 17 to 149 over this period. Expression patterns were similar early, with 67% of up-regulated transcripts after 10 min identical to those at 30 min. The expression profile after 90 min revealed different upregulated transcripts (identities of 13% and 22%, respectively). Nucleotide and amino acid metabolism exemplified the earliest responses to salinity, followed by ORFs related to intracellular transport, protein synthesis, and destination. Transcripts related to energy production were up-regulated throughout the time course with respiration-associated transcripts strongly induced at 30 min. Highly expressed at 90 min were known salinity stress-induced genes, detoxification-related responses, transporters of the major facilitator superfamily, metabolism of energy reserves, nitrogen and sulfur compounds, and lipid, fatty acid/isoprenoid biosynthesis. We chose severe stress conditions to monitor responses in essential biochemical mechanisms. In the mutant, Delta gpd1/gpd2, lacking glycerol biosynthesis, the stress response was magnified with a partially different set of up-regulated ORFs.	Univ Arizona, Dept Biochem, Biosci W, Tucson, AZ 85721 USA	University of Arizona	Bohnert, HJ (corresponding author), Univ Arizona, Dept Biochem, Biosci W, 1041 E Lowell St, Tucson, AZ 85721 USA.	bohnerth@u.arizona.edu	Bohnert, Hans J/A-7104-2009					AKTHAR N, 1997, FEBS LETT, V403, P173; ALBERTYN J, 1994, MOL CELL BIOL, V14, P4135, DOI 10.1128/MCB.14.6.4135; [Anonymous], [No title captured]; Ansell R, 1997, EMBO J, V16, P2179, DOI 10.1093/emboj/16.9.2179; Bilsland-Marchesan E, 2000, MOL CELL BIOL, V20, P3887, DOI 10.1128/MCB.20.11.3887-3895.2000; Blomberg A, 2000, FEMS MICROBIOL LETT, V182, P1; BREWSTER JL, 1994, YEAST, V10, P425, DOI 10.1002/yea.320100402; Burg MB, 1997, ANNU REV PHYSIOL, V59, P437, DOI 10.1146/annurev.physiol.59.1.437; Curcio MJ, 1999, TRENDS GENET, V15, P43, DOI 10.1016/S0168-9525(98)01643-6; Cushman JC, 2000, CURR OPIN PLANT BIOL, V3, P117, DOI 10.1016/S1369-5266(99)00052-7; CYERT MS, 1992, MOL CELL BIOL, V12, P3460, DOI 10.1128/MCB.12.8.3460; Ferrigno P, 1998, EMBO J, V17, P5606, DOI 10.1093/emboj/17.19.5606; GARCIADEBLAS B, 1993, MOL GEN GENET, V236, P363, DOI 10.1007/BF00277134; Gaxiola RA, 1999, P NATL ACAD SCI USA, V96, P1480, DOI 10.1073/pnas.96.4.1480; Godon C, 1998, J BIOL CHEM, V273, P22480, DOI 10.1074/jbc.273.35.22480; Gustin MC, 1998, MICROBIOL MOL BIOL R, V62, P1264, DOI 10.1128/MMBR.62.4.1264-1300.1998; Hasegawa PM, 2000, ANNU REV PLANT PHYS, V51, P463, DOI 10.1146/annurev.arplant.51.1.463; Hohmann S., 1997, YEAST STRESS RESPONS, P101; Jelinsky SA, 1999, P NATL ACAD SCI USA, V96, P1486, DOI 10.1073/pnas.96.4.1486; Kawasaki S, 2001, PLANT CELL, V13, P889, DOI 10.1105/tpc.13.4.889; Kingsbury TJ, 2000, GENE DEV, V14, P1595; Kumar A, 2000, NUCLEIC ACIDS RES, V28, P81, DOI 10.1093/nar/28.1.81; LAW DTS, 1988, MOL CELL BIOL, V8, P912, DOI 10.1128/MCB.8.2.912; Li S, 1998, EMBO J, V17, P6952, DOI 10.1093/emboj/17.23.6952; MAEDA T, 1994, NATURE, V369, P242, DOI 10.1038/369242a0; MAEDA T, 1995, SCIENCE, V269, P554, DOI 10.1126/science.7624781; Marquez JA, 1996, FEBS LETT, V382, P89, DOI 10.1016/0014-5793(96)00157-3; MartinezPastor MT, 1996, EMBO J, V15, P2227, DOI 10.1002/j.1460-2075.1996.tb00576.x; Mendoza I, 1996, J BIOL CHEM, V271, P23061, DOI 10.1074/jbc.271.38.23061; MENDOZA I, 1994, J BIOL CHEM, V269, P8792; Mizoguchi T, 2000, RES PRO CEL, V27, P29; Moskvina E, 1998, YEAST, V14, P1041, DOI 10.1002/(SICI)1097-0061(199808)14:11<1041::AID-YEA296>3.0.CO;2-4; NAKAMURA T, 1993, EMBO J, V12, P4063, DOI 10.1002/j.1460-2075.1993.tb06090.x; Navarre C, 2000, EMBO J, V19, P2515, DOI 10.1093/emboj/19.11.2515; Nelissen B, 1997, FEMS MICROBIOL REV, V21, P113, DOI 10.1111/j.1574-6976.1997.tb00347.x; Nelson DE, 1998, GENET ENG P, V20, P153; Norbeck J, 1996, J BIOL CHEM, V271, P13875, DOI 10.1074/jbc.271.23.13875; Norbeck J, 1997, J BIOL CHEM, V272, P5544, DOI 10.1074/jbc.272.9.5544; Nwaka S, 1998, PROG NUCLEIC ACID RE, V58, P197; O'Rourke SM, 1998, GENE DEV, V12, P2874, DOI 10.1101/gad.12.18.2874; Pardo JM, 1998, P NATL ACAD SCI USA, V95, P9681, DOI 10.1073/pnas.95.16.9681; Planta RJ, 1998, YEAST, V14, P471, DOI 10.1002/(SICI)1097-0061(19980330)14:5<471::AID-YEA241>3.0.CO;2-U; Posas F, 2000, J BIOL CHEM, V275, P17249, DOI 10.1074/jbc.M910016199; Posas F, 1997, SCIENCE, V276, P1702, DOI 10.1126/science.276.5319.1702; Posas F, 1998, CURR OPIN MICROBIOL, V1, P175, DOI 10.1016/S1369-5274(98)80008-8; Proft M, 1999, MOL CELL BIOL, V19, P537; Reiser V, 1999, MOL BIOL CELL, V10, P1147, DOI 10.1091/mbc.10.4.1147; Rep M, 2000, J BIOL CHEM, V275, P8290, DOI 10.1074/jbc.275.12.8290; Rep M, 1999, MICROBIOL-UK, V145, P715, DOI 10.1099/13500872-145-3-715; Rep M, 1999, MOL CELL BIOL, V19, P5474; Roth FP, 1998, NAT BIOTECHNOL, V16, P939, DOI 10.1038/nbt1098-939; Sambrook J., 1989, MOL CLONING LAB MANU; SCHMITT ME, 1990, NUCLEIC ACIDS RES, V18, P3091, DOI 10.1093/nar/18.10.3091; SCHULLER C, 1994, EMBO J, V13, P4382, DOI 10.1002/j.1460-2075.1994.tb06758.x; Serrano R, 1996, INT REV CYTOL, V165, P1, DOI 10.1016/S0074-7696(08)62219-6; SHEPHERD NS, 1989, DEV GENET, V10, P507, DOI 10.1002/dvg.1020100610; Shi HZ, 2000, P NATL ACAD SCI USA, V97, P6896, DOI 10.1073/pnas.120170197; Shoemaker DD, 1996, NAT GENET, V14, P450, DOI 10.1038/ng1296-450; Tamas MJ, 2000, FEBS LETT, V472, P159, DOI 10.1016/S0014-5793(00)01445-9; Uetz P, 2000, NATURE, V403, P623, DOI 10.1038/35001009; WurglerMurphy SM, 1997, MOL CELL BIOL, V17, P1289, DOI 10.1128/MCB.17.3.1289; Zahringer H, 1997, FEBS LETT, V412, P615, DOI 10.1016/S0014-5793(97)00868-5	62	173	179	0	32	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 11	2001	276	19					15996	16007		10.1074/jbc.M008209200	http://dx.doi.org/10.1074/jbc.M008209200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	431GH	11278394	hybrid			2023-01-03	WOS:000168623100059
J	Murphy, CD				Murphy, CD			Methods of treatment: Is there any protection available in Europe?	NATURE BIOTECHNOLOGY			English	Article									Boult Wade Tennant, London WC1X 8BT, England		Murphy, CD (corresponding author), Boult Wade Tennant, Verulam Gardens,70 Grays Rd, London WC1X 8BT, England.							*EPC, 2000, DIPL C REV EPC MUN 2; 1985, OJ EPO, V64	2	1	1	0	0	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	MAY	2001	19	5					481	482		10.1038/88163	http://dx.doi.org/10.1038/88163			2	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	427FU	11329021				2023-01-03	WOS:000168394800029
J	Rossouw, JE; Anderson, GL; Prentice, RL; LaCroix, AZ; Kooperberg, C; Stefanick, ML; Jackson, RD; Beresford, SAA; Howard, BV; Johnson, KC; Kotchen, JM; Ockene, J				Rossouw, JE; Anderson, GL; Prentice, RL; LaCroix, AZ; Kooperberg, C; Stefanick, ML; Jackson, RD; Beresford, SAA; Howard, BV; Johnson, KC; Kotchen, JM; Ockene, J			Risks and benefits of estrogen plus progestin in healthy postmenopausal women - Principal results from the Women's Health Initiative randomized controlled trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HORMONE REPLACEMENT THERAPY; BREAST-CANCER RISK; CORONARY-ARTERY ATHEROSCLEROSIS; CARDIOVASCULAR-DISEASE; SECONDARY PREVENTION; HEART-DISEASE; METAANALYSIS; EVENTS; ASSOCIATION; FRACTURES	Context Despite decades of accumulated observational evidence, the balance of risks and benefits for hormone use in healthy postmenopausal women remains uncertain. Objective To assess the major health benefits and risks of the most commonly used combined hormone preparation in the United States. Design Estrogen plus progestin component of the Women's Health Initiative, a randomized controlled primary prevention trial (planned duration, 8.5 years) in which 16608 postmenopausal women aged 50-79 years with an intact uterus at baseline were recruited by 40 US clinical centers in 1993-1998. Interventions Participants received conjugated equine estrogens, 0.625 mg/d, plus medroxylprogesterone acetate, 2.5 mg/d, in 1 tablet (n = 8506) or placebo (n = 8102). Main Outcomes Measures The primary outcome was coronary heart disease (CHD) (nonfatal myocardial infarction and CHD death), with invasive breast cancer as the primary adverse outcome. A global index summarizing the balance of risks and benefits included the 2 primary outcomes plus stroke, pulmonary embolism (PE), endometrial cancer, colorectal cancer, hip fracture, and death due to other causes. Results On May 31, 2002, after a mean of 5.2 years of follow-up, the data and safety monitoring board recommended stopping the trial of estrogen plus progestin vs placebo because the test statistic for invasive breast cancer exceeded the stopping boundary for this adverse effect and the global index statistic supported risks exceeding benefits. This report includes data on the major clinical outcomes through April 30, 2002. Estimated hazard ratios (HRs) (nominal 95% confidence intervals [Cis]) were as follows: CHD, 1.29 (1.02-1.63) with 286 cases; breast cancer, 1.26 (1.00-1.59) with 290 cases; stroke, 1.41 (1.07-1.85) with 212 cases; PE, 2.13 (1.39-3.25) with 101 cases; colorectal cancer, 0.63 (0.43-0.92) with 112 cases; endometrial cancer, 0.83 (0.47-1.47) with 47 cases; hip fracture, 0.66 (0.45-0.98) with 106 cases; and death due to other causes, 0.92 (0.74-1.14) with 331 cases, Corresponding HRs (nominal 95% Cis) for composite outcomes were 1.22 (1.09-1.36) for total cardiovascular disease (arterial and venous disease), 1,03 (0.90-1.17) for total cancer, 0.76 (0.69-0.85) for combined fractures, 0.98 (0.82-1.18) for total mortality, and 1.15 (1.03-1.28) for the global index. Absolute excess risks per 10000 person-years attributable to estrogen plus progestin were 7 more CHD events, 8 more strokes, 8 more PEs, and 8 more invasive breast cancers, while absolute risk reductions per 10000 1 person-years were 6 fewer colorectal cancers and 5 fewer hip fractures. The absolute excess risk of events included in the global index was 19 per 10000 person-years. Conclusions Overall health risks exceeded benefits from use of combined estrogen plus progestin for an average 5.2-year follow-up among healthy postmenopausal US women. All-cause mortality was not affected during the trial. The risk-benefit profile found in this trial is not consistent with the requirements for a viable intervention for primary prevention of chronic diseases, and the results indicate that this regimen should not be initiated or continued for primary prevention of CHD.	NHLBI, Div Womens Hlth Initiat, Bethesda, MD 20817 USA; Fred Hutchinson Canc Res Ctr, Seattle, WA 98104 USA; Stanford Univ, Ctr Clin, Stanford, CA 94305 USA; Ohio State Univ, Ctr Clin, Columbus, OH 43210 USA; MedStar Res Inst, Washington, DC USA; Univ Tennessee, Memphis, TN USA; Med Coll Wisconsin, Milwaukee, WI 53226 USA; Univ Massachusetts, Sch Med, Worcester, MA USA	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); Fred Hutchinson Cancer Center; Stanford University; University System of Ohio; Ohio State University; University of Tennessee System; University of Tennessee Health Science Center; Medical College of Wisconsin; University of Massachusetts System; University of Massachusetts Worcester	Rossouw, JE (corresponding author), NHLBI, Div Womens Hlth Initiat, 6705 Rockledge Dr,1 Rockledge Ctr,Suite 300,MS-79, Bethesda, MD 20817 USA.	rossouw@nih.gov						ADAMS MR, 1990, ARTERIOSCLEROSIS, V10, P1051, DOI 10.1161/01.ATV.10.6.1051; Alexander KP, 2001, J AM COLL CARDIOL, V38, P1, DOI 10.1016/S0735-1097(01)01329-8; Anderson G, 1998, CONTROL CLIN TRIALS, V19, P61; Angerer P, 2001, ARTERIOSCL THROM VAS, V21, P262, DOI 10.1161/01.ATV.21.2.262; Beral V, 1997, LANCET, V350, P1047, DOI 10.1016/S0140-6736(97)08233-0; Castellsague J, 1998, DRUG SAFETY, V18, P117, DOI 10.2165/00002018-199818020-00003; COLDITZ GA, 1995, NEW ENGL J MED, V332, P1589, DOI 10.1056/NEJM199506153322401; COX DR, 1972, J R STAT SOC B, V34, P187; DEGERHARDSSON VM, 1992, CANCER CAUSE CONTROL, V3, P355; Freedman L, 1996, CONTROL CLIN TRIALS, V17, P509, DOI 10.1016/S0197-2456(96)00016-5; GAIL MH, 1989, J NATL CANCER I, V81, P1879, DOI 10.1093/jnci/81.24.1879; GENANT HK, 1990, OBSTET GYNECOL, V76, P579; Grady D, 2000, ANN INTERN MED, V132, P689, DOI 10.7326/0003-4819-132-9-200005020-00002; Grady D, 2002, JAMA-J AM MED ASSOC, V288, P49, DOI 10.1001/jama.288.1.49; GRADY D, 1992, ANN INTERN MED, V117, P1016, DOI 10.7326/0003-4819-117-12-1016; Greendale GA, 1999, ANN INTERN MED, V130, P262, DOI 10.7326/0003-4819-130-4_Part_1-199902160-00003; Grodstein F, 1999, AM J MED, V106, P574, DOI 10.1016/S0002-9343(99)00063-7; Grodstein F, 2001, ANN INTERN MED, V135, P1, DOI 10.7326/0003-4819-135-1-200107030-00003; Grodstein F, 2000, ANN INTERN MED, V133, P933, DOI 10.7326/0003-4819-133-12-200012190-00008; Heckbert SR, 2001, ARCH INTERN MED, V161, P1709, DOI 10.1001/archinte.161.14.1709; Herrington DM, 2000, NEW ENGL J MED, V343, P522, DOI 10.1056/NEJM200008243430801; Hodis HN, 2001, ANN INTERN MED, V135, P939, DOI 10.7326/0003-4819-135-11-200112040-00005; Hulley S, 2002, JAMA-J AM MED ASSOC, V288, P58, DOI 10.1001/jama.288.1.58; Hulley S, 1998, JAMA-J AM MED ASSOC, V280, P605, DOI 10.1001/jama.280.7.605; IVES DG, 1995, ANN EPIDEMIOL, V5, P275; Judd HL, 1996, JAMA-J AM MED ASSOC, V275, P370, DOI 10.1001/jama.1996.03530290040035; Magnusson C, 1999, INT J CANCER, V81, P339, DOI 10.1002/(SICI)1097-0215(19990505)81:3<339::AID-IJC5>3.3.CO;2-Y; MILLER VT, 1995, JAMA-J AM MED ASSOC, V273, P199, DOI 10.1001/jama.1995.03520270033028; Mosca L, 2001, CIRCULATION, V104, P499, DOI 10.1161/hc2901.092200; OBRIEN PC, 1979, BIOMETRICS, V35, P549, DOI 10.2307/2530245; Pilon D, 2001, OBSTET GYNECOL, V97, P97, DOI 10.1016/S0029-7844(00)01104-2; RIJPKEMA AHM, 1990, MATURITAS, V12, P259, DOI 10.1016/0378-5122(90)90007-S; Ross RK, 2000, JNCI-J NATL CANCER I, V92, P328, DOI 10.1093/jnci/92.4.328; Schairer C, 2000, JAMA-J AM MED ASSOC, V283, P485, DOI 10.1001/jama.283.4.485; Schulman SP, 2002, J AM COLL CARDIOL, V39, P231, DOI 10.1016/S0735-1097(01)01724-7; Simon JA, 2001, CIRCULATION, V103, P638, DOI 10.1161/01.cir.103.5.638; STAMPFER MJ, 1991, PREV MED, V20, P47, DOI 10.1016/0091-7435(91)90006-P; STEINBERG KK, 1991, JAMA-J AM MED ASSOC, V265, P1985, DOI 10.1001/jama.265.15.1985; Stephenson J, 1996, JAMA-J AM MED ASSOC, V275, P1389, DOI 10.1001/jama.275.18.1389; Torgerson DJ, 2001, JAMA-J AM MED ASSOC, V285, P2891, DOI 10.1001/jama.285.22.2891; Vickers MR, 1995, CIBA F SYMP, V191, P150; Viscoli CM, 2001, NEW ENGL J MED, V345, P1243, DOI 10.1056/NEJMoa010534; WEISS NS, 1980, NEW ENGL J MED, V303, P1195, DOI 10.1056/NEJM198011203032102	43	11436	11917	21	1226	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60654-0946 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 17	2002	288	3					321	333		10.1001/jama.288.3.321	http://dx.doi.org/10.1001/jama.288.3.321			13	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	573AK	12117397	Green Published, Bronze			2023-01-03	WOS:000176807000024
J	Grady, D; Herrington, D; Bittner, V; Blumenthal, R; Davidson, M; Hlatky, M; Hsia, J; Hulley, S; Herd, A; Khan, S; Newby, LK; Waters, D; Vittinghoff, E; Wenger, N				Grady, D; Herrington, D; Bittner, V; Blumenthal, R; Davidson, M; Hlatky, M; Hsia, J; Hulley, S; Herd, A; Khan, S; Newby, LK; Waters, D; Vittinghoff, E; Wenger, N		HERS Res Grp	Cardiovascular disease outcomes during 6.8 years of hormone therapy - Heart and Estrogen/progestin Replacement Study follow-up (HERS II)	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							MYOCARDIAL-INFARCTION; ESTROGEN-REPLACEMENT; RANDOMIZED-TRIAL; RISK; PROGESTIN; EVENTS; INITIATION; WOMEN	Context The Heart and Estrogen/progestin Replacement Study (HERS) found no overall reduction in risk of coronary heart disease (CHD) events among postmenopausal women with CHD. However, in the hormone group, findings did suggest a higher risk of CHD events during the first year, and a decreased risk during years 3 to 5. Objective To determine if the risk reduction observed in the later years of HERS persisted and resulted in an overall reduced risk of CHD events with additional years of follow-up. Design and Setting Randomized, blinded, placebo-controlled trial of 4.1 years' duration (HERS) and subsequent unblinded follow-up for 2.7 years (HERS II) conducted at outpatient and community settings at 20 US clinical centers. Participants A total of 2763 postmenopausal women with CHD and average age of 67 years at enrollment in HERS; 2321 women (93% of those surviving) consented to follow-up in HERS II. Intervention Participants were randomly assigned to receive 0.625 mg/d of conjugated estrogens and 2.5 mg of medroxyprogesterone acetate (n=1380), or placebo (n=1383) during HERS; open-label hormone therapy was prescribed at personal physicians' discretion during HERS II, The proportions with at least 80% adherence to hormones declined from 81 % (year 1) to 45% (year 6) in the hormone group, and increased from 0% (year 1) to 8% (year 6) in the placebo group. Main Outcome Measures The primary outcome was nonfatal myocardial infarction and CHD death. Secondary cardiovascular events were coronary revascularization, hospitalization for unstable angina or congestive heart failure, nonfatal ventricular arrhythmia, sudden death, stroke or transient ischemic attack, and peripheral arterial disease. Results There were no significant decreases in rates of primary CHD events or secondary cardiovascular events among women assigned to the hormone group compared with the placebo group in HERS, HERS 11, or overall, The unadjusted relative hazard (RH) for CHD events in HERS was 0.99 (95% confidence interval [CI], 0.81-1.22); HERS II, 1.00 (95% CI, 0.77-1.29); and overall, 0.99 (0.84-1.17). The overall RHs were similar after adjustment for potential confounders and differential use of statins between treatment groups (RH, 0.97; 95 % CI, 0.82-1.14), and in analyses restricted to women who were adherent to randomized treatment assignment (RH, 0.96; 95% CI, 0.77-1.19). Conclusions Lower rates of CHD events among women in the hormone group in the final years of HERS did not persist during additional years of follow-up. After 6.8 years, hormone therapy did not reduce risk of cardiovascular events in women with CHD. Postmenopausal hormone therapy should not be used to reduce risk for CHD events in women with CHD.	Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94105 USA; Univ Calif San Francisco, Dept Med, San Francisco, CA 94105 USA; Wake Forest Univ, Bowman Gray Sch Med, Dept Internal Med, Winston Salem, NC 27103 USA; Univ Alabama Birmingham, Dept Med, Div Cardiovasc Dis, Birmingham, AL 35294 USA; Johns Hopkins Univ, Sch Med, Div Cardiol, Baltimore, MD USA; Rush Presbyterian St Lukes Med Ctr, Chicago, IL 60612 USA; Stanford Univ, Sch Med, Dept Hlth Res & Policy, Palo Alto, CA 94304 USA; Stanford Univ, Sch Med, Dept Med, Palo Alto, CA 94304 USA; George Washington Univ, Dept Med, Washington, DC USA; Univ Calif Los Angeles, Sch Med, Div Cardiol, Los Angeles, CA USA; Cedars Sinai, Div Cardiol, Los Angeles, CA USA; Baylor Coll Med, Dept Med, Houston, TX 77030 USA; Duke Univ, Sch Med, Duke Clin Res Inst, Durham, NC USA; Emory Univ, Sch Med, Dept Med, Atlanta, GA USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; Wake Forest University; Wake Forest Baptist Medical Center; University of Alabama System; University of Alabama Birmingham; Johns Hopkins University; Rush University; Stanford University; Stanford University; George Washington University; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; Cedars Sinai Medical Center; Baylor College of Medicine; Duke University; Emory University	Grady, D (corresponding author), Univ Calif San Francisco, Dept Epidemiol & Biostat, 74 New Montgomery St,Suite 600, San Francisco, CA 94105 USA.	dgrady@itsa.ucsf.edu	Blumenthal, Roger S/H-3223-2018	Blumenthal, Roger S/0000-0003-1910-3168; Hlatky, Mark/0000-0003-4686-9441; Bittner, Vera/0000-0001-9456-850X				Alexander KP, 2001, J AM COLL CARDIOL, V38, P1, DOI 10.1016/S0735-1097(01)01329-8; CANNER PL, 1986, J AM COLL CARDIOL, V8, P1245, DOI 10.1016/S0735-1097(86)80293-5; Furberg CD, 2002, CIRCULATION, V105, P917, DOI 10.1161/hc0802.104280; Grady D, 2000, ANN INTERN MED, V132, P689, DOI 10.7326/0003-4819-132-9-200005020-00002; Grady D, 1998, CONTROL CLIN TRIALS, V19, P314, DOI 10.1016/S0197-2456(98)00010-5; Heckbert SR, 2001, ARCH INTERN MED, V161, P1709, DOI 10.1001/archinte.161.14.1709; Herrington DM, 2000, NEW ENGL J MED, V343, P522, DOI 10.1056/NEJM200008243430801; Hsia J, 2000, CIRCULATION, V102, P2228; Hulley S, 2002, JAMA-J AM MED ASSOC, V288, P58, DOI 10.1001/jama.288.1.58; Hulley S, 1998, JAMA-J AM MED ASSOC, V280, P605, DOI 10.1001/jama.280.7.605; Hulley SB, 2002, EUR HEART J, V23, P89, DOI 10.1053/euhj.2001.2840; KJELSBERG MO, 1990, JAMA-J AM MED ASSOC, V263, P1795; Mosca L, 2001, CIRCULATION, V104, P499, DOI 10.1161/hc2901.092200; Pedersen TR, 2000, AM J CARDIOL, V86, P257, DOI 10.1016/S0002-9149(00)00910-3; Psaty BM, 2001, JAMA-J AM MED ASSOC, V285, P906, DOI 10.1001/jama.285.7.906; Ridker PM, 1997, HAEMOSTASIS, V27, P2; Rossouw JE, 2001, CURR OPIN LIPIDOL, V12, P371, DOI 10.1097/00041433-200108000-00001; Shlipak MG, 2001, ANN INTERN MED, V134, P1043, DOI 10.7326/0003-4819-134-11-200106050-00010; Simon JA, 2001, CIRCULATION, V103, P638, DOI 10.1161/01.cir.103.5.638; Viscoli CM, 2001, NEW ENGL J MED, V345, P1243, DOI 10.1056/NEJMoa010534; Wenger NK, 2000, JAMA-J AM MED ASSOC, V284, P41, DOI 10.1001/jama.284.1.41-a; 2002, WHI HRT UPD	22	1248	1313	0	31	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 3	2002	288	1					49	57		10.1001/jama.288.1.49	http://dx.doi.org/10.1001/jama.288.1.49			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	568YW	12090862	Bronze			2023-01-03	WOS:000176573400019
J	Senior, K				Senior, K			Collated evidence confirms the value of atrial fibrillation prevention	LANCET			English	Article																			0	0	0	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUN 15	2002	359	9323					2093	2093		10.1016/S0140-6736(02)08960-2	http://dx.doi.org/10.1016/S0140-6736(02)08960-2			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	562JX	12086771				2023-01-03	WOS:000176194600019
J	Lambot, M; Fretier, S; De Beeck, AO; Quatannens, B; Lestavel, S; Clavey, W; Dubuisson, J				Lambot, M; Fretier, S; De Beeck, AO; Quatannens, B; Lestavel, S; Clavey, W; Dubuisson, J			Reconstitution of hepatitis C virus envelope glycoproteins into liposomes as a surrogate model to study virus attachment	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DENSITY-LIPOPROTEIN RECEPTOR; VESICULAR STOMATITIS-VIRUS; ENDOPLASMIC-RETICULUM; RECOMBINANT VACCINIA; E2 GLYCOPROTEINS; HUMAN SERA; VERY-LOW; BINDING; PROTEIN; CD81	The envelope glycoproteins, E1 and E2, of hepatitis C virus (HCV) assemble intracellularly to form a noncovalent heterodimer that is expected to be essential for viral assembly and entry. However, due to the lack of a cell culture system supporting efficient HCV replication, it is very difficult to obtain relevant information on the functions of this glycoprotein oligomer. To get better insights into its biological and biochemical properties, HCV envelope glycoprotein heterodimer expressed by a vaccinia virus recombinant was purified by immunoaffinity. Purified E1E2 heterodimer was recognized by conformation-dependent monoclonal antibodies, showing that the proteins were properly folded. In addition, it interacted with human CD81, a putative HCV receptor, as well as with human low and very low density lipoproteins, which have been shown to be associated with infectious HCV particles isolated from patients. Purified E1E2 heterodimer was also reconstituted into liposomes. E1E2-liposomes were recognized by a conformation-dependent monoclonal antibody as well as by human CD81. Together, these data indicate that E1E2-liposomes are a valuable tool to study the molecular requirements for HCV binding to target cells.	Inst Biol Lille, CNRS, UPR2511, Unite Hepatite C, F-59021 Lille, France; Univ Lille 2, Fac Pharm, Inst Pasteur, INSERM,U545, F-59019 Lille, France	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); Le Reseau International des Instituts Pasteur (RIIP); Universite de Lille - ISITE; Institut Pasteur Lille; Universite de Lille	Dubuisson, J (corresponding author), Inst Biol Lille, CNRS, UPR2511, Unite Hepatite C, 1 Rue Calmette,BP447, F-59021 Lille, France.	jean.dubuisson@ibl.fr	Lestavel, Sophie/B-4658-2017; Dubuisson, Jean/E-6813-2016	Lestavel, Sophie/0000-0001-7839-4757; Dubuisson, Jean/0000-0003-1626-7693				Agnello V, 1999, P NATL ACAD SCI USA, V96, P12766, DOI 10.1073/pnas.96.22.12766; Allander T, 2000, VIROLOGY, V277, P358, DOI 10.1006/viro.2000.0617; Baumert TF, 1998, J VIROL, V72, P3827, DOI 10.1128/JVI.72.5.3827-3836.1998; Cocquerel L, 1998, J VIROL, V72, P2183, DOI 10.1128/JVI.72.3.2183-2191.1998; Cocquerel L, 2001, J GEN VIROL, V82, P1629, DOI 10.1099/0022-1317-82-7-1629; CORNET B, 1992, AIDS RES HUM RETROV, V8, P1823, DOI 10.1089/aid.1992.8.1823; CURMAN B, 1980, J BIOL CHEM, V255, P7820; De Beeck AO, 2000, J BIOL CHEM, V275, P31428, DOI 10.1074/jbc.M003003200; Deleersnyder V, 1997, J VIROL, V71, P697, DOI 10.1128/JVI.71.1.697-704.1997; DUBJISSON J, 1996, J VIROL, V70, P778; Dubuisson J, 2000, CURR TOP MICROBIOL, V242, P135; DUBUISSON J, 1994, J VIROL, V68, P6147, DOI 10.1128/JVI.68.10.6147-6160.1994; Duvet S, 1998, J BIOL CHEM, V273, P32088, DOI 10.1074/jbc.273.48.32088; EIDELMAN O, 1984, J BIOL CHEM, V259, P4622; Flint M, 2000, REV MED VIROL, V10, P101, DOI 10.1002/(SICI)1099-1654(200003/04)10:2&lt;101::AID-RMV268&gt;3.0.CO;2-W; Flint M, 2001, Clin Liver Dis, V5, P873, DOI 10.1016/S1089-3261(05)70199-9; Flint M, 2000, J VIROL, V74, P702, DOI 10.1128/JVI.74.2.702-709.2000; Flint M, 1999, J VIROL, V73, P6235, DOI 10.1128/JVI.73.8.6235-6244.1999; Francki RIB, 1991, ARCH VIROL         S, V2, P223; FUERST TR, 1986, P NATL ACAD SCI USA, V83, P8122, DOI 10.1073/pnas.83.21.8122; FUJIKI Y, 1982, J CELL BIOL, V93, P97, DOI 10.1083/jcb.93.1.97; Hamaia S, 2001, BLOOD, V98, P2293, DOI 10.1182/blood.V98.8.2293; Harlow E., 1988, ANTIBODIES LAB MANUA, Vfirst; HARMSEN MC, 1985, EUR J BIOCHEM, V149, P591, DOI 10.1111/j.1432-1033.1985.tb08966.x; HAVEL RJ, 1955, J CLIN INVEST, V34, P1345, DOI 10.1172/JCI103182; Heile JM, 2000, J VIROL, V74, P6885, DOI 10.1128/JVI.74.15.6885-6892.2000; HELENIUS A, 1981, EUR J BIOCHEM, V116, P27, DOI 10.1111/j.1432-1033.1981.tb05296.x; HELENIUS A, 1977, J CELL BIOL, V75, P866, DOI 10.1083/jcb.75.3.866; Higginbottom A, 2000, J VIROL, V74, P3642, DOI 10.1128/JVI.74.8.3642-3649.2000; HOUGHTON M, 1996, FIELDS VIROLOGY, P1035; HUANG RTC, 1980, VIROLOGY, V104, P294, DOI 10.1016/0042-6822(80)90334-7; Lagging LM, 1998, J VIROL, V72, P3539, DOI 10.1128/JVI.72.5.3539-3546.1998; LEMMON MA, 1992, J BIOL CHEM, V267, P7683; MADDEN TD, 1988, INT J BIOCHEM, V20, P889, DOI 10.1016/0020-711X(88)90172-3; MADDEN TD, 1986, CHEM PHYS LIPIDS, V40, P207, DOI 10.1016/0009-3084(86)90071-X; Matsuura Y, 2001, VIROLOGY, V286, P263, DOI 10.1006/viro.2001.0971; METSIKKO K, 1986, EMBO J, V5, P3429, DOI 10.1002/j.1460-2075.1986.tb04665.x; Monazahian M, 1999, J MED VIROL, V57, P223, DOI 10.1002/(SICI)1096-9071(199903)57:3<223::AID-JMV2>3.0.CO;2-4; Monazahian M, 2000, MED MICROBIOL IMMUN, V188, P177, DOI 10.1007/s004300000032; NUSSBAUM O, 1987, J VIROL, V61, P2245, DOI 10.1128/JVI.61.7.2245-2252.1987; Owsianka A, 2001, J GEN VIROL, V82, P1877, DOI 10.1099/0022-1317-82-8-1877; Patel AH, 2000, J GEN VIROL, V81, P2873, DOI 10.1099/0022-1317-81-12-2873; Petracca R, 2000, J VIROL, V74, P4824, DOI 10.1128/JVI.74.10.4824-4830.2000; PETRI WA, 1979, J BIOL CHEM, V254, P4313; Pileri P, 1998, SCIENCE, V282, P938, DOI 10.1126/science.282.5390.938; Prince AM, 1996, J VIRAL HEPATITIS, V3, P11, DOI 10.1111/j.1365-2893.1996.tb00075.x; RALSTON R, 1993, J VIROL, V67, P6753, DOI 10.1128/JVI.67.11.6753-6761.1993; Reed KE, 2000, CURR TOP MICROBIOL, V242, P55; SCHEULE RK, 1986, BIOCHEMISTRY-US, V25, P4223, DOI 10.1021/bi00363a009; Shelness GS, 2001, CURR OPIN LIPIDOL, V12, P151, DOI 10.1097/00041433-200104000-00008; STEGMANN T, 1987, EMBO J, V6, P2651, DOI 10.1002/j.1460-2075.1987.tb02556.x; THOMSSEN R, 1993, MED MICROBIOL IMMUN, V182, P329; THOMSSEN R, 1992, MED MICROBIOL IMMUN, V181, P293, DOI 10.1007/BF00198849; Wunschmann S, 2000, J VIROL, V74, P10055, DOI 10.1128/JVI.74.21.10055-10062.2000; Xu ZM, 2001, EMBO J, V20, P3840, DOI 10.1093/emboj/20.14.3840	55	35	38	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 7	2002	277	23					20625	20630		10.1074/jbc.M111020200	http://dx.doi.org/10.1074/jbc.M111020200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	562NJ	11937498	hybrid			2023-01-03	WOS:000176204500069
J	Kim, YM; Yun, J; Lee, CK; Lee, H; Min, KR; Kim, Y				Kim, YM; Yun, J; Lee, CK; Lee, H; Min, KR; Kim, Y			Oxyresveratrol and hydroxystilbene compounds - Inhibitory effect on tyrosinase and mechanism of action	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DOPA OXIDASE ACTIVITY; TRANS-RESVERATROL; BOMBYX-MORI; KOJIC ACID; PIGMENTATION; PHENOLOXIDASE; PURIFICATION; HYDROQUINONE; TAUTOMERASE; CATECHOLASE	Tyrosinase is responsible for the molting process in insects, undesirable browning of fruits and vegetables, and coloring of skin, hair, and eyes in animals. To clarify the mechanism of the depigmenting property of hydroxystilbene compounds, inhibitory actions of oxyresveratrol and its analogs on tyrosinases from mushroom and murine melanoma B-16 have been elucidated in this study. Oxyresveratrol showed potent inhibitory effect with an IC50 value of 1.2 muM on mushroom tyrosinase activity, which was 32-fold stronger inhibition than kojic acid, a depigmenting agent used as the cosmetic material with skin-whitening effect and the medical agent for hyperpigmentation disorders. Hydroxystilbene compounds of resveratrol, 3,5-dihydroxy-4'-methoxystilbene, and rhapontigenin also showed more than 50% inhibition at 100 muM on mushroom tyrosinase activity, but other methylated or glycosylated hydroxystilbenes of 3,4-dimethoxy-5-hydroxystilbene, trimethylresveratrol, piceid, and rhaponticin did not inhibit significantly. None of the hydroxystilbene compounds except oxyresveratrol exhibited more than 50% inhibition at 100 muM on L-tyrosine oxidation by murine tyrosinase activity; oxyresveratrol showed an IC50 value of 52.7 muM on the enzyme activity. The kinetics and mechanism for inhibition of mushroom tyrosinase exhibited the reversibility of oxyresveratrol as a noncompetitive inhibitor with L-tyrosine as the substrate. The interaction between oxyresveratrol and tyrosinase exhibited a high affinity reflected in a K-i value of 3.2-4.2 x 10(-7) M. Oxyresveratrol did not affect the promoter activity of the tyrosinase gene in murine melanoma B-16 at 10 and 100 muM. Therefore, the depigmenting effect of oxyresveratrol works through reversible inhibition of tyrosinase activity rather than suppression of the expression and synthesis of the enzyme. The number and position of hydroxy substituents seem to play an important role in the inhibitory effects of hydroxystilbene compounds on tyrosinase activity.	Chungbuk Natl Univ, Coll Pharm, Cheongju 361763, South Korea; Chungbuk Natl Univ, Res Ctr Bioresource & Hlth, Cheongju 361763, South Korea; Chonnam Natl Univ, Coll Nat Sci, Kwangju 500757, South Korea	Chungbuk National University; Chungbuk National University; Chonnam National University	Kim, Y (corresponding author), Chungbuk Natl Univ, Coll Pharm, Cheongju 361763, South Korea.							April CS, 1998, GENE, V219, P45, DOI 10.1016/S0378-1119(98)00403-X; Asano T, 2001, J BIOL CHEM, V276, P11100, DOI 10.1074/jbc.M008426200; Battaini G, 2000, J BIOL INORG CHEM, V5, P262, DOI 10.1007/s007750050370; Bhat KPL, 2001, CANCER RES, V61, P7456; Burkitt MJ, 2000, ARCH BIOCHEM BIOPHYS, V381, P253, DOI 10.1006/abbi.2000.1973; Busca R, 2000, PIGM CELL RES, V13, P60, DOI 10.1034/j.1600-0749.2000.130203.x; CANANES J, 1994, J PHARM PHARMACOL, V46, P982; Fremont L, 2000, LIFE SCI, V66, P663, DOI 10.1016/S0024-3205(99)00410-5; GALEAZZI MAM, 1984, ARCH LATINOAM NUTR, V34, P269; Gillespie JP, 1997, ANNU REV ENTOMOL, V42, P611, DOI 10.1146/annurev.ento.42.1.611; Guevara IL, 2001, INT J DERMATOL, V40, P212, DOI 10.1046/j.1365-4362.2001.01167-2.x; Holmes-McNary M, 2000, CANCER RES, V60, P3477; HUGHES L, 1975, J INSECT PHYSIOL, V21, P1373, DOI 10.1016/0022-1910(75)90263-2; IOZUMI K, 1993, J INVEST DERMATOL, V100, P806, DOI 10.1111/1523-1747.ep12476630; Jang MS, 1997, SCIENCE, V275, P218, DOI 10.1126/science.275.5297.218; Kang BS, 1998, MED SCI RES, V26, P235; KUBO I, 1995, J NAT PRODUCTS, V58, P739, DOI 10.1021/np50119a013; Kubo I, 2000, BIOORGAN MED CHEM, V8, P1749, DOI 10.1016/S0968-0896(00)00102-4; Kuriyama T, 1998, BBA-PROTEIN STRUCT M, V1388, P506, DOI 10.1016/S0167-4838(98)00214-3; LERCH K, 1981, MET IONS BIOL SYST, V13, P143; Lim JTE, 1999, DERMATOL SURG, V25, P282, DOI 10.1046/j.1524-4725.1999.08236.x; Maeda K, 1996, J PHARMACOL EXP THER, V276, P765; Marmaras VJ, 1996, ARCH INSECT BIOCHEM, V31, P119, DOI 10.1002/(SICI)1520-6327(1996)31:2&lt;119::AID-ARCH1&gt;3.0.CO;2-V; Mills AA, 2001, GENE DEV, V15, P1461, DOI 10.1101/gad.909301; Moreno JJ, 2000, J PHARMACOL EXP THER, V294, P333; NAPPI AJ, 1993, PIGM CELL RES, V6, P117, DOI 10.1111/j.1600-0749.1993.tb00590.x; NGUYEN QH, 1995, INT J DERMATOL, V34, P75, DOI 10.1111/j.1365-4362.1995.tb03583.x; Oetting WS, 1999, HUM MUTAT, V13, P99, DOI 10.1002/(SICI)1098-1004(1999)13:2<99::AID-HUMU2>3.3.CO;2-3; Okan G, 1999, J EUR ACAD DERMATOL, V13, P218, DOI 10.1111/j.1468-3083.1999.tb00887.x; Olivares C, 2002, BIOCHEMISTRY-US, V41, P679, DOI 10.1021/bi011535n; Parkinson N, 2001, INSECT BIOCHEM MOLEC, V31, P57, DOI 10.1016/S0965-1748(00)00105-3; Perez-Bernal A, 2000, Am J Clin Dermatol, V1, P261; Perez-Gilabert M, 2000, J AGR FOOD CHEM, V48, P695, DOI 10.1021/jf990292r; Perez-Gilabert M, 2001, BIOCHEM BIOPH RES CO, V285, P257, DOI 10.1006/bbrc.2001.5189; PYE AE, 1974, NATURE, V251, P610, DOI 10.1038/251610a0; Riley PA, 2000, J THEOR BIOL, V203, P1, DOI 10.1006/jtbi.1999.1061; Riley PA, 1997, INT J BIOCHEM CELL B, V29, P1235, DOI 10.1016/S1357-2725(97)00013-7; RYU S Y, 1988, Archives of Pharmacal Research (Seoul), V11, P230, DOI 10.1007/BF02861314; Seo B, 1999, PLANTA MED, V65, P683, DOI 10.1055/s-1999-14092; Shin N. H., 1997, NAT PROD SCI, V3, P111; Shin NH, 1998, BIOCHEM BIOPH RES CO, V243, P801, DOI 10.1006/bbrc.1998.8169; Sturm RA, 1998, BIOESSAYS, V20, P712, DOI 10.1002/(SICI)1521-1878(199809)20:9<712::AID-BIES4>3.0.CO;2-I; SUGUMARAN M, 1992, ARCH INSECT BIOCHEM, V19, P271, DOI 10.1002/arch.940190406; Takahashi S, 1996, J ANTIBIOT, V49, P513, DOI 10.7164/antibiotics.49.513; TSUKAMOTO T, 1992, BIOCHEM BIOPH RES CO, V184, P86, DOI 10.1016/0006-291X(92)91161-I; Wang ZR, 2002, INT J MOL MED, V9, P77; WINDER AJ, 1991, EUR J BIOCHEM, V198, P317, DOI 10.1111/j.1432-1033.1991.tb16018.x; Yang CS, 2001, ANNU REV NUTR, V21, P381, DOI 10.1146/annurev.nutr.21.1.381; YOSHIMOTO T, 1985, J BIOCHEM, V97, P1747, DOI 10.1093/oxfordjournals.jbchem.a135233; ZHAO XL, 1995, DEV COMP IMMUNOL, V19, P205, DOI 10.1016/0145-305X(95)00005-E; Zou JG, 1999, BIOCHEM MOL BIOL INT, V47, P1089	51	346	364	2	97	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 3	2002	277	18					16340	16344		10.1074/jbc.M200678200	http://dx.doi.org/10.1074/jbc.M200678200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	550PA	11864987	hybrid			2023-01-03	WOS:000175510400145
J	Kiley, R				Kiley, R			Does the internet harm health? Some evidence exists that the internet does harm health	BMJ-BRITISH MEDICAL JOURNAL			English	Letter									Wellcome Trust Res Labs, Wellcome Lib Hist & Understanding Med, London NW1 2BE, England		Kiley, R (corresponding author), Wellcome Trust Res Labs, Wellcome Lib Hist & Understanding Med, London NW1 2BE, England.	r.kiley@wellcome.ac.uk		Kiley, Robert/0000-0003-4733-2558				[Anonymous], 2001, BMJ-BRIT MED J, V323, P651; Hainer MI, 2000, ANN INTERN MED, V133, P877, DOI 10.7326/0003-4819-133-11-200012050-00011	2	46	46	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JAN 26	2002	324	7331					238	239						4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	517HJ	11809659				2023-01-03	WOS:000173604800039
J	Pollack, MM; Patel, KM				Pollack, MM; Patel, KM			Need for shift in focus in research into quality of intensive care	LANCET			English	Editorial Material							OUTCOMES; UNITS		George Washington Univ, Sch Med, Washington, DC 20052 USA; Childrens Natl Med Ctr, Washington, DC 20010 USA	George Washington University; Children's National Health System	Pollack, MM (corresponding author), George Washington Univ, Sch Med, Washington, DC 20052 USA.	mpollack@cnmc.org						Hannan EL, 1998, PEDIATRICS, V101, P963, DOI 10.1542/peds.101.6.963; Lau J, 1998, LANCET, V351, P123, DOI 10.1016/S0140-6736(97)08468-7; Mitchell PH, 1997, MED CARE, V35, pNS19, DOI 10.1097/00005650-199711001-00003; POLLACK MM, 1994, JAMA-J AM MED ASSOC, V272, P941, DOI 10.1001/jama.272.12.941; Pollack Murray M., 2001, Pediatric Research, V49, p316A; Pronovost PJ, 1999, JAMA-J AM MED ASSOC, V281, P1310, DOI 10.1001/jama.281.14.1310; Ruttimann U E, 2000, Pediatr Crit Care Med, V1, P133, DOI 10.1097/00130478-200010000-00008; SHORTELL SM, 1994, MED CARE, V32, P508, DOI 10.1097/00005650-199405000-00009; Tarnow-Mordi WO, 2000, LANCET, V356, P185, DOI 10.1016/S0140-6736(00)02478-8	9	6	6	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JAN 12	2002	359	9301					95	96		10.1016/S0140-6736(02)07334-8	http://dx.doi.org/10.1016/S0140-6736(02)07334-8			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	510MT	11809247				2023-01-03	WOS:000173212400004
J	Zhang, TD; Chen, GQ; Wang, ZG; Wang, ZY; Chen, SJ; Chen, Z				Zhang, TD; Chen, GQ; Wang, ZG; Wang, ZY; Chen, SJ; Chen, Z			Arsenic trioxide, a therapeutic agent for APL	ONCOGENE			English	Article						arsenic trioxide (AS(2)O(3)); acute promyelocytic leukemia (APL); apoptosis; differentiation; PML-RAR alpha	ACUTE PROMYELOCYTIC LEUKEMIA; TRANS-RETINOIC ACID; PML/RAR-ALPHA PROTEIN; PML-RAR-ALPHA; IN-VITRO; MEDIATED APOPTOSIS; GROWTH-INHIBITION; CLINICAL-EFFICACY; CELL APOPTOSIS; RESISTANT	Acute promyelocytic leukemia (APL) is an interesting model in cancer research, because it can respond to the differentiation/apoptosis induction therapy using all-traps retinoic acid (ATRA) and arsenic trioxide (As2O3). Over the past 5 years, it has been well demonstrated that As2O3 induces a high complete remission (CR) rate in both primary and relapsed APL patients (around 85 similar to 90%). The side effects are mild to moderate in relapsed patients, while severe hepatic lesions have been found in some primary cases. After CR obtained in relapsed patients, chemotherapy in combination with As2O3 as post-remission therapy has given better survival than those treated with As2O3 alone. The effect of As2O3 has been shown to be related to the expression of APL-specific PML-RAR alpha oncoprotein, and there is a synergistic effect between As2O3 and ATRA in an APL mouse model. Cell biology studies have revealed that As2O3 exerts dose-dependent dual effects on APL cells. Apoptosis is evident when cells are treated with 0.5 similar to2.0 muM of As2O3 while partial differentiation is observed using low concentrations (0.1 similar to0.5 muM) of the drug. The apoptosis-inducing effect is associated with the collapse of mitochondrial transmembrane potentials in a thiol-dependent manner, whereas the mechanisms underlying APL cell differentiation induced by low dose arsenic remain to be explored. Interestingly, As2O3 over a wide range of concentration (0.1 similar to2.0 mum) induces degradation of a key leukemogenic protein, PML-RAR alpha, as well as the wild-type PML, thus setting up a good example of targeting therapy for human cancers.	Shanghai Med Univ 2, Rui Jin Hosp, Shanghai Inst Hematol, Shanghai 200025, Peoples R China; Harbin Med Univ, Hosp 1, Harbin 150001, Peoples R China	Shanghai Jiao Tong University; Harbin Medical University	Chen, Z (corresponding author), Shanghai Med Univ 2, Rui Jin Hosp, Shanghai Inst Hematol, 194 Rui Jin Rd II, Shanghai 200025, Peoples R China.	zchen@ms.stn.sh.cn		chen, guo qiang/0000-0003-4936-2363				Agis H, 1999, ANN HEMATOL, V78, P329, DOI 10.1007/s002770050523; Akao Y, 1999, FEBS LETT, V455, P59, DOI 10.1016/S0014-5793(99)00841-8; Andre C, 1996, EXP CELL RES, V229, P253, DOI 10.1006/excr.1996.0368; Barbui T, 1998, BLOOD, V91, P3093, DOI 10.1182/blood.V91.9.3093.3093_3093_3102; Brenner C, 2000, SCIENCE, V289, P1150, DOI 10.1126/science.289.5482.1150; Cai X, 2000, LEUKEMIA, V14, P262, DOI 10.1038/sj.leu.2401650; Camacho LH, 2000, J CLIN ONCOL, V18, P2620, DOI 10.1200/JCO.2000.18.13.2620; Chen GQ, 1997, BLOOD, V89, P3345; Chen GQ, 1996, BLOOD, V88, P1052; Chen YC, 1998, J CELL PHYSIOL, V177, P324, DOI 10.1002/(SICI)1097-4652(199811)177:2<324::AID-JCP14>3.0.CO;2-9; Chen Z, 2001, SEMIN HEMATOL, V38, P26, DOI 10.1053/shem.2001.20863; Cheng GX, 1999, P NATL ACAD SCI USA, V96, P6318, DOI 10.1073/pnas.96.11.6318; Cohen MH, 2001, ONCOLOGIST, V6, P4, DOI 10.1634/theoncologist.6-1-4; Conrad ME, 1999, NEW ENGL J MED, V340, P1043; Costantini P, 2000, ONCOGENE, V19, P307, DOI 10.1038/sj.onc.1203299; Costantini P, 2000, J NATL CANCER I, V92, P1042, DOI 10.1093/jnci/92.13.1042; Dai J, 1999, BLOOD, V93, P268, DOI 10.1182/blood.V93.1.268.401a21_268_277; Deaglio S, 2001, LEUKEMIA RES, V25, P227, DOI 10.1016/S0145-2126(00)00105-3; Galimberti S, 1999, BONE MARROW TRANSPL, V24, P345, DOI 10.1038/sj.bmt.1701875; Gallagher RE, 1998, NEW ENGL J MED, V339, P1389, DOI 10.1056/NEJM199811053391909; Gianni M, 1999, LEUKEMIA, V13, P739, DOI 10.1038/sj.leu.2401419; Gianni M, 1998, BLOOD, V91, P4300, DOI 10.1182/blood.V91.11.4300.411k41_4300_4310; Huang CH, 1999, PACE, V22, P965, DOI 10.1111/j.1540-8159.1999.tb06826.x; Huang CS, 1999, CANCER RES, V59, P3053; Huang SC, 2000, BIOCHEM PHARMACOL, V60, P771, DOI 10.1016/S0006-2952(00)00397-X; Huang SY, 1998, BRIT J HAEMATOL, V103, P1092, DOI 10.1046/j.1365-2141.1998.01079.x; Huff J, 2000, TOXICOL SCI, V55, P17, DOI 10.1093/toxsci/55.1.17; Jiang XH, 2001, INT J CANCER, V91, P173, DOI 10.1002/1097-0215(200002)9999:9999<::AID-IJC1039>3.0.CO;2-D; Jing YK, 1999, BLOOD, V94, P2102, DOI 10.1182/blood.V94.6.2102; Jing YK, 2001, BLOOD, V97, P264, DOI 10.1182/blood.V97.1.264; Kinjo K, 2000, LEUKEMIA, V14, P431, DOI 10.1038/sj.leu.2401646; Kitamura K, 2000, BRIT J HAEMATOL, V108, P696, DOI 10.1046/j.1365-2141.2000.01933.x; Kitamura K, 1997, INT J HEMATOL, V65, P179; Kitamura K, 2000, LEUKEMIA, V14, P1743, DOI 10.1038/sj.leu.2401900; Koken MHM, 1999, ONCOGENE, V18, P1113, DOI 10.1038/sj.onc.1202414; Kroemer G, 1999, JNCI-J NATL CANCER I, V91, P743, DOI 10.1093/jnci/91.9.743; Kwong YL, 1997, BLOOD, V89, P3487, DOI 10.1182/blood.V89.9.3487; Lallemand-Breitenbach V, 1999, J EXP MED, V189, P1043, DOI 10.1084/jem.189.7.1043; Larochette N, 1999, EXP CELL RES, V249, P413, DOI 10.1006/excr.1999.4519; Li YM, 1999, CANCER RES, V59, P776; Lin CP, 2000, LEUKEMIA LYMPHOMA, V38, P191, DOI 10.3109/10428190009060333; Lin CP, 2000, LEUKEMIA LYMPHOMA, V38, P195, DOI 10.3109/10428190009060334; Look AT, 1998, J NATL CANCER I, V90, P86, DOI 10.1093/jnci/90.2.86; McCabe MJ, 2000, J PHARMACOL EXP THER, V295, P724; Melnick A, 1999, BLOOD, V93, P3167, DOI 10.1182/blood.V93.10.3167.410k44_3167_3215; Mervis J, 1996, SCIENCE, V273, P578, DOI 10.1126/science.273.5275.578; Muller S, 1998, EMBO J, V17, P61, DOI 10.1093/emboj/17.1.61; Niu C, 1999, BLOOD, V94, P3315, DOI 10.1182/blood.V94.10.3315.422k16_3315_3324; Ohnishi K, 2000, ANN INTERN MED, V133, P881, DOI 10.7326/0003-4819-133-11-200012050-00012; Ohsawa M, 2000, LEUKEMIA, V14, P941, DOI 10.1038/sj.leu.2401755; Rego EM, 2000, P NATL ACAD SCI USA, V97, P10173, DOI 10.1073/pnas.180290497; Roboz GJ, 2000, BLOOD, V96, P1525, DOI 10.1182/blood.V96.4.1525.h8001525_1525_1530; Seol JG, 2001, INT J ONCOL, V18, P249; Shao WL, 1998, J NATL CANCER I, V90, P124, DOI 10.1093/jnci/90.2.124; Shen Y, 2001, LEUKEMIA, V15, P735, DOI 10.1038/sj.leu.2402106; Shen ZX, 1997, BLOOD, V89, P3354, DOI 10.1182/blood.V89.9.3354; Shen ZY, 1999, INT J MOL MED, V4, P33; Slack JL, 2000, ANN HEMATOL, V79, P227, DOI 10.1007/s002770050585; Soignet SL, 1998, NEW ENGL J MED, V339, P1341, DOI 10.1056/NEJM199811053391901; Sternsdorf T, 1999, MOL CELL BIOL, V19, P5170; Sun H. D., 1992, CHIN J INTEGRAT CHIN, V12, P170; Tallman MS, 1999, SEMIN THROMB HEMOST, V25, P209, DOI 10.1055/s-2007-994922; Tamm I, 1999, NEW ENGL J MED, V340, P1043; Uslu R, 2000, CLIN CANCER RES, V6, P4957; Wang Z Y, 2000, Lancet Oncol, V1, P101, DOI 10.1016/S1470-2045(00)00017-6; Wang ZG, 1998, BLOOD, V92, P1497, DOI 10.1182/blood.V92.5.1497.417k41_1497_1504; Warrell R P Jr, 1999, Haematologica, V84 Suppl EHA-4, P75; ZHANG P, 1996, CHIN J HEMATOL, V17, P58; Zhang T, 2000, MODERN PATHOL, V13, P954, DOI 10.1038/modpathol.3880174; Zhang W, 1998, LEUKEMIA, V12, P1383, DOI 10.1038/sj.leu.2401112; Zhu J, 1999, LEUKEMIA, V13, P1062, DOI 10.1038/sj.leu.2401448; Zhu J, 1997, P NATL ACAD SCI USA, V94, P3978, DOI 10.1073/pnas.94.8.3978; Zhu XH, 1999, J NATL CANCER I, V91, P772, DOI 10.1093/jnci/91.9.772	73	181	201	1	17	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 29	2001	20	49					7146	7153		10.1038/sj.onc.1204762	http://dx.doi.org/10.1038/sj.onc.1204762			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	487TM	11704843				2023-01-03	WOS:000171891900003
J	Skegg, DCG				Skegg, DCG			Hormone therapy and heart disease after the menopause	LANCET			English	Editorial Material							POSTMENOPAUSAL WOMEN; REPLACEMENT THERAPY; ESTROGEN; PREVENTION		Univ Otago, Dept Prevent & Social Med, Dunedin, New Zealand	University of Otago	Skegg, DCG (corresponding author), Univ Otago, Dept Prevent & Social Med, Dunedin, New Zealand.							Barrett-Connor E, 2001, INT J EPIDEMIOL, V30, P423, DOI 10.1093/ije/30.3.423; Barrett-Connor E, 1998, ANNU REV PUBL HEALTH, V19, P55, DOI 10.1146/annurev.publhealth.19.1.55; BARRETTCONNOR E, 1991, ANN INTERN MED, V115, P455, DOI 10.7326/0003-4819-115-6-455; GRADY D, 1992, ANN INTERN MED, V117, P1038; Herrington DM, 2000, NEW ENGL J MED, V343, P522, DOI 10.1056/NEJM200008243430801; Hulley S, 1998, JAMA-J AM MED ASSOC, V280, P605, DOI 10.1001/jama.280.7.605; Mendelsohn ME, 1999, NEW ENGL J MED, V340, P1801, DOI 10.1056/NEJM199906103402306; Mosca L, 2001, CIRCULATION, V104, P499, DOI 10.1161/hc2901.092200; North FM, 2001, NEW ZEAL MED J, V114, P250; Petitti Diana B., 1994, Annals of Epidemiology, V4, P115; Pocock SJ, 2000, NEW ENGL J MED, V342, P1907, DOI 10.1056/NEJM200006223422511; POSTHUMA WFM, 1994, BRIT MED J, V308, P1268; Rosano GMC, 2001, EUR HEART J, V22, P439, DOI 10.1053/euhj.2000.2298; Rossouw JE, 1996, CIRCULATION, V94, P2982, DOI 10.1161/01.CIR.94.11.2982; STURGEON SR, 1995, EPIDEMIOLOGY, V6, P227, DOI 10.1097/00001648-199505000-00006	15	17	17	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	OCT 13	2001	358	9289					1196	1197		10.1016/S0140-6736(01)06336-X	http://dx.doi.org/10.1016/S0140-6736(01)06336-X			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	481NX	11675050				2023-01-03	WOS:000171527000002
J	Robinson, A; Thompson, DG; Wilkin, D; Roberts, C				Robinson, A; Thompson, DG; Wilkin, D; Roberts, C		NW Gastrointestinal Res Grp	Guided self-management and patient-directed follow-up of ulcerative colitis: a randomised trial	LANCET			English	Article							INFLAMMATORY-BOWEL-DISEASE; OUTPATIENT CLINICS; ASTHMA; MINIMIZATION; INFORMATION; EDUCATION; VIEW; CARE; NEED	Background Ulcerative colitis is managed mainly in secondary care by regular outpatient reviews done by specialist clinicians. Alternatives would be to discharge patients to primary care or to provide open-access clinics, but neither of these options reduce patients' dependency on doctors or allow patients' involvement in disease management. We did a randomised controlled trial to assess an alternative to traditional outpatient care. Methods We randomly assigned 203 patients with ulcerative colitis who were undergoing hospital follow-up to receive patient-centred self-management training and follow-up on request (intervention group), or normal treatment and follow-up (control group). The main outcome was the interval between relapse and treatment, and secondary outcomes were rates of primary and secondary care consultation, quality of life, and acceptability to patients. Analysis was by intention to treat. Findings Intervention patients had relapses treated within a mean of 14.8 h (SID 19.1) compared with 49.6 h (65.1) in controls (difference 34.8 h [95% CI 16.4-60.2]). Furthermore, intervention patients compared with controls made significantly fewer visits to hospital (0.9 vs 2.9 per patient per year, difference 2.0 [1.6-2.7]) and to the primary-care physician (0.3 vs 0.9 per patient per year, difference 0.6 [0.2-1.1], p<0.006). Only two patients in the intervention group preferred traditional management. Health-related quality-of-life, scores were unchanged in both groups. Interpretation Self-management of ulcerative colitis accelerates treatment provision and reduces doctor visits, and does not increase morbidity. This approach could be used in long-term management of many other chronic diseases to improve health-service provision and use, and to reduce costs.	Univ Manchester, Hope Hosp, Sect Gastrointestinal Sci, Salford M6 8HD, Lancs, England; Univ Manchester, Natl Primary Care Res & Dev Ctr, Manchester, Lancs, England	University of Manchester; University of Manchester	Robinson, A (corresponding author), Univ Manchester, Hope Hosp, Sect Gastrointestinal Sci, Clin Sci Bldg, Salford M6 8HD, Lancs, England.							ANDERSON RM, 1995, DIABETES CARE, V18, P943, DOI 10.2337/diacare.18.7.943; ARMSTRONG D, 1992, J PUBLIC HEALTH MED, V14, P173; Barber JA, 1998, BRIT MED J, V317, P1195, DOI 10.1136/bmj.317.7167.1195; *BRIT SOC GASTR, 1996, GUID GASTR INFL BOW; Burkey Y, 1997, FAM PRACT, V14, P29, DOI 10.1093/fampra/14.1.29; Coulter A, 1997, J Health Serv Res Policy, V2, P112; DELAMATER AM, 1990, DIABETES CARE, V13, P492, DOI 10.2337/diacare.13.5.492; *DEP HLTH, 1997, NEW NHS MOD DEP EX S, P5; *DEP HLTH, 1999, SAV LIV OUR HLTH NAT; Entwistle VA, 1996, INT J QUAL HEALTH C, V8, P425; Golin CE, 1996, DIABETES CARE, V19, P1153, DOI 10.2337/diacare.19.10.1153; *GOV STAT SERV, 1995, OUTP WARD ATT ENGL F; GUYATT G, 1989, GASTROENTEROLOGY, V96, P804, DOI 10.1016/0016-5085(89)90905-0; KOTSES H, 1995, J ALLERGY CLIN IMMUN, V95, P529, DOI 10.1016/S0091-6749(95)70315-2; Lahdensuo A, 1996, BRIT MED J, V312, P748; Laine C, 1996, JAMA-J AM MED ASSOC, V275, P152, DOI 10.1001/jama.275.2.152; LEITCH AG, 1990, RESP MED, V84, P119, DOI 10.1016/S0954-6111(08)80013-3; Mansfield JC, 1997, J ROY COLL PHYS LOND, V31, P184; MOODY GA, 1993, J ROY SOC MED, V86, P26; PROBERT CSJ, 1993, J ROY SOC MED, V86, P271; RAZ I, 1988, DIABETES CARE, V11, P67, DOI 10.2337/diacare.11.1.67; Reeve H, 1997, FAM PRACT, V14, P24, DOI 10.1093/fampra/14.1.24; Shaw C D, 1981, Health Trends, V13, P107; STEWART MA, 1995, CAN MED ASSOC J, V152, P1423; TAVES DR, 1974, CLIN PHARMACOL THER, V15, P443; Treasure T, 1998, BRIT MED J, V317, P362; Williams JG, 2000, BRIT MED J, V320, P544, DOI 10.1136/bmj.320.7234.544; WILSON SR, 1993, AM J MED, V94, P564, DOI 10.1016/0002-9343(93)90206-5; [No title captured]	29	151	154	0	18	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	SEP 22	2001	358	9286					976	981		10.1016/S0140-6736(01)06105-0	http://dx.doi.org/10.1016/S0140-6736(01)06105-0			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	474YR	11583752				2023-01-03	WOS:000171135300019
J	Inwald, D; Roland, M; Kuitert, L; McKenzie, SA; Petros, A				Inwald, D; Roland, M; Kuitert, L; McKenzie, SA; Petros, A			Oxygen treatment for acute severe asthma	BRITISH MEDICAL JOURNAL			English	Article							NEBULIZED SALBUTAMOL; 100-PERCENT OXYGEN; DRIVING GAS; VENTILATION; PERFUSION; PHENYLEPHRINE; HYPOXEMIA; SAFE		Inst Child Hlth, Portex Dept Anaesthesia Intens Care & Resp Med, London WC1N 1EH, England; St Bartholomews & Royal London Sch Med & Dent, Dept Resp Med, London EC1A 7BE, England; Royal London Hosp, Queen Elizabeth Childrens Serv, London E1 1BB, England; Great Ormond St Hosp Children, Paediat Intens Care Unit, London WC1N 3JF, England	University of London; University College London; University of London; Queen Mary University London; Barts Health NHS Trust; Royal London Hospital; University of London; University College London; Great Ormond Street Hospital for Children NHS Foundation Trust	Inwald, D (corresponding author), Inst Child Hlth, Portex Dept Anaesthesia Intens Care & Resp Med, 30 Guilford St, London WC1N 1EH, England.			Inwald, David/0000-0001-9518-7821				ALLIOTT RJ, 1972, BMJ-BRIT MED J, V1, P539, DOI 10.1136/bmj.1.5799.539; BALLESTER E, 1989, THORAX, V44, P258, DOI 10.1136/thx.44.4.258; BALLESTER E, 1990, AM REV RESPIR DIS, V141, P558, DOI 10.1164/ajrccm/141.3.558; BASS BH, 1969, LANCET, V2, P438; Campbell MJ, 1997, BRIT MED J, V314, P1439, DOI 10.1136/bmj.314.7092.1439; CATES CJ, 2000, COCHRANE DATABASE SY; CHOOKANG YE, 1974, SCOT MED J, V19, P191, DOI 10.1177/003693307401900407; CONNETT G, 1993, THORAX, V48, P574, DOI 10.1136/thx.48.5.574; CRANE J, 1987, NEW ZEAL MED J, V100, P309; DOUGLAS JG, 1985, THORAX, V40, P180, DOI 10.1136/thx.40.3.180; FIELD GB, 1967, CLIN SCI, V32, P279; GLEESON JGA, 1988, ARCH DIS CHILD, V63, P900, DOI 10.1136/adc.63.8.900; GUNAWARDENA KA, 1984, BRIT MED J, V288, P272, DOI 10.1136/bmj.288.6413.272; HARRIS L, 1972, J ALLERGY CLIN IMMUN, V49, P63, DOI 10.1016/0091-6749(72)90057-7; Kotani Y, 1999, J ASTHMA, V36, P583, DOI 10.3109/02770909909087295; MCFADDEN ER, 1968, NEW ENGL J MED, V278, P1027, DOI 10.1056/NEJM196805092781901; MOLFINO NA, 1991, NEW ENGL J MED, V324, P285, DOI 10.1056/NEJM199101313240502; PALMER KNV, 1969, BRIT MED J, V1, P31, DOI 10.1136/bmj.1.5635.31; RODRIGUEZROISIN R, 1989, AM REV RESPIR DIS, V139, P732, DOI 10.1164/ajrccm/139.3.732; Somerville M, 1995, J PUBLIC HEALTH MED, V17, P397; TAL A, 1984, CHEST, V86, P868, DOI 10.1378/chest.86.6.868; WAGNER PD, 1978, AM REV RESPIR DIS, V118, P511; WILLIAMS AJ, 1994, PULM PHARMACOL, V7, P235, DOI 10.1006/pulp.1994.1026; [No title captured], DOI DOI 10.1136/THX.52.2008.S1]	24	23	23	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	JUL 14	2001	323	7304					98	100		10.1136/bmj.323.7304.98	http://dx.doi.org/10.1136/bmj.323.7304.98			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	454GD	11451788	Green Published			2023-01-03	WOS:000169964100022
J	Casarett, DJ; Inouye, SK				Casarett, DJ; Inouye, SK		Amer Coll Physicians Amer Soc In	Diagnosis and management of delirium near the end of life	ANNALS OF INTERNAL MEDICINE			English	Article							ACUTE CONFUSIONAL STATES; DOUBLE-BLIND; BEHAVIORAL SYMPTOMS; TERMINAL CANCER; OPIOID ROTATION; MENTAL STATUS; HALOPERIDOL; LORAZEPAM; OLDER; IMPAIRMENT	Delirium is a common and distressing symptom that constitutes a significant challenge for end-of-life care. However, reliable techniques are available for the diagnosis of delirium, and effective therapies exist as well. This consensus paper uses a case-based format that begins with an overview of the definition and presentation of delirium. Next, strategies for diagnosis are suggested, with attention to the unique challenges that clinicians face in pursuing a diagnostic work-up for patients near the end of life. The paper concludes with a review of therapeutic options.	Vet Affairs Med Ctr, Philadelphia, PA USA; Univ Penn, Philadelphia, PA 19104 USA; Yale Univ, Sch Med, New Haven, CT 06520 USA	University of Pennsylvania; Pennsylvania Medicine; US Department of Veterans Affairs; Veterans Health Administration (VHA); Philadelphia Veterans Affairs Medical Center; University of Pennsylvania; Yale University	Casarett, DJ (corresponding author), Care of Snyder L, Amer Coll Phys, Amer Soc Internal Med, 190 N Independence Mall W, Philadelphia, PA 19106 USA.		Inouye, Sharon/R-7216-2019		NIA NIH HHS [AG00949] Funding Source: Medline	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Albert M S, 1992, J Geriatr Psychiatry Neurol, V5, P14; American Psychiatric Association, 1994, DSM 4 DIAGNOSTIC STA; Beasley CM, 1997, J CLIN PSYCHIAT, V58, P13; Breitbart W, 1997, J PAIN SYMPTOM MANAG, V13, P128, DOI 10.1016/S0885-3924(96)00316-8; Breitbart W, 1996, AM J PSYCHIAT, V153, P231; BRUERA E, 1989, PAIN, V39, P13, DOI 10.1016/0304-3959(89)90169-3; BRUERA E, 1992, J PAIN SYMPTOM MANAG, V7, P192, DOI 10.1016/0885-3924(92)90074-R; BRUERA E, 1995, J PAIN SYMPTOM MANAG, V10, P287, DOI 10.1016/0885-3924(95)00005-J; Burstein HJ, 1999, NEW ENGL J MED, V340, P1733, DOI 10.1056/NEJM199906033402206; Caraceni A, 2000, CANCER-AM CANCER SOC, V89, P1145, DOI 10.1002/1097-0142(20000901)89:5<1145::AID-CNCR24>3.0.CO;2-X; Casarett DJ, 2000, J PAIN SYMPTOM MANAG, V20, P130, DOI 10.1016/S0885-3924(00)00164-0; Christensen DB, 1998, J AM GERIATR SOC, V46, P620, DOI 10.1111/j.1532-5415.1998.tb01081.x; Conley RR, 2000, J CLIN PSYCHIAT, V61, P26; De Deyn PP, 2000, INT J GERIATR PSYCH, V15, pS14, DOI 10.1002/1099-1166(200007)15:1+<::AID-GPS168>3.0.CO;2-#; De Deyn PP, 1999, NEUROLOGY, V53, P946, DOI 10.1212/WNL.53.5.946; DESTOUTZ ND, 1995, J PAIN SYMPTOM MANAG, V10, P378, DOI 10.1016/0885-3924(95)90924-C; DHONNEUR G, 1994, ANESTHESIOLOGY, V81, P87, DOI 10.1097/00000542-199407000-00013; Fainsinger R, 1991, J Palliat Care, V7, P5; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; FRANCIS J, 1988, CLIN RES, V36, pA711; GUSTAFSON Y, 1991, J AM GERIATR SOC, V39, P760, DOI 10.1111/j.1532-5415.1991.tb02697.x; GUSTAFSON Y, 1988, J AM GERIATR SOC, V36, P525, DOI 10.1111/j.1532-5415.1988.tb04023.x; Inouye SK, 1999, NEW ENGL J MED, V340, P669, DOI 10.1056/NEJM199903043400901; Inouye SK, 1996, JAMA-J AM MED ASSOC, V275, P852, DOI 10.1001/jama.275.11.852; INOUYE SK, 1990, ANN INTERN MED, V113, P941, DOI 10.7326/0003-4819-113-12-941; LEIPZIG RM, 1987, PHARMACOLOGY, V35, P47, DOI 10.1159/000138294; MARCANTONIO ER, 1994, JAMA-J AM MED ASSOC, V272, P1518, DOI 10.1001/jama.272.19.1518; MASSIE MJ, 1983, AM J PSYCHIAT, V140, P1048; McCollam JS, 1999, CRIT CARE MED, V27, P2454, DOI 10.1097/00003246-199911000-00022; Mercadante S, 1999, CANCER, V86, P1856, DOI 10.1002/(SICI)1097-0142(19991101)86:9<1856::AID-CNCR30>3.0.CO;2-G; Minagawa H, 1996, CANCER, V78, P1131, DOI 10.1002/(SICI)1097-0142(19960901)78:5<1131::AID-CNCR26>3.0.CO;2-2; NYGAARD HA, 1992, CURR MED RES OPIN, V12, P615, DOI 10.1185/03007999209111528; Olmos M, 2000, ANESTH ANALG, V90, P1157, DOI 10.1097/00000539-200005000-00029; Paramore LC, 1997, J PAIN SYMPTOM MANAG, V13, P83, DOI 10.1016/S0885-3924(96)00299-0; PATT RB, 1994, J PAIN SYMPTOM MANAG, V9, P446, DOI 10.1016/0885-3924(94)90201-1; Pereira J, 1997, CANCER-AM CANCER SOC, V79, P835; POMPEI P, 1995, ARCH INTERN MED, V155, P301, DOI 10.1001/archinte.155.3.301; PORTENOY RK, 1991, PAIN, V47, P13, DOI 10.1016/0304-3959(91)90005-I; Quill TE, 2000, ANN INTERN MED, V132, P408, DOI 10.7326/0003-4819-132-5-200003070-00012; SCHOR JD, 1992, JAMA-J AM MED ASSOC, V267, P827, DOI 10.1001/jama.267.6.827; Steiner N, 1998, J PALLIAT CARE, V14, P6, DOI 10.1177/082585979801400202; Street JS, 2000, ARCH GEN PSYCHIAT, V57, P968, DOI 10.1001/archpsyc.57.10.968; Sulmasy DP, 2000, ANN INTERN MED, V133, P564, DOI 10.7326/0003-4819-133-7-200010030-00027; Swart EL, 1999, CRIT CARE MED, V27, P1461, DOI 10.1097/00003246-199908000-00009; Tariot PN, 1996, J CLIN PSYCHIAT, V57, P21; TRZEPACZ PT, 1988, PSYCHIAT RES, V23, P89, DOI 10.1016/0165-1781(88)90037-6; TRZEPACZ PT, 1995, GEN HOSP PSYCHIAT, V17, P75, DOI 10.1016/0163-8343(94)00095-U; Ventafridda V, 1990, J Palliat Care, V6, P7; Wood MM, 1998, J PAIN SYMPTOM MANAG, V16, P112, DOI 10.1016/S0885-3924(98)00043-8	49	106	110	0	4	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUL 3	2001	135	1					32	40		10.7326/0003-4819-135-1-200107030-00011	http://dx.doi.org/10.7326/0003-4819-135-1-200107030-00011			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	449JC	11434730				2023-01-03	WOS:000169680500005
J	Lawlor, DA; Hopker, SW				Lawlor, DA; Hopker, SW			The effectiveness of exercise as an intervention in the management of depression: systematic review and meta-regression analysis of randomised controlled trials	BMJ-BRITISH MEDICAL JOURNAL			English	Review							AEROBIC EXERCISE; MENTAL-HEALTH; PHYSICAL-ACTIVITY; MAJOR DEPRESSION; OLDER ADULTS; CLINICAL DEPRESSION; GENERAL-PRACTICE; MOOD STATES; SYMPTOMS; METAANALYSIS	Objective To determine the effectiveness of exercise as an intervention in the management of depression. Design Systematic review and meta-regression analysis of randomised controlled trials obtained from five electronic databases (Medline, Embase, Sports Discus, PsycLIT, Cochrane Library) and through contact with experts in the field, bibliographic searches, and hand searches of recent copies of relevant journals, Main outcome measures Standardised mean difference in effect size and weighted mean difference in Beck depression inventory score between exercise and no treatment and between exercise and cognitive therapy Results All of the 14 studies analysed had important methodological weaknesses; randomisation was adequately concealed in only three studies, intention to treat analysis was undertaken in only two, and assessment of outcome was blinded in only one. The participants in most studies were community volunteers, and diagnosis was determined by their score on the Beck depression inventory. When compared with no treatment, exercise reduced symptoms of depression (standardised mean difference in effect size -1.1 (95% confidence interval -1.5 to -0.6); weighted mean difference in Beck depression inventory -7.3 (-10.0 to - 4.6)). The effect size: was significantly seater. in those trials with shorter follow up and in two trials reported only as conference abstracts. The effect of exercise was similar to that of cognitive therapy (standardised mean difference -0.3 (95%, confidence interval -0.7 to 0.1)), Conclusions The effectiveness of exercise in reducing symptoms of depression cannot be determined because of a lack of good quality research on clinical populations with adequate follow up.	Univ Bristol, Dept Social Med, Bristol BS8 2PR, Avon, England; Bradford Community Trust, Shipley BD18 3BP, W Yorkshire, England	University of Bristol	Lawlor, DA (corresponding author), Univ Bristol, Dept Social Med, Bristol BS8 2PR, Avon, England.	D.A.Lawlor@bristol.ac.uk		Lawlor, Debbie A/0000-0002-6793-2262				ANTONELLI F, 1982, INT J SPORT PSYCHOL, V13, P187; AUCHUS MP, 1994, PSYCHOSOC REHABIL J, V18, P99, DOI 10.1037/h0095510; BERLIN JA, 1990, AM J EPIDEMIOL, V132, P612, DOI 10.1093/oxfordjournals.aje.a115704; BERLIN JA, 1989, STAT MED, V8, P141, DOI 10.1002/sim.4780080202; Biddle S, 1995, RES Q EXERCISE SPORT, V66, P292, DOI 10.1080/02701367.1995.10607914; BIDDLE S, 1989, BRIT J HOSP MED, V42, P267; BIDDLE SJH, 1994, PHYSICAL ACTIVITY PR; BLUE FR, 1979, PERCEPT MOTOR SKILL, V48, P228, DOI 10.2466/pms.1979.48.1.228; Blumenthal JA, 1999, ARCH INTERN MED, V159, P2349, DOI 10.1001/archinte.159.19.2349; BOSSCHER RJ, 1993, INT J SPORT PSYCHOL, V24, P170; Broocks A, 1997, PSYCHOTHER PSYCH MED, V47, P379; BURBACH FR, 1997, J MENT HEALTH, V6, P543, DOI DOI 10.1080/09638239718428; BYRNE A, 1993, J PSYCHOSOM RES, V37, P565, DOI 10.1016/0022-3999(93)90050-P; CARLSON DL, 1991, THESIS U WISCONSIN M; CONROY RW, 1982, HOSP COMMUNITY PSYCH, V33, P641; Craft LL, 1998, J SPORT EXERCISE PSY, V20, P339, DOI 10.1123/jsep.20.4.339; DAMATO G, 1990, THESIS HOFSTRA U HEM; DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2; DiLorenzo TM, 1999, PREV MED, V28, P75, DOI 10.1006/pmed.1998.0385; DISHMAN RK, 1995, QUEST, V47, P362, DOI 10.1080/00336297.1995.10484164; DOYNE EJ, 1983, BEHAV THER, V14, P434, DOI 10.1016/S0005-7894(83)80106-3; DOYNE EJ, 1987, J CONSULT CLIN PSYCH, V55, P748, DOI 10.1037/0022-006X.55.5.748; EMERY CF, 1990, GERONTOLOGIST, V30, P516, DOI 10.1093/geront/30.4.516; EMERY CF, 1990, GERONTOLOGIST, V30, P184, DOI 10.1093/geront/30.2.184; EPSTEIN D, 1986, THESIS U NEVADA RENO; FENTEM P, 1994, BRIT MED J, V308, P1291, DOI 10.1136/bmj.308.6939.1291; FETSCH RJ, 1983, AM MENT HLTH COUNSEL, V5, P75; Fox K, 1997, BRIT J GEN PRACT, V47, P367; FREMONT J, 1987, COGNITIVE THER RES, V11, P241, DOI 10.1007/BF01183268; GIARDINELLI L, 1996, MINERVA PSICHIATR, V37, P179; Glenister D, 1996, J ROY SOC HEALTH, V116, P7, DOI 10.1177/146642409611600102; GLESER J, 1990, ISRAEL J PSYCHIAT, V27, P99; GREIST JH, 1979, COMPR PSYCHIAT, V20, P41, DOI 10.1016/0010-440X(79)90058-0; HALES RE, 1987, MIL MED, V152, P299, DOI 10.1093/milmed/152.6.299; HANNAFORD CP, 1988, PSYCHOL REC, V38, P37, DOI 10.1007/BF03395005; HARTZ GW, 1982, PERCEPT MOTOR SKILL, V55, P1217, DOI 10.2466/pms.1982.55.3f.1217; HESSHOMEIER MJ, 1981, THESIS U MONTANA MIS; Hotopf M, 1997, J EPIDEMIOL COMMUN H, V51, P354, DOI 10.1136/jech.51.4.354; JOHNSON DAW, 1973, BRIT MED J, V2, P18, DOI 10.1136/bmj.2.5857.18; KAPLAN K, 1983, OCCUP THER J RES, V3, P173, DOI 10.1177/153944928300300304; KLEIN MH, 1985, INT J MENT HEALTH, V13, P148, DOI 10.1080/00207411.1984.11448982; Kolbjornsrud O-B., 1989, NORDISK PSYKIATRISK, V43, P521; LAFONTAINE TP, 1992, SPORTS MED, V13, P160, DOI 10.2165/00007256-199213030-00002; Leith L. M, 1994, FDN EXERCISE MENTAL, P17; Lepore SJ, 1997, J PERS SOC PSYCHOL, V73, P1030, DOI 10.1037/0022-3514.73.5.1030; MARTINSEN EW, 1993, INT J SPORT PSYCHOL, V24, P185; MARTINSEN EW, 1985, BRIT MED J, V291, P109, DOI 10.1136/bmj.291.6488.109; MARTINSEN EW, 1989, COMPR PSYCHIAT, V30, P324, DOI 10.1016/0010-440X(89)90057-6; MARTINSEN EW, 1994, ACTA PSYCHIAT SCAND, V89, P23, DOI 10.1111/j.1600-0447.1994.tb05797.x; MARTINSEN EW, 1987, STRESS MEDICINE, V3, P93, DOI 10.1002/smi.2460030205; Martinsen EW., 1988, P SPORT HLTH PSYCH E, P77; Martinsen EW, 1988, P SPORT HLTH PSYCH E, P84; MARTINSEN EW, 1989, NORD PSYKIATR TIDSSK, V43, P411; MCCANN IL, 1984, J PERS SOC PSYCHOL, V46, P1142, DOI 10.1037/0022-3514.46.5.1142; MCNEIL JK, 1991, PSYCHOL AGING, V6, P487, DOI 10.1037/0882-7974.6.3.487; Moher D, 1999, LANCET, V354, P1896, DOI 10.1016/S0140-6736(99)04149-5; Moore KA, 1998, ALTERN THER HEALTH M, V4, P48; Mutrie N., 1988, P SPORT HLTH PSYCH E, P96; Mynors-Wallis LM, 2000, BMJ-BRIT MED J, V320, P26, DOI 10.1136/bmj.320.7226.26; Netz Yael, 1994, Clinical Gerontologist, V15, P47, DOI 10.1300/J018v15n01_06; North T C, 1990, Exerc Sport Sci Rev, V18, P379; Palleschi L, 1998, ARCH GERONTOL GERIAT, P381; PAPPAS GP, 1990, PSYCHOSOMATICS, V31, P112, DOI 10.1016/S0033-3182(90)72232-3; Pelham T. W., 1993, PSYCHOSOC REHABIL, V16, P75, DOI DOI 10.1037/H0095650; PERRI S, 1985, INT J AGING HUM DEV, V20, P1984; PEZZAROSSA B, 1991, ANAL PSYCHOTHER PSYC, V10, P163; PLANTE TG, 1996, J PSYCHOS NURS MENT, V34, P39; RAGLIN JS, 1990, SPORTS MED, V9, P323, DOI 10.2165/00007256-199009060-00001; REUTER M, 1984, THESIS PENNSYLVANIA; Rief W, 1996, BRIT J CLIN PSYCHOL, V35, P605, DOI 10.1111/j.2044-8260.1996.tb01216.x; Rosenthal R, 1994, HDB RES SYNTHESIS, P231; ROTH DL, 1987, PSYCHOSOM MED, V49, P355, DOI 10.1097/00006842-198707000-00004; Sachs M L, 1981, Top Clin Nurs, V3, P77; SACHS ML, 1982, J HUMANISTIC ED DEV, V21, P51; Salmon P, 1990, Br J Hosp Med, V43, P107; SCHULZ KF, 1995, JAMA-J AM MED ASSOC, V273, P408, DOI 10.1001/jama.273.5.408; SCOTT MG, 1960, RES QUART, V31, P307; Scully D, 1998, BRIT J SPORT MED, V32, P111, DOI 10.1136/bjsm.32.2.111; SEXTON H, 1989, ACTA PSYCHIAT SCAND, V80, P231, DOI 10.1111/j.1600-0447.1989.tb01332.x; SIMONS AD, 1985, CLIN PSYCHOL REV, V5, P553, DOI 10.1016/0272-7358(85)90034-0; Singh NA, 1997, J GERONTOL A-BIOL, V52, pM27, DOI 10.1093/gerona/52A.1.M27; Sonstroem R J, 1997, Med Health R I, V80, P295; Stewart N J, 1994, Arch Psychiatr Nurs, V8, P22; Streiner DL, 1998, CAN J PSYCHIAT, V43, P1026, DOI 10.1177/070674379804301008; THOMSON J, 1982, PSYCHOL MED, V12, P741, DOI 10.1017/S0033291700049047; THOREN P, 1990, MED SCI SPORT EXER, V22, P417; VANCOPPENHOLLE H, 1993, ISSUES SPECIAL ED RE, V8, P29; VEALE D, 1992, J ROY SOC MED, V85, P541; VEALE D, 1988, P SPORT HLTH PSYCH E, P106; VEALE DMWD, 1987, ACTA PSYCHIAT SCAND, V76, P113, DOI 10.1111/j.1600-0447.1987.tb02872.x; WEINSTEIN WS, 1983, J SPORT PSYCHOL, V5, P288, DOI 10.1123/jsp.5.3.288; WEYERER S, 1994, SPORTS MED, V17, P108, DOI 10.2165/00007256-199417020-00003; WILLIAMS JM, 1986, PERCEPT MOTOR SKILL, V63, P1099, DOI 10.2466/pms.1986.63.3.1099	93	510	520	4	178	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	MAR 31	2001	322	7289					763	767		10.1136/bmj.322.7289.763	http://dx.doi.org/10.1136/bmj.322.7289.763			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	419HL	11282860	Green Published, Green Submitted			2023-01-03	WOS:000167943200024
J	[Anonymous]				[Anonymous]			EUTHANASIA - CONCLUSIONS OF A BMA WORKING PARTY SET UP TO REVIEW THE ASSOCIATIONS GUIDANCE ON EUTHANASIA	BRITISH MEDICAL JOURNAL			English	Editorial Material																		1988, EUTHANASIA REPORT	1	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 14	1988	296	6633					1376	1377						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	N4544	11652526				2023-01-03	WOS:A1988N454400020
J	Takeshita, A; Taguchi, M; Koibuchi, N; Ozawa, Y				Takeshita, A; Taguchi, M; Koibuchi, N; Ozawa, Y			Putative role of the orphan nuclear receptor SXR (steroid and xenobiotic receptor) in the mechanism of CYP3A4 inhibition by xenobiotics	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PREGNANE-X-RECEPTOR; DNA-BINDING DOMAIN; HORMONE RECEPTORS; SIGNALING PATHWAY; RESPONSE ELEMENTS; DRUG-INTERACTIONS; CO-REPRESSOR; COREPRESSOR; COACTIVATOR; EXPRESSION	Cytochrome P450 monooxygenase 3A4 (CYP3A4) is responsible for the metabolism of endogenous steroids and drugs in liver. Many inducers of human CYP3A4, such as rifampicin, bind to the orphan nuclear receptor SXR (steroid and xenobiotic receptor) as ligands and stimulate transcription on xenobiotic response elements located in the CYP3A4 promoter. Conversely, it is not known whether SXR mediates the transcriptional repression. We thus examined transcriptional repression of SXR and its interaction with corepressors, NCoR (nuclear receptor corepressor) and SMRT (silencing mediator for retinoid and thyroid receptors) using reporter assays in the absence and presence of ligand. Cotransfection of SMRT, but not NCoR, inhibited not only basal but also rifampicin-induced transcriptional activity of SXR on the CYP3A4 promoter through specific SMRT-SXR interaction in HepG2 cells. Interestingly, rifampicin also increased the interaction of SXR with SMRT as well as with coactivator SRC-1. On the other hand, the anti-fungal agent ketoconazole decreased SXR interaction with both SRC-1 and SMRT. Ketoconazole partially inhibited corticosterone-induced SXR-mediated transcription on the CYP3A4 promoter. Taken together, our results suggest that the differential interaction of coactivators and corepressors induced by various xenobiotics may alter SXR-mediated transcription. Further, the effects of ketoconazole on the CYP3A4 gene suppression may explain, in part, drug-induced inhibition of the CYP3A4 action at the transcriptional level.	Toranomon Gen Hosp, Div Endocrinol & Metab, Okinaka Mem Inst Med Res, Minato Ku, Tokyo 1058470, Japan; Japan Sci & Technol Corp, Core Res Evolut Sci & Technol, Maebashi, Gumma 3718511, Japan	Toranomon Hospital; Japan Science & Technology Agency (JST)	Takeshita, A (corresponding author), Toranomon Gen Hosp, Div Endocrinol & Metab, Okinaka Mem Inst Med Res, Minato Ku, 2-2-2 Toranomon, Tokyo 1058470, Japan.			Koibuchi, Noriyuki/0000-0002-2247-9740				BECK DJ, 1989, BR J CLIN PHARM, V28, P166; Bertilsson G, 1998, P NATL ACAD SCI USA, V95, P12208, DOI 10.1073/pnas.95.21.12208; Blumberg B, 1998, GENE DEV, V12, P3195, DOI 10.1101/gad.12.20.3195; CHEN JD, 1995, NATURE, V377, P454, DOI 10.1038/377454a0; Cohen RN, 2001, MOL ENDOCRINOL, V15, P1049, DOI 10.1210/me.15.7.1049; Cohen RN, 2000, MOL ENDOCRINOL, V14, P900, DOI 10.1210/me.14.6.900; Glass CK, 2000, GENE DEV, V14, P121; Goodwin B, 1999, MOL PHARMACOL, V56, P1329, DOI 10.1124/mol.56.6.1329; HORLEIN AJ, 1995, NATURE, V377, P397, DOI 10.1038/377397a0; Hu X, 2001, MOL CELL BIOL, V21, P1747, DOI 10.1128/MCB.21.5.1747-1758.2001; Hu X, 1999, NATURE, V402, P93, DOI 10.1038/47069; HUANG YC, 1986, ANTIMICROB AGENTS CH, V30, P206, DOI 10.1128/AAC.30.2.206; Jones SA, 2000, MOL ENDOCRINOL, V14, P27, DOI 10.1210/me.14.1.27; Kliewer SA, 1998, CELL, V92, P73, DOI 10.1016/S0092-8674(00)80900-9; Lehmann JM, 1998, J CLIN INVEST, V102, P1016, DOI 10.1172/JCI3703; Liu Y, 1998, MOL ENDOCRINOL, V12, P34, DOI 10.1210/mend.12.1.0046; Mathur M, 2001, MOL CELL BIOL, V21, P2298, DOI 10.1128/MCB.21.7.2298-2311.2001; MAURICE M, 1992, FASEB J, V6, P752, DOI 10.1096/fasebj.6.2.1371482; McKenna NJ, 1999, ENDOCR REV, V20, P321, DOI 10.1210/er.20.3.321; Misiti S, 1998, ENDOCRINOLOGY, V139, P2493, DOI 10.1210/en.139.5.2493; Moore LB, 2000, J BIOL CHEM, V275, P15122, DOI 10.1074/jbc.M001215200; Smith CL, 1997, MOL ENDOCRINOL, V11, P657, DOI 10.1210/me.11.6.657; Staudinger JL, 2001, P NATL ACAD SCI USA, V98, P3369, DOI 10.1073/pnas.051551698; Sumida A, 2000, BIOCHEM BIOPH RES CO, V267, P756, DOI 10.1006/bbrc.1999.2029; Synold TW, 2001, NAT MED, V7, P584, DOI 10.1038/87912; Tagami T, 1998, BIOCHEM BIOPH RES CO, V253, P358, DOI 10.1006/bbrc.1998.9799; Takeshita A, 1998, J BIOL CHEM, V273, P21554, DOI 10.1074/jbc.273.34.21554; Takeshita A, 1996, ENDOCRINOLOGY, V137, P3594, DOI 10.1210/en.137.8.3594; Takeshita A, 2001, EUR J ENDOCRINOL, V145, P513, DOI 10.1530/eje.0.1450513; Thummel KE, 1998, ANNU REV PHARMACOL, V38, P389, DOI 10.1146/annurev.pharmtox.38.1.389; VASAVADA HA, 1991, P NATL ACAD SCI USA, V88, P10686, DOI 10.1073/pnas.88.23.10686; Waxman DJ, 1999, ARCH BIOCHEM BIOPHYS, V369, P11, DOI 10.1006/abbi.1999.1351; Webb P, 2000, MOL ENDOCRINOL, V14, P1976, DOI 10.1210/me.14.12.1976; Wood JR, 2001, MOL ENDOCRINOL, V15, P1114, DOI 10.1210/me.15.7.1114; Xie W, 2001, P NATL ACAD SCI USA, V98, P3375, DOI 10.1073/pnas.051014398	35	101	104	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 6	2002	277	36					32453	32458		10.1074/jbc.M111245200	http://dx.doi.org/10.1074/jbc.M111245200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	591BC	12072427	hybrid			2023-01-03	WOS:000177859000009
J	Geiderman, JM; Larkin, GL				Geiderman, JM; Larkin, GL			Commercial filming of patient care activities in hospitals	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							INFORMED CONSENT; CARDIOPULMONARY-RESUSCITATION; DOMESTIC VIOLENCE; NEWS MEDIA; EMERGENCY; TELEVISION; HEALTH; MEDICINE; CONFIDENTIALITY; PUBLICATION	Commercial filming of patient care activities is common in hospital settings. This article reviews common circumstances in which patients are commercially filmed, explores the potential positive and negative aspects of filming, and considers the ethical and legal issues associated with commercial filming of patients in hospital settings. We examine the competing goals of commercial filming and the duties of journalists vs the rights of patients to privacy. Current standards and recommendations for commercial filming of patient care activities are reviewed and additional recommendations are offered.	Cedars Sinai Med Ctr, Burns & Allen Res Inst, Ruth & Harry Roman Emergency Dept, Los Angeles, CA 90048 USA; Cedars Sinai Med Ctr, Burns & Allen Res Inst, Dept Emergency Med, Los Angeles, CA 90048 USA; Cedars Sinai Med Ctr, Burns & Allen Res Inst, Cedars Sinai Ctr Hlth Care Eth, Los Angeles, CA 90048 USA; Univ Texas SW, Parkland Mem Hosp, Dept Surg Emergency Med, Dallas, TX USA	Cedars Sinai Medical Center; Cedars Sinai Medical Center; Cedars Sinai Medical Center; University of Texas System; University of Texas Southwestern Medical Center Dallas	Geiderman, JM (corresponding author), Cedars Sinai Med Ctr, Burns & Allen Res Inst, Ruth & Harry Roman Emergency Dept, 8700 Beverly Blvd,Room 1110, Los Angeles, CA 90048 USA.			LARKIN, GREGORY LUKE/0000-0002-8655-7824				Adomat R, 1999, Nurs Stand, V14, P37; ALBERTS MJ, 1992, STROKE, V23, P352, DOI 10.1161/01.STR.23.3.352; ALDERMAN E, 1995, RIGHT PRIVACY, pR13; *AM MED ASS COUNC, 3101 CEJA AM MED ASS; Bauer HM, 1999, WESTERN J MED, V171, P118; Beauchamp T., 1994, PRINCIPLES BIOMEDICA, P120; BLOCK MR, 1985, J FAM PRACTICE, V21, P467; BOROW W, 1993, JAMA-J AM MED ASSOC, V270, P1601, DOI 10.1001/jama.270.13.1601; Clever LH, 1997, JAMA-J AM MED ASSOC, V278, P628, DOI 10.1001/jama.278.8.628; Cohn V, 1996, JAMA-J AM MED ASSOC, V276, P1917; Cohn V, 2001, STAT MED, V20, P1341, DOI 10.1002/sim.671; Collins S, 2001, WESTERN J MED, V175, P384, DOI 10.1136/ewjm.175.6.384; DANIELS N, 1985, JUST HLTH CARE, P36; De Amici D, 2000, ANESTH ANALG, V90, P739, DOI 10.1097/00000539-200003000-00042; DEJONG W, 1990, HEALTH AFFAIR, V9, P30, DOI 10.1377/hlthaff.9.2.30; deSemir V, 1996, LANCET, V347, P1163, DOI 10.1016/S0140-6736(96)90614-5; Diem SJ, 1996, NEW ENGL J MED, V334, P1578, DOI 10.1056/NEJM199606133342406; DIKEMA DS, 1996, AM J EMERG MED, V14, P226; Eitel DR, 1998, J FAM PRACTICE, V46, P251; EPPLER E, 1994, ANN EMERG MED, V24, P202, DOI 10.1016/S0196-0644(94)70131-8; Fontanarosa PB, 1997, JAMA-J AM MED ASSOC, V278, P682, DOI 10.1001/jama.278.8.682; FOUBISTER V, 2000, AM MED NEWS     0327, P43; FRANKEL DH, 1995, LANCET, V345, P1105, DOI 10.1016/S0140-6736(95)90836-6; Frankena W. K., 1973, ETHICS, P47; Freed GL, 1996, JAMA-J AM MED ASSOC, V276, P1869, DOI 10.1001/jama.276.23.1869; Geiderman J, 2000, ANN EMERG MED, V35, P403, DOI 10.1016/S0196-0644(00)70063-1; Geiderman JM, 2001, ANN EMERG MED, V37, P217, DOI 10.1067/mem.2001.113559; GERBNER G, 1981, NEW ENGL J MED, V305, P901, DOI 10.1056/NEJM198110083051530; Holden JD, 2001, J EVAL CLIN PRACT, V7, P65, DOI 10.1046/j.1365-2753.2001.00280.x; Hood CA, 1998, BRIT MED J, V316, P1009, DOI 10.1136/bmj.316.7136.1009; HOYT DB, 1988, J TRAUMA, V28, P435, DOI 10.1097/00005373-198804000-00003; HYMAN A, 1995, JAMA-J AM MED ASSOC, V273, P1781, DOI 10.1001/jama.273.22.1781; ISERSON KI, 1995, ETHICS EMERGENCY MED, P427; Iserson KV, 2001, ANN EMERG MED, V37, P220, DOI 10.1067/mem.2001.113560; JENCKS SF, 1994, JOINT COMM J QUAL IM, V20, P359; Jones RB, 1999, J MED ETHICS, V25, P379, DOI 10.1136/jme.25.5.379; KASSIRER JP, 2000, BOSTON GLOBE    0911, pA17; Knopp RK, 1999, EMERG MED CLIN N AM, V17, P385, DOI 10.1016/S0733-8627(05)70066-3; MANN FA, 1994, J TRAUMA, V36, P226, DOI 10.1097/00005373-199402000-00015; MARTIN H, 2002, LOS ANGELES TIM 0115, pA1; MASON MS, 2000, CHRISTIAN SCI M 0602; McArthur DL, 2001, WESTERN J MED, V175, P380, DOI 10.1136/ewjm.175.6.380; MEAD GE, 1995, J MED ETHICS, V21, P39, DOI 10.1136/jme.21.1.39; Mlinek EJ, 1997, ACAD EMERG MED, V4, P1142, DOI 10.1111/j.1553-2712.1997.tb03697.x; Moreno J, 1998, JAMA-J AM MED ASSOC, V280, P1951, DOI 10.1001/jama.280.22.1951; Moynihan R, 2000, NEW ENGL J MED, V342, P1645, DOI 10.1056/NEJM200006013422206; Nelkin D, 1996, LANCET, V347, P1600, DOI 10.1016/S0140-6736(96)91081-8; Nelkin D, 2001, PERSPECT BIOL MED, V44, P199, DOI 10.1353/pbm.2001.0032; NELKIN D, 1991, MILBANK Q, V69, P293, DOI 10.2307/3350206; PARSONS HM, 1974, SCIENCE, V183, P922, DOI 10.1126/science.183.4128.922; POMPLIO N, 2001, AM J REV         JUL, P14; PROSSER WL, 1960, CALIF LAW REV, V48, P383, DOI 10.2307/3478805; Protection of Human Subjects, 1996, FED REGISTER, V61, P51497; Rawls J, 1999, THEORY JUSTICE, VRev, P3; Rodriguez MA, 1998, WESTERN J MED, V169, P337; Rodriguez RM, 2001, ACAD EMERG MED, V8, P740, DOI 10.1111/j.1553-2712.2001.tb00195.x; Rogers G, 1999, INT J QUAL HEALTH C, V11, P251, DOI 10.1093/intqhc/11.3.251; *ROYAL SOC MED, 1985, PUBL UND SCI REP ROY; Santora TA, 1996, AM J EMERG MED, V14, P564, DOI 10.1016/S0735-6757(96)90100-X; SCHUMACHER WC, 2000, EMERGENCY PHYSIC DEC, P7; SHUCHMAN M, 1997, ANN INTERN MED, V126, P967; Simon RI, 1997, J FORENSIC SCI, V42, P884; SMITH MS, 1988, NEW ENGL J MED, V319, P1421, DOI 10.1056/NEJM198811243192119; Smithline HA, 1999, ACAD EMERG MED, V6, P776, DOI 10.1111/j.1553-2712.1999.tb01205.x; Snider DE, 1997, JAMA-J AM MED ASSOC, V278, P624, DOI 10.1001/jama.278.8.624; Turney J, 1996, LANCET, V347, P1087, DOI 10.1016/S0140-6736(96)90283-4; TUROW J, 1985, J COMMUN, V35, P36, DOI 10.1111/j.1460-2466.1985.tb02971.x; TUROW J, 1996, LANCET, V347, P1382; Warren Samuel D., 1890, HARVARD LAW REV, V4, P193, DOI DOI 10.2307/1321160; Weil TP, 2001, AM J MED QUAL, V16, P23, DOI 10.1177/106286060101600105; WEISS BD, 1982, JAMA-J AM MED ASSOC, V247, P2695, DOI 10.1001/jama.247.19.2695; WINSTEN JA, 1985, HLTH AFF MILLWOOD, V5, P5; Wolfe S, 1999, Clin Perform Qual Health Care, V7, P38; 2000, HLTH CARE PR MA 0914, P18; 2000, HLTH CARE PR MA 0914, P19	75	16	16	0	4	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 17	2002	288	3					373	379		10.1001/jama.288.3.373	http://dx.doi.org/10.1001/jama.288.3.373			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	573AK	12117405	Bronze			2023-01-03	WOS:000176807000032
J	Crawley, LM; Marshall, PA; Lo, B; Koenig, BA				Crawley, LM; Marshall, PA; Lo, B; Koenig, BA		End Life Care Consensus Panel	Strategies for culturally effective end-of-life care	ANNALS OF INTERNAL MEDICINE			English	Article							HEALTH-CARE; AFRICAN-AMERICANS; DECISION-MAKING; ETHNIC DISPARITIES; MEDICAL-RESEARCH; ATTITUDES; CANCER; BLACK; PERCEPTIONS; BEREAVEMENT	As a result of profound worldwide demographic change, physicians will increasingly care for patients from cultural backgrounds other than their own. Differences in beliefs, values, and traditional health care practices are of particular relevance at the end of life. Health care providers and patients and families may not have shared understandings of the meaning of illness or death and may not agree on the best strategies to plan for the end of life or to alleviate pain and suffering. Good end-of-life care may be complicated by disagreements between physicians and patients, difficult interactions, or decisions the physician does not understand. Challenges may result from cultural differences between the patient's background and traditional medical practice. Values so ingrained in physicians as to be unquestioned may be alien to patients from different backgrounds. Physicians need to be sensitive to cultural differences and to develop the skills necessary to work with patients from diverse backgrounds. Community and cultural ties provide a source of great comfort as patients and families prepare for death. This paper describes two cases that raise issues about cross-cultural end-of-life practice and suggests strategies for negotiating common problems. Physicians should assess the cultural background of each patient and inquire about values that may affect care at the end of life. They should become aware of the specific beliefs and practices of the populations they serve, always remembering to inquire whether an individual patient adheres to these cultural beliefs. Attention to cultural difference enables the physician to provide comprehensive and compassionate palliative care at the end of life.	Amer Coll Physicians, Amer Soc Internal Med, Philadelphia, PA 19106 USA	American College of Physicians	Crawley, LM (corresponding author), Amer Coll Physicians, Amer Soc Internal Med, 190 N Independence Mall W, Philadelphia, PA 19106 USA.				NINR NIH HHS [R01 NR029060] Funding Source: Medline	NINR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Nursing Research (NINR))		Bach PB, 1999, NEW ENGL J MED, V341, P1198, DOI 10.1056/NEJM199910143411606; BARKER JC, 1992, WESTERN J MED, V157, P248; Bates MS, 1997, SOC SCI MED, V45, P1433, DOI 10.1016/S0277-9536(97)00068-3; Blackhall LJ, 1999, SOC SCI MED, V48, P1779, DOI 10.1016/S0277-9536(99)00077-5; BLACKHALL LJ, 1995, JAMA-J AM MED ASSOC, V274, P820, DOI 10.1001/jama.274.10.820; Buckman R., 1992, BREAK BAD NEWS GUIDE; Carrillo JE, 1999, ANN INTERN MED, V130, P829, DOI 10.7326/0003-4819-130-10-199905180-00017; Cleeland CS, 1997, ANN INTERN MED, V127, P813, DOI 10.7326/0003-4819-127-9-199711010-00006; Corbie-Smith G, 1999, AM J MED SCI, V317, P5, DOI 10.1097/00000441-199901000-00002; Corbie-Smith G, 1999, J GEN INTERN MED, V14, P537, DOI 10.1046/j.1525-1497.1999.07048.x; Crawley L, 2000, JAMA-J AM MED ASSOC, V284, P2518, DOI 10.1001/jama.284.19.2518; CRAWLEY LM, 2000, HLTH PUBLIC ENSURING, V2, P17; *CROSS CULT HLTH C, 2001, PROF ETHN COMM; Culhane-Pera K A, 1997, Fam Med, V29, P719; Doescher MP, 2000, ARCH FAM MED, V9, P1156, DOI 10.1001/archfami.9.10.1156; Donald Irish, 1993, ETHNIC VARIATIONS DY; Dovidio JF, 1997, J EXP SOC PSYCHOL, V33, P510, DOI 10.1006/jesp.1997.1331; DULA A, 1994, CLIN GERIATR MED, V10, P419, DOI 10.1016/S0749-0690(18)30330-6; EISENBRUCH M, 1984, CULT MED PSYCHIAT, V8, P315, DOI 10.1007/BF00114661; EISENBRUCH M, 1984, CULT MED PSYCHIAT, V8, P283, DOI 10.1007/BF00055172; Engle VF, 1998, J AM GERIATR SOC, V46, P1091, DOI 10.1111/j.1532-5415.1998.tb06646.x; Fiscella K, 2000, JAMA-J AM MED ASSOC, V283, P2579, DOI 10.1001/jama.283.19.2579; FORTIER J, 2002, ASSURING CULTURAL CO; Freeman HP, 2000, NEW ENGL J MED, V342, P1045, DOI 10.1056/NEJM200004063421411; GAMBLE VN, 1993, AM J PREV MED, V9, P35, DOI 10.1016/S0749-3797(18)30664-0; Gamble VN, 1997, AM J PUBLIC HEALTH, V87, P1773, DOI 10.2105/AJPH.87.11.1773; GEISSLER EM, 1998, POCKET GUIDE CULTURA; Green B. Lee, 2000, Ethnicity and Disease, V10, P76; HAHN RA, 1982, CULT MED PSYCHIAT, V6, P215, DOI 10.1007/BF00114191; Hannan EL, 1999, MED CARE, V37, P68, DOI 10.1097/00005650-199901000-00010; Hern HE, 1998, CAMB Q HEALTHC ETHIC, V7, P27, DOI 10.1017/S0963180198701045; Hunt LM, 1998, MED ANTHROPOL Q, V12, P298, DOI 10.1525/maq.1998.12.3.298; KAHN KL, 1994, JAMA-J AM MED ASSOC, V271, P1169, DOI 10.1001/jama.271.15.1169; KAUFERT JM, 1990, SANTE CULTURE HLTH, V7, P209; KLEINMAN A, 1978, ANN INTERN MED, V88, P251, DOI 10.7326/0003-4819-88-2-251; Kleinman Arthur, 1995, WRITING MARGIN DISCO; KOENIG BA, 1995, WESTERN J MED, V163, P244; LaVeist TA, 2000, MED CARE RES REV, V57, P146, DOI 10.1177/107755800773743637; Lipson JG, 1996, CULTURE NURSING CARE; Lo B, 1999, ANN INTERN MED, V130, P744, DOI 10.7326/0003-4819-130-9-199905040-00015; Lock M., 1993, HLTH CULTURES EXPLOR, P139; Marshall P. A., 1998, HDB IMMIGRANT HLTH, P203, DOI DOI 10.1007/978-1-4899-1936-6_; MARSHALL PA, 1998, HLTH CARE ETHICS CRI, P421; Mayberry RM, 2000, MED CARE RES REV, V57, P108, DOI 10.1177/107755800773743628; McKinley ED, 1996, J GEN INTERN MED, V11, P651, DOI 10.1007/BF02600155; Mebane EW, 1999, J AM GERIATR SOC, V47, P579, DOI 10.1111/j.1532-5415.1999.tb02573.x; Morrison RS, 2000, NEW ENGL J MED, V342, P1023, DOI 10.1056/NEJM200004063421406; Murphy ST, 1996, J LAW MED ETHICS, V24, P108, DOI 10.1111/j.1748-720X.1996.tb01843.x; Natl. Comm. Prot. Hum. Subj. Biomed. Behav. Res, 1978, BELM REP ETH PRINC G; Neubauer B J, 1990, Hosp J, V6, P37; Orr R D, 1995, Arch Fam Med, V4, P159; Pan RJ, 1999, PEDIATRICS, V103, P167; Peterson ED, 1997, NEW ENGL J MED, V336, P480, DOI 10.1056/NEJM199702133360706; POULSON J, 1998, PALLIATIVE MED CASE, P244; RUBIN SM, 1994, JAMA-J AM MED ASSOC, V271, P209, DOI 10.1001/jama.271.3.209; Shavers-Hornaday V L, 1997, Ethn Health, V2, P31; Suchman AL, 1997, JAMA-J AM MED ASSOC, V277, P678, DOI 10.1001/jama.277.8.678; Tervalon M, 1998, J HEALTH CARE POOR U, V9, P117; TODD KH, 1993, JAMA-J AM MED ASSOC, V269, P1537, DOI 10.1001/jama.269.12.1537; TRIANDIS HC, 1984, J PERS SOC PSYCHOL, V47, P1363, DOI 10.1037/0022-3514.47.6.1363; van Ryn M, 2000, SOC SCI MED, V50, P813, DOI 10.1016/S0277-9536(99)00338-X; WELCH M, 1997, BEHAV MED PRIMARY CA, P97; Zweifler J, 1998, ACAD MED, V73, P1056, DOI 10.1097/00001888-199810000-00012	63	141	142	1	19	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAY 7	2002	136	9					673	679		10.7326/0003-4819-136-9-200205070-00010	http://dx.doi.org/10.7326/0003-4819-136-9-200205070-00010			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	547XK	11992303				2023-01-03	WOS:000175357900005
J	Hui, JYH; Woo, PCY; Lo, SS; Chan, JCS				Hui, JYH; Woo, PCY; Lo, SS; Chan, JCS			Over-the-counter medication and its effects	LANCET			English	Article									Univ Hong Kong, Queen Mary Hosp, Dept Microbiol, Hong Kong, Hong Kong, Peoples R China; United Christian Hosp, Dept Diagnost Radiol & Organ Imaging, Hong Kong, Hong Kong, Peoples R China	University of Hong Kong; United Christian Hospital	Woo, PCY (corresponding author), Univ Hong Kong, Queen Mary Hosp, Dept Microbiol, Univ Pathol Bldg, Hong Kong, Hong Kong, Peoples R China.		Woo, Patrick Chiu Yat/C-4449-2009	Woo, Patrick Chiu Yat/0000-0001-9401-1832				Duan HQ, 1999, J NAT PROD, V62, P1522, DOI 10.1021/np9902183; Ferraz MB, 1996, SOC SCI MED, V42, P1129, DOI 10.1016/0277-9536(95)00393-2; KIMMERLE R, 1985, AM J MED, V79, P535, DOI 10.1016/0002-9343(85)90046-4; ODRISCOLL J, 1992, BRIT J DERMATOL, V127, P543, DOI 10.1111/j.1365-2133.1992.tb14859.x; SHUSTER S, 1985, BRIT MED J, V291, P38, DOI 10.1136/bmj.291.6487.38	5	7	7	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAR 30	2002	359	9312					1120	1120		10.1016/S0140-6736(02)08157-6	http://dx.doi.org/10.1016/S0140-6736(02)08157-6			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	536YJ	11943261				2023-01-03	WOS:000174729200012
J	Goldman, P				Goldman, P			Herbal medicines today and the roots of modern pharmacology	ANNALS OF INTERNAL MEDICINE			English	Article							PROPHYLACTIC TREATMENT; EPIDEMIOLOGIC RESEARCH; UNITED-STATES; EFFICACY; MIGRAINE; FEVERFEW; HYPERFORIN; DIGOXIN; SAFETY	The transformation of digitalis from a folk medicine, foxglove, to a modem drug, digoxin, illustrates principles of modern pharmacology that have helped make drugs safer and more effective. Digitalis was improved because its preparation was standardized, first by bioassay and then by chemical methods; however, few of today's herbs are standardized by methods that can ensure a consistent product and, hence, consistent safety and efficacy profiles. Many herbs have been evaluated in randomized, controlled trials, and several-St. John's wort and ginkgo, for example-are apparently effective. Yet, many trials of herbs have limited value because of poor design, small samples, and, above all, use of products of uncertain composition and consistency. The uncertain composition of many herbal products raises questions about their safety as does evidence indicating that herbs may have harmful interactions with prescription drugs. Such adverse effects of herbs are probably underreported. Meanwhile, systematic studies, such as those identifying adverse reactions to drugs, are hindered because herbal preparations are not standardized-one: brand of St. John's wort, for example, will differ chemically from another-and, unlike for prescription drugs, there are no databases linking herb consumption to later medical problems. Since herbal medicines are regulated as dietary supplements, they are not subject to the premarketing regulatory clearance required for drugs. The burden of proof, is on the U.S. Food and Drug Administration to show a dietary supplement is unsafe, unlike for drugs, which cannot be approved until the manufacturer has demonstrated safety and effectiveness.	Beth Israel Deaconess Med Ctr, Ctr Alternat Med Res & Educ, Boston, MA 02215 USA; Harvard Univ, Sch Med, Harvard Sch Publ Hlth, Boston, MA 02115 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School; Harvard T.H. Chan School of Public Health	Goldman, P (corresponding author), Beth Israel Deaconess Med Ctr, Ctr Alternat Med Res & Educ, 330 Brookline Ave, Boston, MA 02215 USA.				NATIONAL CENTER FOR COMPLEMENTARY &ALTERNATIVE MEDICINE [R01AT000607] Funding Source: NIH RePORTER; NCCIH NIH HHS [1 RO1 AT00607-01] Funding Source: Medline	NATIONAL CENTER FOR COMPLEMENTARY &ALTERNATIVE MEDICINE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Complementary & Alternative Medicine); NCCIH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Complementary & Alternative Medicine)		Ackermann RT, 2001, ARCH INTERN MED, V161, P813, DOI 10.1001/archinte.161.6.813; Awang D. V. C., 1998, Journal of Herbs, Spices & Medicinal Plants, V5, P95, DOI 10.1300/J044v05n04_11; BEAN WB, 1968, SIR W OSLER APHORISM, P105; Berthold HK, 1998, JAMA-J AM MED ASSOC, V279, P1900, DOI 10.1001/jama.279.23.1900; Blumenthal M, 2000, HERBAL MED EXPANDED; Capasso L, 1998, LANCET, V352, P1864, DOI 10.1016/S0140-6736(05)79939-6; Chatterjee SS, 1998, LIFE SCI, V63, P499, DOI 10.1016/S0024-3205(98)00299-9; Committee on Toxicology, 1997, REP COMM SECR GEN, P1; De Smet P. A. G. M., 1993, ADVERSE EFFECTS HERB, VII; De Smet P. A. G. M., 1992, ADVERSE EFFECTS HERB, VI; DeFeudis FV, 1998, GINKGO BILOBA EXTRAC, P7; DeSmet P., 1997, ADVERSE EFFECTS HERB, V3, P99; DESMET PAG, 1999, ESSENTIALS COMPLEMEN, P108; DeWeerdt CJ, 1996, PHYTOMEDICINE, V3, P225, DOI 10.1016/S0944-7113(96)80057-2; Edmunds CW, 1907, J AMER MED ASSOC, V48, P1744; Eisenberg DM, 1998, JAMA-J AM MED ASSOC, V280, P1569, DOI 10.1001/jama.280.18.1569; Ernst E, 1999, LANCET, V354, P2014, DOI 10.1016/S0140-6736(99)00418-3; Foster DF, 2000, J AM GERIATR SOC, V48, P1560, DOI 10.1111/j.1532-5415.2000.tb03864.x; Gold H, 1941, J PHARMACOL EXP THER, V73, P212; GOLDMAN P, 1981, NEW ENGL J MED, V304, P983; HAMILTON M, 1960, J NEUROL NEUROSUR PS, V23, P56, DOI 10.1136/jnnp.23.1.56; ISRAELSEN LD, 1998, Q REV NATURAL MED, P251; Jick H, 1998, LANCET, V352, P1767, DOI 10.1016/S0140-6736(98)04350-5; Johne A, 1999, CLIN PHARMACOL THER, V66, P338, DOI 10.1053/cp.1999.v66.a101944; Kessler DA, 2000, NEW ENGL J MED, V342, P1742, DOI 10.1056/NEJM200006083422309; Ko RJ, 1998, NEW ENGL J MED, V339, P847, DOI 10.1056/NEJM199809173391214; Laakmann G, 1998, PHYTOMEDICINE, V5, P435, DOI 10.1016/S0944-7113(98)80039-1; Lawson LD, 1998, JAMA-J AM MED ASSOC, V280, P1568, DOI 10.1001/jama.280.18.1568; Linde K., 2000, STJOHNS WORT DEPRESS; LINDENBAUM J, 1971, NEW ENGL J MED, V285, P1344, DOI 10.1056/NEJM197112092852403; Love L, 1998, J TOXICOL-CLIN TOXIC, V36, P263, DOI 10.3109/15563659809028953; Matthews HB, 1999, ENVIRON HEALTH PERSP, V107, P773, DOI 10.2307/3454572; Nortier JL, 2000, NEW ENGL J MED, V342, P1686, DOI 10.1056/NEJM200006083422301; Okada M, 1999, LANCET, V354, P1732, DOI 10.1016/S0140-6736(05)76721-0; Oken BS, 1998, ARCH NEUROL-CHICAGO, V55, P1409, DOI 10.1001/archneur.55.11.1409; Palevitch D, 1997, PHYTOTHER RES, V11, P508, DOI 10.1002/(SICI)1099-1573(199711)11:7<508::AID-PTR153>3.3.CO;2-8; Perry G, 1997, NEW ENGL J MED, V336, P525; Piscitelli SC, 2000, LANCET, V355, P547, DOI 10.1016/S0140-6736(99)05712-8; Rodriguez LAG, 1997, PHARMACOTHERAPY, V17, P721; Ruschitzka F, 2000, LANCET, V355, P548, DOI 10.1016/S0140-6736(99)05467-7; SCHWARZ A. JOHN, 1934, AMER JOUR PHARM, V106, P196; Slifman NR, 1998, NEW ENGL J MED, V339, P806, DOI 10.1056/NEJM199809173391204; SRINIVASAN VS, 1998, PHARMACOPEIAL FORUM, V24, P6623; Stevinson C, 2000, ANN INTERN MED, V133, P420, DOI 10.7326/0003-4819-133-6-200009190-00009; Temin P., 1980, TAKING YOUR MED DRUG; Vogler BK, 1998, CEPHALALGIA, V18, P704, DOI 10.1046/j.1468-2982.1998.1810704.x; WALLER PC, 1985, BRIT MED J, V291, P1128, DOI 10.1136/bmj.291.6502.1128; WITHERING W, 1785, ACCOUNT FOXGLOVE SOM, P2; Yue QY, 2000, LANCET, V355, P576, DOI 10.1016/S0140-6736(05)73227-X; 1906, JAMA, V46, P1027; 1995, CONSUMER REPORTS, V60, P698	51	133	139	0	24	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	OCT 16	2001	135	8	1				594	600		10.7326/0003-4819-135-8_Part_1-200110160-00010	http://dx.doi.org/10.7326/0003-4819-135-8_Part_1-200110160-00010			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	481VY	11601931				2023-01-03	WOS:000171542200005
J	Wenger, NS; Rosenfeld, K				Wenger, NS; Rosenfeld, K			Quality indicators for end-of-life care in vulnerable elders	ANNALS OF INTERNAL MEDICINE			English	Article							NURSING-HOME RESIDENTS; ADVANCE DIRECTIVES; RESUSCITATION PREFERENCES; SUSTAINING TREATMENT; DYING PATIENTS; ILL; PHYSICIANS; DISCUSSIONS; MANAGEMENT; INSIGHTS		Univ Calif Los Angeles, Dept Med, Div Gen Internal Med, Los Angeles, CA 90095 USA; Vet Affairs Greater Los Angeles Health Care Syst, Los Angeles, CA USA	University of California System; University of California Los Angeles; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Greater Los Angeles Healthcare System	Wenger, NS (corresponding author), Univ Calif Los Angeles, Dept Med, Div Gen Internal Med, 911 Broxton Plaza, Los Angeles, CA 90095 USA.	nwenger@mednet.ucla.edu						ADAMOWSKI K, 1994, CAN MED ASSOC J, V150, P326; *AM MED ASS, 1991, COD MED ETH REP AMA; [Anonymous], 1992, ANN INTERN MED, V117, P947; APPELBAUM PS, 1988, NEW ENGL J MED, V319, P1635, DOI 10.1056/NEJM198812223192504; *APS, 1997, APS B, V7, P1; BLACKHALL LJ, 1989, J GEN INTERN MED, V4, P399, DOI 10.1007/BF02599689; BLANCHARD CG, 1988, SOC SCI MED, V27, P1139, DOI 10.1016/0277-9536(88)90343-7; Brody H, 1997, NEW ENGL J MED, V336, P652, DOI 10.1056/NEJM199702273360910; CAMPBELL ML, 1998, AACN CRITICAL CARE P, P61; Canadian Palliative Care Association, 1995, PALL CAR CONS STAND; DANIS M, 1991, NEW ENGL J MED, V324, P882, DOI 10.1056/NEJM199103283241304; DENNIS C, 1998, VACCOS COMMISSION QU; DRANE JF, 1984, JAMA-J AM MED ASSOC, V252, P925, DOI 10.1001/jama.252.7.925; Ehman JW, 1999, ARCH INTERN MED, V159, P1803, DOI 10.1001/archinte.159.15.1803; Emanuel EJ, 1998, LANCET, V351, P21, DOI 10.1016/S0140-6736(98)90329-4; Faber-Langendoen K, 2000, ANN INTERN MED, V133, P886, DOI 10.7326/0003-4819-133-11-200012050-00013; FABERLANGENDOEN K, 1994, CHEST, V106, P880, DOI 10.1378/chest.106.3.880; Field MJ, 1997, APPROACHING DEATH IM; Fischer GS, 1998, J GEN INTERN MED, V13, P447, DOI 10.1046/j.1525-1497.1998.00133.x; Fox E, 1999, JAMA-J AM MED ASSOC, V282, P1638, DOI 10.1001/jama.282.17.1638; GERETY MB, 1993, J AM GERIATR SOC, V41, P953, DOI 10.1111/j.1532-5415.1993.tb06761.x; Goodman MD, 1998, CRIT CARE MED, V26, P701, DOI 10.1097/00003246-199804000-00018; Gregory J J, 1995, N J Med, V92, P438; Hammes BJ, 1998, ARCH INTERN MED, V158, P383, DOI 10.1001/archinte.158.4.383; Hanson LC, 1997, ANN INTERN MED, V126, P381, DOI 10.7326/0003-4819-126-5-199703010-00007; *HAST CTR, 1987, GUID TERM LIF SUST T; Hofmann JC, 1997, ANN INTERN MED, V127, P1, DOI 10.7326/0003-4819-127-1-199707010-00001; KEAY TJ, 1994, J AM GERIATR SOC, V42, P853, DOI 10.1111/j.1532-5415.1994.tb06557.x; KNAUS WA, 1995, JAMA-J AM MED ASSOC, V274, P1591, DOI 10.1001/jama.1995.03530200027032; LANKEN PN, 1991, AM REV RESPIR DIS, V144, P726, DOI 10.1164/ajrccm/144.3_Pt_1.726; Levin JR, 1999, J AM GERIATR SOC, V47, P82, DOI 10.1111/j.1532-5415.1999.tb01905.x; LO B, 1986, ARCH INTERN MED, V146, P1613, DOI 10.1001/archinte.146.8.1613; LUCHINS DJ, 1993, J AM GERIATR SOC, V41, P25; Lynn J, 1997, ANN INTERN MED, V126, P97, DOI 10.7326/0003-4819-126-2-199701150-00001; Martin DK, 1999, ARCH INTERN MED, V159, P86, DOI 10.1001/archinte.159.1.86; MORRISON RS, 1995, JAMA-J AM MED ASSOC, V274, P478, DOI 10.1001/jama.274.6.478; MOWER WR, 1993, ARCH INTERN MED, V153, P375, DOI 10.1001/archinte.153.3.375; PEARLMAN RA, 1993, J CLIN ETHIC, V4, P33; ROBINSON L, 1994, BRIT J GEN PRACT, V44, P461; SCHNEIDERMAN L, 1995, WRONG MED; SCHNEIDERMAN LJ, 1992, ANN INTERN MED, V117, P599, DOI 10.7326/0003-4819-117-7-599; SECKLER AB, 1991, ANN INTERN MED, V115, P92, DOI 10.7326/0003-4819-115-2-92; Shekelle PG, 2001, ANN INTERN MED, V135, P647, DOI 10.7326/0003-4819-135-8_Part_2-200110161-00003; Singer PA, 1999, JAMA-J AM MED ASSOC, V281, P163, DOI 10.1001/jama.281.2.163; Steinhauser KE, 2000, ANN INTERN MED, V132, P825, DOI 10.7326/0003-4819-132-10-200005160-00011; Sulmasy DP, 1996, J MED ETHICS, V22, P344, DOI 10.1136/jme.22.6.344; SULMASY DP, 1992, JAMA-J AM MED ASSOC, V267, P682; SWARTZ RD, 1993, J AM SOC NEPHROL, V3, P1623; Taylor RM, 1996, NEUROLOGY, V46, P870; TENO JM, 1995, J GEN INTERN MED, V10, P179, DOI 10.1007/BF02600252; TENO JM, 1994, HASTINGS CENT REP, V24, pS32, DOI 10.2307/3563482; Tolle SW, 2000, WESTERN J MED, V172, P374, DOI 10.1136/ewjm.172.6.374; *U CAL, 1998, TERM WEAN MECH VENT; UHLMANN RF, 1989, WESTERN J MED, V150, P705; VIRMANI J, 1994, ARCH INTERN MED, V154, P909, DOI 10.1001/archinte.154.8.909; Wenger N. S., 1997, JGIM, V12, P105; Wenger N. S., 1994, Journal of the American Geriatrics Society, V42, pSA67; Wenger NS, 2000, J AM GERIATR SOC, V48, pS44, DOI 10.1111/j.1532-5415.2000.tb03140.x; Wenger NS, 1996, J CLIN ETHIC, V7, P48; Wenger NS, 2001, JAMA-J AM MED ASSOC, V285, P2880, DOI 10.1001/jama.285.22.2880; 1983, PRESIDENTS COMM STUD; 1996, JAMA, V274, P474; 1995, J AM GERIATR SOC, V43, P577	64	54	54	0	10	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	OCT 16	2001	135	8	2				677	685		10.7326/0003-4819-135-8_Part_2-200110161-00006	http://dx.doi.org/10.7326/0003-4819-135-8_Part_2-200110161-00006			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	481WA	11601950				2023-01-03	WOS:000171542400006
J	Glazener, CMA; Herbison, GP; Wilson, PD; MacArthur, C; Lang, GD; Gee, H; Grant, AM				Glazener, CMA; Herbison, GP; Wilson, PD; MacArthur, C; Lang, GD; Gee, H; Grant, AM			Conservative management of persistent postnatal urinary and faecal incontinence: randomised controlled trial	BRITISH MEDICAL JOURNAL			English	Article							PREVALENCE; DELIVERY	Objectives To assess the effect of nurse assessment with reinforcement of pelvic floor muscle training exercises and bladder training compared with standard management among women with persistent incontinence three months postnatally. Design Randomised controlled trial with nine months' follow up. Setting Community intervention in three centres (Dunedin, New Zealand; Birmingham; Aberdeen). Participants 747 women with urinary incontinence three months postnatally, allocated at random to intervention (371) or control (376) groups. Intervention Assessment by nurses of urinary incontinence with conservative advice on pelvic floor exercises at five, seven, and nine months after delivery supplemented with bladder training if appropriate at seven and nine months. Main outcome measures Primary: persistence and severity of urinary incontinence 12 months after delivery. Secondary: performance of pelvic floor exercises, change in coexisting faecal incontinence, wellbeing, anxiety, and depression. Results Women in the intervention group had significantly less urinary incontinence: 167/279 (59.9%) v 169/245 (69.0%), difference 9.1% (95% confidence interval 1.0% to 17.3%, P = 0.037) for any incontinence and 55/279 (19.7%) v 78/245 (31.8%), difference 12.1% (4.7% to 19.6%, P = 0.002) for severe incontinence. Faecal incontinence was also less common: 12/273 (4.4%) v 25/237 (10.5%), difference 6.1% (1.6% to 10.8%, P = 0.012). At 12 months women in the intervention group were more likely to be performing pelvic floor exercises (218/278 (79%) v 118/244 (48% P < 0.001). Conclusions A third of women may have some urinary incontinence three months after childbirth. Conservative management provided by nurses seems to reduce the likelihood of urinary and coexisting faecal incontinence persisting 12 months postpartum. Further trials for faecal incontinence are needed.	Univ Wurzburg, Dept Neurol, D-97080 Wurzburg, Germany; Cranley Clin Dermatol, London W1M 9AD, England; Univ Aberdeen, Hlth Serv Res Unit, Aberdeen AB25 2ZD, Scotland; Univ Otago, Dunedin Sch Med, Dept Prevent & Social Med, Dunedin, New Zealand; Univ Otago, Dunedin Sch Med, Dept Womens & Childrens Hlth, Dunedin, New Zealand; Univ Birmingham, Dept Epidemiol & Publ Hlth, Birmingham B15 2TT, W Midlands, England	University of Wurzburg; University of Aberdeen; University of Otago; University of Otago; University of Birmingham	Glazener, CMA (corresponding author), Univ Wurzburg, Dept Neurol, Josef Schneider Str 11, D-97080 Wurzburg, Germany.		MacArthur, Christine/ABA-8601-2021	MacArthur, Christine/0000-0003-0434-2158	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Berghmans LCM, 1998, BRIT J UROL, V82, P181; CARTWRIGHT A, 1986, J EPIDEMIOL COMMUN H, V40, P267, DOI 10.1136/jech.40.3.267; HAYSMITH EJC, 2001, COCHRANE DATABASE SY; HOSKER G, 2000, COCHRANE DATABASE SY; Jozwik M, 1998, BRIT J OBSTET GYNAEC, V105, P1046, DOI 10.1111/j.1471-0528.1998.tb09934.x; MacArthur C, 1997, BRIT J OBSTET GYNAEC, V104, P46, DOI 10.1111/j.1471-0528.1997.tb10648.x; MACARTHUR C, 1991, HLTH CHILDBIRTH; MACARTHUR C, 1993, BR J MIDWIFERY, V1, P207; Mason L, 2001, MIDWIFERY, V17, P55, DOI 10.1054/midw.2000.0235; MILLARD RJ, 1968, BLADDER CONTROL SIMP; MILLARD RJ, 1987, BLADDER CONTROL SIMP; NORTON C, 2000, COCHRANE DATABASE SY; OBRIEN J, 1991, BRIT MED J, V303, P1308, DOI 10.1136/bmj.303.6813.1308; Sleep J, 1987, Midwifery, V3, P158, DOI 10.1016/S0266-6138(87)80035-9; SNOOKS SJ, 1985, BRIT J UROL, V57, P422, DOI 10.1111/j.1464-410X.1985.tb06302.x; SULTAN AH, 1993, NEW ENGL J MED, V329, P1905, DOI 10.1056/NEJM199312233292601; Wilson P D, 1998, Int Urogynecol J Pelvic Floor Dysfunct, V9, P257, DOI 10.1007/BF01901501; Wilson PD, 1996, BRIT J OBSTET GYNAEC, V103, P154, DOI 10.1111/j.1471-0528.1996.tb09668.x; ZIGMOND AS, 1983, ACTA PSYCHIAT SCAND, V67, P361, DOI 10.1111/j.1600-0447.1983.tb09716.x	19	90	92	3	15	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	SEP 15	2001	323	7313					593	596		10.1136/bmj.323.7313.593	http://dx.doi.org/10.1136/bmj.323.7313.593			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	474CT	11557703	Green Published, Bronze			2023-01-03	WOS:000171087300014
J	Scheidtmann, K; Fries, W; Muller, F; Koenig, E				Scheidtmann, K; Fries, W; Muller, F; Koenig, E			Effect of levodopa in combination with physiotherapy on functional motor recovery after stroke: a prospective, randomised, double-blind study	LANCET			English	Article							SENSORIMOTOR CORTEX ABLATION; AMPHETAMINE; REHABILITATION; THERAPY; RATS; FLUOXETINE; PLASTICITY; DEPRESSION	Background Functional disability is generally caused by hemiplegia after stroke. Physiotherapy used to be the only way of improving motor function in such patients. However, administration of amphetamines in addition to exercise improves motor recovery in animals, probably by increasing the concentration of norepinephrine in the central nervous system. Our aim was to ascertain whether levodopa could enhance the efficacy of physiotherapy after hemiplegia. Methods We did a prospective, randomised, placebo-controlled, double-blind study in which we enrolled 53 primary stroke patients. For the first 3 weeks patients received single doses of levodopa 100 mg or placebo daily in combination with physiotherapy. For the second 3 weeks patients had only physiotherapy. We quantitatively assessed motor function every week with Rivermead motor assessment (IRMA). Findings Six patients were excluded from analyses because of non-neurological complications. Motor recovery was significantly improved after 3 weeks of drug intervention in those on levodopa (RMA improved by 6.4 points) compared with placebo (4.1), and the result was independent of initial degree of impairment (p<0.004). The advantage of the levodopa group was maintained at study endpoint 3 weeks after levodopa was stopped. At the end of the study the total RMA score gain for the levodopa group was 8.2 points compared with 5.7 in the placebo group (p=0.020). Interpretation A single dose of levodopa is well tolerated and, when given in combination with physiotherapy, enhances motor recovery in patients with hemiplegia. In view of its minimal side-effects, levodopa will be a possible add-on during stroke rehabilitation.	Neurol Clin, D-83043 Bad Aibling, Germany; Praxis Neurol Neuropsychol Rehabil, Munich, Germany		Scheidtmann, K (corresponding author), Neurol Clin, D-83043 Bad Aibling, Germany.							BJELKE B, 1993, NEUR ABST, V19, P1653; BOYESON MG, 1990, PHARMACOL BIOCHEM BE, V35, P497, DOI 10.1016/0091-3057(90)90279-Q; BUTEFISCH C, 1995, J NEUROL SCI, V130, P59, DOI 10.1016/0022-510X(95)00003-K; CRISOSTOMO EA, 1988, ANN NEUROL, V23, P94, DOI 10.1002/ana.410230117; Dam M, 1996, STROKE, V27, P1211, DOI 10.1161/01.STR.27.7.1211; Duncan P W, 1997, Top Stroke Rehabil, V3, P1, DOI 10.1080/10749357.1997.11754126; FEENEY DM, 1998, CEREBROVASCULAR DIS; GOLD PE, 1984, BRAIN RES, V305, P103, DOI 10.1016/0006-8993(84)91124-7; Grade C, 1998, ARCH PHYS MED REHAB, V79, P1047, DOI 10.1016/S0003-9993(98)90169-1; HOVDA DA, 1984, BRAIN RES, V298, P358, DOI 10.1016/0006-8993(84)91437-9; Johansson BB, 2000, STROKE, V31, P223, DOI 10.1161/01.STR.31.1.223; KASAMATSU T, 1991, PROG BRAIN RES, V88, P599; Kikuchi K, 2000, BRAIN RES, V860, P130, DOI 10.1016/S0006-8993(00)02034-5; Liepert J, 1999, CURR OPIN NEUROL, V12, P709, DOI 10.1097/00019052-199912000-00009; Lincoln N, 1979, Physiotherapy, V65, P48; Majsak MJ, 1996, TOP STROKE REHABIL, V3, P27; Miyai I, 2000, NEUROREHAB NEURAL RE, V14, P141, DOI 10.1177/154596830001400207; NUTT JG, 1984, CLIN NEUROPHARMACOL, V7, P35; Queen SA, 1997, BRAIN RES, V777, P42, DOI 10.1016/S0006-8993(97)00717-8; Robbins TW, 2000, EXP BRAIN RES, V133, P130, DOI 10.1007/s002210000407; Robinson RG, 2000, AM J PSYCHIAT, V157, P351, DOI 10.1176/appi.ajp.157.3.351; SCHEIDTMANN K, 2000, AKTUELLE NEUROLOGIE, V27, P227; Schultz W, 2000, ANNU REV NEUROSCI, V23, P473, DOI 10.1146/annurev.neuro.23.1.473; Stroemer RP, 1998, STROKE, V29, P2381, DOI 10.1161/01.STR.29.11.2381; Sutton RL, 2000, NEURAL PLAST, V7, P109, DOI 10.1155/NP.2000.109; SUTTON RL, 1992, RESTOR NEUROL NEUROS, V4, P1, DOI 10.3233/RNN-1992-4101; WalkerBatson D, 1996, BRAIN LANG, V55, P27; WALKERBATSON D, 1995, STROKE, V26, P2254, DOI 10.1161/01.STR.26.12.2254; WEINER N, 1980, PHARMACOL BASIS THER, P138	29	291	310	2	23	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	SEP 8	2001	358	9284					787	790		10.1016/S0140-6736(01)05966-9	http://dx.doi.org/10.1016/S0140-6736(01)05966-9			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	472NA	11564483				2023-01-03	WOS:000170989300009
J	Eisenberg, DM; Kessler, RC; Van Rompay, MI; Kaptchuk, TJ; Wilkey, SA; Appel, S; Davis, RB				Eisenberg, DM; Kessler, RC; Van Rompay, MI; Kaptchuk, TJ; Wilkey, SA; Appel, S; Davis, RB			Perceptions about complementary therapies relative to conventional therapies among adults who use both: Results from a national survey	ANNALS OF INTERNAL MEDICINE			English	Article							ALTERNATIVE MEDICINE; HEALTH-CARE; UNCONVENTIONAL MEDICINE; UNITED-STATES; RHEUMATOLOGISTS; PREVALENCE; PHYSICIANS; CHOICE	Background: Little is known about perceptions of complementary and alternative medical (CAM) therapy relative to conventional therapy among patients who use both. Objective: To document perceptions about CAM therapies among persons who use CAM and conventional therapies. Design: Nationally representative, random-household telephone survey. Setting: The 48 contiguous U.S. states. Participants: 831 adults who saw a medical doctor and used CAM therapies in 1997. Measurements: Perceptions about helpfulness and patterns of CAM therapy use relative to conventional therapy use and reasons for nondisclosure of CAM therapies. Results: Of 831 respondents who saw a medical doctor and used CAM therapies in the previous 12 months, 79% perceived the combination to be superior to either one alone. Of 411 respondents who reported seeing both a medical doctor and a CAM provider, 70% typically saw a medical doctor before or concurrent with their visits to a CAM provider; 15% typically saw a CAM provider before seeing a medical doctor. Perceived confidence in CAM providers was not substantially different from confidence in medical doctors. Among the 831 respondents who in the past year had used a CAM therapy and seen a medical doctor, 63% to 72% did not disclose at least one type of CAM therapy to the medical doctor. Among 507 respondents who reported their reasons for nondisclosure of use of 726 alternative therapies, common reasons for nondisclosure were "It wasn't important for the doctor to know" (61%), "The doctor never asked" (60%), "It was none of the doctor's business" (31%), and "The doctor would not understand" (20%). Fewer respondents (14%) thought their doctor would disapprove of or discourage CAM use, and 2% thought their doctor might not continue as their provider. Respondents judged CAM therapies to be more helpful than conventional care for the treatment of headache and neck and back conditions but considered conventional care to be more helpful than CAM therapy for treatment of hypertension. Conclusions: National survey data do not support the view that use of CAM therapy in the United States primarily reflects dissatisfaction with conventional care. Adults who use both appear to value both and tend to be less concerned about their medical doctor's disapproval than about their doctor's inability to understand or incorporate CAM therapy use within the context of their medical management.	Beth Israel Deaconess Med Ctr, Ctr Alternat Med Res & Educ, Boston, MA 02215 USA; Harvard Univ, Sch Med, Boston, MA USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School	Eisenberg, DM (corresponding author), Beth Israel Deaconess Med Ctr, Ctr Alternat Med Res & Educ, 330 Brookline Ave, Boston, MA 02215 USA.	deisenbe@caregroup.harvard.edu	Van Rompay, Maria/G-9452-2012		NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [U24AR043441] Funding Source: NIH RePORTER; NIAMS NIH HHS [U24 AR43441-02S1A1] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Angell M, 1998, NEW ENGL J MED, V339, P839, DOI 10.1056/NEJM199809173391210; Astin JA, 1998, JAMA-J AM MED ASSOC, V279, P1548, DOI 10.1001/jama.279.19.1548; Beyerstein B, 1997, CAN J PUBLIC HEALTH, V88, P149, DOI 10.1007/BF03403878; CAMPION EW, 1993, NEW ENGL J MED, V328, P282, DOI 10.1056/NEJM199301283280413; CHERKIN DC, 1989, WESTERN J MED, V150, P351; Davidoff F, 1998, ANN INTERN MED, V129, P1068, DOI 10.7326/0003-4819-129-12-199812150-00014; Druss BG, 1999, JAMA-J AM MED ASSOC, V282, P651, DOI 10.1001/jama.282.7.651; EISENBERG DM, 1993, NEW ENGL J MED, V328, P246, DOI 10.1056/NEJM199301283280406; Eisenberg DM, 1998, JAMA-J AM MED ASSOC, V280, P1569, DOI 10.1001/jama.280.18.1569; FISHER P, 1994, BRIT MED J, V309, P107, DOI 10.1136/bmj.309.6947.107; GoldbeckWood S, 1996, BRIT MED J, V313, P131, DOI 10.1136/bmj.313.7050.131a; HENTSCHEL C, 1996, EUR J PHYS MED REHAB, V6, P144; Hilsden RJ, 1998, AM J GASTROENTEROL, V93, P697; Kelner M, 1997, SOC SCI MED, V45, P203, DOI 10.1016/S0277-9536(96)00334-6; Lazar JS, 1997, PRIMARY CARE, V24, P699, DOI 10.1016/S0095-4543(05)70305-5; MacLennan AH, 1996, LANCET, V347, P569, DOI 10.1016/S0140-6736(96)91271-4; McGregor KJ, 1996, SOC SCI MED, V43, P1317, DOI 10.1016/0277-9536(95)00405-X; MOORE J, 1985, BRIT MED J, V290, P28, DOI 10.1136/bmj.290.6461.28; MURRAY J, 1993, SOC SCI MED, V37, P983, DOI 10.1016/0277-9536(93)90432-4; MURRAY RH, 1992, NEW ENGL J MED, V326, P61, DOI 10.1056/NEJM199201023260113; Rao JK, 1999, ANN INTERN MED, V131, P409, DOI 10.7326/0003-4819-131-6-199909210-00003; RASMUSSEN NK, 1990, COMPLEMENT MED RES, V4, P16; *RES TRIANGL I, 1997, SUDAAN PROF SOFTW SU; Sackett DL, 1996, BRIT MED J, V312, P71, DOI 10.1136/bmj.312.7023.71; VASKILAMPI T, 1993, CLIN RES METHODOLOGY; Vincent C, 1996, BRIT J CLIN PSYCHOL, V35, P37, DOI 10.1111/j.2044-8260.1996.tb01160.x; VISSER GJ, 1992, BRIT J RHEUMATOL, V31, P485	27	428	436	0	20	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	SEP 4	2001	135	5					344	351		10.7326/0003-4819-135-5-200109040-00011	http://dx.doi.org/10.7326/0003-4819-135-5-200109040-00011			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	468WF	11529698				2023-01-03	WOS:000170780600005
J	Lavery, JV; Boyle, J; Dickens, BM; Maclean, H; Singer, PA				Lavery, JV; Boyle, J; Dickens, BM; Maclean, H; Singer, PA			Origins of the desire for euthanasia and assisted suicide in people with HIV-1 or AIDS: a qualitative study	LANCET			English	Article							TERMINALLY ILL; NETHERLANDS; ATTITUDES; DEATH; CARE; CAREGIVERS	Background Euthanasia and assisted suicide, and policies to address them are the subjects of contentious debate in many countries. However, the question of why people desire euthanasia or assisted suicide has not been coherently answered. We aimed to answer this question in a specific group of patients. Methods We did a qualitative study of 32 people with HIV-1 or AIDS, who were enrolled in the HIV-1 Ontario Observational Database at Sunnybrook and Women's College Health Sciences Centre, Toronto, Ontario, Canada. We elicited participants' experiences of deliberation about euthanasia or assisted suicide, and the meaning of these experiences with in-depth, face-to-face interviews. We analysed our data with grounded theory methods. Findings Participants' desire for euthanasia and assisted suicide were affected by two main factors: disintegration, which resulted from symptoms and loss of function; and loss of community, which we defined as progressive diminishment of opportunities to initiate and maintain close personal relationships. These factors resulted in perceived loss of self. Euthanasia and assisted suicide were seen by participants as means of limiting loss of self. Interpretation These determinants of desire for euthanasia or assisted suicide in people with HIV-1 or AIDS have implications for the debate on these practices, and development of policies to regulate them.	Univ Toronto, Joint Ctr Bioeth, Toronto, ON, Canada; Queens Univ, Queens Hlth Policy Res Unit, Kingston, ON, Canada; Univ Toronto, Fac Law, Dept Philosophy, Toronto, ON M5S 1A1, Canada; Univ Toronto, Fac Publ Hlth Sci, Toronto, ON M5S 1A1, Canada; Univ Toronto, Ctr Res Womens Hlth, Toronto, ON M5S 1A1, Canada; Univ Toronto, Dept Med, Toronto, ON M5S 1A1, Canada; Univ Hlth Network, Toronto, ON, Canada	University of Toronto; Queens University - Canada; University of Toronto; University of Toronto; University of Toronto; University of Toronto; University of Toronto; University Toronto Affiliates; University Health Network Toronto	Lavery, JV (corresponding author), NIH, Fogarty Int Ctr, Div Adv Studies & Policy Anal, Bldg 16, Bethesda, MD 20892 USA.		Lavery, James/E-5254-2012					Angell M, 1996, NEW ENGL J MED, V335, P1676, DOI 10.1056/NEJM199611283352209; Antonovsky A, 1987, UNRAVELING MYSTERY H, P15; ATKINSON JH, 1988, ARCH GEN PSYCHIAT, V45, P859; BARRETT RK, 1995, AIDS PATIENT CARE, V9, P240, DOI 10.1089/apc.1995.9.240; Breitbart W, 1996, AM J PSYCHIAT, V153, P238; CALLAHAN D, 1993, HASTINGS CENT REP, V23, P33, DOI 10.2307/3562588; Chin AE, 1999, NEW ENGL J MED, V340, P577, DOI 10.1056/NEJM199902183400724; Chochinov HM, 1998, PSYCHOSOMATICS, V39, P366, DOI 10.1016/S0033-3182(98)71325-8; Chochinov HM, 1999, LANCET, V354, P816, DOI 10.1016/S0140-6736(99)80011-7; CHOCHINOV HM, 1995, AM J PSYCHIAT, V152, P1185; DWORKIN R, 1993, LIFES DOMINION ARGUM, P210; Emanuel EJ, 1996, LANCET, V347, P1805, DOI 10.1016/S0140-6736(96)91621-9; Emanuel EJ, 2000, JAMA-J AM MED ASSOC, V284, P2460, DOI 10.1001/jama.284.19.2460; Ganzini L, 1998, NEW ENGL J MED, V339, P967, DOI 10.1056/NEJM199810013391406; Giacomini MK, 2000, JAMA-J AM MED ASSOC, V284, P357, DOI 10.1001/jama.284.3.357; Glaser B., 1992, BASICS GROUNDED THEO; GREEN G, 1995, AIDS CARE, V7, P169; Haverkate I, 2000, BRIT MED J, V321, P865, DOI 10.1136/bmj.321.7265.865; JECKER NS, 1993, J CLIN ETHIC, V4, P16; Kissane DW, 1998, LANCET, V352, P1097, DOI 10.1016/S0140-6736(98)05406-3; LAANE HM, 1995, AIDS CARE, V7, P163; Roscoe LA, 2000, NEW ENGL J MED, V343, P1735, DOI 10.1056/NEJM200012073432315; SCHNEIDER SG, 1991, J PERS SOC PSYCHOL, V61, P776, DOI 10.1037/0022-3514.61.5.776; Shortt S, 1999, J Health Serv Res Policy, V4, P230; Singer PA, 1999, JAMA-J AM MED ASSOC, V281, P163, DOI 10.1001/jama.281.2.163; Strauss A., 1990, BASICS GROUNDED THEO; VANDENBOOM F, 1995, AIDS CARE, V7, P175; vanderWal G, 1996, NEW ENGL J MED, V335, P1706; Walker RJ, 1996, HEALTH SOC WORK, V21, P49, DOI 10.1093/hsw/21.1.49; Yalom I., 1980, EXISTENTIAL PSYCHOTH	30	72	72	0	18	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	AUG 4	2001	358	9279					362	367		10.1016/S0140-6736(01)05555-6	http://dx.doi.org/10.1016/S0140-6736(01)05555-6			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	459DE	11502315				2023-01-03	WOS:000170235100010
J	Nallamothu, BK; Saint, S; Kolias, TJ; Eagle, KA				Nallamothu, BK; Saint, S; Kolias, TJ; Eagle, KA			Of nicks and time	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							AORTIC DISSECTION; COCAINE ABUSE; MANAGEMENT		Univ Michigan, Dept Internal Med, Ann Arbor, MI 48109 USA; Vet Affairs Med Ctr, Hlth Serv Res & Dev Field Program, Ann Arbor, MI USA	University of Michigan System; University of Michigan; US Department of Veterans Affairs; Veterans Health Administration (VHA)	Nallamothu, BK (corresponding author), B1F245 Univ Hosp, Ann Arbor, MI 48109 USA.		Saint, Sanjay/AAF-5126-2019					CIGARROA JE, 1993, NEW ENGL J MED, V328, P35, DOI 10.1056/NEJM199301073280107; CREGLER LL, 1986, NEW ENGL J MED, V315, P1495, DOI 10.1056/NEJM198612043152327; EAGLE KA, 1989, CURR PROB CARDIOLOGY, V14, P225, DOI 10.1016/S0146-2806(89)80010-6; Hagan PG, 2000, JAMA-J AM MED ASSOC, V283, P897, DOI 10.1001/jama.283.7.897; HOLLANDER JE, 1995, ACAD EMERG MED, V2, P179, DOI 10.1111/j.1553-2712.1995.tb03191.x; HOLLANDER JE, 1995, NEW ENGL J MED, V333, P1267, DOI 10.1056/NEJM199511093331907; ISNER JM, 1986, NEW ENGL J MED, V315, P1438, DOI 10.1056/NEJM198612043152302; ISSELBACHER EM, 1994, CIRCULATION, V90, P2375, DOI 10.1161/01.CIR.90.5.2375; KLONER RA, 1992, CIRCULATION, V85, P407, DOI 10.1161/01.CIR.85.2.407; Lange RA, 2001, NEW ENGL J MED, V345, P351, DOI 10.1056/NEJM200108023450507; Mendelson JH, 1996, NEW ENGL J MED, V334, P965, DOI 10.1056/NEJM199604113341507; Pretre R, 1997, LANCET, V349, P1461, DOI 10.1016/S0140-6736(96)09372-5; RICH JA, 1991, ANN EMERG MED, V20, P616, DOI 10.1016/S0196-0644(05)82378-9	13	12	12	0	2	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	AUG 2	2001	345	5					359	363		10.1056/NEJM200108023450508	http://dx.doi.org/10.1056/NEJM200108023450508			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	458KM	11484694				2023-01-03	WOS:000170193600009
J	Schwetz, BA				Schwetz, BA			Oral therapy for CMV retinitis	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	News Item									US FDA, Rockville, MD 20857 USA	US Food & Drug Administration (FDA)	Schwetz, BA (corresponding author), US FDA, Rockville, MD 20857 USA.								0	33	33	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 6	2001	285	21					2705	2705						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	437HG	11386912				2023-01-03	WOS:000168985800005
J	Binder, EF; Williams, DB; Schechtman, KB; Jeffe, DB; Kohrt, WM				Binder, EF; Williams, DB; Schechtman, KB; Jeffe, DB; Kohrt, WM			Effects of hormone replacement therapy on serum lipids in elderly women - A randomized, placebo-controlled trial	ANNALS OF INTERNAL MEDICINE			English	Article							CORONARY-HEART-DISEASE; POSTMENOPAUSAL ESTROGEN; CARDIOVASCULAR-DISEASE; FOLLOW-UP; CHOLESTEROL; MORTALITY; OLDER; RISK	Background: Coronary heart disease (CHD) is the leading cause of death among older women. In observational studies, the incidence of CHD has been reduced in postmenopausal women who take hormone replacement therapy (HRT). A low serum level of high-density lipoprotein (HDL) cholesterol is one of the risk factors predictive of death from CHD. Objective: To determine the effects of HRT on serum lipid and lipoprotein levels in elderly women. Design: Randomized, double-blind, placebo-controlled trial. Setting: University research center. Participants: 59 sedentary women 75 years of age or older. Intervention: Participants were assigned to 9 months of oral therapy with placebo or conjugated estrogens, 0.625 mg/d, plus trimonthly medroxyprogesterone acetate, 5 mg/d for 13 days. Measurements: Serum lipid and lipoprotein levels. Results: After 9 months of treatment, women in the HRT group compared with women in the placebo group had decreased low-density lipoprotein cholesterol levels (mean change [+/-SD], -0.47 +/- 0.69 mmol/L [-18.2+/-26.5 mg/dL] vs. -0.06+/-0.32 mmol/L [-2.2 +/-12.2 mg/dL], respectively; between-group difference, 0.41 mmol/L [95% CI, 0.09 to 0.74 mmol/L], 16 mg/dL [95% CI, 3.5 to 28.5 mg/dL]; P = 0.01) and increased HDL cholesterol levels (mean change, 0.21 +/- 0.27 mmol/L [8.1+/-10.5 mg/dL] vs. 0.06+/-0.11 mmol/L [2.4+/-4.3 mg/dL], respectively; between-group difference, 0.15 mmol/L [CI, 0.008 to 0.29 mmol/L], 5.7 mg/dL [CI, 0.8 to 10.6 mg/dL]; P = 0.02). The observed changes were independent of age at menopause onset, baseline lipid values, body weight, waist circumference, percentage body fat, and peak aerobic power. Conclusions: In women 75 years of age or older, HRT improved the lipoprotein profile to the extent observed previously in younger postmenopausal women. Further studies are needed to evaluate whether these effects protect against CHD in this population.	Washington Univ, Sch Med, Div Geriatr & Gerontol, St Louis, MO 63108 USA	Washington University (WUSTL)	Binder, EF (corresponding author), Washington Univ, Sch Med, Div Geriatr & Gerontol, 4488 Forest Pk Blvd,Suite 201, St Louis, MO 63108 USA.	ebinder@imgate.wustl.edu	Jeffe, Donna B./AAI-3732-2020	Jeffe, Donna B./0000-0002-7642-3777	NCRR NIH HHS [5-MO1-RR00036] Funding Source: Medline; NIA NIH HHS [P01-AG13629] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000036] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [P60AG013629] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Abrams J, 1995, Curr Probl Cardiol, V20, P533; Binder EF, 1996, J AM GERIATR SOC, V44, P231, DOI 10.1111/j.1532-5415.1996.tb00907.x; Binder EF, 1999, J GERONTOL A-BIOL, V54, pM353, DOI 10.1093/gerona/54.7.M353; Bjorn I, 1999, MATURITAS, V32, P77, DOI 10.1016/S0378-5122(99)00018-3; BUSH TL, 1987, CIRCULATION, V75, P1102, DOI 10.1161/01.CIR.75.6.1102; CORTI MC, 1995, JAMA-J AM MED ASSOC, V274, P539, DOI 10.1001/jama.274.7.539; ETTINGER B, 1994, OBSTET GYNECOL, V83, P693; Friedman LM., 1981, FUNDAMENTALS CLIN TR; Frost PH, 1996, CIRCULATION, V94, P2381, DOI 10.1161/01.CIR.94.10.2381; Greendale GA, 1998, OBSTET GYNECOL, V92, P982, DOI 10.1016/S0029-7844(98)00305-6; Grodstein F, 1996, NEW ENGL J MED, V335, P453, DOI 10.1056/NEJM199608153350701; Holland KR, 1996, NOISE CONTROL ENG, V44, P231, DOI 10.3397/1.2828407; Kannel William B., 1996, Am J Geriatr Cardiol, V5, P9; KRONMAL RA, 1993, ARCH INTERN MED, V153, P1065, DOI 10.1001/archinte.153.9.1065; KRUMHOLZ HM, 1994, JAMA-J AM MED ASSOC, V272, P1335, DOI 10.1001/jama.272.17.1335; MALENKA DJ, 1988, ARCH INTERN MED, V148, P2247, DOI 10.1001/archinte.148.10.2247; Manolio T A, 1992, Ann Epidemiol, V2, P161, DOI 10.1016/1047-2797(92)90051-Q; MILLER VT, 1995, JAMA-J AM MED ASSOC, V273, P199, DOI 10.1001/jama.1995.03520270033028; *NAT CTR HLTH STAT, 1988, VIT STAT US 1986, V2; Recker RR, 1999, ANN INTERN MED, V130, P897, DOI 10.7326/0003-4819-130-11-199906010-00005; STAMPFER MJ, 1991, NEW ENGL J MED, V325, P756, DOI 10.1056/NEJM199109123251102; Walsh BW, 1998, JAMA-J AM MED ASSOC, V279, P1445, DOI 10.1001/jama.279.18.1445; ZIMETBAUM P, 1992, ARTERIOSCLER THROMB, V12, P416, DOI 10.1161/01.ATV.12.4.416	23	29	34	0	3	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAY 1	2001	134	9					754	760		10.7326/0003-4819-134-9_Part_1-200105010-00012	http://dx.doi.org/10.7326/0003-4819-134-9_Part_1-200105010-00012			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	428PU	11329233				2023-01-03	WOS:000168470700005
J	SMITH, T				SMITH, T			CHEAP, MANAGED DEATH	BRITISH MEDICAL JOURNAL			English	Editorial Material																			0	2	2	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 18	1995	310	6981					744	744		10.1136/bmj.310.6981.744	http://dx.doi.org/10.1136/bmj.310.6981.744			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QN461	11644673	Green Published			2023-01-03	WOS:A1995QN46100079
J	Richards, SCM; Scott, DL				Richards, SCM; Scott, DL			Prescribed exercise in people with fibromyalgia: parallel group randomised controlled trial	BMJ-BRITISH MEDICAL JOURNAL			English	Article							CHRONIC-FATIGUE-SYNDROME; EXAGGERATED PAIN PERCEPTION; CHRONIC WIDESPREAD PAIN; FEAR-AVOIDANCE MODEL; PHYSICAL-FITNESS; GENERAL-POPULATION; PROGRAM; QUESTIONNAIRE; RELAXATION; PREVALENCE	Objectives To evaluate cardiovascular fitness exercise in people with fibromyalgia. Design Randomised controlled trial, Setting Hospital rheumatology outpatients, Group based classes took place at a "healthy living centre." Participants 132 patients with fibromyalgia. Interventions Prescribed graded aerobic exercise (active treatment) and relaxation and flexibility (control treatment), Main outcome measures Participants' self assessment of improvement, tender point count, impact of condition measured by fibromyalgia impact questionnaire, and short form McGill pain questionnaire. Results Compared with relaxation exercise led to significantly more participants rating themselves as much or very much better at three months: 24/69 (35%) v 12/67 (18%), P=0.03, Benefits were maintained or improved at one year follow up when fewer participants in the exercise group fulfilled the criteria for fibromyalgia (31/69 v 44/67, P=0.01). People in the exercise group also had greater reductions in tender point counts (4.2 v 2.0, P=0.02) and in scores on the fibromyalgia impact questionnaire (4.0 v 0.6, P=0.07). Conclusions Prescribed graded aerobic exercise is a simple, cheap, effective, and potentially widely available treatment for fibromyalgia.	Poole Hosp NHS Trust, Poole BH15 2JB, Dorset, England; Kings Coll Hosp London, London SE22 8PT, England	King's College Hospital NHS Foundation Trust; King's College Hospital	Richards, SCM (corresponding author), Poole Hosp NHS Trust, Poole BH15 2JB, Dorset, England.	srichards@poole-tr.swest.nhs.uk						Bailey A, 1999, ARTHRIT CARE RES, V12, P336, DOI 10.1002/1529-0131(199910)12:5<336::AID-ART5>3.0.CO;2-E; Buckelew SP, 1998, ARTHRIT CARE RES, V11, P196, DOI 10.1002/art.1790110307; BURCKHARDT CS, 1991, J RHEUMATOL, V18, P728; BURCKHARDT CS, 1994, J RHEUMATOL, V21, P714; CHALDER T, 1993, J PSYCHOSOM RES, V37, P147, DOI 10.1016/0022-3999(93)90081-P; CROFT P, 1993, J RHEUMATOL, V20, P710; *DEP HLTH, 1997, HLTH LIV CTR; *DEP HLTH, 1997, 9783 MISC DEP HLTH; Fulcher KY, 1997, BRIT MED J, V314, P1647, DOI 10.1136/bmj.314.7095.1647; GARRATT AM, 1993, BMJ-BRIT MED J, V306, P1440, DOI 10.1136/bmj.306.6890.1440; Gowans SE, 1999, ARTHRIT CARE RES, V12, P120, DOI 10.1002/1529-0131(199904)12:2<120::AID-ART7>3.0.CO;2-4; Guy W, ECDEU ASSESSMENT MAN, P218; Guy W., 1976, ECDEU ASSESSMENT MAN, P218; Keel PJ, 1998, CLIN J PAIN, V14, P232, DOI 10.1097/00002508-199809000-00010; Lawrence RC, 1998, ARTHRITIS RHEUM-US, V41, P778, DOI 10.1002/1529-0131(199805)41:5<778::AID-ART4>3.0.CO;2-V; LEDINGHAM J, 1993, BRIT J RHEUMATOL, V32, P139; LETHEM J, 1983, BEHAV RES THER, V21, P401, DOI 10.1016/0005-7967(83)90009-8; Macfarlane GJ, 1999, J RHEUMATOL, V26, P413; Martin L, 1996, J RHEUMATOL, V23, P1050; MCCAIN GA, 1988, ARTHRITIS RHEUM, V31, P1135, DOI 10.1002/art.1780310908; MCCAIN GA, 1986, AM J MED, V81, P73, DOI 10.1016/0002-9343(86)90881-8; MELZACK R, 1987, PAIN, V30, P191, DOI 10.1016/0304-3959(87)91074-8; MENGSHOEL AM, 1992, CLIN EXP RHEUMATOL, V10, P345; OST LG, 1987, BEHAV RES THER, V25, P397, DOI 10.1016/0005-7967(87)90017-9; PHILIPS HC, 1987, BEHAV RES THER, V25, P273, DOI 10.1016/0005-7967(87)90005-2; Powell P, 2001, BRIT MED J, V322, P1; SLADE PD, 1983, BEHAV RES THER, V21, P409, DOI 10.1016/0005-7967(83)90010-4; SURAWY C, 1995, BEHAV RES THER, V33, P535, DOI 10.1016/0005-7967(94)00077-W; Verstappen FTJ, 1997, J MUSCULOSKELET PAIN, V5, P17, DOI 10.1300/J094v05n04_03; White KP, 2000, SCAND J RHEUMATOL, V29, P44; WHITE KP, 1995, J RHEUMATOL, V22, P717; Wigers SH, 1996, J PSYCHOSOM RES, V41, P235, DOI 10.1016/0022-3999(96)00070-0; Wigers SH, 1996, SCAND J RHEUMATOL, V25, P77, DOI 10.3109/03009749609069212; WOLFE F, 1990, ARTHRITIS RHEUM-US, V33, P160, DOI 10.1002/art.1780330203; Wolfe F, 1997, ARTHRITIS RHEUM, V40, P1571, DOI 10.1002/art.1780400905	35	152	164	0	10	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUL 27	2002	325	7357					185	187		10.1136/bmj.325.7357.185	http://dx.doi.org/10.1136/bmj.325.7357.185			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	580PX	12142304	Bronze, Green Published			2023-01-03	WOS:000177243900015
J	Koenig, HG				Koenig, HG			An 83-year-old woman with chronic illness and strong religious beliefs	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CORONARY HEART-DISEASE; OLDER ADULTS; TRANSPLANT RECIPIENTS; CARDIAC-SURGERY; BLOOD-PRESSURE; AMERICAN WOMEN; OF-LIFE; SPIRITUALITY; INVOLVEMENT; DEPRESSION		Duke Univ, Med Ctr, Ctr Geriatr Res Educ & Clin, VA Med Ctr, Durham, NC 27710 USA	Duke University; Geriatric Research Education & Clinical Center	Koenig, HG (corresponding author), Duke Univ, Med Ctr, Ctr Geriatr Res Educ & Clin, VA Med Ctr, Box 3400, Durham, NC 27710 USA.		Koenig, Harold G/F-7379-2011					Ai AL, 1998, GERONTOLOGIST, V38, P591, DOI 10.1093/geront/38.5.591; Astrow AB, 2001, AM J MED, V110, P283; Avants SK, 2001, J PSYCHOACTIVE DRUGS, V33, P39, DOI 10.1080/02791072.2001.10400467; Ayele H, 1999, J AM GERIATR SOC, V47, P453, DOI 10.1111/j.1532-5415.1999.tb07238.x; Bartlett SJ, 2001, ARTHRITIS RHEUM, V44, pS382; BECKER D, 2000, PRAYER BLACK WOMEN B; Benson H., 1975, RELAXATION RESPONSE; BLALOCK SJ, 1995, ANN BEHAV MED, V17, P107, DOI 10.1007/BF02895059; Braam AW, 1997, SOC PSYCH PSYCH EPID, V32, P284, DOI 10.1007/BF00789041; Braam AW, 2001, PSYCHOL MED, V31, P803, DOI 10.1017/S0033291701003956; Braam AW, 1997, ACTA PSYCHIAT SCAND, V96, P199, DOI 10.1111/j.1600-0447.1997.tb10152.x; CEDERBLAD M, 1995, ACTA PSYCHIAT SCAND, V91, P322, DOI 10.1111/j.1600-0447.1995.tb09789.x; Chibnall JT, 2001, SOUTHERN MED J, V94, P374; Cooper-Effa M, 2001, J Am Board Fam Pract, V14, P116; CRONAN TA, 1989, ARTHRITIS RHEUM, V32, P1604, DOI 10.1002/anr.1780321217; Ehman JW, 1999, ARCH INTERN MED, V159, P1803, DOI 10.1001/archinte.159.15.1803; Fitchett G, 1997, J NERV MENT DIS, V185, P320, DOI 10.1097/00005053-199705000-00006; Fox SA, 1998, HEALTH EDUC BEHAV, V25, P742, DOI 10.1177/109019819802500605; Fry PS, 2000, AGING MENT HEALTH, V4, P375, DOI 10.1080/713649965; GOLDBOURT U, 1993, CARDIOLOGY, V82, P100, DOI 10.1159/000175862; HARRIS RC, 1995, J RELIG HEALTH, V34, P17, DOI 10.1007/BF02248635; Hebert RS, 2001, J GEN INTERN MED, V16, P685, DOI 10.1046/j.1525-1497.2001.01034.x; HOGE DR, 1972, J SCI STUD RELIG, V11, P369; Hummer RA, 1999, DEMOGRAPHY, V36, P273, DOI 10.2307/2648114; IDLER EL, 1987, SOC FORCES, V66, P226, DOI 10.2307/2578909; Idler EL, 1997, J GERONTOL B-PSYCHOL, V52, pS306, DOI 10.1093/geronb/52B.6.S306; Idler EL, 1995, SOC FORCES, V74, P683, DOI 10.2307/2580497; Ironson G, 2002, ANN BEHAV MED, V24, P34, DOI 10.1207/S15324796ABM2401_05; JENKINS RA, 1995, J PSYCHOSOC ONCOL, V13, P51, DOI 10.1300/J077V13N01_04; KABATZINN J, 1985, J BEHAV MED, V8, P163, DOI 10.1007/BF00845519; Kaldjian LC, 1998, AIDS, V12, P103, DOI 10.1097/00002030-199801000-00012; Keefe FJ, 2001, J PAIN, V2, P101, DOI 10.1054/jpai.2001.19296; KING DE, 1994, J FAM PRACTICE, V39, P349; Koenig, 2002, SPIRITUALITY PATIENT; Koenig HG, 1998, J NERV MENT DIS, V186, P513, DOI 10.1097/00005053-199809000-00001; KOENIG HG, 1989, J FAM PRACTICE, V28, P441; Koenig HG, 1998, INT J PSYCHIAT MED, V28, P189, DOI 10.2190/75JM-J234-5JKN-4DQD; Koenig HG, 1997, INT J PSYCHIAT MED, V27, P233, DOI 10.2190/40NF-Q9Y2-0GG7-4WH6; Koenig HG, 1998, AM J PSYCHIAT, V155, P536, DOI 10.1176/ajp.155.4.536; KOENIG HG, 1988, J AM GERIATR SOC, V36, P362, DOI 10.1111/j.1532-5415.1988.tb02365.x; KOENIG HG, 1992, AM J PSYCHIAT, V149, P1693; KOENIG HG, 1995, J RELIGIOUS GERONTOL, V9, P1; Koening H, 2001, HDB RELIG HLTH; Lo B, 1999, ANN INTERN MED, V130, P744, DOI 10.7326/0003-4819-130-9-199905040-00015; Matthees BJ, 2001, HEART LUNG, V30, P258, DOI 10.1067/mhl.2001.116135; McEwen BS, 1998, NEW ENGL J MED, V338, P171, DOI 10.1056/NEJM199801153380307; Melkus G, 2001, DIABETES, V50, pA394; Meredith KL, 2001, HEALTH EDUC BEHAV, V28, P40, DOI 10.1177/109019810102800105; Morris EL, 2001, ALTERN THER HEALTH M, V7, P96; Mueller PS, 2001, MAYO CLIN PROC, V76, P1225, DOI 10.4065/76.12.1225; Murphy PL, 2000, NEUROLOGY, V55, P1581, DOI 10.1212/WNL.55.10.1581; OXMAN TE, 1995, PSYCHOSOM MED, V57, P5, DOI 10.1097/00006842-199501000-00002; Pargament KI, 2001, ARCH INTERN MED, V161, P1881, DOI 10.1001/archinte.161.15.1881; PETTERSSON T, 1991, J SCI STUD RELIG, V30, P279, DOI 10.2307/1386973; Post SG, 2000, ANN INTERN MED, V132, P578, DOI 10.7326/0003-4819-132-7-200004040-00010; PRESSMAN P, 1990, AM J PSYCHIAT, V147, P758; *PRINC REL RES CTR, 1982, REL AM, P120; PULCHALSKI CM, 1998, ACAD MED, V73, P970; Rabin B.S., 1999, STRESS IMMUNE FUNCTI; RINGDAL G, 1995, BRIT J CANCER, V73, P1594; Samuel-Hodge CD, 2000, DIABETES CARE, V23, P928, DOI 10.2337/diacare.23.7.928; Schnoll RA, 2000, CANCER PRACT, V8, P298, DOI 10.1046/j.1523-5394.2000.86006.x; Schuster MA, 2001, NEW ENGL J MED, V345, P1507, DOI 10.1056/NEJM200111153452024; Sephton S E, 2001, Breast J, V7, P345, DOI 10.1046/j.1524-4741.2001.20014.x; SILBER TJ, 1985, ADOLESCENCE, V20, P217; Sloan RP, 2000, NEW ENGL J MED, V342, P1913, DOI 10.1056/NEJM200006223422513; Steffen PR, 2001, PSYCHOSOM MED, V63, P523, DOI 10.1097/00006842-200107000-00002; STERN RC, 1992, J ADOLESCENT HEALTH, V13, P612, DOI 10.1016/1054-139X(92)90376-M; Strawbridge WJ, 1997, AM J PUBLIC HEALTH, V87, P957, DOI 10.2105/AJPH.87.6.957; Subach RA, 1999, RENAL FAILURE, V21, P223, DOI 10.3109/08860229909066987; Tix AP, 1998, J CONSULT CLIN PSYCH, V66, P411, DOI 10.1037/0022-006X.66.2.411; Tull ES, 2001, DIABETES, V50, pA397; TURNER JA, 1986, PAIN, V24, P355, DOI 10.1016/0304-3959(86)90121-1; Woods TE, 1999, J PSYCHOSOM RES, V46, P165, DOI 10.1016/S0022-3999(98)00078-6	74	85	88	0	5	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 24	2002	288	4					487	493		10.1001/jama.288.4.487	http://dx.doi.org/10.1001/jama.288.4.487			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	575NZ	12132980				2023-01-03	WOS:000176955400032
J	Berg, AO; Allan, JD; Frame, P; Homer, CJ; Johnson, MS; Klein, JD; Lieu, TA; Mulrow, CD; Orleans, TC; Peipert, JF; Pender, NJ; Siu, AL; Teutsch, SM; Westhoff, C; Woolf, SH				Berg, AO; Allan, JD; Frame, P; Homer, CJ; Johnson, MS; Klein, JD; Lieu, TA; Mulrow, CD; Orleans, TC; Peipert, JF; Pender, NJ; Siu, AL; Teutsch, SM; Westhoff, C; Woolf, SH		US Preventive Services Task Force	Chemoprevention of breast cancer: Recommendations and rationale	ANNALS OF INTERNAL MEDICINE			English	Article							TAMOXIFEN	This statement summarizes the current recommendations of the U.S. Preventive Services Task Force (USPSTF) for chemoprevention of breast cancer. The complete USPSTF recommendation and rationale statement on this topic, including a summary of the supporting evidence, is available through the USPSTF Web site (www.preventiveservices.ahrq.gov), the National Guideline Clearinghouse (www.guideline.gov), and in print through the Agency for Healthcare Research and Quality Publications Clearinghouse (telephone, 800-358-9295; e-mail, ahrqpubs@ahrq.gov). The complete information on which this statement is based, including evidence tables and references, is available in the accompanying article in this issue and in the summary of the evidence and systematic evidence review on the Web sites already mentioned.	Univ Washington, Seattle, WA 98195 USA; Univ Texas, Hlth Sci Ctr, San Antonio, TX USA; Univ Rochester, Rochester, NY USA; Natl Initiat Childrens Healthcare Qual, Boston, MA USA; Univ Med & Dent New Jersey, New Jersey Med Sch, Newark, NJ 07103 USA; Univ Rochester, Sch Med, Rochester, NY USA; Harvard Pilgrim Hlth Care, Boston, MA USA; Harvard Univ, Sch Med, Boston, MA USA; Univ Texas, Hlth Sci Ctr, San Antonio, TX USA; Robert Wood Johnson Generalist Phys Fac Scholars, Natl Program Off, San Antonio, TX USA; Robert Wood Johnson Fdn, Princeton, NJ 08540 USA; Brown Univ, Women & Infants Hosp, Providence, RI USA; Univ Michigan, Ann Arbor, MI 48109 USA; Mt Sinai Sch Med, New York, NY USA; Merck & Co Inc, West Point, PA USA; Columbia Univ, New York, NY USA; Virginia Commonwealth Univ, Fairfax, VA USA	University of Washington; University of Washington Seattle; University of Texas System; University of Texas Health San Antonio; University of Rochester; Rutgers State University New Brunswick; Rutgers State University Medical Center; University of Rochester; Harvard Pilgrim Health Care; Harvard University; Harvard Medical School; University of Texas System; University of Texas Health San Antonio; Robert Wood Johnson Foundation (RWJF); Brown University; Women & Infants Hospital Rhode Island; University of Michigan System; University of Michigan; Icahn School of Medicine at Mount Sinai; Merck & Company; Columbia University; Virginia Commonwealth University	Berg, AO (corresponding author), Univ Washington, Seattle, WA 98195 USA.							*AM COLL OBST GYN, 1999, TAM PREV BREAST CANC; Chlebowski RT, 1999, J CLIN ONCOL, V17, P1939, DOI 10.1200/JCO.1999.17.6.1939; Gail MH, 1999, J NATL CANCER I, V91, P1829, DOI 10.1093/jnci/91.21.1829; Levine M, 2001, CAN MED ASSOC J, V164, P1681	4	55	56	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUL 2	2002	137	1					56	58		10.7326/0003-4819-137-1-200207020-00016	http://dx.doi.org/10.7326/0003-4819-137-1-200207020-00016			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	569VA	12093249				2023-01-03	WOS:000176622000010
J	Conte, MH; Weber, JC				Conte, MH; Weber, JC			Plant biomarkers in aerosols record isotopic discrimination of terrestrial photosynthesis	NATURE			English	Article							ATMOSPHERIC CO2; CARBON-DIOXIDE; ORGANIC-MATTER; LIPIDS; DELTA-C-13; BIOSPHERE; TRENDS; CYCLE	Carbon uptake by the oceans and by the terrestrial biosphere can be partitioned using changes in the C-12/C-13 isotopic ratio (delta(13)C) of atmospheric carbon dioxide(1-4), because terrestrial photosynthesis strongly discriminates against (CO2)-C-13,whereas ocean uptake does not. This approach depends on accurate estimates of the carbon isotopic discrimination of terrestrial photosynthesis (Delta; ref. 5) at large regional scales(6), yet terrestrial ecosystem heterogeneity(7) makes such estimates problematic. Here we show that ablated plant wax compounds in continental air masses can be used to estimate Delta over large spatial scales and at less than monthly temporal resolution. We measured plant waxes in continental air masses advected to Bermuda, which are mainly of North American origin, and used the wax isotopic composition to estimate Delta simply. Our estimates indicate a large (5-6parts per thousand) seasonal variation in Delta of the temperate North American biosphere, with maximum discrimination occurring in late spring, coincident with the onset of production. We suggest that the observed seasonality arises from several factors, including seasonal shifts in the proportions of production by C-3 and C-4 plants, and environmentally controlled adjustments in the photosynthetic discrimination of C-3-plant-dominated ecosystems.	Woods Hole Oceanog Inst, Dept Marine Chem & Geochem, Woods Hole, MA 02543 USA	Woods Hole Oceanographic Institution	Conte, MH (corresponding author), Woods Hole Oceanog Inst, Dept Marine Chem & Geochem, Woods Hole, MA 02543 USA.							Bakwin PS, 1998, GLOBAL BIOGEOCHEM CY, V12, P555, DOI 10.1029/98GB02265; Ballentine DC, 1996, ORG GEOCHEM, V25, P97, DOI 10.1016/S0146-6380(96)00110-6; CIAIS P, 1995, J GEOPHYS RES-ATMOS, V100, P5051, DOI 10.1029/94JD02847; COLLISTER JW, 1994, ORG GEOCHEM, V21, P619, DOI 10.1016/0146-6380(94)90008-6; CONTE MH, 2001, EOS T AGU, V82, pS77; CONTE MH, 2001, IN PRESS ORG GEOCHEM; EHLERINGER JR, 1993, OECOLOGIA, V95, P340, DOI 10.1007/BF00320986; Ehleringer JR, 1997, OECOLOGIA, V112, P285, DOI 10.1007/s004420050311; Farquhar G. D., 1993, Stable isotopes and plant carbon-water relations., P47; Flanagan LB, 1998, TRENDS ECOL EVOL, V13, P10, DOI 10.1016/S0169-5347(97)01275-5; FRANCEY RJ, 1995, NATURE, V373, P326, DOI 10.1038/373326a0; Fung I, 1997, GLOBAL BIOGEOCHEM CY, V11, P507, DOI 10.1029/97GB01751; GULZ PG, 1994, J PLANT PHYSIOL, V143, P453, DOI 10.1016/S0176-1617(11)81807-9; HADLEY JL, 1989, ARCTIC ALPINE RES, V21, P392, DOI 10.2307/1551648; Kawamura, 1995, BIOGEOCHEMICAL PROCE, P31; KORNER C, 1991, OECOLOGIA, V88, P30, DOI 10.1007/BF00328400; LLOYD J, 1994, OECOLOGIA, V99, P201, DOI 10.1007/BF00627732; Lockheart MJ, 1997, ORG GEOCHEM, V26, P137, DOI 10.1016/S0146-6380(96)00135-0; MARSHALL JD, 1994, ECOLOGY, V75, P1887, DOI 10.2307/1941593; MOODY JL, 1995, J GEOPHYS RES-ATMOS, V100, P7179, DOI 10.1029/94JD02830; Peltzer E.T., 1989, CHEM OCEANOGR, V10, P282; Randerson JT, 1997, GLOBAL BIOGEOCHEM CY, V11, P535, DOI 10.1029/97GB02268; Rayner PJ, 1999, TELLUS B, V51, P213, DOI 10.1034/j.1600-0889.1999.t01-1-00008.x; ROGGE WF, 1994, ENVIRON SCI TECHNOL, V28, P1375, DOI 10.1021/es00056a030; SIMONEIT BRT, 1989, J ATMOS CHEM, V8, P251, DOI 10.1007/BF00051497; SMEDLEY MP, 1991, OECOLOGIA, V85, P314, DOI 10.1007/BF00320605; STILL CJ, 1999, EOS T AGU, V80, pF93; TANS PP, 1993, GLOBAL BIOGEOCHEM CY, V7, P353, DOI 10.1029/93GB00053; Vogel J., 1993, STABLE ISOTOPES PLAN, P26; ZAFIRIOU OC, 1985, J GEOPHYS RES-ATMOS, V90, P2409, DOI 10.1029/JD090iD01p02409	30	86	91	0	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUN 6	2002	417	6889					639	641		10.1038/nature00777	http://dx.doi.org/10.1038/nature00777			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	559AE	12050663				2023-01-03	WOS:000176001200045
J	Baader, M; Gnerre, C; Stegeman, JJ; Meyer, UA				Baader, M; Gnerre, C; Stegeman, JJ; Meyer, UA			Transcriptional activation of cytochrome P450CYP2C45 by drugs is mediated by the chicken xenobiotic receptor (CXR) interacting with a phenobarbital response enhancer unit	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CONSTITUTIVE ANDROSTANE RECEPTOR; ORPHAN NUCLEAR RECEPTOR; PREGNANE-X RECEPTOR; GENE; IDENTIFICATION; INDUCTION; EXPRESSION; ELEMENT; CYP2H1; UPDATE	Cytochromes P450 (CYP)-2C enzymes fulfill an important role in xenobiotic metabolism and therefore have extensively been studied in rodents and humans. However, no CYP2C genes have been described in avian species to date. In this paper, we report the cloning, functional analysis, and regulation of chicken CYP2C45. The sequence shares up to 58% amino acid identity with CYP2Cs in other species. The overexpression of CYP2C45 in chicken hepatoma cells leghorn male hepatoma (LMH) led to increased scoparone metabolism. CYP2C45 regulation was studied in LMH cells at the mRNA level and in reporter gene assays using a construct containing 2.6 kb of its 5'-flanking region. Exposure of LMH cells to phenobarbital or metyrapone led to a 95- or 210-fold increase in CYP2C45 mRNA and a 140- or 290-fold increase in reporter gene expression, respectively. A phenobarbital response enhancer unit (PBRU) of 239 bp containing a DR-4 nuclear receptor binding site was identified within the 2.6-kb fragment. Site-specific mutation of the DR-4 revealed the requirement of this motif for CYP2C45 induction by drugs. The chicken xenobiotic receptor CXR interacted with the PBRU in electromobility shift and transactivation assays. Furthermore, the related nuclear receptors, mouse PXR and mouse CAR, transactivated this enhancer element, suggesting evolutionary conservation of nuclear receptor-DNA interactions in CYP2C induction.	Univ Basel, Biozentrum, Dept Pharmacol Neurobiol, CH-4056 Basel, Switzerland; Woods Hole Oceanog Inst, Dept Biol, Woods Hole, MA 02543 USA	University of Basel; Woods Hole Oceanographic Institution	Meyer, UA (corresponding author), Univ Basel, Biozentrum, Dept Pharmacol Neurobiol, Klingelbergstr 50-70, CH-4056 Basel, Switzerland.	Urs-A.Meyer@unibas.ch		Stegeman, John/0000-0001-8204-5357	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P42ES007381] Funding Source: NIH RePORTER; NIEHS NIH HHS [P42 ES07381] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Czerniak R, 2001, INT J TOXICOL, V20, P161, DOI 10.1080/109158101317097746; Gerbal-Chaloin S, 2001, DRUG METAB DISPOS, V29, P242; Handschin C, 2000, J BIOL CHEM, V275, P13362, DOI 10.1074/jbc.275.18.13362; Handschin C, 2001, MOL PHARMACOL, V60, P681; Handschin C, 2001, MOL ENDOCRINOL, V15, P1571, DOI 10.1210/me.15.9.1571; Handschin C, 2000, P NATL ACAD SCI USA, V97, P10769, DOI 10.1073/pnas.97.20.10769; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; Honkakoski P, 1998, MOL CELL BIOL, V18, P5652, DOI 10.1128/MCB.18.10.5652; Honkakoski P, 2000, BIOCHEM J, V347, P321, DOI 10.1042/0264-6021:3470321; IniguezLluhi JA, 1997, J BIOL CHEM, V272, P4149, DOI 10.1074/jbc.272.7.4149; IOANNIDES C, 1996, HUMAN CYP2C, P162; JAISWAL AK, 1990, NUCLEIC ACIDS RES, V18, P4237, DOI 10.1093/nar/18.14.4237; Kemper B, 1998, PROG NUCLEIC ACID RE, V61, P25, DOI 10.1016/S0079-6603(08)60824-7; Kim J, 2001, J BIOL CHEM, V276, P7559, DOI 10.1074/jbc.M008090200; Kliewer SA, 1998, CELL, V92, P73, DOI 10.1016/S0092-8674(00)80900-9; Klose TS, 1999, J BIOCHEM MOL TOXIC, V13, P289, DOI 10.1002/(SICI)1099-0461(1999)13:6<289::AID-JBT1>3.0.CO;2-N; LeCluyse EL, 2001, CHEM-BIOL INTERACT, V134, P283, DOI 10.1016/S0009-2797(01)00163-6; LEVY RH, 1995, EPILEPSIA, V36, pS8, DOI 10.1111/j.1528-1157.1995.tb06007.x; Masahiko N, 2000, EUR J PHARM SCI, V11, P259, DOI 10.1016/S0928-0987(00)00112-3; McGinnity DF, 2000, DRUG METAB DISPOS, V28, P1327; Meyer RP, 2001, BIOCHEM BIOPH RES CO, V285, P32, DOI 10.1006/bbrc.2001.5111; Michalets EL, 1998, PHARMACOTHERAPY, V18, P84; MOREL F, 1990, EUR J BIOCHEM, V191, P437, DOI 10.1111/j.1432-1033.1990.tb19140.x; Nelson DR, 1996, PHARMACOGENETICS, V6, P1, DOI 10.1097/00008571-199602000-00002; Okey AB, 1992, PHARMACOGENETICS DRU, P549; Ourlin JC, 2000, ARCH BIOCHEM BIOPHYS, V373, P375, DOI 10.1006/abbi.1999.1566; Pereira TM, 1998, DNA CELL BIOL, V17, P39, DOI 10.1089/dna.1998.17.39; Quattrochi LC, 2001, DRUG METAB DISPOS, V29, P615; RETTIE AE, 1992, CHEM RES TOXICOL, V5, P54, DOI 10.1021/tx00025a009; Schuetz JD, 1996, MOL PHARMACOL, V49, P63; Sueyoshi T, 2001, ANNU REV PHARMACOL, V41, P123, DOI 10.1146/annurev.pharmtox.41.1.123; Sueyoshi T, 1999, J BIOL CHEM, V274, P6043, DOI 10.1074/jbc.274.10.6043; Warrington JS, 2000, DRUG METAB DISPOS, V28, P392; YASUMORI T, 1993, PHARMACOGENETICS, V3, P291, DOI 10.1097/00008571-199312000-00003	34	29	30	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 3	2002	277	18					15647	15653		10.1074/jbc.M109882200	http://dx.doi.org/10.1074/jbc.M109882200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	550PA	11867618	hybrid			2023-01-03	WOS:000175510400058
J	Dean, B; Schachter, M; Vincent, C; Barber, N				Dean, B; Schachter, M; Vincent, C; Barber, N			Causes of prescribing errors in hospital inpatients: a prospective study	LANCET			English	Article							ADVERSE DRUG EVENTS; INTENSIVE-CARE; UNITED-KINGDOM; MEDICATION; RISK; SAFETY	Background To prevent errors made during the prescription of drugs, we need to know why they arise. Theories of human error used to understand the causes of mistakes made in high-risk industries are being used in health-care. They have not, however, been applied to prescribing errors, which are a great cause of patient harm. Our aim was to use this approach to investigate the causes of such errors. Methods Pharmacists at a UK teaching hospital prospectively identified 88 potentially serious prescribing errors. We interviewed the prescribers who made 44 of these, and analysed our findings with human error theory. Findings Our results suggest that most mistakes were made because of slips in attention, or because prescribers did not apply relevant rules. Doctors identified many risk factors-work environment, workload, whether or not they were prescribing for their own patient, communication within their team, physical and mental well-being, and lack of knowledge. Organisational factors were also identified, and included inadequate training, low perceived importance of prescribing, a hierarchical medical team, and an absence of self-awareness of errors. Interpretation To reduce prescribing errors, hospitals should train junior doctors in the principles of drug dosing before they start prescribing, and enforce good practice in documentation. They should also create a culture in which prescription writing is seen as important, and formally review interventions made by pharmacists, locum arrangements, and the workload of junior doctors, and make doctors aware of situations in which they are likely to commit errors.	Univ London, Sch Pharm, Ctr Practice & Policy, London WC1N 1AX, England; Imperial Coll Sch Med, London, England; UCL, Clin Risk Univ, London, England	University of London; University College London; University of London School of Pharmacy; Imperial College London; University of London; University College London	Dean, B (corresponding author), Hammersmith Hosp NHS Trust, Dept Pharm, Acad Pharm Unit, London W12 0HS, England.	bdean@hhnt.org	Dean, Brian/M-3558-2019; Vincent, Charles A/D-1134-2010	Dean, Brian/0000-0001-7773-4473; Vincent, Charles A/0000-0003-0270-0222; Franklin, Bryony/0000-0002-2892-1245				ADAMS JGU, 1988, ERGONOMICS, V31, P407, DOI 10.1080/00140138808966688; Barber N, 1993, INT J PHARM PRACT, V2, P152; Barber ND, 1997, AM J HEALTH-SYST PH, V54, P397, DOI 10.1093/ajhp/54.4.397; BATES DW, 1995, JAMA-J AM MED ASSOC, V274, P29, DOI 10.1001/jama.274.1.29; Battles JB, 1998, ARCH PATHOL LAB MED, V122, P231; BLEYER WA, 1979, AM J DIS CHILD, V133, P366, DOI 10.1001/archpedi.1979.02130040020002; COTTER SM, 1994, AM J HOSP PHARM, V51, P2676, DOI 10.1093/ajhp/51.21.2676; Dean B, 2000, QUAL HEALTH CARE, V9, P232, DOI 10.1136/qhc.9.4.232; DEAN BS, IN PRESS QUAL HLTH C; *DEP HLTH SOC SERV, 1970, HM7036 DHHS DEP HLTH; Department of Health, 2000, EXP GROUP LEARN ADV; Institute of Medicine, 2000, ERR IS HUM BUILD SAF; Jacklin A, 2001, PHARM PRACT, V11, P100; LEAPE LL, 1995, JAMA-J AM MED ASSOC, V274, P35, DOI 10.1001/jama.1995.03530010049034; LESAR TS, 1990, JAMA-J AM MED ASSOC, V263, P2329, DOI 10.1001/jama.263.17.2329; Lesar TS, 1997, JAMA-J AM MED ASSOC, V277, P312, DOI 10.1001/jama.277.4.312; LESAR TS, 1992, ANN INTERN MED, V117, P537, DOI 10.7326/0003-4819-117-6-537_2; Lesar TS, 1997, ARCH INTERN MED, V157, P1569, DOI 10.1001/archinte.157.14.1569; Lesar TS, 1998, ARCH PEDIAT ADOL MED, V152, P340; MCEWAN D, 1999, THESIS U LONDON; NEALE G, 1995, CLIN RISK MANAGEMENT, P253; PERLSTEIN PH, 1979, AM J DIS CHILD, V133, P376, DOI 10.1001/archpedi.1979.02130040030006; Reason J., 1990, HUMAN ERROR; Rowe C, 1998, ARCH DIS CHILD, V79, P56, DOI 10.1136/adc.79.1.56; Vincent C, 2000, BRIT MED J, V320, P777, DOI 10.1136/bmj.320.7237.777; Vincent C, 1998, BRIT MED J, V316, P1154, DOI 10.1136/bmj.316.7138.1154; VITILLO JA, 1991, DICP ANN PHARMAC, V25, P1388, DOI 10.1177/106002809102501221	27	389	404	0	51	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	APR 20	2002	359	9315					1373	1378		10.1016/S0140-6736(02)08350-2	http://dx.doi.org/10.1016/S0140-6736(02)08350-2			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	542ZQ	11978334				2023-01-03	WOS:000175076200009
J	Fried, TR; Bradley, EH; Towle, VR; Allore, H				Fried, TR; Bradley, EH; Towle, VR; Allore, H			Understanding the treatment preferences of seriously ill patients	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							LIFE-SUSTAINING TREATMENT; DECISION-MAKING; CARE; END; SURVIVAL; OLDER; INTERVENTIONS; PHYSICIANS; PEOPLE; FAMILY	Background: The questions patients are asked about their preferences with regard to life-sustaining treatment usually focus on specific interventions, but the outcomes of treatment and their likelihood affect patients' preferences. Methods: We administered a questionnaire about treatment preferences to 226 persons who were 60 years of age or older and who had a limited life expectancy due to cancer, congestive heart failure, or chronic obstructive pulmonary disease. The study participants were asked whether they would want to receive a given treatment, first when the outcome was known with certainty and then with different likelihoods of an adverse outcome. The outcome without treatment was specified as death from the underlying disease. Results: The burden of treatment (i.e., the length of the hospital stay, extent of testing, and invasiveness of interventions), the outcome, and the likelihood of the outcome all influenced treatment preferences. For a low-burden treatment with the restoration of current health, 98.7 percent of participants said they would choose to receive the treatment (rather than not receive it and die), but 11.2 percent of these participants would not choose the treatment if it had a high burden. If the outcome was survival but with severe functional impairment or cognitive impairment, 74.4 percent and 88.8 percent of these participants, respectively, would not choose treatment. The number of participants who said they would choose treatment declined as the likelihood of an adverse outcome increased, with fewer participants choosing treatment when the possible outcome was functional or cognitive impairment than when it was death. Preferences did not differ according to the primary diagnosis. Conclusions: Advance care planning should take into account patients' attitudes toward the burden of treatment, the possible outcomes, and their likelihood. The likelihood of adverse functional and cognitive outcomes of treatment requires explicit consideration.	Vet Affairs Connecticut Healthcare Syst, Clin Epidemiol Unit, West Haven, CT 06516 USA; Yale Univ, Sch Med, Dept Med, New Haven, CT 06510 USA; Yale Univ, Sch Med, Dept Epidemiol & Publ Hlth, New Haven, CT 06510 USA; Yale Univ, Sch Med, Program Aging, New Haven, CT USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Connecticut Healthcare System; Yale University; Yale University; Yale University	Fried, TR (corresponding author), Vet Affairs Connecticut Healthcare Syst, Clin Epidemiol Unit, 950 Campbell Ave, West Haven, CT 06516 USA.	terri.fried@yale.edu		Allore, Heather/0000-0001-7685-8175	NATIONAL INSTITUTE ON AGING [P30AG021342] Funding Source: NIH RePORTER; NIA NIH HHS [P30 AG021342] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Allen JP, 1996, JAMA-J AM MED ASSOC, V275, P474; BRETT AS, 1991, JAMA-J AM MED ASSOC, V266, P825, DOI 10.1001/jama.266.6.825; Brundage MD, 1997, J CLIN ONCOL, V15, P330, DOI 10.1200/JCO.1997.15.1.330; CHARLSON ME, 1987, J CHRON DIS, V40, P373, DOI 10.1016/0021-9681(87)90171-8; *CONN HOSP, 1996, SUMM GUID IN ADV CAR; Dales RE, 1999, CHEST, V116, P792, DOI 10.1378/chest.116.3.792; Danis M, 1996, CRIT CARE MED, V24, P1811, DOI 10.1097/00003246-199611000-00009; DANIS M, 1988, JAMA-J AM MED ASSOC, V260, P797, DOI 10.1001/jama.260.6.797; DOUKAS DJ, 1991, J FAM PRACTICE, V32, P145; Finucane TE, 1999, JAMA-J AM MED ASSOC, V282, P1670, DOI 10.1001/jama.282.17.1670; Gazmararian JA, 1999, JAMA-J AM MED ASSOC, V281, P545, DOI 10.1001/jama.281.6.545; GILLICK MR, 1995, ANN INTERN MED, V123, P621, DOI 10.7326/0003-4819-123-8-199510150-00009; Hanson LC, 1997, ANN INTERN MED, V126, P381, DOI 10.7326/0003-4819-126-5-199703010-00007; Inouye SK, 1998, JAMA-J AM MED ASSOC, V279, P1187, DOI 10.1001/jama.279.15.1187; KNAUS WA, 1995, ANN INTERN MED, V122, P191, DOI 10.7326/0003-4819-122-3-199502010-00007; LAWTON MP, 1969, GERONTOLOGIST, V9, P179, DOI 10.1093/geront/9.3_Part_1.179; Lo B, 1999, ANN INTERN MED, V130, P772, DOI 10.7326/0003-4819-130-9-199905040-00018; Lynn J, 1997, J AM GERIATR SOC, V45, P526; Lynn J, 1997, ANN INTERN MED, V126, P97, DOI 10.7326/0003-4819-126-2-199701150-00001; MCNEIL BJ, 1982, NEW ENGL J MED, V306, P1259, DOI 10.1056/NEJM198205273062103; MURPHY DJ, 1994, NEW ENGL J MED, V330, P545, DOI 10.1056/NEJM199402243300807; MURPHY DJ, 1990, J CLIN EPIDEMIOL, V43, pS11, DOI 10.1016/0895-4356(90)90213-9; Navari RI, 2000, JAMA-J AM MED ASSOC, V284, P2449, DOI 10.1001/jama.284.19.2449; Patrick DL, 1997, ANN INTERN MED, V127, P509, DOI 10.7326/0003-4819-127-7-199710010-00002; PEARLMAN RA, 1993, J CLIN ETHIC, V4, P33; PFEIFFER E, 1975, J AM GERIATR SOC, V23, P433, DOI 10.1111/j.1532-5415.1975.tb00927.x; Ratner E, 2001, J AM GERIATR SOC, V49, P778, DOI 10.1046/j.1532-5415.2001.49155.x; Rosenfeld KE, 2000, J GEN INTERN MED, V15, P620, DOI 10.1046/j.1525-1497.2000.06289.x; ROYALL DR, 1992, J AM GERIATR SOC, V40, P1221, DOI 10.1111/j.1532-5415.1992.tb03646.x; SACHS GA, 1995, J AM GERIATR SOC, V43, P553, DOI 10.1111/j.1532-5415.1995.tb06106.x; SCHONWETTER RS, 1993, J GEN INTERN MED, V8, P295, DOI 10.1007/BF02600139; Schwartz LM, 1997, ANN INTERN MED, V127, P966, DOI 10.7326/0003-4819-127-11-199712010-00003; SLEVIN ML, 1990, BRIT MED J, V300, P1458, DOI 10.1136/bmj.300.6737.1458; Steinhauser AE, 2000, JAMA-J AM MED ASSOC, V284, P2476, DOI 10.1001/jama.284.19.2476; Tolle SW, 1999, ANN INTERN MED, V130, P681, DOI 10.7326/0003-4819-130-8-199904200-00015; Tulsky JA, 1998, ANN INTERN MED, V129, P441, DOI 10.7326/0003-4819-129-6-199809150-00003; WU AW, 1995, ANN INTERN MED, V122, P342, DOI 10.7326/0003-4819-122-5-199503010-00004	37	917	923	1	37	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	APR 4	2002	346	14					1061	1066		10.1056/NEJMsa012528	http://dx.doi.org/10.1056/NEJMsa012528			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	536YL	11932474	Bronze			2023-01-03	WOS:000174729400007
J	Steinbrook, R				Steinbrook, R			Perspective - The prescription-drug problem	NEW ENGLAND JOURNAL OF MEDICINE			English	Article																			0	16	17	1	4	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAR 14	2002	346	11					790	790		10.1056/NEJM200203143461102	http://dx.doi.org/10.1056/NEJM200203143461102			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	529YM	11893789				2023-01-03	WOS:000174328900001
J	Kabsch, K; Alonso, A				Kabsch, K; Alonso, A			The human papillomavirus type 16 (HPV-16) E5 protein sensitizes human keratinocytes to apoptosis induced by osmotic stress	ONCOGENE			English	Article						fpapillomavirus; keratinocytes; apoptosis; osmotic shock	GROWTH-FACTOR RECEPTOR; EPITHELIAL-CELL LINE; ACTIVATION; GENE; CASPASES; FIBROBLASTS; ONCOPROTEIN; KINASE; HACAT; DEATH	We have studied the role of the HPV-16 E5 protein in apoptosis, using HaCaT cell lines stably transfected with either E5 (HaCaT/E5) or the empty vector (HaCaT/ pMSG) as control. When subjected to a hyperosmolar concentration of sorbitol, HaCaT/E5 cells respond with cytochrome e release, activation of caspase-3, -8, and -9, and PARP-cleavage, showing that the mitochondria and death-receptor mediated apoptotic pathways are involved in subsequent cell death. Similar effects are observed for the control cells only after extended sorbitol treatment. Thus, E5-expressing cells are more sensitive to osmotic stress, perhaps because of modifications of the cellular membranes caused by this strongly hydrophobic molecule.	Deutsch Krebsforschungszentrum, D-69120 Heidelberg, Germany	Helmholtz Association; German Cancer Research Center (DKFZ)	Kabsch, K (corresponding author), Deutsch Krebsforschungszentrum, Neuenheimer Feld 242, D-69120 Heidelberg, Germany.	k.kabsch@dkfz-heidelberg.de						Aragane Y, 1998, J CELL BIOL, V140, P171, DOI 10.1083/jcb.140.1.171; Assefa Z, 2000, J BIOL CHEM, V275, P21416, DOI 10.1074/jbc.M002634200; BOUKAMP P, 1988, J CELL BIOL, V106, P761, DOI 10.1083/jcb.106.3.761; Budihardjo I, 1999, ANNU REV CELL DEV BI, V15, P269, DOI 10.1146/annurev.cellbio.15.1.269; CONRAD M, 1993, J VIROL, V67, P6170, DOI 10.1128/JVI.67.10.6170-6178.1993; Crusius K, 1999, ONCOGENE, V18, P6714, DOI 10.1038/sj.onc.1203075; Crusius K, 1998, EXP CELL RES, V241, P76, DOI 10.1006/excr.1998.4024; Crusius K, 2000, VIRUS GENES, V20, P65, DOI 10.1023/A:1008112207824; Earnshaw WC, 1999, ANNU REV BIOCHEM, V68, P383, DOI 10.1146/annurev.biochem.68.1.383; FAULKNERVALLE G, 1995, J GEN VIROL, V76, P1239; Fesik SW, 2000, CELL, V103, P273, DOI 10.1016/S0092-8674(00)00119-7; HACHISUKA H, 1990, CELL TISSUE RES, V260, P207, DOI 10.1007/BF00297507; HAUSEN HZ, 1991, VIROLOGY, V184, P9, DOI 10.1016/0042-6822(91)90816-T; HAUSEN HZ, 1991, SCIENCE, V254, P1167, DOI 10.1126/science.1659743; Hengartner MO, 2000, NATURE, V407, P770, DOI 10.1038/35037710; Jost M, 2001, J INVEST DERMATOL, V116, P860, DOI 10.1046/j.1523-1747.2001.01356.x; KAUFMANN SH, 1993, CANCER RES, V53, P3976; KELL B, 1994, J GEN VIROL, V75, P2451, DOI 10.1099/0022-1317-75-9-2451; Lang F, 1998, PHYSIOL REV, V78, P247, DOI 10.1152/physrev.1998.78.1.247; LEECHANACHAI P, 1992, ONCOGENE, V7, P19; LEPTAK C, 1991, J VIROL, V65, P7078, DOI 10.1128/JVI.65.12.7078-7083.1991; LEPTAK C, 1992, J VIROL, V66, P1833; OELZE I, 1995, J VIROL, V69, P4489, DOI 10.1128/JVI.69.7.4489-4494.1995; PIM D, 1992, ONCOGENE, V7, P27; Rich T, 2000, NATURE, V407, P777, DOI 10.1038/35037717; Scaffidi C, 1997, J BIOL CHEM, V272, P26953, DOI 10.1074/jbc.272.43.26953; Shimizu H, 1999, J INVEST DERMATOL, V112, P769, DOI 10.1046/j.1523-1747.1999.00582.x; STOLER MH, 1992, HUM PATHOL, V23, P117, DOI 10.1016/0046-8177(92)90232-R; STRAIGHT SW, 1993, J VIROL, V67, P4521, DOI 10.1128/JVI.67.8.4521-4532.1993; Strasser A, 2000, ANNU REV BIOCHEM, V69, P217, DOI 10.1146/annurev.biochem.69.1.217; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; ULLMAN CG, 1994, BIOCHEM SOC T, V22, pS439, DOI 10.1042/bst022439s; Wang J, 2000, J CELL SCI, V113, P753	33	23	25	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 31	2002	21	6					947	953		10.1038/sj.onc.1205147	http://dx.doi.org/10.1038/sj.onc.1205147			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	514FC	11840340				2023-01-03	WOS:000173427100010
J	Hodis, HN; Mack, WJ; Lobo, RA; Shoupe, D; Sevanian, A; Mahrer, PR; Selzer, RH; Liu, CR; Liu, CH; Azen, SP				Hodis, HN; Mack, WJ; Lobo, RA; Shoupe, D; Sevanian, A; Mahrer, PR; Selzer, RH; Liu, CR; Liu, CH; Azen, SP			Estrogen in the prevention of atherosclerosis - A randomized, double-blind, placebo-controlled trial	ANNALS OF INTERNAL MEDICINE			English	Article							INTIMA-MEDIA THICKNESS; HORMONE REPLACEMENT THERAPY; CORONARY-HEART-DISEASE; CAROTID-ARTERY INTIMA; C-REACTIVE PROTEIN; COLESTIPOL-NIACIN THERAPY; POSTMENOPAUSAL WOMEN; MYOCARDIAL-INFARCTION; CARDIOVASCULAR-DISEASE; WALL THICKNESS	Background: Although observational studies suggest that estrogen replacement therapy (ERT) reduces cardiovascular morbidity and mortality in postmenopausal women, use of unopposed ERT for prevention of coronary heart disease in healthy postmenopausal women remains untested. Objective: To determine the effects of unopposed ERT on the progression of subclinical atherosclerosis in healthy postmenopausal women without preexisting cardiovascular disease. Design: Randomized, double-blind, placebo-controlled trial. Setting: University-based clinic. Patients: 222 postmenopausal women 45 years of age or older without preexisting cardiovascular disease and with low-density lipoprotein cholesterol levels of 3.37 mmol/L or greater (greater than or equal to 130 mg/dL). Intervention: unopposed micronized 17 beta -estradiol (1 mg/d) or placebo. All women received dietary counseling. Women received lipid-lowering medication if their low-density lipoprotein cholesterol level exceeded 4.15 mmol/L (160 mg/dL). Measurements: The rate of change in intima-media thickness of the right distal common carotid artery far wall in computer image processed B-mode ultrasonograms obtained at baseline and every 6 months during the 2-year trial. Results: In a multivariable mixed-effects model, among women who had at least one follow-up measurement of carotid intima-media thickness (n = 199), the average rate of progression of subclinical atherosclerosis was lower in those taking unopposed estradiol than in those taking placebo (-0.0017 mm/y vs. 0.0036 mm/y); the placebo-estradiol difference between average progression rates was 0.0053 mm/y (95% Cl, 0.0001 to 0.0105 mm/y) (P = 0.046). Among women who did not receive lipid-lowering medication (n = 77), the placebo-estradiol difference between average rates of progression was 0.0147 mm/y (Cl, 0.0055 to 0.0240) (P = 0.002). Average rates of progression did not differ between estradiol and placebo recipients who took lipid-lowering medication (n = 122) (P > 0.2). Conclusions: overall, the average rate of progression of subclinical atherosclerosis was slower in healthy postmenopausal women taking unopposed ERT with 17 beta -estradiol than in women taking placebo. Reduction In the progression of subclinical atherosclerosis was seen in women who did not take lipid-lowering medication but not in those who took these medications.	Univ So Calif, Atherosclerosis Res Unit, Los Angeles, CA 90033 USA; Kaiser Permanente Med Ctr, Los Angeles, CA 90034 USA; CALTECH, Jet Prop Lab, Pasadena, CA 91125 USA; Columbia Univ, Coll Phys & Surg, New York, NY USA	University of Southern California; Kaiser Permanente; California Institute of Technology; National Aeronautics & Space Administration (NASA); NASA Jet Propulsion Laboratory (JPL); Columbia University	Hodis, HN (corresponding author), Univ So Calif, Atherosclerosis Res Unit, 2250 Alcazar St,CSC 132, Los Angeles, CA 90033 USA.	watcher@usc.edu			NIA NIH HHS [R01-AG-18798] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [R01AG018798] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Adams MR, 1997, ARTERIOSCL THROM VAS, V17, P217, DOI 10.1161/01.ATV.17.1.217; Anthony MS, 2000, CIRCULATION, V101, P714; BARRETTCONNOR E, 1991, ANN INTERN MED, V115, P455, DOI 10.7326/0003-4819-115-6-455; BEACH KW, 1989, ULTRASOUND MED BIOL, V15, P723, DOI 10.1016/0301-5629(89)90112-9; BLANKENHORN DH, 1994, ARTERIOSCLER THROMB, V14, P177, DOI 10.1161/01.ATV.14.2.177; BLANKENHORN DH, 1993, CIRCULATION, V88, P20, DOI 10.1161/01.CIR.88.1.20; Bots ML, 1997, CIRCULATION, V96, P1432, DOI 10.1161/01.CIR.96.5.1432; Byington RP, 1999, CIRCULATION, V100, pE14; BYINGTON RP, 1999, J AM COLL CARDIOL S, pA265; Chambless LE, 1997, AM J EPIDEMIOL, V146, P483, DOI 10.1093/oxfordjournals.aje.a009302; COLDITZ GA, 1987, NEW ENGL J MED, V316, P1105, DOI 10.1056/NEJM198704303161801; Cushman M, 1999, ARTERIOSCL THROM VAS, V19, P893, DOI 10.1161/01.ATV.19.4.893; Cushman M, 1999, CIRCULATION, V100, P717, DOI 10.1161/01.CIR.100.7.717; ESPELAND MA, 1995, AM J EPIDEMIOL, V142, P1011, DOI 10.1093/oxfordjournals.aje.a117553; FALKEBORN M, 1992, BRIT J OBSTET GYNAEC, V99, P821, DOI 10.1111/j.1471-0528.1992.tb14414.x; Grodstein F, 1998, MATURITAS, V30, P19, DOI 10.1016/S0378-5122(98)00055-3; GRODSTEIN F, 1995, PROG CARDIOVASC DIS, V38, P199, DOI 10.1016/S0033-0620(95)80012-3; GRUCHOW HW, 1988, AM HEART J, V115, P954, DOI 10.1016/0002-8703(88)90063-4; Herrington DM, 2000, NEW ENGL J MED, V343, P522, DOI 10.1056/NEJM200008243430801; Hodis HN, 1998, ANN INTERN MED, V128, P262, DOI 10.7326/0003-4819-128-4-199802150-00002; Hodis HN, 1996, ANN INTERN MED, V124, P548, DOI 10.7326/0003-4819-124-6-199603150-00002; Hodis HN, 1999, CURR PRACT MED, V2, P171; HONG MK, 1992, AM J CARDIOL, V69, P176, DOI 10.1016/0002-9149(92)91300-S; HOUGH JL, 1986, ARTERIOSCLEROSIS, V6, P57, DOI 10.1161/01.ATV.6.1.57; Hulley S, 1998, JAMA-J AM MED ASSOC, V280, P605, DOI 10.1001/jama.280.7.605; HUNT K, 1987, BRIT J OBSTET GYNAEC, V94, P620, DOI 10.1111/j.1471-0528.1987.tb03166.x; JOHANSSON S, 1983, EPIDEMIOL REV, V5, P67, DOI 10.1093/oxfordjournals.epirev.a036265; KANNEL WB, 1976, ANN INTERN MED, V85, P447, DOI 10.7326/0003-4819-85-4-447; KUSHWAHA RS, 1991, ARTERIOSCLER THROMB, V11, P23, DOI 10.1161/01.ATV.11.1.23; LAIRD NM, 1982, BIOMETRICS, V38, P963, DOI 10.2307/2529876; LOBO RA, 1990, ANN NY ACAD SCI, V592, P286; MACK WJ, 1993, STROKE, V24, P1779, DOI 10.1161/01.STR.24.12.1779; Mack WJ, 2000, ATHEROSCLEROSIS, V150, P371, DOI 10.1016/S0021-9150(99)00383-4; MANOLIO TA, 1993, CIRCULATION, V88, P2163, DOI 10.1161/01.CIR.88.5.2163; MCFARLAND KF, 1989, AM HEART J, V117, P1209, DOI 10.1016/0002-8703(89)90398-0; McGrath BP, 1998, ARTERIOSCL THROM VAS, V18, P1149, DOI 10.1161/01.ATV.18.7.1149; Mercuri M, 1996, AM J MED, V101, P627, DOI 10.1016/S0002-9343(96)00333-6; MILLER VT, 1995, JAMA-J AM MED ASSOC, V273, P199, DOI 10.1001/jama.1995.03520270033028; Nabulsi AA, 1996, CIRCULATION, V94, P1857, DOI 10.1161/01.CIR.94.8.1857; NACHTIGALL LE, 1979, OBSTET GYNECOL, V54, P74, DOI 10.1097/00006250-197907000-00017; *NAT CTR HLTH STAT, 1988, VIT STAT US, V11; O'Leary DH, 1999, NEW ENGL J MED, V340, P14, DOI 10.1056/NEJM199901073400103; Ridker PM, 1999, CIRCULATION, V100, P713, DOI 10.1161/01.CIR.100.7.713; Ridker PM, 2000, NEW ENGL J MED, V342, P836, DOI 10.1056/NEJM200003233421202; SALONEN JT, 1993, CIRCULATION, V87, P56; SALONEN R, 1995, CIRCULATION, V92, P1758, DOI 10.1161/01.CIR.92.7.1758; SELZER RH, 1994, ATHEROSCLEROSIS, V111, P1, DOI 10.1016/0021-9150(94)90186-4; Selzer RH, 2001, ATHEROSCLEROSIS, V154, P185, DOI 10.1016/S0021-9150(00)00461-5; SULLIVAN JM, 1988, ANN INTERN MED, V108, P358, DOI 10.7326/0003-4819-108-3-358; van Baal WM, 1999, THROMB HAEMOSTASIS, V81, P925, DOI 10.1055/s-0037-1614600; WAGNER JD, 1991, J CLIN INVEST, V88, P1995, DOI 10.1172/JCI115526; Westendorp ICD, 1999, STROKE, V30, P2562, DOI 10.1161/01.STR.30.12.2562; WILLIAMS JK, 1990, CIRCULATION, V81, P1680, DOI 10.1161/01.CIR.81.5.1680; 1974, CHEW PUBLICATION	54	529	538	0	5	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	DEC 4	2001	135	11					939	953		10.7326/0003-4819-135-11-200112040-00005	http://dx.doi.org/10.7326/0003-4819-135-11-200112040-00005			15	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	498PN	11730394				2023-01-03	WOS:000172520000001
J	Morris, MC; Depollier, J; Mery, J; Heitz, F; Divita, G				Morris, MC; Depollier, J; Mery, J; Heitz, F; Divita, G			A peptide carrier for the delivery of biologically active proteins into mammalian cells	NATURE BIOTECHNOLOGY			English	Article							HIV-1 TAT PROTEIN; TRANSDUCTION; DOMAIN; DNA	The development of peptide drugs and therapeutic proteins is limited by the poor permeability and the selectivity of the cell membrane. There is a growing effort to circumvent these problems by designing strategies to deliver full-length proteins into a large number of cells(1-3). A series of small protein domains, termed protein transduction domains (PTDs), have been shown to cross biological membranes efficiently and independently of transporters or specific receptors, and to promote the delivery of peptides and proteins into cells. TAT protein from human immunodeficiency virus (HIV-1) is able to deliver biologically active proteins in vivo and has been shown to be of considerable interest for protein therapeutics(4-9). Similarly, the third alpha -helix of Antennapedia homeodomain(10-12), and VP22 protein from herpes simplex virus(13,14) promote the delivery of covalently linked peptides or proteins into cells. However, these PTD vectors display a certain number of limitations in that they all require crosslinking to the target peptide or protein. Moreover, protein transduction using PTD-TAT fusion protein systems may require denaturation of the protein before delivery to increase the accessibility of the TAT-PTD domain. This requirement introduces an additional delay between the time of delivery and intracellular activation of the protein(1). In this report, we propose a new strategy for protein delivery based on a short amphipathic peptide carrier, Pep-1. This peptide carrier is able to efficiently deliver a variety of peptides and proteins into several cell lines in a fully biologically active form, without the need for prior chemical covalent coupling or denaturation steps. In addition, this peptide carrier presents several advantages or protein therapy, including stability in physiological buffer, lack of toxicity, and lack of sensitivity to serum. Pep-1 technology should be extremely useful for targeting specific protein-protein interactions in living cells and for screening novel therapeutic proteins.	CNRS, Ctr Rech Biochim Macromol, UPR 1086, F-34293 Montpellier 5, France	Centre National de la Recherche Scientifique (CNRS); Universite de Montpellier	Divita, G (corresponding author), CNRS, Ctr Rech Biochim Macromol, UPR 1086, 1919 Route Mende, F-34293 Montpellier 5, France.		MORRIS, May/ABB-2629-2021; MORRIS, May C/J-5940-2016; DIVITA, GILLES/AAV-9214-2021	MORRIS, May/0000-0001-8106-9728; MORRIS, May C/0000-0001-8106-9728; 				Chen YNP, 1999, P NATL ACAD SCI USA, V96, P4325, DOI 10.1073/pnas.96.8.4325; DEROSSI D, 1994, J BIOL CHEM, V269, P10444; Elliott G, 1997, CELL, V88, P223, DOI 10.1016/S0092-8674(00)81843-7; FAWELL S, 1994, P NATL ACAD SCI USA, V91, P664, DOI 10.1073/pnas.91.2.664; Ford KG, 2001, GENE THER, V8, P1, DOI 10.1038/sj.gt.3301383; FRANKEL AD, 1988, CELL, V55, P1189, DOI 10.1016/0092-8674(88)90263-2; Lindgren M, 2000, TRENDS PHARMACOL SCI, V21, P99, DOI 10.1016/S0165-6147(00)01447-4; Luo D, 2000, NAT BIOTECHNOL, V18, P33, DOI 10.1038/71889; MANN DA, 1991, EMBO J, V10, P1733, DOI 10.1002/j.1460-2075.1991.tb07697.x; Morris MC, 2000, CURR OPIN BIOTECH, V11, P461, DOI 10.1016/S0958-1669(00)00128-2; Morris MC, 1999, J BIOL CHEM, V274, P24941, DOI 10.1074/jbc.274.35.24941; Morris MC, 1997, NUCLEIC ACIDS RES, V25, P2730, DOI 10.1093/nar/25.14.2730; Morris MC, 2000, J BIOL CHEM, V275, P28849, DOI 10.1074/jbc.M002942200; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; Nagahara H, 1998, NAT MED, V4, P1449, DOI 10.1038/4042; Phelan A, 1998, NAT BIOTECHNOL, V16, P440, DOI 10.1038/nbt0598-440; Prochiantz A, 2000, CURR OPIN CELL BIOL, V12, P400, DOI 10.1016/S0955-0674(00)00108-3; Schwarze SR, 1999, SCIENCE, V285, P1569, DOI 10.1126/science.285.5433.1569; Schwarze SR, 2000, TRENDS PHARMACOL SCI, V21, P45, DOI 10.1016/S0165-6147(99)01429-7; Vives E, 1997, J BIOL CHEM, V272, P16010, DOI 10.1074/jbc.272.25.16010	20	829	1006	5	181	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	DEC	2001	19	12					1173	1176		10.1038/nbt1201-1173	http://dx.doi.org/10.1038/nbt1201-1173			4	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	498RN	11731788				2023-01-03	WOS:000172524400032
J	White, HD; Simes, RJ; Aylward, PEG; Armstrong, PW; Califf, RM; French, JK; Granger, CB; Marschner, IC; Topol, EJ; Van de Werf, FJ; Wilcox, RG				White, HD; Simes, RJ; Aylward, PEG; Armstrong, PW; Califf, RM; French, JK; Granger, CB; Marschner, IC; Topol, EJ; Van de Werf, FJ; Wilcox, RG		Hirulog Early Reperfusion Occlusi	Thrombin-specific anticoagulation with bivalirudin versus heparin in patients receiving fibrinolytic therapy for acute myocardial infarction: the HERO-2 randomised trial	LANCET			English	Article							TISSUE-PLASMINOGEN-ACTIVATOR; THROMBOLYTIC THERAPY; GUSTO-I; CLINICAL-OUTCOMES; STREPTOKINASE; INHIBITION; PREDICTORS; MORTALITY; ASPIRIN; HIRULOG	Background The combination of fibrinolytic therapy and heparin for acute myocardial infarction fails to achieve reperfusion in 40-70% of patients, and early reocclusion occurs in a substantial number. We did a randomised, open-label trial to compare the thrombin-specific anticoagulant, bivalirudin, with heparin in patients undergoing fibrinolysis with streptokinase for acute myocardial infarction. Methods 17 073 patients with acute ST-elevation myocardial infarction were randomly assigned an intravenous bolus and 48-h infusion of either bivalirudin (n=8516) or heparin (n=8557), together with a standard 1.5 million unit dose of streptokinase given directly after the antithrombotic bolus. The primary endpoint was 30-day mortality. Secondary endpoints included reinfarction within 96 h and bleeding. Strokes and reinfarctions were adjudicated by independent committees who were unaware of treatment allocation. Analysis was by intention to treat. Findings By 30 days, 919 patients (10.8%) in the bivalirudin group and 931 (10.9%) in the heparin group had died (odds ratio 0.99 [95% CI 0.90-1.09], p=0.85). The mortality rates adjusted for baseline risk factors were 10.5% for bivalirudin and 10.9% for heparin (0.96 [0.86-1.07], p=0.46). There were significantly fewer reinfarctions within 96 h in the bivalirudin group than in the heparin group (0.70 [0.56-0.87], p=0.001). Severe bleeding occurred in 58 patients (0.7%) in the bivalirudin group versus 40 patients (0.5%) in the heparin group (p=0.07), and intracerebral bleeding occurred fn 47 (0.6%) versus 32 (0.4%), respectively (p=0.09). The rates of moderate and mild bleeding were significantly higher in the bivalirudin group than the heparin group (1.32 [1.00-1.74], p=0.05; and 1.47 [1.34-1.62], p<0.0001; respectively. Transfusions were given to 118 patients (1.4%) in the bivalirudin group versus 95 patients (1.1%) in the heparin group (1.25 [0.95-1.64], p=0.11). Interpretation Bivalirudin did not reduce mortality compared with unfractionated heparin, but did reduce the rate of adjudicated reinfarction within 96 h by 30%. Small absolute increases were seen in mild and moderate bleeding fn patients given bivalirudin. Bivalirudin is a new anticoagulant treatment option in patients with acute myocardial infarction treated with streptokinase.	Green Lane Hosp, Dept Cardiol, Auckland 1030, New Zealand		White, HD (corresponding author), Green Lane Hosp, Dept Cardiol, Private Bag 92 189, Auckland 1030, New Zealand.	harveyw@adhb.govt.nz	Manolis, Antonis/F-5003-2014; Granger, Christopher B/D-3458-2014; Strahan, Thomas/F-9283-2011; Simes, Robert John/P-1497-2014	Manolis, Antonis/0000-0002-0336-4745; Granger, Christopher B/0000-0002-0045-3291; Topol, Eric/0000-0002-1478-4729; Marschner, Ian/0000-0002-6225-1572; Armstrong, Paul/0000-0002-0460-3445; Aylward, Philip/0000-0002-5358-8552				Antman EM, 1999, CIRCULATION, V99, P2720, DOI 10.1161/01.CIR.99.21.2720; Berkowitz SD, 1997, CIRCULATION, V95, P2508, DOI 10.1161/01.CIR.95.11.2508; BITTL JA, IN PRESS AM HEART J; Braunwald E, 2000, EUR HEART J, V21, P2005; Califf RM, 1997, AM HEART J, V133, P630, DOI 10.1016/S0002-8703(97)70164-9; CHESEBRO JH, 1987, CIRCULATION, V76, P142, DOI 10.1161/01.CIR.76.1.142; Collins R, 1997, NEW ENGL J MED, V336, P847, DOI 10.1056/NEJM199703203361207; GALVANI M, 1994, J AM COLL CARDIOL, V24, P1445, DOI 10.1016/0735-1097(94)90138-4; GORE JM, 1995, CIRCULATION, V92, P2811, DOI 10.1161/01.CIR.92.10.2811; Granger CB, 1998, J AM COLL CARDIOL, V31, P497, DOI 10.1016/S0735-1097(97)00539-1; Granger CB, 1996, CIRCULATION, V93, P870, DOI 10.1161/01.CIR.93.5.870; Hosmer DW, 2000, APPL LOGISTIC REGRES, DOI 10.1002/0471722146; Hudson MP, 2001, CIRCULATION, V104, P1229, DOI 10.1161/hc3601.095717; *INT JOINT EFF COM, 1995, LANCET, V346, P329; Kong DF, 1999, CIRCULATION, V100, P2049, DOI 10.1161/01.CIR.100.20.2049; LEE KL, 1995, CIRCULATION, V91, P1659, DOI 10.1161/01.CIR.91.6.1659; Morrow DA, 2000, CIRCULATION, V102, P2031, DOI 10.1161/01.CIR.102.17.2031; Ronner E, 2000, EUR HEART J, V21, P1530, DOI 10.1053/euhj.1999.2035; ROSS AM, 1993, NEW ENGL J MED, V329, P1615; SIMOONS ML, IN PRESS EUR HEART J; Topol E, 1997, NEW ENGL J MED, V337, P1118; TOPOL E, 1993, NEW ENGL J MED, V329, P673, DOI 10.1056/nejm199309023291001; Topol EJ, 2001, LANCET, V357, P1905; Van de Werf F, 1999, LANCET, V354, P716, DOI 10.1016/S0140-6736(99)07403-6; Van de Werf F, 2001, LANCET, V358, P605; van Domburg R T, 2001, Neth Heart J, V9, P166; WEITZ JI, 1990, J CLIN INVEST, V86, P385, DOI 10.1172/JCI114723; White HD, 1997, CIRCULATION, V96, P2155; White HD, 1998, AM J CARDIOL, V82, p57P, DOI 10.1016/S0002-9149(98)00663-8; White HD, 1998, J AM COLL CARDIOL, V31, P494	30	258	274	0	10	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	DEC 1	2001	358	9296					1855	1863						9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	497NU	11741625				2023-01-03	WOS:000172463000011
J	Schwetz, BA				Schwetz, BA			Safety of aristolochic acid	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	News Item									US FDA, Rockville, MD 20857 USA	US Food & Drug Administration (FDA)	Schwetz, BA (corresponding author), US FDA, Rockville, MD 20857 USA.								0	33	33	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 6	2001	285	21					2705	2705						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	437HG	11386912				2023-01-03	WOS:000168985800004
J	Fabre, JW				Fabre, JW			The allogeneic response and tumor immunity	NATURE MEDICINE			English	Editorial Material							CYTOTOXIC T-LYMPHOCYTES; DENDRITIC CELLS; ALLOGRAFT-REJECTION; CANCER-CELLS; IFN-GAMMA; IN-VIVO; ANTIGENS; HYBRIDS; ALLOREACTIVITY; VACCINATION	The strong allogeneic response to donor MHC molecules in transplantation and the weak response to tumor antigens represent two important and divergent but potentially interactive immune responses. A patient's response to allogeneic MHC molecules might promote an effective T-cell response to self MHC-restricted tumor peptides and the possibilities for this are discussed here. These allogeneic responses might successfully be harnessed to promote the immune eradication of metastatic cancer.	Guys Kings & St Thomas Sch Med, Inst Liver Studies, Dept Clin Sci, London, England	University of London; King's College London	Fabre, JW (corresponding author), Guys Kings & St Thomas Sch Med, Inst Liver Studies, Dept Clin Sci, London, England.							BACH FH, 1966, SCIENCE, V153, P545, DOI 10.1126/science.153.3735.545; BENHAM AM, 1995, TRANSPLANTATION, V59, P1028, DOI 10.1097/00007890-199504150-00019; BEVAN MJ, 1984, IMMUNOL TODAY, V5, P128, DOI 10.1016/0167-5699(84)90233-0; BEVERLY B, 1992, INT IMMUNOL, V4, P661, DOI 10.1093/intimm/4.6.661; BURROWS SR, 1994, J EXP MED, V179, P1155, DOI 10.1084/jem.179.4.1155; DAAR AS, 1983, EUR J CANCER CLIN ON, V19, P209, DOI 10.1016/0277-5379(83)90419-4; FANGMANN J, 1992, J EXP MED, V175, P1521, DOI 10.1084/jem.175.6.1521; FLEMING KA, 1981, J CLIN PATHOL, V34, P779, DOI 10.1136/jcp.34.7.779; FREY AB, 1995, J IMMUNOL, V154, P4613; Gilboa E, 1999, IMMUNITY, V11, P263, DOI 10.1016/S1074-7613(00)80101-6; Gjertsen H A, 1993, Transpl Immunol, V1, P126, DOI 10.1016/0966-3274(93)90005-S; Gong JL, 2000, J IMMUNOL, V165, P1705, DOI 10.4049/jimmunol.165.3.1705; Grene E, 2000, AIDS, V14, P1497, DOI 10.1097/00002030-200007280-00005; HALL BM, 1991, TRANSPLANTATION, V51, P1141, DOI 10.1097/00007890-199106000-00001; HART DNJ, 1980, TRANSPLANTATION, V30, P73, DOI 10.1097/00007890-198007000-00016; HART DNJ, 1981, J EXP MED, V154, P347, DOI 10.1084/jem.154.2.347; HELLSTRO.I, 1967, SCIENCE, V156, P981, DOI 10.1126/science.156.3777.981; HELLSTROM I, 1968, NATURE, V220, P1352, DOI 10.1038/2201352a0; Kelly CM, 1996, TRANSPLANTATION, V61, P1094, DOI 10.1097/00007890-199604150-00018; KIM BS, 1979, J IMMUNOL, V123, P739; Koopman LA, 2000, J EXP MED, V191, P961, DOI 10.1084/jem.191.6.961; Kugler A, 2000, NAT MED, V6, P332, DOI 10.1038/73193; Lahn M, 1997, EUR SURG RES, V29, P292, DOI 10.1159/000129536; LECHLER RI, 1990, IMMUNOL TODAY, V11, P83, DOI 10.1016/0167-5699(90)90033-6; MASON DW, 1984, IMMUNOL REV, V77, P167, DOI 10.1111/j.1600-065X.1984.tb00721.x; MATZINGER P, 1994, ANNU REV IMMUNOL, V12, P991, DOI 10.1146/annurev.immunol.12.1.991; MATZINGER P, 1977, CELL IMMUNOL, V29, P1, DOI 10.1016/0008-8749(77)90269-6; Medzhitov R, 2000, NEW ENGL J MED, V343, P338, DOI 10.1056/NEJM200008033430506; MILLAR JW, 1980, THORAX, V35, P856, DOI 10.1136/thx.35.11.856; MITCHISON NA, 1987, EUR J IMMUNOL, V17, P1579, DOI 10.1002/eji.1830171109; MORALES A, 1976, J UROLOGY, V116, P180, DOI 10.1016/S0022-5347(17)58737-6; Mumberg D, 1999, P NATL ACAD SCI USA, V96, P8633, DOI 10.1073/pnas.96.15.8633; Newton DA, 2000, J IMMUNOTHER, V23, P246, DOI 10.1097/00002371-200003000-00009; Newton DA, 2001, J IMMUNOTHER, V24, P19, DOI 10.1097/00002371-200101000-00003; NISBET NW, 1969, J EXP MED, V129, P459, DOI 10.1084/jem.129.3.459; PAYELLE B, 1981, INT J CANCER, V27, P783, DOI 10.1002/ijc.2910270609; REISERJB, 2000, NATURE IMMUNOL, V1, P291; SANTOSAGUADO J, 1989, P NATL ACAD SCI USA, V86, P8936, DOI 10.1073/pnas.86.22.8936; Shearer GM, 1999, IMMUNOL TODAY, V20, P66, DOI 10.1016/S0167-5699(98)01392-9; STEIMLE V, 1993, CELL, V75, P135, DOI 10.1016/S0092-8674(05)80090-X; Suchin EJ, 2001, J IMMUNOL, V166, P973, DOI 10.4049/jimmunol.166.2.973; THATCHER N, 1984, BRIT J DIS CHEST, V78, P89, DOI 10.1016/0007-0971(84)90101-3; Thurner B, 1999, J EXP MED, V190, P1669, DOI 10.1084/jem.190.11.1669; TOFFALETTI DL, 1983, J IMMUNOL, V130, P2982; Vaughan JW, 1914, J AMER MED ASSOC, V63, P1258	45	82	86	0	4	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	JUN	2001	7	6					649	652		10.1038/89008	http://dx.doi.org/10.1038/89008			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	438YH	11385492				2023-01-03	WOS:000169081500020
J	Ansell, P; Roman, E; Fear, NT; Renfrew, MJ				Ansell, P; Roman, E; Fear, NT; Renfrew, MJ			Vitamin K policies and midwifery practice: questionnaire survey	BRITISH MEDICAL JOURNAL			English	Article							CHILDHOOD-CANCER; PROPHYLAXIS; LEUKEMIA; NEWBORN	Objectives To investigate policies on neonatal vitamin K and their implementation, Design Two phase postal survey. Setting United Kingdom, Participants A 10% random sample of midwives registered with the United Kingdom Central Council for nursing, midwifery, and health visiting, Of 3191 midwives in the sample, 2515 (79%) responded to phase one and 2294 (72%) completed questionnaires on their current jobs (November 1998 to May 1999), In phase two, 853 (62%) of 1383 eligible midwives gave details on 2179 of their earliest jobs (start dates before 1990). Results All the midwives in clinical practice at the time of the survey (2271, 99%) reported that the) were working in areas with official policies on neonatal vitamin K. Seven distinct policies were described: intramuscular vitamin K for all babies (1159, 51.0%); intramuscular vitamin K for babies at "high risk," oral for others (470, 20.7%); oral vitamin K for all babies (323, 14.2%); parental choice for all (124, 5.5%): parental choice for all except babies at high risk. (119, 5.2%); intramuscular vitamin K for babies at high risk only (33, 1.5%); oral vitamin K for babies at high risk only. (17, 0.7%); and a disparate group of policies including intravenous vitamin K for some babies (26, 1.1%). Previous policies were land some may still be) open to individual interpretation and were not always followed. Conclusions Hospital policy is not necessarily a good guide to individual practice. The primary purpose of clinical records is to document patient care, and recording practices reflect this. There is considerable variation in vitamin K policies and midwifery practice in the United Kingdom, and there is no clear consensus on which babies should receive vitamin K intramuscularly.	Univ Leeds, Inst Epidemiol, Leukaemia Res Fund Ctr, Leeds LS2 9LN, W Yorkshire, England; Univ Leeds, Mother & Infant Res Unit, Leeds LS2 9LN, W Yorkshire, England	University of Leeds; University of Leeds	Ansell, P (corresponding author), Univ Leeds, Inst Epidemiol, Leukaemia Res Fund Ctr, Leeds LS2 9LN, W Yorkshire, England.		Fear, Nicola/A-1917-2012; Renfrew, Mary/A-2440-2010	Fear, Nicola/0000-0002-5792-2925; Renfrew, Mary/0000-0003-2905-403X; Roman, Eve/0000-0001-7603-3704				Ansell P, 1996, BRIT MED J, V313, P204, DOI 10.1136/bmj.313.7051.204; Asch DA, 1997, J CLIN EPIDEMIOL, V50, P1129, DOI 10.1016/S0895-4356(97)00126-1; BARTON JS, 1995, BRIT MED J, V310, P632, DOI 10.1136/bmj.310.6980.632; BARTON JS, 1994, LANCET, V343, P1168, DOI 10.1016/S0140-6736(94)90277-1; *DEP HLTH, 1999, NHS HOSP COMM HLTH S; *DEP HLTH, 1998, VIT K NEWB BAB; EKELUND H, 1993, BRIT MED J, V307, P89, DOI 10.1136/bmj.307.6896.89; GOLDING J, 1992, BRIT MED J, V305, P341, DOI 10.1136/bmj.305.6849.341; HANDEL J, 1991, BRIT MED J, V303, P1109, DOI 10.1136/bmj.303.6810.1109; *ISD SCOTL, 2001, SCOTT HLTH STAT 2000; KLEBANOFF MA, 1993, NEW ENGL J MED, V329, P905, DOI 10.1056/NEJM199309233291301; McKinney PA, 1998, BRIT MED J, V316, P173, DOI 10.1136/bmj.316.7126.173; *NAT CHILDB TRUST, 1994, PAR RIGHTS DEN VIT K; OLSEN JH, 1994, BRIT MED J, V308, P895, DOI 10.1136/bmj.308.6933.895; PARKER L, 1998, BRIT MED J, V316, P184; Passmore SJ, 1998, BRIT MED J, V316, P184, DOI 10.1136/bmj.316.7126.184; Passmore SJ, 1998, BRIT MED J, V316, P178, DOI 10.1136/bmj.316.7126.178; *ROYAL COLL MIDW, 1999, RCM MIDWIVES J, V2, P252; vonKries R, 1996, BRIT MED J, V313, P199, DOI 10.1136/bmj.313.7051.199	19	16	16	1	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	MAY 12	2001	322	7295					1148	+		10.1136/bmj.322.7295.1148	http://dx.doi.org/10.1136/bmj.322.7295.1148			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	433HH	11348908	Green Submitted, Bronze, Green Published, Green Accepted			2023-01-03	WOS:000168748900014
J	Zwart, F				Zwart, F			A very special day	BRITISH MEDICAL JOURNAL			English	Editorial Material																			0	2	2	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 26	1997	315	7102					260	260		10.1136/bmj.315.7102.260	http://dx.doi.org/10.1136/bmj.315.7102.260			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XN517	11644985	Green Published			2023-01-03	WOS:A1997XN51700077
J	DUNEA, G				DUNEA, G			EDITORS IN DISTRESS	BRITISH MEDICAL JOURNAL			English	Editorial Material																		1988, BR MED J, V296, P307; 1988, JAMA            0108, P272	2	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 6	1988	297	6645					430	430		10.1136/bmj.297.6645.430	http://dx.doi.org/10.1136/bmj.297.6645.430			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	P5450	11644468	Green Published, Bronze			2023-01-03	WOS:A1988P545000065
J	Baum, M; Buzdar, AU; Cuzick, J; Forbes, J; Houghton, J; Klijn, JGM; Sahmoud, T				Baum, M; Buzdar, AU; Cuzick, J; Forbes, J; Houghton, J; Klijn, JGM; Sahmoud, T		ATAC Trialists' Grp	Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial	LANCET			English	Article							FIRST-LINE THERAPY; ENDOMETRIAL CANCER; RISK; CARCINOMA; SUPERIOR; ARIMIDEX	Background In the adjuvant setting, tamoxifen is the established treatment for postmenopausal women with hormone-sensitive breast cancer. However, it is associated with several side-effects including endometrial cancer and thromboembolic disorders. We aimed to compare the safety and efficacy outcomes of tamoxifen with those of anastrozole alone and the combination of anastrozole plus tamoxifen for 5 years. Methods Participants were postmenopausal patients with invasive operable breast cancer who had completed primary therapy and were eligible to receive adjuvant hormonal therapy. The primary endpoints were disease-free survival and occurrence of adverse events. Analysis for efficacy was by intention to treat. Findings 9386 patients were recruited, of whom 3125 were randomly assigned anastrozole, 3116 tamoxifen, and 3125 combination. Median follow-up was 33.3 months. 7839 (84%) patients were known to be hormone-receptor-positive. Disease-free survival at 3 years was 89.4% on anastrozole and 87.4% on tamoxifen (hazard ratio 0.83 [95% CI 0.71-0.96], p=0.013). Results with the combination were not significantly different from those with tamoxifen alone (87.2%, 1.02 [0.89-1.18], p=0.8). The improvement in disease-free survival with anastrozole was seen in the subgroup of hormone-receptor-positive patients, but not the receptor-negative patients. Incidence of contralateral breast cancer was significantly lower with anastrozole than with tamoxifen (odds ratio 0.42 [0.22-0.79], p=0.007). Anastrozole was significantly better tolerated than tamoxifen with respect to endometrial cancer (p=0.02), vaginal bleeding and discharge (p<0.0001 for both), cerebrovascular events (p=0.0006), venous thromboembolic events (p=0.0006), and hot flushes (p<0.0001). Tamoxifen was significantly better tolerated than anastrozole with respect to musculoskeletal disorders and fractures (p<0.0001 for both). Interpretation Anastrozole is an effective and well tolerated endocrine option for the treatment of postmenopausal patients with hormone-sensitive early breast cancer. Longer follow-up is required before a final benefit:risk assessment can be made.	Canc Res UK, ATAC Secretariat, London NW1 2ND, England; UCL Canc Trials Ctr, London NW1 2ND, England	Cancer Research UK; University of London; University College London; University of London; University College London	Baum, M (corresponding author), Canc Res UK, ATAC Secretariat, Stephenson House,158-160 N Gower St, London NW1 2ND, England.		WILLIAMS, Norman/C-2002-2008	WILLIAMS, Norman/0000-0001-6496-312X				*AM COLL OBST GYN, 2000, OBSTET GYNECOL, V95, pC1; Andrykowski MA, 1999, J PAIN SYMPTOM MANAG, V18, P85, DOI 10.1016/S0885-3924(99)00053-6; BAUM M, 1983, LANCET, V1, P257; Baum M, 2001, BRIT J CANCER, V85, P317, DOI 10.1054/bjoc.2001.1925; Bergman L, 2000, LANCET, V356, P881, DOI 10.1016/S0140-6736(00)02677-5; Bernstein L, 1999, J NATL CANCER I, V91, P1654, DOI 10.1093/jnci/91.19.1654; BISSETT D, 1994, LANCET, V344, P1244, DOI 10.1016/S0140-6736(94)90747-1; Bonneterre J, 2000, J CLIN ONCOL, V18, P3748, DOI 10.1200/JCO.2000.18.22.3748; Bonneterre J, 2001, CANCER, V92, P2247, DOI 10.1002/1097-0142(20011101)92:9<2247::AID-CNCR1570>3.0.CO;2-Y; Buzdar AU, 1998, CANCER-AM CANCER SOC, V83, P1142, DOI 10.1002/(SICI)1097-0142(19980915)83:6<1142::AID-CNCR13>3.3.CO;2-7; Clarke M, 1998, LANCET, V351, P1451; CUTULI BF, 1994, ONCOL REP, V1, P59; Cuzick J, 2000, BREAST CANCER RES, V2, P258, DOI 10.1186/bcr66; CUZICK J, 1985, LANCET, V2, P282; DEWAR J, 2001, EUR J CANC S5, V37, P5; Donnellan PP, 2001, J CLIN ONCOL, V19, P2767; *EARL BREAST CANC, 1992, LANCET, V339, P1; FISHER B, 1989, NEW ENGL J MED, V320, P479, DOI 10.1056/NEJM198902233200802; Geisler J, 1996, BRIT J CANCER, V74, P1286, DOI 10.1038/bjc.1996.531; Howell A, 1997, BRIT MED J, V315, P863, DOI 10.1136/bmj.315.7112.863; LOPRINZI CL, 1993, J CLIN ONCOL, V11, P768, DOI 10.1200/JCO.1993.11.4.768; LOVE RR, 1994, ARCH INTERN MED, V154, P2585, DOI 10.1001/archinte.154.22.2585; Meier CR, 1998, BRIT J CLIN PHARMACO, V45, P608, DOI 10.1046/j.1365-2125.1998.00733.x; Nabholtz JM, 2000, J CLIN ONCOL, V18, P3758, DOI 10.1200/JCO.2000.18.22.3758; Rutqvist LE, 1996, J NATL CANCER I, V88, P1543; SANTEN RJ, 1990, ENDOCR REV, V11, P221, DOI 10.1210/edrv-11-2-221; Van Poznak C, 2001, SEMIN ONCOL, V28, P69, DOI 10.1053/sonc.2001.25445; Wluka A, 2000, MATURITAS, V35, P183, DOI 10.1016/S0378-5122(00)00118-3	28	1507	1554	1	59	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUN 22	2002	359	9324					2131	2139						9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	566RJ	12090977				2023-01-03	WOS:000176441800006
J	Jansen, LA; Sulmasy, DP				Jansen, LA; Sulmasy, DP			Sedation, alimentation, hydration, and equivocation: Careful conversation about care at the end of life	ANNALS OF INTERNAL MEDICINE			English	Editorial Material							PHYSICIAN-ASSISTED SUICIDE; VOLUNTARY ACTIVE EUTHANASIA; TERMINAL SEDATION; LAST RESORT; REFUSAL; PATIENT	In the recent medical ethics literature, several authors have recommended terminal sedation and refusal of hydration and nutrition as important, morally acceptable, and relatively uncontroversial treatment options for end-of-life suffering. However, not all authors use these terms to refer to the same practices. This paper examines the various ways that the terms terminal sedation and refusal of hydration and nutrition have been used in the medical literature. Although some of these practices are ethically appropriate responses to end-of-life suffering, others (at least as they are currently described in the medical ethics literature) are not. This paper identifies and discusses the principles that morally distinguish these practices from one another and specifically describes different features of medical practices and moral principles that affect the moral acceptability of various medical treatments. These distinctions reveal the complexity of the issues surrounding terminal sedation and refusal of hydration and nutrition, a complexity that has not been adequately addressed in recent discussions.	St Vincents Hosp & Med Ctr, John J Conley Dept Eth, New York, NY 10011 USA; New York Med Coll, Bioeth Inst, Valhalla, NY USA	Saint Vincents Hospital Manhattan; New York Medical College	Jansen, LA (corresponding author), St Vincents Hosp & Med Ctr, John J Conley Dept Eth, 153 West 11th St NR815, New York, NY 10011 USA.	ljansen@saintvincentsnyc.org						Beauchamp Tom, 1993, MATTERS LIFE DEATH N, P69; BERNAT JL, 1993, ARCH INTERN MED, V153, P2723, DOI 10.1001/archinte.153.24.2723; Cherny N I, 1994, J Palliat Care, V10, P31; JACOBSEN PB, 2000, CANC CARE J, V3, P1; Kamm FM, 1999, PHILOS PUBLIC AFF, V28, P169, DOI 10.1111/j.1088-4963.1999.00169.x; Keenan J F, 1995, Health Prog, V76, P23; Krakauer E L, 2000, Oncologist, V5, P53, DOI 10.1634/theoncologist.5-1-53; Miller FG, 1998, ANN INTERN MED, V128, P559, DOI 10.7326/0003-4819-128-7-199804010-00007; Quill TE, 1997, NEW ENGL J MED, V337, P1768, DOI 10.1056/NEJM199712113372413; Quill TE, 2000, ANN INTERN MED, V132, P488, DOI 10.7326/0003-4819-132-6-200003210-00011; Quill TE, 2000, ANN INTERN MED, V132, P408, DOI 10.7326/0003-4819-132-5-200003070-00012; Quill TE, 1997, JAMA-J AM MED ASSOC, V278, P2099, DOI 10.1001/jama.278.23.2099; QUINN WS, 1989, PHILOS PUBLIC AFF, V18, P334; Rousseau P, 1996, ARCH INTERN MED, V156, P1785, DOI 10.1001/archinte.156.16.1785; Sulmasy DP, 2000, ANN INTERN MED, V133, P560, DOI 10.7326/0003-4819-133-7-200010030-00021; Sulmasy DP, 1996, CLIN PULM MED, V3, P86; Wein S, 2000, ONCOLOGY-NY, V14, P585	17	89	90	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUN 4	2002	136	11					845	849		10.7326/0003-4819-136-11-200206040-00014	http://dx.doi.org/10.7326/0003-4819-136-11-200206040-00014			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	558KG	12044133				2023-01-03	WOS:000175964500008
J	Lindsay, R; Gallagher, JC; Kleerekoper, M; Pickar, JH				Lindsay, R; Gallagher, JC; Kleerekoper, M; Pickar, JH			Effect of lower doses of conjugated equine estrogens with and without medroxyprogesterone acetate on bone in early postmenopausal women	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HORMONE REPLACEMENT THERAPY; CONTROLLED TRIAL; RANDOMIZED TRIAL; PREVENTION; DENSITY; LIPIDS; OSTEOPOROSIS; LIPOPROTEINS; ENDOMETRIUM; METABOLISM	Context Lower-than-commonly-prescribed doses of conjugated equine estrogens (CEEs) with medroxyprogesterone acetate (MPA) improve vasomotor symptoms and vaginal atrophy, provide acceptable bleeding and lipid profiles, and afford endometrial protection. This lower-dose therapy's protection against loss of bone mineral density (BMD) associated with menopause has not been thoroughly investigated. Objective To determine the effects of lower doses of CEEs only or CEEs-MPA on spine and hip BMD, total body bone mineral content (BMC), and biochemical markers of bone turnover in postmenopausal women. Design and Setting Two-year randomized, double-blind, placebo-control led sub-study of the Women's Health, Osteoporosis, Progestin, Estrogen trial, conducted at 19 US centers between August 1995 and October 2000. Participants Eight hundred twenty-two healthy postmenopausal women aged 40 to 65 years who were within 4 years of their last menstrual period. Interventions Patients were randomly assigned to receive CEEs, 0.625; CEEs, 0.625 and MPA, 2.5; CEEs, 0.45; CEEs, 0.45 and MPA, 2.5; CEEs, 0.45 and AAPA, 1.5; CEES, 0.3; CEEs 0.3 and MPA, 1.5 (all doses in mg/d); or placebo for 2 years. All participants also received elemental calcium at 600 mg/d. Main Outcome Measures Changes from baseline in spine and total hip BMD, total body BMC, and biochemical markers of bone turnover (serum osteocalcin and urinary cross-linked N-telopeptides of type I collagen), assessed at 6-month intervals and compared among treatment groups with a modified intention-to-treat approach. Results At 24 months, women assigned to all of the active treatment groups had significant gains from baseline (P<.001) in spine and hip BMD and total body BMC (except total body BMC in the group receiving CEEs, 0.3 mg/d). These changes were significantly different from those in the placebo group, in which losses of bone mass in spine and total body were evident over the course of the study (P<.001). The loss in hip BMD from baseline in the placebo group was significant at 18 (P=.02) but not at 24 months (P=.06). Osteocalcin and N-telopeptides of type I Collagen were significantly reduced from baseline (P<.001) for all active treatment groups at all time points; no changes were found for the placebo group. For women treated with CEEs alone, the gains in spine BMD for the group taking CEEs, 0.625 mg/d, were significantly higher than those of the group taking CEEs, 0.3 mg/d (P=.02), but not the group treated with CEEs, 0.45 mg/d (P=.48). Conclusions Doses of CEEs or CEEs-MPA lower than 0.625 mg/d effectively increase BMD and BMC in early postmenopausal women.	Helen Hayes Hosp, Dept Internal Med, W Haverstraw, NY 10993 USA; Creighton Univ, Sch Med, Bone Metab Unit, Omaha, NE USA; Wayne State Univ, Sch Med, Div Endocrinol, Detroit, MI USA; Wyeth Ayerst Res, Clin Res & Dev, Philadelphia, PA USA	Creighton University; Wayne State University; Pfizer	Lindsay, R (corresponding author), Helen Hayes Hosp, Dept Internal Med, Rte 9W, W Haverstraw, NY 10993 USA.			gallagher, john christopher/0000-0002-5129-9183				Archer DF, 2001, FERTIL STERIL, V75, P1080, DOI 10.1016/S0015-0282(01)01792-7; Bush TL, 1996, JAMA-J AM MED ASSOC, V276, P1389, DOI 10.1001/jama.276.17.1389; Connelly MT, 1999, ANN INTERN MED, V131, P265, DOI 10.7326/0003-4819-131-4-199908170-00005; DAWSONHUGHES B, 1990, NEW ENGL J MED, V323, P878, DOI 10.1056/NEJM199009273231305; Ettinger B, 1999, MENOPAUSE, V6, P273, DOI 10.1097/00042192-199906030-00015; GALLAGHER JC, 1991, AM J MED, V90, P171; Gambacciani M, 2001, AM J OBSTET GYNECOL, V185, P1180, DOI 10.1067/mob.2001.117669; Genant HK, 1997, ARCH INTERN MED, V157, P2609, DOI 10.1001/archinte.157.22.2609; GENANT HK, 1982, ANN INTERN MED, V97, P699, DOI 10.7326/0003-4819-97-5-699; Grey A, 1996, CLIN ENDOCRINOL, V44, P293, DOI 10.1046/j.1365-2265.1996.667488.x; Komulainen MH, 1998, MATURITAS, V31, P45, DOI 10.1016/S0378-5122(98)00085-1; LINDSAY R, 1980, LANCET, V2, P1151; LINDSAY R, 1984, OBSTET GYNECOL, V63, P759; Lobo R A, 2001, Climacteric, V4, P110, DOI 10.1080/713605084; Lobo RA, 2001, FERTIL STERIL, V76, P13, DOI 10.1016/S0015-0282(01)01829-5; LUFKIN EG, 1992, ANN INTERN MED, V117, P1, DOI 10.7326/0003-4819-117-1-1; MACLENNAN AH, 1993, MED J AUSTRALIA, V159, P102, DOI 10.5694/j.1326-5377.1993.tb137744.x; Mizunuma H, 1997, MATURITAS, V27, P69, DOI 10.1016/S0378-5122(97)01110-9; Pickar JH, 2001, FERTIL STERIL, V76, P25, DOI 10.1016/S0015-0282(01)01828-3; Recker RR, 1999, ANN INTERN MED, V130, P897, DOI 10.7326/0003-4819-130-11-199906010-00005; RIGGS BL, 1995, BONE S5, V17, P505; Speroff L, 1996, JAMA-J AM MED ASSOC, V276, P1397, DOI 10.1001/jama.276.17.1397; Utian WH, 2001, FERTIL STERIL, V75, P1065, DOI 10.1016/S0015-0282(01)01791-5; WEBBER CE, 1994, MATURITAS, V19, P13, DOI 10.1016/0378-5122(94)90037-X	24	242	256	0	4	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 22	2002	287	20					2668	2676		10.1001/jama.287.20.2668	http://dx.doi.org/10.1001/jama.287.20.2668			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	554JQ	12020302	Bronze			2023-01-03	WOS:000175732400026
J	Bancewicz, J; Clark, PI; Smith, DB; Donnelly, RJ; Fayers, PM; Weeden, S; Girling, DJ; Hutchinson, T; Harvey, A; Lyddiard, J; Al-Jilaihawi, AN; Bown, SG; Cottier, B; Jeyasingham, K; Lea, RE; Matthews, HR; Moghissi, K; Morritt, GN; Myskow, MW; Pagliero, KM; Rowland, CR; Yosef, HMA				Bancewicz, J; Clark, PI; Smith, DB; Donnelly, RJ; Fayers, PM; Weeden, S; Girling, DJ; Hutchinson, T; Harvey, A; Lyddiard, J; Al-Jilaihawi, AN; Bown, SG; Cottier, B; Jeyasingham, K; Lea, RE; Matthews, HR; Moghissi, K; Morritt, GN; Myskow, MW; Pagliero, KM; Rowland, CR; Yosef, HMA		Med Res Council Oesophageal Canc	Surgical resection with or without preoperative chemotherapy in oesophageal cancer: a randomised controlled trial	LANCET			English	Article							SQUAMOUS-CELL CARCINOMA; ESOPHAGEAL CANCER; ADENOCARCINOMA; RADIOTHERAPY; SURVIVAL; SURGERY; THERAPY	Background The outlook for patients with oesophageal cancer undergoing surgical resection with curative intent is poor. We aimed to assess the effects of preoperative chemotherapy on survival, dysphagia. and performance status in this group of patients. Methods 802 previously untreated patients with resectable oesophageal cancer of any cell type were randomly allocated either two 4-day cycles, 3 weeks apart, of cisplatin 80 mg/m(2) by infusion over 4 h plus fluorouracil 1000 mg/m(2) daily by continuous infusion for 4 days followed by surgical resection (CS group, n=400), or resection alone (S group, 402). Clinicians could choose to give preoperative radiotherapy to all their patients irrespective of randomisation. Primary outcome measure was survival time, Analysis was by intention to treat, Findings No patients dropped out of the study. Resection was microscopically complete in 233 (60%) of 390 assessable CS patients and 215 (54%) of 397 S patients (p<0.0001). Postoperative complications were reported in 146 (41%) CS and 161 (42%) S patients. Overall survival was better in the CS group (hazard ratio 0.79; 95% Cl 0.67-0.93: p=0.004). Median survival was 512 days (16.8 months) in the CS group compared with 405 days (13.3 months) in the S group (difference 107 days; 95% Cl 30-196), and 2-year survival rates were 43% and 34% (difference 9%: 3-14). Interpretation Two cycles of preoperative cisplatin and fluorouracil improve survival without additional serious adverse events in the treatment of patients with resectable oesophageal cancer.	MRC, Clin Trials Unit, Canc Div, London NW1 2DA, England; Hope Hosp, Salford M6 8HD, Lancs, England; Ctr Cardiothorac, Liverpool, Merseyside, England; Clatterbridge Ctr Oncol, Liverpool, Merseyside, England	Medical Research Council Clinical Trials Unit; Clatterbridge Cancer Centre	Girling, DJ (corresponding author), MRC, Clin Trials Unit, Canc Div, 222 Euston Rd, London NW1 2DA, England.		Bown, Stephen/AAX-6573-2020	Fayers, Peter/0000-0003-4778-1513				AJANI JA, 1990, J CLIN ONCOL, V8, P1231, DOI 10.1200/JCO.1990.8.7.1231; ANCONA E, 1998, CAN J GASTROENTER SB, V12; CAREY RW, 1986, J CLIN ONCOL, V4, P697, DOI 10.1200/JCO.1986.4.5.697; CAREY RW, 1990, P AN M AM SOC CLIN, V9, P105; Fayers PM, 1997, STAT MED, V16, P1413, DOI 10.1002/(SICI)1097-0258(19970630)16:12<1413::AID-SIM578>3.3.CO;2-L; FORASTIERE AA, 1987, J CLIN ONCOL, V5, P1143, DOI 10.1200/JCO.1987.5.8.1143; HILGENBERG AD, 1988, ANN THORAC SURG, V45, P357, DOI 10.1016/S0003-4975(98)90004-2; KELSEN D P, 1986, Seminars in Surgical Oncology, V2, P170, DOI 10.1002/ssu.2980020310; KELSEN DP, 1990, J CLIN ONCOL, V8, P1352, DOI 10.1200/JCO.1990.8.8.1352; Kelsen DP, 1998, NEW ENGL J MED, V339, P1979, DOI 10.1056/NEJM199812313392704; KOK TC, 1997, P AN M AM SOC CLIN, V16, pA277; Law S, 1997, J THORAC CARDIOV SUR, V114, P210, DOI 10.1016/S0022-5223(97)70147-8; MAIPANG T, 1994, J SURG ONCOL, V56, P191, DOI 10.1002/jso.2930560314; NEUHAUS P, 1992, ARCH SURG-CHICAGO, V127, P1446; NYGAARD K, 1992, WORLD J SURG, V16, P1104, DOI 10.1007/BF02067069; Parmar MKB, 1998, STAT MED, V17, P2815, DOI 10.1002/(SICI)1097-0258(19981230)17:24<2815::AID-SIM110>3.0.CO;2-8; ROTH JA, 1988, J THORAC CARDIOV SUR, V96, P242; SHIELDS TW, 1984, ARCH SURG-CHICAGO, V119, P558; Sutton P, 2000, GI CANCER, V3, P231; World Health Organization, 1979, WHO HDB REP RES CANC	20	1116	1135	1	33	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAY 18	2002	359	9319					1727	1733						7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	554MV	12049861				2023-01-03	WOS:000175740500009
J	Miller, J; Chan, BKS; Nelson, HD				Miller, J; Chan, BKS; Nelson, HD			Postmenopausal estrogen replacement and risk for venous thromboembolism: A systematic review and meta-analysis for the US Preventive Services Task Force	ANNALS OF INTERNAL MEDICINE			English	Review							ORAL-CONTRACEPTIVES; BREAST-CANCER; VASCULAR-DISEASE; RANDOMIZED-TRIAL; PUBLICATION BIAS; HORMONE-THERAPY; WOMEN; TAMOXIFEN; HEART; USERS	Background: Postmenopausal estrogen replacement is widely used in the United States but poses important health risks. Purpose: To assess the risk for venous thromboembolism with postmenopausal estrogen replacement by using literature review and meta-analysis. Data Sources: All relevant English-language studies identified in searches of the MEDLINE (1966 to December 2000), HealthSTAR (1975 to December 2000), and Cochrane Library databases, and references lists of key articles. Study Selection: All published studies of postmenopausal estrogen replacement reporting venous thromboembolism as an outcome or adverse event. Data Extraction: 12 studies of estrogen were identified (3 randomized, controlled trials; 8 case-control studies; and I cohort study). Data were extracted on participants, interventions, event rates, and confounders. Two reviewers independently rated study quality on the basis of established criteria. Data Synthesis: A Bayesian meta-analysis was conducted. When data from all studies were pooled, current estrogen use was associated with an increased risk for venous thromboembolism (relative risk, 2.14 [95% credible interval, 1.64 to 2.81]). Estimates did not significantly change when studies were pooled according to study design, quality score, or whether participants had pre-existing coronary artery disease. The absolute rate increase was 1.5 venous thromboembolic events per 10 000 women in 1 year. Six case-control studies that reported risk according to duration of use found that risk was highest in the first year of use (relative risk, 3.49 [credible interval, 2.33 to 5.59]). Conclusion: Postmenopausal estrogen replacement is associated with an increased risk for venous thromboembolism, and this risk may be highest in the first year of use.	Oregon Hlth & Sci Univ, Portland, OR 97201 USA; Vet Affairs Med Ctr, Portland, OR USA	Oregon Health & Science University; US Department of Veterans Affairs; Veterans Health Administration (VHA)	Miller, J (corresponding author), Oregon Hlth & Sci Univ, Mail Code BICC 504,3181 SW Sam Jackson Pk Rd, Portland, OR 97201 USA.							[Anonymous], 1974, NEW ENGL J MED, V290, P15; Crosignani PG, 1996, THROMB HAEMOSTASIS, V75, P476; Cummings SR, 1999, JAMA-J AM MED ASSOC, V281, P2189, DOI 10.1001/jama.281.23.2189; Daly E, 1996, LANCET, V348, P1027, DOI 10.1016/S0140-6736(96)24041-3; Daly E, 1996, LANCET, V348, P977, DOI 10.1016/S0140-6736(96)07113-9; DEVOR M, 1992, AM J MED, V92, P275, DOI 10.1016/0002-9343(92)90077-O; Douketis JD, 1997, ARCH INTERN MED, V157, P1522, DOI 10.1001/archinte.157.14.1522; Duval S, 2000, J AM STAT ASSOC, V95, P89, DOI 10.2307/2669529; Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629; Fisher B, 1998, J NATL CANCER I, V90, P1371, DOI 10.1093/jnci/90.18.1371; Glueck CJ, 1999, AM J CARDIOL, V84, P549, DOI 10.1016/S0002-9149(99)00375-6; Grady D, 2000, ANN INTERN MED, V132, P689, DOI 10.7326/0003-4819-132-9-200005020-00002; Grodstein F, 1996, LANCET, V348, P983, DOI 10.1016/S0140-6736(96)07308-4; Gutthann SP, 1997, BMJ-BRIT MED J, V314, P796, DOI 10.1136/bmj.314.7083.796; Herrington DM, 2000, NEW ENGL J MED, V343, P522, DOI 10.1056/NEJM200008243430801; Hoibraaten E, 2000, THROMB HAEMOSTASIS, V84, P961; Holbraaten E, 1999, THROMB HAEMOSTASIS, V82, P1218; Hulley S, 1998, JAMA-J AM MED ASSOC, V280, P605, DOI 10.1001/jama.280.7.605; Jick H, 1996, LANCET, V348, P981, DOI 10.1016/S0140-6736(96)07114-0; Kearon C, 1998, ANN INTERN MED, V128, P663, DOI 10.7326/0003-4819-128-8-199804150-00011; Keating NL, 1999, ANN INTERN MED, V130, P545, DOI 10.7326/0003-4819-130-7-199904060-00002; Koh KK, 1999, THROMB HAEMOSTASIS, V82, P626, DOI 10.1055/s-0037-1615889; LeBlanc ES, 2001, JAMA-J AM MED ASSOC, V285, P1489, DOI 10.1001/jama.285.11.1489; Lowe G, 2000, THROMB HAEMOSTASIS, V83, P530; Lufkin EG, 1998, J BONE MINER RES, V13, P1747, DOI 10.1359/jbmr.1998.13.11.1747; MILLER VT, 1995, JAMA-J AM MED ASSOC, V273, P199, DOI 10.1001/jama.1995.03520270033028; NACHTIGALL LE, 1979, OBSTET GYNECOL, V54, P74, DOI 10.1097/00006250-197907000-00017; PETITTI DB, 1979, JAMA-J AM MED ASSOC, V242, P1150, DOI 10.1001/jama.242.11.1150; PETITTI DB, 1978, AM J EPIDEMIOL, V108, P480, DOI 10.1093/oxfordjournals.aje.a112646; Powles T, 1998, LANCET, V352, P98; Rosenberg L, 1997, AM J OBSTET GYNECOL, V177, P1275, DOI 10.1016/S0002-9378(97)70063-2; Ruehlmann DO, 1997, BIOCHEM SOC T, V25, P40, DOI 10.1042/bst0250040; Scarabin PY, 1997, ARTERIOSCL THROM VAS, V17, P3071, DOI 10.1161/01.ATV.17.11.3071; Spiegelhalter DJ, 1999, WINBUGS VERSION 1 2; Sutton AJ, 2000, BMJ-BRIT MED J, V320, P1574, DOI 10.1136/bmj.320.7249.1574; SUTTON AJ, 2000, METHODS METAANALYSIS, P57; The Coronary Drug Project, 1973, JAMA-J AM MED ASSOC, V226, P652, DOI DOI 10.1001/JAMA.1973.03230060030009; Varas-Lorenzo C, 1998, AM J EPIDEMIOL, V147, P387; Veronesi U, 1998, LANCET, V352, P93; VESSEY M, 1986, BRIT MED J, V292, P526, DOI 10.1136/bmj.292.6519.526; VREIM CE, 1990, JAMA-J AM MED ASSOC, V263, P2753; Wenger NK, 2000, JAMA-J AM MED ASSOC, V284, P41, DOI 10.1001/jama.284.1.41-a; *WHI DSMB, 2002, STAT REP WHI HRT UPD; Whiteman MK, 1999, AM J HEMATOL, V61, P271	44	141	146	0	3	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAY 7	2002	136	9					680	690		10.7326/0003-4819-136-9-200205070-00011	http://dx.doi.org/10.7326/0003-4819-136-9-200205070-00011			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	547XK	11992304				2023-01-03	WOS:000175357900006
J	Gobin, AS; West, JL				Gobin, AS; West, JL			Cell migration through defined, synthetic extracellular matrix analogues	FASEB JOURNAL			English	Article						PEG; hydrogel; RGD; proteolysis	SMOOTH-MUSCLE-CELLS; ADHESION PEPTIDES; DEGRADATION; HYDROGELS; COLLAGEN; GELS; PROTEOLYSIS; FIBROBLAST; SURFACES; MOTILITY	We have developed synthetic hydrogel extracellular matrix (ECM) analogues that can be used to study mechanisms involved in cell migration, such as receptor-ligand interactions and proteolysis. The biomimetic hydrogels consist of bioinert polyethylene glycol diacrylate derivatives with proteolytically degradable peptide sequences included in the backbone of the polymer and adhesive peptide sequences grafted to the network. Hydrogels have been developed that degrade as cells secrete proteolytic enzymes. Adhesive peptide sequences grafted to the hydrogel provide ligands that can interact with receptors on the cell surface to mediate adhesion and spreading. In this study, we have characterized the effects of adhesive ligand density on fibroblast migration through collagenase-degradable and plasmin-degradable hydrogels and on smooth muscle cell migration through elastase-degradable hydrogels. In all three cases, we found that cell migration has a biphasic dependence on adhesion ligand concentration, with optimal migration at intermediate ligand levels. Furthermore, both adhesive and proteolytically degradable sequences were required for cell migration to occur. These synthetic ECM analogues may be useful for 3-D mechanistic studies of many aspects of cell migration.	Rice Univ, Dept Bioengn, Houston, TX 77005 USA	Rice University	West, JL (corresponding author), Rice Univ, Dept Bioengn, 6100 Main St,MS 142, Houston, TX 77005 USA.	jwest@rice.edu	West, Jennifer L/A-4582-2008	West, Jennifer L/0000-0001-8550-2875				Basbaum CB, 1996, CURR OPIN CELL BIOL, V8, P731, DOI 10.1016/S0955-0674(96)80116-5; Burgess BT, 2000, ANN BIOMED ENG, V28, P110, DOI 10.1114/1.259; DIMILLA PA, 1993, J CELL BIOL, V122, P729, DOI 10.1083/jcb.122.3.729; Elbert DL, 2001, BIOMACROMOLECULES, V2, P430, DOI 10.1021/bm0056299; Friedl P, 1998, MICROSC RES TECHNIQ, V43, P369, DOI 10.1002/(SICI)1097-0029(19981201)43:5<369::AID-JEMT3>3.0.CO;2-6; Friedl P, 2000, CELL MOL LIFE SCI, V57, P41, DOI 10.1007/s000180050498; Heino J, 1996, INT J CANCER, V65, P717, DOI 10.1002/(SICI)1097-0215(19960315)65:6<717::AID-IJC1>3.3.CO;2-P; Hern DL, 1998, J BIOMED MATER RES, V39, P266, DOI 10.1002/(SICI)1097-4636(199802)39:2<266::AID-JBM14>3.0.CO;2-B; HUTTENLOCHER A, 1995, CURR OPIN CELL BIOL, V7, P697, DOI 10.1016/0955-0674(95)80112-X; Kuntz RM, 1997, BIOPHYS J, V72, P1472, DOI 10.1016/S0006-3495(97)78793-9; Lauffenburger DA, 1996, CELL, V84, P359, DOI 10.1016/S0092-8674(00)81280-5; Mann BK, 2001, BIOMATERIALS, V22, P3045, DOI 10.1016/S0142-9612(01)00051-5; Mann BK, 2002, J BIOMED MATER RES, V60, P86, DOI 10.1002/jbm.10042; Mann BK, 2001, BIOMATERIALS, V22, P439, DOI 10.1016/S0142-9612(00)00196-4; MASSIA SP, 1990, ANAL BIOCHEM, V187, P292, DOI 10.1016/0003-2697(90)90459-M; Murphy G, 1999, CURR OPIN CELL BIOL, V11, P614, DOI 10.1016/S0955-0674(99)00022-8; NETZELARNETT S, 1991, J BIOL CHEM, V266, P6747; Olbrich KC, 1996, BIOMATERIALS, V17, P759, DOI 10.1016/0142-9612(96)81412-8; Palecek SP, 1997, NATURE, V385, P537, DOI 10.1038/385537a0; Price JT, 1999, METH MOL B, V129, P231; Schense JC, 2000, NAT BIOTECHNOL, V18, P415, DOI 10.1038/74473; SCOTTBURDEN T, 1989, HYPERTENSION, V13, P295, DOI 10.1161/01.HYP.13.4.295; Sperinde JJ, 1997, MACROMOLECULES, V30, P5255, DOI 10.1021/ma970345a; Tan J, 1999, J BIOMED MATER RES, V46, P465, DOI 10.1002/(SICI)1097-4636(19990915)46:4<465::AID-JBM4>3.0.CO;2-N; West JL, 1999, MACROMOLECULES, V32, P241, DOI 10.1021/ma981296k	25	189	195	0	45	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAR	2002	16	3					751	+		10.1096/fj.01-0759fje	http://dx.doi.org/10.1096/fj.01-0759fje			16	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	537JV	11923220				2023-01-03	WOS:000174755900001
J	Therien, AG; Deber, CM				Therien, AG; Deber, CM			Interhelical packing in detergent micelles - Folding of a cystic fibrosis transmembrane conductance regulator construct	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN CONFORMATIONAL CHANGE; PYRENE EXCIMER FLUORESCENCE; MEMBRANE-SPANNING SEGMENT; CHLORIDE CHANNEL; HELIX; PROXIMITY; PROBE; CFTR; LYSOPHOSPHOLIPIDS; IDENTIFICATION	Using a helix-loop-helix construct consisting of the adjacent transmembrane segments 3 and 4 of the cystic fibrosis transmembrane conductance regulator (CFTR) labeled with pyrene at both N and C termini, we describe a system for the study of intramolecular helix-helix interactions within a polytopic membrane protein. Through measurement of pyrene excimer band intensity as a determinant of helix-helix proximity, we show that the helices retain tertiary contacts in detergent micelles. Notably, the nature of the micellar detergent can alter the stability of these contacts, with perfluorooctanoate highly supportive, lysophosphatidylcholine and lysophosphatidylglycerol somewhat less tolerant, and SDS largely intolerant of such interactions. This construct is further employed to study the role of the acyl chain length of micellar detergents in modulating interhelical packing; detergents having acyl chains of 9 carbons display the greatest extent of helical packing. These results provide important information regarding the role of lipids on membrane protein folding and conformation as well as demonstrate the usefulness of a pyrene-based system in studying the forces that govern interhelical packing.	Hosp Sick Children, Res Inst, Div Struct Biol & Biochem, Toronto, ON M5G 1X8, Canada; Univ Toronto, Dept Biochem, Toronto, ON M5S 1A8, Canada	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto	Deber, CM (corresponding author), Hosp Sick Children, Res Inst, Div Struct Biol & Biochem, 555 Univ Ave, Toronto, ON M5G 1X8, Canada.	deber@sickkids.on.ca	Therien, Alex/AAS-8437-2021					Akabas MH, 1998, BIOCHEMISTRY-US, V37, P12233, DOI 10.1021/bi980969o; Akabas MH, 1997, J BIOENERG BIOMEMBR, V29, P453, DOI 10.1023/A:1022482923122; Bechinger B, 2000, CURR OPIN CHEM BIOL, V4, P639, DOI 10.1016/S1367-5931(00)00143-5; BERR SS, 1989, J PHYS CHEM-US, V93, P2555, DOI 10.1021/j100343a062; Chen MG, 1999, BIOCHEMISTRY-US, V38, P5471, DOI 10.1021/bi982153t; CHEN YH, 1974, BIOCHEMISTRY-US, V13, P3350, DOI 10.1021/bi00713a027; Choma C, 2000, NAT STRUCT BIOL, V7, P161; Dumas F, 1999, FEBS LETT, V458, P271, DOI 10.1016/S0014-5793(99)01148-5; Fisher LE, 1999, J MOL BIOL, V293, P639, DOI 10.1006/jmbi.1999.3126; Gil T, 1998, BBA-REV BIOMEMBRANES, V1376, P245, DOI 10.1016/S0304-4157(98)00022-7; GRACEFFA P, 1980, J BIOL CHEM, V255, P1296; Gratkowski H, 2001, P NATL ACAD SCI USA, V98, P880, DOI 10.1073/pnas.98.3.880; JUNG K, 1993, BIOCHEMISTRY-US, V32, P12273, DOI 10.1021/bi00097a001; Lehrer S S, 1995, Subcell Biochem, V24, P115; Lehrer SS, 1997, METHOD ENZYMOL, V278, P286; LEHRER SS, 1989, FLUORESCENT BIOMOLEC, V51, P423; Liu W, 1998, BIOCHEMISTRY-US, V37, P15457, DOI 10.1021/bi980557f; MacKenzie KR, 1997, SCIENCE, V276, P131, DOI 10.1126/science.276.5309.131; Melnyk RA, 2001, BIOCHEMISTRY-US, V40, P11106, DOI 10.1021/bi010642e; OBLATTMONTAL M, 1994, P NATL ACAD SCI USA, V91, P1495, DOI 10.1073/pnas.91.4.1495; Peng SY, 1998, FEBS LETT, V431, P29, DOI 10.1016/S0014-5793(98)00715-7; Petrache HI, 2000, J MOL BIOL, V302, P727, DOI 10.1006/jmbi.2000.4072; Popot JL, 2000, ANNU REV BIOCHEM, V69, P881, DOI 10.1146/annurev.biochem.69.1.881; POPOT JL, 1990, BIOCHEMISTRY-US, V29, P4031, DOI 10.1021/bi00469a001; Ramjeesingh M, 1999, BIOCHEM J, V342, P119, DOI 10.1042/0264-6021:3420119; Ren JH, 1999, BIOCHEMISTRY-US, V38, P5905, DOI 10.1021/bi982942a; RIORDAN JR, 1989, SCIENCE, V245, P1066; SHEPHERD FH, 1995, ANAL BIOCHEM, V224, P21, DOI 10.1006/abio.1995.1003; Sheppard DN, 1999, PHYSIOL REV, V79, P23; STAFFORD RE, 1988, COLLOID SURFACE, V30, P47; STAFFORD RE, 1989, BIOCHEMISTRY-US, V28, P5113, DOI 10.1021/bi00438a031; Tanford C., 1980, HYDROPHOBIC EFFECT F; Therien AG, 2001, NAT STRUCT BIOL, V8, P597, DOI 10.1038/89631; Wang C, 2000, J BIOL CHEM, V275, P16155, DOI 10.1074/jbc.M000723200; Wigley WC, 1998, BIOCHEMISTRY-US, V37, P844, DOI 10.1021/bi972293n; Xie HB, 2000, BIOCHEMISTRY-US, V39, P15462, DOI 10.1021/bi001432p; Zhou FX, 2001, P NATL ACAD SCI USA, V98, P2250, DOI 10.1073/pnas.041593698; Zhou FX, 2000, NAT STRUCT BIOL, V7, P154	38	28	28	0	4	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 22	2002	277	8					6067	6072		10.1074/jbc.M110264200	http://dx.doi.org/10.1074/jbc.M110264200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	524AF	11748233	hybrid			2023-01-03	WOS:000173989200050
J	Schiller, JH; Harrington, D; Belani, CP; Langer, C; Sandler, A; Krook, J; Zhu, JM; Johnson, DH				Schiller, JH; Harrington, D; Belani, CP; Langer, C; Sandler, A; Krook, J; Zhu, JM; Johnson, DH		Eastern Cooperative Oncology Grp	Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							COOPERATIVE-ONCOLOGY-GROUP; QUALITY-OF-LIFE; RANDOMIZED TRIAL; CISPLATIN; SURVIVAL; COMBINATION; PACLITAXEL; ETOPOSIDE	Background We conducted a randomized study to determine whether any of three chemotherapy regimens was superior to cisplatin and paclitaxel in patients with advanced non-small-cell lung cancer. Methods A total of 1207 patients with advanced non-small-cell lung cancer were randomly assigned to a reference regimen of cisplatin and paclitaxel or to one of three experimental regimens: cisplatin and gemcitabine, cisplatin and docetaxel, or carboplatin and paclitaxel. Results The response rate for all 1155 eligible patients was 19 percent, with a median survival of 7.9 months (95 percent confidence interval, 7.3 to 8.5), a 1-year survival rate of 33 percent (95 percent confidence interval, 30 to 36 percent), and a 2-year survival rate of 11 percent (95 percent confidence interval, 8 to 12 percent). The response rate and survival did not differ significantly between patients assigned to receive cisplatin and paclitaxel and those assigned to receive any of the three experimental regimens. Treatment with cisplatin and gemcitabine was associated with a significantly longer time to the progression of disease than was treatment with cisplatin and paclitaxel but was more likely to cause grade 3, 4, or 5 renal toxicity (in 9 percent of patients, vs. 3 percent of those treated with cisplatin plus paclitaxel). Patients with a performance status of 2 had a significantly lower rate of survival than did those with a performance status of 0 or 1. Conclusions None of four chemotherapy regimens offered a significant advantage over the others in the treatment of advanced non-small-cell lung cancer. (N Engl J Med 2002;346:92-8.) Copyright (C) 2002 Massachusetts Medical Society.	Univ Wisconsin Hosp & Clin, Madison, WI 53792 USA; Dana Farber Canc Inst, Boston, MA 02115 USA; Univ Pittsburgh, Inst Canc, Pittsburgh, PA USA; Fox Chase Canc Ctr, Philadelphia, PA 19111 USA; Indiana Univ, Indianapolis, IN 46204 USA; Duluth Clin, Duluth, MN USA; Vanderbilt Univ, Nashville, TN USA	University of Wisconsin System; University of Wisconsin Madison; Harvard University; Dana-Farber Cancer Institute; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Fox Chase Cancer Center; Indiana University System; Indiana University-Purdue University Indianapolis; Vanderbilt University	Schiller, JH (corresponding author), Univ Wisconsin Hosp & Clin, Madison, WI 53792 USA.		Johnson, David H./A-7437-2009	Belani, Chandra/0000-0001-5049-5329	NATIONAL CANCER INSTITUTE [U10CA023318] Funding Source: NIH RePORTER; NCI NIH HHS [CA-23318] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abratt RP, 1995, P AN M AM SOC CLIN, V14, P375; ALBERTI W, 1995, BRIT MED J, V311, P899; Bonomi P, 2000, J CLIN ONCOL, V18, P623, DOI 10.1200/JCO.2000.18.3.623; BONOMI PD, 1989, J CLIN ONCOL, V7, P1602, DOI 10.1200/JCO.1989.7.11.1602; Cox DR., 1989, ANAL BINARY DATA, V2nd; CRINO L, 1995, P AN M AM SOC CLIN, V14, P352; Cullen MH, 1999, J CLIN ONCOL, V17, P3188, DOI 10.1200/JCO.1999.17.10.3188; GANDARA DR, 1993, J CLIN ONCOL, V11, P873, DOI 10.1200/JCO.1993.11.5.873; GRILLI R, 1993, J CLIN ONCOL, V11, P1866, DOI 10.1200/JCO.1993.11.10.1866; JOHNSON DH, 1999, P AN M AM SOC CLIN, V18, pA461; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; KLASTERSKY J, 1989, J CLIN ONCOL, V7, P1087, DOI 10.1200/JCO.1989.7.8.1087; LANGER CJ, 1995, J CLIN ONCOL, V13, P1860, DOI 10.1200/JCO.1995.13.8.1860; LECHEVALIER T, 1995, P AN M AM SOC CLIN, V14, P350; MANTEL NATHAN, 1966, CANCERCHEMOTHERAP REP, V50, P163; MARINO P, 1994, CHEST, V106, P861, DOI 10.1378/chest.106.3.861; OBRIEN PC, 1979, BIOMETRICS, V35, P549, DOI 10.2307/2530245; RAMSEY SD, 2000, P AN M AM SOC CLIN, V19, pA489; RAPP E, 1988, J CLIN ONCOL, V6, P633, DOI 10.1200/JCO.1988.6.4.633; RUCKDESCHEL JC, 1986, J CLIN ONCOL, V4, P14, DOI 10.1200/JCO.1986.4.1.14; SANDLER AB, 1995, P AN M AM SOC CLIN, V14, P357	21	4169	4539	9	394	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JAN 10	2002	346	2					92	98		10.1056/NEJMoa011954	http://dx.doi.org/10.1056/NEJMoa011954			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	509EM	11784875				2023-01-03	WOS:000173133400004
J	Ely, EW; Wheeler, AP; Thompson, BT; Ancukiewicz, M; Steinberg, KP; Bernard, GR				Ely, EW; Wheeler, AP; Thompson, BT; Ancukiewicz, M; Steinberg, KP; Bernard, GR		Acute Respiratory Distress Syndrom	Recovery rate and prognosis in older persons who develop acute lung injury and the acute respiratory distress syndrome	ANNALS OF INTERNAL MEDICINE			English	Article; Proceedings Paper	International Conference of the American-Lung-Association and the American-Thoracic-Society	MAY 05-10, 2000	TORONTO, CANADA	Amer Lung Assoc, Amer Thorac Soc			CRITICALLY-ILL PATIENTS; INTENSIVE-CARE-UNIT; CONFUSION ASSESSMENT METHOD; ELDERLY MEDICAL PATIENTS; ACTIVATED PROTEIN-C; MECHANICAL VENTILATION; HOSPITALIZED ADULTS; SERIOUSLY ILL; INFORMANT QUESTIONNAIRE; COGNITIVE DECLINE	Background: The incidence of acute respiratory failure requiring mechanical ventilation increases 10-fold from the ages of 55 to 85 years, yet the rate of recovery and outcomes in older persons who develop acute lung injury are poorly defined. Objective: To examine age as an independent risk factor in recovery and intensive care unit discharge after acute lung injury. Design: Prospective cohort study. Setting: 10 U.S. university-based medical centers. Patients: 902 mechanically ventilated patients enrolled in randomized, controlled trials for the treatment of acute lung injury. Ail patients were managed according to a standardized protocol for ventilator management and weaning. Measurements: Frequency and time to achieve well-defined recovery landmarks, duration of ventilation and intensive care unit stay, and survival. Results: Median duration of mechanical ventilation was 19 days (interquartile range, 7 to >28 days) for patients 70 years of age or older (n = 173) compared with 10 days (interquartile range, 5 to 26 days) for patients younger than 70 years of age (n = 729) (P < 0.001). The duration of intensive care unit stay was 21 days for the older group (interquartile range, 11 to >28 days) and 16 days for the younger group (8 to >28 days) (P = 0.004). Survival rates decreased across increasing decades of age (P < 0.001): Patients younger than 70 years of age had a greater 28-day survival rate than patients 70 years of age or older (74.6% vs. 50.3%; P < 0.001). The proportion of survivors achieving physiologic recovery landmarks did not differ between the older and younger age groups, and the median time to pass a 2-hour spontaneous breathing trial was similar between both the older and younger patients (4 days vs. 5 days; P > 0.2). After passing a spontaneous breathing trial, however, older patients required 1 more day than younger patients to achieve unassisted breathing (P = 0.002) and 3 more days to leave the intensive care unit (P = 0.005). In a multivariable Cox proportional hazards analysis, age of 70 years or older was a strong predictor of in-hospital death (hazard ratio, 2.5 [95% Cl, 2.0 to 3.2]; P < 0.001). Conclusions: Although the survival rate among patients 70 years of age or older was high, these patients were twice as likely to die of acute lung injury compared with their younger counterparts, even after adjustment for covariates. Older survivors recovered from respiratory failure and achieved spontaneous breathing at the same rate as younger patients but had greater difficulty achieving liberation from the ventilator and being discharged from the intensive care unit.	Vanderbilt Univ, Med Ctr, Div Allergy Pulm & Crit Care Med, Sch Med, Nashville, TN 37232 USA; Vet Affairs Tennessee Valley Healthcare Res & Edu, Nashville, TN USA; Massachusetts Gen Hosp, Boston, MA 02114 USA; Harvard Univ, Sch Med, Boston, MA USA; Univ Washington, Harborview Med Ctr, Sch Med, Seattle, WA 98104 USA	Vanderbilt University; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Tennessee Valley Healthcare System; Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; Harborview Medical Center; University of Washington; University of Washington Seattle	Ely, EW (corresponding author), Vanderbilt Univ, Med Ctr, Div Allergy Pulm & Crit Care Med, Sch Med, 6th Floor,6109 Med Ctr E, Nashville, TN 37232 USA.	wes.ely@mcmail.vanderbilt.edu	Ely, E. Wesley/Z-2018-2019	Ely, E. Wesley/0000-0003-3957-2172	NHLBI NIH HHS [N01-HR 46054-46064] Funding Source: Medline; NIA NIH HHS [AG01023-01A1] Funding Source: Medline; DIVISION OF LUNG DISEASES [N01HR046054] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); DIVISION OF LUNG DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Agresti A, 1999, STAT MED, V18, P2191, DOI 10.1002/(SICI)1097-0258(19990915/30)18:17/18<2191::AID-SIM249>3.0.CO;2-M; Amato MBP, 1998, NEW ENGL J MED, V338, P347, DOI 10.1056/NEJM199802053380602; Angus DC, 2000, JAMA-J AM MED ASSOC, V284, P2762, DOI 10.1001/jama.284.21.2762; Angus DC, 2001, AM J RESP CRIT CARE, V163, P1389, DOI 10.1164/ajrccm.163.6.2005123; [Anonymous], 1997, JAMA-J AM MED ASSOC, V277, P925; Baltussen R, 1996, HEALTH ECON, V5, P227, DOI 10.1002/(SICI)1099-1050(199605)5:3<227::AID-HEC198>3.3.CO;2-P; Behrendt CE, 2000, CHEST, V118, P1100, DOI 10.1378/chest.118.4.1100; Bernard GR, 1997, CHEST, V112, P164, DOI 10.1378/chest.112.1.164; Bernard GR, 2001, CRIT CARE MED, V29, P2051, DOI 10.1097/00003246-200111000-00003; BERNARD GR, 1994, AM J RESP CRIT CARE, V149, P818, DOI 10.1164/ajrccm.149.3.7509706; Bernard GR, 2001, NEW ENGL J MED, V344, P699, DOI 10.1056/NEJM200103083441001; Bernard GR, 1995, AM J RESP CRIT CARE, V151, pA323; Bernard GR, 1997, SEPSIS, V1, P43, DOI DOI 10.1023/A:1009711301483; BROCHARD L, 1994, AM J RESP CRIT CARE, V150, P896, DOI 10.1164/ajrccm.150.4.7921460; Brook AD, 1999, CRIT CARE MED, V27, P2609, DOI 10.1097/00003246-199912000-00001; Brower RG, 2000, NEW ENGL J MED, V342, P1301, DOI 10.1056/nejm200005043421801; CHARLSON ME, 1987, J CHRON DIS, V40, P373, DOI 10.1016/0021-9681(87)90171-8; Chatila W, 1996, CHEST, V109, P1577, DOI 10.1378/chest.109.6.1577; CHELLURI L, 1992, CRIT CARE MED, V20, P757, DOI 10.1097/00003246-199206000-00010; CHELLURI L, 1995, ARCH INTERN MED, V155, P1013, DOI 10.1001/archinte.155.10.1013; Coplin WM, 2000, AM J RESP CRIT CARE, V161, P1530, DOI 10.1164/ajrccm.161.5.9905102; COX DR, 1972, J R STAT SOC B, V34, P187; Dardaine V, 2001, J AM GERIATR SOC, V49, P564, DOI 10.1046/j.1532-5415.2001.49114.x; Ely EW, 1999, ANN INTERN MED, V131, P96, DOI 10.7326/0003-4819-131-2-199907200-00004; Ely EW, 2001, JAMA-J AM MED ASSOC, V286, P2703, DOI 10.1001/jama.286.21.2703; Ely EW, 2001, CRIT CARE MED, V29, P1370, DOI 10.1097/00003246-200107000-00012; Ely EW, 1999, INTENS CARE MED, V25, P581, DOI 10.1007/s001340050906; Ely EW, 1996, NEW ENGL J MED, V335, P1864, DOI 10.1056/NEJM199612193352502; Ely EW, 1999, AM J RESP CRIT CARE, V159, P439, DOI 10.1164/ajrccm.159.2.9805120; ELY EW, 2001, IN PRESS CHEST, P120; ELY EW, 2001, IN PRESS INTENSIVE C; Epstein SK, 1998, AM J RESP CRIT CARE, V158, P489, DOI 10.1164/ajrccm.158.2.9711045; Esteban A, 1999, AM J RESP CRIT CARE, V159, P512, DOI 10.1164/ajrccm.159.2.9803106; ESTEBAN A, 1995, NEW ENGL J MED, V332, P345, DOI 10.1056/NEJM199502093320601; Esteban A, 1997, AM J RESP CRIT CARE, V156, P459, DOI 10.1164/ajrccm.156.2.9610109; Esteban A, 2000, AM J RESP CRIT CARE, V161, P1450, DOI 10.1164/ajrccm.161.5.9902018; FISHER L, 1993, BIOSTATISTICS METHOD, P542; FISHER L, 1993, BIOSTATISTICS METHOD, P815; FISHER L, 1993, BIOSTATISTICS METHOD, P311; FISHER LD, 1993, BIOSTATISTICS METHOD, P185; FISHER LD, 1993, BIOSTATISTICS METHOD, P385; FRANCIS J, 1990, JAMA-J AM MED ASSOC, V263, P1097, DOI 10.1001/jama.263.8.1097; GEE MH, 1990, J APPL PHYSIOL, V69, P822, DOI 10.1152/jappl.1990.69.3.822; GOLDBERG AI, 1988, CHEST, V94, P1277, DOI 10.1378/chest.94.6.1277; GRAMBSCH PM, 1994, BIOMETRIKA, V81, P515; Hamel MB, 1999, ANN INTERN MED, V131, P721, DOI 10.7326/0003-4819-131-10-199911160-00002; Hamel MB, 2000, J AM GERIATR SOC, V48, pS176, DOI 10.1111/j.1532-5415.2000.tb03129.x; Hamel MB, 1999, ANN INTERN MED, V130, P116, DOI 10.7326/0003-4819-130-2-199901190-00005; HOBBS F, 1996, 65 PLUS US, P1; Hopkins RO, 1999, AM J RESP CRIT CARE, V160, P50, DOI 10.1164/ajrccm.160.1.9708059; INOUYE SK, 1993, ANN INTERN MED, V119, P474, DOI 10.7326/0003-4819-119-6-199309150-00005; Inouye SK, 1996, JAMA-J AM MED ASSOC, V275, P852, DOI 10.1001/jama.275.11.852; Jakob SM, 1997, INTENS CARE MED, V23, P1165, DOI 10.1007/s001340050474; JORM AF, 1991, PSYCHOL MED, V21, P785, DOI 10.1017/S0033291700022418; JORM AF, 1994, PSYCHOL MED, V24, P145, DOI 10.1017/S003329170002691X; KALBFLEISCH JD, 1980, STAT ANAL FAILURE TI, P11; KNAUS WA, 1991, CHEST, V100, P1619, DOI 10.1378/chest.100.6.1619; Kollef MH, 1997, CRIT CARE MED, V25, P567, DOI 10.1097/00003246-199704000-00004; Kress JP, 2000, NEW ENGL J MED, V342, P1471, DOI 10.1056/NEJM200005183422002; Krieger BP, 1997, CHEST, V112, P1029, DOI 10.1378/chest.112.4.1029; LANDAHL S, 1980, ACTA MED SCAND, V207, P225; LEVI M, 1993, JAMA-J AM MED ASSOC, V270, P975, DOI 10.1001/jama.270.8.975; Luhr OR, 1999, AM J RESP CRIT CARE, V159, P1849, DOI 10.1164/ajrccm.159.6.9808136; MARCANTONIO ER, 1994, JAMA-J AM MED ASSOC, V271, P134, DOI 10.1001/jama.271.2.134; MILBERG JA, 1995, JAMA-J AM MED ASSOC, V273, P306, DOI 10.1001/jama.273.4.306; Namen AM, 2001, AM J RESP CRIT CARE, V163, P658, DOI 10.1164/ajrccm.163.3.2003060; OKeeffe S, 1997, J AM GERIATR SOC, V45, P174, DOI 10.1111/j.1532-5415.1997.tb04503.x; Papadopoulos MC, 2000, CRIT CARE MED, V28, P3019, DOI 10.1097/00003246-200008000-00057; PUGH RNH, 1973, BRIT J SURG, V60, P646, DOI 10.1002/bjs.1800600817; Rothenhausler HB, 2001, GEN HOSP PSYCHIAT, V23, P88, DOI 10.1016/S0163-8343(01)00123-2; SAGE WM, 1987, J AM GERIATR SOC, V35, P312, DOI 10.1111/j.1532-5415.1987.tb04637.x; *SAS I, 1990, SAS STAT US GUID, P1030; Seely AJE, 2000, CRIT CARE MED, V28, P2193, DOI 10.1097/00003246-200007000-00003; Shaw AB, 1996, DRUG AGING, V9, P403, DOI 10.2165/00002512-199609060-00003; SINGER PA, 1992, ARCH INTERN MED, V152, P478, DOI 10.1001/archinte.152.3.478; SLOANE PJ, 1992, AM REV RESPIR DIS, V146, P419, DOI 10.1164/ajrccm/146.2.419; Srivastava S, 1999, CRIT CARE MED, V27, P2109, DOI 10.1097/00003246-199910000-00005; Stewart TE, 1998, NEW ENGL J MED, V338, P355, DOI 10.1056/NEJM199802053380603; Suchyta MR, 1997, CHEST, V111, P1334, DOI 10.1378/chest.111.5.1334; TORRES A, 1995, AM J RESP CRIT CARE, V152, P137, DOI 10.1164/ajrccm.152.1.7599812; Vervloet MG, 1998, SEMIN THROMB HEMOST, V24, P33, DOI 10.1055/s-2007-995821; Walter LC, 2001, JAMA-J AM MED ASSOC, V285, P2987, DOI 10.1001/jama.285.23.2987; Ware LB, 2000, NEW ENGL J MED, V342, P1334, DOI 10.1056/NEJM200005043421806; Wiedemann HP, 2000, JAMA-J AM MED ASSOC, V283, P1995; Zilberberg MD, 1998, AM J RESP CRIT CARE, V157, P1159, DOI 10.1164/ajrccm.157.4.9704088	85	167	173	0	11	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JAN 1	2002	136	1					25	36		10.7326/0003-4819-136-1-200201010-00007	http://dx.doi.org/10.7326/0003-4819-136-1-200201010-00007			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine	510BF	11777361				2023-01-03	WOS:000173188300003
J	Degos, L; Wang, ZY				Degos, L; Wang, ZY			All trans retinoic acid in acute promyelocytic leukemia	ONCOGENE			English	Article						differentiation; promyelocytic leukemia; retinoic acid	POLYMERASE CHAIN-REACTION; RECEPTOR-ALPHA; DIFFERENTIATION THERAPY; 15-17 TRANSLOCATION; TRANSRETINOIC ACID; COMPLETE REMISSION; CD56 EXPRESSION; PML GENE; CHEMOTHERAPY; FUSION	All trans retinoic acid (ATRA) is able to induce complete remission (CR) in almost all patients with acute promyelocytic leukemia (APL) through in vivo differentiation of APL blasts. However, it cannot eliminate the leukemic clone and to be effective must be used in combination with anthracycline-based chemotherapy. Experience accumulated over the last 10 years has clearly shown that the combination of ATRA and chemotherapy gives better survival in newly diagnosed APL than chemotherapy alone because of fewer relapses and a higher CR rate experienced by these patients. It is also strongly suggested that maintenance treatment with ATRA, and possibly in combination with low-dose chemotherapy, can further reduce the incidence of relapse. Overall, more than 90% of patients with newly diagnosed APL can achieve CR and about 75% can be cured by the combination of ATRA and chemotherapy.	Hop St Louis, Inst Univ Hematol, AP HP, F-75010 Paris, France; Shanghai Med Univ 2, Rui Jin Hosp, Shanghai Inst Hematol, Shanghai, Peoples R China	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; UDICE-French Research Universities; Universite Paris Cite; Shanghai Jiao Tong University	Degos, L (corresponding author), Hop St Louis, Inst Univ Hematol, AP HP, 1 Ave Claude Vellefaux, F-75010 Paris, France.							Arnould C, 1999, HUM MOL GENET, V8, P1741, DOI 10.1093/hmg/8.9.1741; Avvisati G, 1999, BLOOD, V94, p505A; AVVISATI G, 1991, ANN ONCOL, V2, P405; AVVISATI G, 1990, HEMOSTASIS CANC, P91; Beaumont M, 2000, BLOOD, V96, p321A; BENNETT JM, 1976, BRIT J HAEMATOL, V33, P451, DOI 10.1111/j.1365-2141.1976.tb03563.x; BENNETT JM, 1980, ANN INTERN MED, V92, P261, DOI 10.7326/0003-4819-92-2-261; BERNARD J, 1959, Schweiz Med Wochenschr, V89, P604; BERNARD J, 1973, BLOOD, V41, P489, DOI 10.1182/blood.V41.4.489.489; BIONDI A, 1992, BLOOD, V80, P492; BREITMAN TR, 1981, BLOOD, V57, P1000; CAEN J, 1959, REV FR ETUD CLIN BIO, V4, P363; CAEN J, 1957, C EUR HEMAT KARGER, P502; CASSINAT B, 2001, SEMINARS HEMATOLOGY; CASTAIGNE S, 1990, BLOOD, V76, P1704; CASTAIGNE S, 1992, BLOOD, V79, P3110; CHEN Z, 1993, EMBO J, V12, P1161, DOI 10.1002/j.1460-2075.1993.tb05757.x; CHOMIENNE C, 1990, BLOOD, V76, P1710; CHOMIENNE C, 1986, LEUKEMIA RES, V10, P1301, DOI 10.1016/0145-2126(86)90337-1; CHOMIENNE C, 1986, LEUKEMIA RES, V10, P1079, DOI 10.1016/0145-2126(86)90052-4; CORNIC M, 1992, CANCER RES, V52, P3329; DOMBRET H, 1995, LEUKEMIA, V9, P19; Douer D, 1996, BLOOD, V87, P308, DOI 10.1182/blood.V87.1.308.bloodjournal871308; DUBOIS C, 1994, LEUKEMIA, V8, P1750; Fenaux P, 1999, BLOOD, V94, P1192, DOI 10.1182/blood.V94.4.1192.416k07_1192_1200; FENAUX P, 1993, BLOOD, V82, P3241; FENAUX P, 1992, BLOOD, V80, P2176; Fenaux P, 2000, LEUKEMIA, V14, P1371, DOI 10.1038/sj.leu.2401859; Ferrara F, 2000, J CLIN ONCOL, V18, P1295, DOI 10.1200/JCO.2000.18.6.1295; FRANKEL SR, 1992, ANN INTERN MED, V117, P293; GOLOMB HM, 1976, ARCH INTERN MED, V136, P825, DOI 10.1001/archinte.136.7.825; Guglielmi C, 1998, BRIT J HAEMATOL, V102, P1035, DOI 10.1046/j.1365-2141.1998.00871.x; HILLESTAD LK, 1957, ACTA MED SCAND, V159, P189, DOI 10.1111/j.0954-6820.1957.tb00124.x; HUANG ME, 1988, BLOOD, V72, P567, DOI 10.1182/blood.V72.2.567.567; HUANG W, 1993, BLOOD, V82, P1264, DOI 10.1182/blood.V82.4.1264.bloodjournal8241264; Jansen JH, 1999, BLOOD, V94, P39, DOI 10.1182/blood.V94.1.39.413a26_39_45; KANAMARU A, 1995, BLOOD, V85, P1202, DOI 10.1182/blood.V85.5.1202.bloodjournal8551202; LARSON RA, 1984, AM J MED, V76, P827, DOI 10.1016/0002-9343(84)90994-X; Lo Coco F, 1999, BLOOD, V94, P2225, DOI 10.1182/blood.V94.7.2225.419k03_2225_2229; Menell JS, 1999, NEW ENGL J MED, V340, P994, DOI 10.1056/NEJM199904013401303; MICLEA JM, 1994, LEUKEMIA, V8, P214; MUINDI J, 1992, BLOOD, V79, P299; Murray CK, 1999, J CLIN ONCOL, V17, P293, DOI 10.1200/JCO.1999.17.1.293; Redner RL, 1996, BLOOD, V87, P882, DOI 10.1182/blood.V87.3.882.bloodjournal873882; RODEGHIERO F, 1990, BLOOD, V75, P2112; ROWLEY JD, 1977, LANCET, V1, P549; Schoch C, 1996, BRIT J HAEMATOL, V94, P493, DOI 10.1046/j.1365-2141.1996.d01-1829.x; Slack JL, 1997, J CLIN ONCOL, V15, P1786, DOI 10.1200/JCO.1997.15.5.1786; Tallman MS, 1997, NEW ENGL J MED, V337, P1021, DOI 10.1056/NEJM199710093371501; VAHDAT L, 1994, BLOOD, V84, P3843, DOI 10.1182/blood.V84.11.3843.bloodjournal84113843; Wang ZY, 1999, CHINESE MED J-PEKING, V112, P963; WARRELL RP, 1991, NEW ENGL J MED, V324, P1385, DOI 10.1056/NEJM199105163242002; WARRELL RP, 1994, LEUKEMIA, V8, P929; Wells RA, 1997, NAT GENET, V17, P109, DOI 10.1038/ng0997-109; Zhu J, 1999, LEUKEMIA, V13, P1062, DOI 10.1038/sj.leu.2401448	55	153	166	1	16	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 29	2001	20	49					7140	7145		10.1038/sj.onc.1204763	http://dx.doi.org/10.1038/sj.onc.1204763			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	487TM	11704842				2023-01-03	WOS:000171891900002
J	MacKenzie, K; Millar, A; Wilson, JA; Sellars, C; Deary, IJ				MacKenzie, K; Millar, A; Wilson, JA; Sellars, C; Deary, IJ			Is voice therapy an effective treatment for dysphonia? A randomised controlled trial	BRITISH MEDICAL JOURNAL			English	Article							FUNCTIONAL DYSPHONIA; PERSONALITY; DISORDER; STILL		Glasgow Royal Infirm, Dept Otorhinolaryngol Head & Neck Surg, Glasgow G31 2ER, Lanark, Scotland; Glasgow Royal Infirm, Dept Speech & Language Therapy, Glasgow G31 2ER, Lanark, Scotland; Univ Newcastle Upon Tyne, Dept Otorhinolaryngol Head & Neck Surg, Newcastle Upon Tyne NE7 7DN, Tyne & Wear, England; Univ Edinburgh, Dept Psychol, Edinburgh EH8 9JZ, Midlothian, Scotland	University of Glasgow; University of Glasgow; Newcastle University - UK; University of Edinburgh	MacKenzie, K (corresponding author), Glasgow Royal Infirm, Dept Otorhinolaryngol Head & Neck Surg, Glasgow G31 2ER, Lanark, Scotland.		Deary, Ian J/C-6297-2009	Deary, Ian J/0000-0002-1733-263X; wilson, janet/0000-0002-6416-5870				ARONSON A, 1996, J SPEECH HEAR DISORD, V31, P115; CARDING PN, 1992, EUR J DISORDER COMM, V27, P137; Deary IJ, 1997, BRIT J HEALTH PSYCH, V2, P333, DOI 10.1111/j.2044-8287.1997.tb00547.x; Dunnet CP, 1997, EUR J DISORDER COMM, V32, P333; ELIAS A, 1989, BRIT J DISORD COMMUN, V24, P61; Fairbanks G., 1960, VOICE ARTICULATION D; GERRITSMA EJ, 1991, FOLIA PHONIATR, V43, P13, DOI 10.1159/000266096; HOUSE A, 1987, J PSYCHOSOM RES, V31, P483, DOI 10.1016/0022-3999(87)90006-7; HOUSE AO, 1988, J PSYCHOSOM RES, V32, P311, DOI 10.1016/0022-3999(88)90073-6; JENKINSON C, 1993, BRIT MED J, V306, P1437, DOI 10.1136/bmj.306.6890.1437; LEWIS G, 1992, PSYCHOL MED, V22, P465, DOI 10.1017/S0033291700030415; MATAS M, 1991, CAN J PSYCHIAT, V36, P363, DOI 10.1177/070674379103600509; Scott S, 1997, CLIN OTOLARYNGOL, V22, P37, DOI 10.1046/j.1365-2273.1997.00855.x; Scott S, 1997, PSYCHOL HEALTH MED, V2, P169; White A, 1997, EUR J DISORDER COMM, V32, P307; Wilson DK., 1987, VOICE PROBLEMS CHILD; WILSON JA, 1995, BRIT MED J, V311, P1039, DOI 10.1136/bmj.311.7012.1039; ZIGMOND AS, 1983, ACTA PSYCHIAT SCAND, V67, P361, DOI 10.1111/j.1600-0447.1983.tb09716.x	18	89	93	1	10	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	SEP 22	2001	323	7314					658	661		10.1136/bmj.323.7314.658	http://dx.doi.org/10.1136/bmj.323.7314.658			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	476LP	11566828	Green Published, Green Accepted, Bronze			2023-01-03	WOS:000171228800015
J	Merlo, J; Liedholm, H; Lindblad, U; Bjorck-Linne, A; Falt, J; Lindberg, G; Melander, A				Merlo, J; Liedholm, H; Lindblad, U; Bjorck-Linne, A; Falt, J; Lindberg, G; Melander, A			Prescriptions with potential drug interactions dispensed at Swedish pharmacies in January 1999: cross sectional study	BRITISH MEDICAL JOURNAL			English	Article									Lund Univ, Malmo Univ Hosp, Dept Community Med, S-20502 Malmo, Sweden; Malmo Univ Hosp, NEPI Fdn Med Res Ctr, Malmo, Sweden	Lund University; Skane University Hospital; Lund University; Skane University Hospital	Merlo, J (corresponding author), Lund Univ, Malmo Univ Hosp, Dept Community Med, S-20502 Malmo, Sweden.		Merlo, Juan/E-2136-2011	Merlo, Juan/0000-0001-8379-9708				Rasbash J, 1999, USERS GUIDE MLWIN; SJOQVIST E, 1999, SWEDISH DRUG COMPEND, P1383; SJOQVIST F, 2000, SWEDISH DRUG COMPEND, P1481; STOCKLEY IH, 1996, DRUG INTERACTIONS SO; 1996, INFORMATION LAKEMEDE, V7, P27	5	61	65	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	AUG 25	2001	323	7310					427	428		10.1136/bmj.323.7310.427	http://dx.doi.org/10.1136/bmj.323.7310.427			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	469BX	11520839	Bronze, Green Submitted, Green Published			2023-01-03	WOS:000170793600020
J	Gupta, K; Hooton, TM; Roberts, PL; Stamm, WE				Gupta, K; Hooton, TM; Roberts, PL; Stamm, WE			Patient-initiated treatment of uncomplicated recurrent urinary tract infections in young women	ANNALS OF INTERNAL MEDICINE			English	Article; Proceedings Paper	38th Annual Meeting of the Infectious-Diseases-Society-of-America	SEP 06-11, 2000	NEW ORLEANS, LA	Infect Dis Soc Amer			CHLAMYDIA-TRACHOMATIS INFECTIONS; ACUTE URETHRAL SYNDROME; THERAPY; MANAGEMENT; OFLOXACIN; DIAGNOSIS; CYSTITIS; TRIAL	Background: Recurrent urinary tract infections (UTIs) are a common outpatient problem, resulting in frequent office visits and often requiring the use of prophylactic antimicrobial agents. Patient-initiated treatment of recurrent UTIs may decrease antimicrobial use and improve patient convenience. Objective: To determine the safety and feasibility of patient-initiated treatment of recurrent UTIs. Design: Uncontrolled, prospective clinical trial. Setting: University-based primary health care clinic. Participants: Women at least 18 years of age with a history of recurrent UTIs and no recent pregnancy, hypertension, diabetes, or renal disease. Intervention: After self-diagnosing UTI on the basis of symptoms, participating women initiated therapy with ofloxacin or levofloxacin. Measurements: Accuracy of self-diagnosis determined by evidence of a definite (culture-positive) or probable (sterile pyuria and no alternative diagnosis) UTI on pretherapy urinalysis and culture. Women with a self-diagnosis of UTI that was not microbiologically confirmed were evaluated for alternative diagnoses. Post-therapy interviews and urine cultures were used to assess clinical and microbiological cure rates, adverse events, and patient satisfaction. Results: 88 of 172 women self-diagnosed a total of 172 UTIs. Laboratory evaluation showed a uropathogen in 144 cases (84%), sterile pyuria in 19 cases (11%), and no pyuria or bacteriuria in 9 cases (5%). Clinical and microbiological cures occurred in 92% and 96%, respectively, of culture-confirmed episodes. No serious adverse events occurred. Conclusion: Adherent women can accurately self-diagnose and self-treat recurrent UTIs.	Univ Washington, Dept Med, Div Allergy & Infect Dis, Seattle, WA 98195 USA	University of Washington; University of Washington Seattle	Gupta, K (corresponding author), Univ Washington, Dept Med, Div Allergy & Infect Dis, 1959 NE Pacific St,Box 356523, Seattle, WA 98195 USA.	kalg@u.washington.edu			NIDDK NIH HHS [DK 53369, DK 47549] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK053369, R01DK047549] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BAUER AW, 1966, AM J CLIN PATHOL, V45, P493; Black CM, 1997, CLIN MICROBIOL REV, V10, P160, DOI 10.1128/CMR.10.1.160; DONNER A, 1988, J CLIN EPIDEMIOL, V41, P899, DOI 10.1016/0895-4356(88)90107-2; Engel JD, 1998, UROL CLIN N AM, V25, P685, DOI 10.1016/S0094-0143(05)70057-4; FOXMAN B, 1985, AM J PUBLIC HEALTH, V75, P1308, DOI 10.2105/AJPH.75.11.1308; Hooton TM, 1997, INFECT DIS CLIN N AM, V11, P551, DOI 10.1016/S0891-5520(05)70373-1; Hooton TM, 1996, NEW ENGL J MED, V335, P468, DOI 10.1056/NEJM199608153350703; HOOTON TM, 1991, ANTIMICROB AGENTS CH, V35, P1479, DOI 10.1128/AAC.35.7.1479; KUNIN CM, 1994, CLIN INFECT DIS, V18, P1, DOI 10.1093/clinids/18.1.1; Lennette E.H, 1985, MANUAL CLIN MICROBIO, V4th ed.; McCarthy JM, 1999, AM J MED, V106, P292, DOI 10.1016/S0002-9343(99)00026-1; Schaeffer AJ, 1999, J UROLOGY, V161, P207, DOI 10.1016/S0022-5347(01)62099-8; Schauffler HH, 1996, J FAM PRACTICE, V42, P62; STAMM WE, 1991, REV INFECT DIS, V13, P77; Stamm WE, 1999, J INFECT DIS, V179, pS380, DOI 10.1086/513844; STAMM WE, 1980, NEW ENGL J MED, V303, P409, DOI 10.1056/NEJM198008213030801; STAMM WE, 1983, SEX TRANSM DIS, V10, P318; STAMM WE, 1993, NEW ENGL J MED, V329, P1328, DOI 10.1056/NEJM199310283291808; STAPLETON A, 1990, JAMA-J AM MED ASSOC, V264, P703, DOI 10.1001/jama.264.6.703; Stapleton A, 1999, LANCET, V353, P7, DOI 10.1016/S0140-6736(05)74875-3; Warren JW, 1999, CLIN INFECT DIS, V29, P745, DOI 10.1086/520427; WONG ES, 1985, ANN INTERN MED, V102, P302, DOI 10.7326/0003-4819-102-3-302; ZEGER SL, 1986, BIOMETRICS, V42, P121, DOI 10.2307/2531248	23	144	149	0	7	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUL 3	2001	135	1					9	16		10.7326/0003-4819-135-1-200107030-00004	http://dx.doi.org/10.7326/0003-4819-135-1-200107030-00004			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine	449JC	11434727				2023-01-03	WOS:000169680500002
J	Xue, LY; Chiu, SM; Oleinick, NL				Xue, LY; Chiu, SM; Oleinick, NL			Photochemical destruction of the Bcl-2 oncoprotein during photodynamic therapy with the phthalocyanine photosensitizer Pc 4	ONCOGENE			English	Article						Bcl-2; apoptosis; photodynamic therapy; Pc 4	PROSTATE-CANCER CELLS; CYTOCHROME-C; INDUCED APOPTOSIS; CASPASE ACTIVATION; TYROSINE KINASE; SINGLET OXYGEN; RELEASE; DEATH; MITOCHONDRIA; CLEAVAGE	Photodynamic therapy (PDT), utilizing a photosensitizer and visible light, causes localized oxidative damage. With the mitochondrial photosensitizer Pc 4, PDT induces apoptosis, yet its molecular targets are not known, Here, the anti-apoptotic protein Bcl-2 is shown to be highly sensitive to PDT, as judged on Western blots by the disappearance of anti-Bcl-2-reactive material from the position of the native 26 kDa protein. The loss of Bcl-2 was PDT dose dependent and was observed for both endogenous and overexpressed Bcl-2 in several cell lines, immediately after PDT, and with chilled cells. It was accompanied by a trace of a 23-kDa cleavage product as well as high-molecular weight products that may result from photochemical crosslinking. PDT-induced Bcl-2 loss occurred in MCF-7 cells that do not express caspase-3 or in the presence of protease inhibitors, but was prevented, along with the induction of apoptosis, by the singlet oxygen scavenger L-histidine. Loss of FLAG-Bcl-2 was observed with both anti-FLAG and anti-Bcl-2 antibodies, indicating loss of native protein rather than simple BCL-2-epitope destruction. Photochemical damage was not observed in Bcl-x(L), Bax, Bad, the voltage-dependent anion channel, or the adenine nucleotide translocator. Therefore, Bcl-2 is one target of PDT with Pc 4, and PDT damage to Bcl-2 contributes to its efficient induction of apoptosis.	Case Western Reserve Univ, Sch Med, Dept Radiat Oncol, Cleveland, OH 44106 USA; Case Western Reserve Univ, Sch Med, CWRU Ireland Comprehens Canc Ctr, Cleveland, OH 44106 USA	Case Western Reserve University; Case Western Reserve University	Oleinick, NL (corresponding author), Case Western Reserve Univ, Sch Med, Dept Radiat Oncol, BRB-324,10900 Euclid Ave, Cleveland, OH 44106 USA.				NATIONAL CANCER INSTITUTE [P01CA048735, P30CA043703, R01CA083917] Funding Source: NIH RePORTER; NCI NIH HHS [P01 CA48735, R01 CA83917, P30 CA43703] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AGARWAL R, 1991, CANCER LETT, V56, P125, DOI 10.1016/0304-3835(91)90086-W; Antonsson B, 1997, SCIENCE, V277, P370, DOI 10.1126/science.277.5324.370; BISSONNETTE RP, 1992, NATURE, V359, P552, DOI 10.1038/359552a0; Carthy CM, 1999, LAB INVEST, V79, P953; Cheng EHY, 1997, SCIENCE, V278, P1966, DOI 10.1126/science.278.5345.1966; Colussi VC, 1999, PHOTOCHEM PHOTOBIOL, V69, P236, DOI 10.1562/0031-8655(1999)069<0236:PPTOHO>2.3.CO;2; EGUCHI Y, 1992, NUCLEIC ACIDS RES, V20, P4187, DOI 10.1093/nar/20.16.4187; Fadeel B, 1999, LEUKEMIA, V13, P719, DOI 10.1038/sj.leu.2401411; Fujita N, 1998, BIOCHEM BIOPH RES CO, V246, P484, DOI 10.1006/bbrc.1998.8587; Grandgirard D, 1998, EMBO J, V17, P1268, DOI 10.1093/emboj/17.5.1268; Granville DJ, 1999, BRIT J CANCER, V79, P95, DOI 10.1038/sj.bjc.6690017; Gross A, 1999, GENE DEV, V13, P1899, DOI 10.1101/gad.13.15.1899; Haldar S, 1996, CANCER RES, V56, P1253; HALLIWELL B, 1989, FREE RADICAL BIO MED, P66; He HL, 1998, J BIOL CHEM, V273, P25015, DOI 10.1074/jbc.273.39.25015; He J, 1997, PHOTOCHEM PHOTOBIOL, V65, P581; He J, 1996, PHOTOCHEM PHOTOBIOL, V64, P845, DOI 10.1111/j.1751-1097.1996.tb01845.x; HENDERSON BW, 1992, PHOTOCHEM PHOTOBIOL, V55, P145, DOI 10.1111/j.1751-1097.1992.tb04222.x; HOCKENBERY DM, 1993, CELL, V75, P241, DOI 10.1016/0092-8674(93)80066-N; Jacobson MD, 1996, J CELL BIOL, V133, P1041, DOI 10.1083/jcb.133.5.1041; Janicke RU, 1998, J BIOL CHEM, V273, P9357, DOI 10.1074/jbc.273.16.9357; Kessel D, 1999, CELL DEATH DIFFER, V6, P28, DOI 10.1038/sj.cdd.4400446; Kim HRC, 1999, CANCER RES, V59, P3429; Kirsch DG, 1999, J BIOL CHEM, V274, P21155, DOI 10.1074/jbc.274.30.21155; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; KORSMEYER SJ, 1999, CANCER RES, V59, P1693; LAM M, 1994, P NATL ACAD SCI USA, V91, P6569, DOI 10.1073/pnas.91.14.6569; Lavie G, 1999, BRIT J CANCER, V79, P423, DOI 10.1038/sj.bjc.6690066; MOAN J, 1992, PHOTOCHEM PHOTOBIOL, V55, P931, DOI 10.1111/j.1751-1097.1992.tb08541.x; Oleinick NL, 1998, RADIAT RES, V150, pS146, DOI 10.2307/3579816; OLEINICK NL, 1993, PHOTOCHEM PHOTOBIOL, V57, P242, DOI 10.1111/j.1751-1097.1993.tb02282.x; Qiu Y, 1998, P NATL ACAD SCI USA, V95, P3644, DOI 10.1073/pnas.95.7.3644; Reed JC, 1998, BBA-BIOENERGETICS, V1366, P127, DOI 10.1016/S0005-2728(98)00108-X; Susin SA, 1999, J EXP MED, V189, P381, DOI 10.1084/jem.189.2.381; Trivedi NS, 2000, PHOTOCHEM PHOTOBIOL, V71, P634, DOI 10.1562/0031-8655(2000)071<0634:QAOPLI>2.0.CO;2; TSUJIMOTO Y, 1986, P NATL ACAD SCI USA, V83, P5214, DOI 10.1073/pnas.83.14.5214; Tudor G, 2000, CELL DEATH DIFFER, V7, P574, DOI 10.1038/sj.cdd.4400688; Varnes ME, 1999, BIOCHEM BIOPH RES CO, V255, P673, DOI 10.1006/bbrc.1999.0261; WEISHAUPT KR, 1976, CANCER RES, V36, P2326; Wuerzberger SM, 1998, CANCER RES, V58, P1876; Xue LY, 2001, EXP CELL RES, V263, P145, DOI 10.1006/excr.2000.5108; Xue LY, 1999, ONCOGENE, V18, P3391, DOI 10.1038/sj.onc.1202687; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129; Zhang WG, 1999, PHOTOCHEM PHOTOBIOL, V69, P582, DOI 10.1562/0031-8655(1999)069<0582:ABRVIT>2.3.CO;2	44	180	198	1	18	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 7	2001	20	26					3420	3427		10.1038/sj.onc.1204441	http://dx.doi.org/10.1038/sj.onc.1204441			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	441UW	11423992				2023-01-03	WOS:000169248800012
J	Gunther, C; Schmidt, U; Rudolph, R; Bohm, G				Gunther, C; Schmidt, U; Rudolph, R; Bohm, G			Protein and peptide delivery via engineered polyomavirus-like particles	FASEB JOURNAL			English	Article						drug delivery; in vitro assembly; VP1; WW domain	MURINE POLYOMAVIRUS; WW DOMAIN; BINDING; VP1; DNA; PSEUDOCAPSIDS; COMPLEX; CELLS; SITE	Recent advances in molecular biology have led to the development of new therapeutics to address genetic disorders. The developments in the production and availability of recombinant proteins are likely to have a substantial impact on many diseases in the short term. A major limit for the use of recombinant proteins in clinical applications is their inability to enter cells and be targeted to the appropriate intracellular site. Here, we describe a novel system for the intracellular delivery of peptides and proteins using recombinantly expressed polyomavirus-like particles as universal carriers. The inner surface of the particles was modified by the fusion of a WW domain, which was derived from the mouse formin binding protein 11 (FBP11) to the viral coat protein in order to bind specifically to proline-rich ligands. Physicochemical characterization of the fusion protein demonstrated that the functional units of the VP1-WW protein remained intact. Assembly of the particles in the presence of proline-rich ligands resulted in an efficient encapsidation of the ligands into the particles. Fluorescence-labeled peptides and the green fluorescent protein were used as model ligands. The delivery of the ligands into cultured eukaryotic cells could be demonstrated with confocal laser-scanning microscopy.	Univ Halle Wittenberg, Inst Biotechnol, D-06120 Halle An Der Saale, Germany; ACGT ProGenom AG, D-06120 Halle An Der Saale, Germany	Martin Luther University Halle Wittenberg	Gunther, C (corresponding author), Univ Halle Wittenberg, Inst Biotechnol, Kurt Mothes Str 3, D-06120 Halle An Der Saale, Germany.	constanze.guenther@biochemtech.uni-halle.de						Bedford MT, 1997, EMBO J, V16, P2376, DOI 10.1093/emboj/16.9.2376; BOHM G, 1992, PROTEIN ENG, V5, P191, DOI 10.1093/protein/5.3.191; BORK P, 1994, TRENDS BIOCHEM SCI, V19, P531, DOI 10.1016/0968-0004(94)90053-1; Braun H, 1999, BIOTECHNOL APPL BIOC, V29, P31; CHANG DC, 1993, J VIROL, V67, P6327, DOI 10.1128/JVI.67.10.6327-6331.1993; Chang YJ, 1996, J ENHANC HEAT TRANSF, V3, P15, DOI 10.1615/JEnhHeatTransf.v3.i1.20; Elliott G, 1997, CELL, V88, P223, DOI 10.1016/S0092-8674(00)81843-7; FORSTOVA J, 1995, HUM GENE THER, V6, P297, DOI 10.1089/hum.1995.6.3-297; Koepf EK, 1999, PROTEIN SCI, V8, P841, DOI 10.1110/ps.8.4.841; Koepf EK, 1999, BIOCHEMISTRY-US, V38, P14338, DOI 10.1021/bi991105l; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LEAVITT AD, 1985, J BIOL CHEM, V23, P12803; Macias MJ, 2000, NAT STRUCT BIOL, V7, P375, DOI 10.1038/75144; Macias MJ, 1996, NATURE, V382, P646, DOI 10.1038/382646a0; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; Russell CS, 1999, CLIN GENET, V55, P389, DOI 10.1034/j.1399-0004.1999.550601.x; SAHLI R, 1993, VIROLOGY, V192, P142, DOI 10.1006/viro.1993.1016; SALI A, 1993, J MOL BIOL, V234, P779, DOI 10.1006/jmbi.1993.1626; SALUNKE DM, 1989, BIOPHYS J, V56, P887, DOI 10.1016/S0006-3495(89)82735-3; SALUNKE DM, 1986, CELL, V46, P895, DOI 10.1016/0092-8674(86)90071-1; Schmidt U, 1999, BIOL CHEM, V380, P397, DOI 10.1515/BC.1999.053; Schmidt U, 2000, J VIROL, V74, P1658, DOI 10.1128/JVI.74.4.1658-1662.2000; Schwarze SR, 1999, SCIENCE, V285, P1569, DOI 10.1126/science.285.5433.1569; Scott MD, 1998, CURR PHARM DESIGN, V4, P423; Soeda E, 1998, GENE THER, V5, P1410, DOI 10.1038/sj.gt.3300748; Stehle T, 1996, STRUCTURE, V4, P183, DOI 10.1016/S0969-2126(96)00021-4; Stehle T, 1997, EMBO J, V16, P5139, DOI 10.1093/emboj/16.16.5139; STEHLE T, 1994, NATURE, V369, P160, DOI 10.1038/369160a0; Stubenrauch K, 2000, J CHROMATOGR B, V737, P77, DOI 10.1016/S0378-4347(99)00392-8; SUDOL M, 1995, J BIOL CHEM, V270, P14733, DOI 10.1074/jbc.270.24.14733; Yang F, 1996, NAT BIOTECHNOL, V14, P1246, DOI 10.1038/nbt1096-1246	31	22	26	0	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY 29	2001	15	7					1646	+		10.1096/fj.00-0645fje	http://dx.doi.org/10.1096/fj.00-0645fje			16	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	519CQ	11427514				2023-01-03	WOS:000173707700022
J	Kern, KB				Kern, KB			Thrombolytic therapy during cardiopulmonary resuscitation	LANCET			English	Editorial Material							BLOOD-FLOW; EPINEPHRINE; PERFUSION		Univ Arizona, Sarver Heart Ctr, Dept Med, Tucson, AZ 85724 USA	University of Arizona	Kern, KB (corresponding author), Univ Arizona, Sarver Heart Ctr, Dept Med, Tucson, AZ 85724 USA.	kernk@u.arizona.edu						DAVIES MJ, 1989, EUR HEART J, V10, P203, DOI 10.1093/oxfordjournals.eurheartj.a059467; DEWOOD MA, 1980, NEW ENGL J MED, V303, P897, DOI 10.1056/NEJM198010163031601; HALPERIN HR, 1986, CIRCULATION, V73, P539, DOI 10.1161/01.CIR.73.3.539; KERN KB, 1990, AM HEART J, V120, P324, DOI 10.1016/0002-8703(90)90076-A; MICHAEL JR, 1984, CIRCULATION, V69, P822, DOI 10.1161/01.CIR.69.4.822; RALSTON SH, 1984, ANN EMERG MED, V13, P79, DOI 10.1016/S0196-0644(84)80566-1; Willerson JT, 2000, CIRCULATION, V102, P1	7	7	7	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	MAY 19	2001	357	9268					1549	1550		10.1016/S0140-6736(00)04780-2	http://dx.doi.org/10.1016/S0140-6736(00)04780-2			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	434RR	11377640				2023-01-03	WOS:000168830100006
J	Vantieghem, A; Xu, Y; Assefa, Z; Piette, J; Vandenheede, JR; Merlevede, W; de Witte, PAM; Agostinis, P				Vantieghem, A; Xu, Y; Assefa, Z; Piette, J; Vandenheede, JR; Merlevede, W; de Witte, PAM; Agostinis, P			Phosphorylation of Bcl-2 in G(2)/M phase-arrested cells following photodynamic therapy with hypericin involves a CDK1-mediated signal and delays the onset of apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; N-TERMINAL KINASE; CYTOCHROME-C; GROWTH-FACTOR; HELA-CELLS; P38 MAPK; MICROTUBULES; MECHANISM; INACTIVATION; INVOLVEMENT	The role of Bcl-2 in photodynamic therapy (PDT) is controversial, and some photosensitizers have been shown to induce Bcl-2 degradation with loss of its protective function. Hypericin is a naturally occurring photosensitizer with promising properties for the PDT of cancer. Here we show that, in HeLa cells, photoactivated hypericin does not cause Bcl-2 degradation but induces Bcl-2 phosphorylation in a dose- and time-dependent manner. Bcl-2 phosphorylation is induced by sublethal PDT doses; increasing the photodynamic stress promptly leads to apoptosis, during which Bcl-2 is neither phosphorylated nor degraded. Bcl-2 phosphorylation involves mitochondrial Bcl-2 and correlates with the kinetics of a G(2)/M cell cycle arrest, preceding apoptosis. The co-localization of hypericin with alpha-tubulin and the aberrant mitotic spindles observed following sublethal PDT doses suggest that photodamage to the microtubule network provokes the G(2)/M phase arrest. PDT-induced Bcl-2 phosphorylation is not altered by either the overexpression or inhibition of p38 mitogen-activated protein kinase (p38 MAPK) and c-Jun NH2-terminal protein kinase 1 (JNK1) nor by inhibiting the extracellular signal-regulated kinases (ERKs) or protein kinase C. By contrast, Bcl-2 phosphorylation is selectively suppressed by the cyclin-dependent protein kinase (CDK)-inhibitor roscovitine, completely blocked by the protein synthesis inhibitor cycloheximide and enhanced by the overexpression. of CDK1, suggesting a role for this pathway. However, in an in vitro kinase assay, active CDK1/cyclin B1 complex failed to phosphorylate immunoprecipitated Bcl-2, suggesting that this protein kinase may not directly modify Bcl-2. Mutation of serine-70 to alanine in Bcl-2 abolishes PDT-induced phosphorylation and restores the caspase-3 activation to the same levels of the vector-transfected cells, indicating that Bcl-2 phosphorylation may be a signal to delay apoptosis in G(2)/M phase-arrested cells.	Catholic Univ Louvain, Div Biochem, Fac Med, B-3000 Louvain, Belgium; Catholic Univ Louvain, Lab Pharmaceut Biol & Phytopharmacol, Fac Pharm, B-3000 Louvain, Belgium; Univ Liege, Lab Virol & Immunol, B-4000 Cointe Ougree, Belgium	Universite Catholique Louvain; Universite Catholique Louvain; University of Liege	Agostinis, P (corresponding author), Catholic Univ Louvain, Div Biochem, Fac Med, Campus Gasthuisberg,Herestr 49, B-3000 Louvain, Belgium.	agostinis@med.kuleuven.ae.be	Agostinis, Patrizia/AAO-2468-2020; Agostinis, Patrizia/ABI-1177-2020; Assefa, Zerihun/V-5641-2017	Agostinis, Patrizia/0000-0003-1314-2115; Assefa, Zerihun/0000-0001-7803-5228; de Witte, Peter/0000-0002-9989-9567				Adams JM, 1998, SCIENCE, V281, P1322, DOI 10.1126/science.281.5381.1322; Agostinis P, 2002, INT J BIOCHEM CELL B, V34, P221, DOI 10.1016/S1357-2725(01)00126-1; Ahmad N, 2000, METHOD ENZYMOL, V319, P342; ARION D, 1988, CELL, V55, P371, DOI 10.1016/0092-8674(88)90060-8; Assefa Z, 1999, J BIOL CHEM, V274, P8788, DOI 10.1074/jbc.274.13.8788; Assefa Z, 1997, J INVEST DERMATOL, V108, P886, DOI 10.1111/1523-1747.ep12292595; BAILLY E, 1989, EMBO J, V8, P3985, DOI 10.1002/j.1460-2075.1989.tb08581.x; Basu A, 1998, INT J ONCOL, V13, P659; Basu A, 2000, INT J ONCOL, V16, P497; Berg K, 1997, PHOTOCHEM PHOTOBIOL, V65, P403, DOI 10.1111/j.1751-1097.1997.tb08578.x; Blagosklonny MV, 1999, INT J CANCER, V83, P151, DOI 10.1002/(SICI)1097-0215(19991008)83:2<151::AID-IJC1>3.0.CO;2-5; Blagosklonny MV, 2001, LEUKEMIA, V15, P869, DOI 10.1038/sj.leu.2402134; Blagosklonny MV, 1997, CANCER RES, V57, P130; Boudrez A, 2000, J BIOL CHEM, V275, P25411, DOI 10.1074/jbc.M001676200; Chaloupka R, 1999, FEBS LETT, V462, P295, DOI 10.1016/S0014-5793(99)01538-0; De Souza CPC, 2000, EXP CELL RES, V257, P11, DOI 10.1006/excr.2000.4872; DENG X, 2000, J NATL CANC I MONOGR, V28, P30; Deng XM, 2000, P NATL ACAD SCI USA, V97, P1578, DOI 10.1073/pnas.97.4.1578; Deng XM, 2001, J BIOL CHEM, V276, P23681, DOI 10.1074/jbc.M100279200; Dougherty TJ, 1998, JNCI-J NATL CANCER I, V90, P889, DOI 10.1093/jnci/90.12.889; Fadeel B, 1999, FASEB J, V13, P1647, DOI 10.1096/fasebj.13.13.1647; Fan MY, 2000, J BIOL CHEM, V275, P29980, DOI 10.1074/jbc.M003776200; Fan MY, 2000, CANCER RES, V60, P6403; Furukawa Y, 2000, J BIOL CHEM, V275, P21661, DOI 10.1074/jbc.M906893199; Granville DJ, 1999, BRIT J CANCER, V79, P95, DOI 10.1038/sj.bjc.6690017; HALDAR S, 1995, P NATL ACAD SCI USA, V92, P4507, DOI 10.1073/pnas.92.10.4507; Haldar S, 1996, CANCER RES, V56, P1253; Haldar S, 1998, CANCER RES, V58, P1609; He J, 1996, PHOTOCHEM PHOTOBIOL, V64, P845, DOI 10.1111/j.1751-1097.1996.tb01845.x; Horiuchi M, 1997, J BIOL CHEM, V272, P19022, DOI 10.1074/jbc.272.30.19022; Huang DCS, 1997, EMBO J, V16, P4628, DOI 10.1093/emboj/16.15.4628; Ito T, 1997, J BIOL CHEM, V272, P11671, DOI 10.1074/jbc.272.18.11671; Jordan A, 1998, MED RES REV, V18, P259, DOI 10.1002/(SICI)1098-1128(199807)18:4<259::AID-MED3>3.0.CO;2-U; Juarranz A, 2001, PHOTOCHEM PHOTOBIOL, V73, P283, DOI 10.1562/0031-8655(2001)073<0283:PIBZIP>2.0.CO;2; Kamuhabwa AR, 2001, PHOTOCHEM PHOTOBIOL, V74, P126, DOI 10.1562/0031-8655(2001)074&lt;0126:CPIBHI&gt;2.0.CO;2; Kessel D, 2001, PHOTOCHEM PHOTOBIOL, V74, P318, DOI 10.1562/0031-8655(2001)074<0318:ETBITT>2.0.CO;2; Kim HRC, 1999, CANCER RES, V59, P3429; KRAJEWSKI S, 1993, CANCER RES, V53, P4701; Leclerc S, 2001, J BIOL CHEM, V276, P251, DOI 10.1074/jbc.M002466200; Lewis TS, 1998, ADV CANCER RES, V74, P49, DOI 10.1016/S0065-230X(08)60765-4; Ling YH, 1998, J BIOL CHEM, V273, P18984, DOI 10.1074/jbc.273.30.18984; Matroule JY, 2001, ONCOGENE, V20, P4070, DOI 10.1038/sj.onc.1204546; Maundrell K, 1997, J BIOL CHEM, V272, P25238, DOI 10.1074/jbc.272.40.25238; MAY WS, 1994, J BIOL CHEM, V269, P26865; Meijer L, 1997, EUR J BIOCHEM, V243, P527, DOI 10.1111/j.1432-1033.1997.t01-2-00527.x; Moor ACE, 2000, J PHOTOCH PHOTOBIO B, V57, P1, DOI 10.1016/S1011-1344(00)00065-8; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; Newton K, 1998, CURR OPIN GENET DEV, V8, P68, DOI 10.1016/S0959-437X(98)80064-6; Ngan VK, 2001, MOL PHARMACOL, V60, P225, DOI 10.1124/mol.60.1.225; Oleinick NL, 1998, RADIAT RES, V150, pS146, DOI 10.2307/3579816; PASS HI, 1993, JNCI-J NATL CANCER I, V85, P443, DOI 10.1093/jnci/85.6.443; Pathan N, 2001, NEOPLASIA, V3, P70, DOI 10.1038/sj.neo.7900131; PINES J, 1991, J CELL BIOL, V115, P1, DOI 10.1083/jcb.115.1.1; Poruchynsky MS, 1998, CANCER RES, V58, P3331; RIALET V, 1991, ANTICANCER RES, V11, P1581; Rosini P, 2000, BIOCHEM BIOPH RES CO, V278, P753, DOI 10.1006/bbrc.2000.3871; Ruvolo PP, 2001, LEUKEMIA, V15, P515, DOI 10.1038/sj.leu.2402090; Ruvolo PP, 1998, J BIOL CHEM, V273, P25436, DOI 10.1074/jbc.273.39.25436; Scatena CD, 1998, J BIOL CHEM, V273, P30777, DOI 10.1074/jbc.273.46.30777; Sharman WM, 1999, DRUG DISCOV TODAY, V4, P507, DOI 10.1016/S1359-6446(99)01412-9; Srivastava M, 2001, J BIOL CHEM, V276, P15481, DOI 10.1074/jbc.M006920200; Srivastava RK, 1998, MOL CELL BIOL, V18, P3509, DOI 10.1128/MCB.18.6.3509; Srivastava RK, 1999, P NATL ACAD SCI USA, V96, P3775, DOI 10.1073/pnas.96.7.3775; Stein Gary S., 1989, P133; Stockert JC, 1996, CANCER CHEMOTH PHARM, V39, P167, DOI 10.1007/s002800050554; Torcia M, 2001, J BIOL CHEM, V276, P39027, DOI 10.1074/jbc.M102970200; Vairo G, 2000, MOL CELL BIOL, V20, P4745, DOI 10.1128/MCB.20.13.4745-4753.2000; Vairo G, 1996, ONCOGENE, V13, P1511; Vandenbogaerde AL, 1997, J PHOTOCH PHOTOBIO B, V38, P136, DOI 10.1016/S1011-1344(96)07446-5; Vantieghem A, 2001, PHOTOCHEM PHOTOBIOL, V74, P133, DOI 10.1562/0031-8655(2001)074&lt;0133:DPMCCR&gt;2.0.CO;2; Vantieghem A, 1998, FEBS LETT, V440, P19, DOI 10.1016/S0014-5793(98)01416-1; Yamamoto K, 1999, MOL CELL BIOL, V19, P8469; YAN MH, 1994, NATURE, V372, P798; Yvon AMC, 1999, MOL BIOL CELL, V10, P947, DOI 10.1091/mbc.10.4.947; Zhou XZ, 1999, CELL MOL LIFE SCI, V56, P788, DOI 10.1007/s000180050026; ZHUO S, 1993, J BIOL CHEM, V268, P17754	76	103	108	1	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 4	2002	277	40					37718	37731		10.1074/jbc.M204348200	http://dx.doi.org/10.1074/jbc.M204348200			14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	601LH	12101183	Green Published, hybrid			2023-01-03	WOS:000178447100104
J	Vadhan-Raj, S; Kavanagh, JJ; Freedman, RS; Folloder, J; Currie, LM; Bueso-Ramos, C; Verschraegen, CF; Narvios, AB; Connor, J; Hoots, WK; Broemeling, LD; Lichtiger, B				Vadhan-Raj, S; Kavanagh, JJ; Freedman, RS; Folloder, J; Currie, LM; Bueso-Ramos, C; Verschraegen, CF; Narvios, AB; Connor, J; Hoots, WK; Broemeling, LD; Lichtiger, B			Safety and efficacy of transfusions of autologous cryopreserved platelets derived from recombinant human thrombopoietin to support chemotherapy-associated severe thrombocytopenia: a randomised cross-over study	LANCET			English	Article							VITRO FUNCTIONAL-ACTIVITY; PROGENITOR-CELL TRANSPLANTATION; HIGH-DOSE CHEMOTHERAPY; 2ND-MESSENGER EFFECTORS; DIMETHYL-SULFOXIDE; ENHANCED RETENTION; BREAST-CANCER; STORAGE; REFRACTORINESS; DONORS	Background The increasing demand for platelet products, and concern over the transfusion-associated risks of alloimmunisation and infections, have motivated a search for improved methods aimed at keeping exposure to donor antigens to a minimum. Transfusion of thrombopoietin-derived autofogous platelets might provide an alternative strategy. We aimed to compare the safety and efficacy of this strategy with that of transfusion with fresh allogeneic platelets in patients with severe chemotherapy-induced thrombocytopenia. Methods 20 patients with gynaecological malignancies were treated with two doses of 1.2 wg/kg recombinant human thrombopoietin. From day 12, we aimed to collect 50 units of platelets from these patients by plateletpheresis. Harvested platelets were cryopreserved in ThromboSol and 2% dimethyl sulfoxide (DMSO) for use in subsequent autologous transfusions. Patients then received carboplatin for up to six cycles. Patients were randomly assigned to group A (n=10), which received allogeneic fresh platelets at the first instance of severe thrombocytopenia (platelet count <15 000/&mu;L) and then autologous cryopreserved platelets at the next, or to group B (n=10), which received first autologous and then allogeneic platelets. In subsequent cycles, all patients received autologous platelets while available. The primary endpoint was platelet count increment corrected for the number of platelets transfused and the patients' body-surface area. Analysis was by intention to treat. Findings Treatment with recombinant human thrombopoietin significantly increased platelet count (median 2.3-fold [range 1.5-3.3], p<0.0001) in all but one patient in group A. The median number of platelets collected per patient was 53 units (14-66) in two collections (one to three). There was no significant difference in the corrected platelet count increments (CCIs) between the 19 paired transfusions of cryopreserved autologous platelets and fresh allogeneic platelets (median 1-h CC] 15.7 vs 19.8, p=0.398; median 24-h CCI 13.0 vs 18.1, p=0398). 14 of the 19 patients had a good response (1-h CCI >7.5) to their first transfusion of allogeneic platelets. By contrast, all patients had a good response to their first transfusion of autologous platelets (p=0.063). Moreover, no significant decrease in the CCIs (p=0.405) was seen over six cycles after autologous platelet transfusions (n=63). No transfusion reactions or any serious adverse event was recorded during autologous platelet transfusions. Interpretation Recombinant human thrombopoietin facilitated collection of multiple units of platelets, which could be cryopreserved and reinfused to counteract severe thrombocytopenia during multicycle chemotherapy. Transfusion of autologous cryopreserved platelets derived from recombinant human thrombopoietin can provide a viable strategy to minimise the risks of allogeneic platelet transfusions and provide along-lasting supply of platelet support.	Univ Texas, MD Anderson Canc Ctr, Dept Immunotherapy, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Biostat, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Gynecol Med Therapeut, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Gynecol Oncol, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Hematopathol, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Lab Med, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Pediat, Houston, TX 77030 USA; Life Cell Corp, Dept Med Hematol Oncol, Branchburg, TX USA; Life Cell Corp, Dept GYN Med Therapeut, Branchburg, TX USA; Life Cell Corp, Dept Lab Med, Branchburg, TX USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center	Vadhan-Raj, S (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Immunotherapy, Box 422,1515 Holcombe Blvd, Houston, TX 77030 USA.		Verschraegen, Claire/AAE-7620-2020	Verschraegen, Claire/0000-0001-6544-3089				BAYTHOON H, 1982, J CLIN PATHOL, V35, P870, DOI 10.1136/jcp.35.8.870; BISHOP JF, 1992, TRANSFUSION MED, V2, P35, DOI 10.1111/j.1365-3148.1992.tb00132.x; Bock M, 1995, TRANSFUSION, V35, P921, DOI 10.1046/j.1537-2995.1995.351196110896.x; CALVERT AH, 1989, J CLIN ONCOL, V7, P1748, DOI 10.1200/JCO.1989.7.11.1748; *COMM STAND, 2000, STAND BLOOD BANKS TR; Connor J, 1996, TRANSFUSION, V36, P691, DOI 10.1046/j.1537-2995.1996.36896374372.x; Currie LM, 1999, BRIT J HAEMATOL, V105, P826, DOI 10.1046/j.1365-2141.1999.01411.x; Currie LM, 1998, TRANSFUSION, V38, P160, DOI 10.1046/j.1537-2995.1998.38298193098.x; Goodnough LT, 2001, BLOOD, V98, P1346, DOI 10.1182/blood.V98.5.1346; HOGGE DE, 1995, TRANSFUSION, V35, P645, DOI 10.1046/j.1537-2995.1995.35895357895.x; Holme S, 1998, VOX SANG, V74, P207, DOI 10.1111/j.1423-0410.1998.tb05422.x; KAUSHANSKY K, 1995, BLOOD, V86, P419, DOI 10.1182/blood.V86.2.419.bloodjournal862419; Kruskall MS, 1997, NEW ENGL J MED, V337, P1914, DOI 10.1056/NEJM199712253372609; Kuter DJ, 2001, BLOOD, V98, P1339, DOI 10.1182/blood.V98.5.1339; LAZARUS HM, 1982, TRANSFUSION, V22, P39, DOI 10.1046/j.1537-2995.1982.22182154213.x; Lill M., 1997, Transfusion (Bethesda), V37, p26S; McCullough J, 2000, SEMIN HEMATOL, V37, P3, DOI 10.1016/S0037-1963(00)90047-7; McFarland J, 1997, NEW ENGL J MED, V337, P1861; MURPHY S, 1985, SEMIN HEMATOL, V22, P165; Novotny VMJ, 1999, VOX SANG, V76, P1, DOI 10.1046/j.1423-0410.1999.7610001.x; Pedrazzoli P, 1998, HAEMATOLOGICA, V83, P718; RODAK BF, 1995, DIAGNOSTIC HEMATOL, P554; SCHIFFER CA, 1976, BRIT J HAEMATOL, V34, P377, DOI 10.1111/j.1365-2141.1976.tb03584.x; SCHIFFER CA, 1978, NEW ENGL J MED, V299, P7, DOI 10.1056/NEJM197807062990102; SINTNICOLAAS K, 1995, BLOOD, V85, P824, DOI 10.1182/blood.V85.3.824.bloodjournal853824; Slichter SJ, 1991, HEMATOLOGY BASIC PRI, P1610; Torretta L, 1998, VOX SANG, V75, P224, DOI 10.1046/j.1423-0410.1998.7530224.x; Vadhan-Raj S, 1999, BRIT J HAEMATOL, V104, P403, DOI 10.1046/j.1365-2141.1999.01178.x; Vadhan-Raj S, 2000, ANN INTERN MED, V132, P364, DOI 10.7326/0003-4819-132-5-200003070-00005; VadhanRaj S, 1997, ANN INTERN MED, V126, P673, DOI 10.7326/0003-4819-126-9-199705010-00001; VANKOOIJ M, 1991, BLOOD, V77, P201; Vostal J. G., 2000, Transfusion (Bethesda), V40, P742, DOI 10.1046/j.1537-2995.2000.40060742.x; Wallace EL, 1998, TRANSFUSION, V38, P625, DOI 10.1046/j.1537-2995.1998.38798346630.x; WALLACE EL, 1995, TRANSFUSION, V35, P802, DOI 10.1046/j.1537-2995.1995.351096026360.x	34	46	51	0	3	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUN 22	2002	359	9324					2145	2152		10.1016/S0140-6736(02)09090-6	http://dx.doi.org/10.1016/S0140-6736(02)09090-6			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	566RJ	12090979				2023-01-03	WOS:000176441800008
J	Llovet, JM; Real, MI; Montana, X; Planas, R; Coll, S; Aponte, J; Ayuso, C; Sala, M; Muchart, J; Sola, R; Rodes, J; Bruix, J				Llovet, JM; Real, MI; Montana, X; Planas, R; Coll, S; Aponte, J; Ayuso, C; Sala, M; Muchart, J; Sola, R; Rodes, J; Bruix, J		Barcelona Clin Liver Canc Grp	Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial	LANCET			English	Article							OILY CHEMOEMBOLIZATION; NATURAL-HISTORY; CANCER; EMBOLIZATION; MANAGEMENT; PROGNOSIS; CIRRHOSIS; LIPIODOL	Background There is no standard treatment for unresectable hepatocellular carcinoma. Arterial embolisation is widely used. but evidence of survival benefits is lacking. Methods We did a randomised controlled trial in patients with unresectable hepatocellular carcinoma not suitable for curative treatment, of Child-Pugh class A or B and Okuda stage I or II, to assess the survival benefits of regularly repeated arterial embolisation (gelatin sponge) or chemoembolisation (gelatin sponge plus doxorubicin) compared with conservative treatment. 903 patients were assessed. and 112 (12%) patients were finally included in the study. The primary endpoint was survival, Analyses were by intention to treat. Findings The trial was stopped when the ninth sequential inspection showed that chemoembolisation had survival benefits compared with conservative treatment (hazard ratio of death 0.47 [95% CI 0.25-0.91], p=0.025). 25 of 37 patients assigned embolisation, 21 of 40 assigned chemoembolisation, and 25 of 35 assigned conservative treatment died. Survival probabilities at 1 year and 2 years were 75% and 50% for embolisation: 82% and 63% for chemoembolisation, and 63% and 27% for control (chemoembolisation vs control p=0.009). Chemoembolisation induced objective responses sustained for at least 6 months in 35% (14) of cases, and was associated with a significantly lower rate of portal-vein invasion than conservative treatment. Treatment allocation was the only variable independently related to survival (odds ratio 0.45 [95% CI 0.25-0.81], P=0.02). Interpretation Chemoembolisation improved survival of stringently selected patients with unresectable hepatocellular carcinoma.	Univ Barcelona, Hosp Clin, Inst Digest Dis, Liver Unit, Barcelona, Spain; Univ Barcelona, Hosp Clin, Dept Radiol, Imaging Diagnost Ctr, Barcelona, Spain; Univ Barcelona, Hosp Clin, Dept Stat, Barcelona, Spain; Hosp Germans Trias & Pujol, Dept Gastroenterol, Badalona, Spain; Hosp Germans Trias & Pujol, Dept Radiol, Badalona, Spain; Hosp Mar, Liver Sect, Barcelona, Catalonia, Spain	University of Barcelona; Hospital Clinic de Barcelona; University of Barcelona; Hospital Clinic de Barcelona; University of Barcelona; Hospital Clinic de Barcelona; Hospital Germans Trias i Pujol; Hospital Germans Trias i Pujol; Institut Hospital del Mar d'Investigacions Mediques (IMIM); Hospital del Mar	Bruix, J (corresponding author), Hosp Clin Barcelona, Liver Unit, BCLC Grp, Villarroel 170, Barcelona 08036, Catalonia, Spain.		Sala, Margarita/AAP-6515-2020; Llovet, Josep M/ABB-6264-2021; Llovet, Josep M/D-4340-2014	Llovet, Josep M/0000-0003-0547-2667; Llovet, Josep M/0000-0003-0547-2667; Ayuso, Carmen/0000-0002-9606-6957; Coll, Susanna/0000-0002-0395-9685; Bruix, Jordi/0000-0002-9826-0753				[Anonymous], 1992, DESIGN ANAL SEQUENTI; Bosch FX, 1999, SEMIN LIVER DIS, V19, P271, DOI 10.1055/s-2007-1007117; Bruix J, 1998, HEPATOLOGY, V27, P1578, DOI 10.1002/hep.510270617; Bruix J, 2001, J HEPATOL, V35, P421, DOI 10.1016/S0168-8278(01)00130-1; Bruix J, 2002, HEPATOLOGY, V35, P519, DOI 10.1053/jhep.2002.32089; LIN DY, 1988, GASTROENTEROLOGY, V94, P453, DOI 10.1016/0016-5085(88)90436-2; Llovet JM, 1999, HEPATOLOGY, V29, P62, DOI 10.1002/hep.510290145; Llovet JM, 1999, SEMIN LIVER DIS, V19, P329, DOI 10.1055/s-2007-1007122; MADDEN MV, 1993, GUT, V34, P1598, DOI 10.1136/gut.34.11.1598; Mathurin P, 1998, ALIMENT PHARM THERAP, V12, P111; MILLER AB, 1981, CANCER, V47, P207, DOI 10.1002/1097-0142(19810101)47:1<207::AID-CNCR2820470134>3.0.CO;2-6; MONDAZZI L, 1994, HEPATOLOGY, V19, P1115, DOI 10.1002/hep.1840190508; OBERTI F, 1995, NEW ENGL J MED, V332, P1256; OKUDA K, 1985, CANCER, V56, P918, DOI 10.1002/1097-0142(19850815)56:4<918::AID-CNCR2820560437>3.0.CO;2-E; PELLETIER G, 1990, J HEPATOL, V11, P181, DOI 10.1016/0168-8278(90)90110-D; Pelletier G, 1998, J HEPATOL, V29, P129, DOI 10.1016/S0168-8278(98)80187-6; PUGH RNH, 1973, BRIT J SURG, V60, P646, DOI 10.1002/bjs.1800600817; Simonetti RG, 1997, ANN ONCOL, V8, P117, DOI 10.1023/A:1008285123736; SORENSEN JB, 1993, BRIT J CANCER, V67, P773, DOI 10.1038/bjc.1993.140; Trinchet JC, 1997, J HEPATOL, V27, P756, DOI 10.1016/S0168-8278(97)80095-5; VENOOK AP, 1990, J CLIN ONCOL, V8, P1108, DOI 10.1200/JCO.1990.8.6.1108; VETTER D, 1991, HEPATOLOGY, V13, P427, DOI 10.1002/hep.1840130308	22	2607	2733	5	132	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAY 18	2002	359	9319					1734	1739		10.1016/S0140-6736(02)08649-X	http://dx.doi.org/10.1016/S0140-6736(02)08649-X			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	554MV	12049862				2023-01-03	WOS:000175740500010
J	Guerranti, R; Aguiyi, JC; Neri, S; Leoncini, R; Pagani, R; Marinello, E				Guerranti, R; Aguiyi, JC; Neri, S; Leoncini, R; Pagani, R; Marinello, E			Proteins from Mucuna pruriens and enzymes from Echis carinatus venom - Characterization and cross-reactions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SAW-SCALED VIPER; PLATELET-AGGREGATION INHIBITOR; AMINO-ACID-SEQUENCE; PHOSPHOLIPASE A(2); PROTHROMBIN ACTIVATOR; ANIMAL LECTINS; PURIFICATION; BINDING; COMPLEX	Mucuna pruriens seeds have been widely used against snakebite in traditional medicine. The antivenin property of a water extract of seeds was assessed in vivo in mice. The serum of mice treated with extract was tested for its immunological properties. Two proteins of Echis carinatus venom with apparent molecular masses of 25 and 16 kDa were detected by Western blot analysis carried out using IgG of mice immunized with extract or its partially purified protein fractions. By enzymatic in-gel digestion and electrospray ionization-mass spectrometry/mass spectrometry analysis of immunoreactive venom proteins, phospholipase A(2), the most toxic enzyme of snake venom, was identified. These results demonstrate that the observed antivenin activity has an immune mechanism. Antibodies of mice treated with non-lethal doses of venom reacted against some proteins of M. pruriens extract. Proteins of E. carinatus venom and M. pruriens extract have at least one epitope in common as confirmed by immunodiffusion assay.	Univ Siena, Inst Biochem & Enzymol, I-53100 Siena, Italy; Univ Jos, Dept Pharmacol, Jos, Nigeria	University of Siena; University of Jos	Marinello, E (corresponding author), Univ Siena, Inst Biochem & Enzymol, Via A Moro 2, I-53100 Siena, Italy.		Leoncini, Roberto/D-4050-2012; Leoncini, Roberto/D-2247-2012	Leoncini, Roberto/0000-0001-5587-2074; 				Aguiyi JC, 1999, FITOTERAPIA, V70, P21, DOI 10.1016/S0367-326X(98)00004-5; Bateman A, 1999, NUCLEIC ACIDS RES, V27, P260, DOI 10.1093/nar/27.1.260; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Chen YL, 1996, BIOCHEMISTRY-US, V35, P5264, DOI 10.1021/bi952520q; Chippaux JP, 1998, TOXICON, V36, P823, DOI 10.1016/S0041-0101(97)00160-8; Desterro JMP, 1999, J BIOL CHEM, V274, P10618, DOI 10.1074/jbc.274.15.10618; DRENTH J, 1980, J BIOL CHEM, V255, P2652; DRICKAMER K, 1988, J BIOL CHEM, V263, P9557; DRICKAMER K, 1993, PROG NUCLEIC ACID RE, V45, P207, DOI 10.1016/S0079-6603(08)60870-3; GAN ZR, 1988, J BIOL CHEM, V263, P19827; Guerranti R, 2001, J ETHNOPHARMACOL, V75, P175, DOI 10.1016/S0378-8741(00)00401-3; GUERRANTI R, 1999, J PREV MED HYG, V1, P25; Hofmann K, 1999, NUCLEIC ACIDS RES, V27, P215, DOI 10.1093/nar/27.1.215; Kemparaju K, 1999, TOXICON, V37, P1659, DOI 10.1016/S0041-0101(99)00104-X; KEMPARAJU K, 1994, TOXICON, V32, P1187, DOI 10.1016/0041-0101(94)90348-4; Kerns RT, 1999, ARCH BIOCHEM BIOPHYS, V369, P107, DOI 10.1006/abbi.1999.1345; KIELISZEWSKI MJ, 1994, PLANT J, V5, P849, DOI 10.1046/j.1365-313X.1994.5060849.x; Kini RM, 1996, TOXICON, V34, P1287, DOI 10.1016/S0041-0101(96)00107-9; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Machuka J, 2000, FOOD CHEM, V68, P421, DOI 10.1016/S0308-8146(99)00211-3; Marcinkiewicz C, 1999, J BIOL CHEM, V274, P12468, DOI 10.1074/jbc.274.18.12468; Marcinkiewicz C, 2000, J BIOL CHEM, V275, P31930, DOI 10.1074/jbc.M003209200; MARTZ W, 1992, TOXICON, V30, P1131, DOI 10.1016/0041-0101(92)90429-9; MO HQ, 1994, GLYCOCONJUGATE J, V11, P424, DOI 10.1007/BF00731278; MORITA T, 1978, J BIOCHEM, V83, P559, DOI 10.1093/oxfordjournals.jbchem.a131944; Nagpal A, 1999, ACTA CRYSTALLOGR D, V55, P1240, DOI 10.1107/S0907444999004783; NISHIDA S, 1995, BIOCHEMISTRY-US, V34, P1771, DOI 10.1021/bi00005a034; OUCHTERLONY O, 1986, HDB EXPT IMMUNOLOGY, P321; PENG ML, 1994, BIOCHEM BIOPH RES CO, V205, P68, DOI 10.1006/bbrc.1994.2630; Polgar J, 1996, BIOCHEM J, V319, P961, DOI 10.1042/bj3190961; PRAS N, 1993, PHARM WORLD SCI, V15, P263, DOI 10.1007/BF01871128; RAJYALAKSHMI P, 1994, PLANT FOOD HUM NUTR, V46, P53, DOI 10.1007/BF01088461; REVILLEZA MJR, 1990, PLANT FOOD HUM NUTR, V40, P83, DOI 10.1007/BF02193782; SCHAEFFER RC, 1987, TOXICON, V25, P1343, DOI 10.1016/0041-0101(87)90012-2; Siddhuraju P, 1996, J AGR FOOD CHEM, V44, P2636, DOI 10.1021/jf950776x; Yamada D, 1996, J BIOL CHEM, V271, P5200, DOI 10.1074/jbc.271.9.5200; Yen TY, 2000, J MASS SPECTROM, V35, P990, DOI 10.1002/1096-9888(200008)35:8<990::AID-JMS27>3.0.CO;2-K	37	33	35	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 10	2002	277	19					17072	17078		10.1074/jbc.M201387200	http://dx.doi.org/10.1074/jbc.M201387200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	551MB	11867642	hybrid			2023-01-03	WOS:000175564500097
J	Yaffe, K; Fox, P; Newcomer, R; Sands, L; Lindquist, K; Dane, K; Covinsky, KE				Yaffe, K; Fox, P; Newcomer, R; Sands, L; Lindquist, K; Dane, K; Covinsky, KE			Patient and Caregiver characteristics and nursing home placement in patients with dementia	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ALZHEIMERS-DISEASE DEMONSTRATION; INSTITUTIONALIZATION; PREDICTORS; CARE; TIME; INTERVENTION; ETHNICITY; ADMISSION; BURDEN; DEATH	Context The decision to institutionalize a patient with dementia is complex and is based on patient and caregiver characteristics and the sociocultural context of patients and caregivers. Most studies have determined predictors of nursing home placement primarily according to patient or caregiver characteristics alone. Objective To develop and validate a prognostic model to determine the comprehensive predictors of placement among an ethnically diverse population of patients with dementia. Design, Setting, and Participants The Medicare Alzheimer's Disease Demonstration and Evaluation study, a prospective study at 8 sites in the United States, with enrollment between December 1989 and December 1994 of 5788 community-living persons with advanced dementia. Main Outcome Measures Time to nursing home placement throughout a 36-month follow-up period, assessed by interview and review of Medicare records, and its association with patient and caregiver characteristics, obtained by interview at enrollment. Results Patients were divided into a development (n=3859) and validation (n=1929) cohort. In the development cohort, the Kaplan-Meier estimates of nursing home placement throughout 1, 2, and 3 years were 22%, 40%, and 52%, respectively. After multivariate adjustment, patient characteristics that were associated with nursing home placement were as follows: black ethnicity (hazard ratio, 0.60; 95% confidence interval [CI], 0.48-0.74), Hispanic ethnicity (HR, 0.40; 95% Cl, 0.28-0.56) (both ethnicities were inversely associated with placement), living alone (HR, 1.74; 95% Cl, 1.49-2.02), 1 or more dependencies in activities of daily living (HR, 1.38; 95% Cl, 1.20-1.60), high cognitive impairment (for Mini-Mental Status Examination score less than or equal to20: HR, 1.52; 95% Cl, 1.33-1.73), and 1 or more difficult behaviors (HR, 1.30; 95% Cl, 1.11-1.52). Caregiver characteristics associated with patient placement were age 65 to 74 years (HR, 1.17; 95% Cl, 1.01-1.37), age 75 years or older (HR, 1.55; 95% Cl, 1.31-1.84), and high Zarit Burden Scale score (for highest quartile: HR, 1.73; 95% Cl, 1.49-2.00). Patients were assigned to quartiles of risk based on this model. In the development cohort, patients in the first, second, third, and fourth quartile had a 25%, 42%, 64%, and 91% rate of nursing home placement at 3 years, respectively. In the validation cohort, the respective rates were 21%, 50%, 64%, and 89%. The C statistic for 3-year nursing home placement was 0.66 in the development cohort and 0.63 in the validation cohort. Conclusions Patient and caregiver characteristics are both important determinants of long-term care placement for patients with dementia. Interventions directed at delaying placement, such as reduction of caregiver burden or difficult patient behaviors, need to take into account the patient and caregiver as a unit.	Univ Calif San Francisco, Dept Psychiat, San Francisco, CA 94121 USA; Univ Calif San Francisco, Dept Neurol, San Francisco, CA 94121 USA; Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94121 USA; Univ Calif San Francisco, Dept Med, San Francisco, CA 94121 USA; Univ Calif San Francisco, Inst Hlth & Aging, San Francisco, CA 94121 USA; San Francisco VA Med Ctr, San Francisco, CA USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; US Department of Veterans Affairs; Veterans Health Administration (VHA); San Francisco VA Medical Center	Yaffe, K (corresponding author), Univ Calif San Francisco, Dept Psychiat, Box 111G,4150 Clement St, San Francisco, CA 94121 USA.	kyaffe@itsa.ucsf.edu	Sands, Laura P/E-8919-2015	Sands, Laura P/0000-0003-2446-4486; Lindquist, Karla/0000-0002-1971-2273	NIA NIH HHS [K23-AG00888] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [K23AG000888] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		BRODATY H, 1989, BMJ-BRIT MED J, V299, P1375, DOI 10.1136/bmj.299.6712.1375; Butler R, 1995, ADAPTATIONS AGING, P289; COLERICK EJ, 1986, J AM GERIATR SOC, V34, P493, DOI 10.1111/j.1532-5415.1986.tb04239.x; Covinsky KE, 2001, J GERONTOL A-BIOL, V56, pM707, DOI 10.1093/gerona/56.11.M707; Cummings JL, 1999, NEUROLOGY, V53, P899, DOI 10.1212/WNL.53.5.899; FALCONE D, 1994, J HEALTH POLIT POLIC, V19, P583, DOI 10.1215/03616878-19-3-583; Fisher L, 1999, GERONTOLOGIST, V39, P677, DOI 10.1093/geront/39.6.677; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; Fox P, 2000, ALZ DIS ASSOC DIS, V14, P87, DOI 10.1097/00002093-200004000-00006; Heyman A, 1997, NEUROLOGY, V48, P1304, DOI 10.1212/WNL.48.5.1304; KATZ S, 1963, JAMA-J AM MED ASSOC, V185, P914, DOI 10.1001/jama.1963.03060120024016; KEMPER P, 1991, NEW ENGL J MED, V324, P595, DOI 10.1056/NEJM199102283240905; KEMPER P, 1992, HEALTH SERV RES, V27, P421; Knopman D, 1996, NEUROLOGY, V47, P166, DOI 10.1212/WNL.47.1.166; Knopman DS, 1999, NEUROLOGY, V52, P714, DOI 10.1212/WNL.52.4.714; KNOPMAN DS, 1988, J AM GERIATR SOC, V36, P108, DOI 10.1111/j.1532-5415.1988.tb01778.x; LAWTON MP, 1969, GERONTOLOGIST, V9, P179, DOI 10.1093/geront/9.3_Part_1.179; Leon J, 1998, HEALTH AFFAIR, V17, P206, DOI 10.1377/hlthaff.17.6.206; Michel JP, 2001, AGING CLIN EXP RES, V13, P255, DOI 10.1007/BF03351484; Miller SC, 1998, J GERONTOL B-PSYCHOL, V53, pS341, DOI 10.1093/geronb/53B.6.S341; MITTELMAN MS, 1993, GERONTOLOGIST, V33, P730, DOI 10.1093/geront/33.6.730; Mittelman MS, 1996, JAMA-J AM MED ASSOC, V276, P1725, DOI 10.1001/jama.276.21.1725; MorrowHowell N, 1996, HEALTH SOC WORK, V21, P131, DOI 10.1093/hsw/21.2.131; Newcomer R, 1999, HEALTH SERV RES, V34, P669; Newcomer R, 1999, HEALTH SERV RES, V34, P645; RICE DP, 1993, HEALTH AFFAIR, V12, P164, DOI 10.1377/hlthaff.12.2.164; SALIVE ME, 1993, AM J PUBLIC HEALTH, V83, P1765, DOI 10.2105/AJPH.83.12.1765; Sano M, 1997, NEW ENGL J MED, V336, P1216, DOI 10.1056/NEJM199704243361704; SEVERSON MA, 1994, J AM GERIATR SOC, V42, P181; SHEIKH J I, 1986, Clinical Gerontologist, V5, P165; Smith GE, 2000, J AM GERIATR SOC, V48, P519, DOI 10.1111/j.1532-5415.2000.tb04998.x; STEELE C, 1990, AM J PSYCHIAT, V147, P1049; Stern Y, 1997, JAMA-J AM MED ASSOC, V277, P806, DOI 10.1001/jama.277.10.806; Wallace SP, 1998, J GERONTOL B-PSYCHOL, V53, pS104, DOI 10.1093/geronb/53B.2.S104; Walter LC, 2001, JAMA-J AM MED ASSOC, V285, P2987, DOI 10.1001/jama.285.23.2987; ZARIT SH, 1980, GERONTOLOGIST, V20, P649, DOI 10.1093/geront/20.6.649	36	590	604	1	43	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 24	2002	287	16					2090	2097		10.1001/jama.287.16.2090	http://dx.doi.org/10.1001/jama.287.16.2090			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	542ZK	11966383				2023-01-03	WOS:000175075700026
J	Yazdanbakhsh, M; Kremsner, PG; van Ree, R				Yazdanbakhsh, M; Kremsner, PG; van Ree, R			Immunology - Allergy, parasites, and the hygiene hypothesis	SCIENCE			English	Review							GROWTH-FACTOR-BETA; ANTHELMINTIC TREATMENT; INVERSE ASSOCIATION; HELMINTH INFECTION; DENDRITIC CELLS; HAY-FEVER; IGE; ATOPY; ASTHMA; RESPONSES	The increase of allergic diseases in the industrialized world has often been explained by a decline in infections during childhood. The immunological explanation has been put into the context of the functional T cell subsets known as T helper 1 (T(H)1) and T helper 2 (T(H)2) that display polarized cytokine profiles. It has been argued that bacterial, and viral infections during early life direct the maturing immune system toward T(H)1, which counterbalance proallergic responses of T(H)2 cells. Thus, a reduction in the overall microbial burden will result in weak T(H)1 imprinting and unrestrained T(H)2 responses that allow an increase in allergy. This notion is contradicted by observations that the prevalence of T(H)1-autoimmune diseases is also increasing and that T(H)2-skewed parasitic worm (helminth) infections are not associated with allergy. More recently, elevations of anti-inflammatory cytokines, such as interieukin-10, that occur during tong-term helminth infections have been shown to be inversely correlated with allergy. The induction of a robust anti-inflammatory regulatory network by persistent immune challenge offers a unifying explanation for the observed inverse association of many infections with allergic disorders.	Leiden Univ, Med Ctr, Dept Parasitol, Leiden, Netherlands; Univ Tubingen, Inst Trop Med, Dept Parasitol, D-72074 Tubingen, Germany; Albert Schweitzer Hosp, Res Unit, Lambarene, Gabon; CLB, Immunopathol, Sanquin Res, Dept Allergy, Amsterdam, Netherlands	Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Eberhard Karls University of Tubingen	Yazdanbakhsh, M (corresponding author), Leiden Univ, Med Ctr, Dept Parasitol, Leiden, Netherlands.	M.Yazdanbakhsh@LUMC.NL	Yazdanbakhsh, Maria/AAI-3996-2020	Yazdanbakhsh, Maria/0000-0002-7666-1441				Akdis CA, 1998, J CLIN INVEST, V102, P98, DOI 10.1172/JCI2250; [Anonymous], 1976, LANCET, V1, P894; Araujo MI, 2000, INT ARCH ALLERGY IMM, V123, P145, DOI 10.1159/000024433; Beasley R, 1998, LANCET, V351, P1225, DOI 10.1016/S0140-6736(97)07302-9; Borish L, 1996, J ALLERGY CLIN IMMUN, V97, P1288, DOI 10.1016/S0091-6749(96)70197-5; Buijs J, 1997, EUR RESPIR J, V10, P1467, DOI 10.1183/09031936.97.10071467; Cooper PJ, 1998, J INFECT DIS, V178, P1133, DOI 10.1086/515661; Dai WJ, 1999, IMMUNOLOGY, V97, P107, DOI 10.1046/j.1365-2567.1999.00723.x; de Jong EC, 2002, J IMMUNOL, V168, P1704, DOI 10.4049/jimmunol.168.4.1704; Doetze A, 2000, INT IMMUNOL, V12, P623, DOI 10.1093/intimm/12.5.623; Ebner C, 1997, CLIN EXP ALLERGY, V27, P1007, DOI 10.1111/j.1365-2222.1997.tb01252.x; Elias D, 2001, CLIN EXP IMMUNOL, V123, P219, DOI 10.1046/j.1365-2249.2001.01446.x; Faniran AO, 1999, THORAX, V54, P606, DOI 10.1136/thx.54.7.606; GODFREY R C, 1975, Clinical Allergy, V5, P201, DOI 10.1111/j.1365-2222.1975.tb01853.x; GREENWOOD BM, 1972, LANCET, V1, P169; Hansen G, 1999, J CLIN INVEST, V103, P175, DOI 10.1172/JCI5155; Herfarth H, 2002, GUT, V50, P146, DOI 10.1136/gut.50.2.146; Hirsch CS, 1996, P NATL ACAD SCI USA, V93, P3193, DOI 10.1073/pnas.93.8.3193; Holt PG, 1999, NATURE, V402, pB12; HUSSAIN R, 1992, J IMMUNOL, V148, P2731; JARRETT E, 1980, NATURE, V283, P302, DOI 10.1038/283302a0; Jeannin P, 1998, J IMMUNOL, V160, P3555; King CL, 1996, J IMMUNOL, V156, P4715; Kramer U, 1999, LANCET, V353, P450, DOI 10.1016/S0140-6736(98)06329-6; LARRICK JW, 1983, J ALLERGY CLIN IMMUN, V71, P184, DOI 10.1016/0091-6749(83)90097-0; Lell B, 2001, WIEN KLIN WOCHENSCHR, V113, P927; Loveless MH, 1943, J IMMUNOL, V47, P165; LYNCH NR, 1993, J ALLERGY CLIN IMMUN, V92, P404, DOI 10.1016/0091-6749(93)90119-Z; Lynch NR, 1997, AM J RESP CRIT CARE, V156, P50, DOI 10.1164/ajrccm.156.1.9606081; LYNCH NR, 1987, CLIN ALLERGY, V17, P199, DOI 10.1111/j.1365-2222.1987.tb02004.x; Macaubas C, 1999, CLIN EXP ALLERGY, V29, P1223; MacGlashan DW, 1997, J IMMUNOL, V158, P1438; MAHANTY S, 1995, PARASITE IMMUNOL, V17, P385, DOI 10.1111/j.1365-3024.1995.tb00906.x; Malhotra I, 1999, J IMMUNOL, V162, P6843; Maloy KJ, 2001, NAT IMMUNOL, V2, P816, DOI 10.1038/ni0901-816; MASTERS S, 1985, EPIDEMIOL REV, V7, P49, DOI 10.1093/oxfordjournals.epirev.a036285; Matricardi PM, 2000, BMJ-BRIT MED J, V320, P412, DOI 10.1136/bmj.320.7232.412; Matricardi PM, 2000, CLIN EXP ALLERGY, V30, P1506, DOI 10.1046/j.1365-2222.2000.00994.x; McGuirk P, 2002, J EXP MED, V195, P221, DOI 10.1084/jem.20011288; MERRETT TG, 1976, CLIN ALLERGY, V6, P131, DOI 10.1111/j.1365-2222.1976.tb01890.x; Nyan OA, 2001, CLIN EXP ALLERGY, V31, P1672, DOI 10.1046/j.1365-2222.2001.00987.x; Pessi T, 2000, CLIN EXP ALLERGY, V30, P1804, DOI 10.1046/j.1365-2222.2000.00948.x; Platts-Mills T, 2001, LANCET, V357, P752, DOI 10.1016/S0140-6736(00)04168-4; PRENNER C, 1992, BIOCHEM J, V284, P377, DOI 10.1042/bj2840377; Redpath S, 2001, TRENDS MICROBIOL, V9, P86, DOI 10.1016/S0966-842X(00)01919-3; Riedler J, 2001, LANCET, V358, P1129, DOI 10.1016/S0140-6736(01)06252-3; Rook GAW, 2000, IMMUNOL TODAY, V21, P503, DOI 10.1016/S0167-5699(00)01700-X; Royer B, 2001, CLIN EXP ALLERGY, V31, P694, DOI 10.1046/j.1365-2222.2001.01069.x; Scrivener S, 2001, LANCET, V358, P1493, DOI 10.1016/S0140-6736(01)06579-5; Sears MR, 1997, LANCET, V350, P1015, DOI 10.1016/S0140-6736(97)01468-2; Sepp E, 1997, ACTA PAEDIATR, V86, P956, DOI 10.1111/j.1651-2227.1997.tb15178.x; Shaheen SO, 1996, LANCET, V347, P1792, DOI 10.1016/S0140-6736(96)91617-7; Shirakawa T, 1997, SCIENCE, V275, P77, DOI 10.1126/science.275.5296.77; Stene LC, 2001, LANCET, V357, P607, DOI 10.1016/S0140-6736(00)04067-8; STRACHAN DP, 1989, BRIT MED J, V299, P1259, DOI 10.1136/bmj.299.6710.1259; Thomas WR, 1999, CLIN EXP ALLERGY, V29, P1583, DOI 10.1046/j.1365-2222.1999.00670.x; TURTON JA, 1976, LANCET, V2, P686; van den Biggelaar AHJ, 2000, LANCET, V356, P1723, DOI 10.1016/S0140-6736(00)03206-2; van Die I, 1999, FEBS LETT, V463, P189, DOI 10.1016/S0014-5793(99)01508-2; van Ree R, 2000, J BIOL CHEM, V275, P11451, DOI 10.1074/jbc.275.15.11451; van Ree R, 1999, J ALLERGY CLIN IMMUN, V103, P1000, DOI 10.1016/S0091-6749(99)70169-7; VANDENBIGGELAAR AH, UNPUB; Von Ehrenstein OS, 2000, CLIN EXP ALLERGY, V30, P187, DOI 10.1046/j.1365-2222.2000.00801.x; Wakkach A, 2000, EUR CYTOKINE NETW, V11, P153; Wohlleben G, 2001, TRENDS IMMUNOL, V22, P618, DOI 10.1016/S1471-4906(01)02055-5; Yazdanbakhsh M, 2001, TRENDS IMMUNOL, V22, P372, DOI 10.1016/S1471-4906(01)01958-5; Yemaneberhan H, 1997, LANCET, V350, P85, DOI 10.1016/S0140-6736(97)01151-3	67	1076	1131	3	404	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	APR 19	2002	296	5567					490	494		10.1126/science.296.5567.490	http://dx.doi.org/10.1126/science.296.5567.490			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	544UE	11964470				2023-01-03	WOS:000175179400035
J	Rhodes, M; Newman, C; Read, S				Rhodes, M; Newman, C; Read, S			National service framework for coronary heart disease: audit of English hospitals	BRITISH MEDICAL JOURNAL			English	Article									St Martins Coll, Dept Nursing Studies, Carlisle CA1 2HH, England; Univ Sheffield, No Gen Hosp, Ctr Clin Sci, Sheffield S5 7AU, S Yorkshire, England; Univ Sheffield, Sch Nursing & Midwifery, Sheffield S10 2HL, S Yorkshire, England	University of Cumbria; Northern General Hospital; University of Sheffield; University of Sheffield	Rhodes, M (corresponding author), St Martins Coll, Dept Nursing Studies, Carlisle CA1 2HH, England.							*DEP HLTH, 2000, NAT SERV FRAM COR HE; *NHS CONF, 1999, BINL DIR NHS MAN	2	2	2	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	MAR 23	2002	324	7339					709	709		10.1136/bmj.324.7339.709	http://dx.doi.org/10.1136/bmj.324.7339.709			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	535ML	11909788	Green Published, Bronze			2023-01-03	WOS:000174648200019
J	Hamada, K; Doi, T; Sakurai, M; Matsumoto, K; Yanagisawa, K; Suzuki, T; Kikuchi, N; Okuda, J; Miyazaki, H; Okoshi, H; Zeniya, M; Asukata, I				Hamada, K; Doi, T; Sakurai, M; Matsumoto, K; Yanagisawa, K; Suzuki, T; Kikuchi, N; Okuda, J; Miyazaki, H; Okoshi, H; Zeniya, M; Asukata, I			Effects of hydration on fluid balance and lower-extremity blood viscosity during long airplane flights	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter							THROMBOEMBOLISM; TRAVEL		Otsuka Pharmaceut Co Ltd, Saga Nutraceut Res Inst, Saga, Japan; Japan Airlines Med Serv, Tokyo, Japan	Otsuka Pharmaceutical	Hamada, K (corresponding author), Otsuka Pharmaceut Co Ltd, Saga Nutraceut Res Inst, Saga, Japan.							DILL DB, 1974, J APPL PHYSIOL, V37, P247, DOI 10.1152/jappl.1974.37.2.247; Eklof B, 1996, DERMATOL SURG, V22, P637, DOI 10.1111/j.1524-4725.1996.tb00610.x; Greenleaf JE, 1998, AVIAT SPACE ENVIR MD, V69, P936; Lapostolle F, 2001, NEW ENGL J MED, V345, P779, DOI 10.1056/NEJMoa010378; SLADEN GE, 1969, CLIN SCI, V36, P119; SYMINGTON IS, 1977, BRIT J DIS CHEST, V71, P138, DOI 10.1016/0007-0971(77)90097-3	6	14	14	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 20	2002	287	7					844	845		10.1001/jama.287.7.844-a	http://dx.doi.org/10.1001/jama.287.7.844-a			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	522XP	11851575				2023-01-03	WOS:000173922500022
J	Vernazza, PL				Vernazza, PL			Genital shedding of HIV-1 despite successful antiretroviral therapy	LANCET			English	Editorial Material							IMMUNODEFICIENCY-VIRUS TYPE-1		Canton Hosp, Dept Med, Div Infect Dis, CH-9007 St Gallen, Switzerland	Kantonsspital St. Gallen	Vernazza, PL (corresponding author), Canton Hosp, Dept Med, Div Infect Dis, CH-9007 St Gallen, Switzerland.							Chakraborty H, 2001, AIDS, V15, P621, DOI 10.1097/00002030-200103300-00012; Ellerbrock TV, 2001, J INFECT DIS, V184, P28, DOI 10.1086/321000; Eron JJ, 2000, J INFECT DIS, V181, P1622, DOI 10.1086/315447; Quinn TC, 2000, NEW ENGL J MED, V342, P921, DOI 10.1056/NEJM200003303421303; Vernazza PL, 2000, AIDS, V14, P117, DOI 10.1097/00002030-200001280-00006; Vernazza PL, 2001, REV MED MICROBIOL, V12, P131	6	12	12	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	NOV 10	2001	358	9293					1564	1564		10.1016/S0140-6736(01)06665-X	http://dx.doi.org/10.1016/S0140-6736(01)06665-X			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	492VM	11716875				2023-01-03	WOS:000172188300002
J	Phillips, LS; Branch, WT; Cook, CB; Doyle, JP; El-Kebbi, IM; Gallina, DL; Miller, CD; Ziemer, DC; Barnes, CS				Phillips, LS; Branch, WT; Cook, CB; Doyle, JP; El-Kebbi, IM; Gallina, DL; Miller, CD; Ziemer, DC; Barnes, CS			Clinical inertia	ANNALS OF INTERNAL MEDICINE			English	Article							DEPENDENT DIABETES-MELLITUS; DENSITY-LIPOPROTEIN-CHOLESTEROL; EDUCATION-PROGRAM GUIDELINES; NUTRITION EXAMINATION SURVEY; URBAN AFRICAN-AMERICANS; 3RD NATIONAL-HEALTH; PRIMARY-CARE; GLYCEMIC CONTROL; BLOOD-PRESSURE; PREVENTIVE SERVICES	Medicine has traditionally focused on relieving patient symptoms. However, in developed countries, maintaining good health increasingly involves management of such problems as hypertension, dyslipidemia, and diabetes, which often have no symptoms. Moreover, abnormal blood pressure, lipid, and glucose values are generally sufficient to warrant treatment without further diagnostic maneuvers. Limitations in managing such problems are often due to clinical inertia-failure of health care providers to initiate or intensify therapy when indicated. Clinical inertia is due to at least three problems: overestimation of care provided; use of "soft" reasons to avoid intensification of therapy; and lack of education, training, and practice organization aimed at achieving therapeutic goals. Strategies to overcome clinical inertia must focus on medical students, residents, and practicing physicians. Revised education programs should lead to assimilation of three concepts: the benefits of treating to therapeutic targets, the practical complexity of treating to target for different disorders, and the need to structure routine practice to facilitate effective management of disorders for which resolution of patient symptoms is not sufficient to guide care. Physicians will need to build into their practice a system of reminders and performance feedback to ensure necessary care.	Emory Univ, Sch Med, Div Endocrinol, Atlanta, GA 30322 USA	Emory University	Phillips, LS (corresponding author), Emory Univ, Sch Med, Div Endocrinol, 1639 Pierce Dr,Room 1301, Atlanta, GA 30322 USA.	medlsp@emory.edu			AHRQ HHS [HS-09722] Funding Source: Medline; NIDDK NIH HHS [T32-DK-07298, DK-48124] Funding Source: Medline; AGENCY FOR HEALTHCARE RESEARCH AND QUALITY [R01HS009722] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK048124, T32DK007298] Funding Source: NIH RePORTER	AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); AGENCY FOR HEALTHCARE RESEARCH AND QUALITY(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Allison TG, 1999, MAYO CLIN PROC, V74, P466; *AM DIAB ASS, 1999, DIABETES CARE, V22, pS322; ANDERSON RM, 1988, DIABETES CARE, V11, P519, DOI 10.2337/diacare.11.7.519; Aubert RE, 1998, ANN INTERN MED, V129, P605, DOI 10.7326/0003-4819-129-8-199810150-00004; BANTA HD, 1993, BRIT MED J, V307, P1546, DOI 10.1136/bmj.307.6918.1546; Becker DM, 1998, ARCH INTERN MED, V158, P1533, DOI 10.1001/archinte.158.14.1533; Berlowitz DR, 1998, NEW ENGL J MED, V339, P1957, DOI 10.1056/NEJM199812313392701; Bernard AM, 1999, DIABETES CARE, V22, P661, DOI 10.2337/diacare.22.5.661; Bungard TJ, 2000, ARCH INTERN MED, V160, P41, DOI 10.1001/archinte.160.1.41; BURT VL, 1995, HYPERTENSION, V25, P305, DOI 10.1161/01.HYP.25.3.305; Chaudhry R, 2000, MAYO CLIN PROC, V75, P156; CHENEY C, 1987, AM J MED, V83, P129, DOI 10.1016/0002-9343(87)90507-9; COHEN DI, 1982, MED CARE, V20, P1040, DOI 10.1097/00005650-198210000-00006; COHEN MV, 1991, CIRCULATION, V83, P1294, DOI 10.1161/01.CIR.83.4.1294; Cook CB, 1999, DIABETES CARE, V22, P1494, DOI 10.2337/diacare.22.9.1494; Corkery E, 1997, DIABETES CARE, V20, P254, DOI 10.2337/diacare.20.3.254; Curry SJ, 2000, CHEST, V118, p40S, DOI 10.1378/chest.118.2_suppl.40S; CUSI K, 1995, DIABETES CARE, V18, P843, DOI 10.2337/diacare.18.6.843; DAVIS DA, 1995, JAMA-J AM MED ASSOC, V274, P700; DAVIS DA, 1992, JAMA-J AM MED ASSOC, V268, P1111, DOI 10.1001/jama.268.9.1111; Davis RM, 1999, BRIT MED J, V318, P1090, DOI 10.1136/bmj.318.7191.1090; DEEB LC, 1988, DIABETES CARE, V11, P275, DOI 10.2337/diacare.11.3.275; Demakis JG, 2000, JAMA-J AM MED ASSOC, V284, P1411, DOI 10.1001/jama.284.11.1411; DIMATTEO MR, 1993, HEALTH PSYCHOL, V12, P93, DOI 10.1037/0278-6133.12.2.93; Drass J, 1998, DIABETES CARE, V21, P1282, DOI 10.2337/diacare.21.8.1282; EISENBERG J, 1986, DOCTORS DECISIONS CO; El-Kebbi IM, 1999, DIABETES CARE, V22, P1617, DOI 10.2337/diacare.22.10.1617; ElKebbi IM, 1997, DIABETES CARE, V20, P698, DOI 10.2337/diacare.20.5.698; Elson R B, 1995, Arch Fam Med, V4, P698, DOI 10.1001/archfami.4.8.698; ERAKER SA, 1984, ANN INTERN MED, V100, P258, DOI 10.7326/0003-4819-100-2-258; FOX SA, 1994, ARCH INTERN MED, V154, P2058, DOI 10.1001/archinte.154.18.2058; Freis ED, 1999, ARCH INTERN MED, V159, P2517, DOI 10.1001/archinte.159.21.2517; Fried LP, 1998, JAMA-J AM MED ASSOC, V279, P585, DOI 10.1001/jama.279.8.585; GILES WH, 1993, JAMA-J AM MED ASSOC, V269, P1133, DOI 10.1001/jama.269.9.1133; GORMAN PN, 2000, COCHRANE DIS SYST RE, P3; GRECO PJ, 1993, NEW ENGL J MED, V329, P1271, DOI 10.1056/NEJM199310213291714; GREENFIELD S, 1995, JAMA-J AM MED ASSOC, V274, P1436; Harris MI, 2000, DIABETES CARE, V23, P754, DOI 10.2337/diacare.23.6.754; Harris MI, 1999, DIABETES CARE, V22, P403, DOI 10.2337/diacare.22.3.403; Harris MI, 1998, DIABETES CARE, V21, P518, DOI 10.2337/diacare.21.4.518; Hayes R P, 1995, Clin Perform Qual Health Care, V3, P15; Haynes RB, 2000, COCHRANE DATABASE SY; Hayward RA, 1997, JAMA-J AM MED ASSOC, V278, P1663, DOI 10.1001/jama.278.20.1663; HEADRICK LA, 1992, ARCH INTERN MED, V152, P2490, DOI 10.1001/archinte.152.12.2490; HEMPEL RJ, 1990, SOUTHERN MED J, V83, P1426, DOI 10.1097/00007611-199012000-00014; Hiss RG, 1996, ANN INTERN MED, V124, P146, DOI 10.7326/0003-4819-124-1_Part_2-199601011-00012; Howard G, 2000, ANN EPIDEMIOL, V10, P214, DOI 10.1016/S1047-2797(00)00038-7; Hyman DJ, 2000, ARCH INTERN MED, V160, P2281, DOI 10.1001/archinte.160.15.2281; JOHNSTON ME, 1994, ANN INTERN MED, V120, P135, DOI 10.7326/0003-4819-120-2-199401150-00007; Kottke TE, 1997, MAYO CLIN PROC, V72, P515, DOI 10.4065/72.6.515; KRAVITZ RL, 1993, ARCH INTERN MED, V153, P1869, DOI 10.1001/archinte.153.16.1869; Lagrew DC, 1996, AM J OBSTET GYNECOL, V174, P184, DOI 10.1016/S0002-9378(96)70392-7; LEAF DA, 1995, J GEN INTERN MED, V10, P194, DOI 10.1007/BF02600254; LITZELMAN DK, 1993, ANN INTERN MED, V119, P36, DOI 10.7326/0003-4819-119-1-199307010-00006; LITZELMAN DK, 1993, J GEN INTERN MED, V8, P311, DOI 10.1007/BF02600144; LOMAS J, 1991, JAMA-J AM MED ASSOC, V265, P2202, DOI 10.1001/jama.265.17.2202; LOMAS J, 1989, NEW ENGL J MED, V321, P1306, DOI 10.1056/NEJM198911093211906; MANDELBLATT J, 1995, J FAM PRACTICE, V40, P162; Marcelino JJ, 1996, AM J MED, V100, P605, DOI 10.1016/S0002-9343(96)00011-3; MATERSON BJ, 1993, NEW ENGL J MED, V328, P914, DOI 10.1056/NEJM199304013281303; MATERSON BJ, 1995, J HUM HYPERTENS, V9, P791; McBride P, 1998, ARCH INTERN MED, V158, P1238, DOI 10.1001/archinte.158.11.1238; McDermott MM, 1997, ARCH INTERN MED, V157, P1921, DOI 10.1001/archinte.157.17.1921; MCDONALD CJ, 1984, ANN INTERN MED, V100, P130, DOI 10.7326/0003-4819-100-1-130; MCPHEE SJ, 1986, J GEN INTERN MED, V1, P275, DOI 10.1007/BF02596202; Miller CD, 2000, DIABETES CARE, V23, P444, DOI 10.2337/diacare.23.4.444; Nelson EC, 1998, ANN INTERN MED, V128, P460, DOI 10.7326/0003-4819-128-6-199803150-00007; Nicolucci A, 1998, DIABETES CARE, V21, P1439, DOI 10.2337/diacare.21.9.1439; Nilasena D S, 1995, Proc Annu Symp Comput Appl Med Care, P640; OBRIEN MA, 2000, COCHRANE DATABASE SY; OXMAN AD, 1995, CAN MED ASSOC J, V153, P1423; Pearson TA, 2000, ARCH INTERN MED, V160, P459, DOI 10.1001/archinte.160.4.459; Pickering T G, 1999, Curr Hypertens Rep, V1, P489, DOI 10.1007/s11906-996-0020-0; ROWE R, 2000, COCHRANE DB SYST REV, P3; Sever PS, 1997, AM J HYPERTENS, V10, pS128, DOI 10.1016/S0895-7061(97)00100-3; SHAMOON H, 1993, NEW ENGL J MED, V329, P977, DOI 10.1056/nejm199309303291401; SHERBOURNE CD, 1992, J BEHAV MED, V15, P447, DOI 10.1007/BF00844941; Solberg LI, 1998, MED CARE, V36, P625, DOI 10.1097/00005650-199805000-00003; Stafford RS, 1997, J AM COLL CARDIOL, V29, P139, DOI 10.1016/S0735-1097(96)00441-X; Turner RC, 1999, JAMA-J AM MED ASSOC, V281, P2005, DOI 10.1001/jama.281.21.2005; VINCENT EC, 1995, P ANN S COMPUT APPL, V656, P95; VINICOR F, 1987, J CHRON DIS, V40, P345, DOI 10.1016/0021-9681(87)90050-6; Von Korff M, 1997, ANN INTERN MED, V127, P1097, DOI 10.7326/0003-4819-127-12-199712150-00008; Wagner EH, 2000, BMJ-BRIT MED J, V320, P569, DOI 10.1136/bmj.320.7234.569; Wanger EH, 1998, ANN INTERN MED, V129, P654, DOI 10.7326/0003-4819-129-8-199810150-00015; Weber BE, 1997, ARCH INTERN MED, V157, P2345, DOI 10.1001/archinte.157.20.2345; Williams MV, 1998, ARCH INTERN MED, V158, P166, DOI 10.1001/archinte.158.2.166; Yusuf HR, 1998, PREV MED, V27, P1, DOI 10.1006/pmed.1997.0268	88	1014	1033	0	22	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	NOV 6	2001	135	9					825	834		10.7326/0003-4819-135-9-200111060-00012	http://dx.doi.org/10.7326/0003-4819-135-9-200111060-00012			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	489VT	11694107				2023-01-03	WOS:000172013700007
J	Sargent, DJ; Goldberg, RM; Jacobson, SD; Macdonald, JS; Labianca, R; Haller, DG; Shepherd, LE; Seitz, JF; Francini, G				Sargent, DJ; Goldberg, RM; Jacobson, SD; Macdonald, JS; Labianca, R; Haller, DG; Shepherd, LE; Seitz, JF; Francini, G			A pooled analysis of adjuvant chemotherapy for resected colon cancer in elderly patients	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ADVANCED COLORECTAL-CANCER; BREAST-CANCER; THERAPEUTIC RESPONSE; RANDOMIZED TRIAL; AGE; OLDER; TOXICITY; 5-FLUOROURACIL; FLUOROURACIL; LEVAMISOLE	Background: Adjuvant chemotherapy is standard treatment for patients with resected colon cancer who are at high risk for recurrence, but the efficacy and toxicity of such treatment in patients more than 70 years of age are controversial. Methods: We performed a pooled analysis, based on the intention to treat, of individual patient data from seven phase 3 randomized trials (involving 3351 patients) in which the effects of postoperative fluorouracil plus leucovorin (five trials) or fluorouracil plus levamisole (two trials) were compared with the effects of surgery alone in patients with stage II or III colon cancer. The patients were grouped into four age categories of equal size, and analyses were repeated with 10-year age ranges (less than or equal to 50, 51 to 60, 61 to 70, and >70 years), with the same conclusions. The toxic effects measured in all trials were nausea or vomiting, diarrhea, stomatitis, and leukopenia. Patients in the fluorouracil-plus-leucovorin and fluorouracil-plus-levamisole groups were combined for the efficacy analysis but kept separate for toxicity analyses. Results: Adjuvant treatment had a significant positive effect on both overall survival and time to tumor recurrence (P<0.001 for each, with hazard ratios of death and recurrence of 0.76 [95 percent confidence interval, 0.68 to 0.85] and 0.68 [95 percent confidence interval, 0.60 to 0.76], respectively). The five-year overall survival was 71 percent for those who received adjuvant therapy, as compared with 64 percent for those untreated. No significant interaction was observed between age and the efficacy of treatment. The incidence of toxic effects was not increased among the elderly (age >70 years), except for leukopenia in one study. Conclusions: Selected elderly patients with colon cancer can receive the same benefit from fluorouracil-based adjuvant therapy as their younger counterparts, without a significant increase in toxic effects. (N Engl J Med 2001;345:1091-7.) Copyright (C) Massachusetts Medical Society.	Mayo Clin & Mayo Fdn, Rochester, MN 55905 USA; St Vincent Comprehens Canc Ctr, New York, NY USA; Osped Riuniti Bergamo, I-24100 Bergamo, Italy; Univ Penn, Ctr Canc, Philadelphia, PA 19104 USA; Queens Univ, Natl Canc Inst Canada, Kingston, ON, Canada; Univ Mediterranean, Marseille, France; Univ Siena, I-53100 Siena, Italy	Mayo Clinic; Saint Vincents Hospital Manhattan; Ospedali Riuniti di Bergamo; University of Pennsylvania; Queens University - Canada; Canadian Cancer Trials Group; UDICE-French Research Universities; Aix-Marseille Universite; University of Siena	Sargent, DJ (corresponding author), Mayo Clin & Mayo Fdn, 200 1st St SW, Rochester, MN 55905 USA.		Goldberg, Richard/O-1871-2017; Goldberg, Richard M/M-1311-2013; Cusi, Maria Grazia/H-6309-2019; Labianca, Roberto/N-1847-2016	Goldberg, Richard/0000-0003-3713-6895; Cusi, Maria Grazia/0000-0001-8869-8164; Labianca, Roberto/0000-0001-7149-822X; Sargent, Daniel/0000-0002-2684-4741	NATIONAL CANCER INSTITUTE [U10CA025224] Funding Source: NIH RePORTER; NCI NIH HHS [CA 25224] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aschele, 1995, Cancer Control, V2, P36; Balducci L, 1997, CANCER, V80, P1317, DOI 10.1002/(SICI)1097-0142(19971001)80:7<1317::AID-CNCR18>3.3.CO;2-I; Balducci L, 1992, Oncology (Williston Park), V6, P62; BEGG CB, 1983, CANCER, V52, P1986, DOI 10.1002/1097-0142(19831201)52:11<1986::AID-CNCR2820521103>3.0.CO;2-7; BONADONNA G, 1981, NEW ENGL J MED, V304, P10, DOI 10.1056/NEJM198101013040103; Brower M, 1993, P AM SOC CLIN ONCOL, V12, P195; CAMPBELL PR, 1996, POPULATION PROJECTIO, P86; Cascinu S, 1996, AM J CLIN ONCOL-CANC, V19, P371, DOI 10.1097/00000421-199608000-00010; Chiara S, 1998, CANCER CHEMOTH PHARM, V42, P336, DOI 10.1007/s002800050826; CHRISTMAN K, 1992, JAMA-J AM MED ASSOC, V268, P57, DOI 10.1001/jama.268.1.57; COOPER GS, 1995, CANCER, V75, P775, DOI 10.1002/1097-0142(19950201)75:3<775::AID-CNCR2820750305>3.0.CO;2-D; COVA D, 1998, COMPREHENSIVE GERIAT, P429; COX DR, 1972, J R STAT SOC B, V34, P187; *EARL BREAST CANC, 1992, LANCET, V339, P1; Erlichman C, 1999, J CLIN ONCOL, V17, P1356, DOI 10.1200/JCO.1999.17.5.1356; Extermann M, 1997, CLIN GERIATR MED, V13, P227; FENTIMAN IS, 1990, LANCET, V335, P1020, DOI 10.1016/0140-6736(90)91075-L; FRANCINI G, 1994, GASTROENTEROLOGY, V106, P899, DOI 10.1016/0016-5085(94)90748-X; FREI E, 1980, AM J MED, V69, P585, DOI 10.1016/0002-9343(80)90472-6; Furner SE, 1997, GERIATRIC MED, P37; GELMAN RS, 1984, J CLIN ONCOL, V2, P1404, DOI 10.1200/JCO.1984.2.12.1404; GOODWIN JS, 1993, CANCER-AM CANCER SOC, V72, P594, DOI 10.1002/1097-0142(19930715)72:2<594::AID-CNCR2820720243>3.0.CO;2-#; GOODWIN JS, 1988, ARCH INTERN MED, V148, P2258, DOI 10.1001/archinte.148.10.2258; GRAMBSCH PM, 1994, BIOMETRIKA, V81, P515; Gray RG, 2000, LANCET, V355, P1588; GREENFIELD S, 1987, JAMA-J AM MED ASSOC, V257, P2766, DOI 10.1001/jama.257.20.2766; GUTHEIL J, 1996, CHEMOTHERAPY SOURCE, P317; GUTHRIE TH, 1990, J CLIN ONCOL, V8, P342, DOI 10.1200/JCO.1990.8.2.342; HALL WH, 1990, JAMA-J AM MED ASSOC, V264, P1444; Hutchins LF, 1999, NEW ENGL J MED, V341, P2061, DOI 10.1056/NEJM199912303412706; Jessup JM, 1996, CANCER-AM CANCER SOC, V78, P918; KANE RL, 1999, ESSENTIALS CLIN GERI, P19; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; LABIANCA R, 1995, LANCET, V345, P939; LAURIE JA, 1989, J CLIN ONCOL, V7, P1447, DOI 10.1200/JCO.1989.7.10.1447; Mahoney T, 2000, ARCH SURG-CHICAGO, V135, P182, DOI 10.1001/archsurg.135.2.182; Mamounas E, 1999, J CLIN ONCOL, V17, P1349, DOI 10.1200/JCO.1999.17.5.1349; MANTEL N, 1959, J NATL CANCER I, V22, P719; MILANO G, 1992, J CLIN ONCOL, V10, P1171, DOI 10.1200/JCO.1992.10.7.1171; MOERTEL CG, 1990, NEW ENGL J MED, V322, P352, DOI 10.1056/NEJM199002083220602; MONFARDINI S, 1995, CANCER, V76, P333, DOI 10.1002/1097-0142(19950715)76:2<333::AID-CNCR2820760226>3.0.CO;2-I; MOR V, 1985, J AM GERIATR SOC, V33, P585, DOI 10.1111/j.1532-5415.1985.tb06313.x; O'Connell MJ, 1998, J CLIN ONCOL, V16, P295, DOI 10.1200/JCO.1998.16.1.295; PETERSON B, 1994, CONTROL CLIN TRIALS, V15, P326; PETERSON BA, 1982, CANCER TREAT REP, V66, P889; Popescu RA, 1999, J CLIN ONCOL, V17, P2412, DOI 10.1200/JCO.1999.17.8.2412; Ries LAG .M.K.C, 2001, SEER CANC STAT REV 1; SAMET J, 1986, JAMA-J AM MED ASSOC, V255, P3385, DOI 10.1001/jama.255.24.3385; STEIN BN, 1995, CANCER-AM CANCER SOC, V75, P11, DOI 10.1002/1097-0142(19950101)75:1<11::AID-CNCR2820750104>3.0.CO;2-N; STEINBERG J, 1992, EUR J CANCER, V28A, P1817, DOI 10.1016/0959-8049(92)90011-P; STERNBERG CN, 1989, CANCER, V64, P2448, DOI 10.1002/1097-0142(19891215)64:12<2448::AID-CNCR2820641209>3.0.CO;2-7; SUNDARARAJAN V, 1999, PROG P AM SOC CLIN O, V18, pA413; TRIMBLE EL, 1994, CANCER, V74, P2208, DOI 10.1002/1097-0142(19941001)74:7+<2208::AID-CNCR2820741737>3.0.CO;2-#; Vestal RE, 1997, CANCER, V80, P1302, DOI 10.1002/(SICI)1097-0142(19971001)80:7<1302::AID-CNCR16>3.0.CO;2-B; WALSH SJ, 1989, SEMIN ONCOL, V16, P66; WINAWER SJ, 1984, ADV INTERNAL MED, V30, P471; WINDLE R, 1987, BRIT J SURG, V74, P569, DOI 10.1002/bjs.1800740707; Zalcberg J, 1998, EUR J CANCER, V34, P1871, DOI 10.1016/S0959-8049(98)00259-7	58	670	685	1	12	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 11	2001	345	15					1091	1097		10.1056/NEJMoa010957	http://dx.doi.org/10.1056/NEJMoa010957			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	480QH	11596588				2023-01-03	WOS:000171473100003
J	Marcil, I; Stern, RS				Marcil, I; Stern, RS			Squamous-cell cancer of the skin in patients given PUVA and ciclosporin: nested cohort crossover study	LANCET			English	Article							SEVERE PSORIASIS; TRANSPLANT RECIPIENTS; RISK; CYCLOSPORINE; CARCINOMA; PHOTOCHEMOTHERAPY; THERAPY	Background Immunosuppressive treatments have been associated with an increased risk of skin cancer, especially in patients who have had organ transplants. We aimed to assess the risk of skin cancer in patients taking the ciclosporin who had been exposed to psoralen and ultraviolet-A light (PUVA) and other treatments for severe psoriasis. Methods We did a nested cohort crossover study of 28 participants in the PUVA follow-up study who were on ciclosporin to compare the frequency of squamous-cell carcinoma before and after first use of ciclosporin. We also analysed the entire PUVA study cohort (1380) to assess the relation between use of this drug and frequency of squamous-cell carcinoma. Findings In the 5 years before first use, six of 28 (21%) ciclosporin users developed a total of 20 squamous cell cancers. After ciclosporin use (average follow-up 6 years), 13 (46%) developed a total of 169 squamous-cell carcinomas. In the nested cohort, after adjustment for amount of exposure to PUVA and methotrexate, incidence of tumours was seven times higher after first ciclosporin use than in the previous 5 years (incidence rate ratio 6.9 [95% CI 4.3-11]). Multivariate, analysis of the entire cohort showed that risk of squamous-cell carcinoma after any use of ciclosporin is close to that recorded for at least 200 PUVA treatments (3.1 [2.6-3.7] and 2.8 [2.6-3.2], respectively). Interpretation The risk of squamous cell cancer of the skin is increased by ciclosporin in patients with psoriasis who have been exposed to PUVA. Such risks should be balanced against the effectiveness of the drug and possible newer immunosuppressive agents.	Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Dept Dermatol, Boston, MA 02215 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School	Stern, RS (corresponding author), Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Dept Dermatol, 330 Brookline Ave, Boston, MA 02215 USA.	rstern@caregroup.harvard.edu			NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [N01AR002246, N01AR042214] Funding Source: NIH RePORTER; NIAMS NIH HHS [N01-AR-0-2246, N01-AR-4-2214] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Abrams JR, 2000, J EXP MED, V192, P681, DOI 10.1084/jem.192.5.681; Bavinck JNB, 1996, TRANSPLANTATION, V61, P715, DOI 10.1097/00007890-199603150-00008; BIRKELAND SA, 1995, INT J CANCER, V60, P183, DOI 10.1002/ijc.2910600209; Cribier B, 1999, DERMATOLOGY, V199, P208, DOI 10.1159/000018276; Grundmann-Kollmann M, 2000, J AM ACAD DERMATOL, V42, P835, DOI 10.1067/mjd.2000.104890; HENSELER T, 1987, J AM ACAD DERMATOL, V16, P108, DOI 10.1016/S0190-9622(87)70010-3; Ho VC, 1999, BRIT J DERMATOL, V141, P283; Hojo M, 1999, NATURE, V397, P530, DOI 10.1038/17401; Jensen P, 1999, J AM ACAD DERMATOL, V40, P177, DOI 10.1016/S0190-9622(99)70185-4; Koo J, 1998, BRIT J DERMATOL, V139, P88; LINDELOF B, 1991, LANCET, V338, P91, DOI 10.1016/0140-6736(91)90083-2; Lindelof B, 2000, BRIT J DERMATOL, V143, P513, DOI 10.1046/j.1365-2133.2000.03703.x; LONDON NJ, 1995, LANCET, V346, P403, DOI 10.1016/S0140-6736(95)92780-8; Nabel GJ, 1999, NATURE, V397, P471, DOI 10.1038/17207; Owen CM, 2000, CLIN EXP DERMATOL, V25, P195, DOI 10.1046/j.1365-2230.2000.00612.x; Ramsay HM, 2000, AM J KIDNEY DIS, V36, P167, DOI 10.1053/ajkd.2000.8290; SCOTTO J, 1983, PUBLICATION NIH; STERN RS, 1984, NEW ENGL J MED, V310, P1156, DOI 10.1056/NEJM198405033101805; Stern RS, 1998, JNCI-J NATL CANCER I, V90, P1278, DOI 10.1093/jnci/90.17.1278; STERN RS, 1994, CANCER-AM CANCER SOC, V73, P2759, DOI 10.1002/1097-0142(19940601)73:11<2759::AID-CNCR2820731118>3.0.CO;2-C; STERN RS, 1979, NEW ENGL J MED, V300, P809, DOI 10.1056/NEJM197904123001501; VandeKerkhof PCM, 1997, BRIT J DERMATOL, V136, P275, DOI 10.1046/j.1365-2133.1997.d01-1187.x	22	164	169	0	6	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	SEP 29	2001	358	9287					1042	1045		10.1016/S0140-6736(01)06179-7	http://dx.doi.org/10.1016/S0140-6736(01)06179-7			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	479EY	11589933				2023-01-03	WOS:000171393100008
J	Tattersfield, AE; Harrison, TW				Tattersfield, AE; Harrison, TW			Exacerbations of asthma - still room for improvement	LANCET			English	Editorial Material							INHALED CORTICOSTEROIDS; IPRATROPIUM BROMIDE; MANAGEMENT; AGONISTS		City Hosp, Div Resp Med, Nottingham NG5 1PB, England	University of Nottingham	Tattersfield, AE (corresponding author), City Hosp, Div Resp Med, Nottingham NG5 1PB, England.	anne.tattersfield@nottingham.ac.uk						Abramson MJ, 2001, AM J RESP CRIT CARE, V163, P12, DOI 10.1164/ajrccm.163.1.9910042; [Anonymous], 1995, NHLBI WHO WORKSH REP; CHERVINSKY P, 1994, J ALLERGY CLIN IMMUN, V94, P676, DOI 10.1016/0091-6749(94)90174-0; HAAHTELA T, 1991, NEW ENGL J MED, V325, P388, DOI 10.1056/NEJM199108083250603; HIGGINS RM, 1988, CHEST, V94, P718, DOI 10.1378/chest.94.4.718; Neville RG, 1997, THORAX, V52, P153, DOI 10.1136/thx.52.2.153; *NIH, 1997, 974051 NIH; Pearson M G, 1995, Qual Health Care, V4, P24, DOI 10.1136/qshc.4.1.24; Pearson MG, 1997, THORAX, V52, pS1; Plotnick LH, 1998, BMJ-BRIT MED J, V317, P971, DOI 10.1136/bmj.317.7164.971; Rodrigo CJ, 2000, AM J RESP CRIT CARE, V161, P1862; ROWE BH, 2000, COCHRANE DATABASE SY, V2; Scottish Environment Protection Agency, 1999, EM MAN AC ASTHM, P1; Simpson AJ, 2000, THORAX, V55, P97, DOI 10.1136/thorax.55.2.97; Suissa S, 2000, NEW ENGL J MED, V343, P332, DOI 10.1056/NEJM200008033430504; Tattersfield AE, 2001, THORAX, V56, P272, DOI 10.1136/thorax.56.4.272; 1986, LANCET, V1, P131	17	5	5	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	AUG 25	2001	358	9282					599	601		10.1016/S0140-6736(01)05815-9	http://dx.doi.org/10.1016/S0140-6736(01)05815-9			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	465XP	11530142				2023-01-03	WOS:000170615500003
J	Wenger, NS; Kanouse, DE; Collins, RL; Liu, HH; Schuster, MA; Gifford, AL; Bozzette, SA; Shapiro, MF				Wenger, NS; Kanouse, DE; Collins, RL; Liu, HH; Schuster, MA; Gifford, AL; Bozzette, SA; Shapiro, MF			End-of-life discussions and preferences among persons with HIV	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							PHYSICIAN-ASSISTED SUICIDE; NATIONAL PROBABILITY SAMPLES; LOW-PREVALENCE DISEASES; ADVANCE DIRECTIVES; HOMOSEXUAL-MEN; CARE; COMMUNICATION; AIDS; ATTITUDES; BARRIERS	Context Deficits in advance care planning leave many patients and their physicians unprepared for decisions about end-of-life care. Even though the prognosis has im; proved for many persons with human immunodeficiency virus (HIV) infection, a need for planning remains. Objective To evaluate prevalence of end-of-life discussions, use of advance directives, and preferences concerning end-of-life care and their relationship with patient demographics, clinical status, psychosocial variables, and practitioner characteristics among HIV-infected persons. Design, Setting, and Patients Cross-sectional survey of a US probability sample of 2864, which represents 231 400 adults receiving care for HIV, conducted from January 1996 to April 1997. Main Outcome Measures Communication with physician regarding end-of-life issues, completion of an advance directive, preference for aggressiveness of care,and willingness to tolerate future permanent adverse health states. Results A total of 1432 patients (50%) discussed some aspect of end-of-life care with their practitioner and 1088 (38%) completed an advance directive. Patients were more likely to complete an advance directive after a physician discussion (odds ratio [OR], 5.82; 95% confidence interval [CI], 4.50-7.52). Practitioners discussed end-of-life care less with blacks (OR, 0.57; 95% CI, 0.39-0.83) and Latinos (OR, 0.74; 95% CI, 0.55-0.98) than with whites. Women (OR, 1.39; 95% CI, 1.05-1.84) and patients with children in the household (OR, 1.53; 95% CI, 1.12-2.10) communicated the most with practitioners about end-of-life issues. Patients infected with HIV via injection drug use (OR, 0.64; 95% CI, 0.45-0.89) and those with less education communicated the least with physicians about end-of-life issues. Less denial, greater trust in one's practitioner, and longer patient-practitioner relationship were associated with more advance care planning. Conclusions: Half of all persons infected with HIV are at risk of making end-of-life decisions without prior discussions with their health care practitioners. Blacks, Latinos, intravenous drug users, and less educated individuals need advance care planning interventions in clinical HIV programs.	Univ Calif Los Angeles, Dept Med, Div Gen Internal Med & Hlth Serv Res, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Dept Pediat, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Dept Hlth Serv, Los Angeles, CA 90095 USA; RAND Hlth, Santa Monica, CA USA; San Diego VA Healthcare Syst, Dept Med, La Jolla, CA USA; Univ Calif San Diego, La Jolla, CA 92093 USA	University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; RAND Corporation; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA San Diego Healthcare System; University of California System; University of California San Diego	Wenger, NS (corresponding author), Univ Calif Los Angeles, Dept Med, Div Gen Internal Med & Hlth Serv Res, GIM HSR,911 Broxton Plaza, Los Angeles, CA 90095 USA.	nwenger@mednet.ucla.edu	Gifford, Allen L/D-9329-2016	Gifford, Allen L/0000-0001-6442-1128	AGENCY FOR HEALTHCARE RESEARCH AND QUALITY [U01HS008578] Funding Source: NIH RePORTER; AHRQ HHS [U-01HS08578] Funding Source: Medline	AGENCY FOR HEALTHCARE RESEARCH AND QUALITY(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)		BERRY SH, 1999, MR1090AHCPR RAND; Bindels PJE, 1996, LANCET, V347, P499, DOI 10.1016/S0140-6736(96)91138-1; Bozzette SA, 1998, NEW ENGL J MED, V339, P1897, DOI 10.1056/NEJM199812243392606; Breitbart W, 1996, AM J PSYCHIAT, V153, P238; Cooper-Patrick L, 1999, JAMA-J AM MED ASSOC, V282, P583, DOI 10.1001/jama.282.6.583; COULTON CJ, 1990, J CLIN EPIDEMIOL, V43, pS51, DOI 10.1016/0895-4356(90)90219-F; Curtis JR, 1997, J GEN INTERN MED, V12, P736, DOI 10.1046/j.1525-1497.1997.07158.x; Curtis JR, 1999, AIDS, V13, P1123, DOI 10.1097/00002030-199906180-00017; Curtis JR, 2000, ARCH INTERN MED, V160, P1690, DOI 10.1001/archinte.160.11.1690; DUAN N, 1999, MR1060AHCPR RAND; Emanuel EJ, 1998, LANCET, V351, P21, DOI 10.1016/S0140-6736(98)90329-4; EMANUEL LL, 1995, J AM GERIATR SOC, V43, P440, DOI 10.1111/j.1532-5415.1995.tb05821.x; FOWLER FJ, 1995, MED DECIS MAKING, V15, P195, DOI 10.1177/0272989X9501500301; Frankel MR, 1999, HEALTH SERV RES, V34, P969; FRANKL D, 1989, AM J MED, V86, P645, DOI 10.1016/0002-9343(89)90436-1; HAAS JS, 1993, ARCH INTERN MED, V153, P1241, DOI 10.1001/archinte.153.10.1241; Hofmann JC, 1997, ANN INTERN MED, V127, P1, DOI 10.7326/0003-4819-127-1-199707010-00001; Kaldjian LC, 1998, AIDS, V12, P103, DOI 10.1097/00002030-199801000-00012; Kreuter MW, 2000, ARCH FAM MED, V9, P426, DOI 10.1001/archfami.9.5.426; Littrell J, 1996, SOC WORK HEALTH CARE, V23, P43, DOI 10.1300/J010v23n02_03; Loue S, 1995, J LEGAL MED, V16, P461, DOI 10.1080/01947649509510990; Shapiro MF, 1999, HEALTH SERV RES, V34, P951; Singer PA, 1999, JAMA-J AM MED ASSOC, V281, P163, DOI 10.1001/jama.281.2.163; SLOME L, 1992, J ACQ IMMUN DEF SYND, V5, P712; Slome LR, 1997, NEW ENGL J MED, V336, P417, DOI 10.1056/NEJM199702063360606; STEINBROOK R, 1986, NEW ENGL J MED, V314, P457, DOI 10.1056/NEJM198602133140730; TENO J, 1990, J GEN INTERN MED, V5, P490, DOI 10.1007/BF02600877; Tierney WM, 2001, J GEN INTERN MED, V16, P32, DOI 10.1111/j.1525-1497.2001.00215.x; WACHTER RM, 1993, CRIT CARE CLIN, V9, P125, DOI 10.1016/S0749-0704(18)30212-4; Wilson IB, 1997, J GEN INTERN MED, V12, P784, DOI 10.1046/j.1525-1497.1997.07166.x	30	53	54	0	5	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 13	2001	285	22					2880	2887		10.1001/jama.285.22.2880	http://dx.doi.org/10.1001/jama.285.22.2880			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	440BP	11401609				2023-01-03	WOS:000169156300027
J	Sakiyama-Elbert, SE; Panitch, A; Hubbell, JA				Sakiyama-Elbert, SE; Panitch, A; Hubbell, JA			Development of growth factor fusion proteins for cell-triggered drug delivery	FASEB JOURNAL			English	Article									ETH Zurich, Inst Biomed Engn, CH-8044 Zurich, Switzerland; ETH Zurich, Dept Mat, CH-8044 Zurich, Switzerland; Univ Zurich, Zurich, Switzerland; CALTECH, Div Chem & Chem Engn, Pasadena, CA 91125 USA; Arizona State Univ, Dept Bioengn, Tempe, AZ 85287 USA	Swiss Federal Institutes of Technology Domain; ETH Zurich; Swiss Federal Institutes of Technology Domain; ETH Zurich; University of Zurich; California Institute of Technology; Arizona State University; Arizona State University-Tempe	Hubbell, JA (corresponding author), ETH Zurich, Inst Biomed Engn, Moussonstr 18, CH-8044 Zurich, Switzerland.		Panitch, Alyssa/F-4413-2012; Hubbell, Jeffrey A/A-9266-2008; Sakiyama-Elbert, Shelly/A-6753-2008	Hubbell, Jeffrey A/0000-0003-0276-5456; Sakiyama-Elbert, Shelly/0000-0003-4832-5851					0	129	140	0	20	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAY	2001	15	7					1300	1302		10.1096/fj.00-0564fje	http://dx.doi.org/10.1096/fj.00-0564fje			3	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	431WR	11344120				2023-01-03	WOS:000168655200042
J	Raguram, R; Venkateswaran, A; Ramakrishna, J; Weiss, MG				Raguram, R; Venkateswaran, A; Ramakrishna, J; Weiss, MG			Traditional community resources for mental health: a report of temple healing from India	BRITISH MEDICAL JOURNAL			English	Article							ALTERNATIVE MEDICINE; COMPLEMENTARY	The use of complementary medicine and the traditional medicine of other cultures has been increasing in Europe and North America.(3) Although less well documented, the use of complementary medicines and consultations with traditional healers is widely acknowledged in low income countries, such as India. Here too the limited availability of health services motivates the use of a wide range of alternative systems of care for various ailments, including mental illnesses(4).	Natl Inst Mental Hlth & Neurosci, Bangalore 560029, Karnataka, India; Swiss Trop Inst, Dept Epidemiol & Publ Hlth, CH-4002 Basel, Switzerland	National Institute of Mental Health & Neurosciences - India; University of Basel; Swiss Tropical & Public Health Institute	Raguram, R (corresponding author), Natl Inst Mental Hlth & Neurosci, Bangalore 560029, Karnataka, India.							[Anonymous], 1982, NAT MENT HLTH PROGR; Eisenberg DM, 1998, JAMA-J AM MED ASSOC, V280, P1569, DOI 10.1001/jama.280.18.1569; Ernst E, 2000, BMJ-BRIT MED J, V321, P1133, DOI 10.1136/bmj.321.7269.1133; FISHER P, 1994, BRIT MED J, V309, P107, DOI 10.1136/bmj.309.6947.107; Jablensky A, 2000, EUR ARCH PSY CLIN N, V250, P274, DOI 10.1007/s004060070002; KAPUR RL, 1975, BRIT J PSYCHIAT, V127, P286, DOI 10.1192/bjp.127.3.286; KAPUR RL, 1979, SOC SCI MED-MED ANTH, V13, P27, DOI 10.1016/0160-7987(79)90015-2; OVERALL JE, 1962, PSYCHOL REP, V10, P799; PAKASLAHTI A, 1998, CHANGING PATTERNS FA; RAGHU TM, 1999, CULTURAL ASPECTS SCH; Umbricht D, 1995, SCHIZOPHRENIA BULL, V21, P593, DOI 10.1093/schbul/21.4.593; VENKATESWARAN V, 2001, THESIS NATL I MENTAL; W.H. Organization, 1993, WHO APPL ICD 10 DEAT, V2; Weiss M.G., 2001, ANTHROPOL MED, V8, P5, DOI [10.1080/13648470120070980, DOI 10.1080/13648470120070980]	14	95	97	0	9	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	JUL 6	2002	325	7354					38	40		10.1136/bmj.325.7354.38	http://dx.doi.org/10.1136/bmj.325.7354.38			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	573BC	12098731	Green Published, Green Submitted			2023-01-03	WOS:000176808600025
J	Tinetti, ME; Baker, D; Gallo, WT; Nanda, A; Charpentier, P; O'Leary, J				Tinetti, ME; Baker, D; Gallo, WT; Nanda, A; Charpentier, P; O'Leary, J			Evaluation of restorative care vs usual care for older adults receiving an acute episode of home care	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							MINIMUM DATA SET; ELDERLY-PATIENTS; FUNCTIONAL DECLINE; BRAIN-INJURY; HEALTH-CARE; INTERVENTION; MANAGEMENT; PROGRAM; PEOPLE; HOSPITALIZATION	Context Illness and hospitalization often trigger functional decline among older persons. Home care services implemented for functional decline provide an opportunity, to intervene to improve outcomes. Objective To compare functional status and the likelihood of remaining at home for persons receiving restorative care vs usual home care. Design and Setting Intervention using prospective individual matching conducted between November 1, 1998, and April 30, 2000. Six offices of a home care agency in Connecticut were used. One branch office served as the restorative care unit and the other 5 served as usual care offices. Participants Patients receiving home care through the restorative care office who were 65 years or older; in receipt of Medicare-covered home care lasting at beast 7 days; with absence of severe cognitive impairment; and not terminal, bedridden, or requiring total care were matched with patients from 1 of the usual care offices. The matching factors included age, sex, race, baseline self-care function, cognitive status, whether hospitalization preceded the home care episode, and date of the home care episode. Of the 712 eligible restorative care patients, 691 (97%) were matched with a usual care patient. Intervention Restorative care, provided by the home care agency nursing, therapy, and home health aide staff, was based on principles from geriatric medicine., nursing, rehabilitation, and goal attainment. Main Outcome Measures Remaining at home, functional status at completion of the home care episode, and duration and intensity of home care episode. Results Compared with usual care, and after adjusting for baseline characteristics and other factors, restorative care was associated with a greater likelihood of remaining at home (82% vs 71%; odds ratio [OR], 1.99; 95% confidence interval [CI], 1.47-2.69) and a reduced likelihood of visiting an emergency department (10% vs 20%; OR, 0.44; 95% CI, 0.32-0.61). Home care episodes were shorter (mean [SD], 24.8 [26.8] days vs 34.3 [44.2] days; S = -17821; P<.001). Restorative care patients had better mean (SD) scores than usual care patients in self-care (11.0 [2.1] vs 10.7 [2.5]; P=.07 after adjustment), home management (9.5 [2.9] vs 9.2 [3.0]; P=.05 after adjustment), and mobility (3.3 [0.8] vs 3.2 [0.9]; P=.02 after adjustment). Conclusions This trial suggests that reorganizing the structure and goals of home care can enhance health outcomes of older patients without increasing health care utilization.	Yale Univ, Sch Med, Dept Med, New Haven, CT 06510 USA; Yale Univ, Sch Med, Dept Epidemiol & Publ Hlth, New Haven, CT 06510 USA	Yale University; Yale University	Tinetti, ME (corresponding author), 333 Cedar St,POB 208025, New Haven, CT 06520 USA.	mary.tinetti@yale.edu		Nanda, Aman/0000-0002-3860-3267	NIA NIH HHS [AG10469] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [P60AG010469] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ADAMS CE, 1995, J NURS ADMIN, V25, P27, DOI 10.1097/00005110-199509000-00007; Baker DI, 2001, GERONTOLOGIST, V41, P257, DOI 10.1093/geront/41.2.257; Bernabei R, 1998, JAMA-J AM MED ASSOC, V279, P1877, DOI 10.1001/jama.279.23.1877; Bradley EH, 1999, SOC SCI MED, V49, P267, DOI 10.1016/S0277-9536(99)00107-0; Burrows AB, 2000, AGE AGEING, V29, P165, DOI 10.1093/ageing/29.2.165; CRISLER KS, 1994, STUDY DEV OUTCOME BA, V1; CUMMINGS JE, 1990, ARCH INTERN MED, V150, P1274, DOI 10.1001/archinte.150.6.1274; Eng C, 1997, J AM GERIATR SOC, V45, P223, DOI 10.1111/j.1532-5415.1997.tb04513.x; FEINSTEIN AR, 2002, PRINCIPLES MED STAT, P417; Ferrucci L, 1997, JAMA-J AM MED ASSOC, V277, P728; Fried LP, 1997, J AM GERIATR SOC, V45, P92, DOI 10.1111/j.1532-5415.1997.tb00986.x; Gill TM, 1999, J GERONTOL A-BIOL, V54, pM377, DOI 10.1093/gerona/54.7.M377; GILLICK MR, 1982, SOC SCI MED, V16, P1033, DOI 10.1016/0277-9536(82)90175-7; Graney MJ, 2000, GERONTOLOGIST, V40, P582, DOI 10.1093/geront/40.5.582; Gruber-Baldini AL, 2000, J AM GERIATR SOC, V48, P1601, DOI 10.1111/j.1532-5415.2000.tb03870.x; HOLFORD TR, 1989, AM J EPIDEMIOL, V130, P1247, DOI 10.1093/oxfordjournals.aje.a115453; Inouye SK, 1999, NEW ENGL J MED, V340, P669, DOI 10.1056/NEJM199903043400901; INOUYE SK, 1993, J GEN INTERN MED, V8, P645, DOI 10.1007/BF02598279; JOYCE BM, 1994, AM J PHYS MED REHAB, V73, P10, DOI 10.1097/00002060-199473010-00003; KANE RL, 1994, HEALTH CARE FINANC R, V16, P131; KOCH M, 1994, PHYS THER, V74, P286, DOI 10.1093/ptj/74.4.286; KRAVITZ RL, 1994, J AM GERIATR SOC, V42, P1229, DOI 10.1111/j.1532-5415.1994.tb06502.x; LAWTON MP, 1969, GERONTOLOGIST, V9, P179, DOI 10.1093/geront/9.3_Part_1.179; Leff B, 1999, J AM GERIATR SOC, V47, P697, DOI 10.1111/j.1532-5415.1999.tb01592.x; Lorig K, 1993, GENERATIONS, V17, P11; Madigan E A, 2000, Home Health Care Serv Q, V18, P49; Makuch RW, 1998, STAT MED, V17, P1517, DOI 10.1002/(SICI)1097-0258(19980715)17:13<1517::AID-SIM859>3.0.CO;2-0; MALEC JF, 1991, ARCH PHYS MED REHAB, V72, P138; McCurren C, 1999, APPL NURS RES, V12, P185, DOI 10.1016/S0897-1897(99)80249-3; Morris JN, 1999, J GERONTOL A-BIOL, V54, pM546, DOI 10.1093/gerona/54.11.M546; PROCHASKA JO, 1991, CANCER-AM CANCER SOC, V67, P805, DOI 10.1002/1097-0142(19910201)67:3+<805::AID-CNCR2820671409>3.0.CO;2-4; PRYOR GA, 1988, LANCET, V1, P401; RICH MW, 1995, NEW ENGL J MED, V333, P1190, DOI 10.1056/NEJM199511023331806; ROCKWOOD K, 1993, J CLIN EPIDEMIOL, V46, P1113, DOI 10.1016/0895-4356(93)90110-M; Sager MA, 1996, J AM GERIATR SOC, V44, P251, DOI 10.1111/j.1532-5415.1996.tb00910.x; Shaughnessy PW, 1997, MED CARE, V35, P1225, DOI 10.1097/00005650-199712000-00007; Siu AL, 1996, ARCH INTERN MED, V156, P76, DOI 10.1001/archinte.156.1.76; SOLOMON DH, 1993, J AM GERIATR SOC, V41, P961, DOI 10.1111/j.1532-5415.1993.tb06762.x; Stessman J, 1996, J AM GERIATR SOC, V44, P591; Stinemann MG, 2000, J AM GERIATR SOC, V48, P1734, DOI 10.1111/j.1532-5415.2000.tb03893.x; Tinetti ME, 1999, ARCH PHYS MED REHAB, V80, P916, DOI 10.1016/S0003-9993(99)90083-7; Tinetti ME, 1997, ARCH PHYS MED REHAB, V78, P1237, DOI 10.1016/S0003-9993(97)90338-5; TINETTI ME, 1994, NEW ENGL J MED, V331, P821, DOI 10.1056/NEJM199409293311301; VLADECK BC, 1994, HEALTH CARE FINANC R, V16, P7; Von Korff M, 1997, ANN INTERN MED, V127, P1097, DOI 10.7326/0003-4819-127-12-199712150-00008	45	99	99	0	11	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 24	2002	287	16					2098	2105		10.1001/jama.287.16.2098	http://dx.doi.org/10.1001/jama.287.16.2098			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	542ZK	11966384	Bronze			2023-01-03	WOS:000175075700027
J	Check, E				Check, E			Alternative therapies leave US commission divided	NATURE			English	News Item																		Eisenberg DM, 1998, JAMA-J AM MED ASSOC, V280, P1569, DOI 10.1001/jama.280.18.1569	1	0	0	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAR 28	2002	416	6879					355	355		10.1038/416355b	http://dx.doi.org/10.1038/416355b			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	534UX	11919588	Bronze			2023-01-03	WOS:000174607800007
J	Tsai, E				Tsai, E			Should family members be present during cardiopulmonary resuscitation?	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							WATCH RESUSCITATION; RELATIVES; ROOM		Kingston Gen Hosp, Dept Pediat, Kingston, ON K7L 2V7, Canada	Queens University - Canada	Tsai, E (corresponding author), Kingston Gen Hosp, Dept Pediat, Watkins 3,76 Stuart St, Kingston, ON K7L 2V7, Canada.							ADAMS S, 1994, BRIT MED J, V308, P1687, DOI 10.1136/bmj.308.6945.1687; Back D, 1994, Nurs Times, V90, P34; Back K J, 1991, Pediatr Nurs, V17, P571; Barratt F, 1998, J ACCID EMERG MED, V15, P109; Bassler P C, 1999, J Nurses Staff Dev, V15, P126, DOI 10.1097/00124645-199905000-00007; Belanger M A, 1997, J Emerg Nurs, V23, P238, DOI 10.1016/S0099-1767(97)90015-5; Boie ET, 1999, ANN EMERG MED, V34, P70, DOI 10.1016/S0196-0644(99)70274-X; Boyd R, 2000, Eur J Emerg Med, V7, P51; Brown J R, 1989, Nursing, V19, P46; Connors P, 1996, Nurs Stand, V10, P42; CRISCI C, 1994, BRIT MED J, V309, P406; DOYLE CJ, 1987, ANN EMERG MED, V16, P673, DOI 10.1016/S0196-0644(87)80069-0; DUBIN WR, 1986, ANN EMERG MED, V15, P54, DOI 10.1016/S0196-0644(86)80488-7; Eichhorn D J, 1996, J Cardiovasc Nurs, V10, P59; *EM NURS ASS, 1995, PRES OPT FAM PRES; *EM NURS ASS, 1998, FAM PRES BEDS INV PR; GOLDSCHMIDT D, 2001, CNN MED NEWS    0504; Gyulay J E, 1989, Issues Compr Pediatr Nurs, V12, P71, DOI 10.3109/01460868909038030; Hanson C, 1992, J Emerg Nurs, V18, P104; Hartley D, 2001, JAMA-J AM MED ASSOC, V285, P380, DOI 10.1001/jama.285.4.380; Jarvis A S, 1998, Intensive Crit Care Nurs, V14, P3, DOI 10.1016/S0964-3397(98)80029-3; Meyers T A, 1998, J Emerg Nurs, V24, P400, DOI 10.1016/S0099-1767(98)70005-4; Meyers TA, 2000, AM J NURS, V100, P32, DOI 10.2307/3521954; Mitchell MH, 1997, J ACCID EMERG MED, V14, P366; Offord R J, 1998, Intensive Crit Care Nurs, V14, P288, DOI 10.1016/S0964-3397(98)80690-3; Osuagwu C C, 1991, J Emerg Nurs, V17, P363; Post H, 1989, Nursing, V19, P43; Rattrie E, 2000, Nurs Stand, V14, P32; Reese V, 1994, Nursing, V24, p32V; REESE V, 1994, NURSING, V24, pV32; Resuscitation Council (UK), 1996, SHOULD REL WITN RES; Robinson SM, 1998, LANCET, V352, P614, DOI 10.1016/S0140-6736(97)12179-1; SCHILLING RJ, 1994, BRIT MED J, V309, P406, DOI 10.1136/bmj.309.6951.406; TULLER D, 2001, NY TIMES        0515, pF6; 2000, CIRCULATION S1, V102, P12	35	47	49	0	4	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAR 28	2002	346	13					1019	1021		10.1056/NEJM200203283461312	http://dx.doi.org/10.1056/NEJM200203283461312			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	534UY	11919313				2023-01-03	WOS:000174608600011
J	O'Cathain, A; Walters, SJ; Nicholl, JP; Thomas, KJ; Kirkham, M				O'Cathain, A; Walters, SJ; Nicholl, JP; Thomas, KJ; Kirkham, M			Use of evidence based leaflets to promote informed choice in maternity care: randomised controlled trial in everyday practice	BRITISH MEDICAL JOURNAL			English	Article								Objective To assess the effect of leaflets on promoting informed choice in women using maternity services. Design Cluster trial, with maternity units randomised to use leaflets (intervention units) or offer usual care (control units). Data collected through postal questionnaires. Setting 13 maternity units in Wales. Participants Four separate samples of women using maternity services. Antenatal samples: women reaching 28 weeks' gestation before (n=1386) and after (n=1778) the intervention. Postnatal samples: women at eight weeks after delivery before (n=1741) and after (n=1547) the intervention. Intervention Provision of 10 pairs of Informed Choice leaflets for service users and midwives and a training session for staff in their use. Main outcome measures Change in the proportion of women who reported exercising informed choice. Secondary outcomes: changes in women's knowledge; satisfaction with information, choice, and discussion; and possible consequences of informed choice. Results There was no change in the proportion of women who reported that they exercised informed choice in the intervention units compared with the control units for either antenatal or postnatal women. There was a small increase in satisfaction with information in the antenatal samples in the intervention units compared with the control units (odds ratio 1.40, 95% confidence interval 1.05 to 1.88). Only three quarters of women in the intervention units reported being given at least one of the leaflets, indicating problems with the implementation of the intervention. Conclusion In everyday practice, evidence based leaflets were not effective in promoting informed choice in women using maternity services.	Univ Sheffield, Sch Hlth & Related Res, Sheffield S1 4DA, S Yorkshire, England; Univ Sheffield, Sch Nursing & Midwifery, Womens Informed Childbearing & Hlth Res Grp, Sheffield, S Yorkshire, England	University of Sheffield; University of Sheffield	O'Cathain, A (corresponding author), Univ Sheffield, Sch Hlth & Related Res, Regent Court, Sheffield S1 4DA, S Yorkshire, England.		Nicholl, Jon/B-8257-2008; Sandall, Jane/D-4146-2009	Sandall, Jane/0000-0003-2000-743X; Walters, Stephen/0000-0001-9000-8126				Charles Cathy, 2000, Health Expect, V3, P1, DOI 10.1046/j.1369-6513.2000.00085.x; Degner L F, 1997, Can J Nurs Res, V29, P21; DIEHR P, 1995, STAT MED, V14, P1491, DOI 10.1002/sim.4780141309; Entwistle Vikki A., 2000, Health Expect, V3, P77, DOI 10.1046/j.1369-6513.2000.00087.x; Holmes-Rovner Margaret, 2000, Health Expect, V3, P182, DOI 10.1046/j.1369-6513.2000.00093.x; KIRKHAM M, 2001, INFORMED CHOICE MATE; Murray D.M., 1998, DESIGN ANAL GROUP RA; O'Connor AM, 1999, BRIT MED J, V319, P731, DOI 10.1136/bmj.319.7212.731; OLIVER S, 1996, 7 CRD NHS CTR REV DI; *SAS I, 1989, SAS STAT US GUID VER, V2; Stapleton H, 2002, BMJ-BRIT MED J, V324, P639, DOI 10.1136/bmj.324.7338.639	11	65	63	0	6	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	MAR 16	2002	324	7338					643	646A		10.1136/bmj.324.7338.643	http://dx.doi.org/10.1136/bmj.324.7338.643			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	532QW	11895822	Green Published, Bronze			2023-01-03	WOS:000174487400022
J	Kaptchuk, TJ				Kaptchuk, TJ			Acupuncture: Theory, efficacy, and practice	ANNALS OF INTERNAL MEDICINE			English	Review							EVENTS FOLLOWING ACUPUNCTURE; ADVERSE EVENTS; ELECTROACUPUNCTURE ANALGESIA; ALTERNATIVE MEDICINE; CHINESE-MEDICINE; PLACEBO NEEDLE; CHRONIC PAIN; BACK-PAIN; BRAIN; METAANALYSIS	Traditionally, acupuncture is embedded in naturalistic theories that are compatible with Confucianism and Taoism. Such ideas as yin-yang, qi, dampness, and wind represent East Asian conceptual frameworks that emphasize the reliability of ordinary, human sensory awareness. Many physicians who practice acupuncture reject such prescientific notions. Numerous randomized, controlled trials and more than 25 systematic reviews and meta-analyses have evaluated the clinical efficacy of acupuncture. Evidence from these trials indicates that acupuncture is effective for emesis developing after surgery or chemotherapy in adults and for nausea associated with pregnancy, Good evidence exists that acupuncture is also effective for relieving dental pain. For such conditions as chronic pain, back pain, and headache, the data are equivocal or contradictory. Clinical research on acupuncture poses unique methodologic challenges. Properly performed acupuncture seems to be a safe procedure. Basic-science research provides evidence that begins to offer plausible mechanisms for the presumed physiologic effects of acupuncture. Multiple research approaches have shown that acupuncture activates endogenous opioid mechanisms. Recent data, obtained by using functional magnetic resonance imaging, suggest that acupuncture has regionally specific, quantifiable effects on relevant brain structures. Acupuncture may stimulate gene expression of neuropeptides. The training and provision of acupuncture care in the United States are rapidly expanding.	Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Div Res & Educ Complementary & Integrat Med Thera, Boston, MA 02215 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School	Kaptchuk, TJ (corresponding author), Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Div Res & Educ Complementary & Integrat Med Thera, 330 Brookline Ave, Boston, MA 02215 USA.				NCCIH NIH HHS [1R01AT00402-01] Funding Source: Medline; NIAMS NIH HHS [U24 AR43441] Funding Source: Medline; NATIONAL CENTER FOR COMPLEMENTARY &ALTERNATIVE MEDICINE [R01AT000402] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [U24AR043441] Funding Source: NIH RePORTER	NCCIH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Complementary & Alternative Medicine); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL CENTER FOR COMPLEMENTARY &ALTERNATIVE MEDICINE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Complementary & Alternative Medicine); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Araujo MS, 1998, FORSCH KOMPLEMENTMED, V5, P8; Astin JA, 1998, ARCH INTERN MED, V158, P2303, DOI 10.1001/archinte.158.21.2303; Barnes LL, 1998, CULT MED PSYCHIAT, V22, P413, DOI 10.1023/A:1005403825213; Bates DG, 2000, PERSPECT BIOL MED, V43, P502; Bensoussan A, 2000, ARCH FAM MED, V9, P1071, DOI 10.1001/archfami.9.10.1071; Bensoussan A, 1996, SAFER CHOICE PRACTIC; Berman BM, 1999, J FAM PRACTICE, V48, P213; BOSSUT DF, 1991, BRAIN RES, V549, P47, DOI 10.1016/0006-8993(91)90597-O; *BRIT MED ASS BOAR, 2000, AC EFF SAF PRACT; BUCINSKAITE V, 1994, BRAIN RES, V666, P128, DOI 10.1016/0006-8993(94)90294-1; CASE M, 1999, WALL STREET J   1126, pB1; CHAPMAN CR, 1983, PAIN, V16, P13, DOI 10.1016/0304-3959(83)90082-9; CHEN FP, 1990, ACUPUNCTURE ELECTRO, V15, P107, DOI 10.3727/036012990816358261; CHENG RSS, 1980, LIFE SCI, V26, P631, DOI 10.1016/0024-3205(80)90239-8; Cho ZH, 1998, P NATL ACAD SCI USA, V95, P2670, DOI 10.1073/pnas.95.5.2670; Connelly DM, 1994, TRADITIONAL ACUPUNCT; Cooper RA, 1998, JAMA-J AM MED ASSOC, V280, P795, DOI 10.1001/jama.280.9.795; DeWoskin Kenneth J., 1983, DOCTORS DIVINERS MAG; Diehl D L, 1997, J Altern Complement Med, V3, P119, DOI 10.1089/acm.1997.3.119; Dorfer L, 1999, LANCET, V354, P1023, DOI 10.1016/S0140-6736(98)12242-0; DUNG HC, 1985, CHINESE MED J-PEKING, V98, P835; EPLER DC, 1980, B HIST MED, V54, P337; Ernst E, 1995, Int J Risk Saf Med, V6, P179, DOI 10.3233/JRS-1995-6305; Ernst E, 1997, SCAND J RHEUMATOL, V26, P444, DOI 10.3109/03009749709065717; Ernst E, 1997, PAIN, V71, P123, DOI 10.1016/S0304-3959(97)03368-X; Ernst E, 1998, BRIT DENT J, V184, P443, DOI 10.1038/sj.bdj.4809654; Ernst E, 1999, ARCH OTOLARYNGOL, V125, P269, DOI 10.1001/archotol.125.3.269; Ernst E, 1998, ARCH INTERN MED, V158, P2235, DOI 10.1001/archinte.158.20.2235; Ernst E, 1996, Wien Med Wochenschr, V146, P556; Ernst E, 2001, AM J MED, V110, P481, DOI 10.1016/S0002-9343(01)00651-9; Ernst E, 1997, WIEN KLIN WOCHENSCHR, V109, P60; Ezzo J, 2000, PAIN, V86, P217, DOI 10.1016/S0304-3959(99)00304-8; Ezzo J, 2001, ARTHRITIS RHEUM, V44, P819, DOI 10.1002/1529-0131(200104)44:4<819::AID-ANR138>3.0.CO;2-P; Farquhar J., 1994, KNOWING PRACTICE CLI; Filshie J, 1998, MED ACUPUNCTURE W SC; Gao M, 1997, ACUPUNCTURE ELECTRO, V22, P161, DOI 10.3727/036012997816356662; GRACELY RH, 1985, LANCET, V1, P43; Guo HF, 1996, MOL BRAIN RES, V43, P167, DOI 10.1016/S0169-328X(96)00171-4; HAHN RA, 1982, CULT MED PSYCHIAT, V6, P219, DOI 10.1007/BF00114192; Hammerschlag R, 1998, J ALTERN COMPLEM MED, V4, P159, DOI 10.1089/acm.1998.4.159; Han JS, 1997, J ALTERN COMPLEM MED, V3, pS101, DOI DOI 10.1089/acm.1997.3.s-101; Harper D., 1998, EARLY CHINESE MED LI; HARRIS PE, 1997, COMPLEMENT THER MED, V5, P156; Hsu E, 1996, SOC SCI MED, V42, P421, DOI 10.1016/0277-9536(95)00106-9; HUAI LS, 1976, COMPREHENSIVE TXB, P17; Hui KKS, 2000, HUM BRAIN MAPP, V9, P13, DOI 10.1002/(SICI)1097-0193(2000)9:1<13::AID-HBM2>3.0.CO;2-F; JEWELL D, 2000, COCHRANE DATABASE SY; *JIANGS NEW MED I, 1977, ENC TRAD CHIN PHARM; Jobst K A, 1995, J Altern Complement Med, V1, P57; Kaptchuk TJ, 2000, J CLIN EPIDEMIOL, V53, P786, DOI 10.1016/S0895-4356(00)00206-7; Kaptchuk TJ, 1997, NEW ENGL J MED, V336, P1109; Kaptchuk TJ, 1999, JAMA-J AM MED ASSOC, V281, P1270, DOI 10.1001/jama.281.14.1270; Kaptchuk TJ, 1998, LANCET, V352, P992, DOI 10.1016/S0140-6736(05)61551-6; Kaptchuk TJ, 2001, JAMA-J AM MED ASSOC, V285, P1015, DOI 10.1001/jama.285.8.1015; KAPTCHUK TJ, 2001, FUNDAMENTALS COMPLEM, P43; KAPTCHUK TJ, 2000, NO WEAVER UNDERSTAND; KLARER S, 1997, ENCY HIST SCI TECHNO, P832; KLEIJNEN J, 1991, THORAX, V46, P799, DOI 10.1136/thx.46.11.799; KLEIN L, 1997, SERIES CURRENT BIBLI; Kleinman Arthur, 1995, WRITING MARGIN DISCO; Lao L, 1996, J Altern Complement Med, V2, P27, DOI 10.1089/acm.1996.2.27; LAW M, 1995, ARCH INTERN MED, V155, P1933, DOI 10.1001/archinte.155.18.1933; Lee A, 1999, ANESTH ANALG, V88, P1362, DOI 10.1097/00000539-199906000-00031; Lee ACC, 1999, WESTERN J MED, V171, P153; LINDE K, 2000, COCHRANE DATABASE SY; Linde K., 1999, ESSENTIALS COMPLEMEN, P57; LINDE K, 1996, FORSCH KOMPLEMENTMED, V3, P148; MacPherson H, 2001, BMJ-BRIT MED J, V323, P486, DOI 10.1136/bmj.323.7311.486; MacPherson H, 1999, J ALTERN COMPLEM MED, V5, P47, DOI 10.1089/acm.1999.5.47; MacPherson H, 1997, ACUPUNCTURE PRACTICE; McQuay HJ, 1998, EVIDENCE BASED RESOU; Melchart D, 1999, CEPHALALGIA, V19, P779, DOI 10.1046/j.1468-2982.1999.1909779.x; Melchart D, 1997, Altern Ther Health Med, V3, P33; MIURA K, 1989, TAOIST MEDITATION LO, P331; Murphy PA, 1998, OBSTET GYNECOL, V91, P149, DOI 10.1016/S0029-7844(97)00582-6; MUSSAT M, 1972, PHYSIQUE ACUPUNCTURE; Nahin RL, 2001, BRIT MED J, V322, P161, DOI 10.1136/bmj.322.7279.161; NIELSEN A, 1995, GUA SHA  TRADITIONAL; Norheim A J, 1996, J Altern Complement Med, V2, P291, DOI 10.1089/acm.1996.2.291; Park J, 2001, J NEUROL, V248, P558, DOI 10.1007/s004150170132; Park J, 2001, ARCH INTERN MED, V161, P894, DOI 10.1001/archinte.161.6.894; Park JB, 2000, ARCH OTOLARYNGOL, V126, P489, DOI 10.1001/archotol.126.4.489; PATEL M, 1989, INT J EPIDEMIOL, V18, P900, DOI 10.1093/ije/18.4.900; Peuker ET, 1999, ARCH FAM MED, V8, P553, DOI 10.1001/archfami.8.6.553; POMERANZ B, 1989, SCI BASES ACUPUNCTUR; RAMPES H, 1995, ACU MED, V12, P26; Ramsay DJ, 1998, JAMA-J AM MED ASSOC, V280, P1518; Roetz Heiner, 1993, CONFUCIAN ETHICS AXI; Rosted P, 1998, Oral Dis, V4, P100; Scheid V., 2001, INNOVATION CHINESE M; Shang C., 2001, CLIN ACUPUNCTURE SCI, P69; Smith LA, 2000, PAIN, V86, P119, DOI 10.1016/S0304-3959(00)00234-7; Streitberger K, 1998, LANCET, V352, P364, DOI 10.1016/S0140-6736(97)10471-8; SUN YM, 1984, INT J CHINESE MED, V1, P15; TERRIET G, 1990, J CLIN EPIDEMIOL, V43, P1191, DOI 10.1016/0895-4356(90)90020-P; TERRIET G, 1990, BRIT J GEN PRACT, V40, P379; Ulett GA, 1998, BIOL PSYCHIAT, V44, P129, DOI 10.1016/S0006-3223(97)00394-6; Unschuld Paul O., 1985, MED CHINA HIST IDEAS; van Tulder MW, 1999, SPINE, V24, P1113, DOI 10.1097/00007632-199906010-00011; Vernon H, 1999, Complement Ther Med, V7, P142; Vickers A. J., 1998, Complementary Therapies in Medicine, V6, P185, DOI 10.1016/S0965-2299(98)80026-5; Vickers AJ, 1996, J ROY SOC MED, V89, P303, DOI 10.1177/014107689608900602; Vincent C, 2001, BRIT MED J, V323, P467, DOI 10.1136/bmj.323.7311.467; VINCENT C, 1995, J ROY SOC MED, V88, P199; White A, 2001, BRIT MED J, V323, P485, DOI 10.1136/bmj.323.7311.485; White AR, 1999, RHEUMATOLOGY, V38, P143, DOI 10.1093/rheumatology/38.2.143; White AR, 1999, TOB CONTROL, V8, P393, DOI 10.1136/tc.8.4.393; WILLIAMS GH, 1986, LANCET, V2, P1435; Wu MT, 1999, RADIOLOGY, V212, P133, DOI 10.1148/radiology.212.1.r99jl04133; Yamashita H, 1998, JAMA-J AM MED ASSOC, V280, P1563, DOI 10.1001/jama.280.18.1563-a; Yamashita H, 2001, COMPLEMENT THER MED, V9, P98, DOI 10.1054/ctim.2001.0446; YE J, 1995, PHARM J, V255, pR37; Yong D., 1999, SMJ, V40, P260	113	558	576	13	197	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAR 5	2002	136	5					374	383		10.7326/0003-4819-136-5-200203050-00010	http://dx.doi.org/10.7326/0003-4819-136-5-200203050-00010			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	525VT	11874310				2023-01-03	WOS:000174095300005
J	Olfson, M; Marcus, SC; Druss, B; Elinson, L; Tanielian, T; Pincus, HA				Olfson, M; Marcus, SC; Druss, B; Elinson, L; Tanielian, T; Pincus, HA			National trends in the outpatient treatment of depression	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							MAJOR DEPRESSION; PRIMARY-CARE; COMORBIDITY-SURVEY; MENTAL-DISORDERS; ADDICTIVE-DISORDERS; REUPTAKE INHIBITORS; UNITED-STATES; HEALTH; PSYCHOTHERAPY; SERVICES	Context Recent advances in pharmacotherapy and changing health care environments have focused increased attention on trends in outpatient treatment of depression. Objective To compare trends in outpatient treatment of depressive disorders in the United States in 1987 and 1997. Design and Setting Analysis of service utilization data from 2 nationally representative surveys of the US general population, the 1987 National Medical Expenditure Survey (N=34459) and the 1997 Medical Expenditure Panel Survey (N=32636). Participants Respondents who reported making 1 or more outpatient visits for treatment of depression during that calendar year. Main Outcome Measures Rate of treatment, psychotropic medication use, psychotherapy; number of outpatient treatment visits, type of health care professional, and source of payment. Results The rate of outpatient treatment for depression increased from 0.73 per 100 persons in 1987 to 2.33 in 1997 (P<.001). The proportion of treated individuals who used antidepressant medications increased from 37.3% to 74.5% (P<.001), whereas the proportion who received psychotherapy declined (71.1% vs 60.2%, P=.006). The mean number of depression treatment visits per user declined from 12.6 to 8.7 per year (P=.05). An increasingly large proportion of patients were treated by physicians for their condition (68.9% vs 87.3%, P<.001), and treatment costs were more often covered by third-party payers (39.3% to 55.2%, P<.001). Conclusions Between 1987 and 1997, there was a marked increase in the proportion of the population who received outpatient treatment for depression. Treatment became characterized by greater involvement of physicians, greater use of psychotropic medications, and expanding availability of third-party payment, but fewer outpatient visits and less use of psychotherapy. These changes coincided with the advent of better-tolerated antidepressants, increased penetration of managed care, and the development of rapid and efficient procedures for diagnosing depression in clinical practice.	Columbia Univ Coll Phys & Surg, New York State Psychiat Inst, Dept Psychiat, New York, NY 10032 USA; Univ Penn, Sch Social Work, Philadelphia, PA 19104 USA; Yale Univ, Sch Med, Dept Psychiat, New Haven, CT USA; NIOSH, Pittsburgh Res Lab, Pittsburgh, PA USA; RAND Corp, Pittsburgh, PA USA; Univ Pittsburgh, Dept Psychiat, Pittsburgh, PA USA	Columbia University; New York State Psychiatry Institute; University of Pennsylvania; Yale University; Centers for Disease Control & Prevention - USA; National Institute for Occupational Safety & Health (NIOSH); RAND Corporation; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Olfson, M (corresponding author), Columbia Univ Coll Phys & Surg, New York State Psychiat Inst, Dept Psychiat, 1051 Riverside Dr, New York, NY 10032 USA.	olfsonm@child.cpmc.columbia.edu	Young, Alexander/A-1523-2009; Olfson, Mark/AAA-8547-2021	Young, Alexander/0000-0002-9367-9213; 				[Anonymous], 2000, Am J Psychiatry, V157, P1; BLAZER DG, 1994, AM J PSYCHIAT, V151, P979; COHEN S, 1991, 910037 AHCPR; COHEN SB, 2000, 010001 AHRQ; Dana RH, 1996, PSYCHOL REP, V79, P1395, DOI 10.2466/pr0.1996.79.3f.1395; *DEPR GUID PAN, 1993, 930551 AHCPR, V2; EDWARDS WS, 1989, US DHHS PHS893450; Frank RG, 1996, ARCH GEN PSYCHIAT, V53, P933; GOLDMAN R, 1986, SOC SCI MED, V22, P1047, DOI 10.1016/0277-9536(86)90205-4; Greenfield SF, 2000, AM J PSYCHIAT, V157, P1867, DOI 10.1176/appi.ajp.157.11.1867; Hirschfeld RMA, 2000, J CLIN PSYCHIAT, V61, P268, DOI 10.4088/JCP.v61n0405; Keller MB, 2000, NEW ENGL J MED, V342, P1462, DOI 10.1056/NEJM200005183422001; Kessler RC, 1999, AM J PSYCHIAT, V156, P115, DOI 10.1176/ajp.156.1.115; KESSLER RC, 1994, ARCH GEN PSYCHIAT, V51, P8; Kihlstrom LC, 1998, J BEHAV HEALTH SER R, V25, P367, DOI 10.1007/BF02287508; Langer F., 2000, USE ANTIDEPRESSANTS; Leon AC, 1996, J GEN INTERN MED, V11, P426, DOI 10.1007/BF02600191; Markowitz JC, 1999, CAN J PSYCHIAT, V44, P556, DOI 10.1177/070674379904400603; *MED EC CO INC, 1997, PHYS DESK REF; Murray CJL, 1996, SCIENCE, V274, P740, DOI 10.1126/science.274.5288.740; NARROW WE, 1993, ARCH GEN PSYCHIAT, V50, P95; Nelson JC, 1999, BIOL PSYCHIAT, V46, P1301, DOI 10.1016/S0006-3223(99)00173-0; Nikelly A G, 1995, Health Care Women Int, V16, P229; Olfson M, 1998, ARCH GEN PSYCHIAT, V55, P310, DOI 10.1001/archpsyc.55.4.310; Peretti S, 2000, ACTA PSYCHIAT SCAND, V101, P17, DOI 10.1111/j.1600-0447.2000.tb10944.x; Persons JB, 1996, ARCH GEN PSYCHIAT, V53, P283; REGIER DA, 1988, AM J PSYCHIAT, V145, P1351; REGIER DA, 1993, ARCH GEN PSYCHIAT, V50, P85; *ROP ORG, 1986, ROP REP MED PEOPL MI; Schatzberg AF, 1998, J CLIN PSYCHIAT, V59, P15; Shah BV, 1997, SUDAAN USERS MANUAL; SPITZER RL, 1995, JAMA-J AM MED ASSOC, V274, P1511, DOI 10.1001/jama.274.19.1511; SPITZER RL, 1994, JAMA-J AM MED ASSOC, V272, P1749, DOI 10.1001/jama.272.22.1749; Sturm R, 1999, J BEHAV HEALTH SER R, V26, P360, DOI 10.1007/BF02287297; Thase ME, 1997, ARCH GEN PSYCHIAT, V54, P1009; Trindade E, 1998, CAN MED ASSOC J, V159, P1245; *US DHHS, 1988, INT CLASS DIS 9 REV; Weissman MM, 1996, JAMA-J AM MED ASSOC, V276, P293, DOI 10.1001/jama.276.4.293; Wells KB, 1999, ARCH GEN PSYCHIAT, V56, P897, DOI 10.1001/archpsyc.56.10.897; WELLS KB, 1989, JAMA-J AM MED ASSOC, V262, P914, DOI 10.1001/jama.262.7.914; ZIMMERMAN M, 1994, GEN HOSP PSYCHIAT, V16, P388, DOI 10.1016/0163-8343(94)90114-7; 2001, MENT HLTH REPORT SUR	42	617	628	0	28	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 9	2002	287	2					203	209		10.1001/jama.287.2.203	http://dx.doi.org/10.1001/jama.287.2.203			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	508XK	11779262	Bronze			2023-01-03	WOS:000173114900022
J	Rotem, D; Sal-man, N; Schuldiner, S				Rotem, D; Sal-man, N; Schuldiner, S			In vitro monomer swapping in EmrE, a multidrug transporter from Escherichia coli, reveals that the oligomer is the functional unit	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NA+/H+ ANTIPORTER; MEMBRANE; BINDING; H+; GLUTAMATE; PROTEIN	EmrE is a small multidrug transporter, 110 amino acids long that extrudes various drugs in exchange with protons, thereby rendering Escherichia coli cells resistant to these compounds. Negative dominance studies and radiolabeled substrate-binding studies suggested that EmrE functions as an oligomer. Projection structure of two-dimensional crystals of the protein revealed an asymmetric dimer. To identify the functional unit of EmrE, a novel approach was developed. In this method, quantitative monomer swapping is induced in detergent-solubilized EmrE by exposure to 80 degreesC, a treatment that does not impair transport activity. Oligomer formation is highly specific as judged by several criteria, among them the fact that S-35-EmrE can be "pulled out" from a mixture prepared from generally labeled cells. Using this technique, we show that inactive mutant subunits are functionally complemented when mixed with wild type subunits. The hetero-oligomers thus formed display a decreased affinity to substrates. In addition, sulfhydryl reagents inhibit the above hetero-oligomer even though Cys residues are present only in the inactive monomer. It is concluded that, in EmrE, the oligomer is the functional unit.	Hebrew Univ Jerusalem, Alexander Silberman Inst Life Sci, IL-91904 Jerusalem, Israel	Hebrew University of Jerusalem	Schuldiner, S (corresponding author), Hebrew Univ Jerusalem, Alexander Silberman Inst Life Sci, IL-91904 Jerusalem, Israel.	Shimon.Schuldiner@huji.ac.il	Schuldiner, Shimon/F-7628-2012; Rotem, Dvir/G-1396-2013	Schuldiner, Shimon/0000-0002-4874-6237; Rotem, Dvir/0000-0002-1840-6530; Sal-Man, Neta/0000-0002-1109-479X	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R56NS016708, R01NS016708] Funding Source: NIH RePORTER; NINDS NIH HHS [NS16708] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Arkin IT, 1996, BIOCHEMISTRY-US, V35, P7233, DOI 10.1021/bi960094i; Eskandari S, 2000, P NATL ACAD SCI USA, V97, P8641, DOI 10.1073/pnas.97.15.8641; Friesen RHE, 2000, J BIOL CHEM, V275, P33527, DOI 10.1074/jbc.M004066200; Gerchman Y, 2001, BIOCHEMISTRY-US, V40, P3403, DOI 10.1021/bi002669o; GOLDBERG EB, 1987, P NATL ACAD SCI USA, V84, P2615, DOI 10.1073/pnas.84.9.2615; GOTTESMAN MM, 1993, ANNU REV BIOCHEM, V62, P385, DOI 10.1146/annurev.bi.62.070193.002125; Jack DL, 2000, J BACTERIOL, V182, P2311, DOI 10.1128/JB.182.8.2311-2313.2000; Kilic F, 2000, P NATL ACAD SCI USA, V97, P3106, DOI 10.1073/pnas.060408997; Lee A, 2000, J BACTERIOL, V182, P3142, DOI 10.1128/JB.182.11.3142-3150.2000; Mordoch SS, 1999, J BIOL CHEM, V274, P19480, DOI 10.1074/jbc.274.27.19480; Muth TR, 2000, EMBO J, V19, P234, DOI 10.1093/emboj/19.2.234; NIKAIDO H, 1994, SCIENCE, V264, P382, DOI 10.1126/science.8153625; Ninio S, 2001, J BIOL CHEM, V276, P48250, DOI 10.1074/jbc.M108231200; Schroers A, 1998, J BIOL CHEM, V273, P14269, DOI 10.1074/jbc.273.23.14269; Schuldiner S, 2001, J MOL MICROB BIOTECH, V3, P155; Schuldiner S, 2001, NEWS PHYSIOL SCI, V16, P130; Schwaiger M, 1998, EUR J BIOCHEM, V254, P610, DOI 10.1046/j.1432-1327.1998.2540610.x; TABOR S, 1985, P NATL ACAD SCI USA, V82, P1074, DOI 10.1073/pnas.82.4.1074; Tate CG, 2001, EMBO J, V20, P77, DOI 10.1093/emboj/20.1.77; Veenhoff LM, 2001, EMBO J, V20, P3056, DOI 10.1093/emboj/20.12.3056; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9; Yerushalmi H, 2000, BIOCHEMISTRY-US, V39, P14711, DOI 10.1021/bi001892i; Yerushalmi H, 2000, FEBS LETT, V476, P93, DOI 10.1016/S0014-5793(00)01677-X; YERUSHALMI H, 1995, J BIOL CHEM, V270, P6856, DOI 10.1074/jbc.270.12.6856; Yerushalmi H, 2001, J BIOL CHEM, V276, P12744, DOI 10.1074/jbc.M010979200; Yerushalmi H, 1996, J BIOL CHEM, V271, P31044, DOI 10.1074/jbc.271.49.31044	26	60	62	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 21	2001	276	51					48243	48249		10.1074/jbc.M108229200	http://dx.doi.org/10.1074/jbc.M108229200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	505QL	11572877	hybrid			2023-01-03	WOS:000172927000068
J	Muthuswamy, P; Alausa, M; Reilly, B				Muthuswamy, P; Alausa, M; Reilly, B			The effusion that would not go away.	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Cook Cty Hosp, Dept Med, Chicago, IL 60612 USA; Rush Med Coll, Chicago, IL 60612 USA	John H Stroger Junior Hospital Cook County; Rush University	Reilly, B (corresponding author), Cook Cty Hosp, Dept Med, 1835 W Harrison St, Chicago, IL 60612 USA.							Heffner JE, 1997, CHEST, V111, P970, DOI 10.1378/chest.111.4.970; Kassirer JP., 2009, LEARNING CLIN REASON; Light R, 1995, PLEURAL DIS; Sackett D.L., 1991, CLIN EPIDEMIOLOGY BA, V2nd; WAHL GW, 1999, DIAGNOSTIC STRATEGIE, P349; WRIGHT RS, 1994, CHEST, V106, P950, DOI 10.1378/chest.106.3.950	6	14	14	0	0	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	SEP 6	2001	345	10					756	759		10.1056/NEJMcps011343	http://dx.doi.org/10.1056/NEJMcps011343			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	468RX	11547746				2023-01-03	WOS:000170772900009
J	Farmer, P; Leandre, F; Mukherjee, JS; Claude, MS; Nevil, P; Smith-Fawzi, MC; Koenig, SP; Castro, A; Becerra, MC; Sachs, J; Attaran, A; Kim, JY				Farmer, P; Leandre, F; Mukherjee, JS; Claude, MS; Nevil, P; Smith-Fawzi, MC; Koenig, SP; Castro, A; Becerra, MC; Sachs, J; Attaran, A; Kim, JY			Community-based approaches to HIV treatment in resource-poor settings	LANCET			English	Editorial Material							IMMUNODEFICIENCY-VIRUS TYPE-1; WEIGHT-LOSS; TUBERCULOSIS; TRANSMISSION; PROGRESSION; INFECTION; MORTALITY; SURVIVAL; DISEASES; AIDS		Harvard Univ, Sch Med, Dept Social Med, Boston, MA 02115 USA; Ctr Thomas J White, Cange, Haiti; Harvard Univ, Ctr Int Dev, Boston, MA 02115 USA	Harvard University; Harvard Medical School; Harvard University	Farmer, P (corresponding author), Harvard Univ, Sch Med, Dept Social Med, Boston, MA 02115 USA.	paul_farmer@hms.harvard.edu	Castro, Arachu/L-6664-2014	Castro, Arachu/0000-0003-0428-9174				[Anonymous], 1992, AIDS WORLD; BLATT SP, 1995, J INFECT DIS, V171, P837, DOI 10.1093/infdis/171.4.837; *CDCP, 1996, MMWR-MORBID MORTAL W, V45, P468; *CENTR INT AG, 2001, WORLD FACTB 2000; CHAN ISF, 1995, AIDS, V9, P1145, DOI 10.1097/00002030-199510000-00005; CONNOR EM, 1994, NEW ENGL J MED, V331, P1173, DOI 10.1056/NEJM199411033311801; DESCHAMPS MM, 1993, J ACQ IMMUN DEF SYND, V6, P446; Farmer P, 1991, Semin Respir Infect, V6, P254; Farmer P, 1998, BRIT MED J, V317, P671, DOI 10.1136/bmj.317.7159.671; Farmer P, 1998, INT J TUBERC LUNG D, V2, P869; Farmer P, 1997, AIDS Clin Care, V9, P83; Farmer P, 1997, ANTHR INFECT DIS, P413; Farmer Paul, 1996, WOMEN POVERTY AIDS S; Farmer Paul E., 2000, CATHOLIC ETHICISTS H, P108; FARMER PE, 2000, J RESP DIS, V21, P53; FARMER PE, 2000, EMERGENCE AIDS IMPAC, P139; Farmer PE, 2000, NATL AIDS B, V13, P6; FARMER PE, 2000, LUNG BIOL HEALTH DIS, V144, P447; Freedberg KA, 2001, NEW ENGL J MED, V344, P824, DOI 10.1056/NEJM200103153441108; FUCHS D, 1993, EUR J HAEMATOL, V50, P90; Garber AM, 2000, HANDB ECON, V17, P181; GARRETT L, 2000, NEWSDAY         1129; Gebo KA, 1999, AIDS, V13, P963, DOI 10.1097/00002030-199905280-00013; GELLMAN B, 2000, WASHINGTON POST 0705, P1; GRAHAM NMH, 1993, AM J EPIDEMIOL, V137, P439, DOI 10.1093/oxfordjournals.aje.a116692; GUPTA R, 2000, P M CAMBR MA JUL 5 6; *INT FED RED CROSS, 2000, WORLD DIS REP 2000; *JOINT UN PROGR HI, 2000, REP GLOB HIV AIDS EP; *JOINT UN PROGR HI, 2000, AIDS EP UPD; Mayaud P, 1998, LANCET, V351, P29; McNeil D G Jr, 2000, N Y Times Web; Mocroft A, 1998, LANCET, V352, P1725, DOI 10.1016/S0140-6736(98)03201-2; Moore RD, 1999, AIDS, V13, P1933, DOI 10.1097/00002030-199910010-00017; Palella FJ, 1998, NEW ENGL J MED, V338, P853, DOI 10.1056/NEJM199803263381301; *PAN I, 2000, OUR MEANS COST TREAT; Pecoul B, 1999, JAMA-J AM MED ASSOC, V281, P361, DOI 10.1001/jama.281.4.361; Quinn TC, 2000, NEW ENGL J MED, V342, P921, DOI 10.1056/NEJM200003303421303; Raviglione MC, 1997, LANCET, V350, P624, DOI 10.1016/S0140-6736(97)04146-9; SUMARTOJO E, 1993, AM REV RESPIR DIS, V147, P1311, DOI 10.1164/ajrccm/147.5.1311; United Nations Development Program, 2000, HUM DEV REP 2000; Wheeler DA, 1998, J ACQ IMMUN DEF SYND, V18, P80, DOI 10.1097/00042560-199805010-00012; *WORLD BANK, 1997, 366 WDP; 1973, BMJ, V4, P568	43	338	346	0	5	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	AUG 4	2001	358	9279					404	409		10.1016/S0140-6736(01)05550-7	http://dx.doi.org/10.1016/S0140-6736(01)05550-7			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	459DE	11502340				2023-01-03	WOS:000170235100035
J	Stamp, G; Kruzins, G; Crowther, C				Stamp, G; Kruzins, G; Crowther, C			Perineal massage in labour and prevention of perineal trauma: randomised controlled trial	BMJ-BRITISH MEDICAL JOURNAL			English	Article							CHILDBIRTH; PREGNANCY	Objective To determine the effects of perineal massage in the second stage of labour on perineal outcomes. Design Randomised controlled trial. Participants at 36 weeks' gestation, women expecting normal birth of a singleton were asked to join the study. Women became eligible to be randomised in labour if they progressed to full dilatation of the cervix or 8 cm or more if nulliparous or 5 cm or more if multiparous. 1340 were randomised into the trial. Intervention Massage and sc-etching of the perineum during the second stage of labour with a water soluble lubricant. Main outcome measures Primary outcomes: rates of intact perineum, episiotomies, and first, second, third, and fourth degree tears. Secondary outcomes: pain at three and 10 days postpartum and pain, dyspareunia, resumption of sexual intercourse, and urinary and faecal incontinence and urgency three months postpartum. Results Rates of intact perineums, first and second degree tears, and episiotomies were similar in the massage and the control groups. There were fewer third degree tears in the massage group (12 (1.7%) v 23 (3.6%); absolute risk 2.11, relative risk 0.45; 95% confidence interval 0.23 to 0.93, P < 0.04), though the trial was underpowered to measure this rarer outcome. Groups did not differ in any of the secondary outcomes at the three assessment points. Conclusions The practice of perineal massage in labour does not increase the likelihood of an intact perineum or reduce the risk of pain, dyspareunia, or urinary and faecal problems.	Univ S Australia, Ctr Res Nursing & Hlth Care, Adelaide, SA 5000, Australia; N Adelaide Hlth Serv, Adelaide, SA 5000, Australia; Womens & Childrens Hosp, Adelaide, SA 5006, Australia; Univ Adelaide, Womens & Childrens Hosp, Dept Obstet & Gynaecol, Adelaide, SA, Australia	University of South Australia; Womens & Childrens Hospital Australia; University of Adelaide; Womens & Childrens Hospital Australia	Stamp, G (corresponding author), Univ S Australia, Ctr Res Nursing & Hlth Care, N Terrace, Adelaide, SA 5000, Australia.	georgie.stamp@unisa.edu.au						BALL JA, 1993, MYLES TXB MIDWIVES, P478; CAROLI G, 2001, COCHRANE DATABASE SY; CHAN A, 1998, PREGNANCY OUTCOME S; DEAN AG, 1994, EPIINFO VERSION L WO; Enkin M, 2000, KEIRSE CHALMERS; FLINT C, 1986, SENSITIVE MIDWIFERY, P101; GASKIN IM, 1978, SPIRITUAL MIDWIFERY, P360; Johanson R, 2000, LANCET, V355, P250, DOI 10.1016/S0140-6736(00)00020-9; Kitzinger S, 1984, EPISIOTOMY 2 STAGE L, V2nd; KLEIN MC, 1994, AM J OBSTET GYNECOL, V171, P591, DOI 10.1016/0002-9378(94)90070-1; Labrecque H, 2000, AM J OBSTET GYNECOL, V182, P76, DOI 10.1016/S0002-9378(00)70493-5; Labrecque M, 1999, AM J OBSTET GYNECOL, V180, P593, DOI 10.1016/S0002-9378(99)70260-7; MYLES MF, 1953, TXB MIDWIVES, P304; Renfrew MJ, 1998, BIRTH-ISS PERINAT C, V25, P143; Shipman MK, 1997, BRIT J OBSTET GYNAEC, V104, P787, DOI 10.1111/j.1471-0528.1997.tb12021.x; SLEEP J, 1984, BRIT MED J, V289, P587, DOI 10.1136/bmj.289.6445.587; Sleep J, 1989, EFFECTIVE CARE PREGN, P1129; SLEEP J, 1993, MYLES TXB MIDWIVES, P199; Stamp GE, 1997, MIDWIFERY, V13, P100, DOI 10.1016/S0266-6138(97)90063-2; STAMP GE, IN PRESS AUST J MID	20	65	70	1	20	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	MAY 26	2001	322	7297					1277	1280		10.1136/bmj.322.7297.1277	http://dx.doi.org/10.1136/bmj.322.7297.1277			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	437YW	11375230	Bronze, Green Submitted, Green Published			2023-01-03	WOS:000169027800019
J	[Anonymous]				[Anonymous]			THE RIGHT-TO-DIE	BRITISH MEDICAL JOURNAL			English	Editorial Material																			0	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JAN 1	1994	308	6920					66	66						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MQ096	11644505				2023-01-03	WOS:A1994MQ09600081
J	Yeni, PG; Hammer, SM; Carpenter, CCJ; Cooper, DA; Fischl, MA; Gatell, JM; Gazzard, BG; Hirsch, MS; Jacobsen, DM; Katzenstein, DA; Montaner, JSG; Richman, DD; Saag, MS; Schechter, M; Schooley, RT; Thompson, MA; Vella, S; Volberding, PA				Yeni, PG; Hammer, SM; Carpenter, CCJ; Cooper, DA; Fischl, MA; Gatell, JM; Gazzard, BG; Hirsch, MS; Jacobsen, DM; Katzenstein, DA; Montaner, JSG; Richman, DD; Saag, MS; Schechter, M; Schooley, RT; Thompson, MA; Vella, S; Volberding, PA			Antiretroviral treatment for adult HIV infection in 2002 - Updated recommendations of the international AIDS Society-USA panel	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Review							HUMAN-IMMUNODEFICIENCY-VIRUS; PROTEASE INHIBITOR THERAPY; STRUCTURED TREATMENT INTERRUPTIONS; CD4 CELL COUNT; PLASMA VIRAL LOAD; VIROLOGICAL RESPONSE; DRUG SUSCEPTIBILITY; HIV-1-INFECTED PATIENTS; RANDOMIZED-TRIAL; LACTIC-ACIDOSIS	Objective New information warrants updated recommendations for the 4 central issues in antiretroviral therapy: when to start, what drugs to start with, when to change, and what to change to. These updated recommendations are intended to guide practicing physicians actively involved in human immunodeficiency virus (HIV)- and acquired immunodeficiency syndrome (AIDS)-related care. Participants In 1995, physicians with specific expertise in HIV-related basic science and clinical research, antiretroviral therapy, and HIV patient care were invited by the International AIDS Society-USA to serve on a volunteer panel. In 1999, others were invited to broaden international representation. The 17-member panel met regularly in closed meetings between its last report in 2000 and April 2002 to review current data. The effort was sponsored and funded by the International AIDS Society-USA, a not-for-profit physician education organization. Evidence and Consensus Process The full panel was convened in late 2000 and assigned 7 section committees. A section writer and 3 to 5 section committee members (each panel member served on numerous sections) identified relevant evidence and prepared draft recommendations. Basic science, clinical research, and epidemiologic data from the published literature and abstracts from recent (within 2 years) scientific conferences were considered by strength of evidence. Extrapolations from basic science data and expert opinion of the panel members were included as evidence. Draft sections were combined and circulated to the entire panel and discussed in a series of full-panel conference calls until consensus was reached. Final recommendations represent full consensus agreement of the panel. Conclusions Because of increased awareness of the activity and toxicity of current drugs, the threshold for initiation of therapy has shifted to a later time in the course of HIV disease. However, the optimal time to initiate therapy remains imprecisely defined. Availability of new drugs has broadened options for therapy initiation and management of treatment failure, which remains a difficult challenge.	Int AIDS Soc USA, San Francisco, CA 94129 USA; Columbia Univ Coll Phys & Surg, New York, NY 10032 USA; Brown Univ, Sch Med, Providence, RI 02912 USA; Univ New S Wales, Sydney, NSW, Australia; Univ Miami, Sch Med, Miami, FL USA; Univ Barcelona, Hosp Clin, Barcelona, Spain; Chelsea & Westminster Hosp, London, England; Harvard Univ, Sch Med, Boston, MA USA; Hop Bichat Claude Bernard, Dept Infect Dis, X Bichat Med Sch, F-75877 Paris 18, France; Stanford Univ, Med Ctr, Stanford, CA 94305 USA; Univ British Columbia, Vancouver, BC V5Z 1M9, Canada; Univ Calif San Diego, La Jolla, CA 92093 USA; San Diego VA Healthcare Syst, San Diego, CA USA; Univ Alabama Birmingham, Birmingham, AL USA; Univ Fed Rio de Janeiro, BR-21941 Rio De Janeiro, Brazil; Univ Colorado, Sch Med, Denver, CO USA; AIDS Res Consortium Atlanta, Atlanta, GA USA; Ist Super Sanita, I-00161 Rome, Italy; Univ Calif San Francisco, San Francisco, CA 94143 USA; San Francisco VA Med Ctr, San Francisco, CA USA	Columbia University; Brown University; University of New South Wales Sydney; University of Miami; University of Barcelona; Hospital Clinic de Barcelona; Imperial College London; Harvard University; Harvard Medical School; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Bichat-Claude Bernard - APHP; UDICE-French Research Universities; Universite Paris Cite; Stanford University; University of British Columbia; University of California System; University of California San Diego; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA San Diego Healthcare System; University of Alabama System; University of Alabama Birmingham; Universidade Federal do Rio de Janeiro; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; Istituto Superiore di Sanita (ISS); University of California System; University of California San Francisco; US Department of Veterans Affairs; Veterans Health Administration (VHA); San Francisco VA Medical Center	Yeni, PG (corresponding author), Int AIDS Soc USA, 1001 B OReilly Ave, San Francisco, CA 94129 USA.	patrick.yeni@bch.ap-hop-paris.fr	Vella, Stefano/GZM-0519-2022; VELLA, STEFANO/ABI-3368-2020; VELLA, STEFANO/V-8440-2019	VELLA, STEFANO/0000-0003-2347-5984; katzenstein, david/0000-0002-8593-4560				*ABB LAB, 2000, NORV; *AG PHARM CO, 2001, VIR; *AG PHARM CO, 2001, RESCR DEL; Arpadi SM, 2002, J ACQ IMMUN DEF SYND, V29, P450, DOI 10.1097/00126334-200204150-00004; Bangsberg DR, 2000, AIDS, V14, P357, DOI 10.1097/00002030-200003100-00008; Barouch DH, 2000, P NATL ACAD SCI USA, V97, P4192, DOI 10.1073/pnas.050417697; Baxter JD, 2000, AIDS, V14, pF83, DOI 10.1097/00002030-200006160-00001; Behrens G, 1999, AIDS, V13, pF63, DOI 10.1097/00002030-199907090-00001; Benson CA, 2002, J INFECT DIS, V185, P599, DOI 10.1086/339014; BERNSTEIN B, 2001, 8 C RETR OPP INF FEB; Bossi P, 2000, CLIN INFECT DIS, V30, P227, DOI 10.1086/313629; Bourezane Y, 1998, CLIN INFECT DIS, V27, P1321, DOI 10.1086/517713; Brambilla D, 1999, AIDS, V13, P2269, DOI 10.1097/00002030-199911120-00009; Brivet FG, 2000, J HEPATOL, V32, P364, DOI 10.1016/S0168-8278(00)80088-4; BRUNVEZINET F, 2000, ANTIVIR THER S, V5, P78; BURGER DM, 2001, 2 INT WORKSH CLIN PH; CAHN P, 2001, 1 INT AIDS SOC C HIV; Call SA, 2001, J INFECT DIS, V183, P401, DOI 10.1086/318078; Cameron DW, 1999, AIDS, V13, P213, DOI 10.1097/00002030-199902040-00009; Carcelain G., 1999, Journal de la Societe de Biologie, V193, P5; Carpenter CCJ, 2000, JAMA-J AM MED ASSOC, V283, P381, DOI 10.1001/jama.283.3.381; Carr A, 1998, AIDS, V12, pF51, DOI 10.1097/00002030-199807000-00003; Carr A, 2000, LANCET, V356, P1423, DOI 10.1016/S0140-6736(00)02854-3; *CDCP, 2001, MMWR-MORBID MORTAL W, V49, P1153, DOI DOI 10.1097/01.INF.0000035031.50613.44; CHAISSON RE, 1987, AM REV RESPIR DIS, V136, P570, DOI 10.1164/ajrccm/136.3.570; Chaisson RE, 2000, JAMA-J AM MED ASSOC, V284, P3128, DOI 10.1001/jama.284.24.3128; CHEN R, 2001, 8 C RETR OPP INF FEB; CHEN RY, 2001, 41 INT C ANT AG CHEM; Cleeman JI, 2001, JAMA-J AM MED ASSOC, V285, P2486, DOI 10.1001/jama.285.19.2486; Clements-Mann ML, 1998, J INFECT DIS, V177, P1230, DOI 10.1086/515288; Coghlan ME, 2001, CLIN INFECT DIS, V33, P1914, DOI 10.1086/323783; Cohen CJ, 2002, AIDS, V16, P579, DOI 10.1097/00002030-200203080-00009; CROWE SM, 1991, J ACQ IMMUN DEF SYND, V4, P770; DAQUILA RT, 2002, TOPICS HIV MED, V10, P11; Davey RT, 2000, JAMA-J AM MED ASSOC, V284, P183, DOI 10.1001/jama.284.2.183; Davey RT, 1999, J INFECT DIS, V179, P849, DOI 10.1086/314678; Deeks SG, 2001, NEW ENGL J MED, V344, P472, DOI 10.1056/NEJM200102153440702; Deeks SG, 2000, J INFECT DIS, V181, P946, DOI 10.1086/315334; Deeks SG, 2002, J INFECT DIS, V185, P315, DOI 10.1086/338467; Deeks SG, 2000, CLIN INFECT DIS, V30, pS177, DOI 10.1086/313855; DeGruttola V, 2000, ANTIVIR THER, V5, P41; DeHovitz JA, 2000, J INFECT DIS, V182, P1527, DOI 10.1086/315875; Demeter LM, 2001, ANN INTERN MED, V135, P954, DOI 10.7326/0003-4819-135-11-200112040-00007; DeSimone JA, 2000, ANN INTERN MED, V133, P447, DOI 10.7326/0003-4819-133-6-200009190-00013; DUBE MP, 2000, ANTIVIR THER S5, V5, P26; *DUP PHARM CO, 2000, SUST; Dybul M, 2001, P NATL ACAD SCI USA, V98, P15161, DOI 10.1073/pnas.261568398; EASTERBROOK PJ, 2001, 8 C RETR OPP INF FEB; Echevarria KL, 1999, ANN PHARMACOTHER, V33, P859, DOI 10.1345/aph.18174; EGGER M, 2001, 41 INT C ANT AG CHEM; Farzadegan H, 1998, LANCET, V352, P1510, DOI 10.1016/S0140-6736(98)02372-1; Finzi D, 1999, NAT MED, V5, P512, DOI 10.1038/8394; FISCHL M, 2000, 7 C RETR OPP INF JAN; FISCHL M, 2001, 8 C RETR OPP INF FEB; Fletcher CV, 2000, AIDS, V14, P2495, DOI 10.1097/00002030-200011100-00011; Flexner C, 2000, ANNU REV PHARMACOL, V40, P649, DOI 10.1146/annurev.pharmtox.40.1.649; FORTGANG IS, 1995, AM J GASTROENTEROL, V90, P1433; Garcia F, 2001, AIDS, V15, pF29, DOI 10.1097/00002030-200106150-00002; GERBER JG, 2002, TOP HIV MED, V10, P27; *GLAX, 2001, ZIAG AB; *GLAX SMITH KLIN, 2001, AG AMPR; Glesby MJ, 2001, J INFECT DIS, V184, P519, DOI 10.1086/322779; GRANT RM, 2001, 8 C RETR OPP INF FEB; GREENBERG BH, 1977, ANN INTERN MED, V87, P526, DOI 10.7326/0003-4819-87-5-526; GULICK R, 2001, 1 INT AIDS SOC C HIV; Gulick RM, 2000, J INFECT DIS, V182, P1375, DOI 10.1086/315867; Hammer SM, 1997, NEW ENGL J MED, V337, P725, DOI 10.1056/NEJM199709113371101; Hance AJ, 2001, J VIROL, V75, P6410, DOI 10.1128/JVI.75.14.6410-6417.2001; Haubrich RH, 2001, CLIN INFECT DIS, V33, P1060, DOI 10.1086/322636; HAUBRICH RH, 2000, TOP HIV MED, V8, P9; Havlir DV, 2001, JAMA-J AM MED ASSOC, V286, P171, DOI 10.1001/jama.286.2.171; Havlir DV, 1998, NEW ENGL J MED, V339, P1261, DOI 10.1056/NEJM199810293391801; Havlir DV, 2001, AIDS, V15, P1379, DOI 10.1097/00002030-200107270-00007; Hirsch MS, 2000, JAMA-J AM MED ASSOC, V283, P2417, DOI 10.1001/jama.283.18.2417; Hirsch MS, 1998, JAMA-J AM MED ASSOC, V279, P1984, DOI 10.1001/jama.279.24.1984; HIRSCHTICK RE, 1995, NEW ENGL J MED, V333, P845, DOI 10.1056/NEJM199509283331305; Hockett RD, 1999, J EXP MED, V189, P1545, DOI 10.1084/jem.189.10.1545; Hogg RS, 1998, JAMA-J AM MED ASSOC, V279, P450, DOI 10.1001/jama.279.6.450; Hogg RS, 2001, JAMA-J AM MED ASSOC, V286, P2568, DOI 10.1001/jama.286.20.2568; Hughes MD, 1997, ANN INTERN MED, V126, P929, DOI 10.7326/0003-4819-126-12-199706150-00001; *INT AIDS SOC US R, 2002, UPD DRUG RES MUT HIV; Junghans C, 1999, LANCET, V353, P589, DOI 10.1016/S0140-6736(05)75645-2; KAHN SE, 1989, DIABETES, V38, P562, DOI 10.2337/diabetes.38.5.562; KAPLAN J, 2001, 8 C RETR OPP INF FEB; Kaufmann GR, 2000, AIDS, V14, P959, DOI 10.1097/00002030-200005260-00007; Kemper CA, 2001, AIDS, V15, P609, DOI 10.1097/00002030-200103300-00010; Kempf DJ, 1998, AIDS, V12, pF9, DOI 10.1097/00002030-199805000-00001; KERULY JC, 2001, 8 C RETR OPP INF FEB; Kessler HA, 2002, CLIN INFECT DIS, V34, P535, DOI 10.1086/338638; Kilby JM, 1997, AIDS RES HUM RETROV, V13, P1533, DOI 10.1089/aid.1997.13.1533; Kim S, 2000, AIDS RES HUM RETROV, V16, P645, DOI 10.1089/088922200308873; KING M, 2001, 8 C RETR OPP INF FEB; KNOBEL H, 2001, 8 C RETR OPP INF FEB; KOVACS JA, 1995, NEW ENGL J MED, V332, P567, DOI 10.1056/NEJM199503023320904; KUROWSKI M, 2000, 40 INT C ANT AG CHEM; KUROWSKI M, 2001, 1 INT AIDS SOC C HIV; LANIER ER, 2001, 8 C RETR OPP INF FEB; LAWAL A, 2001, 8 C RETR OPP INF FEB; Le Moing V, 2002, J INFECT DIS, V185, P471, DOI 10.1086/338929; Lenzo NP, 1997, AIDS, V11, P1294, DOI 10.1097/00002030-199710001-00003; Lepri AC, 2001, AIDS, V15, P47, DOI 10.1097/00002030-200101050-00008; Leri F, 1999, AIDS, V13, P1433, DOI 10.1097/00002030-199908200-00001; Levy Y, 1999, LANCET, V353, P1923, DOI 10.1016/S0140-6736(98)07345-0; LEWIS W, 1995, NAT MED, V1, P417, DOI 10.1038/nm0595-417; Li TS, 1998, LANCET, V351, P1682, DOI 10.1016/S0140-6736(97)10291-4; Little SJ, 1999, JAMA-J AM MED ASSOC, V282, P1142, DOI 10.1001/jama.282.12.1142; Lo JC, 1998, LANCET, V351, P867, DOI 10.1016/S0140-6736(97)11443-X; Lonergan JT, 2000, CLIN INFECT DIS, V31, P162, DOI 10.1086/313912; Lori F, 2001, JAMA-J AM MED ASSOC, V286, P2981, DOI 10.1001/jama.286.23.2981; LOUIE M, 2002, 9 C RETR OPP INF FEB; Lyles RH, 2000, J INFECT DIS, V181, P872, DOI 10.1086/315339; MacGregor RR, 1998, J INFECT DIS, V178, P92, DOI 10.1086/515613; Mallal S, 2002, LANCET, V359, P727, DOI 10.1016/S0140-6736(02)07873-X; Marschner IC, 1998, J INFECT DIS, V177, P40, DOI 10.1086/513823; MCGOWAN I, 2001, 8 C RETR OPP INF FEB; Melby T, 2001, 8 C RETR OPP INF FEB; Mellors JW, 1997, ANN INTERN MED, V126, P946, DOI 10.7326/0003-4819-126-12-199706150-00003; MEYER D, 2000, ANTIVIR THER, V5, P54; Miller MD, 2001, NUCLEOS NUCLEOT NUCL, V20, P1025, DOI 10.1081/NCN-100002483; Miller V, 2000, ANTIVIR THER, V5, P49; Miller V, 2000, AIDS, V14, P2857, DOI 10.1097/00002030-200012220-00007; MILLER V, 2002, 9 C RETR OPP INF FEB; Mocroft A, 2000, AIDS, V14, P1545, DOI 10.1097/00002030-200007280-00010; MONTANER J, 2000, 13 INT C AIDS JUL 9; MONTANER JSG, 2001, 41 INT C ANT AG CHEM; MOYLE GJ, 2001, ANTIVIR THER S4, V6, P66; MOYLE GJ, 2001, 3 INT WORKSH ADV DRU; Mulligan K, 2000, J ACQ IMMUN DEF SYND, V23, P35, DOI 10.1097/00042560-200001010-00005; Murphy RL, 1999, J INFECT DIS, V179, P808, DOI 10.1086/314668; Murphy RL, 2001, AIDS, V15, pF1, DOI 10.1097/00002030-200101050-00002; MURPHY RL, 1999, 39 INT C ANT AG CHEM; *NAT CHOL ED PROGR, 1994, CIRCULATION, V89, P1333; Neuvonen PJ, 1998, CLIN PHARMACOL THER, V63, P332, DOI 10.1016/S0009-9236(98)90165-5; Neuvonen PJ, 1996, CLIN PHARMACOL THER, V60, P54, DOI 10.1016/S0009-9236(96)90167-8; Noor MA, 2001, AIDS, V15, pF11, DOI 10.1097/00002030-200105040-00001; OPRAVIL M, 2001, 8 C RETR OPP INF FEB; Palella FJ, 1998, NEW ENGL J MED, V338, P853, DOI 10.1056/NEJM199803263381301; Palmer S, 2001, AIDS RES HUM RETROV, V17, P1167, DOI 10.1089/088922201316912772; Parkin NT, 2000, AIDS, V14, P2877, DOI 10.1097/00002030-200012220-00009; Perilla JL, 1999, HISPANIC J BEHAV SCI, V21, P107, DOI 10.1177/0739986399212001; Petit JM, 2000, HORM METAB RES, V32, P367, DOI 10.1055/s-2007-978655; Phillips AN, 2001, JAMA-J AM MED ASSOC, V286, P2560, DOI 10.1001/jama.286.20.2560; Pialoux G, 1998, NEW ENGL J MED, V339, P1269, DOI 10.1056/NEJM199810293391802; Pirmohamed M, 2001, CURR OPIN ALLERGY CL, V1, P311, DOI 10.1097/00130832-200108000-00006; PODZAMCZER D, 2001, 1 INT AIDS SOC C HIV; Polis MA, 2001, LANCET, V358, P1760, DOI 10.1016/S0140-6736(01)06802-7; Powderly WG, 1999, AIDS, V13, P1873, DOI 10.1097/00002030-199910010-00009; Purnell JQ, 2000, AIDS, V14, P51, DOI 10.1097/00002030-200001070-00006; Raboud JM, 1998, AIDS, V12, P1619, DOI 10.1097/00002030-199813000-00008; Rizzardi GP, 2000, J CLIN INVEST, V105, P777, DOI 10.1172/JCI9079; Roberts AD, 1999, CLIN INFECT DIS, V29, P441, DOI 10.1086/520231; Rosenberg ES, 2000, NATURE, V407, P523, DOI 10.1038/35035103; *ROX LAB INC, 2000, VIR; Ruiz L, 2001, AIDS, V15, pF19, DOI 10.1097/00002030-200106150-00001; Saag MS, 2002, TOPICS HIV MED, V10, P47; Saint-Marc T, 1999, AIDS, V13, P1659, DOI 10.1097/00002030-199909100-00009; Schapiro JM, 1996, ANN INTERN MED, V124, P1039, DOI 10.7326/0003-4819-124-12-199606150-00003; SCHOOLEY R, 2001, 41 INT C ANT AG CHEM; SCHUURMAN R, 1995, J INFECT DIS, V171, P1411, DOI 10.1093/infdis/171.6.1411; Scribner AN, 2000, J ACQ IMMUN DEF SYND, V25, P19, DOI 10.1097/00126334-200009010-00003; Sereti I, 2001, CLIN INFECT DIS, V32, P1738, DOI 10.1086/320758; Shankarappa R, 1999, J VIROL, V73, P10489, DOI 10.1128/JVI.73.12.10489-10502.1999; Smith S C Jr, 2000, Circulation, V101, P111; SPRITZLER J, 2002, 9 C RETR OPP INF FEB; SQUIRES K, 2001, 41 INT C ANT AG CHEM; Staszewski S, 1999, NEW ENGL J MED, V341, P1865, DOI 10.1056/NEJM199912163412501; Staszewski S, 2001, JAMA-J AM MED ASSOC, V285, P1155, DOI 10.1001/jama.285.9.1155; Staszewski S, 1999, INT J CLIN PRACT, P10; Stenzel M S, 2001, AIDS Read, V11, P317; STERLING TR, 2001, 8 C RETR OPP INF FEB; Stone VE, 2001, J ACQ IMMUN DEF SYND, V28, P124, DOI 10.1097/00042560-200110010-00003; Sulkowski MS, 2000, JAMA-J AM MED ASSOC, V283, P74, DOI 10.1001/jama.283.1.74; Tarwater PM, 2001, J ACQ IMMUN DEF SYND, V27, P168, DOI 10.1097/00126334-200106010-00012; Tashima KT, 2001, CLIN INFECT DIS, V33, P2055, DOI 10.1086/323978; Tebas P, 2000, AIDS, V14, pF63, DOI 10.1097/00002030-200003100-00005; Tortajada C, 2000, J ACQ IMMUN DEF SYND, V25, P296, DOI 10.1097/00126334-200012010-00002; Tuldra A, 2000, J ACQ IMMUN DEF SYND, V25, P221, DOI 10.1097/00126334-200011010-00003; Tural C, 2002, AIDS, V16, P209, DOI 10.1097/00002030-200201250-00010; *US FDA, 2001, FDA BRIST MYERS SQUI; *US PHS, 2002, GUID US ANT AG HIV I; *USPHS IDSA PREV O, 2001, USPHS IDSA GUID PREV; van der Valk M, 2001, AIDS, V15, P2407, DOI 10.1097/00002030-200112070-00008; VANGEMEN B, 2001, 3 INT WORKSH ADV DRU; Yamashita TE, 2001, AIDS, V15, P735, DOI 10.1097/00002030-200104130-00009; Zhang LQ, 1999, NEW ENGL J MED, V340, P1605, DOI 10.1056/NEJM199905273402101; Zolopa AR, 1999, ANN INTERN MED, V131, P813, DOI 10.7326/0003-4819-131-11-199912070-00003	186	594	610	0	26	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 10	2002	288	2					222	235		10.1001/jama.288.2.222	http://dx.doi.org/10.1001/jama.288.2.222			14	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	571HC	12095387				2023-01-03	WOS:000176711100023
J	Winthrop, KL; Abrams, M; Yakrus, M; Schwartz, I; Ely, J; Gillies, D; Vugia, DJ				Winthrop, KL; Abrams, M; Yakrus, M; Schwartz, I; Ely, J; Gillies, D; Vugia, DJ			An outbreak of mycobacterial furunculosis associated with footbaths at a nail salon	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							DRINKING-WATER SAMPLES; NONTUBERCULOUS MYCOBACTERIA; NOSOCOMIAL OUTBREAKS; ELECTROPHORESIS; PATTERNS; DNA	Background: In September 2000, a physician in northern California described four patients with persistent, culture-negative boils on the lower extremities. The patients had received pedicures at the same nail salon. We identified and investigated an outbreak of Mycobacterium fortuitum furunculosis among customers of this nail salon. Methods: Patients were defined as salon customers with persistent skin infections below the knee. A case-control study was conducted that included the first 48 patients identified, and 56 unaffected friends and family members who had had a pedicure at the same salon served as controls. Selected M. fortuitum isolates, cultured from patients and the salon environment, were compared by pulsed-field gel electrophoresis. Results: We identified 110 customers of the nail salon who had furunculosis. Cultures from 34 were positive for rapidly growing mycobacteria (32 M. fortuitum and 2 unidentified). Most of the affected patients had more than 1 boil (median, 2; range, 1 to 37). All patients and controls had had whirlpool footbaths. Shaving the legs with a razor before pedicure was a risk factor for infection (70 percent of patients vs. 31 percent of controls; adjusted odds ratio, 4.8; 95 percent confidence interval, 2.1 to 11.1). Cultures from all 10 footbaths at the salon yielded M. fortuitum. The M. fortuitum isolates from three footbaths and 14 patients were indistinguishable by electrophoresis. Conclusions: We identified a large outbreak of rapidly growing mycobacterial infections among persons who had had footbaths and pedicures at one nail salon. Physicians should suspect this cause in patients with persistent furunculosis after exposure to whirlpool footbaths.	Calif Dept Hlth Serv, Div Communicable Dis Control, Berkeley, CA 94704 USA; Ctr Dis Control & Prevent, Epidem Intelligence Serv, Epidemiol Program Off, Atlanta, GA USA; Ctr Dis Control & Prevent, Div AIDS Sexually Transmitted Dis & TB Lab Res, TB Mycobacterial Branch, Atlanta, GA USA; Santa Cruz Cty Dept Hlth, Santa Cruz, CA USA	California Department of Health Care Services; Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA	Winthrop, KL (corresponding author), Calif Dept Hlth Serv, Div Communicable Dis Control, Rm 708,2151 Berkeley Way, Berkeley, CA 94704 USA.							AUBUCHON C, 1986, J BONE JOINT SURG AM, V68A, P766, DOI 10.2106/00004623-198668050-00021; BROWN BA, 2000, MANDELL DOUGLAS BENN, V2, P2630; Butler WR, 2001, CLIN MICROBIOL REV, V14, P704, DOI 10.1128/CMR.14.4.704-726.2001; CARSON LA, 1978, APPL ENVIRON MICROB, V36, P839, DOI 10.1128/AEM.36.6.839-846.1978; COLLINS CH, 1984, J APPL BACTERIOL, V57, P193, DOI 10.1111/j.1365-2672.1984.tb01384.x; Covert TC, 1999, APPL ENVIRON MICROB, V65, P2492; Da Costa Cruz JC, 1938, ACTA MED RIO DE JANE, V1, P297; FISCHEDER R, 1991, ZBL HYG UMWELTMED, V192, P154; HECTOR JSR, 1992, J CLIN MICROBIOL, V30, P1250, DOI 10.1128/JCM.30.5.1250-1255.1992; JONES RJ, 1965, CAN J MICROBIOL, V11, P127, DOI 10.1139/m65-018; Kent P. T., 1985, PUBLIC HLTH MYCOBACT, P31; Kent PT, 1985, PUBLIC HLTH MYCOBACT, P57; Lee W J, 2000, J Dermatol, V27, P264; Nolte N.F., 1999, MANUAL CLIN MICROBIO, P399; SCHULZEROBBECKE R, 1991, J MICROBIOL METH, V14, P177, DOI 10.1016/0167-7012(91)90021-H; TENOVER FC, 1995, J CLIN MICROBIOL, V33, P2233, DOI 10.1128/JCM.33.9.2233-2239.1995; WALLACE RJ, 1983, REV INFECT DIS, V5, P657; Wallace RJ, 1998, ANNU REV MICROBIOL, V52, P453, DOI 10.1146/annurev.micro.52.1.453; WOLINSKY E, 1968, AM REV RESPIR DIS, V97, P1032; YAKRUS MA, 1992, J CLIN MICROBIOL, V30, P1474, DOI 10.1128/JCM.30.6.1474-1478.1992; 2001, NAILS MAGAZINE, V18, P33	21	143	148	0	3	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAY 02	2002	346	18					1366	1371		10.1056/NEJMoa012643	http://dx.doi.org/10.1056/NEJMoa012643			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	546MZ	11986410				2023-01-03	WOS:000175279000004
J	Green, J; Forster, A; Bogle, S; Young, J				Green, J; Forster, A; Bogle, S; Young, J			Physiotherapy for patients with mobility, problems more than 1 year after stroke: a randomised controlled trial	LANCET			English	Article							REHABILITATION	Background Community physiotherapy is often prescribed for stroke patients with long-term mobility problems. We aimed to assess the effectiveness of this treatment in patients who had mobility problems 1 year after stroke. Methods We screened 359 patients older than 50 years for a single-masked, randomised controlled trial to assess the effects of community physiotherapy. Assessments were made at baseline, 3, 6, and 9 months in 170 eligible patients assigned treatment or no intervention. The primary outcome measure was mobility measured by the Rivermead mobility index. Secondary outcome measures were gait speed, number of falls, daily activity (Barthel index scores), social activity (Frenchay activities index), hospital anxiety and depression scale, and emotional stress of carers (general health questionnaire 28). Analyses were by intention to treat. Findings Follow-up was available for 146 patients (86%). Changes in scores on the Rivermead mobility index (score range 0-15) differed significantly between treatment and control groups at 3 months (p=0.018), but only by a median of 1 point (95% CI 0.1), with an interpolated value of 0.55 (0.08-1.04). Gait speed was 2.6 m/min (0.30-4.95) higher in the treatment group at 3 months. Neither treatment effect persisted at 6-months' and 9-months' follow-up. Treatment had no effect on patients' daily activity, social activity, anxiety, depression, and number of falls, or on emotional stress of carers. Interpretation Community physiotherapy treatment for patients with mobility problems 1 year after stroke leads to significant, but clinically small, improvements in mobility and gait speed that are not sustained after treatment ends.	St Lukes Hosp, Dept Hlth Care Elderly, Bradford BD5 0NA, W Yorkshire, England; Bradford Community NHS Trust, Rehabil Serv, Bradford, W Yorkshire, England; Aysgarth Stat, Beaconsfield, England		Green, J (corresponding author), St Lukes Hosp, Dept Hlth Care Elderly, Bradford BD5 0NA, W Yorkshire, England.			Forster, Anne/0000-0001-7466-4414; young, john/0000-0003-4085-9306				Collen F M, 1991, Int Disabil Stud, V13, P50; Collen F M, 1991, Int Disabil Stud, V13, P12; Collen F M, 1990, Int Disabil Stud, V12, P6; Collin C, 1988, Int Disabil Stud, V10, P61; Corr S, 1995, CLIN REHABIL, V9, P291; DAM M, 1993, STROKE, V24, P1186, DOI 10.1161/01.STR.24.8.1186; DOWSWELL G, IN PRESS B J THER RE; Enderby P M, 1987, Int Rehabil Med, V8, P166; FORSTER A, 1995, BRIT MED J, V311, P83, DOI 10.1136/bmj.311.6997.83; GLADMAN JRF, 1995, CLIN REHABIL, V9, P245; GOLDBERG DP, 1979, PSYCHOL MED, V9, P139, DOI 10.1017/S0033291700021644; GREEN J, 1999, BR J THER REHABIL, V6, P216; HODKINSON H M, 1972, Age and Ageing, V1, P233, DOI 10.1093/ageing/1.4.233; HOLBROOK M, 1983, AGE AGEING, V12, P166, DOI 10.1093/ageing/12.2.166; HOLDEN MK, 1986, PHYS THER, V66, P1530, DOI 10.1093/ptj/66.10.1530; LEHMANN JF, 1975, ARCH PHYS MED REHAB, V56, P375; Rodriquez AA, 1996, ARCH PHYS MED REHAB, V77, P801, DOI 10.1016/S0003-9993(96)90260-9; TANGEMAN PT, 1990, ARCH PHYS MED REHAB, V71, P876; WADE D, 2000, NATL CLIN GUIDELINES, P64; WADE DT, 1992, BRIT MED J, V304, P609, DOI 10.1136/bmj.304.6827.609; WALKER MF, 1996, CLIN REHABIL, V10, P23, DOI DOI 10.1177/026921559601000105; Werner RA, 1996, AM J PHYS MED REHAB, V75, P114, DOI 10.1097/00002060-199603000-00006; Wilkinson PR, 1997, STROKE, V28, P507, DOI 10.1161/01.STR.28.3.507; ZIGMOND AS, 1983, ACTA PSYCHIAT SCAND, V67, P361, DOI 10.1111/j.1600-0447.1983.tb09716.x	24	139	145	0	8	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JAN 19	2002	359	9302					199	203		10.1016/S0140-6736(02)07443-3	http://dx.doi.org/10.1016/S0140-6736(02)07443-3			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	512YH	11812553				2023-01-03	WOS:000173350800009
J	Tucker, J; Mccabe, C; McCabe, C; Nicolson, P; Tarnow-Mordi, W; Marlow, N; Baumer, H; Boen, M; Hamilton, K; Meran, JA; Milligan, D; Nicoll, J; Redshaw, M; Rowan, K; Scott, J; Smith, J				Tucker, J; Mccabe, C; McCabe, C; Nicolson, P; Tarnow-Mordi, W; Marlow, N; Baumer, H; Boen, M; Hamilton, K; Meran, JA; Milligan, D; Nicoll, J; Redshaw, M; Rowan, K; Scott, J; Smith, J		UK Neonatgal Staffing Study Grp	Patient volume, staffing, and workload in relation to risk-adjusted outcomes in a random stratified sample of UK neonatal intensive care units: a prospective evaluation	LANCET			English	Article							BIRTH; MORTALITY	Background UK recommendations suggest that large neonatal intensive-care units (NICUs) have better outcomes than small units, although this suggestion remains unproven. We assessed whether patient volume, staffing levels, and workload are associated with risk-adjusted outcomes, and with costs or staff wellbeing. Methods 186 UK NICUs were stratified according to volume of patients, nursing provision, and neonatal consultant provision. Primary outcomes were hospital mortality, mortality or cerebral damage, and nosocomial bacteraemia. We studied 13 515 infants of all birthweights consecutively admitted to 54 randomly selected NICUs. Multiple logistic regression analyses were done with every primary outcome as the dependent variable. Staff wellbeing and stress were assessed by anonymous mental health index (MHI)-5 questionnaires. Findings Data were available for 13 334 (99%) infants. High-volume NICUs treated the sickest infants and had highest crude mortality. Risk-adjusted mortality and mortality or cerebral damage were unrelated to patient volume or staffing provision; however, nosocomial bacteraemia was less frequent in NICUs with low neonatal consultant provision (odds ratio 0.65, 95% Cl 0.43-0.98). Mortality was raised with increasing workload in all types of NICUs. Infants admitted at full capacity versus half capacity were about 50% more likely to die, but there was wide uncertainty around this estimate. Most staff had MHI-5 scores that suggested good mental health. Interpretation The implications of this report for staffing policy, medicolegal risk management, and ethical practice remain to be tested. Centralisation of only the sickest infants could improve efficiency, provided that this does not create excessive workload for staff. Assessment of increased staffing levels that are closer to those in adult intensive care might be appropriate.	Univ Aberdeen, Dept Obstet & Gynaecol, Dugald Baird Ctr Res Womens Hlth, Aberdeen AB25 2ZL, Scotland; Univ Sheffield, ScHARR, Med Care Res Unit, Sheffield S10 2TN, S Yorkshire, England; Univ Sheffield, ScHARR, Sheffield Hlth Econ Grp, Sheffield S10 2TN, S Yorkshire, England; Univ Sydney, Westmead & New Childrens Hosp, Sydney, NSW 2006, Australia	University of Aberdeen; University of Sheffield; University of Sheffield; University of Sydney	Tucker, J (corresponding author), Univ Aberdeen, Dept Obstet & Gynaecol, Dugald Baird Ctr Res Womens Hlth, Aberdeen AB25 2ZL, Scotland.	j.s.tucker@abdn.ac.uk	Parry, Gareth/CAF-6975-2022; Marlow, Neil/D-2918-2009; McCabe, Christopher/E-2051-2016	Marlow, Neil/0000-0001-5890-2953; 				AKAIKE H, 1974, IEEE T AUTOMAT CONTR, VAC19, P716, DOI 10.1109/TAC.1974.1100705; *BRIT ASS PER MED, 1996, STAND HOSP PROV NEON; Brodie SB, 2000, PEDIATR INFECT DIS J, V19, P56, DOI 10.1097/00006454-200001000-00012; COCKBURN F, 1993, LANCET, V342, P193; Costeloe K, 2000, PEDIATRICS, V106, P659, DOI 10.1542/peds.106.4.659; FIELD D, 1991, ARCH DIS CHILD-FETAL, V66, P408, DOI 10.1136/adc.66.4_Spec_No.408; Field D, 1999, ARCH DIS CHILD-FETAL, V80, pF111, DOI 10.1136/fn.80.2.F111; Goldfrad C, 2000, LANCET, V355, P1138, DOI 10.1016/S0140-6736(00)02062-6; GOLDFRAD C, 2000, J EPIDEMIOL COMMUN H, pA9; Jones J, 1995, INT J TECHNOL ASSESS, V11, P762, DOI 10.1017/S0266462300009193; McCabe CJ, 1996, BRIT J PSYCHIAT, V169, P517, DOI 10.1192/bjp.169.4.516; MCFARLANE A, 2000, BIRTH COUNTS STAT PR, P544; Mugford M, 1998, ARCH DIS CHILD-FETAL, V78, pF179; Murphy MK., 1998, HLTH TECHNOLOGY ASSE, V2, pi, DOI [10.3310/hta2030, DOI 10.3310/HTA2030]; *NHS CTR REV DISS, 1996, EFFECTIVE HLTH CARE, V2, P1; O'Neill C, 2000, J PUBLIC HEALTH MED, V22, P108, DOI 10.1093/pubmed/22.1.108; Parmanum J, 2000, BMJ-BRIT MED J, V321, P727, DOI 10.1136/bmj.321.7263.727; Parry GJ, 1998, BRIT MED J, V316, P1931, DOI 10.1136/bmj.316.7149.1931; Pearson G, 1997, LANCET, V349, P1213, DOI 10.1016/S0140-6736(96)12396-5; Phibbs CS, 1996, JAMA-J AM MED ASSOC, V276, P1054, DOI 10.1001/jama.276.13.1054; PICKERING J, 1993, ARCH DIS CHILD-FETAL, V68, P539; Pittet D, 2000, LANCET, V356, P1307, DOI 10.1016/S0140-6736(00)02814-2; Pittet D, 1999, ANN INTERN MED, V130, P126, DOI 10.7326/0003-4819-130-2-199901190-00006; POLLACK MM, 1994, JAMA-J AM MED ASSOC, V272, P941, DOI 10.1001/jama.272.12.941; Redshaw M., 1996, DELIVERING NEONATAL; RICHARDSON DK, 1993, PEDIATRICS, V91, P969; SEPKOWITZ S, 1993, LANCET, V342, P938, DOI 10.1016/0140-6736(93)91992-U; *SOC SERV COMM, 1980, PER NEON MORT 2 REP; Tarnow-Mordi W, 2000, ARCH DIS CHILD-FETAL, V82, pF118; Tarnow-Mordi WO, 2000, LANCET, V356, P185, DOI 10.1016/S0140-6736(00)02478-8; TarnowMordi W, 1997, LANCET, V350, P66, DOI 10.1016/S0140-6736(05)66269-1; TARNOWMORDI W, 2002, RISK ADJUSTED OUTCOM; TARNOWMORDI WO, 1997, SEMIN NEONATOL, V2, P171; Tilford JM, 2000, PEDIATRICS, V106, P289, DOI 10.1542/peds.106.2.289; Tucker J, 1999, ARCH DIS CHILD-FETAL, V80, pF233, DOI 10.1136/fn.80.3.F233; UKOUMUNNE OC, 1999, HEALTH TECHNOL ASSES, V3, P33; WHEELER RHB, 1995, ARCH DIS CHILD, V73, pF32; *WORK GROUP NEON I, 1995, NEON INT CAR ACC AV; 1986, LANCET, V1, P777	39	194	196	0	14	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JAN 12	2002	359	9301					99	107						9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	510MT	11809250				2023-01-03	WOS:000173212400007
J	Lori, F; Lisziewicz, J				Lori, F; Lisziewicz, J			Structured treatment interruptions for the management of HIV infection	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							T-CELL RESPONSES; ANTIRETROVIRAL THERAPY; PROTEASE INHIBITOR; IMMUNE-RESPONSES; VIRUS; DISCONTINUATION; SUPPRESSION; DYNAMICS; AIDS; CD4	Antiretroviral drugs constitute a milestone in the treatment of human immunodeficiency virus (HIV) infection; however, emerging problems limit their long-term use, and an increasing number of patients interrupt the prescribed continuous drug therapy for short or long periods. Some patients appear to benefit from structured treatment interruptions (STI), involving monitored repetition of on-and-off cycles of drugs; however, it is unclear whether patients and/or physicians should consider STI as a treatment option. This review is intended to provide a comprehensive update on the use of STI in clinical settings, and to carefully evaluate the advantages and potential risks for patients infected with HIV. We used a MEDLINE search to find all English-language articles published January 1999 to August 2001 regarding patients treated with highly active antiretroviral therapy for whom treatment interruption was investigated. Priority was assigned to peer-reviewed sources, when available. Otherwise, abstracts from authoritative international conferences were selected through the AIDSLINE database. Results from various studies with respect to type of drug treatment, baseline patient status, number of treatment interruptions, duration of treatment and interruption, changes in viral load, and immune system parameters were analyzed. Patients could be categorized into 3 distinct clinical scenarios: acute infection, chronic drug-suppressed infection and virological drug failure. The STI approach may offer more benefit during acute infection when the patient's immune system remains nearly intact. It is yet to be determined whether STI will facilitate the long-term management of chronic infection by decreasing drug-associated toxicity and improving quality of life without jeopardizing the efficacy of the treatment. Results from randomized controlled trials and more definitive means of gauging the status of the patient's immune system must be available before this treatment method is extended beyond the research setting. Ultimately, a safer approach using therapeutic immunization or vaccination would be preferable for stimulating vigorous T-cell-mediated immune responses and control of HIV during treatment interruption.	Res Inst Genet & Human Therapy, Washington, DC 20007 USA; Policlin San Matteo, Ist Ricovero & Cura Carattere Sci, I-27100 Pavia, Italy	IRCCS Fondazione San Matteo	Lori, F (corresponding author), Res Inst Genet & Human Therapy, 2233 Wisconsin Ave NW,Suite 503, Washington, DC 20007 USA.	rightpv@fin.it		Lisziewicz, Julianna/0000-0002-3349-4495				Amara RR, 2001, SCIENCE, V292, P69, DOI 10.1126/science.1058915; Autran B, 1997, SCIENCE, V277, P112, DOI 10.1126/science.277.5322.112; Barouch DH, 2000, P NATL ACAD SCI USA, V97, P4192, DOI 10.1073/pnas.050417697; Carcelain G, 2001, J VIROL, V75, P234, DOI 10.1128/JVI.75.1.234-241.2001; Carpenter CCJ, 2000, JAMA-J AM MED ASSOC, V283, P381, DOI 10.1001/jama.283.3.381; Champagne P, 2001, NATURE, V410, P106, DOI 10.1038/35065118; Chesney MA, 2000, CLIN INFECT DIS, V30, pS171, DOI 10.1086/313849; Chun TW, 1997, P NATL ACAD SCI USA, V94, P13193, DOI 10.1073/pnas.94.24.13193; Cohen J, 1997, SCIENCE, V277, P1927, DOI 10.1126/science.277.5334.1927; Daar ES, 1998, ANN INTERN MED, V128, P827, DOI 10.7326/0003-4819-128-10-199805150-00005; Davey RT, 1999, P NATL ACAD SCI USA, V96, P15109, DOI 10.1073/pnas.96.26.15109; De Boer RJ, 1998, AIDS, V12, P1567, DOI 10.1097/00002030-199813000-00002; Deeks SG, 2001, NEW ENGL J MED, V344, P472, DOI 10.1056/NEJM200102153440702; deJong MD, 1996, P NATL ACAD SCI USA, V93, P5501, DOI 10.1073/pnas.93.11.5501; DYBUL M, 2001, 8 C RETR OPP INF FEB; EMBRETSON J, 1993, NATURE, V362, P359, DOI 10.1038/362359a0; FAGARD C, 2001, 8 C RETR OPP INF FEB; FAUCI AS, 2001, 1 INT AIDS SOC C PAT; Finzi D, 1997, SCIENCE, V278, P1295, DOI 10.1126/science.278.5341.1295; Hel Z, 2000, NAT MED, V6, P1140, DOI 10.1038/80481; IMBERTI L, 1991, SCIENCE, V254, P860, DOI 10.1126/science.1948066; JACOBSON E, 1999, 39 ANN INT C ANT AG; Kahn JO, 2000, JAMA-J AM MED ASSOC, V284, P2193, DOI 10.1001/jama.284.17.2193; Lisziewicz J, 1999, NEW ENGL J MED, V340, P1683, DOI 10.1056/NEJM199905273402114; Lisziewicz J, 2001, J VIROL, V75, P7621, DOI 10.1128/JVI.75.16.7621-7628.2001; LISZIEWICZ J, 2001, 2 INT C VACC DEV IMM; Lori F, 2000, SCIENCE, V290, P1591, DOI 10.1126/science.290.5496.1591; Lori F, 1999, J INFECT DIS, V180, P1827, DOI 10.1086/315113; Lori F, 2000, LANCET, V355, P287, DOI 10.1016/S0140-6736(99)03515-1; Margolis D, 1999, J ACQ IMMUN DEF SYND, V21, P362; Miller V, 2000, AIDS, V14, P2857, DOI 10.1097/00002030-200012220-00007; Ortiz GM, 1999, J CLIN INVEST, V104, pR13, DOI 10.1172/JCI7371; *PAN CLIN PRACT TR, 2001, GUID US ANT AG HIV I; PANTALEO G, 1993, NATURE, V362, P355, DOI 10.1038/362355a0; Papasavvas E, 2000, J INFECT DIS, V182, P766, DOI 10.1086/315748; Paterson DL, 2000, ANN INTERN MED, V133, P21, DOI 10.7326/0003-4819-133-1-200007040-00004; Pitcher CJ, 1999, NAT MED, V5, P518, DOI 10.1038/8400; PLANA M, 2001, 8 C RETR OPP INF FEB; Rosenberg ES, 2000, NATURE, V407, P523, DOI 10.1038/35035103; Rosenberg ES, 1997, SCIENCE, V278, P1447, DOI 10.1126/science.278.5342.1447; Ruiz L, 2001, AIDS, V15, pF19, DOI 10.1097/00002030-200106150-00001; Soudeyns H, 1993, Semin Immunol, V5, P175, DOI 10.1006/smim.1993.1021; Wong JK, 1997, SCIENCE, V278, P1291, DOI 10.1126/science.278.5341.1291; Zinkernagel RM, 1996, SCIENCE, V271, P173, DOI 10.1126/science.271.5246.173	44	80	82	1	4	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 19	2001	286	23					2981	2987		10.1001/jama.286.23.2981	http://dx.doi.org/10.1001/jama.286.23.2981			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	502VY	11743839				2023-01-03	WOS:000172764500030
J	Griffiths, C; Kaur, G; Gantley, M; Feder, G; Hillier, S; Goddard, J; Packe, G				Griffiths, C; Kaur, G; Gantley, M; Feder, G; Hillier, S; Goddard, J; Packe, G			Influences on hospital admission for asthma in south Asian and white adults: qualitative interview study	BRITISH MEDICAL JOURNAL			English	Article							SOCIOECONOMICALLY DEPRIVED AREAS; SUBCONTINENT ETHNIC-GROUPS; OUTCOMES; RATES; POPULATION; BIRMINGHAM; EDUCATION; IMPACT; CITY; UK	Objective To explore reasons for increased risk of hospital admission among south Asian patients with asthma. Design Qualitative interview study using modified critical incident technique and framework analysis. Setting Newham, east London, a deprived area with a large mixed south Asian population. Participants 58 south Asian and white adults With asthma (49 admitted to hospital with asthma, 9 not admitted); 17 general practitioners; 5 accident and emergency doctors; 2 out of hours general practitioners; 1 asthma specialist nurse. Main outcome measures Patients' and health professionals' views on influences on admission, events leading to admission, general practices' organisation and asthma strategies, doctor-patient relationship, and cultural attitudes to asthma. Results South Asian and white patients admitted to hospital coped differently with asthma. South Asians described less confidence in controlling their asthma, were unfamiliar with the concept of preventive medication, and often expressed less confidence in their general practitioner. South Asians managed asthma exacerbations with family advocacy, without systematic changes in prophylaxis, and without systemic corticosteroids. Patients describing difficulty accessing primary care during asthma exacerbations were registered with practices with weak strategies for asthma care and were often south Asian. Patients with easy access described care suggesting partnerships with their general practitioner, had better confidence to control asthma, and were registered with practices with Well developed asthma strategies that included policies low avoiding hospital admission. Conclusions The different ways of coping with asd)ina exacerbations and accessing care may partly explain the increased risk of hospital admission in south Asian patients. Interventions that increase confidence to control asthma, confidence in the general practitioner, understanding of preventive treatment, and use of systemic corticosteroids in exacerbations may reduce hospital admissions. Development of more sophisticated asthma strategies by practices with better access and partnerships with patients tray also achieve this.	Queen Marys Sch Med & Dent, St Bartholomews & Royal London Sch Med & Dent, Dept Gen Practice & Primary Care, London E1 4NS, England; Royal London Hosp, Dept Human Sci & Med Eth, London E1 2AD, England; Newham Dist Gen Hosp, London, England	University of London; Queen Mary University London; Barts Health NHS Trust; Royal London Hospital	Griffiths, C (corresponding author), Queen Marys Sch Med & Dent, St Bartholomews & Royal London Sch Med & Dent, Dept Gen Practice & Primary Care, London E1 4NS, England.			Feder, Gene/0000-0002-7890-3926				[Anonymous], 1997, SELF EFFICACY; AYRES JG, 1986, BRIT J DIS CHEST, V80, P242, DOI 10.1016/0007-0971(86)90059-8; BINDMAN AB, 1995, JAMA-J AM MED ASSOC, V274, P305, DOI 10.1001/jama.274.4.305; BRADLEY CP, 1992, FAM PRACT, V9, P98, DOI 10.1093/fampra/9.1.98; Clark NM, 1998, PEDIATRICS, V101, P831, DOI 10.1542/peds.101.5.831; *COMM HLTH SCI RES, 2000, SYST REV ACC TREATM; DEPALO VA, 1994, CHEST, V106, P447, DOI 10.1378/chest.106.2.447; *E LOND CIT HLTH A, 2000, HLTH E END ANN PUBL; GIBSON PG, 2000, COCHRANE DATABASE SY; Gilthorpe MS, 1998, RESP MED, V92, P642, DOI 10.1016/S0954-6111(98)90511-X; Green J, 1998, BMJ-BRIT MED J, V316, P1064; Howie JGR, 1999, BMJ-BRIT MED J, V319, P738, DOI 10.1136/bmj.319.7212.738; KELSO TM, 1995, AM J EMERG MED, V13, P632, DOI 10.1016/0735-6757(95)90046-2; Moudgil H, 1998, THORAX, V53, P490, DOI 10.1136/thx.53.6.490; Moudgil H, 2000, THORAX, V55, P177, DOI 10.1136/thorax.55.3.177; MYERS P, 1992, RESP MED, V86, P297, DOI 10.1016/S0954-6111(06)80027-2; Norman P., 1996, PREDICTING HLTH BEHA, P197; ORMEROD LP, 1995, RESP MED, V89, P415, DOI 10.1016/0954-6111(95)90209-0; ORMEROD LP, 1995, RESP MED, V89, P115; Partridge MR, 2000, THORAX, V55, P175, DOI 10.1136/thorax.55.3.175; PATTEN MQ, 1990, QUALITATIVE EVALUATI; Ritchie J, 2002, ANAL QUALITATIVE DAT, P187; Rona RJ, 2000, THORAX, V55, P239, DOI 10.1136/thorax.55.3.239; ROWE BH, 1992, AM J EMERG MED, V10, P301, DOI 10.1016/0735-6757(92)90007-K; SPERBER K, 1995, J ASTHMA, V32, P335, DOI 10.3109/02770909509082758; [No title captured], DOI DOI 10.1136/THX.52.2008.S1]	26	55	55	0	7	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	OCT 27	2001	323	7319					962	966A		10.1136/bmj.323.7319.962	http://dx.doi.org/10.1136/bmj.323.7319.962			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	488CU	11679384	Green Published, Bronze			2023-01-03	WOS:000171918500015
J	Thompson, WT; Cupples, ME; Sibbett, CH; Skan, DI; Bradley, T				Thompson, WT; Cupples, ME; Sibbett, CH; Skan, DI; Bradley, T			Challenge of culture, conscience, and contract to general practitioners' care of their own health: qualitative study	BRITISH MEDICAL JOURNAL			English	Article							DOCTORS; ILLNESS; SICKNESS; STRESS; JOB	Objective To explore general practitioners' perceptions of the effects of their profession and training on their attitudes to illness in themselves and colleagues. Design Qualitative study using focus groups and indepth interviews. Setting Primary care in Northern Ireland. Participants 27 general practitioners, including six recently appointed principals and six who also practised occupational medicine part time. Main outcome measures Participants' views about their own and colleagues' health. Results Participants were concerned about the current level of illness within the profession. They described their need to portray a healthy image to both patients and colleagues. This hindered acknowledgement of personal illness and engaging in health screening. Embarrassment in adopting the role of a patient and concerns about confidentiality also influenced their reactions to personal illness. Doctors' attitudes can impede their access to appropriate health care for themselves, their families, and their colleagues. A sense of conscience towards patients and colleagues and the working arrangements of the practice were cited as reasons for working through illness and expecting colleagues to do likewise. Conclusions General practitioners perceive that their professional position and training adversely influence their attitudes to illness in themselves and their colleagues. Organisational changes within general practice, including revalidation, must take account of barriers experienced by general practitioners in accessing health care. Medical education and culture should strive to promote appropriate self care among doctors.	Queens Univ Belfast, Sch Med, Dept Gen Practice, Belfast BT9 7HR, Antrim, North Ireland; Queens Univ Belfast, Grad Sch Educ, Belfast BT7 1HL, Antrim, North Ireland; Hlth & Safety Execut No Ireland, Employment Med Advisory Serv, Belfast BT6 9FR, Antrim, North Ireland; No Ireland Council Postgrad Med & Dent Educ, Belfast BT7 3JH, Antrim, North Ireland	Queens University Belfast; Queens University Belfast	Cupples, ME (corresponding author), Queens Univ Belfast, Sch Med, Dept Gen Practice, Belfast BT9 7HR, Antrim, North Ireland.			Cupples, Margaret/0000-0002-4248-9700				Appleton K, 1998, BRIT J GEN PRACT, V48, P1059; *BMA BOARD SCI ED, 1993, MORB MORT MED PROF; BRANDON S, 1997, BRIT MED J, V314, P2; Chambers R, 1996, BRIT MED J, V312, P722; CHAMBERS R, 1992, BRIT J GEN PRACT, V42, P153; Clarke J, 1998, IRISH MED J, V91, P175; Forsythe M, 1999, BRIT MED J, V319, P605, DOI 10.1136/bmj.319.7210.605; *GEN MED COUNC, 1998, GOOD MED PRACT; *GEN MED COUNC, 2000, REV DOCT ENS STAND; Gilliland AEV, 1998, BRIT J GEN PRACT, V48, P1663; Glaster B. G., 1967, THEORETICAL SENSITIV; *HLTH POL EC RES U, 2000, WORK REL STRESS SEN; KING MB, 1992, J ROY SOC MED, V85, P605; McKevitt C, 1997, J PUBLIC HEALTH MED, V19, P295, DOI 10.1093/oxfordjournals.pubmed.a024633; McKevitt C, 1997, SOCIOL HEALTH ILL, V19, P644, DOI 10.1111/1467-9566.ep10935530; McKevitt C, 1996, DOCTORS HLTH NEEDS S; MILLAR RL, 2000, RES LIFE STORIES FAM; MORTONWILLIAMS J, 1988, APPL QUALITATIVE RES, P27; PILOWSKI L, 1989, BRIT MED J, V298, P269, DOI 10.1136/bmj.298.6669.269; Schneck SA, 1998, JAMA-J AM MED ASSOC, V280, P2039, DOI 10.1001/jama.280.23.2039; Waldron HA, 1996, ANN OCCUP HYG, V40, P391, DOI 10.1093/annhyg/40.4.391; Wall TD, 1997, BRIT J PSYCHIAT, V171, P519, DOI 10.1192/bjp.171.6.519; Williams S, 1998, IMPROVING HLTH NHS W; 1994, LANCET, V344, P1583	24	107	109	0	18	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	SEP 29	2001	323	7315					728	731		10.1136/bmj.323.7315.728	http://dx.doi.org/10.1136/bmj.323.7315.728			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	478HJ	11576981	Green Published			2023-01-03	WOS:000171340700021
J	Wilson, T; Holt, T				Wilson, T; Holt, T			Complexity science - Complexity and clinical care	BRITISH MEDICAL JOURNAL			English	Article							BEHAVIOR; SMOKING; GLUCOSE; CHAOS		Royal Coll Gen Practitioners, St Paul RCGP Qual Unit, London SW7 1PU, England; Danby Practice, Dale End Surg, Danby YO21 2JE, Whitby, England		Wilson, T (corresponding author), Royal Coll Gen Practitioners, St Paul RCGP Qual Unit, London SW7 1PU, England.		Greenhalgh, Trisha/B-1825-2015	Greenhalgh, Trisha/0000-0003-2369-8088				BALINT M, 1955, LANCET, V1, P683; BAXT WG, 1994, CANCER LETT, V77, P85, DOI 10.1016/0304-3835(94)90090-6; Benson H, 1996, ANNU REV MED, V47, P193; Chantelau E, 1997, BRIT MED J, V315, P185; Cox K, 1995, AUST NZ J SURG, V65, P553, DOI 10.1111/j.1445-2197.1995.tb01693.x; DICLEMENTE CC, 1982, ADDICT BEHAV, V7, P133, DOI 10.1016/0306-4603(82)90038-7; Goldberger AL, 1996, LANCET, V347, P1312, DOI 10.1016/S0140-6736(96)90948-4; Goldstein J., 1994, UNSHACKLED ORG; Greenhalgh T, 1999, BMJ-BRIT MED J, V318, P323, DOI 10.1136/bmj.318.7179.323; GREENHALGH T, IN PRESS BR J GEN PR; Gustafson D. H., 1992, SYSTEMS SUPPORT HLTH; Jack D, 2001, LANCET, V357, P1185, DOI 10.1016/S0140-6736(00)04391-9; Kroll MH, 1999, BIOSYSTEMS, V50, P189, DOI 10.1016/S0303-2647(99)00007-6; Lancaster T, 2000, BRIT MED J, V321, P355, DOI 10.1136/bmj.321.7257.355; Langley Gj., 1996, IMPROVEMENT GUIDE PR; Liszka-Hackzell JJ, 1999, COMPUT BIOMED RES, V32, P132, DOI 10.1006/cbmr.1998.1506; Mullen PD, 1997, BRIT MED J, V314, P691, DOI 10.1136/bmj.314.7082.691; Mynors-Wallis LM, 2000, BMJ-BRIT MED J, V320, P26, DOI 10.1136/bmj.320.7226.26; Plsek P, 2001, BMJ, P323; Queale WS, 1997, ARCH INTERN MED, V157, P545, DOI 10.1001/archinte.157.5.545; Rogers E.M, 1995, DIFFUSION INNOVATION; Ross A, 1998, BRIT MED J, V317, P1525, DOI 10.1136/bmj.317.7171.1525a; Rosser WW, 1996, J FAM PRACTICE, V42, P139; Sackett D.L., 1991, CLIN EPIDEMIOLOGY BA, V2nd; Stacey RD., 1999, STRATEGIC MANAGEMENT; Zimmerman B., 1998, EDGEWARE INSIGHTS CO	26	259	264	1	15	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	SEP 22	2001	323	7314					685	688		10.1136/bmj.323.7314.685	http://dx.doi.org/10.1136/bmj.323.7314.685			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	476LP	11566836	Green Published			2023-01-03	WOS:000171228800029
J	Murray, E; Davis, H; Tai, SS; Coulter, A; Gray, A; Haines, A				Murray, E; Davis, H; Tai, SS; Coulter, A; Gray, A; Haines, A			Randomised controlled trial of an interactive multimedia decision aid on hormone replacement therapy in primary care	BMJ-BRITISH MEDICAL JOURNAL			English	Article							INFORMATION; QUESTIONNAIRE	Objective To determine whether a decision aid on hormone replacement therapy influences decision making and health outcomes. Design Randomised controlled trial. Setting 26 general practices in the United Kingdom. Participants 205 women considering hormone replacement therapy. Intervention Patients' decision aid consisting of an interactive multimedia programme with booklet and printed summary. Outcome measures Patients' and general practitioners' perceptions of who made the decision, decisional conflict, treatment choice, menopausal symptoms, costs, anxiety, and general health status. Results Both patients and general practitioners found the decision aid acceptable. At three months, mean scores for decisional conflict were significantly lower in the intervention group than in the control group (2.5 v 2.8; mean difference - 0.3, 95% confidence interval - 0.5 to - 0.2); this difference was maintained during follow up. A higher proportion of general practitioners perceived that treatment decisions had been made "mainly or only" by the patient in the intervention group than mi the control group (55% v 31%; 24%, 8% to 40%). At three months a lower proportion of women in the intervention group than in the control group were undecided about treatment (14% v 26%; - 12%, - 23% to - 0.4%), and a higher proportion had decided against hormone replacement therapy (46% v 32%; 14%, 1% to 28%); these differences were no longer apparent by nine months. No differences were found between the groups for anxiety, use of health service resources, general health status, or utility. The higher costs of the intervention were largely due to the video disc technology used. Conclusions An interactive multimedia decision aid in the NHS would be popular with patients, reduce decisional conflict, and enable patients to play a more active part in decision making without increasing anxiety. The use of web based technology would reduce the cost of the intervention.	UCL, Royal Free & Univ Coll Med Sch, Dept Primary Care & Populat Sci, London N19 3UA, England; Picker Inst Europe, Oxford OX1 1RX, England; Univ Oxford, Hlth Econ Res Ctr, Oxford OX3 7LF, England	University of London; University College London; University of Oxford	Murray, E (corresponding author), UCL, Royal Free & Univ Coll Med Sch, Dept Primary Care & Populat Sci, London N19 3UA, England.	elizabeth.murray@pcps.ucl.ac.uk	Coulter, Angela/N-6998-2019; Davis, Hilary/J-9356-2015	Coulter, Angela/0000-0002-6308-8375; Davis, Hilary/0000-0002-0271-9655; Murray, Elizabeth/0000-0002-8932-3695; Haines, Andy/0000-0002-8053-4605				BRAZIER JE, 1992, BMJ-BRIT MED J, V305, P160, DOI 10.1136/bmj.305.6846.160; Charles C, 1997, SOC SCI MED, V44, P681, DOI 10.1016/S0277-9536(96)00221-3; Coulter A, 1999, BRIT MED J, V318, P318, DOI 10.1136/bmj.318.7179.318; Department of Health, 1999, SAV LIV OUR HLTH NAT; Dolan P, 1996, HEALTH ECON, V5, P141, DOI 10.1002/(SICI)1099-1050(199603)5:2<141::AID-HEC189>3.0.CO;2-N; ENGLAND SL, 1992, SOC SCI MED, V34, P1217, DOI 10.1016/0277-9536(92)90314-G; Entwistle VA, 1998, INT J TECHNOL ASSESS, V14, P212, DOI 10.1017/S0266462300012204; *FDN INF MED DEC M, 1996, HORM REPL THER SHAR; Flood AB, 1996, J GEN INTERN MED, V11, P342, DOI 10.1007/BF02600045; FOX S, 1 PEW INT AM LIF; General Medical Council (UK), 1998, SEEK PAT CONS ETH CO; Hilditch JR, 1996, MATURITAS, V24, P161, DOI 10.1016/0378-5122(96)01038-9; Hilditch JR, 1996, MATURITAS, V25, P231; ISAACS AJ, 1995, BRIT MED J, V311, P1399, DOI 10.1136/bmj.311.7017.1399; Jones R, 1999, BRIT MED J, V319, P1241, DOI 10.1136/bmj.319.7219.1241; KAPLAN, 1989, MED CARE, V27, P679; KAPLAN SH, 1989, MED CARE, V27, pS110, DOI 10.1097/00005650-198903001-00010; LLEWELLYNTHOMAS HA, 1995, MED DECIS MAKING, V15, P101, DOI 10.1177/0272989X9501500201; MARTEAU TM, 1992, BRIT J CLIN PSYCHOL, V31, P301, DOI 10.1111/j.2044-8260.1992.tb00997.x; Meredith C, 1996, BMJ-BRIT MED J, V313, P724; Molenaar S, 2000, MED DECIS MAKING, V20, P112, DOI 10.1177/0272989X0002000114; Murray E, 2001, BMJ-BRIT MED J, V323, P493, DOI 10.1136/bmj.323.7311.493; O'Connor AM, 1999, BRIT MED J, V319, P731, DOI 10.1136/bmj.319.7212.731; OCONNOR AM, 1995, MED DECIS MAKING, V15, P25, DOI 10.1177/0272989X9501500105; OCONNOR AM, 1993, BRIT MED J, V319, P731; Townsend J, 1998, BRIT J GEN PRACT, V48, P955; WILLIAMS A, 1990, HEALTH POLICY, V16, P199; Wolf AMD, 1996, ARCH INTERN MED, V156, P1333, DOI 10.1001/archinte.156.12.1333	28	102	103	0	3	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	SEP 1	2001	323	7311					490	+		10.1136/bmj.323.7311.490	http://dx.doi.org/10.1136/bmj.323.7311.490			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	469WF	11532844	Bronze, Green Published, Green Accepted			2023-01-03	WOS:000170838500021
J	Altfeld, M; Walker, BD				Altfeld, M; Walker, BD			Less is more? STI in acute and chronic HIV-1 infection	NATURE MEDICINE			English	Editorial Material							STRUCTURED TREATMENT INTERRUPTIONS; CYTOTOXIC T-LYMPHOCYTE; ACTIVE ANTIRETROVIRAL THERAPY; IMMUNODEFICIENCY-VIRUS-INFECTION; CELLULAR IMMUNE-RESPONSES; HIV-1-INFECTED PATIENTS; IMMUNOLOGICAL CONSEQUENCES; VIREMIA; CD8(+); CELLS	Emerging data has indicated that supervised treatment interruption (STI) of highly active antiretroviral therapy might significantly augment immune responses in HIV-1-infected patients and slow disease progression. Here the authors discuss the rationale behind STI and future directions for study.	Massachusetts Gen Hosp, Partners AIDS Res Ctr, Boston, MA 02114 USA; Harvard Univ, Sch Med, Boston, MA USA	Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School	Altfeld, M (corresponding author), Massachusetts Gen Hosp, Partners AIDS Res Ctr, Boston, MA 02114 USA.	maltfeld@partners.org; bwalker@helix.mgh.harvard.edu	Altfeld, Marcus/AAE-7306-2019	Altfeld, Marcus/0000-0001-5972-2997				Altfeld M, 2000, CURR OPIN IMMUNOL, V12, P375, DOI 10.1016/S0952-7915(00)00103-5; Altfeld M, 2001, J EXP MED, V193, P169, DOI 10.1084/jem.193.2.169; Amara RR, 2001, SCIENCE, V292, P69, DOI 10.1126/science.1058915; Autran B, 1997, SCIENCE, V277, P112, DOI 10.1126/science.277.5322.112; Barouch DH, 2000, SCIENCE, V290, P486, DOI 10.1126/science.290.5491.486; BHARDWAJ N, 1994, J CLIN INVEST, V94, P797, DOI 10.1172/JCI117399; Blankson JN, 2001, J INFECT DIS, V183, P657, DOI 10.1086/318545; Carrington M, 1999, SCIENCE, V283, P1748, DOI 10.1126/science.283.5408.1748; Colven R, 2000, ANN INTERN MED, V133, P430, DOI 10.7326/0003-4819-133-6-200009190-00010; Davey RT, 1999, P NATL ACAD SCI USA, V96, P15109, DOI 10.1073/pnas.96.26.15109; Day CL, 2001, J VIROL, V75, P6279, DOI 10.1128/JVI.75.14.6279-6291.2001; Deeks SG, 2001, NEW ENGL J MED, V344, P472, DOI 10.1056/NEJM200102153440702; DYBUL M, 2001, 8 C RETR OPP INF CHI; Flores-Villanueva PO, 2001, P NATL ACAD SCI USA, V98, P5140, DOI 10.1073/pnas.071548198; Garcia F, 1999, AIDS, V13, pF79, DOI 10.1097/00002030-199907300-00002; Garcia F, 2001, AIDS, V15, pF29, DOI 10.1097/00002030-200106150-00002; Goulder PJR, 1999, AIDS, V13, pS121; Goulder PJR, 1997, NAT MED, V3, P212, DOI 10.1038/nm0297-212; GOULDER PJR, IN PRESS NATURE; Harrer T, 1996, AIDS RES HUM RETROV, V12, P585, DOI 10.1089/aid.1996.12.585; Harrer T, 1996, J IMMUNOL, V156, P2616; Hatano H, 2000, AIDS, V14, P1357, DOI 10.1097/00002030-200007070-00008; Hel Z, 2000, NAT MED, V6, P1140, DOI 10.1038/80481; HERMANS P, 2001, 8 C RETR OPP INF CHI; Jin X, 1999, J EXP MED, V189, P991, DOI 10.1084/jem.189.6.991; Kalams SA, 1999, J VIROL, V73, P6715, DOI 10.1128/JVI.73.8.6715-6720.1999; Kilby JM, 2000, ANN INTERN MED, V133, P435, DOI 10.7326/0003-4819-133-6-200009190-00011; Lisziewicz J, 1999, NEW ENGL J MED, V340, P1683, DOI 10.1056/NEJM199905273402114; Lori F, 2000, SCIENCE, V290, P1591, DOI 10.1126/science.290.5496.1591; Lori F, 1999, AIDS RES HUM RETROV, V15, P1333, DOI 10.1089/088922299310034; Lyles RH, 2000, J INFECT DIS, V181, P872, DOI 10.1086/315339; Malhotra U, 2000, J INFECT DIS, V181, P121, DOI 10.1086/315202; MARKOWITZ M, 2001, 8 C RETR OPP INF CHI; McMichael AJ, 2001, NATURE, V410, P980, DOI 10.1038/35073658; Migueles SA, 2000, P NATL ACAD SCI USA, V97, P2709, DOI 10.1073/pnas.050567397; Miller V, 2001, CURR OPIN INFECT DIS, V14, P29, DOI 10.1097/00001432-200102000-00006; Miller V, 2000, AIDS, V14, P2857, DOI 10.1097/00002030-200012220-00007; Montaner LJ, 2001, TRENDS IMMUNOL, V22, P92, DOI 10.1016/S1471-4906(00)01809-3; Neumann AU, 1999, AIDS, V13, P677, DOI 10.1097/00002030-199904160-00008; Ogg GS, 1998, SCIENCE, V279, P2103, DOI 10.1126/science.279.5359.2103; Ortiz GM, 1999, J CLIN INVEST, V104, pR13, DOI 10.1172/JCI7371; Ostrowski MA, 2000, J IMMUNOL, V165, P6133, DOI 10.4049/jimmunol.165.11.6133; Oxenius A, 2000, P NATL ACAD SCI USA, V97, P3382, DOI 10.1073/pnas.97.7.3382; Papasavvas E, 2000, J INFECT DIS, V182, P766, DOI 10.1086/315748; Poignard P, 1999, IMMUNITY, V10, P431, DOI 10.1016/S1074-7613(00)80043-6; Rosenberg ES, 2000, NATURE, V407, P523, DOI 10.1038/35035103; Rosenberg ES, 1997, SCIENCE, V278, P1447, DOI 10.1126/science.278.5342.1447; Ruiz L, 2000, AIDS, V14, P397, DOI 10.1097/00002030-200003100-00013; Ruiz L, 2001, AIDS, V15, pF19, DOI 10.1097/00002030-200106150-00001; Sarawar SR, 2001, P NATL ACAD SCI USA, V98, P6325, DOI 10.1073/pnas.101136898; Schmitz JE, 1999, SCIENCE, V283, P857, DOI 10.1126/science.283.5403.857; VOLBERDING PA, 1990, NEW ENGL J MED, V322, P941, DOI 10.1056/NEJM199004053221401; Walker BD, 2001, NAT IMMUNOL, V2, P473, DOI 10.1038/88656; Zajac AJ, 1998, J EXP MED, V188, P2205, DOI 10.1084/jem.188.12.2205	54	41	41	0	2	NATURE RESEARCH	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	AUG	2001	7	8					881	884		10.1038/90901	http://dx.doi.org/10.1038/90901			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	485EK	11479610				2023-01-03	WOS:000171740400013
J	Thornton, JG; Capogna, G				Thornton, JG; Capogna, G			Reducing likelihood of instrumental delivery with epidural anaesthesia	LANCET			English	Editorial Material							ANALGESIA; LABOR		Univ Leeds, Leeds Gen Infirm, Acad Unit Paediat Obstet & Gynaecol, Leeds LS2 9NS, W Yorkshire, England; Fatebenefratelli Hosp 38, Dept Obstet Anaesthesia, I-00186 Rome, Italy	Leeds General Infirmary; University of Leeds	Thornton, JG (corresponding author), Univ Leeds, Leeds Gen Infirm, Acad Unit Paediat Obstet & Gynaecol, Leeds LS2 9NS, W Yorkshire, England.		Thornton, Jim/B-8336-2008	Thornton, Jim/0000-0001-9764-6876				Burnstein R, 1999, ANAESTHESIA, V54, P634, DOI 10.1046/j.1365-2044.1999.00894.x; Howell CJ, 2001, BRIT J OBSTET GYNAEC, V108, P27, DOI 10.1016/S0306-5456(00)00012-7; HOWELL CJ, 2001, COCHRANE LIB; Nageotte MP, 1997, NEW ENGL J MED, V337, P1715, DOI 10.1056/NEJM199712113372402; REYNOLDS F, 1992, LANCET, V339, P1234, DOI 10.1016/0140-6736(92)91177-A	5	31	33	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUL 7	2001	358	9275					2	2		10.1016/S0140-6736(00)05295-8	http://dx.doi.org/10.1016/S0140-6736(00)05295-8			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	449WV	11454363				2023-01-03	WOS:000169710900002
J	Kirn, D; Martuza, RL; Zwiebel, J				Kirn, D; Martuza, RL; Zwiebel, J			Replication-selective virotherapy for cancer: Biological principles, risk management and future directions	NATURE MEDICINE			English	Review							HERPES-SIMPLEX-VIRUS; NEWCASTLE-DISEASE VIRUS; PROSTATE-SPECIFIC ANTIGEN; PHASE-I TRIAL; GENE-THERAPY; COMPETENT ADENOVIRUS; ATTENUATED ADENOVIRUS; ONCOLYTIC ADENOVIRUS; MALIGNANT-MELANOMA; FIBER PROTEINS	In the search for novel cancer therapies that can be used in conjunction with existing treatments, one promising area of research is the use of viral vectors and whole viruses. This review describes the underlying biological principles and current status of the field, outlines approaches for improving clinical effectiveness and discusses the unique safety and regulatory issues surrounding viral therapies.	Univ London Imperial Coll Sci Technol & Med, Viral & Genet Therapy Programme, Sch Med, London, England; Hammersmith Hosp, Imperial Canc Res Fund, London, England; Harvard Univ, Sch Med, Boston, MA USA; Massachusetts Gen Hosp, Boston, MA 02114 USA; NCI, Div Canc Treatment, Canc Therapy Evaluat Program, Bethesda, MD 20892 USA	Imperial College London; Cancer Research UK; Imperial College London; Harvard University; Harvard Medical School; Harvard University; Massachusetts General Hospital; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Kirn, D (corresponding author), Univ London Imperial Coll Sci Technol & Med, Viral & Genet Therapy Programme, Sch Med, London, England.	d.kirn@icrf.icnet.uk			NINDS NIH HHS [NS32677] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS032677] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ALEMANY N, 2000, CLIN CANCER RES, V6, P3395; BARKER DD, 1987, VIROLOGY, V156, P107, DOI 10.1016/0042-6822(87)90441-7; Batliwalla FM, 1998, MOL MED, V4, P783, DOI 10.1007/BF03401771; Bischoff JR, 1996, SCIENCE, V274, P373, DOI 10.1126/science.274.5286.373; BRYSON JS, 1988, CANCER IMMUNOL IMMUN, V26, P132; CASSEL WA, 1983, CANCER, V52, P856, DOI 10.1002/1097-0142(19830901)52:5<856::AID-CNCR2820520519>3.0.CO;2-4; Chalavi A, 1999, NEOPLASIA, V1, P162; Coffey MC, 1998, SCIENCE, V282, P1332, DOI 10.1126/science.282.5392.1332; Conry RM, 1999, CLIN CANCER RES, V5, P2330; Doronin K, 2000, J VIROL, V74, P6147, DOI 10.1128/JVI.74.13.6147-6155.2000; Douglas JT, 2001, CANCER RES, V61, P813; Eder JP, 2000, CLIN CANCER RES, V6, P1632; Freytag SO, 1998, HUM GENE THER, V9, P1323, DOI 10.1089/hum.1998.9.9-1323; Fueyo J, 2000, ONCOGENE, V19, P2, DOI 10.1038/sj.onc.1203251; Ganly I, 2000, CLIN CANCER RES, V6, P798; Goodrum FD, 1997, J VIROL, V71, P548, DOI 10.1128/JVI.71.1.548-561.1997; Gromeier M, 2000, P NATL ACAD SCI USA, V97, P6803, DOI 10.1073/pnas.97.12.6803; Haag A, 2000, HUM GENE THER, V11, P597, DOI 10.1089/10430340050015789; Hallenbeck PL, 1999, HUM GENE THER, V10, P1721, DOI 10.1089/10430349950017725; Harada JN, 1999, J VIROL, V73, P5333, DOI 10.1128/JVI.73.7.5333-5344.1999; HECHT R, 2000, P AN M AM SOC CLIN, V19, P1039; Heise C, 2000, NAT MED, V6, P1134, DOI 10.1038/80474; Heise C, 1997, NAT MED, V3, P639, DOI 10.1038/nm0697-639; Heise C, 2000, CLIN CANCER RES, V6, P4908; Heise CC, 1999, CANCER GENE THER, V6, P499, DOI 10.1038/sj.cgt.7700071; Heise CC, 1999, CANCER RES, V59, P2623; Hermiston T, 2000, J CLIN INVEST, V105, P1169, DOI 10.1172/JCI9973; Herrlinger U, 1998, GENE THER, V5, P809, DOI 10.1038/sj.gt.3300643; Ikeda K, 1999, NAT MED, V5, P881, DOI 10.1038/11320; Jakubczak JL, 2001, J VIROL, V75, P2972, DOI 10.1128/JVI.75.6.2972-2981.2001; Khuri FR, 2000, NAT MED, V6, P879, DOI 10.1038/78638; Kirn D, 2000, ONCOGENE, V19, P6660, DOI 10.1038/sj.onc.1204094; Kirn D, 2001, GENE THER, V8, P89, DOI 10.1038/sj.gt.3301377; KIRN D, 1998, P CANC GEN THER M SA; Kirn DH, 2000, J CLIN INVEST, V105, P837, DOI 10.1172/JCI9761; Kurihara T, 2000, J CLIN INVEST, V106, P763, DOI 10.1172/JCI9180; LEHNER B, 1990, CANCER IMMUNOL IMMUN, V32, P173, DOI 10.1007/BF01771453; LIEBRICH W, 1991, EUR J CANCER, V27, P703, DOI 10.1016/0277-5379(91)90170-I; LORENCE RM, 1988, J NATL CANCER I, V80, P1305, DOI 10.1093/jnci/80.16.1305; Markert JM, 2000, GENE THER, V7, P867, DOI 10.1038/sj.gt.3301205; Martuza RL, 2000, J CLIN INVEST, V105, P841, DOI 10.1172/JCI9744; MARTUZA RL, 1991, SCIENCE, V252, P854, DOI 10.1126/science.1851332; Mastrangelo MJ, 1999, CANCER GENE THER, V6, P409, DOI 10.1038/sj.cgt.7700066; Mastrangelo MJ, 2000, J CLIN INVEST, V105, P1031, DOI 10.1172/JCI9819; McCart JA, 2000, GENE THER, V7, P1217, DOI 10.1038/sj.gt.3301237; MINETA T, 1995, NAT MED, V1, P938, DOI 10.1038/nm0995-938; MINETA T, 1994, CANCER RES, V54, P3963; Miyatake S, 1997, J VIROL, V71, P5124, DOI 10.1128/JVI.71.7.5124-5132.1997; MOSS B, 1996, VIROLOGY; Mukherjee S, 2000, CANCER GENE THER, V7, P663, DOI 10.1038/sj.cgt.7700133; Nemunaitis J, 2000, CANCER RES, V60, P6359; NEUMUNAITIS J, IN PRESS GENE THER; Norman KL, 2000, J CLIN INVEST, V105, P1035, DOI 10.1172/JCI9871; Puhlmann M, 2000, CANCER GENE THER, V7, P66, DOI 10.1038/sj.cgt.7700075; Rampling R, 2000, GENE THER, V7, P859, DOI 10.1038/sj.gt.3301184; Reid T, 2000, P AN M AM SOC CLIN, V19, P953; Ries SJ, 2000, NAT MED, V6, P1128, DOI 10.1038/80466; Rodriguez R, 1997, CANCER RES, V57, P2559; Roelvink PW, 1999, SCIENCE, V286, P1568, DOI 10.1126/science.286.5444.1568; Rogulski KR, 2000, CANCER RES, V60, P1193; ROMMELAERE J, 1991, J VIROL METHODS, V33, P233, DOI 10.1016/0166-0934(91)90024-T; Rothmann T, 1998, J VIROL, V72, P9470, DOI 10.1128/JVI.72.12.9470-9478.1998; RUSSELL SJ, 1992, LANCET, V339, P1109, DOI 10.1016/0140-6736(92)90698-3; Sauthoff H, 2000, HUM GENE THER, V11, P379, DOI 10.1089/10430340050015851; SOUTHAM CM, 1960, NY ACAD SCI, V22, P656; Stojdl DF, 2000, NAT MED, V6, P821, DOI 10.1038/77558; Strong JE, 1998, EMBO J, V17, P3351, DOI 10.1093/emboj/17.12.3351; Sznol M, 2000, J CLIN INVEST, V105, P1027, DOI 10.1172/JCI9818; TELERMAN A, 1993, P NATL ACAD SCI USA, V90, P8702, DOI 10.1073/pnas.90.18.8702; Toda M, 1998, J IMMUNOL, V160, P4457; Todo T, 1999, HUM GENE THER, V10, P2741, DOI 10.1089/10430349950016483; VASEY P, 2000, P AN M AM SOC CLIN, V19, P1512; WHITLEY RJ, 1993, J CLIN INVEST, V91, P2837, DOI 10.1172/JCI116527; WHYTE P, 1988, J VIROL, V62, P257, DOI 10.1128/JVI.62.1.257-265.1988; Wickham TJ, 1997, J VIROL, V71, P8221, DOI 10.1128/JVI.71.11.8221-8229.1997; Wildner O, 1999, CANCER RES, V59, P410; Yu DC, 1999, CANCER RES, V59, P4200; Yu DC, 2001, CANCER RES, V61, P517	78	344	391	1	65	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	JUL	2001	7	7					781	787		10.1038/89901	http://dx.doi.org/10.1038/89901			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	451NR	11433341				2023-01-03	WOS:000169808600028
J	Birring, SS; Heartin, E; Williams, TJ; Brightling, CE; Pavord, ID				Birring, SS; Heartin, E; Williams, TJ; Brightling, CE; Pavord, ID			Peak expiratory flow sequence in acute exacerbations of asthma	BRITISH MEDICAL JOURNAL			English	Article							DEEP INHALATION		Gen Hosp Kettering, Dept Resp Med, Kettering NN16 8UZ, Northants, England; Univ Hosp Leicester NHS Trust, Dept Resp Med, Inst Lung Hlth, Leicester LE3 9QP, Leics, England	University Hospitals of Leicester NHS Trust; University of Leicester	Birring, SS (corresponding author), Gen Hosp Kettering, Dept Resp Med, Kettering NN16 8UZ, Northants, England.		Birring, Surinder/GWU-6967-2022	brightling, chris/0000-0002-9345-4903; Pavord, Ian/0000-0002-4288-5973				BURNS CB, 1985, J APPL PHYSIOL, V59, P1590, DOI 10.1152/jappl.1985.59.5.1590; LIM TK, 1987, AM REV RESPIR DIS, V135, P591; PELLEGRINO R, 1990, AM REV RESPIR DIS, V142, P822, DOI 10.1164/ajrccm/142.4.822	3	8	8	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	MAY 26	2001	322	7297					1281	1281		10.1136/bmj.322.7297.1281	http://dx.doi.org/10.1136/bmj.322.7297.1281			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	437YW	11375231	Bronze, Green Published, Green Submitted			2023-01-03	WOS:000169027800020
J	Rogan, WJ; Dietrich, KN; Ware, JH; Dockery, DW; Salganik, M; Radcliffe, J; Jones, RL; Ragan, NB; Chisolm, JJ; Rhoads, GG				Rogan, WJ; Dietrich, KN; Ware, JH; Dockery, DW; Salganik, M; Radcliffe, J; Jones, RL; Ragan, NB; Chisolm, JJ; Rhoads, GG		Treatment Lead Exposed Children Tr	The effect of chelation therapy with succimer on neuropsychological development in children exposed to lead.	NEW ENGLAND JOURNAL OF MEDICINE			English	Article; Proceedings Paper	Annual Meeting of the Society-of-Toxicology	MAR   27, 2001	SAN FRANCISCO, CALIFORNIA	Soc Toxicol			PORT-PIRIE COHORT; COGNITIVE FUNCTION; CINCINNATI LEAD; CLINICAL-TRIAL; INTELLIGENCE; AGE	Background: Thousands of children, especially poor children living in deteriorated urban housing, are exposed to enough lead to produce cognitive impairment. It is not known whether treatment to reduce blood lead levels prevents or reduces such impairment. Methods: We enrolled 780 children with blood lead levels of 20 to 44 mug per deciliter (1.0 to 2.1 mu mol per liter) in a randomized, placebo-controlled, double-blind trial of up to three 26-day courses of treatment with succimer, a lead chelator that is administered orally. The children lived in deteriorating inner-city housing and were 12 to 33 months of age at enrollment; 77 percent were black, and 5 percent were Hispanic. Follow-up included tests of cognitive, motor, behavioral, and neuropsychological function over a period of 36 months. Results: During the first six months of the trial, the mean blood lead level in the children given succimer was 4.5 mug per deciliter (0.2 mu mol per liter) lower than the mean level in the children given placebo (95 percent confidence interval, 3.7 to 5.3 mug per deciliter [0.2 to 0.3 mu mol per liter]). At 36 months of follow-up, the mean IQ score of children given succimer was 1 point lower than that of children given placebo, and the behavior of children given succimer was slightly worse as rated by a parent. However, the children given succimer scored slightly better on the Developmental Neuropsychological Assessment, a battery of tests designed to measure neuropsychological deficits thought to interfere with learning. All these differences were small, and none were statistically significant. Conclusions: Treatment with succimer lowered blood lead levels but did not improve scores on tests of cognition, behavior, or neuropsychological function in children with blood lead levels below 45 mug per deciliter. Since succimer is as effective as any lead chelator currently available, chelation therapy is not indicated for children with these blood lead levels. (N Engl J Med 2001;344:1421-6.) Copyright (C) 2001 Massachusetts Medical Society.	NIEHS, Epidemiol Branch, Res Triangle Pk, NC 27709 USA; Univ Cincinnati, Dept Environm Hlth, Cincinnati, OH USA; Harvard Univ, Sch Publ Hlth, Boston, MA 02115 USA; Childrens Hosp Philadelphia, Dept Psychol, Philadelphia, PA 19104 USA; Ctr Dis Control & Prevent, Nutr Biochem Branch, Atlanta, GA USA; Kennedy Krieger Inst, Baltimore, MD USA; Univ Med & Dent New Jersey, Environm & Occupat Hlth Sci Inst, Piscataway, NJ 08854 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); University System of Ohio; University of Cincinnati; Harvard University; Harvard T.H. Chan School of Public Health; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; Centers for Disease Control & Prevention - USA; Kennedy Krieger Institute; Rutgers State University New Brunswick; Rutgers State University Medical Center	Rogan, WJ (corresponding author), NIEHS, Epidemiol Branch, A3-05,POB 12233, Res Triangle Pk, NC 27709 USA.		Jones, Robert L/E-1170-2011; Rogan, Walter/I-6034-2012; , dwdockery/AAO-7272-2021	Rogan, Walter/0000-0002-9302-0160; Dockery, Douglas/0000-0002-6052-4880	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [Z01ES043011, ZIAES043011] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		[Anonymous], 2009, CONNERS COMPREHENS S; Bayley N., 2006, BAYLEY SCALES INFANT, V3rd; BELLINGER D, 1991, PEDIATRICS, V87, P219; BELLINGER D, 1994, PEDIATRICS, V93, pA28; BELLINGER DC, 1992, PEDIATRICS, V90, P855; Bornschein RL, 2000, PEDIATR RES, V48, P593; CDC, 1991, PREV LEAD POIS YOUNG; DIETRICH KN, 1991, NEUROTOXICOL TERATOL, V13, P203, DOI 10.1016/0892-0362(91)90012-L; DIETRICH KN, 1993, NEUROTOXICOL TERATOL, V15, P37, DOI 10.1016/0892-0362(93)90043-N; GRAZIANO JH, 1988, J PEDIATR-US, V113, P751, DOI 10.1016/S0022-3476(88)80396-2; Jonasson G, 1999, EUR RESPIR J, V14, P150, DOI 10.1034/j.1399-3003.1999.14a25.x; Korkman M., 2007, NEPSY; MCMICHAEL AJ, 1988, NEW ENGL J MED, V319, P468, DOI 10.1056/NEJM198808253190803; MILLER DT, 1987, ANALYST, V112, P1701, DOI 10.1039/an9871201701; NIGHTINGALE SL, 1991, JAMA-J AM MED ASSOC, V265, P1802, DOI 10.1001/jama.265.14.1802; Pirkle JL, 1998, ENVIRON HEALTH PERSP, V106, P745, DOI 10.2307/3434264; POCOCK SJ, 1994, BRIT MED J, V309, P1189, DOI 10.1136/bmj.309.6963.1189; Rhoads GG, 1996, PEDIATRICS, V98, P162; Rogan WJ, 1999, PHARMACOEPIDEM DR S, V8, P343; Rogan WJ, 1998, PAEDIATR PERINAT EP, V12, P313; RUFF HA, 1993, JAMA-J AM MED ASSOC, V269, P1641, DOI 10.1001/jama.269.13.1641; SILVERSTEIN AB, 1985, J CLIN PSYCHOL, V41, P95, DOI 10.1002/1097-4679(198501)41:1<95::AID-JCLP2270410116>3.0.CO;2-V; SMYTH AR, 1993, ARCH DIS CHILD, V68, P235, DOI 10.1136/adc.68.2.235; Tong S, 1998, JAMA-J AM MED ASSOC, V280, P1915, DOI 10.1001/jama.280.22.1915; Wechsler D., 2014, WECHSLER PRESCHOOL P	25	223	234	0	7	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAY 10	2001	344	19					1421	1426		10.1056/NEJM200105103441902	http://dx.doi.org/10.1056/NEJM200105103441902			6	Medicine, General & Internal	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	430BQ	11346806				2023-01-03	WOS:000168554000002
J	Greenspan, D; Canchoia, AJ; MacPhail, LA; Cheikh, B; Greenspan, JS				Greenspan, D; Canchoia, AJ; MacPhail, LA; Cheikh, B; Greenspan, JS			Effect of highly active antiretroviral therapy on frequency of oral warts	LANCET			English	Article							MANIFESTATIONS	To investigate changes in the pattern of oral disease associated with highly active antiretroviral therapy (HAART), we assessed the frequency of these lesions in our clinic over 9 years. We retrospectively studied 1280 patients seen between Jury, 1990, and June, 1999, and related oral findings to medication use, immune function, and viral load. We found significant decreases in oral candidosis, hairy leucoplakia, and Kaposi's sarcoma over time, but no change in the occurrence of aphthous ulcers. There was an increase in salivary-gland disease and a striking Increase in warts: three-fold for patients an antiretroviral therapy and six-fold for those an HAART (p = 0.01). This pattern of oral disease in a referral clinic suggests that an increase in oral warts could be occurring as a complication of HAART.	Univ Calif San Francisco, Dept Stomatol, San Francisco, CA 94143 USA; Univ Calif San Francisco, Oral AIDS Ctr, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco	Greenspan, D (corresponding author), Univ Calif San Francisco, Dept Stomatol, San Francisco, CA 94143 USA.		Greenspan, John/AAE-9321-2020		NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [P01DE007946] Funding Source: NIH RePORTER; NIDCR NIH HHS [P0 1 DE 07946] Funding Source: Medline	NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Greenspan D, 1996, LANCET, V348, P729, DOI 10.1016/S0140-6736(96)02308-2; GREENSPAN JS, 1992, ORAL SURG ORAL MED O, V73, P142, DOI 10.1016/0030-4220(92)90185-S; Ledergerber B, 1999, JAMA-J AM MED ASSOC, V282, P2220, DOI 10.1001/jama.282.23.2220; Leigh IM, 1999, J ACQ IMMUN DEF SYND, V21, pS49; Patton LL, 2000, ORAL SURG ORAL MED O, V89, P299, DOI 10.1016/S1079-2104(00)70092-8	5	149	158	0	5	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAY 5	2001	357	9266					1411	1412		10.1016/S0140-6736(00)04578-5	http://dx.doi.org/10.1016/S0140-6736(00)04578-5			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	428TW	11356441				2023-01-03	WOS:000168478200015
J	Borras, JM; Sanchez-Hernandez, A; Navarro, M; Martinez, M; Mendez, E; Ponton, JLL; Espinas, JA; Germa, JR				Borras, JM; Sanchez-Hernandez, A; Navarro, M; Martinez, M; Mendez, E; Ponton, JLL; Espinas, JA; Germa, JR			Compliance, satisfaction, and quality of life of patients with colorectal cancer receiving home chemotherapy or outpatient treatment: a randomised controlled trial	BRITISH MEDICAL JOURNAL			English	Article							OF-LIFE; CARE; PREFERENCES; THERAPY	Objective To compare chemotherapy given at home with outpatient treatment in terms of colorectal cancer patients' safety, compliance: use of health services, quality of life, and satisfaction with treatment. Design Randomised controlled trial. Setting Large teaching hospital. Participants 87 patients receiving adjuvant or palliative chemotherapy for colorectal cancer. Interventions Treatment with fluorouracil (with or without folinic acid or levamisole) at outpatient clinic or at home. Main outcome measures Treatment toxicity patients' compliance with treatment, quality of life, satisfaction with care, and use of health resources. Results 49 patients were treated at outpatient clinic and 45 at home. The two groups were balanced in terms of age, ses, site of cancer, and disease stage. Treatment related toxicity was similar in the two groups (difference 7%, (95% confidence interval - 12% to 26%), but there were more voluntary: withdrawals from treatment in the outpatient group than in the home group (14% v 2%: difference 12% (1% to 24%)). There were no differences between groups in terms of quality of life scores during and after treatment. Levels of patient satisfaction were higher in the home treatment group, specifically with regard to information received and nursing care. There were no significant differences in use of health services. Conclusions Home chemotherapy seemed an acceptable and safe alternative to hospital treatment for patients with colorectal cancer that mall improve compliance and satisfaction with treatment.	Catalan Inst Oncol, Canc Prevent & Control Unit, Hospitalet 08907, Spain; Catalan Inst Oncol, Dept Med Oncol, Hospitalet 08907, Spain; Catalan Inst Oncol, Dept Pharm, Hospitalet 08907, Spain	Catalan Institute of Oncology; Catalan Institute of Oncology; Catalan Institute of Oncology	Borras, JM (corresponding author), Catalan Inst Oncol, Canc Prevent & Control Unit, Gran Via Km 2,7 S-N, Hospitalet 08907, Spain.			Borras, Josep M/0000-0001-7330-6308				AARONSON NK, 1993, J NATL CANCER I, V85, P365, DOI 10.1093/jnci/85.5.365; BAROFSKY I, 1968, HLTH ED Q S, V10, P43; BENJAMIN AE, 1993, MILBANK Q, V71, P129, DOI 10.2307/3350277; CLOSE P, 1995, PEDIATRICS, V95, P896; Cronbach LJ, 1951, PSYCHOMETRIKA, V16, P297; GREEN JA, 1983, BRIT MED J, V287, P778, DOI 10.1136/bmj.287.6395.778; Karnofsky DA, 1949, EVALUATION CHEMOTHER; King MT, 2000, INT J HEALTH SERV, V30, P557, DOI 10.2190/CY03-EV15-K38Y-X4AA; LEWIS C, 1983, AM J MED, V74, P673, DOI 10.1016/0002-9343(83)91026-4; LOWENTHAL RM, 1999, BRIT MED J, V319, P1547; MARKS L, 1992, HOME HOSP CARE REDRA; MCCUSKER J, 1984, MED CARE, V22, P476, DOI 10.1097/00005650-198405000-00011; MOR V, 1988, J CLIN EPIDEMIOL, V41, P771, DOI 10.1016/0895-4356(88)90164-3; Nunally J.C., 1994, PSYCHOMETRIC THEORY; PAYNE SA, 1992, SOC SCI MED, V35, P1505, DOI 10.1016/0277-9536(92)90053-S; PFISTER DG, 1996, BRINGING HOSP HOME, P65; RICHARDSON JL, 1988, J CLIN ONCOL, V6, P1746, DOI 10.1200/JCO.1988.6.11.1746; Rischin D, 2000, MED J AUSTRALIA, V173, P125, DOI 10.5694/j.1326-5377.2000.tb125563.x; SHEPPERD S, COCHRANE COLLABORATI, P98; Smeenk FWJM, 1998, BRIT MED J, V316, P1939, DOI 10.1136/bmj.316.7149.1939; Soderstrom L, 1999, CAN MED ASSOC J, V160, P1151; 1980, NEOPLASMA, V20, P37	22	106	108	0	14	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	APR 7	2001	322	7290					826	828A		10.1136/bmj.322.7290.826	http://dx.doi.org/10.1136/bmj.322.7290.826			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	421KF	11290635	Green Published, Bronze, Green Submitted			2023-01-03	WOS:000168063000022
J	Dowey, JA				Dowey, JA			Child B: A personal view	BRITISH MEDICAL JOURNAL			English	Article																			0	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JAN 18	1997	314	7075					200	200						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WD911	11644899				2023-01-03	WOS:A1997WD91100034
J	Humphrey, LL; Chan, BKS; Sox, HC				Humphrey, LL; Chan, BKS; Sox, HC			Postmenopausal hormone replacement therapy and the primary prevention of cardiovascular disease	ANNALS OF INTERNAL MEDICINE			English	Article							CORONARY-HEART-DISEASE; ACUTE MYOCARDIAL-INFARCTION; SERVICES-TASK-FORCE; ESTROGEN-REPLACEMENT; FOLLOW-UP; SECONDARY PREVENTION; RISK-FACTORS; VENOUS THROMBOEMBOLISM; TREATMENT ADHERENCE; CIGARETTE-SMOKING	Purpose: To evaluate the value of hormone replacement therapy (HRT) in the primary prevention of cardiovascular disease (CVD) and coronary artery disease (CAD). Data Sources: MEDLINE and Cochrane databases were searched for all primary prevention studies reporting CVD or CAD incidence, mortality, or both in association with HRT; reference lists, letters, editorials, and reviews were also reviewed. Data Extraction: All studies were reviewed, abstracted, and rated for quality. Study Selection: Only studies of good or fair quality, according to U.S. Preventive Services Task Force (USPSTF) criteria, were included in the detailed review and meta-analysis. Data Synthesis: The summary relative risk with any HRT use was 0.75 (95% credible interval [Crl], 0.42 to 1.23) for CVD mortality and 0.74 (Crl, 0.36 to 1.45) for CAD mortality. The summary relative risk with any use was 1.28 (Crl, 0.86 to 2.00) for CVD incidence and 0.87 (Crl, 0.62 to 1.21) for CAD incidence. Further analysis of studies adjusting for socioeconomic status, as well as other major CAD risk factors, showed a summary relative risk of 1.07 (Crl, 0.79 to 1.48) for CAD incidence associated with any HRT use. Similar results were found when the analysis was stratified by studies adjusting for alcohol consumption, exercise, or both, in addition to other major risk factors, suggesting confounding by these factors. Conclusions: This meta-analysis differs from previous meta-analyses by evaluating potential explanatory variables of the relationship between HRT, CVD, and CAD. The adjusted meta-analysis is consistent with recent randomized trials that have shown no benefit in the secondary or primary prevention of CVD events. A valid answer to the role of HRT in the primary prevention of CVD will best come from randomized, controlled trials.	Oregon Hlth & Sci Univ, Vet Affairs Med Ctr, Portland, OR 97201 USA; Oregon Hlth & Sci Univ, Portland, OR 97201 USA; Amer Coll Physicians, Amer Soc Internal Med, Philadelphia, PA USA	Oregon Health & Science University; US Department of Veterans Affairs; Veterans Health Administration (VHA); Oregon Health & Science University; American College of Physicians	Humphrey, LL (corresponding author), Oregon Hlth & Sci Univ, Vet Affairs Med Ctr, Portland, OR 97201 USA.				PHS HHS [290-97-0018] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		ADAM S, 1981, BRIT MED J, V282, P1277, DOI 10.1136/bmj.282.6272.1277; Alexander KP, 2001, J AM COLL CARDIOL, V38, P1, DOI 10.1016/S0735-1097(01)01329-8; [Anonymous], 1994, Circulation, V89, P1333; Barrett-Connor E, 1998, ANNU REV PUBL HEALTH, V19, P55, DOI 10.1146/annurev.publhealth.19.1.55; BARRETTCONNOR E, 1991, ANN INTERN MED, V115, P455, DOI 10.7326/0003-4819-115-6-455; BEARD CM, 1989, MAYO CLIN PROC, V64, P1471, DOI 10.1016/S0025-6196(12)65702-4; BUSH TL, 1987, CIRCULATION, V75, P1102, DOI 10.1161/01.CIR.75.6.1102; Bush TL, 1996, EUR HEART J, V17, P9, DOI 10.1093/eurheartj/17.suppl_D.9; BYRD BF, 1977, ANN SURG, V185, P574, DOI 10.1097/00000658-197705000-00010; Cauley JA, 1997, ARCH INTERN MED, V157, P2181, DOI 10.1001/archinte.157.19.2181; CRIQUI MH, 1988, AM J EPIDEMIOL, V128, P606, DOI 10.1093/oxfordjournals.aje.a115008; CROFT P, 1989, BRIT MED J, V298, P165, DOI 10.1136/bmj.298.6667.165; Cushman M, 1999, CIRCULATION, V100, P717, DOI 10.1161/01.CIR.100.7.717; DERBY CA, 1995, AM J OBSTET GYNECOL, V173, P544, DOI 10.1016/0002-9378(95)90280-5; Eaker E, 1994, Heart Dis Stroke, V3, P114; Ettinger B, 1996, OBSTET GYNECOL, V87, P6, DOI 10.1016/0029-7844(95)00358-4; FALKEBORN M, 1992, BRIT J OBSTET GYNAEC, V99, P821, DOI 10.1111/j.1471-0528.1992.tb14414.x; FOLSOM AR, 1995, AM J PUBLIC HEALTH, V85, P1128, DOI 10.2105/AJPH.85.8_Pt_1.1128; GALLAGHER EJ, 1993, JAMA-J AM MED ASSOC, V270, P742, DOI 10.1001/jama.270.6.742; GRADY D, 1992, ANN INTERN MED, V117, P1016, DOI 10.7326/0003-4819-117-12-1016; Grady D, 1998, CONTROL CLIN TRIALS, V19, P314, DOI 10.1016/S0197-2456(98)00010-5; Grodstein F, 1996, NEW ENGL J MED, V335, P453, DOI 10.1056/NEJM199608153350701; Grodstein F, 2001, ANN INTERN MED, V135, P1, DOI 10.7326/0003-4819-135-1-200107030-00003; Grodstein F, 1997, NEW ENGL J MED, V336, P1769, DOI 10.1056/NEJM199706193362501; Grodstein F, 2000, ANN INTERN MED, V133, P933, DOI 10.7326/0003-4819-133-12-200012190-00008; HAMMOND CB, 1979, AM J OBSTET GYNECOL, V133, P525, DOI 10.1016/0002-9378(79)90288-6; Harris RP, 2001, AM J PREV MED, V20, P21, DOI 10.1016/S0749-3797(01)00261-6; Heckbert SR, 2001, ARCH INTERN MED, V161, P1709, DOI 10.1001/archinte.161.14.1709; Heckbert SR, 1997, ARCH INTERN MED, V157, P1330, DOI 10.1001/archinte.157.12.1330; Hemminki E, 1997, BRIT MED J, V315, P149, DOI 10.1136/bmj.315.7101.149; HENDERSON BE, 1986, AM J OBSTET GYNECOL, V154, P1181, DOI 10.1016/0002-9378(86)90696-4; HENDERSON BE, 1991, ARCH INTERN MED, V151, P75, DOI 10.1001/archinte.151.1.75; HERNANDEZ AM, 1990, EPIDEMIOLOGY, V1, P128; Herrington DM, 2000, NEW ENGL J MED, V343, P522, DOI 10.1056/NEJM200008243430801; HORWITZ RI, 1990, LANCET, V336, P542, DOI 10.1016/0140-6736(90)92095-Y; Hulley S, 1998, JAMA-J AM MED ASSOC, V280, P605, DOI 10.1001/jama.280.7.605; HUMPHREY LL, IN PRESS SYSTEMATIC; HUNT K, 1990, BRIT J OBSTET GYNAEC, V97, P1080, DOI 10.1111/j.1471-0528.1990.tb02494.x; JICK H, 1978, JAMA-J AM MED ASSOC, V239, P1407, DOI 10.1001/jama.239.14.1407; LAFFERTY FW, 1994, AM J MED, V97, P66, DOI 10.1016/0002-9343(94)90050-7; LAVECCHIA C, 1987, AM J EPIDEMIOL, V125, P832, DOI 10.1093/oxfordjournals.aje.a114599; LENFANT C, 2000, NHLBI DIRECTOR PRELI; Lowe G, 2000, THROMB HAEMOSTASIS, V83, P530; MANN RD, 1994, J CLIN EPIDEMIOL, V47, P307, DOI 10.1016/0895-4356(94)90014-0; Matthews KA, 1996, AM J EPIDEMIOL, V143, P971; MCMAHON B, 1978, CORONARY HEART DIS Y; Miller J, 2002, ANN INTERN MED, V136, P680, DOI 10.7326/0003-4819-136-9-200205070-00011; MILLER VT, 1995, JAMA-J AM MED ASSOC, V273, P199, DOI 10.1001/jama.1995.03520270033028; NACHTIGALL LE, 1979, OBSTET GYNECOL, V54, P74, DOI 10.1097/00006250-197907000-00017; *NIH, 2001, HRT UPD; Persson I, 1997, J CLIN EPIDEMIOL, V50, P611, DOI 10.1016/S0895-4356(97)00004-8; Petitti DB, 1998, JAMA-J AM MED ASSOC, V280, P650, DOI 10.1001/jama.280.7.650; PETITTI DB, 1987, OBSTET GYNECOL, V70, P289; PFEFFER RI, 1978, AM J EPIDEMIOL, V107, P479, DOI 10.1093/oxfordjournals.aje.a112567; Price DT, 1997, ANN INTERN MED, V127, P895, DOI 10.7326/0003-4819-127-10-199711150-00007; PSATY BM, 1994, ARCH INTERN MED, V154, P1333, DOI 10.1001/archinte.154.12.1333; Psaty BM, 2001, JAMA-J AM MED ASSOC, V285, P906, DOI 10.1001/jama.285.7.906; Redelmeier DA, 1998, NEW ENGL J MED, V338, P1516, DOI 10.1056/NEJM199805213382106; ROSE G, 1981, BRIT HEART J, V45, P13, DOI 10.1136/hrt.45.1.13; ROSENBERG L, 1993, AM J EPIDEMIOL, V137, P54, DOI 10.1093/oxfordjournals.aje.a116602; ROSS RK, 1981, LANCET, V1, P858; Rossouw JE, 2002, JAMA-J AM MED ASSOC, V288, P321, DOI 10.1001/jama.288.3.321; Schairer C, 1997, EPIDEMIOLOGY, V8, P59, DOI 10.1097/00001648-199701000-00010; Shlipak MG, 2000, JAMA-J AM MED ASSOC, V283, P1845, DOI 10.1001/jama.283.14.1845; Sidney S, 1997, ANN INTERN MED, V127, P501, DOI 10.7326/0003-4819-127-7-199710010-00001; Sourander L, 1998, LANCET, V352, P1965, DOI 10.1016/S0140-6736(98)05066-1; STAMPFER MJ, 1991, NEW ENGL J MED, V325, P756, DOI 10.1056/NEJM199109123251102; STAMPFER MJ, 1991, PREV MED, V20, P47, DOI 10.1016/0091-7435(91)90006-P; STAMPFER MJ, 1985, NEW ENGL J MED, V313, P1044, DOI 10.1056/NEJM198510243131703; STURGEON SR, 1995, EPIDEMIOLOGY, V6, P227, DOI 10.1097/00001648-199505000-00006; SUTTON AJ, 2000, METHODS META ANALYSI; SZKLO M, 1984, PREV MED, V13, P510, DOI 10.1016/0091-7435(84)90019-7; TAKANO L, 2001, J GEN INTERN MED S1, V16, P177; TALBOTT E, 1977, AM J CARDIOL, V39, P858, DOI 10.1016/S0002-9149(77)80040-4; THOMPSON SG, 1989, J EPIDEMIOL COMMUN H, V43, P173, DOI 10.1136/jech.43.2.173; VANDENBROUCKE JP, 1995, EPIDEMIOLOGY, V6, P207; Varas-Lorenzo C, 2000, CIRCULATION, V101, P2572, DOI 10.1161/01.CIR.101.22.2572; Viscoli CM, 2001, NEW ENGL J MED, V345, P1243, DOI 10.1056/NEJMoa010534; Wenger NK, 2000, JAMA-J AM MED ASSOC, V284, P41, DOI 10.1001/jama.284.1.41-a; WILSON PWF, 1985, NEW ENGL J MED, V313, P1038, DOI 10.1056/NEJM198510243131702; WOLF PH, 1991, AM J OBSTET GYNECOL, V164, P489, DOI 10.1016/S0002-9378(11)80006-2	81	210	212	0	8	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	AUG 20	2002	137	4					273	284		10.7326/0003-4819-137-4-200208200-00012	http://dx.doi.org/10.7326/0003-4819-137-4-200208200-00012			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	585BB	12186518				2023-01-03	WOS:000177502300008
J	Bascom, PB; Tolle, SW				Bascom, PB; Tolle, SW			Responding to requests for physician-assisted suicide - "These are uncharted waters for both of us. ... "	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							AMYOTROPHIC-LATERAL-SCLEROSIS; TERMINALLY-ILL PATIENTS; OF-LIFE CARE; PATIENT REQUESTS; OREGON DEATH; LAST RESORT; EUTHANASIA; END; DEPRESSION; ATTITUDES	Studies of dying patients have shown that about half would like the option of physician-assisted suicide (PAS) to be available for possible future use. Those percentages decrease significantly with each step patients take toward action. Studies show that although about 10% of patients seriously consider PAS, only 1% of dying patients specifically request it, and 1 in 10 of those patients actually receive and take a lethal prescription. However, most patients' desires for PAS diminish as their underlying concerns are identified and addressed directly. To help identify concerns motivating a patient's request for PAS, physicians should talk with patients about their expectations and fears, options for end-of-life care, goals, family concerns and burdens, suffering or physical symptoms, sense of meaning and quality of life, and symptoms of depression. A patient with advanced amyotrophic lateral sclerosis (ALS) who requested PAS illustrates how a hasty response may adversely affect patient care and the health care team. Although physicians should remain mindful of their personal, moral, and legal concerns, these concerns should not override their willingness to explore what motivates a patient to make this request. When this approach is taken, suffering can be optimally alleviated and, in almost all cases, the patient's wishes can be met without PAS.	Oregon Hlth & Sci Univ, Div Gen Internal Med & Geriatr, Ctr Eth Hlth Care, Portland, OR 97201 USA	Oregon Health & Science University	Bascom, PB (corresponding author), Oregon Hlth & Sci Univ, Div Gen Internal Med & Geriatr, Ctr Eth Hlth Care, L475, Portland, OR 97201 USA.	bascomp@ohsu.edu						Angell M, 1997, NEW ENGL J MED, V336, P50, DOI 10.1056/NEJM199701023360108; Back AL, 1996, JAMA-J AM MED ASSOC, V275, P919, DOI 10.1001/jama.275.12.919; BLOCH SD, 1994, ARCH INTERN MED, V154, P2039, DOI 10.1001/archinte.154.18.2039; Block SD, 2000, ANN INTERN MED, V132, P209, DOI 10.7326/0003-4819-132-3-200002010-00007; Block SD, 2001, JAMA-J AM MED ASSOC, V285, P2898, DOI 10.1001/jama.285.22.2898; Breitbart W, 1996, AM J PSYCHIAT, V153, P238; Breitbart W, 2000, JAMA-J AM MED ASSOC, V284, P2907, DOI 10.1001/jama.284.22.2907; BRODY H, 1992, NEW ENGL J MED, V327, P1384, DOI 10.1056/NEJM199211053271912; Byock I R, 1994, J Palliat Care, V10, P8; CASSEL EJ, 1982, NEW ENGL J MED, V306, P639, DOI 10.1056/NEJM198203183061104; Chochinov HM, 1997, AM J PSYCHIAT, V154, P674; COHAN SR, 1996, CANCER, V77, P576; COLBURN D, 2003, OREGONIAN       0527, pA1; *COUNC ETH JUD AFF, 1997, COD MED ETH CURR OP; Emanuel EJ, 2000, ANN INTERN MED, V133, P527, DOI 10.7326/0003-4819-133-7-200010030-00011; EMANUEL EJ, 1994, ANN INTERN MED, V121, P793, DOI 10.7326/0003-4819-121-10-199411150-00010; Emanuel EJ, 2000, JAMA-J AM MED ASSOC, V284, P2460, DOI 10.1001/jama.284.19.2460; Field MJ, 1997, APPROACHING DEATH IM; Foley KM, 1997, NEW ENGL J MED, V336, P54, DOI 10.1056/NEJM199701023360109; Ganzini L, 2000, NEW ENGL J MED, V342, P557, DOI 10.1056/NEJM200002243420806; Ganzini L, 1998, NEW ENGL J MED, V339, P967, DOI 10.1056/NEJM199810013391406; Ganzini L, 2001, JAMA-J AM MED ASSOC, V285, P2363, DOI 10.1001/jama.285.18.2363; GAYLIN W, 1988, JAMA-J AM MED ASSOC, V259, P2139; HALEY K, 1998, TASK FORCE IMPROVE C; Hedberg K, 2002, NEW ENGL J MED, V346, P450, DOI 10.1056/NEJM200202073460614; JACOBSON JA, 1995, J CLIN ETHIC, V6, P149; Jansen LA, 2002, ANN INTERN MED, V136, P845, DOI 10.7326/0003-4819-136-11-200206040-00014; Kitchens LW, 1998, ANN INTERN MED, V128, P576, DOI 10.7326/0003-4819-128-7-199804010-00012; KNAUS WA, 1995, JAMA-J AM MED ASSOC, V274, P1591, DOI 10.1001/jama.1995.03530200027032; Lee MA, 1996, NEW ENGL J MED, V334, P310, DOI 10.1056/NEJM199602013340507; Lynn J, 2001, JAMA-J AM MED ASSOC, V285, P925, DOI 10.1001/jama.285.7.925; Meier DE, 1998, NEW ENGL J MED, V338, P1193, DOI 10.1056/NEJM199804233381706; Meier DE, 2001, JAMA-J AM MED ASSOC, V286, P3007, DOI 10.1001/jama.286.23.3007; MILLER FG, 1994, NEW ENGL J MED, V331, P119, DOI 10.1056/NEJM199407143310211; Moyers B.D., 2000, OUR OWN TERMS MOYERS; Muskin PR, 1998, JAMA-J AM MED ASSOC, V279, P323, DOI 10.1001/jama.279.4.323; Orentlicher D, 1996, NEW ENGL J MED, V335, P663, DOI 10.1056/NEJM199608293350912; Passik SD, 1998, J CLIN ONCOL, V16, P1594, DOI 10.1200/JCO.1998.16.4.1594; PELLEGRINO ED, 1993, JAMA-J AM MED ASSOC, V270, P874, DOI 10.1001/jama.270.7.874; Prigerson HG, 2001, JAMA-J AM MED ASSOC, V286, P1369, DOI 10.1001/jama.286.11.1369; Quill TE, 2000, ANN INTERN MED, V132, P488, DOI 10.7326/0003-4819-132-6-200003210-00011; QUILL TE, 1993, JAMA-J AM MED ASSOC, V270, P870, DOI 10.1001/jama.270.7.870; Quill TE, 2000, ANN INTERN MED, V132, P408, DOI 10.7326/0003-4819-132-5-200003070-00012; QUILL TE, 1991, NEW ENGL J MED, V324, P691, DOI 10.1056/NEJM199103073241010; QUILL TE, 1992, NEW ENGL J MED, V327, P1380, DOI 10.1056/NEJM199211053271911; Quill TE, 1997, JAMA-J AM MED ASSOC, V278, P2099, DOI 10.1001/jama.278.23.2099; QUILL TE, 1995, ANN INTERN MED, V122, P368, DOI 10.7326/0003-4819-122-5-199503010-00008; Quill TE, 2000, JAMA-J AM MED ASSOC, V284, P2502, DOI 10.1001/jama.284.19.2502; Reagan P, 1999, LANCET, V353, P1265, DOI 10.1016/S0140-6736(98)12219-5; RIMER S, 2002, NY TIMES        0112, pA9; Silveira MJ, 2000, JAMA-J AM MED ASSOC, V284, P2483, DOI 10.1001/jama.284.19.2483; Singer PA, 1999, JAMA-J AM MED ASSOC, V281, P163, DOI 10.1001/jama.281.2.163; Slome LR, 1997, NEW ENGL J MED, V336, P417, DOI 10.1056/NEJM199702063360606; Snyder L, 2001, ANN INTERN MED, V135, P209, DOI 10.7326/0003-4819-135-3-200108070-00015; Sullivan AD, 2000, NEW ENGL J MED, V342, P598, DOI 10.1056/NEJM200002243420822; Sulmasy DP, 1999, ARCH INTERN MED, V159, P545, DOI 10.1001/archinte.159.6.545; Sulmasy DP, 1998, J LAW MED ETHICS, V26, P55, DOI 10.1111/j.1748-720X.1998.tb01906.x; Tolle S, 1994, SUNDAY OREGONIA 1113, pC1; van der Maas PJ, 1991, LANCET, V338, P669, DOI 10.1016/0140-6736(91)91241-L; Veldink JH, 2002, NEW ENGL J MED, V346, P1638, DOI 10.1056/NEJMsa012739; 2002, NY TIMES        0401, pA9; 2001, FED REG         1109, V66, P56607	62	62	62	0	9	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 3	2002	288	1					91	98		10.1001/jama.288.1.91	http://dx.doi.org/10.1001/jama.288.1.91			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	568YW	12090867				2023-01-03	WOS:000176573400024
J	Trouiller, P; Olliaro, P; Torreele, E; Orbinski, J; Laing, R; Ford, N				Trouiller, P; Olliaro, P; Torreele, E; Orbinski, J; Laing, R; Ford, N			Drug development for neglected diseases: a deficient market and a public-health policy failure	LANCET			English	Article							PRIVATE PARTNERSHIPS; COUNTRIES	There is a lack of effective, safe, and affordable pharmaceuticals to control Infectious diseases that cause high mortality and morbidity among poor people in the developing world. We analysed outcomes of pharmaceutical research and development over the past 25 years, and reviewed current public and private Initiatives aimed at correcting the Imbalance in research and development that leaves diseases that occur predominantly In the developing world largely unaddressed. We compiled data by searches of Medline and databases of the US Food and Drug Administration and the European Agency for the Evaluation of Medicinal Products, and reviewed current public and private Initiatives through an analysis of recently published studies. We found that, of 1393 new chemical entities marketed between 1975 and 1999, only 16 were for tropical diseases and tuberculosis. There Is a 13-fold greater chance of a drug being brought to market for central-nervous-system disorders or cancer than for a neglected disease. The pharmaceutical Industry argues that research and development is too costly and risky to invest in low-return neglected diseases, and public and private initiatives have tried to overcome this market limitation through incentive packages and public-private partnerships. The lack of drug research and development for "non-profitable" infectious diseases will require new strategies. No sustainable solution will result for diseases that predominantly affect poor people in the South without the establishment of an International pharmaceutical policy for all neglected diseases. Private-sector research obligations should be explored, and a public-sector not-for-profit research and development capacity promoted.	CHU Grenoble, F-38043 Grenoble 9, France; WHO, World Bank, Special Programme Res & Training Trop Dis, Geneva, Switzerland; Free Univ Brussels VIB, Dept Immunol Parasitol & Ultrastruct, Rhode St Genese, Belgium; Univ Toronto, Munk Ctr Int Studies, Toronto, ON, Canada; Boston Univ, Sch Publ Hlth, Boston, MA USA; Med Sans Frontieres, London, England; Med Sans Frontieres, Drugs Neglected Dis Working Grp, Geneva, Switzerland	CHU Grenoble Alpes; Communaute Universite Grenoble Alpes; UDICE-French Research Universities; Universite Grenoble Alpes (UGA); The World Bank; World Health Organization; Flanders Institute for Biotechnology (VIB); Vrije Universiteit Brussel; University of Toronto; Boston University; Doctors Without Borders; Doctors Without Borders	Trouiller, P (corresponding author), CHU Grenoble, BP 217, F-38043 Grenoble 9, France.	PTrouiller@chu-grenoble.fr						ANDERSON J, 1996, 7 WELLC TRUST; Buse K, 2000, B WORLD HEALTH ORGAN, V78, P699; Buse K, 2000, B WORLD HEALTH ORGAN, V78, P549; CORREA C, 2000, INTELLECTUAL PROPERT, P42; Dimasi J. A., 1995, INT J ECON BUS, V2, P201, DOI DOI 10.1080/758519309; DiMasi JA, 2001, CLIN PHARMACOL THER, V69, P297, DOI 10.1067/mcp.2001.115446; DiMasi JA, 2001, CLIN PHARMACOL THER, V69, P286, DOI 10.1067/mcp.2001.115132; Drews J, 1998, DRUG DISCOV TODAY, V3, P491, DOI 10.1016/S1359-6446(98)01252-5; *EUR FED PHARM IND, 2000, PHARM IND FIG; Folkers GK, 2001, JAMA-J AM MED ASSOC, V286, P458, DOI 10.1001/jama.286.4.458; Goldman D P, 1992, Int J Technol Assess Health Care, V8, P583; Haffner ME, 1998, DRUG INF J, V32, P93, DOI 10.1177/009286159803200113; *HLTH IMS, 1999, MARK REP; JENSSENS PG, 1992, MED HYGIENE AFRIQUE, P590; KADAR M, 1995, REV PRESCRIRE, V15, P844; Kaitin KI, 2000, DRUG INF J, V34, P1; KANAVOS P, 1999, PHARM PRICING REIMBU; Lee J.W., 2000, FRAMEWORK R D EVALUA; Makinen M, 2000, B WORLD HEALTH ORGAN, V78, P55; MURRAY HW, 2001, RECENT ADV TROPICAL, P490; Pecoul B, 1999, JAMA-J AM MED ASSOC, V281, P361, DOI 10.1001/jama.281.4.361; Pecoul B, 2001, FATAL IMBALANCE CRIS; Stephenson I, 2000, DRUGS, V60, P985, DOI 10.2165/00003495-200060050-00002; Trouiller P, 1999, TROP MED INT HEALTH, V4, P412, DOI 10.1046/j.1365-3156.1999.00420.x; Trouiller P, 1998, Int J Infect Dis, V3, P61, DOI 10.1016/S1201-9712(99)90010-3; *UN DEV PROGR, 2001, HUM DEV REP 2001 MAK; *UN POL RES SCI ME, 1996, MAL RES AUD INT ACT; Vial HJ, 1999, PARASITOL TODAY, V15, P393, DOI 10.1016/S0169-4758(99)01524-0; Webber D, 2001, B WORLD HEALTH ORGAN, V79, P735; Wheeler C, 2001, B WORLD HEALTH ORGAN, V79, P728; WHO, 1996, INV HLTH RES DEV; *WHO, 1997, HLTH REF DRUG FIN OV, P9; WIRTH D, 2001, HARVEST NOTYET REAPE; YOUNG B, 2001, R D MYTHS CASE DRUG	34	510	522	1	78	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JUN 22	2002	359	9324					2188	2194		10.1016/S0140-6736(02)09096-7	http://dx.doi.org/10.1016/S0140-6736(02)09096-7			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	566RJ	12090998				2023-01-03	WOS:000176441800026
J	Foster, G				Foster, G			Supporting community efforts to assist orphans in Africa	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							CHILDREN; FAMILY; AIDS; CARE		Mutare Prov Hosp, Mutare, Zimbabwe		Foster, G (corresponding author), Mutare Prov Hosp, Mutare, Zimbabwe.							*AG INT DEV, 2001, PRINC GUID PROGR ORP; ANKRAH EM, 1993, AIDS CARE, V5, P5, DOI 10.1080/09540129308258580; Caldwell J. C., 1997, HLTH T REV S2, V7, P169; Drew RS, 1998, AIDS CARE, V10, pS9, DOI 10.1080/09540129850124325; Foster C, 2000, AIDS, V14, pS275; Foster G, 1996, AIDS CARE, V8, P389, DOI 10.1080/09540129650125597; Foster G, 1998, AIDS CARE, V10, pS17, DOI 10.1080/09540129850124334; FOSTER G, 1995, AIDS CARE, V7, P3, DOI 10.1080/09540129550126911; FOSTER G, 2002, 14 INT C AIDS BARC S; FOSTER G, IN PRESS HIV DEV; Foster G., 2000, PSYCHOL HEALTH MED, V5, P55, DOI DOI 10.1080/135485000106007; FOSTER G, IN PRESS AIDS AFRICA; Foster Geoff., 1997, HLTH T REV S2, V7, P155; Hunter S, 2000, CHILDREN BRINK EXECU; HUNTER S, 1998, CHIDLREN BRINK STRAT; LEE T, 1999, FOCUS EVALUATION REP; LEVINE C, 1994, ORPHANS HIV EPIDEMIC; Makame V, 2002, ACTA PAEDIATR, V91, P459, DOI 10.1080/080352502317371724; Ntozi J P, 1997, Health Transit Rev, V7 Suppl, P1; PHIRI SN, 2001, EXPANDING STRENGTHEN; *SYN PROJ, 2001, USAID PROJ PROF CHIL; *UNAIDS, 1999, REV HOUS COMM RESP H; *UNAIDS, 2001, CAR OUR CHILDR PROM; *UNICEF, 2001, SIT AN ORPH CHILDR N; VERHOEF HS, 2002, PROMOTING POSITIVE C, V3; WOODS E, 2002, REALITY US RHETORIC	26	51	52	0	5	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUN 13	2002	346	24					1907	1910		10.1056/NEJMsb020718	http://dx.doi.org/10.1056/NEJMsb020718			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	561NA	12063378				2023-01-03	WOS:000176146100012
J	Arai, Y; Kondo, T; Tanabe, K; Zhao, QL; Li, FJ; Ogawa, R; Li, M; Kasuya, M				Arai, Y; Kondo, T; Tanabe, K; Zhao, QL; Li, FJ; Ogawa, R; Li, M; Kasuya, M			Enhancement of hyperthermia-induced apoptosis by local anesthetics on human histiocytic lymphoma U937 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RANDOMIZED-TRIAL; LEUKEMIA-CELLS; MELANOMA; ATP; MITOCHONDRIA; POTENTIATION; RADIOTHERAPY; IRRADIATION; LIDOCAINE; MECHANISM	The combined effects of hyperthermia. at 44 degreesC and local anesthetics on apoptosis in human histiocytic lymphoma U937 cells were investigated. When the cells were exposed to hyperthermia for 10 min marginal DNA fragmentation and nuclear fragmentation were observed. In the presence of amide-type local anesthetics further enhancement was found depending on concentration. The order of the concentration required for maximum induction was the reverse order of the lipophilicity (prilocaine > lidocaine > bupivacaine). Western blotting revealed that in hyperthermia there was initial release of Ca2+ from the intracellular store site as indicated by increased expression of the type 1 inositol-1,4,5-trisphosphate receptor. However, the combination with lidocaine did not induce any further enhancement. Lidocaine enhanced the decrease in ATP content and the increase in intracellular Ca2+ concentration in individual cells induced by hyperthermia. In addition, superoxide formation, decrease in the mitochondrial membrane potential, and activation of intracellular caspase-3 were found in the cells treated with hyperthermia and lidocaine. All of these were suppressed in part in the presence of the intracellular Ca2+ ion chelator BAPTA-AM (bis-(O-aminophenoxy)-ethane-N,N,N',N'-tetraacetic acid-acetoxymethyl). The present results indicate that local anesthetics at optimal concentrations enhance hyperthermia-induced apoptosis via Ca2+- and mitochondria-dependent pathways. Initial release of Ca2+ from intracellular store sites caused by hyperthermia and followed by the subsequent increase in the intracellular Ca2+ concentration and the additional activation of the mitochondrial caspase-dependent pathway (partly regulated by intracellular Ca2+ concentration) plays a crucial role in the enhancement of apoptosis induced by the combination of hyperthermia and lidocaine.	Toyama Med & Pharmaceut Univ, Fac Med, Dept Radiol Sci, Toyama 9300194, Japan; Toyama Med & Pharmaceut Univ, Fac Med, Dept Publ Hlth, Toyama 9300194, Japan	University of Toyama; University of Toyama	Kondo, T (corresponding author), Toyama Med & Pharmaceut Univ, Fac Med, Dept Radiol Sci, 2630 Sugitani, Toyama 9300194, Japan.	kondot@ms.toyama-mpu.ac.jp						Arita K, 2000, BIOCHEM PHARMACOL, V60, P905, DOI 10.1016/S0006-2952(00)00406-8; Bruno T, 1998, ONCOL RES, V10, P143; BUTTERWORTH JF, 1990, ANESTHESIOLOGY, V72, P711, DOI 10.1097/00000542-199004000-00022; CLARK AW, 1983, CANCER RES, V43, P1716; COSS RA, 1989, INT J HYPERTHER, V5, P383, DOI 10.3109/02656738909140465; Eguchi Y, 1997, CANCER RES, V57, P1835; Eguchi Y, 1999, CANCER RES, V59, P2174; Gorman A, 1997, FEBS LETT, V404, P27, DOI 10.1016/S0014-5793(97)00069-0; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; GROUSELLE M, 1990, BIOCHEM J, V271, P269, DOI 10.1042/bj2710269; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HABARA Y, 1991, CELL CALCIUM, V12, P533, DOI 10.1016/0143-4160(91)90073-N; Hopcia KL, 1996, RADIAT RES, V145, P315, DOI 10.2307/3578987; Jayaraman T, 1997, MOL CELL BIOL, V17, P3005, DOI 10.1128/MCB.17.6.3005; Kameda K, 2001, INT J RADIAT ONCOL, V49, P1369, DOI 10.1016/S0360-3016(01)01437-7; Karniel M, 2000, MOL GENET METAB, V69, P40, DOI 10.1006/mgme.1999.2954; Khan AA, 1996, SCIENCE, V273, P503, DOI 10.1126/science.273.5274.503; Kimura C, 1998, EXP CELL RES, V239, P411, DOI 10.1006/excr.1997.3912; KINGSTON CA, 1993, ANTICANCER RES, V13, P2335; KONDO T, 1993, CELL CALCIUM, V14, P621, DOI 10.1016/0143-4160(93)90087-M; Li M, 2000, J BIOL CHEM, V275, P39702, DOI 10.1074/jbc.M007369200; MIZUNO S, 1982, CANCER RES, V42, P4726; OVERGAARD J, 1989, INT J RADIAT ONCOL, V16, P535, DOI 10.1016/0360-3016(89)90470-7; Overgaard J, 1996, INT J HYPERTHER, V12, P3, DOI 10.3109/02656739609023685; ROBINS HI, 1984, CANCER, V54, P2831, DOI 10.1002/1097-0142(19841215)54:12<2831::AID-CNCR2820541202>3.0.CO;2-8; ROBINS HI, 1983, CANCER RES, V43, P3187; SCURR C, 1990, SCI FDN ANESTHESIA, P636; Seegenschmiedt M. H., 1995, Strahlentherapie und Onkologie, V171, P560; SELLINS KS, 1987, J IMMUNOL, V139, P3199; Senisterra GA, 2000, INT J HYPERTHER, V16, P1, DOI 10.1080/026567300285385; Sneed PK, 1998, INT J RADIAT ONCOL, V40, P287, DOI 10.1016/S0360-3016(97)00731-1; UEDA I, 1977, ANESTHESIOLOGY, V46, P327, DOI 10.1097/00000542-197705000-00004; van der Zee J, 2000, LANCET, V355, P1119, DOI 10.1016/S0140-6736(00)02059-6; VANHEERDE WL, 1995, THROMB HAEMOSTASIS, V73, P172; Vernon CC, 1996, INT J RADIAT ONCOL, V35, P731; Wessalowski R, 1998, CANCER, V82, P793, DOI 10.1002/(SICI)1097-0142(19980215)82:4<793::AID-CNCR24>3.3.CO;2-Q; YATVIN MB, 1979, SCIENCE, V205, P195, DOI 10.1126/science.451588; YAU TM, 1979, RADIAT RES, V80, P523, DOI 10.2307/3574994; Zapata JM, 1998, J BIOL CHEM, V273, P6916, DOI 10.1074/jbc.273.12.6916	39	68	71	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 24	2002	277	21					18986	18993		10.1074/jbc.M108084200	http://dx.doi.org/10.1074/jbc.M108084200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	558PM	11861640	hybrid			2023-01-03	WOS:000175975800097
J	Ruitenberg, M; Kannt, A; Bamberg, E; Fendler, K; Michel, H				Ruitenberg, M; Kannt, A; Bamberg, E; Fendler, K; Michel, H			Reduction of cytochrome c oxidase by a second electron leads to proton translocation	NATURE			English	Article							BO UBIQUINOL OXIDASE; PARACOCCUS-DENITRIFICANS; ESCHERICHIA-COLI; SUBUNIT-I; SITE; STATE	Cytochrome c oxidase, the terminal enzyme of cellular respiration in mitochondria and many bacteria, reduces O-2 to water. This four-electron reduction process is coupled to translocation (pumping) of four protons across the mitochondrial or bacterial membrane(1); however, proton pumping is poorly understood. Proton pumping was thought to be linked exclusively to the oxidative phase, that is, to the transfer of the third and fourth electron(2). Upon re-evaluation of these data, however, this proposal has been questioned(3,4), and a transport mechanism including proton pumping in the reductive phase-that is, during the transfer of the first two electrons-was suggested. Subsequently, additional studies reported that proton pumping during the reductive phase can occur, but only when it is immediately preceded by an oxidative phase(5). To help clarify the issue we have measured the generation of the electric potential across the membrane, starting from a defined one-electron reduced state. Here we show that a second electron transfer into the enzyme leads to charge translocation corresponding to pumping of one proton without necessity for a preceding turnover.	Max Planck Inst Biophys, Dept Mol Membrane Biol, D-60528 Frankfurt, Germany; Max Planck Inst Biophys, Dept Biophys Chem, D-60596 Frankfurt, Germany	Max Planck Society; Max Planck Society	Michel, H (corresponding author), Max Planck Inst Biophys, Dept Mol Membrane Biol, Heinrich Hoffmann Str 7, D-60528 Frankfurt, Germany.	fendler@mpibp-frankfurt.mpg.de; michel@mpibp-frankfurt.mpg.de	Kannt, Aimo/AAZ-6898-2020	Kannt, Aimo/0000-0002-5197-2286; Fendler, Klaus/0000-0002-5699-7060				BRZEZINSKI P, 1985, FEBS LETT, V187, P111, DOI 10.1016/0014-5793(85)81224-2; FergusonMiller S, 1996, CHEM REV, V96, P2889, DOI 10.1021/cr950051s; GREENWOOD C, 1974, BIOCHEM J, V137, P205, DOI 10.1042/bj1370205; IWATA S, 1995, NATURE, V376, P660, DOI 10.1038/376660a0; Jasaitis A, 1999, BIOCHEMISTRY-US, V38, P2697, DOI 10.1021/bi982275l; Konstantinov AA, 1997, P NATL ACAD SCI USA, V94, P9085, DOI 10.1073/pnas.94.17.9085; Michel H, 1998, P NATL ACAD SCI USA, V95, P12819, DOI 10.1073/pnas.95.22.12819; Michel H, 1999, BIOCHEMISTRY-US, V38, P15129, DOI 10.1021/bi9910934; Michel H, 1998, ANNU REV BIOPH BIOM, V27, P329, DOI 10.1146/annurev.biophys.27.1.329; MITCHELL R, 1994, BBA-BIOENERGETICS, V1186, P19, DOI 10.1016/0005-2728(94)90130-9; MOODY AJ, 1991, BIOCHEM SOC T, V19, P617, DOI 10.1042/bst0190617; NILSSON T, 1992, P NATL ACAD SCI USA, V89, P6497, DOI 10.1073/pnas.89.14.6497; OLIVEBERG M, 1991, BIOCHEMISTRY-US, V30, P7053, DOI 10.1021/bi00243a003; Ruitenberg M, 2000, P NATL ACAD SCI USA, V97, P4632, DOI 10.1073/pnas.080079097; THOMAS JW, 1993, BIOCHEMISTRY-US, V32, P11173, DOI 10.1021/bi00092a029; THOMAS JW, 1993, BIOCHEMISTRY-US, V32, P10923, DOI 10.1021/bi00091a048; Verkhovsky MI, 1999, NATURE, V400, P480, DOI 10.1038/22813; Verkhovsky MI, 2001, BIOCHEMISTRY-US, V40, P7077, DOI 10.1021/bi010030u; VYGODINA TV, 1988, ANN NY ACAD SCI, V550, P124, DOI 10.1111/j.1749-6632.1988.tb35329.x; WIKSTROM M, 1989, NATURE, V338, P776, DOI 10.1038/338776a0; WIKSTROM MKF, 1977, NATURE, V266, P271, DOI 10.1038/266271a0; WITT SN, 1987, J BIOL CHEM, V262, P1446	22	98	100	0	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAY 2	2002	417	6884					99	102		10.1038/417099a	http://dx.doi.org/10.1038/417099a			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	546ZM	11986672				2023-01-03	WOS:000175307200046
J	Sah, JF; Ito, H; Kolli, BK; Peterson, DA; Sassa, S; Chang, KP				Sah, JF; Ito, H; Kolli, BK; Peterson, DA; Sassa, S; Chang, KP			Genetic rescue of Leishmania deficiency in porphyrin biosynthesis creates mutants suitable for analysis of cellular events in uroporphyria and for photodynamic therapy	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DELTA-AMINOLEVULINIC-ACID; MEXICANA-AMAZONENSIS; MULTIDRUG-RESISTANCE; IN-VITRO; PROMASTIGOTES; IDENTIFICATION; AMPLIFICATION; DEHYDRATASE; METABOLISM; CRITHIDIA	Leishmania was found deficient in at least five and most likely seven of the eight enzymes in the heme biosynthesis pathway, accounting for their growth requirement for heme compounds. The xenotransfection of this trypanosomatid protozoan led to their expression of the mammalian genes encoding delta-aminolevulinate (ALA) dehydratase and porphobilinogen deaminase, the second and the third enzymes of the pathway, respectively. These transfectants still require hemin or protoporphyrin IX for growth but produce porphyrin when ALA was supplied exogenously. Leishmania is thus deficient in all first three enzymes of the pathway. Uroporphyrin I was produced as the sole intermediate by these transfectants, further indicating that they are also deficient in at least two porphyrinogen-metabolizing enzymes downstream of porphobilinogen deaminase, i.e. uroporphyrinogen III co-synthase and uroporphyrinogen decarboxylase. Pulsing the transfectants with ALA induced their transition from aporphyria to uroporphyria. Uroporphyrin I emerged in these cells initially as diffused throughout the cytosol, rendering them sensitive to UV irradiation. The porphyrin was subsequently sequestered in cytoplasmic vacuoles followed by its release and accumulation in the extracellular milieu, concomitant with a reduced photosensitivity of the cells. These events may represent cellular mechanisms for disposing soluble toxic waste from the cytosol. Monocytic tumor cells were rendered photosensitive by infection with uroporphyric Leishmania, suggestive of their potential application for photodynamic therapy.	Finch Univ Hlth Sci Chicago Med Sch, Dept Microbiol & Immunol, N Chicago, IL 60064 USA; Finch Univ Hlth Sci Chicago Med Sch, Dept Neurosci, N Chicago, IL 60064 USA; Rockefeller Univ, New York, NY 10021 USA	Chicago Medical School; Chicago Medical School; Rockefeller University	Chang, KP (corresponding author), Finch Univ Hlth Sci Chicago Med Sch, Dept Microbiol & Immunol, 3333 Green Bay Rd, N Chicago, IL 60064 USA.	changk@mail.finchcms.edu		Sah, Jerome/0000-0001-9478-7155	NIAID NIH HHS [AI 20486] Funding Source: Medline; NIDDK NIH HHS [DK32890] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI020486] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK032890] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ABBAS A, 1993, J BIOL CHEM, V268, P8541; Abels C, 1997, J PHOTOCH PHOTOBIO B, V40, P76, DOI 10.1016/S1011-1344(97)00027-4; Afonso S G, 1990, J Enzyme Inhib, V3, P303, DOI 10.3109/14756369009030379; ANDERSON WL, 1978, ANAL BIOCHEM, V91, P481, DOI 10.1016/0003-2697(78)90534-1; BEAUMONT C, 1989, J BIOL CHEM, V264, P14829; Bermudez R, 1997, MOL BIOCHEM PARASIT, V90, P43, DOI 10.1016/S0166-6851(97)00131-X; CHANG CS, 1985, MOL BIOCHEM PARASIT, V16, P267, DOI 10.1016/0166-6851(85)90069-6; Chang KP, 1999, CLIN DERMATOL, V17, P269, DOI 10.1016/S0738-081X(99)00055-3; CHANG KP, 1983, INT REV CYTOL, P267; CHANG KP, 1975, P NATL ACAD SCI USA, V72, P2979, DOI 10.1073/pnas.72.8.2979; Chen DQ, 2000, INFECT IMMUN, V68, P80, DOI 10.1128/IAI.68.1.80-86.2000; DU YB, 1994, P NATL ACAD SCI USA, V91, P8437, DOI 10.1073/pnas.91.18.8437; ELLENBERGER TE, 1989, J BIOL CHEM, V264, P15094; Essodaigui M, 1999, MOL BIOCHEM PARASIT, V100, P73, DOI 10.1016/S0166-6851(99)00036-5; GALBRAITH RA, 1988, MOL BIOCHEM PARASIT, V29, P47, DOI 10.1016/0166-6851(88)90118-1; Gibson SL, 1999, BRIT J CANCER, V80, P998, DOI 10.1038/sj.bjc.6690454; Glerum DM, 1996, YEAST, V12, P1421; Gueiros FJ, 1995, EXP PARASITOL, V81, P480, DOI 10.1006/expr.1995.1141; GUO GG, 1994, J BIOL CHEM, V269, P12399; Ha DS, 1996, MOL BIOCHEM PARASIT, V77, P57, DOI 10.1016/0166-6851(96)02580-7; HART DT, 1982, EXP PARASITOL, V54, P397, DOI 10.1016/0014-4894(82)90049-2; Hilf R, 1999, PHOTOCHEM PHOTOBIOL, V70, P334, DOI 10.1111/j.1751-1097.1999.tb08145.x; KAPPAS A, 1995, PEDIATRICS, V95, P468; KAPPAS A, 1969, P NATL ACAD SCI USA, V64, P557, DOI 10.1073/pnas.64.2.557; Kawazu SI, 1997, GENE, V196, P49, DOI 10.1016/S0378-1119(97)00190-X; KURLANDZKA A, 1985, J GEN MICROBIOL, V131, P2909; LIU X, 1992, MOL CELL BIOL, V12, P4112, DOI 10.1128/MCB.12.9.4112; McCaughan JS, 1999, DRUG AGING, V15, P49, DOI 10.2165/00002512-199915010-00005; McGwire BS, 1996, J BIOL CHEM, V271, P7903, DOI 10.1074/jbc.271.14.7903; Sagar R, 1995, MICROBIOL RES, V150, P419, DOI 10.1016/S0944-5013(11)80024-8; SALZMAN TA, 1985, INT J BIOCHEM, V17, P1343, DOI 10.1016/0020-711X(85)90058-8; SALZMAN TA, 1982, COMP BIOCHEM PHYS B, V72, P663, DOI 10.1016/0305-0491(82)90523-5; SANDBERG S, 1982, ACTA DERM-VENEREOL, P75; SANDBERG S, 1982, J CLIN INVEST, V70, P693, DOI 10.1172/JCI110664; SASSA S, 1982, ENZYME, V28, P133, DOI 10.1159/000459097; SASSA S, 1974, P NATL ACAD SCI USA, V71, P732, DOI 10.1073/pnas.71.3.732; SASSA S, 1976, J EXP MED, V143, P305, DOI 10.1084/jem.143.2.305; SASSA S, 1995, WILLIAMS HEMATOLOGY, P726; Sengupta S, 1999, J BIOL CHEM, V274, P2758, DOI 10.1074/jbc.274.5.2758; Srivastava P, 1997, MOL CELL BIOCHEM, V171, P65, DOI 10.1023/A:1006830113376; STEIGER RF, 1976, J PARASITOL, V62, P1010, DOI 10.2307/3279200; STUBNICER AC, 1988, NUCLEIC ACIDS RES, V16, P3102, DOI 10.1093/nar/16.7.3102; TAKETANI S, 1984, BIOCHIM BIOPHYS ACTA, V798, P226, DOI 10.1016/0304-4165(84)90308-8; WANG W, 1975, CELL, V6, P75, DOI 10.1016/0092-8674(75)90076-8	44	62	68	2	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 26	2002	277	17					14902	14909		10.1074/jbc.M200107200	http://dx.doi.org/10.1074/jbc.M200107200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	545EH	11836252	hybrid			2023-01-03	WOS:000175203000071
J	Smidt, N; van der Windt, DAWM; Assendelft, WJJ; Deville, WLJM; Korthals-de Bos, IBC; Bouter, LM				Smidt, N; van der Windt, DAWM; Assendelft, WJJ; Deville, WLJM; Korthals-de Bos, IBC; Bouter, LM			Corticosteroid injections, physiotherapy, or a wait-and-see policy for lateral epicondylitis: a randomised controlled trial	LANCET			English	Article							MUSCULOSKELETAL DISORDERS; TENNIS ELBOW; PRIMARY-CARE; PREVALENCE; THERAPY; PAIN	Background Lateral epicondylitis is generally treated with corticosteroid injections or physiotherapy. Dutch clinical guidelines recommend a wait-and-see policy. We compared the efficacy of these approaches. Methods Patients with lateral epicondylitis of at least 6 weeks' duration were recruited by family doctors. We randomly allocated eligible patients to 6 weeks of treatment with corticosteroid injections, physiotherapy, or a wait-and-see policy. Outcome measures included general improvement, severity of the main complaint, pain, elbow disability, and patient satisfaction. Severity of elbow complaints, grip strength, and pressure pain threshold were assessed by a research physiotherapist who was unaware of treatment allocation. We assessed all outcomes at 3, 6, 12, 26, and 52 weeks. The principal analysis was done on an intention-to-treat basis. Findings We randomly assigned 185 patients. At 6 weeks, corticosteroid injections were significantly better than all other therapy options for all outcome measures. Success rates were 92% (57) compared with 47% (30) for physiotherapy and 32% (19) for wait-and-see policy. However, recurrence rate in the injection group was high. Long-term differences between injections and physiotherapy were significantly in favour of physiotherapy. Success rates at 52 weeks were 69% (43) for injections, 91% (58) for physiotherapy, and 83% (49) for a wait-and-see policy. Physiotherapy had better results than a wait-and-see policy, but differences were not significant. Interpretation Patients should be properly informed about the advantages and disadvantages of the treatment options for lateral epicondylitis. The decision to treat with physiotherapy or to adopt a wait-and-see policy might depend on available resources, since the relative gain of physiotherapy is small.	VU Univ Med Ctr, Fac Med, Inst Res Extramural Med, NL-1081 BT Amsterdam, Netherlands; VU Univ Med Ctr, Dept Gen Practice, NL-1081 BT Amsterdam, Netherlands; Univ Amsterdam, Acad Med Ctr, Dept Gen Practice, Div Publ Hlth, NL-1105 AZ Amsterdam, Netherlands; Netherlands Inst Hlth Serv Res, Utrecht, Netherlands	Vrije Universiteit Amsterdam; VU UNIVERSITY MEDICAL CENTER; Vrije Universiteit Amsterdam; VU UNIVERSITY MEDICAL CENTER; University of Amsterdam; Academic Medical Center Amsterdam; Netherlands Institute for Health Services Research	Smidt, N (corresponding author), VU Univ Med Ctr, Fac Med, Inst Res Extramural Med, NL-1081 BT Amsterdam, Netherlands.		Assendelft, W.J.J./H-8008-2014; assendelft, willem/AAW-1854-2021; Deville, Walter/B-5160-2013	Assendelft, W.J.J./0000-0002-2966-3778; assendelft, willem/0000-0002-2966-3778; Bouter, Lex/0000-0002-2659-5482				ALLANDER E, 1974, SCAND J RHEUMATOL, V3, P145, DOI 10.3109/03009747409097141; [Anonymous], 1994, REUMA ONDERZOEK MEER; Assendelft WJJ, 1996, BRIT J GEN PRACT, V46, P209; BECKERMAN H, 1993, BRIT J GEN PRACT, V43, P73; BINDER A, 1985, BRIT MED J, V290, P512, DOI 10.1136/bmj.290.6467.512; CHARD MD, 1989, BR J RHEUMATOL, V28, P187; Cyriax JH, 1936, J BONE JOINT SURG, V18, P921; de Wolf A N, 1984, Ned Tijdschr Geneeskd, V128, P2191; DEWOLF AN, 1995, MUSCULOSKELETAL DISO, P106; ERNST E, 1992, BRIT J CLIN PRACT, V46, P55; ERNST E, 1994, EUR J PHYS MED, V4, P50; FISCHER AA, 1987, PAIN, V30, P115, DOI 10.1016/0304-3959(87)90089-3; HAMILTON PG, 1986, J ROY COLL GEN PRACT, V36, P464; Hay EM, 1999, BRIT MED J, V319, P964, DOI 10.1136/bmj.319.7215.964; Hudak PL, 1996, ARCH PHYS MED REHAB, V77, P586, DOI 10.1016/S0003-9993(96)90300-7; Kivi P, 1982, SCAND J REHABIL MED, V15, P37; LABELLE H, 1992, J BONE JOINT SURG BR, V74, P646, DOI 10.1302/0301-620X.74B5.1388172; MENS JMA, 1993, MOD MED          JAN, P41; Murtagh J E, 1988, Aust Fam Physician, V17, P90; Nussbaum EL, 1998, PHYS THER, V78, P160, DOI 10.1093/ptj/78.2.160; Pienimaki TT., 1996, PHYSIOTHERAPY, V82, P522; RABKIN JG, 1986, PSYCHIAT RES, V19, P75, DOI 10.1016/0165-1781(86)90094-6; SMIDT N, 2001, CONSERVATIVE TRETMEN, P121; STRATFORD P, 1987, Physiotherapy Canada, V39, P250; STRATFORD PW, 1989, PHYS THER, V69, P276, DOI 10.1093/ptj/69.4.276; STRATFORD PW, 1994, CLIN J SPORT MED, V4, P88, DOI DOI 10.1097/00042752-199404000-00004; van der Windt DAWM, 1999, PAIN, V81, P257, DOI 10.1016/S0304-3959(99)00016-0; van der Windt DAWM, 1998, BRIT MED J, V317, P1292, DOI 10.1136/bmj.317.7168.1292; VERHAAR IAN, 1992, TENNIS ELBOW; Verhaar JAN, 1996, J BONE JOINT SURG BR, V78B, P128, DOI 10.1302/0301-620X.78B1.0780128	30	424	436	3	43	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	FEB 23	2002	359	9307					657	662		10.1016/S0140-6736(02)07811-X	http://dx.doi.org/10.1016/S0140-6736(02)07811-X			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	526AZ	11879861	Green Submitted			2023-01-03	WOS:000174107400009
J	van Lommel, P; van Wees, R; Meyers, V; Elfferich, I				van Lommel, P; van Wees, R; Meyers, V; Elfferich, I			Near-death experience in survivors of cardiac arrest: a prospective study in the Netherlands	LANCET			English	Article							SYNCOPE	Background Some people report a near-death experience (NDE) after a life-threatening crisis. We aimed to establish the cause of this experience and assess factors that affected its frequency, depth, and content. Methods In a prospective study, we included 344 consecutive cardiac patients who were successfully resuscitated after cardiac arrest in ten Dutch hospitals. We compared demographic, medical, pharmacological, and psychological data between patients who reported NDE and patients who did not (controls) after resuscitation. In a longitudinal study of life changes after NDE, we compared the groups 2 and 8 years later. Findings 62 patients (18%) reported NDE, of whom 41 (12%) described a core experience. Occurrence of the experience was not associated with duration of cardiac arrest or unconsciousness, medication, or fear of death before cardiac arrest. Frequency of NDE was affected by how we defined NDE, the prospective nature of the research in older cardiac patients, age, surviving cardiac arrest in first myocardial infarction, more than one cardiopulmonary resuscitation (CPR) during stay in hospital, previous NDE, and memory problems after prolonged CPR. Depth of the experience was affected by sex, surviving CPR outside hospital, and fear before cardiac arrest. Significantly more patients who had an NDE, especially a deep experience, died within 30 days of CPR (p<0.0001). The process of transformation after NDE took several years, and differed from those of patients who survived cardiac arrest without NDE. Interpretation We do not know why so few cardiac patients report NDE after CPR, although age plays a part. With a purely physiological explanation such as cerebral anoxia for the experience, most patients who have been clinically dead should report one.	Hosp Rijnstate, Div Cardiol, NL-6800 TA Arnhem, Netherlands; Capelle AD, Ijssel, Netherlands	Rijnstate Hospital	van Lommel, P (corresponding author), Hosp Rijnstate, Div Cardiol, POB 9555, NL-6800 TA Arnhem, Netherlands.							AMINOFF MJ, 1988, ANN INTERN MED, V108, P791, DOI 10.7326/0003-4819-108-6-791; [Anonymous], 1998, MED PSYCHIAT, V1, P92; Appelby L., 1989, BMJ-BRIT MED J, V298, P976; Atwater P.M.H., 1988, COMING BACK LIFE AFT; Blackmore S., 1993, DYING LIVE SCI NEAR; CLUTE HL, 1990, ANESTHESIOLOGY, V73, P821, DOI 10.1097/00000542-199011000-00004; DICKEY W, 1992, BRIT HEART J, V67, P334; Greyson B, 2000, LANCET, V355, P460; GREYSON B, 1993, PSYCHIATRY, V56, P390; Greyson B, 1998, PERSPECT BIOL MED, V42, P14; GREYSON B, 1983, J NERV MENT DIS, V171, P369, DOI 10.1097/00005053-198306000-00007; Grof S., 1977, HUMAN ENCOUNTER DEAT; Groth-Marnat G, 1998, J HUMANIST PSYCHOL, V38, P110, DOI 10.1177/00221678980383005; Jansen K. L. R, 1996, NEAR DEATH EXPERIENC, P265; LEMPERT T, 1994, LANCET, V344, P829, DOI 10.1016/S0140-6736(94)92389-2; MEDUNA LJ, 1950, CARBON DIOXIDE THERA; Morse M., 1996, NEAR DEATH EXPERIENC, P299; MORSE M, 1990, TRANSFORMED LIGHT; OWENS JE, 1990, LANCET, V336, P1175, DOI 10.1016/0140-6736(90)92780-L; Parnia S, 2001, RESUSCITATION, V48, P149, DOI 10.1016/S0300-9572(00)00328-2; Penfield W., 1958, EXCITABLE CORTEX CON; Ring K., 1984, HEADING OMEGA SEARCH; Ring K, 1980, LIFE DEATH SCI INVES; Ring K., 1999, MINDSIGHT NEAR DEATH; ROBERTS G, 1988, BRIT J PSYCHIAT, V153, P607, DOI 10.1192/bjp.153.5.607; SABOM MB, 1988, LIGHT DEATH 1 DOCTOR, P37; SABORN M, 1982, RECOLLECTIONS DEATH; Schmied I, 1999, TODESNAHE INTERDISZI, P217; SCHOENBECK SB, 1991, J NEAR DEATH STUDIES, V9, P211; SCHROTERKUNHARD.M, 1999, TODESNAHE INTERDISZI, P65; WHINNERY JE, 1990, ARCH NEUROL-CHICAGO, V47, P764, DOI 10.1001/archneur.1990.00530070058012	31	268	282	4	123	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	DEC 15	2001	358	9298					2039	2045		10.1016/S0140-6736(01)07100-8	http://dx.doi.org/10.1016/S0140-6736(01)07100-8			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	502BB	11755611				2023-01-03	WOS:000172722800013
J	Schaumberg, DA; Buring, JE; Sullivan, DA; Dana, MR				Schaumberg, DA; Buring, JE; Sullivan, DA; Dana, MR			Hormone replacement therapy and dry eye syndrome	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CORONARY HEART-DISEASE; POSTMENOPAUSAL WOMEN; SJOGRENS-SYNDROME; STEROID-HORMONES; EPIDEMIOLOGY; GLANDS; PREVENTION; HEALTH; TRIAL	Context Postmenopausal hormone replacement therapy (HRT) use is common in the United States. Some research suggests that estrogen may have detrimental effects on the tear film and could influence the development of dry eye syndrome, but few data are available on this relationship. Objective To determine the relationship of HRT and dry eye syndrome. Design, Setting, and Participants The Women's Health Study, a large cohort study in which 25665 postmenopausal women provided information about use of HRT at baseline (1992), 12, and 36 months and dry eye syndrome at 48 months. Main Outcome Measures (1) Clinically diagnosed dry eye syndrome, as reported by participants; (2) severe symptoms (both ocular dryness and irritation either constantly or often); and (3) either clinically diagnosed dry eye syndrome or severe symptoms, compared between women who used HRT vs those who did not. Results For the combined end point of either clinically diagnosed dry eye syndrome or severe symptoms, the multivariable-adjusted odds ratios were 1.69 (95% confidence interval [CI], 1.49-1.91) for estrogen use alone and 1.29 (95% Cl, 1.13-1.48) for estrogen plus progesterone/progestin use compared with no HRT use, Each 3-year increase in the duration of HRT use was associated with a significant 15% (95% CI, 11%-19%) elevation in risk of clinically diagnosed dry eye syndrome or severe symptoms. Results were similar for the combined end point of clinically diagnosed dry eye syndrome and severe symptoms. Conclusions These data suggest that women who use HRT, particularly estrogen alone, are at increased risk of dry eye syndrome. Physicians caring for women who are taking or considering HRT should be apprised of this potential complication.	Harvard Univ, Brigham & Womens Hosp, Sch Med, Div Prevent Med,Dept Med, Boston, MA 02215 USA; Harvard Univ, Brigham & Womens Hosp, Sch Med, Div Prevent Med,Dept Ambulatory Care & Prevent, Boston, MA 02215 USA; Harvard Univ, Brigham & Womens Hosp, Sch Med, Div Prevent Med,Dept Ophthalmol, Boston, MA 02215 USA; Harvard Univ, Sch Med, Schepens Eye Res Inst, Boston, MA 02215 USA; Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02215 USA	Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University; Harvard Medical School; Schepens Eye Research Institute; Harvard University; Harvard T.H. Chan School of Public Health	Schaumberg, DA (corresponding author), Harvard Univ, Brigham & Womens Hosp, Sch Med, Div Prevent Med,Dept Med, 900 Commonwealth Ave E, Boston, MA 02215 USA.			Sullivan, David A/0000-0002-3424-3778	NCI NIH HHS [CA47988] Funding Source: Medline; NEI NIH HHS [EY00365, K23 EY000365-04, K23 EY000365-05] Funding Source: Medline; NHLBI NIH HHS [HL43851] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA047988] Funding Source: NIH RePORTER; NATIONAL EYE INSTITUTE [K23EY000365] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL043851] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BELCHETZ PE, 1994, NEW ENGL J MED, V330, P1062; BRENNAN NA, 1989, OPTOMETRY VISION SCI, V66, P834, DOI 10.1097/00006324-198912000-00006; Bush TL, 1996, JAMA-J AM MED ASSOC, V276, P1389, DOI 10.1001/jama.276.17.1389; Caffery BE, 1998, ADV EXP MED BIOL, V438, P805; Davis S, 2001, J REPROD MED, V46, P291; Esmaeli B, 2000, OPHTHALMOLOGY, V107, P180, DOI 10.1016/S0161-6420(99)00040-8; Frieling UM, 2000, ARCH DERMATOL, V136, P179, DOI 10.1001/archderm.136.2.179; GILBARD JP, 1994, PRINCIPLES PRACTICE, P257; Grodstein F, 1997, NEW ENGL J MED, V336, P1769, DOI 10.1056/NEJM199706193362501; GURWOOD AS, 1995, OPTOMETRY VISION SCI, V72, P29, DOI 10.1097/00006324-199501000-00006; Hulley S, 1998, JAMA-J AM MED ASSOC, V280, P605, DOI 10.1001/jama.280.7.605; Hunter David J., 1990, Annals of Epidemiology, V1, P13; Keating NL, 1999, ANN INTERN MED, V130, P545, DOI 10.7326/0003-4819-130-7-199904060-00002; Korb DR, 2000, CORNEA, V19, P483, DOI 10.1097/00003226-200007000-00016; Lemp MA, 1998, ADV EXP MED BIOL, V438, P791; McCarty CA, 1998, OPHTHALMOLOGY, V105, P1114, DOI 10.1016/S0161-6420(98)96016-X; McMonnies C W, 1987, J Am Optom Assoc, V58, P296; MILLER VT, 1995, JAMA-J AM MED ASSOC, V273, P199, DOI 10.1001/jama.1995.03520270033028; Moss SE, 2000, ARCH OPHTHALMOL-CHIC, V118, P1264; Nagler RM, 2000, SEMIN ARTHRITIS RHEU, V30, P209, DOI 10.1053/sarh.2000.18234; Nelson JD, 2000, ADV THER, V17, P84, DOI 10.1007/BF02854841; Nichols KK, 2000, CORNEA, V19, P477, DOI 10.1097/00003226-200007000-00015; Oden NL, 1998, ADV EXP MED BIOL, V438, P807; Rexrode KM, 2000, J WOMEN HEALTH GEN-B, V9, P19, DOI 10.1089/152460900318911; SATO EH, 1994, INVEST OPHTH VIS SCI, V35, P2632; STAMPFER MJ, 1991, PREV MED, V20, P47, DOI 10.1016/0091-7435(91)90006-P; Sullivan DA, 1999, ANN NY ACAD SCI, V876, P312, DOI 10.1111/j.1749-6632.1999.tb07656.x; Sullivan DA, 1998, ADV EXP MED BIOL, V438, P11; Sullivan DA, 1998, ADV EXP MED BIOL, V438, P327; SULLIVAN DA, 1997, RES PREVENT BLINDNES, P57; Taskinen MR, 1998, ANN MED, V30, P443, DOI 10.3109/07853899809002485; Tavani A, 1999, DRUG AGING, V14, P347, DOI 10.2165/00002512-199914050-00003; TAYLOR HR, 1980, ANN OPHTHALMOL, V12, P531; THODY AJ, 1989, PHYSIOL REV, V69, P383, DOI 10.1152/physrev.1989.69.2.383; *WRIT GROUP PEPI T, 1995, JAMA-J AM MED ASSOC, V274, P1676	35	252	271	0	7	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 7	2001	286	17					2114	2119		10.1001/jama.286.17.2114	http://dx.doi.org/10.1001/jama.286.17.2114			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	490CD	11694152	Bronze, Green Published			2023-01-03	WOS:000172032100030
J	Horton, R				Horton, R			Euthanasia and assisted suicide: what does the Dutch vote mean?	LANCET			English	Editorial Material							OF-LIFE CARE; END		Lancet, London WC1X 8RR, England		Horton, R (corresponding author), Lancet, London WC1X 8RR, England.							Asch DA, 1997, SOC SCI MED, V45, P1661, DOI 10.1016/S0277-9536(97)00125-1; Bolmsjo I, 2000, J PALLIAT CARE, V16, P20, DOI 10.1177/082585970001600204; Carron A T, 1999, Ann Intern Med, V130, P82; Dworkin R, 1997, NEW YORK REV BOOKS, V44, P41; Ferrand E, 2001, LANCET, V357, P9, DOI 10.1016/S0140-6736(00)03564-9; Ganzini L, 2000, NEW ENGL J MED, V343, P151; Ganzini L, 2000, NEW ENGL J MED, V342, P557, DOI 10.1056/NEJM200002243420806; Groenewoud JH, 2000, NEW ENGL J MED, V342, P551, DOI 10.1056/NEJM200002243420805; HORTON R, 2000, NEW YORK REV    0810, P30; Kohlwes RJ, 2001, ARCH INTERN MED, V161, P657, DOI 10.1001/archinte.161.5.657; Prendergast TJ, 1998, AM J RESP CRIT CARE, V158, P1163, DOI 10.1164/ajrccm.158.4.9801108; Rabow MW, 2000, JAMA-J AM MED ASSOC, V283, P771, DOI 10.1001/jama.283.6.771; Roscoe LA, 2000, NEW ENGL J MED, V343, P1735, DOI 10.1056/NEJM200012073432315; Singer PA, 1999, JAMA-J AM MED ASSOC, V281, P163, DOI 10.1001/jama.281.2.163; Sullivan AD, 2001, NEW ENGL J MED, V344, P605, DOI 10.1056/NEJM200102223440811; Weber W, 2001, LANCET, V357, P1189, DOI 10.1016/S0140-6736(00)04400-7	16	12	12	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	APR 21	2001	357	9264					1221	1222		10.1016/S0140-6736(00)04450-0	http://dx.doi.org/10.1016/S0140-6736(00)04450-0			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	425YY	11418143				2023-01-03	WOS:000168323300005
J	Agovino, T				Agovino, T			Democracy and health care in Serbia	LANCET			English	Article											Agovino, T (corresponding author), 230 Garth Rd, Scarsdale, NY 10583 USA.								0	2	2	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	APR 7	2001	357	9262					1121	1122		10.1016/S0140-6736(00)04265-3	http://dx.doi.org/10.1016/S0140-6736(00)04265-3			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	420GA	11297983				2023-01-03	WOS:000167996200033
J	Johnson, JR; Manges, AR; O'Bryan, TT; Riley, LW				Johnson, JR; Manges, AR; O'Bryan, TT; Riley, LW			A disseminated multidrug-resistant clonal group of uropathogenic Escherichia coli in pyelonephritis	LANCET			English	Article							URINARY-TRACT INFECTIONS	In acute pyelonephritis, bacterial resistance to cotrimoxazole predicts treatment failure, but the clonal basis of such resistance is undefined. We did molecular and serological analyses of 170 Escherichia coli urine isolates obtained in 1994-96 from women with acute pyelonephritis. 12 (7%) of the pyelonephritis isolates were in clonal group A (CGA; responsible for 38-51% of co-trimoxazole resistance in acute cystitis), including ten (34%) of 29 isolates that were resistant to co-trimoxazole. CGA isolates were obtained from diverse locations across the USA and were related to the 015:K52:H1 clone of the 1986-87 outbreak in London, UK. Thus, CGA is broadly disseminated and contributes to cotrimoxazole resistance in pyelonephritis as well as in cystitis.	Vet Affairs Med Ctr, Med Serv, Minneapolis, MN 55417 USA; Univ Minnesota, Dept Med, Minneapolis, MN 55455 USA; Univ Calif Berkeley, Sch Publ Hlth, Div Epidemiol & Publ Hlth Biol, Berkeley, CA 94720 USA; Univ Calif Berkeley, Sch Publ Hlth, Div Infect Dis & Immun, Berkeley, CA 94720 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); Minneapolis VA Health Care System; University of Minnesota System; University of Minnesota Twin Cities; University of California System; University of California Berkeley; University of California System; University of California Berkeley	Johnson, JR (corresponding author), Vet Affairs Med Ctr, Med Serv, Minneapolis, MN 55417 USA.				NIDDK NIH HHS [DK-47504] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK047504] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Gupta K, 2001, ANN INTERN MED, V135, P41, DOI 10.7326/0003-4819-135-1-200107030-00012; JOHNSON JR, 1999, 99 GEN M AM SOC MICR, P31; Manges AR, 2001, NEW ENGL J MED, V345, P1007, DOI 10.1056/NEJMoa011265; ONEILL PM, 1990, J MED MICROBIOL, V33, P23, DOI 10.1099/00222615-33-1-23; Talan DA, 2000, JAMA-J AM MED ASSOC, V283, P1583, DOI 10.1001/jama.283.12.1583	5	89	90	0	8	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUN 29	2002	359	9325					2249	2251		10.1016/S0140-6736(02)09264-4	http://dx.doi.org/10.1016/S0140-6736(02)09264-4			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	567YJ	12103291				2023-01-03	WOS:000176514500013
J	Keenan, SP; Powers, C; McCormack, DG; Block, G				Keenan, SP; Powers, C; McCormack, DG; Block, G			Noninvasive positive-pressure ventilation for postextubation respiratory distress - A Randomized controlled trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							OBSTRUCTIVE PULMONARY-DISEASE; NASAL MASK VENTILATION; MECHANICAL VENTILATION; SUPPORT VENTILATION; FACE MASK; ACUTE EXACERBATIONS; FAILURE	Context Noninvasive positive-pressure ventilation (NPPV) has been demonstrated to be effective in preventing the need for endotracheal intubation in some patients who present with acute respiratory failure. It is also used for patients who develop acute respiratory distress after extubation, but there are no randomized controlled trials that address its effectiveness in this population. Objective To determine the effectiveness of NPPV compared with standard medical therapy in preventing the need for endotracheal reintubation in high-risk patients who develop respiratory distress during the first 48 hours after extubation. Design Randomized, controlled, unblinded study with concealed allocation conducted between August 1, 1996 and October 31, 1999. Setting An intensive care unit (ICU) in an academic, tertiary care hospital in Ontario. Patients Eighty-one patients with a history of cardiac or respiratory disease or who initially required ventilatory support for more than 2 days and who developed respiratory distress within 48 hours of extubation. Interventions Patients were randomly assigned to receive standard medical therapy alone (supplemental oxygen to maintain oxygen saturation by pulse oximetry greater than or equal to95%; n=42) or NPPV by face mask plus standard medical therapy (n=39). Main Outcome Measures Rates of reintubation, duration of mechanical ventilation, lengths of ICU and hospital stay, and hospital mortality. Results Comparing the NPPV group with the standard-therapy group, there was no difference in the rate of reintubation (72% vs 69%; relative risk, 1.04; 95% confidence interval, 0.78-1.38) or hospital mortality (31% for both groups; relative risk, 0.99; 95% confidence interval, 0.52-1.91). Similarly, no difference was found in duration of mechanical ventilation or length of ICU or hospital stay. Conclusions The addition of NPPV to standard medical therapy does not improve outcome in heterogeneous groups of patients who develop respiratory distress during the first 48 hours after extubation.	Royal Columbian Hosp, Dept Med, New Westminster, BC, Canada; St Pauls Hosp, Ctr Hth Evaluat & Outcome Sci, Vancouver, BC V6Z 1Y6, Canada; Univ British Columbia, Vancouver, BC V5Z 1M9, Canada; Univ Western Ontario, Dept Med, Div Crit Care, London Hlth Sci Ctr, London, ON, Canada; Univ Western Ontario, Dept Med, Div Resp Med, London Hlth Sci Ctr, London, ON, Canada; Univ Western Ontario, Dept Anaesthesia, London Hlth Sci Ctr, London, ON, Canada	St. Paul's Hospital; University of Saskatchewan; University of British Columbia; London Health Sciences Centre; Western University (University of Western Ontario); London Health Sciences Centre; Western University (University of Western Ontario); London Health Sciences Centre; Western University (University of Western Ontario)	Keenan, SP (corresponding author), Suite 103,250 Keary St, New Westminster, BC V3L 5E7, Canada.	Sean_Keenan@telus.net	Block, Geoffrey/AAV-8070-2021; Mccormack, David/G-3331-2011	Block, Geoffrey/0000-0002-4646-7074; 				Andeev S, 1998, J ANESTIZIOL REA MAY, V3, P45; Angus RM, 1996, THORAX, V51, P1048, DOI 10.1136/thx.51.10.1048; Antonelli M, 1998, NEW ENGL J MED, V339, P429, DOI 10.1056/NEJM199808133390703; Antonelli M, 2000, JAMA-J AM MED ASSOC, V283, P235, DOI 10.1001/jama.283.2.235; Barbe F, 1996, EUR RESPIR J, V9, P1240, DOI 10.1183/09031936.96.09061240; BENHAMOU D, 1992, CHEST, V102, P912, DOI 10.1378/chest.102.3.912; BOTT J, 1993, LANCET, V341, P1555, DOI 10.1016/0140-6736(93)90696-E; BROCHARD L, 1995, NEW ENGL J MED, V333, P817, DOI 10.1056/NEJM199509283331301; Celikel T, 1998, CHEST, V114, P1636, DOI 10.1378/chest.114.6.1636; Confalonieri M, 1999, AM J RESP CRIT CARE, V160, P1585, DOI 10.1164/ajrccm.160.5.9903015; FOGLIO C, 1992, CHEST, V101, P1533, DOI 10.1378/chest.101.6.1533; Girault C, 1999, AM J RESP CRIT CARE, V160, P86, DOI 10.1164/ajrccm.160.1.9802120; Hilbert G, 1998, EUR RESPIR J, V11, P1349, DOI 10.1183/09031936.98.11061349; Hilbert G, 2001, NEW ENGL J MED, V344, P481, DOI 10.1056/NEJM200102153440703; Jiang J S, 1999, Respirology, V4, P161, DOI 10.1046/j.1440-1843.1999.00168.x; Keenan SP, 2000, JAMA-J AM MED ASSOC, V284, P2376, DOI 10.1001/jama.284.18.2376; KRAMER N, 1995, AM J RESP CRIT CARE, V151, P1799, DOI 10.1164/ajrccm.151.6.7767523; MARION W, 1994, CRIT CARE MED, V99, P681; Martin TJ, 2000, AM J RESP CRIT CARE, V161, P807, DOI 10.1164/ajrccm.161.3.9808143; Masip J, 2000, LANCET, V356, P2126, DOI 10.1016/S0140-6736(00)03492-9; Meduri GU, 1996, CHEST, V109, P179, DOI 10.1378/chest.109.1.179; MEDURI GU, 1994, CRIT CARE MED, V22, P1584; MEDURI GU, 1989, CHEST, V95, P865, DOI 10.1378/chest.95.4.865; MEDURI GU, 1991, CHEST, V100, P445, DOI 10.1378/chest.100.2.445; Nava S, 1998, ANN INTERN MED, V128, P721, DOI 10.7326/0003-4819-128-9-199805010-00004; PENNOCK BE, 1994, CHEST, V105, P441, DOI 10.1378/chest.105.2.441; Plant PK, 2000, LANCET, V355, P1931, DOI 10.1016/S0140-6736(00)02323-0; ROSINHA SRP, 2000, AM J RESP CRIT CARE, V161, pA262; Wood KA, 1998, CHEST, V113, P1339, DOI 10.1378/chest.113.5.1339; WYSOCKI M, 1995, CHEST, V107, P761, DOI 10.1378/chest.107.3.761; WYSOCKI M, 1993, CHEST, V103, P907, DOI 10.1378/chest.103.3.907	31	246	267	0	3	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 26	2002	287	24					3238	3244		10.1001/jama.287.24.3238	http://dx.doi.org/10.1001/jama.287.24.3238			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	566FF	12076220	Bronze			2023-01-03	WOS:000176415800028
J	Owens, PL; Bradley, EH; Horwitz, SM; Viscoll, CM; Kernan, WN; Brass, LM; Sarrel, PM; Horwitz, RI				Owens, PL; Bradley, EH; Horwitz, SM; Viscoll, CM; Kernan, WN; Brass, LM; Sarrel, PM; Horwitz, RI			Clinical assessment of function among women with a recent cerebrovascular event: A self-reported versus performance-based measure	ANNALS OF INTERNAL MEDICINE			English	Article							PHYSICAL PERFORMANCE; DISABILITY; STROKE; CAPACITY; ABILITY; SCALES	Background: Self-reported functional status is a commonly used health measure in clinical settings, yet the optimal approach for assessing function is often debated. Objective: To examine the agreement between a self-reported and a performance-based measure of function and the relative ability of each measure to predict long-term health outcomes. Design: Prospective cohort study. Setting: 20 hospitals in Connecticut and Massachusetts. Participants: 620 postmenopausal women (46 to 91 years of age) who had experienced a stroke or transient ischemic attack. Measurements: A self-reported and a performance-based measure of function were assessed at baseline (before intervention) by using the Barthel index and the Physical Performance Test. Results: Disagreement between the self-reported and performance-based measure of function was common (slight disagreement, 55.0%; substantial disagreement, 19.3%). Most women (95.4%) overreported their level of function. Women who were more clinically impaired (risk ratio [RR] for more comorbid conditions, 1.52 [95% CI, 1.17 to 1.97]; RR for recent stroke, 2.33 [CI, 1.45 to 3.73]; and RR for cognitive Impairment, 1.76 [CI, 1.34 to 2.32]); who were less educated (RR = 1.30 [CI, 1.02 to 1.67]); and who were of nonwhite ethnicity (RR 1.43 [CI, 1.07 to 1.91]) were more likely to overreport their level of function. An impaired performance-based measure of function predicted subsequent stroke or death (hazard ratio, 1.50, [CI, 1.06 to 2.11]); however, an impaired self-reported measure of function was not likely to predict these outcomes. Conclusions: Clinicians should be aware that results of self-reported and performance-based measures of function can differ In women who have experienced a recent cerebrovascular event Although more difficult to collect, results of a performance-based measure may provide information about long-term health outcomes that is not available from a self-reported measure.	Agcy Healthcare Res & Qual, Rockville, MD 20852 USA	Agency for Healthcare Research & Quality	Owens, PL (corresponding author), Agcy Healthcare Res & Qual, 2101 E Jefferson,Suite 605, Rockville, MD 20852 USA.	POwens@ahrq.gov		Horwitz, Sarah/0000-0002-5262-1170	NIMH NIH HHS [5T32-MH15783, 5T32-MH19545] Funding Source: Medline; PHS HHS [R01-N531251] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTH [T32MH015783, T32MH019545] Funding Source: NIH RePORTER	NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		BROTT T, 1989, STROKE, V20, P864, DOI 10.1161/01.STR.20.7.864; Brown M, 2000, J GERONTOL A-BIOL, V55, pM350, DOI 10.1093/gerona/55.6.M350; CRESS ME, 1995, J AM GERIATR SOC, V43, P93, DOI 10.1111/j.1532-5415.1995.tb06372.x; DOMBOVY ML, 1986, STROKE, V17, P363, DOI 10.1161/01.STR.17.3.363; ELAM JT, 1991, AM J PUBLIC HEALTH, V81, P1127, DOI 10.2105/AJPH.81.9.1127; Ferrer M, 1999, AM J EPIDEMIOL, V149, P228; FLANDERS WD, 1987, J CHRON DIS, V40, P697, DOI 10.1016/0021-9681(87)90106-8; Fleiss J. L., 1981, STAT METHODS RATES P, V2, P22; FLEISS JL, 1973, EDUC PSYCHOL MEAS, V33, P613, DOI 10.1177/001316447303300309; FOLSTEIN M, 1985, J AM GERIATR SOC, V33, P228, DOI 10.1111/j.1532-5415.1985.tb07109.x; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; Gill TM, 1998, ANN INTERN MED, V128, P96, DOI 10.7326/0003-4819-128-2-199801150-00004; GURALNIK JM, 1989, J GERONTOL, V44, pM141, DOI 10.1093/geronj/44.5.M141; GURALNIK JM, 1994, J GERONTOL, V49, pM85, DOI 10.1093/geronj/49.2.M85; GURALNIK JM, 1995, GERIATRIC ASSESSMENT, P59; Hoeymans N, 1996, J CLIN EPIDEMIOL, V49, P1103, DOI 10.1016/0895-4356(96)00210-7; Hosmer DW, 1999, WILEY PS TX; HUBER MR, 1994, FAULKNER GRAYS MED O, V2, P9; KEITH RA, 1994, ARCH PHYS MED REHAB, V75, P478, DOI 10.1016/0003-9993(94)90175-9; KELLYHAYES M, 1992, AM J PUBLIC HEALTH, V82, P841, DOI 10.2105/AJPH.82.6.841; Kempen GIJM, 1996, J GERONTOL B-PSYCHOL, V51, pP254, DOI 10.1093/geronb/51B.5.P254; Kempen GIJM, 1996, AGE AGEING, V25, P458, DOI 10.1093/ageing/25.6.458; Kernan W N, 1998, J Stroke Cerebrovasc Dis, V7, P85, DOI 10.1016/S1052-3057(98)80026-8; KERNAN WN, 1991, ANN INTERN MED, V114, P552, DOI 10.7326/0003-4819-114-7-552; Kivinen P, 1998, J CLIN EPIDEMIOL, V51, P1243, DOI 10.1016/S0895-4356(98)00115-2; KURIANSKY JB, 1976, J CLIN PSYCHOL, V32, P95, DOI 10.1002/1097-4679(197601)32:1<95::AID-JCLP2270320129>3.0.CO;2-J; LAPLANTE M, 1996, DISABILITY US PREVAL; LITTLE AG, 1986, BRIT J CLIN PSYCHOL, V25, P51, DOI 10.1111/j.2044-8260.1986.tb00670.x; MAHONEY F I, 1965, Md State Med J, V14, P61; MCDOWELL I, 1996, MEASURING HLTH GUIDE, P47; Merrill SS, 1997, J GERONTOL A-BIOL, V52, pM19, DOI 10.1093/gerona/52A.1.M19; MYERS AM, 1993, J GERONTOL, V48, pM196, DOI 10.1093/geronj/48.5.M196; RADLOFF L S, 1977, Applied Psychological Measurement, V1, P385, DOI 10.1177/014662167700100306; REUBEN DB, 1992, J GERONTOL, V47, pM106, DOI 10.1093/geronj/47.4.M106; REUBEN DB, 1990, J AM GERIATR SOC, V38, P1105, DOI 10.1111/j.1532-5415.1990.tb01373.x; REUBEN DB, 1995, J AM GERIATR SOC, V43, P17, DOI 10.1111/j.1532-5415.1995.tb06236.x; RODGERS H, 1993, AGE AGEING, V22, P161, DOI 10.1093/ageing/22.3.161; ROZZINI R, 1993, J AM GERIATR SOC, V41, P1109, DOI 10.1111/j.1532-5415.1993.tb06460.x; SAGER MA, 1992, J AM GERIATR SOC, V40, P457, DOI 10.1111/j.1532-5415.1992.tb02011.x; SHAH S, 1989, J CLIN EPIDEMIOL, V42, P703, DOI 10.1016/0895-4356(89)90065-6; Sherman SE, 1998, J GEN INTERN MED, V13, P817, DOI 10.1046/j.1525-1497.1998.00245.x; WADE DT, 1987, J NEUROL NEUROSUR PS, V50, P177, DOI 10.1136/jnnp.50.2.177	42	13	14	0	4	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUN 4	2002	136	11					802	811		10.7326/0003-4819-136-11-200206040-00008	http://dx.doi.org/10.7326/0003-4819-136-11-200206040-00008			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	558KG	12044128				2023-01-03	WOS:000175964500003
J	Fraser, C; Power, M; Hamdy, S; Rothwell, J; Hobday, D; Hollander, I; Tyrell, P; Hobson, A; Williams, S; Thompson, D				Fraser, C; Power, M; Hamdy, S; Rothwell, J; Hobday, D; Hollander, I; Tyrell, P; Hobson, A; Williams, S; Thompson, D			Driving plasticity in human adult motor cortex is associated with improved motor function after brain injury	NEURON			English	Article							TRANSCRANIAL MAGNETIC STIMULATION; ACUTE STROKE; REORGANIZATION; RECOVERY; FMRI; EXCITABILITY; ACTIVATION; ASPIRATION; DYSPHAGIA; MRI	Changes in somatosensory input can remodel human cortical motor organization, yet the input characteristics that promote reorganization and their functional significance have not been explored. Here we show with transcranial magnetic stimulation that sensory-driven reorganization of human motor cortex is highly dependent upon the frequency, intensity, and duration of stimulus applied. Those patterns of input associated with enhanced excitability (5 Hz, 75% maximal tolerated intensity for 10 min) induce stronger cortical activation to fMRI. When applied to acutely dysphagic stroke patients, swallowing corticobulbar excitability is increased mainly in the undamaged hemisphere, being strongly correlated with an improvement in swallowing function. Thus, input to the human adult brain can be programmed to promote beneficial changes in neuroplasticity and function after cerebral injury.	Hope Hosp, Univ Dept Gastroenterol, Salford M6 8HD, Lancs, England; Hope Hosp, Univ Dept Stroke Med, Salford M6 8HD, Lancs, England; Inst Neurol, Sobell Dept Neurophysiol, London WC1N 3BG, England; Univ Manchester, Dept Imaging Sci & Biomed Engn, Manchester M13 9PL, Lancs, England	University of London; University College London; University of Manchester	Hamdy, S (corresponding author), Hope Hosp, Univ Dept Gastroenterol, Salford M6 8HD, Lancs, England.		Williams, Steve R/C-8945-2011; Williams, Steve C/D-6979-2011; Hamdy, Shaheen/O-5039-2014	Williams, Steve R/0000-0001-5940-1675; Williams, Steve C/0000-0003-4299-1941; Hamdy, Shaheen/0000-0001-9640-7427; Rothwell, John/0000-0003-1367-6467				BENECKE R, 1991, EXP BRAIN RES, V83, P419; Buonomano DV, 1998, ANNU REV NEUROSCI, V21, P149, DOI 10.1146/annurev.neuro.21.1.149; Classen J, 1998, J NEUROPHYSIOL, V79, P1117, DOI 10.1152/jn.1998.79.2.1117; Cohen LG, 1998, J CLIN NEUROPHYSIOL, V15, P305, DOI 10.1097/00004691-199807000-00003; Cohen LG, 1997, NATURE, V389, P180, DOI 10.1038/38278; Cook IJ, 1999, GASTROENTEROLOGY, V116, P455, DOI 10.1016/S0016-5085(99)70144-7; DONOGHUE JP, 1996, SUBSTRATES MECH LEAR; FORMAN SD, 1995, MAGNET RESON MED, V33, P636, DOI 10.1002/mrm.1910330508; Friston K.J., 1994, HUM BRAIN MAPP, V1, P153, DOI DOI 10.1002/HBM.460010207; GORDON C, 1987, BRIT MED J, V295, P411, DOI 10.1136/bmj.295.6595.411; Hallett M, 2000, NATURE, V406, P147, DOI 10.1038/35018000; Hamdy S, 1999, AM J PHYSIOL-GASTR L, V277, pG219, DOI 10.1152/ajpgi.1999.277.1.G219; Hamdy S, 1996, NAT MED, V2, P1217, DOI 10.1038/nm1196-1217; Hamdy S, 1997, AM J PHYSIOL-GASTR L, V272, pG802, DOI 10.1152/ajpgi.1997.272.4.G802; Hamdy S, 1998, GASTROENTEROLOGY, V115, P1104, DOI 10.1016/S0016-5085(98)70081-2; Hamdy S, 1998, NAT NEUROSCI, V1, P64, DOI 10.1038/264; Hobday DI, 2001, BRAIN, V124, P361, DOI 10.1093/brain/124.2.361; KIDD D, 1995, QJM-MON J ASSOC PHYS, V88, P409; Liepert J, 2000, STROKE, V31, P1210, DOI 10.1161/01.STR.31.6.1210; MAHONEY F I, 1965, Md State Med J, V14, P61; Medical research council of the United Kingdom, 1976, AIDS EX PER NERV SYS; Muellbacher W, 2000, CLIN NEUROPHYSIOL, V111, P1002, DOI 10.1016/S1388-2457(00)00284-4; Nudo RJ, 1996, SCIENCE, V272, P1791, DOI 10.1126/science.272.5269.1791; Ridding MC, 2000, EXP BRAIN RES, V131, P135, DOI 10.1007/s002219900269; Ridding MC, 1997, ELECTROMYOGR MOTOR C, V105, P340, DOI 10.1016/S0924-980X(97)00041-6; Rosenbek JC, 1996, DYSPHAGIA, V11, P93, DOI 10.1007/BF00417897; Stefan K, 2000, BRAIN, V123, P572, DOI 10.1093/brain/123.3.572; Thacker NA, 1999, JMRI-J MAGN RESON IM, V10, P582, DOI 10.1002/(SICI)1522-2586(199910)10:4<582::AID-JMRI12>3.0.CO;2-X; Thacker NA, 1999, PHYSIOL MEAS, V20, P251, DOI 10.1088/0967-3334/20/3/303; Thulborn KR, 1999, STROKE, V30, P749, DOI 10.1161/01.STR.30.4.749; Vokurka EA, 1999, JMRI-J MAGN RESON IM, V10, P550, DOI 10.1002/(SICI)1522-2586(199910)10:4<550::AID-JMRI8>3.0.CO;2-Q; WEILLER C, 1995, ANN NEUROL, V37, P723, DOI 10.1002/ana.410370605	32	263	294	2	31	CELL PRESS	CAMBRIDGE	1100 MASSACHUSETTS AVE,, CAMBRIDGE, MA 02138 USA	0896-6273			NEURON	Neuron	MAY 30	2002	34	5					831	840		10.1016/S0896-6273(02)00705-5	http://dx.doi.org/10.1016/S0896-6273(02)00705-5			10	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	558DV	12062028	Bronze			2023-01-03	WOS:000175951800016
J	Dodart, JC; Bales, KR; Gannon, KS; Greene, SJ; DeMattos, RB; Mathis, C; DeLong, CA; Wu, S; Wu, X; Holtzman, DM; Paul, SM				Dodart, JC; Bales, KR; Gannon, KS; Greene, SJ; DeMattos, RB; Mathis, C; DeLong, CA; Wu, S; Wu, X; Holtzman, DM; Paul, SM			Immunization reverses memory deficits without reducing brain A beta burden in Alzheimer's disease model	NATURE NEUROSCIENCE			English	Article							AMYLOID PRECURSOR PROTEIN; APP(V717F) TRANSGENIC MICE; MOUSE MODEL; APOLIPOPROTEIN-E; PEPTIDE; PATHOLOGY; HYPOTHESIS; PLAQUES	We have previously shown that chronic treatment with the monoclonal antibody m266, which is specific for amyloid beta-peptide (Abeta), increases plasma concentrations of Abeta and reduces Abeta burden in the PDAPP transgenic mouse model of Alzheimer's disease (AD). We now report that administration of m266 to PDAPP mice can rapidly reverse memory deficits in both an object recognition task and a holeboard learning and memory task, but without altering brain Abeta burden. We also found that an Abeta/antibody complex was present in both the plasma and the cerebrospinal fluid of m266-treated mice. Our data indicate that passive immunization with this anti-Abeta monoclonal antibody can very rapidly reverse memory impairment in certain learning and memory tasks in the PDAPP mouse model of AD, owing perhaps to enhanced peripheral clearance and (or) sequestration of a soluble brain Abeta species.	Eli Lilly & Co, Lilly Corp Ctr, Lilly Res Labs, Neurosci Discovery Res, Indianapolis, IN 46285 USA; Washington Univ, Sch Med, Ctr Study Nervous Syst Injury, Alzheimers Dis Res Ctr,Dept Neurol Mol Biol & Pha, St Louis, MO 63110 USA; Univ Strasbourg 1, CNRS, UMR 7521, F-67000 Strasbourg, France	Eli Lilly; Washington University (WUSTL); Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg	Paul, SM (corresponding author), Eli Lilly & Co, Lilly Corp Ctr, Lilly Res Labs, Neurosci Discovery Res, Indianapolis, IN 46285 USA.		MATHIS, CHANTAL mb/B-6399-2013; Paul, Steve/ABE-5400-2020	MATHIS, CHANTAL mb/0000-0002-6663-5282; 				Bales KR, 1999, P NATL ACAD SCI USA, V96, P15233, DOI 10.1073/pnas.96.26.15233; Bard F, 2000, NAT MED, V6, P916, DOI 10.1038/78682; DeMattos RB, 2001, P NATL ACAD SCI USA, V98, P8850, DOI 10.1073/pnas.151261398; Dodart JC, 2000, NEUROBIOL DIS, V7, P71, DOI 10.1006/nbdi.1999.0278; Dodart JC, 1997, NEUROREPORT, V8, P1173, DOI 10.1097/00001756-199703240-00023; Dodart JC, 2000, REV NEUROSCIENCE, V11, P75; Dodart JC, 1999, BEHAV NEUROSCI, V113, P982, DOI 10.1037/0735-7044.113.5.982; Dodart JC, 2000, NEUROREPORT, V11, P603, DOI 10.1097/00001756-200002280-00034; ENNACEUR A, 1988, BEHAV BRAIN RES, V31, P47, DOI 10.1016/0166-4328(88)90157-X; GAMES D, 1995, NATURE, V373, P523, DOI 10.1038/373523a0; HARDY JA, 1992, SCIENCE, V256, P184, DOI 10.1126/science.1566067; Janus C, 2000, NATURE, V408, P979, DOI 10.1038/35050110; Johnson D, 1997, EDN, V42, P94; Koistinaho M, 2001, P NATL ACAD SCI USA, V98, P14675, DOI 10.1073/pnas.261562998; Lue LF, 1999, AM J PATHOL, V155, P853, DOI 10.1016/S0002-9440(10)65184-X; McLean CA, 1999, ANN NEUROL, V46, P860, DOI 10.1002/1531-8249(199912)46:6<860::AID-ANA8>3.0.CO;2-M; Morgan D, 2000, NATURE, V408, P982, DOI 10.1038/35050116; Neve RL, 1998, TRENDS NEUROSCI, V21, P15, DOI 10.1016/S0166-2236(97)01168-5; Schenk D, 1999, NATURE, V400, P173, DOI 10.1038/22124; SEUBERT P, 1992, NATURE, V359, P325, DOI 10.1038/359325a0; Sigurdsson EM, 2001, AM J PATHOL, V159, P439, DOI 10.1016/S0002-9440(10)61715-4; Weiner HL, 2000, ANN NEUROL, V48, P567, DOI 10.1002/1531-8249(200010)48:4<567::AID-ANA3>3.3.CO;2-N	22	747	843	0	58	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1097-6256			NAT NEUROSCI	Nat. Neurosci.	MAY	2002	5	5					452	457		10.1038/nn842	http://dx.doi.org/10.1038/nn842			6	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	546JY	11941374				2023-01-03	WOS:000175272000016
J	Lewis, JH; Schonlau, M; Munoz, JA; Asch, SM; Rosen, MR; Yang, H; Escarce, JJ				Lewis, JH; Schonlau, M; Munoz, JA; Asch, SM; Rosen, MR; Yang, H; Escarce, JJ			Compliance among pharmacies in California with a prescription-drug discount program for Medicare beneficiaries	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							IMPACT	Background: Several states have developed prescription-drug discount programs for Medicare beneficiaries. In California, Senate Bill 393, enacted in 1999, requires pharmacies participating in the state Medicaid program (Medi-Cal) to charge customers who present a Medicare card amounts based on Medi-Cal rates. Because Medicare beneficiaries may not be accustomed to presenting their Medicare cards at pharmacies, we assessed the compliance of pharmacies with Senate Bill 393. Methods: Fifteen Medicare beneficiaries who received special training and acted as ``standardized patients'' visited a random sample of pharmacies in the San Francisco Bay area and Los Angeles County in April and May 2001. According to a script, they asked for the prices of three commonly prescribed drugs: rofecoxib, sertraline, and atorvastatin. The script enabled us to determine whether and when, during their interactions with pharmacists or salespeople, the discounts specified in Senate Bill 393 were offered. Pharmacies at which the appropriate discounts were offered were considered compliant. Results: The patients completed visits to 494 pharmacies. Seventy-five percent of the pharmacies complied with the prescription-drug discount program; at only 45 percent, however, was the discount offered before it was specifically requested. The discount was offered at 91 percent of pharmacies that were part of a chain, as compared with 58 percent of independent pharmacies (P<0.001). Compliance was higher in the San Francisco Bay area than in Los Angeles County (84 percent vs. 72 percent, P=0.004) and was higher in high-income than low-income neighborhoods (81 percent vs. 69 percent, P=0.002). A Medicare beneficiary taking all three drugs would have saved an average of $55.70 per month as compared with retail prices (a savings of 20 percent). Conclusions: Discounts required under California's prescription-drug discount program for Medicare beneficiaries offer substantial savings. Many patients, however, especially those who use independent pharmacies or who live in low-income neighborhoods, may not receive the discounts. (N Engl J Med 2002;346:830-5.) Copyright (C) 2002 Massachusetts Medical Society.	RAND Corp, Hlth, Santa Monica, CA 90407 USA; Greater Los Angeles Vet Affairs Hlth Care Syst, Los Angeles, CA USA	RAND Corporation; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Greater Los Angeles Healthcare System	Lewis, JH (corresponding author), RAND Corp, Hlth, 1700 Main St, Santa Monica, CA 90407 USA.							Agresti A., 1990, CATEGORICAL DATA ANA; Ansell BJ, 1999, JAMA-J AM MED ASSOC, V282, P2051, DOI 10.1001/jama.282.21.2051; *BUR CENS, 2000, STAT ABSTR US 2000, P13; *CAL BOARD PHARM, 2002, CAL STAT BOARD PHARM; *CAL DEP HLTH SERV, 2001, PRESCR DRUG DISC PRO; Cochran WG, 1977, SAMPLING TECHNIQUES, V3rd; Davis M, 1999, HEALTH AFFAIR, V18, P231, DOI 10.1377/hlthaff.18.1.231; Frank RG, 2001, HEALTH AFFAIR, V20, P115, DOI 10.1377/hlthaff.20.2.115; GIBSON MJ, 1999, MUCH MED BENEFICIARI; Glassman P A, 2000, Jt Comm J Qual Improv, V26, P644; Hosmer Jr D. W, 2004, APPL LOGISTIC REGRES; Hughes SL, 1995, ARTHRIT CARE RES, V8, P257, DOI 10.1002/art.1790080409; Lebowitz BD, 1997, JAMA-J AM MED ASSOC, V278, P1186, DOI 10.1001/jama.278.14.1186; *LEG COUNS CAL, 2002, OFF CAL LEG INF; Mueller C, 1997, AM J PUBLIC HEALTH, V87, P1626, DOI 10.2105/AJPH.87.10.1626; Newhouse JP, 2000, JAMA-J AM MED ASSOC, V283, P2161, DOI 10.1001/jama.283.16.2161; Peabody JW, 2000, JAMA-J AM MED ASSOC, V283, P1715, DOI 10.1001/jama.283.13.1715; Poisal JA, 2001, HEALTH AFFAIR, V20, P74, DOI 10.1377/hlthaff.20.2.74; Soumerai SB, 1999, NEW ENGL J MED, V340, P976; Stuart B, 2001, HEALTH AFFAIR, V20, P86, DOI 10.1377/hlthaff.20.2.86; Zhang J, 1998, JAMA-J AM MED ASSOC, V280, P1690, DOI 10.1001/jama.280.19.1690	21	6	6	0	0	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAR 14	2002	346	11					830	835		10.1056/NEJMsa122601	http://dx.doi.org/10.1056/NEJMsa122601			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	529YM	11893795	Bronze			2023-01-03	WOS:000174328900007
J	Chen, CL; Weiss, NS; Newcomb, P; Barlow, WN; White, E				Chen, CL; Weiss, NS; Newcomb, P; Barlow, WN; White, E			Hormone replacement therapy in relation to breast cancer	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							MENOPAUSAL ESTROGENS; RISK; CARCINOMA; PROLIFERATION; PROGESTERONE; WOMEN; STAGE	Context Studies of long-term hormone replacement therapy (HRT) suggest an associated increased risk of breast cancer, but whether this association differs according to histologic type of cancer has not been extensively studied. Objective To determine whether the association between HRT and risk of breast cancer varies by HRT formulation and differs across histologic cancer types. Design, Setting, and Participants Nested case-control study among 705 postmenopausal women enrolled in the Group Health Cooperative of Puget Sound (GHC) who were aged 50 to 74 years and had primary invasive breast cancer diagnosed between July 1, 1990, and December 31, 1995 (cases), and 692 randomly selected aged-matched female members of GHC (controls). Main Outcome Measure Incidence and type of breast cancer by duration of HRT use in the 5-year period ending 1 year before diagnosis, which was ascertained from computerized pharmacy records. Results The incidence of breast cancer, all histologic types combined, was increased by 60% to 85% in recent long-term users of HRT, whether estrogen alone or estrogen plus progestin. Longer use of HRT (odds ratio [OR], 3.07 for 57 months or more; 95% confidence interval [CI], 1.55-6.06) and current use of combination therapy (OR, 3.91; 95% CI, 2.05-7.44) were associated with increased risk of lobular breast cancer. Long-term HRT use was associated with a 50% increase in nonlobular cancer (OR, 1.52 for 57 months or more; 95% CI, 1.01-2.29). Conclusion Our data add to the growing body of evidence that recent long-term use of HRT is associated with an increased risk of breast cancer and that such use may be related particularly to lobular tumors.	Fred Hutchinson Canc Res Ctr, Div Publ Hlth Sci, Seattle, WA 98109 USA; Univ Washington, Dept Epidemiol, Seattle, WA 98195 USA; Univ Washington, Ctr Hlth Studies, Grp Hlth Cooperat, Seattle, WA 98195 USA; Univ Washington, Dept Biostat, Seattle, WA 98195 USA	Fred Hutchinson Cancer Center; University of Washington; University of Washington Seattle; Group Health Cooperative; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle	White, E (corresponding author), Fred Hutchinson Canc Res Ctr, Div Publ Hlth Sci, 1100 Fairview Ave N,MP702, Seattle, WA 98109 USA.	ewhite@fhcrc.org			NATIONAL CANCER INSTITUTE [U01CA063731] Funding Source: NIH RePORTER; NCI NIH HHS [UO1CA63731] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANDERSON TJ, 1989, HUM PATHOL, V20, P1139, DOI 10.1016/S0046-8177(89)80003-6; Beral V, 1997, LANCET, V350, P1047, DOI 10.1016/S0140-6736(97)08233-0; BERGKVIST L, 1989, NEW ENGL J MED, V321, P293, DOI 10.1056/NEJM198908033210505; BRINTON LA, 1986, BRIT J CANCER, V54, P825, DOI 10.1038/bjc.1986.246; CLARKE CL, 1990, ENDOCR REV, V11, P266, DOI 10.1210/edrv-11-2-266; COLDITZ GA, 1995, NEW ENGL J MED, V332, P1589, DOI 10.1056/NEJM199506153322401; DIXON JM, 1982, HISTOPATHOLOGY, V6, P149, DOI 10.1111/j.1365-2559.1982.tb02712.x; EWERTZ M, 1988, INT J CANCER, V42, P832, DOI 10.1002/ijc.2910420606; GAMBRELL RD, 1983, OBSTET GYNECOL, V62, P435; Graham JD, 1997, ENDOCR REV, V18, P502, DOI 10.1210/er.18.4.502; HARRIS RE, 1992, J NATL CANCER I, V84, P1575, DOI 10.1093/jnci/84.20.1575; HIATT RA, 1984, CANCER, V54, P139, DOI 10.1002/1097-0142(19840701)54:1<139::AID-CNCR2820540128>3.0.CO;2-X; Hofseth LJ, 1999, J CLIN ENDOCR METAB, V84, P4559, DOI 10.1210/jc.84.12.4559; HULKA BS, 1982, AM J OBSTET GYNECOL, V143, P638, DOI 10.1016/0002-9378(82)90108-9; JICK H, 1980, AM J EPIDEMIOL, V112, P586, DOI 10.1093/oxfordjournals.aje.a113031; KAUFMAN DW, 1991, AM J EPIDEMIOL, V134, P1375, DOI 10.1093/oxfordjournals.aje.a116041; KELSEY JL, 1993, EPIDEMIOL REV, V15, P36, DOI 10.1093/oxfordjournals.epirev.a036115; KEY TJA, 1988, EUR J CANCER CLIN ON, V24, P29, DOI 10.1016/0277-5379(88)90173-3; LAVECCHIA C, 1992, INT J CANCER, V50, P161, DOI 10.1002/ijc.2910500131; LAVECCHIA C, 1995, BRIT J CANCER, V72, P244, DOI 10.1038/bjc.1995.310; Li CI, 2000, CANCER, V88, P2561, DOI 10.1002/1097-0142(20000601)88:11<2561::AID-CNCR19>3.3.CO;2-O; Li CI, 2000, CANCER, V88, P2570, DOI 10.1002/1097-0142(20000601)88:11<2570::AID-CNCR20>3.0.CO;2-O; LIPWORTH L, 1995, INT J CANCER, V62, P548, DOI 10.1002/ijc.2910620510; LOBO RA, 1991, J CLIN ENDOCR METAB, V73, P925, DOI 10.1210/jcem-73-5-925; Magnusson C, 1999, INT J CANCER, V81, P339, DOI 10.1002/(SICI)1097-0215(19990505)81:3<339::AID-IJC5>3.3.CO;2-Y; MILLS PK, 1989, CANCER, V64, P591, DOI 10.1002/1097-0142(19890801)64:3<591::AID-CNCR2820640305>3.0.CO;2-U; NANDI S, 1995, P NATL ACAD SCI USA, V92, P3650, DOI 10.1073/pnas.92.9.3650; NEWCOMB PA, 1995, AM J EPIDEMIOL, V142, P788, DOI 10.1093/oxfordjournals.aje.a117717; Newcomer LM, 1999, AM J EPIDEMIOL, V149, pS79; NEWSTEAD GM, 1992, RADIOLOGY, V184, P623, DOI 10.1148/radiology.184.3.1324506; NOMURA AMY, 1986, INT J CANCER, V37, P49, DOI 10.1002/ijc.2910370109; PALMER JR, 1991, AM J EPIDEMIOL, V134, P1386, DOI 10.1093/oxfordjournals.aje.a116042; Persson I, 1997, INT J CANCER, V72, P758, DOI 10.1002/(SICI)1097-0215(19970904)72:5<758::AID-IJC9>3.3.CO;2-2; PIKE MC, 1993, EPIDEMIOL REV, V15, P17, DOI 10.1093/oxfordjournals.epirev.a036102; PRESTONMARTIN S, 1990, CANCER RES, V50, P7415; RISCH HA, 1994, AM J EPIDEMIOL, V139, P670, DOI 10.1093/oxfordjournals.aje.a117057; Ross RK, 2000, JNCI-J NATL CANCER I, V92, P328, DOI 10.1093/jnci/92.4.328; Schairer C, 2000, JAMA-J AM MED ASSOC, V283, P485, DOI 10.1001/jama.283.4.485; SCHUURMAN AG, 1995, CANCER CAUSE CONTROL, V6, P416, DOI 10.1007/BF00052181; STANFORD JL, 1995, JAMA-J AM MED ASSOC, V274, P137, DOI 10.1001/jama.274.2.137; STIERER M, 1993, ANN SURG, V218, P13, DOI 10.1097/00000658-199307000-00004; TALAMINI R, 1985, INT J EPIDEMIOL, V14, P70, DOI 10.1093/ije/14.1.70; Taplin SH, 1997, CANCER EPIDEM BIOMAR, V6, P625; THOMPSON RS, 1988, HMO PRACT, V2, P178; WEINSTEIN AL, 1993, INT J EPIDEMIOL, V22, P781, DOI 10.1093/ije/22.5.781; WINGO PA, 1987, JAMA-J AM MED ASSOC, V257, P209, DOI 10.1001/jama.257.2.209; YANG CP, 1992, CANCER CAUSE CONTROL, V3, P475, DOI 10.1007/BF00051360	47	247	255	0	6	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 13	2002	287	6					734	741		10.1001/jama.287.6.734	http://dx.doi.org/10.1001/jama.287.6.734			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	520XR	11851540	Bronze			2023-01-03	WOS:000173809500030
J	Schroeder, K; Fahey, T				Schroeder, K; Fahey, T			Systematic review of randomised controlled trials of over the counter cough medicines for acute cough in adults	BRITISH MEDICAL JOURNAL			English	Article							RESPIRATORY-TRACT INFECTION; COMMON COLD; ANTITUSSIVE EFFICACY; DEXTROMETHORPHAN; TOLERABILITY; CODEINE	Objectives To determine whether over the counter cough medicines are effective for acute cough in adults. Design Systematic review of randomised controlled trials. Data sources Search of die Cochrane Acute Respiratory Infections Group specialised register, Cochrane Controlled Trials Register, Medline, Embase, and the UK Department of Health National Research Register in all languages. Included studies All randomised controlled trials that compared oral over the counter cough preparations with placebo in adults with acute cough due to upper respiratory tract infection in ambulatory settings and that had cough symptoms as an outcome. Results 15 trials involving 2166 participants met all the inclusion criteria. Antihistamines seemed to be no better than placebo. There was conflicting evidence on the effectiveness of antitussives, expectorants, anthihistamine-decongestant combinations, and other drug combinations compared with placebo. Conclusion Over the Counter cough medicines for acute cough cannot be recommended because there is no good evidence for their effectiveness. Even when trials had significant results, the effect sizes were small and of doubtful clinical relevance. Because of the small number of trials in each category, the results have to be interpreted cautiously.	Univ Bristol, Div Primary Hlth Care, Bristol BS6 6JL, Avon, England	University of Bristol	Schroeder, K (corresponding author), Univ Bristol, Div Primary Hlth Care, Bristol BS6 6JL, Avon, England.		Fahey, Tom/C-9367-2012	Fahey, Tom/0000-0002-5896-5783				ADAMS R, 1993, ADV THER, V10, P263; BANDERALI G, 1995, J INT MED RES, V23, P175, DOI 10.1177/030006059502300304; BANKS I, 2001, NHS DIRECT HEALTHCAR; BERKOWITZ RB, 1991, ANN ALLERGY, V67, P593; BERKOWITZ RB, 1989, ANN ALLERGY, V63, P336; CASS LJ, 1953, NEW ENGL J MED, V249, P132, DOI 10.1056/NEJM195307232490402; CHERNISH SM, 1963, ANN ALLERGY, V21, P677; CURLEY FJ, 1988, AM REV RESPIR DIS, V138, P305, DOI 10.1164/ajrccm/138.2.305; ECCLES R, 1992, J CLIN PHARM THER, V17, P175, DOI 10.1111/j.1365-2710.1992.tb01289.x; Freestone C, 1997, J PHARM PHARMACOL, V49, P1045, DOI 10.1111/j.2042-7158.1997.tb06039.x; GAFFEY MJ, 1988, PEDIATR INFECT DIS J, V7, P223, DOI 10.1097/00006454-198803000-00032; GASTPAR H, 1984, CURR MED RES OPIN, V9, P21, DOI 10.1185/03007998409109554; IRWIN RS, 1993, DRUGS, V46, P80, DOI 10.2165/00003495-199346010-00006; KUHN JJ, 1982, CHEST, V82, P713, DOI 10.1378/chest.82.6.713; KURTH W, 1978, MED WELT, V29, P1906; Lee PCL, 2000, J PHARM PHARMACOL, V52, P1137, DOI 10.1211/0022357001774903; Morice A, 1998, PRESCRIBER, V9, P74; MOSS C, 2001, OTC DIRECTORY 2001 2; NESSWETHA W, 1967, ARZNEI-FORSCHUNG, V17, P1324; Parvez L, 1996, PULM PHARMACOL THER, V9, P299, DOI 10.1006/pulp.1996.0039; REYNOLDS JEF, 1993, MARTINDALE EXTRA PHA, P741; ROBINSON RE, 1977, CURR THER RES CLIN E, V22, P284; *ROYAL COLL GEN PR, 1992, MORB STAT GEN PRACT; SCHROEDER K, 2001, COCHRANE DATABASE SY; SCHROEDER K, 2001, COCHRANE DATABASE SY, V3; SMITH MBH, 1993, JAMA-J AM MED ASSOC, V269, P2258, DOI 10.1001/jama.269.17.2258; THACKRAY P, 1978, J INT MED RES, V6, P161, DOI 10.1177/030006057800600218; The Proprietary Association of Great Britain, 2000, ANN REV REP; TUKIAINEN H, 1986, EUR J RESPIR DIS, V69, P95; ZIMENT I, 1976, JAMA-J AM MED ASSOC, V236, P193, DOI 10.1001/jama.236.2.193; 1999, DRUG THER B, V37, P19	31	92	97	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	FEB 9	2002	324	7333					329	+		10.1136/bmj.324.7333.329	http://dx.doi.org/10.1136/bmj.324.7333.329			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	521XH	11834560	Bronze, Green Published			2023-01-03	WOS:000173866300018
J	Mintzes, B; Barer, ML; Kravitz, RL; Kazanjian, A; Bassett, K; Lexchin, J; Evans, RG; Pan, R; Marion, SA				Mintzes, B; Barer, ML; Kravitz, RL; Kazanjian, A; Bassett, K; Lexchin, J; Evans, RG; Pan, R; Marion, SA			Influence of direct to consumer pharmaceutical advertising and patients' requests on prescribing decisions: two site cross sectional survey	BRITISH MEDICAL JOURNAL			English	Article									Univ British Columbia, Ctr Hlth Serv & Policy Res, Vancouver, BC V6T 1Z3, Canada; Univ British Columbia, Dept Hlth Care & Epidemiol, Vancouver, BC V5Z 1M9, Canada; Univ Calif Davis, Ctr Hlth Serv Res Primary Care, Sacramento, CA 95817 USA; York Univ, Sch Hlth Policy & Management, N York, ON M3J 1P3, Canada; Univ Calif Davis, Med Ctr, Ctr Hlth Serv Res Primary Care, PC AWARE, Davis, CA 95616 USA	University of British Columbia; University of British Columbia; University of California System; University of California Davis; York University - Canada; University of California System; University of California Davis	Mintzes, B (corresponding author), Univ British Columbia, Ctr Hlth Serv & Policy Res, Vancouver, BC V6T 1Z3, Canada.		Kravitz, Richard/AAF-7425-2021	Kravitz, Richard/0000-0001-5575-529X				Findlay S, 2000, PRESCRIPTION DRUGS M; IMS Health, 2001, US LEAD PROD DTC SPE; Silversides A, 2001, CAN MED ASSOC J, V165, P462; *THER PROD PROGR, 1999, DIR CONS ADV PRESCR; WATSON R, 2001, BMJ-BRIT MED J, V323, P184	5	158	162	0	19	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	FEB 2	2002	324	7332					278	279		10.1136/bmj.324.7332.278	http://dx.doi.org/10.1136/bmj.324.7332.278			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	519LT	11823361	Green Published, Bronze			2023-01-03	WOS:000173728300020
J	Margolin, A; Kleber, HD; Avants, SK; Konefal, J; Gawin, F; Stark, E; Sorensen, J; Midkiff, E; Wells, E; Jackson, TR; Bullock, M; Culliton, PD; Boles, S; Vaughan, R				Margolin, A; Kleber, HD; Avants, SK; Konefal, J; Gawin, F; Stark, E; Sorensen, J; Midkiff, E; Wells, E; Jackson, TR; Bullock, M; Culliton, PD; Boles, S; Vaughan, R			Acupuncture for the treatment of cocaine addiction - A randomized controlled trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							SUBSTANCE-ABUSE TREATMENT; AURICULAR ACUPUNCTURE; TREATMENT SERVICES; DEPENDENCE; THERAPIES; EFFICACY; ADJUNCT	Context Auricular acupuncture is widely used to treat cocaine addiction in the United States and Europe. However, evidence from controlled studies regarding this treatment's effectiveness has been inconsistent. Objective To investigate the effectiveness of auricular acupuncture as a treatment for cocaine addiction. Design Randomized, controlled, single-blind clinical trial conducted from November 1996 to April 1999. Setting Six community-based clinics in the United States: 3 hospital-affiliated clinics and 3 methadone maintenance programs. Patients Six hundred twenty cocaine-dependent adult patients (mean age, 38.8 years; 69.2% men); 412 used cocaine only and 208 used both opiates and cocaine and were receiving methadone maintenance. Intervention Patients were randomly assigned to receive auricular acupuncture (n=222), a needle-insertion control condition (n=203), or a relaxation control condition (n=195). Treatments were offered 5 times weekly for 8 weeks. Concurrent drug counseling was also offered to patients in all conditions. Main Outcome Measures Cocaine use during treatment and at the 3- and 6-month postrandomization follow-up based on urine toxicology screens; retention in treatment. Results Intent-to-treat analysis of urine samples showed a significant overall reduction in cocaine use (odds ratio, 1.40; 95% confidence interval, 1.11-1.74; P=.002) but no differences by treatment condition (P=.90 for acupuncture vs both control conditions). There were also no differences between the conditions in treatment retention (44%-46% for the full 8 weeks). Counseling sessions in all 3 conditions were poorly attended. Conclusions Within the clinical context of this study, acupuncture was not more effective than a needle insertion or relaxation control in reducing cocaine use. Our study does not support the use of acupuncture as a stand-alone treatment for cocaine addiction or in contexts in which patients receive only minimal concurrent psychosocial treatment. Research will be needed to examine acupuncture's contribution to addiction treatment when provided in an ancillary role.	Yale Univ, Sch Med, Subst Abuse Ctr, New Haven, CT 06519 USA; Columbia Univ, Natl Ctr Addict & Subst Abuse, New York, NY USA; Columbia Univ, Sch Med, New York, NY USA; Univ Miami, Sch Med, Miami, FL USA; Univ Calif Los Angeles, Lab Study Addict, Los Angeles, CA USA; Univ Calif San Francisco, San Francisco, CA 94143 USA; San Francisco Gen Hosp, San Francisco, CA 94110 USA; Evergreen Treatment Serv, Seattle, WA USA; Hennepin Cty Med Ctr, Minneapolis, MN 55415 USA	Yale University; Columbia University; Columbia University; University of Miami; University of California System; University of California Los Angeles; University of California System; University of California San Francisco; San Francisco General Hospital Medical Center; Hennepin County Medical Center	Margolin, A (corresponding author), Yale Univ, Sch Med, Subst Abuse Ctr, 34 Pk St, New Haven, CT 06519 USA.	arthur.margolin@yale.edu			NIDA NIH HHS [R01-DAO8513, R01-DA00277] Funding Source: Medline; NATIONAL INSTITUTE ON DRUG ABUSE [R01DA008513] Funding Source: NIH RePORTER	NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)		Agosti V, 1996, AM J DRUG ALCOHOL AB, V22, P29, DOI 10.3109/00952999609001643; AVANTS SK, 1995, J SUBST ABUSE TREAT, V12, P195; Avants SK, 2000, ARCH INTERN MED, V160, P2305, DOI 10.1001/archinte.160.15.2305; BRUMBAUGH AG, 1995, TRANSFORMATION RECOV; BULLOCK ML, 1989, LANCET, V1, P1435; Bullock ML, 1999, J SUBST ABUSE TREAT, V16, P31, DOI 10.1016/S0740-5472(98)00002-6; Crits-Christoph P, 1999, ARCH GEN PSYCHIAT, V56, P493, DOI 10.1001/archpsyc.56.6.493; First M., 1996, CLINICIAN VERSION SC; Gurevich MI, 1996, J SUBST ABUSE TREAT, V13, P165, DOI 10.1016/0740-5472(96)00028-1; HIGGINS ST, 1993, AM J PSYCHIAT, V150, P763; HORVATH AO, 1989, J COUNS PSYCHOL, V36, P223, DOI 10.1037/0022-0167.36.2.223; KONEFAL J, 1994, J ADDICT DIS, V13, P71; LIANG KY, 1986, BIOMETRIKA, V73, P13, DOI 10.1093/biomet/73.1.13; LIPTON DS, 1994, J SUBST ABUSE TREAT, V11, P205, DOI 10.1016/0740-5472(94)90077-9; Margolin A, 1998, JAMA-J AM MED ASSOC, V280, P1626, DOI 10.1001/jama.280.18.1626; Margolin A, 1995, DRUG ALCOHOL DEPEN, V40, P125, DOI 10.1016/0376-8716(95)01198-6; Margolin A, 1998, J ALTERN COMPLEM MED, V4, P405, DOI 10.1089/acm.1998.4.405; Margolin A, 1996, J SUBST ABUSE TREAT, V13, P471, DOI 10.1016/S0740-5472(96)00065-7; MARGOLIN A, 1995, AM J CHINESE MED, V23, P105, DOI 10.1142/S0192415X95000146; MARGOLIN A, IN PRESS J ALTERN CO; MCLELLAN AT, 1992, J NERV MENT DIS, V180, P101, DOI 10.1097/00005053-199202000-00007; MCLELLAN AT, 1980, J NERV MENT DIS, V168, P26, DOI 10.1097/00005053-198001000-00006; Miller WR, 1996, PSYCHOL ADDICT BEHAV, V10, P81, DOI 10.1037/0893-164X.10.2.81; *NADA, 1999, REG TRAIN RES MAN; Office of National Drug Control Policy, 2000, NAT DRUG CONTR STRAT; POKLIS A, 1987, J ANAL TOXICOL, V11, P228, DOI 10.1093/jat/11.5.228; Richard AJ, 1995, J SUBST ABUSE TREAT, V12, P401, DOI 10.1016/0740-5472(95)02013-6; SMITH MO, 1997, SUBSTANCE ABUJSE COM, P484; *SUBST AB MENT HLT, 2000, PUBL SMA; ULETT GA, 1992, BEYOND YIN YANG; Vincent C, 1990, COMPLEMENT MED RES, V4, P8; WELLS EA, 1995, AM J ADDICTION, V4, P198, DOI 10.3109/10550499509038105; WOODY G, ADDICTION COUNSELING	33	92	102	0	20	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 2	2002	287	1					55	63		10.1001/jama.287.1.55	http://dx.doi.org/10.1001/jama.287.1.55			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	506NK	11754709				2023-01-03	WOS:000172978500026
J	Clark, P; Rennie, L; Rawlinson, S				Clark, P; Rennie, L; Rawlinson, S			Quality improvement report - Effect of a formal education transfusions	BMJ-BRITISH MEDICAL JOURNAL			English	Article								Problem Failure of correct identification and insufficient monitoring of patients receiving transfusions continue to be appreciable and avoidable causes of morbidity and mortality. Design A study by a regional transfusion service and a transfusion nurse specialist of the effects of an education programme based on the current national guidelines on identification and monitoring of patients receiving transfusions. Setting A large United Kingdom teaching hospital which houses the headquarters of the regional transfusion service. Key measures for improvement Improvement in compliance with published national guidelines on the prescription and administration of blood transfusions. Strategy for change An audit of current compliance followed by dissemination. by a transfusion nurse specialist of a clinical skills package (based on the best practice for transfusion) to all staff involved in giving transfusions. This was supported by trained instructors and the display of standard operating procedures for transfusion in all clinical areas. Effect of change An improvement in compliance with. the national guidelines to over 95% in six out of seven of the recommendations on best practice was seen 18 months after the initial intervention. Lessons learnt The study shows that education of those who prescribe and administer transfusions, as recommended by bodies concerned with the hazards of transfusion, can improve the safety of transfusions.	Ninewells Hosp, E Scotland Blood Transfus Serv, Dept Transfus Med, Dundee DD1 9SY, Scotland	University of Dundee	Clark, P (corresponding author), Ninewells Hosp, E Scotland Blood Transfus Serv, Dept Transfus Med, Dundee DD1 9SY, Scotland.	peter.clark@snbts.csa.scot.nhs.uk						Dinc L, 2000, INT J NURS STUD, V37, P371, DOI 10.1016/S0020-7489(00)00016-X; Kelsey P, 1999, TRANSFUSION MED, V9, P227; LOVE EM, 2001, SERIOUS HAZARDS TRAN; MCCLELLAND B, 1996, HDB TRANSFUSION MED, P30; ROWNTREE D, 1996, PREPARING MAT OPEN D; van den Arend IJM, 2000, DIABETIC MED, V17, P190, DOI 10.1046/j.1464-5491.2000.00232.x	6	26	26	0	2	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	NOV 10	2001	323	7321					1118	1120		10.1136/bmj.323.7321.1118	http://dx.doi.org/10.1136/bmj.323.7321.1118			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	492VN	11701582	Green Published			2023-01-03	WOS:000172188400021
J	Wilson, JF; Weale, ME; Smith, AC; Gratrix, F; Fletcher, B; Thomas, MG; Bradman, N; Goldstein, DB				Wilson, JF; Weale, ME; Smith, AC; Gratrix, F; Fletcher, B; Thomas, MG; Bradman, N; Goldstein, DB			Population genetic structure of variable drug response	NATURE GENETICS			English	Article							FUNCTIONAL-SIGNIFICANCE; CYP1A2 GENE; METABOLISM; CYP2D6; POLYMORPHISMS; DEBRISOQUINE; MEPHENYTOIN; CYP2C19; HUMANS; DEFECT	Geographic patterns of genetic variation, including variation at drug metabolizing enzyme (DME) loci and drug targets, indicate that geographic structuring of inter-individual variation in drug response may occur frequently. This raises two questions: how to represent human population genetic structure in the evaluation of drug safety and efficacy, and how to relate this structure to drug response. We address these by (i) inferring the genetic structure present in a heterogeneous sample and (ii) comparing the distribution of DME variants across the inferred genetic clusters of individuals. We find that commonly used ethnic labels are both insufficient and inaccurate representations of the inferred genetic clusters, and that drug-metabolizing profiles, defined by the distribution of DME variants, differ significantly among the clusters. We note, however, that the complexity of human demographic history means that there is no obvious natural clustering scheme, nor an obvious appropriate degree of resolution. Our comparison of drug-metabolizing profiles across the inferred clusters establishes a framework for assessing the appropriate level of resolution in relating genetic structure to drug response.	UCL, Dept Biol, Galton Lab, London, England; Univ Oxford, Dept Zool, Oxford OX1 3PS, England; UCL, Dept Biol, Ctr Genet Anthropol, London, England; Genost Ltd, London WC1A 2HN, England	University of London; University College London; University of Oxford; University of London; University College London	Wilson, JF (corresponding author), UCL, Dept Biol, Galton Lab, Mortimer St, London, England.	d.goldstein@ucl.ac.uk	Goldstein, David/AAY-8125-2020; Weale, Michael E/F-2587-2010; Wilson, James F/A-5704-2009; Thomas, Mark G/A-2219-2012	Weale, Michael E/0000-0003-4593-1186; Wilson, James F/0000-0001-5751-9178; Thomas, Mark G/0000-0002-2452-981X				Basile VS, 2000, MOL PSYCHIATR, V5, P410, DOI 10.1038/sj.mp.4000736; Bernal ML, 1999, PHARMACOGENETICS, V9, P657, DOI 10.1097/00008571-199910000-00013; BLUM M, 1991, P NATL ACAD SCI USA, V88, P5237, DOI 10.1073/pnas.88.12.5237; Daly D. A., 1993, AM J SPEECH-LANG PAT, V2, P6, DOI [10.1044/1058-0360.0202.06., DOI 10.1044/1058-0360.0202.06]; Evans WE, 1999, SCIENCE, V286, P487, DOI 10.1126/science.286.5439.487; Ferguson RJ, 1998, J PHARMACOL EXP THER, V284, P356; Gaedigk A, 1998, PHARMACOGENETICS, V8, P305, DOI 10.1097/00008571-199808000-00004; Gaedigk A, 1999, PHARMACOGENETICS, V9, P669, DOI 10.1097/01213011-199912000-00002; Goldstein JA, 1996, METHOD ENZYMOL, V272, P210, DOI 10.1016/S0076-6879(96)72025-6; GOUGH AC, 1990, NATURE, V347, P773, DOI 10.1038/347773a0; KAGIMOTO M, 1990, J BIOL CHEM, V265, P17209; KOHLMEIER L, 1997, DESIGN CONCEPTS NUTR, P312; Krajinovic M, 1999, BLOOD, V93, P1496, DOI 10.1182/blood.V93.5.1496.405a36_1496_1501; Meyer UA, 1997, ANNU REV PHARMACOL, V37, P269, DOI 10.1146/annurev.pharmtox.37.1.269; Pritchard JK, 2000, GENETICS, V155, P945; Raymond M, 1995, EVOLUTION, V49, P1280, DOI 10.1111/j.1558-5646.1995.tb04456.x; Sachse C, 1999, BRIT J CLIN PHARMACO, V47, P445, DOI 10.1046/j.1365-2125.1999.00898.x; Seielstad MT, 1998, NAT GENET, V20, P278, DOI 10.1038/3088; WEBER WW, 1997, PHARMACOGENETICS; Wilson JF, 2000, AM J HUM GENET, V67, P926, DOI 10.1086/303083; 1998, INT C HARM ETHN FACT	21	326	339	0	14	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	NOV	2001	29	3					265	269		10.1038/ng761	http://dx.doi.org/10.1038/ng761			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	488AC	11685208				2023-01-03	WOS:000171911000011
J	Chodosh, J; Ferrell, BA; Shekelle, PG; Wenger, NS				Chodosh, J; Ferrell, BA; Shekelle, PG; Wenger, NS			Quality indicators for pain management in vulnerable elders	ANNALS OF INTERNAL MEDICINE			English	Article							CHRONIC MUSCULOSKELETAL PAIN; PLACEBO-CONTROLLED TRIAL; GENERAL-POPULATION; NUTRITION EXAMINATION; DEPRESSIVE SYMPTOMS; DIABETIC NEUROPATHY; RANDOMIZED TRIAL; NATIONAL-HEALTH; PEPTIC-ULCER; DRUG-USE		Univ Calif Los Angeles, Div Geriatr, Dept Med, Los Angeles, CA 90095 USA; RAND Corp, Hlth, Santa Monica, CA 90406 USA; Vet Affairs Greater Los Angeles Healthcare Syst, Los Angeles, CA USA	University of California System; University of California Los Angeles; RAND Corporation; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Greater Los Angeles Healthcare System	Chodosh, J (corresponding author), Univ Calif Los Angeles, Div Geriatr, Dept Med, Los Angeles, CA 90095 USA.	jchodosh@mednet.ucla.edu		Chodosh, Joshua/0000-0001-7784-4306				ANDERSEN S, 1987, PAIN S, V4, P332; Becker N, 1997, PAIN, V73, P393, DOI 10.1016/S0304-3959(97)00126-7; Bernabei R, 1998, JAMA-J AM MED ASSOC, V279, P1877, DOI 10.1001/jama.279.23.1877; BRATTBERG G, 1989, PAIN, V37, P215, DOI 10.1016/0304-3959(89)90133-4; Brochet B, 1998, AGE AGEING, V27, P279, DOI 10.1093/ageing/27.3.279; CLEELAND CS, 1994, NEW ENGL J MED, V330, P592, DOI 10.1056/NEJM199403033300902; COONER E, 1997, 628200 NATL COUNC AG; CROOK J, 1984, PAIN, V18, P299, DOI 10.1016/0304-3959(84)90824-8; Davis M A, 1988, Clin Geriatr Med, V4, P241; DIETRICH AJ, 1982, J FAM PRACTICE, V15, P929; Ellison Neil M., 1993, P185; Ettinger WH, 1997, JAMA-J AM MED ASSOC, V277, P25, DOI 10.1001/jama.277.1.25; Ferrell BA, 1997, AGING-CLIN EXP RES, V9, P99, DOI 10.1007/BF03340134; Ferrell BA, 1998, J AM GERIATR SOC, V46, P635, DOI 10.1111/j.1532-5415.1998.tb01084.x; FERRELL BA, 1990, J AM GERIATR SOC, V38, P409, DOI 10.1111/j.1532-5415.1990.tb03538.x; Foley K, 1994, PRINCIPLES GERIATRIC, P317; GLARE P, 1992, J PAIN SYMPTOM MANAG, V7, P369, DOI 10.1016/0885-3924(92)90092-V; GRIFFIN MR, 1988, ANN INTERN MED, V109, P359, DOI 10.7326/0003-4819-109-5-359; GRIFFIN MR, 1991, ANN INTERN MED, V114, P257, DOI 10.7326/0003-4819-114-4-257; GURWITZ JH, 1990, JAMA-J AM MED ASSOC, V264, P471, DOI 10.1001/jama.264.4.471; HAMEROFF SR, 1984, J CLIN PSYCHIAT, V45, P47; LAVSKYSHULAN M, 1985, J AM GERIATR SOC, V33, P23, DOI 10.1111/j.1532-5415.1985.tb02855.x; MAGNI G, 1993, PAIN, V53, P163, DOI 10.1016/0304-3959(93)90076-2; MAGNI G, 1990, PAIN, V43, P299, DOI 10.1016/0304-3959(90)90027-B; MAX MB, 1991, PAIN, V45, P3, DOI 10.1016/0304-3959(91)90157-S; MAX MB, 1992, NEW ENGL J MED, V326, P1250, DOI 10.1056/NEJM199205073261904; Mobily P., 1994, J AGING HEALTH, V6, P139, DOI DOI 10.1177/089826439400600201; PANERAI AE, 1990, ACTA NEUROL SCAND, V82, P34; PARMELEE PA, 1991, J GERONTOL, V46, pP15, DOI 10.1093/geronj/46.1.P15; PFEIFER MA, 1993, DIABETES CARE, V16, P1103, DOI 10.2337/diacare.16.8.1103; POPP B, 1996, PAIN ELDERLY, P21; RODRIGUEZ LAG, 1994, LANCET, V343, P769, DOI 10.1016/S0140-6736(94)91843-0; ROGERS M, 1989, J CLIN GASTROENTEROL, V11, P132; ROY R, 1986, CAN FAM PHYSICIAN, V32, P513; Shekelle PG, 2001, ANN INTERN MED, V135, P647, DOI 10.7326/0003-4819-135-8_Part_2-200110161-00003; *US AG HLTH CAR PO, 1994, AHCPR PUBL; Wilson PR, 1997, ANESTHESIOLOGY, V86, P995; World Health Organization,, 1986, CANC PAIN REL	38	26	26	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	OCT 16	2001	135	8	2				731	735		10.7326/0003-4819-135-8_Part_2-200110161-00012	http://dx.doi.org/10.7326/0003-4819-135-8_Part_2-200110161-00012			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	481WA	11601956				2023-01-03	WOS:000171542400012
J	Anglaret, X				Anglaret, X			Trimethoprim-sulfamethoxazole prophylaxis in sub-Saharan Africa	LANCET			English	Editorial Material							HUMAN-IMMUNODEFICIENCY-VIRUS; STREPTOCOCCUS-PNEUMONIAE; COTE-DIVOIRE; RESISTANCE; ABIDJAN; ADULTS; TRIAL		Univ Bordeaux 2, INSERM, U330, F-33076 Bordeaux, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite de Bordeaux	Anglaret, X (corresponding author), Univ Bordeaux 2, INSERM, U330, F-33076 Bordeaux, France.		Anglaret, Xavier/F-7333-2013; Anglaret, Xavier/T-2757-2019	Anglaret, Xavier/0000-0003-3319-8423				Anglaret X, 1999, LANCET, V353, P1463, DOI 10.1016/S0140-6736(98)07399-1; Badri M, 2001, AIDS, V15, P1143, DOI 10.1097/00002030-200106150-00009; BLOLAND PB, 1991, LANCET, V337, P518, DOI 10.1016/0140-6736(91)91299-A; Boeree MJ, 1999, LANCET, V354, P334, DOI 10.1016/S0140-6736(05)75236-3; COLEBUNDERS R, 1987, ANN INTERN MED, V107, P599, DOI 10.7326/0003-4819-107-4-599_2; Huovinen P, 2001, CLIN INFECT DIS, V32, P1608, DOI 10.1086/320532; Martin JN, 1999, J INFECT DIS, V180, P1809, DOI 10.1086/315132; Maynart M, 2001, J ACQ IMMUN DEF SYND, V26, P130, DOI 10.1097/00126334-200102010-00004; Meynard JL, 1996, CLIN INFECT DIS, V22, P437, DOI 10.1093/clinids/22.3.437; RodriguezBarradas MC, 1997, J INFECT DIS, V175, P590, DOI 10.1093/infdis/175.3.590; *UNAIDS WHO, 2001, PROV WHO UNAIDS SECR; Wiktor SZ, 1999, LANCET, V353, P1469, DOI 10.1016/S0140-6736(99)03465-0	12	12	12	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	SEP 29	2001	358	9287					1027	1028		10.1016/S0140-6736(01)06227-4	http://dx.doi.org/10.1016/S0140-6736(01)06227-4			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	479EY	11589928				2023-01-03	WOS:000171393100003
J	Labrecque, M; Eason, E; Marcoux, S				Labrecque, M; Eason, E; Marcoux, S			Perineal massage in pregnancy - Such massage significantly decreases perineal trauma at birth	BRITISH MEDICAL JOURNAL			English	Letter									Univ Laval, Dept Family Med, Quebec City, PQ G1K 7P4, Canada; Univ Ottawa, Dept Obstet & Gynaecol, Ottawa, ON, Canada; Univ Laval, Dept Social & Prevent Med, Quebec City, PQ G1K 7P4, Canada	Laval University; University of Ottawa; Laval University	Labrecque, M (corresponding author), Univ Laval, Dept Family Med, Quebec City, PQ G1K 7P4, Canada.			Halligan, Steve/0000-0003-0632-5108				Labrecque M, 1999, AM J OBSTET GYNECOL, V180, P593, DOI 10.1016/S0002-9378(99)70260-7; Stamp G, 2001, BMJ-BRIT MED J, V322, P1277, DOI 10.1136/bmj.322.7297.1277	2	2	2	0	10	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	SEP 29	2001	323	7315					753	754		10.1136/bmj.323.7315.753b	http://dx.doi.org/10.1136/bmj.323.7315.753b			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	478HJ	11675731				2023-01-03	WOS:000171340700039
J	Levinsky, NG; Yu, W; Ash, A; Moskowitz, M; Gazelle, G; Saynina, O; Emanuel, EJ				Levinsky, NG; Yu, W; Ash, A; Moskowitz, M; Gazelle, G; Saynina, O; Emanuel, EJ			Influence of age on medicare expenditures and medical care in the last year of life	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ILL HOSPITALIZED ADULTS; SERIOUSLY ILL; DEATH; MORBIDITY; DECISIONS	Context Expenditures for Medicare beneficiaries in the last year of life decrease with increasing age. The cause of this phenomenon is uncertain. Objectives To examine this pattern in detail and evaluate whether decreases in aggressiveness of medical care explain the phenomenon. Design, Setting, and Patients Analysis of sample Medicare data for beneficiaries aged 65 years or older from Massachusetts (n=34131) and California (n=19064) who died in 1996. Main Outcome Measure Medical expenditures during the last year of life, analyzed by age group, sex, race, place and cause of death, comorbidity, and use of hospital services. Results For Massachusetts and California, respectively, Medicare expenditures per beneficiary were $35300 and $27800 among those aged 65 through 74 years vs $22000 and $21600 for those aged 85 years or older. The pattern of decreasing Medicare expenditures with age is pervasive, persisting throughout the last year of life in both states for both sexes, for black and white beneficiaries, for persons with varying levels of comorbidity, and for those receiving hospice vs conventional care, regardless of cause and site of death. The aggressiveness of medical care in both Massachusetts and California also decreased with age, as judged by less frequent hospital and intensive care unit admissions and by markedly decreasing use of cardiac catheterization, dialysis, ventilators, and pulmonary artery monitors, regardless of cause of death. Decrease in the cost of hospital services accounts for approximately 80% of the decrease in Medicare expenditures with age in both states. Conclusions Medicare expenditures in the last year of life decrease with age, especially for those aged 85 years or older. This is in large part because the aggressiveness of medical care in the last year of life decreases with increasing age.	Boston Univ, Med Ctr, Sch Med, Dept Med,Sect Gen Internal Med,Hlth Care Res Unit, Boston, MA 02118 USA; US Dept Vet Affairs, Hlth Econ Resource Ctr Hlth Sci, Res Serv, Menlo Pk, CA USA; US Dept Vet Affairs, Hlth Econ Resource Ctr Hlth Sci, Dev Serv, Menlo Pk, CA USA; US Dept Vet Affairs, Ctr Cooperat Studies Hlth Serv, Menlo Pk, CA USA; Harvard Vanguard Med Associates, Palliat & Support Med Program, Boston, MA USA; Natl Bur Econ Res, Palo Alto, CA USA; NIH, Dept Clin Bioeth, Bethesda, MD 20892 USA	Boston University; US Department of Veterans Affairs; US Department of Veterans Affairs; US Department of Veterans Affairs; Harvard Vanguard Medical Associates; National Bureau of Economic Research; National Institutes of Health (NIH) - USA	Levinsky, NG (corresponding author), Boston Univ, Med Ctr, Sch Med, Dept Med,Sect Gen Internal Med,Hlth Care Res Unit, 715 Albany St, Boston, MA 02118 USA.		Ash, Arlene/AAG-2914-2019	Ash, Arlene/0000-0002-8448-0253	CLINICAL CENTER [Z01CL010508] Funding Source: NIH RePORTER	CLINICAL CENTER		Callahan D, 2000, NEW ENGL J MED, V342, P654, DOI 10.1056/NEJM200003023420910; CHARLSON ME, 1987, J CHRON DIS, V40, P373, DOI 10.1016/0021-9681(87)90171-8; FRIES JF, 1980, NEW ENGL J MED, V303, P130, DOI 10.1056/NEJM198007173030304; Hamel MB, 1999, ANN INTERN MED, V131, P721, DOI 10.7326/0003-4819-131-10-199911160-00002; Hamel MB, 2000, J AM GERIATR SOC, V48, pS176, DOI 10.1111/j.1532-5415.2000.tb03129.x; Hamel MB, 1996, J AM GERIATR SOC, V44, P1043, DOI 10.1111/j.1532-5415.1996.tb02935.x; Hamel MB, 1999, ANN INTERN MED, V130, P116, DOI 10.7326/0003-4819-130-2-199901190-00005; Johnson MF, 2000, J CLIN ETHIC, V11, P323; Levinsky NG, 1999, J AM GERIATR SOC, V47, P553, DOI 10.1111/j.1532-5415.1999.tb02569.x; Lubitz J, 1984, Health Care Financ Rev, V5, P117; LUBITZ JD, 1993, NEW ENGL J MED, V328, P1092, DOI 10.1056/NEJM199304153281506; PICKLE LW, 1996, ATLAS US MORTALITY, P4; RILEY G, 1987, INQUIRY-J HEALTH CAR, V24, P233; Yu W, 2000, J GEN INTERN MED, V15, P97, DOI 10.1046/j.1525-1497.2000.02349.x	14	148	148	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 19	2001	286	11					1349	1355		10.1001/jama.286.11.1349	http://dx.doi.org/10.1001/jama.286.11.1349			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	473DJ	11560540	Green Published, Bronze			2023-01-03	WOS:000171024500028
J	Harries, AD; Nyangulu, DS; Hargreaves, NJ; Kaluwa, O; Salaniponi, FM				Harries, AD; Nyangulu, DS; Hargreaves, NJ; Kaluwa, O; Salaniponi, FM			Preventing antiretroviral anarchy in sub-Saharan Africa	LANCET			English	Editorial Material							TUBERCULOSIS; AIDS	Combination antiretroviral therapy has dramatically improved the survival of patients living with HIV and AIDS In Industrialised countries of the world. Despite this enormous benefit, there are some major problems and obstacles to be overcome.(1) Treatment of HIV-infection is likely to be lifelong.(2) Unfortunately, many HIV-Infected individuals cannot tolerate the toxic effects of the drugs, or have difficulty complying with treatment which involves large numbers of pills and complicated dosing schedules. Poor adherence to treatment leads to the emergence of drug-resistant viral strains that need new combinations of drugs or new drugs altogether.	Natl TB Control Programme, Community Hlth Sci Unit, Lilongwe, Malawi; Univ Liverpool Liverpool Sch Trop Med, Liverpool, Merseyside, England; Natl AIDS Control Programme, Lilongwe, Malawi	Liverpool School of Tropical Medicine	Harries, AD (corresponding author), British High Commiss, POB 30042, Lilongwe 3, Malawi.	adharries@malawi.net	Franzeck, Fabian C/B-5055-2011					Attaran A, 2001, LANCET, V357, P57, DOI 10.1016/S0140-6736(00)03576-5; Bosman MCJ, 2000, INT J TUBERC LUNG D, V4, P606; Carr A, 2000, LANCET, V356, P1423, DOI 10.1016/S0140-6736(00)02854-3; Fauci AS, 1999, NEW ENGL J MED, V341, P1046, DOI 10.1056/NEJM199909303411406; HARRIES AD, 1996, WHOTB96200; Harrington M, 2000, LANCET, V355, P2147, DOI 10.1016/S0140-6736(00)02388-6; Horton R, 2000, LANCET, V356, P1541, DOI 10.1016/S0140-6736(00)03122-6; Kumar S, 2001, LANCET, V357, P616, DOI 10.1016/S0140-6736(05)71411-2; MAHER D, 1997, WHOTB97220; Mukadi YD, 2001, AIDS, V15, P143, DOI 10.1097/00002030-200101260-00002; Pozniak AL, 1999, AIDS, V13, P435, DOI 10.1097/00002030-199903110-00001; Quinn TC, 2000, NEW ENGL J MED, V342, P921, DOI 10.1056/NEJM200003303421303; Raviglione MC, 1997, LANCET, V350, P624, DOI 10.1016/S0140-6736(97)04146-9; *UNAIDS, 2000, AIDS EP UPD; Volmink J, 2000, LANCET, V355, P1345, DOI 10.1016/S0140-6736(00)02124-3; *WHO, 2000, GLOB TUB CONTR WHO R; *WHO, 2001, WHOHIS200004; Wood E, 2000, LANCET, V355, P2095, DOI 10.1016/S0140-6736(00)02375-8; World Health Organization, 1994, WHOTB94179	19	180	186	0	3	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	AUG 4	2001	358	9279					410	414		10.1016/S0140-6736(01)05551-9	http://dx.doi.org/10.1016/S0140-6736(01)05551-9			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	459DE	11502341				2023-01-03	WOS:000170235100036
J	Irnich, D; Behrens, N; Molzen, H; Konig, A; Gleditsch, J; Krauss, M; Natalis, M; Senn, E; Beyer, A; Schops, P				Irnich, D; Behrens, N; Molzen, H; Konig, A; Gleditsch, J; Krauss, M; Natalis, M; Senn, E; Beyer, A; Schops, P			Randomised trial of acupuncture compared with conventional massage and "sham" laser acupuncture for treatment of chronic neck pain	BMJ-BRITISH MEDICAL JOURNAL			English	Article								Objectives To compare the efficacy of acupuncture and conventional massage for the treatment of chronic neck pain. Design Prospective, randomised, placebo controlled trial. Setting Three outpatient departments in Germany. Participants 177 patients aged 18-85 years with chronic neck pain. Interventions Patients were randomly allocated to five treatments over three weeks with acupuncture (56), massage (60, or "sham" laser acupuncture (61). Main outcome measures Primary outcome measure: maximum pain related to motion (visual analogue scale) irrespective of direction of movement one week after treatment. Secondary outcome measures: range of motion (3D ultrasound real time motion analyser), pain related to movement in sic six directions (visual analogue scale), pressure pain threshold (pressure algometer), changes of spontaneous pain, motion related pain, global complaints (seven point scale), and quality of life (SF-36). Assessments were performed before, during,and one week and three months after treatment. Patients' beliefs in treatment were assessed. Results One week after five treatments the acupuncture group showed a significantly greater improvement in motion related pain compared with massage (difference 24.22 (95% confidence interval 16.5 to 31.9), P=0.005) but not compared with sham laser (17.28 (10.0 to 24.6), P=0.33). Differences between acupuncture and massage or sham laser were greater in the subgroup who had had pain for longer than five years (n=75) and in patients with myofascial pain syndrome (n=129). The acupuncture group had the best results in most secondary outcome measures. There were no differences in patients' beliefs in treatment. Conclusion Acupuncture is a effective short term treatment for patients with chronic neck pain, but there is only limited evidence for long term effects after five treatments.	Univ Munich, Dept Anaesthesiol, D-81377 Munich, Germany; Univ Munich, Dept Phys Med & Rehabil, D-81377 Munich, Germany; Biometr Ctr Therapeut Studies, D-80336 Munich, Germany; Univ Wurzburg, Dept Orthopaed, D-97074 Wurzburg, Germany; Reha Klin Bellikon, CH-5454 Bellikon, Switzerland	University of Munich; University of Munich; University of Wurzburg	Irnich, D (corresponding author), Univ Munich, Dept Anaesthesiol, Marchioninistr 15, D-81377 Munich, Germany.	Dominik.Irnich@lrz.uni-muenchen.de		Cummings, Mike/0000-0003-2224-8835				Aker PD, 1996, BMJ-BRIT MED J, V313, P1291; ATKINS CJ, 1992, ARTHRITIS RHEUM, V35, P407, DOI 10.1002/art.1780350408; Bland JH., 1987, DISORDERS CERVICAL S; Bogduk N, 1984, Aust Fam Physician, V13, P26; Borghouts JAJ, 1998, PAIN, V77, P1, DOI 10.1016/S0304-3959(98)00058-X; BOVIM G, 1994, SPINE, V19, P1307, DOI 10.1097/00007632-199406000-00001; BRAVERMAN DL, 1999, PHYS MED REHABIL CLI, V3, P631; Cheng X, 1987, CHINESE ACUPUNCTURE; FISHER P, 1994, BRIT MED J, V309, P107, DOI 10.1136/bmj.309.6947.107; FRICTON JR, 1985, ORAL SURG ORAL MED O, V60, P615, DOI 10.1016/0030-4220(85)90364-0; Frymoyer J, 1997, ADULT SPIEN PRINCIPL, P130; GROSS AR, 2000, COCHRANE DATABASE SY; IRNICH D, 1999, DTSCH Z AKUPUNKT, V2, P81; Natalis M, 1999, ULTRASCHALL MED, V20, P70, DOI 10.1055/s-1999-14237; Ramsay DJ, 1998, JAMA-J AM MED ASSOC, V280, P1518; Schops P, 2000, SCHMERZ, V14, P160, DOI 10.1007/s004820070041; Smith LA, 2000, PAIN, V86, P119, DOI 10.1016/S0304-3959(00)00234-7; Stovner LJ, 1996, SPINE, V21, P2735, DOI 10.1097/00007632-199612010-00006; Thompson JW, 1993, ACUPUNCTURE TRIGGER, V2nd; Travell J.G., 1992, MYOFASCIAL PAIN DYSF; Vincent C, 1990, COMPLEMENT MED RES, V4, P8; WARE JE, 1992, MED CARE, V30, P473, DOI 10.1097/00005650-199206000-00002; White AR, 1999, RHEUMATOLOGY, V38, P143, DOI 10.1093/rheumatology/38.2.143	23	176	180	0	18	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUN 30	2001	322	7302					1574	1577		10.1136/bmj.322.7302.1574	http://dx.doi.org/10.1136/bmj.322.7302.1574			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	449QT	11431299	Green Published, Green Submitted, Bronze			2023-01-03	WOS:000169699200026
J	Bates, DW				Bates, DW			A 40-year-old woman who noticed a medication error	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ADVERSE DRUG EVENTS; PHYSICIAN ORDER ENTRY; HOSPITALIZED-PATIENTS; HIV-INFECTION; MANAGEMENT; PREVENTION; INTERVENTION; GUIDELINES; MODEL		Brigham & Womens Hosp, Dept Med, Div Gen Med, Boston, MA 02115 USA; Partners Healthcare Syst, Ctr Appl Med Informat Syst Res, Boston, MA USA	Harvard University; Brigham & Women's Hospital; Partners Healthcare System	Bates, DW (corresponding author), Brigham & Womens Hosp, Dept Med, Div Gen Med, 75 Francis St, Boston, MA 02115 USA.	dbates@partners.org	Bates, David/AAE-7283-2019					Bates DW, 1998, JAMA-J AM MED ASSOC, V280, P1311, DOI 10.1001/jama.280.15.1311; Bates DW, 2000, BRIT MED J, V320, P788, DOI 10.1136/bmj.320.7237.788; BATES DW, 1995, J GEN INTERN MED, V10, P199, DOI 10.1007/BF02600255; Bates DW, 1999, ARCH INTERN MED, V159, P2553, DOI 10.1001/archinte.159.21.2553; BATES DW, 1995, JAMA-J AM MED ASSOC, V274, P29, DOI 10.1001/jama.274.1.29; Bates DW, 1999, J AM MED INFORM ASSN, V6, P313, DOI 10.1136/jamia.1999.00660313; BERENS MJ, 2001, NURSING ACCIDENTS UN; COHEN MR, 1997, HOSP PHARM, V32, P338; Cook RI, 1994, HUMAN ERROR MED, P255; Evans RS, 1998, NEW ENGL J MED, V338, P232, DOI 10.1056/NEJM199801223380406; EVANS RS, 1994, ANN PHARMACOTHER, V28, P523, DOI 10.1177/106002809402800417; Gandhi TK, 2000, J GEN INTERN MED, V15, P149, DOI 10.1046/j.1525-1497.2000.04199.x; GLASER J, 1996, P 1996 HEALTHC INF M; HALAMKA JD, 2000, PROVIDER CONSUMER PO; *I MED, 1999, ERR IS HUM BUILD SAF; Jaber LA, 1996, ANN PHARMACOTHER, V30, P238, DOI 10.1177/106002809603000305; JOHNSON JA, 1995, ARCH INTERN MED, V155, P1949, DOI 10.1001/archinte.155.18.1949; *KAIS FAM FDN, 2001, DEC 2000 NAT SURV AM; Kraman SS, 1999, ANN INTERN MED, V131, P963, DOI 10.7326/0003-4819-131-12-199912210-00010; Lambert BL, 1999, MED CARE, V37, P1214, DOI 10.1097/00005650-199912000-00005; Lazarou J, 1998, JAMA-J AM MED ASSOC, V279, P1200, DOI 10.1001/jama.279.15.1200; LEAPE LL, 1994, JAMA-J AM MED ASSOC, V272, P1851, DOI 10.1001/jama.272.23.1851; LEAPE LL, 1995, JAMA-J AM MED ASSOC, V274, P35, DOI 10.1001/jama.1995.03530010049034; Leape LL, 1999, JAMA-J AM MED ASSOC, V282, P267, DOI 10.1001/jama.282.3.267; Nightingale PG, 2000, BMJ-BRIT MED J, V320, P750, DOI 10.1136/bmj.320.7237.750; Paterson DL, 2000, ANN INTERN MED, V133, P21, DOI 10.7326/0003-4819-133-1-200007040-00004; *PRINC SURV RES AS, 1999, DEC 1999 HLTH NEW IN; Purdy BD, 2000, ANN PHARMACOTHER, V34, P833, DOI 10.1345/aph.19399; RAISCH DW, 1993, ANN PHARMACOTHER, V27, P1173, DOI 10.1177/106002809302701002; Raschke RA, 1998, JAMA-J AM MED ASSOC, V280, P1317, DOI 10.1001/jama.280.15.1317; Reason J., 1990, HUMAN ERROR; SAFRAN C, 1995, LANCET, V346, P341, DOI 10.1016/S0140-6736(95)92226-1; Schiff GD, 1998, JAMA-J AM MED ASSOC, V279, P1024, DOI 10.1001/jama.279.13.1024; Urquhart J, 1997, CLIN PHARMACOKINET, V32, P345, DOI 10.2165/00003088-199732050-00001; *US DEP JUST, 2001, CURR US EL PRESCR; Winker MA, 2000, JAMA-J AM MED ASSOC, V283, P1600, DOI 10.1001/jama.283.12.1600; 2001, BUILDING INFORMATION	37	19	22	0	5	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 27	2001	285	24					3134	3140		10.1001/jama.285.24.3134	http://dx.doi.org/10.1001/jama.285.24.3134			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	444FF	11427143				2023-01-03	WOS:000169388900028
J	Watkins, RE; Wisely, GB; Moore, LB; Collins, JL; Lambert, MH; Williams, SP; Willson, TM; Kliewer, SA; Redinbo, MR				Watkins, RE; Wisely, GB; Moore, LB; Collins, JL; Lambert, MH; Williams, SP; Willson, TM; Kliewer, SA; Redinbo, MR			The human nuclear xenobiotic receptor PXR: Structural determinants of directed promiscuity	SCIENCE			English	Article							PREGNANE-X-RECEPTOR; LIGAND-BINDING DOMAIN; CRYSTAL-STRUCTURE; JOHNS-WORT; SIGNALING PATHWAY; MOLECULAR-BASIS; CHOLESTEROL; COACTIVATOR; ANTAGONISM; ACTIVATION	The human nuclear pregnane X receptor (hPXR) activates cytochrome P450-3A expression in response to a wide variety of xenobiotics and plays a critical role in mediating dangerous drug-drug interactions. We present the crystal structures of the ligand-binding domain of hPXR both alone and in complex with the cholesterol-lowering drug SR12813 at resolutions of 2.5 and 2.75 angstroms, respectively. The hydrophobic ligand-binding cavity of hPXR contains a small number of polar residues, permitting SR12813 to bind in three distinct orientations. The position and nature of these polar residues were found to be critical for establishing the precise pharmacologic activation profile of PXR. Our findings provide important insights into how hPXR detects xenobiotics and may prove useful in predicting and avoiding drug-drug interactions.	Univ N Carolina, Dept Chem, Chapel Hill, NC 27599 USA; Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA; Univ N Carolina, Sch Med, Dept Biochem & Biophys, Chapel Hill, NC 27599 USA; GlaxoSmithKline, Nucl Receptor Discovery Res, Res Triangle Pk, NC 27709 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; GlaxoSmithKline	Redinbo, MR (corresponding author), Univ N Carolina, Dept Chem, Chapel Hill, NC 27599 USA.		feinstein, doug/M-9414-2019	Williams, Shawn/0000-0001-8311-2638				Berkhout TA, 1996, J BIOL CHEM, V271, P14376, DOI 10.1074/jbc.271.24.14376; Berkhout TA, 1997, ATHEROSCLEROSIS, V133, P203, DOI 10.1016/S0021-9150(97)00131-7; Bertilsson G, 1998, P NATL ACAD SCI USA, V95, P12208, DOI 10.1073/pnas.95.21.12208; Blumberg B, 1998, GENE DEV, V12, P3195, DOI 10.1101/gad.12.20.3195; BOURGUET W, 1995, NATURE, V375, P377, DOI 10.1038/375377a0; BRUNGER AT, 1993, ACTA CRYSTALLOGR D, V49, P24, DOI 10.1107/S0907444992007352; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Brzozowski AM, 1997, NATURE, V389, P753, DOI 10.1038/39645; Gampe RT, 2000, MOL CELL, V5, P545, DOI 10.1016/S1097-2765(00)80448-7; Goodwin B, 1999, MOL PHARMACOL, V56, P1329, DOI 10.1124/mol.56.6.1329; Jones SA, 2000, MOL ENDOCRINOL, V14, P27, DOI 10.1210/me.14.1.27; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kliewer SA, 1998, CELL, V92, P73, DOI 10.1016/S0092-8674(00)80900-9; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Lehmann JM, 1998, J CLIN INVEST, V102, P1016, DOI 10.1172/JCI3703; MAUREL P, 1996, CYTOCHROMES P450 MET, P241; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; Moore LB, 2000, P NATL ACAD SCI USA, V97, P7500, DOI 10.1073/pnas.130155097; Moore LB, 2000, J BIOL CHEM, V275, P15122, DOI 10.1074/jbc.M001215200; Moras D, 1998, CURR OPIN CELL BIOL, V10, P384, DOI 10.1016/S0955-0674(98)80015-X; Navaza J, 1997, METHOD ENZYMOL, V276, P581, DOI 10.1016/S0076-6879(97)76079-8; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Nolte RT, 1998, NATURE, V395, P137, DOI 10.1038/25931; ONATE SA, 1995, SCIENCE, V270, P1354; Piscitelli SC, 2000, LANCET, V355, P547, DOI 10.1016/S0140-6736(99)05712-8; READ RJ, 1986, ACTA CRYSTALLOGR A, V42, P140, DOI 10.1107/S0108767386099622; RENAUD JP, 1995, NATURE, V378, P681, DOI 10.1038/378681a0; Rochel N, 2000, MOL CELL, V5, P173, DOI 10.1016/S1097-2765(00)80413-X; Ruschitzka F, 2000, LANCET, V355, P548, DOI 10.1016/S0140-6736(99)05467-7; Savas U, 2000, DRUG METAB DISPOS, V28, P529; Shiau AK, 1998, CELL, V95, P927, DOI 10.1016/S0092-8674(00)81717-1; Weatherman RV, 1999, ANNU REV BIOCHEM, V68, P559, DOI 10.1146/annurev.biochem.68.1.559; Wentworth JM, 2000, J ENDOCRINOL, V166, pR11, DOI 10.1677/joe.0.166R011; Williams SP, 1998, NATURE, V393, P392, DOI 10.1038/30775; Xie W, 2000, NATURE, V406, P435, DOI 10.1038/35019116	35	635	661	1	31	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUN 22	2001	292	5525					2329	2333		10.1126/science.1060762	http://dx.doi.org/10.1126/science.1060762			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	445KD	11408620				2023-01-03	WOS:000169455900058
J	Srivastava, M; Ahmad, N; Gupta, S; Mukhtar, H				Srivastava, M; Ahmad, N; Gupta, S; Mukhtar, H			Involvement of Bcl-2 and Bax in photodynamic therapy-mediated apoptosis - Antisense Bcl-2 oligonucleotide sensitizes RIF 1 cells to photodynamic therapy apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOCHROME-C RELEASE; HELA-CELLS; ACTIVATION; DEATH; CLEAVAGE; INHIBITION; SURVIVAL; INDUCTION; PATHWAY; CANCER	Photodynamic therapy (PDT), a promising treatment modality, is an oxidative stress that induces apoptosis in many cancer cells in vitro and tumors in vivo. Understanding the mechanism(s) involved in POT-mediated apoptosis may improve its therapeutic efficacy. Although studies suggest the involvement of multiple pathways, the triggering event(s) responsible for PDT-mediated apoptotic response is(are) not clear. To investigate the role of Bcl-2 in POT-mediated apoptosis, we employed Bcl-2-antisense and -overexpression approaches in two cell types differing in their responses toward PDT apoptosis, In the first approach, we treated radiation-induced fibrosarcoma (RIF 1) cells, which are resistant to silicon phthalocyanine (Pc 4)-PDT apoptosis, with Bcl-2-antisense oligonucleotide. This treatment resulted in sensitization of RIF 1 cells to PDT-mediated apoptosis as demonstrated by i) cleavage of poly(ADP-ribose) polymerase, ii) DNA ladder formation, iii) terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling (TUNEL) positive cells, and iv) DEVDase activity. This treatment also resulted in oligonucleotide concentration-dependent decrease in cell viability and down-regulation of Bcl-2 protein with a concomitant increase in apoptosis, However, the level of Bax, a pro-apoptotic member of Bcl-2 family, remained unaltered. In the second approach, an overexpression of Bcl-2 in PDT apoptosis-sensitive human epidermoid carcinoma (A431) cells resulted in enhanced apoptosis and up-regulation of Bax following PDT. In both the approaches, the increased Bax/Bcl-2 ratio was associated with an increased apoptotic response of PDT, Our data also demonstrated that PDT results in modulation of other Bcl-2 family members in a way that the overall ratio of pro apoptotic and anti-apoptotic member proteins favors apoptosis.	Case Western Reserve Univ, Dept Dermatol, Cleveland, OH 44106 USA; Univ Hosp Cleveland, Res Inst, Cleveland, OH 44106 USA	Case Western Reserve University; University Hospitals of Cleveland	Mukhtar, H (corresponding author), Case Western Reserve Univ, Dept Dermatol, 11100 Euclid Ave, Cleveland, OH 44106 USA.	hxm4@po.cwru.edu		Gupta, Sanjay/0000-0002-9492-3249	NCI NIH HHS [R01 CA 51802, P30 CA 43703, P01 CA 48735] Funding Source: Medline; NIAMS NIH HHS [P30 AR 39750] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA048735, R01CA051802, P30CA043703] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P30AR039750] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		AGARWAL ML, 1993, CANCER RES, V53, P5897; AGARWAL ML, 1991, CANCER RES, V51, P5993; Agarwal R, 1996, PHOTOCHEM PHOTOBIOL, V63, P547, DOI 10.1111/j.1751-1097.1996.tb03082.x; Ahmad N, 1999, ONCOGENE, V18, P1891, DOI 10.1038/sj.onc.1202493; Ahmad N, 2000, METHOD ENZYMOL, V319, P342; Ahmad N, 1998, P NATL ACAD SCI USA, V95, P6977, DOI 10.1073/pnas.95.12.6977; Antonsson B, 1997, SCIENCE, V277, P370, DOI 10.1126/science.277.5324.370; Antonsson B, 2000, EXP CELL RES, V256, P50, DOI 10.1006/excr.2000.4839; Assefa Z, 1999, J BIOL CHEM, V274, P8788, DOI 10.1074/jbc.274.13.8788; BAFFY G, 1993, J BIOL CHEM, V268, P6511; Cheng EHY, 1997, SCIENCE, V278, P1966, DOI 10.1126/science.278.5345.1966; Chinnaiyan AM, 1996, J BIOL CHEM, V271, P4573; Colussi VC, 1999, PHOTOCHEM PHOTOBIOL, V69, P236, DOI 10.1562/0031-8655(1999)069<0236:PPTOHO>2.3.CO;2; Dougherty TJ, 1998, JNCI-J NATL CANCER I, V90, P889, DOI 10.1093/jnci/90.12.889; Gao G, 2000, J CELL BIOCHEM, V80, P53; GOMER CJ, 1991, PHOTOCHEM PHOTOBIOL, V54, P1093, DOI 10.1111/j.1751-1097.1991.tb02133.x; Granville DJ, 1998, FEBS LETT, V437, P5, DOI 10.1016/S0014-5793(98)01193-4; Granville DJ, 1999, BRIT J CANCER, V79, P95, DOI 10.1038/sj.bjc.6690017; Gupta S, 1998, CANCER RES, V58, P1785; He J, 1996, PHOTOCHEM PHOTOBIOL, V64, P845, DOI 10.1111/j.1751-1097.1996.tb01845.x; Janicke RU, 1998, J BIOL CHEM, V273, P15540, DOI 10.1074/jbc.273.25.15540; Kalka K, 2000, J AM ACAD DERMATOL, V42, P389, DOI 10.1016/S0190-9622(00)90209-3; Kessel D, 1998, J PHOTOCH PHOTOBIO B, V42, P89, DOI 10.1016/S1011-1344(97)00127-9; Kim HRC, 1999, CANCER RES, V59, P3429; Klotz LO, 1998, CANCER RES, V58, P4297; Korsmeyer SJ, 1999, CANCER RES, V59, p1693S; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Miayake H, 2000, J NATL CANCER I, V92, P34, DOI 10.1093/jnci/92.1.34; Murphy AN, 1999, ANN NY ACAD SCI, V893, P19, DOI 10.1111/j.1749-6632.1999.tb07815.x; NUNEZ G, 1990, J IMMUNOL, V144, P3602; Oleinick NL, 1998, RADIAT RES, V150, pS146, DOI 10.2307/3579816; OLTVAI ZN, 1994, CELL, V79, P189, DOI 10.1016/0092-8674(94)90188-0; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; Reed JC, 1997, NATURE, V387, P773, DOI 10.1038/42867; Reed John C., 1995, Current Opinion in Oncology, V7, P541, DOI 10.1097/00001622-199511000-00012; Rosse T, 1998, NATURE, V391, P496, DOI 10.1038/35160; Separovic D, 1998, PHOTOCHEM PHOTOBIOL, V68, P101, DOI 10.1111/j.1751-1097.1998.tb03259.x; Separovic D, 1997, CANCER RES, V57, P1717; Tajiri H, 1998, CANCER LETT, V128, P205, DOI 10.1016/S0304-3835(98)00066-4; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; Varnes ME, 1999, BIOCHEM BIOPH RES CO, V255, P673, DOI 10.1006/bbrc.1999.0261; VAUX DL, 1988, NATURE, V335, P440, DOI 10.1038/335440a0; YIN XM, 1994, NATURE, V369, P321, DOI 10.1038/369321a0; ZAIDI SIA, 1993, PHOTOCHEM PHOTOBIOL, V58, P204, DOI 10.1111/j.1751-1097.1993.tb09550.x; Zhang WG, 1999, PHOTOCHEM PHOTOBIOL, V69, P582, DOI 10.1562/0031-8655(1999)069<0582:ABRVIT>2.3.CO;2	45	85	89	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 4	2001	276	18					15481	15488		10.1074/jbc.M006920200	http://dx.doi.org/10.1074/jbc.M006920200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	429QQ	11278320	hybrid			2023-01-03	WOS:000168528800126
J	Cozzi, PJ; Malhotra, S; Mcauliffe, P; Kooby, DA; Federoff, HJ; Huryk, B; Johnson, P; Scardino, PT; Heston, WDW; Fong, Y				Cozzi, PJ; Malhotra, S; Mcauliffe, P; Kooby, DA; Federoff, HJ; Huryk, B; Johnson, P; Scardino, PT; Heston, WDW; Fong, Y			Intravesical oncolytic viral therapy using attenuated, replication-competent herpes simplex viruses G207 and Nv1020 is effective in the treatment of bladder cancer in an orthotopic syngeneic model	FASEB JOURNAL			English	Article									Mem Sloan Kettering Canc Ctr, Dept Surg, New York, NY 10021 USA; Mem Sloan Kettering Canc Ctr, George M OBrien Urol Res Ctr, New York, NY 10021 USA; Mem Sloan Kettering Canc Ctr, Dept Urol, New York, NY 10021 USA; Univ Rochester, Med Ctr, Dept Neurol, Rochester, NY 14642 USA; Univ Rochester, Med Ctr, Dept Med, Rochester, NY 14642 USA; NeuroVir Therapeut Inc, Vancouver, BC, Canada	Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; University of Rochester; University of Rochester	Fong, Y (corresponding author), Mem Sloan Kettering Canc Ctr, Dept Surg, 1275 York Ave, New York, NY 10021 USA.								0	68	76	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAY	2001	15	7					1306	1308		10.1096/fj.00-0533fje	http://dx.doi.org/10.1096/fj.00-0533fje			3	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	431WR	11344122				2023-01-03	WOS:000168655200044
J	Weiss, SC; Emanuel, LL; Fairclough, DL; Emanuel, EJ				Weiss, SC; Emanuel, LL; Fairclough, DL; Emanuel, EJ			Understanding the experience of pain in terminally ill patients	LANCET			English	Article							COOPERATIVE-ONCOLOGY-GROUP; CANCER PAIN; OPIOID ANALGESICS; FAMILY MEMBERS; HOSPICE; CAREGIVERS; CARE	Background Terminally ill patients commonly experience substantial pain. Unresolved pain has been cited as evidence that end-of-life care is of poor quality. However, the data on which that conclusion is based are limited. We aimed to provide additional data on the experience of pain in such patients. Methods We interviewed 988 terminally ill patients from six randomly selected US sites. We asked them who had treated their pain in the previous 4 weeks (primary-care physician, pain specialist, or both), and whether they wanted more pain medication than they were receiving, or why they did not want more. Findings 496 (50%) terminally ill patients reported moderate or severe pain. 514 (52%) individuals had seen a primary-care physician for treatment of pain in the previous 4 weeks and 198 (20%) saw a pain specialist. Of those who had been treated by their primary-care physician, 287 (29%) wanted more therapy, 613 (62%) wanted their pain therapy to remain the same, and 89 (9%) wanted to reduce or stop their pain therapy. Several reasons for not wanting additional therapy were offered-fear of addiction, dislike of mental or physical side-effects, and not wanting to take more pills or injections. We saw no association between disease and amount of pain between disease and the desire for more treatment. Black patients were more likely to seek additional pain therapy, see a pain specialist, and refuse additional medication because of fear of addiction than other populations. Interpretation Although half of terminally ill patients experienced moderate to severe pain, only 30% of them wanted additional pain treatment from their primary-care physician. The number of patients experiencing pain remains too high. However, the number is not as large as perceived. Additionally, most are willing to tolerate pain. Furthermore, the experience of pain is constant across major terminal diseases.	NIH, Dept Clin Bioeth, Warren G Magnuson Clin Ctr, Bethesda, MD 20892 USA; Northwestern Univ, Sch Med, Chicago, IL USA; AMC Canc Res Ctr, Ctr Res Methodol & Biometr, Denver, CO USA	National Institutes of Health (NIH) - USA; Northwestern University; AMC Cancer Research Center	Weiss, SC (corresponding author), NIH, Dept Clin Bioeth, Warren G Magnuson Clin Ctr, Bldg 10,Room 1C118, Bethesda, MD 20892 USA.							Arnst C, 1999, BUS WEEK, P190; Bonica J. J., 1980, PAIN, P335; BRESCIA FJ, 1992, J CLIN ONCOL, V10, P149, DOI 10.1200/JCO.1992.10.1.149; Cleeland CS, 1997, ANN INTERN MED, V127, P813, DOI 10.7326/0003-4819-127-9-199711010-00006; CLEELAND CS, 1994, NEW ENGL J MED, V330, P592, DOI 10.1056/NEJM199403033300902; DAUT RL, 1982, CANCER-AM CANCER SOC, V50, P1913, DOI 10.1002/1097-0142(19821101)50:9<1913::AID-CNCR2820500944>3.0.CO;2-R; DAUT RL, 1983, PAIN, V17, P197, DOI 10.1016/0304-3959(83)90143-4; EMANMUEL LL, IN PRESS J PALLIATIV; Emanuel EJ, 1999, NEW ENGL J MED, V341, P956, DOI 10.1056/NEJM199909233411306; Emanuel EJ, 2000, ANN INTERN MED, V132, P451, DOI 10.7326/0003-4819-132-6-200003210-00005; Field MJ, 1997, APPROACHING DEATH IM; Foley KM, 1998, OXFORD TXB PALLIATIV, P310; Jacox A, 1994, AHCPR PUBLICATION; Joranson DE, 2000, JAMA-J AM MED ASSOC, V283, P1710, DOI 10.1001/jama.283.13.1710; KNAUS WA, 1995, JAMA-J AM MED ASSOC, V274, P1591, DOI 10.1001/jama.1995.03530200027032; Lynn J, 1997, ANN INTERN MED, V126, P97, DOI 10.7326/0003-4819-126-2-199701150-00001; MCKEGNEY FP, 1981, GEN HOSP PSYCHIAT, V3, P95, DOI 10.1016/0163-8343(81)90050-5; MORRIS JN, 1986, J CHRON DIS, V39, P27, DOI 10.1016/0021-9681(86)90104-9; Morrison RS, 2000, NEW ENGL J MED, V342, P1023, DOI 10.1056/NEJM200004063421406; OSTER MW, 1978, ARCH INTERN MED, V138, P1801, DOI 10.1001/archinte.138.12.1801; Paice JA, 1998, J PAIN SYMPTOM MANAG, V16, P1, DOI 10.1016/S0885-3924(98)00025-6; Parker RA, 1999, JAMA-J AM MED ASSOC, V281, P1937, DOI 10.1001/jama.281.20.1937; Petrosino B M, 1985, Hosp J, V1, P3; PORTENOY RK, 1994, EUR J CANCER, V30A, P1326, DOI 10.1016/0959-8049(94)90182-1; PORTENOY RK, 1992, CANCER, V70, P616; Singer PA, 1999, JAMA-J AM MED ASSOC, V281, P163, DOI 10.1001/jama.281.2.163; STEIN WM, 1993, J PAIN SYMPTOM MANAG, V8, P474, DOI 10.1016/0885-3924(93)90190-7; Tay W. K. J., 1994, Annals Academy of Medicine Singapore, V23, P191; TWYCROSS RG, 1982, PAIN, V14, P303, DOI 10.1016/0304-3959(82)90137-3; VONROENN JH, 1993, ANN INTERN MED, V119, P121, DOI 10.7326/0003-4819-119-2-199307150-00005; Ward SE, 1996, RES NURS HEALTH, V19, P205, DOI 10.1002/(SICI)1098-240X(199606)19:3<205::AID-NUR4>3.0.CO;2-O	31	149	152	0	8	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	APR 28	2001	357	9265					1311	1315		10.1016/S0140-6736(00)04515-3	http://dx.doi.org/10.1016/S0140-6736(00)04515-3			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	427ND	11343734				2023-01-03	WOS:000168411400008
J	Ahmad, N; Kalka, K; Mukhtar, H				Ahmad, N; Kalka, K; Mukhtar, H			In vitro and in vivo inhibition of epidermal growth factor receptor-tyrosine kinase pathway by photodynamic therapy	ONCOGENE			English	Article						PDT; EGFR; Shc; cell cycle; apoptosis	ACTIVATED PROTEIN-KINASE; MEDIATED APOPTOSIS; INDUCED ABLATION; CARCINOMA-CELLS; MOUSE SKIN; HELA-CELLS; TUMORS; A431; INVOLVEMENT; PROGRESSION	PDT, a new therapeutic procedure for the management of many malignant conditions including skin cancer, involves the administration of a photosensitizing compound followed by illumination of the lesion with visible light, We earlier showed an involvement of: (i) WAF1/ p21-cyclins (D1 and E)-cdk (2 and 6) network; and (ii) Rb/E2F-DP machinery during silicon phthalocyanine (Pc4)-PDT-mediated cell cycle dysregulation and apoptosis of human epidermoid carcinoma (A431) cells, Here, we investigated the involvement of EGFR-pathway during antiproliferative responses of Pc4-PDT in A431 cells and during ablation of murine skin papillomas. Pc4-PDT of A431 cells was found to result in a time-dependent down-modulation of the protein expression and phosphorylation of EGFR and Shc (an immediate downstream molecule in EGFR-pathway), during progressive increase in apoptotic response. To establish the relevance of these in vitro findings to in vivo situations, we subjected chemically- as well as ultraviolet B radiation-induced squamous papillomas in SENCAR and SKH-1 hairless mice, respectively, to Pc4-PDT, and assessed its effect on EGFR-pathway during ablation of these tumors. Pc4-PDT was found to result in a time-dependent: (i) inhibition of protein expressions of EGFR; and (ii) tyrosine phosphorylation of EGFR and Shc; and (iii) induction of apoptosis, during the regression of these tumors, These data suggest the involvement of EGFR-pathway during the antiproliferative effects of PDT, It is tempting to speculate that inhibitors of EGFR could enhance the therapeutic efficacy of PDT.	Case Western Reserve Univ, Dept Dermatol, Cleveland, OH 44106 USA	Case Western Reserve University	Mukhtar, H (corresponding author), Case Western Reserve Univ, Dept Dermatol, 11100 Euclid Ave, Cleveland, OH 44106 USA.				NATIONAL CANCER INSTITUTE [R01CA051802, P30CA043703, P01CA048735] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P30AR039750] Funding Source: NIH RePORTER; NCI NIH HHS [P01 CA 48735, P30 CA 43703, R01 CA 51802] Funding Source: Medline; NIAMS NIH HHS [P30 AR 39750] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Agarwal R, 1996, PHOTOCHEM PHOTOBIOL, V63, P547, DOI 10.1111/j.1751-1097.1996.tb03082.x; Ahmad N, 1999, ONCOGENE, V18, P1891, DOI 10.1038/sj.onc.1202493; Ahmad N, 1998, P NATL ACAD SCI USA, V95, P6977, DOI 10.1073/pnas.95.12.6977; Ahmad N, 1998, BIOCHEM BIOPH RES CO, V247, P294, DOI 10.1006/bbrc.1998.8748; Ahmad N, 2000, J INVEST DERMATOL, V115, P1041, DOI 10.1046/j.1523-1747.2000.00147.x; Assefa Z, 1999, J BIOL CHEM, V274, P8788, DOI 10.1074/jbc.274.13.8788; Chiu SM, 2000, INT J ONCOL, V16, P423; Colussi VC, 1999, PHOTOCHEM PHOTOBIOL, V69, P236, DOI 10.1562/0031-8655(1999)069<0236:PPTOHO>2.3.CO;2; Dougherty TJ, 1998, JNCI-J NATL CANCER I, V90, P889, DOI 10.1093/jnci/90.12.889; Engbrecht BW, 1999, CANCER RES, V59, P4334; Fry DW, 1999, PHARMACOL THERAPEUT, V82, P207, DOI 10.1016/S0163-7258(98)00050-3; Graness A, 2000, BIOCHEM J, V347, P441, DOI 10.1042/0264-6021:3470441; Granville DJ, 1998, FEBS LETT, V437, P5, DOI 10.1016/S0014-5793(98)01193-4; Granville DJ, 1998, FEBS LETT, V422, P151, DOI 10.1016/S0014-5793(97)01616-5; Gupta S, 1998, CANCER RES, V58, P1785; Hansen LA, 2000, CANCER RES, V60, P3328; Kalka K, 2000, CANCER RES, V60, P5984; Kalka K, 2000, J AM ACAD DERMATOL, V42, P389, DOI 10.1016/S0190-9622(00)90209-3; Kawaguchi T, 2000, BRIT J CANCER, V82, P418; Kessler JJ, 1998, LAND DEGRAD DEV, V9, P95, DOI 10.1002/(SICI)1099-145X(199803/04)9:2<95::AID-LDR289>3.0.CO;2-Y; Kim HRC, 1999, CANCER RES, V59, P3429; Mukhtar H, 1996, PHOTOCHEM PHOTOBIOL, V63, P355, DOI 10.1111/j.1751-1097.1996.tb03040.x; Nakamura T, 1996, ONCOGENE, V13, P1111; Oleinick NL, 1998, RADIAT RES, V150, pS146, DOI 10.2307/3579816; OLEINICK NL, 1993, PHOTOCHEM PHOTOBIOL, V57, P242, DOI 10.1111/j.1751-1097.1993.tb02282.x; SchmidtUllrich RK, 1997, ONCOGENE, V15, P1191, DOI 10.1038/sj.onc.1201275; Tajiri H, 1998, CANCER LETT, V128, P205, DOI 10.1016/S0304-3835(98)00066-4; Varnes ME, 1999, BIOCHEM BIOPH RES CO, V255, P673, DOI 10.1006/bbrc.1999.0261; Whitacre CM, 2000, CLIN CANCER RES, V6, P2021; Woodburn JR, 1999, PHARMACOL THERAPEUT, V82, P241, DOI 10.1016/S0163-7258(98)00045-X; ZAIDI SIA, 1993, PHOTOCHEM PHOTOBIOL, V58, P771, DOI 10.1111/j.1751-1097.1993.tb04969.x; Zhang WG, 1999, CANCER LETT, V138, P189, DOI 10.1016/S0304-3835(99)00013-0	33	54	57	1	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 26	2001	20	18					2314	2317		10.1038/sj.onc.1204313	http://dx.doi.org/10.1038/sj.onc.1204313			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	427KZ	11402326				2023-01-03	WOS:000168404500013
J	Kirk, O; Reiss, P; Uberti-Foppa, C; Bickel, M; Gerstoft, J; Pradier, C; Wit, FW; Ledergerber, B; Lundgren, JD; Furrer, H; Seven European HIV Cohorts				Kirk, O; Reiss, P; Uberti-Foppa, C; Bickel, M; Gerstoft, J; Pradier, C; Wit, FW; Ledergerber, B; Lundgren, JD; Furrer, H; Seven European HIV Cohorts			Safe interruption of maintenance therapy against previous infection with four common HIV-associated opportunistic pathogens during potent antiretroviral therapy	ANNALS OF INTERNAL MEDICINE			English	Article							PNEUMOCYSTIS-CARINII-PNEUMONIA; PLACEBO-CONTROLLED TRIAL; ACQUIRED-IMMUNODEFICIENCY-SYNDROME; AVIUM COMPLEX BACTEREMIA; MYCOBACTERIUM-AVIUM; CYTOMEGALOVIRUS RETINITIS; PRIMARY PROPHYLAXIS; SECONDARY PROPHYLAXIS; HIV-1-INFECTED PATIENTS; TOXOPLASMA ENCEPHALITIS	Background: The safety of interrupting maintenance therapy for previous opportunistic infections other than Pneumocystis carinii pneumonia among patients with HIV infection who respond to potent antiretroviral therapy has not been well documented. Objective: To assess the safety of interrupting maintenance therapy for cytomegalovirus (CMV) end-organ disease, disseminated Mycobacterium avium complex (MAC) infection, cerebral toxoplasmosis, and extrapulmonary cryptococcosis in patients receiving antiretroviral therapy. Design: Observational study. Setting: Seven European HIV cohorts. Patients: 358 patients taking potent antiretroviral therapy (greater than or equal to3 drugs) who interrupted maintenance therapy at a CD4 lymphocyte count greater than 50 x 10(6) cells/L. Measurements: Recurrence of opportunistic infection after interruption of maintenance therapy. Results: 379 interruptions of maintenance therapy were identified: 162 for CMV disease, 103 for MAC infection, 75 for toxoplasmosis, and 39 for cryptococcosis. During 781 person-years of follow-up, five patients had relapse. Two relapses (one of CMV disease and one of MAC infection) were diagnosed after maintenance therapy was interrupted when the CD4 lymphocyte count was less than 100 x 106 cells/L or when only one recent measurement exceeded this value. Two relapses (one of CMV disease and one of MAC infection) were diagnosed after maintenance therapy was interrupted once CD4 counts were greater than 100 x 106 cells/L for 10 and 8 months, respectively. One relapse (toxoplasmosis) was diagnosed after maintenance therapy interruption at a CD4 lymphocyte count greater than 200 x 106 cells/L for 15 months. The overall incidences of recurrent CMV disease, MAC infection, toxoplasmosis, and cryptococcosis were 0.54 per 100 person-years (95% Cl, 0.07 to 1.95 per 100 person-years), 0.90 per 100 person-years (Cl, 0.11 to 3.25 per 100 person-years), 0.84 per 100 person-years (Cl, 0.02 to 4.68 per 100 person-years), and 0.00 per 100 person-years (Cl, 0.00 to 5.27 per 100 person-years), respectively. Conclusion: Maintenance therapy against previous infection with CMV, MAC, Toxoplasma gondii, or Cryptococcus neoformans in patients with HIV infection can be interrupted after sustained CD4 count increases to greater than 200 (or possibly 100 to 200) x 106 cells/L for at least 6 months after the start of potent antiretroviral therapy.	Univ Copenhagen, Hvidovre Hosp, Coordinating Ctr EuroSIDA, Dept Infect Dis, DK-2650 Hvidovre, Denmark; Rigshosp, DK-2100 Copenhagen, Denmark; Univ Amsterdam, Acad Med Ctr, NL-1105 AZ Amsterdam, Netherlands; Hosp San Raffaele, I-20132 Milan, Italy; JW Goethe Univ Clin, Frankfurt, Germany; Hop Archet, Nice, France; Univ Zurich Hosp, CH-8091 Zurich, Switzerland; Univ Hosp Bern, CH-3010 Bern, Switzerland	University of Copenhagen; Rigshospitalet; University of Copenhagen; University of Amsterdam; Academic Medical Center Amsterdam; Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele; Goethe University Frankfurt; Goethe University Frankfurt Hospital; CHU Nice; University of Zurich; University Zurich Hospital; University of Bern; University Hospital of Bern	Kirk, O (corresponding author), Univ Copenhagen, Hvidovre Hosp, Coordinating Ctr EuroSIDA, Dept Infect Dis, Kettegaard Alle, DK-2650 Hvidovre, Denmark.	oki@cphiv.dk	VALLET, Yannick/F-9979-2011; Foppa, Caterina Uberti/ABH-3089-2020; Pradier, Christian/AAE-9669-2022; Furrer, Hansjakob/G-6768-2013; Wit, Ferdinand/AAC-3803-2019; Pradier, Christian/AFE-8255-2022; kirk, ole/ABB-4746-2021; Lundgren, Jens/AAE-6876-2019; Ledergerber, Bruno/B-5656-2009	Foppa, Caterina Uberti/0000-0001-5271-9138; Furrer, Hansjakob/0000-0002-1375-3146; Ledergerber, Bruno/0000-0002-6881-4401; Lundgren, Jens/0000-0001-8901-7850				*1999 USPHS IDSA, 1999, MMWR-MORBID MORTAL W, V48, P1; *2001 USPHS IDSA, 2001, UIG PREV OPP INF PER; Aberg JA, 1998, J INFECT DIS, V178, P1446, DOI 10.1086/314469; Autran B, 1997, SCIENCE, V277, P112, DOI 10.1126/science.277.5322.112; BOZZETTE SA, 1991, NEW ENGL J MED, V324, P580, DOI 10.1056/NEJM199102283240902; Brodt HR, 1997, AIDS, V11, P1731, DOI 10.1097/00002030-199714000-00010; Carr A, 1998, LANCET, V351, P256, DOI 10.1016/S0140-6736(97)07529-6; Curi ALL, 2001, BRIT J OPHTHALMOL, V85, P471, DOI 10.1136/bjo.85.4.471; Currier JS, 2000, ANN INTERN MED, V133, P493, DOI 10.7326/0003-4819-133-7-200010030-00008; de Quiros JCLB, 2001, NEW ENGL J MED, V344, P159, DOI 10.1056/NEJM200101183440301; Dube MP, 1997, J INFECT DIS, V176, P1225, DOI 10.1086/514116; El-Sadr WM, 2000, NEW ENGL J MED, V342, P1085, DOI 10.1056/NEJM200004133421503; FEINSTEIN A, 1984, STAT MED, V3, P341, DOI 10.1002/sim.4780030409; Foudraine NA, 1998, AIDS, V12, P35, DOI 10.1097/00002030-199801000-00005; Furrer H, 2000, LANCET, V355, P2217, DOI 10.1016/S0140-6736(00)02407-7; Furrer H, 1999, NEW ENGL J MED, V340, P1301, DOI 10.1056/NEJM199904293401701; Furrer H, 2001, AIDS, V15, P501, DOI 10.1097/00002030-200103090-00009; Furrer H, 2000, AIDS, V14, P1409, DOI 10.1097/00002030-200007070-00014; Hadad DJ, 1998, CLIN INFECT DIS, V26, P758, DOI 10.1086/514577; HAVERKOS HW, 1987, AM J MED, V82, P907, DOI 10.1016/0002-9343(87)90151-3; JACOBSON MA, 1993, J INFECT DIS, V168, P112, DOI 10.1093/infdis/168.1.112; JACOBSON MA, 1988, J MED VIROL, V25, P339, DOI 10.1002/jmv.1890250311; Jouan M, 2001, AIDS, V15, P23, DOI 10.1097/00002030-200101050-00006; Katlama C, 1996, CLIN INFECT DIS, V22, P268, DOI 10.1093/clinids/22.2.268; Kirk O, 1999, AIDS, V13, P1647, DOI 10.1097/00002030-199909100-00007; Komanduri KV, 2001, J INFECT DIS, V183, P1285, DOI 10.1086/319683; Komanduri KV, 1998, NAT MED, V4, P953, DOI 10.1038/nm0898-953; Ledergerber B, 2001, NEW ENGL J MED, V344, P168, DOI 10.1056/NEJM200101183440302; Li TS, 1998, LANCET, V351, P1682, DOI 10.1016/S0140-6736(97)10291-4; Lundgren JD, 1997, J ACQ IMMUN DEF SYND, V16, P153, DOI 10.1097/00042560-199711010-00003; Macdonald JC, 1998, J INFECT DIS, V177, P1182, DOI 10.1086/515281; Martinez E, 2000, AIDS, V14, P2615, DOI 10.1097/00002030-200011100-00029; Martinez E, 1999, AIDS, V13, P147; Murphy M, 1997, AIDS, V11, P261; Mussini C, 2000, J INFECT DIS, V181, P1635, DOI 10.1086/315471; Nieuwkerk PT, 2001, ARCH INTERN MED, V161, P1962, DOI 10.1001/archinte.161.16.1962; Nwokolo NC, 2001, AIDS, V15, P1438, DOI 10.1097/00002030-200107270-00015; PALESTINE AG, 1991, ANN INTERN MED, V115, P665, DOI 10.7326/0003-4819-115-9-665; Pocock SJ, 2000, NEW ENGL J MED, V342, P1907, DOI 10.1056/NEJM200006223422511; Pradier C, 1997, AIDS, V11, P832; RENOLD C, 1992, MEDICINE, V71, P224, DOI 10.1097/00005792-199207000-00005; Rizzardi GP, 1996, J INFECTION, V32, P123, DOI 10.1016/S0163-4453(96)91312-2; Schneider MME, 1999, LANCET, V353, P201, DOI 10.1016/S0140-6736(98)07204-3; Soriano V, 2000, AIDS, V14, P383, DOI 10.1097/00002030-200003100-00011; Sudre P, 2000, SCHWEIZ MED WSCHR, V130, P1493; Tural C, 1998, J INFECT DIS, V177, P1080, DOI 10.1086/517399; Vrabec TR, 1998, OPHTHALMOLOGY, V105, P1259, DOI 10.1016/S0161-6420(98)97031-2; Weverling GJ, 1999, LANCET, V353, P1293, DOI 10.1016/S0140-6736(99)03287-0; Whitcup SM, 1999, JAMA-J AM MED ASSOC, V282, P1633, DOI 10.1001/jama.282.17.1633; Whitcup SM, 1997, JAMA-J AM MED ASSOC, V277, P1519, DOI 10.1001/jama.277.19.1519; Yangco BG, 2000, ANN INTERN MED, V132, P201, DOI 10.7326/0003-4819-132-3-200002010-00005	51	93	98	0	5	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	AUG 20	2002	137	4					239	250		10.7326/0003-4819-137-4-200208200-00008	http://dx.doi.org/10.7326/0003-4819-137-4-200208200-00008			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	585BB	12186514				2023-01-03	WOS:000177502300004
J	Kreiss, K; Gomaa, A; Kullman, G; Fedan, K; Simoes, EJ; Enright, PL				Kreiss, K; Gomaa, A; Kullman, G; Fedan, K; Simoes, EJ; Enright, PL			Clinical bronchiolitis obliterans in workers at a microwave-popcorn plant	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							VALUES; SAMPLE	Background In May 2000, eight persons who had formerly worked at a microwave-popcorn production plant were reported to have severe bronchiolitis obliterans. No recognized cause was identified in the plant. Therefore, we medically evaluated current employees and assessed their occupational exposures. Methods Questionnaire responses and spirometric findings in participating workers were compared with data from the third National Health and Nutrition Examination Survey, after adjustment for age and smoking status. We evaluated the relation between exposures and health-related outcomes by analyzing the rates of symptoms and abnormalities according to current and cumulative exposure to diacetyl, the predominant ketone in artificial butter flavoring and in the air at the plant. Results Of the 135 current workers at the plant, 117 (87 percent) completed the questionnaire. These 117 workers had 2.6 times the expected rates of chronic cough and shortness of breath, according to comparisons with the national data, and twice the expected rates of physician-diagnosed asthma and chronic bronchitis. Overall, the workers had 3.3 times the expected rate of airway obstruction; those who had never smoked had 10.8 times the expected rate. Workers directly involved in the production of microwave popcorn had higher rates of shortness of breath on exertion and skin problems that had developed since they started work than workers in other parts of the plant. There was a strong relation between the quartile of estimated cumulative exposure to diacetyl and the frequency and extent of airway obstruction. Conclusions The excess rates of lung disease and lung-function abnormalities and the relation between exposure and outcomes in this working population indicate that they probably had occupational bronchiolitis obliterans caused by the inhalation of volatile butter-flavoring ingredients.	NIOSH, Div Resp Dis Studies, Morgantown, WV 26505 USA; Missouri Dept Hlth & Senior Serv, Off Epidemiol, Jefferson City, MO USA	Centers for Disease Control & Prevention - USA; National Institute for Occupational Safety & Health (NIOSH)	Kreiss, K (corresponding author), NIOSH, Div Resp Dis Studies, H2800,1095 Willowdale Rd, Morgantown, WV 26505 USA.	kkreiss@cdc.gov	Simoes, Eduardo J/H-4546-2018	Simoes, Eduardo J/0000-0003-4371-4305				AKPINARELCI M, 2002, AM J RESP CRIT CARE, V165, pA526; [Anonymous], 1995, AM J RESP CRIT CARE, V152, P1107, DOI 10.1164/ajrccm.152.3.7663792; [Anonymous], 1991, AM REV RESPIR DIS, V144, P1202, DOI 10.1164/ajrccm/144.5.1202; [Anonymous], 1995, AM J RESP CRIT CARE, V152, P2185; Centers for Disease Control and Prevention (CDC), 2002, MMWR Morb Mortal Wkly Rep, V51, P345; Eller P., 1994, DHHS NIOSH PUBLICATI, V94-113; FERRIS BG, 1978, AM REV RESPIR DIS, V118, P1; Hankinson JL, 1999, AM J RESP CRIT CARE, V159, P179, DOI 10.1164/ajrccm.159.1.9712108; HUBBS AF, 2002, TOXICOL SCI S, V66, P194; *INT BAK SERV INC, 1986, DHHS NIOSH PUBL; *INT LAB OFF, 1980, OCC SAF HLTH SER, V22; King T. E., 1998, FISHMANS PULMONARY D, P825; Lockey J., 2002, AM J RESP CRIT CARE, V165, pA461; MILLER A, 1983, AM REV RESPIR DIS, V127, P270; MONSON RR, 1990, OCCUPATIONAL EPIDEMI, P114; MORGAN RH, 1979, AM J ROENTGENOL, V132, P803, DOI 10.2214/ajr.132.5.803; National Center for Health Statistics, 1996, 3 NAT HLTH NUTR EX S; Parmet AJ, 2002, J OCCUP ENVIRON MED, V44, P216, DOI 10.1097/00043764-200203000-00002; SAS Institute, 1990, SAS STAT US GUID VER	19	316	323	1	22	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	AUG 1	2002	347	5					330	338		10.1056/NEJMoa020300	http://dx.doi.org/10.1056/NEJMoa020300			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	587WC	12151470	Bronze			2023-01-03	WOS:000177665900005
J	Perl, TM; Cullen, JJ; Wenzel, RP; Zimmerman, MB; Pfaller, MA; Sheppard, D; Twombley, J; French, PP; Herwaldt, LA				Perl, TM; Cullen, JJ; Wenzel, RP; Zimmerman, MB; Pfaller, MA; Sheppard, D; Twombley, J; French, PP; Herwaldt, LA		Mupirocin Risk Staphyloccocus Aure	Intranasal mupirocin to prevent postoperative staphylococcus aureus infections	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							SURGICAL-SITE INFECTIONS; NASAL CARRIAGE; NOSOCOMIAL INFECTIONS; METHICILLIN-RESISTANT; HEMODIALYSIS-PATIENTS; WOUND INFECTIONS; ELIMINATION; OINTMENT; CALCIUM; COST	Background: Patients with nasal carriage of Staphylococcus aureus have an increased risk of surgical-site infections caused by that organism. Treatment with mupirocin ointment can reduce the rate of nasal carriage and may prevent postoperative S. aureus infections. Methods: We conducted a randomized, double-blind, placebo-controlled trial to determine whether intranasal treatment with mupirocin reduces the rate of S. aureus infections at surgical sites and prevents other nosocomial infections. Results: Of 4030 enrolled patients who underwent general, gynecologic, neurologic, or cardiothoracic surgery, 3864 were included in the intention-to-treat analysis. Overall, 2.3 percent of mupirocin recipients and 2.4 percent of placebo recipients had S. aureus infections at surgical sites. Of the 891 patients (23.1 percent of the 3864 who completed the study) who had S. aureus in their anterior nares, 444 received mupirocin and 447 received placebo. Among the patients with nasal carriage of S. aureus, 4.0 percent of those who received mupirocin had nosocomial S. aureus infections, as compared with 7.7 percent of those who received placebo (odds ratio for infection, 0.49; 95 percent confidence interval, 0.25 to 0.92; P=0.02). Conclusions: Prophylactic intranasal application of mupirocin did not significantly reduce the rate of S. aureus surgical-site infections overall, but it did significantly decrease the rate of all nosocomial S. aureus infections among the patients who were S. aureus carriers.	Johns Hopkins Univ Hosp, Johns Hopkins Med Inst, Div Infect Dis, Baltimore, MD 21287 USA; Johns Hopkins Univ Hosp, Dept Hosp Epidemiol & Infect Control, Baltimore, MD 21287 USA; Univ Iowa, Coll Med, Iowa City, IA USA; Univ Iowa, Coll Publ Hlth, Iowa City, IA USA; Univ Iowa Hosp & Clin, Iowa City, IA 52242 USA; GlaxoSmithKline, Collegeville, PA USA	Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins Medicine; University of Iowa; University of Iowa; University of Iowa; GlaxoSmithKline	Perl, TM (corresponding author), Johns Hopkins Univ Hosp, Johns Hopkins Med Inst, Div Infect Dis, 425 Osler,600 N Wolfe St, Baltimore, MD 21287 USA.			Cullen, Joseph/0000-0002-2222-1328; Herwaldt, Loreen/0000-0002-9530-6859				Baron E.J., 1999, MANUAL CLIN MICROBIO, V7th; Bloom BS, 1996, AM J KIDNEY DIS, V27, P687, DOI 10.1016/S0272-6386(96)90104-3; BOELAERT JR, 1991, J HOSP INFECT, V19, P41, DOI 10.1016/0195-6701(91)90202-J; BOELAERT JR, 1993, NEPHROL DIAL TRANSPL, V8, P235; BOYCE JM, 1990, INFECT CONT HOSP EP, V11, P89; BRODERICK A, 1990, AM J EPIDEMIOL, V131, P734, DOI 10.1093/oxfordjournals.aje.a115558; Campbell W, 1999, CRIT CARE MED, V27, P798, DOI 10.1097/00003246-199904000-00039; Cimochowski GE, 2001, ANN THORAC SURG, V71, P1572, DOI 10.1016/S0003-4975(01)02519-X; CULVER DH, 1991, AM J MED, V91, pS152, DOI 10.1016/0002-9343(91)90361-Z; DOEBBELING BN, 1993, CLIN INFECT DIS, V17, P466, DOI 10.1093/clinids/17.3.466; EMORI TG, 1993, CLIN MICROBIOL REV, V6, P428, DOI 10.1128/CMR.6.4.428-442.1993; Finlay JE, 1997, ANTIMICROB AGENTS CH, V41, P1137, DOI 10.1128/AAC.41.5.1137; GARNER JS, 1988, AM J INFECT CONTROL, V16, P128, DOI 10.1016/0196-6553(88)90053-3; Gernaat-van der Sluis AJ, 1998, ACTA ORTHOP SCAND, V69, P412; GREEN JW, 1977, ANN SURG, V185, P264, DOI 10.1097/00000658-197703000-00002; HALL M, 1998, DHHS PHS PUBL, P98; HORAN TC, 1993, INFECT CONT HOSP EP, V14, P73, DOI 10.2307/30147164; Kirkland KB, 1999, INFECT CONT HOSP EP, V20, P725, DOI 10.1086/501572; Kluytmans J, 1997, CLIN MICROBIOL REV, V10, P505, DOI 10.1128/CMR.10.3.505; Kluytmans JAJW, 1996, INFECT CONT HOSP EP, V17, P793; Kluytmans JAJW, 1996, INFECT CONT HOSP EP, V17, P780; MCCABE WR, 1962, ARCH INTERN MED, V110, P856, DOI 10.1001/archinte.1962.03620240038007; MEST DR, 1994, ANESTH ANALG, V78, P644; MOR V, 1984, CANCER-AM CANCER SOC, V53, P2002, DOI 10.1002/1097-0142(19840501)53:9<2002::AID-CNCR2820530933>3.0.CO;2-W; MORALES E, 1993, 33 INT C ANT AG CHEM; *NAT COMM CLIN LAB, 1999, M100S9 NCCLS, V19; NELSON RM, 1986, ANN THORAC SURG, V42, P240, DOI 10.1016/S0003-4975(10)62726-9; Perl TM, 1998, ANN PHARMACOTHER, V32, pS7, DOI 10.1177/106002809803200104; Pujol M, 1996, AM J MED, V100, P509, DOI 10.1016/S0002-9343(96)00014-9; REAGAN DR, 1991, ANN INTERN MED, V114, P101, DOI 10.7326/0003-4819-114-2-101; Tenover FC, 1997, INFECT CONT HOSP EP, V18, P426; TRILLA A, 1993, INFECT CONT HOSP EP, V14, P29; VandenBergh MFQ, 1996, INFECT CONT HOSP EP, V17, P786; von Eiff C, 2001, NEW ENGL J MED, V344, P11, DOI 10.1056/NEJM200101043440102; WENZEL RP, 1995, J HOSP INFECT, V31, P13, DOI 10.1016/0195-6701(95)90079-9	35	521	532	1	21	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUN 13	2002	346	24					1871	1877		10.1056/NEJMoa003069	http://dx.doi.org/10.1056/NEJMoa003069			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	561NA	12063371				2023-01-03	WOS:000176146100005
J	Wong, PWY; Yeo, AHJ; Deol, HK; Saunders, SMF; Ham, RJ				Wong, PWY; Yeo, AHJ; Deol, HK; Saunders, SMF; Ham, RJ			Ischaemic ulcer from a chemical burn	LANCET			English	Editorial Material									Barts & London NHS Trust, Royal London Hosp, Dept Vasc Surg, London, England	Barts Health NHS Trust; Royal London Hospital	Wong, PWY (corresponding author), Barts & London NHS Trust, Royal London Hosp, Dept Vasc Surg, London, England.								0	2	2	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAY 4	2002	359	9317					1563	1563		10.1016/S0140-6736(02)08515-X	http://dx.doi.org/10.1016/S0140-6736(02)08515-X			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	549RN	12047965				2023-01-03	WOS:000175460700009
J	Chochinov, HM				Chochinov, HM			Dignity-conserving cre - A new model for palliative care - Helping the patient feel valued	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							PHYSICIAN-ASSISTED SUICIDE; TERMINALLY-ILL PATIENTS; OF-LIFE; FIGHTING SPIRIT; END; EUTHANASIA; DEATH; CANCER; ATTITUDES; FAMILY	The basic tenets of palliative care may be summarized as the goal of helping patients to die with dignity. The term "dignity" provides an overarching framework that may guide the physician, patient, and family in defining the objectives and therapeutic considerations fundamental to end-of-life care. Dignity-conserving care is care that may conserve or bolster the dignity of dying patients. Using segments of interviews with a patient with advanced lung cancer, his wife, and his palliative care physician, this article illustrates and explores various aspects of dignity-conserving care and the model on which it is based. Dignity-conserving care offers an approach that clinicians can use to explicitly target the maintenance of dignity as a therapeutic objective and as a principle of bedside care for patients nearing death.	Univ Manitoba, Dept Psychiat, Winnipeg, MB R3T 2N2, Canada; Canc Care, Winnipeg, MB, Canada	University of Manitoba	Chochinov, HM (corresponding author), FR CPC, PX246,771 Bannatyne Ave, Winnipeg, MB R3E 3N4, Canada.	chochin@cc.umanitoba.ca		Chochinov, Harvey/0000-0003-2656-4704				ABIVEN M, 1991, World Health Forum, V12, P375; Andershed B, 2001, J ADV NURS, V34, P554, DOI 10.1046/j.1365-2648.2001.01785.x; Back AL, 1996, JAMA-J AM MED ASSOC, V275, P919, DOI 10.1001/jama.275.12.919; Barthow C, 1997, Int J Nurs Pract, V3, P206, DOI 10.1111/j.1440-172X.1997.tb00103.x; BLOCH SD, 1994, ARCH INTERN MED, V154, P2039, DOI 10.1001/archinte.154.18.2039; Block SD, 2001, JAMA-J AM MED ASSOC, V285, P2898, DOI 10.1001/jama.285.22.2898; Breitbart W, 2000, JAMA-J AM MED ASSOC, V284, P2907, DOI 10.1001/jama.284.22.2907; BREITBART W, 1998, TXB PSYCHOONCOLOGY, P437; Byock I R, 1994, J Palliat Care, V10, P8; Byock IR, 1996, CLIN GERIATR MED, V12, P237; Caraceni A, 1999, PAIN, V82, P263, DOI 10.1016/S0304-3959(99)00073-1; CASSEL EJ, 1982, NEW ENGL J MED, V306, P639, DOI 10.1056/NEJM198203183061104; CASSEM NH, 1987, MASSACHUSETTS GEN HO, P332; Chater S, 1998, PALLIATIVE MED, V12, P255, DOI 10.1191/026921698671831786; Cherny N I, 1994, J Palliat Care, V10, P57; Chochinov HM, 1998, PSYCHOSOMATICS, V39, P366, DOI 10.1016/S0033-3182(98)71325-8; Chochinov HM, 1999, LANCET, V354, P816, DOI 10.1016/S0140-6736(99)80011-7; Chochinov HM, 2002, SOC SCI MED, V54, P433, DOI 10.1016/S0277-9536(01)00084-3; CHOCHINOV HM, 1995, AM J PSYCHIAT, V152, P1185; Cohen S R, 1992, J Palliat Care, V8, P40; Daaleman TP, 2000, JAMA-J AM MED ASSOC, V284, P2514, DOI 10.1001/jama.284.19.2514; Dobratz M C, 1993, West J Nurs Res, V15, P708, DOI 10.1177/019394599301500604; Emanuel EJ, 1998, LANCET, V351, P21, DOI 10.1016/S0140-6736(98)90329-4; Emanuel EJ, 2000, JAMA-J AM MED ASSOC, V284, P2460, DOI 10.1001/jama.284.19.2460; Field MJ, 1997, APPROACHING DEATH IM; Fisher BJ, 1995, INT J AGING HUM DEV, V41, P239, DOI 10.2190/HA9X-H48D-9GYB-85XW; FRANKL VE, 1963, MANS SEARCH MEANING, P171; Ganzini L, 1999, NEUROLOGY, V52, P1434, DOI 10.1212/WNL.52.7.1434; Ganzini L, 2000, NEW ENGL J MED, V342, P557, DOI 10.1056/NEJM200002243420806; Greer SS, 2000, LANCET, V355, P847, DOI 10.1016/S0140-6736(05)72464-8; HINTON J, 1981, J PSYCHOSOM RES, V25, P337, DOI 10.1016/0022-3999(81)90045-3; Hinton J, 1999, PALLIATIVE MED, V13, P19, DOI 10.1191/026921699672169546; Holland JC, 1999, PSYCHO-ONCOLOGY, V8, P14, DOI 10.1002/(SICI)1099-1611(199901/02)8:1<14::AID-PON321>3.0.CO;2-E; *I MED, 1997, APPR DEATH IMPR CAR; Kade W J, 2000, Ann Intern Med, V132, P504; Kagawa-Singer M, 2001, JAMA-J AM MED ASSOC, V286, P2993, DOI 10.1001/jama.286.23.2993; Kant Immanuel, 1987, FUNDAMENTAL PRINCIPL; Katz J S, 2001, Am J Hosp Palliat Care, V18, P321, DOI 10.1177/104990910101800507; Kinsella G, 1998, J PALLIATIVE CARE, V14, P37, DOI 10.1177/082585979801400206; Kristjanson LJ, 1996, J PALLIATIVE CARE, V12, P10, DOI 10.1177/082585979601200403; Lichter I, 1993, Palliat Med, V7, P133; LICHTER I, 1991, Palliative Medicine, V5, P138; Lynn J, 1997, J AM GERIATR SOC, V45, P526; MADAN TN, 1992, SOC SCI MED, V35, P425, DOI 10.1016/0277-9536(92)90335-N; Meier DE, 1998, NEW ENGL J MED, V338, P1193, DOI 10.1056/NEJM199804233381706; NELSON DV, 1989, J BEHAV MED, V12, P341, DOI 10.1007/BF00844928; NEMCEKOVA M, 1998, B MED ETHICS, P13; Payne SA, 1996, PALLIATIVE MED, V10, P307, DOI 10.1177/026921639601000406; PORTENOY RK, 1994, QUAL LIFE RES, V3, P183, DOI 10.1007/BF00435383; Portenoy RK, 1997, PSYCHOSOMATICS, V38, P277, DOI 10.1016/S0033-3182(97)71465-8; Pullman D, 1996, Health Law J, V4, P197; PULLMAN D, IN PRESS THEOR MED B; QUILL TE, 1991, NEW ENGL J MED, V324, P691, DOI 10.1056/NEJM199103073241010; Quill TE, 2000, JAMA-J AM MED ASSOC, V284, P2502, DOI 10.1001/jama.284.19.2502; SEALE C, 1994, SOC SCI MED, V39, P647, DOI 10.1016/0277-9536(94)90021-3; Singer PA, 1999, JAMA-J AM MED ASSOC, V281, P163, DOI 10.1001/jama.281.2.163; Steinhauser AE, 2000, JAMA-J AM MED ASSOC, V284, P2476, DOI 10.1001/jama.284.19.2476; Stewart AL, 1999, J PAIN SYMPTOM MANAG, V17, P93, DOI 10.1016/S0885-3924(98)00131-6; Sullivan AD, 2000, NEW ENGL J MED, V342, P598, DOI 10.1056/NEJM200002243420822; Sulmasy Daniel P, 1994, Linacre Q, V61, P27; TAYLOR SE, 1983, AM PSYCHOL, V38, P1161, DOI 10.1037/0003-066X.38.11.1161; TIGGES KN, 1999, OXFORD TXB PALLIATIV, P829; Turner K, 1996, J PALLIAT CARE, V12, P7, DOI 10.1177/082585979601200203; van der Maas PJ, 1991, LANCET, V338, P669, DOI 10.1016/0140-6736(91)91241-L; van der Maas PJ, 1996, NEW ENGL J MED, V335, P1699, DOI 10.1056/NEJM199611283352227; WANZER SH, 1989, NEW ENGL J MED, V320, P844, DOI 10.1056/NEJM198903303201306; Wilson KG, 2000, ARCH INTERN MED, V160, P2454, DOI 10.1001/archinte.160.16.2454; Wool M S, 1988, Adv Psychosom Med, V18, P37; 1946, WEBSTERS INT DICT, P730	69	386	393	0	41	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 1	2002	287	17					2253	2260		10.1001/jama.287.17.2253	http://dx.doi.org/10.1001/jama.287.17.2253			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	546EZ	11980525				2023-01-03	WOS:000175260600025
J	Sehgal, AR; Leon, JB; Siminoff, LA; Singer, ME; Bunosky, LM; Cebul, RD				Sehgal, AR; Leon, JB; Siminoff, LA; Singer, ME; Bunosky, LM; Cebul, RD			Improving the quality of hemodialysis treatment - A community-based randomized controlled trial to overcome patient-specific barriers	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CORE INDICATORS PROJECT; DIALYSIS; ADEQUACY; SURVIVAL; CLUSTER	Context Mortality rates among US hemodialysis patients are the highest in the industrialized world at 23% per year. Measures of dialysis dose (Kt/V) correspond strongly with survival and are inadequate in one sixth of patients. Inadequate dialysis is also associated with increased hospitalizations and high inpatient costs. Our previous work identified 3 barriers to adequate hemodialysis: dialysis underprescription, catheter use, and shortened treatment time. Objective To determine the effect of a tailored intervention on adequacy of hemodialysis. Design and Setting Community-based randomized controlled trial with recruitment from April 1999 to June 2000 at 29 hemodialysis facilities in northeast Ohio. Participants Forty-four nephrologists and their 169 randomly selected adult patients receiving inadequate hemodialysis. Intervention Nephrologists were randomly assigned to an intervention (n=21) or control (n=23) group. For patients in the intervention group (n=85), depending on the barrier(s) present, a study coordinator gave nephrologists recommendations about optimizing dialysis prescriptions, expedited conversion of catheters to surgically created grafts or fistulas, and educated patients about the importance of compliance with treatment time. Patients in the control group (n=84) continued to receive usual care. Main Outcome Measures Changes in Kt/V and specific barriers after 6 months. Results At baseline, intervention and control patients had similar Kt/V measurements, specific barriers, and demographic and medical characteristics. After 6 months, intervention patients had 2-fold larger increases in Kt/V compared with control patients (+0.20 vs +0.10; P<.001) and were more likely to achieve their facility Kt/V goal (62% vs 42%; P=.01). Intervention patients also had nearly 3-fold larger increases in dialysis prescription (+0.16 vs +0.06; P<.001) and were 4 times more likely to change from use of catheters to use of fistulas/grafts (28% vs 7%; P=.04). Conclusions An intervention tailored to patient-specific barriers resulted in increased hemodialysis dose. Extending this approach to the 33000 persons in the United States receiving inadequate hemodialysis may substantially enhance patient survival, diminish hospitalizations, and decrease inpatient expenditures.	Metrohlth Med Ctr, Div Nephrol, Cleveland, OH 44109 USA; Metrohlth Med Ctr, Ctr Hlth Care Res & Policy, Cleveland, OH 44109 USA; Case Western Reserve Univ, Dept Med, Cleveland, OH 44106 USA; Case Western Reserve Univ, Dept Epidemiol & Biostat, Cleveland, OH 44106 USA; Case Western Reserve Univ, Ctr Biomed Eth, Cleveland, OH 44106 USA	MetroHealth System; MetroHealth System; Case Western Reserve University; Case Western Reserve University; Case Western Reserve University	Sehgal, AR (corresponding author), Metrohlth Med Ctr, Div Nephrol, 2500 MetroHlth Dr, Cleveland, OH 44109 USA.		Siminoff, Laura A/H-6277-2012; Singer, Mendel/S-8775-2019	Singer, Mendel/0000-0002-3331-3340	NIDDK NIH HHS [DK54178, DK51472] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK051472, P50DK054178] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BRYK A, 1996, HIERARCHICAL LINEAR; Chertow GM, 1997, KIDNEY INT, V51, P1578, DOI 10.1038/ki.1997.216; DAUGIRDAS JT, 1993, J AM SOC NEPHROL, V4, P1205; Depner TA., 1991, PRESCRIBING HEMODIAL, V2nd Ed.; DONNER A, 1993, J CLIN EPIDEMIOL, V46, P123, DOI 10.1016/0895-4356(93)90050-B; DONNER A, 1981, AM J EPIDEMIOL, V114, P906, DOI 10.1093/oxfordjournals.aje.a113261; Frankenfield DL, 1999, AM J KIDNEY DIS, V34, P721, DOI 10.1016/S0272-6386(99)70399-9; Friedman L. M., 1998, FUNDAMENTALS CLIN TR; GOTCH FA, 1985, KIDNEY INT, V28, P526, DOI 10.1038/ki.1985.160; Hakim RM, 2001, HDB DIALYSIS, V3rd, P236; HAYS RD, 1994, QUAL LIFE RES, V3, P329, DOI 10.1007/BF00451725; Held PJ, 1996, KIDNEY INT, V50, P550, DOI 10.1038/ki.1996.348; Helgerson SD, 1997, AM J KIDNEY DIS, V29, P851, DOI 10.1016/S0272-6386(97)90458-3; *HLTH CAR FIN ADM, 1998, PROF MED CHARTB 1998; *HLTH CAR FIN ADM, 2000, 2000 ANN REP ESRD CL; Hulley S. B., 1988, DESIGNING CLIN RES; Klar N, 2000, DESIGN ANAL CLUSTER, DOI [10.17843/rpmesp.2016.333.2293, DOI 10.17843/RPMESP.2016.333.2293]; Kloppenburg WD, 1999, KIDNEY INT, V55, P1961, DOI 10.1046/j.1523-1755.1999.00412.x; Leggat JE, 1998, AM J KIDNEY DIS, V32, P139, DOI 10.1053/ajkd.1998.v32.pm9669435; Leon JB, 2001, AM J NEPHROL, V21, P200, DOI 10.1159/000046248; Lowrie EG, 1999, KIDNEY INT, V56, P729, DOI 10.1046/j.1523-1755.1999.00584.x; McClellan WM, 1999, AM J KIDNEY DIS, V34, P1075, DOI 10.1016/S0272-6386(99)70013-2; McCullough K. P., 2000, Journal of the American Society of Nephrology, V11, p325A; MCLAUGHLIN CP, 1994, CONTINUOUS QUALITY I; *NAT KIDN FDN, 1997, AM J KIDNEY DIS S, V30, pS15; Owen WF, 1998, JAMA-J AM MED ASSOC, V280, P1764, DOI 10.1001/jama.280.20.1764; Sehgal AR, 2002, SEMIN DIALYSIS, V15, P35, DOI 10.1046/j.1525-139x.2002.00013.x; Sehgal AR, 1998, AM J KIDNEY DIS, V31, P593, DOI 10.1053/ajkd.1998.v31.pm9531174; Sehgal AR, 2001, AM J KIDNEY DIS, V37, P1223, DOI 10.1053/ajkd.2001.24526; Sehgal AR, 1997, AM J KIDNEY DIS, V30, P514, DOI 10.1016/S0272-6386(97)90310-3; *US REN DAT SYST, 2000, USRDS 2000 ANN DAT R; Wickstrom G, 2000, SCAND J WORK ENV HEA, V26, P363, DOI 10.5271/sjweh.555	32	47	53	0	3	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 17	2002	287	15					1961	1967		10.1001/jama.287.15.1961	http://dx.doi.org/10.1001/jama.287.15.1961			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	541NC	11960538				2023-01-03	WOS:000174989800024
J	Gendreau, MA; DeJohn, C				Gendreau, MA; DeJohn, C			Current concepts - Responding to medical events during commercial airline flights	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							CARDIAC-ARREST; AIR-QUALITY; EMERGENCIES; AIRCRAFT; TRAVEL; TUBERCULOSIS; OUTBREAK		Lahey Clin Fdn, Dept Emergency Med, Burlington, MA 01805 USA; FAA, Civil Aerosp Med Inst, Oklahoma City, OK USA	Lahey Hospital & Medical Center	Gendreau, MA (corresponding author), Lahey Clin Fdn, Dept Emergency Med, 41 Mall Rd, Burlington, MA 01805 USA.	mgndru@massmed.org						*AER MED ASS, 1997, MED GUID AIRL TRAV; *AIR TRANSP ASS, 1997, AIR TRANSP ASS MED I; Alexander J K, 1995, Cardiol Clin, V13, P271; AMLER RW, 1982, JAMA-J AM MED ASSOC, V248, P2129, DOI 10.1001/jama.248.17.2129; [Anonymous], 1976, MMWR MORB MORTAL WKL, V25, P317; *AV CONS PROT DIV, 2001, FACT SHEET STEPS TAK; BARRY M, 1989, JAMA-J AM MED ASSOC, V261, P728, DOI 10.1001/jama.261.5.728; Bettes TN, 1999, AM FAM PHYSICIAN, V60, P801; BLUMEN IJ, 1992, CRIT CARE CLIN, V8, P597, DOI 10.1016/S0749-0704(18)30243-4; Cheatham ML, 1999, AM SURGEON, V65, P1160; COLWELL C, 1999, PHYSICIANS WKLY, V16; *CONS UN, 1999, SEEING RED AIR RAG, V15, P15; COTTRELL JJ, 1988, CHEST, V93, P81, DOI 10.1378/chest.93.1.81; CREWDSON J, 1998, CHICAGO TRIBUNE 1122; CUMMINS RO, 1988, JAMA-J AM MED ASSOC, V260, P3668; CUMMINS RO, 1989, JAMA-J AM MED ASSOC, V261, P1295, DOI 10.1001/jama.261.9.1295; *DAN, 2002, DIV AL NETW; DAVIES GRW, 1982, AVIAT SPACE ENVIR MD, V53, P694; DEJOHN CA, 2000, DOTFAAAM0013 FED AV; Donaldson E, 1996, AUST NZ J SURG, V66, P431, DOI 10.1111/j.1445-2197.1996.tb00777.x; Dowdall N, 2000, BRIT MED J, V321, P1336, DOI 10.1136/bmj.321.7272.1336; EberhartPhillips J, 1997, EPIDEMIOL INFECT, V118, P79, DOI 10.1017/S095026889600948X; GILMORE A, 1989, CAN MED ASSOC J, V140, P197; GONG H, 1992, CHEST, V101, P1104, DOI 10.1378/chest.101.4.1104; Goodwin T, 2000, BRIT MED J, V321, P1338, DOI 10.1136/bmj.321.7272.1338; Han HM, 2000, AVIAT SPACE ENV MED, V71, P330; HARDING RM, 1993, AVIATION MED, P30; HEDBERG CW, 1992, JAMA-J AM MED ASSOC, V268, P3208, DOI 10.1001/jama.268.22.3208; Hedouin V, 1998, Med Law, V17, P503; Hocking MB, 1998, AM IND HYG ASSOC J, V59, P446, DOI 10.1080/15428119891010181; Hocking MB, 2000, CHEMOSPHERE, V41, P603, DOI 10.1016/S0045-6535(99)00537-8; HORDINSKY JR, 1991, DOTFAAAM912 FED AV A; Kenyon TA, 1996, NEW ENGL J MED, V334, P933, DOI 10.1056/NEJM199604113341501; Kovac C, 1999, BRIT MED J, V318, P12; KUKJIAN S, 2001, BOSTON GLOBE    1223, pA1; Lien D, 1998, Can Respir J, V5, P95; Lyznicki JM, 2000, AVIAT SPACE ENVIR MD, V71, P832; MCKENAS DK, 2000, AVIATION TODAY   MAR; MOSER MR, 1979, AM J EPIDEMIOL, V110, P1; NewsonSmith MS, 1997, AVIAT SPACE ENVIR MD, V68, P1134; ORourke MF, 1997, CIRCULATION, V96, P2849, DOI 10.1161/01.CIR.96.9.2849; Page RL, 2000, NEW ENGL J MED, V343, P1210, DOI 10.1056/NEJM200010263431702; Parmet AJ, 1999, AVIAT SPACE ENVIR MD, V70, P817; Rayman RB, 1997, AVIAT SPACE ENVIR MD, V68, P432; Rayman RB, 1998, AVIAT SPACE ENVIR MD, V69, P1007; Robertson RM, 2000, NEW ENGL J MED, V343, P1259, DOI 10.1056/NEJM200010263431709; Rosenberg Craig A., 1997, Journal of Emergency Medicine, V15, P159, DOI 10.1016/S0736-4679(96)00314-9; SCHWARTZ GB, 1982, JAMA-J AM MED ASSOC, V247, P1007; *SEL COMM SCI TECH, 2000, 5 SEL COMM SCI TECH; SKJENNA OW, 1991, CAN MED ASSOC J, V144, P287; SPEIZER C, 1989, ANN EMERG MED, V18, P26, DOI 10.1016/S0196-0644(89)80306-3; Thibeault C, 1997, AVIAT SPACE ENVIR MD, V68, P80; *US HOUS REPR SUBC, 1997, MED KITS COMM AIRL; WALLACE WA, 1995, BRIT MED J, V311, P374, DOI 10.1136/bmj.311.7001.374; WICK RL, 1995, AVIAT SPACE ENVIR MD, V66, P220; 2001, CABIN CREW SAFET NOV; 2001, MMWR MORB MORTAL WKL, V50, P485; 1999, BMJ, V318, P672; 1998, CABIN AIR SAFETY OCT	59	117	119	1	10	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	APR 4	2002	346	14					1067	1073		10.1056/NEJMra012774	http://dx.doi.org/10.1056/NEJMra012774			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	536YL	11932475				2023-01-03	WOS:000174729400008
J	Lorig, K				Lorig, K			Partnerships between expert patients and physicians	LANCET			English	Editorial Material							SELF-MANAGEMENT PROGRAM; ARTHRITIS; EDUCATION; OUTCOMES		Stanford Univ, Sch Med, Dept Med,Stanford Patient Educ Res Ctr, Div Rheumatol & Immunol, Palo Alto, CA 94304 USA	Stanford University	Lorig, K (corresponding author), Stanford Univ, Sch Med, Dept Med,Stanford Patient Educ Res Ctr, Div Rheumatol & Immunol, Palo Alto, CA 94304 USA.							Barlow JH, 1998, BRIT J RHEUMATOL, V37, P1315; CLARK NM, 1988, GERONTOLOGIST, V28, P491, DOI 10.1093/geront/28.4.491; Corbin J.M., 1988, UNENDING WORK CARE M; Department of Health, 2001, EXP PAT NEW APPR CHR; Hart JT, 1995, J PUBLIC HEALTH MED, V17, P383; LORIG K, 1985, ARTHRITIS RHEUM, V28, P680, DOI 10.1002/art.1780280612; Lorig KR, 1999, MED CARE, V37, P5, DOI 10.1097/00005650-199901000-00003; LORIG KR, 1993, ARTHRITIS RHEUM, V36, P439, DOI 10.1002/art.1780360403; Lorig KR, 2001, MED CARE, V39, P1217, DOI 10.1097/00005650-200111000-00008; Schwarzer R., 1992, SELF EFFICACY THOUGH	10	111	111	0	2	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAR 9	2002	359	9309					814	815		10.1016/S0140-6736(02)07959-X	http://dx.doi.org/10.1016/S0140-6736(02)07959-X			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	529YV	11897275				2023-01-03	WOS:000174329600004
J	Minsky, BD				Minsky, BD			Adjuvant radiation therapy for rectal cancer: is there finally an answer?	LANCET			English	Editorial Material									Mem Sloan Kettering Canc Ctr, Dept Radiat Oncol, New York, NY 10021 USA	Memorial Sloan Kettering Cancer Center	Minsky, BD (corresponding author), Mem Sloan Kettering Canc Ctr, Dept Radiat Oncol, 1275 York Ave, New York, NY 10021 USA.	minskyb@mskcc.org						Camma C, 2000, JAMA-J AM MED ASSOC, V284, P1008, DOI 10.1001/jama.284.8.1008; Grann A, 2001, INT J RADIAT ONCOL, V49, P987, DOI 10.1016/S0360-3016(00)01529-7; HALL WH, 1990, JAMA-J AM MED ASSOC, V264, P1444; Kapiteijn E, 2001, NEW ENGL J MED, V345, P638, DOI 10.1056/NEJMoa010580; Pahlman L, 1997, NEW ENGL J MED, V336, P980; ROH MS, 2001, P AN M AM SOC CLIN, V20, pA123; Sauer R., 2000, International Journal of Radiation Oncology Biology Physics, V48, P119, DOI 10.1016/S0360-3016(00)80034-6; SKIBBER JM, 2001, CANC PRINCIPLES PRAC, P1271	8	14	17	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	OCT 20	2001	358	9290					1285	1286		10.1016/S0140-6736(01)06453-4	http://dx.doi.org/10.1016/S0140-6736(01)06453-4			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	484RC	11684204				2023-01-03	WOS:000171702500003
J	Obeso, JA; Guridi, J; Rodriguez-Oroz, MC; Agid, Y; Bejjani, P; Bonnet, AM; Lang, AE; Lozano, AM; Kumar, R; Benabid, A; Pollack, P; Krack, P; Rehncrona, S; Ekberg, R; Grabowski, M; Albanese, A; Scerrati, M; Moro, E; Koller, W; Wilkinson, SB; Pahwa, R; Volkmann, J; Allert, N; Freund, HJ; Kulisevsky, J; Gironell, A; Molet, J; Tronnier, V; Fogel, W; Krause, M; Funk, T; Kern, C; Kestenbach, U; Iansek, R; Rosenfeld, J; Churchyard, A; O'Sullivan, D; Pell, M; Markus, R; Bayes, A; Blesa, R; Oliver, B; Olanow, CW; Germano, IM; Brin, M; Jankovic, J; Grossman, RG; Ondo, WG; Vitek, JL; Bakay, RAE; DeLong, MR; Tolosa, E; Rumia, J; Valldeoriola, F; Benabid, A; Albanese, A; DeLong, MR; Lang, AM; Lozano, A; Obeso, JA; Olanow, CW; Pollack, P; Koller, WC; Vitek, J; Wilkinson, S				Obeso, JA; Guridi, J; Rodriguez-Oroz, MC; Agid, Y; Bejjani, P; Bonnet, AM; Lang, AE; Lozano, AM; Kumar, R; Benabid, A; Pollack, P; Krack, P; Rehncrona, S; Ekberg, R; Grabowski, M; Albanese, A; Scerrati, M; Moro, E; Koller, W; Wilkinson, SB; Pahwa, R; Volkmann, J; Allert, N; Freund, HJ; Kulisevsky, J; Gironell, A; Molet, J; Tronnier, V; Fogel, W; Krause, M; Funk, T; Kern, C; Kestenbach, U; Iansek, R; Rosenfeld, J; Churchyard, A; O'Sullivan, D; Pell, M; Markus, R; Bayes, A; Blesa, R; Oliver, B; Olanow, CW; Germano, IM; Brin, M; Jankovic, J; Grossman, RG; Ondo, WG; Vitek, JL; Bakay, RAE; DeLong, MR; Tolosa, E; Rumia, J; Valldeoriola, F; Benabid, A; Albanese, A; DeLong, MR; Lang, AM; Lozano, A; Obeso, JA; Olanow, CW; Pollack, P; Koller, WC; Vitek, J; Wilkinson, S		Deep-Brain Stimulation Parkinsons	Deep-brain stimulation of the subthalamic nucleus or the pars interna of the globus pallidus in Parkinson's disease.	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							FETAL NIGRAL TRANSPLANTATION; HIGH-FREQUENCY STIMULATION; FOLLOW-UP; ELECTRICAL-STIMULATION; MOVEMENT-DISORDERS; MEDIAL PALLIDOTOMY; 2 PARTS; MODEL	Background: Increased neuronal activity in the subthalamic nucleus and the pars interna of the globus pallidus is thought to account for motor dysfunction in patients with Parkinson's disease. Although creating lesions in these structures improves motor function in monkeys with induced parkinsonism and patients with Parkinson's disease, such lesions are associated with neurologic deficits, particularly when they are created bilaterally. Deep-brain stimulation simulates the effects of a lesion without destroying brain tissue. Methods: We performed a prospective, double-blind, crossover study in patients with advanced Parkinson's disease, in whom electrodes were implanted in the subthalamic nucleus or pars interna of the globus pallidus and who then underwent bilateral high-frequency deep-brain stimulation. We compared scores on the motor portion of the Unified Parkinson's Disease Rating Scale when the stimulation was randomly assigned to be turned on or off. We performed unblinded evaluations of motor function preoperatively and one, three, and six months postoperatively. Results: Electrodes were implanted bilaterally in 96 patients in the subthalamic-nucleus group and 38 patients in the globus-pallidus group. Three months after the procedures were performed, double-blind, crossover evaluations demonstrated that stimulation of the subthalamic nucleus was associated with a median improvement in the motor score (as compared with no stimulation) of 49 percent, and stimulation of the pars interna of the globus pallidus with a median improvement of 37 percent (P<0.001 for both comparisons). Between the preoperative and six-month visits, the percentage of time during the day that patients had good mobility without involuntary movements increased from 27 percent to 74 percent (P<0.001) with subthalamic stimulation and from 28 percent to 64 percent (P<0.001) with pallidal stimulation. Adverse events included intracranial hemorrhage in seven patients and infection necessitating removal of the leads in two. Conclusions: Bilateral stimulation of the subthalamic nucleus or pars interna of the globus pallidus is associated with significant improvement in motor function in patients with Parkinson's disease whose condition cannot be further improved with medical therapy. (N Engl J Med 2001;345:956-63.) Copyright (C) 2001 Massachusetts Medical Society.			Obeso, JA (corresponding author), Clin Univ, Ave Pio XII 36, Pamplona 31008, Spain.	jobeso@unav.es; warren.olanow@mssm.edu	germano, isabelle m/J-8327-2017; Moro, Elena/AAC-3136-2019; Volkmann, Jens/AAK-7570-2020; Lozano, Andres M/A-5058-2012; Rodriguez-Oroz, Maria Cruz/D-1490-2018; Lang, Anthony/ABF-8114-2021; Guridi, Jorge/G-2288-2018; ARBOIX, JORDI RUMIÀ/AAA-3408-2019	germano, isabelle m/0000-0002-3992-373X; Rodriguez-Oroz, Maria Cruz/0000-0001-5962-772X; Guridi, Jorge/0000-0001-5714-5145; ARBOIX, JORDI RUMIÀ/0000-0002-8755-8124; Krack, Paul/0000-0002-3508-7295; Lang, Anthony/0000-0003-1229-3667; Lozano, Andres M./0000-0001-8257-3694				ALBIN RL, 1989, TRENDS NEUROSCI, V12, P366, DOI 10.1016/0166-2236(89)90074-X; Alvarez L, 2001, MOVEMENT DISORD, V16, P72, DOI 10.1002/1531-8257(200101)16:1<72::AID-MDS1019>3.0.CO;2-6; Ashby P, 2000, PROG NEUROL SURG, V15, P236; Baron MS, 1996, ANN NEUROL, V40, P355, DOI 10.1002/ana.410400305; Benabid AL, 1996, J NEUROSURG, V84, P203, DOI 10.3171/jns.1996.84.2.0203; BENABID AL, 1987, APPL NEUROPHYSIOL, V50, P344; BERGMAN H, 1990, SCIENCE, V249, P1436, DOI 10.1126/science.2402638; DELONG MR, 1990, TRENDS NEUROSCI, V13, P281, DOI 10.1016/0166-2236(90)90110-V; Fahn S., 1987, RECENT DEV PARKINSON, V2, P153; Fine J, 2000, NEW ENGL J MED, V342, P1708, DOI 10.1056/NEJM200006083422304; Ghika J, 1998, J NEUROSURG, V89, P713, DOI 10.3171/jns.1998.89.5.0713; GOETZ CG, 1994, MOVEMENT DISORD, V9, P390, DOI 10.1002/mds.870090403; Guridi J, 1996, BRAIN, V119, P1717, DOI 10.1093/brain/119.5.1717; Hariz MI, 1999, J NEUROSURG, V90, P175; Hariz MI, 2000, PROG NEUROL SURG, V15, P246; Hauser RA, 1999, ARCH NEUROL-CHICAGO, V56, P179, DOI 10.1001/archneur.56.2.179; Kishore A, 1997, BRAIN, V120, P729, DOI 10.1093/brain/120.5.729; Kumar R, 1998, NEUROLOGY, V51, P850, DOI 10.1212/WNL.51.3.850; Lang AE, 1998, NEW ENGL J MED, V339, P1130, DOI 10.1056/NEJM199810153391607; Lang AE, 1998, NEW ENGL J MED, V339, P1044, DOI 10.1056/NEJM199810083391506; Lang AE, 1997, NEW ENGL J MED, V337, P1036, DOI 10.1056/NEJM199710093371503; Limousin P, 1998, NEW ENGL J MED, V339, P1105, DOI 10.1056/NEJM199810153391603; LINDVALL O, 1994, ANN NEUROL, V35, P172, DOI 10.1002/ana.410350208; Obeso JA, 2000, ANN NEUROL, V47, pS22; Obeso JA, 2000, TRENDS NEUROSCI, V23, pS8, DOI 10.1016/S1471-1931(00)00028-8; Olanow CW, 1996, TRENDS NEUROSCI, V19, P102, DOI 10.1016/S0166-2236(96)80038-5; Olanow CW, 2001, ADV NEUROL, V86, P421; Olanow CW, 2001, NEUROLOGY, V56, pS1, DOI 10.1212/WNL.56.suppl_5.S1; Pahwa R, 1997, NEUROLOGY, V49, P249, DOI 10.1212/WNL.49.1.249; Samuel M, 1998, BRAIN, V121, P59, DOI 10.1093/brain/121.1.59; Schuurman PR, 2000, NEW ENGL J MED, V342, P461, DOI 10.1056/NEJM200002173420703; Snedecor G.W., 1983, AMES IOWA STATE U PR, V6th; Tasker R R, 1990, Neurosurg Clin N Am, V1, P841; Tasker RR, 1998, TXB STEREOTACTIC FUN, P1179; VIDAKOVIC A, 1994, J NEUROL NEUROSUR PS, V57, P945, DOI 10.1136/jnnp.57.8.945; Vitek JL, 1998, J NEUROSURG, V88, P1027, DOI 10.3171/jns.1998.88.6.1027; Volkmann J, 1998, ANN NEUROL, V44, P953, DOI 10.1002/ana.410440615; WICHMANN T, 1994, J NEUROPHYSIOL, V72, P521, DOI 10.1152/jn.1994.72.2.521	38	1154	1222	6	203	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	SEP 27	2001	345	13					956	963		10.1056/nejmoa000827	http://dx.doi.org/10.1056/nejmoa000827			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	475NF	11575287	Green Published, Bronze			2023-01-03	WOS:000171170000004
J	Petitto, LA; Holowka, S; Sergio, LE; Ostry, D				Petitto, LA; Holowka, S; Sergio, LE; Ostry, D			Language rhythms in baby hand movements	NATURE			English	Article									York Univ, Dept Kinesiol & Hlth Sci, N York, ON M3J 1P3, Canada; Haskins Labs Inc, New Haven, CT 06511 USA; McGill Univ, Dept Psychol, Montreal, PQ H3A 1B1, Canada	York University - Canada; Yale University; Haskins Laboratories; McGill University	Petitto, LA (corresponding author), Dartmouth Coll, Dept Psychol, 302 Silsby Hall, Hanover, NH 03755 USA.		Sergio, Lauren/AAK-3274-2020; Galantucci, Bruno/E-5770-2010					Jusczyk P.W., 1997, DISCOVERY SPOKEN LAN; Lieberman Philip, 2000, HUMAN LANGUAGE OUR R; Locke J.L., 1993, CHILDS PATH SPOKEN L; Locke JL, 2000, SCIENCE, V288, P449, DOI 10.1126/science.288.5465.449; MacNeilage PF, 2000, SCIENCE, V288, P527, DOI 10.1126/science.288.5465.527; MEIER RP, 1995, LANGUAGE, GESTURE, AND SPACE, P391; Petitto LA, 2000, P NATL ACAD SCI USA, V97, P13961, DOI 10.1073/pnas.97.25.13961; PETITTO LA, 1991, SCIENCE, V251, P1493, DOI 10.1126/science.2006424; Pinker S, 1992, ADAPTED MIND EVOLUTI, P451; STUDDERTKENNEDY MG, 1991, COGNITION SYMBOLIC P, P38; van der Stelt J. M., 1986, WENNER GREN CTR IN B, P163; Vihman M. M., 1996, PHONOLOGICAL DEV ORI	12	69	71	0	16	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	SEP 6	2001	413	6851					35	36		10.1038/35092613	http://dx.doi.org/10.1038/35092613			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	469EG	11544514				2023-01-03	WOS:000170801200027
J	Verheugt, FWA				Verheugt, FWA			GUSTO V: the bottom line of fibrinolytic reperfusion therapy	LANCET			English	Editorial Material							ACUTE MYOCARDIAL-INFARCTION; PRIMARY ANGIOPLASTY; THROMBOLYSIS; TRIAL		Radboud Univ Nijmegen Med Ctr, Heartctr, Div Cardiol, NL-6525 Nijmegen, Netherlands	Radboud University Nijmegen	Verheugt, FWA (corresponding author), Radboud Univ Nijmegen Med Ctr, Heartctr, Div Cardiol, NL-6525 Nijmegen, Netherlands.	f.verheugt@cardio.azn.nl	Verheugt, F.W.A./H-8105-2014					[Anonymous], 1988, LANCET, V2, P349; Antman EM, 1999, CIRCULATION, V99, P2720, DOI 10.1161/01.CIR.99.21.2720; *ASSENT 2 STEER CO, 1999, LANCET, V354, P1716; Lupker RV, 2000, JAMA-J AM MED ASSOC, V284, P60; Ross AM, 1999, J AM COLL CARDIOL, V34, P1954, DOI 10.1016/S0735-1097(99)00444-1; ROSS AM, 1993, NEW ENGL J MED, V329, P1615; Topol E, 1997, NEW ENGL J MED, V337, P1118; TOPOL E, 1993, NEW ENGL J MED, V329, P673, DOI 10.1056/nejm199309023291001; Topol EJ, 2000, CIRCULATION, V101, P2788; Topol EJ, 1996, NEW ENGL J MED, V335, P775; Veen G, 1999, AM J CARDIOL, V84, P763, DOI 10.1016/S0002-9149(99)00434-8; Verheugt FWA, 1996, J AM COLL CARDIOL, V27, P766, DOI 10.1016/0735-1097(95)00492-0; White HD, 1999, LANCET, V354, P695, DOI 10.1016/S0140-6736(99)00263-9	13	11	11	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JUN 16	2001	357	9272					1898	1899		10.1016/S0140-6736(00)05087-X	http://dx.doi.org/10.1016/S0140-6736(00)05087-X			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	444YZ	11425404				2023-01-03	WOS:000169431000002
J	Torgerson, DJ; Bell-Syer, SEM				Torgerson, DJ; Bell-Syer, SEM			Hormone replacement therapy and prevention of nonvertebral fractures - A meta-analysis of randomized trials	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Review							POSTMENOPAUSAL WOMEN; ESTROGEN REPLACEMENT; HIP FRACTURE; BONE MASS; OSTEOPOROSIS; RISK; HEART; COMBINATION; ALENDRONATE; ESTRADIOL	Context Hormone replacement therapy (HRT) is widely considered to reduce fractures, but this belief is based on observational data; evidence from randomized trials is lacking. Objective To conduct a systematic review of all randomized trials of HRT that have reported or collected nonvertebral fracture data but that may not have focused on fracture prevention. Data Sources The MEDLINE, EMBASE, Science Citation Index, and Cochrane Controlled Trials Register databases were searched from 1997 through 2000 and a search was conducted of all recent systematic reviews to identify older studies. Authors were contacted to establish whether fracture data had been collected but not reported. Researchers in the field and pharmaceutical companies also were contacted to try to identify unpublished studies. Study Selection Trials were included in which participants had been randomized to at least 12 months of therapy and data on nonvertebral fractures at any other site and due to any cause were available. Of 70 initially identified studies, 22 were included in the analysis. Data Extraction Both investigators extracted data independently and appraised trial quality according to the Jadad scale, which assesses the methods of randomization, concealment allocation, and reporting of withdrawals and dropouts. Disagreements were resolved by discussion. Data Synthesis There was an overall 27% reduction in nonvertebral fractures in a pooled analysis (reduction favoring HRT in relative risk [RR], 0.73; 95% confidence interval [CI], 0.56-0.94; P=.02). This effect was greater among women randomized to HRT who had a mean age younger than 60 years (RR, 0.67; 95% CI, 0.46-0.98; P=.03), Among women with a mean age of 60 years or older, there was a reduced effect (RR, 0.88; 95% CI, 0.71-1.08; P=.22). For hip and wrist fractures alone, the effectiveness of HRT appeared more marked (RR, 0.60; 95% CI, 0.40-0.91; P=.02), particularly for women younger than 60 years (RR, 0.45; 95% CI, 0.26-0.79; P=.005). Conclusions Our meta-analysis of randomized controlled trials of HRT noted a statistically significant reduction in nonvertebral fractures. However, this effect may be attenuated in older women.	Univ York, Dept Hlth Studies, Heslington YO10 5DQ, England; Univ York, Ctr Hlth Econ, Heslington YO10 5DQ, England	University of York - UK; University of York - UK	Torgerson, DJ (corresponding author), Univ York, Dept Hlth Studies, Genesis 6,Univ Rd, Heslington YO10 5DQ, England.	djt6@york.ac.uk	Torgerson, David/L-4566-2019	Torgerson, David/0000-0002-1667-4275				AITKEN JM, 1973, BMJ-BRIT MED J, V3, P515, DOI 10.1136/bmj.3.5879.515; Alexandersen P, 1999, J CLIN ENDOCR METAB, V84, P3013, DOI 10.1210/jc.84.9.3013; Barrett-Connor E, 1998, BMJ-BRIT MED J, V317, P457; Bjarnason NH, 2000, BONE, V26, P561, DOI 10.1016/S8756-3282(00)00272-6; Black DM, 1996, LANCET, V348, P1535, DOI 10.1016/S0140-6736(96)07088-2; Bush TL, 1996, JAMA-J AM MED ASSOC, V276, P1389, DOI 10.1001/jama.276.17.1389; CAULEY JA, 1995, ANN INTERN MED, V122, P9, DOI 10.7326/0003-4819-122-1-199501010-00002; Cauley JA, 2001, AM J MED, V110, P442, DOI 10.1016/S0002-9343(01)00647-7; Cheng S, 2000, OSTEOPOROSIS INT, V11, pS175; Cohen FJ, 1998, CALCIFIED TISSUE INT, V63, P277, DOI 10.1007/s002239900526; Delmas PD, 2000, OSTEOPOROSIS INT, V11, P177, DOI 10.1007/PL00004180; Eiken P, 1997, BRIT J OBSTET GYNAEC, V104, P702, DOI 10.1111/j.1471-0528.1997.tb11981.x; Ettinger B, 1999, MENOPAUSE, V6, P282, DOI 10.1097/00042192-199906040-00003; Fitzpatrick LA, 2000, MAYO CLIN PROC, V75, P559, DOI 10.4065/75.6.559; Formica CA, 1998, OSTEOPOROSIS INT, V8, P1, DOI 10.1007/s001980050040; Freedman M, 2001, J NATL CANCER I, V93, P51, DOI 10.1093/jnci/93.1.51; Gallagher JC, 1999, J BONE MINER RES, V14, pS209; Genant HK, 1997, ARCH INTERN MED, V157, P2609, DOI 10.1001/archinte.157.22.2609; Herrington DM, 2000, NEW ENGL J MED, V343, P522, DOI 10.1056/NEJM200008243430801; Hulley S, 1998, JAMA-J AM MED ASSOC, V280, P605, DOI 10.1001/jama.280.7.605; HUTCHINSON TA, 1979, LANCET, V2, P705; Ismail AA, 2000, OSTEOPOROSIS INT, V11, P248, DOI 10.1007/s001980050288; Komulainen MH, 1998, MATURITAS, V31, P45, DOI 10.1016/S0378-5122(98)00085-1; Lees B, 2001, OSTEOPOROSIS INT, V12, P251, DOI 10.1007/s001980170113; LINDSAY R, 1990, OBSTET GYNECOL, V76, P290; LUFKIN EG, 1992, ANN INTERN MED, V117, P1, DOI 10.7326/0003-4819-117-1-1; McClung MR, 2001, NEW ENGL J MED, V344, P333, DOI 10.1056/NEJM200102013440503; Michaelsson K, 1998, OSTEOPOROSIS INT, V8, P540, DOI 10.1007/s001980050096; Michaelsson K, 1998, BMJ-BRIT MED J, V316, P1858; Moher D., 1999, HEALTH TECHNOL ASSES, V3, pi, DOI [DOI 10.3310/HTA3120, 10.3310/hta3120]; Mosekilde L, 2000, MATURITAS, V36, P181, DOI 10.1016/S0378-5122(00)00158-4; Mulnard RI, 2000, JAMA-J AM MED ASSOC, V283, P1007, DOI 10.1001/jama.283.8.1007; NACHTIGALL LE, 1979, OBSTET GYNECOL, V53, P277; NAESSEN T, 1990, ANN INTERN MED, V113, P95, DOI 10.7326/0003-4819-113-2-95; Orr-Walker BJ, 2000, ARCH INTERN MED, V160, P2161, DOI 10.1001/archinte.160.14.2161; Ravn P, 1999, ANN INTERN MED, V131, P935, DOI 10.7326/0003-4819-131-12-199912210-00005; Recker RR, 1999, ANN INTERN MED, V130, P897, DOI 10.7326/0003-4819-130-11-199906010-00005; Reginster JY, 2000, CALCIFIED TISSUE INT, V67, P191, DOI 10.1007/s002230001135; *ROYAL COLL PHYS, 1997, BMJ-BRIT MED J, V315, P149; Stevenson JC, 2000, OSTEOPOROSIS INT, V11, pS25; THOMPSON SG, 1994, BMJ-BRIT MED J, V309, P1351, DOI 10.1136/bmj.309.6965.1351; Weiss SR, 1999, OBSTET GYNECOL, V94, P330, DOI 10.1016/S0029-7844(99)00313-0; Wimalawansa SJ, 1998, AM J MED, V104, P219, DOI 10.1016/S0002-9343(98)00029-1; WINDELER J, 1995, BRIT MED J, V310, P454, DOI 10.1136/bmj.310.6977.454	44	345	362	0	7	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 13	2001	285	22					2891	2897		10.1001/jama.285.22.2891	http://dx.doi.org/10.1001/jama.285.22.2891			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	440BP	11401611				2023-01-03	WOS:000169156300029
J	Pell, JP; Sirel, JM; Marsden, AK; Ford, I; Cobbe, SM				Pell, JP; Sirel, JM; Marsden, AK; Ford, I; Cobbe, SM			Effect of reducing ambulance response times on deaths from out of hospital cardiac arrest: cohort study	BRITISH MEDICAL JOURNAL			English	Article							AUTOMATED EXTERNAL DEFIBRILLATORS; EMERGENCY MEDICAL TECHNICIANS; AMERICAN-HEART-ASSOCIATION; HEALTH-PROFESSIONALS; CLINICAL-EXPERIENCE; UTSTEIN STYLE; MANAGEMENT; STATEMENT; SCOTLAND; EFFICACY	Objectives To determine the association between ambulance response time and survival from out of hospital cardiopulmonary arrest and to estimate the effect of reducing response times. Design Cohort study. Setting Scottish Ambulance Service. Subjects All out of hospital cardiopulmonary arrests due to cardiac disease attended by the Scottish Ambulance Service during May 1991 to March 1998. Main outcome measures Survival rate to hospital discharge and potential improvement from reducing response times. Results Of 13 822 arrests not witnessed by ambulance crews but attended by them within 15 minutes, complete data were available for 10 554 (76%). Of these patients, 653 (6%) survived to hospital discharge. After other significant covariates were adjusted for, shorter response time was significantly associated with increased probability of receiving defibrillation and survival to discharge among those defibrillated. Reducing the 90th centile for response time to 8 minutes increased the predicted survival to 8%, and reducing it to 5 minutes increased survival to 10-11% (depending on the model used). Conclusions Reducing ambulance response times to 5 minutes could almost double the survival rate for cardiac arrests not witnessed by ambulance crews.	Univ Glasgow, Glasgow Royal Infirm, Dept Med Cardiol, Glasgow G31 2ER, Lanark, Scotland; Scottish Ambulance Serv Headquarters, Edinburgh, Midlothian, Scotland; Univ Glasgow, Robertson Ctr Biostat, Glasgow G12 8QQ, Lanark, Scotland	University of Glasgow; University of Glasgow	Cobbe, SM (corresponding author), Univ Glasgow, Glasgow Royal Infirm, Dept Med Cardiol, Glasgow G31 2ER, Lanark, Scotland.		Ford, Ian/ABE-6145-2020	Pell, Jill/0000-0002-8898-7035				BEAGLEHOLE R, 1986, BMJ-BRIT MED J, V292, P33, DOI 10.1136/bmj.292.6512.33; COBB LA, 1992, CIRCULATION, V85, P98; COBBE SM, 1991, BRIT MED J, V302, P1517, DOI 10.1136/bmj.302.6791.1517; CUMMINS RO, 1987, JAMA-J AM MED ASSOC, V257, P1605, DOI 10.1001/jama.257.12.1605; CUMMINS RO, 1991, CIRCULATION, V84, P960, DOI 10.1161/01.CIR.84.2.960; CUMMINS RO, 1991, CIRCULATION, V83, P1832, DOI 10.1161/01.CIR.83.5.1832; CUMMINS RO, 1989, ANN EMERG MED, V18, P1269, DOI 10.1016/S0196-0644(89)80257-4; Dracup K, 1997, ANN INTERN MED, V126, P645, DOI 10.7326/0003-4819-126-8-199704150-00010; Evans T, 1998, BMJ-BRIT MED J, V316, P1031; Kuisma M, 1996, HEART, V76, P18, DOI 10.1136/hrt.76.1.18; *NHS, 1996, REV AMB PERF STAND F; Nichol G, 1996, ANN EMERG MED, V27, P711, DOI 10.1016/S0196-0644(96)70188-9; Norris RM, 1998, BMJ-BRIT MED J, V316, P1065; Rayner M, 1998, CORONARY HEART DIS S; SEDGWICK ML, 1992, RESUSCITATION, V24, P73, DOI 10.1016/0300-9572(92)90175-C; STULTS KR, 1986, CIRCULATION, V73, P701, DOI 10.1161/01.CIR.73.4.701; STULTS KR, 1984, NEW ENGL J MED, V310, P219, DOI 10.1056/NEJM198401263100403; WEAVER WD, 1986, AM J CARDIOL, V57, P1017, DOI 10.1016/0002-9149(86)90667-3; WEAVER WD, 1988, NEW ENGL J MED, V319, P661, DOI 10.1056/NEJM198809153191101	19	164	165	0	9	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	JUN 9	2001	322	7299					1385	1388		10.1136/bmj.322.7299.1385	http://dx.doi.org/10.1136/bmj.322.7299.1385			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	442KN	11397740	Green Published, Bronze, Green Accepted, Green Submitted			2023-01-03	WOS:000169284600014
J	Enne, VI; Livermore, DM; Stephens, P; Hall, LMC				Enne, VI; Livermore, DM; Stephens, P; Hall, LMC			Persistence of sulphonamide resistance in Escherichia coli in the UK despite national prescribing restriction	LANCET			English	Article							GRAM-NEGATIVE BACTERIA; ANTIBIOTIC-RESISTANCE; CONSUMPTION; EVOLUTION; FINLAND	Background There is a clear association between heavy antimicrobial consumption within a population and the frequent recovery of resistant bacteria, but whether a reduction in antimicrobial use can reverse this process is less clear. We investigated the effect of a national restriction of sulphonamide prescribing in the UK on the prevalence of sulphonamide resistance in Escherichia coli. Methods Consecutive clinical isolates of E coli were collected at the Royal London Hospital in 1991 and 1999. These collections, each of more than 350 isolates, were compared. Minimum inhibitory concentrations of sulphamethoxazole and eight other antimicrobials were determined. The presence and locations of sulphonamide-resistance genes were examined by PCR, plasmid extraction, Southern hybridisation, and transconjugation. Findings Despite a huge decrease in sulphonamide prescriptions (from 320 000 prescriptions per year in 1991 to 7 000 in 1999), the frequency of resistance remained high in 1999 (165/359 [46.0%] vs 143/360 [39.7%] in 1991; difference 6.2% [95% CI -0.9 to 13.3]). Integron- borne sulI was present in 16.4% of isolates in 1991 and 17.5% in 1999, The prevalence of sulII increased from 26.7% in 1991 to 36.5% in 1999 (difference 9.8% [3.1 to 16.5] p=0.0046). SulII was located on large plasmids, at least some of which were conjugative multiresistance determinants. Interpretation These results show that a huge decrease in antibiotic prescribing does not necessarily reduce resistance within a useful time. The main reason seems to be the genetic linkage of the index resistance to other resistance determinants.	St Bartholomews & Royal London Sch Med & Dent, Dept Med Microbiol, London E1 2AD, England; Cent Publ Hlth Lab, Antibiot Resistance Monitoring & Reference Lab, London NW9 5HT, England; IMS Hlth, Pinner, Middx, England	University of London; Queen Mary University London; Public Health England	Hall, LMC (corresponding author), St Bartholomews & Royal London Sch Med & Dent, Dept Med Microbiol, London E1 2AD, England.		Enne, Virve/AAP-2357-2021					[Anonymous], 1995, DRUG THER B, V33, P92; BOUMA JE, 1988, NATURE, V335, P351, DOI 10.1038/335351a0; *BRIT SOC ANT CHEM, 1998, BSAC STAND DISK SENS, P19; Hall RM, 1997, CIBA F SYMP, V207, P192; Huovinen P, 1997, CIBA F SYMP, V207, P36; LAWRENSON RA, 1998, J INFORM PRIMARY MAY; LIU PYF, 1992, J ANTIMICROB CHEMOTH, V30, P429, DOI 10.1093/jac/30.4.429; LIVERMORE DM, 1996, ANTIBIOTICS LAB MED, P561; *NCCLS, 1999, PERF STAND ANT SUSC, V19, P32; RADSTROM P, 1991, ANTIMICROB AGENTS CH, V35, P1840, DOI 10.1128/AAC.35.9.1840; Sambrook J., 1989, MOL CLONING LAB MANU; Schrag SJ, 1997, P ROY SOC B-BIOL SCI, V264, P1287, DOI 10.1098/rspb.1997.0178; Seppala H, 1997, NEW ENGL J MED, V337, P441, DOI 10.1056/NEJM199708143370701; *VET MED DIR, 2001, SAL ANT PROD US VET	14	340	354	1	79	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	APR 28	2001	357	9265					1325	1328		10.1016/S0140-6736(00)04519-0	http://dx.doi.org/10.1016/S0140-6736(00)04519-0			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	427ND	11343738				2023-01-03	WOS:000168411400011
J	Collet, JP; Vanasse, M; Marois, P; Amar, M; Goldberg, J; Lambert, J; Lassonde, M; Hardy, P; Fortin, J; Tremblay, SD; Montgomery, D; Lacroix, J; Robinson, A; Majnemer, A				Collet, JP; Vanasse, M; Marois, P; Amar, M; Goldberg, J; Lambert, J; Lassonde, M; Hardy, P; Fortin, J; Tremblay, SD; Montgomery, D; Lacroix, J; Robinson, A; Majnemer, A		HBO-CP Res Grp	Hyperbaric oxygen for children with cerebral palsy: a randomised multicentre trial	LANCET			English	Article							MOTOR FUNCTION MEASURE; THERAPY	Background The use of hyperbaric oxygen for children with cerebral palsy has spread worldwide, despite little scientific evidence of efficacy. We did a randomised trial to assess the efficacy and side-effects of this form of therapy in children with cerebral palsy. Methods 111 children with cerebral palsy aged 3-12 years were randomly assigned hyperbaric oxygen (n=57) or slightly pressurised room air (n=54). All children received 40 treatments over 2 months. Hyperbaric oxygen treatment was Ih in 100% oxygen at 1.75 atmospheres absolute (ATA); children on slightly pressurised air received air at 1.3 ATA (the lowest pressure at which pressure can be felt, thereby ensuring the maintenance of masking). The main outcome measure was gross motor function. Secondary outcomes included performance in activities of daily living, attention, working memory, and speech. Findings For all outcomes, both groups improved over the course of the study, but without any difference between the two treatments. The score on the global gross motor function measure increased by 3.0% in the children on slightly pressurised air and 2.9% in those on hyperbaric oxygen. The mean difference between treatments was -0.40 (95% CI -1.69 to 0.90, p=0.544). Other changes were seen in speech, attention, memory, and functional skills. Ear problems occurred in 27 children treated by hyperbaric oxygen and in 15 treated with hyperbaric air (p=0.004). Interpretation In this study, hyperbaric oxygen did not improve the condition of children with cerebral palsy compared with slightly pressurised air. The improvement seen in both groups for all dimensions tested deserves further consideration.	Sir Mortimer B Davis Jewish Gen Hosp, Randomised Clin Trial Unit, Montreal, PQ H3T 1E2, Canada; Hop St Justine, Pediat Neurol Dept, Montreal, PQ H3T 1C5, Canada; Hop St Justine, Speech Therapy Dept, Montreal, PQ H3T 1C5, Canada; Hop St Justine, Ctr Readaptat Marie Enfant, Montreal, PQ H3T 1C5, Canada; Hop St Justine, Pediat Intens Care Unit, Montreal, PQ H3T 1C5, Canada; Ctr Hosp Hotel Dieu Levis, Levis, PQ, Canada; McGill Univ, Dept Educ Phys, Montreal, PQ, Canada; Inst Maritime Quebec, Montreal, PQ, Canada; Ctr Hosp Reg Rimouski, Montreal, PQ, Canada; Univ Montreal, Fac Med, Dept Social & Prevent Med, Montreal, PQ H3C 3J7, Canada; Univ Montreal, Dept Psychol, Montreal, PQ H3C 3J7, Canada; McGill Univ, Sch Phys & Occupat Therapy, Montreal, PQ, Canada	McGill University; Universite de Montreal; Universite de Montreal; Universite de Montreal; Universite de Montreal; Laval University; McGill University; Universite de Montreal; Universite de Montreal; McGill University	Collet, JP (corresponding author), Sir Mortimer B Davis Jewish Gen Hosp, Randomised Clin Trial Unit, 3755 Cote Ste Catherine,Suite A132, Montreal, PQ H3T 1E2, Canada.							BIETHER JK, 1993, PEDIAT PERINATOL EPI, V6, P339; Blanshard J, 1996, CLIN OTOLARYNGOL, V21, P400, DOI 10.1046/j.1365-2273.1996.00813.x; BLEILE K, 1994, MANUAL ARTICULATION, P120; BOWER E, 1992, DEV MED CHILD NEUROL, V34, P25; DELATOLAS J, 1993, ETUDE EPIDEMIOLOGIQU; DUDLEY JG, 1980, BATTERIE TESTS LANGA; FELDMAN AB, 1990, PHYS THER, V70, P602, DOI 10.1093/ptj/70.10.602; Greenberg LM, 1996, TOVA TEST VARIABLES; HAMPSON NB, 1999, HYPERBARIC OXYGENTHE; Kent R, 1994, REFERENCE MANUAL COM; KUBAN KCK, 1994, NEW ENGL J MED, V330, P188, DOI 10.1056/NEJM199401203300308; LEILE KJ, 1993, ARTICULATORY PHONOLO; MACHADO JJ, 1989, AM COLL HYP MED ORL; Molnar GE, 1985, PEDIAT REHABILITATIO, P481; Montgomery D, 1999, UNDERSEA HYPERBAR M, V26, P235; Neubauer R, 1985, MED SUBACQUEA IPERBA, V5, P75; Neubauer RA, 1998, NEUROL RES, V20, pS33; Nighoghossian N, 1997, J NEUROL SCI, V150, P27, DOI 10.1016/S0022-510X(97)05398-7; Nordmark E, 1997, SCAND J REHABIL MED, V29, P25; Pervin L. A, 1993, PERSONALITY THEORY R; Prefontaine R. R., 1968, VOCABULAIRE ORAL ENF; QIBIAO W, 1995, P 11 INT C HYP MED F, P79; ROTHSTEIN JM, 1991, PHYS THER, V71, P589, DOI 10.1093/ptj/71.8.589; RUSSELL DJ, 1989, DEV MED CHILD NEUROL, V31, P341; Trahan J, 1999, PEDIAT PHYS THER, V11, P12; *U MONTR, 1993, EX ENF DYSPR PROT EX	26	102	112	1	7	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	FEB 24	2001	357	9256					582	586		10.1016/S0140-6736(00)04054-X	http://dx.doi.org/10.1016/S0140-6736(00)04054-X			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	404UB	11558483				2023-01-03	WOS:000167119100009
J	KAHTAN, S; FITTON, P				KAHTAN, S; FITTON, P			LISTEN TO ME	BRITISH MEDICAL JOURNAL			English	Editorial Material																			0	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 28	1993	307	6903					571	571		10.1136/bmj.307.6903.571	http://dx.doi.org/10.1136/bmj.307.6903.571			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LV180	11643162	Bronze, Green Published			2023-01-03	WOS:A1993LV18000081
J	Liu, B; Krieger, M				Liu, B; Krieger, M			Highly purified scavenger receptor class B type I reconstituted into posphatidylcholine/cholesterol liposomes mediates high affinity high density lipoprotein binding and selective lipid uptake	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHOLESTERYL ESTER TRANSFER; SR-BI; PLASMA-MEMBRANES; DEFICIENT MICE; HDL; EXPRESSION; CD36; METABOLISM; CELLS; RAT	The murine class B, type I scavenger receptor mSR-BI is a high and low density lipoprotein (HDL and LDL) receptor that mediates selective uptake of cholesteryl esters. Here we describe a reconstituted phospholipid/ cholesterol liposome assay of the binding and selective uptake activities of SR-BI derived from detergent-solubilized cells. The assay, employing lysates from epitope-tagged receptor (mSR-BI-t1)-expressing mammalian and insect cells, recapitulated many features of SR-BI activity in intact cells, including high affinity and saturable I-125-HDL binding, selective lipid uptake from [H-3]cholesteryl ether-labeled HDL, and poor inhibition of HDL receptor activity by LDL. The novel properties of a mutated receptor (Q402R/Q418R, normal LDL binding but loss of most HDL binding) were reproduced in the assay, as was the ability of the SR-BI homologue CD36 to bind HDL but not mediate efficient lipid uptake. In this assay, essentially homogeneously pure mSR-BI-t1, prepared by single-step immunoaffinity chromatography, mediated high affinity HDL binding and efficient selective lipid uptake from HDL. Thus, SR-BI-mediated HDL binding and selective lipid uptake are intrinsic properties of the receptor that do not require the intervention of other proteins or specific cellular structures or compartments.	MIT, Dept Biol, Cambridge, MA 02139 USA	Massachusetts Institute of Technology (MIT)	Krieger, M (corresponding author), MIT, Dept Biol, Rm 68-483, Cambridge, MA 02139 USA.		Eckhardt, Erik/G-1567-2010; Krieger, Marco/AAE-8611-2020		NHLBI NIH HHS [HL 52212] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL052212] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Acton S, 1996, SCIENCE, V271, P518, DOI 10.1126/science.271.5248.518; ACTON SL, 1994, J BIOL CHEM, V269, P21003; Arai T, 1999, J BIOL CHEM, V274, P2366, DOI 10.1074/jbc.274.4.2366; Azhar S, 2002, J LIPID RES, V43, P861; Babitt J, 1997, J BIOL CHEM, V272, P13242, DOI 10.1074/jbc.272.20.13242; Braun A, 2002, CIRC RES, V90, P270, DOI 10.1161/hh0302.104462; BROWN MS, 1986, SCIENCE, V232, P34, DOI 10.1126/science.3513311; Calvo D, 1998, J LIPID RES, V39, P777; Calvo D, 1997, ARTERIOSCL THROM VAS, V17, P2341, DOI 10.1161/01.ATV.17.11.2341; Connelly MA, 1999, J BIOL CHEM, V274, P41, DOI 10.1074/jbc.274.1.41; de la Llera-Moya M, 1999, J LIPID RES, V40, P575; GLASS C, 1983, P NATL ACAD SCI-BIOL, V80, P5435, DOI 10.1073/pnas.80.17.5435; Gu XJ, 2000, J BIOL CHEM, V275, P9120, DOI 10.1074/jbc.275.13.9120; Gu XJ, 1998, J BIOL CHEM, V273, P35388, DOI 10.1074/jbc.273.41.26338; Gu XJ, 2000, J BIOL CHEM, V275, P29993, DOI 10.1074/jbc.275.39.29993; Holm TM, 2002, BLOOD, V99, P1817, DOI 10.1182/blood.V99.5.1817; Ikemoto M, 2000, P NATL ACAD SCI USA, V97, P6538, DOI 10.1073/pnas.100114397; Ji Y, 1999, J BIOL CHEM, V274, P33398, DOI 10.1074/jbc.274.47.33398; Jian B, 1998, J BIOL CHEM, V273, P5599, DOI 10.1074/jbc.273.10.5599; Kozarsky KF, 2000, ARTERIOSCL THROM VAS, V20, P721, DOI 10.1161/01.ATV.20.3.721; Kozarsky KF, 1997, NATURE, V387, P414, DOI 10.1038/387414a0; Krieger M, 1999, ANNU REV BIOCHEM, V68, P523, DOI 10.1146/annurev.biochem.68.1.523; Liadaki KN, 2000, J BIOL CHEM, V275, P21262, DOI 10.1074/jbc.M002310200; Liu T, 2002, J BIOL CHEM, V277, P21576, DOI 10.1074/jbc.M112103200; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Mardones P, 2001, J LIPID RES, V42, P170; Miettinen HE, 2001, J CLIN INVEST, V108, P1717, DOI 10.1172/JCI13288; MOLDAY RS, 1983, BIOCHEMISTRY-US, V22, P653, DOI 10.1021/bi00272a020; MORRISON JR, 1994, J BIOL CHEM, V269, P13911; OQUENDO P, 1989, CELL, V58, P95, DOI 10.1016/0092-8674(89)90406-6; PARKES JG, 1990, BIOCHEM CELL BIOL, V68, P870, DOI 10.1139/o90-129; PIETERS NM, 1994, BIOCHIM BIOPHYS ACTA, V1225, P125; Reaven E, 1998, ENDOCRINOLOGY, V139, P2847, DOI 10.1210/en.139.6.2847; REAVEN E, 1984, J CLIN INVEST, V74, P1384, DOI 10.1172/JCI111549; Reaven E, 2001, P NATL ACAD SCI USA, V98, P1613, DOI 10.1073/pnas.98.4.1613; Reeves PJ, 1996, P NATL ACAD SCI USA, V93, P11487, DOI 10.1073/pnas.93.21.11487; Rigotti A, 1997, P NATL ACAD SCI USA, V94, P12610, DOI 10.1073/pnas.94.23.12610; Rigotti A, 1996, J BIOL CHEM, V271, P33545, DOI 10.1074/jbc.271.52.33545; RIGOTTI A, 1995, J BIOL CHEM, V270, P16221, DOI 10.1074/jbc.270.27.16221; RINNINGER F, 1993, BIOCHIM BIOPHYS ACTA, V1166, P275, DOI 10.1016/0005-2760(93)90108-L; RINNINGER F, 1993, BIOCHIM BIOPHYS ACTA, V1166, P284, DOI 10.1016/0005-2760(93)90109-M; Rodrigueza WV, 1999, J BIOL CHEM, V274, P20344, DOI 10.1074/jbc.274.29.20344; Sambrook J., 1989, MOL CLONING LAB MANU; SCHNEIDER WJ, 1980, J BIOL CHEM, V255, P1442; Sehayek E, 1998, P NATL ACAD SCI USA, V95, P10194, DOI 10.1073/pnas.95.17.10194; SHI XY, 1992, BIOCHEMISTRY-US, V31, P3230, DOI 10.1021/bi00127a026; Silver DL, 2001, J BIOL CHEM, V276, P25287, DOI 10.1074/jbc.M101726200; Stangl H, 1999, J BIOL CHEM, V274, P32692, DOI 10.1074/jbc.274.46.32692; STEIN Y, 1983, BIOCHIM BIOPHYS ACTA, V752, P98, DOI 10.1016/0005-2760(83)90237-0; Swarnakar S, 1999, J BIOL CHEM, V274, P29733, DOI 10.1074/jbc.274.42.29733; Trigatti B, 1999, P NATL ACAD SCI USA, V96, P9322, DOI 10.1073/pnas.96.16.9322; Ueda Y, 2000, J BIOL CHEM, V275, P20368, DOI 10.1074/jbc.M000730200; VELAN B, 1993, BIOCHEM J, V296, P649, DOI 10.1042/bj2960649; Werder M, 2001, BIOCHEMISTRY-US, V40, P11643, DOI 10.1021/bi0109820; Williams DL, 2002, J LIPID RES, V43, P544	55	54	60	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 13	2002	277	37					34125	34135		10.1074/jbc.M204265200	http://dx.doi.org/10.1074/jbc.M204265200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	592WD	12110672	hybrid			2023-01-03	WOS:000177959100079
J	Wells, M; Sturdee, DW; Barlow, DH; Ulrich, LG; O'Brien, K; Campbell, MJ; Vessey, MP; Bragg, A				Wells, M; Sturdee, DW; Barlow, DH; Ulrich, LG; O'Brien, K; Campbell, MJ; Vessey, MP; Bragg, A		UK Continuous Combined Hormone Re	Effect on endometrium of long term treatment with continuous combined oestrogen-progestogen replacement therapy: follow up study	BMJ-BRITISH MEDICAL JOURNAL			English	Article							POSTMENOPAUSAL WOMEN; ESTRADIOL; RISK; ACETATE; CANCER; REGIMEN	Objective To determine effects of five years of treatment with an oral continuous combined regimen of 2 mg 17beta-oestradiol and 1 mg norethisterone acetate on endometrial histology in postmenopausal women. Design Follow up study in postmenopausal women. Setting 31 menopause clinics in the United Kingdom. Participants 534 postmenopausal women, all with an intact uterus, who had completed nine months of treatment with oral continuous combined 2 mg 17beta-oestradiol and 1 mg norethisterone acetate agreed to take part in a long term follow up study. Women were assigned to different groups on the basis of the treatment status immediately before entering the original study: 360 women had taken sequential oestrogen-progestogen hormone replacement therapy, 164 had taken no hormone replacement therapy, and 10 had taken unopposed oestrogen therapy. Methods Endometrial aspiration specimens were taken before the women started the continuous combined regimen, after 9 and 24-36 months, and at the end of the five year treatment period or on withdrawal from the study. Main outcome measure Results of endometrial histology. Results The duration of treatment with continuous combined hormone replacement therapy was 4.4 (range 1.1-5.9) years. Data on endometrial specimens were available for 526 women after nine months of treatment, 465 women after 24-36 months of treatment, and 398 women who completed the five years treatment (345 women) or were withdrawn between the two latter visits for biopsies (53 women). No cases of endometrial hyperplasia or malignancy were detected at biopsy; 69% of women had an endometrium classified as atrophic or unassessable on completion of the study or withdrawal from it. Before the continuous combined therapy was started, complex hyperplasia was detected in 21 women who had taken sequential hormone replacement therapy before the study and in one who had taken unopposed oestrogen. All of these women had normal results on histological examination of endometrial tissue after nine months of treatment with continuous combined hormone replacement therapy, and hyperplasia did not recur after up to five years of treatment. Conclusions Long term treatment (for up to five years) with continuous combined hormone replacement therapy containing oestradiol 2 mg and norethisterone 1 mg daily was associated with neither endometrial hyperplasia nor malignancy. In women who had complex hyperplasia during previous sequential or unopposed regimens, the endometrium returned to normal during treatment with continuous combined hormone replacement therapy. These findings provide reassurance about the long term safety of this continuous combined regimen in terms of the endometrium.	Univ Sheffield, Sch Med, Div Genom Med, Sect Oncol & Pathol,Acad Unit Pathol, Sheffield S10 2RX, S Yorkshire, England; Solihull Hosp, Dept Obstet & Gynaecol, Solihull B91 2JL, W Midlands, England; Univ Oxford, John Radcliffe Hosp, Oxford OX3 9DU, England; Copenhagen Cty Hosp Gentofte, Dept Obstet & Gynaecol, DK-2900 Hellerup, Denmark; Novo Nordisk AS, Dept Med, Crawley RH11 9RT, W Sussex, England; No Gen Hosp, Community Sci Ctr, Sch Hlth Related Res, Sheffield S5 7AU, S Yorkshire, England; Inst Hlth Sci, Dept Publ Hlth, Oxford OX3 7LF, England	University of Sheffield; Heart of England NHS Foundation Trust; University of Oxford; Novo Nordisk; Northern General Hospital; University of Oxford	Wells, M (corresponding author), Univ Sheffield, Sch Med, Div Genom Med, Sect Oncol & Pathol,Acad Unit Pathol, Sheffield S10 2RX, S Yorkshire, England.	m.wells@sheffield.ac.uk	Campbell, Michael J/I-4253-2014; Barlow, David/F-8738-2011; Sturdee, David/ABF-9792-2020	Campbell, Michael J/0000-0003-3529-2739; 				AinMelk Y, 1996, FERTIL STERIL, V66, P962, DOI 10.1016/S0015-0282(16)58690-7; ARCHER DF, 1991, AM J OBSTET GYNECOL, V165, P317, DOI 10.1016/0002-9378(91)90084-5; Beresford SAA, 1997, LANCET, V349, P458, DOI 10.1016/S0140-6736(96)07365-5; Comerci JT, 1997, GYNECOL ONCOL, V64, P425, DOI 10.1006/gyno.1996.4559; CORNIER E, 1984, AM J OBSTET GYNECOL, V148, P109, DOI 10.1016/S0002-9378(84)80043-5; HAWTHORN RJS, 1991, BRIT J OBSTET GYNAEC, V98, P939, DOI 10.1111/j.1471-0528.1991.tb13519.x; Hill DA, 2000, AM J OBSTET GYNECOL, V183, P1456, DOI 10.1067/mob.2000.108081; Judd HL, 1996, JAMA-J AM MED ASSOC, V275, P370, DOI 10.1001/jama.1996.03530290040035; Kurman RJ, 2000, OBSTET GYNECOL, V96, P373, DOI 10.1016/S0029-7844(00)00944-3; LEATHER AT, 1991, OBSTET GYNECOL, V78, P1008; MATTSSON LA, 1982, MATURITAS, V4, P95, DOI 10.1016/0378-5122(82)90035-4; MCGONIGLE KF, 1994, GYNECOL ONCOL, V55, P126, DOI 10.1006/gyno.1994.1261; Nand SL, 1998, OBSTET GYNECOL, V91, P678, DOI 10.1016/S0029-7844(98)00038-6; OBEL EB, 1993, MATURITAS, V16, P13, DOI 10.1016/0378-5122(93)90129-6; Perry W, 1998, GYNECOL ENDOCRINOL, V12, P109, DOI 10.3109/09513599809024959; Piegsa K, 1997, EUR J OBSTET GYN R B, V72, P175, DOI 10.1016/S0301-2115(96)02670-X; Pike MC, 1997, J NATL CANCER I, V89, P1110, DOI 10.1093/jnci/89.15.1110; RAVNIKAR VA, 1996, EUR MENOPAUSE J S, V3, P90; REES M, 1994, LANCET, V343, P250, DOI 10.1016/S0140-6736(94)91108-8; SPORRONG T, 1988, BRIT J OBSTET GYNAEC, V95, P1042, DOI 10.1111/j.1471-0528.1988.tb06511.x; SPOWART KJM, 1992, GYNAECOL ENDOSC, V1, P33; Stadberg E, 1996, MATURITAS, V23, P31, DOI 10.1016/0378-5122(95)00949-3; STALAND B, 1981, MATURITAS, V3, P145, DOI 10.1016/0378-5122(81)90006-2; STALAND B, 1985, ACTA OBSTET GYN SCAN, P29; STURDEE DW, 1994, LANCET, V344, P979, DOI 10.1016/S0140-6736(94)91640-3; Sturdee DW, 2000, BRIT J OBSTET GYNAEC, V107, P1392, DOI 10.1111/j.1471-0528.2000.tb11654.x; UDOFF L, 1995, OBSTET GYNECOL, V86, P306, DOI 10.1016/0029-7844(95)00115-8; Weiderpass E, 1999, J NATL CANCER I, V91, P1131, DOI 10.1093/jnci/91.13.1131; WEINSTEIN L, 1990, AM J OBSTET GYNECOL, V162, P1534, DOI 10.1016/0002-9378(90)90917-V; WOODRUFF JD, 1994, AM J OBSTET GYNECOL, V170, P1213	30	45	46	0	6	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	AUG 3	2002	325	7358					239	242A		10.1136/bmj.325.7358.239	http://dx.doi.org/10.1136/bmj.325.7358.239			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	582FL	12153918	Green Published, Bronze			2023-01-03	WOS:000177339000015
J	Brader, ML; Sukumar, M; Pekar, AH; McClellan, DS; Chance, RE; Flora, DB; Cox, AL; Irwin, L; Myers, SR				Brader, ML; Sukumar, M; Pekar, AH; McClellan, DS; Chance, RE; Flora, DB; Cox, AL; Irwin, L; Myers, SR			Hybrid insulin cocrystals for controlled release delivery	NATURE BIOTECHNOLOGY			English	Article							ALBUMIN-BINDING; ACTING INSULIN; TIME-ACTION; CRYSTALS; THERAPY; ANALOG; PHENOL; HELIX; NN304; DOGS	The ability to tailor the release profile of a drug by manipulating its formulation matrix offers important therapeutic advantages. We show here that human insulin can be cocrystallized at preselected ratios with the fully active lipophilically modified insulin derivative octanoyl-N-LysB29-human insulin (C8-HI). The cocrystal is analogous to the NPH (neutral protamine Hagedorn) crystalline complex formed with human insulin, which is commonly used as the long-acting insulin component of diabetes therapy. The in vitro and in vivo release rates of the cocrystal can be controlled by adjusting the relative proportions of the two insulin components. We identified a cocrystal composition comprising 75% C8-HI and 25% human insulin that exhibits near-ideal basal pharmacodynamics in somatostatin-treated beagle dogs. The dependence of release rate on cocrystal ratio provides a robust mechanism for modulating insulin pharmacodynamics. These findings show that a crystalline protein matrix may accommodate a chemical modification that alters the dissolution rate of the crystal in a therapeutically useful way, yet that is structurally innocuous enough to preserve the pharmaceutical integrity of the original microcrystalline entity and the pharmacological activity of the parent molecule.	Eli Lilly & Co, Lilly Res Labs, Bioprod Pharmaceut Dev, Indianapolis, IN 46285 USA; Eli Lilly & Co, Lilly Res Labs, Phys & Struct Characterizat, Indianapolis, IN 46285 USA; Eli Lilly & Co, Lilly Res Labs, Bio Res Technol & Prot, Indianapolis, IN 46285 USA; Eli Lilly & Co, Lilly Res Labs, Endocrine Res, Indianapolis, IN 46285 USA	Eli Lilly; Eli Lilly; Eli Lilly; Eli Lilly	Brader, ML (corresponding author), Eli Lilly & Co, Lilly Res Labs, Bioprod Pharmaceut Dev, Indianapolis, IN 46285 USA.							Abel JJ, 1926, P NATL ACAD SCI USA, V12, P132, DOI 10.1073/pnas.12.2.132; BAKER E N, 1970, Journal of Molecular Biology, V54, P605, DOI 10.1016/0022-2836(70)90131-2; BAKER EN, 1988, PHILOS T ROY SOC B, V319, P369, DOI 10.1098/rstb.1988.0058; BALSCHMIDT P, 1991, ACTA CRYSTALLOGR B, V47, P975, DOI 10.1107/S010876819100842X; BANERJEE PS, 1991, PEPTIDE PROTEIN DELI, V4, P487; Brader ML, 1997, TECH PROT CHEM, V8, P289, DOI 10.1016/S1080-8914(97)80030-0; Brange J., 1987, GALENICS INSULIN; BREMS DN, 1992, PROTEIN ENG, V5, P527, DOI 10.1093/protein/5.6.527; DeFelippis MR, 1998, J PHARM SCI, V87, P170, DOI 10.1021/js970285m; Defelippis MR, 2000, PHARM FORMULATION DE, P113; DEREWENDA U, 1989, NATURE, V338, P594, DOI 10.1038/338594a0; FELIG P, 1984, JAMA-J AM MED ASSOC, V251, P393, DOI 10.1001/jama.251.3.393; GALLOWAY JA, 1994, HORM METAB RES, V26, P591, DOI 10.1055/s-2007-1001766; HAGEDORS H. C., 1936, Journal of the American Medical Association, V106, P177; Hamilton-Wessler M, 1999, DIABETOLOGIA, V42, P1254, DOI 10.1007/s001250051301; Hassiepen U, 1999, BIOPHYS J, V77, P1638, DOI 10.1016/S0006-3495(99)77012-8; Heinemann L, 1999, DIABETIC MED, V16, P332, DOI 10.1046/j.1464-5491.1999.00081.x; Jen A, 2001, PHARM RES-DORDR, V18, P1483, DOI 10.1023/A:1013057825942; KATSOYANNIS PG, 1981, STRUCTURAL STUDIES M, P454; Krayenbuhl C., 1946, REP STENO MEM HOSP N, V1, P60; Kurtzhals P, 1995, BIOCHEM J, V312, P725, DOI 10.1042/bj3120725; LANGER R, 1990, SCIENCE, V249, P1527, DOI 10.1126/science.2218494; MACPHERSON A, 1999, CRYSTALLIZATION BIOL; Markussen J, 1996, DIABETOLOGIA, V39, P281; Myers SR, 1997, DIABETES, V46, P637, DOI 10.2337/diabetes.46.4.637; OHKUBO Y, 1995, DIABETES RES CLIN PR, V28, P103, DOI 10.1016/0168-8227(95)01064-K; Owens DR, 2001, LANCET, V358, P739, DOI 10.1016/S0140-6736(01)05842-1; Putney SD, 1998, NAT BIOTECHNOL, V16, P153, DOI 10.1038/nbt0298-153; Radziuk J, 1998, DIABETOLOGIA, V41, P116, DOI 10.1007/s001250050876; Radziuk J, 1998, DIABETOLOGIA, V41, P489; Ribel U, 1985, DIABETES 1985, P891; SHAH VP, 1992, PHARM TECHNOL, V5, P35; SHAMOON H, 1993, NEW ENGL J MED, V329, P977, DOI 10.1056/nejm199309303291401; STEINER DF, 1973, NATURE, V243, P528, DOI 10.1038/243528a0; Stevens RC, 2000, CURR OPIN STRUC BIOL, V10, P558, DOI 10.1016/S0959-440X(00)00131-7; Whittingham JL, 1997, BIOCHEMISTRY-US, V36, P2826, DOI 10.1021/bi9625105; WHITTINGHAM JL, 1995, BIOCHEMISTRY-US, V34, P15553, DOI 10.1021/bi00047a022; Yip CM, 1998, BIOPHYS J, V75, P1172, DOI 10.1016/S0006-3495(98)74036-6	38	67	78	5	48	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	AUG	2002	20	8					800	804		10.1038/nbt722	http://dx.doi.org/10.1038/nbt722			5	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	579MU	12134168				2023-01-03	WOS:000177182500030
J	Bates, DW				Bates, DW			Unexpected hypoglycemia in a critically ill patient	ANNALS OF INTERNAL MEDICINE			English	Article							ADVERSE DRUG EVENTS; MEDICATION ERRORS; DISPENSING ERROR; ADRENAL CRISIS; COMA; CHLORPROPAMIDE; ANESTHESIA; PREVENTION; SECONDARY; MEDICINE	Administration of the wrong medication is a serious and understudied problem. Because physicians are not directly involved in the drug administration process, they tend to overlook the possibility of adverse drug events and medication errors in their differential diagnoses of patient illnesses or acute deterioration. This article analyzes the case of a patient with iatrogenic hypoglycemia due to administration of the wrong medication: Insulin instead of heparin was used to flush the patient's arterial line. In addition to assessing the results of the institution's "root-cause analysis" of the factors contributing to this particular adverse event and the institution's response, this article reviews the literature on preventing medication errors. Key strategies that might have been helpful in this case include using checklists for common emergency conditions (such as altered level of consciousness) and automated paging for "panic laboratory values," as well as instituting protocols for medication administration. Changing the system of administering medications by bar coding drugs, with checks of the medication, patient, and provider, could have prevented this accident. Finally, organizations need to strive for a "culture of safety" by providing opportunities to discuss errors and adverse events in constructive, supportive environments and by resisting pressure to find a scapegoat.	Brigham & Womens Hosp, Div Gen Internal Med & Primary Care, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital	Bates, DW (corresponding author), Brigham & Womens Hosp, Div Gen Internal Med & Primary Care, 75 Francis St,PBB-A3, Boston, MA 02115 USA.	dbates@partners.org	Bates, David/AAE-7283-2019					ALLAN EL, 1990, AM J HOSP PHARM, V47, P555, DOI 10.1093/ajhp/47.3.555; [Anonymous], 1999, ERR IS HUMAN BUILDIN; BARKER KN, 1995, AM J HEALTH-SYST PH, V52, P400, DOI 10.1093/ajhp/52.4.400; BATES DW, 1995, J GEN INTERN MED, V10, P199, DOI 10.1007/BF02600255; BATES DW, 1995, JAMA-J AM MED ASSOC, V274, P29, DOI 10.1001/jama.274.1.29; BOUCHARD P, 1982, DIABETES, V31, P40, DOI 10.2337/diabetes.31.1.40; Brient K, 1995, Healthc Inform, V12, P42; BRIENT K, 1995, HEALTHC INFORM, V12, P42; BRIENT K, 1995, HEALTHC INFORM, V12, P40; BROWNING RG, 1990, ANN EMERG MED, V19, P683, DOI 10.1016/S0196-0644(05)82479-5; CATELLIER CR, 1992, CAN MED ASSOC J, V146, P1525; COHEN M, 1999, MED ERRORS; Cohen M R, 1998, J Healthc Risk Manag, V18, P16; Cryer P., 1992, HOSP PRACT OFF ED, V27, P129; Cryer P., 1992, HOSP PRACT OFF ED, V27, P125; CRYER PE, 1992, HOSP PRACT, V27, P119; CULLEN DJ, 1990, ANESTHESIOLOGY, V73, P593; CURRIE M, 1993, ANAESTH INTENS CARE, V21, P596, DOI 10.1177/0310057X9302100517; DAVIES JM, 1994, CAN J ANAESTH, V41, P83, DOI 10.1007/BF03009795; Fischer JE, 2000, INTENS CARE MED, V26, P105, DOI 10.1007/s001340050021; FISCHER KF, 1986, NEW ENGL J MED, V315, P1245, DOI 10.1056/NEJM198611133152002; Flynn EA, 2002, AM J HEALTH-SYST PH, V59, P436, DOI 10.1093/ajhp/59.5.436; GORDON MR, 1988, AM J MED, V85, P271; HEIFETZ S, 1987, NEW ENGL J MED, V316, P223; HILFIKER D, 1984, NEW ENGL J MED, V310, P118, DOI 10.1056/NEJM198401123100211; HOLLIMAN CJ, 1992, ANN EMERG MED, V21, P347, DOI 10.1016/S0196-0644(05)82648-4; HUMINER D, 1989, ARCH INTERN MED, V149, P1890, DOI 10.1001/archinte.149.8.1890; *JOINT COMM ACCR H, 2001, REV JOINT COMM STAND; Kraman SS, 1999, ANN INTERN MED, V131, P963, DOI 10.7326/0003-4819-131-12-199912210-00010; Kuperman GJ, 1999, J AM MED INFORM ASSN, V6, P512, DOI 10.1136/jamia.1999.0060512; Kuperman GJ, 1998, J AM MED INFORM ASSN, V5, P112, DOI 10.1136/jamia.1998.0050112; Laing I, 1998, ANN CLIN BIOCHEM, V35, P545, DOI 10.1177/000456329803500411; LEAPE LL, 1994, JAMA-J AM MED ASSOC, V272, P1851, DOI 10.1001/jama.272.23.1851; LEAPE LL, 1995, JAMA-J AM MED ASSOC, V274, P35, DOI 10.1001/jama.1995.03530010049034; Lee AJ, 1997, ANN PHARMACOTHER, V31, P727, DOI 10.1177/106002809703100611; LEVINSON W, 1989, JAMA-J AM MED ASSOC, V261, P2252, DOI 10.1001/jama.261.15.2252; Marks V, 1999, ENDOCRIN METAB CLIN, V28, P555, DOI 10.1016/S0889-8529(05)70088-8; MCDONALD CJ, 1976, NEW ENGL J MED, V295, P1351, DOI 10.1056/NEJM197612092952405; MILLER DR, 1977, NEW ENGL J MED, V297, P339; Perlitz Y, 1999, Obstet Gynecol Surv, V54, P717, DOI 10.1097/00006254-199911000-00023; Randolph AG, 1998, BRIT MED J, V316, P969, DOI 10.1136/bmj.316.7136.969; Reason J., 1990, HUMAN ERROR; Rex J H, 2000, Jt Comm J Qual Improv, V26, P563; ROBINSON I, 1994, J FAM PRACTICE, V38, P78; SELTZER HS, 1989, ENDOCRIN METAB CLIN, V18, P163, DOI 10.1016/S0889-8529(18)30395-5; SERVICE FJ, 1995, NEW ENGL J MED, V332, P1144, DOI 10.1056/NEJM199504273321707; Sexton JB, 2000, BMJ-BRIT MED J, V320, P745, DOI 10.1136/bmj.320.7237.745; Shojania K, 1999, J RHEUMATOL, V26, P195; SHOJANIA K, 2001, AHRQ PUBLICATION; SHUMAK SL, 1991, ARCH INTERN MED, V151, P1877; SLEDGE ED, 1993, SOUTHERN MED J, V86, P1272, DOI 10.1097/00007611-199311000-00020; SOUMERAI SB, 1984, MILBANK FUND Q, V62, P447, DOI 10.2307/3349860; SPADAFORA MP, 1986, AM J EMERG MED, V4, P384, DOI 10.1016/0735-6757(86)90323-2; Studdert DM, 2001, JAMA-J AM MED ASSOC, V286, P217, DOI 10.1001/jama.286.2.217; Tissot E, 1999, INTENS CARE MED, V25, P353, DOI 10.1007/s001340050857; Turnbull J E, 1998, Jt Comm Perspect, V18, P34; VESELY DL, 1982, GERIATRICS, V37, P71; WALD H, 2001, AHRQ PUBLICATION; Wass CT, 1996, MAYO CLIN PROC, V71, P801; WOFE R, 1998, EMERGENCY MED CONCEP; WU AW, 1991, JAMA-J AM MED ASSOC, V265, P2089, DOI 10.1001/jama.265.16.2089; YAMADA KA, 2001, WASHINGTON MANUAL ME; 1998, SWEET REWARD REDUCIN	63	33	34	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUL 16	2002	137	2					110	116		10.7326/0003-4819-137-2-200207160-00009	http://dx.doi.org/10.7326/0003-4819-137-2-200207160-00009			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	575VN	12118966				2023-01-03	WOS:000176969300005
J	Ostrowsky, BE; Whitener, C; Bredenberg, HK; Carson, LA; Holt, S; Hutwagner, L; Arduino, MJ; Jarvis, WR				Ostrowsky, BE; Whitener, C; Bredenberg, HK; Carson, LA; Holt, S; Hutwagner, L; Arduino, MJ; Jarvis, WR			Serratia marcescens bacteremia traced to an infused narcotic	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							INTENSIVE-CARE-UNIT; FENTANYL; OUTBREAK; EPIDEMIC; RISK	Background: From June 30, 1998, through March 21, 1999, several patients in the surgical intensive care unit of a hospital acquired Serratia marcescens bacteremia. We investigated this outbreak. Methods: A case was defined as the occurrence of S. marcescens bacteremia in any patient in the surgical intensive care unit during the period of the epidemic. To identify risk factors, we compared patients with S. marcescens bacteremia with randomly selected controls. Isolates from patients and from medications were evaluated by pulsed-field gel electrophoresis. The hair of one employee was tested for fentanyl. Results: Twenty-six patients with S. marcescens bacteremia were identified; eight (31 percent) had polymicrobial bacteremia, and seven of these had Enterobacter cloacae and S. marcescens in the same culture. According to univariate analysis, patients with S. marcescens bacteremia stayed in the surgical intensive care unit longer than controls (13.5 vs. 4.0 days, P<0.001), were more likely to have received fentanyl in the surgical intensive care unit (odds ratio, 31; P<0.001), and were more likely to have been exposed to two particular respiratory therapists (odds ratios, 13.1 and 5.1; P<0.001 for both comparisons). In a multivariate analysis, receipt of fentanyl and exposure to the two respiratory therapists (adjusted odds ratio for one therapist, 6.7; P=0.002; adjusted odds ratio for the other therapist, 9.5; P=0.02) remained significant. One respiratory therapist had been reported for tampering with fentanyl; his hair sample tested positive for fentanyl. Cultures of fentanyl infusions from two case patients yielded S. marcescens and E. cloacae. The isolates from the case patients and from the fentanyl infusions had similar patterns on pulsed-field gel electrophoresis. After removal of the implicated respiratory therapist, no further cases occurred. Conclusions: An outbreak of S. marcescens and E. cloacae bacteremia in a surgical intensive care unit was traced to extrinsic contamination of the parenteral narcotic fentanyl by a health care worker. Our findings underscore the risk of complications in patients that is associated with illicit narcotic use by health care workers.	Ctr Dis Control & Prevent, Epidemiol Program Off, Natl Ctr Infect Dis, Div Healthcare Qual Promot, Atlanta, GA USA; Ctr Dis Control & Prevent, Epidemiol Program Off, Div Appl Publ Hlth Training, Epidem Intelligence Serv, Atlanta, GA USA; Ctr Dis Control & Prevent, Epidemiol Program Off, Div Publ Hlth Surveillance & Informat, Atlanta, GA USA; Penn State Univ, Milton S Hershey Med Ctr, Coll Med, Hershey, PA 17033 USA	Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health	Ostrowsky, BE (corresponding author), Virginia Commonwealth Univ, Med Coll Virginia, Dept Epidemiol & Infect Control, POB 980019, Richmond, VA 23298 USA.		Arduino, Matthew/C-1461-2012	Arduino, Matthew/0000-0001-7072-538X				American Public Health Association, 1998, STAND METH EX WAT WA; Archibald LK, 1997, PEDIATR INFECT DIS J, V16, P1045, DOI 10.1097/00006454-199711000-00008; Archibald LK, 1997, INFECT CONT HOSP EP, V18, P704; Berens AIL, 1996, LANCET, V347, P1334, DOI 10.1016/S0140-6736(96)90981-2; CLEARY TJ, 1981, AM J INFECT CONTROL, V9, P107, DOI 10.1016/S0196-6553(81)80090-9; DONOWITZ LG, 1979, JAMA-J AM MED ASSOC, V242, P1749, DOI 10.1001/jama.242.16.1749; EHRENKRANZ NJ, 1980, LANCET, V2, P1289; GOLDSTEIN A, 2000, WASHINGTON POST 0414, pB1; GOLDSTEIN A, 2000, WASHINGTON POST 0301, pB4; HAYS LR, 1992, ANESTHESIOLOGY, V77, P819, DOI 10.1097/00000542-199210000-00029; HIBBS J, 1991, JAMA-J AM MED ASSOC, V265, P1011, DOI 10.1001/jama.265.8.1011; HOFFMAN JP, 1996, DHHS SMA PUBLICATION; KNAUS WA, 1991, CHEST, V100, P1619, DOI 10.1378/chest.100.6.1619; LAI E, 1989, BIOTECHNIQUES, V7, P34; MAKI DG, 1991, JAMA-J AM MED ASSOC, V265, P981, DOI 10.1001/jama.265.8.981; MIECZKOWSKI T, 1995, HAIR ANAL DRUG DETEC, P1; Passaro DJ, 1997, J INFECT DIS, V175, P992, DOI 10.1086/514008; PETERSEN NJ, 1973, HEALTH LAB SCI, V10, P18; Sachs H, 1998, J CHROMATOGR B, V713, P147, DOI 10.1016/S0378-4347(98)00168-6; SMIALEK JE, 1994, J FORENSIC SCI, V39, P159; STANLEY TH, 1989, ANESTH ANALG, V69, P21; VILLARINO ME, 1989, J CLIN MICROBIOL, V27, P2433, DOI 10.1128/JCM.27.11.2433-2436.1989; WARD CF, 1983, JAMA-J AM MED ASSOC, V250, P922, DOI 10.1001/jama.250.7.922; WEBB SF, 1975, CHEST, V68, P703, DOI 10.1378/chest.68.5.703; YU VL, 1979, NEW ENGL J MED, V300, P887, DOI 10.1056/NEJM197904193001604	25	51	52	0	0	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAY 16	2002	346	20					1529	1537		10.1056/NEJMoa012370	http://dx.doi.org/10.1056/NEJMoa012370			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	551LV	12015392	Green Published, Bronze			2023-01-03	WOS:000175563900004
J	Eastwood, PR; Szollosi, I; Platt, PR; Hillman, DR				Eastwood, PR; Szollosi, I; Platt, PR; Hillman, DR			Comparison of upper airway collapse during general anaesthesia and sleep	LANCET			English	Article							PRESSURE	Measurement of the collapsibility of the upper airway while a patient is awake is not a good guide to such collapsibility during sleep, presumably because of differences in respiratory drive, muscle tone, and sensitivity of reflexes. To assess whether a relation existed between general anaesthesia and sleep, we measured collapsibility of the upper airway during general anaesthesia and severity of sleep-disordered breathing in 25 people who were having minor surgery on their limbs. Anaesthetised patients who needed positive pressure to maintain airway patency had more severe sleep-disordered breathing than did those whose airways remained patent at or below atmospheric pressure. Such an association was strongest during rapid-eye-movement (REM) sleep. Our findings suggest that sleep-disordered breathing should be considered in all patients with a pronounced tendency for upper airway obstruction during anaesthesia or during recovery from it.	Sir Charles Gairdner Hosp, Dept Pulm Physiol, Nedlands, WA 6009, Australia; Sir Charles Gairdner Hosp, Dept Anaesthesia, Nedlands, WA 6009, Australia; Univ Western Australia, Dept Human Movement & Exercise Sci, Nedlands, WA 6009, Australia	University of Western Australia; University of Western Australia; University of Western Australia	Eastwood, PR (corresponding author), Sir Charles Gairdner Hosp, Dept Pulm Physiol, Hosp Ave, Nedlands, WA 6009, Australia.		Eastwood, Peter R/H-9129-2014	Eastwood, Peter R/0000-0002-4490-4138; Hillman, David/0000-0001-9987-539X				Flemons WW, 1999, SLEEP, V22, P667, DOI 10.1093/sleep/22.5.667; HORNER RL, 1994, J PHYSIOL-LONDON, V476, P141; REMMERS JE, 1978, J APPL PHYSIOL, V44, P931, DOI 10.1152/jappl.1978.44.6.931; SMITH PL, 1988, J APPL PHYSIOL, V64, P789, DOI 10.1152/jappl.1988.64.2.789; YOUNG T, 1993, NEW ENGL J MED, V328, P1230, DOI 10.1056/NEJM199304293281704	5	122	128	0	4	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	APR 6	2002	359	9313					1207	1209		10.1016/S0140-6736(02)08224-7	http://dx.doi.org/10.1016/S0140-6736(02)08224-7			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	539AB	11955541				2023-01-03	WOS:000174846300013
J	MacArthur, C; Winter, HR; Bick, DE; Knowles, H; Lilford, R; Henderson, C; Lancashire, RJ; Braunholtz, DA; Gee, H				MacArthur, C; Winter, HR; Bick, DE; Knowles, H; Lilford, R; Henderson, C; Lancashire, RJ; Braunholtz, DA; Gee, H			Effects of redesigned community postnatal care on womens' health 4 months after birth: a cluster randomised controlled trial	LANCET			English	Article							MATERNAL HEALTH; DEPRESSION; CHILDBIRTH; PREVENTION; SUPPORT	Background Much postpartum physical and psychological morbidity is not addressed by present care, which tends to focus on routine examinations. We undertook a cluster randomised controlled trial to assess community postnatal care that has been redesigned to identify and manage individual needs. Methods We randomly allocated 36 general practice clusters from the West Midlands health region of the UK to intervention (n=17) or control (19) care. Midwives from the practices recruited women and provided care. 1087 (53%) of 2064 women were in practices randomly assigned to the intervention group, with 977 (47%) women in practices assigned to the control group. Care was led by midwives, with no routine contact with general practitioners, and was extended to 3 months. Midwives used symptom checklists and the Edinburgh postnatal depression scale (EPDS) to identify health needs and guidelines for the management of these needs. Primary outcomes at 4 months were obtained by postal questionnaire and included the women's short form 36 physical (PCS) and mental (MCS) component summary scores and the EPDS. Secondary outcomes were women's views about care. Multilevel analysis accounted for possible cluster effects. Findings 801 (77%) of 1087 women in the intervention group and 702 (76%) of 977 controls responded at 4 months. Women's mental health measures were significantly better in the intervention group (MCS, 3.03 [95% CI 1.53-4.52]; EPDS -1.92 [-2.55 to -1.29]; EPDS 13+ odds ratio 0.57 [0.43-0.76]) than in controls, but the physical health score did not differ. Interpretation Redesign of care so that it is midwife-led, flexible, and tailored to needs, could help to improve women's mental health and reduce probable depression at 4 months' postpartum.	Univ Birmingham, Dept Epidemiol & Publ Hlth, Birmingham, W Midlands, England; Radcliffe Infirm, RCN Inst, Oxford OX2 6HE, England; Bournemouth Univ, Inst Hlth, Poole BH12 5BB, Dorset, England; Univ Birmingham, Sch Hlth Sci Nursing, Birmingham, W Midlands, England; Birmingham Womens Hosp NHS Trust, Birmingham, W Midlands, England	University of Birmingham; Radcliffe Infirmary; Bournemouth University; University of Birmingham; Birmingham Women's Hospital	MacArthur, C (corresponding author), Univ Birmingham, Dept Epidemiol & Publ Hlth, Birmingham, W Midlands, England.		MacArthur, Christine/ABA-8601-2021; Bick, Debra/P-9575-2018	MacArthur, Christine/0000-0003-0434-2158; Bick, Debra/0000-0002-8557-7276				Altman DG, 1991, PRACTICAL STAT MED R; [Anonymous], 1995, BR J MIDWIFE; Audit Commission, 1997, 1 CLASS DEL IMPR MAT; BICK DE, 2001, POSTNATAL CARE EVIDE; Brown S, 2000, BRIT J OBSTET GYNAEC, V107, P1194, DOI 10.1111/j.1471-0528.2000.tb11607.x; Brown S, 1998, BRIT J OBSTET GYNAEC, V105, P156, DOI 10.1111/j.1471-0528.1998.tb10045.x; Brugha TS, 2000, PSYCHOL MED, V30, P1273, DOI 10.1017/S0033291799002937; CLEMENT S, 1999, COMMUNITY BASED MAT, pCH18; COX JL, 1987, BRIT J PSYCHIAT, V150, P782, DOI 10.1192/bjp.150.6.782; *DEP HLTH, COMM MAT SERV SUMM I; Elliott SA, 2000, BRIT J CLIN PSYCHOL, V39, P223, DOI 10.1348/014466500163248; Expert Maternity Group Department of Health, 1993, CHANG CHILDB; GARCIA J, 1994, MIDWIFERY, V10, P40, DOI 10.1016/0266-6138(94)90007-8; GLAZENER CMA, 1995, BRIT J OBSTET GYNAEC, V102, P282, DOI 10.1111/j.1471-0528.1995.tb09132.x; Gunn J, 1998, BRIT J OBSTET GYNAEC, V105, P991, DOI 10.1111/j.1471-0528.1998.tb10263.x; *HOUS COMM SEL COM, 1992, WINT REP; MACARTHUR C, 1991, HLTH CHILDBIRTH; Marchant S, 1995, BRIT J MIDWIFERY, V3, P34; Marsh J, 1991, Midwifery, V7, P177, DOI 10.1016/S0266-6138(05)80196-2; Morrell CJ, 2000, BRIT MED J, V321, P593, DOI 10.1136/bmj.321.7261.593; OAKLEY A, 2000, EXPT KNOWING, P182; Oakley A., 1992, SOCIAL SUPPORT MOTHE; OAKLEY A, 1994, EUR J PUBLIC HEALTH, V4, P265; OKOUMUNNE OC, 1999, HEALTH TECHNOL ASSES, V3, P1; PREMARANTNE UN, THORAX, V52, pA18; Rasbash J., 2000, USERS GUIDE MLWIN MU; RAY KL, 2000, COCHRANE LIB, V4; REID M, 1999, 2 CTR PRAGMATIC RAND; *ROYAL COLL MIDW, 2000, LIF BIRTH REFL POSTN; Saurel-Cubizolles MJ, 2000, BRIT J OBSTET GYNAEC, V107, P1202, DOI 10.1111/j.1471-0528.2000.tb11608.x; SHARIF K, 1993, J OBSTET GYNAECOL, V13, P251; Shields N, 1997, J REPROD INFANT PSYC, V15, P91, DOI DOI 10.1080/02646839708404537; STAMP EE, 1995, BIRTH-ISS PERINAT C, V22, P138; Townsend PP., 1988, HLTH DEPRIVATION INE; Trevelyan J, 1994, Nurs Times, V90, P38; Turnbull D, 1996, LANCET, V348, P213; WARE JE, 1994, PHYSICAL MENTAL HLTH	37	164	165	2	17	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	FEB 2	2002	359	9304					378	385		10.1016/S0140-6736(02)07596-7	http://dx.doi.org/10.1016/S0140-6736(02)07596-7			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	518UP	11844507				2023-01-03	WOS:000173686500007
J	Schapowal, A				Schapowal, A		Petasites Study Grp	Randomised controlled trial of butterbur and cetirizine for treating seasonal allergic rhinitis	BMJ-BRITISH MEDICAL JOURNAL			English	Article							QUALITY-OF-LIFE; ST-JOHNS WORT; LEUKOTRIENE-SYNTHESIS; FRENCH VERSION; EXTRACT	Objectives To compare the efficacy and tolerability of butterbur (Petasites hybridus) with cetirizine in patients with seasonal allergic rhinitis (hay fever). Design Randomised, double blind, parallel group comparison. Setting Four outpatient general medicine and allergy clinics in Switzerland and Germany. Participants 131 patients were screened for seasonal allergic rhinitis and 125 patients were randomised (butterbur 61; cetirizine 64). Interventions Butterbur (carbon dioxide extract tablets, ZE 339) one tablet, four dines daily, or cetirizine, one tablet hi the evening, both given for two consecutive weeks. Main outcome measures Scores on SF-36 questionnaire and clinical global impression scale. Results Improvement in SF-36 score was similar in the two treatment groups for all items tested hierarchically. Butterbur and cetirizine were also similarly effective with regard to global improvement scores on the clinical global impression scale (median score 3 in both groups). Both treatments were well tolerated. ha the cetirizine group, two thirds (8/12) of reported adverse events were associated with sedative effects (drowsiness and fatigue) despite the drug being considered a non-sedating antihistamine. Conclusions The effects of butterbur arc similar to those of cetirizine in patients with seasonal allergic rhinitis when evaluated blindly by patients and doctors. Butterbur should be considered for treating seasonal allergic rhinitis when the sedative effects of antihistamines need to be avoided.	Allergy Clin, CH-7302 Landquart, Switzerland		Schapowal, A (corresponding author), Allergy Clin, Hochwangstr 3, CH-7302 Landquart, Switzerland.	andreas.chapowal@freesurf.ch						BERMAN BA, 1988, J ALLERGY CLIN IMMUN, V81, P980, DOI 10.1016/0091-6749(88)90165-0; BICKEL D, 1994, PLANTA MED, V60, P318, DOI 10.1055/s-2006-959492; BOUSQUET J, 1994, J ALLERGY CLIN IMMUN, V94, P182, DOI 10.1016/0091-6749(94)90038-8; Bousquet J, 1996, J ALLERGY CLIN IMMUN, V98, P309, DOI 10.1016/S0091-6749(96)70155-0; *BRIT MED ASS ROYA, 1998, BRIT NAT FORM; BRUNE K, 1993, PLANTA MED, V59, P494, DOI 10.1055/s-2006-959746; Guy W, 1976, ECDEU ASSESSMENT MAN; KNAPP HR, 1990, NEW ENGL J MED, V323, P1745, DOI 10.1056/NEJM199012203232506; Meier B., 1994, HAGERS HDB PHARMAZEU, P81; Schellenberg R, 2001, BRIT MED J, V322, P134, DOI 10.1136/bmj.322.7279.134; Thomet OAR, 2001, BIOCHEM PHARMACOL, V61, P1041, DOI 10.1016/S0006-2952(01)00552-4; Wheatley D, 1997, PHARMACOPSYCHIATRY, V30, P77, DOI 10.1055/s-2007-979523; Woelk H, 2000, BMJ-BRIT MED J, V321, P536, DOI 10.1136/bmj.321.7260.536	14	79	82	0	6	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JAN 19	2002	324	7330					144	146		10.1136/bmj.324.7330.144	http://dx.doi.org/10.1136/bmj.324.7330.144			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	514ZH	11799030	Green Published, Bronze			2023-01-03	WOS:000173470600017
J	Ong, JP; Achkar, EA				Ong, JP; Achkar, EA			A retained pharmacy	NEW ENGLAND JOURNAL OF MEDICINE			English	Article									Cleveland Clin Fdn, Cleveland, OH 44195 USA	Cleveland Clinic Foundation	Ong, JP (corresponding author), Cleveland Clin Fdn, 9500 Euclid Ave, Cleveland, OH 44195 USA.								0	0	0	0	2	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	DEC 27	2001	345	26					1889	1889		10.1056/NEJMicm980909	http://dx.doi.org/10.1056/NEJMicm980909			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	505TY	11756580				2023-01-03	WOS:000172932700005
J	Elphick, HE; Tan, A; Ashby, D; Smyth, RL				Elphick, HE; Tan, A; Ashby, D; Smyth, RL			Systematic reviews and lifelong diseases	BMJ-BRITISH MEDICAL JOURNAL			English	Article							CYSTIC-FIBROSIS; CONTROLLED TRIALS; BETA-LACTAM; AMINOGLYCOSIDE; TOBRAMYCIN; GENTAMICIN		Univ Liverpool, Inst Child Hlth, Alder Hey Childrens Hosp, Liverpool L12 2AP, Merseyside, England; Univ London, Barts & London Queen Marys Sch Med & Dent, Wolfson Inst Prevent Med, London EC1M 6B9, England	Alder Hey Children's NHS Foundation Trust; Alder Hey Children's Hospital; University of Liverpool; University of London; Queen Mary University London	Smyth, RL (corresponding author), Univ Liverpool, Inst Child Hlth, Alder Hey Childrens Hosp, Liverpool L12 2AP, Merseyside, England.	r.l.smyth@liv.ac.uk						Akbar A, 1999, ACTA PAEDIATR, V88, P783; Black N, 1996, BRIT MED J, V312, P1215; Cheng K, 1996, LANCET, V348, P639, DOI 10.1016/S0140-6736(96)05169-0; Cheng K, 2000, PEDIATR PULM, V29, P1; ELPHICK HE, 2001, COCHRANE LIB; Ernst E, 2001, BRIT MED J, V323, P546, DOI 10.1136/bmj.323.7312.546; Frederiksen B, 1996, PEDIATR PULM, V21, P153, DOI 10.1002/(SICI)1099-0496(199603)21:3<153::AID-PPUL1>3.0.CO;2-R; GODSON C, 1988, SCAND J GASTROENTERO, V23, P70, DOI 10.3109/00365528809090220; GOTSCHE PC, 2001, COCHRANE LIB; Katbamna B, 1999, EAR HEARING, V20, P393, DOI 10.1097/00003446-199910000-00002; Leibovici L, 1999, BRIT MED J, V318, P1614, DOI 10.1136/bmj.318.7198.1614; MCLAUGHLIN FJ, 1983, J INFECT DIS, V147, P559, DOI 10.1093/infdis/147.3.559; Mehta A, 2001, LANCET, V358, P1546, DOI 10.1016/S0140-6736(01)06593-X; Mulheran M, 1997, BRIT J AUDIOL, V31, P5, DOI 10.3109/03005364000000004; MULHERIN D, 1991, IRISH J MED SCI, V160, P173, DOI 10.1007/BF02961666; PADOAN R, 1987, PEDIATR INFECT DIS J, V6, P648, DOI 10.1097/00006454-198707000-00006; PO ALW, 2001, 8 COCHR C CAP TOWN S; SCHULZ KF, 1995, JAMA-J AM MED ASSOC, V273, P408, DOI 10.1001/jama.273.5.408; Scott CS, 2001, PEDIATR PULM, V31, P314, DOI 10.1002/ppul.1047; SHAREK PJ, 2001, COCHRANE LIB; Smith AL, 1999, J PEDIATR-US, V134, P413, DOI 10.1016/S0022-3476(99)70197-6; TAYLOR RFH, 1993, RESP MED, V87, P535, DOI 10.1016/0954-6111(93)90010-W; *UK CYST FIBR TRUS, 2000, ANT TREATM CYST FIBR	23	22	22	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	AUG 17	2002	325	7360					381	384		10.1136/bmj.325.7360.381	http://dx.doi.org/10.1136/bmj.325.7360.381			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	587DV	12183313	Green Published			2023-01-03	WOS:000177626000025
J	Wuest, T; Gerlach, E; Banerjee, D; Gerspach, J; Moosmayer, D; Pfizenmaier, K				Wuest, T; Gerlach, E; Banerjee, D; Gerspach, J; Moosmayer, D; Pfizenmaier, K			TNF-Selectokine: a novel prodrug generated for tumor targeting and site-specific activation of tumor necrosis factor	ONCOGENE			English	Article						tumor stroma targeting; tumor associated proteases; TNFR2 signaling; juxtatropic membrane TNF like action	FACTOR-ALPHA; FACTOR RECEPTOR; STROMAL FIBROBLASTS; PROTEIN; CANCER; CELLS; INVOLVEMENT; VASCULATURE; EXPRESSION; THERAPY	We describe a TNF fusion protein designated TNF-Selectokine, which is a homo-trimeric molecule comprised of a single chain antibody (scFv) targeting module, a trimerization domain and TINE TNF-Selectokine exerts high bioactivity towards the targeted and adjacent, antigen negative cells. Membrane targeting dependent immobilization of the TNF-Selectokine induced cell death in TNFR1 and TNFR2 dependent manner, thus cell bound TNF-Selectokine mimicks membrane TNF. To restrict TNF activity to the tumor, a prototype of a TNF-Selectokine prodrug was constructed by insertion of a TNFR1 fragment, separated from TNF by a protease-sensitive linker. The prodrug exerts minimal TNF activity, but can be activated in vitro several thousand-fold by proteolytic digest, showing the principal feasibility of this approach. Choice of cleavage site(s) recognized by protease(s) typically associated with a given carcinoma should allow high dose systemic application of the respective TNF prodrug that unveils its specific bioactivity only in targeted tissues.	Univ Stuttgart, Inst Cell Biol & Immunol, D-70569 Stuttgart, Germany	University of Stuttgart	Pfizenmaier, K (corresponding author), Univ Stuttgart, Inst Cell Biol & Immunol, Allmandring 31, D-70569 Stuttgart, Germany.	klaus.pfizenmaier@po.uni-stuttgart.de						BANNER DW, 1993, CELL, V73, P431, DOI 10.1016/0092-8674(93)90132-A; Black RA, 1997, NATURE, V385, P729, DOI 10.1038/385729a0; Brocks B, 2001, MOL MED, V7, P461, DOI 10.1007/BF03401851; Christ O, 2001, CLIN CANCER RES, V7, P985; CORCORAN AE, 1994, EUR J BIOCHEM, V223, P831, DOI 10.1111/j.1432-1033.1994.tb19059.x; CORTI A, 1992, BIOCHEM J, V284, P905, DOI 10.1042/bj2840905; Curnis F, 2000, NAT BIOTECHNOL, V18, P1185, DOI 10.1038/81183; De Petro G, 1998, CANCER RES, V58, P2234; DeFeo-Jones D, 2000, NAT MED, V6, P1248, DOI 10.1038/81351; Eggermont A M, 2001, Curr Oncol Rep, V3, P359, DOI 10.1007/s11912-001-0090-8; GARINCHESA P, 1990, P NATL ACAD SCI USA, V87, P7235, DOI 10.1073/pnas.87.18.7235; Gasparri A, 1999, CANCER RES, V59, P2917; Ghiso JAA, 1999, EUR J BIOCHEM, V263, P295, DOI 10.1046/j.1432-1327.1999.00507.x; Grell M, 1998, P NATL ACAD SCI USA, V95, P570, DOI 10.1073/pnas.95.2.570; GRELL M, 1995, CELL, V83, P793, DOI 10.1016/0092-8674(95)90192-2; Huang PS, 2001, CURR OPIN GENET DEV, V11, P104, DOI 10.1016/S0959-437X(00)00164-7; Kammerer RA, 1998, J BIOL CHEM, V273, P10602, DOI 10.1074/jbc.273.17.10602; KONTERMANN RE, 1995, BIOL CHEM H-S, V376, P473, DOI 10.1515/bchm3.1995.376.8.473; Lejeune FJ, 1998, CURR OPIN IMMUNOL, V10, P573, DOI 10.1016/S0952-7915(98)80226-4; Locksley RM, 2001, CELL, V104, P487, DOI 10.1016/S0092-8674(01)00237-9; Mersmann M, 2001, INT J CANCER, V92, P240, DOI 10.1002/1097-0215(200102)9999:9999<::AID-IJC1170>3.3.CO;2-L; Nooijen PTGA, 1998, CANCER RES, V58, P4880; Paciucci R, 1998, ONCOGENE, V16, P625, DOI 10.1038/sj.onc.1201564; Park JE, 1999, J BIOL CHEM, V274, P36505, DOI 10.1074/jbc.274.51.36505; ROSENBLUM MG, 1995, CANCER IMMUNOL IMMUN, V40, P322, DOI 10.1007/BF01519633; Ruegg C, 1998, NAT MED, V4, P408, DOI 10.1038/nm0498-408; Scherf U, 1996, CLIN CANCER RES, V2, P1523; SCHMID EF, 1995, BLOOD, V86, P1836, DOI 10.1182/blood.V86.5.1836.bloodjournal8651836; Stoelcker B, 2000, AM J PATHOL, V156, P1171, DOI 10.1016/S0002-9440(10)64986-3; Takasaki W, 1997, NAT BIOTECHNOL, V15, P1266, DOI 10.1038/nbt1197-1266; Wajant H, 2001, INT J BIOCHEM CELL B, V33, P19, DOI 10.1016/S1357-2725(00)00064-9	31	24	31	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 20	2002	21	27					4257	4265		10.1038/sj.onc.1205193	http://dx.doi.org/10.1038/sj.onc.1205193			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	562AA	12082613				2023-01-03	WOS:000176174200008
J	Nowak, AP; Breedveld, V; Pakstis, L; Ozbas, B; Pine, DJ; Pochan, D; Deming, TJ				Nowak, AP; Breedveld, V; Pakstis, L; Ozbas, B; Pine, DJ; Pochan, D; Deming, TJ			Rapidly recovering hydrogel scaffolds from self-assembling diblock copolypeptide amphiphiles	NATURE			English	Article							BLOCK; MICELLES	Protein-based hydrogels are used for many applications, ranging from food and cosmetic thickeners to support matrices for drug delivery and tissue replacement(1-3). These materials are usually prepared using proteins extracted from natural sources, which can give rise to inconsistent properties unsuitable for medical applications(4). Recent developments have utilized recombinant DNA methods to prepare artificial protein hydrogels with specific association mechanisms and responsiveness to various stimuli(5,6). Here we synthesize diblock copolypeptide amphiphiles containing charged and hydrophobic segments. Dilute solutions of these copolypeptides would be expected to form micelles; instead, they form hydrogels that retain their mechanical strength up to temperatures of about 90 degreesC and recover rapidly after stress. The use of synthetic materials permits adjustment of copolymer chain length and composition, which we varied to study their effect on hydrogel formation and properties. We find that gelation depends not only on the amphiphilic nature of the polypeptides, but also on chain conformations-alpha-helix, beta-strand or random coil. Indeed, shape-specific supramolecular assembly is integral to the gelation process, and provides a new class of peptide-based hydrogels with potential for applications in biotechnology.	Univ Calif Santa Barbara, Dept Mat, Santa Barbara, CA 93106 USA; Univ Calif Santa Barbara, Dept Chem, Santa Barbara, CA 93106 USA; Univ Calif Santa Barbara, Mat Res Lab, Santa Barbara, CA 93106 USA; Univ Calif Santa Barbara, Dept Chem Engn, Santa Barbara, CA 93106 USA; Univ Delaware, Dept Mat Sci & Engn, Newark, DE 19716 USA; Univ Delaware, Delaware Biotechnol Inst, Newark, DE 19716 USA	University of California System; University of California Santa Barbara; University of California System; University of California Santa Barbara; University of California System; University of California Santa Barbara; University of California System; University of California Santa Barbara; University of Delaware; University of Delaware	Deming, TJ (corresponding author), Univ Calif Santa Barbara, Dept Mat, Santa Barbara, CA 93106 USA.	tdeming@mrl.ucsb.edu	Breedveld, Victor/AAJ-5123-2020; Breedveld, Victor/A-6822-2009; Deming, Timothy/I-5411-2013; Pine, David J/B-7740-2016	Pine, David J/0000-0002-3304-6684; Deming, Timothy/0000-0002-0594-5025				Adler A J, 1973, Methods Enzymol, V27, P675; Buitenhuis J, 1997, J CHEM PHYS, V107, P262, DOI 10.1063/1.474346; Cha JN, 2000, NATURE, V403, P289, DOI 10.1038/35002038; CLARK AH, 1987, ADV POLYM SCI, V83, P57; Crocker JC, 2000, PHYS REV LETT, V85, P888, DOI 10.1103/PhysRevLett.85.888; DAGANI R, 1997, CHEM ENG NEWS, V23, P26; Deming TJ, 1999, MACROMOLECULES, V32, P4500, DOI 10.1021/ma9902899; Deming TJ, 1997, NATURE, V390, P386, DOI 10.1038/37084; Falini G, 2000, J CHEM SOC DALTON, P3983, DOI 10.1039/b003334k; Guenoun P, 2000, LANGMUIR, V16, P4436, DOI 10.1021/la991036b; Hamley IW, 2000, LANGMUIR, V16, P2508, DOI 10.1021/la991035j; Hoffmann H, 1996, CURR OPIN COLLOID IN, V1, P726, DOI 10.1016/S1359-0294(96)80074-4; KATCHALSKI E, 1958, ADV PROTEIN CHEM, V13, P243, DOI 10.1016/S0065-3233(08)60600-2; Kavanagh GM, 1998, PROG POLYM SCI, V23, P533, DOI 10.1016/S0079-6700(97)00047-6; KLEIN HF, 1975, CHEM BER-RECL, V108, P944, DOI 10.1002/cber.19751080327; KUBOTA S, 1974, J AM CHEM SOC, V96, P4684, DOI 10.1021/ja00821a060; Lee KY, 2001, CHEM REV, V101, P1869, DOI 10.1021/cr000108x; Liu L, 1999, NATURE, V397, P141, DOI 10.1038/16426; MASON TG, 1995, PHYS REV LETT, V74, P1250, DOI 10.1103/PhysRevLett.74.1250; Moffitt M, 1996, ACCOUNTS CHEM RES, V29, P95, DOI 10.1021/ar940080+; Okano T, 1998, BIORELATED POLYM GEL; Peppas NA, 2000, ANNU REV BIOMED ENG, V2, P9, DOI 10.1146/annurev.bioeng.2.1.9; Petka WA, 1998, SCIENCE, V281, P389, DOI 10.1126/science.281.5375.389; Tsitsilianis C, 2000, MACROMOLECULES, V33, P2936, DOI 10.1021/ma991410e; Wang C, 1999, NATURE, V397, P417, DOI 10.1038/17092; Ward A. G., 1977, SCI TECHNOLOGY GELAT; Won YY, 1999, SCIENCE, V283, P960, DOI 10.1126/science.283.5404.960; Yu M, 1999, J AM CHEM SOC, V121, P12210, DOI 10.1021/ja993637v	28	705	738	12	717	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAY 23	2002	417	6887					424	428		10.1038/417424a	http://dx.doi.org/10.1038/417424a			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	554HZ	12024209				2023-01-03	WOS:000175730900034
J	Cohen, MH; Eisenberg, DM				Cohen, MH; Eisenberg, DM			Potential physician malpractice liability associated with complementary and integrative medical therapies	ANNALS OF INTERNAL MEDICINE			English	Article							LOW-BACK-PAIN; ALTERNATIVE MEDICINE; GINKGO-BILOBA; UNITED-STATES; TRIAL; SURVIVAL; PLACEBO	Physicians are increasingly grappling with medical liability issues as complementary and integrative health care practices are made available in conventional medical settings. This article proposes a framework in which physicians can assess potential malpractice liability issues in counseling patients about complementary and integrative therapies. The framework classifies complementary and integrative therapies according to whether the evidence reported in the medical and scientific literature supports both safety and efficacy; supports safety, but evidence regarding efficacy is inconclusive; supports efficacy, but evidence regarding safety is inconclusive; or indicates either serious risk or inefficacy. Clinical examples in each category help guide the clinician on how to counsel patients regarding use of complementary and alternative medical therapies in a given clinical situation. Specific strategies to reduce the risk for potential malpractice liability include the following: 1) determine the clinical risk level; 2) document the literature supporting the therapeutic choice; 3) provide adequate informed consent; 4) continue to monitor the patient conventionally; and 5) for referrals, inquire about the competence of the complementary and alternative medicine provider. This framework provides a basis for clinical decisions involving complementary and integrative care.	Harvard Univ, Sch Med, Div Res & Educ Complementary & Integrat Med Thera, Landmark Ctr, Boston, MA 02215 USA	Harvard University; Harvard Medical School	Cohen, MH (corresponding author), Harvard Univ, Sch Med, Div Res & Educ Complementary & Integrat Med Thera, Landmark Ctr, 401 Pk Dr,Suite 22A, Boston, MA 02215 USA.							ADAMS KE, IN PRESS ANN INTERN; [Anonymous], 1991, CA-CANCER J CLIN, V41, P187; BIGOS SJ, 1994, LOW BACK PROBLEMS AD; Cardini F, 1998, JAMA-J AM MED ASSOC, V280, P1580, DOI 10.1001/jama.280.18.1580; CHLEBOWSKI RT, 1992, BREAST CANCER RES TR, V20, P73; COHEN M, 2000, COMPLEMENTARY MED LE; COHEN MH, 1999, CURR PRACT MED, V2, P87; COHEN MH, 2001, DESKTOP GUIDE COMPLE, P404; Cohen Michael, 1998, COMPLEMENTARY ALTERN; Eisenberg DM, 1997, ANN INTERN MED, V127, P61, DOI 10.7326/0003-4819-127-1-199707010-00010; EISENBERG DM, 1993, NEW ENGL J MED, V328, P246, DOI 10.1056/NEJM199301283280406; Eisenberg DM, 1998, JAMA-J AM MED ASSOC, V280, P1569, DOI 10.1001/jama.280.18.1569; EISENBERG DM, IN PRESS CREDENTIALI; Ernst E, 1999, J PAIN SYMPTOM MANAG, V17, P65, DOI 10.1016/S0885-3924(98)00129-8; Ernst E, 1999, LANCET, V354, P2014, DOI 10.1016/S0140-6736(99)00418-3; Ernst E, 2001, ARCH INTERN MED, V161, P2288, DOI 10.1001/archinte.161.19.2288; Ezzo J, 2000, PAIN, V86, P217, DOI 10.1016/S0304-3959(99)00304-8; Fugh-Berman A, 2000, LANCET, V355, P134, DOI 10.1016/S0140-6736(99)06457-0; FURROW BR, 1995, HLTH LAW CASES MAT P; GLOCK MH, 1995, NIH PUB; Goldman P, 2001, ANN INTERN MED, V135, P594, DOI 10.7326/0003-4819-135-8_Part_1-200110160-00010; Holmes MD, 1999, CANCER, V86, P826, DOI 10.1002/(SICI)1097-0142(19990901)86:5&lt;826::AID-CNCR19&gt;3.0.CO;2-0; KENT GP, 1988, AM J EPIDEMIOL, V127, P591, DOI 10.1093/oxfordjournals.aje.a114834; Koes BW, 1996, SPINE, V21, P2860, DOI 10.1097/00007632-199612150-00013; LeBars PL, 1997, JAMA-J AM MED ASSOC, V278, P1327, DOI 10.1001/jama.278.16.1327; LEE MH, 1990, KRUSENS HDB PHYSICAL; Linde K, 1996, BRIT MED J, V313, P253, DOI 10.1136/bmj.313.7052.253; McAlindon TE, 2000, JAMA-J AM MED ASSOC, V283, P1469, DOI 10.1001/jama.283.11.1469; MOERTEL CG, 1982, NEW ENGL J MED, V306, P201, DOI 10.1056/NEJM198201283060403; Nahin RL, 2001, BRIT MED J, V322, P161, DOI 10.1136/bmj.322.7279.161; Norred C L, 2000, AANA J, V68, P13; Nortier JL, 2000, NEW ENGL J MED, V342, P1686, DOI 10.1056/NEJM200006083422301; Oken BS, 1998, ARCH NEUROL-CHICAGO, V55, P1409, DOI 10.1001/archneur.55.11.1409; Piscitelli SC, 2000, LANCET, V355, P547, DOI 10.1016/S0140-6736(99)05712-8; Ramsay DJ, 1998, JAMA-J AM MED ASSOC, V280, P1518; Sheikh NM, 1997, ARCH INTERN MED, V157, P913, DOI 10.1001/archinte.157.8.913; Spencer JW, 1999, COMPLEMENTARY ALTERN, P3; SPIEGEL D, 1989, LANCET, V2, P888; SPIEGEL D, 1983, PSYCHOSOM MED, V45, P333, DOI 10.1097/00006842-198308000-00007; Studdert DM, 1998, JAMA-J AM MED ASSOC, V280, P1610, DOI 10.1001/jama.280.18.1610; Taylor MA, 2000, BMJ-BRIT MED J, V321, P471, DOI 10.1136/bmj.321.7259.471; Wetzel MS, 1998, JAMA-J AM MED ASSOC, V280, P784, DOI 10.1001/jama.280.9.784; White A., 2001, DESKTOP GUIDE COMPLE; WILLMS D, 1991, WESTERN J MED, V154, P736; Wilt TJ, 1998, JAMA-J AM MED ASSOC, V280, P1604, DOI 10.1001/jama.280.18.1604; WRIGHT RS, 1991, WESTERN J MED, V154, P102; 2001, COCHRANE LIB	48	103	104	0	7	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	APR 16	2002	136	8					596	603		10.7326/0003-4819-136-8-200204160-00009	http://dx.doi.org/10.7326/0003-4819-136-8-200204160-00009			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	543WY	11955028				2023-01-03	WOS:000175125800005
J	Margolis, DJ; Knauss, J; Bilker, W				Margolis, DJ; Knauss, J; Bilker, W			Hormone replacement therapy and prevention of pressure ulcers and venous leg ulcers	LANCET			English	Article								Pressure ulcers and venous leg ulcers are common chronic wounds. Oestrogens in the form of hormone replacement therapy (HRT) might have an effect on wound healing, but this possibility has not been studied In detail. Using a case-cohort study including elderly patients in the UK General Practice Research Database, we showed that patients who received HRT were less likely to develop a venous leg ulcer (age-adjusted relative risk 0.65 [95% CI 0.61-0.69]) or a pressure ulcer (0.68 [0.62-0.76]) than those who did not use HRT. Therefore, we believe that HRT could be beneficial for the prevention of these wounds.	Univ Penn, Sch Med, Dept Dermatol, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Dept Biostat & Epidemiol, Philadelphia, PA 19104 USA	University of Pennsylvania; University of Pennsylvania	Margolis, DJ (corresponding author), Univ Penn, Sch Med, Dept Dermatol, 815 Blockley Hall,423 Guardian Dr, Philadelphia, PA 19104 USA.		Bilker, Warren/AAS-3515-2021		NIAMS NIH HHS [AR-02212, AR-44695] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR044695, K24AR002212, R29AR044695] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Ashcroft GS, 1999, AM J PATHOL, V155, P1137, DOI 10.1016/S0002-9440(10)65217-0; Calvin M, 2000, MATURITAS, V34, P195, DOI 10.1016/S0378-5122(99)00079-1; Krasner D., 2001, CHRONIC WOUND CARE C; MARGOLIS DJ, IN PRESS ANN EPIDEMI; PRENTICE RL, 1986, BIOMETRIKA, V73, P1	5	69	71	0	5	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	FEB 23	2002	359	9307					675	677		10.1016/S0140-6736(02)07806-6	http://dx.doi.org/10.1016/S0140-6736(02)07806-6			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	526AZ	11879867				2023-01-03	WOS:000174107400015
J	von Gunten, CF				von Gunten, CF			Secondary and tertiary palliative care in US hospitals	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							TERMINALLY ILL PATIENTS; LIFE; END; CONSULTATION; SERVICE; EXPERIENCE; MANAGEMENT; ILLNESS; FAMILY; UNIT	Palliative care services provide secondary and tertiary levels of palliative care, the interdisciplinary care of patients in which the goal is comfort and quality of life. Primary palliative care refers to the basic skills and competencies required of all physicians and other health care professionals. Secondary palliative care refers to the specialist clinicians and organizations that provide consultation and specialty care. Tertiary palliative care refers to the academic medical centers where specialist knowledge for the most complex cases is practiced, researched, and taught. The case of Reverend J, a man with advanced cancer admitted to an acute palliative care unit in a teaching hospital, illustrates the use of secondary and tertiary clinical palliative care services in hospitals and health care systems.	San Diego Hospice, Ctr Palliat Studies, San Diego, CA USA; Univ Calif San Diego, Dept Med, San Diego, CA 92103 USA	University of California System; University of California San Diego	von Gunten, CF (corresponding author), 4311 3rd Ave, San Diego, CA 92103 USA.							Axelsson B, 1998, PALLIATIVE MED, V12, P41, DOI 10.1191/026921698671336362; BILLINGS JA, IN PRESS J PALLIAT M; Byock I, 1997, DYING WELL PROSPECT; Campbell M L, 1996, AACN Clin Issues, V7, P159, DOI 10.1097/00044067-199602000-00015; Campbell ML, 1997, CRIT CARE MED, V25, P197, DOI 10.1097/00003246-199701000-00034; CAMPBELL ML, 1991, HEART LUNG, V20, P345; CARLSON RW, 1988, JAMA-J AM MED ASSOC, V259, P378, DOI 10.1001/jama.259.3.378; Cassell, 1994, NATURE SUFFERING GOA; Cohen SR, 2001, PALLIATIVE MED, V15, P363, DOI 10.1191/026921601680419401; Dowdy MD, 1998, CRIT CARE MED, V26, P252, DOI 10.1097/00003246-199802000-00020; DOYLE D, 1997, OXFORD TXB PALLIATIV; Emanuel EJ, 1999, NEW ENGL J MED, V341, P956, DOI 10.1056/NEJM199909233411306; Emanuel EJ, 2000, ANN INTERN MED, V132, P451, DOI 10.7326/0003-4819-132-6-200003210-00005; EMANUEL LL, 2002, EPEC CURRICULUM ED P; FERRELL E, 2002, END LIFE NURSING ED; Field MJ, 1997, APPROACHING DEATH IM; Frankl V. E., 1984, MANS SEARCH MEANING; Jurchak M, 2000, J CLIN ETHIC, V11, P49; Kellar N, 1996, J NURS ADMIN, V26, P16, DOI 10.1097/00005110-199603000-00011; KNAUS WA, 1995, JAMA-J AM MED ASSOC, V274, P1591, DOI 10.1001/jama.1995.03530200027032; Lanser P, 2001, Healthc Benchmarks, V8, P68; Lanser P, 2001, HEALTHC BENCHMARKS, V8, P62; Lilly CM, 2000, AM J MED, V109, P469, DOI 10.1016/S0002-9343(00)00524-6; Lothian ST, 1999, AM J HEALTH-SYST PH, V56, P1119, DOI 10.1093/ajhp/56.11.1119; Lynn J, 2000, JAMA-J AM MED ASSOC, V284, P2508, DOI 10.1001/jama.284.19.2508; Manfredi PL, 2000, J PAIN SYMPTOM MANAG, V20, P166, DOI 10.1016/S0885-3924(00)00163-9; MEIER D, 2002, PLANNING HOSP BASED; MUIRE C, 1999, TOPICS PALLIATIVE CA, V4, P131; Ng K, 1998, J PAIN SYMPTOM MANAG, V16, P307, DOI 10.1016/S0885-3924(98)00097-9; PAN CS, IN PRESS J PALLIAT M; RABOW MW, IN PRESS J PALLIAT M; Saunders C, 1984, MANAGEMENT TERMINAL, P232; SAUNDERS DC, 1982, MED CLIN N AM, V66, P1169, DOI 10.1016/S0025-7125(16)31390-6; Singer PA, 1999, JAMA-J AM MED ASSOC, V281, P163, DOI 10.1001/jama.281.2.163; Steinhauser AE, 2000, JAMA-J AM MED ASSOC, V284, P2476, DOI 10.1001/jama.284.19.2476; TENO J, 2002, TOOLKIT INSTRUMENTS; TENO J, 2002, BROWN SITE DEATH ATL; von Gunten C F, 1998, J Palliat Med, V1, P45; von Gunten C F, 2000, J Palliat Med, V3, P441; von Gunten C F, 1998, J Palliat Med, V1, P265, DOI 10.1089/jpm.1998.1.265; von Gunten C F, 1995, Am J Hosp Palliat Care, V12, P38, DOI 10.1177/104990919501200413; von Gunten C F, 2000, J Palliat Med, V3, P157, DOI 10.1089/10966210050085223; VONGUNTEN CF, 2002, CAPC MANUAL EVERYTHI; Weiss SC, 2001, LANCET, V357, P1311, DOI 10.1016/S0140-6736(00)04515-3; Weissman DE, 1997, ARCH INTERN MED, V157, P733, DOI 10.1001/archinte.157.7.733; WENNBERG G, 2002, DARTMOUTH ATLAS HLTH; Wilkinson EK, 1999, PALLIATIVE MED, V13, P197, DOI 10.1191/026921699673563105	47	123	125	0	10	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 20	2002	287	7					875	881		10.1001/jama.287.7.875	http://dx.doi.org/10.1001/jama.287.7.875			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	522XP	11851580				2023-01-03	WOS:000173922500027
J	Rosenthal, MB; Berndt, ER; Donohue, JM; Frank, RG; Epstein, AM				Rosenthal, MB; Berndt, ER; Donohue, JM; Frank, RG; Epstein, AM			Promotion of prescription drugs to consumers.	NEW ENGLAND JOURNAL OF MEDICINE			English	Article								Background: Spending on prescription drugs is the fastest growing component of the health care budget. There is public concern about the possibility that direct-to-consumer advertising of prescription drugs will result in inappropriate prescribing and higher costs of care. Guidelines issued in 1997 by the Food and Drug Administration (FDA) regarding advertising to consumers through electronic media are considered by some to be responsible for unleashing a flood of direct-to-consumer advertising. Methods: Using data on spending for promotional purposes and sales of prescription drugs, we examined industrywide trends for various types of promotion. We also tracked the relation between promotional efforts and sales over time. Finally, we documented the variation in direct-to-consumer advertising among and within five therapeutic classes of drugs and compared the variation in the intensity of such advertising with variation in the intensity of promotion to health care professionals. Results: Annual spending on direct-to-consumer advertising for prescription drugs tripled between 1996 and 2000, when it reached nearly $2.5 billion. Despite this increase, such advertising accounts for only 15 percent of the money spent on drug promotion and is highly concentrated on a subgroup of products. Within a therapeutic class, there is marked variation in the intensity of direct-to-consumer advertising, and the amount of such advertising for specific products fluctuates over time. The initial surge in direct-to-consumer advertising preceded the 1997 FDA guidelines that clarified the rules for electronic direct-to-consumer advertising, and thus the 1997 guidelines may not have been the most important reason for the overall increase. Conclusions: Although the use of direct-to-consumer advertising has grown disproportionately to other forms of promotion, it continues to account for a small proportion of total promotional efforts. Nevertheless, physicians must assist patients in evaluating health-related information obtained through direct advertising. (N Engl J Med 2002;346:498-505.) Copyright (C) 2002 Massachusetts Medical Society.	Harvard Univ, Sch Publ Hlth, Dept Hlth Policy & Management, Boston, MA 02115 USA; MIT, Alfred P Sloan Sch Management, Cambridge, MA 02139 USA; Harvard Univ, Sch Med, Dept Hlth Care Policy, Boston, MA 02115 USA	Harvard University; Harvard T.H. Chan School of Public Health; Massachusetts Institute of Technology (MIT); Harvard University; Harvard Medical School	Rosenthal, MB (corresponding author), Harvard Univ, Sch Publ Hlth, Dept Hlth Policy & Management, 677 Huntington Ave, Boston, MA 02115 USA.			Rosenthal, Meredith/0000-0003-3410-0184; Donohue, Julie/0000-0003-2418-6017				[Anonymous], 2001, PREVENTION MAGAZINE, P46; BERNDT ER, 2001, LONG SHADOW PATIENT; Heffler S, 2001, HEALTH AFFAIR, V20, P193, DOI 10.1377/hlthaff.20.2.193; *J KAIS FAM FDN, 2001, PRESCR DRUG TRENDS C; Lipsky MS, 1997, J FAM PRACTICE, V45, P495; *NIH CAR MAN, 2001, PRESCR DRUG EXP 2000; PASTORE M, 2001, HEALTHCARE WEB ADVER; *PHARM RES MAN AM, 2000, IND PROF 2000; SCHWARTZ RK, 1989, SOC SCI MED, V28, P577, DOI 10.1016/0277-9536(89)90252-9; Wilkes MS, 2000, HEALTH AFFAIR, V19, P110, DOI 10.1377/hlthaff.19.2.110	10	282	287	0	18	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	FEB 14	2002	346	7					498	505		10.1056/NEJMsa012075	http://dx.doi.org/10.1056/NEJMsa012075			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	521AE	11844852				2023-01-03	WOS:000173815300007
J	Reddel, HK; Toelle, BG; Marks, GB; Ware, SI; Jenkins, CR; Woolcock, AJ				Reddel, HK; Toelle, BG; Marks, GB; Ware, SI; Jenkins, CR; Woolcock, AJ			Analysis of adherence to peak flow monitoring when recording of data is electronic	BRITISH MEDICAL JOURNAL			English	Article							PERENNIAL ALLERGIC RHINITIS; QUALITY-OF-LIFE; ST-JOHNS WORT; LEUKOTRIENE-SYNTHESIS; PETASITES-HYBRIDUS; FRENCH VERSION; QUESTIONNAIRE; ASTHMA; TRIAL		Royal Prince Alfred Hosp, Inst Resp Med, Camperdown, NSW 2050, Australia; Univ Sydney, Camperdown, NSW 2050, Australia	University of Sydney; University of Sydney	Reddel, HK (corresponding author), Royal Prince Alfred Hosp, Inst Resp Med, POB M77,Missenden Rd, Camperdown, NSW 2050, Australia.		Reddel, Helen/AAC-3394-2020; Reddel, Helen/ABD-6338-2021; Marks, Guy B./F-5058-2013; Toelle, Brett G/B-1531-2008	Reddel, Helen/0000-0002-6695-6350; Marks, Guy B./0000-0002-8976-8053; Toelle, Brett G/0000-0002-7375-0019				AUSTEN KF, 1981, HARRISONS PRINCIPLES; BERMAN BA, 1988, J ALLERGY CLIN IMMUN, V81, P980, DOI 10.1016/0091-6749(88)90165-0; BICKEL D, 1994, PLANTA MED, V60, P318, DOI 10.1055/s-2006-959492; BOUSQUET J, 1994, J ALLERGY CLIN IMMUN, V94, P182, DOI 10.1016/0091-6749(94)90038-8; Bousquet J, 1996, J ALLERGY CLIN IMMUN, V98, P309, DOI 10.1016/S0091-6749(96)70155-0; *BRIT MED ASS ROYA, 1998, BRIT NAT FORM; BRUNE K, 1993, PLANTA MED, V59, P494, DOI 10.1055/s-2006-959746; CHOWIENCZYK PJ, 1994, BRIT MED J, V309, P1618, DOI 10.1136/bmj.309.6969.1618; GIBSON PG, 1998, COCHRANE LIB; Guy W, 1976, ECDEU ASSESSMENT MAN; KNAPP HR, 1990, NEW ENGL J MED, V323, P1745, DOI 10.1056/NEJM199012203232506; Meier B., 1994, HAGERS HDB PHARMAZEU, P81; Reddel HK, 2000, EUR RESPIR J, V16, P226, DOI 10.1034/j.1399-3003.2000.16b08.x; Reddel HK, 1998, EUR RESPIR J, V12, P853, DOI 10.1183/09031936.98.12040853; Schellenberg R, 2001, BRIT MED J, V322, P134, DOI 10.1136/bmj.322.7279.134; Thomet OAR, 2001, BIOCHEM PHARMACOL, V61, P1041, DOI 10.1016/S0006-2952(01)00552-4; Verschelden P, 1996, EUR RESPIR J, V9, P880, DOI 10.1183/09031936.96.09050880; Wheatley D, 1997, PHARMACOPSYCHIATRY, V30, P77, DOI 10.1055/s-2007-979523; Woelk H, 2000, BMJ-BRIT MED J, V321, P536, DOI 10.1136/bmj.321.7260.536	20	40	57	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	JAN 19	2002	324	7330					146	147		10.1136/bmj.324.7330.146	http://dx.doi.org/10.1136/bmj.324.7330.146			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	514ZH	11799031	Green Published, Bronze			2023-01-03	WOS:000173470600018
J	Eagles, JM				Eagles, JM			SAD - help arrives with the dawn?	LANCET			English	Editorial Material							WINTER DEPRESSION; LIGHT; SIMULATION		Royal Cornhill Hosp, Dept Psychiat, Aberdeen AB25 2ZH, Scotland		Eagles, JM (corresponding author), Royal Cornhill Hosp, Dept Psychiat, Aberdeen AB25 2ZH, Scotland.							Ando K, 1996, BIOL PSYCHIAT, V39, P22, DOI 10.1016/0006-3223(95)00109-3; Avery DH, 2001, BIOL PSYCHIAT, V50, P205, DOI 10.1016/S0006-3223(01)01200-8; Brainard GC, 2001, J NEUROSCI, V21, P6405; Eagles JM, 1999, BRIT J PSYCHIAT, V175, P472, DOI 10.1192/bjp.175.5.472; Lewy AJ, 1998, ARCH GEN PSYCHIAT, V55, P890, DOI 10.1001/archpsyc.55.10.890; LEWY AJ, 1987, SCIENCE, V235, P352, DOI 10.1126/science.3798117; Lingjaerde O, 1998, ACTA PSYCHIAT SCAND, V98, P73, DOI 10.1111/j.1600-0447.1998.tb10045.x; Michalak EE, 2001, BRIT J PSYCHIAT, V179, P31, DOI 10.1192/bjp.179.1.31; TERMAN M, 1989, BIOL PSYCHIAT, V25, P966, DOI 10.1016/0006-3223(89)90276-X; Thompson C., 2001, SEASONAL AFFECTIVE D, P151	10	3	3	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	DEC 22	2001	358	9299					2100	2100		10.1016/S0140-6736(01)07232-4	http://dx.doi.org/10.1016/S0140-6736(01)07232-4			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	505GV	11784620				2023-01-03	WOS:000172905800005
J	Bozzetti, F; Braga, M; Gianotti, L; Gavazzi, C; Mariani, L				Bozzetti, F; Braga, M; Gianotti, L; Gavazzi, C; Mariani, L			Postoperative enteral versus parenteral nutrition in malnourished patients with gastrointestinal cancer: a randomised multicentre trial	LANCET			English	Article							CLINICAL-TRIAL; TOTAL GASTRECTOMY; ELEMENTAL DIET; SURGERY; SUPPORT; RESECTION; MODIFY	Background Although current opinion favours the use of enteral over parenteral nutrition, the clinical benefits of early postoperative nutrition in patients undergoing elective surgery have never been clearly shown. We aimed to test the hypothesis that postoperative enteral nutrition is better (fewer postoperative complications) than parenteral nutrition containing similar energy and nitrogen amounts (112 kJ kg(-1)day(-1) and 1.4 g aminoacid kg(-1)day(-1)). Methods We did a randomised multicentre clinical trial in patients with gastrointestinal cancer who were malnourished and candidates for major elective surgery. 159 patients were assigned to enteral nutrition and 158 to parenteral nutrition. The primary endpoint was the occurrence of postoperative complications, and secondary endpoints were length of postoperative hospital stay, adverse effects, and treatment crossover. Analysis was by intention to treat. Findings Postoperative complications occurred in 54 (34%) patients fed enterally versus 78 (49%) fed parenterally (relative risk 0.69, 95% CI 0.53-0.90, p=0.005). Length of postoperative stay was 13.4 days and 15.0 days in the enteral nutrition and parenteral nutrition groups, respectively (p=0.009). Adverse effects occurred in 56 (35%) patients fed enterally versus 22 (14%) patients fed parenterally (2.50, 1.61-3.86, p<0.0001). 14 (9%) patients on enteral nutrition had to switch to parenteral nutrition, whereas none of those fed parenterally crossed over to enteral feeding. Interpretation We conclude that early enteral nutrition significantly reduces the complication rate and duration of postoperative stay compared with parenteral nutrition, although parenteral nutrition is better tolerated than enteral nutrition.	Italian Soc Parenteral & Enteral Nutr, Milan, Italy; Ist Sci San Raffaele, Milan, Italy; Ist Nazl Studio & Cura Tumori, I-20133 Milan, Italy	Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele; Fondazione IRCCS Istituto Nazionale Tumori Milan	Bozzetti, F (corresponding author), Residenza Querce, Milano Due, I-20090 Milan, Italy.		Mariani, Luigi/C-2580-2017; Gavazzi, Cecilia/E-9345-2017; Mariani, Luigi/AAB-9464-2019	Mariani, Luigi/0000-0001-6208-4084; Gavazzi, Cecilia/0000-0001-5251-0086; 				*ASPEN BOARD DIR, 1995, JPEN J PARENTER ENTE, V19, P1; Baigrie RJ, 1996, AUST NZ J SURG, V66, P668, DOI 10.1111/j.1445-2197.1996.tb00714.x; BeierHolgersen R, 1996, GUT, V39, P833, DOI 10.1136/gut.39.6.833; BOWER RH, 1986, ARCH SURG-CHICAGO, V121, P1040; Bozzetti F, 2000, JPEN-PARENTER ENTER, V24, P7, DOI 10.1177/014860710002400107; BOZZETTI F, 1982, ANN SURG, V196, P170, DOI 10.1097/00000658-198208000-00009; Carr CS, 1996, BRIT MED J, V312, P869, DOI 10.1136/bmj.312.7035.869; FONG YM, 1989, ANN SURG, V210, P449, DOI 10.1097/00000658-198910000-00005; Harrison LE, 1997, JPEN-PARENTER ENTER, V21, P202, DOI 10.1177/0148607197021004202; HEYLEN AM, 1987, CLIN NUTR, V6, P131, DOI 10.1016/0261-5614(87)90046-X; IOVINELLI G, 1993, JPEN-PARENTER ENTER, V17, P445, DOI 10.1177/0148607193017005445; KUDSK KA, 1994, SURGERY, V116, P516; Lipman TO, 1998, JPEN-PARENTER ENTER, V22, P167, DOI 10.1177/0148607198022003167; LOWRY SF, 1990, J TRAUMA, V30, pS10; MOORE FA, 1992, ANN SURG, V216, P172, DOI 10.1097/00000658-199208000-00008; MUGGIASULLAM M, 1985, AM J SURG, V149, P106, DOI 10.1016/S0002-9610(85)80018-0; PETERSON VM, 1988, SURGERY, V104, P199; Reynolds JV, 1997, JPEN-PARENTER ENTER, V21, P196, DOI 10.1177/0148607197021004196; RHOADS JE, 1955, ANN NY ACAD SCI, V63, P268, DOI 10.1111/j.1749-6632.1955.tb32095.x; RYAN JA, 1981, AM SURGEON, V47, P393; SAGAR S, 1979, BMJ-BRIT MED J, V1, P293, DOI 10.1136/bmj.1.6159.293; Salis C., 1998, Rivista Italiana di Nutrizione Parenterale ed Enterale, V16, P14; Sand J, 1997, EUR J SURG, V163, P761; SCHROEDER D, 1991, JPEN-PARENTER ENTER, V15, P376, DOI 10.1177/0148607191015004376; SINPE, 1995, RIV ITAL NUTR PAR S2, V13, pS2; SMITH RC, 1985, BRIT J SURG, V72, P458, DOI 10.1002/bjs.1800720619; Studley HO, 1936, J AMER MED ASSOC, V106, P458, DOI 10.1001/jama.1936.02770060032009; VONMEYENFELDT MF, 1992, CLIN NUTR, V11, P180, DOI 10.1016/0261-5614(92)90026-M; WILLIFORD WO, 1991, NEW ENGL J MED, V325, P525	29	327	363	1	22	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	NOV 3	2001	358	9292					1487	1492		10.1016/S0140-6736(01)06578-3	http://dx.doi.org/10.1016/S0140-6736(01)06578-3			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	490MN	11705560				2023-01-03	WOS:000172055800010
J	Simon, JA; Hunninghake, DB; Agarwal, SK; Lin, F; Cauley, JA; Ireland, CC; Pickar, JH				Simon, JA; Hunninghake, DB; Agarwal, SK; Lin, F; Cauley, JA; Ireland, CC; Pickar, JH		Heart Estrogen Progestin Replaceme	Effect of estrogen plus progestin on risk for biliary tract surgery in postmenopausal women with coronary artery disease - The heart and estrogen/progestin replacement study	ANNALS OF INTERNAL MEDICINE			English	Article							HMG-COA REDUCTASE; GALLBLADDER-DISEASE; GALLSTONE DISEASE; CHOLESTEROL SATURATION; SYMPTOMATIC GALLSTONES; SECONDARY PREVENTION; ORAL-CONTRACEPTIVES; ASCORBIC-ACID; THERAPY; CHOLECYSTECTOMY	Background: Animal and observational epidemiologic studies have reported that estrogens may increase the risk for gallstones. No major clinical trials have examined the effect of estrogen plus progestin therapy in postmenopausal women on the risk for biliary tract surgery. Objective: To determine the effect of estrogen plus progestin on the risk for biliary tract surgery in postmenopausal women with known coronary artery disease. Design: Randomized, double-blind placebo-controlled trial of postmenopausal hormone therapy for coronary heart disease. Setting: 20 U.S. clinical centers. Participants: 2253 postmenopausal women with a gallbladder, 44 to 79 years of age at baseline, in the Heart and Estrogen/progestin Replacement Study (HERS). Intervention: conjugated equine estrogens, 0.625 mg, plus medroxyprogesterone acetate, 2.5 mg, daily in one tablet or identical placebo. Measurements: Documented biliary tract surgery. Results: A total of 147 women (7%) were hospitalized for biliary tract surgery in HERS. Treatment with estrogen plus progestin resulted in a marginally significant 38% increase in the relative risk for biliary tract surgery (P = 0.05). A small absolute difference in risk suggested that for every 185 women treated with estrogen plus progestin, one additional woman had biliary tract surgery per year. After adjustment for baseline and in-study statin use, the association was attenuated further (P = 0.09). After adjustment for treatment assignment and other variables, increased body mass index, fibric acid use, and a history of nonsurgical gallbladder disease were associated with an increased risk for biliary tract surgery, whereas statin use was associated with a decreased risk (for each comparison, P < 0.05). Conclusion: Estrogen plus progestin therapy among postmenopausal women with known coronary disease resulted in a marginally significant increase In the risk for biliary tract surgery.	Vet Affairs Med Ctr, Gen Internal Med Sect 111A1, San Francisco, CA 94121 USA; Univ Calif San Francisco, Sch Med, San Francisco, CA 94143 USA; Cedars Sinai Med Ctr, Burns & Allen Res Inst, Dept Obstet & Gynecol, Los Angeles, CA 90048 USA; Univ Minnesota, Sch Med, Minneapolis, MN 55455 USA; Univ Pittsburgh, Grad Sch Publ Hlth, Dept Epidemiol, Pittsburgh, PA 15261 USA; Wyeth Ayerst Res, Pittsburgh, PA 19101 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); University of California System; University of California San Francisco; Cedars Sinai Medical Center; University of Minnesota System; University of Minnesota Twin Cities; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pfizer	Simon, JA (corresponding author), Vet Affairs Med Ctr, Gen Internal Med Sect 111A1, 4150 Clement St, San Francisco, CA 94121 USA.	jasimon@itsa.ucsf.edu	Cauley, Jane A/N-4836-2015	Cauley, Jane A/0000-0003-0752-4408				Altman DG, 1998, BRIT MED J, V317, P1309, DOI 10.1136/bmj.317.7168.1309; Chapman BA, 1998, DIGEST DIS SCI, V43, P349, DOI 10.1023/A:1018862507469; DIEHL AK, 1991, GASTROENTEROL CLIN N, V20, P1; DUANE WC, 1988, HEPATOLOGY, V8, P1147, DOI 10.1002/hep.1840080531; EVERHART JE, 1993, ANN INTERN MED, V119, P1029, DOI 10.7326/0003-4819-119-10-199311150-00010; EVERSON GT, 1991, J CLIN INVEST, V87, P237, DOI 10.1172/JCI114977; FRICK MH, 1992, NIH CONSENSUS STATE, V10, P1; FRIEDMAN GD, 1966, J CHRON DIS, V19, P273, DOI 10.1016/0021-9681(66)90132-9; Gilloteaux J, 1997, MICROSC RES TECHNIQ, V39, P56, DOI 10.1002/(SICI)1097-0029(19971001)39:1<56::AID-JEMT5>3.0.CO;2-Y; GRODSTEIN F, 1994, OBSTET GYNECOL, V84, P207; GRODSTEIN F, 1994, OBSTET GYNECOL, V83, P5; HENRIKSSON P, 1989, J CLIN INVEST, V84, P811, DOI 10.1172/JCI114240; HONORE LH, 1980, J REPROD MED, V25, P187; HOOGERBRUGGE VD, 1990, GUT, V31, P348; Hulley S, 1999, JAMA-J AM MED ASSOC, V281, P796; Hulley S, 1998, JAMA-J AM MED ASSOC, V280, P605, DOI 10.1001/jama.280.7.605; JOHNSTON DE, 1993, NEW ENGL J MED, V328, P412, DOI 10.1056/NEJM199302113280608; JORGENSEN T, 1988, GUT, V29, P433, DOI 10.1136/gut.29.4.433; KAKAR F, 1988, AM J PUBLIC HEALTH, V78, P564, DOI 10.2105/AJPH.78.5.564; LAVECCHIA C, 1992, J EPIDEMIOL COMMUN H, V46, P234, DOI 10.1136/jech.46.3.234; LIN DY, 1989, J AM STAT ASSOC, V84, P1074, DOI 10.2307/2290085; LOGAN GM, 1990, GASTROENTEROLOGY, V98, P1572, DOI 10.1016/0016-5085(90)91092-K; MACLURE KM, 1989, NEW ENGL J MED, V321, P563, DOI 10.1056/NEJM198908313210902; MESSA C, 1990, DIGESTION, V46, P214, DOI 10.1159/000200348; MILLER VT, 1995, JAMA-J AM MED ASSOC, V273, P199, DOI 10.1001/jama.1995.03520270033028; NACHTIGALL LE, 1979, OBSTET GYNECOL, V54, P74, DOI 10.1097/00006250-197907000-00017; OCONNELL MB, 1995, J CLIN PHARMACOL, V35, pS18, DOI 10.1002/j.1552-4604.1995.tb04143.x; PAUMGARTNER G, 1991, LANCET, V338, P1117, DOI 10.1016/0140-6736(91)91972-W; PETITTI DB, 1988, GASTROENTEROLOGY, V94, P91, DOI 10.1016/0016-5085(88)90614-2; PETITTI DB, 1981, NEW ENGL J MED, V304, P1396, DOI 10.1056/NEJM198106043042305; *SAS I INC, 1997, SAS; Simon JA, 1998, J CLIN EPIDEMIOL, V51, P257, DOI 10.1016/S0895-4356(97)80280-6; Simon JA, 2000, ARCH INTERN MED, V160, P931, DOI 10.1001/archinte.160.7.931; THORNTON J, 1983, LANCET, V2, P819; Uhler ML, 2000, MENOPAUSE, V7, P162, DOI 10.1097/00042192-200007030-00006; VANERPECUM KJ, 1991, GASTROENTEROLOGY, V100, P482, DOI 10.1016/0016-5085(91)90220-F; 1977, N ENGL J MED, V296, P1185; 1974, N ENGL J MED, V290, P15; 1999, STATA STAT SOFTWARE	39	71	72	0	3	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	OCT 2	2001	135	7					493	501		10.7326/0003-4819-135-7-200110020-00008	http://dx.doi.org/10.7326/0003-4819-135-7-200110020-00008			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	477EF	11578152				2023-01-03	WOS:000171269600003
J	White, A; Hayhoe, S; Hart, A; Ernst, E				White, A; Hayhoe, S; Hart, A; Ernst, E			Adverse events following acupuncture: prospective survey of 32 000 consultations with doctors and physiotherapists	BRITISH MEDICAL JOURNAL			English	Article									Univ Exeter, Sch Postgrad Med & Hlth Sci, Dept Complementary Med, Exeter EX2 4NT, Devon, England; Colchester Dist Gen Hosp, Pain Clin, Colchester CO4 5JL, Essex, England; Univ Cent Lancashire, Fac Sci, Preston PR1 2HE, Lancs, England	University of Exeter; University of Central Lancashire	White, A (corresponding author), Univ Exeter, Sch Postgrad Med & Hlth Sci, Dept Complementary Med, Exeter EX2 4NT, Devon, England.							*BRIT MED ASS ETH, 1993, MED ETH TOD ITS PRAC; Edwards IR, 2000, LANCET, V356, P1255, DOI 10.1016/S0140-6736(00)02799-9; Ernst E, 1997, PAIN, V71, P123, DOI 10.1016/S0304-3959(97)03368-X; EYPASCH E, 1995, BRIT MED J, V311, P619, DOI 10.1136/bmj.311.7005.619; White A, 1997, ACUPUNCT MED, V15, P67	5	237	245	2	13	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	SEP 1	2001	323	7311					485	486		10.1136/bmj.323.7311.485	http://dx.doi.org/10.1136/bmj.323.7311.485			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	469WF	11532840	Bronze, Green Published			2023-01-03	WOS:000170838500017
J	MacArthur, C; Shennan, AH; May, A; Whyte, J; Hickman, N; Cooper, G; Bick, D; Crewe, L; Garston, H; Gold, L; Lancashire, R; Lewis, M; Moore, P; Wilson, M; Bharmal, S; Elton, C; Halligan, A; Hussain, W; Patterson, M; Squire, P; de Swiet, M				MacArthur, C; Shennan, AH; May, A; Whyte, J; Hickman, N; Cooper, G; Bick, D; Crewe, L; Garston, H; Gold, L; Lancashire, R; Lewis, M; Moore, P; Wilson, M; Bharmal, S; Elton, C; Halligan, A; Hussain, W; Patterson, M; Squire, P; de Swiet, M		Comparative Obstet Mobile Epidural	Effect of low-dose mobile versus traditional epidural techniques on mode of delivery: a randomised controlled trial	LANCET			English	Article							LABOR; ANALGESIA; BUPIVACAINE; FENTANYL	Background Epidural analgesia is the most effective labour pain relief but is associated with increased rates of instrumental vaginal delivery and other effects, which might be related to the poor motor function associated with traditional epidural. New techniques that preserve motor function could reduce obstetric intervention. We did a randomised controlled trial to compare low-dose combined spinal epidural and low-dose infusion [mobile) techniques with traditional epidural technique. Methods Between Feb 1, 1999, and April 30, 2000, we randomly assigned 1054 nulliparous women requesting epidural pain relief to traditional (n=353), low-dose combined spinal epidural (n=351), or low-dose infusion epidural (n=350). Primary outcome was mode of delivery, and secondary outcomes were progress of labour, efficacy of procedure, and effect on neonates. We obtained data during labour and interviewed women postnatally. Findings The normal vaginal delivery rate was 35.1% in the traditional epidural group, 42.7% in the low-dose combined spinal group (odds ratio 1.38 [95% CI 1.01-1.89]; p=0.04); and 42.9% in the low-dose infusion group (1.39 [1.01-1.90]; p=0.04). These differences were accounted for by a reduction in instrumental vaginal delivery. Overall, 5 min APGAR scores of 7 or less were more frequent with low-dose technique. High-level resuscitation was more frequent in the low-dose infusion group. Interpretation The use of low-dose epidural techniques for labour analgesia has benefits for delivery outcome. Continued routine use of traditional epidurals might not be justified.	Univ Birmingham, Dept Epidemiol & Publ Hlth, Birmingham B15 2TT, W Midlands, England; Univ Birmingham, Dept Anaesthet, Birmingham B15 2TT, W Midlands, England; Univ Leicester, Dept Anaesthet, Leicester LE1 7RH, Leics, England; Univ Leicester, Dept Obstet, Leicester LE1 7RH, Leics, England; Univ Leicester, Dept Gynaecol, Leicester LE1 7RH, Leics, England	University of Birmingham; University of Birmingham; University of Leicester; University of Leicester; University of Leicester	Shennan, AH (corresponding author), St Thomas Hosp, Univ London Kings Coll, Guys Kings & St Thomas Sch Med, Maternal & Fetal Res Unit, London SE1 7EH, England.		Bick, Debra/P-9575-2018; MacArthur, Christine/ABA-8601-2021	Bick, Debra/0000-0002-8557-7276; MacArthur, Christine/0000-0003-0434-2158; Wilson, Matthew/0000-0002-9704-5189				Bloom SL, 1998, NEW ENGL J MED, V339, P76, DOI 10.1056/NEJM199807093390203; BREEN TW, 1993, ANESTH ANALG, V77, P919; Burnstein R, 1999, ANAESTHESIA, V54, P634, DOI 10.1046/j.1365-2044.1999.00894.x; COLLIS RE, 1995, LANCET, V345, P1413, DOI 10.1016/S0140-6736(95)92602-X; Fernando R, 1997, ANAESTHESIA, V52, P517, DOI 10.1111/j.1365-2044.1997.154-az0160.x; HOWELL CJ, COCHRANE LIB; Khor LJH, 2000, ANAESTHESIA, V55, P1168, DOI 10.1046/j.1365-2044.2000.01720.x; MURPHY JD, 1991, BRIT MED J, V302, P564, DOI 10.1136/bmj.302.6776.564; Nageotte MP, 1997, NEW ENGL J MED, V337, P1715, DOI 10.1056/NEJM199712113372402; Russell R, 1999, INT J OBSTET ANESTH, V8, P56, DOI 10.1016/S0959-289X(99)80153-8	10	210	217	0	5	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUL 7	2001	358	9275					19	23						5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	449WV	11454372				2023-01-03	WOS:000169710900011
J	Bennett, JJ; Tjuvajev, J; Johnson, P; Doubrovin, M; Akhurst, T; Malholtra, S; Hackman, T; Balatoni, J; Finn, R; Larson, SM; Federoff, H; Blasberg, R; Fong, YM				Bennett, JJ; Tjuvajev, J; Johnson, P; Doubrovin, M; Akhurst, T; Malholtra, S; Hackman, T; Balatoni, J; Finn, R; Larson, SM; Federoff, H; Blasberg, R; Fong, YM			Positron emission tomography imaging for herpes virus infection: Implications for oncolytic viral treatments of cancer	NATURE MEDICINE			English	Article							KINASE GENE-TRANSFER; REPLICATION-COMPETENT; CHEMOTHERAPEUTIC-AGENTS; LIVER METASTASES; MALIGNANT GLIOMA; COLON-CARCINOMA; PHASE-I; THERAPY; EXPRESSION; TYPE-1	Molecular therapy using viruses would benefit greatly from a non-invasive modality for assessing dissemination of viruses. Here we investigated whether positron emission tomography (PET) scanning using [I-124]-5-iodo-2'-fluoro-1-beta -D-arabinofuranosyl-uracil (FIAU) could image cells infected with herpes simplex viruses (HSV). Using replication-competent HSV-1 oncolytic viruses with thymidine kinase (TK) under control of different promoters, we demonstrate that viral infection, proliferation and promoter characteristics all interact to influence FIAU accumulation and imaging. In vivo, as few as 1 x 10(7) viral particles injected into a 0.5-cm human colorectal tumor can be detected by [I-124]FIAU PET imaging. PET signal intensity is significantly greater at 48 hours compared with that at 8 hours after viral injection, demonstrating that PET scanning can detect changes in TK activity resulting from local viral proliferation. We also show the ability of FIAU-PET scanning to detect differences in viral infectivity at 0.5 log increments. Non-invasive imaging might be useful in assessing biologically relevant distribution of virus in therapies using replication-competent HSV.	Mem Sloan Kettering Canc Ctr, Dept Surg, New York, NY 10021 USA; Mem Sloan Kettering Canc Ctr, Dept Neurol, New York, NY 10021 USA; Mem Sloan Kettering Canc Ctr, Dept Radiol & Med Phys, New York, NY 10021 USA; Mem Sloan Kettering Canc Ctr, Radiochem Cyclotron Core Facil, New York, NY 10021 USA; Neurovir, Vancouver, BC, Canada; Univ Rochester, Ctr Aging & Dev Biol, Rochester, NY USA	Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; University of Rochester	Fong, YM (corresponding author), Mem Sloan Kettering Canc Ctr, Dept Surg, 1275 York Ave, New York, NY 10021 USA.	fongy@mskcc.org	Doubrovin, Mikhail/C-5859-2017	Doubrovin, Mikhail/0000-0001-6607-2646	NCI NIH HHS [R24 CA83084, R01 CA72632, P50 CA86438, R01 CA61524, R01 CA69769, R01 CA75416] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA061524, R01CA072632, R24CA083084, P50CA086438, R01CA075416, R01CA069769] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Advani SJ, 1999, CANCER RES, V59, P2055; Alauddin MM, 1996, NUCL MED BIOL, V23, P787, DOI 10.1016/0969-8051(96)00075-3; Balatoni J. A., 1997, Journal of Labelled Compounds and Radiopharmaceuticals, V40, P103; Bennett JJ, 2000, J MOL MED-JMM, V78, P166, DOI 10.1007/s001090000092; Carew JF, 1999, HUM GENE THER, V10, P1599, DOI 10.1089/10430349950017608; CARUSO M, 1993, P NATL ACAD SCI USA, V90, P7024, DOI 10.1073/pnas.90.15.7024; DELUCA NA, 1988, J VIROL, V62, P732, DOI 10.1128/JVI.62.3.732-743.1988; Gambhir SS, 1999, P NATL ACAD SCI USA, V96, P2333, DOI 10.1073/pnas.96.5.2333; Heise C, 1997, NAT MED, V3, P639, DOI 10.1038/nm0697-639; JOLLY D, 1994, CANCER GENE THER, V1, P51; Karpoff HM, 1997, J CLIN INVEST, V99, P799, DOI 10.1172/JCI119226; KOOBY DA, 1999, FASEB J, V6, P499; LORENCE RM, 1994, CANCER RES, V54, P6017; Markert JM, 2000, GENE THER, V7, P867, DOI 10.1038/sj.gt.3301205; MCGEOCH DJ, 1985, J MOL BIOL, V181, P1, DOI 10.1016/0022-2836(85)90320-1; MEIGNIER B, 1988, J INFECT DIS, V158, P602, DOI 10.1093/infdis/158.3.602; MINETA T, 1995, NAT MED, V1, P938, DOI 10.1038/nm0995-938; ORKIN SH, 1997, REPORT RECOMMENDATIO, P135; Rampling R, 2000, GENE THER, V7, P859, DOI 10.1038/sj.gt.3301184; TJUVAJEV JG, 1995, CANCER RES, V55, P6126; Tjuvajev JG, 1998, CANCER RES, V58, P4333; Tjuvajev JG, 1999, CANCER RES, V59, P5186; Tjuvajev JG, 1996, CANCER RES, V56, P4087; Tjuvajev Juri G., 1999, Neoplasia (New York), V1, P315, DOI 10.1038/sj.neo.7900053; Topf N, 1998, GENE THER, V5, P507, DOI 10.1038/sj.gt.3300611; Toyoizumi T, 1999, HUM GENE THER, V10, P3013, DOI 10.1089/10430349950016410; YAZAKI T, 1995, CANCER RES, V55, P4752; Yoon SS, 2000, FASEB J, V14, P301, DOI 10.1096/fasebj.14.2.301; Zuckerman JB, 1999, HUM GENE THER, V10, P2973, DOI 10.1089/10430349950016384	29	87	99	0	6	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	JUL	2001	7	7					859	863		10.1038/89991	http://dx.doi.org/10.1038/89991			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	451NR	11433353				2023-01-03	WOS:000169808600040
J	Pimm, SL; van Aarde, RJ				Pimm, SL; van Aarde, RJ			Population control - African elephants and contraception	NATURE			English	Article									Columbia Univ, Ctr Environm Res & Conservat, New York, NY 10027 USA; Univ Pretoria, Conservat Ecol Res Unit, ZA-0002 Pretoria, South Africa	Columbia University; University of Pretoria	Pimm, SL (corresponding author), Columbia Univ, Ctr Environm Res & Conservat, 1200 Amsterdam Ave, New York, NY 10027 USA.							Fayrer-Hosken RA, 2000, NATURE, V407, P149, DOI 10.1038/35025136; van Aarde R, 1999, ANIM CONSERV, V2, P287, DOI 10.1017/S1367943099000621; Whyte I, 1998, ANIM CONSERV, V1, P77, DOI 10.1111/j.1469-1795.1998.tb00014.x	3	17	18	0	19	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUN 14	2001	411	6839					766	766		10.1038/35081154	http://dx.doi.org/10.1038/35081154			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	441TV	11459047	Bronze			2023-01-03	WOS:000169246400037
J	Dubois, M; Deme, B; Gulik-Krzywicki, T; Dedieu, JC; Vautrin, C; Desert, S; Perez, E; Zemb, T				Dubois, M; Deme, B; Gulik-Krzywicki, T; Dedieu, JC; Vautrin, C; Desert, S; Perez, E; Zemb, T			Self-assembly of regular hollow icosahedra in salt-free catanionic solutions	NATURE			English	Article							VESICLES	Self-assembled structures having a regular hollow icosahedral form (such as those observed for proteins of virus capsids) can occur as a result of biomineralization processes(1), but are extremely rare in mineral crystallites(2). Compact icosahedra made from a boron oxide have been reported(3), but equivalent structures made of synthetic organic components such as surfactants have not hitherto been observed. It is, however, well known that lipids, as well as mixtures of anionic and cationic single chain surfactants, can readily form bilayers(4,5) that can adopt a variety of distinct geometric forms: they can fold into soft vesicles or random bilayers (the so-called sponge phase) or form ordered stacks of flat or undulating membranes(6). Here we show that in salt-free mixtures of anionic and cationic surfactants, such bilayers can self-assemble into hollow aggregates with a regular icosahedral shape. These aggregates are stabilized by the presence of pores located at the vertices of the icosahedra. The resulting structures have a size of about one micrometre and mass of about 10(10) daltons, making them larger than any known icosahedral protein assembly(7) or virus capsid(8). We expect the combination of wall rigidity and holes at vertices of these icosahedral aggregates to be of practical value for controlled drug or DNA release.	CEA Saclay, Serv Chim Mol, F-91191 Gif Sur Yvette, France; Inst Max Von Laue Paul Langevin, F-38042 Grenoble 09, France; CNRS, Ctr Genet Mol, F-91198 Gif Sur Yvette, France; IMRCP, CNRS, URA 470, F-31062 Toulouse, France	CEA; UDICE-French Research Universities; Universite Paris Saclay; Institut Laue-Langevin (ILL); Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay; Centre National de la Recherche Scientifique (CNRS)	Dubois, M (corresponding author), CEA Saclay, Serv Chim Mol, F-91191 Gif Sur Yvette, France.	duboism@scm.saclay.cea.fr	ZEMB, Thomas N/E-5958-2010; Demé, Bruno/AAG-1620-2021	Demé, Bruno/0000-0002-9523-7662				CRICK FHC, 1956, NATURE, V177, P473, DOI 10.1038/177473a0; Donath E, 1998, ANGEW CHEM INT EDIT, V37, P2202, DOI 10.1002/(SICI)1521-3773(19980904)37:16<2201::AID-ANIE2201>3.0.CO;2-E; Dubois M, 2000, PROG COLL POL SCI S, V115, P238; Dubois M, 1998, CR ACAD SCI II C, V1, P567, DOI 10.1016/S1387-1609(98)80012-1; Dubois M, 2000, CURR OPIN COLLOID IN, V5, P27, DOI 10.1016/S1359-0294(00)00032-7; Fogden A, 1997, J PHYS II, V7, P229, DOI 10.1051/jp2:1997121; Fogden A, 1997, COLLOID SURFACE A, V129, P157, DOI 10.1016/S0927-7757(97)00034-4; GRACIAA A, 1989, J PHYS CHEM-US, V93, P4167, DOI 10.1021/j100347a055; Hubert H, 1998, NATURE, V391, P376, DOI 10.1038/34885; Hyde ST, 1997, COLLOID SURFACE A, V129, P207, DOI 10.1016/S0927-7757(97)00038-1; KALER EW, 1989, SCIENCE, V245, P1371, DOI 10.1126/science.2781283; KIMOTO K, 1966, J APPL PHYS, V16, P941; KLUG A, 1959, BIOCHIM BIOPHYS ACTA, V32, P203, DOI 10.1016/0006-3002(59)90570-0; KLUG A., 1960, ADVANCES IN VIRUS RES, V7, P225; NELSON DR, 1989, SOLID STATE PHYS, V42, P1; PARENTE RA, 1985, BIOCHIM BIOPHYS ACTA, V812, P493, DOI 10.1016/0005-2736(85)90324-4; Radtchenko IL, 2000, J COLLOID INTERF SCI, V230, P272, DOI 10.1006/jcis.2000.7068; Regev O, 1999, LANGMUIR, V15, P642, DOI 10.1021/la9803474; SACKMANN E, 1995, HDB BIOL PHYSICS B, V1; SCAMEHORN JF, 1989, SURFACTANT SCI SERIE, V33, pCH10; SCHNUR JM, 1993, SCIENCE, V262, P1669, DOI 10.1126/science.262.5140.1669; Spector MS, 1996, LANGMUIR, V12, P4704, DOI 10.1021/la960218s; THOMAS BN, 1995, SCIENCE, V267, P1635, DOI 10.1126/science.267.5204.1635; Thompson D.W., 1961, GROWTH FORM; WALS J, 1997, MOL CELL, V1, P59; Zemb T, 1999, SCIENCE, V283, P816, DOI 10.1126/science.283.5403.816	26	302	311	4	119	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUN	2001	411	6838					672	675		10.1038/35079541	http://dx.doi.org/10.1038/35079541			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	439JC	11395764				2023-01-03	WOS:000169112500038
J	Brattebo, G; Hofoss, D; Flaatten, H; Muri, AK; Gjerde, S; Plsek, PE				Brattebo, G; Hofoss, D; Flaatten, H; Muri, AK; Gjerde, S; Plsek, PE			Quality improvement report - Effect of a scoring system and protocol for sedation on duration of patients' need for ventilator support in a surgical intensive care unit	BMJ-BRITISH MEDICAL JOURNAL			English	Article								Problem Need for improved sedation strategy for adults receiving ventilator support. Design Observational study of effect of introduction of guidelines to improve the doctors' and nurses' Performance. The project was a prospective improvement and was part of a national quality improvement collaborative. Background and setting A general mixed surgical. intensive care unit in a university hospital; all doctors and nurses in the unit; all adult patients (> 18 years) treated by intermittent positive pressure ventilation for more than 24 hours. Key measures for improvement Reduction in patients' mean time on a ventilator and length of stay in intensive care over a period of 11 months; anonymous reporting of critical incidents; staff perceptions of ease and of consequences of changes. Strategies for change Multiple measures (protocol development, educational presentations, written guidelines, posters, flyers, emails, personal discussions, and continuous feedback) were tested, rapidly assessed, and adopted if beneficial. Effects of change Mean ventilator time decreased by 9.1 days (95% confidence interval 0.7 to 3.6 days) from 7.4 days before intervention to 5.3 days after. Mean stay decreased by 1.0 day (-0.9 to 2.9 days) from 9.3 days to 8.3 days. No accidental extubations or other incidents were identified. Lessons learnt Relatively simple changes in sedation practice had significant effects on length of ventilator support. The change process was well received by e staff and increased their interest in identifying other areas for improvement,	Haukeland Hosp, Dept Anaesthesia & Intens Care, N-5021 Bergen, Norway; HELTEF, Fdn Hlth Serv Res, N-1474 Nordbyhagen, Norway; Paul E Plsek & Associates, Roswell, GA 30075 USA	University of Bergen; Haukeland University Hospital	Brattebo, G (corresponding author), Haukeland Hosp, Dept Anaesthesia & Intens Care, N-5021 Bergen, Norway.	gbra@haukeland.no	Flaatten, Hans/AAG-7030-2020	Flaatten, Hans/0000-0001-9186-3482; Brattebo, Guttorm/0000-0002-7124-5641				BARR J, 1995, CRIT CARE CLIN, V11, P827, DOI 10.1016/S0749-0704(18)30041-1; Brock WA, 1998, NEW HORIZ-SCI PRACT, V6, P61; Brook AD, 1999, CRIT CARE MED, V27, P2609, DOI 10.1097/00003246-199912000-00001; Carey RG, 1995, MEASURING QUALITY IM; Clemmer TP, 1999, CRIT CARE MED, V27, P1768, DOI 10.1097/00003246-199909000-00011; Devlin JW, 1999, CRIT CARE MED, V27, P1271, DOI 10.1097/00003246-199907000-00008; Flaatten Hans, 1997, Acta Anaesthesiologica Scandinavica, V41, P193; Flaatten Hans, 1997, Acta Anaesthesiologica Scandinavica, V41, P175; Kollef MH, 1998, NEW HORIZ-SCI PRACT, V6, P52; Kollef MH, 1998, CHEST, V114, P541, DOI 10.1378/chest.114.2.541; Kress JP, 2000, NEW ENGL J MED, V342, P1471, DOI 10.1056/NEJM200005183422002; LEGALL JR, 1993, JAMA-J AM MED ASSOC, V270, P2957, DOI 10.1001/jama.270.24.2957; Marx WH, 1999, J TRAUMA, V46, P625, DOI 10.1097/00005373-199904000-00011; Plsek P E, 1999, Pediatrics, V103, P203; RAINEY TG, 1998, BREAKTHROUGH SERIES	15	144	152	1	10	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUN 8	2002	324	7350					1386	1389		10.1136/bmj.324.7350.1386	http://dx.doi.org/10.1136/bmj.324.7350.1386			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	563BQ	12052813	Green Published			2023-01-03	WOS:000176234100028
J	D'Acremont, V; Landry, P; Darioli, R; Stuerchler, D; Pecoud, A; Genton, B				D'Acremont, V; Landry, P; Darioli, R; Stuerchler, D; Pecoud, A; Genton, B			Treatment of imported malaria in an ambulatory setting: prospective study	BRITISH MEDICAL JOURNAL			English	Article									Policlin Med Univ, CH-1005 Lausanne, Switzerland; Swiss Fed Off Publ Hlth, Bern, Switzerland		Genton, B (corresponding author), Policlin Med Univ, CH-1005 Lausanne, Switzerland.			Whitty, Christopher/0000-0002-6076-5027				Evans MRW, 2000, HOSP MED, V61, P162, DOI 10.12968/hosp.2000.61.3.1308; GENTON B, 2001, TRAVELERS MALARIA, P371; HATZ C, 2001, TRAVELERS MALARIA, P431; Kain KC, 1998, CLIN INFECT DIS, V27, P142, DOI 10.1086/514616	4	37	37	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	APR 13	2002	324	7342					875	876		10.1136/bmj.324.7342.875	http://dx.doi.org/10.1136/bmj.324.7342.875			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	542PA	11950734	Green Published, Bronze			2023-01-03	WOS:000175052200018
J	Shinefield, H; Black, S; Fattom, A; Horwith, G; Rasgon, S; Ordonez, J; Yeoh, H; Law, D; Robbins, JB; Schneerson, R; Muenz, L; Naso, R				Shinefield, H; Black, S; Fattom, A; Horwith, G; Rasgon, S; Ordonez, J; Yeoh, H; Law, D; Robbins, JB; Schneerson, R; Muenz, L; Naso, R			Use of a Staphylococcus aureus conjugate vaccine in patients receiving hemodialysis.	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							RECOMBINANT EXOPROTEIN-A; CAPSULAR POLYSACCHARIDES; ANTIBODIES; INFECTIONS; IMMUNOGENICITY; BACTEREMIA; TYPE-5; MICE	Background: In patients with decreased resistance to infection, Staphylococcus aureus is a major cause of bacteremia and its complications. The capsular polysaccharides are essential for the pathogenesis of and immunity to S. aureus infection and are targets for vaccines. Methods: In a double-blind trial involving patients with end-stage renal disease who were receiving hemodialysis, we evaluated the safety, immunogenicity, and efficacy of a vaccine with S. aureus type 5 and 8 capsular polysaccharides conjugated to nontoxic recombinant Pseudomonas aeruginosa exotoxin A. Between April 1998 and August 1999, 1804 adult patients at 73 hemodialysis centers were randomly assigned to receive a single intramuscular injection of either vaccine or saline. IgG antibodies to S. aureus type 5 and 8 capsular polysaccharides were measured for up to two years, and episodes of S. aureus bacteremia were recorded. Efficacy was estimated by comparing the incidence of S. aureus bacteremia in the patients who received the vaccine with the incidence in the control patients. Results: Reactions to the vaccine were generally mild to moderate, and most resolved within two days. The capsular polysaccharides elicited an antibody response of at least 80 microg per milliliter (the estimated minimal level conferring protection) in 80 percent of patients for type 5 and in 75 percent of patients for type 8. The efficacy during weeks 3 to 54 was only 26 percent (P=0.23). However, between weeks 3 and 40 after vaccination, S. aureus bacteremia developed in 11 of 892 patients in the vaccine group who could be evaluated for bacteremia, as compared with 26 of 906 patients in the control group (estimate of efficacy, 57 percent; 95 percent confidence interval, 10 to 81 percent; nominal P=0.02). Conclusions: In patients receiving hemodialysis, a conjugate vaccine can confer partial immunity against S. aureus bacteremia for approximately 40 weeks, after which protection wanes as antibody levels decrease. (N Engl J Med 2002;346:491-6.) Copyright (C) 2002 Massachusetts Medical Society.	Kaiser Permanente Vaccine Study Ctr, Oakland, CA 94612 USA; Nabi, Rockville, MD USA; So Calif Kaiser Permanente, Los Angeles, CA USA; NICHHD, Bethesda, MD 20892 USA; Larry Muenz & Associates, Rockville, MD USA; Total Renal Res, Minneapolis, MN USA	Kaiser Permanente; Kaiser Permanente; National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)	Shinefield, H (corresponding author), Kaiser Permanente Vaccine Study Ctr, 1 Kaiser Plaza,16th Fl, Oakland, CA 94612 USA.							ARBEIT RD, 1984, DIAGN MICR INFEC DIS, V2, P85, DOI 10.1016/0732-8893(84)90002-6; Archer GL, 2001, NEW ENGL J MED, V344, P55, DOI 10.1056/NEJM200101043440110; Bloembergen W E, 1996, Adv Ren Replace Ther, V3, P201; BRESLOW NE, 1987, IARC SCI PUBLICATION, V82; CHOU MY, 1989, J FORMOS MED ASSOC, V88, P352; *CYT, 1998, SOFTW MAN STATX 4; Essawi T, 1998, TROP MED INT HEALTH, V3, P576, DOI 10.1046/j.1365-3156.1998.00265.x; FATTOM A, 1990, INFECT IMMUN, V58, P2367, DOI 10.1128/IAI.58.7.2367-2374.1990; FATTOM A, 1992, INFECT IMMUN, V60, P584, DOI 10.1128/IAI.60.2.584-589.1992; Fattom A, 1999, AM J VET RES, V60, P530; FATTOM A, 1993, INFECT IMMUN, V61, P1023, DOI 10.1128/IAI.61.3.1023-1032.1993; Fattom AI, 1996, INFECT IMMUN, V64, P1659, DOI 10.1128/IAI.64.5.1659-1665.1996; Goetz A, 1999, INFECT CONT HOSP EP, V20, P689, DOI 10.1086/501567; HOEN B, 1996, 36 INT C ANT AG CHEM, P233; KARAKAWA WW, 1985, J CLIN MICROBIOL, V22, P445, DOI 10.1128/JCM.22.3.445-447.1985; KARAKAWA WW, 1988, INFECT IMMUN, V56, P1090, DOI 10.1128/IAI.56.5.1090-1095.1988; Karakawa WW., 1982, SEMIN INFECT DIS, V4, P285; KESSLER M, 1993, NEPHRON, V64, P95, DOI 10.1159/000187285; LANDESMAN SH, 1981, REV INFECT DIS, V3, pS184; Lowy FD, 1998, NEW ENGL J MED, V339, P520, DOI 10.1056/NEJM199808203390806; Na'was T, 1998, J CLIN MICROBIOL, V36, P414; QUARLES LD, 1985, AM J KIDNEY DIS, V6, P412, DOI 10.1016/S0272-6386(85)80104-9; Richards MJ, 1999, CRIT CARE MED, V27, P887, DOI 10.1097/00003246-199905000-00020; ROBBINS JB, 1973, PEDIATR RES, V7, P103, DOI 10.1203/00006450-197303000-00001; ROBBINS JB, 1995, ANN NY ACAD SCI, V754, P68, DOI 10.1111/j.1749-6632.1995.tb44439.x; ROUBICEK C, 1995, NEPHROLOGIE, V16, P229; Rubin RJ, 1999, EMERG INFECT DIS, V5, P9, DOI 10.3201/eid0501.990102; Smith TL, 1999, NEW ENGL J MED, V340, P493, DOI 10.1056/NEJM199902183400701; Welch PG, 1996, J AM SOC NEPHROL, V7, P247	29	351	387	0	17	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	FEB 14	2002	346	7					491	496		10.1056/NEJMoa011297	http://dx.doi.org/10.1056/NEJMoa011297			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	521AE	11844850				2023-01-03	WOS:000173815300005
J	Steinbrook, R				Steinbrook, R			Physician-assisted suicide in Oregon - An uncertain future	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material																		Angell M, 1999, NEW ENGL J MED, V341, P1923, DOI 10.1056/NEJM199912163412509; ASHCROFT J, 2001, COMMUNICATION   1106; BRADSHAW S, 2001, COMMUNICATION   0627; Burt RA, 1997, NEW ENGL J MED, V337, P1234, DOI 10.1056/NEJM199710233371712; Chin AE, 1999, NEW ENGL J MED, V340, P577, DOI 10.1056/NEJM199902183400724; CHRISTIE T, 2000, KNIGHTRIDDER TR 1218; Douglas CD, 2001, MED J AUSTRALIA, V175, P511, DOI 10.5694/j.1326-5377.2001.tb143704.x; *DRUG ENF ADM, 1991, AUT REP CONS ORD SYS; EGAN T, 1997, NY TIMES        1119, pA16; Ganzini L, 2000, NEW ENGL J MED, V342, P1538; Ganzini L, 2000, NEW ENGL J MED, V342, P557, DOI 10.1056/NEJM200002243420806; Ganzini L, 2001, JAMA-J AM MED ASSOC, V285, P2363, DOI 10.1001/jama.285.18.2363; GROOPMAN J, 2001, NY TIMES        1109, pA27; Hedberg K, 2002, NEW ENGL J MED, V346, P450, DOI 10.1056/NEJM200202073460614; Meier DE, 1998, NEW ENGL J MED, V338, P1193, DOI 10.1056/NEJM199804233381706; *NHPCO, 2001, STATS RES RES NHPCO; Sullivan AD, 2000, NEW ENGL J MED, V342, P598, DOI 10.1056/NEJM200002243420822; Sullivan AD, 2001, NEW ENGL J MED, V344, P605, DOI 10.1056/NEJM200102223440811; 2001, OREGONIAN       1107	19	19	19	0	0	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	FEB 7	2002	346	6					460	464		10.1056/NEJM200202073460624	http://dx.doi.org/10.1056/NEJM200202073460624			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	518UN	11832544				2023-01-03	WOS:000173686400029
J	Parker, RA				Parker, RA			Caring for patients at the end of life: Reflections after 12 years of practice	ANNALS OF INTERNAL MEDICINE			English	Editorial Material								Physicians have the privilege and authority to assist patients and their families at the end of life. Regardless of diagnosis, commonalities occur in the dying process, and palliative care benefits patients and families. This perspective chronicles my experience over 12 years caring for 95 patients at the end of life, illustrated in part with six vignettes. I describe interactions with families, discuss logistic issues around dying, examine the do-not-resuscitate issue, and highlight experiences with home visits. I also touch on how I communicate with the family after a death. I hope to express the significance of what I have learned while assisting patients and families at this critical juncture.	Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Healthcare Associates, Boston, MA 02215 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School	Parker, RA (corresponding author), Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Healthcare Associates, 1 Autumn St, Boston, MA 02215 USA.	raparker@caregroup.harvard.edu							0	4	4	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JAN 1	2002	136	1					72	75		10.7326/0003-4819-136-1-200201010-00012	http://dx.doi.org/10.7326/0003-4819-136-1-200201010-00012			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	510BF	11777365				2023-01-03	WOS:000173188300007
J	McPhee, S; Markowitz, AJ				McPhee, S; Markowitz, AJ			Psychological considerations, growth, and transcendence at the end of life - The art of the possible	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material														Markowitz, Amy/0000-0001-9314-2814				Block SD, 2001, JAMA-J AM MED ASSOC, V285, P2898, DOI 10.1001/jama.285.22.2898; Hall D, 1998, WITHOUT POEMS; Kenyon Jane, 1996, OTHERWISE NEW SELECT; Nouwen H. J. M., 1994, OUR GREATEST GIFT ME	4	3	3	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 19	2001	286	23					3002	3002		10.1001/jama.286.23.3002	http://dx.doi.org/10.1001/jama.286.23.3002			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	502VY	11743842				2023-01-03	WOS:000172764500033
J	McDevitt, MR; Ma, DS; Lai, LT; Simon, J; Borchardt, P; Frank, RK; Wu, K; Pellegrini, V; Curcio, MJ; Miederer, M; Bander, NH; Scheinberg, DA				McDevitt, MR; Ma, DS; Lai, LT; Simon, J; Borchardt, P; Frank, RK; Wu, K; Pellegrini, V; Curcio, MJ; Miederer, M; Bander, NH; Scheinberg, DA			Tumor therapy with targeted atomic nanogenerators	SCIENCE			English	Article							IN-VITRO; RADIOIMMUNOTHERAPY; ANTIBODY; AC-225; CONSTRUCTS; GROWTH; MICE	A single, high linear energy transfer alpha particle can kill a target cell. We have developed methods to target molecular-sized generators of alpha-emitting isotope cascades to the inside of cancer cells using actinium-225 coupled to internalizing monoclonal antibodies. In vitro, these constructs specifically killed leukemia, lymphoma, breast, ovarian, neuroblastoma, and prostate cancer cells at becquerel (picocurie) levels. Injection of single doses of the constructs at kilobecquerel (nanocurie) levels into mice bearing solid prostate carcinoma or disseminated human lymphoma induced tumor regression and prolonged survival, without toxicity, in a substantial fraction of animals. Nanogenerators targeting a wide variety of cancers may be possible.	Mem Sloan Kettering Canc Ctr, Mol Pharmacol & Therapeut Program, New York, NY 10021 USA; Dow Chem Co USA, Freeport, TX 77541 USA; Cornell Univ, Weill Med Coll, New York Presbyterian Hosp, Dept Urol, New York, NY 10021 USA	Memorial Sloan Kettering Cancer Center; Dow Chemical Company; Cornell University; NewYork-Presbyterian Hospital	Scheinberg, DA (corresponding author), Mem Sloan Kettering Canc Ctr, Mol Pharmacol & Therapeut Program, 1275 York Ave, New York, NY 10021 USA.	d-scheinberg@ski.mskcc.org	Miederer, Matthias/C-4405-2014; Miederer, Matthias/ABA-5988-2020	Miederer, Matthias/0000-0001-5075-5995	NCI NIH HHS [R01 CA55349] Funding Source: Medline; PHS HHS [P01 33049] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA055349] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ballangrud AM, 2001, CANCER RES, V61, P2008; Bidart JM, 1999, CLIN CHEM, V45, P1695; Chappell LL, 2000, BIOCONJUGATE CHEM, V11, P510, DOI 10.1021/bc990153f; Davis IA, 1999, NUCL MED BIOL, V26, P581, DOI 10.1016/S0969-8051(99)00024-4; Deal KA, 1999, J MED CHEM, V42, P2988, DOI 10.1021/jm990141f; GEERLINGS MW, 1993, NUCL MED COMMUN, V14, P121, DOI 10.1097/00006231-199302000-00009; GHETIE MA, 1994, BLOOD, V83, P1329; GLEAVE ME, 1992, CANCER RES, V52, P1598; HUMM JL, 1993, RADIAT RES, V134, P143, DOI 10.2307/3578453; Jurcic JG, 1997, BLOOD, V90, P1850; Kennel SJ, 2000, CANCER BIOTHER RADIO, V15, P235, DOI 10.1089/108497800414329; Liu H, 1998, CANCER RES, V58, P4055; Ma D, 2000, J NUCL MED, V41, p268P; MA D, IN PRESS LEUKEMIA; McDevitt MR, 1998, EUR J NUCL MED, V25, P1341, DOI 10.1007/s002590050306; McDevitt MR, 2000, CANCER RES, V60, P6095; McDevitt MR, 1999, APPL RADIAT ISOTOPES, V50, P895, DOI 10.1016/S0969-8043(98)00151-1; McDevitt MR, 1999, J NUCL MED, V40, P1722; Nikula TK, 1999, J NUCL MED, V40, P166; Smith-Jones PM, 2000, CANCER RES, V60, P5237; Zalutsky MR, 2000, CURR PHARM DESIGN, V6, P1433, DOI 10.2174/1381612003399275	21	346	399	0	53	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 16	2001	294	5546					1537	1540		10.1126/science.1064126	http://dx.doi.org/10.1126/science.1064126			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	493TX	11711678				2023-01-03	WOS:000172240500052
J	Phillips, PS; Nolan, JP				Phillips, PS; Nolan, JP			Training in basic and advanced life support in UK medical schools: questionnaire survey	BRITISH MEDICAL JOURNAL			English	Article							CARDIOPULMONARY RESUSCITATION		Univ Southampton, Southampton Gen Hosp, Fac Med, Southampton SO16 6YD, Hants, England; Royal United Hosp, Dept Anaesthesia & Intens Care Med, Bath BA1 3NG, Avon, England	University of Southampton	Phillips, PS (corresponding author), Univ Southampton, Southampton Gen Hosp, Fac Med, Southampton SO16 6YD, Hants, England.		Nolan, Jerry P./ABF-2561-2020	Nolan, Jerry/0000-0003-3141-3812				CASEY WF, 1984, J ROY SOC MED, V77, P921, DOI 10.1177/014107688407701105; *GEN MED COUNC, 1997, NEW DOCT REC GEN CLI; Perkins GD, 1999, RESUSCITATION, V41, P19, DOI 10.1016/S0300-9572(99)00037-4; SKINNER DV, 1985, BRIT MED J, V290, P1549, DOI 10.1136/bmj.290.6481.1549; The Royal College of Physicians of London, 1987, J ROY COLL PHYS LOND, V21, P175	5	53	53	1	4	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	JUL 7	2001	323	7303					22	23		10.1136/bmj.323.7303.22	http://dx.doi.org/10.1136/bmj.323.7303.22			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	451WA	11440938	Green Published, Bronze			2023-01-03	WOS:000169824300019
J	Rosenberg, SA				Rosenberg, SA			Progress in human tumour immunology and immunotherapy	NATURE			English	Article							CYTOTOXIC T-LYMPHOCYTES; ACTIVATED KILLER-CELLS; METASTATIC MELANOMA; RECOMBINANT INTERLEUKIN-2; INFILTRATING LYMPHOCYTES; AUTOLOGOUS TUMOR; ANTIGEN; IDENTIFICATION; CANCER; RESPONSES	Studies of the administration of interleukin-2 to patients with metastatic melanoma or kidney cancer have shown that immunological manipulations can mediate the durable regression of metastatic cancer. The molecular identification of cancer antigens has opened new possibilities for the development of effective immunotherapies for patients with cancer. Clinical studies using immunization with peptides derived from cancer antigens have shown that high levels of lymphocytes with anti-tumour activity can be raised in cancer-bearing patients. Highly avid anti-tumour lymphocytes can be isolated from immunized patients and grown in vitro for use in cell-transfer therapies. Current studies are aimed at understanding the mechanisms that enable the cancer to escape from immune attack.	NCI, Div Clin Sci, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Rosenberg, SA (corresponding author), NCI, Div Clin Sci, Bldg 10,Room 2B42,10 Ctr Dr,MSC 1502, Bethesda, MD 20892 USA.							Atkins MB, 1999, J CLIN ONCOL, V17, P2105, DOI 10.1200/JCO.1999.17.7.2105; BOEL P, 1995, IMMUNITY, V2, P167, DOI 10.1016/S1074-7613(95)80053-0; Boon T, 1997, IMMUNOL TODAY, V18, P267, DOI 10.1016/S0167-5699(97)80020-5; Brandle D, 1996, J EXP MED, V183, P2501, DOI 10.1084/jem.183.6.2501; BRICHARD V, 1993, J EXP MED, V178, P489, DOI 10.1084/jem.178.2.489; Butterfield LH, 1999, CANCER RES, V59, P3134; Chaux P, 1999, J EXP MED, V189, P767, DOI 10.1084/jem.189.5.767; Chen YT, 1997, P NATL ACAD SCI USA, V94, P1914, DOI 10.1073/pnas.94.5.1914; Chiari R, 1999, CANCER RES, V59, P5785; COX AL, 1994, SCIENCE, V264, P716, DOI 10.1126/science.7513441; DALLAL RM, 2000, PRINCIPLES PRACTICE, P705; Dudley ME, 2000, CANCER J, V6, P69; Eder JP, 2000, CLIN CANCER RES, V6, P1632; FYFE G, 1995, J CLIN ONCOL, V13, P688, DOI 10.1200/JCO.1995.13.3.688; GAUGLER B, 1994, J EXP MED, V179, P921, DOI 10.1084/jem.179.3.921; Gong JL, 2000, J IMMUNOL, V165, P1705, DOI 10.4049/jimmunol.165.3.1705; Gueguen M, 1998, J IMMUNOL, V160, P6188; HEWITT HB, 1976, BRIT J CANCER, V33, P241, DOI 10.1038/bjc.1976.37; HUNT DF, 1992, SCIENCE, V255, P1261, DOI 10.1126/science.1546328; IOANNIDES CG, 1993, CELL IMMUNOL, V151, P225, DOI 10.1006/cimm.1993.1233; ITOH K, 1988, J EXP MED, V168, P1419, DOI 10.1084/jem.168.4.1419; Jager E, 1998, J EXP MED, V187, P265, DOI 10.1084/jem.187.2.265; JEROME KR, 1991, CANCER RES, V51, P2908; KAWAKAMI Y, 1994, P NATL ACAD SCI USA, V91, P6458, DOI 10.1073/pnas.91.14.6458; KAWAKAMI Y, 1994, P NATL ACAD SCI USA, V91, P3515, DOI 10.1073/pnas.91.9.3515; Kawashima I, 1998, HUM IMMUNOL, V59, P1, DOI 10.1016/S0198-8859(97)00255-3; KLEIN E, 1960, CANCER RES, V20, P452; Landsteiner K, 1942, P SOC EXP BIOL MED, V49, P688, DOI 10.3181/00379727-49-13670; Li K, 1998, CANCER IMMUNOL IMMUN, V47, P32, DOI 10.1007/s002620050501; LOWY DR, 2001, CANC PRINCIPLES PRAC, P3189; Mandruzzato S, 1997, J EXP MED, V186, P785, DOI 10.1084/jem.186.5.785; Marincola FM, 2000, PRINCIPLES PRACTICE, P601; Marshall JL, 1999, J CLIN ONCOL, V17, P332, DOI 10.1200/JCO.1999.17.1.332; Marshall JL, 2000, J CLIN ONCOL, V18, P3964, DOI 10.1200/JCO.2000.18.23.3964; MUUL LM, 1987, J IMMUNOL, V138, P989; OLD LJ, 1962, ANN NY ACAD SCI, V101, P80, DOI 10.1111/j.1749-6632.1962.tb26446.x; Panelli MC, 2000, J IMMUNOL, V164, P4382, DOI 10.4049/jimmunol.164.8.4382; PAPADOPOULOS EB, 1994, NEW ENGL J MED, V330, P1185, DOI 10.1056/NEJM199404283301703; Parkhurst MR, 1996, J IMMUNOL, V157, P2539; Pieper R, 1999, J EXP MED, V189, P757, DOI 10.1084/jem.189.5.757; Restifo NP, 2000, GENE THER, V7, P89, DOI 10.1038/sj.gt.3301117; Robbins PF, 1996, J EXP MED, V183, P1185, DOI 10.1084/jem.183.3.1185; ROSENBERG SA, 1992, JAMA-J AM MED ASSOC, V268, P2416, DOI 10.1001/jama.268.17.2416; ROSENBERG SA, 1987, NEW ENGL J MED, V316, P889, DOI 10.1056/NEJM198704093161501; Rosenberg SA, 1998, ANN SURG, V228, P307, DOI 10.1097/00000658-199809000-00004; Rosenberg SA, 1999, J IMMUNOL, V163, P1690; Rosenberg SA, 1998, NAT MED, V4, P321, DOI 10.1038/nm0398-321; Rosenberg SA, 1998, J NATL CANCER I, V90, P1894, DOI 10.1093/jnci/90.24.1894; Rosenberg SA, 1999, IMMUNITY, V10, P281, DOI 10.1016/S1074-7613(00)80028-X; ROSENBERG SA, 1985, NEW ENGL J MED, V313, P1485, DOI 10.1056/NEJM198512053132327; ROSENBERG SA, 1994, J NATL CANCER I, V86, P1159, DOI 10.1093/jnci/86.15.1159; ROSENBERG SA, 1988, NEW ENGL J MED, V319, P1676, DOI 10.1056/NEJM198812223192527; ROSENBERG SA, 2000, PRINCIPLES PRACTICE; SalazarOnfray F, 1997, CANCER RES, V57, P4348; Stoler DL, 1999, P NATL ACAD SCI USA, V96, P15121, DOI 10.1073/pnas.96.26.15121; Theobald M, 1995, P NATL ACAD SCI USA, V92, P11993, DOI 10.1073/pnas.92.26.11993; TOPALIAN SL, 1994, P NATL ACAD SCI USA, V91, P9461, DOI 10.1073/pnas.91.20.9461; TSANG KY, 1995, J NATL CANCER I, V87, P982, DOI 10.1093/jnci/87.13.982; VANDENEYNDE B, 1995, J EXP MED, V182, P689, DOI 10.1084/jem.182.3.689; VANDERBRUGGEN P, 1991, SCIENCE, V254, P1643, DOI 10.1126/science.1840703; Visseren MJW, 1997, INT J CANCER, V73, P125, DOI 10.1002/(SICI)1097-0215(19970926)73:1<125::AID-IJC19>3.0.CO;2-F; Vissers JLM, 1999, CANCER RES, V59, P5554; Vonderheide RH, 1999, IMMUNITY, V10, P673, DOI 10.1016/S1074-7613(00)80066-7; WALTER EA, 1995, NEW ENGL J MED, V333, P1038, DOI 10.1056/NEJM199510193331603; Wang RB, 1998, SCIENCE, V282, P476, DOI 10.1126/science.282.5388.476; WANG RF, 1995, J EXP MED, V181, P799, DOI 10.1084/jem.181.2.799; Wang RF, 1999, SCIENCE, V284, P1351, DOI 10.1126/science.284.5418.1351; Wang RF, 1999, J EXP MED, V189, P1659, DOI 10.1084/jem.189.10.1659; Wang RF, 1996, J EXP MED, V184, P2207, DOI 10.1084/jem.184.6.2207; Wang RF, 1998, J IMMUNOL, V161, P3596; WOGLOM WILLIAM H., 1929, CANCER REV, V4, P129; WOLFEL T, 1995, SCIENCE, V269, P1281, DOI 10.1126/science.7652577; Yee C, 1996, J IMMUNOL, V157, P4079; Zeng G, 2000, J IMMUNOL, V165, P1153, DOI 10.4049/jimmunol.165.2.1153	74	1101	1217	2	252	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAY 17	2001	411	6835					380	384		10.1038/35077246	http://dx.doi.org/10.1038/35077246			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	432RT	11357146				2023-01-03	WOS:000168710000061
J	Aboff, BM; Collier, VU; Farber, NJ; Ehrenthal, DB				Aboff, BM; Collier, VU; Farber, NJ; Ehrenthal, DB			Residents' prescription writing for nonpatients	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article; Proceedings Paper	21st Annual Meeting of the Society-of-General-Internal-Medicine	APR 23-25, 1998	CHICAGO, IL	Soc Gen Internal Med			PHYSICIANS	Context Writing prescriptions is one of the most tangible new responsibilities that residents acquire after graduating from medical school, During their regular duties, house officers' prescription writing is carefully monitored. Little is known, however, about residents' patterns of prescription writing outside of supervision or about residents' knowledge of the ethical and legal guidelines that regulate prescription writing. Objective To study what factors influence residents' decision to write prescriptions for nonpatients. Design, Setting, and Participants Survey distributed in December 1997 to 92 internal medicine and family practice residents at a US community-based teaching hospital. Eighty percent responded. Main Outcome Measures Self-reported prescribing activities for nonpatients and for individuals in 12 hypothetical vignettes. Results Eighty-five percent of respondents reported having written prescriptions for nonpatients, Based on their responses to the vignettes, under certain circumstances, up to 95% of residents would write a prescription for an individual who is not their patient (eg, a sibling). Thirteen percent of residents believed that some ethical guidelines on prescription-writing activity existed. Only 4% of residents reported being aware of federal or state laws addressing the appropriateness of physician prescription writing for nonpatients. None of the residents were able to describe the circumstances that make prescription writing for nonpatients illegal or unethical based on legal statutes or ethical guidelines, respectively, Conclusions In a sample of community-based internal medicine and family practice residents, unsupervised prescription writing by residents for individuals who are not their patients is a common occurrence. Since residency training is a time when practice habits are established, it is important that all residents learn about the ethical, legal, and liability implications of writing prescriptions for nonpatients.	Christiana Care Hlth Syst, Dept Med, Wilmington, DE 19899 USA	Christiana Care Health System	Aboff, BM (corresponding author), Christiana Care Hlth Syst, Dept Med, 501 W 14th St, Wilmington, DE 19899 USA.	baboff@christianacare.org						AACH RD, 1992, ANN INTERN MED, V116, P245, DOI 10.7326/0003-4819-116-3-245; AJZEN I, 1977, PSYCHOL BULL, V84, P888, DOI 10.1037/0033-2909.84.5.888; *AM COLL PHYS AM S, 1999, ACP ASIM OBSERVER, V19, P1; *AM MED ASS, 1997, AMA CURR OP COUNC ET; Christie JD, 1998, JAMA-J AM MED ASSOC, V280, P1253, DOI 10.1001/jama.280.14.1253; CLARK AW, 1988, J MED EDUC, V63, P44; Desalvo KB, 2000, J INVEST MED, V48, p226A; DUSDIEKER LB, 1993, AM J DIS CHILD, V147, P146, DOI 10.1001/archpedi.1993.02160260036018; FINKEL SK, 1996, VITAL SIGNS      JUN; HOWARD ML, 1995, LEGAL MED, P265; HUGHES PH, 1991, JAMA-J AM MED ASSOC, V265, P2069, DOI 10.1001/jama.265.16.2069; LAPUMA J, 1991, NEW ENGL J MED, V325, P1290, DOI 10.1056/NEJM199110313251806; LAPUMA J, 1992, JAMA-J AM MED ASSOC, V257, P1810	13	13	13	0	2	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 17	2002	288	3					381	385		10.1001/jama.288.3.381	http://dx.doi.org/10.1001/jama.288.3.381			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine	573AK	12117406	Bronze			2023-01-03	WOS:000176807000033
J	Chiarelli, P; Cockburn, J				Chiarelli, P; Cockburn, J			Promoting urinary continence in women after delivery: randomised controlled trial	BMJ-BRITISH MEDICAL JOURNAL			English	Article							AUSTRALIAN WOMEN; INCONTINENCE; PREVALENCE; PREGNANCY; DISTRESS; SYMPTOM	Objectives To test the effectiveness of a physiotherapist delivered intervention designed to prevent urinary incontinence among women three months after giving birth. Design Prospective randoinised controlled trial with women randomised to receive the intervention (which entailed training in pelvic floor exercises and incorporated strategies to improve adherence) or usual postpartum care. Setting Postpartum wards of three tertiary teaching hospitals in the Hunter region, New South Wales, Australia. Participants Women who had forceps or ventouse deliveries or whose babies had a high birth weight (greater than or equal to 4000 g), or both-676 (348 in the intervention group and 328 in the usual care group) provided endpoint data at three months, Main outcome measures Urinary incontinence at three months is measured as a dichotomous variable. The severity of incontinence was also measured. Self report of the frequency of performance of pelvic floor exercises was recorded. Results At three months after delivery, the prevalence of incontinence in the intervention group was 31.0% (108 women) and in the usual care group 38.4% (125 women); difference 7.4% (95% confidence interval 0.2% to 14.6%, P=0.044). At follow up significantly fewer women with incontinence were classified as severe in the intervention group (10.1%) v (17.0%), difference 7.0%, 1.6% to 11.8%). The proportions of women reporting doing pelvic floor exercises at adequate levels was 84% (80% to 88%) for the intervention group and 58% (52% to 63%) for the usual care group (P=0.001). Conclusions The intervention promoting urinary continence reduced die prevalence of urinary incontinence after giving birth, particularly its severity, and promoted the performance of pelvic floor exercises at adequate levels; both continence and adherence to die programme were measured at three months after delivery in women who had forceps or ventouse deliveries or babies weighing 4000 g or more.	Univ Newcastle, Fac Hlth, Sch Populat Hlth Sci, Callaghan, NSW 2308, Australia	University of Newcastle	Chiarelli, P (corresponding author), Univ Newcastle, Fac Hlth, Sch Populat Hlth Sci, Box 24, Callaghan, NSW 2308, Australia.	Pauline.Chiarelli@newcastle.edu.au	Sandall, Jane/D-4146-2009	Sandall, Jane/0000-0003-2000-743X				BO K, 1994, NEUROUROL URODYNAM, V13, P35, DOI 10.1002/nau.1930130106; Chiarelli P, 1997, AUST NZ J OBSTET GYN, V37, P66, DOI 10.1111/j.1479-828X.1997.tb02220.x; Chiarelli P, 1999, NEUROUROL URODYNAM, V18, P567, DOI 10.1002/(SICI)1520-6777(1999)18:6<567::AID-NAU7>3.0.CO;2-F; Chiarelli P, 1999, AUST J PHYSIOTHER, V45, P111, DOI 10.1016/S0004-9514(14)60343-3; CHIARELLI P, 1999, AUST CONTINENCE J, V5, P41; CLARK A, 1993, J REPROD MED, V38, P679; Cummings K M, 1980, J Behav Med, V3, P123; Doran CM, 2001, MED J AUSTRALIA, V174, P456, DOI 10.5694/j.1326-5377.2001.tb143374.x; Foldspang A, 1999, AM J PUBLIC HEALTH, V89, P209, DOI 10.2105/AJPH.89.2.209; GUNTHORPE W, 1998, THESIS NEWCASTLE; HAHN I, 1993, BRIT J UROL, V72, P421, DOI 10.1111/j.1464-410X.1993.tb16170.x; HERZOG AR, 1988, PSYCHOL AGING, V3, P115, DOI 10.1037/0882-7974.3.2.115; HSU T, 1990, J AM GERIATR SOC, V38, P292; *INT CONT SOC, 1976, BR J UROL, V48, P39; LAGRO-JANSSEN T, 1992, Scandinavian Journal of Primary Health Care, V10, P211; MILLER Y, IN PRESS NEUROUROL U; NYGAARD I, 1990, OBSTET GYNECOL, V75, P848; Persson J, 2000, OBSTET GYNECOL, V96, P440, DOI 10.1016/S0029-7844(00)00950-9; POCOCK SJ, 1982, STATISTICIAN, V31, P1; SANDVIK H, 1993, J EPIDEMIOL COMMUN H, V47, P497, DOI 10.1136/jech.47.6.497; SAYER T, 1994, PHYSIOTHERAPY, V80, P143; SAYER TR, 1990, NEUROUROL URODYNAM, V9, P319; SIMEONOVA Z, 1990, Scandinavian Journal of Primary Health Care, V8, P203, DOI 10.3109/02813439008994959; UEBERSAX JS, 1995, NEUROUROL URODYNAM, V14, P131, DOI 10.1002/nau.1930140206; VIKTRUP L, 1992, OBSTET GYNECOL, V79, P945; Wilson PD, 1996, BRIT J OBSTET GYNAEC, V103, P154, DOI 10.1111/j.1471-0528.1996.tb09668.x	26	71	76	1	17	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	MAY 25	2002	324	7348					1241	+		10.1136/bmj.324.7348.1241	http://dx.doi.org/10.1136/bmj.324.7348.1241			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	557EJ	12028976	Bronze, Green Published			2023-01-03	WOS:000175894900016
J	Vanderlinde, ES; Heal, JM; Blumberg, N				Vanderlinde, ES; Heal, JM; Blumberg, N			Autologous transfusion	BRITISH MEDICAL JOURNAL			English	Review							HIP-REPLACEMENT SURGERY; HOMOLOGOUS BLOOD-TRANSFUSIONS; COLORECTAL-CANCER SURGERY; INFECTIOUS COMPLICATIONS; POSTOPERATIVE INFECTION; ALLOGENEIC TRANSFUSION; BACTERIAL-INFECTION; COST-EFFECTIVENESS; DONATION; MULTICENTER		Univ Rochester, Med Ctr, Transfus Med Unit, Transfus Med & Blood Bank, Rochester, NY 14642 USA; Univ Rochester, Med Ctr, Dept Pathol & Lab Med, Rochester, NY 14642 USA; Univ Rochester, Med Ctr, Dept Med, Rochester, NY 14642 USA	University of Rochester; University of Rochester; University of Rochester	Blumberg, N (corresponding author), Univ Rochester, Med Ctr, Transfus Med Unit, Transfus Med & Blood Bank, Box 608,601 Elmwood Ave, Rochester, NY 14642 USA.							Bae H, 2001, J BONE JOINT SURG BR, V83B, P676, DOI 10.1302/0301-620X.83B5.10560; Bierbaum BE, 1999, J BONE JOINT SURG AM, V81A, P2, DOI 10.2106/00004623-199901000-00002; BIRKMEYER JD, 1993, TRANSFUSION, V33, P544, DOI 10.1046/j.1537-2995.1993.33793325048.x; Blumberg N, 1996, AM J SURG, V171, P324, DOI 10.1016/S0002-9610(97)89635-3; BLUMBERG N, 2000, SCI BASIS TRANSFUSIO, P427; Body SC, 1999, J CARDIOTHOR VASC AN, V13, P410, DOI 10.1016/S1053-0770(99)90212-4; Borghi B, 2000, EUR J ANAESTH, V17, P411, DOI 10.1046/j.1365-2346.2000.00693.x; BULL BS, 1990, BLOOD CELLS, V16, P5; BUSCH ORC, 1993, NEW ENGL J MED, V328, P1372, DOI 10.1056/NEJM199305133281902; Chan ACW, 1998, AM J SURG, V175, P461, DOI 10.1016/S0002-9610(98)00085-3; COUSIN MT, 1994, ANN CHIR, V48, P818; deCastro RM, 1999, AM J OBSTET GYNECOL, V180, P1491, DOI 10.1016/S0002-9378(99)70044-X; Faris PM, 1996, J BONE JOINT SURG AM, V78A, P62, DOI 10.2106/00004623-199601000-00009; Farrer A, 1997, J Vasc Nurs, V15, P111, DOI 10.1016/S1062-0303(97)90028-5; Faught C, 1998, TRANSFUS MED REV, V12, P206, DOI 10.1016/S0887-7963(98)80061-8; Feagan BG, 2000, ANN INTERN MED, V133, P845, DOI 10.7326/0003-4819-133-11-200012050-00008; FERNANDEZ MC, 1992, TRANSFUSION, V32, P318, DOI 10.1046/j.1537-2995.1992.32492263444.x; Forgie MA, 1998, ARCH INTERN MED, V158, P610, DOI 10.1001/archinte.158.6.610; HEALY JC, 1994, ARCH PATHOL LAB MED, V118, P465; Hebert PC, 1999, NEW ENGL J MED, V340, P409, DOI 10.1056/NEJM199902113400601; HEISS MM, 1993, LANCET, V342, P1328, DOI 10.1016/0140-6736(93)92247-Q; HEISS MM, 1994, J CLIN ONCOL, V12, P1859, DOI 10.1200/JCO.1994.12.9.1859; HOWARD HL, 1993, CLIN LAB HAEMATOL, V15, P165; Kinoshita Y, 2000, SURGERY, V127, P185, DOI 10.1067/msy.2000.102048; MEZROW CK, 1992, TRANSFUSION, V32, P27, DOI 10.1046/j.1537-2995.1992.32192116427.x; MURPHY P, 1991, TRANSFUSION, V31, P212, DOI 10.1046/j.1537-2995.1991.31391165169.x; Napier JAF, 1997, BRIT J ANAESTH, V78, P768, DOI 10.1093/bja/78.6.768; Network for the Advancement of Transfusion Alternatives, 2000, TRANSF MED ALT BLOOD; Newman JH, 1997, J BONE JOINT SURG BR, V79B, P630, DOI 10.1302/0301-620X.79B4.7272; Sauaia A, 1999, AM J SURG, V178, P549, DOI 10.1016/S0002-9610(99)00242-1; Shinozuka N, 2000, AM J SURG, V179, P42, DOI 10.1016/S0002-9610(99)00256-1; Spahn DR, 2000, ANESTHESIOLOGY, V93, P242, DOI 10.1097/00000542-200007000-00035; Thomas D, 2001, BRIT J ANAESTH, V86, P669, DOI 10.1093/bja/86.5.669; Thomas MJG, 1996, TRANSFUSION, V36, P626, DOI 10.1046/j.1537-2995.1996.36796323061.x; TRIULZI DJ, 1992, TRANSFUSION, V32, P517, DOI 10.1046/j.1537-2995.1992.32692367194.x; VAMVAKAS EC, 1995, TRANSFUSION, V35, P150, DOI 10.1046/j.1537-2995.1995.35295125738.x; VIGNALI A, 1995, EUR J SURG, V161, P487; [No title captured]	38	68	74	6	15	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	MAR 30	2002	324	7340					772	775		10.1136/bmj.324.7340.772	http://dx.doi.org/10.1136/bmj.324.7340.772			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	538KY	11923162	Green Published			2023-01-03	WOS:000174816200019
J	Dibas, MI; Gonzales, EB; Das, P; Bell-Horner, CL; Dillon, GH				Dibas, MI; Gonzales, EB; Das, P; Bell-Horner, CL; Dillon, GH			Identification of a novel residue within the second transmembrane domain that confers use-facilitated block by picrotoxin in glycine alpha 1 receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DROSOPHILA GABA RECEPTOR; GATED CHLORIDE CHANNEL; BETA-SUBUNIT; AMINO-ACID; CYSTEINE MUTANTS; POINT MUTATION; RAT; BICUCULLINE; MECHANISMS; RESISTANCE	The central nervous system convulsant picrotoxin (PTX) inhibits GABA(A) and glutamate-gated Cl- channels in a use-facilitated fashion, whereas PTX inhibition of glycine and GABA(C) receptors displays little or no use-facilitated block. We have identified a residue in the extracellular aspect of the second transmembrane domain that converted picrotoxin inhibition of glycine alpha1 receptors from non-use-facilitated to use-facilitated. In wild type alpha1. receptors, PTX inhibited glycine-gated Cl- current in a competitive manner and had equivalent effects on peak and steady-state currents, confirming a lack of use-facilitated block. Mutation of the second transmembrane domain 15'-serine to glutamine (alpha1(S15'Q) receptors) converted the mechanism of PTX blockade from competitive to non-competitive. However, more notable was the fact that in alpha1(S15'Q) receptors, PTX had insignificant effects on peak current amplitude and dramatically enhanced current decay kinetics. Similar results were found in al(S15'N) receptors. The reciprocal mutation in the 132 subunit of alpha1beta2 GABA(A) receptors (alpha1beta2(N15'S) receptors) decreased the magnitude of use-facilitated PTX inhibition. Our results implicate a specific amino acid at the extracellular aspect of the ion channel in determining use-facilitated characteristics of picrotoxin blockade. Moreover, the data are consistent with the suggestion that picrotoxin may interact with two domains in ligand-gated anion channels.	Univ N Texas, Hlth Sci Ctr, Dept Pharmacol & Neurosci, Ft Worth, TX 76107 USA	University of North Texas System; University of North Texas Health Science Center	Dillon, GH (corresponding author), Univ N Texas, Hlth Sci Ctr, Dept Pharmacol & Neurosci, 3500 Camp Bowie Blvd, Ft Worth, TX 76107 USA.	gdillon@hsc.unt.edu		Gonzales, Eric B./0000-0001-8596-9053	NIEHS NIH HHS [ES 07904] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES007904, R29ES007904] Funding Source: NIH RePORTER	NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		AKAIKE N, 1985, EXPERIENTIA, V41, P70; Cestari IN, 2000, J NEUROCHEM, V74, P827, DOI 10.1046/j.1471-4159.2000.740827.x; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CULLY DF, 1994, NATURE, V371, P707, DOI 10.1038/371707a0; DILLON GH, 1995, BRIT J PHARMACOL, V115, P539, DOI 10.1111/j.1476-5381.1995.tb16368.x; Dong CJ, 1996, VISION RES, V36, P3997, DOI 10.1016/S0042-6989(96)00141-1; ENZ R, 1995, NEUROREPORT, V6, P1569, DOI 10.1097/00001756-199507310-00026; Etter A, 1999, J NEUROCHEM, V72, P318, DOI 10.1111/jnc.1999.72.1.318; FFRENCHCONSTANT RH, 1993, NATURE, V363, P449, DOI 10.1038/363449a0; FFRENCHCONSTANT RH, 1991, P NATL ACAD SCI USA, V88, P7209, DOI 10.1073/pnas.88.16.7209; GURLEY D, 1995, RECEPTOR CHANNEL, V3, P13; Huang RQ, 1999, J NEUROPHYSIOL, V82, P1233, DOI 10.1152/jn.1999.82.3.1233; IM WB, 1995, NEUROSCI LETT, V186, P203, DOI 10.1016/0304-3940(95)11293-6; INOUE M, 1988, NEUROSCI RES, V5, P380, DOI 10.1016/0168-0102(88)90024-7; JARBOE CH, 1968, J MED CHEM, V11, P729, DOI 10.1021/jm00310a020; Koltchine VV, 1999, MOL PHARMACOL, V56, P1087, DOI 10.1124/mol.56.5.1087; Krishek BJ, 1996, NEUROPHARMACOLOGY, V35, P1289, DOI 10.1016/S0028-3908(96)00089-5; LANGOSCH D, 1988, P NATL ACAD SCI USA, V85, P7394, DOI 10.1073/pnas.85.19.7394; LI TB, 2000, SOC NEUR ABSTR, V26, P629; LYNCH JW, 1995, J BIOL CHEM, V270, P13799, DOI 10.1074/jbc.270.23.13799; Maskell PD, 2001, BRIT J PHARMACOL, V132, P205, DOI 10.1038/sj.bjp.0703824; NEWLAND CF, 1992, J PHYSIOL-LONDON, V447, P191, DOI 10.1113/jphysiol.1992.sp018998; Perret P, 1999, J BIOL CHEM, V274, P25350, DOI 10.1074/jbc.274.36.25350; PRIBILLA I, 1992, EMBO J, V11, P4305, DOI 10.1002/j.1460-2075.1992.tb05529.x; Rajendra S, 1997, PHARMACOL THERAPEUT, V73, P121, DOI 10.1016/S0163-7258(96)00163-5; REDDY GL, 1993, J BIOL CHEM, V268, P14608; Shan Q, 2001, J NEUROCHEM, V76, P1109, DOI 10.1046/j.1471-4159.2001.00124.x; SIMMONDS MA, 1980, EUR J PHARMACOL, V80, P347; Steward LJ, 2000, MOL PHARMACOL, V57, P1249; TEHRANI MHJ, 1985, J NEUROCHEM, V45, P1311, DOI 10.1111/j.1471-4159.1985.tb05560.x; TRIFILETTI RR, 1984, MOL PHARMACOL, V26, P470; WAFFORD KA, 1994, NEURON, V12, P775, DOI 10.1016/0896-6273(94)90330-1; Walters RJ, 2000, NAT NEUROSCI, V3, P1274, DOI 10.1038/81800; Wang CT, 1999, BIOPHYS J, V77, P691, DOI 10.1016/S0006-3495(99)76924-9; WANG TL, 1995, P NATL ACAD SCI USA, V92, P11751, DOI 10.1073/pnas.92.25.11751; WANG TL, 1994, J NEUROSCI, V14, P6524; Williams DB, 1999, BIOPHYS J, V77, P2563, DOI 10.1016/S0006-3495(99)77091-8; Xu M, 1995, BIOPHYS J, V69, P1858, DOI 10.1016/S0006-3495(95)80056-1; Ye Q, 1998, J BIOL CHEM, V273, P3314, DOI 10.1074/jbc.273.6.3314; YOON KW, 1993, J PHYSIOL-LONDON, V464, P423, DOI 10.1113/jphysiol.1993.sp019643; ZHANG DX, 1995, P NATL ACAD SCI USA, V92, P11756, DOI 10.1073/pnas.92.25.11756; ZHANG HG, 1994, J PHYSIOL-LONDON, V479, P65, DOI 10.1113/jphysiol.1994.sp020278; Zhorov BS, 2000, BIOPHYS J, V78, P1786, DOI 10.1016/S0006-3495(00)76729-4	43	40	40	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 15	2002	277	11					9112	9117		10.1074/jbc.M111356200	http://dx.doi.org/10.1074/jbc.M111356200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	531DK	11744711	hybrid			2023-01-03	WOS:000174400600051
J	Bhargava, B; Tripuraneni, P				Bhargava, B; Tripuraneni, P			Role of intracoronary brachytherapy for in-stent restenosis?	LANCET			English	Editorial Material							INHIBITS RECURRENCE; RADIATION THERAPY; BETA-RADIATION; ANGIOPLASTY; RADIOTHERAPY; IMPLANTATION; TRIAL		All India Inst Med Sci, Cardiothorac Sci Ctr, New Delhi 110029, India; Scripps Res Inst, Dept Radiat Oncol, La Jolla, CA USA	All India Institute of Medical Sciences (AIIMS) New Delhi; Scripps Research Institute	Bhargava, B (corresponding author), All India Inst Med Sci, Cardiothorac Sci Ctr, New Delhi 110029, India.							Bonan R, 1999, J INVASIVE CARDIOL, V11, P749; GRUBE E, 2001, SCI SESS AM HEART AS; Hoffmann R, 1996, CIRCULATION, V94, P1247, DOI 10.1161/01.CIR.94.6.1247; KUNTZ R, 2001, J AM COLL CARDIOL SA, V37; LANSKY A, 2000, 10 T CATH THER M WAS; Leon MB, 2001, NEW ENGL J MED, V344, P250, DOI 10.1056/NEJM200101253440402; LEON MB, 2000, J AM COLL CARDIOL SA, V35; Minar E, 2000, CIRCULATION, V102, P2694, DOI 10.1161/01.CIR.102.22.2694; MORICE M, 2001, 23 C EUR SOC CARD SE; Popma JJ, 2000, J AM COLL CARDIOL, V36, P311; Raizner AE, 2000, CIRCULATION, V102, P951, DOI 10.1161/01.CIR.102.9.951; Sapirstein W, 2001, NEW ENGL J MED, V344, P297, DOI 10.1056/NEJM200101253440410; SERRUYS PW, 1994, NEW ENGL J MED, V331, P489, DOI 10.1056/NEJM199408253310801; SERRUYS PW, 2000, CIRCULATION S2, V102, P18; Sousa JE, 2001, CIRCULATION, V103, P192; Teirstein PS, 1997, NEW ENGL J MED, V336, P1697, DOI 10.1056/NEJM199706123362402; VANDENBR.HA, 1968, AMER J ROENTGENOL RA, V103, P723, DOI 10.2214/ajr.103.4.723; Verin V, 2001, NEW ENGL J MED, V344, P243, DOI 10.1056/NEJM200101253440401; Waksman R, 2001, CIRCULATION, V103, P2332; Waksman R, 2000, CIRCULATION, V101, P2165, DOI 10.1161/01.CIR.101.18.2165; Waksman R, 2000, J AM COLL CARDIOL, V36, P65, DOI 10.1016/S0735-1097(00)00681-1; Waksman R, 2000, CIRCULATION, V101, P1895, DOI 10.1161/01.CIR.101.16.1895; WAKSMAN R, 1995, CIRCULATION, V92, P1383, DOI 10.1161/01.CIR.92.6.1383; Waksman R, 2001, J VASC INTERV RADIOL, V12, P915, DOI 10.1016/S1051-0443(07)61569-3; WAKSMAN R, 2001, J AM COLL CARDIOL SA, V37	25	5	5	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	FEB 16	2002	359	9306					543	544		10.1016/S0140-6736(02)07720-6	http://dx.doi.org/10.1016/S0140-6736(02)07720-6			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	523FP	11867105				2023-01-03	WOS:000173943600004
J	Keenan, SP				Keenan, SP			Weaning protocols: here to stay	LANCET			English	Editorial Material							MECHANICAL VENTILATION; DURATION; TRIAL; TIME		Royal Columbian Hosp, Intens Care Unit, New Westminster, BC V3L 5E7, Canada		Keenan, SP (corresponding author), Royal Columbian Hosp, Intens Care Unit, New Westminster, BC V3L 5E7, Canada.							BROCHARD L, 1994, AM J RESP CRIT CARE, V150, P896, DOI 10.1164/ajrccm.150.4.7921460; COHEN IL, 1991, CRIT CARE MED, V19, P1278, DOI 10.1097/00003246-199110000-00010; Ely EW, 1996, NEW ENGL J MED, V335, P1864, DOI 10.1056/NEJM199612193352502; ESTEBAN A, 1995, NEW ENGL J MED, V332, P345, DOI 10.1056/NEJM199502093320601; Henneman E, 2001, CRIT CARE MED, V29, P297, DOI 10.1097/00003246-200102000-00013; Horst HM, 1998, ARCH SURG-CHICAGO, V133, P483, DOI 10.1001/archsurg.133.5.483; Kollef MH, 1997, CRIT CARE MED, V25, P567, DOI 10.1097/00003246-199704000-00004; Marelich GP, 2000, CHEST, V118, P459, DOI 10.1378/chest.118.2.459; MORRIS AH, 1994, AM J RESP CRIT CARE, V149, P295, DOI 10.1164/ajrccm.149.2.8306022; Vitacca M, 2001, AM J RESP CRIT CARE, V164, P225, DOI 10.1164/ajrccm.164.2.2008160; Wood G, 1995, Respir Care, V40, P219; ZAPOL WM, 1979, JAMA-J AM MED ASSOC, V242, P2193, DOI 10.1001/jama.242.20.2193	12	8	9	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JAN 19	2002	359	9302					186	187		10.1016/S0140-6736(02)07465-2	http://dx.doi.org/10.1016/S0140-6736(02)07465-2			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	512YH	11812550				2023-01-03	WOS:000173350800006
J	Noda, W; Nishiwaki, Y; Kawahara, M; Negoro, S; Sugiura, T; Yokoyama, A; Fukuoka, M; Mori, K; Watanabe, K; Tamura, T; Yamamoto, S; Saijo, N				Noda, W; Nishiwaki, Y; Kawahara, M; Negoro, S; Sugiura, T; Yokoyama, A; Fukuoka, M; Mori, K; Watanabe, K; Tamura, T; Yamamoto, S; Saijo, N		Japan Clin Oncology Grp	Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CYCLOPHOSPHAMIDE; DOXORUBICIN; VINCRISTINE; ALTERNATION; ONCOLOGY; REGIMENS; TRIAL	Background Irinotecan hydrochloride, a topoisomerase I inhibitor, is effective against small-cell lung cancer. In a phase 2 study of irinotecan plus cisplatin in patients with extensive small-cell lung cancer, there was a high response rate and a promising median survival time. Methods We conducted a multicenter, randomized, phase 3 study in which we compared irinotecan plus cisplatin with etoposide plus cisplatin in patients with extensive (metastatic) small-cell lung cancer. Results The planned size of the study population was 230 patients, but enrollment was terminated early because an interim analysis found a statistically significant difference in survival between the patients assigned to receive irinotecan and cisplatin and those assigned to receive etoposide and cisplatin; as a result, only 154 patients were enrolled. The median survival was 12.8 months in the irinotecan-plus-cisplatin group and 9.4 months in the etoposide-plus-cisplatin group (P=0.002 by the unadjusted log-rank test). At two years, the proportion of patients surviving was 19.5 percent in the irinotecan-plus-cisplatin group and 5.2 percent in the etoposide-plus-cisplatin group. Severe or life-threatening myelosuppression was more frequent in the etoposide-plus-cisplatin group than in the irinotecan-plus-cisplatin group, and severe or life-threatening diarrhea was more frequent in the irinotecan-plus-cisplatin group than in the etoposide-plus-cisplatin group. Conclusions Irinotecan plus cisplatin is an effective treatment for metastatic small-cell lung cancer. (N Engl J Med 2002;346:85-91.) Copyright (C) 2002 Massachusetts Medical Society.	Kanagawa Canc Ctr, Yokohama, Kanagawa, Japan; Natl Canc Ctr Hosp E, Chiba, Japan; Natl Kinki Cent Hosp Chest Dis, Osaka, Japan; Osaka City Gen Hosp, Osaka, Japan; Niigata Canc Ctr Hosp, Niigata, Japan; Aichi Canc Ctr, Nagoya, Aichi 464, Japan; Kinki Univ, Sch Med, Osaka 589, Japan; Tochigi Canc Ctr, Utsunomiya, Tochigi, Japan; Yokohama Municipal Citizens Hosp, Yokohama, Kanagawa, Japan; Natl Canc Ctr, Cent Hosp, Tokyo 104, Japan; Natl Canc Ctr, Res Inst, Canc Informat & Epidemiol Div, Tokyo 104, Japan	Kanagawa Prefectural Cancer Center; National Cancer Center - Japan; Osaka City General Hospital; Aichi Cancer Center; Kindai University (Kinki University); Tochigi Prefectural Cancer Center; National Cancer Center - Japan; National Cancer Center - Japan	Saijo, N (corresponding author), Natl Canc Ctr, Chuo Ku, Tsukiji 5-1-1, Tokyo 1040045, Japan.							AARONSON NK, 1993, J NATL CANCER I, V85, P365, DOI 10.1093/jnci/85.5.365; Aisner J, 1996, J CLIN ONCOL, V14, P658, DOI 10.1200/JCO.1996.14.2.658; DEMETS DL, 1994, STAT MED, V13, P1341, DOI 10.1002/sim.4780131308; FUKUOKA M, 1991, J NATL CANCER I, V83, P855, DOI 10.1093/jnci/83.12.855; IHDE DC, 1992, NEW ENGL J MED, V327, P1434; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; Kudoh S, 1998, J CLIN ONCOL, V16, P1068, DOI 10.1200/JCO.1998.16.3.1068; MASUDA N, 1992, J CLIN ONCOL, V10, P1225, DOI 10.1200/JCO.1992.10.8.1225; REBOUSSIN DM, 2001, PROGRAMS COMPUTING G; ROTH BJ, 1992, J CLIN ONCOL, V10, P282, DOI 10.1200/JCO.1992.10.2.282; TOBINAI K, 1993, JPN J CLIN ONCOL, V23, P250, DOI 10.1093/oxfordjournals.jjco.a039642; World Health Organization, 1979, WHO HDB REP RES CANC, V48	12	979	1034	1	12	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JAN 10	2002	346	2					85	91		10.1056/NEJMoa003034	http://dx.doi.org/10.1056/NEJMoa003034			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	509EM	11784874	Bronze			2023-01-03	WOS:000173133400003
J	Manges, AR; Johnson, JR; Foxman, B; O'Bryan, TT; Fullerton, KE; Riley, LW				Manges, AR; Johnson, JR; Foxman, B; O'Bryan, TT; Fullerton, KE; Riley, LW			Widespread distribution of urinary tract infections caused by a multidrug-resistant Escherichia coli clonal group	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							POLYMERASE CHAIN-REACTION; SEROTYPE O-15-K52-H1; STRAINS; SEQUENCES; WOMEN; PYELONEPHRITIS; UROPATHOGENS; BACTEREMIA; PREVALENCE; UROSEPSIS	Background: The management of urinary tract infections is complicated by the increasing prevalence of antibiotic-resistant strains of Escherichia coli. We studied the clonal composition of E. coli isolates that were resistant to trimethoprim-sulfamethoxazole from women with community-acquired urinary tract infections. Methods: Prospectively collected E. coli isolates from women with urinary tract infections in a university community in California were evaluated for antibiotic susceptibility, O:H serotype, DNA fingerprinting, pulsed-field gel electrophoretic pattern, and virulence factors. The prevalence and characteristics of an antibiotic-resistant clone were evaluated in this group of isolates and in those from comparison cohorts in Michigan and Minnesota. Results: Fifty-five of the 255 E. coli isolates (22 percent) from the California cohort were resistant to trimethoprim-sulfamethoxazole as well as other antibiotics. There was a common pattern of DNA fingerprinting, suggesting that the isolates belonged to the same clonal group (clonal group A), in 28 of 55 isolates with trimethoprim-sulfamethoxazole resistance (51 percent) and in 2 of 50 randomly selected isolates that were susceptible to trimethoprim-sulfamethoxazole (4 percent, P<0.001). In addition, 11 of 29 resistant isolates (38 percent) from the Michigan cohort and 7 of 18 (39 percent) from the Minnesota cohort belonged to clonal group A. Most of the clonal group A isolates were serotype O11:H(nt) or O77:H(nt), with similar patterns of virulence factors, antibiotic susceptibility, and electrophoretic features. Conclusions: In three geographically diverse communities, a single clonal group accounted for nearly half of community-acquired urinary tract infections in women that were caused by E. coli strains with resistance to trimethoprim-sulfamethoxazole. The widespread distribution and high prevalence of E. coli clonal group A have major public health implications. (N Engl J Med 2001;345:1007-13.) Copyright (C) 2001 Massachusetts Medical Society.	Univ Calif Berkeley, Sch Publ Hlth, Div Epidemiol & Publ Hlth Biol, Berkeley, CA 94720 USA; Minneapolis Vet Affairs Med Ctr, Med Serv, Minneapolis, MN USA; Univ Minnesota, Dept Med, Minneapolis, MN 55455 USA; Univ Michigan, Sch Publ Hlth, Dept Epidemiol, Ann Arbor, MI 48109 USA	University of California System; University of California Berkeley; US Department of Veterans Affairs; Veterans Health Administration (VHA); Minneapolis VA Health Care System; University of Minnesota System; University of Minnesota Twin Cities; University of Michigan System; University of Michigan	Riley, LW (corresponding author), Univ Calif Berkeley, Sch Publ Hlth, Div Epidemiol & Publ Hlth Biol, 140 Warren Hall, Berkeley, CA 94720 USA.			Foxman, Betsy/0000-0001-6682-238X	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R23DK035368, R01DK047504, R01DK035368] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK-47504, DK35368] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Bender JB, 1997, NEW ENGL J MED, V337, P388, DOI 10.1056/NEJM199708073370604; Bettelheim K. A., 1997, P85; Cooke EM, 1974, ESCHERICHIA COLI MAN, P31; Dalmau D, 1996, J HOSP INFECT, V34, P233, DOI 10.1016/S0195-6701(96)90073-0; Donnenberg Michael S., 1996, P135; DORN CR, 1993, J AM VET MED ASSOC, V203, P1583; Foxman B, 1997, J INFECT DIS, V175, P989, DOI 10.1086/514007; Foxman B, 2000, AM J EPIDEMIOL, V151, P1194, DOI 10.1093/oxfordjournals.aje.a010170; Foxman B, 2000, ANN EPIDEMIOL, V10, P509, DOI 10.1016/S1047-2797(00)00072-7; Gupta K, 1999, JAMA-J AM MED ASSOC, V281, P736, DOI 10.1001/jama.281.8.736; HARDY K, 1983, BACTERIAL PLASMIDS; Hooton TM, 1997, INFECT DIS CLIN N AM, V11, P551, DOI 10.1016/S0891-5520(05)70373-1; HULTON CSJ, 1991, MOL MICROBIOL, V5, P825, DOI 10.1111/j.1365-2958.1991.tb00755.x; Johnson JR, 2000, J INFECT DIS, V181, P2122; Johnson JR, 1998, J INFECT DIS, V177, P1120, DOI 10.1086/517409; Johnson JR, 2000, CLIN DIAGN LAB IMMUN, V7, P265, DOI 10.1128/CDLI.7.2.265-273.2000; JOHNSON JR, 1991, CLIN MICROBIOL REV, V4, P80, DOI 10.1128/CMR.4.1.80-128.1991; JOHNSON JR, 1988, INFECT IMMUN, V56, P405, DOI 10.1128/IAI.56.2.405-412.1988; Johnson JR, 2000, INFECT IMMUN, V68, P1587, DOI 10.1128/IAI.68.3.1587-1599.2000; Johnson JR, 2000, J INFECT DIS, V181, P261, DOI 10.1086/315217; Johnson JR, 2000, INFECT IMMUN, V68, P3327, DOI 10.1128/IAI.68.6.3327-3336.2000; JOHNSON JR, 1999, 99 GEN M AM SOC MICR, P31; Kahlmeter G, 2000, J ANTIMICROB CHEMOTH, V46, P15, DOI 10.1093/jac/46.suppl_1.15; MANIATIS T, 1991, CLIN MICROBIOL REV, V4, P80; MOBLEY HLT, 1990, INFECT IMMUN, V58, P1281, DOI 10.1128/IAI.58.5.1281-1289.1990; *NAT COMM CLIN LAB, 2000, M100S10 NCCLS, V14, P8; National Archives, 2000, M7A5 NCCLS, P1; Olesen B, 1995, J HOSP INFECT, V31, P295, DOI 10.1016/0195-6701(95)90208-2; PHILLIPS I, 1988, LANCET, V1, P1038; Prats G, 2000, J CLIN MICROBIOL, V38, P201; SHARPLES GJ, 1990, NUCLEIC ACIDS RES, V18, P6503, DOI 10.1093/nar/18.22.6503; Talan DA, 2000, JAMA-J AM MED ASSOC, V283, P1583, DOI 10.1001/jama.283.12.1583; TENOVER FC, 1995, J CLIN MICROBIOL, V33, P2233, DOI 10.1128/JCM.33.9.2233-2239.1995; TULLUS K, 1984, J INFECT DIS, V150, P728, DOI 10.1093/infdis/150.5.728; VERSALOVIC J, 1991, NUCLEIC ACIDS RES, V19, P6823, DOI 10.1093/nar/19.24.6823; Versalovic James, 1994, Methods in Molecular and Cellular Biology, V5, P25; WOODS CR, 1993, J CLIN MICROBIOL, V31, P1927, DOI 10.1128/JCM.31.7.1927-1931.1993; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9	38	361	371	0	29	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 4	2001	345	14					1007	1013		10.1056/NEJMoa011265	http://dx.doi.org/10.1056/NEJMoa011265			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	478HF	11586952				2023-01-03	WOS:000171340400001
J	Gattinoni, L; Tognoni, G; Pesenti, A; Taccone, P; Mascheroni, D; Labarta, V; Malacrida, R; Di Giulio, P; Fumagalli, R; Pelosi, P; Brazzi, L; Latini, R				Gattinoni, L; Tognoni, G; Pesenti, A; Taccone, P; Mascheroni, D; Labarta, V; Malacrida, R; Di Giulio, P; Fumagalli, R; Pelosi, P; Brazzi, L; Latini, R		Prone-Supine Study Grp	Effect of prone positioning on the survival of patients with acute respiratory failure	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ACUTE LUNG INJURY; OXYGENATION	Background: Although placing patients with acute respiratory failure in a prone (face down) position improves their oxygenation 60 to 70 percent of the time, the effect on survival is not known. Methods: In a multicenter, randomized trial, we compared conventional treatment (in the supine position) of patients with acute lung injury or the acute respiratory distress syndrome with a predefined strategy of placing patients in a prone position for six or more hours daily for 10 days. We enrolled 304 patients, 152 in each group. Results: The mortality rate was 23.0 percent during the 10-day study period, 49.3 percent at the time of discharge from the intensive care unit, and 60.5 percent at 6 months. The relative risk of death in the prone group as compared with the supine group was 0.84 at the end of the study period (95 percent confidence interval, 0.56 to 1.27), 1.05 at the time of discharge from the intensive care unit (95 percent confidence interval, 0.84 to 1.32), and 1.06 at six months (95 percent confidence interval, 0.88 to 1.28). During the study period the mean (+/-SD) increase in the ratio of the partial pressure of arterial oxygen to the fraction of inspired oxygen, measured each morning while patients were supine, was greater in the prone than the supine group (63.0+/-66.8 vs. 44.6+/-68.2, P=0.02). The incidence of complications related to positioning (such as pressure sores and accidental extubation) was similar in the two groups. Conclusions: Although placing patients with acute respiratory failure in a prone position improves their oxygenation, it does not improve survival.	Univ Milan, Osped Maggiore Milano, Ist Ricovero & Cura Carattere Sci, Ist Anestesia & Rianimaz, Milan, Italy; Univ Milano Bicocca, Osped S Gerardo, Ist Anestesia & Rianimaz, Monza, Italy; Ist Ric Farmacol Mario Negri, Milan, Italy; Lugano Civ Hosp, Dept Intens Care & Anesthesia, Lugano, Switzerland	IRCCS Ca Granda Ospedale Maggiore Policlinico; University of Milan; San Gerardo Hospital; University of Milano-Bicocca; Istituto di Ricerche Farmacologiche Mario Negri IRCCS	Gattinoni, L (corresponding author), Osped Maggiore Policlin IRCCS, Ist Anestesia & Rianimaz, Via Francesco Sforza 35, I-20122 Milan, Italy.		Brazzi, Luca/AAS-4978-2020; Pesenti, Antonio/H-7483-2012; Rocco, Patricia/I-7460-2012; Latini, Roberto/AAB-1410-2020; Fumagalli, Roberto/AAB-9746-2019	Brazzi, Luca/0000-0001-7059-0622; Pesenti, Antonio/0000-0003-2593-729X; Rocco, Patricia/0000-0003-1412-7136; Latini, Roberto/0000-0002-3729-4650; Fumagalli, Roberto/0000-0003-0398-1329; Gattinoni, Luciano/0000-0001-5380-2494; Pelosi, Paolo/0000-0001-5055-3023				ALBERT RK, 1987, AM REV RESPIR DIS, V135, P628; BERNARD GR, 1994, AM J RESP CRIT CARE, V149, P818, DOI 10.1164/ajrccm.149.3.7509706; Broccard A, 2000, CRIT CARE MED, V28, P295, DOI 10.1097/00003246-200002000-00001; Brower RG, 2000, NEW ENGL J MED, V342, P1301, DOI 10.1056/nejm200005043421801; DOUGLAS WW, 1977, AM REV RESPIR DIS, V115, P559; Human Medicines Evaluation Unit, 1996, ICH TOP E6 GUID GOOD, P17; KNAUS WA, 1985, CRIT CARE MED, V13, P818, DOI 10.1097/00003246-198510000-00009; LEGALL JR, 1994, JAMA-J AM MED ASSOC, V271, P1321; LEGALL JR, 1993, JAMA-J AM MED ASSOC, V270, P2957, DOI 10.1001/jama.270.24.2957; *NAT PRESS ULC ADV, 1989, DECUBITUS, V2, P24; PAPPERT D, 1994, CHEST, V106, P1511, DOI 10.1378/chest.106.5.1511; Pelosi P, 1998, AM J RESP CRIT CARE, V157, P387, DOI 10.1164/ajrccm.157.2.97-04023; PIEHL MA, 1976, CRIT CARE MED, V4, P13, DOI 10.1097/00003246-197601000-00003; POCOCK SJ, 1983, CLIN TRIALS PRACTICA, P231; SLUTSKY AS, 1994, INTENS CARE MED, V20, P378	15	691	765	1	22	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	AUG 23	2001	345	8					568	573		10.1056/NEJMoa010043	http://dx.doi.org/10.1056/NEJMoa010043			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	464ZH	11529210				2023-01-03	WOS:000170562900003
J	Heyland, DK; Novak, F; Drover, JW; Jain, A; Su, XY; Suchner, U				Heyland, DK; Novak, F; Drover, JW; Jain, A; Su, XY; Suchner, U			Should immunonutrition become routine in critically ill patients? A systematic review of the evidence	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							IMMUNE-ENHANCING DIET; ENTERAL NUTRITION; RANDOMIZED-TRIAL; ARGININE SUPPLEMENTATION; ARTIFICIAL NUTRITION; CLINICAL-TRIAL; DOUBLE-BLIND; FISH-OIL; CANCER; SURGERY	Context Several nutrients have been shown to influence immunologic and inflammatory responses in humans. Whether these effects translate into an improvement in clinical outcomes in critically ill patients remains unclear. Objective To examine the relationship between enteral nutrition supplemented with immune-enhancing nutrients and infectious complications and mortality rates in critically ill patients. Data Sources The databases of MEDLINE, EMBASE, Biosis, and CINAHL were searched for articles published from 1990 to 2000. Additional data sources included the Cochrane Controlled Trials Register from 1990 to 2000, personal files, abstract proceedings, and relevant reference fists of articles identified by database review. Study Selection A total of 326 titles, abstracts, and articles were reviewed. Primary studies were included If they were randomized trials of critically ill or surgical patients that evaluated the effect of enteral nutrition supplemented with some combination of arginine, glutamine, nucleotides, and omega-3 fatty acids on infectious complication and mortality rates compared with standard enteral nutrition, and included clinically important outcomes, such as mortality. Data Extraction Methodological quality of individual studies was scored and necessary data were abstracted in duplicate and independently. Data Synthesis Twenty-two randomized trials with a total of 2419 patients compared the use of immunonutrition with standard enteral nutrition in surgical and critically Ill patients. With respect to mortality, immunonutrition was associated with a pooled risk ratio (RR) of 1.10 (95% confidence interval [CI], 0.93-1.31). Immunonutrition was associated with lower infectious complications (RR, 0.66; 95% CI, 0.54-0.80). Since there was significant heterogeneity across studies, we examined several a priori subgroup analyses. We found that studies using commercial formulas with high arginine content were associated with a significant reduction in infectious complications and a trend toward a lower mortality rate compared with other immune-enhancing diets. Studies of surgical patients were associated with a significant reduction in infectious complication rates compared with studies of critically Ill patients. In studies of critically ill patients, studies with a high-quality score were associated with increased mortality and a significant reduction in infectious complication rates compared with studies with a low-quality score. Conclusion Immunonutrition may decrease infectious complication rates but it is not associated with an overall mortality advantage. However, the treatment effect varies depending on the intervention, the patient population, and the methodological quality of the study.	Queens Univ, Kingston Gen Hosp, Dept Med, Kingston, ON K7L 2V7, Canada; Queens Univ, Kingston Gen Hosp, Dept Surg, Kingston, ON K7L 2V7, Canada; Univ Munich, Grosshadern Univ Hosp, Dept Anesthesiol, Munich, Germany	Queens University - Canada; Queens University - Canada; University of Munich	Heyland, DK (corresponding author), Queens Univ, Kingston Gen Hosp, Dept Med, Angada 3,76 Stuart St, Kingston, ON K7L 2V7, Canada.	dkh2@post.queensu.ca	Novak, Frantisek/F-4268-2017; Suchner, Ulrich/AAC-7723-2020; Xia, Xianfeng/F-9169-2011	Novak, Frantisek/0000-0001-5582-3977; 				Alexander JW, 1998, NUTRITION, V14, P627, DOI 10.1016/S0899-9007(98)00004-5; Atkinson S, 1998, CRIT CARE MED, V26, P1164, DOI 10.1097/00003246-199807000-00013; Bastian L, 1998, Langenbecks Arch Chir Suppl Kongressbd, V115, P1083; Bastian L, 1998, UNFALLCHIRURG, V101, P105, DOI 10.1007/s001130050242; Beale RJ, 1999, CRIT CARE MED, V27, P2799, DOI 10.1097/00003246-199912000-00032; BOWER RH, 1995, CRIT CARE MED, V23, P436, DOI 10.1097/00003246-199503000-00006; Braga M, 1996, EUR J SURG, V162, P105; Braga M, 1996, ARCH SURG-CHICAGO, V131, P1257; Braga M, 1999, ARCH SURG-CHICAGO, V134, P428, DOI 10.1001/archsurg.134.4.428; Braga M, 1998, NUTRITION, V14, P831, DOI 10.1016/S0899-9007(98)00103-8; BRAGA M, 1995, INFUSIONSTHERAPIE, V22, P280; Braga M, 1998, CRIT CARE MED, V26, P24, DOI 10.1097/00003246-199801000-00012; BRAGA M, 1999, JPEN J PARENTER ENTE, V23, pS2; BROWN RO, 1994, PHARMACOTHERAPY, V14, P314; CERRA FB, 1990, NUTRITION, V6, P84; CHENDRASEKHAR A, 1997, CRIT CARE MED, V25, pA135; DALY JM, 1990, CRIT CARE MED, V18, pS86; DALY JM, 1992, SURGERY, V112, P56; DALY JM, 1995, ANN SURG, V221, P327, DOI 10.1097/00000658-199504000-00002; DEMPSEY DT, 1988, AM J CLIN NUTR, V47, P352, DOI 10.1093/ajcn/47.2.352; DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2; Di Carlo V, 1999, DIGEST SURG, V16, P320, DOI 10.1159/000018742; DiGiovine B, 1999, AM J RESP CRIT CARE, V160, P976, DOI 10.1164/ajrccm.160.3.9808145; Engel JM, 1997, ANASTH INTENSIV NOTF, V32, P234, DOI 10.1055/s-2007-995043; Evoy D, 1998, NUTRITION, V14, P611, DOI 10.1016/S0899-9007(98)00005-7; FAGON JY, 1994, INFECT CONT HOSP EP, V15, P428; Fleming TR, 1996, ANN INTERN MED, V125, P605, DOI 10.7326/0003-4819-125-7-199610010-00011; Gadek JE, 1999, CRIT CARE MED, V27, P1409, DOI 10.1097/00003246-199908000-00001; Galban C, 2000, CRIT CARE MED, V28, P643, DOI 10.1097/00003246-200003000-00007; Gianotti L, 2000, PANCREAS, V21, P344, DOI 10.1097/00006676-200011000-00004; Gianotti L, 1999, JPEN-PARENTER ENTER, V23, P314, DOI 10.1177/0148607199023006314; Gianotti L, 1997, ARCH SURG-CHICAGO, V132, P1222, DOI 10.1001/archsurg.1997.01430350072012; Gianotti Luca, 1998, Rivista Italiana di Nutrizione Parenterale ed Enterale, V16, P173; GONCE SJ, 1990, JPEN-PARENTER ENTER, V14, P237, DOI 10.1177/0148607190014003237; GOTTSCHLICH MM, 1990, JPEN-PARENTER ENTER, V14, P225, DOI 10.1177/0148607190014003225; GREGOIRE G, 1995, J CLIN EPIDEMIOL, V48, P159, DOI 10.1016/0895-4356(94)00098-B; Hasselmann M., 1997, INTENS CARE MED, V23, pS136; HEDGES LV, 1982, PSYCHOL BULL, V92, P490, DOI 10.1037/0033-2909.92.2.490; Heslin MJ, 1997, ANN SURG, V226, P567, DOI 10.1097/00000658-199710000-00016; Heyland DK, 1999, AM J RESP CRIT CARE, V159, P1249, DOI 10.1164/ajrccm.159.4.9807050; Heyland DK, 1998, JAMA-J AM MED ASSOC, V280, P2013, DOI 10.1001/jama.280.23.2013; Heys SD, 1999, ANN SURG, V229, P467, DOI 10.1097/00000658-199904000-00004; HOUDIJK AP, 1999, JPEN J PARENTER E S5, V23, P52; Houdijk APJ, 1998, LANCET, V352, P772, DOI 10.1016/S0140-6736(98)02007-8; Jones C, 1999, NUTRITION, V15, P108, DOI 10.1016/S0899-9007(98)00172-5; Kenler AS, 1996, ANN SURG, V223, P316, DOI 10.1097/00000658-199603000-00013; Kudsk KA, 1996, ANN SURG, V224, P531, DOI 10.1097/00000658-199610000-00011; Leleiko NS, 1995, NUTRITION, V11, P725; LIEBERMAN MD, 1990, NUTRITION, V6, P88; LORENTE JA, 1993, CRIT CARE MED, V21, P1287, DOI 10.1097/00003246-199309000-00010; MEAKINS JL, 1979, ANN SURG, V190, P286, DOI 10.1097/00000658-197909000-00003; Mendez C, 1997, J TRAUMA, V42, P933, DOI 10.1097/00005373-199705000-00026; MOORE FA, 1994, J TRAUMA, V37, P607, DOI 10.1097/00005373-199410000-00014; Morais A A, 1995, Rev Hosp Clin Fac Med Sao Paulo, V50, P276; NAYLOR AF, 1967, BIOMETRICS, V23, P349, DOI 10.2307/2528167; Ogawa K, 2000, SURGERY, V127, P329, DOI 10.1067/msy.2000.103498; RODRIGO CM, 1997, NUTR HOSP, V12, P80; Rothman J., 1986, MODERN EPIDEMIOLOGY; ROTHMAN KJ, 1979, EPIDEMIOLOGICAL ANAL; Saffle JR, 1997, J TRAUMA, V42, P793, DOI 10.1097/00005373-199705000-00008; SAITO H, 1987, ARCH SURG-CHICAGO, V122, P784; Schilling J, 1996, NUTRITION, V12, P423, DOI 10.1016/S0899-9007(96)00096-2; SCHULZ KF, 1995, JAMA-J AM MED ASSOC, V273, P408, DOI 10.1001/jama.273.5.408; Senkal M, 1999, ARCH SURG-CHICAGO, V134, P1309, DOI 10.1001/archsurg.134.12.1309; Senkal M, 1997, CRIT CARE MED, V25, P1489, DOI 10.1097/00003246-199709000-00015; Snyderman CH, 1999, LARYNGOSCOPE, V109, P915, DOI 10.1097/00005537-199906000-00014; Sugimoto K, 1999, CRIT CARE MED, V27, pA91, DOI 10.1097/00003246-199912001-00236; TALABISKA DG, 1993, FASEB J, V7, pA378; TEPASKE R, 1999, EUSIS K OSL; Weimann A, 1998, NUTRITION, V14, P165, DOI 10.1016/S0899-9007(97)00429-2; WHITEHEAD A, 1991, STAT MED, V10, P1665, DOI 10.1002/sim.4780101105; WILMORE DW, 1991, NEW ENGL J MED, V325, P695, DOI 10.1056/NEJM199109053251005; WILMORE DW, 1996, BRIT J SURG, V83, P305; Wu DY, 1998, P NUTR SOC, V57, P503, DOI 10.1079/PNS19980074	74	591	623	2	23	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 22	2001	286	8					944	953		10.1001/jama.286.8.944	http://dx.doi.org/10.1001/jama.286.8.944			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	465EU	11509059				2023-01-03	WOS:000170577300029
J	Reynolds, NJ; Franklin, V; Gray, JC; Diffey, BL; Farr, PM				Reynolds, NJ; Franklin, V; Gray, JC; Diffey, BL; Farr, PM			Narrow-band ultraviolet B and broad-band ultraviolet A phototherapy in adult atonic eczema: a randomised controlled trial	LANCET			English	Article							ATOPIC-DERMATITIS; UVB PHOTOTHERAPY; T-CELLS; PSORIASIS; PHOTOCHEMOTHERAPY; CYCLOSPORINE; INDUCTION; APOPTOSIS; EXPOSURE; THERAPY	Background Narrow-band ultraviolet B (UVB) is an effective treatment for psoriasis, and open studies suggest that this phototherapy might improve atopic eczema. We did a randomised controlled trial to compare narrow-band UVB, UVA, and visible light phototherapy as second-line, adjunctive treatments in adult patients with moderate to severe atopic eczema. Methods Phototherapy was administered twice a week for 12 weeks. 26 patients were randomly assigned narrow-band UVB, 24 were assigned UVA, and 23 visible fluorescent light. The primary endpoints were change in total disease activity (sum of scores at six body sites) and change in extent of disease after 24 treatments compared with baseline. Data were analysed by the method of summary measures. Findings 13 patients withdrew or were excluded from analysis. Mean reductions in total disease activity over 24 treatments in patients who received narrow-band UVB and UVA, respectively, were 9.4 points (95% CI 3.6 to 15.2)and 4.4 points ( - 1.0 to 9.8) more than in patients who received visible light. Mean reductions in extent of disease after 24 treatments with narrow-band UVB and UVA were 6.7% (1.5 to 11.9) and -1.0% (-5.3 to 3.3)compared with visible light. A small proportion of patients developed erythema after phototherapy or had a flare in their eczema sufficient to withdraw from treatment. Interpretation Narrow-band UVB is an effective adjunctive treatment for moderate to severe atopic eczema, and the treatment is well tolerated by most patients.	Newcastle Univ, Sch Med, Dept Dermatol, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England; Univ Teesside, Postgrad Inst Hlth, Middlesbrough, Cleveland, England; Newcastle Gen Hosp, Dept Reg Med Phys, Newcastle Upon Tyne NE4 6BE, Tyne & Wear, England	Newcastle University - UK; University of Teesside; Newcastle General Hospital	Reynolds, NJ (corresponding author), Newcastle Univ, Sch Med, Dept Dermatol, Framlington Pl, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England.	n.j.reynolds@ncl.ac.uk		Reynolds, Nick/0000-0002-6484-825X				Barr RM, 1999, J INVEST DERMATOL, V112, P692, DOI 10.1046/j.1523-1747.1999.00570.x; BerthJones J, 1996, BRIT J DERMATOL, V135, P25, DOI 10.1111/j.1365-2133.1996.tb00706.x; Bilsland D, 1997, BRIT J DERMATOL, V137, P327, DOI 10.1046/j.1365-2133.1997.18441939.x; Charman CR, 1999, BRIT J DERMATOL, V140, P109; deBerker DAR, 1997, J AM ACAD DERMATOL, V36, P577, DOI 10.1016/S0190-9622(97)70246-9; ENK CD, 1995, J IMMUNOL, V154, P4851; FISCHER T, 1976, ACTA DERM-VENEREOL, V56, P473; GEORGE SA, 1993, BRIT J DERMATOL, V128, P49, DOI 10.1111/j.1365-2133.1993.tb00147.x; GIBBS NK, 1995, J INVEST DERMATOL, V104, P359, DOI 10.1111/1523-1747.ep12665385; Gordon PM, 1998, BRIT J DERMATOL, V139, P811; HARPER J, 1994, BRIT MED J, V308, P489, DOI 10.1136/bmj.308.6927.489; HERSEY P, 1983, J IMMUNOL, V131, P171; HudsonPeacock MJ, 1996, BRIT J DERMATOL, V135, P332, DOI 10.1111/j.1365-2133.1996.tb01179.x; JECKLER J, 1988, BRIT J DERMATOL, V119, P697, DOI 10.1111/j.1365-2133.1988.tb03490.x; JEKLER J, 1991, BRIT J DERMATOL, V125, P569, DOI 10.1111/j.1365-2133.1991.tb14796.x; JEKLER J, 1990, J AM ACAD DERMATOL, V22, P49, DOI 10.1016/0190-9622(90)70006-4; KRUEGER JG, 1995, J EXP MED, V182, P2057, DOI 10.1084/jem.182.6.2057; Krutmann J, 1999, J INVEST DERM SYMP P, V4, P70, DOI 10.1038/sj.jidsp.5640185; Krutmann J, 1998, J AM ACAD DERMATOL, V38, P589, DOI 10.1016/S0190-9622(98)70123-9; MATTHEWS JNS, 1993, STAT MED, V12, P27, DOI 10.1002/sim.4780120105; MATTHEWS JNS, 1990, BRIT MED J, V300, P230, DOI 10.1136/bmj.300.6719.230; McGinley J, 1998, BRIT J DERMATOL, V139, P428; MORISON WL, 1979, BRIT J DERMATOL, V101, P513, DOI 10.1111/j.1365-2133.1979.tb15094.x; Morita A, 1997, J EXP MED, V186, P1763, DOI 10.1084/jem.186.10.1763; Ozawa M, 1999, J EXP MED, V189, P711, DOI 10.1084/jem.189.4.711; Powles AV, 1998, BRIT J DERMATOL, V138, P443; SHEEHAN MP, 1992, LANCET, V340, P13, DOI 10.1016/0140-6736(92)92424-E; SOWDEN JM, 1991, LANCET, V338, P137, DOI 10.1016/0140-6736(91)90134-B; VANWEELDEN H, 1988, BRIT J DERMATOL, V119, P11; Walters IB, 1999, J AM ACAD DERMATOL, V40, P893, DOI 10.1016/S0190-9622(99)70076-9; WILLIAMS HC, 1994, BRIT J DERMATOL, V131, P383, DOI 10.1111/j.1365-2133.1994.tb08530.x; YOUNG AR, 1995, LANCET, V345, P1431, DOI 10.1016/S0140-6736(95)92617-8	33	163	173	0	12	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JUN 23	2001	357	9273					2012	2016		10.1016/S0140-6736(00)05114-X	http://dx.doi.org/10.1016/S0140-6736(00)05114-X			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	446JB	11438134				2023-01-03	WOS:000169509200011
J	Smellie, JM; Barratt, TM; Chantler, C; Gordon, I; Prescod, NP; Ransley, PG; Woolf, AS				Smellie, JM; Barratt, TM; Chantler, C; Gordon, I; Prescod, NP; Ransley, PG; Woolf, AS			Medical versus surgical treatment in children with severe bilateral vesicoureteric reflux and bilateral nephropathy: a randomised trial	LANCET			English	Article							WEIGHT HEIGHT VELOCITY; INTERNATIONAL REFLUX; RENAL SCARS; 5-YEAR; STANDARDS; MATURITY; BIRTH	Background Nephropathy associated with vesicoureteric reflux (VUR) and urinary tract infection can result in end-stage renal failure, hypertension, or both. Whether long-term VUR contributes to these outcomes is unknown. We compared, in a randomised trial. medical with surgical management of children with bilateral severe VUR and bilateral nephropathy. Methods We stratified by age and glomerular filtration rate (GFR) 25 boys and 27 girls aged 1-12 years and randomly assigned them to medical or surgical management. At enrolment and 4 years' follow-up we estimated GFR from the plasma clearance of Cr-51-labelled edetic acid (EDTA), and did intravenous urography. We also did a metastable Tc-99m-labelled dimercaptosuccinic acid (DMSA) assay and contrast cystography. The change in GFR at 4 years, expressed as a percentage change between enrolment and 4 years, was available for 26 of 27 patients in the medical and 24 of 25 in the surgical group. We assessed GFR in 48 patients 10 years after enrolment. Findings Mean GFR at enrolment was 72.4 mL/min per 1.73 m(2) (SD 24.1) in the medical and 71.7 mL/min per 1.73 m(2) (22.6) in the surgical group. The mean percentage change in Gm at 4 years was -2.4% (SE 4.5) versus 4.7% (5.0) in the medical and surgical groups, respectively. The difference in change in GFR at 4 years between the two groups was not significant(7.1%, 95% CI -6.4% to 20.6%). Interpretation Our data do not lend support to the view that the outcome for renal function is improved by surgical correction of VUR in children with bilateral disease.	UCL, Great Ormond St Hosp Children NHS Trust, London WC1N 1EH, England; UCL, Inst Child Hlth, London WC1N 1EH, England; Kings Coll London, Guys Hosp, Sch Dent, London WC2R 2LS, England; Kings Coll London, Guys Hosp, Sch Med, London WC2R 2LS, England; Kings Coll London, St Thomas Hosp, Sch Med, London WC2R 2LS, England; Kings Coll London, St Thomas Hosp, Sch Dent, London WC2R 2LS, England	University of London; University College London; Great Ormond Street Hospital for Children NHS Foundation Trust; University of London; University College London; Guy's & St Thomas' NHS Foundation Trust; University of London; King's College London; Guy's & St Thomas' NHS Foundation Trust; University of London; King's College London; Guy's & St Thomas' NHS Foundation Trust; University of London; King's College London; Guy's & St Thomas' NHS Foundation Trust; University of London; King's College London	Barratt, TM (corresponding author), UCL, Great Ormond St Hosp Children NHS Trust, London WC1N 1EH, England.	M.Barratt@ich.ucl.ac.uk	Woolf, Adrian S./AAZ-1075-2020	Woolf, Adrian S./0000-0001-5541-1358				[Anonymous], 1987, PEDIATRICS, V79, P1; APERIA A, 1975, ACTA PAEDIATR SCAND, V64, P393, DOI 10.1111/j.1651-2227.1975.tb03853.x; ASTLEY R, 1983, British Medical Journal, V287, P171; ASTLEY R, 1987, BRIT MED J, V295, P237; BERGSTROM J, 1986, CLIN NEPHROL, V25, P1; CHANTLER C, 1972, ARCH DIS CHILD, V47, P613, DOI 10.1136/adc.47.254.613; COHEN SJ, 1997, PEDIAT UROLOGY, P466; Du Bois D, 1916, ARCH INTERN MED, V17, P863, DOI 10.1001/archinte.1916.00080130010002; Feather SA, 2000, AM J HUM GENET, V66, P1420, DOI 10.1086/302864; FOGO A, 1999, PEDIAT NEPHROLOGY, P1183; HINCHLIFFE SA, 1992, PEDIATR NEPHROL, V6, P439, DOI 10.1007/BF00874007; HODSON CJ, 1979, REFLUX NEPHROPATHY, P29; LEBOWITZ RL, 1985, PEDIATR RADIOL, V15, P105, DOI 10.1007/BF02388714; LEWIS M, 1999, 2 REN ASS UK REN REG, P175; OLBING H, 1992, J UROLOGY, V148, P1653, DOI 10.1016/S0022-5347(17)36995-1; Olbing H, 2000, RADIOLOGY, V216, P731, DOI 10.1148/radiology.216.3.r00au35731; Piepsz A, 1998, EUR J PEDIATR, V157, P753, DOI 10.1007/s004310050929; POLITANO VA, 1958, J UROLOGY, V79, P932, DOI 10.1016/S0022-5347(17)66369-9; RANSLEY PG, 1978, BRIT J RADIOL      S, V14, P1; RISDON RA, 1993, CLIN NEPHROL, V40, P308; Smellie J, 1975, Kidney Int Suppl, V4, pS65; SMELLIE JM, 1994, BRIT MED J, V308, P1193, DOI 10.1136/bmj.308.6938.1193; SMELLIE JM, 1985, BRIT MED J, V290, P1957, DOI 10.1136/bmj.290.6486.1957; SMELLIE JM, 1995, ARCH DIS CHILD, V72, P251, DOI 10.1136/adc.72.3.251; Smellie JM, 1998, PEDIATR NEPHROL, V12, P727, DOI 10.1007/s004670050535; SMELLIE JM, 1992, PEDIATR NEPHROL, V6, P223, DOI 10.1007/BF00878353; TANNER JM, 1966, ARCH DIS CHILD, V41, P454, DOI 10.1136/adc.41.219.454; Wennerstrom M, 2000, J PEDIATR-US, V136, P30, DOI 10.1016/S0022-3476(00)90045-3	28	160	171	0	6	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	APR 28	2001	357	9265					1329	1333		10.1016/S0140-6736(00)04520-7	http://dx.doi.org/10.1016/S0140-6736(00)04520-7			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	427ND	11343739				2023-01-03	WOS:000168411400012
J	Eisenberg, MS; Mengert, TJ				Eisenberg, MS; Mengert, TJ			Primary care: Cardiac resuscitation	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							AMERICAN-HEART-ASSOCIATION; AUTOMATED EXTERNAL DEFIBRILLATORS; INTERPOSED ABDOMINAL COMPRESSION; TO-MOUTH VENTILATION; CARDIOPULMONARY-RESUSCITATION; VENTRICULAR-FIBRILLATION; LIFE-SUPPORT; MYOCARDIAL-INFARCTION; HEALTH-PROFESSIONALS; IMPROVING SURVIVAL		Univ Washington, Med Ctr, Emergency Med Serv, Dept Med,Div Emergency Med, Seattle, WA 98195 USA	University of Washington; University of Washington Seattle	Eisenberg, MS (corresponding author), Univ Washington, Med Ctr, Emergency Med Serv, Dept Med,Div Emergency Med, Box 356123, Seattle, WA 98195 USA.							*AM HEART ASS, 1998, 1999 HEART STROK STA; BABBS CF, 1994, AM HEART J, V127, P412, DOI 10.1016/0002-8703(94)90132-5; Ballew KA, 1995, RESUSCITATION, V30, P203, DOI 10.1016/0300-9572(95)00894-2; Bardy GH, 1996, CIRCULATION, V94, P2507, DOI 10.1161/01.CIR.94.10.2507; Baubin M, 1999, RESUSCITATION, V41, P33, DOI 10.1016/S0300-9572(99)00033-7; Becker L, 1996, CARDIAC ARREST SCI P, P28; Becker LB, 1997, CIRCULATION, V96, P2102, DOI 10.1161/01.CIR.96.6.2102; BECKER LB, 1991, ANN EMERG MED, V20, P355, DOI 10.1016/S0196-0644(05)81654-3; BERGNER L, 1985, AM J PUBLIC HEALTH, V75, P1321, DOI 10.2105/AJPH.75.11.1321; BONNIN MJ, 1993, JAMA-J AM MED ASSOC, V270, P1457, DOI 10.1001/jama.270.12.1457; Brown J, 2000, JAMA-J AM MED ASSOC, V284, P1438, DOI 10.1001/jama.284.11.1438; Cobb LA, 1999, JAMA-J AM MED ASSOC, V281, P1182, DOI 10.1001/jama.281.13.1182; CUMMINS RO, 1984, LANCET, V2, P318; CUMMINS RO, 1991, CIRCULATION, V84, P960, DOI 10.1161/01.CIR.84.2.960; CUMMINS RO, 1991, CIRCULATION, V83, P1832, DOI 10.1161/01.CIR.83.5.1832; CUMMINS RO, 1988, J AM COLL CARDIOL, V11, P597, DOI 10.1016/0735-1097(88)91537-9; Cummins RO, 1997, CIRCULATION, V95, P2172, DOI 10.1161/01.CIR.95.8.2172; CUMMINS RO, 1985, JAMA-J AM MED ASSOC, V253, P2408, DOI 10.1001/jama.253.16.2408; Domanski MJ, 1997, CIRCULATION, V95, P2694, DOI 10.1161/01.CIR.95.12.2694; Eisenberg M., 1997, LIFE BALANCE EMERGEN, P251; Eisenberg MS, 2000, JAMA-J AM MED ASSOC, V284, P1435, DOI 10.1001/jama.284.11.1435; EISENBERG MS, 1990, ANN EMERG MED, V19, P179, DOI 10.1016/S0196-0644(05)81805-0; EISENBERG MS, 1979, JAMA-J AM MED ASSOC, V241, P1905, DOI 10.1001/jama.241.18.1905; EISENBERG MS, 1997, LIFE BALANCE EMERGEN, P188; EISENBERG MS, 1984, SUDDEN CARDIAC DEATH; GILLUM RF, 1994, J AM COLL CARDIOL, V23, P1273, DOI 10.1016/0735-1097(94)90367-0; Gliner BE, 1999, RESUSCITATION, V41, P133, DOI 10.1016/S0300-9572(99)00040-4; Gliner Bradford E., 1998, Biomedical Instrumentation and Technology, V32, P631; Gregoratos G, 1998, J AM COLL CARDIOL, V31, P1175; Hallstrom A, 2000, NEW ENGL J MED, V342, P1546, DOI 10.1056/NEJM200005253422101; HALPERIN HR, 1996, CARDIAC ARREST SCI P, P252; Hossack KF, 1982, J CARDIAC REHABIL, V2, P402; Iserson KV, 1999, GRAVE WORDS NOTIFYIN; Kataoka K, 1998, NEUROSCI RES, V32, P103, DOI 10.1016/S0168-0102(98)00076-5; KELLERMANN AL, 1993, JAMA-J AM MED ASSOC, V270, P1433, DOI 10.1001/jama.270.12.1433; KOUWENHOVEN WB, 1960, JAMA-J AM MED ASSOC, V173, P1064, DOI 10.1001/jama.1960.03020280004002; Kudenchuk PJ, 1999, NEW ENGL J MED, V341, P871, DOI 10.1056/NEJM199909163411203; LARSEN MP, 1993, ANN EMERG MED, V22, P1652, DOI 10.1016/S0196-0644(05)81302-2; Levine RL, 1997, NEW ENGL J MED, V337, P301, DOI 10.1056/NEJM199707313370503; LOMBARDI G, 1994, JAMA-J AM MED ASSOC, V271, P678; MYERBURG RJ, 1997, HEART DIS TXB CARDIO, V1, P742; ORNATO JP, 1998, TXB CARDIOVASCULAR M, P1779; OSBORN LA, 1996, CARDIAC ARREST SCI P, P243; Page RL, 2000, NEW ENGL J MED, V343, P1210, DOI 10.1056/NEJM200010263431702; Plaisance P, 1999, NEW ENGL J MED, V341, P569, DOI 10.1056/NEJM199908193410804; Poole JE, 1997, J CARDIOVASC ELECTR, V8, P1373, DOI 10.1111/j.1540-8167.1997.tb01034.x; REICHENBACH DD, 1977, AM J CARDIOL, V39, P865, DOI 10.1016/S0002-9149(77)80041-6; RIEGEL B, 1997, SUDDEN CARDIAC DEATH, P275; Rubertsson S, 2000, TXB CRITICAL CARE, P9; Rumball C J, 1997, Prehosp Emerg Care, V1, P1, DOI 10.1080/10903129708958776; SACK JB, 1992, CIRCULATION, V86, P1692, DOI 10.1161/01.CIR.86.6.1692; SAFAR P, 1994, CRIT CARE MED, V22, P1703; SAFAR P, 1958, JAMA-J AM MED ASSOC, V167, P335, DOI 10.1001/jama.1958.72990200026008c; Smith SC, 1998, CIRCULATION, V97, P1321, DOI 10.1161/01.CIR.97.13.1321; SWANSON RW, 1993, ANN EMERG MED, V22, P350, DOI 10.1016/S0196-0644(05)80464-0; Valenzuela TD, 2000, NEW ENGL J MED, V343, P1206, DOI 10.1056/NEJM200010263431701; Valenzuela TD, 1997, CIRCULATION, V96, P3308; van Walraven C, 1999, ARCH INTERN MED, V159, P129, DOI 10.1001/archinte.159.2.129; WEAVER WD, 1986, ANN EMERG MED, V15, P1181; 2000, CIRCULATION S1, V102, P1; 1999, HLTH DEVICES, V28, P186	61	337	368	0	12	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	APR 26	2001	344	17					1304	1313		10.1056/NEJM200104263441707	http://dx.doi.org/10.1056/NEJM200104263441707			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	424UM	11320390				2023-01-03	WOS:000168252400007
J	Little, RF; Gutierrez, M; Jaffe, ES; Pau, A; Horne, M; Wilson, W				Little, RF; Gutierrez, M; Jaffe, ES; Pau, A; Horne, M; Wilson, W			HIV-associated non-Hodgkin lymphoma - Incidence, presentation, and prognosis	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ACQUIRED-IMMUNODEFICIENCY-SYNDROME; IMMUNE-DEFICIENCY SYNDROME; EPSTEIN-BARR-VIRUS; LYMPHOPROLIFERATIVE DISORDERS; INTENSIVE CHEMOTHERAPY; DRUG-INTERACTIONS; AIDS; INFECTION; SURVIVAL; CLASSIFICATION	Patients with acquired immunodeficiency syndrome (AIDS)-associated non-Hodgkin lymphoma often present with multiple poor prognostic features, including significant tumor burden, advanced immunosuppression, and other concurrent morbidities, Strategies to manage such complex multiple-disease cases have often incorporated the assumption that prospects for long-term survival are poor and that intensive therapy cannot be tolerated and so is not justified. Since the advent of highly active antiretroviral therapy-for human immunodeficiency virus infection, life expectancy has improved substantially for patients in whom the virus can be successfully suppressed. Thus, for complicated cases involving AIDS-associated malignancy, a reassess ment of treatment strategies and the potential for long-term survival is warranted. Here, we present the case of a patient with poor prognosis due to AIDS-associated lymphoma with leptomeningeal involvement, advanced immunosuppression, and deep venous thrombosis. The management of this case illustrates that a multidisciplinary approach to complex AIDS cases involving malignancy and concurrent morbidity can result in a return to functional health in affected patients. Successful strategies for achieving favorable outcomes currently exist with available therapies.	NCI, HIV & AIDS Malignancy Branch, Div Clin Sci, Bethesda, MD 20892 USA; NCI, Med Branch, Bethesda, MD 20892 USA; NCI, Canc Res Ctr, Pathol Lab, Bethesda, MD 20892 USA; NIH, Ctr Clin, Dept Clin Pathol, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH Clinical Center (CC)	Little, RF (corresponding author), NCI, HIV & AIDS Malignancy Branch, Div Clin Sci, Bldg 10,Room 10S255,9000 Rockville Pike, Bethesda, MD 20892 USA.	rlittle@helix.nih.gov	Jaffe, Elaine/G-8981-2014					Aboulafia D M, 1994, Cancer Pract, V2, P297; ANTINORI A, 1999, 6 C RETR OPP INF JAN; BERAL V, 1990, LANCET, V335, P123, DOI 10.1016/0140-6736(90)90001-L; BERAL V, 1991, LANCET, V337, P805, DOI 10.1016/0140-6736(91)92513-2; CARBONE PP, 1971, CANCER RES, V31, P1860; COSTAGLIOLA D, 1998, 12 INT C AIDS JUN 28; Cote TR, 1997, INT J CANCER, V73, P645, DOI 10.1002/(SICI)1097-0215(19971127)73:5&lt;645::AID-IJC6&gt;3.0.CO;2-X; Davi F, 1998, J CLIN ONCOL, V16, P3788, DOI 10.1200/JCO.1998.16.12.3788; Deeks SG, 1997, JAMA-J AM MED ASSOC, V277, P145, DOI 10.1001/jama.277.2.145; ENTING RH, 1994, J NEUROL NEUROSUR PS, V57, P150, DOI 10.1136/jnnp.57.2.150; FAUCI A, 1998, GUIDELINES USE ANTIR; FAUCI AS, 2000, GUIDELINES USE ANTIR; FISHER RI, 1993, NEW ENGL J MED, V328, P1002, DOI 10.1056/NEJM199304083281404; Freimuth WW, 1996, ADV EXP MED BIOL, V394, P279; Grulich AE, 1999, J ACQ IMMUN DEF SYND, V21, pS27; HAGEMEISTER FB, 1994, ANN ONCOL, V5, pS41, DOI 10.1093/annonc/5.suppl_2.S41; HARRIS NL, 1994, BLOOD, V84, P1361; Irwin David, 1993, Current Opinion in Oncology, V5, P852, DOI 10.1097/00001622-199309000-00013; Jaffe ES, 1997, CANCER SURV, V30, P233; JONES J, 1998, 2 NAT AIDS MAL C APR; Kaplan L D, 1993, AIDS Clin Rev, P145; Kaplan LD, 1997, NEW ENGL J MED, V336, P1641, DOI 10.1056/NEJM199706053362304; Kempf DJ, 1997, ANTIMICROB AGENTS CH, V41, P654, DOI 10.1128/AAC.41.3.654; Kingma DW, 1999, ARCH PATHOL LAB MED, V123, P83; Knowles DM, 1999, MODERN PATHOL, V12, P200; KWAK LW, 1990, J CLIN ONCOL, V8, P963, DOI 10.1200/JCO.1990.8.6.963; LAI GM, 1991, INT J CANCER, V49, P696, DOI 10.1002/ijc.2910490512; Lai R, 1998, MODERN PATHOL, V11, P864; LEVINE AM, 1991, HEMATOL ONCOL CLIN N, V5, P331, DOI 10.1016/S0889-8588(18)30445-3; LEVINE AM, 1987, SEMIN ONCOL, V14, P34; LEVINE AM, 1991, CANCER, V68, P2466, DOI 10.1002/1097-0142(19911201)68:11<2466::AID-CNCR2820681124>3.0.CO;2-G; LEVINE AM, 1994, ANN ONCOL, V5, pS29, DOI 10.1093/annonc/5.suppl_2.S29; LEVINE AM, 1992, MED CLIN N AM, V76, P253, DOI 10.1016/S0025-7125(16)30379-0; LEVINE AM, 1993, JNCI-J NATL CANCER I, V85, P1382, DOI 10.1093/jnci/85.17.1382; LITTLE RF, 1999, 35 ANN M AM SOC CLIN; MACKALL CL, 1994, BLOOD, V84, P2221; Mellors JW, 1996, SCIENCE, V272, P1167, DOI 10.1126/science.272.5265.1167; Mewissen MW, 1999, RADIOLOGY, V211, P39, DOI 10.1148/radiology.211.1.r99ap4739; MORAN CA, 1992, MODERN PATHOL, V5, P85; National Cancer Institute (NCI), 1973, SEER CANC STAT REV; Navarro JT, 1998, HAEMATOLOGICA, V83, P508; PELICCI PG, 1986, J EXP MED, V164, P2049, DOI 10.1084/jem.164.6.2049; RAPHAEL MM, 1994, AM J CLIN PATHOL, V101, P773, DOI 10.1093/ajcp/101.6.773; RATNER L, 1999, 3 NAT AIDS MAL M MAY; ROITHMANN S, 1992, EUR J CANCER, V28A, P1501, DOI 10.1016/0959-8049(92)90553-E; SPARANO J, 1998, 2 NAT AIDS MAL C APR; Sparano JA, 1996, J CLIN ONCOL, V14, P3026, DOI 10.1200/JCO.1996.14.11.3026; Taburet AM, 1996, CLIN PHARMACOKINET, V30, P385, DOI 10.2165/00003088-199630050-00005; Tirelli U, 1995, LEUKEMIA LYMPHOMA, V20, P91, DOI 10.3109/10428199509054758; Tirelli U, 1996, HEMATOL ONCOL, V14, P7, DOI 10.1002/(SICI)1099-1069(199603)14:1<7::AID-HON556>3.0.CO;2-D; Vaccher E, 1996, J CLIN ONCOL, V14, P2217, DOI 10.1200/JCO.1996.14.8.2217; VACCNER E, 1998, 12 INT C AIDS JUN 28; van Besien K, 1998, BLOOD, V91, P1178, DOI 10.1182/blood.V91.4.1178; WILSON WH, 1993, J CLIN ONCOL, V11, P1573, DOI 10.1200/JCO.1993.11.8.1573; WILSON WH, 1998, 34 ANN M AM SOC CLIN; YOUSEM DM, 1990, J COMPUT ASSIST TOMO, V14, P255, DOI 10.1097/00004728-199003000-00018; ZHOUPAN XR, 1993, CANCER RES, V53, P5121; ZIEGLER JL, 1984, NEW ENGL J MED, V311, P565, DOI 10.1056/NEJM198408303110904; 1985, MMWR MORB MORTAL WKL, V34, P373; 1999, MMWR MORB MORTAL WKL, V48, pSS2	60	54	56	0	1	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 11	2001	285	14					1880	1885		10.1001/jama.285.14.1880	http://dx.doi.org/10.1001/jama.285.14.1880			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	418DY	11308402				2023-01-03	WOS:000167876700029
J	Howell, CJ; Dean, T; Lucking, L; Dziedzic, K; Jones, PW; Johanson, RB				Howell, CJ; Dean, T; Lucking, L; Dziedzic, K; Jones, PW; Johanson, RB			Randomised study of long term outcome after epidural versus non-epidural analgesia during labour	BMJ-BRITISH MEDICAL JOURNAL			English	Article							LOW-BACK-PAIN; ANESTHESIA	Objective To determine whether epidural analgesia during labour is associated with long term backache. Design Follow up after randomised controlled trial. Analysis by intention to treat. Setting Department of obstetrics and gynaecology at one NHS trust. Participants 369 women: 184 randomised to epidural group (treatment as allocated received by 123) and 185 randomised to non-epidural group (treatment as allocated received by 133). In the follow up study 151 women were from the epidural group and 155 from the non-epidural group. Main outcome measures Self reported low back pain, disability, and limitation of movement assessed through one to one interviews with physiotherapist, questionnaire on back pain and disability, physical measurements of spinal mobility. Results There were no significant differences between groups in demographic details or other key characteristics. The mean time interval from delivery to interview was 26 months. There were no significant differences in the onset or duration of low back pain, with nearly a third of women in each group reporting pain in the week before interview. There were no differences in self reported measures of disability in activities of daily living and no significant differences in measurements of spinal mobility. Conclusions After childbirth there are no differences in the incidence of long term low back pain, disability, or movement restriction between women who receive epidural pain relief and women who receive other forms of pain relief.	N Staffordshire Hosp NHS Trust, Acad Dept Obstet & Gynaecol, Stoke On Trent ST4 6QG, Staffs, England; Haywood Hosp, Staffordshire Rheumatol Ctr, Physiotherapy Dept, Stoke On Trent ST6 7AG, Staffs, England; Univ Keele, Dept Physiotherapy Studies, Keele ST5 5BG, Staffs, England; Univ Keele, Primary Care Sci Res Ctr, Keele ST5 5BG, Staffs, England; Univ Keele, Dept Math, Keele ST5 5BG, Staffs, England	University Hospital of North Staffordshire NHS Trust; Keele University; Keele University; Keele University	Howell, CJ (corresponding author), N Staffordshire Hosp NHS Trust, Acad Dept Obstet & Gynaecol, Stoke On Trent ST4 6QG, Staffs, England.	charlotte@kogs.freeserve.co.uk						BREEN TW, 1994, ANESTHESIOLOGY, V81, P29, DOI 10.1097/00000542-199407000-00006; Chamberlain G, 1993, PAIN ITS RELIEF CHIL; GAUVIN MG, 1990, PHYS THER, V70, P443, DOI 10.1093/ptj/70.7.443; Howell C.J, 2000, COCHRANE DB SYST REV; Howell CJ, 2001, BRIT J OBSTET GYNAEC, V108, P27, DOI 10.1016/S0306-5456(00)00012-7; MACARTHUR A, 1995, BRIT MED J, V311, P1336, DOI 10.1136/bmj.311.7016.1336; Macarthur AJ, 1997, ANESTH ANALG, V85, P1066, DOI 10.1097/00000539-199711000-00019; MACARTHUR C, 1993, BRIT MED J, V307, P64, DOI 10.1136/bmj.307.6895.64; MACARTHUR C, 1990, BRIT MED J, V301, P9, DOI 10.1136/bmj.301.6742.9; MacLeod J, 1995, Int J Obstet Anesth, V4, P21, DOI 10.1016/0959-289X(95)82164-6; MACRAE IF, 1969, ANN RHEUM DIS, V28, P584, DOI 10.1136/ard.28.6.584; Moher D, 2001, LANCET, V357, P1191, DOI 10.1016/S0140-6736(00)04337-3; ORVIETO R, 1994, ACTA OBSTET GYN SCAN, V73, P209, DOI 10.3109/00016349409023441; OSTGAARD HC, 1992, SPINE, V17, P53, DOI 10.1097/00007632-199201000-00008; ROLAND M, 1983, SPINE, V8, P141, DOI 10.1097/00007632-198303000-00004; RUSSELL R, 1993, BRIT MED J, V306, P1299, DOI 10.1136/bmj.306.6888.1299; SCOTT DB, 1990, BRIT J ANAESTH, V64, P537, DOI 10.1093/bja/64.5.537; SVENSSON HO, 1990, SPINE, V15, P371, DOI 10.1097/00007632-199005000-00006; WADDELL G, 1992, SPINE, V17, P617, DOI 10.1097/00007632-199206000-00001; WADDELL G, 1991, CLIN EVALUATION DISA, P155	20	54	58	0	3	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	AUG 17	2002	325	7360					357	359		10.1136/bmj.325.7360.357	http://dx.doi.org/10.1136/bmj.325.7360.357			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	587DV	12183305	Green Published, Bronze			2023-01-03	WOS:000177626000016
J	Lamas, GA; Lee, KL; Sweeney, MO; Silverman, R; Leon, A; Yee, R; Marinchak, RA; Flaker, G; Schron, E; Orav, EJ; Hellkamp, AS; Goldman, L; Greer, S; McAnulty, J; Ellenbogen, K; Ehlert, F; Freedman, RA; Estes, NAM; Greenspon, A				Lamas, GA; Lee, KL; Sweeney, MO; Silverman, R; Leon, A; Yee, R; Marinchak, RA; Flaker, G; Schron, E; Orav, EJ; Hellkamp, AS; Goldman, L; Greer, S; McAnulty, J; Ellenbogen, K; Ehlert, F; Freedman, RA; Estes, NAM; Greenspon, A		Mode Select Trial Sinus-Node Dysfunct	Ventricular pacing or dual-chamber pacing for sinus-node dysfunction	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							TERM FOLLOW-UP; MYOCARDIAL-INFARCTION; PACEMAKER SYNDROME; RANDOMIZED TRIAL; CLINICAL-TRIALS; MODE SELECTION; ATRIAL; MORBIDITY; SURVIVAL; LIFE	Background: Dual-chamber (atrioventricular) and single-chamber (ventricular) pacing are alternative treatment approaches for sinus-node dysfunction that causes clinically significant bradycardia. However, it is unknown which type of pacing results in the better outcome. Methods: We randomly assigned a total of 2010 patients with sinus-node dysfunction to dual-chamber pacing (1014 patients) or ventricular pacing (996 patients) and followed them for a median of 33.1 months. The primary end point was death from any cause or nonfatal stroke. Secondary end points included the composite of death, stroke, or hospitalization for heart failure; atrial fibrillation; heart-failure score; the pacemaker syndrome; and the quality of life. Results: The incidence of the primary end point did not differ significantly between the dual-chamber group (21.5 percent) and the ventricular-paced group (23.0 percent, P=0.48). In patients assigned to dual-chamber pacing, the risk of atrial fibrillation was lower (hazard ratio, 0.79; 95 percent confidence interval, 0.66 to 0.94; P=0.008), and heart-failure scores were better (P<0.001). The differences in the rates of hospitalization for heart failure and of death, stroke, or hospitalization for heart failure were not significant in unadjusted analyses but became marginally significant in adjusted analyses. Dual-chamber pacing resulted in a small but measurable increase in the quality of life, as compared with ventricular pacing. Conclusions: In sinus-node dysfunction, dual-chamber pacing does not improve stroke-free survival, as compared with ventricular pacing. However, dual-chamber pacing reduces the risk of atrial fibrillation, reduces signs and symptoms of heart failure, and slightly improves the quality of life. Overall, dual-chamber pacing offers significant improvement as compared with ventricular pacing.	Univ Miami, Sch Med, Miami Beach, FL USA; Mt Sinai Med Ctr, Div Cardiol, Miami Beach, FL 33140 USA; Duke Univ, Sch Med, Durham, NC USA; Duke Clin Res Inst, Durham, NC USA; Brigham & Womens Hosp, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA USA; Heart Care Ctr, Fayetteville, AR USA; Emory Univ, Atlanta, GA 30322 USA; Crawford W Long Mem Hosp, Atlanta, GA USA; Univ Hosp London, London, ON, Canada; Lankenau Hosp, Wynnewood, PA USA; Univ Missouri Hosp & Clin, Columbia, MO USA; NHLBI, Div Epidemiol & Clin Applicat, Bethesda, MD 20892 USA; Univ Calif San Francisco, Dept Med, San Francisco, CA USA; Baptist Med Ctr, Little Rock, AR USA; Oregon Hlth Sci Univ, Portland, OR 97201 USA; Virginia Commonwealth Univ, Med Coll Virginia, Richmond, VA 23298 USA; St Lukes Roosevelt Hosp, New York, NY USA; Univ Utah, Hlth Sci Ctr, Salt Lake City, UT USA; Tufts Univ New England Med Ctr, Boston, MA 02111 USA; Thomas Jefferson Univ Hosp, Philadelphia, PA 19107 USA	University of Miami; Mount Sinai Medical Center; Duke University; Duke University; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Emory University; Western University (University of Western Ontario); Lankenau Medical Center; University of Missouri System; University of Missouri Columbia; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); University of California System; University of California San Francisco; Oregon Health & Science University; Virginia Commonwealth University; Mount Sinai St. Luke's; Mount Sinai West; Utah System of Higher Education; University of Utah; Tufts Medical Center; Jefferson University	Lamas, GA (corresponding author), Cardiovasc Associates Miami, 4300 Alton Rd,Suite 207, Miami Beach, FL 33140 USA.		Ellenbogen, Kenneth/AAJ-3992-2021		NHLBI NIH HHS [U01 HL 55981, U01 HL 49804, U01 HL 53973] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [U01HL055981, U01HL053973, U01HL049804] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANDERSEN HR, 1994, LANCET, V344, P1523, DOI 10.1016/S0140-6736(94)90347-6; Andersen HR, 1997, LANCET, V350, P1210, DOI 10.1016/S0140-6736(97)03425-9; CHARLSON ME, 1987, J CHRON DIS, V40, P373, DOI 10.1016/0021-9681(87)90171-8; Connolly SJ, 1996, CIRCULATION, V94, P578, DOI 10.1161/01.CIR.94.3.578; Connolly SJ, 2000, NEW ENGL J MED, V342, P1385, DOI 10.1056/NEJM200005113421902; COX DR, 1972, J R STAT SOC B, V34, P187; Ellenbogen KA, 1997, AM J CARDIOL, V79, P1226, DOI 10.1016/S0002-9149(97)00085-4; Ellenbogen KA, 2000, AM J CARDIOL, V86, P59, DOI 10.1016/S0002-9149(00)00828-6; Elmqvist R, 1960, P 2 INT C MED EL, P253; GOLDMAN L, 1981, CIRCULATION, V64, P1227, DOI 10.1161/01.CIR.64.6.1227; Gregoratos G, 1998, J AM COLL CARDIOL, V31, P1175; HELDMAN D, 1990, PACE, V13, P1742, DOI 10.1111/j.1540-8159.1990.tb06883.x; HESSELSON AB, 1992, J AM COLL CARDIOL, V19, P1542, DOI 10.1016/0735-1097(92)90616-U; Kalbfleisch J.D., 1980, STAT ANAL FAILURE TI; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; KAPLAN SH, 1987, J CHRON DIS, V40, pS27, DOI 10.1016/S0021-9681(87)80029-2; Lamas G A, 1989, J Card Surg, V4, P89, DOI 10.1111/j.1540-8191.1989.tb00261.x; Lamas GA, 1997, HEART, V78, P218, DOI 10.1136/hrt.78.3.218; Lamas GA, 2000, AM HEART J, V140, P541, DOI 10.1067/mhj.2000.109652; LAMAS GA, 1989, AM J CARDIOL, V63, P1167, DOI 10.1016/0002-9149(89)90173-2; LAMAS GA, 1995, CIRCULATION, V91, P1063, DOI 10.1161/01.CIR.91.4.1063; Lamas GA, 1998, NEW ENGL J MED, V338, P1097, DOI 10.1056/NEJM199804163381602; LAN KKG, 1983, BIOMETRIKA, V70, P659, DOI 10.2307/2336502; Nielsen JC, 1998, CIRCULATION, V97, P987; OBRIEN PC, 1979, BIOMETRICS, V35, P549, DOI 10.2307/2530245; Ovsyshcher IE, 1998, CIRCULATION, V97, P2368, DOI 10.1161/01.CIR.97.23.2368; ROSENQVIST M, 1988, AM HEART J, V116, P16, DOI 10.1016/0002-8703(88)90244-X; SAMET P, 1966, AM J CARDIOL, V18, P522, DOI 10.1016/0002-9149(66)90004-X; STEWART WJ, 1984, AM J CARDIOL, V54, P308, DOI 10.1016/0002-9149(84)90188-7; TSEVAT J, 1991, MED CARE, V29, P1153, DOI 10.1097/00005650-199111000-00007; Ware J.E, 1994, PHYS MENTAL HLTH SUM; WARE JE, 1992, MED CARE, V30, P473, DOI 10.1097/00005650-199206000-00002; Wharton JM, 1998, CIRCULATION, V98, P494	33	661	693	0	12	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUN 13	2002	346	24					1854	1862		10.1056/NEJMoa013040	http://dx.doi.org/10.1056/NEJMoa013040			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	561NA	12063369	Green Published			2023-01-03	WOS:000176146100003
J	O'Dowd, CD; Jimenez, JL; Bahreini, R; Flagan, RC; Seinfeld, JH; Hameri, K; Pirjola, L; Kulmala, M; Jennings, SG; Hoffmann, T				O'Dowd, CD; Jimenez, JL; Bahreini, R; Flagan, RC; Seinfeld, JH; Hameri, K; Pirjola, L; Kulmala, M; Jennings, SG; Hoffmann, T			Marine aerosol formation from biogenic iodine emissions	NATURE			English	Article							BOUNDARY-LAYER; ATMOSPHERIC PARTICLES; SIZE; MACROALGAE; NUCLEATION; CHEMISTRY; CLIMATE; RELEASE; BROMINE	The formation of marine aerosols and cloud condensation nuclei-from which marine clouds originate-depends ultimately on the availability of new, nanometre-scale particles in the marine boundary layer. Because marine aerosols and clouds scatter incoming radiation and contribute a cooling effect to the Earth's radiation budget(1), new particle production is important in climate regulation. It has been suggested that sulphuric acid-derived from the oxidation of dimethyl sulphide-is responsible for the production of marine aerosols and cloud condensation nuclei. It was accordingly proposed that algae producing dimethyl sulphide play a role in climate regulation 2, but this has been difficult to prove and, consequently, the processes controlling marine particle formation remains largely undetermined(3,4). Here, using smog chamber experiments under coastal atmospheric conditions, we demonstrate that new particles can form from condensable iodine-containing vapours, which are the photolysis products of biogenic iodocarbons emitted from marine algae. Moreover, we illustrate, using aerosol formation models, that concentrations of condensable iodine-containing vapours over the open ocean are sufficient to influence marine particle formation. We suggest therefore that marine iodocarbon emissions have a potentially significant effect on global radiative forcing.	Natl Univ Ireland Univ Coll Galway, Dept Phys, Galway, Ireland; Univ Helsinki, Dept Phys Sci, Div Atmospher Sci, FIN-00014 Helsinki, Finland; CALTECH, Dept Environm Sci & Engn, Pasadena, CA 91125 USA; CALTECH, Dept Chem Engn, Pasadena, CA 91125 USA; Finnish Inst Occupat Hlth, FIN-00250 Helsinki, Finland; Helsinki Polytech Technol, PL 4020, FIN-00099 Helsinki, Finland; Inst Spectrochem & Appl Spect, D-44139 Dortmund, Germany	Ollscoil na Gaillimhe-University of Galway; University of Helsinki; California Institute of Technology; California Institute of Technology; Finnish Institute of Occupational Health	O'Dowd, CD (corresponding author), Natl Univ Ireland Univ Coll Galway, Dept Phys, Galway, Ireland.	colin.odowd@cmas.demon.co.uk	O'Dowd, Colin D/K-8904-2012; Hoffmann, Thorsten/A-7490-2012; Kulmala, Markku T/I-7671-2016; Jimenez, Jose L/A-5294-2008	O'Dowd, Colin D/0000-0002-3068-2212; Kulmala, Markku T/0000-0003-3464-7825; Jimenez, Jose L/0000-0001-6203-1847; Hoffmann, Thorsten/0000-0003-0939-271X; Hameri, Kaarle/0000-0003-2667-2174				Allan BJ, 2001, GEOPHYS RES LETT, V28, P1945, DOI 10.1029/2000GL012468; ANACHE S, 2001, APPL ENVIRON MICROB, V67, P2718; Baker AR, 2000, ATMOS ENVIRON, V34, P4331, DOI 10.1016/S1352-2310(00)00208-9; BERRESHEIM H, IN PRESS J GEOPHYS R; Bloss WJ, 2001, J PHYS CHEM A, V105, P7840, DOI 10.1021/jp0044936; Capaldo KP, 1999, J GEOPHYS RES-ATMOS, V104, P3483, DOI 10.1029/1998JD100080; Carpenter LJ, 1999, J GEOPHYS RES-ATMOS, V104, P1679, DOI 10.1029/98JD02746; CHARLSON RJ, 1987, NATURE, V326, P655, DOI 10.1038/326655a0; Cocker DR, 2001, ENVIRON SCI TECHNOL, V35, P2594, DOI 10.1021/es0019169; DALMASO M, IN PRESS J GEOPHYS R; GABLER HE, 1993, INT J ENVIRON AN CH, V50, P129, DOI 10.1080/03067319308027591; Giese B, 1999, ENVIRON SCI TECHNOL, V33, P2432, DOI 10.1021/es980731n; Goodwin KD, 1997, LIMNOL OCEANOGR, V42, P1725, DOI 10.4319/lo.1997.42.8.1725; Houghton J. T., 2001, CLIMATE CHANGE 2001; Huang S, 2001, ATMOS ENVIRON, V35, P1421, DOI 10.1016/S1352-2310(00)00368-X; Jayne JT, 2000, AEROSOL SCI TECH, V33, P49, DOI 10.1080/027868200410840; Katoshevski D, 1999, J AEROSOL SCI, V30, P503, DOI 10.1016/S0021-8502(98)00740-X; Korhonen P, 1999, J GEOPHYS RES-ATMOS, V104, P26349, DOI 10.1029/1999JD900784; Kulmala M, 2000, NATURE, V404, P66, DOI 10.1038/35003550; Laturnus F, 2000, FRESEN J ANAL CHEM, V368, P297, DOI 10.1007/s002160000491; Leck C, 1999, GEOPHYS RES LETT, V26, P3577, DOI 10.1029/1999GL010807; Lushnikov AA, 1998, PHYS REV LETT, V81, P5165, DOI 10.1103/PhysRevLett.81.5165; MAKELA JM, IN PRESS J GEOPHYS R; McFiggans G, 2000, J GEOPHYS RES-ATMOS, V105, P14371, DOI 10.1029/1999JD901187; Murphy DM, 1997, GEOPHYS RES LETT, V24, P3197, DOI 10.1029/97GL03195; ODOWD CD, IN PRESS J GEOPHYS R; Pirjola L, 2000, J GEOPHYS RES-ATMOS, V105, P26531, DOI 10.1029/2000JD900310; SLINGO A, 1990, NATURE, V343, P49, DOI 10.1038/343049a0; VAKEVA M, IN PRESS J GEOPHYS R; WIMSCHNEIDER A, 1995, FRESEN J ANAL CHEM, V353, P191, DOI 10.1007/BF00322957	30	553	565	5	234	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUN 6	2002	417	6889					632	636		10.1038/nature00775	http://dx.doi.org/10.1038/nature00775			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	559AE	12050661				2023-01-03	WOS:000176001200043
J	Simmonds, P; Kurtz, J; Tedder, RS				Simmonds, P; Kurtz, J; Tedder, RS			The UK blood transfusion service: over a (patent) barrel?	LANCET			English	Editorial Material							TRANSMITTED VIRAL-INFECTIONS; COST-EFFECTIVENESS; HEPATITIS-C; INTERFERON-ALPHA-2B		Univ Edinburgh, Lab Clin & Mol Biol, Edinburgh EH9 1QH, Midlothian, Scotland; Windeyer Inst Med Sci, Dept Virol, London, England; Birmingham Ctr, Natl Blood Serv, Birmingham, W Midlands, England	University of Edinburgh; University of London; University College London	Simmonds, P (corresponding author), Univ Edinburgh, Lab Clin & Mol Biol, Edinburgh EH9 1QH, Midlothian, Scotland.			Simmonds, Peter/0000-0002-7964-4700				Briggs A, 2000, BRIT MED J, V320, P246, DOI 10.1136/bmj.320.7229.246; Courouce AM, 1996, NEW ENGL J MED, V335, P1609; Jaeckel E, 2001, NEW ENGL J MED, V345, P1452, DOI 10.1056/NEJMoa011232; Schreiber GB, 1996, NEW ENGL J MED, V334, P1685, DOI 10.1056/NEJM199606273342601; *SER HAZ TRANSF ST, 2000, SER HAZ TRANSF ANN R; VAMVAKAS EC, 1994, TRANSFUSION, V34, P471, DOI 10.1046/j.1537-2995.1994.34694295060.x; Younossi ZM, 1999, HEPATOLOGY, V30, P1318, DOI 10.1002/hep.510300518	7	32	32	0	2	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAY 18	2002	359	9319					1713	1714		10.1016/S0140-6736(02)08663-4	http://dx.doi.org/10.1016/S0140-6736(02)08663-4			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	554MV	12049856				2023-01-03	WOS:000175740500004
J	Clark, D				Clark, D			Between hope and acceptance: the medicalisation of dying	BRITISH MEDICAL JOURNAL			English	Article									Univ Sheffield, Trent Palliat Care Ctr, Acad Palliat Med Unit, Sheffield S11 9NE, S Yorkshire, England	University of Sheffield	Clark, D (corresponding author), Univ Sheffield, Trent Palliat Care Ctr, Acad Palliat Med Unit, Sykes House, Sheffield S11 9NE, S Yorkshire, England.		Clark, David/A-1645-2009					AHMEDZAI S, 1997, PROGR PALLIATIVE CAR, V5, P235; Ahronheim JC, 1996, ARCH INTERN MED, V156, P2094, DOI 10.1001/archinte.156.18.2094; Audit Commission, 1999, CRIT SUCC PLAC EFF E; Bauman Zygmunt, 1992, MORTALITY IMMORTALIT; Bion J, 1996, BRIT J ANAESTH, V77, P1; Biswas B., 1993, FUTURE PALLIATIVE CA, P135; Clark D, 1999, SOC SCI MED, V49, P727, DOI 10.1016/S0277-9536(99)00098-2; CLARK D, 1999, REFLECTIONS PALLIATI; Clark David, 1999, MORTALITY, V4, P225, DOI 10.1080/713685979; CLINCH JJ, 1998, OXFORD TXB PALLIATIV; Doyle D, 1993, Palliat Med, V7, P253, DOI 10.1177/026921639300700401; Good P, 2001, PALLIATIVE MED, V15, P493, DOI 10.1191/026921601682553987; Illich, 1977, MED NEMESIS EXPROPRI; KEARNEY M, 1992, Palliative Medicine, V6, P39, DOI 10.1177/026921639200600107; Mathers N, 1997, BRIT J GEN PRACT, V47, P177; Moskowitz E, 1995, HASTINGS CENT REP  S, P53; Mount B, 1997, HOSPICE CARE INT SCE; Paci E, 2001, J PAIN SYMPTOM MANAG, V21, P179, DOI 10.1016/S0885-3924(01)00263-9; Seymour J., 2001, CRITICAL MOMENTS DEA; *SMAC SNMAC, 1992, PRINC PROV PALL CAR; [No title captured]	21	169	170	0	20	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	APR 13	2002	324	7342					905	907		10.1136/bmj.324.7342.905	http://dx.doi.org/10.1136/bmj.324.7342.905			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	542PA	11950744	Green Published			2023-01-03	WOS:000175052200030
J	Lenzer, J				Lenzer, J			Alteplase for stroke: money and optimistic claims buttress the "brain attack" campaign	BRITISH MEDICAL JOURNAL			English	Article							ACUTE ISCHEMIC STROKE; CONFLICT-OF-INTEREST; THROMBOLYTIC THERAPY; PUBLICATION BIAS; PHYSICIANS; EXPERIENCE; TRIALS		Oak Ridge Journalism, Ellenville, NY 12428 USA		Lenzer, J (corresponding author), Oak Ridge Journalism, Ellenville, NY 12428 USA.							*AAEM WORK GROUP T, POST STAT AM AC EM M; Albers GW, 2000, JAMA-J AM MED ASSOC, V283, P1145, DOI 10.1001/jama.283.9.1145; Allison DB, 1996, INT J OBESITY, V20, P931; *AM HEART ASS COLL, 2000, CIRCULATION S1, V102, P204; American Heart Association, 2000, ANN REP 1999; Angell M, 2000, NEW ENGL J MED, V342, P1516, DOI 10.1056/NEJM200005183422009; Bodenheimer T, 2000, NEW ENGL J MED, V342, P1539, DOI 10.1056/NEJM200005183422024; *CAEP COMM THROMB, POS STAT THROMB THER; Chew LD, 2000, J GEN INTERN MED, V15, P478, DOI 10.1046/j.1525-1497.2000.08014.x; Choudhry NK, 2002, JAMA-J AM MED ASSOC, V287, P612, DOI 10.1001/jama.287.5.612; Clark WM, 2000, STROKE, V31, P811, DOI 10.1161/01.STR.31.4.811; Friedberg M, 1999, JAMA-J AM MED ASSOC, V282, P1453, DOI 10.1001/jama.282.15.1453; Hankey GJ, 1997, MED J AUSTRALIA, V166, P419, DOI 10.5694/j.1326-5377.1997.tb123193.x; Hoffman JR, 2001, ANN EMERG MED, V38, P605, DOI 10.1067/mem.2001.119276; Hoffman JR, 2000, WESTERN J MED, V173, P149, DOI 10.1136/ewjm.173.3.149; Jorgensen HS, 1999, BRIT MED J, V319, P288, DOI 10.1136/bmj.319.7205.288; Katzan IL, 2000, JAMA-J AM MED ASSOC, V283, P1151, DOI 10.1001/jama.283.9.1151; LENZER JL, 2001, MOTHER JONES     JUN; Lexchin J, 1999, WESTERN J MED, V171, P238; Li J, 1998, J Emerg Med, V16, P757; LIBMAN RB, 1995, ARCH NEUROL-CHICAGO, V52, P1119, DOI 10.1001/archneur.1995.00540350113023; LOCKYER B, 1999, WHATS NONPROFITS NAM, P4; Marler JR, 2000, NEUROLOGY, V55, P1649, DOI 10.1212/WNL.55.11.1649; Marsa L., 1997, PRESCRIPTION PROFITS, V160; RENNIE D, 1992, JAMA-J AM MED ASSOC, V267, P411, DOI 10.1001/jama.267.3.411; SOLOMON R, 2001, ACEP NEWS        MAY; Wardlaw JM, 1997, LANCET, V350, P607, DOI 10.1016/S0140-6736(97)03022-5; Welch SJ, 1997, CHEST, V112, P865, DOI 10.1378/chest.112.4.865-a	28	75	76	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	MAR 23	2002	324	7339					723	726		10.1136/bmj.324.7339.723	http://dx.doi.org/10.1136/bmj.324.7339.723			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	535ML	11909792	Green Published			2023-01-03	WOS:000174648200023
J	Shanafelt, TD; Bradley, KA; Wipf, JE; Back, AL				Shanafelt, TD; Bradley, KA; Wipf, JE; Back, AL			Burnout and self-reported patient care in an internal medicine residency program	ANNALS OF INTERNAL MEDICINE			English	Article							HOUSE STAFF; DEPRESSION; PHYSICIANS; STRESS; SATISFACTION; MANAGEMENT; DISORDERS; QUESTIONS; DISTRESS; VALIDITY	Background: Burnout is a syndrome of depersonalization, emotional exhaustion, and a sense of low personal accomplishment. Little is known about burnout in residents or its relationship to patient care. Objective: To determine the prevalence of burnout in medical residents and explore its relationship to self-reported patient care practices. Design: Cross-sectional study using an anonymous, mailed survey. Setting: University-based residency program in Seattle, Washington. Participants: 115 internal medicine residents. Measurements: Burnout was measured by using the Maslach Burnout Inventory and was defined as scores in the high range for medical professionals on the depersonalization or emotional exhaustion subscales. Five questions developed for this study assessed self-reported patient care practices that suggested suboptimal care (for example, "I did not fully discuss treatment options or answer a patient's questions" or "I made ... errors that were not due to a lack of knowledge or inexperience"). Depression and at-risk alcohol use were assessed by using validated screening questionnaires. Results: Of 115 (76%) responding residents, 87 (76%) met the criteria for burnout. Compared with non-burned-out residents, burned-out residents were significantly more likely to self-report providing at least one type of suboptimal patient care at least monthly (53% vs. 21%; P=0.004). In multivariate analyses, burnout-but not sex, depression, or at-risk alcohol use-was strongly associated with self-report of one or more suboptimal patient care practices at least monthly (odds ratio, 8.3 [95% Cl, 2.6 to 26.5]). When each domain of burnout was evaluated separately, only a high score for depersonalization was associated with self-reported suboptimal patient care practices (in a dose-response relationship). Conclusion: Burnout was common among resident physicians and was associated with self-reported suboptimal patient care practices.	Univ Washington, Vet Affairs NW Hlth Serv Res & Dev Ctr Excellence, Seattle, WA 98195 USA	University of Washington; University of Washington Seattle	Back, AL (corresponding author), Vet Affairs Puget Sound Hlth Care Syst, 1660 S Columbian Way S-111, Seattle, WA 98108 USA.	tonyback@u.washington.edu			NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [K23AA000313] Funding Source: NIH RePORTER	NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))		[Anonymous], 1995, BURNOUT HELPING TEAC; Asch DA, 1997, J CLIN EPIDEMIOL, V50, P1129, DOI 10.1016/S0895-4356(97)00126-1; Burack JH, 1999, J GEN INTERN MED, V14, P49, DOI 10.1046/j.1525-1497.1999.00280.x; Bush K, 1998, ARCH INTERN MED, V158, P1789, DOI 10.1001/archinte.158.16.1789; CLARK DC, 1987, JAMA-J AM MED ASSOC, V257, P2921, DOI 10.1001/jama.257.21.2921; COLFORD JM, 1989, JAMA-J AM MED ASSOC, V261, P889, DOI 10.1001/jama.261.6.889; DECKARD GJ, 1992, J INFECT DIS, V165, P224, DOI 10.1093/infdis/165.2.224; EISENBERG J, 1986, DOCTORS DECISIONS CO; FIRTHCOZENS J, 1987, BRIT MED J, V295, P533, DOI 10.1136/bmj.295.6597.533; GALLERY ME, 1992, ANN EMERG MED, V21, P58, DOI 10.1016/S0196-0644(05)82238-3; GIRARD DE, 1986, WESTERN J MED, V144, P93; Goldberg R, 1996, ACAD EMERG MED, V3, P1156, DOI 10.1111/j.1553-2712.1996.tb03379.x; Grassi L, 2000, PSYCHOTHER PSYCHOSOM, V69, P329, DOI 10.1159/000012416; Gundersen L, 2001, ANN INTERN MED, V135, P145, DOI 10.7326/0003-4819-135-2-200107170-00023; HAFFERTY FW, 1994, ACAD MED, V69, P861, DOI 10.1097/00001888-199411000-00001; HSU K, 1987, AM J PSYCHIAT, V144, P1561; HUGHES PH, 1991, JAMA-J AM MED ASSOC, V265, P2069, DOI 10.1001/jama.265.16.2069; KELLER KL, 1989, ANN EMERG MED, V18, P42; Kenagy JW, 1999, JAMA-J AM MED ASSOC, V281, P661, DOI 10.1001/jama.281.7.661; Kilfedder CJ, 2001, J ADV NURS, V34, P383, DOI 10.1046/j.1365-2648.2001.01769.x; Kohn LT, 2000, ERR IS HUMAN BUILDIN; KORAN LM, 1988, WESTERN J MED, V148, P97; Lee RT, 1996, J APPL PSYCHOL, V81, P123, DOI 10.1037/0021-9010.81.2.123; Leiter MP, 1998, SOC SCI MED, V47, P1611, DOI 10.1016/S0277-9536(98)00207-X; LEITER MP, 1994, ANXIETY STRESS COPIN, V7, P357, DOI 10.1080/10615809408249357; Lemkau J, 1994, Fam Pract Res J, V14, P213; Levey RE, 2001, ACAD MED, V76, P142, DOI 10.1097/00001888-200102000-00010; LICHTENSTEIN R, 1984, MED CARE, V22, P56, DOI 10.1097/00005650-198401000-00005; Lichtenstein R L, 1984, Med Care Rev, V41, P139, DOI 10.1177/107755878404100301; Maslach C, 2001, ANNU REV PSYCHOL, V52, P397, DOI 10.1146/annurev.psych.52.1.397; Maslach C., 1996, MASLACH BURNOUT INVE; MCAULIFFE WE, 1986, NEW ENGL J MED, V315, P805, DOI 10.1056/NEJM198609253151305; MCCUE JD, 1991, ARCH INTERN MED, V151, P2273, DOI 10.1001/archinte.151.11.2273; NESBITT D, 1988, ANN INTERN MED, V109, P154, DOI 10.7326/0003-4819-109-2-154; Parker PA, 1995, J BEHAV MED, V18, P581, DOI 10.1007/BF01857897; Purdy R R, 1987, Fam Med, V19, P203; RAFFERTY JP, 1986, J CLIN PSYCHOL, V42, P488, DOI 10.1002/1097-4679(198605)42:3<488::AID-JCLP2270420315>3.0.CO;2-S; RAMIREZ AJ, 1995, BRIT J CANCER, V71, P1263, DOI 10.1038/bjc.1995.244; REUBEN DB, 1985, ARCH INTERN MED, V145, P286, DOI 10.1001/archinte.145.2.286; REUBEN DB, 1984, PSYCHOSOMATICS, V25, P815, DOI 10.1016/S0033-3182(84)72942-2; SAUNDERS JB, 1993, ADDICTION, V88, P791, DOI 10.1111/j.1360-0443.1993.tb02093.x; SMITH JW, 1986, JAMA-J AM MED ASSOC, V255, P1155, DOI 10.1001/jama.255.9.1155; SPITZER RL, 1994, JAMA-J AM MED ASSOC, V272, P1749, DOI 10.1001/jama.272.22.1749; Whooley MA, 1997, J GEN INTERN MED, V12, P439, DOI 10.1046/j.1525-1497.1997.00076.x; Yao DC, 2000, JAMA-J AM MED ASSOC, V284, P1099, DOI 10.1001/jama.284.9.1099	45	1328	1364	3	153	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAR 5	2002	136	5					358	367		10.7326/0003-4819-136-5-200203050-00008	http://dx.doi.org/10.7326/0003-4819-136-5-200203050-00008			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	525VT	11874308				2023-01-03	WOS:000174095300003
J	Esteban, A; Anzueto, A; Frutos, F; Alia, I; Brochard, L; Stewart, TE; Benito, S; Epstein, SK; Apezteguia, C; Nightingale, P; Arroliga, AC; Tobin, MJ				Esteban, A; Anzueto, A; Frutos, F; Alia, I; Brochard, L; Stewart, TE; Benito, S; Epstein, SK; Apezteguia, C; Nightingale, P; Arroliga, AC; Tobin, MJ		Mech Ventilation Int Study G	Characteristics and outcomes in adult patients receiving mechanical ventilation - A 28-day international study	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							RESPIRATORY-DISTRESS-SYNDROME; OBSTRUCTIVE PULMONARY-DISEASE; INTENSIVE-CARE UNITS; ACUTE LUNG INJURY; MEDICAL ICU; FAILURE; DEFINITIONS; MORTALITY; SURVIVAL; MULTICENTER	Context The outcome of patients receiving mechanical ventilation for particular indications has been studied, but the outcome in a large number of unselected, heterogeneous patients has not been reported. Objective To determine the survival of patients receiving mechanical ventilation and the relative importance of factors influencing survival. Design, Setting, and Subjects Prospective cohort of consecutive adult patients admitted to 361 intensive care units who received mechanical ventilation for more than 12 hours between March 1, 1998, and March 31, 1998. Data were collected on each patient at initiation of mechanical ventilation and daily throughout the course of mechanical ventilation for up to 28 days. Main Outcome Measure All-cause mortality during intensive care unit stay. Results Of the 15757 patients admitted, a total of 5183 (33%) received mechanical ventilation for a mean (SD) duration of 5.9 (7.2) days. The mean (SD) length of stay in the intensive care unit was 11.2 (13.7) days. Overall mortality rate in the intensive care unit was 30.7% (1590 patients) for the entire population, 52% (120) in patients who received ventilation because of acute respiratory distress syndrome, and 22% (115) in patients who received ventilation for an exacerbation of chronic obstructive pulmonary disease. Survival of unselected patients receiving mechanical ventilation for more than 12 hours was 69%. The main conditions independently associated with increased mortality were (1) factors present at the start of mechanical ventilation (odds ratio [OR], 2.98; 95% confidence interval [CI], 2.44-3.63; P<.001 for coma), (2) factors related to patient management (OR, 3.67; 95% CI, 2.02-6.66; P<.001 for plateau airway pressure >35 cm H2O), and (3) developments occurring over the course of mechanical ventilation (OR, 8.71; 95% CI, 5.44-13.94; P<.001 for ratio of Pao(2) to fraction of inspired oxygen <100). Conclusion Survival among mechanically ventilated patients depends not only on the factors present at the start of mechanical ventilation, but also on the development of complications and patient management in the intensive care unit.	Hosp Univ Getafe, Unidad Cuidados Intens, Madrid 28905, Spain; Univ Texas, Hlth Sci Ctr, San Antonio, TX USA; Hop Henri Mondor, F-94010 Creteil, France; Univ Toronto, Mt Sinai Hosp, Toronto, ON M5G 1X5, Canada; Hosp Santa Creu & Sant Pau, Barcelona, Spain; Tufts Univ New England Med Ctr, Tupper Res Inst, Boston, MA 02111 USA; Hosp Prof Posadas, Buenos Aires, DF, Argentina; Univ S Manchester Hosp, Manchester M20 8LR, Lancs, England; Cleveland Clin Fdn, Cleveland, OH 44195 USA; Hines Vet Affairs Hosp, Maywood, IL USA; Loyola Univ, Chicago, IL 60611 USA	Hospital Universitario de Getafe; University of Texas System; University of Texas Health San Antonio; Assistance Publique Hopitaux Paris (APHP); Universite Paris-Est-Creteil-Val-de-Marne (UPEC); Hopital Universitaire Henri-Mondor - APHP; University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Hospital of Santa Creu i Sant Pau; Tufts Medical Center; Wythenshawe Hospital NHS Foundation Trust; Wythenshawe Hospital; Cleveland Clinic Foundation; US Department of Veterans Affairs; Veterans Health Administration (VHA); Edward Hines Jr. VA Hospital; Loyola University Chicago	Esteban, A (corresponding author), Hosp Univ Getafe, Unidad Cuidados Intens, Carretera Toledo Km 12 5, Madrid 28905, Spain.		Arroliga, Alejandro/AAX-3933-2021; Lapinsky, Stephen/C-4624-2015	Lapinsky, Stephen/0000-0002-6930-0306; Frutos-Vivar, Fernando/0000-0002-4648-9636; benito, salvador/0000-0002-6333-5823				Amato MBP, 1998, NEW ENGL J MED, V338, P347, DOI 10.1056/NEJM199802053380602; [Anonymous], 1989, AM REV RESPIR DIS, V139, P1058; Behrendt CE, 2000, CHEST, V118, P1100, DOI 10.1378/chest.118.4.1100; BERNARD GR, 1994, AM J RESP CRIT CARE, V149, P818, DOI 10.1164/ajrccm.149.3.7509706; BONE RC, 1992, CHEST, V101, P1644, DOI 10.1378/chest.101.6.1644; BROCHARD L, 1994, AM J RESP CRIT CARE, V150, P896, DOI 10.1164/ajrccm.150.4.7921460; Brochard L, 1998, AM J RESP CRIT CARE, V158, P1831, DOI 10.1164/ajrccm.158.6.9801044; Brower RG, 1999, CRIT CARE MED, V27, P1492, DOI 10.1097/00003246-199908000-00015; Brower RG, 2000, NEW ENGL J MED, V342, P1301, DOI 10.1056/nejm200005043421801; Croce MA, 1999, J TRAUMA, V46, P361, DOI 10.1097/00005373-199903000-00001; DOYLE RL, 1995, AM J RESP CRIT CARE, V152, P1818, DOI 10.1164/ajrccm.152.6.8520742; Ely EW, 1999, ANN INTERN MED, V131, P96, DOI 10.7326/0003-4819-131-2-199907200-00004; Ely EW, 2000, CRIT CARE MED, V28, P408, DOI 10.1097/00003246-200002000-00020; Epstein SK, 1999, CHEST, V116, P732, DOI 10.1378/chest.116.3.732; ESTEBAN A, 1995, NEW ENGL J MED, V332, P345, DOI 10.1056/NEJM199502093320601; Esteban A, 1997, AM J RESP CRIT CARE, V156, P459, DOI 10.1164/ajrccm.156.2.9610109; Esteban A, 2000, AM J RESP CRIT CARE, V161, P1450, DOI 10.1164/ajrccm.161.5.9902018; ESTEBAN A, 1994, CHEST, V106, P1188, DOI 10.1378/chest.106.4.1188; Ferring M, 1997, EUR RESPIR J, V10, P1297, DOI 10.1183/09031936.97.10061297; KNAUS WA, 1994, AM J RESP CRIT CARE, V150, P311, DOI 10.1164/ajrccm.150.2.8049808; Kollef MH, 1997, CHEST, V111, P434, DOI 10.1378/chest.111.2.434; Krafft P, 1996, INTENS CARE MED, V22, P519, DOI 10.1007/s001340050125; Luhr OR, 1999, AM J RESP CRIT CARE, V159, P1849, DOI 10.1164/ajrccm.159.6.9808136; Navarrete-Navarro P, 2000, INTENS CARE MED, V26, P1624, DOI 10.1007/s001340000683; Nevins ML, 2001, CHEST, V119, P1840, DOI 10.1378/chest.119.6.1840; Roupie E, 1999, INTENS CARE MED, V25, P920, DOI 10.1007/s001340050983; SENEFF MG, 1995, JAMA-J AM MED ASSOC, V274, P1852, DOI 10.1001/jama.274.23.1852; SLOANE PJ, 1992, AM REV RESPIR DIS, V146, P419, DOI 10.1164/ajrccm/146.2.419; Steiner T, 1997, STROKE, V28, P711, DOI 10.1161/01.STR.28.4.711; Stewart TE, 1998, NEW ENGL J MED, V338, P355, DOI 10.1056/NEJM199802053380603; SUCHYTA M, 2000, AM J RESP CRIT CARE, V161, pA210; SUCHYTA MR, 1992, CHEST, V101, P1074, DOI 10.1378/chest.101.4.1074; Tobin MJ, 2000, NEW ENGL J MED, V342, P1360, DOI 10.1056/NEJM200005043421808; Valta P, 1999, CRIT CARE MED, V27, P2367, DOI 10.1097/00003246-199911000-00008; VASILYEV S, 1995, CHEST, V107, P1083, DOI 10.1378/chest.107.4.1083; Zilberberg MD, 1998, AM J RESP CRIT CARE, V157, P1159, DOI 10.1164/ajrccm.157.4.9704088	36	1077	1173	1	44	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 16	2002	287	3					345	355		10.1001/jama.287.3.345	http://dx.doi.org/10.1001/jama.287.3.345			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	511YQ	11790214	Bronze			2023-01-03	WOS:000173294700029
J	Ingelfinger, JR				Ingelfinger, JR			Diet and kidney stones	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material																			0	6	6	1	6	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JAN 10	2002	346	2					74	76		10.1056/NEJM200201103460202	http://dx.doi.org/10.1056/NEJM200201103460202			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	509EM	11784872				2023-01-03	WOS:000173133400001
J	Pack, CC; Berezovskii, VK; Born, RT				Pack, CC; Berezovskii, VK; Born, RT			Dynamic properties of neurons in cortical area MT in alert and anaesthetized macaque monkeys	NATURE			English	Article							PRIMARY VISUAL-CORTEX; MOTION PERCEPTION; SEGREGATION; SELECTIVITY; COHERENCE; MODEL	In order to see the world with high spatial acuity, an animal must sample the visual image with many detectors that restrict their analyses to extremely small regions of space. The visual cortex must then integrate the information from these localized receptive fields to obtain a more global picture of the surrounding environment. We studied this process in single neurons within the middle temporal visual area (MT) of macaques using stimuli that produced conflicting local and global information about stimulus motion. Neuronal responses in alert animals initially reflected predominantly the ambiguous local motion features, but gradually converged to an unambiguous global representation. When the same animals were anaesthetized, the integration of local motion signals was markedly impaired even though neuronal responses remained vigorous and directional tuning characteristics were intact. Our results suggest that anaesthesia preferentially affects the visual processing responsible for integrating local signals into a global visual representation.	Harvard Univ, Sch Med, Dept Neurobiol, Boston, MA 02115 USA	Harvard University; Harvard Medical School	Pack, CC (corresponding author), Harvard Univ, Sch Med, Dept Neurobiol, 220 Longwood Ave, Boston, MA 02115 USA.		Berezovskii, Vladimir/AAB-5253-2022; Born, Richard/M-6454-2019; Berezovskii, Vladimir/B-9866-2013	Born, Richard/0000-0003-4360-427X; Berezovskii, Vladimir/0000-0003-4077-3940				ADELSON EH, 1982, NATURE, V300, P523, DOI 10.1038/300523a0; Alais D, 1997, VISION RES, V37, P143, DOI 10.1016/0042-6989(95)00320-7; ALBRIGHT TD, 1992, SCIENCE, V255, P1141, DOI 10.1126/science.1546317; Born RT, 2000, NEURON, V26, P725, DOI 10.1016/S0896-6273(00)81208-8; BORN RT, 1991, P NATL ACAD SCI USA, V88, P7066, DOI 10.1073/pnas.88.16.7066; Castelo-Branco M, 2000, NATURE, V405, P685, DOI 10.1038/35015079; Ferster D, 1996, NATURE, V380, P249, DOI 10.1038/380249a0; Hildreth E., 1984, MEASUREMENT VISUAL M; Lamme VAF, 2000, TRENDS NEUROSCI, V23, P571, DOI 10.1016/S0166-2236(00)01657-X; LAMME VAF, 1995, J NEUROSCI, V15, P1605; Lamme VAF, 1998, P NATL ACAD SCI USA, V95, P3263, DOI 10.1073/pnas.95.6.3263; Liden L, 1999, VISION RES, V39, P3301, DOI 10.1016/S0042-6989(99)00055-3; MARR D, 1981, PROC R SOC SER B-BIO, V211, P151, DOI 10.1098/rspb.1981.0001; MIKAMI A, 1986, J NEUROPHYSIOL, V55, P1328, DOI 10.1152/jn.1986.55.6.1328; Movshon J. A., 1985, EXPT BRAIN RES S, V11, P117, DOI DOI 10.1007/978-3-662-09224-8_7.; Movshon JA, 1996, J NEUROSCI, V16, P7733; MUKHERJEE P, 1995, J NEUROPHYSIOL, V74, P1222, DOI 10.1152/jn.1995.74.3.1222; O'Keefe LP, 1998, VISUAL NEUROSCI, V15, P305, DOI 10.1017/S0952523898152094; Pack CC, 2001, NATURE, V409, P1040, DOI 10.1038/35059085; ROBINSON DA, 1963, IEEE T BIO-MED ENG, VBM10, P137, DOI 10.1109/TBMEL.1963.4322822; RODMAN HR, 1989, EXP BRAIN RES, V75, P53; Simoncelli EP, 1998, VISION RES, V38, P743, DOI 10.1016/S0042-6989(97)00183-1; SNODDERLY DM, 1995, J NEUROPHYSIOL, V74, P2100, DOI 10.1152/jn.1995.74.5.2100; STONER GR, 1992, NATURE, V358, P412, DOI 10.1038/358412a0; STONER GR, 1990, NATURE, V344, P153, DOI 10.1038/344153a0; Wallach H, 1935, PSYCHOL FORSCH, V20, P325, DOI 10.1007/BF02409790; WILSON HR, 1992, VISUAL NEUROSCI, V9, P79, DOI 10.1017/S0952523800006386	27	108	108	0	5	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	DEC 20	2001	414	6866					905	908		10.1038/414905a	http://dx.doi.org/10.1038/414905a			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	503RB	11780062				2023-01-03	WOS:000172813300045
J	Cole, BF; Gelber, RD; Gelber, S; Coates, AS; Goldhirsch, A				Cole, BF; Gelber, RD; Gelber, S; Coates, AS; Goldhirsch, A			Polychemotherapy for early breast cancer: an overview of the randomised clinical trials with quality-adjusted survival analysis	LANCET			English	Article							ADJUVANT CHEMOTHERAPY; METAANALYSIS	Background Overview analysis involving 18 000 women with breast cancer in 47 randomised trials showed that prolonged chemotherapy significantly reduces the risk of relapse and death compared with no chemotherapy. Here we express the size of the benefit in terms of quality-adjusted survival time gained. Methods We used the Q-TWIST method (Quality-adjusted Time Without Symptoms of disease and Toxicity of treatment) to provide treatment comparisons within 10 years' follow-up, incorporating differences in quality of life associated with times patients spend with chemotherapy toxic effects, after relapse, and without symptoms of relapse or toxicity. Findings Within 10 years' follow-up the benefit of increased relapse-free and overall survival for younger women (<50 years old) who received polychemotherapy balanced the burdens in terms of acute toxic side-effects, especially among women enrolled in trials that did not include tamoxifen. Overall, chemotherapy-treated younger women gained an average of 10.3 months of relapse-free survival and 5.4 months of overall survival within 10 years (p<0.0001 for both) compared with the no-chemotherapy group. Polychemotherapy provided more quality-adjusted time than control across nearly all values of utility weights for time spent undergoing chemotherapy and time after relapse. The range of benefit was from -0.6 to 10.3 months. For older women (50-69 years) overall, polychemotherapy also provided significant benefit compared with no chemotherapy but, compared with younger women, the size of benefit was less and the range of utility-weight values favouring polychemotherapy was smaller. Average gains for older women treated with polychemotherapy (with or without tamoxifen) were 6.8 months of relapse-free survival (p<0.0001) and 2.9 months of overall survival (p=0.0001) within 10 years. The range of quality-adjusted benefit was -3.1 to 6.8 months. For older women with oestrogen-receptor-poor tumours who did not receive tamoxifen (9% of the total), the benefit of polychemotherapy was significant and similar to that observed for younger women. Interpretation The benefits of adjuvant chemotherapy within 10 years outweigh the burdens especially for younger women (<50 years old) and among older women (50-69 years) to a lesser degree. Additional studies to compare the quality-adjusted survival of chemotherapy plus endocrine therapy versus endocrine therapy alone are required for younger patients with tumours that express steroid-hormone receptors.	Dartmouth Coll, Sch Med, Dartmouth Hitchcock Med Ctr, Lebanon, NH 03756 USA; Harvard Univ, Sch Publ Hlth, Dana Farber Canc Inst, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA USA; Frontier Sci & Technol Res Fdn Inc, Boston, MA USA; Australian Canc Soc, Sydney, NSW, Australia; Univ Sydney, Sydney, NSW 2006, Australia; European Inst Oncol, Milan, Italy	Dartmouth College; Harvard University; Dana-Farber Cancer Institute; Harvard T.H. Chan School of Public Health; Harvard University; Harvard Medical School; Frontier Science Foundation; University of Sydney; IRCCS European Institute of Oncology (IEO)	Cole, BF (corresponding author), Dartmouth Coll, Sch Med, Dartmouth Hitchcock Med Ctr, 7927 Rubin Bldg, Lebanon, NH 03756 USA.	bernard.cole@dartmouth.edu			NCI NIH HHS [CA-75362, CA-06516] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA006516] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABE O, 1992, LANCET, V339, P71; Abe O, 1998, LANCET, V352, P930; [Anonymous], 1992, Lancet, V339, P1; Clarke M, 1998, LANCET, V351, P1451; Coates AS, 1998, LANCET, V352, P1783, DOI 10.1016/S0140-6736(05)79861-5; COATES AS, 1992, INTRO NEW TREATMENTS; COLE BF, 1995, STAT MED, V14, P1771, DOI 10.1002/sim.4780141606; DAVIDSON N, 1999, P AN M AM SOC CLIN, V18, pA67; Gelber R D, 1995, Cancer J Sci Am, V1, P114; GELBER RD, 1991, ANN INTERN MED, V114, P621, DOI 10.7326/0003-4819-114-8-621; Gelber RD, 1996, LANCET, V347, P1066, DOI 10.1016/S0140-6736(96)90277-9; Gelber RD, 1998, RECENT RESULTS CANC, V152, P373; GELBER RD, 1992, MONOGR NATL CANC I, V11, P127; GELBER RD, 1995, QUALITY LIFE PHARMAC, P437; GLASZIOU PP, 1990, STAT MED, V9, P1259, DOI 10.1002/sim.4780091106; GOLDHIRSCH A, 1989, J CLIN ONCOL, V7, P36, DOI 10.1200/JCO.1989.7.1.36; GOLDHIRSCH A, 1995, ISRAEL J MED SCI, V31, P144; SIMES RJ, 1989, P AN M AM SOC CLIN, V8, P52; TANCINI G, 1983, J CLIN ONCOL, V1, P2, DOI 10.1200/JCO.1983.1.1.2; TORRANCE GW, 1987, J CHRON DIS, V40, P593, DOI 10.1016/0021-9681(87)90019-1; Weinstein MC, 1980, CLIN DECISION ANAL	21	99	102	0	7	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JUL 28	2001	358	9278					277	286		10.1016/S0140-6736(01)05483-6	http://dx.doi.org/10.1016/S0140-6736(01)05483-6			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	457AF	11498214				2023-01-03	WOS:000170114400011
J	MORRISON, R				MORRISON, R			PATIENTS SENSE OF COMPLETION	BRITISH MEDICAL JOURNAL			English	Editorial Material											MORRISON, R (corresponding author), EASTBOURNE HOSP NHS TRUST,EASTBOURNE,E SUSSEX,ENGLAND.								0	9	9	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 25	1994	308	6945					1722	1722		10.1136/bmj.308.6945.1722	http://dx.doi.org/10.1136/bmj.308.6945.1722			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NU483	11644549	Green Published			2023-01-03	WOS:A1994NU48300095
J	Hulley, S; Furberg, C; Barrett-Connor, E; Cauley, J; Grady, D; Haskell, W; Knopp, R; Lowery, M; Satterfield, S; Schrott, H; Vittinghoff, E; Hunninghake, D				Hulley, S; Furberg, C; Barrett-Connor, E; Cauley, J; Grady, D; Haskell, W; Knopp, R; Lowery, M; Satterfield, S; Schrott, H; Vittinghoff, E; Hunninghake, D		HERS Res Grp	Noncardiovascular disease outcomes during 6.8 years of hormone therapy - Heart and Estrogen/progestin Replacement Study follow-up (HERS II)	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ESTROGEN PLUS PROGESTIN; POSTMENOPAUSAL WOMEN; BREAST-CANCER; VENOUS THROMBOEMBOLISM; RANDOMIZED TRIAL; ELDERLY WOMEN; RISK; PREVENTION; FRACTURES; METAANALYSIS	Context The Heart and Estrogen/progestin Replacement Study (HERS) was a randomized trial of estrogen plus progestin therapy after menopause. Objective To examine the effect of long-term postmenopausal hormone therapy on common noncardiovascular disease outcomes. Design and Setting Randomized, blinded, placebo-controlled trial of 4.1 years' duration (HERS) and subsequent open-label observational follow-up for 2.7 years (HERS II), carried out between 1993 and 2000 in outpatient and community settings at 20 US clinical centers. Participants A total of 2763 postmenopausal women with coronary disease and average age of 67 years at enrollment in HERS; 2321 women (93% of those surviving) consented to follow-up in HERS II. Intervention Participants were randomly assigned to receive 0.625 mg/d of conjugated estrogens plus 2.5 mg of medroxyprogesterone acetate (n = 1380) or placebo (n = 1383) during HERS; open-label hormone therapy was prescribed at personal physicians' discretion during HERS II. The proportions with at least 80% adherence to hormones declined from 81% (year 1) to 45% (year 6) in the hormone group and increased from 0% (year 1) to 8% (year 6) in the placebo group. Main Outcome Measures Thromboembolic events, biliary tract surgery, cancer, fracture, and total mortality. Results Comparing women assigned to hormone therapy with those assigned to placebo, the unadjusted intention-to-treat relative hazard (RH) for venous thromboembolism declined from 2.66 (95% confidence interval [CI], 1.41-5.04) during HERS to 1.40 (95% CI, 0.64-3.05) during HERS II (P for time trend=.08); it was 2.08 overall for the 6.8 years (95% CI, 1.28-3.40), and 3 of the 73 women with thromboembolism died within 30 days due to pulmonary embolism. The overall RH for biliary tract surgery was 1.48 (95% CI, 1.12-1.95); for any cancer, 1.19 (95% CI, 0.95-1.50); and for any fracture, 1.04 (95% CI, 0.87-1.25). There were 261 deaths among those assigned to hormone therapy and 239 among those assigned to placebo (RH, 1.10; 95% CI, 0.92-1.31). Adjusted and as-treated analyses did not alter our conclusions. Conclusions Treatment for 6.8 years with estrogen plus progestin in older women with coronary disease increased the rates of venous thromboembolism and biliary tract surgery. Trends in other disease outcomes were not favorable and should be assessed in larger trials and in broader populations.	Univ Calif San Francisco, Sch Med, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA; Wake Forest Univ, Bowman Gray Sch Med, Dept Publ Hlth Sci, Winston Salem, NC 27103 USA; Univ Calif San Diego, Dept Family & Prevent Med, Div Epidemiol, San Diego, CA 92103 USA; Univ Pittsburgh, Grad Sch Publ Hlth, Dept Epidemiol, Pittsburgh, PA USA; Stanford Univ, Dept Med, Stanford, CA 94305 USA; Univ Washington, Sch Med, Dept Med, Seattle, WA 98195 USA; Univ Miami, Sch Med, Miami, FL USA; Univ Tennessee, Dept Prevent Med, Memphis, TN USA; Univ Iowa, Coll Publ Hlth & Med, Iowa City, IA USA; Univ Minnesota, Dept Med, Minneapolis, MN 55455 USA; Univ Minnesota, Dept Pharmacol, Minneapolis, MN 55455 USA	University of California System; University of California San Francisco; Wake Forest University; Wake Forest Baptist Medical Center; University of California System; University of California San Diego; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Stanford University; University of Washington; University of Washington Seattle; University of Miami; University of Tennessee System; University of Tennessee Health Science Center; University of Iowa; University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities	Hulley, S (corresponding author), Univ Calif San Francisco, Sch Med, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA.		lowery, maeve/AAG-2575-2019; Cauley, Jane A/N-4836-2015	lowery, maeve/0000-0003-1354-7606; Cauley, Jane A/0000-0003-0752-4408				Anderson G, 1998, CONTROL CLIN TRIALS, V19, P61; BARRETTCONNOR E, 1991, ANN INTERN MED, V115, P455, DOI 10.7326/0003-4819-115-6-455; BURKMAN RT, 2001, BRIT J HAEMATOL, V115, P415; Bush TL, 1996, JAMA-J AM MED ASSOC, V276, P1389, DOI 10.1001/jama.276.17.1389; BUSH TL, 1987, CIRCULATION, V75, P1102, DOI 10.1161/01.CIR.75.6.1102; CAULEY JA, 1995, ANN INTERN MED, V122, P9, DOI 10.7326/0003-4819-122-1-199501010-00002; Cauley JA, 2001, AM J MED, V110, P442, DOI 10.1016/S0002-9343(01)00647-7; *CDC RES GROUP, 1977, NEW ENGL J MED, V296, P1185; *CDP RES GROUP, 1973, JAMA-J AM MED ASSOC, V226, P652; Clemons M, 2001, NEW ENGL J MED, V344, P276, DOI 10.1056/NEJM200101253440407; Colditz GA, 1997, ANN NY ACAD SCI, V833, P129, DOI 10.1111/j.1749-6632.1997.tb48598.x; *COLL GROUP, 1997, LANCET, V350, P985; Cummings SR, 1999, JAMA-J AM MED ASSOC, V281, P2189, DOI 10.1001/jama.281.23.2189; Cummings SR, 1998, JAMA-J AM MED ASSOC, V280, P2077, DOI 10.1001/jama.280.24.2077; Daly E, 1996, LANCET, V348, P977, DOI 10.1016/S0140-6736(96)07113-9; Fisher B, 1998, J NATL CANCER I, V90, P1371, DOI 10.1093/jnci/90.18.1371; Grady D, 2000, ANN INTERN MED, V132, P689, DOI 10.7326/0003-4819-132-9-200005020-00002; Grady D, 1997, JAMA-J AM MED ASSOC, V278, P477, DOI 10.1001/jama.1997.03550060053030; Grady D, 2002, JAMA-J AM MED ASSOC, V288, P49, DOI 10.1001/jama.288.1.49; GRADY D, 1995, OBSTET GYNECOL, V85, P304, DOI 10.1016/0029-7844(94)00383-O; GRADY D, 1992, ANN INTERN MED, V117, P1016, DOI 10.7326/0003-4819-117-12-1016; Grady D, 1998, CONTROL CLIN TRIALS, V19, P314, DOI 10.1016/S0197-2456(98)00010-5; Grady D, 2001, JAMA-J AM MED ASSOC, V285, P2909, DOI 10.1001/jama.285.22.2909; Grady D, 2000, ANN INTERN MED, V133, P999, DOI 10.7326/0003-4819-133-12-200012190-00016; Greendale GA, 1998, OBSTET GYNECOL, V92, P982, DOI 10.1016/S0029-7844(98)00305-6; Grodstein F, 1999, AM J MED, V106, P574, DOI 10.1016/S0002-9343(99)00063-7; Grodstein F, 1996, LANCET, V348, P983, DOI 10.1016/S0140-6736(96)07308-4; Grodstein F, 1997, NEW ENGL J MED, V336, P1769, DOI 10.1056/NEJM199706193362501; Gutthann SP, 1997, BMJ-BRIT MED J, V314, P796, DOI 10.1136/bmj.314.7083.796; Hulley S, 1998, JAMA-J AM MED ASSOC, V280, P605, DOI 10.1001/jama.280.7.605; Jick H, 1996, LANCET, V348, P981, DOI 10.1016/S0140-6736(96)07114-0; JOHNSTON DE, 1993, NEW ENGL J MED, V328, P412, DOI 10.1056/NEJM199302113280608; MacLennan A, 2001, Climacteric, V4, P58, DOI 10.1080/713605036; Matthews KA, 1996, AM J EPIDEMIOL, V143, P971; McClung MR, 2001, NEW ENGL J MED, V344, P333, DOI 10.1056/NEJM200102013440503; NORDSTROM M, 1992, J INTERN MED, V232, P155, DOI 10.1111/j.1365-2796.1992.tb00565.x; Petitti Diana B., 1994, Annals of Epidemiology, V4, P115; Psaty BM, 2001, JAMA-J AM MED ASSOC, V285, P906, DOI 10.1001/jama.285.7.906; Siegfried JM, 2001, LANCET ONCOL, V2, P506, DOI 10.1016/S1470-2045(01)00457-0; Simon JA, 2001, ANN INTERN MED, V135, P493, DOI 10.7326/0003-4819-135-7-200110020-00008; Torgerson DJ, 2001, JAMA-J AM MED ASSOC, V285, P2891, DOI 10.1001/jama.285.22.2891; Vandenbroucke JP, 2001, NEW ENGL J MED, V344, P1527, DOI 10.1056/NEJM200105173442007; Villareal DT, 2001, JAMA-J AM MED ASSOC, V286, P815, DOI 10.1001/jama.286.7.815	43	523	561	0	7	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 3	2002	288	1					58	66		10.1001/jama.288.1.58	http://dx.doi.org/10.1001/jama.288.1.58			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	568YW	12090863	Bronze			2023-01-03	WOS:000176573400020
J	Lawrence, D				Lawrence, D			Cancer incidence in the USA could double by 2050, report predicts	LANCET			English	News Item																		Edwards BK, 2002, CANCER-AM CANCER SOC, V94, P2766, DOI 10.1002/cncr.10593	1	5	5	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAY 18	2002	359	9319					1755	1755		10.1016/S0140-6736(02)08668-3	http://dx.doi.org/10.1016/S0140-6736(02)08668-3			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	554MV	12049905				2023-01-03	WOS:000175740500020
J	Wang, RF; Wang, HY				Wang, RF; Wang, HY			Enhancement of antitumor immunity by prolonging antigen presentation on dendritic cells	NATURE BIOTECHNOLOGY			English	Article							CYTOTOXIC T-LYMPHOCYTES; TYROSINASE-RELATED PROTEIN-2; TUMOR REJECTION ANTIGEN; IN-VIVO; HUMAN CANCER; PEPTIDE; MELANOMA; VACCINATION; DELIVERY; IDENTIFICATION	Vaccination with dendritic cells (DCs) pulsed with antigenic peptides derived from various tumor antigens has great, but as yet significantly unrealized, potential in cancer treatment. Here, we describe a strategy for prolonged presentation of an MHC class I-restricted self-peptide on DCs through linkage of it to a cell penetrating peptide (CPP). DCs loaded with a peptide derived from tyrosinase-related protein 2 (TRP2) covalently linked to a CPP1 sequence retained full capacity to stimulate T cells for at least 24 h, completely protected immunized mice from subsequent tumor challenge, and significantly inhibited lung metastases in a 3-day tumor model. DCs pulsed with TRP2 alone failed to provide any of these protections. In addition, we demonstrate that both CD4+ and CD8+ T cells were required for potent antitumor immunity. This CPP-based approach may be generally applicable to enhance the efficacy of DC-based peptide vaccines against cancer and other diseases.	Baylor Coll Med, Ctr Cell & Gene Therapy, Houston, TX 77030 USA; Baylor Coll Med, Dept Immunol, Houston, TX 77030 USA	Baylor College of Medicine; Baylor College of Medicine	Wang, RF (corresponding author), Baylor Coll Med, Ctr Cell & Gene Therapy, 1 Baylor Plaza, Houston, TX 77030 USA.	rongfuw@bcm.tmc.edu						Banchereau J, 1998, NATURE, V392, P245, DOI 10.1038/32588; Bellone M, 2000, J IMMUNOL, V165, P2651, DOI 10.4049/jimmunol.165.5.2651; Bloom MB, 1997, J EXP MED, V185, P453, DOI 10.1084/jem.185.3.453; Boon T, 1996, J EXP MED, V183, P725, DOI 10.1084/jem.183.3.725; Bowne WB, 1999, J EXP MED, V190, P1717, DOI 10.1084/jem.190.11.1717; Caron NJ, 2001, MOL THER, V3, P310, DOI 10.1006/mthe.2001.0279; Casares N, 2001, EUR J IMMUNOL, V31, P1780, DOI 10.1002/1521-4141(200106)31:6<1780::AID-IMMU1780>3.0.CO;2-I; Cella M, 1997, NATURE, V388, P782, DOI 10.1038/42030; Celluzzi CM, 1996, J EXP MED, V183, P283, DOI 10.1084/jem.183.1.283; Dallal RM, 2000, CURR OPIN IMMUNOL, V12, P583, DOI 10.1016/S0952-7915(00)00146-1; Elliott G, 1997, CELL, V88, P223, DOI 10.1016/S0092-8674(00)81843-7; FAWELL S, 1994, P NATL ACAD SCI USA, V91, P664, DOI 10.1073/pnas.91.2.664; FRANKEL AD, 1988, CELL, V55, P1189, DOI 10.1016/0092-8674(88)90263-2; Gilboa E, 1999, IMMUNITY, V11, P263, DOI 10.1016/S1074-7613(00)80101-6; GREENBERG PD, 1991, ADV IMMUNOL, V49, P281; Houghton AN, 2001, CURR OPIN IMMUNOL, V13, P134, DOI 10.1016/S0952-7915(00)00195-3; Hung K, 1998, J EXP MED, V188, P2357, DOI 10.1084/jem.188.12.2357; Kim DT, 1997, J IMMUNOL, V159, P1666; Labeur MS, 1999, J IMMUNOL, V162, P168; LIN YZ, 1995, J BIOL CHEM, V270, P14255, DOI 10.1074/jbc.270.24.14255; Lindgren M, 2000, TRENDS PHARMACOL SCI, V21, P99, DOI 10.1016/S0165-6147(00)01447-4; Ludewig B, 1999, IMMUNOL REV, V169, P45, DOI 10.1111/j.1600-065X.1999.tb01305.x; Nestle FO, 1998, NAT MED, V4, P328, DOI 10.1038/nm0398-328; Overwijk WW, 1999, P NATL ACAD SCI USA, V96, P2982, DOI 10.1073/pnas.96.6.2982; Paglia P, 1996, J EXP MED, V183, P317, DOI 10.1084/jem.183.1.317; Pardoll DM, 1998, CURR OPIN IMMUNOL, V10, P588, DOI 10.1016/S0952-7915(98)80228-8; Parkhurst MR, 1996, J IMMUNOL, V157, P2539; Parkhurst MR, 1998, CANCER RES, V58, P4895; Phelan A, 1998, NAT BIOTECHNOL, V16, P440, DOI 10.1038/nbt0598-440; Rojas M, 1998, NAT BIOTECHNOL, V16, P370, DOI 10.1038/nbt0498-370; Rosenberg SA, 1998, NAT MED, V4, P321, DOI 10.1038/nm0398-321; Schreurs MWJ, 2000, CANCER RES, V60, P6995; Schuler G, 1997, J EXP MED, V186, P1183, DOI 10.1084/jem.186.8.1183; Schwarze SR, 1999, SCIENCE, V285, P1569, DOI 10.1126/science.285.5433.1569; Slansky JE, 2000, IMMUNITY, V13, P529, DOI 10.1016/S1074-7613(00)00052-2; Specht JM, 1997, J EXP MED, V186, P1213, DOI 10.1084/jem.186.8.1213; Srivastava PK, 2000, NAT IMMUNOL, V1, P363, DOI 10.1038/80795; SUHRBIER A, 1993, J IMMUNOL, V150, P2169; Thurner B, 1999, J EXP MED, V190, P1669, DOI 10.1084/jem.190.11.1669; Toes REM, 1999, J EXP MED, V189, P753, DOI 10.1084/jem.189.5.753; Wang RF, 1999, IMMUNOL REV, V170, P85, DOI 10.1111/j.1600-065X.1999.tb01331.x; Wang RF, 1996, J EXP MED, V184, P2207, DOI 10.1084/jem.184.6.2207; Wang RF, 2001, TRENDS IMMUNOL, V22, P269, DOI 10.1016/S1471-4906(01)01896-8; Winzler C, 1997, J EXP MED, V185, P317, DOI 10.1084/jem.185.2.317; Young JW, 1996, J EXP MED, V183, P7, DOI 10.1084/jem.183.1.7; Zeh HJ, 1999, J IMMUNOL, V162, P989	46	89	111	0	13	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	FEB	2002	20	2					149	154		10.1038/nbt0202-149	http://dx.doi.org/10.1038/nbt0202-149			6	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	517FT	11821860				2023-01-03	WOS:000173601000023
J	De Weerdt, W; Feys, H				De Weerdt, W; Feys, H			Assessment of physiotherapy for patients with stroke	LANCET			English	Editorial Material							RANDOMIZED CONTROLLED TRIAL; POSTSTROKE REHABILITATION; SINGLE-BLIND; FORCED USE; METAANALYSIS; INTENSITY; PROGRAM; THERAPY; GAIT		Katholieke Univ Leuven, Fac Phys Educ & Physiotherapy, Dept Rehabil Sci, B-3001 Heverlee, Belgium	KU Leuven	De Weerdt, W (corresponding author), Katholieke Univ Leuven, Fac Phys Educ & Physiotherapy, Dept Rehabil Sci, B-3001 Heverlee, Belgium.							Carr JH., 2000, MOVEMENT SCI FDN PHY; DAVIES PM, 2000, STEPS FOLLOW; Duncan P, 1998, STROKE, V29, P2055, DOI 10.1161/01.STR.29.10.2055; Duncan P W, 1997, Top Stroke Rehabil, V3, P1, DOI 10.1080/10749357.1997.11754126; Feys HM, 1998, STROKE, V29, P785, DOI 10.1161/01.STR.29.4.785; Glanz M, 1996, ARCH PHYS MED REHAB, V77, P549, DOI 10.1016/S0003-9993(96)90293-2; GLANZ M, 1995, ARCH PHYS MED REHAB, V76, P508, DOI 10.1016/S0003-9993(95)80503-6; Hanger HC, 2000, CLIN REHABIL, V14, P370, DOI 10.1191/0269215500cr339oa; Kwakkel G, 1997, STROKE, V28, P1550, DOI 10.1161/01.STR.28.8.1550; Kwakkel G, 1999, LANCET, V354, P191, DOI 10.1016/S0140-6736(98)09477-X; Langhammer B, 2000, CLIN REHABIL, V14, P361, DOI 10.1191/0269215500cr338oa; Parry RH, 1999, CLIN REHABIL, V13, P187, DOI 10.1191/026921599676198929; Perfetti C, 2001, EXERCICE THERAPEUTIQ; Roper TA, 1999, AGE AGEING, V28, P9, DOI 10.1093/ageing/28.1.9; Shumway-Cook A., 1995, MOTOR CONTROL THEORY; Thaut MH, 1997, J NEUROL SCI, V151, P207, DOI 10.1016/S0022-510X(97)00146-9; van der Lee JH, 1999, STROKE, V30, P2369, DOI 10.1161/01.STR.30.11.2369; Visintin M, 1998, STROKE, V29, P1122, DOI 10.1161/01.STR.29.6.1122; Walker MF, 1999, LANCET, V354, P278, DOI 10.1016/S0140-6736(98)11128-5; WOLF SL, 1989, EXP NEUROL, V104, P125, DOI 10.1016/S0014-4886(89)80005-6	20	19	20	0	2	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JAN 19	2002	359	9302					182	183		10.1016/S0140-6736(02)07461-5	http://dx.doi.org/10.1016/S0140-6736(02)07461-5			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	512YH	11812546				2023-01-03	WOS:000173350800002
J	Bernardi, L; Sleight, P; Bandinelli, G; Cencetti, S; Fattorini, L; Wdowczyc-Szulc, J; Lagi, A				Bernardi, L; Sleight, P; Bandinelli, G; Cencetti, S; Fattorini, L; Wdowczyc-Szulc, J; Lagi, A			Effect of rosary prayer and yoga mantras on autonomic cardiovascular rhythms: comparative study	BRITISH MEDICAL JOURNAL			English	Article							HEART-RATE-VARIABILITY; MORTALITY; FAILURE; HUMANS	Objective To test whether rhythmic formulas such as the rosary and yoga mantras can synchronise and reinforce inherent cardiovascular rhythms and modify, baroreflex sensitivity. Design Comparison of effects of recitation of the Ave Maria (in Latin) or of a mantra, during spontaneous and metronome controlled breathing, on breathing rate and oil spontaneous oscillations in RR interval, and on blood pressure and cerebral circulation. Setting Florence and Pavia, Italy. Participants 23 healthy adults. Main outcome measures Breathing rate, regularity of breathing, baroreflex sensitivity, frequency of cardiovascular oscillations. Results Both prayer and mantra caused striking, powerful, and synchronous increases in existing cardiovascular rhythms when recited six times a minute. Baroreflex sensitivity also increased significantly, from 9.5 (SD 4.6) to 11.5 (4.9) ms/mm. Hg, P < 0.05. Conclusion Rhythm formulas that involve breathing at six breaths per minute induce favourable psychological and possibly physiological effects.	Univ Pavia, Dipartimento Med Interna, I-27100 Pavia, Italy; John Radcliffe Hosp, Dept Cardiovasc Med, Oxford OX3 9DU, England; Unita Osped S Maria Nuova, Dipartimento Med Interna, I-50100 Florence, Italy; Univ Gdansk, Dept Cardiol, PL-80211 Gdansk, Poland	University of Pavia; University of Oxford; Fahrenheit Universities; University of Gdansk	Bernardi, L (corresponding author), Univ Pavia, Dipartimento Med Interna, I-27100 Pavia, Italy.							Bernardi L, 1998, LANCET, V351, P1308, DOI 10.1016/S0140-6736(97)10341-5; Bernardi L, 2000, J AM COLL CARDIOL, V35, P1462, DOI 10.1016/S0735-1097(00)00595-7; Bernardi L, 2001, J HYPERTENS, V19, P2221, DOI 10.1097/00004872-200112000-00016; Cencetti S, 1999, HEART, V82, P365, DOI 10.1136/hrt.82.3.365; DEBOER RW, 1987, AM J PHYSIOL, V253, pH680, DOI 10.1152/ajpheart.1987.253.3.H680; Friedman EH, 2000, INT J CARDIOL, V73, P199, DOI 10.1016/S0167-5273(00)00214-X; HEWITT J, 1983, YOGA BREATHING POSTU; La Rovere MT, 1998, LANCET, V351, P478; LEHMANN J, 1976, KREUZFAHRER; Mayer S, 1876, SITZUNGSBERICHT MATH, V74, P281; Nolan J, 1998, CIRCULATION, V98, P1510, DOI 10.1161/01.CIR.98.15.1510; Piepoli M, 1997, CIRCULATION, V95, P1813; SLEIGHT P, 1995, CLIN SCI, V88, P103, DOI 10.1042/cs0880103	13	226	238	1	38	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	DEC 22	2001	323	7327					1446	1449		10.1136/bmj.323.7327.1446	http://dx.doi.org/10.1136/bmj.323.7327.1446			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	506PA	11751348	Green Published			2023-01-03	WOS:000172979900007
J	Padkin, A; Rowan, K; Black, N				Padkin, A; Rowan, K; Black, N			Using high quality clinical databases to complement the results of randomised controlled trials: the case of recombinant human activated protein C	BRITISH MEDICAL JOURNAL			English	Article							CARE		Univ London London Sch Hyg & Trop Med, Dept Publ Hlth & Policy, Hlth Serv Res Unit, London WC1E 7HT, England; Intens Care Natl Audit & Res Ctr, London WC1H 9HR, England	University of London; London School of Hygiene & Tropical Medicine; Intensive Care National Audit & Research Centre	Padkin, A (corresponding author), Univ London London Sch Hyg & Trop Med, Dept Publ Hlth & Policy, Hlth Serv Res Unit, London WC1E 7HT, England.							APPLEBY P, 1994, LANCET, V343, P311, DOI 10.1016/S0140-6736(94)91161-4; Assmann SF, 2000, LANCET, V355, P1064, DOI 10.1016/S0140-6736(00)02039-0; Bernard GR, 2001, NEW ENGL J MED, V344, P699, DOI 10.1056/NEJM200103083441001; Black N, 2001, BRIT MED J, V323, P275, DOI 10.1136/bmj.323.7307.275; Black N, 1996, BRIT MED J, V312, P1215; BONE RC, 1992, CHEST, V101, P1644, DOI 10.1378/chest.101.6.1644; *BRIT MED ASS, 1992, 33 BMA RPS; Britton A, 1999, J Health Serv Res Policy, V4, P112; Goldfrad C, 2000, LANCET, V355, P1138, DOI 10.1016/S0140-6736(00)02062-6; MATHER CMP, 1995, ANAESTHESIA, V50, P189, DOI 10.1111/j.1365-2044.1995.tb04552.x; MOHER D, 1995, CONTROL CLIN TRIALS, V16, P62, DOI 10.1016/0197-2456(94)00031-W; Roland M, 1998, BRIT MED J, V316, P285, DOI 10.1136/bmj.316.7127.285; ROWAN K, 2001, PROGRAMME INTENSIVE, P51; ROWAN K, 2000, HLTH CARE UK     SPR, P42; Turner S, 1998, BRIT MED J, V316, P343, DOI 10.1136/bmj.316.7128.343	15	43	43	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	OCT 20	2001	323	7318					923	926		10.1136/bmj.323.7318.923	http://dx.doi.org/10.1136/bmj.323.7318.923			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	486BH	11668142	Green Accepted, Green Published			2023-01-03	WOS:000171798200028
J	Xie, W; Evans, RM				Xie, W; Evans, RM			Orphan nuclear receptors: The exotics of xenobiotics	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Review							PREGNANE-X-RECEPTOR; P450 GENE INDUCTION; SIGNALING PATHWAY; DRUG-METABOLISM; CAR; ACTIVATION; HEPATOCYTES; DEFINES; LIGANDS; SXR		Salk Inst Biol Studies, Howard Hughes Med Inst, La Jolla, CA 92037 USA; Salk Inst Biol Studies, Gene Express Lab, La Jolla, CA 92037 USA	Howard Hughes Medical Institute; Salk Institute; Salk Institute	Evans, RM (corresponding author), Salk Inst Biol Studies, Howard Hughes Med Inst, 10010 N Torrey Pines Rd, La Jolla, CA 92037 USA.		Xie, Wen/M-1768-2016; Evans, Ronald/AAF-4001-2019	Evans, Ronald/0000-0002-9986-5965				BAES M, 1994, MOL CELL BIOL, V14, P1544, DOI 10.1128/MCB.14.3.1544; Barwick JL, 1996, MOL PHARMACOL, V50, P10; Bertilsson G, 1998, P NATL ACAD SCI USA, V95, P12208, DOI 10.1073/pnas.95.21.12208; Blumberg B, 1998, GENE DEV, V12, P3195, DOI 10.1101/gad.12.20.3195; Blumberg B, 1998, GENE DEV, V12, P3149, DOI 10.1101/gad.12.20.3149; DENISON MS, 1995, J BIOL CHEM, V270, P18175, DOI 10.1074/jbc.270.31.18175; EMA M, 1992, BIOCHEM BIOPH RES CO, V184, P246, DOI 10.1016/0006-291X(92)91185-S; Forman BM, 1998, NATURE, V395, P612, DOI 10.1038/26996; GONZALEZ FJ, 1992, TRENDS PHARMACOL SCI, V13, P346, DOI 10.1016/0165-6147(92)90107-H; Honkakoski P, 1998, MOL CELL BIOL, V18, P5652, DOI 10.1128/MCB.18.10.5652; Howell SR, 1998, DRUG METAB DISPOS, V26, P234; Kliewer SA, 1998, CELL, V92, P73, DOI 10.1016/S0092-8674(00)80900-9; MAUREL P, 1996, CYTOCHROMES P450 MET, P241; Moore LB, 2000, P NATL ACAD SCI USA, V97, P7500, DOI 10.1073/pnas.130155097; Moore LB, 2000, J BIOL CHEM, V275, P15122, DOI 10.1074/jbc.M001215200; Savas U, 1999, MOL PHARMACOL, V56, P851, DOI 10.1124/mol.56.5.851; Staudinger JL, 2001, P NATL ACAD SCI USA, V98, P3369, DOI 10.1073/pnas.051551698; Strom SC, 1996, METHOD ENZYMOL, V272, P388, DOI 10.1016/S0076-6879(96)72044-X; Synold TW, 2001, NAT MED, V7, P584, DOI 10.1038/87912; Tzameli I, 2000, MOL CELL BIOL, V20, P2951, DOI 10.1128/MCB.20.9.2951-2958.2000; Wan YJY, 2000, MOL CELL BIOL, V20, P4436, DOI 10.1128/MCB.20.12.4436-4444.2000; Waxman DJ, 1999, ARCH BIOCHEM BIOPHYS, V369, P11, DOI 10.1006/abbi.1999.1351; Wei P, 2000, NATURE, V407, P920, DOI 10.1038/35038112; Xie W, 2000, NATURE, V406, P435, DOI 10.1038/35019116; Xie W, 2000, GENE DEV, V14, P3014, DOI 10.1101/gad.846800; Xie W, 2001, P NATL ACAD SCI USA, V98, P3375, DOI 10.1073/pnas.051014398	26	170	185	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 12	2001	276	41					37739	37742		10.1074/jbc.R100033200	http://dx.doi.org/10.1074/jbc.R100033200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	481NU	11459851	hybrid			2023-01-03	WOS:000171526500003
J	MacPherson, H; Thomas, K; Walters, S; Fitter, M				MacPherson, H; Thomas, K; Walters, S; Fitter, M			The York acupuncture safety study: prospective survey of 34 000 treatments by traditional acupuncturists	BMJ-BRITISH MEDICAL JOURNAL			English	Article									Fdn Tradit Chinese Med, York YO24 4EY, N Yorkshire, England; Univ Sheffield, Med Care Res Unit, Sheffield S1 4DA, S Yorkshire, England; Univ Sheffield, Sheffield Hlth Econ Grp, Sch Hlth & Related Res, Sheffield S1 4DA, S Yorkshire, England	University of Sheffield; University of Sheffield	MacPherson, H (corresponding author), Fdn Tradit Chinese Med, York YO24 4EY, N Yorkshire, England.	hugh@ftcm.org.uk		MacPherson, Hugh/0000-0003-4255-4768; Walters, Stephen/0000-0001-9000-8126				*BRIT MED ASS BOAR, 2000, AC EFF SAF PRACT; EYPASCH E, 1995, BRIT MED J, V311, P619, DOI 10.1136/bmj.311.7005.619; *HOUS LORDS, 2000, COMPL ALT MED; MacPherson H, 1999, J ALTERN COMPLEM MED, V5, P223, DOI 10.1089/acm.1999.5.223; Tramer MR, 2000, PAIN, V85, P169, DOI 10.1016/S0304-3959(99)00267-5	5	247	256	1	13	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	SEP 1	2001	323	7311					486	487		10.1136/bmj.323.7311.486	http://dx.doi.org/10.1136/bmj.323.7311.486			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	469WF	11532841	Bronze, Green Published			2023-01-03	WOS:000170838500018
J	Snell, B				Snell, B			Inappropriate drug donations: the need for reforms	LANCET			English	Editorial Material									Macfarlane Burnet Ctr Med Res, Int Hlth Unit, Fairfield, Vic 3078, Australia		Snell, B (corresponding author), Macfarlane Burnet Ctr Med Res, Int Hlth Unit, POB 254, Fairfield, Vic 3078, Australia.							Forte GB, 1998, NEW ENGL J MED, V338, P1473; WHO, 1999, GUID SAF DISP UNW PH; World Health Organization, 1999, GUID DRUG DON	3	7	8	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	AUG 18	2001	358	9281					578	580		10.1016/S0140-6736(01)05712-9	http://dx.doi.org/10.1016/S0140-6736(01)05712-9			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	464NB	11520548				2023-01-03	WOS:000170537700036
J	Kaptchuk, TJ; Eisenberg, DM				Kaptchuk, TJ; Eisenberg, DM			Varieties of healing. 1: Medical pluralism in the United States	ANNALS OF INTERNAL MEDICINE			English	Article							ALTERNATIVE MEDICINE; COMPLEMENTARY; TRENDS; CARE	Medicine has become interested in unconventional healing practices, ostensibly because of recent demographic research that reveals a thriving medical market of multiple options. This essay presents a historical overview of medical pluralism in the United States. Consistent evidence is examined suggesting that unconventional medicine has been a persistent presence in U.S. health care. Despite parallels with the past, the recent widespread interest in alternative medicine also represents a dramatic reconfiguration of medical pluralism-from historical antagonism to what might arguably be described as a topical acknowledgment of postmodern medical diversity. This recent shift may have less to do with acknowledging "new" survey data than with representing shifts in medicine's institutional authority in a consumer-driven health care environment. This essay is an introduction to a discussion of a taxonomy of contemporary U.S. medical pluralism, which also appears in this issue.	Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School	Kaptchuk, TJ (corresponding author), Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, 330 Brookline Ave,W-K-400, Boston, MA 02215 USA.				NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [U24AR043441] Funding Source: NIH RePORTER; NIAMS NIH HHS [U24 AR43441] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ARMSTRONG D, 1991, GREAT AM MED SHOW; Astin JA, 1998, ARCH INTERN MED, V158, P2303, DOI 10.1001/archinte.158.21.2303; Astin JA, 1998, JAMA-J AM MED ASSOC, V279, P1548, DOI 10.1001/jama.279.19.1548; Bagley CM, 1999, ANN INTERN MED, V131, P229, DOI 10.7326/0003-4819-131-3-199908030-00018; BAKX K, 1991, SOCIOL HEALTH ILL, V13, P20, DOI 10.1111/1467-9566.ep11340307; Barzansky B, 2000, JAMA-J AM MED ASSOC, V284, P1114, DOI 10.1001/jama.284.9.1114; BEARDSLEY EJ, 1924, J MED SOC NEW JERSEY, V21, P275; BERMAN ALEX, 1951, BULL HIST MED, V25-25, P405; BRINSMADE TC, 1958, TMSSNY, P257; BRODY JE, 1999, NY TIMES HLTH F 0209; CANT SL, 1991, SOCIOLOGY HLTH ILLNE, V13, P139; Cassedy J. H., 1991, MED AM; COLLINS SD, 1944, INCIDENCE ILLNESS VO; COWART VS, 1988, JAMA-J AM MED ASSOC, V259, P3229; CRAMP AJ, 1929, NEW ENGL J MED, V201, P1297; CRAMP AJ, 1921, NOSTRUMS QUACKERY PS; EASTHOPE G, 1993, AUST NZ J SOCIOL, V29, P289; Eisenberg DM, 1998, JAMA-J AM MED ASSOC, V280, P1569, DOI 10.1001/jama.280.18.1569; Ernst E, 1996, J ROY COLL PHYS LOND, V30, P410; Ernst Robert, 1991, WEAKNESS IS CRIME LI; ESTES JW, 1991, B HIST MED, V65, P162; Falk IS, 1933, INCIDENCE ILLNESS RE; FANER AW, 1992, GUIDE AM MED ASS HIS; FITZ RH, 1894, T ASSOC AM PHYSICIAN, V8, P1; Fontanarosa PB, 1998, JAMA-J AM MED ASSOC, V280, P1618, DOI 10.1001/jama.280.18.1618; GABE J, 1994, CHALLENGING MED; GEVITZ N, 1989, PERSPECT BIOL MED, V32, P281; GoldbeckWood S, 1996, BRIT MED J, V313, P131, DOI 10.1136/bmj.313.7050.131a; HAEHL R, 1995, S HAHNEMANN HIS LIFE, V2; HAHNEMANN S, 1980, ORGANON MED; HOLMES OW, 1842, HOMOEOPATHY ITS KIND; IDLER EL, 1989, CULT MED PSYCHIAT, V13, P1, DOI 10.1007/BF00052680; JONES RK, 1985, SICKNESS SECTARIANIS; Kaptchuk TJ, 1998, ANN INTERN MED, V129, P1061, DOI 10.7326/0003-4819-129-12-199812150-00011; KAPTCHUK TJ, 1996, COMPLEMENTARY MED OB; KAPTCHUK TJ, 1986, HEALING ARTS JOURNEY; Kett J, 1968, FORMATION AM MED PRO; KING D, 1858, QUACKERY UNMASKED CO; KLEINMAN AM, 1973, INQUIRY, V16, P206, DOI 10.1080/00201747308601685; *LANDM HEALTHC, 1998, LANDM REP PUBL PERC; LESLIE C, 1980, SOC SCI MED-MED ANTH, V14, P191, DOI 10.1016/0160-7987(80)90044-7; MOORE JS, 1993, CHIROPRACTIC AM HIST; MURPHY LR, 1991, ENTER PHYSICIAN TRAN; Nissenbaum Stephen, 1980, SEX DIET DEBILITY JA; Paramore LC, 1997, J PAIN SYMPTOM MANAG, V13, P83, DOI 10.1016/S0885-3924(96)00299-0; Pelletier KR, 1997, AM J HEALTH PROMOT, V12, P112, DOI 10.4278/0890-1171-12.2.112; PORTER R, 1982, HLTH SALE QUACKERY E; PRESS I, 1980, SOC SCI MED-MED ANTH, V14, P45, DOI 10.1016/0160-7987(80)90040-X; ROBERTS JB, 1896, J AM MED SOC, V26, P299; ROEBUCK JB, 1972, J HEALTH SOC BEHAV, V13, P162, DOI 10.2307/2136898; ROREM CR, 1932, COST MED; ROTHESTEIN WG, 1985, AM PHYSICIANS 19 CEN; Sergeant MJ, 2000, ANN INTERN MED, V132, P675, DOI 10.7326/0003-4819-132-8-200004180-00013; Starr P., 1982, SOCIAL TRANSFORMATIO; Stokstad E, 2000, SCIENCE, V288, P1568, DOI 10.1126/science.288.5471.1568; VANDENNOORT S, 1983, ARCH NEUROL-CHICAGO, V40, P673, DOI 10.1001/archneur.1983.04050100013004; WAITE FC, 1940, OHIO STATE ARCHAEOLO, V49, P322; WARNER JH, 1987, MED FRINGE MED ORTHO; Whorton J C, 1975, Bull Hist Med, V49, P466; Williams SJ, 1996, SOC SCI MED, V42, P1609, DOI 10.1016/0277-9536(95)00313-4; WROBEL A, 1987, PSEUDO SCI SOC 19 CE; Young J.H, 1967, MED MESSIAHS SOCIAL; Young JH., 1961, TOADSTOOL MILLIONAIR; 1836, BOSTON MED SURG J, V15, P241; 1829, BOSTON MED SURG J, V366; [No title captured]; 1837, BOSTON MED SURG J, V17, P322; 1962, JAMA, V180, P53	68	97	98	0	17	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	AUG 7	2001	135	3					189	195		10.7326/0003-4819-135-3-200108070-00011	http://dx.doi.org/10.7326/0003-4819-135-3-200108070-00011			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	460FX	11487486				2023-01-03	WOS:000170298500005
J	Carmody, J				Carmody, J			Celebrating science - Scientists feel passion, but they need to convey it in their writing, too.	NATURE			English	Editorial Material									Univ New S Wales, Sch Physiol & Pharmacol, Sydney, NSW 2052, Australia	University of New South Wales Sydney	Carmody, J (corresponding author), Univ New S Wales, Sch Physiol & Pharmacol, Sydney, NSW 2052, Australia.							Simmons R, 2001, NATURE, V411, P243, DOI 10.1038/35077175	1	1	1	0	0	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUL 26	2001	412	6845					383	383		10.1038/35086659	http://dx.doi.org/10.1038/35086659			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	456DQ	11473290	Bronze			2023-01-03	WOS:000170068200022
J	Weller, IVD; Williams, IG				Weller, IVD; Williams, IG			ABC of AIDS - Antiretroviral drugs	BRITISH MEDICAL JOURNAL			English	Article																			0	30	30	0	5	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	JUN 9	2001	322	7299					1410	1412		10.1136/bmj.322.7299.1410	http://dx.doi.org/10.1136/bmj.322.7299.1410			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	442KN	11397751	Green Published			2023-01-03	WOS:000169284600021
J	Schwetz, BA				Schwetz, BA			Labeling changes for Orlaam	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	News Item									US FDA, Rockville, MD 20857 USA	US Food & Drug Administration (FDA)	Schwetz, BA (corresponding author), US FDA, Rockville, MD 20857 USA.								0	33	33	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 6	2001	285	21					2705	2705						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	437HG	11386912				2023-01-03	WOS:000168985800006
J	Malhotra, A; White, DP				Malhotra, A; White, DP			Obstructive sleep apnoea	LANCET			English	Review							POSITIVE AIRWAY PRESSURE; GENIOGLOSSAL ELECTROMYOGRAM RESPONSES; COST-EFFECTIVENESS ANALYSIS; PLACEBO-CONTROLLED TRIAL; SOFT PALATAL MUCOSA; MUSCLE ACTIVATION; NEGATIVE-PRESSURE; DAYTIME FUNCTION; BLOOD-PRESSURE; CPAP THERAPY	Obstructive sleep apnoea is a disease of increasing importance because of Its neurocognitive and cardiovascular sequelae. Abnormalities in the anatomy of the pharynx, the physiology of the upper airway muscle dilator, and the stability of ventilatory control are important causes of repetitive pharyngeal collapse during sleep. Obstructive sleep apnoea can be diagnosed on the basis of characteristic history (snoring, daytime sleepiness) and physical examination (increased neck circumference), but overnight polysomnography is needed to confirm presence of the disorder. Repetitive pharyngeal collapse causes recurrent arousals from sleep, leading to sleepiness and increased risk of motor vehicle and occupational accidents. The surges in hypoxaemia, hypercapnia, and catecholamine associated with this disorder have now been implicated in development of hypertension, but the association between obstructive sleep apnoea and myocardial infarction, stroke, and congestive heart failure is not proven. Continuous positive airway pressure, the treatment of choice for obstructive sleep apnoea, reduces sleepiness and Improves hypertension.	Harvard Univ, Brigham & Womens Hosp, Sch Med, Boston, MA 02115 USA; Harvard Univ, Massachusetts Gen Hosp, Sch Med, Boston, MA USA	Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University; Harvard Medical School; Massachusetts General Hospital	Malhotra, A (corresponding author), RF 486,221 Longwood Bldg, Boston, MA 02115 USA.	Amalhotra1@partners.org						Akahoshi T, 2001, J PHYSIOL-LONDON, V531, P677, DOI 10.1111/j.1469-7793.2001.0677h.x; Ayappa I, 2000, SLEEP, V23, P763, DOI 10.1093/sleep/23.6.763; Barnes M, 2002, AM J RESP CRIT CARE, V165, P773, DOI 10.1164/ajrccm.165.6.2003166; Berry RB, 1997, AM J RESP CRIT CARE, V156, P127, DOI 10.1164/ajrccm.156.1.9608037; Berry RB, 1997, SLEEP, V20, P654, DOI 10.1093/sleep/20.8.654; BERTHONJONES M, 1993, SLEEP, V16, pS120, DOI 10.1093/sleep/16.suppl_8.S120; Bixler EO, 1998, AM J RESP CRIT CARE, V157, P144, DOI 10.1164/ajrccm.157.1.9706079; Brooks D, 1997, J CLIN INVEST, V99, P106, DOI 10.1172/JCI119120; Broughton R, 1996, J CLIN NEUROPHYSIOL, V13, P272, DOI 10.1097/00004691-199607000-00002; BURGER CD, 1992, AM REV RESPIR DIS, V145, P846, DOI 10.1164/ajrccm/145.4_Pt_1.846; Chesson AL, 1997, SLEEP, V20, P406; DAVIES RJO, 1992, THORAX, V47, P101, DOI 10.1136/thx.47.2.101; Dixon JB, 2001, ARCH INTERN MED, V161, P102, DOI 10.1001/archinte.161.1.102; Douglas NJ, 2001, AM J RESP CRIT CARE, V163, P1310, DOI 10.1164/ajrccm.163.6.2007021; DOUGLAS NJ, 1992, LANCET, V339, P347, DOI 10.1016/0140-6736(92)91660-Z; Engleman HM, 1997, THORAX, V52, P114, DOI 10.1136/thx.52.2.114; Engleman HM, 1999, AM J RESP CRIT CARE, V159, P461, DOI 10.1164/ajrccm.159.2.9803121; Engleman HM, 1998, THORAX, V53, P341, DOI 10.1136/thx.53.5.341; Epstein L, 2000, AM J RESP CRITICAL S, V161, pA358; Epstein LJE, 1998, CHEST, V113, P97, DOI 10.1378/chest.113.1.97; Faccenda JF, 2001, AM J RESP CRIT CARE, V163, P344, DOI 10.1164/ajrccm.163.2.2005037; Ferguson KA, 1997, AM J RESP CRIT CARE, V155, P1748, DOI 10.1164/ajrccm.155.5.9154887; Ferguson KA, 1996, CHEST, V109, P1269, DOI 10.1378/chest.109.5.1269; Field AE, 2001, INT J OBESITY, V25, P1113, DOI 10.1038/sj.ijo.0801643; Flemons WW, 1999, SLEEP, V22, P667, DOI 10.1093/sleep/22.5.667; Fogel RB, 2001, AM J RESP CRIT CARE, V164, P2025, DOI 10.1164/ajrccm.164.11.2102048; Friberg D, 1997, REGUL PEPTIDES, V71, P29, DOI 10.1016/S0167-0115(97)01016-1; Friberg D, 1998, LARYNGOSCOPE, V108, P431, DOI 10.1097/00005537-199803000-00022; Friberg D, 1998, AM J RESP CRIT CARE, V157, P586, DOI 10.1164/ajrccm.157.2.96-06049; GLEESON K, 1990, AM REV RESPIR DIS, V142, P295, DOI 10.1164/ajrccm/142.2.295; Gottlieb DJ, 1999, AM J RESP CRIT CARE, V159, P502, DOI 10.1164/ajrccm.159.2.9804051; Gozal D, 1998, PEDIATRICS, V102, P616, DOI 10.1542/peds.102.3.616; Gugger M, 1997, EUR RESPIR J, V10, P587; Hack M, 2000, THORAX, V55, P224, DOI 10.1136/thorax.55.3.224; HAPONIK EF, 1983, AM REV RESPIR DIS, V127, P221; Hilton MF, 2001, EUR RESPIR J, V17, P1258, DOI 10.1183/09031936.01.00009301; HORNER RL, 1994, J PHYSIOL-LONDON, V476, P141; HORNER RL, 1991, J PHYSIOL-LONDON, V436, P15, DOI 10.1113/jphysiol.1991.sp018536; HORNER RL, 1991, J PHYSIOL-LONDON, V436, P31, DOI 10.1113/jphysiol.1991.sp018537; Horner RL, 1996, SLEEP, V19, P827, DOI 10.1093/sleep/19.10.827; Hosselet JJ, 1998, AM J RESP CRIT CARE, V157, P1461, DOI 10.1164/ajrccm.157.5.9708008; Hoy CJ, 1999, AM J RESP CRIT CARE, V159, P1096, DOI 10.1164/ajrccm.159.4.9808008; Hoy CJ, 1997, AM J RESP CRIT CARE, V155, p304A; Hudgel DW, 2000, SLEEP, V23, P645; HUDGEL DW, 1990, J APPL PHYSIOL, V69, P443, DOI 10.1152/jappl.1990.69.2.443; Hudgel DW, 1997, CHEST, V111, P265, DOI 10.1378/chest.111.2.265; HUNG J, 1990, LANCET, V336, P261, DOI 10.1016/0140-6736(90)91799-G; Isono S, 1997, J APPL PHYSIOL, V82, P1319, DOI 10.1152/jappl.1997.82.4.1319; Jenkinson C, 1999, LANCET, V353, P2100, DOI 10.1016/S0140-6736(98)10532-9; Jenkinson C, 1997, J SLEEP RES, V6, P199, DOI 10.1046/j.1365-2869.1997.00043.x; Karason K, 2000, ARCH INTERN MED, V160, P1797, DOI 10.1001/archinte.160.12.1797; Kimoff J, 2001, AM J RESP CRIT CARE, V164, P250; Kingshott RN, 2000, SLEEP, V23, P1109, DOI 10.1093/sleep/23.8.1j; Kline LR, 1999, AM J RESP CRIT CARE, V159, pA427; Kobayashi I, 1996, J APPL PHYSIOL, V80, P1595, DOI 10.1152/jappl.1996.80.5.1595; Kubin L, 1996, SLEEP, V19, P187; KUBIN L, 1994, BRAIN RES, V645, P291, DOI 10.1016/0006-8993(94)91663-2; Lavie P, 2000, BRIT MED J, V320, P479, DOI 10.1136/bmj.320.7233.479; LAVIE P, 1995, SLEEP, V18, P149, DOI 10.1093/sleep/18.3.149; Lindberg E, 2001, AM J RESP CRIT CARE, V164, P2031, DOI 10.1164/ajrccm.164.11.2102028; Loube DI, 1999, CHEST, V115, P1333, DOI 10.1378/chest.115.5.1333; Malhotra A, 2000, AM J RESP CRIT CARE, V161, P1746, DOI 10.1164/ajrccm.161.5.9907109; Malhotra A, 2002, AM J RESP CRIT CARE, V165, P71, DOI 10.1164/ajrccm.165.1.2011065; Malhotra A, 2000, AM J RESP CRIT CARE, V162, P1058, DOI 10.1164/ajrccm.162.3.9912067; MATHEW OP, 1982, J APPL PHYSIOL, V52, P438, DOI 10.1152/jappl.1982.52.2.438; MATHEW OP, 1982, J APPL PHYSIOL, V52, P445, DOI 10.1152/jappl.1982.52.2.445; MATHEW OP, 1984, J APPL PHYSIOL, V56, P500, DOI 10.1152/jappl.1984.56.2.500; Meza S, 1998, J APPL PHYSIOL, V84, P3, DOI 10.1152/jappl.1998.84.1.3; Mezzanotte WS, 1996, AM J RESP CRIT CARE, V153, P1880, DOI 10.1164/ajrccm.153.6.8665050; MEZZANOTTE WS, 1992, J CLIN INVEST, V89, P1571, DOI 10.1172/JCI115751; Millman RP, 1998, CHEST, V113, P992, DOI 10.1378/chest.113.4.992; Montserrat JM, 2001, AM J RESP CRIT CARE, V164, P608, DOI 10.1164/ajrccm.164.4.2006034; Montserrat JM, 1997, AM J RESP CRIT CARE, V155, P211, DOI 10.1164/ajrccm.155.1.9001314; Nieto FJ, 2000, JAMA-J AM MED ASSOC, V283, P1829, DOI 10.1001/jama.283.14.1829; ONAL E, 1981, AM REV RESPIR DIS, V124, P215; ONAL E, 1981, J APPL PHYSIOL, V50, P1052, DOI 10.1152/jappl.1981.50.5.1052; Peppard PE, 2000, NEW ENGL J MED, V342, P1378, DOI 10.1056/NEJM200005113421901; Pepperell JCT, 2002, LANCET, V359, P204, DOI 10.1016/S0140-6736(02)07445-7; Phillips B, 1996, HOSP PRACT, V31, P193; Phillips BG, 1999, J HYPERTENS, V17, P61, DOI 10.1097/00004872-199917010-00010; Pillar F, 2000, AM J RESP CRIT CARE, V162, P1627, DOI 10.1164/ajrccm.162.5.2003131; PILLAR G, 1994, CHEST, V106, P1702, DOI 10.1378/chest.106.6.1702; Pittman SD, 2000, COMPUT CARDIOL, V27, P485, DOI 10.1109/CIC.2000.898563; Powell NB, 1998, CLIN CHEST MED, V19, P77, DOI 10.1016/S0272-5231(05)70433-0; Powell NB, 1997, CHEST, V111, P1348, DOI 10.1378/chest.111.5.1348; Powell NB, 1998, CHEST, V113, P1163, DOI 10.1378/chest.113.5.1163; Rechtschaffen A., 1968, MANUAL STANDARDIZED; Redline S, 1997, AM J RESP CRIT CARE, V155, P186, DOI 10.1164/ajrccm.155.1.9001310; Redline S, 1998, AM J RESP CRIT CARE, V157, P858, DOI 10.1164/ajrccm.157.3.9709042; REEVESHOCHE MK, 1995, AM J RESP CRIT CARE, V151, P443, DOI 10.1164/ajrccm.151.2.7842204; REMMERS JE, 1978, J APPL PHYSIOL, V44, P931, DOI 10.1152/jappl.1978.44.6.931; Reuveni H, 2001, MED DECIS MAKING, V21, P451, DOI 10.1177/02729890122062802; RILEY RW, 1993, J ORAL MAXIL SURG, V51, P742, DOI 10.1016/S0278-2391(10)80412-4; RILEY RW, 1994, OTOLARYNG HEAD NECK, V111, P717, DOI 10.1016/S0194-5998(94)70557-7; RILEY RW, 1993, OTOLARYNG HEAD NECK, V108, P117, DOI 10.1177/019459989310800203; Scheuller M, 2001, OTOLARYNG HEAD NECK, V125, P299, DOI 10.1067/mhn.2001.119139; SCHWAB RJ, 1995, AM J RESP CRIT CARE, V152, P1673, DOI 10.1164/ajrccm.152.5.7582313; SERIES F, 1993, ANN INTERN MED, V119, P449, DOI 10.7326/0003-4819-119-6-199309150-00001; Shahar E, 2001, AM J RESP CRIT CARE, V163, P19, DOI 10.1164/ajrccm.163.1.2001008; SOMERS VK, 1988, CLIN EXP HYPERTENS A, V10, P413, DOI 10.3109/10641968809075998; SOMERS VK, 1995, J CLIN INVEST, V96, P1897, DOI 10.1172/JCI118235; STRADLING JR, 1991, THORAX, V46, P85, DOI 10.1136/thx.46.2.85; Stradling JR, 1997, THORAX, V52, P72, DOI 10.1136/thx.52.1.72; Strollo PJ, 1996, SLEEP, V19, pS255, DOI 10.1093/sleep/19.suppl_10.S255; SUGERMAN HJ, 1992, AM J CLIN NUTR, V55, P597, DOI 10.1093/ajcn/55.2.597s; SURATT PM, 1983, AM REV RESPIR DIS, V127, P487, DOI 10.1164/arrd.1983.127.4.487; Teran-Santos J, 1999, NEW ENGL J MED, V340, P847, DOI 10.1056/NEJM199903183401104; VANDEGRAAFF WB, 1988, J APPL PHYSIOL, V65, P2124, DOI 10.1152/jappl.1988.65.5.2124; VANDEGRAAFF WB, 1991, J APPL PHYSIOL, V70, P1328, DOI 10.1152/jappl.1991.70.3.1328; Walker-Engstrom ML, 2002, CHEST, V121, P739, DOI 10.1378/chest.121.3.739; Weiss JW, 1996, SLEEP, V19, P388, DOI 10.1093/sleep/19.5.388; WEISS JW, 1993, SLEEP, V16, pS39; WETTER DW, 1994, ARCH INTERN MED, V154, P2219, DOI 10.1001/archinte.154.19.2219; WHEATLEY JR, 1993, J APPL PHYSIOL, V75, P2117, DOI 10.1152/jappl.1993.75.5.2117; WHEATLEY JR, 1993, AM REV RESPIR DIS, V148, P597, DOI 10.1164/ajrccm/148.3.597; WHEATLEY JR, 1993, SLEEP, V16, pS87, DOI 10.1093/sleep/16.suppl_8.S87; White DP, 1998, SLEEP, V21, P188; White DP, 1998, SLEEP, V21, P198, DOI 10.1093/sleep/21.2.198; Whittle AT, 1997, THORAX, V52, P1068, DOI 10.1136/thx.52.12.1068; Younes M, 2001, AM J RESP CRIT CARE, V163, P1181, DOI 10.1164/ajrccm.163.5.2007013; Young T, 2002, AM J RESP CRIT CARE, V165, P1217, DOI 10.1164/rccm.2109080; YOUNG T, 1993, NEW ENGL J MED, V328, P1230, DOI 10.1056/NEJM199304293281704; Young T, 2001, AM J RESP CRIT CARE, V163, P597, DOI 10.1164/ajrccm.163.3.ed09-01a	123	745	773	9	147	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JUL 20	2002	360	9328					237	245		10.1016/S0140-6736(02)09464-3	http://dx.doi.org/10.1016/S0140-6736(02)09464-3			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	576DX	12133673				2023-01-03	WOS:000176988500028
J	Peacock, JE; Herrington, DA; Wade, JC; Lazarus, HM; Reed, MD; Sinclair, JW; Haverstock, DC; Kowalsky, SF; Hurd, DD; Cushing, DA; Harman, CP; Donowitz, GR				Peacock, JE; Herrington, DA; Wade, JC; Lazarus, HM; Reed, MD; Sinclair, JW; Haverstock, DC; Kowalsky, SF; Hurd, DD; Cushing, DA; Harman, CP; Donowitz, GR			Ciprofloxacin plus piperacillin compared with tobramycin plus piperacillin as empirical therapy in febrile neutropenic patients - A randomized, double-blind trial	ANNALS OF INTERNAL MEDICINE			English	Article							CANCER-PATIENTS; INTRAVENOUS CIPROFLOXACIN; ANTIBIOTIC-THERAPY; PSEUDOMONAS-AERUGINOSA; ESCHERICHIA-COLI; FEVER; RESISTANCE; CEFTAZIDIME; COMBINATION; EPISODES	Background: Therapy with an aminoglycoside and a beta-lactam remains common empirical therapy for febrile neutropenic patients. Concerns of aminoglycoside-induced ototoxicity and nephrotoxicity have led to studies of alternate regimens. Objective: To determine whether ciprofloxacin-piperacillin is equivalent to tobramycin-piperacillin as empirical therapy for neutropenic fever. Design: Randomized, double-blind multicenter trial. Setting: Seven U.S. university-affiliated hospitals and one private research center. Patients: Febrile (temperature greater than or equal to 38 degreesC), neutropenic (neutrophil level < 1 x 10(9) cells/L) hospitalized patients who had leukemia, lymphoma, or solid tumors, or were undergoing bone marrow transplantation. Interventions: Patients received piperacillin, 50 mg/kg of body weight intravenously every 4 hours, and ciprofloxacin, 400 mg intravenously every 8 hours, or tobramycin, 2 mg/kg intravenously every 8 hours. Measurements: Success was defined as resolution of infection and previously positive cultures without the need to give additional antimicrobial agents. Results: 543 febrile episodes were evaluated, of which 471 were clinically evaluable (234 in the ciprofloxacin-piperacillin group and 237 in the tobramycin-piperacillin group). Success rates in the ciprofloxacin-piperacillin group (63 of 234 febrile episodes) and tobramycin-piperacillin group (52 of 237 episodes) were similar (27% vs. 22%, respectively; difference, 5.0 percentage points [95% Cl, -2.3 to 12.8 percentage points]), as was survival (96.2% of patients receiving ciprofloxacin-piperacillin versus 94.1% of patients receiving tobramycin-piperacillin; difference, 2.1 percentage points [Cl, -2.2 to 6.4 percentage points]). Additions to the initial antimicrobial regimen were the most common reason for treatment failure in both groups (accounting for 67% of failures in the ciprofloxacin-piperacillin group and 72% in the tobramycin-piperacillin group; difference, 5.0 percentage points [Cl, -13.8 to 3.7 percentage points]). Fevers resolved faster in patients receiving ciprofloxacin-piperacillin than in patients receiving tobramycin-piperacillin (mean, 5 vs. 6 days) (P = 0.005). No significant differences in adverse events or toxicity were noted (P = 0.083). Conclusion: Ciprofloxacin-piperacillin is as safe and effective as tobramycin-piperacillin for empirical therapy of neutropenic fever.	Univ Virginia Hlth Syst, Div Infect Dis, Charlottesville, VA 22908 USA; Univ Maryland, Ctr Canc, Baltimore, MD 21201 USA; Univ Hosp Cleveland, Rainbow Babies & Childrens Hosp, Cleveland, OH 44106 USA; Case Western Reserve Univ, Cleveland, OH 44106 USA; Bayer Corp, West Haven, CT USA; Wake Forest Univ, Sch Med, Winston Salem, NC 27109 USA	University of Virginia; University System of Maryland; University of Maryland Baltimore; Case Western Reserve University; Case Western Reserve University Hospital; University Hospitals of Cleveland; Rainbow Babies & Children's Hospital; Case Western Reserve University; Bayer AG; Wake Forest University	Donowitz, GR (corresponding author), Univ Virginia Hlth Syst, Div Infect Dis, POB 801343, Charlottesville, VA 22908 USA.							Archibald L, 1997, CLIN INFECT DIS, V24, P211, DOI 10.1093/clinids/24.2.211; BAYSTON KF, 1989, AM J MED, V87, pS269, DOI 10.1016/0002-9343(89)90078-8; BERNSTEIN JM, 1986, ARCH INTERN MED, V146, P2329, DOI 10.1001/archinte.146.12.2329; BODEY GP, 1993, CLIN INFECT DIS, V17, pS378, DOI 10.1093/clinids/17.Supplement_2.S378; BROWN AE, 1989, AM J MED, V87, pS266, DOI 10.1016/0002-9343(89)90077-6; BRUMMETT RE, 1989, ANTIMICROB AGENTS CH, V33, P797, DOI 10.1128/AAC.33.6.797; BUSTAMANTE CI, 1990, ANTIMICROB AGENTS CH, V34, P1814, DOI 10.1128/AAC.34.9.1814; Carmeli Y, 1999, ANTIMICROB AGENTS CH, V43, P1379, DOI 10.1128/AAC.43.6.1379; CHALKLEY LJ, 1985, ANTIMICROB AGENTS CH, V28, P331, DOI 10.1128/AAC.28.2.331; CHAN CC, 1989, ANTIMICROB AGENTS CH, V33, P87, DOI 10.1128/AAC.33.1.87; Cordonnier C, 1997, CLIN INFECT DIS, V24, P41, DOI 10.1093/clinids/24.1.41; deLalla F, 1997, DRUGS, V53, P789, DOI 10.2165/00003495-199753050-00005; Edson RS, 1999, MAYO CLIN PROC, V74, P519, DOI 10.4065/74.5.519; Elting LS, 2000, J CLIN ONCOL, V18, P3699, DOI 10.1200/JCO.2000.18.21.3699; FERNANDES CJ, 1990, DIAGN MICR INFEC DIS, V13, P79, DOI 10.1016/0732-8893(90)90090-I; Finberg RW, 1999, NEW ENGL J MED, V341, P362, DOI 10.1056/NEJM199907293410509; FLAHERTY JP, 1989, AM J MED, V87, pS278, DOI 10.1016/0002-9343(89)90080-6; Freifeld A, 1999, NEW ENGL J MED, V341, P305, DOI 10.1056/NEJM199907293410501; Ghazal HH, 1997, CLIN THER, V19, P520, DOI 10.1016/S0149-2918(97)80136-1; Giamarellou H, 2000, ANTIMICROB AGENTS CH, V44, P3264, DOI 10.1128/AAC.44.12.3264-3271.2000; Griggs JJ, 1998, AM J HEMATOL, V58, P293, DOI 10.1002/(SICI)1096-8652(199808)58:4<293::AID-AJH7>3.0.CO;2-L; Hathorn JW, 1997, CLIN INFECT DIS, V24, pS256, DOI 10.1093/clinids/24.Supplement_2.S256; Hughes WT, 1997, CLIN INFECT DIS, V25, P551, DOI 10.1086/513764; Jones RN, 1999, CLIN INFECT DIS, V29, P495, DOI 10.1086/598621; KAHLMETER G, 1984, J ANTIMICROB CHEMOTH, V13, P9, DOI 10.1093/jac/13.suppl_A.9; KELSEY SM, 1989, AM J MED, V87, pS274, DOI 10.1016/0002-9343(89)90079-X; Kern WV, 1999, NEW ENGL J MED, V341, P312, DOI 10.1056/NEJM199907293410502; Marie JP, 1998, J ANTIMICROB CHEMOTH, V41, P57, DOI 10.1093/jac/41.suppl_4.57; MEUNIER F, 1991, ANTIMICROB AGENTS CH, V35, P873, DOI 10.1128/AAC.35.5.873; ORLANDO PL, 1990, DIAGN MICR INFEC DIS, V13, P93, DOI 10.1016/0732-8893(90)90091-9; Pizzo PA, 1999, NEW ENGL J MED, V341, P893, DOI 10.1056/NEJM199909163411207; PIZZO PA, 1993, NEW ENGL J MED, V328, P1323; ROLSTON KVI, 1989, AM J MED, V87, pS261, DOI 10.1016/0002-9343(89)90076-4; SANDERS CC, 1988, REV INFECT DIS, V10, P516; SCHIMPFF S, 1971, NEW ENGL J MED, V284, P1061, DOI 10.1056/NEJM197105132841904; SMITH GM, 1988, J ANTIMICROB CHEMOTH, V21, P647, DOI 10.1093/jac/21.5.647; Thomson CJ, 1999, J ANTIMICROB CHEMOTH, V43, P31, DOI 10.1093/jac/43.suppl_1.31; van Kraaij MGJ, 1998, EUR J CLIN MICROBIOL, V17, P591, DOI 10.1007/BF01708627; Viscoli C, 1998, J ANTIMICROB CHEMOTH, V41, P65, DOI 10.1093/jac/41.suppl_4.65; 1991, MED LETT DRUGS THER, V33, P75	40	37	39	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUL 16	2002	137	2					77	86		10.7326/0003-4819-137-2-200207160-00005	http://dx.doi.org/10.7326/0003-4819-137-2-200207160-00005			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	575VN	12118962				2023-01-03	WOS:000176969300001
J	Pandha, HS; Kirby, RS				Pandha, HS; Kirby, RS			PC-SPES: phytotherapy for prostate cancer	LANCET			English	Editorial Material							CHINESE HERBAL PREPARATION; IN-VITRO; ETHANOLIC EXTRACTS; CELLS; SUPPLEMENT; EXPRESSION; APOPTOSIS; THERAPY; TRIAL		St George Hosp, Sch Med, Dept Oncol, London SW17 0RE, England; St George Hosp, Sch Med, Dept Urol, London SW17 0RE, England	St Georges University London; St Georges University London	Pandha, HS (corresponding author), St George Hosp, Sch Med, Dept Oncol, London SW17 0RE, England.							Carraro JC, 1996, PROSTATE, V29, P231, DOI 10.1002/(SICI)1097-0045(199610)29:4&lt;231::AID-PROS4&gt;3.0.CO;2-E; Chen S, 2001, UROLOGY, V58, P28, DOI 10.1016/S0090-4295(01)01239-0; De la Taille A, 2000, J UROLOGY, V164, P1229, DOI 10.1097/00005392-200010000-00021; Di Silverio F, 1993, Minerva Urol Nefrol, V45, P143; DiPaola RS, 1998, NEW ENGL J MED, V339, P785, DOI 10.1056/NEJM199809173391201; Duda RB, 1996, ANN SURG ONCOL, V3, P515, DOI 10.1007/BF02306082; Halicka HD, 1997, INT J ONCOL, V11, P437; Hsieh TC, 1998, INT J ONCOL, V13, P1199; Hsieh TC, 1997, BIOCHEM MOL BIOL INT, V42, P535; IKEZOE T, 2002, ANN M AM ASS CANC RE; Kubota T, 2000, PROSTATE, V42, P163; Pfeifer BL, 2000, BJU INT, V85, P481, DOI 10.1046/j.1464-410x.2000.00476.x; Small EJ, 2000, J CLIN ONCOL, V18, P3595, DOI 10.1200/JCO.2000.18.21.3595; Small EJ, 1997, J CLIN ONCOL, V15, P382, DOI 10.1200/JCO.1997.15.1.382; Smith DC, 1998, UROLOGY, V52, P257, DOI 10.1016/S0090-4295(98)00173-3; SOVAK M, 2002, ANN M AM ASS CANC RE; Tiwari RK, 1999, INT J ONCOL, V14, P713; Wang SY, 1997, INT J CANCER, V70, P699, DOI 10.1002/(SICI)1097-0215(19970317)70:6&lt;699::AID-IJC12&gt;3.0.CO;2-5; Weinrobe MC, 2001, NEW ENGL J MED, V345, P1213, DOI 10.1056/NEJM200110183451616; Zhu BT, 1997, CANCER RES, V57, P2419	20	10	11	0	2	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUN 29	2002	359	9325					2213	2215		10.1016/S0140-6736(02)09313-3	http://dx.doi.org/10.1016/S0140-6736(02)09313-3			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	567YJ	12103281				2023-01-03	WOS:000176514500003
J	Badri, M; Wilson, D; Wood, R				Badri, M; Wilson, D; Wood, R			Effect of highly active antiretroviral therapy on incidence of tuberculosis in South Africa: a cohort study	LANCET			English	Article							SUB-SAHARAN AFRICA; HIV-INFECTION; PULMONARY TUBERCULOSIS; MORTALITY; ADULTS; IMMUNODEFICIENCY; PREVALENCE; PREVENTION; ILLNESSES; IMPACT	Background Studies of the effect of highly active antiretroviral therapy (HAART) on the risk of HIV-1-associated tuberculosis have had variable results, We set out to determine the effect of HAART on the risk of tuberculosis in South Africa. Methods We compared the risk of tuberculosis in 264 patients who received HAART in phase III clinical trials and a prospective cohort of 770 non-HAART patients who were attending Somerset Hospital adult HIV clinic, University of Cape Town, between 1992 and 2001. Poisson regression models were fitted to determine risk of tuberculosis; patients were stratified by CD4 count, WHO clinical stage, and socioeconomic status. Findings HAART was associated with a lower incidence of tuberculosis (2.4 vs 9.7 cases per 100 patient-years, adjusted rate ratio 0.19 [95% Cl 0.09-0.38]; p<0.0001). This finding was apparent across all strata of socioeconomic status, baseline WHO stage, and CD4 count, except in patients with CD4 counts of more than 350 cells/&mu;L. The number of tuberculosis cases averted by HAART was greatest in patients with WHO stage 3 or 4 (18.8 averted cases per 100 patient-years, adjusted rate ratio 0.22 [0.09-0.41]; p=0.03) and in those with CD4 counts of less than 200 cells/&mu;L (14.2 averted cases per 100 patient-years, adjusted rate ratio 0.18 [0.07-0.47]; P<0.0001). Interpretation HAART reduced the incidence of HIV-1-associated tuberculosis by more than 80% (95% Cl 62-91) in an area endemic with tuberculosis and HIV-1. The protective effect of HAART was greatest in symptomatic patients and those with advanced immune suppression.	Univ Cape Town, Somerset Hosp, HIV Clin Res Unit, ZA-8005 Cape Town, South Africa	University of Cape Town	Wood, R (corresponding author), Univ Cape Town, Somerset Hosp, HIV Clin Res Unit, ZA-8005 Cape Town, South Africa.		Wood, Robin/G-8509-2011; Badri, Motasim/E-1141-2013	Badri, Motasim/0000-0002-5268-6492				ACKAH AN, 1995, LANCET, V345, P607, DOI 10.1016/S0140-6736(95)90519-7; Badri M, 2002, INT J TUBERC LUNG D, V6, P231; Badri M, 2001, INT J TUBERC LUNG D, V5, P225; Brodt HR, 1997, AIDS, V11, P1731, DOI 10.1097/00002030-199714000-00010; *CAP METR COUNC, 1997, LEV LIV CAP METR AR; De Cock KM, 1999, INT J TUBERC LUNG D, V3, P457; DECOCK KM, 1992, JAMA-J AM MED ASSOC, V268, P1581, DOI 10.1001/jama.1992.03490120095035; Dye C, 1999, JAMA-J AM MED ASSOC, V282, P677, DOI 10.1001/jama.282.7.677; Girardi E, 2000, AIDS, V14, P1985, DOI 10.1097/00002030-200009080-00015; Halsey NA, 1998, LANCET, V351, P786, DOI 10.1016/S0140-6736(97)06532-X; Harries AD, 2001, LANCET, V357, P1519, DOI 10.1016/S0140-6736(00)04639-0; Jones JL, 2000, INT J TUBERC LUNG D, V4, P1026; LANGE JMA, 1993, AIDS, V7, P1675, DOI 10.1097/00002030-199312000-00021; Ledergerber B, 1999, JAMA-J AM MED ASSOC, V282, P2220, DOI 10.1001/jama.282.23.2220; LEROY V, 1997, AM J EPIDEMIOL, V145, P295; MUKADI Y, 1993, LANCET, V342, P143, DOI 10.1016/0140-6736(93)91346-N; NAIDO P, 2001, 11 JOINT C STD ID SO; Santoro-Lopes G, 2002, CLIN INFECT DIS, V34, P543, DOI 10.1086/338641; UNAIDS, 2000, AIDS EP UPD DEC 2000; WHALEN C, 1995, AM J RESP CRIT CARE, V151, P129, DOI 10.1164/ajrccm.151.1.7812542; Whalen CC, 2000, AIDS, V14, P1219, DOI 10.1097/00002030-200006160-00020; *WHO, 2000, 1 M GLOB WORK GROUP; *WHO, 1990, WKLY EPIDEMIOL REC, V65, P221; Wilkinson D, 1998, BRIT MED J, V317, P625, DOI 10.1136/bmj.317.7159.625; Wood R, 2000, J ACQ IMMUN DEF SYND, V23, P75; World Health Organization, 2002, SCAL ANT THER RES LT	26	430	433	0	5	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUN 15	2002	359	9323					2059	2064		10.1016/S0140-6736(02)08904-3	http://dx.doi.org/10.1016/S0140-6736(02)08904-3			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	562JX	12086758				2023-01-03	WOS:000176194600006
J	Abraham, WT; Fisher, WG; Smith, AL; Delurgio, DB; Leon, AR; Loh, E; Kocovic, DZ; Packer, M; Clavell, AL; Hayes, DL; Ellestad, M; Messenger, J; Trupp, RJ; Underwood, J; Pickering, F; Truex, C; McAtee, P				Abraham, WT; Fisher, WG; Smith, AL; Delurgio, DB; Leon, AR; Loh, E; Kocovic, DZ; Packer, M; Clavell, AL; Hayes, DL; Ellestad, M; Messenger, J; Trupp, RJ; Underwood, J; Pickering, F; Truex, C; McAtee, P		MIRACLE Study Grp	Cardiac resynchronization in chronic heart failure	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							INTRAVENTRICULAR-CONDUCTION DELAY; LEFT-VENTRICULAR FUNCTION; DILATED CARDIOMYOPATHY; EXERCISE CAPACITY; RANDOMIZED TRIAL; MORTALITY; VESNARINONE; EXPERIENCE; RATIONALE; PROGNOSIS	Background: Previous studies have suggested that cardiac resynchronization achieved through atrial-synchronized biventricular pacing produces clinical benefits in patients with heart failure who have an intraventricular conduction delay. We conducted a double-blind trial to evaluate this therapeutic approach. Methods: Four hundred fifty-three patients with moderate-to-severe symptoms of heart failure associated with an ejection fraction of 35 percent or less and a QRS interval of 130 msec or more were randomly assigned to a cardiac-resynchronization group (228 patients) or to a control group (225 patients) for six months, while conventional therapy for heart failure was maintained. The primary end points were the New York Heart Association functional class, quality of life, and the distance walked in six minutes. Results: As compared with the control group, patients assigned to cardiac resynchronization experienced an improvement in the distance walked in six minutes (+39 vs. +10 m, P=0.005), functional class (P<0.001), quality of life (-18.0 vs. -9.0 points, P=0.001), time on the treadmill during exercise testing (+81 vs. +19 sec, P=0.001), and ejection fraction (+4.6 percent vs. -0.2 percent, P<0.001). In addition, fewer patients in the group assigned to cardiac resynchronization than control patients required hospitalization (8 percent vs. 15 percent) or intravenous medications (7 percent vs. 15 percent) for the treatment of heart failure (P<0.05 for both comparisons). Implantation of the device was unsuccessful in 8 percent of patients and was complicated by refractory hypotension, bradycardia, or asystole in four patients (two of whom died) and by perforation of the coronary sinus requiring pericardiocentesis in two others. Conclusions: Cardiac resynchronization results in significant clinical improvement in patients who have moderate-to-severe heart failure and an intraventricular conduction delay.	Univ Kentucky, Coll Med, Div Cardiovasc Med, Kentucky Clin, Lexington, KY 40536 USA; Emory Univ, Atlanta, GA 30322 USA; Crawford W Long Mem Hosp, Atlanta, GA USA; Univ Penn, Philadelphia, PA 19104 USA; Columbia Univ, Coll Phys & Surg, New York, NY USA; Mayo Med Ctr, Rochester, MN USA; Long Beach Mem Med Ctr, Long Beach, CA USA; Long Beach Mem Hosp Med Ctr, Long Beach, CA USA	University of Kentucky; Emory University; University of Pennsylvania; Columbia University; Mayo Clinic	Abraham, WT (corresponding author), Univ Kentucky, Coll Med, Div Cardiovasc Med, Kentucky Clin, Rm L-543,740 Limestone St, Lexington, KY 40536 USA.		Tang, Anthony S/E-6203-2014					Aaronson KD, 1997, CIRCULATION, V95, P2660, DOI 10.1161/01.CIR.95.12.2660; Abraham WT, 2000, J CARD FAIL, V6, P369, DOI 10.1054/jcaf.2000.20841; Auricchio A, 1999, CIRCULATION, V99, P2993, DOI 10.1161/01.CIR.99.23.2993; Braunschweig F, 2000, EUR J HEART FAIL, V2, P399, DOI 10.1016/S1388-9842(00)00113-6; Bristow MR, 2000, J CARD FAIL, V6, P276, DOI 10.1054/jcaf.2000.9501; BROPHY JM, 1994, CAN J CARDIOL, V10, P543; Cazeau S, 2001, NEW ENGL J MED, V344, P873, DOI 10.1056/NEJM200103223441202; Cleland JGF, 2001, EUR J HEART FAIL, V3, P481, DOI 10.1016/S1388-9842(01)00176-3; Cohn JN, 1998, NEW ENGL J MED, V339, P1810, DOI 10.1056/NEJM199812173392503; COX DR, 1972, J R STAT SOC B, V34, P187; Daubert JC, 1998, PACE, V21, P239, DOI 10.1111/j.1540-8159.1998.tb01096.x; Etienne Y, 2001, EUR J HEART FAIL, V3, P441, DOI 10.1016/S1388-9842(01)00145-3; Farwell D, 2000, EUR HEART J, V21, P1246, DOI 10.1053/euhj.1999.1985; FELDMAN AM, 1993, NEW ENGL J MED, V329, P149, DOI 10.1056/NEJM199307153290301; GOLDSTEIN S, 1988, JAMA-J AM MED ASSOC, V259, P539; Gras D, 1998, PACE, V21, P2249, DOI 10.1111/j.1540-8159.1998.tb01162.x; GUNDERSEN T, 1994, EUR HEART J, V15, P1659; GUYATT GH, 1985, CAN MED ASSOC J, V132, P919; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; Kass DA, 1999, CIRCULATION, V99, P1567, DOI 10.1161/01.CIR.99.12.1567; Kerwin WF, 2000, J AM COLL CARDIOL, V35, P1221, DOI 10.1016/S0735-1097(00)00555-6; Lau CP, 2000, PACE, V23, P1722; Leclercq C, 2000, AM HEART J, V140, P862, DOI 10.1067/mhj.2000.110570; Leclercq C, 1998, J AM COLL CARDIOL, V32, P1825, DOI 10.1016/S0735-1097(98)00492-6; Littmann L, 2000, J ELECTROCARDIOL, V33, P115, DOI 10.1054/jelc.2000.20330; Naughton JHR, 1973, EXERCISE TESTING EXE, P79; Packer M, 1996, CIRCULATION, V94, P2793, DOI 10.1161/01.CIR.94.11.2793; PACKER M, 1993, NEW ENGL J MED, V329, P1, DOI 10.1056/NEJM199307013290101; Packer M, 2001, J CARD FAIL, V7, P176, DOI 10.1054/jcaf.2001.25652; Pitt B, 2000, LANCET, V355, P1582, DOI 10.1016/S0140-6736(00)02213-3; Pitt B, 1997, LANCET, V349, P747, DOI 10.1016/S0140-6736(97)01187-2; Rector TS, 1987, HEART FAIL, V3, P198, DOI DOI 10.1177/1474515111435605; SAVAGE IR, 1956, ANN MATH STAT, V27, P590, DOI 10.1214/aoms/1177728170; Saxon LA, 1998, J CARDIOVASC ELECTR, V9, P13, DOI 10.1111/j.1540-8167.1998.tb00862.x; Shamim W, 1999, INT J CARDIOL, V70, P171, DOI 10.1016/S0167-5273(99)00077-7; The Criteria Committee of the New York Heart Association, 1994, NOM CRIT DIAGN DIS H; UNVERFERTH DV, 1984, AM J CARDIOL, V54, P147, DOI 10.1016/0002-9149(84)90320-5; Valls-Bertault V, 2001, EUROPACE, V3, P60, DOI 10.1053/eupc.2000.0138; Xiao HB, 1996, INT J CARDIOL, V53, P163, DOI 10.1016/0167-5273(95)02502-2; XIAO HB, 1992, BRIT HEART J, V68, P403	40	3456	3665	1	91	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUN 13	2002	346	24					1845	1853		10.1056/NEJMoa013168	http://dx.doi.org/10.1056/NEJMoa013168			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	561NA	12063368				2023-01-03	WOS:000176146100002
J	Delmas, PD				Delmas, PD			Treatment of postmenopausal osteoporosis	LANCET			English	Review							BONE-MINERAL DENSITY; HORMONE REPLACEMENT THERAPY; VERTEBRAL FRACTURE RISK; VITAMIN-D SUPPLEMENTATION; BREAST-CANCER; RANDOMIZED-TRIAL; HIP FRACTURE; BIOCHEMICAL MARKERS; DOUBLE-BLIND; ESTABLISHED OSTEOPOROSIS	The aim of treatment of postmenopausal osteoporosis Is to reduce the frequency of vertebral and non-vertebral fractures (especially at the hip), which are responsible for morbidity associated with the disease. Results of large placebo controlled trials have shown that alendronate, raloxifene, risedronate, the 1-34 fragment of parathyroid hormone, and nasal calcitonin, greatly reduce the risk of vertebral fractures. Furthermore, a large reduction of non-vertebral fractures has been shown for alendronate, risedronate, and the 1-34 fragment of parathyroid hormone. Calcium and vitamin D supplementation is not sufficient to treat individuals with osteoporosis but Is useful, especially In elderly women in care homes. Hormone replacement therapy remains a valuable option for the prevention of osteoporosis in early postmenopausal women. Choice of treatment depends on age, the presence or absence of prevalent fractures, especially at the spine, and the degree of bone mineral density measured at the spine and hip. Non-pharmacological interventions include adequate calcium Intake and diet, selected exercise programmes, reduction of other risk factors for osteoporotic fractures, and reduction of the risk of falls in elderly individuals.	Univ Lyon 1, F-69365 Lyon, France; INSERM Res, U403, F-69008 Lyon, France	UDICE-French Research Universities; Universite Claude Bernard Lyon 1; Institut National de la Sante et de la Recherche Medicale (Inserm)	Delmas, PD (corresponding author), Hop Edouard Herriot, Pavillon F, F-69437 Lyon 03, France.	delmas@lyon151.inserm.fr						Alexandersen P, 2001, JAMA-J AM MED ASSOC, V285, P1482, DOI 10.1001/jama.285.11.1482; [Anonymous], 1994, JAMA, V272, P1942; Barrett-Connor E, 2002, JAMA-J AM MED ASSOC, V287, P847, DOI 10.1001/jama.287.7.847; Beresford SAA, 1997, LANCET, V349, P458, DOI 10.1016/S0140-6736(96)07365-5; Bergkvist L, 1996, DRUG SAFETY, V15, P360, DOI 10.2165/00002018-199615050-00006; Berning B, 1996, BONE, V19, P395, DOI 10.1016/S8756-3282(96)00219-0; Bjarnason NH, 1996, J CLIN ENDOCR METAB, V81, P2419, DOI 10.1210/jc.81.7.2419; Bjarnason NH, 2001, OSTEOPOROSIS INT, V12, P922, DOI 10.1007/s001980170020; Black DM, 2000, J CLIN ENDOCR METAB, V85, P4118, DOI 10.1210/jc.85.11.4118; Black DM, 1996, LANCET, V348, P1535, DOI 10.1016/S0140-6736(96)07088-2; Boivin GY, 2000, BONE, V27, P687, DOI 10.1016/S8756-3282(00)00376-8; Bone HG, 2000, J CLIN ENDOCR METAB, V85, P720, DOI 10.1210/jc.85.2.720; Bush TL, 1996, JAMA-J AM MED ASSOC, V276, P1389, DOI 10.1001/jama.276.17.1389; Cauley JA, 2001, BREAST CANCER RES TR, V65, P125, DOI 10.1023/A:1006478317173; CAULEY JA, 1995, ANN INTERN MED, V122, P9, DOI 10.7326/0003-4819-122-1-199501010-00002; CHAPUY MC, 1994, BRIT MED J, V308, P1081, DOI 10.1136/bmj.308.6936.1081; CHAPUY MC, 1992, NEW ENGL J MED, V327, P1637, DOI 10.1056/NEJM199212033272305; Chesnut CH, 2000, AM J MED, V109, P267, DOI 10.1016/S0002-9343(00)00490-3; CHRISTIANSEN C, 1981, LANCET, V1, P459; COLDITZ GA, 1995, NEW ENGL J MED, V332, P1589, DOI 10.1056/NEJM199506153322401; Cranney A, 2001, OSTEOPOROSIS INT, V12, P140, DOI 10.1007/s001980170147; Cummings SR, 2000, JAMA-J AM MED ASSOC, V283, P1318, DOI 10.1001/jama.283.10.1318; Cummings SR, 1999, JAMA-J AM MED ASSOC, V281, P2189, DOI 10.1001/jama.281.23.2189; Cummings SR, 1998, JAMA-J AM MED ASSOC, V280, P2077, DOI 10.1001/jama.280.24.2077; DawsonHughes B, 1997, NEW ENGL J MED, V337, P670, DOI 10.1056/NEJM199709043371003; DAWSONHUGHES B, 1990, NEW ENGL J MED, V323, P878, DOI 10.1056/NEJM199009273231305; deGroen PC, 1996, NEW ENGL J MED, V335, P1016, DOI 10.1056/NEJM199610033351403; Delmas P D, 1997, Osteoporos Int, V7 Suppl 1, pS3; Delmas PD, 1997, NEW ENGL J MED, V337, P1641, DOI 10.1056/NEJM199712043372301; Delmas PD, 1997, J CLIN ONCOL, V15, P955, DOI 10.1200/JCO.1997.15.3.955; Delmas PD, 2000, OSTEOPOROSIS INT, V11, pS2, DOI 10.1007/s001980070002; Delmas PD, 2000, BONE, V26, P553, DOI 10.1016/S8756-3282(00)00271-4; Delmas PD, 2000, BONE, V27, P1, DOI 10.1016/S8756-3282(00)00301-X; Ettinger B, 1999, JAMA-J AM MED ASSOC, V282, P637, DOI 10.1001/jama.282.7.637; FELSON DT, 1993, NEW ENGL J MED, V329, P1141, DOI 10.1056/NEJM199310143291601; Feskanich D, 1999, AM J CLIN NUTR, V69, P74; FIATARONE MA, 1990, JAMA-J AM MED ASSOC, V263, P3029, DOI 10.1001/jama.263.22.3029; FISHER B, 1994, J NATL CANCER I, V86, P527, DOI 10.1093/jnci/86.7.527; Fleisch H., 2000, BISPHOSPHONATES BONE; GALLAGHER JC, 1990, ANN INTERN MED, V113, P649, DOI 10.7326/0003-4819-113-9-649; GALLAGHER JC, 1989, P SOC EXP BIOL MED, V191, P287; GARNERO P, 1994, J CLIN ENDOCR METAB, V79, P1693, DOI 10.1210/jc.79.6.1693; GREY AB, 1995, AM J MED, V99, P636, DOI 10.1016/S0002-9343(99)80251-4; Grodstein F, 1996, NEW ENGL J MED, V335, P453, DOI 10.1056/NEJM199608153350701; Grodstein F, 1996, LANCET, V348, P983, DOI 10.1016/S0140-6736(96)07308-4; HARRIS ST, 1993, AM J MED, V95, P557, DOI 10.1016/0002-9343(93)90350-X; Harris ST, 1999, JAMA-J AM MED ASSOC, V282, P1344, DOI 10.1001/jama.282.14.1344; Harris ST, 2001, J CLIN ENDOCR METAB, V86, P1890, DOI 10.1210/jc.86.5.1890; HEIKINHEIMO RJ, 1992, CALCIFIED TISSUE INT, V51, P105, DOI 10.1007/BF00298497; Hosking D, 1998, NEW ENGL J MED, V338, P485, DOI 10.1056/NEJM199802193380801; Jiang G, 2000, J BONE MINER RES, V15, pS169; JOHANNES EJ, 1997, GYNECOL ENDOCRINOL, V11, P25; Johnell O, 2002, J CLIN ENDOCR METAB, V87, P985, DOI 10.1210/jc.87.3.985; Kannus P, 2000, NEW ENGL J MED, V343, P1506, DOI 10.1056/NEJM200011233432101; KIEL DP, 1987, NEW ENGL J MED, V317, P1169, DOI 10.1056/NEJM198711053171901; Klibanski A, 2001, JAMA-J AM MED ASSOC, V285, P785; Lane JM, 2000, OSTEOPOROSIS INT, V11, pS206; LAURITZEN JB, 1993, LANCET, V341, P11, DOI 10.1016/0140-6736(93)92480-H; LIBERMAN UA, 1995, NEW ENGL J MED, V333, P1437, DOI 10.1056/NEJM199511303332201; LINDSAY R, 1980, LANCET, V2, P1151; Lindsay R, 2001, JAMA-J AM MED ASSOC, V285, P320, DOI 10.1001/jama.285.3.320; Lindsay R, 1997, LANCET, V350, P550, DOI 10.1016/S0140-6736(97)02342-8; LINDSAY R, 1981, LANCET, V1, P729; Lips P, 1996, ANN INTERN MED, V124, P400, DOI 10.7326/0003-4819-124-4-199602150-00003; LOVE RR, 1992, NEW ENGL J MED, V326, P852, DOI 10.1056/NEJM199203263261302; LUFKIN EG, 1994, OSTEOPOROSIS INT, V4, P320, DOI 10.1007/BF01622190; LUFKIN EG, 1992, ANN INTERN MED, V117, P1, DOI 10.7326/0003-4819-117-1-1; MAMELLE N, 1988, LANCET, V2, P361, DOI 10.1016/S0140-6736(88)92834-6; Marcus R., 1996, PRINCIPLES BONE BIOL, P1435; MARIE PJ, 1993, J BONE MINER RES, V8, P607; MAXIM P, 1995, OSTEOPOROSIS INT, V5, P23, DOI 10.1007/BF01623654; McCloskey E, 2001, BONE, V28, P310, DOI 10.1016/S8756-3282(00)00437-3; McClung M, 1998, ANN INTERN MED, V128, P253, DOI 10.7326/0003-4819-128-4-199802150-00001; McClung MR, 2001, NEW ENGL J MED, V344, P333, DOI 10.1056/NEJM200102013440503; Meunier PJ, 2002, J CLIN ENDOCR METAB, V87, P2060, DOI 10.1210/jc.87.5.2060; Meunier PJ, 1998, OSTEOPOROSIS INT, V8, P4, DOI 10.1007/s001980050041; Mortensen L, 1998, J CLIN ENDOCR METAB, V83, P396, DOI 10.1210/jc.83.2.396; Mundy G, 1999, SCIENCE, V286, P1946, DOI 10.1126/science.286.5446.1946; Neer RM, 2001, NEW ENGL J MED, V344, P1434, DOI 10.1056/NEJM200105103441904; NIELSEN SP, 1994, BRIT J OBSTET GYNAEC, V101, P319, DOI 10.1111/j.1471-0528.1994.tb13618.x; Nieves JW, 1998, AM J CLIN NUTR, V67, P18, DOI 10.1093/ajcn/67.1.18; ORIMO H, 1994, CALCIFIED TISSUE INT, V54, P370, DOI 10.1007/BF00305521; ORIMO H, 1987, BONE MINER, V3, P47; ORIMO H, 1993, 4TH P INT S OST, P148; OVERGAARD K, 1989, BRIT MED J, V299, P477, DOI 10.1136/bmj.299.6697.477; OVERGAARD K, 1992, BRIT MED J, V305, P556, DOI 10.1136/bmj.305.6853.556; PAGANINIHILL A, 1981, ANN INTERN MED, V95, P28, DOI 10.7326/0003-4819-95-1-28; Pols HAP, 1999, OSTEOPOROSIS INT, V9, P461, DOI 10.1007/PL00004171; Ravn P, 1998, BONE, V22, P559, DOI 10.1016/S8756-3282(98)00044-1; Recker RR, 1996, J BONE MINER RES, V11, P1961; Reginster JY, 2000, OSTEOPOROSIS INT, V11, P83, DOI 10.1007/s001980050010; REGINSTER JY, 1995, AM J MED, V98, P452, DOI 10.1016/S0002-9343(99)80344-1; REID IR, 1995, AM J MED, V98, P331, DOI 10.1016/S0002-9343(99)80310-6; REID IR, 1994, J CLIN ENDOCR METAB, V79, P1595, DOI 10.1210/jc.79.6.1595; RIGGS BL, 1990, NEW ENGL J MED, V322, P802, DOI 10.1056/NEJM199003223221203; Riggs BL, 1996, BONE, V18, pS197, DOI 10.1016/8756-3282(95)00502-1; Schnitzer T, 2000, AGING CLIN EXP RES, V12, P1; Seeman E, 2001, TRENDS ENDOCRIN MET, V12, P281, DOI 10.1016/S1043-2760(01)00460-X; Shiraki M, 2000, J BONE MINER RES, V15, P515, DOI 10.1359/jbmr.2000.15.3.515; STORM T, 1990, NEW ENGL J MED, V322, P1265, DOI 10.1056/NEJM199005033221803; SZULC P, 1993, J CLIN INVEST, V91, P1769, DOI 10.1172/JCI116387; Taaffe DR, 1999, J AM GERIATR SOC, V47, P1208, DOI 10.1111/j.1532-5415.1999.tb05201.x; Tang MX, 1996, LANCET, V348, P429, DOI 10.1016/S0140-6736(96)03356-9; TILYARD MW, 1992, NEW ENGL J MED, V326, P357, DOI 10.1056/NEJM199202063260601; TINETTI ME, 1994, NEW ENGL J MED, V331, P821, DOI 10.1056/NEJM199409293311301; Tonino RP, 2000, J CLIN ENDOCR METAB, V85, P3109, DOI 10.1210/jc.85.9.3109; Torgerson D J, 2001, BMC Musculoskelet Disord, V2, P7, DOI 10.1186/1471-2474-2-7; Torgerson DJ, 2001, JAMA-J AM MED ASSOC, V285, P2891, DOI 10.1001/jama.285.22.2891; Walsh BW, 1998, JAMA-J AM MED ASSOC, V279, P1445, DOI 10.1001/jama.279.18.1445; WATTS NB, 1990, NEW ENGL J MED, V323, P73, DOI 10.1056/NEJM199007123230201; Yaffe K, 2001, NEW ENGL J MED, V344, P1207, DOI 10.1056/NEJM200104193441604	111	458	486	0	54	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JUN 8	2002	359	9322					2018	2026		10.1016/S0140-6736(02)08827-X	http://dx.doi.org/10.1016/S0140-6736(02)08827-X			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	563BA	12076571				2023-01-03	WOS:000176232500028
J	Greenspan, SL; Schneider, DL; McClung, MR; Miller, PD; Schnitzer, TJ; Bonin, R; Smith, E; DeLucca, P; Gormley, GJ; Melton, ME				Greenspan, SL; Schneider, DL; McClung, MR; Miller, PD; Schnitzer, TJ; Bonin, R; Smith, E; DeLucca, P; Gormley, GJ; Melton, ME			Alendronate improves bone mineral density in elderly women with osteoporosis residing in long-term care facilities - A randomized, double-blind, placebo-controlled trial	ANNALS OF INTERNAL MEDICINE			English	Article							CALCIUM SUPPLEMENTATION; POSTMENOPAUSAL WOMEN; VERTEBRAL FRACTURES; NURSING-HOME; PREVALENCE; RISK	Background: Many elderly female residents of long-term care facilities have osteoporosis and could benefit from intervention to increase bone density. Objective: To examine the efficacy and safety of alendronate for treatment of osteoporosis in elderly female residents of long-term care facilities. Design: Multicenter, randomized, double-blind, placebo-controlled 2-year study. Setting: 25 long-term care facilities. Patients: 327 elderly women with osteoporosis. Intervention: Patients were randomly assigned to receive alendronate, 10 mg/d, or placebo. All patients also received vitamin D, 400 IU/d, and some patients received supplemental calcium (total intake, approximately 1500 mg/d). Measurements: Bone mineral density (BMD) of the spine and hip and biochemical markers of bone turnover. Results: Alendronate produced significantly greater increases in BMD than did placebo (24-month differences: spine, 4.4% [95% CI, 3.3% to 5.5%]; femoral neck, 3.4% [CI, 2.3% to 4.4%]). Alendronate produced greater decreases from baseline in biochemical markers of bone turnover than did placebo (P < 0.001). Conclusion: Alendronate increased BMD at both the spine and hip in elderly female residents of long-term care facilities.	Merck & Co Inc, Whitehouse Stn, NJ 08889 USA; Beth Israel Deaconess Med Ctr, Boston, MA USA; Univ Calif San Diego, La Jolla, CA 92093 USA; Oregon Osteoporosis Ctr, Portland, OR USA; Colorado Ctr Bone Res, Lakewood, CO USA; Rush Presbyterian St Lukes Med Ctr, Chicago, IL USA	Merck & Company; Harvard University; Beth Israel Deaconess Medical Center; University of California System; University of California San Diego; Oregon Osteoporosis Center; Colorado Center For Bone Research; Rush University	Melton, ME (corresponding author), Merck & Co Inc, 1 Merck Dr WS 3CD-45, Whitehouse Stn, NJ 08889 USA.	mary_melton@merck.com	McClung, Michael/ABA-4100-2021	McClung, Michael/0000-0002-7827-0778				[Anonymous], 1999, HLTH AGING CHARTBOOK; BARAN RW, 1998, CONSULTANT PHARM, V13, P685; Black DM, 1996, LANCET, V348, P1535, DOI 10.1016/S0140-6736(96)07088-2; Bone HG, 2000, CLIN THER, V22, P15, DOI 10.1016/S0149-2918(00)87974-6; Bone HG, 1997, J CLIN ENDOCR METAB, V82, P265, DOI 10.1210/jc.82.1.265; CHAPUY MC, 1992, NEW ENGL J MED, V327, P1637, DOI 10.1056/NEJM199212033272305; Cummings SR, 1998, JAMA-J AM MED ASSOC, V280, P2077, DOI 10.1001/jama.280.24.2077; DAWSONHUGHES B, 1990, NEW ENGL J MED, V323, P878, DOI 10.1056/NEJM199009273231305; KOMAR L, 1993, J AM GERIATR SOC, V41, P1057, DOI 10.1111/j.1532-5415.1993.tb06452.x; LIBERMAN UA, 1995, NEW ENGL J MED, V333, P1437, DOI 10.1056/NEJM199511303332201; LOOKER AC, 1995, J BONE MINER RES, V10, P796; REID IR, 1995, AM J MED, V98, P331, DOI 10.1016/S0002-9343(99)80310-6; SAS Institute, 2014, SAS STAT SOFTW CHANG; Schnitzer T, 2000, AGING CLIN EXP RES, V12, P1; SUZMAN RM, 1992, OLDEST OLD; Zimmerman SI, 1999, OSTEOPOROSIS INT, V9, P151	16	84	87	0	5	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAY 21	2002	136	10					742	746		10.7326/0003-4819-136-10-200205210-00009	http://dx.doi.org/10.7326/0003-4819-136-10-200205210-00009			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	553FF	12020142				2023-01-03	WOS:000175664600004
J	Herrington, DM; Howard, TD; Hawkins, GA; Reboussin, DM; Xu, JF; Zheng, SL; Brosnihan, KB; Meyers, DA; Bleecker, ER				Herrington, DM; Howard, TD; Hawkins, GA; Reboussin, DM; Xu, JF; Zheng, SL; Brosnihan, KB; Meyers, DA; Bleecker, ER			Estrogen-receptor polymorphisms and effects of estrogen replacement on high-density lipoprotein cholesterol in women with coronary disease.	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							BONE-MINERAL DENSITY; DINUCLEOTIDE REPEAT POLYMORPHISM; POSTMENOPAUSAL CAUCASIAN WOMEN; FRAGMENT-LENGTH-POLYMORPHISM; BREAST-CANCER SUSCEPTIBILITY; ATHEROSCLEROSIS-REGRESSION; ENZYMATIC DETERMINATION; SPONTANEOUS-ABORTION; CONTROLLED-TRIAL; ARTERY DISEASE	Background: Sequence variants in the gene encoding estrogen receptor alpha (ER-alpha) may modify the effects of hormone-replacement therapy on levels of high-density lipoprotein (HDL) cholesterol and other outcomes related to estrogen treatment in postmenopausal women. Methods: We characterized 309 women with coronary artery disease who were enrolled in the Estrogen Replacement and Atherosclerosis trial with respect to eight previously described and two newly identified ER-alpha polymorphisms, and we examined the association between these polymorphisms and the response of HDL cholesterol and other lipids to treatment with estrogen alone or estrogen plus progestin. Results: After adjustment for age, race, diabetes status, body-mass index, smoking status, alcohol intake, and frequency of exercise, the 18.9 percent of the women who had the IVS1-401 C/C genotype (i.e., with C on both chromosomes in intervening sequence 1 at position 401 before exon 2) had an increase in the HDL cholesterol level with hormone-replacement therapy that was more than twice the increase observed in the other women (13.1 mg per deciliter vs. 6.0 mg per deciliter, P for treatment-by-genotype interaction = 0.004); this effect was limited to changes in the HDL subfraction 3 (HDL3) (P for interaction = 0.04). Similar patterns of response were observed for three other highly linked ER-alpha intron 1 polymorphisms close to the IVS1-401 site (range of P values for interaction = 0.07 to 0.005). The pattern of increased response of HDL cholesterol in women with the IVS1-401 C/C genotype was evident in both the women receiving estrogen and those receiving estrogen plus progestin, was preserved across racial and ethnic groups, and was significant among women who were compliant with the study medication (P<0.001). Conclusions: Postmenopausal women with coronary disease who have the ER-alpha IVS1-401 C/C genotype, or several other closely related genotypes, have an augmented response of HDL cholesterol to hormone-replacement therapy. (N Engl J Med 2002;346:967-74.) Copyright (C) 2002 Massachusetts Medical Society.	Wake Forest Univ, Bowman Gray Sch Med, Dept Internal Med, Winston Salem, NC 27157 USA; Wake Forest Univ, Bowman Gray Sch Med, Dept Pediat, Winston Salem, NC 27157 USA; Wake Forest Univ, Bowman Gray Sch Med, Dept Publ Hlth Sci, Winston Salem, NC 27157 USA; Wake Forest Univ, Bowman Gray Sch Med, Hypertens & Vasc Dis Ctr, Winston Salem, NC 27157 USA	Wake Forest University; Wake Forest Baptist Medical Center; Wake Forest University; Wake Forest Baptist Medical Center; Wake Forest University; Wake Forest Baptist Medical Center; Wake Forest University; Wake Forest Baptist Medical Center	Herrington, DM (corresponding author), Wake Forest Univ, Bowman Gray Sch Med, Dept Internal Med, Med Ctr Blvd, Winston Salem, NC 27157 USA.				NCRR NIH HHS [M01 RR 07122] Funding Source: Medline; NHLBI NIH HHS [HL46488] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR007122] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL046488] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALLAIN CC, 1974, CLIN CHEM, V20, P470; ANDERSEN TI, 1994, HUM GENET, V94, P665; ARMANINI D, 1985, NEW ENGL J MED, V313, P1178, DOI 10.1056/NEJM198511073131902; Austin MA, 1998, AM J HUM GENET, V62, P406, DOI 10.1086/301712; BERKOWITZ GS, 1994, AM J OBSTET GYNECOL, V171, P1579, DOI 10.1016/0002-9378(94)90405-7; Brinton EA, 1996, ARTERIOSCL THROM VAS, V16, P431, DOI 10.1161/01.ATV.16.3.431; BURSTEIN M, 1960, CLIN CHIM ACTA, V5, P609, DOI 10.1016/0009-8981(60)90075-9; CASTAGNOLI A, 1987, NUCLEIC ACIDS RES, V15, P866, DOI 10.1093/nar/15.2.866; Del Senno L., 1992, Human Molecular Genetics, V1, P354; Deng HW, 1998, HUM GENET, V103, P576, DOI 10.1007/s004390050872; Deng HW, 2000, J CLIN ENDOCR METAB, V85, P2748, DOI 10.1210/jc.85.8.2748; FOSSATI P, 1982, CLIN CHEM, V28, P2077; FRICK MH, 1987, NEW ENGL J MED, V317, P1237, DOI 10.1056/NEJM198711123172001; FRIEDEWALD WT, 1972, CLIN CHEM, V18, P499; GEHRING U, 1974, CELL, V3, P301, DOI 10.1016/0092-8674(74)90145-7; GERHARD M, 1995, CIRCULATION, V92, P5, DOI 10.1161/01.CIR.92.1.5; GIDEZ LI, 1982, J LIPID RES, V23, P1206; GORDON DJ, 1989, CIRCULATION, V79, P8, DOI 10.1161/01.CIR.79.1.8; Gotoda T, 1997, ARTERIOSCL THROM VAS, V17, P1376, DOI 10.1161/01.ATV.17.7.1376; GRIFFIN JE, 1980, NEW ENGL J MED, V302, P198, DOI 10.1056/NEJM198001243020404; Han K, 1999, OSTEOPOROSIS INT, V9, P290, DOI 10.1007/s001980050150; Han KO, 1997, J CLIN ENDOCR METAB, V82, P991, DOI 10.1210/jc.82.4.991; Hedges YK, 1999, CIRCULATION, V99, P2688, DOI 10.1161/01.CIR.99.20.2688; Herrington DM, 2000, NEW ENGL J MED, V343, P522, DOI 10.1056/NEJM200008243430801; Herrington DM, 2000, CONTROL CLIN TRIALS, V21, P257, DOI 10.1016/S0197-2456(00)00054-4; Herrington DM, 2000, CONTROL CLIN TRIALS, V21, P414; HILL SM, 1989, CANCER RES, V49, P145; Hoshino S, 2000, J BONE MINER METAB, V18, P153, DOI 10.1007/s007740050106; Jeng MH, 1998, ENDOCRINOLOGY, V139, P4164, DOI 10.1210/en.139.10.4164; Kassi EN, 2001, EUR J CLIN INVEST, V31, P86, DOI 10.1046/j.1365-2362.2001.00762.x; Kikuchi T, 2000, ACTA PAEDIATR, V89, P42, DOI 10.1080/080352500750029040; KINNUNEN PKJ, 1984, METHOD ENZYMAT AN, V4, P34; Kobayashi S, 1996, J BONE MINER RES, V11, P306; LEHRER S, 1990, LANCET, V335, P622, DOI 10.1016/0140-6736(90)90410-7; LEHRER S, 1993, HYPERTENSION, V21, P439, DOI 10.1161/01.HYP.21.4.439; *LIP CLIN RES PROG, 1982, MAN CLIN OP, V1; Mack WJ, 1996, ARTERIOSCL THROM VAS, V16, P697, DOI 10.1161/01.ATV.16.5.697; MAHANEY MC, 1995, ARTERIOSCL THROM VAS, V15, P1730, DOI 10.1161/01.ATV.15.10.1730; Matsubara Y, 1997, ARTERIOSCL THROM VAS, V17, P3006, DOI 10.1161/01.ATV.17.11.3006; O'Neil JP, 1998, MUTAT RES-REV MUTAT, V411, P179, DOI 10.1016/S1383-5742(98)00013-1; Ongphiphadhanakul B, 2000, CLIN ENDOCRINOL, V52, P581, DOI 10.1046/j.1365-2265.2000.00979.x; PARL FF, 1989, BREAST CANCER RES TR, V14, P57, DOI 10.1007/BF01805976; PIKE JW, 1984, SCIENCE, V224, P879, DOI 10.1126/science.6326262; PONGLIKITMONGKOL M, 1988, EMBO J, V7, P3385, DOI 10.1002/j.1460-2075.1988.tb03211.x; Robins SJ, 2001, JAMA-J AM MED ASSOC, V285, P1585, DOI 10.1001/jama.285.12.1585; ROESCHLA.P, 1974, Z KLIN CHEM KLIN BIO, V12, P226; SANO M, 1995, BIOCHEM BIOPH RES CO, V217, P378, DOI 10.1006/bbrc.1995.2787; SCHACHTER BS, 1994, AM J EPIDEMIOL, V140, P1144, DOI 10.1093/oxfordjournals.aje.a117216; Schubert EL, 1999, J STEROID BIOCHEM, V71, P21, DOI 10.1016/S0960-0760(99)00126-0; Scohy S, 2000, NUCLEIC ACIDS RES, V28, P3743, DOI 10.1093/nar/28.19.3743; SMITH EP, 1995, NEW ENGL J MED, V332, P131; Sudhir K, 1997, CIRCULATION, V96, P3774; SULLIVAN JM, 1988, ANN INTERN MED, V108, P358, DOI 10.7326/0003-4819-108-3-358; Syvanne M, 1998, CIRCULATION, V98, P1993, DOI 10.1161/01.CIR.98.19.1993; Trinder P, 1969, ANN CLIN BIOCH INT J, V6, P24; WATTS GF, 1993, METABOLISM, V42, P1461, DOI 10.1016/0026-0495(93)90199-X; Weir B., 1996, GENETIC DATA ANAL; YAICH L, 1992, CANCER RES, V52, P77	58	293	303	0	13	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAR 28	2002	346	13					967	974		10.1056/NEJMoa012952	http://dx.doi.org/10.1056/NEJMoa012952			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	534UY	11919305	Bronze			2023-01-03	WOS:000174608600003
J	Brookmeyer, R; Blades, N				Brookmeyer, R; Blades, N			Prevention of inhalational anthrax in the US outbreak	SCIENCE			English	Article									Johns Hopkins Bloomberg Sch Publ Hlth, Dept Biostat, Baltimore, MD 21205 USA	Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health	Brookmeyer, R (corresponding author), Johns Hopkins Bloomberg Sch Publ Hlth, Dept Biostat, Baltimore, MD 21205 USA.							Brookmeyer R, 2001, Biostatistics, V2, P233, DOI 10.1093/biostatistics/2.2.233; Inglesby TV, 1999, JAMA-J AM MED ASSOC, V281, P1735, DOI 10.1001/jama.281.18.1735; Jernigan JA, 2001, EMERG INFECT DIS, V7, P933, DOI 10.3201/eid0706.010604; MESELSON M, 1994, SCIENCE, V266, P1202, DOI 10.1126/science.7973702	4	53	54	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAR 8	2002	295	5561					1861	1861		10.1126/science.1068474	http://dx.doi.org/10.1126/science.1068474			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	529KW	11884746				2023-01-03	WOS:000174299500029
J	Holzer, M; Cerchiari, E; Martens, P; Roine, R; Sterz, F; Eisenburger, P; Havel, C; Kofler, J; Oschatz, E; Rohrbach, K; Scheinecker, W; Schorkhuber, W; Behringer, W; Zeiner, A; Valentin, A; De Meyer, M; Takunen, O; Tiainen, M; Hachimi-Idrissi, S; Huyghens, L; Fischer, M; Walger, P; Bartsch, A; Foedisch, M; Cerchiari, E; Bonizzoli, M; Pagni, E; Laggner, AN; Kaff, A; Schneider, B; Mullner, M				Holzer, M; Cerchiari, E; Martens, P; Roine, R; Sterz, F; Eisenburger, P; Havel, C; Kofler, J; Oschatz, E; Rohrbach, K; Scheinecker, W; Schorkhuber, W; Behringer, W; Zeiner, A; Valentin, A; De Meyer, M; Takunen, O; Tiainen, M; Hachimi-Idrissi, S; Huyghens, L; Fischer, M; Walger, P; Bartsch, A; Foedisch, M; Cerchiari, E; Bonizzoli, M; Pagni, E; Laggner, AN; Kaff, A; Schneider, B; Mullner, M		Hypothermia Cardiac Arrest Study G	Mild therapeutic hypothermia to improve the neurologic outcome after cardiac arrest	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CEREBRAL BLOOD-FLOW; RESUSCITATIVE HYPOTHERMIA; CARDIOPULMONARY BYPASS; MODERATE HYPOTHERMIA; DOGS; ISCHEMIA; REPERFUSION; METABOLISM; SURVIVAL; TRIAL	Background: Cardiac arrest with widespread cerebral ischemia frequently leads to severe neurologic impairment. We studied whether mild systemic hypothermia increases the rate of neurologic recovery after resuscitation from cardiac arrest due to ventricular fibrillation. Methods: In this multicenter trial with blinded assessment of the outcome, patients who had been resuscitated after cardiac arrest due to ventricular fibrillation were randomly assigned to undergo therapeutic hypothermia (target temperature, 32degreesC to 34degreesC, measured in the bladder) over a period of 24 hours or to receive standard treatment with normothermia. The primary end point was a favorable neurologic outcome within six months after cardiac arrest; secondary end points were mortality within six months and the rate of complications within seven days. Results: Seventy-five of the 136 patients in the hypothermia group for whom data were available (55 percent) had a favorable neurologic outcome (cerebral-performance category, 1 [good recovery] or 2 [moderate disability]), as compared with 54 of 137 (39 percent) in the normothermia group (risk ratio, 1.40; 95 percent confidence interval, 1.08 to 1.81). Mortality at six months was 41 percent in the hypothermia group (56 of 137 patients died), as compared with 55 percent in the normothermia group (76 of 138 patients; risk ratio, 0.74; 95 percent confidence interval, 0.58 to 0.95). The complication rate did not differ significantly between the two groups. Conclusions: In patients who have been successfully resuscitated after cardiac arrest due to ventricular fibrillation, therapeutic mild hypothermia increased the rate of a favorable neurologic outcome and reduced mortality. Copyright (R) 2002 Massachusetts Medical Society.	Univ Vienna, Klin Notfallmed, Vienna, Austria; Osped Niguarda Ca Granda, Milan, Italy; AZ Sint Jan, Brugge, Belgium; Univ Helsinki Hosp, Helsinki, Finland; Krankenhaus Rudolfstiftung, Vienna, Austria; Helsinki Yliopistollisen Keskussairaalan, Helsinki, Finland; Free Univ Brussels, Acad Ziekenhuis, Brussels, Belgium; Univ Bonn, Fak Med, D-5300 Bonn, Germany; Evangel Waldkrankenhaus, Bonn, Germany; Azienda Ospedalieria Careggi, Florence, Italy; Rettungs & Krankenbeforderungsdienst Stadt Wien, Vienna, Austria; Univ Vienna, Inst Med Stat, Vienna, Austria	University of Vienna; IRCCS Ca Granda Ospedale Maggiore Policlinico; Ospedale Niguarda Ca' Granda; University of Helsinki; Helsinki University Central Hospital; Rudolfstiftung Hospital; Universite Libre de Bruxelles; Vrije Universiteit Brussel; University of Bonn; University of Florence; Azienda Ospedaliero Universitaria Careggi; University of Vienna	Sterz, F (corresponding author), Univ Vienna, Allgemeines Krankenhaus Stadt Wien, Klin Notfallmed, Wahringer Gurtel 18-20-6D, A-1090 Vienna, Austria.		Hachimi Idrissi, Said/I-6422-2018; Kofler, Julia/AAJ-8032-2021	Hachimi Idrissi, Said/0000-0002-8455-1410; Fischer, Matthias/0000-0003-4728-8497				ABRAMSON NS, 1991, NEW ENGL J MED, V324, P1225; Benson DW, 1958, ANESTH ANALG, V38, P423; Bernard SA, 1997, ANN EMERG MED, V30, P146, DOI 10.1016/S0196-0644(97)70133-1; BUSTO R, 1989, STROKE, V20, P904, DOI 10.1161/01.STR.20.7.904; CHOPP M, 1989, J CEREBR BLOOD F MET, V9, P141, DOI 10.1038/jcbfm.1989.21; Clifton GL, 2001, NEW ENGL J MED, V344, P556, DOI 10.1056/NEJM200102223440803; COIMBRA C, 1992, ACTA PHYSIOL SCAND, V146, P543, DOI 10.1111/j.1748-1716.1992.tb09462.x; Colbourne F, 1999, J CEREBR BLOOD F MET, V19, P742, DOI 10.1097/00004647-199907000-00003; CUMMINS RO, 1991, CIRCULATION, V84, P960, DOI 10.1161/01.CIR.84.2.960; CUZICK J, 1985, STAT MED, V4, P87, DOI 10.1002/sim.4780040112; DEMPSEY RJ, 1987, NEUROSURGERY, V21, P177, DOI 10.1227/00006123-198708000-00007; deVreedeSwagemakers JJM, 1997, J AM COLL CARDIOL, V30, P1500, DOI 10.1016/S0735-1097(97)00355-0; HEGNAUER AH, 1954, AM J PHYSIOL, V178, P138, DOI 10.1152/ajplegacy.1954.178.1.138; Hickey RW, 2000, CRIT CARE MED, V28, P3511, DOI 10.1097/00003246-200010000-00027; *HUM MED EV UN, 1995, INT C HARM ICH 135 9, P1; JENNETT B, 1975, LANCET, V1, P480; KRAMER RS, 1968, J THORAC CARDIOV SUR, V56, P699, DOI 10.1016/S0022-5223(19)42797-9; KUBOYAMA K, 1993, CRIT CARE MED, V21, P1348, DOI 10.1097/00003246-199309000-00019; LEONOV Y, 1990, J CEREBR BLOOD F MET, V10, P57, DOI 10.1038/jcbfm.1990.8; LEONOV Y, 1990, STROKE, V21, P1600, DOI 10.1161/01.STR.21.11.1600; Markarian GZ, 1996, NEUROSURGERY, V38, P542; MEZROW CK, 1992, ANN THORAC SURG, V54, P609, DOI 10.1016/0003-4975(92)91002-Q; Nagao K, 2000, J AM COLL CARDIOL, V36, P776, DOI 10.1016/S0735-1097(00)00779-8; NATALE JE, 1989, STROKE, V20, P770, DOI 10.1161/01.STR.20.6.770; NEGOVSKY VA, 1988, CRIT CARE MED, V16, P942, DOI 10.1097/00003246-198810000-00004; RAVITCH MM, 1961, NEW ENGL J MED, V264, P36, DOI 10.1056/NEJM196101052640109; Safar P, 2001, NEW ENGL J MED, V345, P66; Safar P, 1996, STROKE, V27, P105, DOI 10.1161/01.STR.27.1.105; SAFAR P, 1988, CARDIOPULMONARY CERE, P267; SCHULZ KF, 1995, JAMA-J AM MED ASSOC, V273, P408, DOI 10.1001/jama.273.5.408; STERZ F, 1992, RESUSCITATION, V24, P27, DOI 10.1016/0300-9572(92)90171-8; STERZ F, 1991, CRIT CARE MED, V19, P379, DOI 10.1097/00003246-199103000-00017; WEINRAUCH V, 1992, STROKE, V23, P1454, DOI 10.1161/01.STR.23.10.1454; WILLIAMS GR, 1958, ANN SURG, V148, P462, DOI 10.1097/00000658-195809000-00014; Yanagawa Y, 1998, RESUSCITATION, V39, P61, DOI 10.1016/S0300-9572(98)00118-X; Zeiner A, 2000, STROKE, V31, P86, DOI 10.1161/01.STR.31.1.86; Zhang J, 1998, JAMA-J AM MED ASSOC, V280, P1690, DOI 10.1001/jama.280.19.1690	37	3475	3580	3	127	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	FEB 21	2002	346	8					549	556						8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	522ZK	11856793				2023-01-03	WOS:000173926700002
J	Knudtson, ML; Wyse, DG; Galbraith, PD; Brant, R; Hildebrand, K; Paterson, D; Richardson, D; Burkart, C; Burgess, E				Knudtson, ML; Wyse, DG; Galbraith, PD; Brant, R; Hildebrand, K; Paterson, D; Richardson, D; Burkart, C; Burgess, E		Program Assess Alternative Treat	Chelation therapy for ischemic heart disease - A randomized controlled trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CORONARY-ARTERY DISEASE; DOUBLE-BLIND; INTERMITTENT CLAUDICATION; MYOCARDIAL-INFARCTION; QUESTIONNAIRE; EDTA	Context Chelation therapy using EDTA is an unproven but widely used alternative therapy for ischemic heart disease. Objective To determine if current EDTA protocols have a favorable impact on exercise ischemia threshold and quality of life measures in patients with stable ischemic heart disease. Design Double-blind, randomized, placebo-controlled trial conducted between January 1996 and January 2000. Setting Participants were recruited from a cohort of cardiac catheterization patients and practices of cardiologists in Calgary, Alberta. Participants We screened 3140 patients, performed a qualifying treadmill test in 171, and enrolled 84. Entry criteria included age at least 21 years with coronary artery disease proven by angiography or a documented myocardial infarction and stable angina while receiving optimal medical therapy. The required treadmill test used a gradual ramping protocol and patients had to demonstrate at least 1-mm ST depression. Interventions Patients were randomly assigned to receive infusion with either weight-adjusted (40 mg/kg) EDTA chelation therapy (n=41) or placebo (n=43) for 3 hours per treatment, twice weekly for 15 weeks and once per month for an additional 3 months. Patients in both groups took oral multivitamin therapy as welt. Main Outcome Measure Change from baseline to 27-week follow-up in time to ischemia (1-mm ST depression). Results Thirty-nine patients in each group completed the 27-week protocol. One chelation patient had therapy discontinued for a transient rise in serum, creatinine. The mean (SD) baseline exercise time to ischemia was 572 (172) and 589 (176) seconds in the placebo and chelation groups, respectively. The corresponding mean changes in time to ischemia at 27 weeks were 54 seconds (95% confidence interval [CI], 23-84 seconds; P<.001) and 63 seconds (95% CI, 29-95 seconds; P<.001), for a difference of 9 seconds (95% CI, -36 to 53 seconds; P=.69). Exercise capacity and quality of life scores improved by similar degrees in both groups. Conclusion Based on exercise time to ischemia, exercise capacity, and quality of life measurements, there is no evidence to support a beneficial effect of chelation therapy in patients with ischemic heart disease, stable angina, and a positive treadmill test for ischemia.	Univ Calgary, Div Cardiol, Calgary, AB, Canada; Calgary Reg Hlth Author, Calgary, AB, Canada	University of Calgary	Knudtson, ML (corresponding author), Foothills Med Ctr, 1403 29th St NW, Calgary, AB T2N 2T9, Canada.			Brant, Rollin/0000-0002-8026-2451				Adams MR, 2000, ANNU REV MED, V51, P149, DOI 10.1146/annurev.med.51.1.149; ADES PA, 1989, AM J CARDIOL, V63, P1032, DOI 10.1016/0002-9149(89)90073-8; BENSON H, 1979, NEW ENGL J MED, V300, P1424; Bienenfeld L, 1996, AM HEART J, V132, P1207, DOI 10.1016/S0002-8703(96)90465-2; Casdorph HR, 1981, J HOLIST MED, V3, P53; CLARKE NE, 1955, AM J MED SCI, V229, P142, DOI 10.1097/00000441-195502000-00004; CLARKE NE, 1960, AM J MED SCI, V232, P654; CRANTON EM, 1984, J HOLISTIC MED, V6, P6; DUDLEY H, 1955, NEW ENGL J MED, V52, P331; Eisenberg DM, 1998, JAMA-J AM MED ASSOC, V280, P1569, DOI 10.1001/jama.280.18.1569; Ernst E, 2000, AM HEART J, V140, P139, DOI 10.1067/mhj.2000.107548; FOLLI G, 1978, ACTA CARDIOL, V33, P231; Ghali WA, 2000, CAN J CARDIOL, V16, P1225; GRIER MT, 1993, ANN PHARMACOTHER, V27, P1504, DOI 10.1177/106002809302701217; GULDAGER B, 1992, J INTERN MED, V231, P261, DOI 10.1111/j.1365-2796.1992.tb00533.x; HLATKY MA, 1989, AM J CARDIOL, V64, P651, DOI 10.1016/0002-9149(89)90496-7; KITCHELL JR, 1963, AM J CARDIOL, V11, P501, DOI 10.1016/0002-9149(63)90011-0; KOEN A, 1963, J CHRON DIS, V16, P329, DOI 10.1016/0021-9681(63)90083-3; Laine C, 1998, AM J MED, V105, P373, DOI 10.1016/S0002-9343(98)00291-5; Lamas GA, 2000, AM HEART J, V140, P4, DOI 10.1067/mhj.2000.107549; LASLETT LJ, 1985, CIRCULATION, V71, P958, DOI 10.1161/01.CIR.71.5.958; MCCANN D, 1962, CIRC RES, V9, P880; OLSZEWER E, 1990, J NATL MED ASSOC, V82, P173; OLSZEWER E, 1989, J ADV MED, V2, P197; Quan H, 2001, AM J MED, V111, P686, DOI 10.1016/S0002-9343(01)00999-8; ROMANO M, 1989, CLIN CARDIOL, V12, P39; ROZEMA TC, 1997, J ADV MED, V10, P1; SALONEN JT, 1992, CIRCULATION, V86, P803, DOI 10.1161/01.CIR.86.3.803; SPERTUS JA, 1995, J AM COLL CARDIOL, V25, P333, DOI 10.1016/0735-1097(94)00397-9; VANRIJ AM, 1994, CIRCULATION, V90, P1194, DOI 10.1161/01.CIR.90.3.1194; Ware J.E, 1994, PHYS MENTAL HLTH SUM; WEBER JR, 1985, AM J CARDIOL, V56, P141	32	79	81	0	4	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 23	2002	287	4					481	486		10.1001/jama.287.4.481	http://dx.doi.org/10.1001/jama.287.4.481			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	513VX	11798370	Bronze			2023-01-03	WOS:000173401900025
J	Newman, AJ; Bavelier, D; Corina, D; Jezzard, P; Neville, HJ				Newman, AJ; Bavelier, D; Corina, D; Jezzard, P; Neville, HJ			A critical period for right hemisphere recruitment in American Sign Language processing	NATURE NEUROSCIENCE			English	Article							2ND LANGUAGE; MATURATIONAL CONSTRAINTS; CEREBRAL ORGANIZATION; BILINGUAL BRAIN; ACQUISITION; ENGLISH; AGE; COMPREHENSION; VARIABILITY; EXPERIENCE	Signed languages such as American Sign Language (ASL) are natural languages that are formally similar to spoken languages, and thus present an opportunity to examine the effects of language structure and modality on the neural organization for language. Native learners of spoken languages show predominantly left-lateralized patterns of neural activation for language processing, whereas native learners of ASL show extensive right hemisphere (RH) and LH activation. We demonstrate that the RH angular gyrus is active during ASL processing only in native signers (hearing, ASL-English bilinguals) but not in those who acquired ASL after puberty (hearing, native English speakers). This is the first demonstration of a 'sensitive' or 'critical' period for language in an RH structure. This has implications for language acquisition and for understanding age-related changes in neuroplasticity more generally.	Univ Oregon 1227, Dept Psychol, Eugene, OR 97403 USA; Univ Rochester, Dept Brain & Cognit Sci, Rochester, NY 14627 USA; Univ Washington, Dept Psychol, Seattle, WA 98195 USA; John Radcliffe Hosp, FMRIB Ctr, Oxford OX3 9DU, England	University of Oregon; University of Rochester; University of Washington; University of Washington Seattle; University of Oxford	Newman, AJ (corresponding author), Univ Oregon 1227, Dept Psychol, Eugene, OR 97403 USA.		; Newman, Aaron/A-6835-2011	Bavelier, Daphne/0000-0002-5904-1240; Newman, Aaron/0000-0001-5290-8342; Jezzard, Peter/0000-0001-7912-2251	NIDCD NIH HHS [R29 DCO3099, DC00128] Funding Source: Medline; NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS [R29DC003099] Funding Source: NIH RePORTER	NIDCD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD)); NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD))		BANDETTINI PA, 1993, MAGNET RESON MED, V30, P161, DOI 10.1002/mrm.1910300204; Bavelier D, 1998, NEUROREPORT, V9, P1537, DOI 10.1097/00001756-199805110-00054; Chee MWL, 1999, J NEUROSCI, V19, P3050; Corina D, 1998, APHASIA IN ATYPICAL POPULATIONS, P261; CURTIS S, 1977, GENIE PSYCHOL STUDY; Decety J, 1997, BRAIN, V120, P1763, DOI 10.1093/brain/120.10.1763; Dehaene S, 1997, NEUROREPORT, V8, P3809, DOI 10.1097/00001756-199712010-00030; DEMONET JF, 1992, BRAIN, V115, P1753, DOI 10.1093/brain/115.6.1753; Flege JE, 1999, J MEM LANG, V41, P78, DOI 10.1006/jmla.1999.2638; Friederici AD, 2000, BRAIN LANG, V74, P289, DOI 10.1006/brln.2000.2313; Grezes J, 1999, BRAIN, V122, P1875, DOI 10.1093/brain/122.10.1875; Hickok G, 1999, BRAIN LANG, V66, P233, DOI 10.1006/brln.1998.1995; Hickok G, 1998, TRENDS COGN SCI, V2, P465, DOI 10.1016/S1364-6613(98)01263-7; Hickok G, 1996, NATURE, V381, P699, DOI 10.1038/381699a0; JOHNSON JS, 1989, COGNITIVE PSYCHOL, V21, P60, DOI 10.1016/0010-0285(89)90003-0; Kim KHS, 1997, NATURE, V388, P171, DOI 10.1038/40623; Klein D, 1999, NEUROREPORT, V10, P2841, DOI 10.1097/00001756-199909090-00026; Klima E.S., 1979, SIGNS LANGUAGE; Lenneberg E.H., 1967, BIOL FDN LANGUAGE; Neville HJ, 1997, BRAIN LANG, V57, P285, DOI 10.1006/brln.1997.1739; Neville HJ, 1998, P NATL ACAD SCI USA, V95, P922, DOI 10.1073/pnas.95.3.922; NEWPORT EL, 1990, COGNITIVE SCI, V14, P11, DOI 10.1207/s15516709cog1401_2; OJEMANN GA, 1978, ARCH NEUROL-CHICAGO, V35, P409, DOI 10.1001/archneur.1978.00500310011002; OYAMA S, 1976, J PSYCHOLINGUIST RES, V5, P261, DOI 10.1007/BF01067377; Paradis M, 1998, APHASIA IN ATYPICAL POPULATIONS, P35; PENFIELD W, 1959, SPEECH MECHANISMS BR; Perani D, 1996, NEUROREPORT, V7, P2439, DOI 10.1097/00001756-199611040-00007; Perani D, 1998, BRAIN, V121, P1841, DOI 10.1093/brain/121.10.1841; RADEMACHER J, 1992, J COGNITIVE NEUROSCI, V4, P352, DOI 10.1162/jocn.1992.4.4.352; SODERFELDT B, 1994, BRAIN LANG, V46, P59, DOI 10.1006/brln.1994.1004; TURNER R, 1993, MAGNET RESON MED, V29, P277, DOI 10.1002/mrm.1910290221; WeberFox CM, 1996, J COGNITIVE NEUROSCI, V8, P231, DOI 10.1162/jocn.1996.8.3.231; WISE R, 1991, BRAIN, V114, P1803, DOI 10.1093/brain/114.4.1803; ZATORRE RJ, 1992, SCIENCE, V256, P846, DOI 10.1126/science.1589767; ZOLAMORGAN S, 1988, SPATIAL COGNITION BR	35	138	146	0	19	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1097-6256			NAT NEUROSCI	Nat. Neurosci.	JAN	2002	5	1					76	80		10.1038/nn775	http://dx.doi.org/10.1038/nn775			5	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology	507MG	11753419				2023-01-03	WOS:000173031800019
J	Kane, B				Kane, B			Cancer chemotherapy: Teaching old drugs new tricks	ANNALS OF INTERNAL MEDICINE			English	Editorial Material																			0	2	2	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	DEC 18	2001	135	12					1107	1110		10.7326/0003-4819-135-12-200112180-00035	http://dx.doi.org/10.7326/0003-4819-135-12-200112180-00035			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	502TW	11747409				2023-01-03	WOS:000172759700027
J	Chertow, GM; Lee, J; Kuperman, GJ; Burdick, E; Horsky, J; Seger, DL; Lee, R; Mekala, A; Song, J; Komaroff, AL; Bates, DW				Chertow, GM; Lee, J; Kuperman, GJ; Burdick, E; Horsky, J; Seger, DL; Lee, R; Mekala, A; Song, J; Komaroff, AL; Bates, DW			Guided medication dosing for inpatients with renal insufficiency	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article; Proceedings Paper	31st Congress of the American-Society-of-Nephrology	OCT 24-28, 1998	PHILADELPHIA, PENNSYLVANIA	Amer Soc Nephrol			ADVERSE DRUG EVENTS; FAILURE; INTERVENTION; PREVENTION; MORTALITY	Context Usual drug-prescribing practices may not consider the effects of renal insufficiency on the disposition of certain drugs. Decision aids may help optimize prescribing behavior and reduce medical error. Objective To determine if a system application for adjusting drug close and frequency in patients with renal insufficiency, when merged with a computerized order entry system, improves drug prescribing and patient outcomes. Design, Setting, and Patients Four consecutive 2-month intervals consisting of control (usual computerized order entry) alternating with intervention (computerized order entry plus decision support system), conducted in September 1997-April 1998 with outcomes assessed among a consecutive sample of 17 828 adults admitted to an urban tertiary care teaching hospital. Intervention Real-time computerized decision support system for prescribing drugs in patients with renal insufficiency. During intervention periods, the adjusted dose list, default dose amount, and default frequency were displayed to the order-entry user and a notation was provided that adjustments had been made based on renal insufficiency. During control periods, these recommended adjustments were not revealed to the order-entry user, and the unadjusted parameters were displayed. Main Outcome Measures Rates of appropriate prescription by dose and frequency, length of stay, hospital and pharmacy costs, and changes in renal function, compared among patients with renal insufficiency who were hospitalized during the intervention vs control periods. Results A total of 7490 patients were found to have some degree of renal insufficiency. In this group, 97 151 orders were written on renally cleared or nephrotoxic medications, of which 14440 (15%) had at least 1 dosing parameter modified Ely the computer based on renal function. The fraction of prescriptions deemed appropriate during the intervention vs control periods by dose was 67% vs 54% (P<.001) and by frequency was 59% vs 35% (P<.001). Mean (SD) length of stay was 4.3 (4.5) days vs 4.5 (4.8) days in the intervention vs control periods, respectively (P=.009). There were no significant differences in estimated hospital and pharmacy costs or in the proportion of patients who experienced a decline in renal function during hospitalization. Conclusions Guided medication dosing for inpatients with renal insufficiency appears to result in improved dose and frequency choices. This intervention demonstrates a way in which computer-based decision support systems can improve care.	Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Med,Div Gen Internal Med, Boston, MA 02115 USA; Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Med,Renal Div, Boston, MA 02115 USA; Partners Healthcare Syst, Dept Informat Syst, Boston, MA USA	Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard Medical School; Partners Healthcare System	Chertow, GM (corresponding author), UCSF Laurel Hts, Dept Med Res, 3333 Calif St,Suite 430, San Francisco, CA 94118 USA.			Horsky, Jan/0000-0001-6326-9427; Kuperman, Gilad/0000-0002-4130-1577; Chertow, Glenn/0000-0002-7599-0534				Bates DW, 1998, JAMA-J AM MED ASSOC, V280, P1311, DOI 10.1001/jama.280.15.1311; BATES DW, 1995, JAMA-J AM MED ASSOC, V274, P29, DOI 10.1001/jama.274.1.29; COCKCROFT DW, 1976, NEPHRON, V16, P31, DOI 10.1159/000180580; Dries DL, 2000, J AM COLL CARDIOL, V35, P681, DOI 10.1016/S0735-1097(99)00608-7; EDWARDS N, 1994, HEALTH CARE FINANC R, V16, P45; Evans RS, 1998, NEW ENGL J MED, V338, P232, DOI 10.1056/NEJM199801223380406; HOU SH, 1983, AM J MED, V74, P243, DOI 10.1016/0002-9343(83)90618-6; Jha AK, 1998, J AM MED INFORM ASSN, V5, P305, DOI 10.1136/jamia.1998.0050305; Leape LL, 2000, JAMA-J AM MED ASSOC, V284, P95, DOI 10.1001/jama.284.1.95; Levy EM, 1996, JAMA-J AM MED ASSOC, V275, P1489, DOI 10.1001/jama.275.19.1489; Nightingale PG, 2000, BMJ-BRIT MED J, V320, P750, DOI 10.1136/bmj.320.7237.750; Nolan CR, 1998, J AM SOC NEPHROL, V9, P710; Obialo CI, 2000, ARCH INTERN MED, V160, P1309, DOI 10.1001/archinte.160.9.1309; RIND DM, 1994, ARCH INTERN MED, V154, P1511, DOI 10.1001/archinte.154.13.1511; Wang R, 1998, ARCH INTERN MED, V158, P2464, DOI 10.1001/archinte.158.22.2464	15	304	311	0	7	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 12	2001	286	22					2839	2844		10.1001/jama.286.22.2839	http://dx.doi.org/10.1001/jama.286.22.2839			6	Medicine, General & Internal	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	500YC	11735759	Bronze			2023-01-03	WOS:000172655400032
J	Delbanco, T; Hartman, EE				Delbanco, T; Hartman, EE			A 35-year-old woman experiencing difficulty with breastfeeding, 18 months later	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article																		Lawrence RA, 2001, JAMA-J AM MED ASSOC, V285, P73, DOI 10.1001/jama.285.1.73	1	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 24	2001	286	16					2022	+		10.1001/jama.286.16.2022	http://dx.doi.org/10.1001/jama.286.16.2022			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	485JD	11667940				2023-01-03	WOS:000171750500027
J	Rensen, PCN; Sliedregt, LAJM; Ferns, A; Kieviet, E; van Rossenberg, SMW; van Leeuwen, SH; van Berkel, TJC; Biessen, EAL				Rensen, PCN; Sliedregt, LAJM; Ferns, A; Kieviet, E; van Rossenberg, SMW; van Leeuwen, SH; van Berkel, TJC; Biessen, EAL			Determination of the upper size limit for uptake and processing of ligands by the asialoglycoprotein receptor on hepatocytes in vitro and in vivo	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOW-DENSITY-LIPOPROTEIN; ACETYLGALACTOSAMINE-SPECIFIC LECTIN; FUCOSE-CONTAINING GLYCOPROTEINS; E-ENRICHED LIPOSOMES; RAT KUPFFER CELLS; N-ACETYLGALACTOSAMINE; HIGH-AFFINITY; CLUSTER GLYCOSIDES; MOLECULAR-CLONING; MACROPHAGE LECTIN	The asialoglycoprotein receptor (ASGPr) on hepatocytes plays a role in the clearance of desialylated proteins from the serum. Although its sugar preference (N-acetylgalactosamine (GalNAc) >> galactose) and the effects of ligand valency (tetraantennary > triantennary >> diantennary >> monoantennary) and sugar spacing (20 Angstrom >> 10 Angstrom >> 4 Angstrom) are well documented, the effect of particle size on recognition and uptake of ligands by the receptor is poorly defined. In the present study, we assessed the maximum ligand size that still allows effective processing by the ASGPr of mouse hepatocytes in vivo and in vitro. Hereto, we synthesized a novel glycolipid, which possesses a highly hydrophobic steroid moiety for stable incorporation into liposomes, and a triantennary GalNAc(3)-terminated cluster glycoside with a high nanomolar affinity (2 nm) for the ASGPr. Incorporation of the glycolipid into small (30 nm) [H-3]cholesteryl oleate-labeled long circulating liposomes (1-50%, w/w) caused a concentration-dependent increase in particle clearance that was liver-specific (reaching 85 +/- 7% of the injected dose at 30 min after injection) and mediated by the ASGPr on hepatocytes, as shown by competition studies with asialoorosomucoid in vivo. By using glycolipid-laden liposomes of various sizes between 30 and 90 nm, it was demonstrated that particles with a diameter of >70 nm could no longer be recognized and processed by the ASGPr in vivo. This threshold size for effective uptake was not related to the physical barrier raised by the fenestrated sinusoidal endothelium, which shields hepatocytes from the circulation, because similar results were obtained by studying the uptake of liposomes on isolated mouse hepatocytes in vitro. From these data we conclude that in addition to the species, valency, and orientation of sugar residues, size is also an important determinant for effective recognition and processing of substrates by the ASGPr. Therefore, these data have important implications for the design of ASGPr-specific carriers that are aimed at hepatocyte-directed delivery of drugs and genes.	Leiden Univ, Sylvius Lab, Leiden Amsterdam Ctr Drug Res, Div Biopharmaceut, NL-2300 RA Leiden, Netherlands	Leiden University; Leiden University - Excl LUMC	Rensen, PCN (corresponding author), Leiden Univ, Sylvius Lab, Leiden Amsterdam Ctr Drug Res, Div Biopharmaceut, POB 9503, NL-2300 RA Leiden, Netherlands.	p.rensen@lacdr.leidenuniv.nl	Van Berkel, Theo/ABD-7677-2021; Rensen, Patrick C.N./D-7176-2018	Rensen, Patrick C.N./0000-0002-8455-4988				AHMED H, 1990, BIOCHEMISTRY-US, V29, P5315, DOI 10.1021/bi00474a015; Andre S, 2000, PHARMACEUT RES, V17, P985, DOI 10.1023/A:1007535506705; ASHWELL G, 1982, ANNU REV BIOCHEM, V51, P531, DOI 10.1146/annurev.bi.51.070182.002531; BAENZIGER JU, 1980, CELL, V22, P611, DOI 10.1016/0092-8674(80)90371-2; BAENZIGER JU, 1980, J BIOL CHEM, V255, P4607; Bider MD, 1996, J BIOL CHEM, V271, P31996, DOI 10.1074/jbc.271.50.31996; BIESSEN EAL, 1994, BIOCHEM J, V299, P291, DOI 10.1042/bj2990291; Biessen EAL, 1996, ARTERIOSCL THROM VAS, V16, P1552, DOI 10.1161/01.ATV.16.12.1552; BIESSEN EAL, 1995, CIRCULATION, V91, P1847, DOI 10.1161/01.CIR.91.6.1847; BIESSEN EAL, 1995, J MED CHEM, V38, P1538, DOI 10.1021/jm00009a014; BIESSEN EAL, 1994, BIOCHEM J, V302, P283, DOI 10.1042/bj3020283; BIJSTERBOSCH MK, 1992, ARTERIOSCLER THROMB, V12, P1153, DOI 10.1161/01.ATV.12.10.1153; BIJSTERBOSCH MK, 1991, ARTERIOSCLER THROMB, V11, P1806, DOI 10.1161/01.ATV.11.6.1806; BIJSTERBOSCH MK, 1992, MOL PHARMACOL, V41, P404; BIJSTERBOSCH MK, 1990, BIOCHEM J, V270, P233, DOI 10.1042/bj2700233; CONNOLLY DT, 1982, J BIOL CHEM, V257, P939; DESCHUYTENEER M, 1984, BIOL CELL, V50, P17, DOI 10.1111/j.1768-322X.1984.tb00251.x; DINI L, 1991, CELL MOL BIOL, V37, P165; Dotzauer A, 2000, J VIROL, V74, P10950, DOI 10.1128/JVI.74.23.10950-10957.2000; DRICKAMER K, 1993, ANNU REV CELL BIOL, V9, P237, DOI 10.1146/annurev.cb.09.110193.001321; Goswami S K, 1970, J Chromatogr, V53, P389, DOI 10.1016/S0021-9673(01)98486-9; HALTIWANGER RS, 1986, J BIOL CHEM, V261, P7433; HANGELAND JJ, 1995, BIOCONJUGATE CHEM, V6, P695, DOI 10.1021/bc00036a006; HOYLE GW, 1988, J BIOL CHEM, V263, P7487; HUBBARD AL, 1983, J CELL BIOL, V96, P217, DOI 10.1083/jcb.96.1.217; II M, 1990, J BIOL CHEM, V265, P11295; IMAI Y, 1994, J IMMUNOL METHODS, V171, P23, DOI 10.1016/0022-1759(94)90224-0; Iobst ST, 1996, J BIOL CHEM, V271, P6686, DOI 10.1074/jbc.271.12.6686; ISHIBASHI S, 1994, J BIOL CHEM, V269, P27803; Kichler A, 1998, J DRUG TARGET, V6, P201, DOI 10.3109/10611869808997894; KOLBBACHOFEN V, 1981, BIOCHIM BIOPHYS ACTA, V645, P293, DOI 10.1016/0005-2736(81)90200-5; KOLBBACHOFEN V, 1982, CELL, V29, P859, DOI 10.1016/0092-8674(82)90447-0; KUIPER J, 1994, BIOCHEM J, V299, P285, DOI 10.1042/bj2990285; LEE RT, 1987, GLYCOCONJUGATE J, V4, P317, DOI 10.1007/BF01048365; LEE RT, 1990, J BIOL CHEM, V265, P7864; LEE RT, 1986, BIOCHEMISTRY-US, V25, P6835, DOI 10.1021/bi00370a016; Lee RT, 1997, BIOCONJUGATE CHEM, V8, P762, DOI 10.1021/bc9700796; LEE RT, 1984, BIOCHEMISTRY-US, V23, P4255, DOI 10.1021/bi00313a037; LEE YC, 1983, J BIOL CHEM, V258, P199; LEHRMAN MA, 1986, J BIOL CHEM, V261, P7419; LEHRMAN MA, 1986, J BIOL CHEM, V261, P7426; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MACDONALD RC, 1991, BIOCHIM BIOPHYS ACTA, V1061, P297, DOI 10.1016/0005-2736(91)90295-J; MCFARLANE AS, 1958, NATURE, V182, P53, DOI 10.1038/182053a0; MERWIN JR, 1994, BIOCONJUGATE CHEM, V5, P612, DOI 10.1021/bc00030a017; OZAKI K, 1992, J BIOL CHEM, V267, P9229; OZAKI K, 1995, GLYCOCONJUGATE J, V12, P268, DOI 10.1007/BF00731329; REDGRAVE TG, 1975, ANAL BIOCHEM, V65, P42, DOI 10.1016/0003-2697(75)90488-1; Rensen PCN, 1997, MOL PHARMACOL, V52, P445, DOI 10.1124/mol.52.3.445; Rensen PCN, 1997, J LIPID RES, V38, P1070; Rifai A, 2000, J EXP MED, V191, P2171, DOI 10.1084/jem.191.12.2171; ROELEN HCPF, 1991, J MED CHEM, V34, P1036, DOI 10.1021/jm00107a024; Rotundo RF, 1998, HEPATOLOGY, V28, P475, DOI 10.1002/hep.510280227; Rump ET, 1998, BIOCONJUGATE CHEM, V9, P341, DOI 10.1021/bc970176z; SATO M, 1992, J BIOCHEM-TOKYO, V111, P331, DOI 10.1093/oxfordjournals.jbchem.a123758; SCHLEPPERSCHAFER J, 1986, EXP CELL RES, V165, P494, DOI 10.1016/0014-4827(86)90602-6; Seglen P O, 1976, Methods Cell Biol, V13, P29, DOI 10.1016/S0091-679X(08)61797-5; Shimada K, 1997, BBA-BIOMEMBRANES, V1326, P329, DOI 10.1016/S0005-2736(97)00036-9; Sliedregt LAJM, 1999, J MED CHEM, V42, P609, DOI 10.1021/jm981078h; SPIESS M, 1990, BIOCHEMISTRY-US, V29, P1009, DOI 10.1021/bi00495a001; Tozawa R, 2001, J BIOL CHEM, V276, P12624, DOI 10.1074/jbc.M011063200; TREICHEL U, 1994, J GEN VIROL, V75, P3021, DOI 10.1099/0022-1317-75-11-3021; VANBERKEL TJC, 1985, J BIOL CHEM, V260, P2203; VANBERKEL TJC, 1985, J BIOL CHEM, V260, P2694; Versluis AJ, 1998, BRIT J CANCER, V78, P1607, DOI 10.1038/bjc.1998.730; WADHWA MS, 1995, J DRUG TARGET, V3, P111, DOI 10.3109/10611869509059211; WALL DA, 1980, CELL, V21, P79, DOI 10.1016/0092-8674(80)90116-6; WHITEHEAD PH, 1966, BIOCHIM BIOPHYS ACTA, V124, P209, DOI 10.1016/0304-4165(66)90336-9; WISSE E, 1985, HEPATOLOGY, V5, P683, DOI 10.1002/hep.1840050427; Wu GY, 1998, ADV DRUG DELIVER REV, V29, P243, DOI 10.1016/S0169-409X(97)00082-3; Yamazaki N, 2000, ADV DRUG DELIVER REV, V43, P225, DOI 10.1016/S0169-409X(00)00071-5	71	164	200	6	37	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 5	2001	276	40					37577	37584		10.1074/jbc.M101786200	http://dx.doi.org/10.1074/jbc.M101786200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	478YD	11479285	hybrid			2023-01-03	WOS:000171375700094
J	Jones, JK; Fife, D; Curkendall, S; Goehring, E; Guo, JJF; Shannon, M				Jones, JK; Fife, D; Curkendall, S; Goehring, E; Guo, JJF; Shannon, M			Coprescribing and codispensing of cisapride and contraindicated drugs	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							IMPACT	Context Cisapride, an oral prokinetic drug indicated for the symptomatic treatment of nocturnal heartburn due to gastroesophageal reflux disease, was approved by the US Food and Drug Administration in July 1993. After reports of serious cardiac arrhythmias and deaths during administration of cisapride, most involving concomitant exposure to another drug, a series of label changes and warnings were issued in February 1995, October 1995, June 1998, and June 1999. Cisapride was removed from general distribution in July 2000. Objective To determine the frequency of contraindicted coprescribing and codispensings, in which cisapride and a contraindicated drug were prescribed or dispensed to the same patient for overlapping periods, and the proportion of contraindicated coprescribing by the same physicians and codispensing by the same pharmacies. Design and Setting Retrospective study of prescription claims from a managed care organization database for all patients with cisapride prescriptions between July 1993 and December 1998. Participants A total of 38757 adult and pediatric patients who had a cisapride prescription immediately preceded by at least 60 days of insurance eligibility. Main Outcome Measure Proportion of cisapride prescriptions or dispensing occurring during the same treatment period as a drug contraindicated at that time prescribed by the same physicians or dispensed by the same pharmacies. Results Of 131485 cisapride prescriptions dispensed after the warnings began, 4414 (3.4%) overlapped with at least 1 drug contraindicated in the labeling at the time of the prescription. Of all overlapping prescription pairs, 2190 (50%) were by the same physicians, 3908 (89%) were by the same pharmacies, and 765 (17%) were dispensed on the same day. Conclusion Prescriptions dispensed by the same pharmacies accounted for afar higher proportion of contraindicated medication pairs than prescriptions from the same physicians. The pharmacy may be an important and underutilized intervention point to prevent contraindicated drugs from being used together.	Degge Grp Ltd, Res, Arlington, VA 22209 USA; Janssen Res Inst, Dept Epidemiol Drug Safety & Surveillance, Titusville, NJ USA; Univ Cincinnati, Med Ctr, Coll Pharm, Cincinnati, OH 45267 USA; Jorie Kent Associates Inc, Milton, DE USA	Johnson & Johnson; Johnson & Johnson USA; University System of Ohio; University of Cincinnati	Curkendall, S (corresponding author), Degge Grp Ltd, Res, 1616 N Ft Myer Dr,1430, Arlington, VA 22209 USA.							Cavuto NJ, 1996, JAMA-J AM MED ASSOC, V275, P1086, DOI 10.1001/jama.275.14.1086; McMullin ST, 1999, ARCH INTERN MED, V159, P2077, DOI 10.1001/archinte.159.17.2077; *MED EC CO, 2000, PHYS DESK REF, P1451; Piquette RK, 1999, ANN PHARMACOTHER, V33, P22, DOI 10.1345/aph.18107; Smalley W, 2000, JAMA-J AM MED ASSOC, V284, P3036, DOI 10.1001/jama.284.23.3036; SOUMERAI SB, 1989, MILBANK Q, V67, P268, DOI 10.2307/3350142; SOUMERAI SB, 1987, AM J PUBLIC HEALTH, V77, P1518, DOI 10.2105/AJPH.77.12.1518; Thompson D, 1996, JAMA-J AM MED ASSOC, V275, P1339, DOI 10.1001/jama.275.17.1339; *US FOOD DRUG ADM, 2000, JAMA-J AM MED ASSOC, V283, P2228; Wysowski DK, 1996, NEW ENGL J MED, V335, P290, DOI 10.1056/NEJM199607253350416	10	42	43	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 3	2001	286	13					1607	1609		10.1001/jama.286.13.1607	http://dx.doi.org/10.1001/jama.286.13.1607			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	478HH	11585484	Bronze			2023-01-03	WOS:000171340600028
J	Gill, TM; Desai, MM; Gahbauer, EA; Holford, TR; Williams, CS				Gill, TM; Desai, MM; Gahbauer, EA; Holford, TR; Williams, CS			Restricted activity among community-living older persons: Incidence, precipitants, and health care utilization	ANNALS OF INTERNAL MEDICINE			English	Article							BASE-LINE VULNERABILITY; RANDOMIZED-TRIAL; PREVENTING DISABILITY; FUNCTIONAL DEPENDENCE; ADULTS; SYMPTOMS; PEOPLE; DISEASE; EVENTS; FALLS	Background: Restricted activity is a potentially important indicator of health and functional status. Yet, relatively little is known about the incidence, precipitants, or health care utilization associated with restricted activity among older persons. Objective: To more accurately estimate the rate of restricted activity among community-living older persons, to identify the health-related and non-health-related problems that lead to restricted activity, and to determine whether restricted activity is associated with increased health care utilization. Design: Prospective cohort study. Setting: New Haven, Connecticut. Participants: 754 nondisabled members of a large health plan, 70 years of age or older, who were categorized according to their risk for disability (low, intermediate, or high). Measurements: Occurrence of restricted activity (defined as having stayed in bed for at least half a day or having cut down on one's usual activities because of an illness, injury, or another problem), problems leading to restricted activity, and health care utilization were ascertained during monthly telephone interviews for up to 2 years. Results: In median follow-up of 15 months, 76.6% of participants reported restricted activity during at least 1 month and 39.3% reported restricted activity during 2 consecutive months. The rates of restricted activity per 100 person-months were 19.0 episodes for all participants and 16.9, 27.3, and 22.7 episodes for participants at low, intermediate, and high risk for disability, respectively. Of the 24 prespecified health-related and non-health-related problems, the rates per 100 person-months of restricted activity ranged from 0.1 episode for "problem with alcohol" to 65.5 episodes for "been fatigued." On average, participants identified 4.5 different problems as a cause for their restricted activity, Health care utilization was substantially greater during months with restricted activity than months without restricted activity. The corresponding rates per 100 person-months were 63.8 and 45.1 for physician office visits, 12.5 and 1.0 for emergency department visits, 14.1 and 0.3 for hospital admissions, and 67.6 and 45.1 for any health care utilization (P<0.001 for each pairwise comparison). Conclusions: Restricted activity is common among community-living older persons, regardless of risk for disability, and it is usually attributable to several concurrent health-related problems. Although restricted activity is associated with a. substantial increase in health care utilization, older persons with restricted activity often do not seek medical attention.	Yale Univ, Sch Med, Dorothy Adler Geriat Assessment Ctr, New Haven, CT 06504 USA; Dept Vet Affairs, Connecticut Healthcare Syst, West Haven, CT USA	Yale University; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Connecticut Healthcare System	Gill, TM (corresponding author), Yale Univ, Sch Med, Dorothy Adler Geriat Assessment Ctr, 20 York St, New Haven, CT 06504 USA.		Gill, Thomas M./H-7043-2019; Fazli, Ghazal/AAE-8320-2022	Gill, Thomas M./0000-0002-6450-0368; Desai, Mayur/0000-0001-6616-0945	NATIONAL INSTITUTE ON AGING [K23AG000759, R01AG017560] Funding Source: NIH RePORTER; NIA NIH HHS [K23AG00759, 1RO1AG17560-01A1] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Baker DW, 1998, SOC SCI MED, V47, P1601, DOI 10.1016/S0277-9536(98)00215-9; BRODY EM, 1983, GERONTOLOGIST, V23, P75, DOI 10.1093/geront/23.1.75; BRODY EM, 1983, J AM GERIATR SOC, V31, P489, DOI 10.1111/j.1532-5415.1983.tb05124.x; Feinstein AR., 1987, CLINIMETRICS; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; Fried LP, 1997, J AM GERIATR SOC, V45, P92, DOI 10.1111/j.1532-5415.1997.tb00986.x; Gill TM, 1999, J GERONTOL A-BIOL, V54, pM377, DOI 10.1093/gerona/54.7.M377; Glynn RJ, 1996, BMJ-BRIT MED J, V312, P364; GURALNIK JM, 1995, NEW ENGL J MED, V332, P556, DOI 10.1056/NEJM199503023320902; Haas J, 1998, NEW ENGL J MED, V338, P1694, DOI 10.1056/NEJM199806043382312; HILL AB, 1965, P ROY SOC MED, V58, P295, DOI 10.1177/003591576505800503; Inouye SK, 1996, JAMA-J AM MED ASSOC, V275, P852, DOI 10.1001/jama.275.11.852; Institute of Medicine, 1996, HLTH OUTC OLD PEOPL; Jones R, 2000, BMJ-BRIT MED J, V320, P596, DOI 10.1136/bmj.320.7235.596; KOSOROK MR, 1992, AM J PUBLIC HEALTH, V82, P1263, DOI 10.2105/AJPH.82.9.1263; Leveille SG, 1998, J AM GERIATR SOC, V46, P1191, DOI 10.1111/j.1532-5415.1998.tb04533.x; Leveille SG, 2000, J GERONTOL B-PSYCHOL, V55, pS41; Lorig KR, 1999, MED CARE, V37, P5, DOI 10.1097/00005650-199901000-00003; *NAT CTR HLTH STAT, 1986, DHHS PUBL; Nevitt MC, 2000, ARCH INTERN MED, V160, P77, DOI 10.1001/archinte.160.1.77; RAKOWSKI W, 1988, MED CARE, V26, P278, DOI 10.1097/00005650-198803000-00005; Reuben DB, 1999, J AM GERIATR SOC, V47, P269, DOI 10.1111/j.1532-5415.1999.tb02988.x; Rothman KJ, 1998, MODERN EPIDEMIOLOGY; *SAS I, 1996, SAS SOFTW SYST VERS; SCHOLES D, 1991, AM J PUBLIC HEALTH, V81, P485, DOI 10.2105/AJPH.81.4.485; STUKEL TA, 1994, STAT MED, V13, P1781, DOI 10.1002/sim.4780131709; Szklo M, 1998, EPIDEMIOL REV, V20, P81, DOI 10.1093/oxfordjournals.epirev.a017974; TINETTI ME, 1995, JAMA-J AM MED ASSOC, V273, P1348, DOI 10.1001/jama.273.17.1348; TINETTI ME, 1994, J GERONTOL, V49, pM140, DOI 10.1093/geronj/49.3.M140; *US DHEW, 1979, DHEW PUBL; VERBRUGGE LM, 1985, SOC SCI MED, V20, P855, DOI 10.1016/0277-9536(85)90343-0; VERBRUGGE LM, 1987, MED CARE, V25, P539, DOI 10.1097/00005650-198706000-00008; WAGNER EH, 1994, AM J PUBLIC HEALTH, V84, P1800, DOI 10.2105/AJPH.84.11.1800; WAGNER EH, 1993, J AM GERIATR SOC, V41, P241, DOI 10.1111/j.1532-5415.1993.tb06700.x	34	247	248	0	14	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	SEP 4	2001	135	5					313	321		10.7326/0003-4819-135-5-200109040-00007	http://dx.doi.org/10.7326/0003-4819-135-5-200109040-00007			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	468WF	11529694				2023-01-03	WOS:000170780600001
J	Meegan, ME; Conroy, RM; Lengeny, SO; Renhault, K; Nyangole, L				Meegan, ME; Conroy, RM; Lengeny, SO; Renhault, K; Nyangole, L			Effect on neonatal tetanus mortality after a culturally-based health promotion programme	LANCET			English	Article								The Maasai have high rates of death from neonatal tetanus, partly due to their custom of packing the umbilical stump with cow dung. We report on the effect of a simple health promotion programme, designed In consultation with the local community and carried out by local women. After introduction of the programme in 1981, neonatal (<6 weeks of age) tetanus rates fell sharply, and by 1988 annual death rates had dropped to 0.75 (range 0-3) per 1000 births in the intervention areas compared with 82 (74-93) per 1000 in control areas.	Royal Coll Surgeons Ireland, Dublin 2, Ireland; ICROSS Kenya, Ngong Hills, Kenya; McMaster Univ, Fac Med, Hamilton, ON L8S 4L8, Canada; Minist Hlth, Nairobi, Kenya	Royal College of Surgeons - Ireland; McMaster University	Conroy, RM (corresponding author), Royal Coll Surgeons Ireland, Mercer Bldg, Dublin 2, Ireland.		Conroy, Ronan/C-6416-2008	Conroy, Ronan/0000-0001-5983-8682				ANITAOBONG OE, 1993, ANN TROP PAEDIATR, V13, P7; Bennett J, 1996, INT J EPIDEMIOL, V25, P879, DOI 10.1093/ije/25.4.879; MULL DS, 1990, SOC SCI MED, V30, P675, DOI 10.1016/0277-9536(88)90253-5; Mustafa BEM, 1996, J TROP PEDIATRICS, V42, P110, DOI 10.1093/tropej/42.2.110; 1996, SOZ PRAVENTIVMED, V41, P262	5	43	46	0	2	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	AUG 25	2001	358	9282					640	641		10.1016/S0140-6736(01)05787-7	http://dx.doi.org/10.1016/S0140-6736(01)05787-7			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	465XP	11530155				2023-01-03	WOS:000170615500016
J	Back, AL; Pearlman, RA				Back, AL; Pearlman, RA			Desire for physician-assisted suicide: requests for a better death?	LANCET			English	Editorial Material							TERMINALLY ILL; PATIENT REQUESTS; HASTENED DEATH; CARE; EUTHANASIA; ATTITUDES; CANCER; LIFE; END		Univ Washington, Vaterans Affairs Puget Sound Hlth Care Syst, Seattle, WA 98108 USA	University of Washington; University of Washington Seattle	Back, AL (corresponding author), Univ Washington, Vaterans Affairs Puget Sound Hlth Care Syst, Seattle, WA 98108 USA.							Angell M, 1997, NEW ENGL J MED, V336, P50, DOI 10.1056/NEJM199701023360108; Back AL, 1996, JAMA-J AM MED ASSOC, V275, P919, DOI 10.1001/jama.275.12.919; BLOCH SD, 1994, ARCH INTERN MED, V154, P2039, DOI 10.1001/archinte.154.18.2039; Breitbart W, 2000, JAMA-J AM MED ASSOC, V284, P2907, DOI 10.1001/jama.284.22.2907; CHOCHINOV HM, 1995, AM J PSYCHIAT, V152, P1185; Dworkin G, 1998, EUTHANASIA PHYSICIAN; Foley KM, 1997, NEW ENGL J MED, V336, P54, DOI 10.1056/NEJM199701023360109; Ganzini L, 1998, NEW ENGL J MED, V339, P967, DOI 10.1056/NEJM199810013391406; Meier DE, 1998, NEW ENGL J MED, V338, P1193, DOI 10.1056/NEJM199804233381706; Rosenfeld B, 2000, CANCER, V88, P2868, DOI 10.1002/1097-0142(20000615)88:12<2868::AID-CNCR30>3.0.CO;2-K; Singer PA, 1999, JAMA-J AM MED ASSOC, V281, P163, DOI 10.1001/jama.281.2.163; Steinhauser KE, 2000, ANN INTERN MED, V132, P825, DOI 10.7326/0003-4819-132-10-200005160-00011; Sullivan AD, 2000, NEW ENGL J MED, V342, P598, DOI 10.1056/NEJM200002243420822; van der Maas PJ, 1996, NEW ENGL J MED, V335, P1699, DOI 10.1056/NEJM199611283352227	14	8	8	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	AUG 4	2001	358	9279					344	345		10.1016/S0140-6736(01)05583-0	http://dx.doi.org/10.1016/S0140-6736(01)05583-0			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	459DE	11502307				2023-01-03	WOS:000170235100002
J	Llevadot, J; Giugliano, RP; Antman, EM				Llevadot, J; Giugliano, RP; Antman, EM			Bolus fibrinolytic therapy in acute myocardial infarction	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							TISSUE-PLASMINOGEN-ACTIVATOR; RECOMBINANT STAPHYLOKINASE VARIANTS; THROMBOLYTIC THERAPY; INTRACRANIAL HEMORRHAGE; ALTERED IMMUNOREACTIVITY; CORONARY THROMBOLYSIS; REPERFUSION THERAPY; THROMBIN INHIBITION; PLATELET ACTIVATION; ABCIXIMAB	Context New bolus fibrinolytics derived from the human tissue-type plasminogen activator (tPA) have emerged as a means of dissolution of occlusive thrombosis associated with acute myocardial infarction. Objective To review the new bolus fibrinolytic drugs derived from tPA, reteplase, lanoteplase, and tenecteplase, Data Sources The MEDLINE, EMBASE, and Current Contents databases were searched for articles from 1983 to 2001, using the index terms pharmacokinetics, pharmacodynamics, plasminogen activator, reteplase, lanoteplase, and tenecteplase. Additional data sources included bibliographies of articles identified on MEDLINE, EMBASE, and Current Content, inquiry of experts and pharmaceutical companies, and preliminary data presented at recent national and international cardiology conferences. Study Selection We selected for review studies that evaluated the pharmacokinetics and pharmacodynamics of reteplase, lanoteplase, and tenecteplase, and assessed the effects of these bolus fibrinolytic drugs on the angiographic and immediate and long-term outcomes of patients, Of 138 articles identified, 38 were analyzed. Data Extraction Data quality was determined by publication in the peer-reviewed literature or presentation at an official cardiology society-sponsored meeting. Data Synthesis Tenecteplase and reteplase are comparable with accelerated infusion recombinant tPA in terms of efficacy and safety but more convenient because they are administered by bolus injection. Lanoteplase and heparin bolus plus infusion is as effective as tPA with regard to mortality, but the rate of intracranial hemorrhage is significantly higher. Conclusion Given the ease of administration and the similar outcomes compared with accelerated infusion recombinant tPA, it is likely that a key component of contemporary reperfusion will include a bolus fibrinolytic.	Brigham & Womens Hosp, Div Cardiovasc, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA USA	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School	Giugliano, RP (corresponding author), TIMI Study Grp, 333 Longwood Ave,Suite 402, Boston, MA 02115 USA.	rgiugliano@partners.org	Giugliano, Robert/N-7233-2017	Giugliano, Robert/0000-0003-4110-7675				[Anonymous], 1986, LANCET, V1, P397; [Anonymous], 1989, NEW ENGL J MED, V320, P618; Antman EM, 2000, EUR HEART J, V21, P1944, DOI 10.1053/euhj.2000.2243; ANTMAN EM, 1994, CIRCULATION, V90, P1624, DOI 10.1161/01.CIR.90.4.1624; Antman EM, 1999, CIRCULATION, V99, P2720, DOI 10.1161/01.CIR.99.21.2720; Antman EM, 1996, CIRCULATION, V94, P911, DOI 10.1161/01.CIR.94.5.911; Armstrong PW, 2001, CIRCULATION, V103, P1171, DOI 10.1161/01.CIR.103.8.1171; BENEDICT CR, 1995, CIRCULATION, V92, P3032, DOI 10.1161/01.CIR.92.10.3032; Bode C, 1996, CIRCULATION, V94, P891, DOI 10.1161/01.CIR.94.5.891; BRAUNWALD E, 1993, NEW ENGL J MED, V329, P1650, DOI 10.1056/NEJM199311253292211; Braunwald E, 2000, EUR HEART J, V21, P2005; Cannon CP, 2000, AM J CARDIOL, V85, p17C; Cannon CP, 1998, CIRCULATION, V98, P2805, DOI 10.1161/01.CIR.98.25.2805; CANNON CP, 1994, J AM COLL CARDIOL, V24, P1602, DOI 10.1016/0735-1097(94)90163-5; Cannon CP, 1997, CIRCULATION, V95, P351; Cannon CP, 1999, J THROMB THROMBOLYS, V7, P171, DOI 10.1023/A:1008841721975; Collen D, 2000, CIRCULATION, V102, P1766; Collen D, 1996, CIRCULATION, V93, P857, DOI 10.1161/01.CIR.93.5.857; Collen D, 1996, CIRCULATION, V94, P207, DOI 10.1161/01.CIR.94.2.207; Collen D, 1996, CIRCULATION, V94, P197, DOI 10.1161/01.CIR.94.2.197; COLLEN D, 1988, BLOOD, V71, P216; COLLEN D, 1999, MOL BASIS CARDIOVASC, P537; Coller BS, 1997, THROMB HAEMOSTASIS, V78, P730; Coulter SA, 2000, CIRCULATION, V101, P2690, DOI 10.1161/01.CIR.101.23.2690; de Lemos JA, 2000, CIRCULATION, V101, P239, DOI 10.1161/01.CIR.101.3.239; den Heijer P, 1998, CIRCULATION, V98, P2117, DOI 10.1161/01.CIR.98.20.2117; DEWOOD MA, 1980, NEW ENGL J MED, V303, P897, DOI 10.1056/NEJM198010163031601; Eikelboom JW, 2001, JAMA-J AM MED ASSOC, V285, P444, DOI 10.1001/jama.285.4.444; FITZGERALD DJ, 1988, CIRCULATION, V77, P142, DOI 10.1161/01.CIR.77.1.142; Giugliano RP, 2000, J AM COLL CARDIOL, V35, p407A; Giugliano RP, 2001, AM HEART J, V141, P742, DOI 10.1067/mhj.2001.114975; GIUGLIANO RP, 1997, CIRCULATION S1, V96, P535; *GLOB UT STREPT TI, 1993, NEW ENGL J MED, V329, P673; Granger CB, 1996, CIRCULATION, V93, P870, DOI 10.1161/01.CIR.93.5.870; Granger CB, 2000, CIRCULATION, V102, P590; HANSEN L, 1988, J BIOL CHEM, V263, P15713; Harrington RA, 1998, J AM COLL CARDIOL, V32, P2003; *INT JOINT EFF COM, 1995, LANCET, V346, P329; KEYT BA, 1994, P NATL ACAD SCI USA, V91, P3670, DOI 10.1073/pnas.91.9.3670; KOHNERT U, 1992, PROTEIN ENG, V5, P93, DOI 10.1093/protein/5.1.93; LARSEN GR, 1989, BLOOD, V73, P1842, DOI 10.1182/blood.V73.7.1842.1842; LARSEN GR, 1991, J BIOL CHEM, V266, P8156; LEIZOROVICZ A, 1993, NEW ENGL J MED, V329, P383; Mehta SR, 2000, LANCET, V356, P449, DOI 10.1016/S0140-6736(00)02552-6; MERLINI PA, 1995, J AM COLL CARDIOL, V25, P203, DOI 10.1016/0735-1097(94)00360-3; NEUHAUS KL, 1994, J AM COLL CARDIOL, V24, P55, DOI 10.1016/0735-1097(94)90541-X; Ohman EM, 1997, CIRCULATION, V95, P846; OWEN J, 1988, BLOOD, V72, P616; Paoni NF, 1996, THROMB HAEMOSTASIS, V75, P820; PAONI NF, 1993, THROMB HAEMOSTASIS, V70, P307; PASSAMANI E, 1985, NEW ENGL J MED, V312, P932; RAWLES J, 1994, J AM COLL CARDIOL, V23, P1, DOI 10.1016/0735-1097(94)90494-4; Roe Matthew T., 2001, HeartDrug, V1, P5, DOI 10.1159/000022704; ROSS A, 2000, AM COLL CARD 49 SCI; ROSS AM, 1993, NEW ENGL J MED, V329, P1615; SIMES RJ, 1995, CIRCULATION, V91, P1923, DOI 10.1161/01.CIR.91.7.1923; SIMOONS ML, 1993, LANCET, V342, P1523, DOI 10.1016/S0140-6736(05)80089-3; SMALLING RW, 1995, CIRCULATION, V91, P2725, DOI 10.1161/01.CIR.91.11.2725; TEBBE U, 1993, AM J CARDIOL, V72, P518, DOI 10.1016/0002-9149(93)90345-D; TOPOL E, 1994, CIRCULATION, V90, P1631; Topol E, 1997, NEW ENGL J MED, V337, P1118; Topol EJ, 2000, CIRCULATION, V101, P2788; Topol EJ, 1996, NEW ENGL J MED, V335, P775; Topol EJ, 2001, LANCET, V357, P1905; Van de Werf F, 1999, LANCET, V354, P716, DOI 10.1016/S0140-6736(99)07403-6; Van de Werf F, 1999, AM HEART J, V137, P786, DOI 10.1016/S0002-8703(99)70400-X; VandeWerf F, 1997, NEW ENGL J MED, V337, P1124; WALLENTIN L, 2000, G WASH U 16 INT S TH; Ware JH, 1997, NEW ENGL J MED, V337, P1159, DOI 10.1056/NEJM199710163371610; WEAVER WD, 1993, JAMA-J AM MED ASSOC, V270, P1211, DOI 10.1001/jama.270.10.1211; 2000, LANCET, V356, P1848	71	56	59	0	1	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 25	2001	286	4					442	449		10.1001/jama.286.4.442	http://dx.doi.org/10.1001/jama.286.4.442			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	456DZ	11466123				2023-01-03	WOS:000170069000016
J	Gupta, K; Hooton, TM; Stamm, WE				Gupta, K; Hooton, TM; Stamm, WE			Increasing antimicrobial resistance and the management of uncomplicated community-acquired urinary tract infections	ANNALS OF INTERNAL MEDICINE			English	Review							ESCHERICHIA-COLI; TRIMETHOPRIM-SULFAMETHOXAZOLE; CLINICAL PHARMACOKINETICS; RANDOMIZED-TRIAL; GENERAL-PRACTICE; RISK-FACTORS; WOMEN; CIPROFLOXACIN; AMOXICILLIN; BACTERIA	Community-acquired urinary tract infections (UTIs) are among the most common bacterial infections in women. Therapy for these infections is usually begun before results of microbiological tests are known. Furthermore, in women with acute uncomplicated cystitis, empirical therapy without a pretherapy urine culture is often used. The rationale for this approach is based on the highly predictable spectrum of etiologic agents causing UTI and their antimicrobial resistance patterns. However, antimicrobial resistance among uropathogens causing community-acquired UTIs, both cystitis and pyelonephritis, is increasing. Most important has been the increasing resistance to trimethoprim-sulfamethoxazole (TMP-SMX), the current drug of choice for treatment of acute uncomplicated cystitis in women. What implications do these trends have for treatment of community-acquired UTIs? Preliminary data suggest that clinical cure rates may be lower among women with uncomplicated cystitis treated with TMP-SMX when the infecting pathogen is resistant to TMP-SMX. Women with pyelonephritis also have less bacterial eradication and lower clinical cure rates when treated with TMP-SMX for an infection that is resistant to the drug. Therefore, in the outpatient setting, identifying risk factors for TMP-SMX resistance and knowing the prevalence of TMP-SMX resistance in the local community are important steps in choosing an appropriate therapeutic agent. When choosing a treatment regimen, physicians should consider such factors as in vitro susceptibility, adverse effects, cost-effectiveness, and selection of resistant strains. Using a management strategy that takes these variables into account is essential for maintaining the safety and efficacy of treatment for acute UTI.	Univ Washington, Sch Med, Div Allergy & Infect Dis, Seattle, WA 98195 USA	University of Washington; University of Washington Seattle	Stamm, WE (corresponding author), Univ Washington, Sch Med, Div Allergy & Infect Dis, 1959 NE Pacific St,BB1225,Box 356523, Seattle, WA 98195 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK053369] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 53369] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Acar JF, 1997, CLIN INFECT DIS, V24, pS67, DOI 10.1093/clinids/24.Supplement_1.S67; AMSDEN GW, 2000, MANDELL DOUGLAS BENN, P551; ARANCIBIA A, 1980, ANTIMICROB AGENTS CH, V17, P199, DOI 10.1128/AAC.17.2.199; BAILEY RR, 1995, NEW ZEAL MED J, V108, P465; Christiaens T, 1998, ACTA CLIN BELG, V53, P184, DOI 10.1080/17843286.1998.11754161; COLE M, 1978, J ANTIMICROB CHEMOTH, V4, P580, DOI 10.1093/jac/4.6.580; Dyer IE, 1998, WESTERN J MED, V169, P265; ENA J, 1995, J UROLOGY, V153, P117, DOI 10.1097/00005392-199501000-00040; Fish DN, 1997, CLIN PHARMACOKINET, V32, P101, DOI 10.2165/00003088-199732020-00002; Garcia-Rodriguez JA, 1998, CHEMOTHERAPY, V44, P28, DOI 10.1159/000048461; GRUNEBERG RN, 1994, J ANTIMICROB CHEMOTH, V33, P1; Gupta K, 1999, JAMA-J AM MED ASSOC, V281, P736, DOI 10.1001/jama.281.8.736; GUPTA K, IN PRESS CLIN INFECT; HOOTON TM, 1995, JAMA-J AM MED ASSOC, V273, P41; Hooton TM, 1997, INFECT DIS CLIN N AM, V11, P551, DOI 10.1016/S0891-5520(05)70373-1; Iqbal J, 1997, JPN J MED SCI BIOL, V50, P241, DOI 10.7883/yoken1952.50.241; MASTERTON RG, 1995, J ANTIMICROB CHEMOTH, V35, P129, DOI 10.1093/jac/35.1.129; McCarthy JM, 1999, AM J MED, V106, P292, DOI 10.1016/S0002-9343(99)00026-1; *MICR INC, 2001, MICR HEALTHC SER DAT, V108; MURRAY BE, 1990, ANTIMICROB AGENTS CH, V34, P515, DOI 10.1128/AAC.34.4.515; NICOLLE LE, 1993, SCAND J INFECT DIS, V25, P631, DOI 10.3109/00365549309008553; NIGHTINGALE CH, 1975, J PHARM SCI-US, V64, P1899, DOI 10.1002/jps.2600641202; Orrett F. A., 1998, SMJ, V39, P256; PATEL RB, 1980, CLIN PHARMACOKINET, V5, P405, DOI 10.2165/00003088-198005050-00001; Patel SS, 1997, DRUGS, V53, P637, DOI 10.2165/00003495-199753040-00007; Perrin M, 1999, J HOSP INFECT, V41, P273, DOI 10.1053/jhin.1998.0521; RECKENDORF HK, 1962, ANTIMICROBIAL AGENTS, V2, P531; REVES RR, 1990, ANTIMICROB AGENTS CH, V34, P1429, DOI 10.1128/AAC.34.7.1429; RUBIN RH, 1980, JAMA-J AM MED ASSOC, V244, P561, DOI 10.1001/jama.244.6.561; RUSSO TA, 1995, J INFECT DIS, V172, P440, DOI 10.1093/infdis/172.2.440; RYDBERG J, 1986, SCAND J INFECT DIS, V18, P457, DOI 10.3109/00365548609032364; Sahm DF, 2001, ANTIMICROB AGENTS CH, V45, P1402, DOI 10.1128/AAC.45.5.1402-1406.2001; SAHM DF, 1999, 39 INT C ANT AG CHEM; SPENCER RC, 1994, J ANTIMICROB CHEMOTH, V33, P121, DOI 10.1093/jac/33.suppl_A.121; STAMM WE, 1993, NEW ENGL J MED, V329, P1328, DOI 10.1056/NEJM199310283291808; Steinke DT, 1999, J ANTIMICROB CHEMOTH, V43, P841, DOI 10.1093/jac/43.6.841; Talan DA, 2000, JAMA-J AM MED ASSOC, V283, P1583, DOI 10.1001/jama.283.12.1583; TRIENEKENS T, 1994, J ANTIMICROB CHEMOTH, V33, P1064, DOI 10.1093/jac/33.5.1064; VANCEBRYAN K, 1990, CLIN PHARMACOKINET, V19, P434, DOI 10.2165/00003088-199019060-00003; Warren JW, 1999, CLIN INFECT DIS, V29, P745, DOI 10.1086/520427; Weber G, 1997, EUR J CLIN MICROBIOL, V16, P834, DOI 10.1007/BF01700414; Wright SW, 1999, J GEN INTERN MED, V14, P606, DOI 10.1046/j.1525-1497.1999.10128.x; Zhanel GG, 2000, ANTIMICROB AGENTS CH, V44, P1089, DOI 10.1128/AAC.44.4.1089-1092.2000; 1997, MED LETT DRUGS THER, V39, P66	44	377	401	0	15	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUL 3	2001	135	1					41	50		10.7326/0003-4819-135-1-200107030-00012	http://dx.doi.org/10.7326/0003-4819-135-1-200107030-00012			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	449JC	11434731				2023-01-03	WOS:000169680500006
J	Woolhead, CA; Mant, A; Kim, SJ; Robinson, C; Rodger, A				Woolhead, CA; Mant, A; Kim, SJ; Robinson, C; Rodger, A			Conformation of a purified "spontaneously" inserting thylakoid membrane protein precursor in aqueous solvent and detergent micelles	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL RECOGNITION PARTICLE; ESCHERICHIA-COLI; INDEPENDENT INSERTION; HELIX; SEC; INTEGRATION	Subunit W of photosystem II (PsbW) is a single-span thylakoid membrane protein that is synthesized with a cleavable hydrophobic signal peptide and integrated into the thylakoid membrane by an apparently spontaneous mechanism. In this study, we have analyzed the secondary structure of the pre-protein at early stages of the insertion pathway, using purified recombinant pre-PsbW. We show that the protein remains soluble in Tris buffer after removal of detergent. Under these conditions pre-PsbW contains no detectable alpha -helix, whereas substantial alpha -helical. structure is present in SDS micelles, In aqueous buffer, the tryptophan fluorescence emission characteristics are intermediate between those of solvent exposed and hydrophobic environments, suggesting the formation of a partially folded structure. If denaturants are excluded from the purification protocol, pre-PsbW purifies instead as a 180-kDa oligomer with substantial alpha -helical structure. Mature-size PsbW was prepared by removal of the presequence, and we show that this protein also contains alpha -helix in detergent but in lower quantities than the pre-protein. We therefore propose that pre-PsbW contains alpha -helical structure in both the mature protein and the signal peptide in nonpolar environments. We propose that pre-PsbW acquires its alpha -helical structure only during the later, membrane-bound stages of the insertion pathway, after which it forms a "helical hairpin"-type loop intermediate in the thylakoid membrane.	Univ Warwick, Dept Biol Sci, Coventry CV4 7AL, W Midlands, England; Univ Warwick, Dept Chem, Coventry CV4 7AL, W Midlands, England	University of Warwick; University of Warwick	Robinson, C (corresponding author), Univ Warwick, Dept Biol Sci, Gibbet Hill Rd, Coventry CV4 7AL, W Midlands, England.	Crobinson@bio.warwick.ac.uk	Rodger, Alison/A-1063-2009	Rodger, Alison/0000-0002-7111-3024; Mant, Alexandra/0000-0001-7169-209X				Bryson EA, 1999, BIOCHEMISTRY-US, V38, P9758, DOI 10.1021/bi990119o; CLAROS MG, 1994, COMPUT APPL BIOSCI, V10, P685; Dalbey RE, 1999, TRENDS BIOCHEM SCI, V24, P17, DOI 10.1016/S0968-0004(98)01333-4; deGier JWL, 1996, FEBS LETT, V399, P307, DOI 10.1016/S0014-5793(96)01354-3; GEBERT JF, 1988, J BIOL CHEM, V263, P16652; GIERASCH LM, 1989, BIOCHEMISTRY-US, V28, P923, DOI 10.1021/bi00429a001; HARRIS ELV, 1995, PROTEIN PURIFICATION; Johnson WC, 1999, PROTEINS, V35, P307, DOI 10.1002/(SICI)1097-0134(19990515)35:3<307::AID-PROT4>3.0.CO;2-3; Kim SJ, 1998, FEBS LETT, V424, P105, DOI 10.1016/S0014-5793(98)00148-3; Kogata N, 1999, FEBS LETT, V447, P329, DOI 10.1016/S0014-5793(99)00305-1; KUHN A, 1995, FEMS MICROBIOL REV, V17, P185; Ladokhin AS, 1999, J MOL BIOL, V285, P1363, DOI 10.1006/jmbi.1998.2346; LI XX, 1995, P NATL ACAD SCI USA, V92, P3789, DOI 10.1073/pnas.92.9.3789; LORKOVIC ZJ, 1995, P NATL ACAD SCI USA, V92, P8930, DOI 10.1073/pnas.92.19.8930; MACFARLANE J, 1995, EUR J BIOCHEM, V233, P766, DOI 10.1111/j.1432-1033.1995.766_3.x; MICHL D, 1994, EMBO J, V13, P1310, DOI 10.1002/j.1460-2075.1994.tb06383.x; Miroux B, 1996, J MOL BIOL, V260, P289, DOI 10.1006/jmbi.1996.0399; Robinson D, 1996, PLANT J, V10, P149, DOI 10.1046/j.1365-313X.1996.10010149.x; Rodger A., 2000, SPECTROPHOTOMETRY SP, P99; ROISE D, 1986, EMBO J, V5, P1327, DOI 10.1002/j.1460-2075.1986.tb04363.x; Samuelson JC, 2000, NATURE, V406, P637, DOI 10.1038/35020586; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; Thompson SJ, 1998, J BIOL CHEM, V273, P18979, DOI 10.1074/jbc.273.30.18979; Traxler B, 1996, J BIOL CHEM, V271, P12394, DOI 10.1074/jbc.271.21.12394; Tu CJ, 1999, J BIOL CHEM, V274, P27219, DOI 10.1074/jbc.274.38.27219; Ulbrandt ND, 1997, CELL, V88, P187, DOI 10.1016/S0092-8674(00)81839-5; Valent QA, 1997, MOL MICROBIOL, V25, P53, DOI 10.1046/j.1365-2958.1997.4431808.x; White SH, 1999, ANNU REV BIOPH BIOM, V28, P319, DOI 10.1146/annurev.biophys.28.1.319	28	10	10	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 4	2001	276	18					14607	14613		10.1074/jbc.M009600200	http://dx.doi.org/10.1074/jbc.M009600200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	429QQ	11278526	hybrid			2023-01-03	WOS:000168528800013
J	Beecham, L; Dorozynski, A; Sheldon, T; Turone, F; Mach, A; Bosch, X; Charatan, FB; Mahkorn, DT; Siegel-Itzkovich, J				Beecham, L; Dorozynski, A; Sheldon, T; Turone, F; Mach, A; Bosch, X; Charatan, FB; Mahkorn, DT; Siegel-Itzkovich, J			Viagra falls: the debate over rationing continues	BRITISH MEDICAL JOURNAL			English	Editorial Material																			0	6	6	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	SEP 26	1998	317	7162					836	838						3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	125DN	11645103				2023-01-03	WOS:000076222300013
J	Isley, WL				Isley, WL			Growth hormone therapy for adults: Not ready for prime time?	ANNALS OF INTERNAL MEDICINE			English	Article							CARDIOVASCULAR RISK-FACTORS; CORONARY-HEART-DISEASE; GH-DEFICIENT ADULTS; REPLACEMENT THERAPY; BODY-COMPOSITION; HYPOPITUITARY ADULTS; GLUCOCORTICOID REPLACEMENT; PREMATURE MORTALITY; INSULIN SENSITIVITY; CARDIAC-PERFORMANCE	Human growth hormone is now readily available and approved for treatment of the growth hormone deficiency syndrome in adults. However, physicians have been slow to adopt this therapeutic modality. Reasons for skepticism about the use of growth hormone for the growth hormone deficiency syndrome include doubts about whether growth hormone deficiency causes increased morbidity and mortality in patients with hypopituitarism; availability of highly efficacious, easier to use, and less expensive agents for certain aspects of the growth hormone deficiency syndrome, especially cardiovascular disease; and concerns about possible toxicity in adults. Long-term studies in patients receiving appropriate comprehensive management for other hormonal deficiencies and for concomitant abnormalities will be required to convince physicians of the utility and safety of growth hormone replacement therapy.	Univ Missouri, Sch Med, Kansas City, MO 64108 USA	University of Missouri System; University of Missouri Kansas City	Isley, WL (corresponding author), St Lukes Lipid & Diabet Res Ctr, Plaza 1,Suite 128,4320 Wornall Rd, Kansas City, MO 64111 USA.	wisley@saint-lukes.org						AlShoumer KAS, 1997, J CLIN ENDOCR METAB, V82, P2653, DOI 10.1210/jc.82.8.2653; Attanasio AF, 1997, J CLIN ENDOCR METAB, V82, P82, DOI 10.1210/jc.82.1.82; Barkan AL, 2000, TRENDS ENDOCRIN MET, V11, P238, DOI 10.1016/S1043-2760(00)00267-8; Bates AS, 1999, CLIN ENDOCRINOL, V50, P315, DOI 10.1046/j.1365-2265.1999.00650.x; Bates AS, 1996, J CLIN ENDOCR METAB, V81, P1169, DOI 10.1210/jc.81.3.1169; Baum HBA, 1996, ANN INTERN MED, V125, P883, DOI 10.7326/0003-4819-125-11-199612010-00003; BENGTSSON BA, 1993, J CLIN ENDOCR METAB, V76, P309, DOI 10.1210/jc.76.2.309; BESHYAH SA, 1995, J CLIN ENDOCR METAB, V80, P356, DOI 10.1210/jc.80.2.356; BESHYAH SA, 1995, CLIN ENDOCRINOL, V42, P73, DOI 10.1111/j.1365-2265.1995.tb02601.x; Bhasin S, 1997, J CLIN ENDOCR METAB, V82, P3, DOI 10.1210/jc.82.1.3; Black DM, 2000, J CLIN ENDOCR METAB, V85, P4118, DOI 10.1210/jc.85.11.4118; BOWEN J, 1992, STROKE, V23, P908, DOI 10.1161/01.STR.23.6.908; Bulow B, 1997, CLIN ENDOCRINOL, V46, P75, DOI 10.1046/j.1365-2265.1997.d01-1749.x; Bulow B, 2000, J CLIN ENDOCR METAB, V85, P574, DOI 10.1210/jc.85.2.574; Carroll PV, 1998, J CLIN ENDOCR METAB, V83, P382, DOI 10.1210/jc.83.2.382; Carroll PV, 2000, TRENDS ENDOCRIN MET, V11, P231, DOI 10.1016/S1043-2760(00)00268-X; Chrisoulidou A, 2000, J CLIN ENDOCR METAB, V85, P3762, DOI 10.1210/jc.85.10.3762; Christiansen JS, 2001, J CLIN ENDOCR METAB, V86, P1868; Christopher M, 1998, J CLIN ENDOCR METAB, V83, P1668, DOI 10.1210/jc.83.5.1668; Colao A, 1999, J CLIN ENDOCR METAB, V84, P3950, DOI 10.1210/jc.84.11.3950; Colao A, 2001, J CLIN ENDOCR METAB, V86, P1874, DOI 10.1210/jc.86.5.1874; CUNEO RC, 1991, J APPL PHYSIOL, V70, P695, DOI 10.1152/jappl.1991.70.2.695; CUNEO RC, 1993, METABOLISM, V42, P1519, DOI 10.1016/0026-0495(93)90145-E; CUNEO RC, 1992, CLIN ENDOCRINOL, V37, P387, DOI 10.1111/j.1365-2265.1992.tb02347.x; Downs JR, 1998, JAMA-J AM MED ASSOC, V279, P1615, DOI 10.1001/jama.279.20.1615; DUNNE FP, 1995, CLIN ENDOCRINOL, V43, P623, DOI 10.1111/j.1365-2265.1995.tb02928.x; EDEN S, 1993, ARTERIOSCLER THROMB, V13, P296, DOI 10.1161/01.ATV.13.2.296; Evans LM, 1999, CLIN ENDOCRINOL, V50, P457; Gotherstrom G, 2001, J CLIN ENDOCR METAB, V86, P4657, DOI 10.1210/jc.86.10.4657; Greenspan SL, 1999, ANN INTERN MED, V130, P750, DOI 10.7326/0003-4819-130-9-199905040-00016; Grodstein F, 2000, ANN INTERN MED, V133, P933, DOI 10.7326/0003-4819-133-12-200012190-00008; Hansen TB, 1995, CLIN ENDOCRINOL, V43, P689, DOI 10.1111/j.1365-2265.1995.tb00536.x; Hansson L, 1998, LANCET, V351, P1755, DOI 10.1016/S0140-6736(98)04311-6; Hew FL, 1996, J CLIN ENDOCR METAB, V81, P555, DOI 10.1210/jc.81.2.555; Hulley S, 1998, JAMA-J AM MED ASSOC, V280, P605, DOI 10.1001/jama.280.7.605; Johannsson G, 1996, J CLIN ENDOCR METAB, V81, P1575, DOI 10.1210/jc.81.4.1575; Johansson AG, 1999, J CLIN ENDOCR METAB, V84, P2002, DOI 10.1210/jc.84.6.2002; JORGENSEN JOL, 1989, LANCET, V1, P1221; Khaw KT, 2001, BMJ-BRIT MED J, V322, P15, DOI 10.1136/bmj.322.7277.15; MARKUSSIS V, 1992, LANCET, V340, P1188, DOI 10.1016/0140-6736(92)92892-J; MARTIN JB, 1992, PROG BRAIN RES, V93, P31; McClung MR, 2001, NEW ENGL J MED, V344, P333, DOI 10.1056/NEJM200102013440503; McConnell EM, 2001, CLIN ENDOCRINOL, V54, P593, DOI 10.1046/j.1365-2265.2001.01269.x; *MED EC, 2001, 2001 DRUG TOP RED BO; Meier C, 2001, J CLIN ENDOCR METAB, V86, P4860, DOI 10.1210/jc.86.10.4860; Mendelsohn ME, 2001, CIRCULATION, V104, P2256, DOI 10.1161/circ.104.19.2256; Miller KK, 2001, J CLIN ENDOCR METAB, V86, P561, DOI 10.1210/jc.86.2.561; MURROS KE, 1989, ARCH NEUROL-CHICAGO, V46, P449, DOI 10.1001/archneur.1989.00520400109029; NASS R, 1995, J CLIN ENDOCR METAB, V80, P552, DOI 10.1210/jc.80.2.552; OLIVECRONA H, 1993, BRIT MED J, V306, P1726, DOI 10.1136/bmj.306.6894.1726-a; ONeal D, 1996, J CLIN ENDOCR METAB, V81, P2448, DOI 10.1210/jc.81.7.2448; Peacey SR, 1997, CLIN ENDOCRINOL, V46, P255, DOI 10.1046/j.1365-2265.1997.780907.x; PEDERSEN TR, 1994, LANCET, V344, P1383; Ridker PM, 1999, CIRCULATION, V100, P230, DOI 10.1161/01.CIR.100.3.230; Ridker PM, 2001, JAMA-J AM MED ASSOC, V285, P2481, DOI 10.1001/jama.285.19.2481; ROSEN T, 1990, LANCET, V336, P285, DOI 10.1016/0140-6736(90)91812-O; Rosenfalck AM, 2000, J CLIN ENDOCR METAB, V85, P4173, DOI 10.1210/jc.85.11.4173; SALOMON F, 1989, NEW ENGL J MED, V321, P1797, DOI 10.1056/NEJM198912283212605; SAWIN CT, 1994, NEW ENGL J MED, V331, P1249, DOI 10.1056/NEJM199411103311901; Schnitzer T, 2000, AGING CLIN EXP RES, V12, P1; Sesmilo G, 2000, ANN INTERN MED, V133, P111, DOI 10.7326/0003-4819-133-2-200007180-00010; SHAHI M, 1992, BRIT HEART J, V67, P92; SHEPHERD J, 1995, NEW ENGL J MED, V333, P1301, DOI 10.1056/NEJM199511163332001; Stavrou S, 2001, ENDOCRIN METAB CLIN, V30, P545, DOI 10.1016/S0889-8529(05)70201-2; Thomas AM, 2001, J CLIN ENDOCR METAB, V86, P1871, DOI 10.1210/jc.86.5.1871; Tognoni G, 2001, LANCET, V357, P89, DOI 10.1016/S0140-6736(00)03539-X; Tomlinson JW, 2001, LANCET, V357, P425, DOI 10.1016/S0140-6736(00)04006-X; TOOGOOD AA, 1994, CLIN ENDOCRINOL, V41, P511, DOI 10.1111/j.1365-2265.1994.tb02583.x; Vance ML, 1999, NEW ENGL J MED, V341, P1206, DOI 10.1056/NEJM199910143411607; Villareal DT, 2000, CLIN ENDOCRINOL, V53, P561, DOI 10.1046/j.1365-2265.2000.01131.x; Wang C, 2000, J CLIN ENDOCR METAB, V85, P2839, DOI 10.1210/jc.85.8.2839; WEAVER JU, 1994, CLIN ENDOCRINOL, V41, P639, DOI 10.1111/j.1365-2265.1994.tb01830.x; WEAVER JU, 1995, J CLIN ENDOCR METAB, V80, P153, DOI 10.1210/jc.80.1.153; WHITEHEAD HM, 1992, CLIN ENDOCRINOL, V36, P45, DOI 10.1111/j.1365-2265.1992.tb02901.x; Wichers M, 1999, CLIN ENDOCRINOL, V50, P759, DOI 10.1046/j.1365-2265.1999.00723.x; Wuster C, 2001, J BONE MINER RES, V16, P398, DOI 10.1359/jbmr.2001.16.2.398; Yusuf S, 2000, NEW ENGL J MED, V342, P145	77	14	15	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	AUG 6	2002	137	3					190	196		10.7326/0003-4819-137-3-200208060-00011	http://dx.doi.org/10.7326/0003-4819-137-3-200208060-00011			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	580XP	12160367				2023-01-03	WOS:000177262300006
J	Corcoy, R				Corcoy, R			Uses of error - Iatrogenic adrenergic crisis	LANCET			English	Editorial Material									Hosp Sant Pau, Barcelona 08025, Spain	Hospital of Santa Creu i Sant Pau	Corcoy, R (corresponding author), Hosp Sant Pau, Barcelona 08025, Spain.		Corcoy, Rosa/A-2140-2009	Corcoy, Rosa/0000-0001-5055-6814					0	0	0	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAY 25	2002	359	9320					1850	1850		10.1016/S0140-6736(02)08704-4	http://dx.doi.org/10.1016/S0140-6736(02)08704-4			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	555CK	12044393				2023-01-03	WOS:000175775500026
J	Lewith, GT; Watkins, AD; Hyland, ME; Shaw, S; Broomfield, JA; Dolan, G; Holgate, ST				Lewith, GT; Watkins, AD; Hyland, ME; Shaw, S; Broomfield, JA; Dolan, G; Holgate, ST			Use of ultramolecular potencies of allergen to treat asthmatic people allergic to house dust mite: double blind randomised controlled clinical trial	BMJ-BRITISH MEDICAL JOURNAL			English	Article							NEGATIVE AFFECT; PLACEBO; HOMEOPATHY; VALIDATION	Objective To evaluate the efficacy of homoeopathic immunotherapy on lung function and respiratory symptoms in asthmatic people allergic to house dust mite. Design Double blind randomised controlled trial. Setting 38 general practices in Hampshire and Dorset Participants 242 people with asthma and positive results to skin prick test for house dust mite; 202 completed clinic based assessments, and 186 completed diary based assessments. Intervention After a four week baseline assessment participants were randomised to receive oral homoeopathic immunotherapy or placebo and dien assessed over 16 weeks with three clinic visits mid diary assessments every other week. Outcome measure Clinic based assessments: forced expiratory volume in one second (FEN,), quality of life, mid mood. Diary based assessments: morning mid evening peak expiratory flow, visual analogue scale of severity of asthma, quality of life, and daily mood. Results There was no difference in most outcomes between placebo and homoeopathic immunotherapy. There was a different pattern of change over the trial for three of the diary assessments: morning peak expiratory flow (P=0.025), visual analogue scale (P=0.017), and mood (P=0.035). At week three there was significant deterioration for visual analogue scale (P=0.047) mid mood (P=0.013) in the homoeopathic immunotherapy group compared with the placebo group. Any improvement in participants' asthma was independent of belief in complementary medicine. Conclusion Homoeopathic immunotherapy is not effective in the treatment of patients with asthma. The cliff rent patterns of change between homoeopathic immunotherapy and placebo over the course of the stud), are unexplained.	Southampton Gen Hosp, Southampton SO16 6YD, Hants, England; Univ Plymouth, Dept Psychol, Plymouth PL4 8AA, Devon, England; Univ Plymouth, Sch Math & Stat, Plymouth PL4 8AA, Devon, England	University of Southampton; University of Plymouth; University of Plymouth	Lewith, GT (corresponding author), Southampton Gen Hosp, Southampton SO16 6YD, Hants, England.	GL3@soton.ac.uk		Hyland, Michael/0000-0003-3879-0469; Lewith, George/0000-0002-2364-3960				Aabel S, 2000, Br Homeopath J, V89, P169, DOI 10.1054/homp.1999.0440; British Medical Association, 1993, COMPL MED NEW APPR G; DUTARTRE D, 1990, ACT HOMEOPATHIQUE, V1, P21; Eizayaga FX, 1996, BR HOMEOPATH J, V85, P28; Ernst E, 1998, PEDIATR ASTHMA ALLER, V12, P29, DOI 10.1089/pai.1998.12.29; Finnigan M, 1991, COMPLEMENT MED RES, V5, P83; FINNIGAN MD, 1991, COMPLEMENT MED RES, V5, P79; FISHER P, 1994, BRIT MED J, V309, P107, DOI 10.1136/bmj.309.6947.107; HAHNEMANN S, 1980, ORGANON MED, P156; HIGGINS BG, 1992, AM REV RESPIR DIS, V145, P588, DOI 10.1164/ajrccm/145.3.588; *HOUS LORDS SEL CO, 2000, 6 HOUS LORDS SEL COM; HYLAND ME, 1995, BRIT J CLIN PSYCHOL, V34, P601, DOI 10.1111/j.2044-8260.1995.tb01494.x; HYLAND ME, 1995, THORAX, V50, P724, DOI 10.1136/thx.50.7.724; LETTS M, 1998, JURYS OUT NATL ASTHM; Linde K, 1997, LANCET, V350, P834, DOI 10.1016/S0140-6736(97)02293-9; *NAT ASS HLTH AUTH, 1993, COMPL THER NHS; *NHLBI WHO, 1996, NAT HEART LUNG BLOOD; Nolleveaux, 1992, HOMEOPATHIE FRANCAIS, V80, P24; *OFF TECHN ASS, 1990, OTAH405; Office of Technology Assessment, 1990, UNC CANC TREATM; PIOCOCK SJ, 1983, CLIN TRIALS PRACTICA; QUANJER PH, 1983, B EUR PHYSIOPATH RES, V19, P1; REILLY D, 1994, LANCET, V344, P1601, DOI 10.1016/S0140-6736(94)90407-3; REILLY DT, 1986, LANCET, V2, P881; Taylor MA, 2000, BMJ-BRIT MED J, V321, P471, DOI 10.1136/bmj.321.7259.471; WATSON D, 1988, J PERS SOC PSYCHOL, V54, P1020, DOI 10.1037/0022-3514.54.6.1020; WATSON D, 1985, PSYCHOL BULL, V98, P219, DOI 10.1037/0033-2909.98.2.219; WATSON D, 1988, J PERS SOC PSYCHOL, V54, P1063, DOI 10.1037/0022-3514.54.6.1063; WATT J, 1988, TALKING HLTH CONVENN; *WORK PART EUR COM, 1983, B EUR PHYSIOPATHO S5, V19, P1; 2001, BMJ, V322, P169	31	67	68	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	MAR 2	2002	324	7336					520	523		10.1136/bmj.324.7336.520	http://dx.doi.org/10.1136/bmj.324.7336.520			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	528DT	11872551	Green Published, Bronze			2023-01-03	WOS:000174229700021
J	Lo, B; Ruston, D; Kates, LW; Arnold, RM; Cohen, CB; Faber-Langendoen, K; Pantilat, SZ; Puchalski, CM; Quill, TR; Rabow, MW; Schreiber, S; Sulmasy, DP; Tulsky, JA				Lo, B; Ruston, D; Kates, LW; Arnold, RM; Cohen, CB; Faber-Langendoen, K; Pantilat, SZ; Puchalski, CM; Quill, TR; Rabow, MW; Schreiber, S; Sulmasy, DP; Tulsky, JA		Working Grp Religious Spiritual Is	Discussing religious and spiritual issues at the end of life - A practical guide for physicians	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							FAMILY MEDICINE; CARE; ATTITUDES; BELIEFS; ETHICS; INTERVIEW; CANCER; PRAYER; ILL; ME	As patients near the end of life, their spiritual and religious concerns may be awakened or intensified. Many physicians, however, feel unskilled and uncomfortable discussing these concerns. This article suggests how physicians might respond when patients or families raise such concerns. First, some patients may explicitly base decisions about life-sustaining interventions on their spiritual or religious beliefs. Physicians need to explore those beliefs to help patients think through their preferences regarding specific interventions. Second, other patients may not bring up spiritual or religious concerns but are troubled by them. Physicians should identify such concerns and listen to them empathetically, without trying to alleviate the patient's spiritual suffering or offering premature reassurance. Third, some patients or families may have religious reasons for insisting on life-sustaining interventions that physicians advise against. The physician should listen and try to understand the patient's viewpoint. Listening respectfully does not require the physician to agree with the patient or misrepresent his or her own views. Patients and families who feel that the physician understands them and cares about them may be more willing to consider the physician's views on prognosis and treatment. By responding to patients' spiritual and religious concerns and needs, physicians may help them find comfort and closure near the end of life.	Univ Calif San Francisco, Div Gen Internal Med, Program Med Eth, San Francisco, CA 94143 USA; Univ Pittsburgh, Sch Med, Ctr Bioeth & Hlth Law, Div Gen Internal Med, Pittsburgh, PA USA; Georgetown Univ, Kennedy Inst Eth, Washington, DC 20057 USA; SUNY Upstate Med Univ, Ctr Bioeth & Humanities, Syracuse, NY USA; George Washington Univ, Sch Med, Inst Spiritual & Hlth, Div Aging Studies, St Louis, MO USA; Univ Rochester, Sch Med, Dept Med, Program Biopsychol Studies, Rochester, NY USA; Hackensack Univ Med Ctr, Hackensack, NJ USA; New York Med Coll, Bioeth Inst, St Vincents Manhattan, John J Conley Dept Eth, New York, NY USA; Duke Univ, Dept Med, Program Med Encounter & Palliat Care, Durham, NC USA	University of California System; University of California San Francisco; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Georgetown University; State University of New York (SUNY) System; State University of New York (SUNY) Upstate Medical Center; George Washington University; University of Rochester; Hackensack University Medical Center; New York Medical College; Duke University	Lo, B (corresponding author), Room C 126,521 Parnassus Ave, San Francisco, CA 94143 USA.	bernie@medicine.ucsf.edu						*ASS CLIN PAST ED, 2001, OBJ CLIN PAST ED; Astrow AB, 2001, AM J MED, V110, P283; Baile WF, 1999, ONCOLOGY-NY, V13, P1021; BERNARDIN JC, 1998, GIFT PEACE PERSONAL; Byock I, 1997, DYING WELL PROSPECT; Clinebell H.J., 1984, BASIC TYPES PASTORAL; Cohen CB, 2000, HASTINGS CENT REP, V30, P40, DOI 10.2307/3528046; Cohen CB, 2001, HASTINGS CENT REP, V31, P29, DOI 10.2307/3527702; Coulehan JL, 2001, ANN INTERN MED, V135, P221, DOI 10.7326/0003-4819-135-3-200108070-00022; DAALEMAN TP, 1994, J FAM PRACTICE, V39, P564; Ehman JW, 1999, ARCH INTERN MED, V159, P1803, DOI 10.1001/archinte.159.15.1803; Ellis MR, 1999, J FAM PRACTICE, V48, P105; Emanuel EJ, 2000, ANN INTERN MED, V132, P451, DOI 10.7326/0003-4819-132-6-200003210-00005; Faber-Langendoen K, 2000, ANN INTERN MED, V132, P482, DOI 10.7326/0003-4819-132-6-200003210-00010; KING DE, 1994, J FAM PRACTICE, V39, P349; Levinson W, 2000, JAMA-J AM MED ASSOC, V284, P1021, DOI 10.1001/jama.284.8.1021; Lo B, 1999, ANN INTERN MED, V130, P744, DOI 10.7326/0003-4819-130-9-199905040-00015; LO B, 2000, RESOLVING ETHICAL DI, P128; Maguire P, 1996, EUR J CANCER, V32A, P78, DOI 10.1016/0959-8049(95)00527-7; Maguire P., 2000, COMMUNICATION SKILLS; Matthews DA, 1998, ARCH FAM MED, V7, P118, DOI 10.1001/archfami.7.2.118; *N CUMM FDN, 1997, SPIR BELI DYING PROC; Oyama O, 1998, ARCH FAM MED, V7, P431, DOI 10.1001/archfami.7.5.431; Platt FW, 2001, ANN INTERN MED, V134, P1079, DOI 10.7326/0003-4819-134-11-200106050-00020; Post SG, 2000, ANN INTERN MED, V132, P578, DOI 10.7326/0003-4819-132-7-200004040-00010; Prendergast TJ, 1997, AM J RESP CRIT CARE, V155, P15, DOI 10.1164/ajrccm.155.1.9001282; Puchalski C, 2000, J Palliat Med, V3, P129, DOI 10.1089/jpm.2000.3.129; Puchalski C., 1999, SUPPORT VOICE, V5, P12; Puchalski CM, 1999, SPIRITUAL LIFE, V45, P154; QUINN TE, 2001, ANN INTERN MED, V135, P51; Rabow MW, 1999, WESTERN J MED, V171, P260; Roter DL, 2000, ARCH INTERN MED, V160, P3477, DOI 10.1001/archinte.160.22.3477; Rushton C H, 1996, Pediatr Nurs, V22, P64; Savulescu J, 1998, J MED ETHICS, V24, P382, DOI 10.1136/jme.24.6.382; Singer PA, 1998, ARCH INTERN MED, V158, P879, DOI 10.1001/archinte.158.8.879; Sloan RP, 2000, NEW ENGL J MED, V342, P1913, DOI 10.1056/NEJM200006223422513; Sloan RP, 1999, LANCET, V353, P664, DOI 10.1016/S0140-6736(98)07376-0; Speck P., 1998, OXFORD TXB PALLIATIV, P805; Steinhauser AE, 2000, JAMA-J AM MED ASSOC, V284, P2476, DOI 10.1001/jama.284.19.2476; STONE D, 1999, DIFFICULT CONSERVATI; Suchman AL, 1997, JAMA-J AM MED ASSOC, V277, P678, DOI 10.1001/jama.277.8.678; Sulmasy DP., 1997, HEALERS CALLING SPIR; Taylor EJ, 1999, PSYCHO-ONCOLOGY, V8, P386; TULSKY JA, 1995, J GEN INTERN MED, V10, P436, DOI 10.1007/BF02599915; Tulsky JA, 1998, ANN INTERN MED, V129, P441, DOI 10.7326/0003-4819-129-6-199809150-00003	45	198	201	0	18	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 13	2002	287	6					749	754		10.1001/jama.287.6.749	http://dx.doi.org/10.1001/jama.287.6.749			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	520XR	11851542				2023-01-03	WOS:000173809500032
J	Castaneda, C; Gordon, PL; Uhlin, KL; Levey, AS; Kehayias, JJ; Dwyer, JT; Fielding, RA; Roubenoff, R; Singh, MF				Castaneda, C; Gordon, PL; Uhlin, KL; Levey, AS; Kehayias, JJ; Dwyer, JT; Fielding, RA; Roubenoff, R; Singh, MF			Resistance training to counteract the catabolism of a low-protein diet in patients with chronic renal insufficiency - A randomized, controlled trial	ANNALS OF INTERNAL MEDICINE			English	Article							SKELETAL-MUSCLE; NUTRITIONAL-STATUS; BODY-COMPOSITION; ELDERLY-WOMEN; WEIGHT-LOSS; FAILURE; EXERCISE; DISEASE; RESTRICTION; PROGRESSION	Background: Chronic renal insufficiency leads to muscle wasting, which may be exacerbated by low-protein diets prescribed to delay disease progression. Resistance training increases protein utilization and muscle mass. Objective: To determine the efficacy of resistance training in improving protein utilization and muscle mass in patients with chronic renal insufficiency treated with a low-protein diet. Design: Randomized, controlled trial. Setting: Tufts University, Boston, Massachusetts. Patients: 26 older patients with moderate renal insufficiency (17 men, 9 women) who had achieved stabilization on a low-protein diet. Intervention: During a run-in period of 2 to 8 weeks, patients were instructed and their adherence to the low-protein diet (0.6 g/kg of body weight per day) was evaluated. They were randomly assigned to a low-protein diet plus resistance training (n = 14) or a low-protein diet alone (n = 12) for 12 weeks. Measurements: Total body potassium, mid-thigh muscle area, type I and II muscle-fiber cross-sectional area, and protein turnover. Results: Mean protein intake was 0.64 +/- 0.07 g/kg per day after stabilization. Total body potassium and type I and II muscle-fiber cross-sectional areas increased in patients who performed resistance training by a mean (+/- SD) of 4% +/- 8%, 24% +/- 31%, and 22% +/- 29%, respectively, compared with those who did not. Leucine oxidation and serum prealbumin levels also improved significantly. Patients assigned to resistance training maintained body weight compared with those who were not. Improvement in muscle strength was significantly greater with resistance training (32% +/- 14%) than without (-13% +/- 20%) (P < 0.001). Conclusion: By improving muscle mass, nutritional status, and function, resistance training seems to be effective against the catabolism of a low-protein diet and uremia in patients with renal failure.	Tufts Univ, New England Med Ctr, Boston, MA 02111 USA; Boston Univ, Sargent Coll Hlth & Rehabil Sci, Boston, MA 02215 USA; Univ Sydney, Lidcombe, NSW, Australia	Tufts Medical Center; Tufts University; Boston University; University of Sydney	Castaneda, C (corresponding author), Tufts Univ, USDA, Human Nutr Res Ctr Aging, 711 Washington St, Boston, MA 02111 USA.	ccastaneda@hnrc.tufts.edu	Dwyer, Johanna/AAI-5027-2020	Dwyer, Johanna/0000-0002-0783-1769; Roubenoff, Ronenn/0000-0002-3959-3179	NATIONAL INSTITUTE ON AGING [R01AG013457] Funding Source: NIH RePORTER; NIA NIH HHS [R01 AG13457] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Balady GJ, 1998, MED SCI SPORT EXER, V30, P1009; Ballor DL, 1996, METABOLISM, V45, P179, DOI 10.1016/S0026-0495(96)90050-5; BLUMENKRANTZ MJ, 1980, AM J CLIN NUTR, V33, P1567, DOI 10.1093/ajcn/33.7.1567; Boyce ML, 1997, AM J KIDNEY DIS, V30, P180, DOI 10.1016/S0272-6386(97)90051-2; Braith RW, 1996, J AM COLL CARDIOL, V28, P1471, DOI 10.1016/S0735-1097(96)00347-6; CAMPBELL WW, 1995, AM J PHYSIOL-ENDOC M, V268, pE1143, DOI 10.1152/ajpendo.1995.268.6.E1143; Cappy C S, 1999, J Ren Nutr, V9, P63; Castaneda C, 1998, J Ren Nutr, V8, P2, DOI 10.1016/S1051-2276(98)90031-0; Castaneda C, 2000, J Nutr Health Aging, V4, P85; CASTANEDA C, 1995, AM J CLIN NUTR, V62, P30, DOI 10.1093/ajcn/62.1.30; CORTI MC, 1994, JAMA-J AM MED ASSOC, V272, P1036, DOI 10.1001/jama.272.13.1036; DOLECEK TA, 1995, J AM DIET ASSOC, V95, P1307, DOI 10.1016/S0002-8223(95)00342-8; ERICSSON F, 1983, NEPHRON, V33, P173, DOI 10.1159/000182937; Evans WJ, 1998, SEMIN ONCOL, V25, P112; FIATARONE MA, 1990, JAMA-J AM MED ASSOC, V263, P3029, DOI 10.1001/jama.263.22.3029; FIATARONE MA, 1994, NEW ENGL J MED, V330, P1769, DOI 10.1056/NEJM199406233302501; FIATARONE MA, 1993, J GERONTOL, V48, P77, DOI 10.1093/geronj/48.Special_Issue.77; FISHER KD, 1985, AM J CLIN NUTR, V42, P1318; Foldvari M, 2000, J GERONTOL A-BIOL, V55, pM192, DOI 10.1093/gerona/55.4.M192; Guarnieri G, 1997, KIDNEY INT, V52, pS41; GUARNIERI GF, 1989, KIDNEY INT, V36, pS195; Kasiske BL, 1998, AM J KIDNEY DIS, V31, P954, DOI 10.1053/ajkd.1998.v31.pm9631839; Kehayias JJ, 1997, AM J CLIN NUTR, V66, P904, DOI 10.1093/ajcn/66.4.904; Kopple JD, 1997, KIDNEY INT, V52, P778, DOI 10.1038/ki.1997.395; Kopple JD, 1999, J NUTR, V129, p247S, DOI 10.1093/jn/129.1.247S; KOPPLE JD, 1986, KIDNEY INT, V29, P734, DOI 10.1038/ki.1986.59; Levey AS, 1999, J AM SOC NEPHROL, V10, P2426; LEVEY AS, 1993, J AM SOC NEPHROL, V4, P1159; LOWRIE EG, 1990, AM J KIDNEY DIS, V15, P458, DOI 10.1016/S0272-6386(12)70364-5; MARONI BJ, 1985, KIDNEY INT, V27, P58, DOI 10.1038/ki.1985.10; Maroni BJ, 1997, ANNU REV NUTR, V17, P435, DOI 10.1146/annurev.nutr.17.1.435; MATTHEWS DE, 1980, AM J PHYSIOL, V238, pE473, DOI 10.1152/ajpendo.1980.238.5.E473; PAINTER P, 1994, AM J KIDNEY DIS, V24, pS2; Pedrini MT, 1996, ANN INTERN MED, V124, P627, DOI 10.7326/0003-4819-124-7-199604010-00002; Pu CT, 2001, J APPL PHYSIOL, V90, P2341, DOI 10.1152/jappl.2001.90.6.2341; Rall LC, 1996, ARTHRITIS RHEUM, V39, P1115, DOI 10.1002/art.1780390707; RALL LC, 1995, NUTR ASSESSMENT ELDE, P1; Remuzzi G, 1997, KIDNEY INT, V51, P2, DOI 10.1038/ki.1997.2; Roubenoff R, 1997, AM J CLIN NUTR, V66, P192, DOI 10.1093/ajcn/66.1.192; Singh MAF, 1999, AM J PHYSIOL-ENDOC M, V277, pE135; SNETSELAAR L, 1994, J AM DIET ASSOC, V94, P986, DOI 10.1016/0002-8223(94)92190-3; WEIR JBD, 1949, J PHYSIOL-LONDON, V109, P1, DOI 10.1113/jphysiol.1949.sp004363; YOUNG VR, 1990, AM J CLIN NUTR, V51, P270, DOI 10.1093/ajcn/51.2.270	43	165	167	0	12	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	DEC 4	2001	135	11					965	976		10.7326/0003-4819-135-11-200112040-00008	http://dx.doi.org/10.7326/0003-4819-135-11-200112040-00008			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	498PN	11730397				2023-01-03	WOS:000172520000003
J	McNamee, D; Sharp, D				McNamee, D; Sharp, D			New drug classes 2001	LANCET			English	Editorial Material									Lancet, London WC1X 8RR, England		McNamee, D (corresponding author), Lancet, London WC1X 8RR, England.								0	0	0	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	NOV 3	2001	358	9292					1478	1478		10.1016/S0140-6736(01)06572-2	http://dx.doi.org/10.1016/S0140-6736(01)06572-2			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	490MN	11705558				2023-01-03	WOS:000172055800008
J	Ades, PA				Ades, PA			Medical progress: Cardiac rehabilitation and secondary prevention of coronary heart disease.	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							ACUTE MYOCARDIAL-INFARCTION; RISK-FACTOR MODIFICATION; QUALITY-OF-LIFE; CONTROLLED-TRIAL; ARTERY-DISEASE; WEIGHT-LOSS; FUNCTIONAL-CAPACITY; SMOKING-CESSATION; EXERCISE THERAPY; OLDER		Fletcher Allen Hlth Care, Burlington, VT 05401 USA; Univ Vermont, Coll Med, Dept Med, Div Cardiol, Burlington, VT 05405 USA	University of Vermont Medical Center; University of Vermont	Ades, PA (corresponding author), Fletcher Allen Hlth Care, McClure 1,MCHV Campus, Burlington, VT 05401 USA.	philip.ades@vtmednet.org			NATIONAL INSTITUTE ON AGING [R01AG015114] Funding Source: NIH RePORTER; NIA NIH HHS [R01 AG15114-03] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Ades P A, 1997, J Cardiopulm Rehabil, V17, P222, DOI 10.1097/00008483-199707000-00002; Ades P A, 1999, J Cardiopulm Rehabil, V19, P255, DOI 10.1097/00008483-199907000-00007; Ades PA, 1999, J AM GERIATR SOC, V47, P98, DOI 10.1111/j.1532-5415.1999.tb01909.x; ADES PA, 1992, AM J CARDIOL, V69, P1422, DOI 10.1016/0002-9149(92)90894-5; Ades PA, 1996, CIRCULATION, V94, P323, DOI 10.1161/01.CIR.94.3.323; ADES PA, 1992, ARCH INTERN MED, V152, P1033, DOI 10.1001/archinte.152.5.1033; Ades PA, 1999, ARCH INTERN MED, V159, P2357, DOI 10.1001/archinte.159.19.2357; Ades PA, 1996, ANN INTERN MED, V124, P568, DOI 10.7326/0003-4819-124-6-199603150-00005; Ades PA, 2000, AM HEART J, V139, P543, DOI 10.1016/S0002-8703(00)90100-5; ADES PA, 1989, AM J CARDIOL, V63, P1032, DOI 10.1016/0002-9149(89)90073-8; ADES PA, 1995, J GERONTOL A-BIOL, V50, pM7, DOI 10.1093/gerona/50A.1.M7; ADES PA, 1990, AM HEART J, V120, P585, DOI 10.1016/0002-8703(90)90015-P; *AM HEART ASS, 1999, HEART STROK FACTS; Appel LJ, 1997, NEW ENGL J MED, V336, P1117, DOI 10.1056/NEJM199704173361601; Balady GJ, 2000, CIRCULATION, V102, P1069, DOI 10.1161/01.CIR.102.9.1069; Belardinelli R, 1999, CIRCULATION, V99, P1173, DOI 10.1161/01.CIR.99.9.1173; BLANKENHORN DH, 1988, JAMA-J AM MED ASSOC, V259, P2698; Bramlet DA, 1997, AM J CARDIOL, V80, pH39, DOI 10.1016/S0002-9149(97)00819-9; Brochu M, 2000, J Cardiopulm Rehabil, V20, P96, DOI 10.1097/00008483-200003000-00003; Brochu M, 2000, J Cardiopulm Rehabil, V20, P180, DOI 10.1097/00008483-200005000-00006; BROWN G, 1990, NEW ENGL J MED, V323, P1289, DOI 10.1056/NEJM199011083231901; Burke LE, 1997, ANN BEHAV MED, V19, P239, DOI 10.1007/BF02892289; CallesEscandon J, 1996, AM J CLIN NUTR, V64, P7, DOI 10.1093/ajcn/64.1.7; CANNISTRA LB, 1995, AM J CARDIOL, V75, P890, DOI 10.1016/S0002-9149(99)80682-1; Carlson JJ, 2000, AM J CARDIOL, V86, P17, DOI 10.1016/S0002-9149(00)00822-5; CHIRIKOS TN, 1986, SOC SCI MED, V22, P1329, DOI 10.1016/0277-9536(86)90096-1; Cleeman JI, 2001, JAMA-J AM MED ASSOC, V285, P2486, DOI 10.1001/jama.285.19.2486; COATS AJS, 1992, CIRCULATION, V85, P2119, DOI 10.1161/01.CIR.85.6.2119; DEBUSK RF, 1994, ANN INTERN MED, V120, P721, DOI 10.7326/0003-4819-120-9-199405010-00001; DENNIS C, 1988, JAMA-J AM MED ASSOC, V260, P214, DOI 10.1001/jama.260.2.214; DUNBAR-JACOB J, 1991, Annals of Behavioral Medicine, V13, P31; Dylewicz P, 2000, CHEST, V117, P47, DOI 10.1378/chest.117.1.47; EHSANI AA, 1986, CIRCULATION, V74, P938; Evenson K R, 1998, J Cardiopulm Rehabil, V18, P192, DOI 10.1097/00008483-199805000-00002; FOREYT JP, 1993, ANN INTERN MED, V119, P698, DOI 10.7326/0003-4819-119-7_Part_2-199310011-00014; Fragnoli-Munn K, 1998, J Cardiopulm Rehabil, V18, P416, DOI 10.1097/00008483-199811000-00003; Franklin BA, 1998, CHEST, V114, P902, DOI 10.1378/chest.114.3.902; Frasure-Smith N, 2000, CIRCULATION, V101, P1919, DOI 10.1161/01.CIR.101.16.1919; Friedman DB, 1997, AM J CARDIOL, V79, P281, DOI 10.1016/S0002-9149(96)00748-5; Gordon NF, 1997, AM J CARDIOL, V80, pH69, DOI 10.1016/S0002-9149(97)00825-4; HAGBERG JM, 1991, MED SCI SPORT EXER, V23, P661; Hambrecht R, 2000, NEW ENGL J MED, V342, P454, DOI 10.1056/NEJM200002173420702; HAMBRECHT R, 1995, J AM COLL CARDIOL, V25, P1239, DOI 10.1016/0735-1097(94)00568-B; Harvey-Berino J, 1998, CORONARY ARTERY DIS, V9, P795, DOI 10.1097/00019501-199809120-00003; HASKELL WL, 1994, CIRCULATION, V89, P975, DOI 10.1161/01.CIR.89.3.975; HELLERSTEIN HK, 1968, B NEW YORK ACAD MED, V44, P1028; KATZEL LI, 1995, METABOLISM, V44, P307, DOI 10.1016/0026-0495(95)90159-0; Kaufmann P, 1997, EUR HEART J, V18, P1853; KAVANAGH T, 1973, MED SCI SPORT EXER, V5, P34; Keteyian SJ, 1996, ANN INTERN MED, V124, P1051, DOI 10.7326/0003-4819-124-12-199606150-00004; Kobashigawa JA, 1999, NEW ENGL J MED, V340, P976; Kokkinos PF, 2000, CORONARY ARTERY DIS, V11, P99, DOI 10.1097/00019501-200003000-00002; KONSTAM M, 1994, AHCPR PUBLICATION; KRUSE WHH, 1991, PATIENT COMPLIANCE M, P175; LAPLANTE MP, 1989, DATA DISABILITY NATL; LAVIE CJ, 1993, J AM COLL CARDIOL, V22, P678, DOI 10.1016/0735-1097(93)90176-2; Lavie CJ, 1996, CHEST, V109, P52, DOI 10.1378/chest.109.1.52; Lee JY, 1996, MED SCI SPORT EXER, V28, P47, DOI 10.1097/00005768-199601000-00013; LEVIN LA, 1991, J INTERN MED, V230, P427, DOI 10.1111/j.1365-2796.1991.tb00468.x; Linden W, 1996, ARCH INTERN MED, V156, P2302; Malfatto G, 1998, AM J CARDIOL, V81, P834, DOI 10.1016/S0002-9149(98)00021-6; McBride P, 1998, ARCH INTERN MED, V158, P1238, DOI 10.1001/archinte.158.11.1238; MENDOZA SG, 1991, METABOLISM, V40, P368, DOI 10.1016/0026-0495(91)90147-O; Mertens DJ, 1998, J SPORT MED PHYS FIT, V38, P310; MILLER NH, 1984, CIRCULATION, V70, P645, DOI 10.1161/01.CIR.70.4.645; NEILL WA, 1985, ARCH INTERN MED, V145, P1642, DOI 10.1001/archinte.145.9.1642; Newby LK, 2000, NEW ENGL J MED, V342, P749, DOI 10.1056/NEJM200003163421101; Niebauer J, 1997, CIRCULATION, V96, P2534, DOI 10.1161/01.CIR.96.8.2534; OCONNOR GT, 1989, CIRCULATION, V80, P234, DOI 10.1161/01.CIR.80.2.234; OLDRIDGE N, 1993, AM J CARDIOL, V72, P154, DOI 10.1016/0002-9149(93)90152-3; OLDRIDGE N, 1991, AM J CARDIOL, V67, P1084, DOI 10.1016/0002-9149(91)90870-Q; Oldridge N. B., 1984, J CARDIAC REHABIL, V4, P166; OLDRIDGE NB, 1988, JAMA-J AM MED ASSOC, V260, P945, DOI 10.1001/jama.260.7.945; Oldridge NB, 1983, J CARDIAC REHABIL, V3, P257; ORNISH D, 1990, LANCET, V336, P129, DOI 10.1016/0140-6736(90)91656-U; Ornish D, 1999, JAMA-J AM MED ASSOC, V281, P1380; PASHKOW FJ, 1993, J AM COLL CARDIOL, V21, P822, DOI 10.1016/0735-1097(93)90116-I; PEDERSEN TR, 1994, LANCET, V344, P1383; PINSKY JL, 1990, AM J PUBLIC HEALTH, V80, P1363, DOI 10.2105/AJPH.80.11.1363; REDWOOD DR, 1972, NEW ENGL J MED, V286, P959, DOI 10.1056/NEJM197205042861801; ROSENMAN RH, 1975, JAMA-J AM MED ASSOC, V233, P872, DOI 10.1001/jama.233.8.872; ROSSOUW JE, 1990, NEW ENGL J MED, V323, P1112, DOI 10.1056/NEJM199010183231606; Rubins HB, 1999, NEW ENGL J MED, V341, P410, DOI 10.1056/NEJM199908053410604; Ruderman N., 1995, HLTH PROFESSIONALS G; Ruzumna P, 1996, CURR OPIN CARDIOL, V11, P269, DOI 10.1097/00001573-199605000-00007; Sacks FM, 1996, NEW ENGL J MED, V335, P1001, DOI 10.1056/NEJM199610033351401; Salomaa V, 2000, CIRCULATION, V101, P1913, DOI 10.1161/01.CIR.101.16.1913; Savage PD, 2000, AM HEART J, V140, P527, DOI 10.1067/mhj.2000.109219; Schachinger V, 2000, CIRCULATION, V101, P1899, DOI 10.1161/01.CIR.101.16.1899; Schairer J R, 1998, J Cardiopulm Rehabil, V18, P290, DOI 10.1097/00008483-199807000-00006; SCHULER G, 1992, CIRCULATION, V86, P1, DOI 10.1161/01.CIR.86.1.1; SINGH RB, 1992, BRIT MED J, V304, P1015, DOI 10.1136/bmj.304.6833.1015; SMITH SC, 1995, CIRCULATION, V92, P2; STEVENSON LW, 1995, J AM COLL CARDIOL, V25, P163, DOI 10.1016/0735-1097(94)00357-V; STRATTON JR, 1991, CIRCULATION, V83, P1692, DOI 10.1161/01.CIR.83.5.1692; Sueta, 1999, AM J CARDIOL, V84, P1143; Sueta CA, 1999, AM J CARDIOL, V83, P1303, DOI 10.1016/S0002-9149(99)00117-4; SUZUKI T, 1992, CLIN CARDIOL, V15, P358, DOI 10.1002/clc.4960150510; TAYLOR CB, 1990, ANN INTERN MED, V113, P118, DOI 10.7326/0003-4819-113-2-118; Thomas R J, 1996, J Cardiopulm Rehabil, V16, P402, DOI 10.1097/00008483-199611000-00010; Tremblay A, 1999, OBES RES, V7, P556, DOI 10.1002/j.1550-8528.1999.tb00714.x; VANCAMP SP, 1986, JAMA-J AM MED ASSOC, V256, P1160, DOI 10.1001/jama.256.9.1160; VONGVANICH P, 1996, J CARDIOPULM REHABIL, V16, P23; Wannamethee SG, 2000, CIRCULATION, V102, P1358, DOI 10.1161/01.CIR.102.12.1358; WARNER JG, 1995, CIRCULATION, V92, P773, DOI 10.1161/01.CIR.92.4.773; WENGER NK, 1973, JAMA-J AM MED ASSOC, V224, P511, DOI 10.1001/jama.224.4.511; Wenger NK, 1995, AHCPR PUBLICATION; WILHELMSSON C, 1975, LANCET, V1, P416; WILLIAMS MA, 1985, AM J CARDIOL, V55, P263, DOI 10.1016/0002-9149(85)90357-1; Wilson K, 2000, ARCH INTERN MED, V160, P939, DOI 10.1001/archinte.160.7.939	110	502	525	0	34	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	SEP 20	2001	345	12					892	902		10.1056/NEJMra001529	http://dx.doi.org/10.1056/NEJMra001529			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	473JW	11565523				2023-01-03	WOS:000171039600007
J	Kearon, C; Ginsberg, JS; Douketis, J; Crowther, M; Brill-Edwards, P; Weitz, JI; Hirsh, J				Kearon, C; Ginsberg, JS; Douketis, J; Crowther, M; Brill-Edwards, P; Weitz, JI; Hirsh, J			Management of suspected deep venous thrombosis in outpatients by using clinical assessment and D-dimer testing	ANNALS OF INTERNAL MEDICINE			English	Article							WHOLE-BLOOD ASSAY; SIMPLIRED-D-DIMER; VEIN THROMBOSIS; PULMONARY-EMBOLISM; NONINVASIVE DIAGNOSIS; THROMBOEMBOLISM; SCORE; MODEL	Background: When deep venous thrombosis is suspected, objective testing is required to confirm or refute the diagnosis. Objective: To determine whether the combination of a low clinical suspicion and a normal D-dimer result rules out deep venous thrombosis. Design: Prospective cohort study. Setting: Three tertiary care hospitals in Canada. Patients: 445 outpatients with a suspected first episode of deep venous thrombosis. Interventions: Patients were categorized as having low, moderate, or high pretest probability of thrombosis and underwent whole-blood D-dimer testing. Patients with a low pretest probability and a negative result on the D-dimer test had no further diagnostic testing and received no anticoagulant therapy. Additional diagnostic testing was done in all other patients. Measurements: Venous thromboembolic events during 3-month follow-up. Results: 177 (40%) patients had both a low pretest probability and a negative D-dimer result. One of these patients had deep venous thrombosis during follow-up (negative predictive value, 99.4% [95% CI, 96.9% to 100%]). Conclusion: The combination of a low pretest probability of deep venous thrombosis and a negative result on a whole-blood D-dimer test rules out deep venous thrombosis in a large proportion of symptomatic outpatients.	Hamilton Civ Hosp, Res Ctr, Hamilton, ON, Canada; McMaster Univ, Hamilton, ON L8S 4L8, Canada	McMaster University; McMaster University	Kearon, C (corresponding author), McMaster Univ, Henderson Gen Hosp, Room 401,711 Concess St, Hamilton, ON L8V 1C3, Canada.		Weitz, Jeffrey/AAD-1929-2019; Douketis, James/AAO-5659-2021; ginsberg, jeffrey s/ABC-1065-2020	Weitz, Jeffrey/0000-0002-1092-7550; 				Anand SS, 1998, JAMA-J AM MED ASSOC, V279, P1094, DOI 10.1001/jama.279.14.1094; Becker DM, 1996, ARCH INTERN MED, V156, P939, DOI 10.1001/archinte.156.9.939; Bigaroni A, 2000, THROMB HAEMOSTASIS, V83, P788, DOI 10.1055/s-0037-1613912; BOUNAMEAUX H, 1994, THROMB HAEMOSTASIS, V71, P1; Ginsberg JS, 1997, ARCH INTERN MED, V157, P1077, DOI 10.1001/archinte.157.10.1077; Ginsberg JS, 1998, ANN INTERN MED, V129, P1006, DOI 10.7326/0003-4819-129-12-199812150-00003; JOHN MA, 1990, THROMB RES, V58, P273, DOI 10.1016/0049-3848(90)90097-V; Kearon C, 1998, ANN INTERN MED, V128, P663, DOI 10.7326/0003-4819-128-8-199804150-00011; KEARON C, 1995, HAEMOSTASIS, V25, P72; Lee AYY, 1998, BAILLIERE CLIN HAEM, V11, P587, DOI 10.1016/S0950-3536(98)80084-X; Miron MJ, 2000, J INTERN MED, V247, P249, DOI 10.1046/j.1365-2796.2000.00605.x; Perrier A, 1999, LANCET, V353, P190, DOI 10.1016/S0140-6736(98)05248-9; van der Graaf F, 2000, THROMB HAEMOSTASIS, V83, P191; Wells PS, 1998, J INTERN MED, V243, P15; Wells PS, 1998, ANN INTERN MED, V129, P997, DOI 10.7326/0003-4819-129-12-199812150-00002; WELLS PS, 1995, LANCET, V345, P1326, DOI 10.1016/S0140-6736(95)92535-X; WELLS PS, 1995, CIRCULATION, V91, P2184, DOI 10.1161/01.CIR.91.8.2184; Wells PS, 1998, LANCET, V351, P1405, DOI 10.1016/S0140-6736(05)79444-7	18	149	155	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUL 17	2001	135	2					108	111		10.7326/0003-4819-135-2-200107170-00011	http://dx.doi.org/10.7326/0003-4819-135-2-200107170-00011			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	452DR	11453710				2023-01-03	WOS:000169842300004
J	Grodstein, F; Manson, JE; Stampfer, MJ				Grodstein, F; Manson, JE; Stampfer, MJ			Postmenopausal hormone use and secondary prevention of coronary events in the nurses' health study - A prospective, observational study	ANNALS OF INTERNAL MEDICINE			English	Article							ESTROGEN REPLACEMENT THERAPY; ARTERY-DISEASE; HEART-DISEASE; WOMEN; RISK; REPRODUCIBILITY; PROGESTIN; MORTALITY; VALIDITY; TRIAL	Background: The Heart and Estrogen/progestin Replacement Study (HERS) was the first randomized clinical trial of combined hormone therapy and secondary prevention of coronary events. The trial had overall null results but reported an unexpected increased risk for recurrent events in the initial year, followed by a decrease during the final years. Objective: To provide additional data on a time trend in risk for recurrent heart disease. Design: A prospective, observational cohort study of secondary prevention of coronary heart disease. Setting: Nurses' Health Study. Patients: 2489 postmenopausal women with previous myocardial infarction or documented atherosclerosis; 213 cases of recurrent nonfatal myocardial infarction or coronary death were identified from 1976 through 1996. Measurements: Information on hormone status and on recurrent disease was collected by using biennial questionnaires. Multi-variable-adjusted relative risks and 95% CIs were calculated from logistic regression models. Results: A trend of decreasing risk for recurrent major coronary heart disease events with increasing duration of hormone use was observed (P for trend = 0.002). For short-term current users, the multivariate-adjusted relative risk for major coronary heart disease was 1.25 (95% CI, 0.78 to 2.00) compared with never-users. However, after longer-term hormone use, the rate of second events was lower in current users than in never-users (relative risk, 0.38 [CI, 0.22 to 0.66]). No clear differences emerged between users of estrogen alone and users of estrogen combined with progestin. Overall, with up to 20 years of follow-up, the relative risk for a second event among current users of hormone therapy was 0.65 (CI, 0.45 to 0.95) compared with never-users. Conclusions: The risk for recurrent major coronary events seems to increase among short-term hormone users with previous coronary disease but to decrease with longer-term use.	Harvard Univ, Sch Med, Brigham & Womens Hosp, Channing Lab, Boston, MA 02115 USA; Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University; Harvard T.H. Chan School of Public Health	Grodstein, F (corresponding author), Harvard Univ, Sch Med, Brigham & Womens Hosp, Channing Lab, 181 Longwood Ave, Boston, MA 02115 USA.				NCI NIH HHS [CA40356] Funding Source: Medline; NHLBI NIH HHS [HL34594] Funding Source: Medline; NIA NIH HHS [AG13482] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA040356, R37CA040356] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL034594] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R29AG013482] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		BARRETTCONNOR E, 1991, ANN INTERN MED, V115, P455, DOI 10.7326/0003-4819-115-6-455; BUSH TL, 1987, CIRCULATION, V75, P1102, DOI 10.1161/01.CIR.75.6.1102; COLDITZ GA, 1987, AM J EPIDEMIOL, V126, P319, DOI 10.1093/aje/126.2.319; CUPPLES LA, 1988, STAT MED, V7, P205, DOI 10.1002/sim.4780070122; Cushman M, 1999, CIRCULATION, V100, P717, DOI 10.1161/01.CIR.100.7.717; DAGOSTINO RB, 1990, STAT MED, V9, P1501, DOI 10.1002/sim.4780091214; Daly E, 1996, LANCET, V348, P977, DOI 10.1016/S0140-6736(96)07113-9; GREENLAND S, 1985, AM J EPIDEMIOL, V122, P495, DOI 10.1093/oxfordjournals.aje.a114131; GRODSTEIN F, 1994, OBSTET GYNECOL, V83, P5; GRODSTEIN F, 1995, PROG CARDIOVASC DIS, V38, P199, DOI 10.1016/S0033-0620(95)80012-3; Grodstein F, 1996, NEW ENGL J MED, V335, P453, DOI 10.1056/NEJM199608153350701; Grodstein F, 1996, LANCET, V348, P983, DOI 10.1016/S0140-6736(96)07308-4; HENDERSON BE, 1991, ARCH INTERN MED, V151, P75, DOI 10.1001/archinte.151.1.75; Herrington DM, 2000, NEW ENGL J MED, V343, P522, DOI 10.1056/NEJM200008243430801; Herrington DM, 1999, ANN INTERN MED, V131, P463, DOI 10.7326/0003-4819-131-6-199909210-00012; Hodis HN, 2000, CIRCULATION, V102, P837; Hulley S, 1998, JAMA-J AM MED ASSOC, V280, P605, DOI 10.1001/jama.280.7.605; Khan MA, 2000, AM J CARDIOL, V86, P330, DOI 10.1016/S0002-9149(00)00926-7; KIM SC, 1995, CIRCULATION S1, V92, P674; Matthews KA, 1996, AM J EPIDEMIOL, V143, P971; NEWTON KM, 1997, AM J EPIDEMIOL, V145, P69; OKeefe JH, 1997, J AM COLL CARDIOL, V29, P1; *ORG WH, 1971, ID REG REP 5 WORK GR; Rimm E B, 1990, Epidemiology, V1, P466, DOI 10.1097/00001648-199011000-00009; ROSANO GMC, 1993, LANCET, V342, P133, DOI 10.1016/0140-6736(93)91343-K; Rothman K, 1986, MODERN EPIDEMIOLOGY; Rothman KJ, 1979, NIH PUBLICATION, V79-1649, P31; STAMPFER MJ, 1984, AM J EPIDEMIOL, V119, P837, DOI 10.1093/oxfordjournals.aje.a113804; SULLIVAN JM, 1990, ARCH INTERN MED, V150, P2557, DOI 10.1001/archinte.150.12.2557; SULLIVAN JM, 1994, J AM COLL CARDIOL, V23, pA49; WILLETT W, 1983, AM J EPIDEMIOL, V117, P651, DOI 10.1093/oxfordjournals.aje.a113598; WILLETT WC, 1985, AM J EPIDEMIOL, V122, P51, DOI 10.1093/oxfordjournals.aje.a114086	32	219	233	0	3	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUL 3	2001	135	1					1	8		10.7326/0003-4819-135-1-200107030-00003	http://dx.doi.org/10.7326/0003-4819-135-1-200107030-00003			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	449JC	11434726	Green Submitted, Green Published			2023-01-03	WOS:000169680500001
J	Manson, JE; Martin, KA				Manson, JE; Martin, KA			Postmenopausal hormone-replacement therapy.	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CORONARY-HEART-DISEASE; ESTROGEN REPLACEMENT; SECONDARY PREVENTION; COLORECTAL-CANCER; RISK; PROGESTIN; EVENTS	Patient 1 is a 52-year-old woman at average risk for breast cancer and osteoporosis who is having menopause-related hot flashes and disturbed sleep. atient 2 is a 58-year-old woman with osteopenia whose mother had breast cancer. atient 3 is a 65-year-old woman with a history of coronary revascularization and documented osteoporosis. Each wants to know whether hormone-replacement therapy is right for her.	Harvard Univ, Sch Med, Brigham & Womens Hosp, Div Prevent Med,Dept Med, Boston, MA 02215 USA; Harvard Univ, Massachusetts Gen Hosp, Sch Med, Reprod Endocrine Unit, Boston, MA USA	Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University; Harvard Medical School; Massachusetts General Hospital	Manson, JE (corresponding author), Harvard Univ, Sch Med, Brigham & Womens Hosp, Div Prevent Med,Dept Med, 900 Commonwealth Ave E, Boston, MA 02215 USA.	jmanson@rics.bwh.harvard.edu	Davis, Susan R/A-3111-2009	Davis, Susan R/0000-0002-2955-0415				*AM COLL OBST GYN, 1998, ACOG ED B, V247; Barrett-Connor E, 1998, BMJ-BRIT MED J, V317, P457; Barrett-Connor E, 1998, ANNU REV PUBL HEALTH, V19, P55, DOI 10.1146/annurev.publhealth.19.1.55; Beral V, 1997, LANCET, V350, P1047, DOI 10.1016/S0140-6736(97)08233-0; CHAE CU, 1999, CLIN TRIALS CARDIOVA, P399; Clarke S, 2000, EUR HEART J, V21, P212; Col NF, 1999, ARCH INTERN MED, V159, P1458, DOI 10.1001/archinte.159.13.1458; Ettinger B, 1999, JAMA-J AM MED ASSOC, V282, P2124; ETTINGER B, 1994, MENOPAUSE, V1, P19; Grady D, 2000, ANN INTERN MED, V132, P689, DOI 10.7326/0003-4819-132-9-200005020-00002; GRADY D, 1995, OBSTET GYNECOL, V85, P304, DOI 10.1016/0029-7844(94)00383-O; Grodstein F, 2000, J AM GERIATR SOC, V48, P746, DOI 10.1111/j.1532-5415.2000.tb04748.x; Grodstein F, 2000, ANN INTERN MED, V133, P933, DOI 10.7326/0003-4819-133-12-200012190-00008; Hemminki E, 1997, BRIT MED J, V315, P149, DOI 10.1136/bmj.315.7101.149; Herrington DM, 2000, NEW ENGL J MED, V343, P522, DOI 10.1056/NEJM200008243430801; Hulley S, 1998, JAMA-J AM MED ASSOC, V280, P605, DOI 10.1001/jama.280.7.605; *JAC I WOM HLTH EX, 2000, GUID COUNS WOM MAN M; Kanis J, 1998, OSTEOPOROSIS INT, V8, pS1; Kanis JA, 1999, QJM-MON J ASSOC PHYS, V92, P143, DOI 10.1093/qjmed/92.3.143; Keating NL, 1999, ANN INTERN MED, V130, P545, DOI 10.7326/0003-4819-130-7-199904060-00002; LENFANT C, 2000, PRELIMINARY TRENDS W; MACLENNAN SC, 1995, MED J AUSTRALIA, V162, P491, DOI 10.5694/j.1326-5377.1995.tb140014.x; MANSON JE, 1994, AM HEART J, V128, P1337, DOI 10.1016/0002-8703(94)90257-7; MILLER VT, 1995, JAMA-J AM MED ASSOC, V273, P199, DOI 10.1001/jama.1995.03520270033028; Mosca L, 1999, CIRCULATION, V99, P2480, DOI 10.1161/01.CIR.99.18.2480; Mulnard RI, 2000, JAMA-J AM MED ASSOC, V283, P1007, DOI 10.1001/jama.283.8.1007; NAMS, 2000, MENOPAUSE, V7, P76; Nanda K, 1999, OBSTET GYNECOL, V93, P880, DOI 10.1016/S0029-7844(98)00424-4; Nawaz H, 1999, AM J PREV MED, V17, P250; *POSTM ESTR PROG I, 1995, JAMA-J AM MED ASSOC, V274, P1676; Psaty BM, 2001, JAMA-J AM MED ASSOC, V285, P906, DOI 10.1001/jama.285.7.906; Schairer C, 2000, JAMA-J AM MED ASSOC, V283, P485, DOI 10.1001/jama.283.4.485; Shlipak MG, 2000, JAMA-J AM MED ASSOC, V283, P1845, DOI 10.1001/jama.283.14.1845; United States Preventive Services Task Force, 1996, GUID CLIN PREV SERV; 1999, ENDOCR PRAC, V5, P355	35	144	152	0	2	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUL 1	2001	345	1					34	U6		10.1056/NEJM200107053450106	http://dx.doi.org/10.1056/NEJM200107053450106			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	449QJ	11439947				2023-01-03	WOS:000169697600006
J	Laine, C; Hauck, WW; Gourevitch, MN; Rothman, J; Cohen, A; Turner, BJ				Laine, C; Hauck, WW; Gourevitch, MN; Rothman, J; Cohen, A; Turner, BJ			Regular outpatient medical and drug abuse care and subsequent hospitalization of persons who use illicit drugs	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							COST-EFFECTIVENESS; METHADONE-MAINTENANCE; SUBSTANCE-ABUSE; COMPLICATIONS; PREDICTORS; PROGRESSION; RETENTION; OUTCOMES; ALCOHOL; DISEASE	Context Patients and the public could benefit from identification of factors that prevent drug users' heavy reliance on inpatient care; however, optimal health care delivery models for illicit drug users remain ill-defined. Objective To evaluate associations of outpatient medical and drug abuse care with drug users' subsequent hospitalization rates. Design and Setting Retrospective cohort study of data from longitudinally linked claims for all ambulatory physician/clinic services and drug abuse services covered by the New York State Medicaid program. Subjects A total of 11 556 human immunodeficiency virus (HIV)-positive and 46687 HIV-negative drug users. Main Outcome Measures Hospitalization in federal fiscal year (FFY) 1997 compared by 4 patterns of care in FFY 1996. regular drug abuse care (greater than or equal to6 months in 1 program), regular medical care (>35% of care from 1 clinic, group practice, or individual physician), both, or neither. Results Hospitalization occurred in 55.6% of HIV-positive and 37.5% of HIV-negative drug users, with a mean of 27.5 and 24.5 inpatient days, respectively. In HIV-positive drug users, the adjusted odds ratio (AOR) for hospitalization was lowest among those with both regular medical and drug abuse care (AOR, 0.76; 95% confidence interval [CI], 0.67-0.85) followed by those with regular medical care alone (AOR, 0.82; 95% CI, 0.74-0.91) and regular drug abuse care alone (AOR, 0.85; 95% CI, 0.76-0.96) vs those with neither. In HIV-negative drug users, the AOR of hospitalization was lower for those with regular medical and drug abuse care (AOR, 0.73; 95% CI, 0.68-0.79), regular drug abuse care alone (AOR, 0.71; 95% CI, 0.66-0.76), and regular medical care (AOR, 0.91; 95% CI, 0.86-0.95) vs those with neither. Both types of care showed favorable effects for all but drug abuse-related hospitalizations. Conclusion Our data indicate that regular drug abuse care with regular medical care for drug users is associated with less subsequent hospitalization.	Univ Penn, Div Gen Internal Med, Sch Med, Philadelphia, PA 19104 USA; Thomas Jefferson Univ, Jefferson Med Coll, Div Internal Med, Philadelphia, PA 19107 USA; Thomas Jefferson Univ, Jefferson Med Coll, Ctr Res Med Educ & Hlth Care, Philadelphia, PA 19107 USA; Thomas Jefferson Univ, Jefferson Med Coll, Div Clin Pharmacol, Philadelphia, PA 19107 USA; New York State Dept Hlth, AIDS Inst, Albany, NY USA; Montefiore Med Ctr, Albert Einstein Coll Med, Dept Psychiat & Behav Sci, Div Subst Abuse, Bronx, NY 10467 USA	University of Pennsylvania; Jefferson University; Jefferson University; Jefferson University; State University of New York (SUNY) System; Montefiore Medical Center; Yeshiva University; Albert Einstein College of Medicine	Turner, BJ (corresponding author), Univ Penn, Div Gen Internal Med, Sch Med, 1122 Blockley Hall 6021,423 Guardian Dr, Philadelphia, PA 19104 USA.	bturner@mail.med.upenn.edu	Cohen, Abigail/K-9180-2013	Cohen, Abigail/0000-0002-7425-7218; Gourevitch, Marc/0000-0001-6865-2126	NATIONAL INSTITUTE ON DRUG ABUSE [R01DA011606] Funding Source: NIH RePORTER; NIDA NIH HHS [R01 DA11606] Funding Source: Medline	NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA))		Aszalos R, 1999, J SUBST ABUSE TREAT, V17, P149, DOI 10.1016/S0740-5472(98)00075-0; Ball J.C., 2012, EFFECTIVENESS METHAD; Barnett PG, 1999, ADDICTION, V94, P479, DOI 10.1046/j.1360-0443.1999.9444793.x; BATKI SL, 1996, 11 INT C AIDS JUL 7; Brettle RP, 1996, INT J STD AIDS, V7, P151, DOI 10.1258/0956462961917483; CHERUBIN CE, 1993, ANN INTERN MED, V119, P1017, DOI 10.7326/0003-4819-119-10-199311150-00009; Chou CP, 1998, SUBST USE MISUSE, V33, P2281, DOI 10.3109/10826089809056258; D'Agostino RB, 1998, STAT MED, V17, P2265, DOI 10.1002/(SICI)1097-0258(19981015)17:19<2265::AID-SIM918>3.0.CO;2-B; Etheridge RM, 1999, DRUG ALCOHOL DEPEN, V57, P99, DOI 10.1016/S0376-8716(99)00087-3; Ettner SL, 1999, MED CARE, V37, P547, DOI 10.1097/00005650-199906000-00004; Fanning TR, 1995, AIDS PUBLIC POLICY J, V10, P39; FLEISHMAN JA, 1994, HEALTH SERV RES, V29, P527; FOX K, 1995, AM J PUBLIC HEALTH, V85, P48, DOI 10.2105/AJPH.85.1.48; French MT, 2000, SOC SCI MED, V50, P1703, DOI 10.1016/S0277-9536(99)00411-6; Gourevitch MN, 1998, INT J TUBERC LUNG D, V2, P531; Hendryx MS, 1998, ADM POLICY MENT HLTH, V25, P437, DOI 10.1023/A:1022248725615; KEYES M, 1991, J ACQ IMMUN DEF SYND, V4, P1015; KOPSTEIN A, 1992, BR J ADDICT, V87, P281; LANGE WR, 1992, POSTGRAD MED, V92, P205; LANGE WR, 1992, POSTGRAD MED, V2, P211; Magura S, 1998, ADDICTION, V93, P51, DOI 10.1046/j.1360-0443.1998.931516.x; MAKOWER RM, 1992, ARCH EMERG MED, V9, P32; MARKSON LE, 1994, HLTH CARE FINANC REV, V15, P1; MOOS RH, 1994, J STUD ALCOHOL, V55, P561, DOI 10.15288/jsa.1994.55.561; NEIMCRYK SJ, 1998, J COMMUNITY HLTH, V23, P137; Newschaffer CJ, 1998, J URBAN HEALTH, V75, P153, DOI 10.1007/BF02344936; Pettinati H M, 1993, Psychiatr Q, V64, P173, DOI 10.1007/BF01065868; RAWLINGS MK, 1998, INTERSCI C ANTIMICRO, V31, P38; RAWSON RA, 1995, J SUBST ABUSE TREAT, V12, P117, DOI 10.1016/0740-5472(94)00080-B; ROSS HE, 1988, ARCH GEN PSYCHIAT, V45, P1023; Samet J. H., 1996, SUBSTANCE ABUSE, V17, P181; Sees KL, 2000, JAMA-J AM MED ASSOC, V283, P1303, DOI 10.1001/jama.283.10.1303; SELWYN PA, 1992, NEW ENGL J MED, V327, P1697, DOI 10.1056/NEJM199212103272401; Single E, 1999, AM J PUBLIC HEALTH, V89, P385, DOI 10.2105/AJPH.89.3.385; Stein M D, 1993, J Subst Abuse, V5, P187, DOI 10.1016/0899-3289(93)90062-G; STEIN MD, 1994, J ACQ IMMUN DEF SYND, V7, P469; TURNER BJ, 1994, MED CARE, V32, P902, DOI 10.1097/00005650-199409000-00002; Turner BJ, 2000, MED CARE, V38, P911, DOI 10.1097/00005650-200009000-00005; Turner BJ, 1996, J ACQ IMMUN DEF SYND, V12, P259, DOI 10.1097/00042560-199607000-00005; Webber MP, 1998, EPIDEMIOLOGY, V9, P613, DOI 10.1097/00001648-199811000-00008; Zaric GS, 2000, AM J PUBLIC HEALTH, V90, P1100, DOI 10.2105/AJPH.90.7.1100	41	121	121	0	4	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 9	2001	285	18					2355	2362		10.1001/jama.285.18.2355	http://dx.doi.org/10.1001/jama.285.18.2355			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	427NB	11343483				2023-01-03	WOS:000168411200027
J	Thornton, S				Thornton, S			Personal view - The child B case - Reflections of a chief executive	BRITISH MEDICAL JOURNAL			English	Editorial Material																			0	0	0	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 21	1997	314	7097					1838	1839		10.1136/bmj.314.7097.1838a	http://dx.doi.org/10.1136/bmj.314.7097.1838a			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XG166	11644948	Green Published			2023-01-03	WOS:A1997XG16600064
J	BRAHAMS, D				BRAHAMS, D			CHLORAMBUCIL INFERTILITY AND SPERM BANKING	LANCET			English	Editorial Material																			0	4	4	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 15	1992	339	8790					420	420		10.1016/0140-6736(92)90098-N	http://dx.doi.org/10.1016/0140-6736(92)90098-N			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HD659	11659388				2023-01-03	WOS:A1992HD65900016
J	Weidle, PJ; Malamba, S; Mwebaze, R; Sozi, C; Rukundo, G; Downing, R; Hanson, D; Ochola, D; Mugyenyi, P; Mermin, J; Samb, B; Lackritz, E				Weidle, PJ; Malamba, S; Mwebaze, R; Sozi, C; Rukundo, G; Downing, R; Hanson, D; Ochola, D; Mugyenyi, P; Mermin, J; Samb, B; Lackritz, E			Assessment of a pilot antiretroviral drug therapy programme in Uganda: patients' response, survival, and drug resistance	LANCET			English	Article							HIV-INFECTED PATIENTS; CONTROLLED-TRIAL; REVERSE-TRANSCRIPTASE; VIROLOGICAL FAILURE; ADULTS; ZIDOVUDINE; INHIBITORS; INDINAVIR; PROTEASE	Background Little is known about how to implement antiretroviral treatment programmes in resource-limited countries. We assessed the UNAIDS/Uganda Ministry of Health HIV Drug Access Initiative-one of the first pilot antiretroviral programmes in Africa-in which patients paid for their medications at negotiated reduced prices. Methods We assessed patients' clinical and laboratory information from August, 1998, to July, 2000, from three of the five accredited treatment centres in Uganda, and tested a subset of specimens for phenotypic drug resistance. Findings 912 patients presented for care at five treatment centres. We assessed the care of 476 patients at three centres, of whom 399 started antiretroviral therapy. 204 (51%) received highly active antiretroviral therapy (HAART), 189 (47%) dual nucleoside reverse transcriptase inhibitors (2NRTI), and six (2%) NRTI monotherapy. Median baseline CD4 cell counts were 73 cells/muL (IQR 15-187); viral load was 193 817 copies/mL (37 013-651 716). The probability of remaining alive and in care was 0.63 (95% Cl 0.58-0.67) at 6 months and 0.49 (0.43-0.55) at 1 year. Patients receiving HAART had greater virological responses than those receiving 2NRTI. Cox's proportional hazards models adjusted for viral load and regimen showed that a CD4 cell count of less than 50 cells/muL (vs 50 cells/muL or more) was strongly associated with death (hazard ratio 2.93 [1.51-5.68], p=0.001). Among 82 patients with a viral load of more than 1000 copies/mL more than 90 days into therapy, phenotypic resistance to NRTIs was found for 47 (57%): 29 of 37 (78%) who never received HAART versus 18 of 45 (40%) who received HAART (p=0.0005). Interpretation This pilot programme successfully expanded access to antiretroviral drugs in Uganda. Identification and treatment of patients earlier in the course of their illness and increased use of HAART could improve probability of survival and decrease drug resistance.	CDCP, Div HIV AIDS Prevent, Natl Ctr HIV STD & TB Prevent, Atlanta, GA 30333 USA; Uganda Virus Res Inst, CDC Uganda, Entebbe, Uganda; Nsambya Hosp, Kampala, Uganda; Mildmay HIV Care & Rehabil Ctr, Kampala, Uganda; Mulago Hosp, Kampala, Uganda; Uganda Minist Hlth, Kampala, Uganda; UN AIDS Program, Kampala, Uganda; Joint Clin Res Ctr, Kampala, Uganda; UNAIDS, Geneva, Switzerland; CDC, Flobal AIDS Program, NCHSTP, Atlanta, GA 30333 USA	Centers for Disease Control & Prevention - USA; Uganda Virus Research Institute; Mulago National Referral Hospital; Joint Clinic Research Center - United Arab Emirates; UNAIDS; Centers for Disease Control & Prevention - USA	Weidle, PJ (corresponding author), CDCP, Div HIV AIDS Prevent, Natl Ctr HIV STD & TB Prevent, Mailstop E-45,1600 Clifton Rd, Atlanta, GA 30333 USA.	pweidle@cdc.gov	Mermin, Jonathan/J-9847-2012	Lackritz, Eve/0000-0002-5397-7291				Adler MW, 1998, LANCET, V351, P232, DOI 10.1016/S0140-6736(05)78276-3; Binswanger HP, 2001, SCIENCE, V292, P221, DOI 10.1126/science.1057504; Cameron DW, 1998, LANCET, V351, P543, DOI 10.1016/S0140-6736(97)04161-5; Carpenter CCJ, 2000, JAMA-J AM MED ASSOC, V283, P381, DOI 10.1001/jama.283.3.381; Cohen J, 2000, SCIENCE, V289, P368, DOI 10.1126/science.289.5478.368; Colebunders R, 1997, AIDS, V11 Suppl B, pS107; Descamps D, 2000, JAMA-J AM MED ASSOC, V283, P205, DOI 10.1001/jama.283.2.205; Farmer P, 2001, LANCET, V358, P404, DOI 10.1016/S0140-6736(01)05550-7; Gartland M, 2000, AIDS, V14, P367, DOI 10.1097/00002030-200003100-00009; Gilks C F, 1997, AIDS, V11 Suppl B, pS99; Hammer SM, 1997, NEW ENGL J MED, V337, P725, DOI 10.1056/NEJM199709113371101; Henry K, 1998, J ACQ IMMUN DEF SYND, V19, P339, DOI 10.1097/00042560-199812010-00004; Hertogs K, 1998, ANTIMICROB AGENTS CH, V42, P269, DOI 10.1093/jac/42.2.269; Hirsch M, 1999, J INFECT DIS, V180, P659, DOI 10.1086/314948; Larder BA, 2000, AIDS, V14, pS111; LIANG KY, 1986, BIOMETRIKA, V73, P13, DOI 10.1093/biomet/73.1.13; Lucas GM, 1999, ANN INTERN MED, V131, P81, DOI 10.7326/0003-4819-131-2-199907200-00002; Montaner JSG, 1998, JAMA-J AM MED ASSOC, V279, P930, DOI 10.1001/jama.279.12.930; Rani S, 2022, SPAT INF RES, V30, P417, DOI 10.1007/s41324-022-00442-9; *REP UG, 2000, NATL STRAT FRAM HIV; Romano L, 2002, J MED VIROL, V66, P143, DOI 10.1002/jmv.2123; Rubin DB, 1987, MULTIPLE IMPUTATIONS; SCHOOFS M, 2001, WALL STREET J   0626, pA1; SCHOOPS M, 2001, WALL STREET J   0307, pA14; *UNAIDS, 2001, ACC ACC HIV CAR SUPP; *UNAIDS, 1998, ACC DRUGS UNAIDS TEC; World Health Organization, 2002, SCAL ANT THER RES LT	27	229	235	0	1	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JUL 6	2002	360	9326					34	40		10.1016/S0140-6736(02)09330-3	http://dx.doi.org/10.1016/S0140-6736(02)09330-3			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	569JR	12114039				2023-01-03	WOS:000176599700009
J	Marseille, E; Hofmann, PB; Kahn, JG				Marseille, E; Hofmann, PB; Kahn, JG			HIV prevention before HAART in sub-Saharan Africa	LANCET			English	Article							COST-EFFECTIVENESS; SEXUAL TRANSMISSION; INFECTION; TANZANIA; HEALTH; AIDS	Data on the cost-effectiveness of HIV prevention in sub-Saharan Africa and on highly active antiretroviral therapy (HAART) indicate that prevention is at least 28 times more cost effective than HAART. We aim to show that funding HAART at the expense of prevention means greater loss of life. To maximise health benefits, the next major increments of HIV funding in sub-Saharan Africa should be devoted mainly to prevention and to some non-HAART treatment and care. Funds should be allocated to HAART primarily for demonstration projects that will help prepare for scaled-up HAART provision following broad population coverage by prevention programmes. UNAIDS and the London School of Hygiene and Tropical Medicine recently estimated that at least US$9.2 billion annually is required to mount an appropriate response to the HIV pandemic, including substantial funding for HAART. To date, US$1.96 billion has been committed to the newly-established UN Global Fund to Fight AIDS, Tuberculosis, and Malaria. It is a moral Imperative that expanded programmes to control HIV be implemented without delay, and that the goal of US$9.2 billion or more in annual spending be attained as rapidly as possible. The findings and recommendations of this analysis pertain to the phasing in of additional HIV-related activities during the current period of improved but inadequate funding.	Univ Calif San Francisco, Ctr AIDS Prevent Studies, Inst Hlth Policy Studies, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA; Univ Calif San Francisco, AIDS Res Inst, San Francisco, CA 94143 USA; Provenance Hlth Partners, Moraga, CA USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco	Marseille, E (corresponding author), Univ Calif San Francisco, Ctr AIDS Prevent Studies, Inst Hlth Policy Studies, Dept Epidemiol & Biostat, Box 0936, San Francisco, CA 94143 USA.				NIDA NIH HHS [DA09531] Funding Source: Medline; NATIONAL INSTITUTE ON DRUG ABUSE [R01DA009531] Funding Source: NIH RePORTER	NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)		[Anonymous], 2000, WORLD HLTH REP; [Anonymous], 1997, CONFR AIDS PUBL PRIO; Attaran A, 2001, LANCET, V357, P57, DOI 10.1016/S0140-6736(00)03576-5; Blower SM, 2000, SCIENCE, V287, P650, DOI 10.1126/science.287.5453.650; CALLAHAN D, 1990, NEW ENGL J MED, V322, P1810, DOI 10.1056/NEJM199006213222511; Farmer P, 2001, LANCET, V358, P404, DOI 10.1016/S0140-6736(01)05550-7; Gray RH, 2001, LANCET, V357, P1149, DOI 10.1016/S0140-6736(00)04331-2; GROSSKURTH H, 1995, LANCET, V346, P530, DOI 10.1016/S0140-6736(95)91380-7; Jha P, 2001, SCIENCE, V292, P224, DOI 10.1126/science.1058187; Jonsen A R, 1986, Law Med Health Care, V14, P172; KIRK P, 2000, GUARDIAN        0331; KLURFELD J, 2001, NEWSDAY         0701; Lamptey P R, 1997, AIDS, V11 Suppl B, pS63; Law MG, 2001, AIDS, V15, P1287, DOI 10.1097/00002030-200107060-00011; Marseille E, 1999, LANCET, V354, P803, DOI 10.1016/S0140-6736(99)80009-9; Marseille E, 2001, SOC SCI MED, V52, P135, DOI 10.1016/S0277-9536(00)00282-3; MARSEILLE E, 2001, UN GEN ASS SPEC SESS; Merson MH, 2000, AIDS, V14, pS68; MOSES S, 1991, AIDS, V5, P407, DOI 10.1097/00002030-199104000-00008; PAGESHAFER KA, 1999, MMWR-MORBID MORTAL W, V48, P45; Parker RG, 2000, AIDS, V14, pS22, DOI 10.1097/00002030-200006001-00004; Pilcher CD, 2001, JAMA-J AM MED ASSOC, V286, P1713, DOI 10.1001/jama.286.14.1713; Quinn TC, 2000, NEW ENGL J MED, V342, P921, DOI 10.1056/NEJM200003303421303; Schwartlander B, 2001, SCIENCE, V292, P2434, DOI 10.1126/science.1062876; Sweat M, 2000, LANCET, V356, P113, DOI 10.1016/S0140-6736(00)02447-8; *UNAIDS, 2001, CALC COST EFF GLOB C; *UNAIDS WHO, 2000, AIDS EP UPD; 2001, WASHINGTON TIME 0802, pA15	28	153	154	0	9	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAY 25	2002	359	9320					1851	1856		10.1016/S0140-6736(02)08705-6	http://dx.doi.org/10.1016/S0140-6736(02)08705-6			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	555CK	12044394				2023-01-03	WOS:000175775500027
J	Petrovic, P; Kalso, E; Petersson, KM; Ingvar, M				Petrovic, P; Kalso, E; Petersson, KM; Ingvar, M			Placebo and opioid analgesia - Imaging a shared neuronal network	SCIENCE			English	Article							POSITRON-EMISSION-TOMOGRAPHY; ANTERIOR CINGULATE CORTEX; RECEPTOR-BINDING; ELECTRICAL-STIMULATION; THALAMIC-STIMULATION; CEREBRAL ACTIVATION; PERIAQUEDUCTAL GRAY; C-11 DIPRENORPHINE; MOTOR CORTEX; CHRONIC PAIN	It has been suggested that placebo analgesia involves both higher order cognitive networks and endogenous opioid systems. The rostral anterior cingulate cortex (rACC) and the brainstem are implicated in opioid analgesia, suggesting a similar role for these structures in placebo analgesia. Using positron emission tomography, we confirmed that both opioid and placebo analgesia are associated with increased activity in the rACC. We also observed a covariation between the activity in the rACC and the brainstem during both opioid and placebo analgesia, but not during the pain-only condition. These findings indicate a related neural mechanism in placebo and opioid analgesia.	Karolinska Inst, Dept Clin Neurosci, Cognit Neurophysiol Res Grp, S-17176 Stockholm, Sweden; Helsinki Univ Hosp, Dept Anaesthesia & Intens Care Med, Pain Clin, Helsinki, Finland	Karolinska Institutet; University of Helsinki; Helsinki University Central Hospital	Ingvar, M (corresponding author), Karolinska Inst, Dept Clin Neurosci, Cognit Neurophysiol Res Grp, S-17176 Stockholm, Sweden.		GNC, GNC/B-5716-2013; Petersson, Karl Magnus/HDO-0143-2022; Petersson, Karl Magnus/E-8188-2012; Petrovic, Predrag/AAS-6736-2020	Petersson, Karl Magnus/0000-0002-8245-0392; Petersson, Karl Magnus/0000-0002-8245-0392; Petrovic, Predrag/0000-0002-5536-945X; Ingvar, Martin/0000-0002-9041-5714				Adler LJ, 1997, ANESTH ANALG, V84, P120, DOI 10.1097/00000539-199701000-00023; Amanzio M, 1999, J NEUROSCI, V19, P484, DOI 10.1523/JNEUROSCI.19-01-00484.1999; Benedetti F, 1999, J NEUROSCI, V19, P3639; Casey KL, 2000, J NEUROPHYSIOL, V84, P525, DOI 10.1152/jn.2000.84.1.525; Cavada C, 2000, CEREB CORTEX, V10, P220, DOI 10.1093/cercor/10.3.220; Davis KD, 2000, J NEUROSURG, V92, P64, DOI 10.3171/jns.2000.92.1.0064; DEVINSKY O, 1995, BRAIN, V118, P279, DOI 10.1093/brain/118.1.279; Duncan GH, 1998, J NEUROPHYSIOL, V80, P3326, DOI 10.1152/jn.1998.80.6.3326; Faymonville ME, 2000, ANESTHESIOLOGY, V92, P1257, DOI 10.1097/00000542-200005000-00013; FELDMAN PL, 1991, J MED CHEM, V34, P2202, DOI 10.1021/jm00111a041; Fields H., 1999, TXB PAIN; Firestone LL, 1996, ANESTH ANALG, V82, P1247, DOI 10.1097/00000539-199606000-00025; Friston K.J., 1994, HUM BRAIN MAPP, V2, P189, DOI [10.1002/hbm.460020402, DOI 10.1002/HBM.460020402]; Friston Karl J., 1994, Human Brain Mapping, V2, P56, DOI 10.1002/hbm.460020107; Garcia-Larrea L, 1999, PAIN, V83, P259, DOI 10.1016/S0304-3959(99)00114-1; Garcia-Larrea L, 1997, STEREOT FUNCT NEUROS, V68, P141, DOI 10.1159/000099915; Gyulai FE, 1997, ANESTHESIOLOGY, V86, P538, DOI 10.1097/00000542-199703000-00005; HARDY SGP, 1985, BRAIN RES, V339, P281; HARDY SGP, 1981, NEUROSCI LETT, V22, P97, DOI 10.1016/0304-3940(81)90070-7; Ingvar M, 1999, PHILOS T R SOC B, V354, P1347, DOI 10.1098/rstb.1999.0483; JONES AKP, 1994, BRIT J RHEUMATOL, V33, P909; Jones AKP, 1999, J CEREBR BLOOD F MET, V19, P803, DOI 10.1097/00004647-199907000-00011; Kupers RC, 2000, PAIN, V87, P295, DOI 10.1016/S0304-3959(00)00295-5; LEVINE JD, 1978, LANCET, V2, P654, DOI 10.1016/S0140-6736(78)92762-9; OLESON TD, 1980, BRAIN RES, V194, P79, DOI 10.1016/0006-8993(80)91320-7; Petrovic P, 2000, PAIN, V85, P19, DOI 10.1016/S0304-3959(99)00232-8; PEYRON R, 1995, PAIN, V62, P275, DOI 10.1016/0304-3959(94)00211-V; PRICE D, 1999, PSYCHOL MECH PAIN AN, P155; PRICE D, 1999, PSYCHOL MECH PAIN AN, P137; Rainville P, 1999, J COGNITIVE NEUROSCI, V11, P110, DOI 10.1162/089892999563175; ROYCE GJ, 1983, EXP BRAIN RES, V50, P157; Talairach J., 1988, CO PLANAR STEREOTAXI; Vogt B., 1993, NEUROBIOLOGY CINGULA, P313; Wagner KJ, 2001, ANESTHESIOLOGY, V94, P732, DOI 10.1097/00000542-200105000-00008; WALL PD, 1999, TXB PAIN, P1419; WESTMORELAND CL, 1993, ANESTHESIOLOGY, V79, P893, DOI 10.1097/00000542-199311000-00005; Willoch F, 1999, AM J NEURORADIOL, V20, P686; WILLOCH F, 2001, THESIS U OSLO; Zhang YQ, 1997, PAIN, V72, P127, DOI 10.1016/S0304-3959(97)00025-0; Zubieta JK, 2001, SCIENCE, V293, P311, DOI 10.1126/science.1060952	40	1002	1024	1	95	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAR 1	2002	295	5560					1737	1740		10.1126/science.1067176	http://dx.doi.org/10.1126/science.1067176			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	527XH	11834781	Green Published			2023-01-03	WOS:000174212900053
J	Waksman, R; Raizner, AE; Yeung, AC; Lansky, AJ; Vandertie, L				Waksman, R; Raizner, AE; Yeung, AC; Lansky, AJ; Vandertie, L		INHIBIT Investigators	Use of localised intracoronary beta radiation in treatment of in-stent restenosis: the INHIBIT randomised controlled trial	LANCET			English	Article							CORONARY-ARTERY DISEASE; BALLOON ANGIOPLASTY; INTRAVASCULAR ULTRASOUND; BRACHYTHERAPY; MECHANISMS; RECURRENCE; PLACEMENT; PATTERNS; THERAPY	Background In-stent restenosis is a major limitation of intracoronary stenting. lonising gamma radiation has been shown to reduce recurrence of restenosis after stent placement. We aimed to compare the effects of intracoronary beta radiation treatment with those of placebo for clinical and angiographic outcomes of patients with diffuse in-stent restenosis. Methods 332 patients with in-stent restenosis underwent successful coronary intervention, and were then randomly allocated to intracoronary beta radiation with a phosphorus-32 source (n=166) or placebo (166) delivered into a centreing balloon catheter through an automatic afterloader. Longer lesions (>22 mm of dilated length) were treated with tandem positioning of the study wire. The primary safety endpoint was major adverse cardiac events, defined as death, myocardial infarction, and repeat target-lesion revascularisation at 9 months. The primary efficacy endpoint was binary angiographic restenosis rate in the analysis segment during 9-months' follow-up. Analysis was by intention to treat. Findings Procedural success, and in-hospital and 30-day complications were similar among the two groups. 24 (15%) patients in the radiated group had the primary safety endpoint of death, myocardial infarction, or repeat target-lesion revascularlsation over 290 days compared with 15 (31%) in the placebo group (difference 16% [95% CI 7-25], p=0.0006). Binary angiographic restenosis rate was lower in the radiated group than the placebo group for the entire analysed segment (difference 25% [14-37], p<0.0001). Interpretation Vascular brachytherapy using pure beta-emitter P-32 delivered into a centreing catheter via an automatic afterloader can be used to reduce overall revascularisation in patients undergoing treatment for diffuse in-stent restenosis.	Washington Hosp Ctr, Cardiovasc Brachytherapy Inst, Washington, DC 20010 USA; Baylor Univ, Houston, TX 77030 USA; Stanford Univ, Stanford, CA 94305 USA; Cardiol Res Fdn, New York, NY USA; Guidant Corp, Santa Clara, CA USA	MedStar Washington Hospital Center; Baylor University; Stanford University; Cardiovascular Research Foundation (CRF)	Waksman, R (corresponding author), Washington Hosp Ctr, Cardiovasc Brachytherapy Inst, Washington, DC 20010 USA.	ron.waksman@medstar.net	Webb, Delores D/G-3047-2010					BAIM DS, 1993, AM J CARDIOL, V71, P364, DOI 10.1016/0002-9149(93)90813-R; DUSSAILLANT GR, 1995, J AM COLL CARDIOL, V26, P720, DOI 10.1016/0735-1097(95)00249-4; FISCHMAN DL, 1994, NEW ENGL J MED, V331, P496, DOI 10.1056/NEJM199408253310802; Hoffmann R, 1996, CIRCULATION, V94, P1247, DOI 10.1161/01.CIR.94.6.1247; Kastrati A, 1997, J AM COLL CARDIOL, V30, P1428, DOI 10.1016/S0735-1097(97)00334-3; Kim HS, 2001, J AM COLL CARDIOL, V37, P1026, DOI 10.1016/S0735-1097(01)01112-3; Kleiman NS, 2000, J AM COLL CARDIOL, V36, P310, DOI 10.1016/S0735-1097(00)00805-6; Leon MB, 2001, NEW ENGL J MED, V344, P250, DOI 10.1056/NEJM200101253440402; Mehran R, 1999, CIRCULATION, V100, P1872, DOI 10.1161/01.CIR.100.18.1872; Mehran R, 1997, CIRCULATION, V96, P2183; Raizner AE, 1998, CIRCULATION, V98, P651; SERRUYS PW, 1994, NEW ENGL J MED, V331, P489, DOI 10.1056/NEJM199408253310801; Sharma SK, 1998, J AM COLL CARDIOL, V32, P1358, DOI 10.1016/S0735-1097(98)00382-9; Teirstein PS, 1997, NEW ENGL J MED, V336, P1697, DOI 10.1056/NEJM199706123362402; VanBelle E, 1997, CIRCULATION, V96, P1454, DOI 10.1161/01.CIR.96.5.1454; Verin V, 2001, NEW ENGL J MED, V344, P243, DOI 10.1056/NEJM200101253440401; Waksman R, 2001, CIRCULATION, V103, P2332; Waksman R, 2000, CIRCULATION, V101, P2165, DOI 10.1161/01.CIR.101.18.2165; Waksman R, 2000, J AM COLL CARDIOL, V36, P65, DOI 10.1016/S0735-1097(00)00681-1; Waksman R, 2000, CIRCULATION, V101, P1895, DOI 10.1161/01.CIR.101.16.1895	20	218	224	0	5	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	FEB 16	2002	359	9306					551	557		10.1016/S0140-6736(02)07741-3	http://dx.doi.org/10.1016/S0140-6736(02)07741-3			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	523FP	11867107				2023-01-03	WOS:000173943600006
J	Meeker, WC; Haldeman, S				Meeker, WC; Haldeman, S			Chiropractic: A profession at the crossroads of mainstream and alternative medicine	ANNALS OF INTERNAL MEDICINE			English	Review							LOW-BACK-PAIN; RANDOMIZED CLINICAL-TRIAL; SPINAL MANIPULATIVE THERAPY; CHRONIC NECK PAIN; BETA-ENDORPHIN LEVELS; PRIMARY-CARE; CERVICAL-SPINE; MANUAL THERAPY; FOLLOW-UP; CONSERVATIVE TREATMENT	Chiropractic is a large and well-established health care profession in the United States. In this overview, we briefly examine the development of chiropractic from humble and contentious beginnings to its current state at the crossroads of alternative and mainstream medicine. Chiropractic has taken on many of the attributes of an established profession, improving its educational and licensing systems and substantially increasing its market share in the past two decades. The public increasingly uses chiropractic largely for spinal pain syndromes and appears to be highly satisfied with the results. Of all the so-called alternative professions, chiropractic has made the largest inroads into private and public health care financing systems and is increasingly viewed as an effective specialty by many in the medical profession. Much of the positive evolution of chiropractic can be ascribed to a quarter century-long research effort focused on the core chiropractic procedure of spinal manipulation. This effort has helped bring spinal manipulation out of the investigational category to become one of the most studied forms of conservative treatment for spinal pain. Chiropractic theory is still controversial, but recent expansion in federal support of chiropractic research bodes well for further scientific development. The medical establishment has not yet fully accepted chiropractic as a mainstream form of care. The next decade should determine whether chiropractic maintains the trappings of an alternative health care profession or becomes fully integrated into all health care systems.	Palmer Ctr Chiropract Res, Davenport, IA 52803 USA; Univ Calif Irvine, Irvine, CA USA	University of California System; University of California Irvine	Meeker, WC (corresponding author), Palmer Ctr Chiropract Res, 741 Brady St, Davenport, IA 52803 USA.	Meeker_b@palmer.edu		haldeman, scott/0000-0002-8688-9562	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [U24AR045166] Funding Source: NIH RePORTER; NIAMS NIH HHS [U24 AR45166] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Aker PD, 1996, BMJ-BRIT MED J, V313, P1291; ANDERSON R, 1992, J MANIP PHYSIOL THER, V15, P181; ANDERSON R, 1992, PRINCIPLES PRACTICE, P3; Andersson GBJ, 1999, NEW ENGL J MED, V341, P1426, DOI 10.1056/NEJM199911043411903; Arkuszewski Z., 1988, MANUAL MED, V3, P132; ARKUSZEWSKI Z, 1986, MANUAL MED, V2, P68; Assendelft WJJ, 1996, J FAM PRACTICE, V42, P475; ASSENDELFT WJJ, 1995, JAMA-J AM MED ASSOC, V274, P1942, DOI 10.1001/jama.274.24.1942; Astin JA, 1998, ARCH INTERN MED, V158, P2303, DOI 10.1001/archinte.158.21.2303; BAIRD R, 1996, J AM CHIROPRACTIC AS, V33, P36; Balon J, 1998, NEW ENGL J MED, V339, P1013, DOI 10.1056/NEJM199810083391501; Bergmann TF, 1993, CHIROPRACTIC TECHNIQ; BERGQUISTULLMAN M, 1977, ACTA ORTHOP SCAND S, V170, P1; Bigos S, 1994, AHCPR PUBLICATION; BLOMBERG S, 1994, SPINE, V19, P569, DOI 10.1097/00007632-199403000-00013; BOGDUK N, 1981, J ANAT, V132, P39; Bogduk N, 1985, MANUELLE MED, V23, P77; BOLINE PD, 1995, J MANIP PHYSIOL THER, V18, P148; Bolton PS, 2000, J MANIP PHYSIOL THER, V23, P101, DOI 10.1016/S0161-4754(00)90075-7; Borkan JM, 1998, SPINE, V23, P1992, DOI 10.1097/00007632-199809150-00016; Bove G, 1998, JAMA-J AM MED ASSOC, V280, P1576, DOI 10.1001/jama.280.18.1576; BRENNAN PC, 1992, J MANIP PHYSIOL THER, V15, P83; BRODIN H, 1982, MANUELLE MED, V20, P90; Bronfort G, 1996, J Manipulative Physiol Ther, V19, P570; Bronfort G, 1999, NEUROL CLIN, V17, P91, DOI 10.1016/S0733-8619(05)70116-X; Bronfort G., 1989, AM J CHIROPRACTIC ME, V2, P145; BRONFORT G, 1996, P 1996 INT C SPIN MA, P105; Budgell BS, 2000, J MANIP PHYSIOL THER, V23, P104, DOI 10.1016/S0161-4754(00)90076-9; Burton AK, 2000, EUR SPINE J, V9, P202, DOI 10.1007/s005869900113; CAREY TS, 1995, SPINE, V20, P312, DOI 10.1097/00007632-199502000-00009; CAREY TS, 1995, NEW ENGL J MED, V333, P913, DOI 10.1056/NEJM199510053331406; Carey TS, 1996, SPINE, V21, P339, DOI 10.1097/00007632-199602010-00018; CARLSSON J, 1990, CEPHALALGIA, V10, P131, DOI 10.1046/j.1468-2982.1990.1003131.x; CASSIDY JD, 1992, J MANIP PHYSIOL THER, V15, P570; Chapman-Smith D, 2000, CHIROPRACTIC PROFESS; CHERKIN DC, 1989, WESTERN J MED, V150, P351; Cherkin DC, 1998, NEW ENGL J MED, V339, P1021, DOI 10.1056/NEJM199810083391502; Christensen MG, 2000, JOB ANAL CHIROPRACTI; Cooper RA, 1996, HEALTH AFFAIR, V15, P226, DOI 10.1377/hlthaff.15.3.226; COOPERSTEIN R, 1995, ADV CHIROPRATIC, V2, P437; COULEHAN JL, 1985, CULT MED PSYCHIAT, V9, P353; Coulter I, 1998, ALTERN THER HEALTH M, V4, P64; COULTER I, 1992, PRINCIPLES PRACTICE, P53; COULTER ID, 1995, ADV CHIROPRACTIC, V3, P431; COXHEAD CE, 1981, LANCET, V1, P1065; Cramer GD, 2000, J MANIP PHYSIOL THER, V23, P380, DOI 10.1067/mmt.2000.108145; Davis PT, 1998, J MANIP PHYSIOL THER, V21, P317; DELITTO A, 1993, PHYS THER, V73, P216, DOI 10.1093/ptj/73.4.216; DELITTO A, 1993, PHYS THER, V73, P226, DOI 10.1093/ptj/73.4.226; Dishman JD, 2000, SPINE, V25, P2519, DOI 10.1097/00007632-200010010-00015; DORAN DML, 1975, BRIT MED J, V2, P161, DOI 10.1136/bmj.2.5964.161; Dvorak J., 1985, MAN MED, V2, P1; Eisenberg DM, 1998, JAMA-J AM MED ASSOC, V280, P1569, DOI 10.1001/jama.280.18.1569; EVANS DP, 1978, RHEUMATOL REHABIL, V17, P46, DOI 10.1093/rheumatology/17.1.46; FARRELL JP, 1982, MED J AUSTRALIA, V1, P160, DOI 10.5694/j.1326-5377.1982.tb132242.x; GATTERMAN MI, 1995, FDN CHIROPRACTIC SUB; GIBSON T, 1985, LANCET, V1, P1258; Giles LGF, 1999, J MANIP PHYSIOL THER, V22, P376, DOI 10.1016/S0161-4754(99)70082-5; GILES LGF, 1987, BRIT J RHEUMATOL, V26, P362; GLOVER JR, 1974, BRIT J IND MED, V31, P59; GODFREY CM, 1984, SPINE, V9, P301, DOI 10.1097/00007632-198404000-00015; GOLDSTEIN M, 1975, US PHS PUBLICATION; Gordon NP, 1998, WESTERN J MED, V169, P153; HADLER NM, 1987, SPINE, V12, P703, DOI 10.1097/00007632-198709000-00012; Haldeman S, 2000, J MANIP PHYSIOL THER, V23, P112, DOI 10.1016/S0161-4754(00)90078-2; Haldeman S, 1999, SPINE, V24, P785, DOI 10.1097/00007632-199904150-00010; HALDEMAN S, 1992, GUIDELINES CHIROPRAC; Hawk C, 2000, J AM GERIATR SOC, V48, P534, DOI 10.1111/j.1532-5415.2000.tb05000.x; Hawk C, 1997, J MANIP PHYSIOL THER, V20, P147; HAWK C, 1995, J MANIP PHYSIOL THER, V18, P57; Hawk C, 1999, ALTERN THER HEALTH M, V5, P56; HAWK C, 1996, ADV CHIROPRACTIC, V3, P287; Heikkila H, 2000, MANUAL THER, V5, P151, DOI 10.1054/math.2000.0357; Helliwell P S, 1989, Proc Inst Mech Eng H, V203, P187, DOI 10.1243/PIME_PROC_1989_203_037_01; Hemmila HM, 1997, ARCH PHYS MED REHAB, V78, P571, DOI 10.1016/S0003-9993(97)90420-2; HERZOG W, 1991, J MANIP PHYSIOL THER, V14, P104; HERZOG W, 1995, ADV CHIROPRACTIC, V3, P269; HOEHLER FK, 1981, JAMA-J AM MED ASSOC, V245, P1835, DOI 10.1001/jama.245.18.1835; Hondras MA, 1999, PAIN, V81, P105, DOI 10.1016/S0304-3959(99)00004-4; HONDRAS MA, 2001, COCHRANE DATABASE SY, V1; HOWE DH, 1983, J ROY COLL GEN PRACT, V33, P574; HOYT WH, 1979, J AM OSTEOPATH ASSOC, V78, P322; Hurwitz EL, 1998, AM J PUBLIC HEALTH, V88, P771, DOI 10.2105/AJPH.88.5.771; Hurwitz EL, 1996, SPINE, V21, P1746, DOI 10.1097/00007632-199608010-00007; JACKSON P, 2001, J AM CHIROPR ASS, V38, P27; JENSEN GA, 1997, AHCPR PUBLICATION, P39; JENSEN OK, 1990, CEPHALALGIA, V10, P241, DOI 10.1046/j.1468-2982.1990.1005241.x; Jordan A, 1998, SPINE, V23, P311, DOI 10.1097/00007632-199802010-00005; Kaptchuk TJ, 1998, ARCH INTERN MED, V158, P2215, DOI 10.1001/archinte.158.20.2215; Keller TS, 2000, J MANIP PHYSIOL THER, V23, P585, DOI 10.1067/mmt.2000.110947; KELNER M, 1980, CHIROPRACTORS DO THE; Kinalski R, 1989, J MANUAL MED, V4, P44; Kleynhans AM., 1992, PRINCIPLES PRACTICE, V2; Klougart N, 1996, J Manipulative Physiol Ther, V19, P371; Koes BW, 1996, SPINE, V21, P2860, DOI 10.1097/00007632-199612150-00013; KOES BW, 1992, SPINE, V17, P28, DOI 10.1097/00007632-199201000-00005; KOES BW, 1993, J MANIP PHYSIOL THER, V16, P211; KOKJOHN K, 1992, J MANIP PHYSIOL THER, V15, P279; LANTZ CA, 1995, FDN CHIROPRACTIC SUB, P149; LEE KP, 1995, NEUROLOGY, V45, P1213, DOI 10.1212/WNL.45.6.1213; MACDONALD RS, 1990, SPINE, V15, P364, DOI 10.1097/00007632-199005000-00005; Mainous AG, 2000, ARCH FAM MED, V9, P446, DOI 10.1001/archfami.9.5.446; Marchiori DM, 2014, CLIN IMAGING SKELETA; MATHEWS JA, 1987, BRIT J RHEUMATOL, V26, P416; MCKINNEY LA, 1989, BRIT MED J, V299, P1006, DOI 10.1136/bmj.299.6706.1006; MEADE TW, 1995, BRIT MED J, V311, P349, DOI 10.1136/bmj.311.7001.349; MEADE TW, 1990, BRIT MED J, V300, P1431, DOI 10.1136/bmj.300.6737.1431; MEALY K, 1986, BRIT MED J, V292, P656, DOI 10.1136/bmj.292.6521.656; Mierau D, 1988, MANUAL MED, V3, P135; MOORE JS, 1993, CHIROPRACTIC AM HIST; Mootz R, 1997, AHCPR PUBLICATION; Mootz RD, 1997, AHCPR PUBLICATION, P67; MORGAN JP, 1985, J AM OSTEOPATH ASSOC, V85, P308; Morley J, 2001, J ALTERN COMPLEM MED, V7, P65, DOI 10.1089/107555301300004547; NANSEL DD, 1989, J MANIP PHYSIOL THER, V12, P419; Nelson CF, 1998, J MANIP PHYSIOL THER, V21, P511; NIELSEN NH, 1995, CLIN EXP ALLERGY, V25, P80, DOI 10.1111/j.1365-2222.1995.tb01006.x; Nilsson N, 1997, J Manipulative Physiol Ther, V20, P326; NORDEMAR R, 1981, PAIN, V10, P93, DOI 10.1016/0304-3959(81)90050-6; NWUGA VCB, 1982, AM J PHYS MED REHAB, V61, P273; Nyiendo J, 2001, J MANIP PHYSIOL THER, V24, P92, DOI 10.1067/mmt.2001.112565; ONGLEY MJ, 1987, LANCET, V2, P143; OTHS K, 1994, CULT MED PSYCHIAT, V18, P83, DOI 10.1007/BF01384878; PARKER GB, 1978, AUST NZ J MED, V8, P589, DOI 10.1111/j.1445-5994.1978.tb04845.x; POPE MH, 1994, SPINE, V19, P2571, DOI 10.1097/00007632-199411001-00013; Postacchini F, 1988, NEURO-ORTHOPEDICS, V6, P28; Rasmussen G. G., 1979, MANUAL MED, V17, P8; REED WR, 1994, J MANIP PHYSIOL THER, V17, P596; Rupert RL, 2000, J MANIP PHYSIOL THER, V23, P10, DOI 10.1016/S0161-4754(00)90108-8; Rupert RL, 2000, J MANIP PHYSIOL THER, V23, P1, DOI 10.1016/S0161-4754(00)90107-6; RUPERT RL, 1985, ICA INT REV CHIR WIN, P58; SANDERS GE, 1990, J MANIP PHYSIOL THER, V13, P391; Senstad O, 1997, SPINE, V22, P435, DOI 10.1097/00007632-199702150-00017; Shekelle PG, 1998, NEW ENGL J MED, V339, P1074, DOI 10.1056/NEJM199810083391509; SHEKELLE PG, 1995, MED CARE, V33, P842, DOI 10.1097/00005650-199508000-00008; SHEKELLE PG, 1992, ANN INTERN MED, V117, P590, DOI 10.7326/0003-4819-117-7-590; Siehl D, 1971, J Am Osteopath Assoc, V70, P433; SIMSWILLIAMS H, 1978, BMJ-BRIT MED J, V2, P1338, DOI 10.1136/bmj.2.6148.1338; SIMSWILLIAMS H, 1979, BMJ-BRIT MED J, V2, P1318, DOI 10.1136/bmj.2.6201.1318; Skargren EI, 1998, SPINE, V23, P1875, DOI 10.1097/00007632-199809010-00016; Skargren EI, 1997, SPINE, V22, P2167, DOI 10.1097/00007632-199709150-00015; SLOOP PR, 1982, SPINE, V7, P532, DOI 10.1097/00007632-198211000-00003; SPITZER WO, 1995, SPINE, V20, pS1; Stano M, 1992, J Am Health Policy, V2, P39; Suter E, 2000, J MANIP PHYSIOL THER, V23, P76, DOI 10.1016/S0161-4754(00)90071-X; TAYLOR JAM, 1995, SPINE, V20, P1147, DOI 10.1097/00007632-199505150-00006; TERRETT ACJ, 1984, AM J PHYS MED REHAB, V63, P217; Triano J, 1997, SPINE, V22, P1955, DOI 10.1097/00007632-199709010-00003; TRIANO JJ, 1995, SPINE, V20, P948, DOI 10.1097/00007632-199504150-00013; Tuchin PJ, 2000, J MANIP PHYSIOL THER, V23, P91, DOI 10.1016/S0161-4754(00)90073-3; vanTulder MW, 1997, SPINE, V22, P2128, DOI 10.1097/00007632-199709150-00012; VERNON HT, 1986, J MANIP PHYSIOL THER, V9, P115; VERNON HT, 1990, J MANIP PHYSIOL THER, V13, P13; Vicenzino B, 1996, PAIN, V68, P69, DOI 10.1016/S0304-3959(96)03221-6; Von Kuster T, 1980, CHIROPRACTIC HLTH CA; Vroomen PCAJ, 2000, J SPINAL DISORD, V13, P463, DOI 10.1097/00002517-200012000-00001; Waagen GN, 1986, MANUAL MED, V2, P63; Walsh MJ, 1999, J MANIP PHYSIOL THER, V22, P582, DOI 10.1016/S0161-4754(99)70018-7; WARDWELL W, 1992, CHIROPRACTIC HIST EV; WATERWORTH RF, 1985, NEW ZEAL MED J, V98, P372; Wiberg JMM, 1999, J MANIP PHYSIOL THER, V22, P517, DOI 10.1016/S0161-4754(99)70003-5; Wreje Ullacarin, 1992, Scandinavian Journal of Primary Health Care, V10, P310, DOI 10.3109/02813439209014080; YATES RG, 1988, J MANIP PHYSIOL THER, V11, P484; ZYLBERGOLD RS, 1981, ARCH PHYS MED REHAB, V62, P176; 1999, FED REG, V64, P59380	165	164	165	1	24	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	FEB 5	2002	136	3					216	227		10.7326/0003-4819-136-3-200202050-00010	http://dx.doi.org/10.7326/0003-4819-136-3-200202050-00010			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	517YD	11827498				2023-01-03	WOS:000173637400005
J	Kagawa-Singer, M; Blackhall, LJ				Kagawa-Singer, M; Blackhall, LJ			Negotiating cross-cultural issues at the end of life - "You got to go where he lives"	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							RACIAL-DIFFERENCES; DECISION-MAKING; HEALTH-CARE; CANCER; ATTITUDES; ETHNICITY; BLACK; PHYSICIANS; RACE; PREFERENCES	Culture fundamentally shapes how individuals make meaning out of illness, suffering, and dying. With increasing diversity in the United States, encounters between patients and physicians of different backgrounds are becoming more common. Thus the risk for cross-cultural misunderstandings surrounding care at the end of life is also increasing. Studies have shown cultural differences in attitudes toward truth telling, life-prolonging technology, and decision-making styles at the end of life. Using 2 case studies of patients, one of an African American couple in the southern United States and the other of a Chinese-American family in Hawaii, we outline some of the major issues involved in cross-cultural care and indicate how the patient, family, and clinician can navigate among differing cultural beliefs, values, and practices. Skilled use of cross-cultural understanding and communication techniques increases the likelihood that both the process and outcomes of care are satisfactory for all involved.	Univ Calif Los Angeles, Sch Publ Hlth & Asian Amer Studies, Los Angeles, CA 90095 USA; Univ Virginia, Ctr Palliat Care & Res, Charlottesville, VA USA; Univ Virginia, Ctr Biomed Eth, Charlottesville, VA USA	University of California System; University of California Los Angeles; University of Virginia; University of Virginia	Kagawa-Singer, M (corresponding author), Univ Calif Los Angeles, Sch Publ Hlth & Asian Amer Studies, 650 Charles E Young Dr, Los Angeles, CA 90095 USA.		Wang, Zi Dan/GZH-3012-2022					ABRAHAM J, 2000, PHYSICIANS GUIDE PAI; ANNAS GJ, 1979, AM J LAW MED, V4, P367; [Anonymous], 2000, OFF PRES FED REGIST, V65; Ayanian JZ, 1999, NEW ENGL J MED, V341, P1661, DOI 10.1056/NEJM199911253412206; Bach PB, 1999, NEW ENGL J MED, V341, P1198, DOI 10.1056/NEJM199910143411606; BARKER JC, 1992, WESTERN J MED, V157, P248; BERLIN EA, 1983, WESTERN J MED, V139, P934; BEYENE Y, 1992, W J MED, P328; Blackhall LJ, 2001, J URBAN HEALTH, V78, P59, DOI 10.1093/jurban/78.1.59; Blackhall LJ, 1999, SOC SCI MED, V48, P1779, DOI 10.1016/S0277-9536(99)00077-5; BLACKHALL LJ, 1995, JAMA-J AM MED ASSOC, V274, P820, DOI 10.1001/jama.274.10.820; BLENDON RJ, 1989, JAMA-J AM MED ASSOC, V261, P278, DOI 10.1001/jama.261.2.278; Braun K. L, 2000, CULTURAL ISSUES END; BUCHMAN R, 1992, BREAK BAD NEWS; CARALIS PV, 1993, J CLIN ETHIC, V4, P155; CARRESE JA, 1995, JAMA-J AM MED ASSOC, V274, P826, DOI 10.1001/jama.274.10.826; Carrillo JE, 1999, ANN INTERN MED, V130, P829, DOI 10.7326/0003-4819-130-10-199905180-00017; Chadwick G L, 1997, J Int Assoc Physicians AIDS Care, V3, P27; Chen J, 2001, NEW ENGL J MED, V344, P1443, DOI 10.1056/NEJM200105103441906; Cooper-Patrick L, 1999, JAMA-J AM MED ASSOC, V282, P583, DOI 10.1001/jama.282.6.583; Corbie-Smith G, 1999, J GEN INTERN MED, V14, P537, DOI 10.1046/j.1525-1497.1999.07048.x; *COUNC EC ADV, 1997, CHANG AM IND SOC EC, P40; Crawley L, 2000, JAMA-J AM MED ASSOC, V284, P2518, DOI 10.1001/jama.284.19.2518; CRAWLEY L, 2001, INNOVATIONS END LIFE; CRAWLEY L, 2001, RESPECTING CULTURAL; DALLAVORGIA P, 1992, J MED ETHICS, V18, P67, DOI 10.1136/jme.18.2.67; Dana R., 1993, MULTICULTURAL ASSESS; DAVIDSON MN, 1991, TRANSPLANT P, V23, P2531; DEVORE W, 1990, SOCIAL WORK PRACTICE; EMANUEL LL, 1993, HASTINGS CENT REP, V23, P6, DOI 10.2307/3562059; Emanuel LL, 2000, ARCH FAM MED, V9, P1181, DOI 10.1001/archfami.9.10.1181; Ersek M, 1998, Oncol Nurs Forum, V25, P1683; Fadiman A., 1997, SPIRIT CATCHES YOU Y; Fang J, 1996, NEW ENGL J MED, V335, P1545, DOI 10.1056/NEJM199611213352101; Fielding R, 1996, PSYCHO-ONCOL, V5, P321, DOI 10.1002/(SICI)1099-1611(199612)5:4<321::AID-PON226>3.0.CO;2-K; Francis CK, 2001, J NATL MED ASSOC, V93, P157; FRIEDMAN L C, 1988, Journal of Psychosocial Oncology, V6, P75; Gilbert Daniel Todd, 1998, HDB SOCIAL PSYCHOL, V2; Hallowell A. I., 1955, CULTURE EXPERIENCE; Haynes MA, 1999, UNEQUAL BURDEN CANC, DOI 10.17226/6377; Hern HE, 1998, CAMB Q HEALTHC ETHIC, V7, P27, DOI 10.1017/S0963180198701045; Hofmann JC, 1997, ANN INTERN MED, V127, P1, DOI 10.7326/0003-4819-127-1-199707010-00001; IRISH D, 1993, ETHNIC VARIATIONS; Ishii S., 1984, CROSS CURR, V11, P49; Kagawa-Singer M., 1994, GERONTOLOGY GERIATRI, V15, P101; KAGAWASINGER M, 1994, J COMMUNITY PSYCHOL, P192; KATON W, 1980, WESTERN J MED, V133, P9; Kim MS, 1996, COMMUN MONOGR, V63, P29, DOI 10.1080/03637759609376373; Kleinman A., 1988, ILLNESS NARRATIVES; Kleinman A., 1980, PATIENTS HEALERS CON; KOENIG BA, 1995, WESTERN J MED, V163, P244; KOENIG BA, 1993, I MED WORKSH DYING D; Lamont EB, 2001, ANN INTERN MED, V134, P1096, DOI 10.7326/0003-4819-134-12-200106190-00009; Lebra TS., 1976, JAPANESE PATTERNS BE, DOI [10.1515/9780824846404, DOI 10.1515/9780824846404]; LIKE RC, 2000, PATIENT CARE, P189; McKinley ED, 1996, J GEN INTERN MED, V11, P651, DOI 10.1007/BF02600155; Morrison RS, 1998, ARCH INTERN MED, V158, P2493, DOI 10.1001/archinte.158.22.2493; Mouton C., 2000, CULTURAL ISSUES END, P71; MULLER JH, 1992, WESTERN J MED, V157, P323; Murphy ST, 1996, J LAW MED ETHICS, V24, P108, DOI 10.1111/j.1748-720X.1996.tb01843.x; *NAT BIOETH ADV CO, 2001, ETH POL ISS RES INV, P250; *NAT BIOETH ADV CO, 2001, ENS VOL INF CONS PRO, P103; NOVACK DH, 1979, JAMA-J AM MED ASSOC, V241, P897, DOI 10.1001/jama.241.9.897; OKEN D, 1961, JAMA-J AM MED ASSOC, V175, P1120, DOI 10.1001/jama.1961.03040130004002; ORENTLICHER D, 1990, JAMA-J AM MED ASSOC, V263, P2344; PARRY JK, 1990, SOCIAL WORK PRACTICE; Paul B., 1955, HLTH CULTURE COMMUNI; Peterson ED, 1997, NEW ENGL J MED, V336, P480, DOI 10.1056/NEJM199702133360706; ROTHENBERG LS, 1996, ANN REV LAW ETHICS, V4, P335; Schulman KA, 1999, NEW ENGL J MED, V340, P618, DOI 10.1056/NEJM199902253400806; Stuart MR, 1993, 15 MINUTE HOUR APPL; Surbone A, 2000, ANN NY ACAD SCI, V913, P52; Takayama T, 2001, SOC SCI MED, V53, P1335, DOI 10.1016/S0277-9536(00)00413-5; THOMSEN OO, 1993, LANCET, V341, P473, DOI 10.1016/0140-6736(93)90218-6; Tong K L, 1994, J Palliat Care, V10, P26; Uba L, 1994, ASIAN AM PERSONALITY; Veatch, 2000, CROSS CULTURAL PERSP; Wellisch D, 1999, PSYCHO-ONCOL, V8, P207, DOI 10.1002/(SICI)1099-1611(199905/06)8:3<207::AID-PON357>3.0.CO;2-B; YEO G, 2000, CULTURAL ISSUES END, P356; ZANE N, IN PRESS ASIAN AM ME	80	369	370	2	42	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 19	2001	286	23					2993	3001		10.1001/jama.286.23.2993	http://dx.doi.org/10.1001/jama.286.23.2993			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	502VY	11743841				2023-01-03	WOS:000172764500032
J	Cook, DJ; Guyatt, G; Rocker, G; Sjokvist, P; Weaver, B; Dodek, P; Marshall, J; Leasa, D; Levy, M; Varon, J; Fisher, M; Cook, R				Cook, DJ; Guyatt, G; Rocker, G; Sjokvist, P; Weaver, B; Dodek, P; Marshall, J; Leasa, D; Levy, M; Varon, J; Fisher, M; Cook, R		Canadian Critical Care Trials Grp	Cardiopulmonary resuscitation directives on admission to intensive-care unit: an international observational study	LANCET			English	Article							ADVANCE DIRECTIVES; LIFE-SUPPORT; CONTROLLED TRIAL; DECISION-MAKING; PREFERENCES; PHYSICIANS; CHOICES; PATIENT; ORDERS; ILL	Background Resuscitation directives should be a sign of patient's preference. Our objective was to ascertain prevalence, predictors, and procurement pattern of cardiopulmonary resuscitation directives within 24 h of admission to the intensive-care unit (ICU). Methods We enrolled 2916 patients aged 18 years and older from 15 ICUs in four countries, and recorded whether, when, and by whom their cardiopulmonary resuscitation directives were established. By polychotomous logistic regression we identified factors associated with a resuscitate or do-not-resuscitate directive. Findings Of 2916 patients, 318 (11%; 95% CI 9.8-12.1) had an explicit resuscitation directive. In 159 (50%; 44.4-55.6) patients, the directive was do-not-resuscitate. Directives were established by residents for 145 (46%; 40.0-51.3) patients. Age strongly predicted do-not-resuscitate directives: for 50-64, 65-74, and 75 years and older, odds ratios were 3.4 (95% CI 1.6-7.3), 4.4 (2.2-9.2), and 8.8 (4.4-17.8), respectively. APACHE II scores greater than 20 predicted resuscitate and do-not-resuscitate directives in a similar way. An explicit directive was likely for patients admitted at night (odds ratio 1.4 [1.0-1.9] and 1.6 [1.2-2.3] for resuscitate and do-not-resuscitate, respectively) and during weekends (1.9 [1.3-2.7] and 2.2 [1.5-3.2], respectively). Inability to make a decision raised the likelihood of a do-not-resuscitate (3.7 [2.6-5.4]) than a resuscitate (1.7 [1.2-2.3]) directive (p=0.0005). Within Canada and the USA, cities differed strikingly, as did centres within cities. Interpretation Cardiopulmonary resuscitation directives established within 24 h of admission to ICU are uncommon. As well as clinical factors, timing and location of admission might determine rate and nature of resuscitation directives.	Dalhousie Univ, Dept Med, Halifax, NS, Canada; McMaster Univ, Dept Med, Hamilton, ON, Canada; McMaster Univ, Dept Clin Epidemiol & Biostat, Hamilton, ON, Canada; Univ British Columbia, Program Crit Care Med, Vancouver, BC V5Z 1M9, Canada; Univ Toronto, Dept Surg, Toronto, ON, Canada; Univ Western Ontario, Dept Med, London, ON, Canada; Univ Waterloo, Dept Stat & Actuarial Sci, Waterloo, ON N2L 3G1, Canada; Huddinge Univ, Dept Anaesthesia & Intens Care, Stockholm, Sweden; Brown Univ, Dept Med, Providence, RI 02912 USA; Baylor Coll Med, Dept Med, Houston, TX 77030 USA; Univ Sydney, Dept Anaesthesia & Med, Sydney, NSW 2006, Australia	Dalhousie University; McMaster University; McMaster University; University of British Columbia; University of Toronto; Western University (University of Western Ontario); University of Waterloo; Brown University; Baylor College of Medicine; University of Sydney	Cook, DJ (corresponding author), St Josephs Hosp, Dept Med, Hamilton, ON L8N 4A6, Canada.		Varon, Joseph/R-5198-2019; Varon, Joseph/T-9481-2019	Varon, Joseph/0000-0002-7622-9974; Cook, Richard/0000-0002-1414-4908				AGRESTI A, 1990, CATEGORICAL DATA ANA, P306; BEDELL SE, 1984, NEW ENGL J MED, V310, P1089, DOI 10.1056/NEJM198404263101706; BRISLIN RW, 1970, J CROSS CULT PSYCHOL, V1, P185, DOI 10.1177/135910457000100301; CHWALOW AJ, 1992, FUNDAM CLIN PHARM, V6, P319, DOI 10.1111/j.1472-8206.1992.tb00126.x; COOK DJ, 1995, JAMA-J AM MED ASSOC, V273, P703, DOI 10.1001/jama.273.9.703; CURTIS JR, 1995, JAMA-J AM MED ASSOC, V273, P124, DOI 10.1001/jama.273.2.124; DANIS M, 1994, ANN INTERN MED, V120, P567, DOI 10.7326/0003-4819-120-7-199404010-00006; Dexter PR, 1998, ANN INTERN MED, V128, P102, DOI 10.7326/0003-4819-128-2-199801150-00005; Emergency Cardiac Care Committee and Subcommittees American Heart Association, 1992, JAMA-J AM MED ASSOC, V268, P2282; Goldfrad C, 2000, LANCET, V355, P1138, DOI 10.1016/S0140-6736(00)02062-6; Goodlin SJ, 1999, JAMA-J AM MED ASSOC, V282, P2333, DOI 10.1001/jama.282.24.2333; Hakim RB, 1996, ANN INTERN MED, V125, P284, DOI 10.7326/0003-4819-125-4-199608150-00005; Hayes S, 1999, J ROY COLL PHYS LOND, V33, P348; Hofmann JC, 1997, ANN INTERN MED, V127, P1, DOI 10.7326/0003-4819-127-1-199707010-00001; JAYES RL, 1993, JAMA-J AM MED ASSOC, V270, P2213, DOI 10.1001/jama.270.18.2213; JOHNSON RF, 1995, CHEST, V107, P752, DOI 10.1378/chest.107.3.752; JOHNSTON SC, 1995, ARCH INTERN MED, V155, P1025, DOI 10.1001/archinte.155.10.1025; Johnston SC, 1998, J GEN INTERN MED, V13, P43, DOI 10.1046/j.1525-1497.1998.00008.x; Keenan SP, 1998, CRIT CARE MED, V26, P245, DOI 10.1097/00003246-199802000-00018; Kernerman P, 1997, J CRIT CARE, V12, P155, DOI 10.1016/S0883-9441(97)90026-5; KNAUS WA, 1985, CRIT CARE MED, V13, P818, DOI 10.1097/00003246-198510000-00009; Lyons RA, 2000, LANCET, V355, P595, DOI 10.1016/S0140-6736(00)01265-4; Molloy DW, 2000, JAMA-J AM MED ASSOC, V283, P1437, DOI 10.1001/jama.283.11.1437; MORRISON RS, 1994, ARCH INTERN MED, V154, P2311, DOI 10.1001/archinte.154.20.2311; ORENTLICHER D, 1991, JAMA-J AM MED ASSOC, V265, P1868; OSBORNE M, 1994, LANCET, V343, P778, DOI 10.1016/S0140-6736(94)91845-7; Phillips RS, 1996, AM J MED, V100, P128, DOI 10.1016/S0002-9343(97)89450-8; Sjokvist P., 1998, CLIN INTENSIVE CARE, V9, P81, DOI [10.3109/tcic.9.2.81.85, DOI 10.3109/TCIC.9.2.81.85]; Sulmasy DP, 1998, ANN INTERN MED, V128, P621, DOI 10.7326/0003-4819-128-8-199804150-00002; Walter SD, 1998, CRIT CARE MED, V26, P44, DOI 10.1097/00003246-199801000-00015; WENGER NS, 1994, J GEN INTERN MED, V9, P539, DOI 10.1007/BF02599276	31	91	96	0	7	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	DEC 8	2001	358	9297					1941	1945		10.1016/S0140-6736(01)06960-4	http://dx.doi.org/10.1016/S0140-6736(01)06960-4			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	500HZ	11747918				2023-01-03	WOS:000172622200011
J	Viscoli, CM; Brass, LM; Kernan, WN; Sarrel, PM; Suissa, S; Horwitz, RI				Viscoli, CM; Brass, LM; Kernan, WN; Sarrel, PM; Suissa, S; Horwitz, RI			A clinical trial of estrogen-replacement therapy after ischemic stroke.	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CORONARY-HEART-DISEASE; POSTMENOPAUSAL ESTROGEN; MYOCARDIAL-INFARCTION; FOLLOW-UP; RISK; PROGESTIN; USERS; PREVENTION; HORMONES; COHORT	Background: Observational studies have suggested that estrogen-replacement therapy may reduce a woman's risk of stroke and death. Methods: We conducted a randomized, double-blind, placebo-controlled trial of estrogen therapy (1 mg of estradiol-17 beta per day) in 664 postmenopausal women (mean age, 71 years) who had recently had an ischemic stroke or transient ischemic attack. Women were recruited from 21 hospitals in the United States and were followed for the occurrence of stroke or death. Results: During a mean follow-up period of 2.8 years, there were 99 strokes or deaths among the women in the estradiol group, and 93 among those in the placebo group (relative risk in the estradiol group, 1.1; 95 percent confidence interval, 0.8 to 1.4). Estrogen therapy did not reduce the risk of death alone (relative risk, 1.2; 95 percent confidence interval, 0.8 to 1.8) or the risk of nonfatal stroke (relative risk, 1.0; 95 percent confidence interval, 0.7 to 1.4). The women who were randomly assigned to receive estrogen therapy had a higher risk of fatal stroke (relative risk, 2.9; 95 percent confidence interval, 0.9 to 9.0), and their nonfatal strokes were associated with slightly worse neurologic and functional deficits. Conclusions: Estradiol does not reduce mortality or the recurrence of stroke in postmenopausal women with cerebrovascular disease. This therapy should not be prescribed for the secondary prevention of cerebrovascular disease.	Yale Univ, Sch Med, Dept Internal Med, New Haven, CT 06510 USA; Yale Univ, Sch Med, Dept Neurol, New Haven, CT 06510 USA; Yale Univ, Sch Med, Dept Epidemiol & Publ Hlth, New Haven, CT 06510 USA; Yale Univ, Sch Med, Dept Obstet & Gynecol, New Haven, CT 06510 USA; Vet Affairs Connecticut Healthcare Syst, West Haven, CT USA; McGill Univ, Dept Epidemiol & Biostat, Montreal, PQ, Canada; McGill Univ, Dept Med, Montreal, PQ, Canada	Yale University; Yale University; Yale University; Yale University; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Connecticut Healthcare System; McGill University; McGill University	Viscoli, CM (corresponding author), Yale Univ, Sch Med, Dept Med, 333 Cedar St,Rm 1072 LMP,POB 208056, New Haven, CT 06520 USA.				PHS HHS [1-RO1-N531251] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		[Anonymous], 1995, JAMA-J AM MED ASSOC, V274, P1676; BARRETTCONNOR E, 1991, ANN INTERN MED, V115, P455, DOI 10.7326/0003-4819-115-6-455; Berman RS, 1996, J WOMENS HLTH, V5, P213, DOI [10.1089/jwh.1996.5.213, DOI 10.1089/JWH.1996.5.213]; BOYSEN G, 1988, STROKE, V19, P1345, DOI 10.1161/01.STR.19.11.1345; BROTT T, 1989, STROKE, V20, P864, DOI 10.1161/01.STR.20.7.864; CASAGRANDE JT, 1978, BIOMETRICS, V34, P483, DOI 10.2307/2530613; COX DR, 1972, J R STAT SOC B, V34, P187; Cushman M, 1999, CIRCULATION, V100, P717, DOI 10.1161/01.CIR.100.7.717; Daly E, 1996, LANCET, V348, P977, DOI 10.1016/S0140-6736(96)07113-9; FALKEBORN M, 1993, ARCH INTERN MED, V153, P1201, DOI 10.1001/archinte.153.10.1201; FINUCANE FF, 1993, ARCH INTERN MED, V153, P73, DOI 10.1001/archinte.153.1.73; GEBARA OCE, 1995, CIRCULATION, V91, P1952, DOI 10.1161/01.CIR.91.7.1952; Grodstein F, 1996, NEW ENGL J MED, V335, P453, DOI 10.1056/NEJM199608153350701; Hulley S, 1998, JAMA-J AM MED ASSOC, V280, P605, DOI 10.1001/jama.280.7.605; HUNT K, 1990, BRIT J OBSTET GYNAEC, V97, P1080, DOI 10.1111/j.1471-0528.1990.tb02494.x; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; Karanjia PN, 1997, NEUROLOGY, V48, P346, DOI 10.1212/WNL.48.2.346; Kernan W N, 1998, J Stroke Cerebrovasc Dis, V7, P85, DOI 10.1016/S1052-3057(98)80026-8; KERNAN WN, 1991, ANN INTERN MED, V114, P552, DOI 10.7326/0003-4819-114-7-552; KNATTERUD G, 1988, JAMA-J AM MED ASSOC, V260, P2849; Koh KK, 1997, NEW ENGL J MED, V336, P683, DOI 10.1056/NEJM199703063361002; LIEBERMAN EH, 1994, ANN INTERN MED, V121, P936, DOI 10.7326/0003-4819-121-12-199412150-00005; MANTEL NATHAN, 1966, CANCERCHEMOTHERAP REP, V50, P163; MILLER VT, 1995, JAMA-J AM MED ASSOC, V273, P199, DOI 10.1001/jama.1995.03520270033028; MOHONEY FI, 1965, MD STATE MED J, P61; Murphy DD, 1998, J NEUROSCI, V18, P2550; OBRIEN PC, 1979, BIOMETRICS, V35, P549, DOI 10.2307/2530245; PADWICK ML, 1986, NEW ENGL J MED, V315, P930, DOI 10.1056/NEJM198610093151504; PAGANINIHILL A, 1988, BMJ-BRIT MED J, V297, P519, DOI 10.1136/bmj.297.6647.519; Pedersen AT, 1997, LANCET, V350, P1277, DOI 10.1016/S0140-6736(97)06005-4; PETITTI DB, 1979, JAMA-J AM MED ASSOC, V242, P1150, DOI 10.1001/jama.242.11.1150; Petitti DB, 1998, STROKE, V29, P23, DOI 10.1161/01.STR.29.1.23; PFEFFER RI, 1978, J CHRON DIS, V31, P389, DOI 10.1016/0021-9681(78)90003-6; PFEFFER RI, 1976, AM J EPIDEMIOL, V103, P445, DOI 10.1093/oxfordjournals.aje.a112246; RAVNIKAR VA, 1987, AM J OBSTET GYNECOL, V156, P1332, DOI 10.1016/0002-9378(87)90173-6; ROSENBERG SH, 1980, WESTERN J MED, V133, P292; SARREL PM, 1990, MATURITAS, V12, P287, DOI 10.1016/0378-5122(90)90008-T; Simon JA, 2001, CIRCULATION, V103, P638, DOI 10.1161/01.cir.103.5.638; STAMPFER MJ, 1991, NEW ENGL J MED, V325, P756, DOI 10.1056/NEJM199109123251102; STAMPFER MJ, 1991, PREV MED, V20, P47, DOI 10.1016/0091-7435(91)90006-P; THOMPSON SG, 1989, J EPIDEMIOL COMMUN H, V43, P173, DOI 10.1136/jech.43.2.173; TUNSTALLPEDOE H, 1994, CIRCULATION, V90, P583, DOI 10.1161/01.CIR.90.1.583; van Baal WM, 1999, THROMB HAEMOSTASIS, V81, P925, DOI 10.1055/s-0037-1614600; WHISNANT JP, 1990, STROKE, V21, P707, DOI 10.1161/01.STR.21.5.707; WILSON PWF, 1985, NEW ENGL J MED, V313, P1038, DOI 10.1056/NEJM198510243131702	45	651	667	0	11	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	OCT 25	2001	345	17					1243	1249		10.1056/NEJMoa010534	http://dx.doi.org/10.1056/NEJMoa010534			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	485RU	11680444				2023-01-03	WOS:000171773100004
J	Taylor, RB; Shakoor, O; Behrens, RH; Everard, M; Low, AS; Wangboonskul, J; Raid, RG; Kolawole, JA				Taylor, RB; Shakoor, O; Behrens, RH; Everard, M; Low, AS; Wangboonskul, J; Raid, RG; Kolawole, JA			Pharmacopoeial quality of drugs supplied by Nigerian pharmacies	LANCET			English	Article							SUBSTANDARD DRUGS	Background The quality of medicines available in some less-developed countries is inadequate in terms of content of active ingredient. Reasons for the poor quality of drugs include widespread counterfeiting of medicines in less-developed countries, excessive decomposition of active ingredient as a result of high temperature and humidity, and poor quality assurance during the manufacture of medicinal products. Our aim was to investigate the quality of different drugs obtained from retail pharmacies in two urban areas of Nigeria, and, in instances of poor quality, to ascertain the reason why. Methods We randomly collected 581 samples of 27 different drugs from 35 pharmacies in Lagos and Abuja in Nigeria. We analysed the medicines for drug content by validated chromatographic methods, and compared our results with pharmacopoeial requirements. Findings 279 (48%) samples did not comply with set pharmacopoeial limits, and this proportion was uniform for the various types of drugs tested. Although some preparations contained no active ingredient, most had amounts just outside the pharmacopoeial limits. We identified samples with both too much and too little active drug content. Interpretation The most probable cause of the poor quality of drugs is absence of adequate quality assurance during manufacture. Substandard drugs sold in the pharmacies of less-developed countries could contribute to global microbial resistance and therapeutic failure of infectious diseases.	Robert Gordon Univ, Sch Pharm, Aberdeen AB10 1FR, Scotland; London Sch Hyg & Trop Med, Dept Infect & Trop Dis, London WC1, England; Khon Kaen Univ, Fac Pharmaceut Sci, Khon Kaen, Thailand; Univ Jos, Dept Pharm, Jos, Nigeria	Robert Gordon University; University of London; London School of Hygiene & Tropical Medicine; Khon Kaen University; University of Jos	Taylor, RB (corresponding author), Robert Gordon Univ, Sch Pharm, Aberdeen AB10 1FR, Scotland.			Behrens, Ron/0000-0002-8166-2633				ABDI YA, 1995, LANCET, V346, P1161, DOI 10.1016/S0140-6736(95)91834-5; [Anonymous], 1990, ACUTE RESP INFECT CH; Arya S C, 1995, World Health Forum, V16, P269; CAMPBELL H, 1995, ARCH DIS CHILD, V73, P281, DOI 10.1136/adc.73.4.281; Dye C, 1999, JAMA-J AM MED ASSOC, V282, P677, DOI 10.1001/jama.282.7.677; HOGERZEIL HV, 1991, LANCET, V338, P754, DOI 10.1016/0140-6736(91)91470-F; KELLY JC, 1990, ANN EMERG MED, V19, P47, DOI 10.1016/S0196-0644(05)82141-9; KIBWAGE IO, 1992, E AFR MED J, V69, P577; Low AS, 1999, ANALYST, V124, P1589, DOI 10.1039/a907400g; PETRALANDA I, 1995, LANCET, V345, P1433, DOI 10.1016/S0140-6736(95)92620-8; Roy J, 1994, World Health Forum, V15, P406; Shakoor O, 1997, TROP MED INT HEALTH, V2, P839, DOI 10.1046/j.1365-3156.1997.d01-403.x; TENHAM M, 1992, ADVERSE DRUG REACT T, V11, P59; WONDEMAGEGNEHU E, 1995, COUNTERFEIT SUBSTAND; 1999, WORLD HLTH REPORT 19, P49	15	139	142	0	17	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUN 16	2001	357	9272					1933	1936		10.1016/S0140-6736(00)05065-0	http://dx.doi.org/10.1016/S0140-6736(00)05065-0			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	444YZ	11425415				2023-01-03	WOS:000169431000013
J	Vastag, B				Vastag, B			Mixed message on prescription drug abuse	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	News Item																			0	5	5	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 2	2001	285	17					2183	2184		10.1001/jama.285.17.2183	http://dx.doi.org/10.1001/jama.285.17.2183			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	424WC	11325305				2023-01-03	WOS:000168256100003
J	Ahmedzai, SH				Ahmedzai, SH			Window of opportunity for pain control in the terminally ill	LANCET			English	Editorial Material							CANCER PAIN; MORPHINE; ANALGESIA; FENTANYL; RATS		Univ Sheffield, Royal Hallamshire Hosp, Acad Palliat Med Unit, Sheffield S10 2JF, S Yorkshire, England	University of Sheffield	Ahmedzai, SH (corresponding author), Univ Sheffield, Royal Hallamshire Hosp, Acad Palliat Med Unit, Sheffield S10 2JF, S Yorkshire, England.	s.ahmedzai@sheffield.ac.uk		Ahmedzai, Sam/0000-0002-2028-8510				Ahmedzai S, 1997, J PAIN SYMPTOM MANAG, V13, P254, DOI 10.1016/S0885-3924(97)00082-1; BEITBART W, 1998, OXFORD TXB PALLIATIV, P437; Burton AW, 1999, REGION ANESTH PAIN M, V24, P208, DOI 10.1016/S1098-7339(99)90129-3; Dalal S, 1998, J PAIN SYMPTOM MANAG, V16, P245, DOI 10.1016/S0885-3924(98)00084-0; Inturrisi CE, 1998, PROG PAIN RES MANAG, V12, P275; Megens AAHP, 1998, J PAIN SYMPTOM MANAG, V15, P253, DOI 10.1016/S0885-3924(97)00371-0; Mercadante S, 2001, J PAIN SYMPTOM MANAG, V21, P255, DOI 10.1016/S0885-3924(00)00236-0; NUGENT M, IN PRESS J PAIN SYMP; Nurmikko TJ, 1998, BRIT MED J, V317, P1438, DOI 10.1136/bmj.317.7170.1438; Paice JA, 1998, J PAIN SYMPTOM MANAG, V16, P1, DOI 10.1016/S0885-3924(98)00025-6; Ross FB, 2000, PAIN, V84, P421, DOI 10.1016/S0304-3959(99)00230-4; Sapir R, 1999, J PAIN SYMPTOM MANAG, V17, P266, DOI 10.1016/S0885-3924(98)00156-0; Skilbeck J, 1998, PALLIATIVE MED, V12, P245, DOI 10.1191/026921698677124622; *WHO, 1990, WHO TECH REP SER, V804	14	14	14	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	APR 28	2001	357	9265					1304	1305		10.1016/S0140-6736(00)04525-6	http://dx.doi.org/10.1016/S0140-6736(00)04525-6			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	427ND	11343728				2023-01-03	WOS:000168411400002
J	Pooga, M; Kut, C; Kihlmark, M; Hallbrink, M; Fernaeus, S; Raid, R; Land, T; Hallberg, E; Bartfai, T; Langel, U				Pooga, M; Kut, C; Kihlmark, M; Hallbrink, M; Fernaeus, S; Raid, R; Land, T; Hallberg, E; Bartfai, T; Langel, U			Cellular translocation of proteins by transportan	FASEB JOURNAL			English	Article						peptide-mediated transport; cell-penetrating peptides; drug delivery; transport vectors; protein transduction	GREEN FLUORESCENT PROTEIN; IN-VIVO; INTRACELLULAR DELIVERY; TRANSDUCTION; PEPTIDES; CELLS; REAGENTS; DNA	Proteins with molecular masses ranging from 30 kDa. (green fluorescent protein, GFP) to 150 kDa (monoclonal and polyclonal antibodies) were coupled to the cellular translocating peptide transportan. We studied the ability of the resulting protein-peptide constructs to penetrate into Bowes melanoma, BRL, and COS-7 cells. After 0.5-3 h incubation with recombinant GFP coupled to transportan, most of the GFP fluorescence was found in intracellular membranes of BRL and COS-7 cells, which suggests that transportan could internalize covalently linked proteins of about 30 kDa in a folded state. Transportan could internalize covalently coupled molecules of even larger size; that is, avidin and antibodies, (up to 150 kDa). The covalent bond between the transport peptide and its cargo is not obligatory because streptavidin was translocated into the cells within 15 min as a noncovalent complex with biotinylated transportan. Inside the cells, the delivered streptavidin was first located mainly in close proximity to the plasma membrane and was later distributed to the perinuclear region. Most of the internalized streptavidin was confined to vesicular structures, but a significant fraction of the protein was distributed in the cytoplasm. Our data suggest that transportan can deliver proteins and other hydrophilic macromolecules into intact mammalian cells, and this finding demonstrates good potential as powerful cellular delivery vector for scientific and therapeutic purposes.	Scripps Res Inst, Dept Neuropharmacol, Harold L Dorris Neurol Res Ctr, La Jolla, CA 92037 USA; Univ Stockholm, Arrhenius Lab, Dept Neurochem & Neurotoxicol, S-10691 Stockholm, Sweden; Estonian Bioctr, EE-51010 Tartu, Estonia; Sodertorns Hogskola Univ Coll, Sect Nat Sci, S-14104 Huddinge, Sweden; Univ Stockholm, Arrhenius Lab, Dept Biochem, S-10691 Stockholm, Sweden; Univ Tartu, Inst Zool & Hydrobiol, EE-51014 Tartu, Estonia	Scripps Research Institute; Stockholm University; Estonian Biocentre; Sodertorn University; Stockholm University; University of Tartu	Langel, U (corresponding author), Scripps Res Inst, Dept Neuropharmacol, Harold L Dorris Neurol Res Ctr, 10550 N Torrey Pines Rd,Mail SR-307, La Jolla, CA 92037 USA.	ulangel@scripps.edu	Pooga, Margus/A-8575-2011	Pooga, Margus/0000-0003-4532-4087; Hallberg, Einar/0000-0003-2092-457X				ADAM SA, 1989, NATURE, V337, P276, DOI 10.1038/337276a0; Derossi D, 1996, J BIOL CHEM, V271, P18188, DOI 10.1074/jbc.271.30.18188; Derossi D, 1998, TRENDS CELL BIOL, V8, P84, DOI 10.1016/S0962-8924(97)01214-2; Elliott G, 1997, CELL, V88, P223, DOI 10.1016/S0092-8674(00)81843-7; Ezhevsky SA, 1997, P NATL ACAD SCI USA, V94, P10699, DOI 10.1073/pnas.94.20.10699; FAWELL S, 1994, P NATL ACAD SCI USA, V91, P664, DOI 10.1073/pnas.91.2.664; Kato D, 1998, FEBS LETT, V427, P203, DOI 10.1016/S0014-5793(98)00426-8; Lindgren M, 2000, TRENDS PHARMACOL SCI, V21, P99, DOI 10.1016/S0165-6147(00)01447-4; Nagahara H, 1998, NAT MED, V4, P1449, DOI 10.1038/4042; Niemeyer CM, 1999, NUCLEIC ACIDS RES, V27, P4553, DOI 10.1093/nar/27.23.4553; Ormo M, 1996, SCIENCE, V273, P1392, DOI 10.1126/science.273.5280.1392; PEETERS JM, 1989, J IMMUNOL METHODS, V120, P133, DOI 10.1016/0022-1759(89)90298-6; Phelan A, 1998, NAT BIOTECHNOL, V16, P440, DOI 10.1038/nbt0598-440; Pooga M, 1998, FASEB J, V12, P67, DOI 10.1096/fasebj.12.1.67; Pooga M, 1998, NAT BIOTECHNOL, V16, P857, DOI 10.1038/nbt0998-857; Prochiantz A, 1996, CURR OPIN NEUROBIOL, V6, P629, DOI 10.1016/S0959-4388(96)80095-X; Rojas M, 1998, NAT BIOTECHNOL, V16, P370, DOI 10.1038/nbt0498-370; Schwarze SR, 1999, SCIENCE, V285, P1569, DOI 10.1126/science.285.5433.1569; Schwarze SR, 2000, TRENDS PHARMACOL SCI, V21, P45, DOI 10.1016/S0165-6147(99)01429-7; Soomets U, 2000, BBA-BIOMEMBRANES, V1467, P165, DOI 10.1016/S0005-2736(00)00216-9; Tsien RY, 1998, ANNU REV BIOCHEM, V67, P509, DOI 10.1146/annurev.biochem.67.1.509	21	149	162	0	24	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	APR 27	2001	15	6					1451	+		10.1096/fj.00-0780fje	http://dx.doi.org/10.1096/fj.00-0780fje			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	519BV	11387254				2023-01-03	WOS:000173705800015
J	HOWARD, R				HOWARD, R			MEMORABLE PATIENTS - INSIGHT AND HONESTY	BRITISH MEDICAL JOURNAL			English	Editorial Material														Howard, Robert/0000-0002-3071-2338					0	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 20	1993	306	6880					764	764		10.1136/bmj.306.6880.764	http://dx.doi.org/10.1136/bmj.306.6880.764			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KU173	11643118	Green Published, Bronze			2023-01-03	WOS:A1993KU17300027
J	Koffman, J				Koffman, J			There must be a better way	BRITISH MEDICAL JOURNAL			English	Editorial Material														Koffman, Jonathan/0000-0001-8513-5681					0	2	2	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JUN 27	1998	316	7149					1989	1990		10.1136/bmj.316.7149.1989a	http://dx.doi.org/10.1136/bmj.316.7149.1989a			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZY568	11682719				2023-01-03	WOS:000074636700086
J	Boettcher, B				Boettcher, B			Fatal episodes in medical history	BRITISH MEDICAL JOURNAL			English	Editorial Material																			0	0	0	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	DEC 5	1998	317	7172					1603	1603						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	146VC	9836691				2023-01-03	WOS:000077451700090
